PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ozaki, M; Sasner, M; Yano, R; Lu, HS; Buonanno, A				Ozaki, M; Sasner, M; Yano, R; Lu, HS; Buonanno, A			Neuregulin-beta induces expression of an NMDA-receptor subunit	NATURE			English	Article							NEU DIFFERENTIATION FACTOR; ACETYLCHOLINE-RECEPTOR; DEVELOPING CEREBELLUM; GENE-EXPRESSION; MESSENGER-RNAS; SINGLE-CHANNEL; GRANULE CELLS; MUSCLE; ERBB3; SYNAPSES	Neuregulins (also known as ARLA, NDF, heregulin, GGF) are a family of widely expressed growth and differentiation factors. Neuregulins secreted from motor neurons accumulate at maturing neuromuscular junctions, where they stimulate transcription of genes encoding specific acetylcholine receptors. How these factors function at central synapses, however, is unknown. In the maturing cerebellum, neuregulins are concentrated in glutamatergic messy fibres that innervate granule cells in the internal granule-cell layer(1). We have analysed the effects of neuregulins on the expression of genes encoding NMDA (N-methyl-D-aspartate) receptors in the cerebellum, because receptor composition changes dramatically as expression of the receptor NR2C subunit is specifically induced in neurons in the internal granule-cell layer during synaptogenesis. Here we report that addition of a neuregulin-beta isoform to cultured cerebellar slices specifically increases the expression of NR2C messenger RNAs by at least 100-fold; effects are only minor with a neuregulin-alpha isoform. This stimulation of NR2C expression requires synaptic activity by NMDA receptors, as well as neuregulin-beta. Addition of the NMDA-receptor-channel blocker AP-5 prevents upregulation of the NR2C subunit by neuregulin, whereas an AMPA/kainate-receptor antagonist does not. Consistent with these effects of neuregulin, we find that granule cells express its receptors ErbB2 and ErbB4 before the NR2C subunit of the NMDA receptor. Our results indicate that neuregulins regulate the composition of neurotransmitter receptors in maturing synapses in the brain, in a manner analogous to the neuromuscular junction.	NIH,MOL NEUROBIOL UNIT,LDN,BETHESDA,MD 20892; RIKEN,FRONTIER RES PROGRAM,LAB CELLULAR INFORMAT PROC,WAKO,SAITAMA 35101,JAPAN; AMGEN INC,DEPT PROT STRUCT,THOUSAND OAKS,CA 91320	National Institutes of Health (NIH) - USA; RIKEN; Amgen				Sasner, Michael/0000-0002-6612-6111				AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; ANGERER LM, 1981, NUCLEIC ACIDS RES, V9, P2819, DOI 10.1093/nar/9.12.2819; AUDINAT E, 1994, EUR J NEUROSCI, V6, P1792, DOI 10.1111/j.1460-9568.1994.tb00572.x; BUONANNO A, 1995, SOC NEUR ABSTR, V21; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carroll SL, 1997, J NEUROSCI, V17, P1642; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; FARRANT M, 1994, NATURE, V368, P335, DOI 10.1038/368335a0; Feldmeyer D, 1996, J NEUROCYTOL, V25, P857, DOI 10.1007/BF02284847; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Kadotani H, 1996, J NEUROSCI, V16, P7859; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; LEVI G, 1982, BRAIN RES, V239, P425, DOI 10.1016/0006-8993(82)90520-0; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; SANDROCK AW, 1995, J NEUROSCI, V15, P6124; Shahar A, 1989, DISSECTION TISSUE CU, V1, P203; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; Takahashi T, 1996, J NEUROSCI, V16, P4376; TANAKA M, 1994, BRAIN RES, V641, P319, DOI 10.1016/0006-8993(94)90161-9; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027	30	219	226	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					691	694		10.1038/37795	http://dx.doi.org/10.1038/37795			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414162				2022-12-28	WOS:A1997YM50800033
J	Langer, RD; Pierce, JJ; OHanlan, KA; Johnson, SR; Espeland, MA; Trabal, JF; Barnabei, VM; Merino, MJ; Scully, RE				Langer, RD; Pierce, JJ; OHanlan, KA; Johnson, SR; Espeland, MA; Trabal, JF; Barnabei, VM; Merino, MJ; Scully, RE			Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ASYMPTOMATIC POSTMENOPAUSAL WOMEN; PREOPERATIVE ASSESSMENT; MYOMETRIAL INVASION; THICKNESS; SONOGRAPHY; CANCER; ADENOCARCINOMA; CARCINOMA	Background Transvaginal ultrasonography is a noninvasive procedure that may be used to detect endometrial disease. However, its usefulness in screening for asymptomatic disease in postmenopausal women before or during treatment with estrogen or estrogen-progesterone replacement is not known. Methods We compared the sensitivity and specificity of transvaginal ultrasonography and endometrial biopsy for the detection of endometrial disease in 448 postmenopausal women who received estrogen alone, cyclic or continuous estrogen-progesterone, or placebo for three years. Results Concurrent ultrasonographic and biopsy results were available for 577 examinations in the 448 women, 99 percent of whom were undergoing routine annual follow-up. Endometrial thickness was less than 5 mm in 45 percent of the examinations, 5 to 10 mm in 41 percent, more than 10 mm in 12 percent, and not measured in 2 percent, and it was higher in the women receiving estrogen alone than in the other groups. Biopsy detected 11 cases of serious disease: 1 case of adenocarcinoma, 2 cases of atypical simple hyperplasia, and 8 cases of complex hyperplasia. Biopsy also detected simple hyperplasia in 20 cases. At a threshold value of 5 mm for endometrial thickness. transvaginal ultrasonography had a positive predictive value of 9 percent for detecting any abnormality, with 90 percent sensitivity, 48 percent specificity, and a negative predictive value of 99 percent. With this threshold, a biopsy would be indicated in more than half the women, only 4 percent of whom had serious disease. Conclusions Transvaginal ultrasonography has a poor positive predictive value but a high negative predictive value for detecting serious endometrial disease in asymptomatic postmenopausal women. (C) 1997, Massachusetts Medical Society.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103; STANFORD UNIV,DEPT OBSTET & GYNECOL,PALO ALTO,CA 94304; UNIV IOWA,COLL MED,IOWA CITY,IA 52242; UNIV TEXAS,HLTH SCI CTR,DEPT OBSTET & GYNECOL,SAN ANTONIO,TX 78284; GEORGE WASHINGTON UNIV,MED CTR,DEPT OBSTET & GYNECOL,WASHINGTON,DC 20037; NATL CANC INST,BETHESDA,MD; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114	Wake Forest University; Wake Forest Baptist Medical Center; Stanford University; University of Iowa; University of Texas System; University of Texas Health San Antonio; George Washington University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Massachusetts General Hospital	Langer, RD (corresponding author), UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,9500 GILMAN DR,MC 0978,LA JOLLA,CA 92093, USA.		O'Hanlan, Katherine/A-4073-2017	O'Hanlan, Katherine/0000-0002-7577-4188; Barnabei, Vanessa/0000-0002-9650-0143	NHLBI NIH HHS [U01-HL40195, U01-HL40154, U01-HL40185] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL040154, U01HL040195, U01HL040185] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDOLF E, 1993, OBSTET GYNECOL, V82, P936; ARCHER DF, 1991, AM J OBSTET GYNECOL, V165, P317, DOI 10.1016/0002-9378(91)90084-5; BRECKENRIDGE JW, 1982, AM J ROENTGENOL, V139, P529, DOI 10.2214/ajr.139.3.529; CHAMBERS CB, 1986, AM J OBSTET GYNECOL, V154, P1194, DOI 10.1016/0002-9378(86)90698-8; FLEISCHER AC, 1990, J CLIN ULTRASOUND, V18, P337, DOI 10.1002/jcu.1870180420; GORDON AN, 1989, GYNECOL ONCOL, V34, P175, DOI 10.1016/0090-8258(89)90136-4; GORDON AN, 1990, GYNECOL ONCOL, V39, P321, DOI 10.1016/0090-8258(90)90260-R; GRANBERG S, 1991, AM J OBSTET GYNECOL, V164, P47, DOI 10.1016/0002-9378(91)90622-X; GRONROOS M, 1993, CANCER, V71, P1279, DOI 10.1002/1097-0142(19930215)71:4<1279::AID-CNCR2820710418>3.0.CO;2-4; LIN MC, 1991, RADIOLOGY, V180, P427, DOI 10.1148/radiology.180.2.1829843; MALPANI A, 1990, J CLIN ULTRASOUND, V18, P173, DOI 10.1002/jcu.1870180306; MILLER VT, 1995, CONTROL CLIN TRIALS, V16, pS54, DOI 10.1016/0197-2456(94)00113-H; NASRI MN, 1989, BRIT J OBSTET GYNAEC, V96, P1333, DOI 10.1111/j.1471-0528.1989.tb03233.x; OSMERS R, 1989, INT J GYNECOL OBSTET, V28, P283, DOI 10.1016/0020-7292(89)90732-7; OSMERS R, 1990, INT J GYNECOL OBSTET, V32, P35, DOI 10.1016/0020-7292(90)90979-U; *PEPI TRIAL WRIT G, 1996, JAMA-J AM MED ASSOC, V275, P370; *PEPI TRIAL WRIT G, 1995, JAMA-J AM MED ASSOC, V273, P199; REQUARD CK, 1981, RADIOLOGY, V140, P781, DOI 10.1148/radiology.140.3.7280250; Rose PG, 1996, NEW ENGL J MED, V335, P640, DOI 10.1056/NEJM199608293350907; *SAS I INC, 1990, SAS GRAPH SOFTW REF; SCHURZ B, 1988, MATURITAS, V9, P367, DOI 10.1016/0378-5122(88)90102-8; Smith P, 1991, Acta Obstet Gynecol Scand, V70, P591, DOI 10.3109/00016349109007922; SNEDECOR GW, 1980, STATISTICAL METHODS, P206; TESSLER FN, 1989, RADIOLOGY, V170, P553, DOI 10.1148/radiology.170.2.2643149; VARNER RE, 1991, OBSTET GYNECOL, V78, P195	25	163	167	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 18	1997	337	25					1792	1798		10.1056/NEJM199712183372502	http://dx.doi.org/10.1056/NEJM199712183372502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL855	9400035				2022-12-28	WOS:A1997YL85500002
J	Blader, P; Rastegar, S; Fischer, N; Strahle, U				Blader, P; Rastegar, S; Fischer, N; Strahle, U			Cleavage of the BMP-4 antagonist chordin by zebrafish tolloid	SCIENCE			English	Article							BONE MORPHOGENETIC PROTEIN-1; DROSOPHILA-MELANOGASTER; PATTERN-FORMATION; LARVAL CUTICLE; ZYGOTIC LOCI; SPEMANN ORGANIZER; XENOPUS CHORDIN; C-PROTEINASE; BETA FAMILY; GENE	Dorsoventral patterning of vertebrate and Drosophila embryos requires bone morphogenetic proteins (BMPs) and antagonists of BMP activity. The Drosophila gene tolloid encodes a metalloprotease similar to BMP-1 that interacts genetically with decapentaplegic, the Drosophila homolog of vertebrate BMP-2/4. Zebrafish embryos overexpressing a zebrafish homolog of tolloid were shown to resemble loss-of-function mutations in chordino, the zebrafish homolog of the Xenopus BMP-4 antagonist Chordin. Furthermore, Chordin was degraded by COS cells expressing Tolloid. These data suggest that Tolloid antagonizes Chordin activity by proteolytically cleaving Chordin, A conserved function for zebrafish and Drosophila Tolloid during embryogenesis is proposed.	UNIV STRASBOURG 1,INSERM,CNRS,INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Rastegar, Sepand/E-2324-2015; Straehle, Uwe/K-7054-2013	Rastegar, Sepand/0000-0003-4411-5646; Blader, Patrick/0000-0003-3299-6108				BLADER P, UNPUB; BOURGUET W, 1995, PROTEIN EXPRES PURIF, V6, P604, DOI 10.1006/prep.1995.1079; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALE L, 1992, DEVELOPMENT, V115, P573; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FINELLI AL, 1994, DEVELOPMENT, V120, P861; FRANCOIS V, 1995, CELL, V80, P19, DOI 10.1016/0092-8674(95)90446-8; FUKAGAWA M, 1994, DEV BIOL, V163, P175, DOI 10.1006/dbio.1994.1133; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Hammerschmidt M, 1996, GENE DEV, V10, P2452, DOI 10.1101/gad.10.19.2452; Hammerschmidt M, 1996, DEVELOPMENT, V123, P95; HOLLEY SA, 1995, NATURE, V376, P249, DOI 10.1038/376249a0; JOLY JS, 1993, DEVELOPMENT, V119, P1261; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Mullins MC, 1996, DEVELOPMENT, V123, P81; Neave B, 1997, MECH DEVELOP, V62, P183, DOI 10.1016/S0925-4773(97)00659-X; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; PUSCHEL AW, 1992, MECH DEVELOP, V38, P197, DOI 10.1016/0925-4773(92)90053-M; Sarras MP, 1996, BIOESSAYS, V18, P439, DOI 10.1002/bies.950180604; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9; Westerfield M, 1995, ZEBRAFISH BOOK; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6; ZUSMAN SB, 1985, DEV BIOL, V111, P359, DOI 10.1016/0012-1606(85)90490-7	42	162	174	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1937	1940		10.1126/science.278.5345.1937	http://dx.doi.org/10.1126/science.278.5345.1937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395394				2022-12-28	WOS:A1997YL00200032
J	Krishnan, V; Pereira, FA; Qiu, Y; Chen, CH; Beachy, PA; Tsai, SY; Tsai, MJ				Krishnan, V; Pereira, FA; Qiu, Y; Chen, CH; Beachy, PA; Tsai, SY; Tsai, MJ			Mediation of Sonic Hedgehog induced expression of COUP-TFII by a protein phosphatase	SCIENCE			English	Article							TERMINAL CLEAVAGE PRODUCT; MOTOR-NEURON INDUCTION; FLOOR PLATE; KINASE-A; GENE; RECEPTOR; NOTOCHORD; HOMOLOG; TUBE	A Sonic hedgehog (Shh) response element was identified in the chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) promoter that binds to a factor distinct from Gli, a gene known to mediate Shh signaling. Although this binding activity is specifically stimulated by Shh-N (amino-terminal signaling domain), it can also be unmasked with protein phosphatase treatment in the mouse cell line P19, and induction by Shh-N can be blocked by phosphatase inhibitors. Thus, Shh-N signaling may result in dephosphorylation of a target factor that is required for activation of COUP-TFII-, Islet1-, and Gli response element-dependent gene expression. This finding identifies another step in the Shh-N signaling pathway.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205	Baylor College of Medicine; Howard Hughes Medical Institute; Johns Hopkins University				Pereira, Fred/0000-0003-2100-0280				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; CHEN CH, COMMUNICATION; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Concordet JP, 1996, DEVELOPMENT, V122, P2835; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hammerschmidt M, 1996, GENE DEV, V10, P647, DOI 10.1101/gad.10.6.647; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Krishnan V, 1997, MOL ENDOCRINOL, V11, P1458, DOI 10.1210/me.11.10.1458; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MONSOROBURQ AH, 1995, MECH DEVELOP, V53, P157, DOI 10.1016/0925-4773(95)00426-2; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229	24	123	129	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1947	1950		10.1126/science.278.5345.1947	http://dx.doi.org/10.1126/science.278.5345.1947			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395397				2022-12-28	WOS:A1997YL00200035
J	Wintterlin, J; Volkening, S; Janssens, TVW; Zambelli, T; Ertl, G				Wintterlin, J; Volkening, S; Janssens, TVW; Zambelli, T; Ertl, G			Atomic and macroscopic reaction rates of a surface-catalyzed reaction	SCIENCE			English	Article							SCANNING-TUNNELING-MICROSCOPY; CARBON-MONOXIDE OXIDATION; PT(111) SURFACE; CO; OXYGEN; KINETICS; NI(110); CU(110); SITES	The catalytic oxidation of carbon monoxide (CO) on a platinum (111) surface was studied by scanning tunneling microscopy. The adsorbed oxygen atoms and CO molecules were imaged with atomic resolution, and their reactions to carbon dioxide (CO2) were monitored as functions of time. The results allowed the formulation of a rate law that takes the distribution of the reactants in separate domains into account. From temperature-dependent measurements, the kinetic parameters were obtained. Their values agree well with data from macroscopic measurements. In this way, a kinetic description of a chemical reaction was achieved that is based solely on the statistics of the underlying atomic processes.			Wintterlin, J (corresponding author), MAX PLANCK GESELL,FRITZ HABER INST,FARADAYWEG 4-6,D-14195 BERLIN,GERMANY.			Janssens, Ton V.W./0000-0002-1225-0942				AKHTER S, 1986, SURF SCI, V171, P527, DOI 10.1016/0039-6028(86)91058-7; ALLERS KH, 1994, J CHEM PHYS, V100, P3985, DOI 10.1063/1.466332; AVERY NR, 1983, CHEM PHYS LETT, V96, P371, DOI 10.1016/0009-2614(83)80692-7; BARTEAU MA, 1981, SURF SCI, V104, P161, DOI 10.1016/0039-6028(81)90128-X; CAMPBELL CT, 1980, J CHEM PHYS, V73, P5862, DOI 10.1063/1.440029; CONRAD H, 1978, SURF SCI, V76, P323, DOI 10.1016/0039-6028(78)90101-2; Crew WW, 1996, SURF SCI, V349, P275, DOI 10.1016/0039-6028(96)80026-4; CREW WW, 1994, SURF SCI, V319, pL34, DOI 10.1016/0039-6028(94)90587-8; Dumesic JA, 1993, MICROKINETICS HETERO; ENGEL T, 1979, ADV CATAL, V28, P1, DOI DOI 10.1016/S0360-0564(08)60133-9; ERTL G, 1977, SURF SCI, V64, P393, DOI 10.1016/0039-6028(77)90052-8; FROITZHEIM H, 1977, APPL PHYS, V13, P147, DOI 10.1007/BF00882473; GLAND JL, 1983, J CHEM PHYS, V78, P963, DOI 10.1063/1.444801; GLAND JL, 1980, SURF SCI, V95, P587, DOI 10.1016/0039-6028(80)90197-1; GLAND JL, 1985, SURF SCI, V151, P260, DOI 10.1016/0039-6028(85)90465-0; Laidler K. J., 1987, CHEM KINETICS; Lang N. D., 1989, Comments on Condensed Matter Physics, V14, P253; LEIBSLE FM, 1993, NATURE, V363, P706, DOI 10.1038/363706a0; LEIBSLE FM, 1994, PHYS REV LETT, V72, P2569, DOI 10.1103/PhysRevLett.72.2569; RUAN L, 1992, PHYS REV LETT, V69, P3523, DOI 10.1103/PhysRevLett.69.3523; SILVERBERG M, 1985, J CHEM PHYS, V83, P6501, DOI 10.1063/1.449550; Sprunger PT, 1995, SURF SCI, V344, P98, DOI 10.1016/0039-6028(95)00852-7; Walters L., 1982, CHEM PHYSICS SOLID S, P73; Wintterlin J, 1996, PHYS REV LETT, V77, P123, DOI 10.1103/PhysRevLett.77.123; WINTTERLIN J, IN PRESS SURF SCI; Xu MD, 1996, J CHEM PHYS, V104, P8825, DOI 10.1063/1.471606; Zambelli T, 1996, SCIENCE, V273, P1688, DOI 10.1126/science.273.5282.1688	27	295	300	4	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1931	1934		10.1126/science.278.5345.1931	http://dx.doi.org/10.1126/science.278.5345.1931			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395392				2022-12-28	WOS:A1997YL00200030
J	Hess, RF; Dakin, SC				Hess, RF; Dakin, SC			Absence of contour linking in peripheral vision	NATURE			English	Article							VISUAL-CORTEX; INTEGRATION; SYSTEM	Human foveal vision is subserved initially by groups of spatial, temporal and orientational 'filters', the outputs of which are combined to define perceptual objects, Although a great deal is known about the filtering properties of individual cortical cells, relatively little is known about the nature of this 'linking' process. One recent approach(1) has shown that the process can be thought of in terms of an association field whose strength is determined conjointly by the orientation and distance of the object. Here we describe a fundamental difference in this feature-linking process in central and peripheral parts of the visual field, which provides insight into the ways that foveal and peripheral visual perception differ(2,3). In the fovea, performance can be explained only by intercellular Linking operations whereas in the periphery intracellular filtering will suffice. This difference represents a substantial economy in cortical neuronal processing of peripheral visual information and may allow a recent theory of intercellular binding to be tested(4-7).			Hess, RF (corresponding author), MCGILL UNIV,DEPT OPHTHALMOL,MONTREAL,PQ H3A 1A1,CANADA.		Dakin, Steven C/B-7610-2008; Hess, Robert F/A-5624-2008	Dakin, Steven C/0000-0002-3548-9104; 				Aubert H., 1857, ARCHIV F UR OPHTHALM, V3, P1; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; FIELD DJ, 1993, VISION RES, V33, P173, DOI 10.1016/0042-6989(93)90156-Q; GILBERT CD, 1989, J NEUROSCI, V9, P2432; KREITER AK, 1994, EUROPEAN J NEUROSC S, V7, P153; PHILLIPS G, 1983, J OPT SOC AM, V62, P226; SCHNEIDER GE, 1969, SCIENCE, V163, P895, DOI 10.1126/science.163.3870.895; TSO DY, 1988, J NEUROSCI, V8, P1712; von der Malsburg Ch., 1983, SYNERGETICS BRAIN, P238; VONDERMALSBURG C, 1988, NEUROBIOLOGY NEOCORT, P69; Wang YZ, 1996, VISION RES, V36, P1737, DOI 10.1016/0042-6989(95)00249-9; Watt R., 1991, UNDERSTANDING VISION; WATT RJ, 1985, VISION RES, V25, P1661, DOI 10.1016/0042-6989(85)90138-5	13	125	125	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					602	604		10.1038/37593	http://dx.doi.org/10.1038/37593			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403687				2022-12-28	WOS:A1997YK85300047
J	Marczin, N; Riedel, B; Gal, J; Polak, J; Yacoub, M				Marczin, N; Riedel, B; Gal, J; Polak, J; Yacoub, M			Exhaled nitric oxide during lung transplantation	LANCET			English	Letter									UNIV LONDON SCH PHARM,NATL HEART & LUNG INST,DEPT CARDIOTHORAC SURG,HAREFIELD UB9 6JH,MIDDX,ENGLAND; HAREFIELD HOSP,DEPT ANAESTHET,HAREFIELD UB9 6JH,MIDDX,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,LONDON W12 0HS,ENGLAND	Imperial College London; University of London; University College London; University of London School of Pharmacy; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Imperial College London								Date H, 1996, J THORAC CARDIOV SUR, V111, P913, DOI 10.1016/S0022-5223(96)70364-1; DUSTING GJ, 1995, ANN MED, V27, P395, DOI 10.3109/07853899509002593; Kharitonov SA, 1996, CURR OPIN ANAESTH, V9, P542; Marczin N, 1997, LANCET, V349, P1742, DOI 10.1016/S0140-6736(05)62953-4; PINSKY DJ, 1995, THROMB HAEMOSTASIS, V74, P58	5	46	47	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1681	1682		10.1016/S0140-6736(05)64281-X	http://dx.doi.org/10.1016/S0140-6736(05)64281-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400523				2022-12-28	WOS:A1997YK21100023
J	Tierney, JF; Stewart, LA; Parmar, MKB; Fletcher, CDM; Jones, G; Mosseri, V; Patel, M; deElvira, MCR; Souhami, RL; Sylvester, R; Tursz, T; Alvegard, TA; Sigurdsson, H; Antman, K; Bacchi, M; Baker, LH; Benjamin, RS; Brady, MF; Bramwell, V; Bui, BN; Edmonson, JH; Leyvraz, S; Omura, GA; Rouesse, J; Ryan, L; vanOosterom, AT; Yang, JC				Tierney, JF; Stewart, LA; Parmar, MKB; Fletcher, CDM; Jones, G; Mosseri, V; Patel, M; deElvira, MCR; Souhami, RL; Sylvester, R; Tursz, T; Alvegard, TA; Sigurdsson, H; Antman, K; Bacchi, M; Baker, LH; Benjamin, RS; Brady, MF; Bramwell, V; Bui, BN; Edmonson, JH; Leyvraz, S; Omura, GA; Rouesse, J; Ryan, L; vanOosterom, AT; Yang, JC			Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data	LANCET			English	Article							RANDOMIZED TRIAL; ONCOLOGY-GROUP; UTERINE SARCOMAS; ACTINOMYCIN-D; ADRIAMYCIN; DOXORUBICIN; CYCLOPHOSPHAMIDE; COMBINATION; EXTREMITIES; RECURRENCE	Background Individually, randomised trials have not shown conclusively whether adjuvant chemotherapy benefits adult patients with localised resectable soft-tissue sarcoma. Methods A quantitative meta-analysis of updated data from individual patients from all available randomised trials was carried out to assess whether adjuvant chemotherapy improves overall survival, recurrence-free survival, and local and distant recurrence-free intervals (RFI) and whether chemotherapy is differentially effective in patients defined by age, sex, disease status at randomisation, disease site, histology, grade, tumour size, extent of resection, and use of radiotherapy. Findings 1568 patients from 14 trials of doxorubicin-based adjuvant chemotherapy were included (median follow-up 9.4 years). Hazard ratios of 0.73 (95% CI 0.56-0.94, p=0.016) for local RFI, 0.70 (0.57-0.85, p=0.0003) for distant RFI, and 0.75 (0.64-0.87, p=0.0001) for overall recurrence-free survival, correspond to absolute benefits from adjuvant chemotherapy of 6% (95% CI 1-10), 10% (5-15), and 10% (5-15), respectively, at 10 years. For overall survival, the hazard ratio of 0.89 (0.76-1.03) was not significant (p=0.12), but represents an absolute benefit of 4% (1-9) at 10 years. These results were not affected by prespecified changes in the groups of patients analysed. There was no consistent evidence that the relative effect of adjuvant chemotherapy differed for any subgroup of patients for any endpoint. However, the best evidence of an effect of adjuvant chemotherapy for survival was seen in patients with sarcomas of the extremities. Interpretation The meta-analysis provides evidence that adjuvant doxorubicin-based chemotherapy significantly improves the time to local and distant recurrence and overall recurrence-free survival. There is a trend towards improved overall survival.	UNIV LUND HOSP, JUBILEUM INST, LUND, SWEDEN; COLUMBIA UNIV, COLUMBIA PRESBYTERIAN MED CTR, NEW YORK, NY 10032 USA; MASSACHUSETTS GEN HOSP, DANA FARBER CANC INST, BOSTON, MA 02114 USA; SIAK COORDINATING CTR, BERN, SWITZERLAND; UNIV MICHIGAN, CTR COMPREHENS CANC, ANN ARBOR, MI 48109 USA; UNIV TEXAS, MD ANDERSON CANC CTR, HOUSTON, TX USA; ROSWELL PK CANC INST, STAT OFF, GYNECOL ONCOL GRP, BUFFALO, NY USA; CHRISTIE HOSP, MANCHESTER, LANCS, ENGLAND; INST BERGONIE, BORDEAUX, FRANCE; MAYO CLIN, ROCHESTER, MN USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; IST ORTOPED RIZZOLI, BOLOGNA, ITALY; HAMILTON REG CANC CTR, HAMILTON, ON L8V 1C3, CANADA; UNIV LAUSANNE HOSP, LAUSANNE, SWITZERLAND; SWISS GRP CLIN CANC RES, BERN, SWITZERLAND; INST CURIE, DEPT BIOSTAT, PARIS, FRANCE; UNIV ALABAMA, BIRMINGHAM, AL USA; CTR RENE HUGUENIN, ST CLOUD, FRANCE; UCL, EUROPEAN GRP BLOOD & MARROW TRANSPLANTAT, LONDON, ENGLAND; DANA FARBER CANC INST, STAT OFF, EASTERN COOPERAT ONCOL GRP, BOSTON, MA 02115 USA; UCL, SCH MED, DEPT ONCOL, LONDON W1N 8AA, ENGLAND; EORTC DATA CTR, METAANAL UNIT, BRUSSELS, BELGIUM; INST GUSTAVE ROUSSY, VILLEJUIF, FRANCE; UNIV ZIEKENHUIZEN, DEPT ONCOL, LOUVAIN, BELGIUM; NCI, SURG BRANCH, BETHESDA, MD 20892 USA	Lund University; Skane University Hospital; Columbia University; NewYork-Presbyterian Hospital; Harvard University; Dana-Farber Cancer Institute; Massachusetts General Hospital; University of Michigan System; University of Michigan; University of Texas System; UTMD Anderson Cancer Center; Roswell Park Cancer Institute; Christie NHS Foundation Trust; Christie Hospital; UNICANCER; Institut Bergonie; Mayo Clinic; Harvard University; Brigham & Women's Hospital; IRCCS Istituto Ortopedico Rizzoli; McMaster University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Group for Clinical Cancer Research (SAKK); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Alabama System; University of Alabama Birmingham; Rene Huguenin Hospital; University of London; University College London; Harvard University; Dana-Farber Cancer Institute; University of London; University College London; UCL Medical School; European Organisation for Research & Treatment of Cancer; UNICANCER; Gustave Roussy; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			; Ryan, Louise/A-4562-2009	Stewart, Lesley/0000-0003-0287-4724; Tierney, Jayne/0000-0002-4734-3014; Ryan, Louise/0000-0001-5957-2490				ALVEGARD TA, 1989, J CLIN ONCOL, V7, P1504, DOI 10.1200/JCO.1989.7.10.1504; ANTMAN K, 1984, J CLIN ONCOL, V2, P601, DOI 10.1200/JCO.1984.2.6.601; BAKER L H, 1988, P130; BAKER LH, 1987, J CLIN ONCOL, V5, P851, DOI 10.1200/JCO.1987.5.6.851; BENJAMIN R S, 1975, Medical and Pediatric Oncology, V1, P63, DOI 10.1002/mpo.2950010109; BLUM RH, 1974, ANN INTERN MED, V80, P249, DOI 10.7326/0003-4819-80-2-249; BORDEN EC, 1990, CANCER, V66, P862, DOI 10.1002/1097-0142(19900901)66:5<862::AID-CNCR2820660509>3.0.CO;2-R; BRAMWELL V, 1994, J CLIN ONCOL, V12, P1137, DOI 10.1200/JCO.1994.12.6.1137; CHANG AE, 1988, J CLIN ONCOL, V6, P1491, DOI 10.1200/JCO.1988.6.9.1491; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; Delaney T F, 1991, Oncology (Williston Park), V5, P105; Dickersin K, 1995, SYSTEMATIC REV, P17; Edmonson, 1985, CANCER TREAT S, V3, P89; EDMONSON JH, 1984, J CLIN ONCOL, V2, P1390, DOI 10.1200/JCO.1984.2.12.1390; EILBER FR, 1988, AM J CLIN ONCOL-CANC, V11, P39, DOI 10.1097/00000421-198802000-00009; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GHERLINZONI F, 1986, J CLIN ONCOL, V4, P552, DOI 10.1200/JCO.1986.4.4.552; GLENN J, 1985, SURGERY, V97, P316; GLENN J, 1985, CANCER, V55, P1206, DOI 10.1002/1097-0142(19850315)55:6<1206::AID-CNCR2820550612>3.0.CO;2-E; GOTTLIEB JA, 1975, CANCER CHEMOTH REP 3, V6, P271; Jones G.W., 1991, CLIN INVEST MED S19, V14, pA772; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KINSELLA TJ, 1988, J CLIN ONCOL, V6, P18, DOI 10.1200/JCO.1988.6.1.18; LERNER HJ, 1987, J CLIN ONCOL, V5, P613, DOI 10.1200/JCO.1987.5.4.613; MCGRATH PC, 1995, CLIN PLAST SURG, V22, P21; MERTENS WC, 1995, HEMATOL ONCOL CLIN N, V9, P801, DOI 10.1016/S0889-8588(18)30072-8; OMURA GA, 1985, J CLIN ONCOL, V3, P1240, DOI 10.1200/JCO.1985.3.9.1240; PICCI P, 1988, P144; PINEDO HM, 1986, RADIOTHER ONCOL, V5, P193, DOI 10.1016/S0167-8140(86)80049-4; PIVER MS, 1988, J SURG ONCOL, V38, P233, DOI 10.1002/jso.2930380406; Ravaud A, 1990, ADJUVANT THERAPY CAN, P556; ROSENBERG SA, 1983, CANCER-AM CANCER SOC, V52, P424, DOI 10.1002/1097-0142(19830801)52:3<424::AID-CNCR2820520307>3.0.CO;2-8; Salmon SE., 1987, ADJUVANT THERAPY CAN, P735; Salmon SE., 1990, ADJUVANT THERAPY CAN, P529; SCHOENFELD DA, 1982, CANCER, V50, P2757, DOI 10.1002/1097-0142(19821215)50:12<2757::AID-CNCR2820501211>3.0.CO;2-J; TIERNEY JF, 1995, BRIT J CANCER, V72, P469, DOI 10.1038/bjc.1995.357; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZALUPSKI MM, 1993, ADJUVANT THERAPY CAN, V7, P385	38	690	717	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1647	1654						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400508				2022-12-28	WOS:A1997YK21100008
J	Tylee, A				Tylee, A			Counselling in primary care	LANCET			English	Editorial Material											Tylee, A (corresponding author), ROYAL COLL GEN PRACTITIONERS,INST PSYCHIAT,UNIT MENTAL HLTH EDUC PRIMARY CARE,LONDON SE5 8AF,ENGLAND.							*DEP HLTH, 1996, NHSE REV PSYCH; Priest RG, 1996, BRIT MED J, V313, P858; Roth A., 1996, WHAT WORKS WHOM CRIT; SIBBALD B, 1993, BMJ-BRIT MED J, V306, P29, DOI 10.1136/bmj.306.6869.29	4	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1643	1643		10.1016/S0140-6736(05)64268-7	http://dx.doi.org/10.1016/S0140-6736(05)64268-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400503				2022-12-28	WOS:A1997YK21100003
J	Okuchi, T				Okuchi, T			Hydrogen partitioning into molten iron at high pressure: Implications for Earth's core	SCIENCE			English	Article							PERIDOTITE KLB-1; THERMAL HISTORY; WATER REACTION; HYDRIDE; EVOLUTION; SILICATE; ORIGIN; SYSTEM; METALS; GPA	Because of dissolution of lighter elements such as sulfur, carbon, hydrogen, and oxygen, Earth's outer core is about 10 percent less dense than molten iron at the relevant pressure and temperature conditions. To determine whether hydrogen can account for a major part of the density deficit and is therefore an important constituent in the molten iron outer core, the hydrogen concentration in molten iron was measured at 7.5 gigapascals. From these measurements, the metal-silicate melt partitioning coefficient of hydrogen was determined as a function of temperature. If the magma ocean of primordial Earth was hydrous, more than 95 mole percent of H2O in this ocean should have reacted with iron to form FeHx, and about 60 percent of the density deficit is reconciled by adding hydrogen to the core.			Okuchi, T (corresponding author), TOKYO INST TECHNOL,DEPT EARTH & PLANETARY SCI,MEGURO KU,2-12-1 OOKAYAMA,TOKYO 152,JAPAN.		Okuchi, Takuo/B-1884-2011	Okuchi, Takuo/0000-0001-6907-0945				ABE Y, 1985, J GEOPHYS RES, V90, pC545, DOI 10.1029/JB090iS02p0C545; ABE Y, 1986, J GEOPHYS RES-SOLID, V91, pE291, DOI 10.1029/JB091iB13p0E291; BADDING JV, 1991, SCIENCE, V253, P421, DOI 10.1126/science.253.5018.421; FUKAI Y, 1985, ADV PHYS, V34, P263, DOI 10.1080/00018738500101751; FUKAI Y, 1983, JPN J APPL PHYS 1, V22, P207, DOI 10.1143/JJAP.22.207; FUKAI Y, 1983, P JPN ACAD B-PHYS, V59, P158, DOI 10.2183/pjab.59.158; FUKAI Y, 1984, NATURE, V308, P174, DOI 10.1038/308174a0; FUKAI Y, 1986, J GEOPHYS RES-SOLID, V91, P9222, DOI 10.1029/JB091iB09p09222; FUKAI Y, 1992, HIGH PRESSURE RES AP, P373; FUKAI Y, 1991, J LESS-COMMON MET, V8, P172; FUKAI Y, 1984, KAGAKU, V54, P36; GROSSMAN L, 1974, REV GEOPHYS, V12, P71, DOI 10.1029/RG012i001p00071; HISHINUMA T, 1994, P JPN ACAD B-PHYS, V70, P71, DOI 10.2183/pjab.70.71; INOUE T, 1994, PHYS EARTH PLANET IN, V85, P237, DOI 10.1016/0031-9201(94)90116-3; Inoue T, 1992, HIGH PRESSURE RES AP, P323; OKUCHI T, IN PRESS HIGH PRESSU; RINGWOOD AE, 1977, GEOCHEM J, V11, P111, DOI 10.2343/geochemj.11.111; STEVENSON DJ, 1981, SCIENCE, V214, P611, DOI 10.1126/science.214.4521.611; STEVENSON DJ, 1977, NATURE, V268, P130, DOI 10.1038/268130a0; Stevenson DJ., 1990, ORIGIN EARTH, P231; STOLPER E, 1982, GEOCHIM COSMOCHIM AC, V46, P2609, DOI 10.1016/0016-7037(82)90381-7; SUZUKI A, 1995, SCIENCE, V269, P216, DOI 10.1126/science.269.5221.216; SUZUKI T, 1984, PHYS EARTH PLANET IN, V36, P135, DOI 10.1016/0031-9201(84)90014-1; TAKAHASHI E, 1986, J GEOPHYS RES-SOLID, V91, P9367, DOI 10.1029/JB091iB09p09367; TAKAHASHI E, 1993, PHILOS T ROY SOC A, V342, P105, DOI 10.1098/rsta.1993.0008; YAGI T, 1995, GEOPHYS RES LETT, V22, P1933, DOI 10.1029/95GL01792; YAMAKATA M, 1992, P JPN ACAD B-PHYS, V68, P172, DOI 10.2183/pjab.68.172	27	165	168	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1781	1784		10.1126/science.278.5344.1781	http://dx.doi.org/10.1126/science.278.5344.1781			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388177				2022-12-28	WOS:A1997YJ90100043
J	Bangham, CRM; Phillips, RE				Bangham, CRM; Phillips, RE			What is required of an HIV vaccine?	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; T-LYMPHOCYTE RESPONSE; IN-VIVO; MONOCLONAL-ANTIBODIES; IMMUNE-RESPONSES; ESCAPE MUTANTS; NEF GENE; PROTECTION; INFECTION; DISEASE	Mounting evidence suggests that the early dissemination of HIV in human beings evokes air immune response that is responsible for containment of the infection during the long symptom-free period. Loss of this immune control coincides with a final escalation of the viraemia and the terminal failure of the immune system. Other studies imply that pre-emptive vaccination of monkeys with attenuated forms of simian immunodeficiency virus (SIV) produces a substantial degree of resistance to superinfection with fully virulent viruses. Here we consider how observations from natural and experimental systems might influence thought as to what is required to produce safe induced immunity against HIV. We concentrate on three questions: what is the nature of the immune response that contains the infection? How does this response fail? How could a vaccine enhance protective immunity so that it exceeds the efficacy of this natural response?	JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,MOL SCI DIV,OXFORD OX3 9DU,ENGLAND	University of Oxford	Bangham, CRM (corresponding author), ST MARYS HOSP,IMPERIAL COLL SCH MED,DEPT IMMUNOL,NORFOLK PL,LONDON W2 1PG,ENGLAND.			Bangham, Charles/0000-0003-2624-3599	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AEBISCHER T, 1991, P NATL ACAD SCI USA, V88, P11047, DOI 10.1073/pnas.88.24.11047; ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; Amor S, 1996, J GEN VIROL, V77, P281, DOI 10.1099/0022-1317-77-2-281; Bachmann MF, 1997, SCIENCE, V276, P2024, DOI 10.1126/science.276.5321.2024; BARLOW DJ, 1986, NATURE, V322, P747, DOI 10.1038/322747a0; BOLIN SR, 1995, AM J VET RES, V56, P755; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Burns JW, 1996, SCIENCE, V272, P104, DOI 10.1126/science.272.5258.104; Coffin JM, 1996, FIELDS VIROLOGY, P1767; Cohen J, 1997, SCIENCE, V277, P32, DOI 10.1126/science.277.5322.32; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; HOLLAND JJ, 1992, CURR TOP MICROBIOL, V176, P1; Jager E, 1996, INT J CANCER, V66, P470, DOI 10.1002/(SICI)1097-0215(19960516)66:4<470::AID-IJC10>3.0.CO;2-C; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KLENERMAN P, 1995, EUR J IMMUNOL, V25, P1927, DOI 10.1002/eji.1830250720; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lehner T, 1996, NAT MED, V2, P767, DOI 10.1038/nm0796-767; Matteucci D, 1996, J VIROL, V70, P617, DOI 10.1128/JVI.70.1.617-622.1996; MCCUNE JM, 1995, CELL, V82, P183, DOI 10.1016/0092-8674(95)90305-4; MCMICHAEL AJ, 1995, OXFORD TXB MED, P141; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; PAUL WE, 1995, CELL, V82, P177, DOI 10.1016/0092-8674(95)90304-6; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PINCUS SH, 1995, J VIROL, V69, P7152, DOI 10.1128/JVI.69.11.7152-7158.1995; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; PUTKONEN P, 1995, NAT MED, V1, P914, DOI 10.1038/nm0995-914; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; RUPRECHT RM, 1990, P NATL ACAD SCI USA, V87, P5558, DOI 10.1073/pnas.87.14.5558; Schutten M, 1996, J GEN VIROL, V77, P1667, DOI 10.1099/0022-1317-77-8-1667; TRAVERS K, 1995, SCIENCE, V268, P1612, DOI 10.1126/science.7539936; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VITIELLO A, 1995, J CLIN INVEST, V95, P341, DOI 10.1172/JCI117662; WEIDT G, 1995, J VIROL, V69, P7147, DOI 10.1128/JVI.69.11.7147-7151.1995; WIGZELL H, 1991, FASEB J, V5, P2406, DOI 10.1096/fasebj.5.10.2065889; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; ZHANG JY, 1994, J VIROL, V68, P2409, DOI 10.1128/JVI.68.4.2409-2414.1994; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	45	13	24	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1617	1621		10.1016/S0140-6736(97)03258-3	http://dx.doi.org/10.1016/S0140-6736(97)03258-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393353				2022-12-28	WOS:A1997YH98600044
J	Waterhouse, J; Reilly, T; Atkinson, G				Waterhouse, J; Reilly, T; Atkinson, G			Jet-lag	LANCET			English	Article							HUMAN CIRCADIAN-RHYTHMS; PHASE RESPONSE CURVE; BODY-TEMPERATURE; BRIGHT LIGHT; TIME ZONES; TRANSMERIDIAN FLIGHT; CORE TEMPERATURE; MELATONIN; SLEEP; PERFORMANCE				Waterhouse, J (corresponding author), LIVERPOOL JOHN MOORES UNIV,SCH HUMAN SCI,SPORT & EXERCISE SCI RES INST,MOUNTFORD BLDG,BYROM ST,LIVERPOOL L3 3AF,MERSEYSIDE,ENGLAND.		Atkinson, Greg/ABA-2278-2021	Atkinson, Greg/0000-0002-5459-9042				Akerstedt T, 1995, J SLEEP RES, V4, P1, DOI 10.1111/j.1365-2869.1995.tb00219.x; Akerstedt T, 1997, CHRONOBIOL INT, V14, P145, DOI 10.3109/07420529709001152; Arendt J, 1997, CHRONOBIOL INT, V14, P185, DOI 10.3109/07420529709001155; ARENDT J, 1982, BRIT MED J, V284, P144, DOI 10.1136/bmj.284.6310.144; ARENDT J, 1988, ANN REV CHRONOPHARMA, V5, P53; Arendt J, 1992, BIOL RHYTHMS CLIN LA, P348; ASCHOFF J, 1965, CIRCADIAN CLOCKS; Atkinson G, 1997, CLIN PHARM SPORTS EX, P293; Boivin DB, 1996, NATURE, V379, P540, DOI 10.1038/379540a0; BREZINSKI A, 1997, NEW ENGL J MED, V336, P186, DOI DOI 10.1056/NEJM199701163360306; Cagnacci A, 1997, CHRONOBIOL INT, V14, P205, DOI 10.3109/07420529709001156; CAGNACCI A, 1992, J CLIN ENDOCR METAB, V75, P447, DOI 10.1210/jc.75.2.447; Campbell S.S., 1992, WHY WE NAP EVOLUTION, P71; CAMPBELL SS, 1994, CHRONOBIOL INT, V11, P126, DOI 10.3109/07420529409055899; COLQUHOUN WP, 1984, AVIAT SPACE ENVIR MD, V55, P493; CZEISLER CA, 1995, CIBA F SYMP, V183, P254; DAAN S, 1984, PSYCHOPHARMACOL BULL, V20, P566; DAWSON D, 1993, J PINEAL RES, V15, P1, DOI 10.1111/j.1600-079X.1993.tb00503.x; Dawson D, 1996, PHARMACOL THERAPEUT, V69, P15, DOI 10.1016/0163-7258(95)02020-9; DAWSON D, 1993, CHRONOBIOL INT, V10, P94, DOI 10.3109/07420529309059697; Dinges D.F., 1992, WHY WE NAP, P118, DOI [10.1007/978-1-4757-2210-9_9, DOI 10.1007/978-1-4757-2210-9_9]; Dinges DF, 1995, J SLEEP RES, V4, P4, DOI 10.1111/j.1365-2869.1995.tb00220.x; DOLLINS AB, 1994, P NATL ACAD SCI USA, V91, P1824, DOI 10.1073/pnas.91.5.1824; DOLLINS AB, 1993, PSYCHOPHARMACOLOGY, V112, P490, DOI 10.1007/BF02244899; DRENNAN M, 1989, AM J PHYSIOL, V257, pR136, DOI 10.1152/ajpregu.1989.257.1.R136; Ebling FJP, 1996, PROG NEUROBIOL, V50, P109, DOI 10.1016/S0301-0082(96)00032-9; FOLKARD S, 1990, PHILOS T ROY SOC B, V327, P543, DOI 10.1098/rstb.1990.0097; GANDER PH, 1993, AVIAT SPACE ENVIR MD, V64, P189; GANDER PH, 1989, AVIAT SPACE ENVIR MD, V60, P733; GRAEBER RC, 1986, AVIAT SPACE ENVIR MD, V57, pB10; GRAEBER RC, 1989, PRINCIPLES PRACTICE, P324; GUNDEL A, 1992, CHRONOBIOL INT, V9, P148, DOI 10.3109/07420529209064526; GUNDEL A, 1989, CHRONOBIOL INT, V6, P147, DOI 10.3109/07420528909064625; HASTINGS MH, 1995, CIBA F SYMP, V183, P175; HONMA K, 1987, EXPERIENTIA, V43, P1205, DOI 10.1007/BF01945525; Houpt TA, 1996, PHYSIOL BEHAV, V59, P561, DOI 10.1016/0031-9384(95)02111-6; JEHUE R, 1993, MED SCI SPORT EXER, V25, P127, DOI 10.1249/00005768-199301000-00017; Lack LC, 1996, J SLEEP RES, V5, P1, DOI 10.1046/j.1365-2869.1996.00005.x; LAVIE P, 1989, SLEEP, V12, P522; LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030; LEWY AJ, 1992, CHRONOBIOL INT, V9, P380, DOI 10.3109/07420529209064550; LEWY AJ, 1995, CIBA F SYMP, V183, P303; LINO A, 1993, BIOL PSYCHIAT, V34, P587, DOI 10.1016/0006-3223(93)90208-U; MILLS JN, 1978, J PHYSIOL-LONDON, V285, P455, DOI 10.1113/jphysiol.1978.sp012582; MINORS D, 1982, INT J CHRONOBIOL, V7, P165; MINORS DS, 1991, NEUROSCI LETT, V133, P36, DOI 10.1016/0304-3940(91)90051-T; MINORS DS, 1995, J BIOL RHYTHM, V9, P257; Mistlberger RE, 1996, J BIOL RHYTHM, V11, P208, DOI 10.1177/074873049601100303; MOLINE ML, 1992, SLEEP, V15, P28, DOI 10.1093/sleep/15.1.28; MONK TH, 1988, AVIAT SPACE ENVIR MD, V59, P703; MOORE RY, 1995, CIBA F SYMP, V183, P88; NAITOH P, 1993, CHRONOBIOL INT, V10, P109, DOI 10.1080/07420529309059699; Naitoh P, 1992, WHY WE NAP, P199; NAVE R, 1995, EUR J PHARMACOL, V275, P213, DOI 10.1016/0014-2999(94)00769-4; NEWHOUSE P, 1989, NEURPSYCHOPHARMACOLO, V92, P153; NICHOLSON AN, 1985, AVIAT SPACE ENVIR MD, V56, P105; NICHOLSON AN, 1984, AVIAT SPACE ENVIR MD, V55, P102; OCONNOR PJ, 1991, J APPL PHYSIOL, V70, P756, DOI 10.1152/jappl.1991.70.2.756; PETRIE K, 1989, BRIT MED J, V298, P705, DOI 10.1136/bmj.298.6675.705; PRESTON FS, 1973, AEROSPACE MED, V44, P438; REDFERN P H, 1989, Human Psychopharmacology, V4, P159, DOI 10.1002/hup.470040303; Redlin U, 1997, CHRONOBIOL INT, V14, P221, DOI 10.3109/07420529709001157; REEBS S, 1994, J BIOL RHYTHM, V4, P39; Reid K, 1996, J SLEEP RES, V5, P150, DOI 10.1046/j.1365-2869.1996.t01-1-00006.x; Reilly T, 1997, BIOL RHYTHMS EXERCIS; REILLY T, 1997, J SPORTS SCI, V15, P62; REINBERG A, 1988, ANN REV CHRONOPHARMA, V4, P171; REPPERT SM, 1988, SCIENCE, V242, P78, DOI 10.1126/science.2845576; ROBERTSON D, 1984, CAFFEINE, P77; ROGERS AS, 1989, ERGONOMICS, V32, P1193, DOI 10.1080/00140138908966890; Rosekind MR, 1995, J SLEEP RES, V4, P62, DOI 10.1111/j.1365-2869.1995.tb00229.x; SAMEL A, 1991, J BIOL RHYTHM, V6, P235, DOI 10.1177/074873049100600304; Samel A, 1995, J SLEEP RES, V4, P30, DOI 10.1111/j.1365-2869.1995.tb00223.x; SIMON P, 1994, PSYCHOPHARMACOLOGY, V114, P597, DOI 10.1007/BF02244990; SPITZER RL, 1997, BIOMETRICS RES; Steinlechner S, 1996, ACTA NEUROBIOL EXP, V56, P363; Stone BM, 1997, CHRONOBIOL INT, V14, P133, DOI 10.3109/07420529709001151; STONE BM, 1993, ERGONOMICS, V36, P1465, DOI 10.1080/00140139308968014; SUVANTO S, 1993, ERGONOMICS, V36, P613, DOI 10.1080/00140139308967924; TSAI TH, 1988, J INTERDISCIPL CYCLE, V19, P89; TUREK FW, 1987, LIFE SCI, V40, P1033, DOI 10.1016/0024-3205(87)90564-9; VANREETH O, 1989, NATURE, V339, P49, DOI 10.1038/339049a0; Walsh JK, 1995, J SLEEP RES, V4, P80, DOI 10.1111/j.1365-2869.1995.tb00233.x; Waterhouse J., 1989, BIOL RHYTHMS CLIN PR, P136; WEGMANN HM, 1985, HOURS WORK, P263; WRIGHT JE, 1983, AVIAT SPACE ENVIR MD, V54, P132; WURTMAN RJ, 1995, LANCET, V346, P1491, DOI 10.1016/S0140-6736(95)92509-0; ZHDANOVA IV, 1995, CLIN PHARMACOL THER, V57, P552, DOI 10.1016/0009-9236(95)90040-3	88	121	123	1	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1611	1616		10.1016/S0140-6736(97)07569-7	http://dx.doi.org/10.1016/S0140-6736(97)07569-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393352				2022-12-28	WOS:A1997YH98600043
J	Su, XZ; Kirkman, LA; Fujioka, H; Wellems, TE				Su, XZ; Kirkman, LA; Fujioka, H; Wellems, TE			Complex polymorphisms in an similar to 330 kDa protein are linked to chloroquine-resistant P-falciparum in Southeast Asia and Africa	CELL			English	Article							PARASITE PLASMODIUM-FALCIPARUM; INFECTED HUMAN-ERYTHROCYTES; DRUG-RESISTANCE; CROSS-RESISTANCE; PFMDR1 GENE; MALARIA; INVITRO; AMPLIFICATION; PYRIMETHAMINE; SENSITIVITY	Chloroquine resistance in a P. falciparum cross maps as a Mendelian trait to a 36 kb segment of chromosome 7. This segment harbors cg2, a gene encoding a unique similar to 330 kDa protein with complex polymorphisms. A specific set of polymorphisms in 20 chloroquine-resistant parasites from Asia and Africa, in contrast with numerous differences in 21 sensitive parasites, suggests selection of a cg2 allele originating in Indochina over 40 years ago. One chloroquine-sensitive clone exhibited this allele, suggesting another resistance component. South American parasites have cg2 polymorphisms consistent with a separate origin of resistance. CG2 protein is found at the parasite periphery, a site of chloroquine transport, and in association with hemozoin of the digestive vacuole, where chloroquine inhibits heme polymerization.	NIAID, NIH, BETHESDA, MD 20892 USA; CASE WESTERN RESERVE UNIV, INST PATHOL, CLEVELAND, OH 44106 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Case Western Reserve University				Su, Xinzhuan/0000-0003-3246-3248	NIAID NIH HHS [AI-35827] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035827] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKAWA M, 1990, ADV PARASIT, V29, P151, DOI 10.1016/S0065-308X(08)60106-2; Allen M J, 1994, PCR Methods Appl, V4, P71; BABIKER HA, 1994, PARASITOLOGY, V109, P413, DOI 10.1017/S0031182000080665; BARNES DA, 1992, EMBO J, V11, P3067, DOI 10.1002/j.1460-2075.1992.tb05378.x; BAYOUMI RAL, 1993, T ROY SOC TROP MED H, V87, P454, DOI 10.1016/0035-9203(93)90034-N; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; BRAY PG, 1994, MOL BIOCHEM PARASIT, V63, P87, DOI 10.1016/0166-6851(94)90011-6; BRAY PG, 1992, BIOCHEM PHARMACOL, V44, P1317, DOI 10.1016/0006-2952(92)90532-N; BRAY PG, 1992, BIOCHEM PHARMACOL, V43, P1219, DOI 10.1016/0006-2952(92)90495-5; COWMAN AF, 1994, P NATL ACAD SCI USA, V91, P1143, DOI 10.1073/pnas.91.3.1143; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; CREEDON KA, 1994, J BIOL CHEM, V269, P16364; De DY, 1996, AM J TROP MED HYG, V55, P579, DOI 10.4269/ajtmh.1996.55.579; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLAN SA, 1993, MOL BIOCHEM PARASIT, V61, P137, DOI 10.1016/0166-6851(93)90166-U; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FITCH CD, 1970, SCIENCE, V169, P289, DOI 10.1126/science.169.3942.289; FITCH CD, 1983, CIBA F SYMP, V94, P222; FITCH CD, 1969, P NATL ACAD SCI USA, V64, P1181, DOI 10.1073/pnas.64.4.1181; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FOOTE SJ, 1990, P NATL ACAD SCI USA, V87, P3014, DOI 10.1073/pnas.87.8.3014; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; FREESE JA, 1991, B WORLD HEALTH ORGAN, V69, P707; Galfre G, 1981, Methods Enzymol, V73, P3; GEARY TG, 1983, J PARASITOL, V69, P97, DOI 10.2307/3281283; GINSBURG H, 1991, BIOCHEM PHARMACOL, V41, P1463, DOI 10.1016/0006-2952(91)90562-J; Hawley SR, 1996, ANTIMICROB AGENTS CH, V40, P2345, DOI 10.1128/AAC.40.10.2345; Kirkman LA, 1996, EXP PARASITOL, V83, P147, DOI 10.1006/expr.1996.0058; Kotecka BM, 1997, ANTIMICROB AGENTS CH, V41, P1369, DOI 10.1128/AAC.41.6.1369; KROGSTAD DJ, 1992, BIOCHEM PHARMACOL, V43, P57, DOI 10.1016/0006-2952(92)90661-2; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; Liang H, 1997, MOL BIOCHEM PARASIT, V84, P241, DOI 10.1016/S0166-6851(96)02791-0; Loureiro LF, 1996, ANN TROP MED PARASIT, V90, P223, DOI 10.1080/00034983.1996.11813048; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; MARTINEY JA, 1995, J BIOL CHEM, V270, P22393, DOI 10.1074/jbc.270.38.22393; PAYNE D, 1987, PARASITOL TODAY, V3, P241, DOI 10.1016/0169-4758(87)90147-5; PETERS W, 1989, LANCET, V2, P334, DOI 10.1016/S0140-6736(89)90522-9; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/pnas.87.8.3018; PETERSON DS, 1995, P NATL ACAD SCI USA, V92, P7100, DOI 10.1073/pnas.92.15.7100; Ridley RG, 1996, ANTIMICROB AGENTS CH, V40, P1846, DOI 10.1128/AAC.40.8.1846; ROBSON KJH, 1990, P ROY SOC B-BIOL SCI, V242, P205, DOI 10.1098/rspb.1990.0126; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Sanchez CP, 1997, J BIOL CHEM, V272, P2652, DOI 10.1074/jbc.272.5.2652; SAUL A, 1988, MOL BIOCHEM PARASIT, V27, P35, DOI 10.1016/0166-6851(88)90022-9; SIXSMITH DG, 1984, AM J TROP MED HYG, V33, P772, DOI 10.4269/ajtmh.1984.33.772; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; Su XZ, 1996, NUCLEIC ACIDS RES, V24, P1574, DOI 10.1093/nar/24.8.1574; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Sullivan DJ, 1996, P NATL ACAD SCI USA, V93, P11865, DOI 10.1073/pnas.93.21.11865; TRIGLIA T, 1991, MOL CELL BIOL, V11, P5244, DOI 10.1128/MCB.11.10.5244; VERDIER F, 1985, ANTIMICROB AGENTS CH, V27, P561, DOI 10.1128/AAC.27.4.561; vonSeidlein L, 1997, T ROY SOC TROP MED H, V91, P450, DOI 10.1016/S0035-9203(97)90281-9; WALKERJONAH A, 1992, MOL BIOCHEM PARASIT, V51, P313, DOI 10.1016/0166-6851(92)90081-T; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x; YAYON A, 1985, P NATL ACAD SCI USA, V82, P2784, DOI 10.1073/pnas.82.9.2784	64	297	311	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 28	1997	91	5					593	603		10.1016/S0092-8674(00)80447-X	http://dx.doi.org/10.1016/S0092-8674(00)80447-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393853	Bronze			2022-12-28	WOS:A1997YH96000007
J	Womack, C; Roger, S; Lavin, M				Womack, C; Roger, S; Lavin, M			Personal paper - Disclosure of clinical audit records in law: risks and possible defences	BRITISH MEDICAL JOURNAL			English	Article									PETERBOROUGH HOSP NHS TRUST,DEPT RISK & LITIGAT,PETERBOROUGH PE3 6DA,ENGLAND		Womack, C (corresponding author), PETERBOROUGH HOSP NHS TRUST,DEPT CLIN AUDIT,CLIN AUDIT COMM,PETERBOROUGH PE3 6DA,ENGLAND.							ALLISON G, 1995, HLTH CARE RISK R SEP, P13; *BRIT MED ASS CLIN, 1995, ETH ISS AUD; *NCEPOD, 1989, REP NAT CONF ENQ PER, P11; *NHS EX, 1996, PROM CLIN EFF; *NHS EX, 1993, CLIN AUD M IMPR STAN; PANTING GP, 1992, DISCLOSURE MED RECOR	6	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 22	1997	315	7119					1369	1370		10.1136/bmj.315.7119.1369	http://dx.doi.org/10.1136/bmj.315.7119.1369			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402783	Green Published			2022-12-28	WOS:A1997YJ21800032
J	Cadogan, J; Eastell, R; Jones, N; Barker, ME				Cadogan, J; Eastell, R; Jones, N; Barker, ME			Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GROWTH FACTOR-I; CALCIUM SUPPLEMENTATION; POSTMENOPAUSAL WOMEN; DENSITY; MASS; CHILDREN; PUBERTY; OSTEOPOROSIS; CONSUMPTION; FEMALES	Objectives: To investigate the effect of milli supplementation on total body bone mineral acquisition in adolescent girls. Design: 18 month, open randomised intervention trial. Subjects: 82 white girls aged 12.2 (SD 0.3) years, recruited from four secondary schools in Sheffield. Intervention: 568 ml (one pint) of whole or reduced fat milk per day for 18 months. Main outcome measures: Total body bone mineral content and bone mineral density measured by dual energy X ray absorptiometry. Outcome measures to evaluate mechanism included biochemical markers of bone turnover (osteocalcin, bone alkaline phosphatase, deoxypyridinoline, N-telopeptide of type I collagen), and hormones important to skeletal growth (parathyroid hormone, oestradiol, insulin-like growth factor I). Results: 80 subjects completed the trial. Daily milk intake at baseline averaged 150 ml in both groups. The intervention group consumed, on average, an additional 300 ml a day throughout the trial. Compared with the control group, the intervention group had greater increases of bone mineral density (9.6% v 8.5%, P = 0.017; repeated measures analysis of valiance) and bone mineral content (27.0% v 24.1%, P = 0.009). No significant differences in increments in height, weight, lean body mass, and fat mass were observed between the groups. Bone turnover was not affected by milk supplementation. Serum concentrations of insulin-like growth factor I increased in the milk group compared with the control group (35% v 25%, P = 0.02). Conclusion: Increased milk consumption significantly enhances bone mineral acquisition in adolescent girls and could favourably modify attainment of peak bone mass.	UNIV SHEFFIELD, NO GEN HOSP, CTR HUMAN NUTR, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND; UNIV SHEFFIELD, NO GEN HOSP, DEPT HUMAN METAB & CLIN BIOCHEM, SHEFFIELD S5 7AU, S YORKSHIRE, ENGLAND; UNIV SHEFFIELD, SCH MED, DEPT PUBL HLTH MED, SHEFFIELD S10 2RX, S YORKSHIRE, ENGLAND	Northern General Hospital; University of Sheffield; Northern General Hospital; University of Sheffield; University of Sheffield			Eastell, Richard/G-5851-2011	Eastell, Richard/0000-0002-0323-3366; Barker, Margo/0000-0002-1016-5787				ADAMSON A, 1992, BRIT J NUTR, V68, P543, DOI 10.1079/BJN19920114; BAKER IA, 1980, J EPIDEMIOL COMMUN H, V34, P31, DOI 10.1136/jech.34.1.31; BARAN D, 1990, J CLIN ENDOCR METAB, V70, P264, DOI 10.1210/jcem-70-1-264; Barger-Lux MJ, 1992, CLIN APPL NUTR, V2, P39; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; Bonjour JP, 1997, J CLIN INVEST, V99, P1287, DOI 10.1172/JCI119287; CHAN GM, 1995, J PEDIATR-US, V126, P551, DOI 10.1016/S0022-3476(95)70348-9; Department of Health, 1991, DIET REF VAL FOOD EN; Department of Health, 1989, DIETS BRIT SCHOOLCH; DUKE PM, 1980, PEDIATRICS, V66, P918; FEHILY AM, 1992, AM J CLIN NUTR, V56, P579, DOI 10.1093/ajcn/56.3.579; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; HEANEY RP, 1994, J BONE MINER RES, V9, P1515; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; JUUL A, 1994, J CLIN ENDOCR METAB, V78, P744, DOI 10.1210/jc.78.3.744; KANIS JA, 1992, BONE, V13, pS7, DOI 10.1016/S8756-3282(09)80004-5; KATZMAN DK, 1991, J CLIN ENDOCR METAB, V73, P1332, DOI 10.1210/jcem-73-6-1332; LANGFORD KS, 1993, EUR J CLIN INVEST, V23, P503, DOI 10.1111/j.1365-2362.1993.tb00958.x; LEE WTK, 1995, BRIT J NUTR, V74, P125, DOI 10.1079/BJN19950112; LLOYD T, 1993, JAMA-J AM MED ASSOC, V270, P841, DOI 10.1001/jama.270.7.841; Lloyd T, 1996, J BONE MINER RES, V11, pS154; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; MATKOVIC V, 1990, AM J CLIN NUTR, V52, P878, DOI 10.1093/ajcn/52.5.878; MATKOVIC V, 1979, AM J CLIN NUTR, V32, P540, DOI 10.1093/ajcn/32.3.540; MATKOVIC V, 1994, J CLIN INVEST, V93, P799, DOI 10.1172/JCI117034; Matkovic V, 1995, PHYS MED REHAB CLIN, V6, P595; Ministry of Agriculture Fisheries and Food, 1991, 50 YEARS NAT FOOD SU; MURPHY S, 1994, BRIT MED J, V308, P939, DOI 10.1136/bmj.308.6934.939; OTT SM, 1991, NEW ENGL J MED, V325, P1646, DOI 10.1056/NEJM199112053252310; PRICE JS, 1994, EUR J CLIN NUTR, V48, pS131; PRINCE R, 1995, J BONE MINER RES, V10, P1068, DOI 10.1002/jbmr.5650100711; REID IR, 1995, AM J MED, V98, P331, DOI 10.1016/S0002-9343(99)80310-6; RIDDOCH C, 1991, ARCH DIS CHILD, V66, P1426, DOI 10.1136/adc.66.12.1426; RODAN G, 1995, OSTEOPOROSIS ETIOLOG; ROSS R J M, 1990, Nutrition Research Reviews, V3, P143, DOI 10.1079/NRR19900010; SANDLER RB, 1985, AM J CLIN NUTR, V42, P270, DOI 10.1093/ajcn/42.2.270; SLEMENDA CW, 1993, J BONE MINER RES, V8, pS154; TANNER JM, 1976, J PEDIATR-US, V89, P1000, DOI 10.1016/S0022-3476(76)80620-8; TEEGARDEN D, 1995, J BONE MINER RES, V10, P711, DOI 10.1002/jbmr.5650100507	40	430	453	1	38	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 15	1997	315	7118					1255	1260		10.1136/bmj.315.7118.1255	http://dx.doi.org/10.1136/bmj.315.7118.1255			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390050	Green Published			2022-12-28	WOS:A1997YG64500016
J	Scott, G; Goldberg, D; Weir, M; Cameron, S; Peutherer, J; Carrington, D; Follett, E; Leadbetter, G; Scoular, A				Scott, G; Goldberg, D; Weir, M; Cameron, S; Peutherer, J; Carrington, D; Follett, E; Leadbetter, G; Scoular, A			Prevalence of HIV-1 infection among heterosexual men and women attending genitourinary clinics in Scotland: unlinked anonymous testing	BRITISH MEDICAL JOURNAL			English	Article									RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,GLASGOW G20 9NB,LANARK,SCOTLAND; ROYAL FREE HOSP,DEPT GENITOURINARY MED,LONDON NW3 2QG,ENGLAND; RUCHILL HOSP,REG VIRUS LAB,GLASGOW G20 9NB,LANARK,SCOTLAND; UNIV EDINBURGH,DEPT MICROBIOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT VIROL,LONDON SW17 0RE,ENGLAND; ROYAL INFIRM,DEPT GENITOURINARY MED,GLASGOW G4 0SF,LANARK,SCOTLAND; ROYAL INFIRM,DEPT GENITOURINARY MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Edinburgh; St Georges University London; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh								ARTENSTEIN AW, 1995, LANCET, V346, P1197, DOI 10.1016/S0140-6736(95)92900-2; Goldberg D, 1996, SCOT MED J, V41, P131, DOI 10.1177/003693309604100501; MacDonagh SE, 1996, BRIT MED J, V313, P532; *U COLL MIDDL SCH, 1993, DIS REP CDR REV, V3, pR1; *UK HLTH DEP, 1995, HIV AIDS HLTH PROM E	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1281	1282		10.1136/bmj.315.7118.1281	http://dx.doi.org/10.1136/bmj.315.7118.1281			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390056	Green Published			2022-12-28	WOS:A1997YG64500023
J	Egger, M; Hirschel, B; Francioli, P; Sudre, P; Wirz, M; Flepp, M; Rickenbach, M; Malinverni, R; Vernazza, P; Battegay, M; Bernasconi, E; Burgisser, P; Erb, P; Fierz, W; Grob, P; Gruninger, U; Jeannerod, L; Ledergerber, B; Luthy, R; Matter, L; Opravil, M; Paccaud, F; Perrin, L; Pichler, W; Piffaretti, GC; Rutschmann, O; Zanetti, G				Egger, M; Hirschel, B; Francioli, P; Sudre, P; Wirz, M; Flepp, M; Rickenbach, M; Malinverni, R; Vernazza, P; Battegay, M; Bernasconi, E; Burgisser, P; Erb, P; Fierz, W; Grob, P; Gruninger, U; Jeannerod, L; Ledergerber, B; Luthy, R; Matter, L; Opravil, M; Paccaud, F; Perrin, L; Pichler, W; Piffaretti, GC; Rutschmann, O; Zanetti, G			Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CUBIC MILLIMETER; AIDS; ZIDOVUDINE; SURVIVAL; BIAS	Objectives: To examine trends in disease progression and survival among patients enrolled in the Swiss HIV cohort study during 1988-96 and to assess the influence of new antiretroviral combination therapies. Design: Prospective multicentre study, with follow up visits planned at six monthly intervals. Setting Seven HIV units at university centres and cantonal hospitals in Switzerland. Patients: 3785 men (mean age 35.0 years) and 1391 women (30.3 years) infected with HIV 2023 participants had a history of intravenous drug misuse; 1764 were men who had sex with men; 1261 were infected heterosexually; and 164 had other or unknown modes of transmission. 601 participants had had an AIDS defining illness. Results: During more than 15 000 years of follow up, there were 1456 first AIDS defining diagnoses and 1903 deaths. Compared with those enrolled during 1988-90, the risk of progression to a first AIDS diagnosis was reduced by 18% (relative risk 0.82 (95% confidence interval 0.73 to 0.93)) among participants enrolled in 1991-2, by 23% (0.77 (0.65 to 0.91)) among those enrolled in 1993-4, and by 73% (0.27 (0.18 to 0.39)) among those enrolled in 1995-6. Mortality was reduced by 19% (0.81 (0.73 to 0.90)), 26% (0.74 (0.63 to 0.87)), and 62% (0.38 (0.25 to 0.97)) respectively. Compared wth no antiretroviral treatment, the risk of an initial AIDS diagnosis after CD4 lymphocyte counts fell to < 200 cells x 10(6)/l was reduced by 16% (0.84 (0.73 to 0.97)) with dual therapy, and 42% (0.58 (0.37 to 0.92)) with triple therapy. Mortality was reduced by 23% (0.77 (0.68 to 0.88)), 31% (0.69 (0.60 to 0.80)), and 65% (0.35 (0.20 to 0.60)) respectively. Conclusions: The introduction of antiretroviral combination therapies outside the selected patient groups included in clinical trials has led to comparable reductions in disease progression and mortality.	UNIV BERN, OUTPATIENT DEPT INTERNAL MED, BERN, SWITZERLAND; UNIV GENEVA, DIV INFECT DIS, GENEVA, SWITZERLAND; UNIV LAUSANNE, DIV HOSP PREVENT MED & INFECT DIS, LAUSANNE, SWITZERLAND; UNIV LAUSANNE, DEPT SOCIAL & PREVENT MED, LAUSANNE, SWITZERLAND; UNIV ZURICH, DIV INFECT DIS, ZURICH, SWITZERLAND; CANTONAL HOSP ST GALL, DIV INTERNAL MED, ST GALLEN, SWITZERLAND; UNIV BASEL, OUTPATIENT DEPT INTERNAL MED, BASEL, SWITZERLAND; UNIV BERN, DEPT SOCIAL & PREVENT MED, BERN, SWITZERLAND	University of Bern; University of Geneva; University of Lausanne; University of Lausanne; University of Zurich; Kantonsspital St. Gallen; University of Basel; University of Bern			Ledergerber, Bruno/B-5656-2009; paccaud, fred/M-7516-2019	Ledergerber, Bruno/0000-0002-6881-4401; Egger, Matthias/0000-0001-7462-5132				[Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 1996, Lancet, V348, P283; BABIKER A, 1997, 6 EUR C CLIN ASP TRE; BrunVezinet F, 1997, LANCET, V350, P983, DOI 10.1016/S0140-6736(97)03380-1; CAMERON DW, 1996, 11 INT C AIDS VANC 7; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; COX DR, 1972, J R STAT SOC B, V34, P187; Dorrucci M, 1997, AIDS, V11, P461, DOI 10.1097/00002030-199704000-00009; Feinberg M, 1997, LANCET, V349, P1408, DOI 10.1016/S0140-6736(97)22020-9; FEINSTEIN A, 1984, STAT MED, V3, P341, DOI 10.1002/sim.4780030409; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Gazzard BG, 1997, LANCET, V349, P1086, DOI 10.1016/S0140-6736(96)12073-0; Glesby MJ, 1996, ANN INTERN MED, V124, P999, DOI 10.7326/0003-4819-124-11-199606010-00008; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; LEDERGERBER B, 1994, SOZ PRAVENTIV MED, V39, P387, DOI 10.1007/BF01299670; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; PERNEGER TV, 1995, BMJ-BRIT MED J, V311, P1468, DOI 10.1136/bmj.311.7018.1468; Saravolatz LD, 1996, NEW ENGL J MED, V335, P1099, DOI 10.1056/NEJM199610103351503; SELIGMANN M, 1994, LANCET, V343, P871; Staszewski S, 1997, AIDS, V11, P477, DOI 10.1097/00002030-199704000-00011; TIBSHIRANI R, 1982, CLIN INVEST MED, V5, P63; VONOVERBECK J, 1994, AIDS, V8, P1307, DOI 10.1097/00002030-199409000-00014; WHITMOREOVERTON SE, 1993, AIDS, V7, P415, DOI 10.1097/00002030-199303000-00017; 1997, MMWR-MORBID MORTAL W, V16, P165; 1997, B BUNDESAMT GES 0127, P10	30	524	532	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	1997	315	7117					1194	1199		10.1136/bmj.315.7117.1194	http://dx.doi.org/10.1136/bmj.315.7117.1194			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393221	Green Published			2022-12-28	WOS:A1997YF25200018
J	Adrogue, HJ; Madias, NE				Adrogue, HJ; Madias, NE			Management of life-threatening acid-base disorders - First of two parts	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CO2 TITRATION CURVE; LACTIC-ACIDOSIS; PERMISSIVE HYPERCAPNIA; DIABETIC-KETOACIDOSIS; SODIUM-BICARBONATE; CIRCULATORY FAILURE; METABOLIC-ACIDOSIS; COLLECTING DUCT; CARDIAC-MUSCLE; ANION GAP		Tufts Univ New England Med Ctr, Div Nephrol, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Tupper Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Vet Affairs Med Ctr, Renal Sect, Houston, TX 77030 USA	Tufts Medical Center; Tufts Medical Center; Tufts University; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Madias, NE (corresponding author), Tufts Univ New England Med Ctr, Div Nephrol, Box 172,750 Washington St, Boston, MA 02111 USA.							*ABB LAB, 1995, THAM TROM; ADROGUE HJ, 1985, J APPL PHYSIOL, V58, P1231, DOI 10.1152/jappl.1985.58.4.1231; ADROGUE HJ, 1989, AM J PHYSIOL, V257, pF1087, DOI 10.1152/ajprenal.1989.257.6.F1087; ADROGUE HJ, 1978, AM J PHYSIOL, V235, pF291, DOI 10.1152/ajprenal.1978.235.4.F291; ADROGUE HJ, 1988, AM J PHYSIOL, V255, pE812, DOI 10.1152/ajpendo.1988.255.6.E812; ADROGUE HJ, 1984, KIDNEY INT, V25, P591, DOI 10.1038/ki.1984.62; ADROGUE HJ, 1989, NEW ENGL J MED, V320, P1312, DOI 10.1056/NEJM198905183202004; ADROGUE HJ, 1986, MEDICINE, V65, P163, DOI 10.1097/00005792-198605000-00004; ADROGUE HJ, 1981, AM J MED, V71, P456, DOI 10.1016/0002-9343(81)90182-0; ADROGUE HJ, 1983, J CLIN INVEST, V71, P867, DOI 10.1172/JCI110841; ADROGUE HJ, 1982, NEW ENGL J MED, V307, P1603, DOI 10.1056/NEJM198212233072603; Adrogue HJ, 1996, FLUIDS ELECTROLYTES, P643; ADROGUE HJ, 1997, RESP FAILURE, P125; ALDROGUE HJ, 1995, PRINCIPLES PRACTICE, P953; AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; AMATO MBP, 1994, AM J RESP CRIT CARE, V149, pA75; BATLLE DC, 1985, J CLIN INVEST, V75, P1517, DOI 10.1172/JCI111856; BAUD FJ, 1988, NEW ENGL J MED, V319, P97, DOI 10.1056/NEJM198807143190206; BERSIN RM, 1988, CIRCULATION, V77, P227, DOI 10.1161/01.CIR.77.1.227; BRASCH H, 1982, EUR J CLIN PHARMACOL, V22, P257, DOI 10.1007/BF00545225; Cardenas VJ, 1996, CRIT CARE MED, V24, P827, DOI 10.1097/00003246-199605000-00017; CARLISLE EJF, 1991, J AM SOC NEPHROL, V1, P1019; CHATTON JY, 1990, AM J PHYSIOL, V259, pF613, DOI 10.1152/ajprenal.1990.259.4.F613; COHEN RD, 1994, DIABETES REV, V2, P86; COOPER DJ, 1990, ANN INTERN MED, V112, P492, DOI 10.7326/0003-4819-112-7-492; DASILVA JCT, 1991, AM J PHYSIOL, V260, pF204, DOI 10.1152/ajprenal.1991.260.2.F204; DRIES DJ, 1995, J TRAUMA, V39, P984, DOI 10.1097/00005373-199511000-00028; ENGLAND BK, 1991, AM J PHYSIOL, V260, pC277, DOI 10.1152/ajpcell.1991.260.2.C277; FABER MD, 1994, SEMIN NEPHROL, V14, P8; FEIHL F, 1994, AM J RESP CRIT CARE, V150, P1722, DOI 10.1164/ajrccm.150.6.7952641; FINCH CA, 1979, J CLIN INVEST, V64, P129, DOI 10.1172/JCI109431; GARELLA S, 1988, KIDNEY INT, V33, P735, DOI 10.1038/ki.1988.60; GENTILELLO LM, 1995, J TRAUMA, V39, P846, DOI 10.1097/00005373-199511000-00007; HILL JB, 1973, NEW ENGL J MED, V288, P1110, DOI 10.1056/NEJM197305242882107; HINDMAN BJ, 1990, ANESTHESIOLOGY, V72, P1064, DOI 10.1097/00000542-199006000-00018; Hood V., 1994, DIABETES REV ALEX, V2, P177; HOOD VL, 1991, CONT MANAGEMENT CRIT, V1, P1; Jaber BL, 1997, AM J KIDNEY DIS, V30, P561, DOI 10.1016/S0272-6386(97)90317-6; KERBER RE, 1983, AM J PHYSIOL, V244, pH825, DOI 10.1152/ajpheart.1983.244.6.H825; KETTE F, 1990, CIRCULATION, V81, P1660, DOI 10.1161/01.CIR.81.5.1660; KRAUT JA, 1995, TXB NEPHROLOGY, V1, P449; KUCERA RR, 1989, CRIT CARE MED, V17, P1320, DOI 10.1097/00003246-198912000-00015; LANDRY DW, 1992, J CLIN INVEST, V89, P2071, DOI 10.1172/JCI115820; LEBOVITZ HE, 1995, LANCET, V345, P767, DOI 10.1016/S0140-6736(95)90645-2; LEUNG, 1995, CRIT CARE MED, V23, P420; LEUNG JM, 1994, CRIT CARE MED, V22, P1540, DOI 10.1097/00003246-199410000-00007; MADIAS NE, 1983, J APPL PHYSIOL, V55, P1187, DOI 10.1152/jappl.1983.55.4.1187; MADIAS NE, 1985, KIDNEY INT, V27, P538, DOI 10.1038/ki.1985.44; MADIAS NE, 1984, J APPL PHYSIOL, V56, P1640, DOI 10.1152/jappl.1984.56.6.1640; MADIAS NE, 1987, AM J KIDNEY DIS, V10, P250, DOI 10.1016/S0272-6386(87)80182-8; MADIAS NE, 1986, KIDNEY INT, V29, P752, DOI 10.1038/ki.1986.62; MADIAS NE, 1995, FLUID ELECTROLYTE AC, P223; MADIAS NE, 1982, ACID BASE, P307; MADIAS NE, 1993, DIS KIDNEY, V3, P2669; MITCH WE, 1994, J CLIN INVEST, V93, P2127, DOI 10.1172/JCI117208; NARINS RG, 1987, ANN INTERN MED, V106, P615, DOI 10.7326/0003-4819-106-4-615; Newell KA, 1996, TRANSPLANTATION, V62, P1353, DOI 10.1097/00007890-199611150-00030; OKUDA Y, 1993, J CLIN ENDOCR METAB, V81, P314; ORCHARD CH, 1994, CARDIOVASC RES, V28, P1312, DOI 10.1093/cvr/28.9.1312; ORCHARD CH, 1990, AM J PHYSIOL, V258, pC967, DOI 10.1152/ajpcell.1990.258.6.C967; REAICH D, 1992, AM J PHYSIOL, V263, pE735, DOI 10.1152/ajpendo.1992.263.4.E735; SHAPIRO JI, 1990, AM J PHYSIOL, V258, pH1835, DOI 10.1152/ajpheart.1990.258.6.H1835; STACPOOLE PW, 1992, NEW ENGL J MED, V327, P1564, DOI 10.1056/NEJM199211263272204; STACPOOLE PW, 1986, ANN INTERN MED, V105, P276, DOI 10.7326/0003-4819-105-2-276; SUN JH, 1987, SURGERY, V102, P835; WANG F, 1986, NEW ENGL J MED, V315, P1591, DOI 10.1056/NEJM198612183152506; WEISFELDT ML, 1991, JAMA-J AM MED ASSOC, V266, P2129, DOI 10.1001/jama.266.15.2129; WRENN KD, 1991, AM J MED, V91, P119, DOI 10.1016/0002-9343(91)90003-G; YATANI A, 1981, J MOL CELL CARDIOL, V13, P147, DOI 10.1016/0022-2828(81)90212-1	69	186	195	2	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 1	1998	338	1					26	34		10.1056/NEJM199801013380106	http://dx.doi.org/10.1056/NEJM199801013380106			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN801	9414329				2022-12-28	WOS:000071209200006
J	Aguilar, OM; Albertal, M				Aguilar, OM; Albertal, M			Poor skin turgor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Kansas, Med Ctr, Kansas City, KS 66103 USA	University of Kansas; University of Kansas Medical Center	Aguilar, OM (corresponding author), Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.								0	2	2	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	1998	338	1					25	25		10.1056/NEJM199801013380105	http://dx.doi.org/10.1056/NEJM199801013380105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN801	9414328				2022-12-28	WOS:000071209200005
J	Barry, MJ				Barry, MJ			A 73-year-old man with symptomatic benign prostatic hyperplasia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							URINARY-TRACT SYMPTOMS; BLADDER OUTLET OBSTRUCTION; TRANSURETHRAL RESECTION; MODERATE SYMPTOMS; EVALUATING MEN; LASER-ABLATION; PRESSURE-FLOW; FINASTERIDE; MORTALITY; ANTIGEN		Massachusetts Gen Hosp, Gen Med Unit, Boston, MA 02215 USA; Massachusetts Gen Hosp, Hlth Serv Res Program, Boston, MA 02215 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Barry, MJ (corresponding author), Care of Hartman EE, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, E Campus,330 Brookline Ave,LY318, Boston, MA 02215 USA.				AHRQ HHS [HS 08397] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAMS P, 1994, UROLOGY, V44, P153, DOI 10.1016/S0090-4295(94)80119-3; ABRAMS P, 1995, BRIT J UROL, V76, P11; Andersen JT, 1997, UROLOGY, V49, P839, DOI 10.1016/S0090-4295(97)00185-4; ANSON K, 1995, UROLOGY, V46, P305, DOI 10.1016/S0090-4295(99)80211-8; Barry M, 1997, ANNU REV MED, V48, P177, DOI 10.1146/annurev.med.48.1.177; Barry M.J., 1997, DIS MANAG CLIN OUTCO, V1, P5, DOI DOI 10.1016/S1088-3371(96)00004-6; BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; Barry MJ, 1997, J UROLOGY, V158, P488, DOI 10.1016/S0022-5347(01)64510-5; Barry MJ, 1997, J UROLOGY, V157, P10, DOI 10.1016/S0022-5347(01)65267-4; Blute ML, 1997, UROLOGY, V50, P163, DOI 10.1016/S0090-4295(97)00276-8; Boyle P, 1996, UROLOGY, V48, P398, DOI 10.1016/S0090-4295(96)00353-6; Boyle Peter, 1997, Journal of Urology, V157, P134; Catalona WJ, 1997, JAMA-J AM MED ASSOC, V277, P1452, DOI 10.1001/jama.277.18.1452; CATALONA WJ, 1994, J UROLOGY, V151, P1283, DOI 10.1016/S0022-5347(17)35233-3; Coley CM, 1997, ANN INTERN MED, V126, P468, DOI 10.7326/0003-4819-126-6-199703150-00010; Coley CM, 1997, ANN INTERN MED, V126, P394, DOI 10.7326/0003-4819-126-5-199703010-00010; CONCATO J, 1992, JAMA-J AM MED ASSOC, V287, P1077; COWLES RS, 1995, UROLOGY, V46, P155, DOI 10.1016/S0090-4295(99)80185-X; delaRosette JJMCH, 1997, J UROLOGY, V157, P430, DOI 10.1016/S0022-5347(01)65164-4; DOLL HA, 1992, J UROLOGY, V147, P1566, DOI 10.1016/S0022-5347(17)37628-0; EPSTEIN JI, 1992, J CELL BIOCHEM, P78; GARRAWAY WM, 1991, LANCET, V338, P469, DOI 10.1016/0140-6736(91)90543-X; Gerber GS, 1996, UROLOGY, V47, P840, DOI 10.1016/S0090-4295(96)00040-4; GERBER GS, 1995, UROLOGY, V45, P193, DOI 10.1016/0090-4295(95)80004-2; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; Guess HA, 1996, J UROLOGY, V155, P3, DOI 10.1016/S0022-5347(01)66524-8; JARDIN A, 1991, LANCET, V337, P1457, DOI 10.1016/0140-6736(91)93140-5; JONLER M, 1994, CURR OPIN UROL, V4, P29; Kabalin JN, 1997, UROLOGY, V49, P160, DOI 10.1016/S0090-4295(96)00566-3; Kaplan SA, 1997, UROLOGY, V49, P157, DOI 10.1016/S0090-4295(96)00565-1; KIRBY R, 1994, SHARED CARE PROSTATI; Lepor H, 1996, NEW ENGL J MED, V335, P533, DOI 10.1056/NEJM199608223350801; LEPOR H, 1990, J UROLOGY, V143, P533, DOI 10.1016/S0022-5347(17)40012-7; Lowe FC, 1996, UROLOGY, V48, P12, DOI 10.1016/S0090-4295(96)00077-5; LUYAO GL, 1994, UROLOGY, V44, P692, DOI 10.1016/S0090-4295(94)80208-4; MALENKA DJ, 1990, J UROLOGY, V144, P224, DOI 10.1016/S0022-5347(17)39416-8; MCCONNELL JD, 1994, UROLOGY, V44, P156, DOI 10.1016/S0090-4295(94)80120-7; MCCONNELL JD, 1994, AHCPR PUBLICATION; McConnell John D., 1997, Journal of Urology, V157, P313; McConnell John D., 1997, Journal of Urology, V157, P367; MONDA JM, 1994, J UROLOGY, V151, P1291, DOI 10.1016/S0022-5347(17)35234-5; Naslund MJ, 1997, UROLOGY, V50, P167, DOI 10.1016/S0090-4295(97)00277-X; OGDEN CW, 1993, LANCET, V341, P14, DOI 10.1016/0140-6736(93)92482-9; Ornstein DK, 1997, J UROLOGY, V157, P880, DOI 10.1016/S0022-5347(01)65072-9; Partin AW, 1996, UROLOGY, V48, P55, DOI 10.1016/S0090-4295(96)00611-5; PETERS CA, 1987, NEW ENGL J MED, V317, P599, DOI 10.1056/NEJM198709033171004; Roehrborn CG, 1997, UROLOGY, V49, P548, DOI 10.1016/S0090-4295(97)00031-9; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; Rosier PFWM, 1996, J UROLOGY, V155, P1649, DOI 10.1016/S0022-5347(01)66153-6; WAGNER EH, 1995, MED CARE, V33, P765, DOI 10.1097/00005650-199508000-00002; WASSON JH, 1995, NEW ENGL J MED, V332, P75, DOI 10.1056/NEJM199501123320202; YALLA SV, 1995, J UROLOGY, V153, P674, DOI 10.1016/S0022-5347(01)67682-1	52	9	9	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2178	2184						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9417013				2022-12-28	WOS:000071022200035
J	Hay, JA; Maldonado, L; Weingarten, SR; Ellrodt, AG				Hay, JA; Maldonado, L; Weingarten, SR; Ellrodt, AG			Prospective evaluation of a clinical guideline recommending hospital length of stay in upper gastrointestinal tract hemorrhage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED TRIAL; EARLY ENDOSCOPY; SCORING SYSTEM; PEPTIC-ULCERS; MORTALITY; SIGNS; POPULATION	Context.-Upper gastrointestinal tract hemorrhage (UGIH) is a common and potentially life-threatening disorder. Resource utilization can vary without adverse effect on patient outcome. Clinical practice guidelines are a potential solution to reduce variation in practice while improving patient outcomes. Objective.-To validate prospectively the safety, acceptability, and impact of a clinical practice guideline defining the medically appropriate length of stay (LOS) for patients hospitalized with UGIH. Design.-Prospective, controlled time-series study with an alternate-month design. Outcome surveyors and patients were blinded to study group allocation. Guideline.-A retrospectively validated scoring system using 4 independent variables: hemodynamics, time from bleeding, comorbidity, and esophagogastroduodenoscopy (EGD) findings to predict risk of adverse events. The quantitative risk for the low-risk subset was 0.6% (95% confidence interval [CI], 0.0%-2.0%) for subsequent complications and 0% (95% CI, 0.0%-0.9%) for life-threatening complications from this retrospective evaluation. Setting.-A 1000-bed, not-for-profit, university-affiliate teaching hospital. Patients.-Consecutive adult patients hospitalized for acute UGIH. Intervention.-Concurrent feedback of guideline recommendation (same-day hospital discharge) to physicians caring for patients at low risk for complication. No risk information was provided during control months. Results.-Seventy percent (209/299) of UGIH patients achieved low-risk status according to the guideline and were therefore potentially suitable for early discharge from the hospital. Providing real-time quantitative risk information (intervention group only) was associated with an increase in guideline compliance from 30% to 70% (P<.001) and a decrease in mean (SD) LOS from 4.6 (3.5) days to 2.9 (1.3) days (mean reduction of 1.7 days per patient; P<.001). No differences in complications, patient health status, or patient satisfaction were found when measured 1 month after discharge. An independent variable predicting decreased hospital LOS for low-risk UGIH patients was early EGD. Conclusions.-Implementation of the clinical practice guideline safely reduced hospital LOS for selected low-risk patients with acute UGIH. Further prospective validation in other settings is warranted.	Healthcare Partners Med Grp, Pasadena, CA 91105 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Hlth Serv Res, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Hay, JA (corresponding author), Healthcare Partners Med Grp, 55 E Calif Blvd, Pasadena, CA 91105 USA.							BORDLEY DR, 1985, JAMA-J AM MED ASSOC, V253, P3282, DOI 10.1001/jama.253.22.3282; BORNMAN PC, 1985, BRIT MED J, V291, P245, DOI 10.1136/bmj.291.6490.245; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CARSTENSEN HE, 1980, SCAND J GASTROENTERO, V15, P103, DOI 10.3109/00365528009181439; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; Cooper GS, 1996, GASTROENTEROLOGY, V111, P385, DOI 10.1053/gast.1996.v111.pm8690203; Dixon W.J, 1990, BMDP STAT SOFTWARE; EVERETT S, 1996, GUT               S1, V39, pA4; FLEISCHER D, 1983, GASTROENTEROLOGY, V84, P538; FLEISCHER DE, 1990, J CLIN GASTROENTE S2, V12, P41; GILBERT DA, 1990, GASTROINTEST ENDOSC, V36, P8; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; HALL WH, 1989, JAMA-J AM MED ASSOC, V262, P1369; Hay JA, 1996, AM J MED, V100, P313, DOI 10.1016/S0002-9343(97)89490-9; HAY JA, 1995, AM J GASTROENTEROL, V90, P1661; LAINE L, 1987, NEW ENGL J MED, V316, P1613, DOI 10.1056/NEJM198706253162601; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; MCMAHON LF, 1989, MED CARE, V27, P623, DOI 10.1097/00005650-198906000-00005; MORGAN AG, 1977, BRIT MED J, V2, P237, DOI 10.1136/bmj.2.6081.237; *NAT CTR HLTH STAT, 1991, VIT HLTH STAT, V13; *NIH CONS DEV PAN, 1990, GASTROINTEST ENDOS S, V36, P31; OSHITA Y, 1986, ENDOSCOPY, V18, P11, DOI 10.1055/s-2007-1018419; PANES J, 1987, LANCET, V2, P1292; PETERSON WL, 1981, NEW ENGL J MED, V304, P925, DOI 10.1056/NEJM198104163041601; PIMPL W, 1987, ENDOSCOPY, V19, P101, DOI 10.1055/s-2007-1013010; PROVENZALE D, 1987, AM J MED SCI, V294, P26, DOI 10.1097/00000441-198707000-00004; RICHTER JM, 1991, J CLIN GASTROENTEROL, V13, P268, DOI 10.1097/00004836-199106000-00005; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X; SAEED ZA, 1995, GASTROINTEST ENDOSC, V41, P561, DOI 10.1016/S0016-5107(95)70191-5; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706	34	136	137	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2151	2156		10.1001/jama.278.24.2151	http://dx.doi.org/10.1001/jama.278.24.2151			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9417008				2022-12-28	WOS:000071022200030
J	Ferrer, M; Alonso, J; Morera, J; Marrades, RM; Khalaf, A; Aguar, MC; Plaza, V; Prieto, L; Anto, JM				Ferrer, M; Alonso, J; Morera, J; Marrades, RM; Khalaf, A; Aguar, MC; Plaza, V; Prieto, L; Anto, JM		Quality Life Chronic Obstructive Pulm Dis Stud	Chronic obstructive pulmonary disease stage and health-related quality of life	ANNALS OF INTERNAL MEDICINE			English	Article							GEORGE RESPIRATORY QUESTIONNAIRE; SPANISH VERSION; OF-LIFE; MANAGEMENT; ADAPTATION; VALIDITY; OUTCOMES; PROFILE	Background: The American Thoracic Society recently recommended that chronic obstructive pulmonary disease be staged on the basis of the percentage of predicted FEV1. Objective: To examine 1) the relation between the American Thoracic Society system for staging chronic obstructive pulmonary disease and health-related quality of life and 2) the effect of self-reported comorbid conditions on health-related quality of life. Design: Cross-sectional study. Setting: Outpatient clinics of respiratory departments of four hospitals and one primary health care center in Spain. Patients: 321 consecutive male patients with chronic obstructive pulmonary disease. Measurements: Functional respiratory impairment, FEV1, respiratory symptoms, and health-related quality of life. Respiratory symptoms and health-related quality of life were measured by using the Spanish version of the St. George's Respiratory Questionnaire and the Nottingham Health Profile. Results: Patient scores on the St. George's Respiratory Questionnaire were moderately to strongly associated with disease staging (r = 0.27 to 0.51). Compared with reference values, values for health-related quality of life for patients with stage I disease were substantially higher on the St. George's Respiratory Questionnaire (6 and 34; P < 0.001) and values for impairment were significantly greater in stage I patients with comorbid conditions (19 and 36; P = 0.001). At least one concomitant chronic condition was found in 84% of study patients. Comorbid conditions only partly influenced the observed pattern of deterioration of health-related quality of life with worsening stages of disease. Conclusion: Staging criteria for chronic obstructive pulmonary disease based on percentage of predicted FEV1 separated groups of patients with varying degrees of impair ment in health-related quality of life. Contrary to expectations, even patients with mild disease showed substantially compromised health-related quality of life. Comorbid conditions influenced the relation between chronic obstructive pulmonary disease and health-related quality of life.	Hosp Badalona Germans Trias & Pujol, Dept Pneumol, E-08915 Badalona, Spain; Hosp Mar, Inst Municipal Invest Med, Hosp Clin & Prov, Barcelona, Spain; Hosp Vic, Barcelona, Spain; Hosp Magdalena, Dept Pneumol, E-12004 Castellon de La Plana, Spain	Hospital Germans Trias i Pujol; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; University of Barcelona; Hospital Clinic de Barcelona	Anto, JM (corresponding author), Hosp Mar, Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, Carrer Doctor Aiguader 80, E-08003 Barcelona, Spain.		MArrades, Ramón M/AFU-6757-2022; Ferrer, Montse/A-5510-2010; Alonso, Jordi/A-5514-2010; Anto, J M/H-2676-2014	Ferrer, Montse/0000-0001-9867-7391; Alonso, Jordi/0000-0001-8627-9636; Anto, J M/0000-0002-4736-8529; Plaza, Vicente/0000-0003-2567-5496				ALONSO J, 1995, MED CLIN-BARCELONA, V104, P771; ALONSO J, 1990, AM J PUBLIC HEALTH, V80, P704, DOI 10.2105/AJPH.80.6.704; ALONSO J, 1994, QUAL LIFE RES, V3, P385, DOI 10.1007/BF00435390; ALONSO J, 1992, MED CARE, V30, pMS125, DOI 10.1097/00005650-199205001-00011; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; ARINO EC, 1988, ANN MED BARCELONA, V74, P231; Brooks SM, 1982, ATS NEWS, V8, P12; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; CURTIS JR, 1994, THORAX, V49, P162, DOI 10.1136/thx.49.2.162; Domingo Salvany A, 1989, Gac Sanit, V3, P320; FEINSTEIN AR, 1970, J CHRON DIS, V23, P455, DOI 10.1016/0021-9681(70)90054-8; Ferrer M, 1996, EUR RESPIR J, V9, P1160, DOI 10.1183/09031936.96.09061160; *GRUP TRAB SEPAR P, 1985, NORM ESP FORZ; JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Ketelaars CAJ, 1996, THORAX, V51, P39, DOI 10.1136/thx.51.1.39; MAHLER DA, 1987, CLIN CHEST MED, V8, P215; MCSWEENY AJ, 1982, ARCH INTERN MED, V142, P473, DOI 10.1001/archinte.142.3.473; Okubadejo AA, 1996, THORAX, V51, P44, DOI 10.1136/thx.51.1.44; PRIGATANO GP, 1984, ARCH INTERN MED, V144, P1613, DOI 10.1001/archinte.144.8.1613; ROCA J, 1986, B EUR PHYSIOPATH RES, V22, P217; *SAS I, 1989, SAS STAT US GUID VER; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; Ware J. E., 1993, SF36 HLTH SURVEY MAN	26	288	298	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1072	1079		10.7326/0003-4819-127-12-199712150-00003	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412309				2022-12-28	WOS:000070936600003
J	Gane, E; Saliba, F; Valdecasas, GJC; OGrady, J; Pescovitz, MD; Lyman, S; Robinson, CA				Gane, E; Saliba, F; Valdecasas, GJC; OGrady, J; Pescovitz, MD; Lyman, S; Robinson, CA			Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients	LANCET			English	Article							HIGH-DOSE ACYCLOVIR; IMMUNE GLOBULIN PROPHYLAXIS; PLACEBO-CONTROLLED TRIAL; DONATED ORGAN; VIRUS DISEASE; THERAPY; INFECTIONS; REJECTION; DONOR; AIDS	Background Cytomegalovirus (CMV) disease is a frequent cause of serious morbidity after solid-organ transplantation. The prophylactic regimens used to prevent CMV infection and disease have shown limited benefit in seronegative recipients. We studied the safety and efficacy of oral ganciclovir in the prevention of CMV disease following orthotopic liver transplantation. Methods Between December, 1993, and April, 1995, 304 liver-transplant recipients were randomised to receive oral ganciclovir 1000 mg or matching placebo three times a day. Seronegative recipients of seronegative livers were excluded. Study drug was administered as soon as the patient was able to take medication by mouth (no later than day 10) until the 98th day after transplantation. Patients were assessed at specified times throughout the first 6 months after surgery for evidence of CMV infection, CMV disease, rejection, opportunistic infections, and possible drug toxicity. Findings The Kaplan-Meier estimate of the 6-month incidence of CMV disease was 29 (18.9%) of 154 in the placebo group, compared with seven (4.8%) of 150 in the ganciclovir group (p<0.001). In the high-risk group of seronegative recipients (R-) of seropositive livers (D+), incidence of CMV disease was 11 (44.0%) of 25 in the placebo group, three (14.8%) of 21 in the ganciclovir group (p=0.02). Significant benefit was also observed in those receiving antibodies to lymphocytes, where the incidence of CMV disease was 12 (32.9%) of 37 in the placebo group and two (4.6%) of 44 in the ganciclovir group (p=0.002). Oral ganciclovir reduced the incidence of CMV infection (placebo 79 [51.5%] of 154; ganciclovir 37 [24.5%] of 150; p<0.001) and also reduced symptomatic herpes-simplex infections (Kaplan-Meier estimates: placebo 36 [23.5%] of 154; ganciclovir five [3.5%] of 150; p<0.001). Interpretation Oral ganciclovir is a safe and effective method for the prevention of CMV disease after orthotopic liver transplantation.	UNIV LONDON KINGS COLL,SCH MED,INST LIVER STUDIES,LONDON,ENGLAND; HOP PAUL BROUSSE,VILLEJUIF,FRANCE; HOSP CLIN BARCELONA,BARCELONA,SPAIN; ST JAMES UNIV HOSP,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; INDIANA UNIV,MED CTR,INDIANAPOLIS,IN; ROCHE GLOBAL DEV,PALO ALTO,CA	University of London; King's College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; University of Barcelona; Hospital Clinic de Barcelona; Saint James's University Hospital; Indiana University System; Indiana University-Purdue University Indianapolis; Roche Holding			SALIBA, Faouzi/T-7456-2018					BALFOUR HH, 1989, NEW ENGL J MED, V320, P1381, DOI 10.1056/NEJM198905253202105; BOIVIN G, 1993, J INFECT DIS, V168, P332, DOI 10.1093/infdis/168.2.332; DREW WL, 1995, NEW ENGL J MED, V333, P615, DOI 10.1056/NEJM199509073331002; DREW WL, 1991, J INFECT DIS, V163, P716, DOI 10.1093/infdis/163.4.716; ERICE A, 1989, NEW ENGL J MED, V320, P289, DOI 10.1056/NEJM198902023200505; GONWA T, 1995, 14 ANN M AM SOC TRAN, P184; GOODRICH JM, 1993, ANN INTERN MED, V118, P173, DOI 10.7326/0003-4819-118-3-199302010-00003; HIBBERD PL, 1995, ANN INTERN MED, V123, P18, DOI 10.7326/0003-4819-123-1-199507010-00002; Lurain NS, 1996, TRANSPLANTATION, V62, P497, DOI 10.1097/00007890-199608270-00012; MARTIN M, 1994, TRANSPLANTATION, V58, P779; MCCARTHY JM, 1993, TRANSPLANTATION, V55, P1277, DOI 10.1097/00007890-199306000-00013; MERIGAN TC, 1992, NEW ENGL J MED, V326, P1182, DOI 10.1056/NEJM199204303261803; OGRADY JG, 1988, LANCET, V2, P302; *OR GANC EUR AUSTR, 1995, AIDS, V9, P471; PATEL R, 1996, TRANSPLANTATOIN, V61, P1270; PAYA CV, 1993, J HEPATOL, V18, P185, DOI 10.1016/S0168-8278(05)80245-4; PORTELA D, 1995, J INFECT DIS, V171, P1014, DOI 10.1093/infdis/171.4.1014; Rosen HR, 1997, TRANSPLANTATION, V63, P476, DOI 10.1097/00007890-199702150-00026; SINGH N, 1988, J INFECT DIS, V158, P124, DOI 10.1093/infdis/158.1.124; SINGH N, 1994, ANN INTERN MED, V120, P375, DOI 10.7326/0003-4819-120-5-199403010-00004; SNYDMAN DR, 1987, NEW ENGL J MED, V317, P1049, DOI 10.1056/NEJM198710223171703; SNYDMAN DR, 1993, ANN INTERN MED, V119, P984, DOI 10.7326/0003-4819-119-10-199311150-00004; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; SPECTOR SA, 1995, J INFECT DIS, V171, P1431, DOI 10.1093/infdis/171.6.1431; STRATTA RJ, 1992, ARCH SURG-CHICAGO, V127, P55; STRATTA RJ, 1989, ARCH SURG-CHICAGO, V124, P1433; STRATTA RJ, 1992, TRANSPLANTATION, V5, P90; SUTHERLAND S, 1992, J MED VIROL, V37, P170, DOI 10.1002/jmv.1890370304; VANDENBERG AP, 1993, TRANSPLANTATION, V55, P847, DOI 10.1097/00007890-199304000-00031; WINSTON DJ, 1995, LANCET, V346, P69, DOI 10.1016/S0140-6736(95)92110-9; Winston DJ, 1995, TRANSPLANTATION, V60, P1357	31	362	370	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 13	1997	350	9093					1729	1733		10.1016/S0140-6736(97)05535-9	http://dx.doi.org/10.1016/S0140-6736(97)05535-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413463				2022-12-28	WOS:A1997YL55400008
J	Link, DR; Natale, G; Shao, R; Maclennan, JE; Clark, NA; Korblova, E; Walba, DM				Link, DR; Natale, G; Shao, R; Maclennan, JE; Clark, NA; Korblova, E; Walba, DM			Spontaneous formation of macroscopic chiral domains in a fluid smectic phase of achiral molecules	SCIENCE			English	Article							FERROELECTRIC LIQUID-CRYSTALS; MESOMORPHIC BEHAVIOR; BIS<4-(4-ALKOXYPHENYLIMINOMETHYL)BENZOATES>; FILMS	A smectic liquid-crystal phase made from achiral molecules with bent cores was found to have fluid layers that exhibit two spontaneous symmetry-breaking instabilities: polar molecular orientational ordering about the layer normal and molecular tilt. These instabilities combine to form a chiral layer structure with a handedness that depends on the sign of the tilt. The bulk states are either antiferroelectric-racemic, with the layer polar direction and handedness alternating in sign from layer to layer, or antiferroelectric-chiral, which is of uniform layer handedness. Both states exhibit an electric field-induced transition from antiferroelectric to ferroelectric.	UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder	Link, DR (corresponding author), UNIV COLORADO,DEPT PHYS,CONDENSED MATTER LAB,BOULDER,CO 80309, USA.		Clark, Noel A/AAP-9116-2020; Korblova, Eva/AAC-3502-2021; Maclennan, Joseph E/A-9836-2013; Clark, Noel A./E-9011-2010; Walba, David/F-7284-2013	Korblova, Eva/0000-0002-3818-4373; Maclennan, Joseph E/0000-0002-3587-554X; Clark, Noel A./0000-0001-9301-5540; 				AKUTAGAWA T, 1994, LIQ CRYST, V17, P659, DOI 10.1080/02678299408037337; [Anonymous], 1975, J PHYS PARIS; Brazovskii S.A, 1975, JETP, V41, P85, DOI [10.1142/9789814317344_0016, DOI 10.1142/9789814317344_0016]; Brown ME, 1996, CHEM MATER, V8, P1588, DOI 10.1021/cm960264d; CLARK NA, 1980, APPL PHYS LETT, V36, P899, DOI 10.1063/1.91359; FLIEGNER D, 1993, PHYS REV LETT, V70, P1842; Friedrich R, 1888, MONATSHEFTE CHEM VER, V9, P421, DOI [10.1007/BF01516710, DOI 10.1007/BF01516710]; FUKUDA A, 1994, J MATER CHEM, V4, P997, DOI 10.1039/jm9940400997; GOODBY JW, 1989, NATURE, V337, P449, DOI 10.1038/337449a0; GREEN MM, 1995, SCIENCE, V268, P1860, DOI 10.1126/science.268.5219.1860; LIFSON S, 1989, J AM CHEM SOC, V111, P8850, DOI 10.1021/ja00206a013; Link DR, 1996, PHYS REV LETT, V77, P2237, DOI 10.1103/PhysRevLett.77.2237; MATSUNAGA Y, 1993, MOL CRYST LIQ CRYS A, V237, P311, DOI 10.1080/10587259308030145; MATSUZAKI H, 1993, LIQ CRYST, V14, P105, DOI 10.1080/02678299308027306; MEYER RB, 1975, J PHYS LETT-PARIS, V36, pL69, DOI 10.1051/jphyslet:0197500360306900; Niori T, 1996, J MATER CHEM, V6, P1231, DOI 10.1039/jm9960601231; PANG JZ, 1992, PHYS REV LETT, V69, P2783, DOI 10.1103/PhysRevLett.69.2783; PINDAK R, 1980, PHYS REV LETT, V45, P1193, DOI 10.1103/PhysRevLett.45.1193; RENN SR, 1988, PHYS REV A, V38, P2132, DOI 10.1103/PhysRevA.38.2132; Selinger JV, 1996, PHYS REV LETT, V76, P58, DOI 10.1103/PhysRevLett.76.58; WALBA DM, 1991, FERROELECTRICS, V121, P247, DOI 10.1080/00150199108217629; WEISSFLOG W, 1997, EUR C LIQ CRYST ZAK, P201; WEISSFLOG W, COMMUNICATION; YOUNG CY, 1978, PHYS REV LETT, V40, P773, DOI 10.1103/PhysRevLett.40.773; [No title captured]	25	1138	1145	6	218	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1924	1927		10.1126/science.278.5345.1924	http://dx.doi.org/10.1126/science.278.5345.1924			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395390				2022-12-28	WOS:A1997YL00200028
J	Ordway, JM; TallaksenGreene, S; Gutekunst, CA; Bernstein, EM; Cearley, JA; Wiener, HW; Dure, LS; Lindsey, R; Hersch, SM; Jope, RS; Albin, RL; Detloff, PJ				Ordway, JM; TallaksenGreene, S; Gutekunst, CA; Bernstein, EM; Cearley, JA; Wiener, HW; Dure, LS; Lindsey, R; Hersch, SM; Jope, RS; Albin, RL; Detloff, PJ			Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse	CELL			English	Article							LESCH-NYHAN SYNDROME; HUNTINGTONS-DISEASE; IN-VITRO; MODEL; POLYGLUTAMINE; DEFICIENCY; PATHOGENESIS; EXPANSION; CELLS; MICE	The mutations responsible for several human neurodegenerative disorders are expansions of translated CAG repeats beyond a normal size range. To address the role of repeat context, we have introduced a 146-unit CAG repeat into the mouse hypoxanthine phosphoribosyltransferase gene (Hprt). Mutant mice express a form of the HPRT protein that contains a long polyglutamine repeat. These mice develop a phenotype similar to the human translated CAG repeat disorders. Repeat containing mice show a late onset neurological phenotype that progresses to premature death. Neuronal intranuclear inclusions are present in affected mice. Our results show that CAG repeats do not need to be located within one of the classic repeat disorder genes to have a neurotoxic effect.	UNIV ALABAMA,DEPT BIOCHEM & MOL GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PSYCHIAT & BEHAV NEUROBIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT ORAL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PEDIAT NEUROL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT COMPARAT MED,BIRMINGHAM,AL 35294; UNIV MICHIGAN,DEPT NEUROL,ANN ARBOR,MI 48104; EMORY UNIV,DEPT NEUROL,ATLANTA,GA 30329	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Michigan System; University of Michigan; Emory University			Longo, Kenneth A/A-5631-2010; Dure, Leon/B-3243-2008		NIA NIH HHS [AG06569, AG08671] Funding Source: Medline; NINDS NIH HHS [NS34492] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG006569] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHA JHJ, 1994, LIFE SCI, V54, P1459, DOI 10.1016/0024-3205(94)90012-4; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DUNNETT SB, 1989, BRAIN RES, V501, P401, DOI 10.1016/0006-8993(89)90659-8; FINGER S, 1988, J NEUROL SCI, V86, P203, DOI 10.1016/0022-510X(88)90099-8; Gusella JF, 1996, COLD SPRING HARB SYM, V61, P615; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; JINNAH HA, 1993, J NEUROCHEM, V60, P2036, DOI 10.1111/j.1471-4159.1993.tb03488.x; JINNAH HA, 1994, J NEUROSCI, V14, P1164; JINNAH HA, 1991, BEHAV NEUROSCI, V105, P1004, DOI 10.1037/0735-7044.105.6.1004; KAZEMIESFARJANI P, 1995, HUM MOL GENET, V4, P523, DOI 10.1093/hmg/4.4.523; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nasir J, 1996, HUM MOL GENET, V5, P1431, DOI 10.1093/hmg/5.Supplement_1.1431; Ordway JM, 1996, BIOTECHNIQUES, V21, P609; Orr HT, 1996, COLD SPRING HARB SYM, V61, P649; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; QUARREL O, 1991, HUNTINGTONS DISEASE, P37; REDDY RS, 1997, CURR OPIN CELL BIOL, V9, P364; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Ruppert SML, 1996, HYBRIDOMA, V15, P55, DOI 10.1089/hyb.1996.15.55; Saudou F, 1996, COLD SPRING HARB SYM, V61, P639; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SKINNER PJ, 1997, ATAXIN 1 EXPANDED GL; STRITTMATTER WJ, 1997, COLD SPRING HARB SYM, V61, P597; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WILLIAMSON DJ, 1992, J INHERIT METAB DIS, V15, P665, DOI 10.1007/BF01799622; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62; Zoghbi HY, 1996, NAT GENET, V14, P237, DOI 10.1038/ng1196-237	33	301	305	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					753	763		10.1016/S0092-8674(00)80464-X	http://dx.doi.org/10.1016/S0092-8674(00)80464-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413985	Bronze			2022-12-28	WOS:A1997YL43900007
J	Vaughan, CW; Ingram, SL; Connor, MA; Christie, MJ				Vaughan, CW; Ingram, SL; Connor, MA; Christie, MJ			How opioids inhibit GABA-mediated neurotransmission	NATURE			English	Article							ARACHIDONIC-ACID METABOLITES; HIPPOCAMPUS IN-VITRO; LIPOXYGENASE METABOLITES; PRESYNAPTIC INHIBITION; PROTEIN-KINASE; RAT; CELLS; CHANNELS; NOCICEPTION; ACTIVATION	The midbrain region periaqueductal grey (FAG) is rich in opioid receptors and endogenous opioids and is a major target of analgesic action in the central nervous system(1). It has been proposed that the analgesic effect of opioids on the FAG works by suppressing the inhibitory influence of the neurotransmitter GABA (gamma-aminobutyric acid) on neurons that form part of a descending antinociceptive pathway(2). Opioids inhibit GABA-mediated (GABAergic) synaptic transmission in the FAG and other brain regions by reducing the probability of presynaptic neurotransmitter release(3,4), but the mechanisms involved remain uncertain. Here we report that opioid inhibition of GABAergic synaptic currents in the FAG is controlled by a presynaptic voltage-dependent potassium conductance, Opioid receptors of the mu type in GABAergic presynaptic terminals are specifically coupled to this potassium conductance by a pathway involving phospholipase A(2), arachidonic acid and 12-lipoxygenase. Furthermore, opioid inhibition of GABAergic synaptic transmission is potentiated by inhibitors of the enzymes cyclooxygenase and 5-lipoxygenase, presumably because more arachidonic acid is available for conversion to IZ-lipoxygenase products, These mechanisms account for the analgesic action of cyclooxygenase inhibitors in the PAG(5) and their synergism with opioids(6).			Vaughan, CW (corresponding author), UNIV SYDNEY,DEPT PHARMACOL,SYDNEY,NSW 2006,AUSTRALIA.		Christie, MacDonald J/F-4724-2013; Connor, Mark/A-4197-2008	Christie, MacDonald J/0000-0002-0622-609X; Connor, Mark/0000-0003-2538-2001; Vaughan, Christopher/0000-0003-4314-7689				BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BLACKWELL GJ, 1983, BRIT MED BULL, V39, P260, DOI 10.1093/oxfordjournals.bmb.a071830; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; CAPOGNA M, 1993, J PHYSIOL-LONDON, V470, P539, DOI 10.1113/jphysiol.1993.sp019874; Duerson K, 1996, NEUROPHARMACOLOGY, V35, P949, DOI 10.1016/0028-3908(96)00131-1; EVANS JF, 1991, MOL PHARMACOL, V40, P22; Fukuda K, 1996, J NEUROCHEM, V67, P1309; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; KURACHI Y, 1989, PFLUG ARCH EUR J PHY, V414, P102, DOI 10.1007/BF00585635; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; MAVES TJ, 1994, ANESTHESIOLOGY, V80, P1094, DOI 10.1097/00000542-199405000-00018; NORTH RA, 1993, OPIOIDS, V1, P773; PIOMELLI D, 1990, TRENDS PHARMACOL SCI, V11, P367, DOI 10.1016/0165-6147(90)90182-8; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SHAPIRO MS, 1994, J NEUROSCI, V14, P7109; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; Simmons ML, 1996, MOL PHARMACOL, V50, P80; TORTORICI V, 1995, EUR J NEUROSCI, V7, P1857, DOI 10.1111/j.1460-9568.1995.tb00706.x; Vaughan CW, 1997, J PHYSIOL-LONDON, V498, P463, DOI 10.1113/jphysiol.1997.sp021872; Vaughan CW, 1997, J NEUROSCI, V17, P996; WIMPEY TL, 1991, NEURON, V6, P281, DOI 10.1016/0896-6273(91)90363-5	22	400	415	1	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					611	614		10.1038/37610	http://dx.doi.org/10.1038/37610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403690				2022-12-28	WOS:A1997YK85300050
J	Golombek, MP; Cook, RA; Economou, T; Folkner, WM; Haldemann, AFC; Kallemeyn, PH; Knudsen, JM; Manning, RM; Moore, HJ; Parker, TJ; Rieder, R; Schofield, JT; Smith, PH; Vaughan, RM				Golombek, MP; Cook, RA; Economou, T; Folkner, WM; Haldemann, AFC; Kallemeyn, PH; Knudsen, JM; Manning, RM; Moore, HJ; Parker, TJ; Rieder, R; Schofield, JT; Smith, PH; Vaughan, RM			Overview of the Mars Pathfinder Mission and assessment of landing site predictions	SCIENCE			English	Article							THERMAL INERTIA; PHYSICAL-PROPERTIES; ALBEDO	Chemical analyses returned by Mars Pathfinder indicate that some rocks may be high in silica, implying differentiated parent materials. Rounded pebbles and cobbles and a possible conglomerate suggest fluvial processes that imply liquid water in equilibrium with the atmosphere and thus a warmer and wetter past. The moment of inertia indicates a central metallic core of 1300 to 2000 kilometers in radius. Composite airborne dust particles appear magnetized by freeze-dried maghemite stain or cement that may have been leached from crustal materials by an active hydrologic cycle. Remote-sensing data at a scale of generally greater than similar to 1 kilometer and an Earth analog correctly predicted a rocky plain safe for landing and roving with a variety of rocks deposited by catastrophic floods that are relatively dust-free.	UNIV CHICAGO, ENRICO FERMI INST, CHICAGO, IL 60637 USA; UNIV COPENHAGEN, NIELS BOHR INST, DK-1168 COPENHAGEN, DENMARK; US GEOL SURVEY, ASTROGEOL TEAM, MENLO PK, CA 94025 USA; MAX PLANCK INST CHEM, D-55128 MAINZ, GERMANY; UNIV ARIZONA, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA	University of Chicago; University of Copenhagen; Niels Bohr Institute; United States Department of the Interior; United States Geological Survey; Max Planck Society; University of Arizona	Golombek, MP (corresponding author), CALTECH, JET PROP LAB, 4800 OAK GROVE DR, PASADENA, CA 91109 USA.		Haldemann, Albert F C/I-9224-2012	Haldemann, Albert F C/0000-0003-3741-8841				Baker V.R., 1992, CHANNELS VALLEY NETW, P493; BAKER VR, 1972, 144 GEOL SOC AM, P73; Christensen, 1992, MARS, P686; CHRISTENSEN PR, 1986, ICARUS, V68, P217, DOI 10.1016/0019-1035(86)90020-5; CHRISTENSEN PR, 1982, J GEOPHYS RES, V87, P9985, DOI 10.1029/JB087iB12p09985; CHRISTENSEN PR, 1986, J GEOPHYS RES-SOLID, V91, P3533, DOI 10.1029/JB091iB03p03533; Edgett KS, 1997, J GEOPHYS RES-PLANET, V102, P4107, DOI 10.1029/96JE02825; Farmer C. B., 1977, Journal of Geophysical Research, V82, P4225, DOI 10.1029/JS082i028p04225; FOLKNER WM, 1997, SCIENCE, V278, P1748; Golombek M, 1997, J GEOPHYS RES-PLANET, V102, P4117, DOI 10.1029/96JE03319; Golombek MP, 1997, J GEOPHYS RES-PLANET, V102, P3967, DOI 10.1029/96JE03318; Golombek MP, 1997, J GEOPHYS RES-PLANET, V102, P3953, DOI 10.1029/96JE02805; GOLOMBEK MP, 1995, MARS PATHFINDER LA 1, V2, P63; GOLOMBEK MP, 1994, MARS PATHFINDER LA 2, P47; GUINNESS EA, 1987, J GEOPHYS RES E S, V575; HABERLE RM, 1991, ICARUS, V90, P187, DOI 10.1016/0019-1035(91)90100-8; Haldeman AFC, 1997, J GEOPHYS RES-PLANET, V102, P4097, DOI 10.1029/96JE03321; Harmon JK, 1997, J GEOPHYS RES-PLANET, V102, P4081, DOI 10.1029/96JE01953; HAYASHI JN, 1995, J GEOPHYS RES-PLANET, V100, P5277, DOI 10.1029/94JE02449; HOWINGTONKRAUS E, 1995, MARS PATHF LAND SI 2, V2, P38; HVIID SF, 1997, SCIENCE, V278, P1767; Kieffer H. H., 1977, Journal of Geophysical Research, V82, P4249, DOI 10.1029/JS082i028p04249; Komatsu G, 1997, J GEOPHYS RES-PLANET, V102, P4151, DOI 10.1029/96JE02564; KONOPLIV AS, 1995, JPL PUBL, P73; Longhi J., 1992, MARS, V1, P184, DOI [10.2307/j.ctt207g59v.10, DOI 10.2307/J.CTT207G59V.10]; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; Mitchell JK., 1972, P 3 LUNAR SCI C, P3235; OLHOEFT GR, 1975, EARTH PLANET SC LETT, V24, P394, DOI 10.1016/0012-821X(75)90146-6; PALLUCONI FD, 1981, ICARUS, V45, P415, DOI 10.1016/0019-1035(81)90044-0; PLESKOT LK, 1981, ICARUS, V45, P179, DOI 10.1016/0019-1035(81)90013-0; Pollack J. B., 1977, Journal of Geophysical Research, V82, P4479, DOI 10.1029/JS082i028p04479; POLLACK JB, 1979, J GEOPHYS RES, V84, P2929, DOI 10.1029/JB084iB06p02929; Rice JW, 1997, J GEOPHYS RES-PLANET, V102, P4185, DOI 10.1029/96JE02824; RIEDER R, 1997, SCIENCE, V278, P1770; *ROV TEAM, 1997, SCIENCE, V278, P1764; Schofield JT, 1997, SCIENCE, V278, P1752, DOI 10.1126/science.278.5344.1752; SMITH PH, 1997, SCIENCE, V278, P1757; SPENCER DA, 1995, 95379 AM ASTR SOC AM; THOMPSON TW, 1989, P LUN PLAN SCI C, V19, P409; Yoder CF, 1997, J GEOPHYS RES-PLANET, V102, P4065, DOI 10.1029/96JE03642; Zurek R.W., 1992, MARS, P835; [No title captured]	42	187	194	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1743	1748		10.1126/science.278.5344.1743	http://dx.doi.org/10.1126/science.278.5344.1743			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388167				2022-12-28	WOS:A1997YJ90100033
J	Rahn, T; Wahlen, M				Rahn, T; Wahlen, M			Stable isotope enrichment in stratospheric nitrous oxide	SCIENCE			English	Article							ELECTRON-IMPACT IONIZATION; CROSS-SECTIONS; N2O; RATIOS; NITRIFICATION; THRESHOLD; METHANE; CARBON; WATER	Nitrous oxide is a greenhouse gas that also plays a role in the cycling of stratospheric ozone. Air Samples from the lower stratosphere exhibit N-15/N-14 and O-18/O-16 enrichment in nitrous oxide, which can be accounted for with a simple model describing an irreversible destruction process. The observed enrichments are quite large and incompatible with those determined for the main stratospheric nitrous oxide loss processes of photolysis and reaction with excited atomic oxygen. Thus, although no stratospheric source needs to be invoked, the data indicate that present understanding of stratospheric nitrous oxide chemistry is incomplete.			Rahn, T (corresponding author), UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093, USA.		Rahn, Thom/C-5211-2012					BOUWMAN AF, 1995, J GEOPHYS RES-ATMOS, V100, P2785, DOI 10.1029/94JD02946; FROIDEVAUX L, 1982, GEOPHYS RES LETT, V9, P854, DOI 10.1029/GL009i008p00854; Iga I, 1996, J GEOPHYS RES-PLANET, V101, P9261, DOI 10.1029/96JE00467; JOHNSTON J, 1993, J GEOPHYS RES, V100, P16801; Junge C. E., 1963, AIR CHEM RADIOACTIVI, DOI 10.1002/ange.19650770328; KEELING CD, 1989, ASPECTS CLIMATE VARI, P165, DOI DOI 10.1029/GM055P0165; KHALIL MAK, 1992, J GEOPHYS RES-ATMOS, V97, P14651, DOI 10.1029/92JD01222; KIM KR, 1993, SCIENCE, V262, P1855, DOI 10.1126/science.262.5141.1855; KIM KR, 1990, NATURE, V347, P58, DOI 10.1038/347058a0; MANDERNACK K, UNPUB; Manning MR, 1997, J GEOPHYS RES-ATMOS, V102, P10673, DOI 10.1029/96JD02743; MATSUO S, 1983, GEOCHEM J, V17, P231; McElroy MB, 1996, GLOBAL BIOGEOCHEM CY, V10, P651, DOI 10.1029/96GB02346; Michener R. H., 1994, STABLE ISOTOPES ECOL, P93; MINSCHWANER K, 1993, J GEOPHYS RES-ATMOS, V98, P10543, DOI 10.1029/93JD00223; MOORE H, 1974, TELLUS, V26, P169, DOI 10.1111/j.2153-3490.1974.tb01963.x; Quay PD, 1991, GLOBAL BIOGEOCHEM CY, V5, P25, DOI 10.1029/91GB00003; RAHN TA, 1996, EOS, V77, pS51; SCHMIDT U, 1985, J ATMOS CHEM, V3, P363, DOI 10.1007/BF00122524; STEVENS CM, 1972, EARTH PLANET SC LETT, V16, P147, DOI 10.1016/0012-821X(72)90183-5; STEVENS CM, 1993, ATMOSPHERIC METHANE, P62; Straub HC, 1996, J CHEM PHYS, V105, P4015, DOI 10.1063/1.472275; TANAKA N, 1995, INT J MASS SPECTROM, V142, P163, DOI 10.1016/0168-1176(94)04100-L; *US AIR FORC, 1972, US AIR FORC TECHN MA; WAHLEN M, 1985, NATURE, V313, P780, DOI 10.1038/313780a0; WAHLEN M, 1993, ANNU REV EARTH PL SC, V21, P407, DOI 10.1146/annurev.ea.21.050193.002203; WAHLEN M, 1989, SCIENCE, V245, P286, DOI 10.1126/science.245.4915.286; WAHLEN M, 1989, EOS T AGU, V70, P1017; *WORLD MET ORG, 1995, 37 WORLD MET ORG; YOSHIDA N, 1988, NATURE, V335, P528, DOI 10.1038/335528a0; Yoshinari T, 1997, MAR CHEM, V56, P253, DOI 10.1016/S0304-4203(96)00073-4; YOSHINARI T, 1985, NATURE, V317, P349, DOI 10.1038/317349a0; Yung YL, 1997, SCIENCE, V278, P1778, DOI 10.1126/science.278.5344.1778	33	106	108	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1776	1778		10.1126/science.278.5344.1776	http://dx.doi.org/10.1126/science.278.5344.1776			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388175				2022-12-28	WOS:A1997YJ90100041
J	Schofield, JT; Barnes, JR; Crisp, D; Haberle, RM; Larsen, S; Magalhaes, JA; Murphy, JR; Seiff, A; Wilson, G				Schofield, JT; Barnes, JR; Crisp, D; Haberle, RM; Larsen, S; Magalhaes, JA; Murphy, JR; Seiff, A; Wilson, G			The Mars Pathfinder atmospheric structure investigation meteorology (ASI/MET) experiment	SCIENCE			English	Article							MARTIAN ATMOSPHERE; BOUNDARY-LAYER; THERMAL TIDES; DUST STORMS; DEVILS; MODEL	The Mars Pathfinder atmospheric structure investigation/meteorology (ASI/MET) experiment measured the vertical density, pressure, and temperature structure of the martian atmosphere from the surface to 160 km, and monitored surface meteorology and climate for 83 sols (1 sol = 1 martian day = 24.7 hours). The atmospheric structure and the weather record are similar to those observed by the Viking 1 lander (VL-1) at the same latitude, altitude, and season 21 years ago, but there are differences related to diurnal effects and the surface properties of the landing site. These include a cold nighttime upper atmosphere; atmospheric temperatures that are 10 to 12 degrees kelvin warmer near the surface; light slope-controlled winds; and dust devils, identified by their pressure, wind, and temperature signatures. The results are consistent with the warm, moderately dusty atmosphere seen by VL-1.	OREGON STATE UNIV,COLL OCEAN & ATMOSPHER SCI,CORVALLIS,OR 97331; NASA,AMES RES CTR,MOFFETT FIELD,CA 94035; RISO NATL LAB,DK-4000 ROSKILDE,DENMARK; SAN JOSE STATE UNIV FDN,SAN JOSE,CA; ARIZONA STATE UNIV,TEMPE,AZ	Oregon State University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Technical University of Denmark; California State University System; San Jose State University; Arizona State University; Arizona State University-Tempe	Schofield, JT (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.		Crisp, David/F-6642-2017	Crisp, David/0000-0002-4573-9998				CLANCY R, UNPUB; Clancy RT, 1996, ICARUS, V122, P36, DOI 10.1006/icar.1996.0108; Folkner W. M., COMMUNICATION; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; GIERASCH P, 1968, PLANET SPACE SCI, V16, P615, DOI 10.1016/0032-0633(68)90102-5; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; HABERLE RM, 1993, J ATMOS SCI, V50, P1544, DOI 10.1175/1520-0469(1993)050<1544:ABLMFM>2.0.CO;2; Haberle RM, 1997, J GEOPHYS RES-PLANET, V102, P13301, DOI 10.1029/97JE01334; Hess S. L., 1977, Journal of Geophysical Research, V82, P4559, DOI 10.1029/JS082i028p04559; JAKOSKY BM, IN PRESS ICARUS; JAMES PB, 1992, MARS, P934; LOPEZPUERTAS M, 1995, ICARUS, V114, P113, DOI 10.1006/icar.1995.1047; MAGALHAES JA, 1995, ICARUS, V113, P277, DOI 10.1006/icar.1995.1024; MURPHY JR, 1990, J GEOPHYS RES-SOLID, V95, P14555, DOI 10.1029/JB095iB09p14555; Nier A. O., 1977, Journal of Geophysical Research, V82, P4341, DOI 10.1126/science.194.4271.1298; Rivell T, 1997, J SPACECRAFT ROCKETS, V34, P265, DOI 10.2514/2.3211; RYAN JA, 1983, J GEOPHYS RES-OCEANS, V88, P1005, DOI 10.1029/JC088iC15p11005; Seiff A, 1997, J GEOPHYS RES-PLANET, V102, P4045, DOI 10.1029/96JE03320; Seiff A., 1977, Journal of Geophysical Research, V82, P4364, DOI 10.1029/JS082i028p04364; SHARMAN RD, 1980, J ATMOS SCI, V37, P1994, DOI 10.1175/1520-0469(1980)037<1994:MAPPFV>2.0.CO;2; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; THOMAS P, 1985, SCIENCE, V230, P175, DOI 10.1126/science.230.4722.175; TILLMAN JE, 1994, J ATMOS SCI, V51, P1709, DOI 10.1175/1520-0469(1994)051<1709:TBLOMF>2.0.CO;2; TILLMAN JE, 1988, J GEOPHYS RES-ATMOS, V93, P9433, DOI 10.1029/JD093iD08p09433; TILLMAN JE, 1993, J GEOPHYS RES-PLANET, V98, P10963, DOI 10.1029/93JE01084; Wilson RJ, 1996, J ATMOS SCI, V53, P1290, DOI 10.1175/1520-0469(1996)053<1290:CMSOTT>2.0.CO;2; WOLFF MJ, IN PRESS B AM ASTRON; Zurek R.W., 1992, MARS, P835; ZUREK RW, 1981, SCIENCE, V213, P437, DOI 10.1126/science.213.4506.437	29	340	343	2	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1752	1758		10.1126/science.278.5344.1752	http://dx.doi.org/10.1126/science.278.5344.1752			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388169				2022-12-28	WOS:A1997YJ90100035
J	Grisso, JA; Ness, RB; Hendrix, S				Grisso, JA; Ness, RB; Hendrix, S			Update in women's health	ANNALS OF INTERNAL MEDICINE			English	Article							HYSTERECTOMY; SMEARS		UNIV PITTSBURGH, DEPT MED, PITTSBURGH, PA 15261 USA; WAYNE STATE UNIV, DEPT OBSTET & GYNECOL, DETROIT, MI 48201 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wayne State University	Grisso, JA (corresponding author), UNIV PENN, MED CTR, CTR CLIN EPIDEMIOL & BIOSTAT, 420 SERV DR, FLOOR 3-R, PHILADELPHIA, PA 19104 USA.							CHAN KWA, 1994, ARTHRITIS RHEUM-US, V37, P814, DOI 10.1002/art.1780370606; EDELMAN P, 1997, ATLANTIC MONTHLY MAR, P43; FISCHER G, 1995, J FAM PRACTICE, V41, P16; Kaplan SH, 1996, NEW ENGL J MED, V335, P1282, DOI 10.1056/NEJM199610243351706; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; MCEWEN JE, 1992, AM J HUM GENET, V51, P785; Pearce KF, 1996, NEW ENGL J MED, V335, P1559, DOI 10.1056/NEJM199611213352103; Salamone LM, 1996, ARCH INTERN MED, V156, P1293, DOI 10.1001/archinte.156.12.1293; Sheffield JVL, 1997, ANN INTERN MED, V127, P43, DOI 10.7326/0003-4819-127-1-199707010-00008; 1996, ACAD MED, V71, P801	10	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					1006	1012		10.7326/0003-4819-127-11-199712010-00011	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412282				2022-12-28	WOS:A1997YJ08000008
J	Frey, M				Frey, M			Risks and prevention of Dupuytren's contracture	LANCET			English	Editorial Material											Frey, M (corresponding author), UNIV VIENNA,SCH MED,DEPT SURG,PLAST & RECONSTRUCT SURG SECT,WAEHRINGER GUERTEL 18,A-1090 VIENNA,AUSTRIA.							Burge P, 1997, J BONE JOINT SURG BR, V79B, P206, DOI 10.1302/0301-620X.79B2.6990; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; Sinha A, 1997, J BONE JOINT SURG BR, V79B, P211, DOI 10.1302/0301-620X.79B2.6670	3	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1568	1568		10.1016/S0140-6736(05)64010-X	http://dx.doi.org/10.1016/S0140-6736(05)64010-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393334				2022-12-28	WOS:A1997YH98600006
J	Hegde, RS; Lingappa, VR				Hegde, RS; Lingappa, VR			Membrane protein biogenesis: Regulated complexity at the endoplasmic reticulum	CELL			English	Review							SCRAPIE PRION PROTEIN; HUMAN P-GLYCOPROTEIN; ER MEMBRANE; TRANSMEMBRANE ORIENTATION; SECRETORY PROTEINS; CONDUCTING CHANNEL; RECOGNITION EVENT; STOP TRANSFER; TRANSLOCATION; INTEGRATION		UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Hegde, RS (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,BOX 0444,SAN FRANCISCO,CA 94143, USA.			Lingappa, Vishwanath R./0000-0003-0962-6571; Hegde, Ramanujan/0000-0001-8338-852X				Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; BAZAN JF, 1987, PROTEIN ENG, V1, P125, DOI 10.1093/protein/1.2.125; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; DUNLOP J, 1995, EMBO J, V14, P3609, DOI 10.1002/j.1460-2075.1995.tb00030.x; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FINBOW ME, 1993, EXP CELL RES, V207, P261, DOI 10.1006/excr.1993.1192; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; KEHRY M, 1980, CELL, V21, P393, DOI 10.1016/0092-8674(80)90476-6; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; Kuroiwa T, 1996, J BIOL CHEM, V271, P6423, DOI 10.1074/jbc.271.11.6423; Levy D, 1996, Essays Biochem, V31, P49; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; MCCUNE JM, 1980, J EXP MED, V152, P463, DOI 10.1084/jem.152.2.463; Millman JS, 1997, CELL, V89, P673, DOI 10.1016/S0092-8674(00)80248-2; MORRISON TG, 1975, J BIOL CHEM, V250, P6955; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PASTAN I, 1991, ANNU REV MED, V42, P277, DOI 10.1146/annurev.med.42.1.277; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SIEGEL V, 1995, CELL, V82, P167, DOI 10.1016/0092-8674(95)90301-1; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SKACH WR, 1993, J BIOL CHEM, V268, P6903; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; YOST CS, 1983, CELL, V34, P759; ZHANG JT, 1995, BIOCHEMISTRY-US, V34, P9159, DOI 10.1021/bi00028a027; ZHANG JT, 1993, J BIOL CHEM, V268, P15101	50	71	72	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					575	582		10.1016/S0092-8674(00)80445-6	http://dx.doi.org/10.1016/S0092-8674(00)80445-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393851	Bronze			2022-12-28	WOS:A1997YH96000005
J	Duan, D; Winter, C; Cowley, S; Hume, JR; Horowitz, B				Duan, D; Winter, C; Cowley, S; Hume, JR; Horowitz, B			Molecular identification of a volume-regulated chloride channel	NATURE			English	Article							RESISTANCE P-GLYCOPROTEIN; CL CURRENTS; PROTEIN; CELLS; EXPRESSION; MYOCYTES; ELECTROPHYSIOLOGY; CLONING	A volume-regulated chloride current (I-Cl.vol) is ubiquitously present in mammalian cells, and is required for the regulation of electrical activity cell volume, intracellular pH, immunological responses, cell proliferation and differentiation. However, the molecule responsible for I-Cl.vol has yet to be determined(1-3). Although three putative chloride channel proteins expressed from cloned genes (P-glycoprotein(4), pI(Cln), (ref. 5) and ClC-2 (ref. 6)) have been proposed to be the molecular equivalent of I-Cl.vol, neither P-glycoprotein nor pI(Cln), is thought to be a chloride channel or part thereof(7,8), and the properties of expressed ClC-2 channels differ from native I-Cl.vol (refs. 3, 6). Here we report that functional expression in NIH/3T3 cells of a cardiac clone of another member of the CIC family, ClC-3, results in a large basally active chloride conductance, which is strongly modulated by cell volume and exhibits many properties identical to those of I-Cl.vol in native cells(1-3,9-13). A mutation of asparagine to lysine at position 579 at the end of the transmembrane domains of ClC-3 abolishes the outward rectification and changes the anion selectivity from I- > Cl- to Cl- > I- but leaves swelling activation intact. Because ClC-3 is a channel protein belonging to a large gene family of chloride channels(3,14), these results indicate that ClC-3 encodes I-Cl.vol in many native mammalian cells.	UNIV NEVADA,SCH MED,DEPT CELL BIOL & PHYSIOL,RENO,NV 89557	Nevada System of Higher Education (NSHE); University of Nevada Reno								BORSANI G, 1995, GENOMICS, V27, P131, DOI 10.1006/geno.1995.1015; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUAN D, 1995, CIRC RES, V77, P379, DOI 10.1161/01.RES.77.2.379; Duan D, 1997, CIRC RES, V80, P103, DOI 10.1161/01.RES.80.1.103; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P266; FORENZ C, 1996, P NATL ACAD SCI USA, V93, P13362; GRIMDER S, 1992, NATURE, V360, P759; GSCHWENTNER M, 1995, PFLUG ARCH EUR J PHY, V430, P464, DOI 10.1007/BF00373882; HAMILL OP, 1981, PFLUGERS ARCH, V422, P143; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; Jentsch TJ, 1996, CURR OPIN NEUROBIOL, V6, P303, DOI 10.1016/S0959-4388(96)80112-7; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KAWASAKI M, 1995, NEURON, V14, P1285, DOI 10.1016/0896-6273(95)90275-9; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; LUCKIE DB, 1994, AM J PHYSIOL, V267, pC650, DOI 10.1152/ajpcell.1994.267.2.C650; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; Meyer K, 1996, J GEN PHYSIOL, V108, P177, DOI 10.1085/jgp.108.3.177; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; Nilius B, 1996, GEN PHARMACOL-VASC S, V27, P1131, DOI 10.1016/S0306-3623(96)00061-4; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Shuba LM, 1996, J PHYSIOL-LONDON, V491, P69, DOI 10.1113/jphysiol.1996.sp021197; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VANDENBERG JI, 1994, J GEN PHYSIOL, V104, P997, DOI 10.1085/jgp.104.6.997; Vogalis F, 1996, AM J PHYSIOL-GASTR L, V271, pG629, DOI 10.1152/ajpgi.1996.271.4.G629	30	401	444	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					417	421		10.1038/37151	http://dx.doi.org/10.1038/37151			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389484				2022-12-28	WOS:A1997YH54900068
J	Ellrodt, G; Cook, DJ; Lee, J; Cho, M; Hunt, D; Weingarten, S				Ellrodt, G; Cook, DJ; Lee, J; Cho, M; Hunt, D; Weingarten, S			Evidence-based disease management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-PRACTICE GUIDELINES; DEPENDENT DIABETES-MELLITUS; MEDICAL LITERATURE; USERS GUIDES; INTERVENTIONAL TRIAL; COST-EFFECTIVENESS; CRITICAL PATHWAYS; PRIMARY-CARE; RECOMMENDATIONS; DECISION	Disease management is an approach to patient care that emphasizes coordinated, comprehensive care along the continuum of disease and across health care delivery systems, Evidence-based medicine is an approach to practice and teaching that integrates pathophysiological rationale, caregiver experience, and patient preferences with valid and current clinical research evidence, Using diabetes mellitus as an example, we describe the importance of evidence-based medicine to the development of disease management programs, We present a method for developing and implementing evidence-based clinical guidelines, clinical pathways, and algorithms and describe the creation of systems to measure and report processes and outcomes that could drive quality improvement in diabetes care, Multidisciplinary teams are ideally suited to develop, lead, and implement evidence-based disease management programs, since they play an essential role in the preventive, diagnostic, and therapeutic decisions for patients with diabetes throughout the course of their disease.	UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, DIV GEN INTERNAL MED, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, HLTH SERV RES FELLOWSHIP PROGRAM, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, DEPT MED, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR, SCH MED, DEPT PHARM, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, CEDARS SINAI MED CTR,SCH MED,HLTH SERV RES, DEPT MED, LOS ANGELES, CA 90048 USA; MCMASTER UNIV, FAC HLTH SCI, DEPT MED, DIV GEN INTERNAL MED, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, FAC HLTH SCI, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON L8N 3Z5, CANADA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; McMaster University; McMaster University								ALBERTI KGMM, 1994, DIABETIC MED, V11, P899, DOI 10.1111/j.1464-5491.1994.tb00376.x; Aucott JN, 1996, J GEN INTERN MED, V11, P139, DOI 10.1007/BF02600265; BARONDESS JA, 1993, ANN INTERN MED, V119, P153, DOI 10.7326/0003-4819-119-2-199307150-00010; BLANK LL, 1992, ANN INTERN MED, V117, P778; BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502; CLARK CM, 1995, NEW ENGL J MED, V332, P1210, DOI 10.1056/NEJM199505043321807; COOK DJ, 1995, CHEST, V108, pS227, DOI 10.1378/chest.108.4_Supplement.227S; COOK DJ, 1995, CAN MED ASSOC J, V153, P755; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; DEIGNAN M, 1995, PATIENT FOCUSED CARE; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; ECKMAN MH, 1995, JAMA-J AM MED ASSOC, V273, P712, DOI 10.1001/jama.273.9.712; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P287, DOI 10.1001/jama.263.2.287; ELLRODT AG, 1995, ANN INTERN MED, V122, P277, DOI 10.7326/0003-4819-122-4-199502150-00007; ELLRODT AG, 1995, PATIENT FOCUSED CARE; Epstein RS, 1996, ANN INTERN MED, V124, P832, DOI 10.7326/0003-4819-124-9-199605010-00008; Fang E, 1996, ARCH FAM MED, V5, P528, DOI 10.1001/archfami.5.9.528; FELD MJ, 1990, CLIN PRACTICE GUIDEL; FITZGERALD JF, 1994, ARCH INTERN MED, V154, P1721, DOI 10.1001/archinte.154.15.1721; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GUYAT GH, 1993, JAMA-J AM MED ASSOC, V270, P2096, DOI 10.1001/jama.270.17.2096; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; Harris JM, 1996, ANN INTERN MED, V124, P838, DOI 10.7326/0003-4819-124-9-199605010-00009; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P447, DOI 10.1136/jamia.1994.95153434; Hayward RSA, 1996, J GEN INTERN MED, V11, P176, DOI 10.1007/BF02600272; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; Hiss RG, 1996, ANN INTERN MED, V124, P180, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00021; Javitt JC, 1996, ANN INTERN MED, V124, P164, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00017; KASISKE BL, 1993, ANN INTERN MED, V118, P129, DOI 10.7326/0003-4819-118-2-199301150-00009; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; LARSEN RA, 1989, INFECT CONT HOSP EP, V10, P316, DOI 10.2307/30146474; LavizzoMourey R, 1996, ANN INTERN MED, V124, P919, DOI 10.7326/0003-4819-124-10-199605150-00010; Lee TH, 1996, J GEN INTERN MED, V11, P174, DOI 10.1007/BF02600271; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LUMSDON K, 1995, HOSP HEALTH NETWORK, V69, P34; MEYER LC, 1993, CASE MANAGER, V4, P54; Mulrow CD, 1996, J GEN INTERN MED, V11, P185, DOI 10.1007/BF02600275; NANNIPIERI M, 1995, DIABETES CARE, V18, P1, DOI 10.2337/diacare.18.1.1; NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; NOBLE J, 1994, J GEN INTERN MED, V9, pS31, DOI 10.1007/BF02598116; OBrien BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1417; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1971; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1249; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1793; OXMAN AD, 1994, CAN MED ASSOC J, V150, P1575; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; PETERS AL, 1991, ANN INTERN MED, V115, P45, DOI 10.7326/0003-4819-115-1-45; Quickel KE, 1996, ANN INTERN MED, V124, P160, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00016; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Sackett D. L., 1995, EVIDENCE BASED MED, V1, P5; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SCHOENBAUM SC, 1995, AGENCY HLTH CARE POL; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIEGEL JE, 1992, J AM SOC NEPHROL, V3, pS111; SINGER DE, 1992, ANN INTERN MED, V116, P683; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; TAN MH, 1992, CAN MED ASSOC J, V147, P697; The Boston Consulting Group, 1995, PROM DIS MAN; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; TINKER LF, 1994, J AM DIET ASSOC, V94, P507, DOI 10.1016/0002-8223(94)90212-7; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; WEINGARTEN SR, IN PRESS AM REV RESP; WILCZYNSKI NL, 1994, P ANN S COMP APPL ME, V17, P601; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630; Yandell B, 1995, Qual Manag Health Care, V3, P55	74	273	276	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1687	1692		10.1001/jama.278.20.1687	http://dx.doi.org/10.1001/jama.278.20.1687			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388089				2022-12-28	WOS:A1997YG85900031
J	Klenerman, P; Hengartner, H; Zinkernagel, RM				Klenerman, P; Hengartner, H; Zinkernagel, RM			A non-retroviral RNA virus persists in DNA form	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; T-CELL MEMORY; IMMUNOLOGICAL MEMORY; INFECTION; SEQUENCE; ANTIGEN; ESCAPE; ASSAY	Infection of adult mice with lymphocytic choriomeningitis virus (LCMV), a non-cytopathic segmented RNA virus, leads initially to generalized infection, followed by clearance and subsequent lifelong immunity. Indirect evidence has suggested that viral antigens may persist in lymphoid tissues during the phase of immunological memory, but viral genomic RNA has not been detected in previous studies(1,2). During a search for persistent virus in the spleen, we identified LCMV-specific sequences present as DNA by polymerase chain reaction (PCR) in mice over 200 days after infection. In vivo and in vitro studies revealed that reverse transcription of viral RNA into complementary DNA occurred after acute infection of cells of its natural hosts, mouse and hamster, but not of other species and could be inhibited in vitro by azidothymidine (AZT), indicating that this was mediated by endogenous reverse transcriptase activity. These findings reveal a surprising and new pathway of interaction between exogenous RNA viruses and endogenous retroviral, and perhaps other host components, that results in the persistence of virally determined DNA. We speculate that the latter may function in vivo as a form of DNA vaccine.	UNIV ZURICH HOSP,INST EXPT IMMUNOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital				klenerman, paul/0000-0003-4307-9161				Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; Coffin J, 1993, REVERSE TRANSCRIPTAS, P445; HEIDMANN O, 1991, CELL, V64, P159, DOI 10.1016/0092-8674(91)90217-M; KAGI D, 1994, NATURE, V369, P91; Kundig TM, 1996, P NATL ACAD SCI USA, V93, P9716, DOI 10.1073/pnas.93.18.9716; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LEHMANNG.F, 1967, NATURE, V213, P770, DOI 10.1038/213770a0; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P28; Loewer Roswitha, 1996, Proceedings of the National Academy of Sciences of the United States of America, V93, P5177; MOSKOPHIDIS D, 1995, J VIROL, V69, P2187, DOI 10.1128/JVI.69.4.2187-2193.1995; OLDSTONE MB, 1971, SCIENCE, V174, P843, DOI 10.1126/science.174.4011.843; OLDSTONE MBA, 1982, NATURE, V300, P360, DOI 10.1038/300360a0; Oxenius A, 1995, EUR J IMMUNOL, V25, P3402, DOI 10.1002/eji.1830251230; PEASE LR, 1980, NATURE, V286, P398, DOI 10.1038/286398a0; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; Planz O, 1997, P NATL ACAD SCI USA, V94, P6874, DOI 10.1073/pnas.94.13.6874; Planz O, 1996, NATURE, V382, P726, DOI 10.1038/382726a0; PYRA H, 1994, P NATL ACAD SCI USA, V91, P1544, DOI 10.1073/pnas.91.4.1544; RAWLS WE, 1976, J GEN VIROL, V33, P421, DOI 10.1099/0022-1317-33-3-421; ROMANOWSKI V, 1985, VIRUS RES, V3, P101, DOI 10.1016/0168-1702(85)90001-2; Salvato MS, 1993, ARENAVIRIDAE, P133; SILVER J, 1993, NUCLEIC ACIDS RES, V21, P3593, DOI 10.1093/nar/21.15.3593; SKYULEV Y, 1996, IMMUNITY, V4, P565; SLIFKA MK, 1995, J VIROL, V69, P1895, DOI 10.1128/JVI.69.3.1895-1902.1995; SMITH MS, 1987, J VIROL, V61, P3769, DOI 10.1128/JVI.61.12.3769-3773.1987; WIENER AM, 1986, ANNU REV BIOCHEM, V55, P631; YOKOYAMA M, 1995, J VIROL, V69, P2684, DOI 10.1128/JVI.69.4.2684-2688.1995; ZHDANOV VM, 1975, NATURE, V256, P471, DOI 10.1038/256471a0; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333	30	142	145	1	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					298	301		10.1038/36876	http://dx.doi.org/10.1038/36876			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384383				2022-12-28	WOS:A1997YG66700066
J	Macfarlane, J; Holmes, W; Macfarlane, R; Britten, N				Macfarlane, J; Holmes, W; Macfarlane, R; Britten, N			Influence of patients' expectations on antibiotic management of acute lower respiratory tract illness in general practice: questionnaire study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE BRONCHITIS; PRIMARY-CARE; CONSULTATION; COMMUNITY	Objective: To assess patients' views and expectations when they consult their general practitioner with acute lower respiratory symptoms and the influence these have on management. Design: General practitioners studied consecutive, previously well adults and recorded clinical data, the certainty regarding their prescribing decision, and the influence of non-clinical factors on that decision. Patients completed a questionnaire at home after the consultation. Setting: 76 doctors from suburban, inner city, and rural practices. Subjects: 1014 eligible patients entered; 787 (78%) returned the questionnaire. Main outcome measures: The views of the patient, the views of and antibiotic prescription by the doctor. Results: Most patients thought that their symptoms were caused by an infection (662) and that antibiotics would help (656) and had both wanted (564) and expected (561) such a prescription. 146 requested an antibiotic, 587 received one. Of the 643 patients who thought they had an infection, 582 wanted an antibiotic and thought it would help. Severity of symptoms did not relate to wanting antibiotics. For those prescribed antibiotics, their doctor thought they were definitely indicated in only 116 cases and not indicated in 126. Patient pressure most commonly influenced the decision to prescribe even when the doctor thought antibiotics were not indicated. Doctors considered antibiotics definitely indicated in only 1% of the group in whom patient pressure influenced the prescribing decision. Patients who did not receive an antibiotic that they wanted were much more likely to express dissatisfaction. Dissatisfied patients reconsulted for the same symptoms twice as often as satisfied patients. Conclusion: Patients presenting with acute lower respiratory symptoms often believe that infection is the problem and antibiotics the answer. Patients' expectations have a significant influence on prescribing, even when their doctor judges that antibiotics are not indicated.	SHERRINGTON PK MED PRACTICE, NOTTINGHAM NG5 2EJ, ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DEPT GEN PRACTICE, LONDON SE11 6SP, ENGLAND	University of London; King's College London	Macfarlane, J (corresponding author), CITY HOSP NOTTINGHAM, RESP INFECT UNIT, HUCKNALL RD, NOTTINGHAM NG5 1PB, ENGLAND.							Armstrong D, 1996, BRIT MED J, V312, P949; *AUD COMM, 1994, PRESCR IMPR MOR RAT; BAIN DJG, 1983, BRIT MED J, V287, P1269, DOI 10.1136/bmj.287.6401.1269; BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BRITTEN N, 1995, BRIT MED J, V310, P1084, DOI 10.1136/bmj.310.6987.1084; BRITTEN N, 1996, THESIS U LONDON; CARTWRIGHT A, 1981, GENERAL PRACTICE REV; Davey PG, 1996, BRIT MED J, V312, P613, DOI 10.1136/bmj.312.7031.613; HOLMES WF, IN PRESS BR J GEN PR; Howie J G, 1973, J R Coll Gen Pract, V23, P895; HOWIE JGR, 1991, BRIT J GEN PRACT, V41, P48; HOWIE JGR, 1978, BRIT MED J, V2, P1342, DOI 10.1136/bmj.2.6148.1342; HOWIE JGR, 1974, BRIT MED J, V2, P540, DOI 10.1136/bmj.2.5918.540; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Macfarlane J, 1997, RESP MED, V91, P427, DOI 10.1016/S0954-6111(97)90258-4; Macfarlane JT, 1997, BRIT J GEN PRACT, V47, P719; MOLSTAD S, 1994, FAM PRACT, V11, P282, DOI 10.1093/fampra/11.3.282; MONTO A S, 1971, American Journal of Epidemiology, V94, P269; MORRELL DC, 1986, BMJ-BRIT MED J, V292, P870, DOI 10.1136/bmj.292.6524.870; Nicholson KG, 1996, BMJ-BRIT MED J, V313, P1119, DOI 10.1136/bmj.313.7065.1119; ORR PH, 1993, J FAM PRACTICE, V36, P507; RAPAPORT J, 1979, J R COLL GEN PRACT, V29, P468; VENKATESAN P, 1995, THORAX, V50, P481, DOI 10.1136/thx.50.5.481; VERHEIJ TJM, 1989, FAM PRACT, V6, P66, DOI 10.1093/fampra/6.1.66; VIRJI A, 1991, FAM PRACT, V8, P314, DOI 10.1093/fampra/8.4.314; WEBB S, 1994, BRIT J GEN PRACT, V44, P165	26	336	346	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	1997	315	7117					1211	1214		10.1136/bmj.315.7117.1211	http://dx.doi.org/10.1136/bmj.315.7117.1211			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393228	Green Published			2022-12-28	WOS:A1997YF25200027
J	Greenberger, NJ				Greenberger, NJ			Update in gastroenterology	ANNALS OF INTERNAL MEDICINE			English	Bibliography											Greenberger, NJ (corresponding author), UNIV KANSAS, MED CTR, DEPT MED, RAINBOW BLVD & 39TH ST, KANSAS CITY, KS 66103 USA.								0	13	13	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					827	834		10.7326/0003-4819-127-9-199711010-00009	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382405				2022-12-28	WOS:A1997YD89800008
J	Dyson, DC; Danbe, KH; Bamber, JA; Crites, YM; Field, DR; Maier, JA; Newman, LA; Ray, DA; Walton, DL; Armstrong, MA				Dyson, DC; Danbe, KH; Bamber, JA; Crites, YM; Field, DR; Maier, JA; Newman, LA; Ray, DA; Walton, DL; Armstrong, MA			Monitoring women at risk for preterm labor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	17th Annual Meeting of the Society-of-Perinatal-Obstetricians	JAN 20-26, 1997	ANAHEIM, CALIFORNIA	Soc Perinatal Obstetricians			UTERINE ACTIVITY; BIRTH; TRIAL; PREVENTION; CONTACT	Background Preterm birth is a major cause of perinatal morbidity and mortality. Whether the rate of preterm birth can be reduced by frequent contact between nurses and pregnant women or home monitoring of uterine activity is not known. Methods We randomly assigned 2422 pregnant women with known risk factors for preterm labor (including 844 women who were pregnant with twins) to receive education and to have one of the following: weekly contact with a nurse, daily contact with a nurse, or daily contact with a nurse and home monitoring of uterine activity. The nurses elicited the women's own assessments of their symptoms and signs of preterm labor. The primary end point was the incidence of birth at less than 35 weeks' gestation. Secondary end points included cervical status at the time preterm labor was diagnosed and birth weight. Results There were no significant differences among the groups in the incidence of birth at less than 35 weeks (14 percent in the weekly-contact group, 13 percent in the daily-contact group, and 14 percent in the home-monitoring group), in the mean amount of cervical dilatation at the time preterm labor was diagnosed (1.8 cm, 1.5 cm, and 1.4 cm, respectively), or in such neonatal outcomes as birth weights of less than 1500 g or less than 2500 g. However, daily contact with a nurse increased the mean number of unscheduled visits to obstetricians (1.2 in the weekly-contact group, 1.8 in the daily-contact group, and 2.3 in the home-monitoring group) and the proportion of women who received prophylactic tocolytic drugs (12 percent, 14 percent, and 19 percent, respectively). Conclusions Women who have daily contact with a nurse, with or without home monitoring of uterine activity, have no better pregnancy outcomes than women who have weekly contact with a nurse. (C) 1998, Massachusetts Medical Society.	Kaiser Permanente Med Care Program, Dept Obstet, Div Maternal Fetal Med, Santa Clara, CA USA; Kaiser Permanente Med Care Program, Dept Gynecol, Div Maternal Fetal Med, Santa Clara, CA USA	Kaiser Permanente; Kaiser Permanente	Dyson, DC (corresponding author), Kaiser Permanente Med Ctr, Dept Obstet & Gynecol, 900 Kiely Blvd,Bldg J,Suite 2, Santa Clara, CA 95051 USA.			Walton, David/0000-0002-8461-2551				CREASY RK, 1991, NEW ENGL J MED, V325, P727, DOI 10.1056/NEJM199109053251009; CURRY SJ, 1995, J CONSULT CLIN PSYCH, V63, P1005, DOI 10.1037/0022-006X.63.6.1005; DEVOE LD, 1995, AM J OBSTET GYNECOL, V173, P1120; DYSON DC, 1991, AM J OBSTET GYNECOL, V164, P756, DOI 10.1016/0002-9378(91)90510-X; GRIMES DA, 1992, OBSTET GYNECOL, V79, P137; HERRON MA, 1982, OBSTET GYNECOL, V59, P452; HILL WC, 1990, OBSTET GYNECOL S, V76, pS3; IAMS JD, 1988, AM J OBSTET GYNECOL, V159, P595, DOI 10.1016/S0002-9378(88)80016-4; KATZ M, 1986, OBSTET GYNECOL, V68, P773; MORRISON JC, 1987, AM J OBSTET GYNECOL, V156, P536, DOI 10.1016/0002-9378(87)90046-9; MOU SM, 1991, AM J OBSTET GYNECOL, V165, P858, DOI 10.1016/0002-9378(91)90429-U; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PORTO M, 1987, SOC PER OBST 7 ANN M; SACHS BP, 1991, NEW ENGL J MED, V325, P1374, DOI 10.1056/NEJM199111073251911; WALL MA, 1995, PEDIATRICS, V96, P622; WAPNER RJ, 1995, AM J OBSTET GYNECOL, V172, P1026, DOI 10.1016/0002-9378(95)90038-1; WOOLF SH, 1993, JAMA-J AM MED ASSOC, V270, P369	17	92	98	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	1998	338	1					15	19		10.1056/NEJM199801013380103	http://dx.doi.org/10.1056/NEJM199801013380103			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN801	9414326				2022-12-28	WOS:000071209200003
J	Meyer, GS; Gibbons, RV				Meyer, GS; Gibbons, RV			House calls to the elderly - A vanishing practice among physicians	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOME CARE; FAMILY PHYSICIANS; GENERAL-PRACTITIONERS; HEALTH; VISITS; INTERNISTS; ATTITUDES; TRIAL	Background Despite the growth in other home health care services, the number of house calls by physicians has declined dramatically during this century. We determined the frequency of house calls made by physicians to elderly U.S. patients in 1993 and analyzed the characteristics of the physicians and patients involved. Methods We analyzed a 5 percent random sample of the 1993 Medicare Part B claims data for beneficiaries over the age of 65 who were not enrolled in health maintenance organizations (HMOs). With supplemental information from the Area Resource Pile and the American Medical Association's Physician I Masterfile, we determined how many house; calls were made, their cost, and a number of specific characteristics of the physicians and the patients. Results In our 1993 sample, 36,350 house calls were made to 11,917 of the 1,357,262 patients. When extrapolated to all Medicare beneficiaries over age 65 and not enrolled in HMOs, these figures correspond to 727,000 house calls to 238,340 patients nationwide. We estimated the cost of these house calls to be $63 million. The patients who received house calls from physicians were older than those who did not, were more likely to die within the calendar year, had higher rates of hospitalization, and were more likely to receive care from other home health providers, hospice programs, and skilled-nursing facilities. Patients residing in rural areas and those in areas with high physician-to-population ratios had an increased likelihood of receiving a house call. The physicians who made house calls were more likely than others to be generalists, osteopaths, older, male, board-certified, practicing in the Northeast, and in solo practice. Conclusions A very small percentage (0.88 percent) of elderly Medicare patients, mainly those who are very sick and near the end of life, receive house calls from physicians. (C) 1997, Massachusetts Medical Society.	UNIFORMED SERV UNIV HLTH SCI,DEPT PREVENT MED,BETHESDA,MD 20814; UNIFORMED SERV UNIV HLTH SCI,DEPT BIOMETR,BETHESDA,MD 20814; WALTER REED ARMY MED CTR,WASHINGTON,DC 20307; UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA								ADELMAN AM, 1994, J FAM PRACTICE, V39, P39; *AM MED ASS, 1992, PHYS CURR PROC TERM; Aylin P, 1996, BRIT MED J, V313, P207, DOI 10.1136/bmj.313.7051.207; BAYNE G, 1991, AM ACAD HOME CARE PH, V3, P6; BOLING PA, 1991, J GEN INTERN MED, V6, P335, DOI 10.1007/BF02597433; BOLING PA, 1992, J AM GERIATR SOC, V40, P1241, DOI 10.1111/j.1532-5415.1992.tb03650.x; BOLING PA, 1990, ARCH INTERN MED, V150, P2833; CAMPION EW, 1995, NEW ENGL J MED, V333, P1213, DOI 10.1056/NEJM199511023331810; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; *COLL STAT, 1996, STAT REF MAN VERS 5; *COUNC SCI AFF, 1991, JAMA-J AM MED ASSOC, V265, P769; *COUNC SCI AFF, 1990, JAMA-J AM MED ASSOC, V263, P1241; *COUNC SCI AFF COU, 1991, JAMA-J AM MED ASSOC, V265, P2340; DRISCOLL CE, 1991, AM ACAD HOME CARE PH, V3, P7; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; ELIXHAUSER A, 1996, AHCPR PUBL; GOLDBERG AI, 1995, PEDIATRICS, V95, P928; Goldberg J H, 1995, Med Econ, V72, P121; GREENGOLD MC, 1995, ACAD MED, V70, pS35, DOI 10.1097/00001888-199501000-00022; HANSEN FR, 1995, AGING-CLIN EXP RES, V7, P202, DOI 10.1007/BF03324316; Hayton A, 1986, Fam Pract Res J, V6, P22; *HLTH CAR DIN ADM, 1994, HCFA PUBL; *HLTH CAR FIN ADM, 1990, FED REGISTER, V55, P18179; *INT CLASS DIS, 1995, ICM9CM INT CLASS DIS; KEENAN JM, 1991, J AM GERIATR SOC, V39, P1100, DOI 10.1111/j.1532-5415.1991.tb02876.x; KEENAN JM, 1992, ARCH INTERN MED, V152, P2025, DOI 10.1001/archinte.152.10.2025; KEENAN JM, 1989, J AM GERIATR SOC, V37, P1076, DOI 10.1111/j.1532-5415.1989.tb06924.x; KNIGHT AL, 1991, AM FAM PHYSICIAN, V44, P1733; KRISTIANSEN IS, 1993, J EPIDEMIOL COMMUN H, V47, P481, DOI 10.1136/jech.47.6.481; LANG F, 1996, FAM MED, V28, P434; MAKUC DM, 1991, VITAL HLTH STATIST 2, V112; *MED MED STAT SUPP, 1995, HLTH CAR FIN REV S, V16; *OFF RES PLANN BUR, 1993, US DOC AR RES FIL FE; Parente S T, 1995, Am J Med Qual, V10, P162, DOI 10.1177/0885713X9501000402; ROBACK G, 1992, PHYSICIAN CHARACTERI; ROSENBLATT RA, 1996, PROCEDURAL GROUPER; SCANAMEO AM, 1995, GERIATRICS-US, V50, P33; SCHUELER MS, 1987, WESTERN J MED, V147, P92; SCHWARTZBERG JG, 1993, AM ACADEMY HOME CARE, V5, P1; SCHWARTZBERG JG, 1993, AM ACADEMY HOME CARE, V5, P3; Shah A, 1994, Int Psychogeriatr, V6, P179, DOI 10.1017/S1041610294001742; STAMBLER HV, 1988, PUBLIC HEALTH REP, V103, P184; STARR P, 1982, SOCIAL TRANSFORMATIO, P359; STEINKULLER JS, 1992, AM J DIS CHILD, V146, P1064, DOI 10.1001/archpedi.1992.02160210066023; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; Welch HG, 1996, NEW ENGL J MED, V335, P324, DOI 10.1056/NEJM199608013350506	46	87	87	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 18	1997	337	25					1815	1820		10.1056/NEJM199712183372507	http://dx.doi.org/10.1056/NEJM199712183372507			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL855	9400040	Bronze			2022-12-28	WOS:A1997YL85500007
J	Callahan, CM				Callahan, CM			Chronic active adolescence	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Indiana Univ, Sch Med, Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	Callahan, CM (corresponding author), Indiana Univ, Sch Med, Regenstrief Inst Hlth Care, 1001 W 10th St,RG6, Indianapolis, IN 46202 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1124	1125		10.7326/0003-4819-127-12-199712150-00012	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412317				2022-12-28	WOS:000070936600011
J	IkeshimaKataoka, H; Skeath, JB; Nabeshima, Y; Doe, CQ; Matsuzaki, F				IkeshimaKataoka, H; Skeath, JB; Nabeshima, Y; Doe, CQ; Matsuzaki, F			Miranda directs Prospero to a daughter cell during Drosophila asymmetric divisions	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; GANGLION MOTHER CELLS; GENE; PROTEIN; NUMB; EXPRESSION; FATES; SEGREGATION; MARKERS	Asymmetric cell division is a general process used in many developmental contexts to create two differently fated cells from a single progenitor cell. Intrinsic mechanisms like the asymmetric transmission of tell-fate determinants during cell division, and extrinsic cell-interaction mechanisms, can mediate asymmetric divisions(1-3). During embryonic development of the Drosophila central nervous system, neural stem cells called neuroblasts divide asymmetrically to produce another multipotent neuroblast and a ganglion mother cell (GMC) of more restricted developmental potential. Intrinsic mechanisms promote asymmetric division of neuroblasts: for example, the transcription factor Prospero localizes to the basal cell cortex of mitotic neuroblasts and then segregates exclusively into the GMC, which buds off from the basal side of the neuroblast(4-6). In the GMC, Prospero translocates to the nucleus, where it establishes differential gene expression between sibling cells. Here we report the identification of a gene, miranda, which encodes a new protein that co-localizes with Prospero in mitotic neuroblasts, tethers Prospero to the basal cortex of mitotic neuroblasts, directing Prospero into the GMC, and releases Prospero from the cell cortex within GMCs. miranda thus creates intrinsic differences between sibling cells by mediating the asymmetric segregation of a transcription factor into only one daughter cell during neural stem-cell division.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DEPT MOL GENET,KODAIRA,TOKYO 187,JAPAN; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; UNIV ILLINOIS,HOWARD HUGHES MED INST,URBANA,IL 61801; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801	National Center for Neurology & Psychiatry - Japan; Washington University (WUSTL); Howard Hughes Medical Institute; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign								BRAND AH, 1993, DEVELOPMENT, V118, P401; BROADUS J, 1995, MECH DEVELOP, V53, P393, DOI 10.1016/0925-4773(95)00454-8; CamposOrtega JA, 1996, NEURON, V17, P1, DOI 10.1016/S0896-6273(00)80274-3; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DOE CQ, 1992, DEVELOPMENT, V116, P855; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JAN YN, 1995, NEURON, V14, P1; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Lin HF, 1997, TRENDS GENET, V13, P33, DOI 10.1016/S0168-9525(96)10050-0; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; OTOUSA JE, 1989, J NEUROGENET, V6, P41, DOI 10.3109/01677068909107099; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; UEMERA T, 1989, CELL, V5, P349; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203	23	258	262	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					625	629		10.1038/37641	http://dx.doi.org/10.1038/37641			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403694				2022-12-28	WOS:A1997YK85300054
J	VanBuskirk, AM; Pidwell, DJ; Adams, PW; Orosz, CG				VanBuskirk, AM; Pidwell, DJ; Adams, PW; Orosz, CG			Transplantation immunology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							T-CELL ACTIVATION; ALLOGRAFT-REJECTION; ORGAN-TRANSPLANTATION; HEART-TRANSPLANTATION; LYMPHOCYTE-RESPONSES; MHC MOLECULES; RISK-FACTORS; PEPTIDE; POPULATIONS; IMMUNE	The practice of clinical and experimental transplantation continues to evolve at a rapid pace. To appreciate the current transplant practices, it is first necessary to review transplant immunology in its proper context, ie, as a component of the complex series of events that promote the repair of damaged tissues. These processes are generally catagorized as inflammation, immunity, and tissue repair/reinforcement. In general, there are 3 forms of graft rejection:hyperacute, acute, and chronic rejection. All 3 forms of graft rejection represent pathologic consequences of one or more of these repair-related processes. The various graft rejection responses also illustrate several complex immunologic principles that need to be considered. These include the definition of an alloantigen, the structure and function of major histocompatibility complex molecules, and the behavior of antigen-presenting cells and alloreactive T cells. This review combines these concepts and principles into a discussion of the 3 forms of graft rejection, each of which is addressed at the level of histopathology, pathobiology, incidence, and clinical strategies.	JEWISH HOSP, TISSUE TYPING LAB, LOUISVILLE, KY 40202 USA; OHIO STATE UNIV, CLIN HISTOCOMPATIBIL LAB, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University	VanBuskirk, AM (corresponding author), OHIO STATE UNIV, DEPT SURG, DIV TRANSPLANTAT, 363 MEANS HALL, 1654 UPHAM DR, COLUMBUS, OH 43210 USA.							ALLISON AC, 1993, TRANSPLANT REV, V7, P129, DOI DOI 10.1016/S0955-470X(05)80012-6; ALMOND PS, 1993, TRANSPLANTATION, V55, P752, DOI 10.1097/00007890-199304000-00013; Armstrong AT, 1997, TRANSPLANTATION, V63, P941, DOI 10.1097/00007890-199704150-00006; Azuma H, 1995, J HEART LUNG TRANSPL, V14, pS136; BASADONNA GP, 1993, TRANSPLANTATION, V55, P993, DOI 10.1097/00007890-199305000-00007; BEATTY PG, 1997, MANUAL CLIN LAB IMMU, P1123; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; Bluestone JA, 1996, CLIN TRANSPLANT, V10, P104; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; Bradley J, 1992, TRANSPLANT REV, V6, P115; Bradley J A, 1996, Int Rev Immunol, V13, P245, DOI 10.3109/08830189609061751; BRAUN WE, 1989, HUM IMMUNOL, V26, P245, DOI 10.1016/0198-8859(89)90003-7; Brazelton TR, 1996, CURR OPIN IMMUNOL, V8, P710, DOI 10.1016/S0952-7915(96)80090-2; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Brown MA, 1997, CRIT REV IMMUNOL, V17, P1; CHAPMAN JR, 1986, TRANSPLANTATION, V42, P608, DOI 10.1097/00007890-198612000-00007; CHIEN YH, 1993, IMMUNOL TODAY, V14, P597, DOI 10.1016/0167-5699(93)90199-U; Clement JD, 1996, TRANSPLANTATION, V62, P388, DOI 10.1097/00007890-199608150-00015; Cotran R.S., 1994, ROBBINS PATHOLOGIC B, V5th ed., P51; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; DALMASSO AP, 1992, IMMUNOPHARMACOLOGY, V24, P149, DOI 10.1016/0162-3109(92)90020-D; Danovitch G, 1996, TRANSPLANTATION, V61, P722; DAYNES RA, 1992, CHEM IMMUNOL, V54, P1; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; Dubey C, 1996, J IMMUNOL, V157, P3280; EICH D, 1991, J HEART LUNG TRANSPL, V10, P45; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Germain Ronald N., 1993, P629; Gill RG, 1996, IMMUNOL REV, V149, P75, DOI 10.1111/j.1600-065X.1996.tb00900.x; GREGORY CR, 1995, TRANSPLANTATION, V59, P655, DOI 10.1097/00007890-199503150-00002; HALL BM, 1984, IMMUNOL REV, V77, P31, DOI 10.1111/j.1600-065X.1984.tb00717.x; HALL BM, 1991, TRANSPLANTATION, V51, P1141, DOI 10.1097/00007890-199106000-00001; HALLORAN PF, 1992, TRANSPLANTATION, V53, P550, DOI 10.1097/00007890-199203000-00011; HAYRY P, 1993, TRANSPLANT REV, V7, P1; HINTZEN RQ, 1995, J IMMUNOL, V154, P2612; ISONIEMI H, 1994, TRANSPLANTATION, V57, P68, DOI 10.1097/00007890-199401000-00013; JOHNSON JG, 1993, IMMUNOL RES, V12, P48, DOI 10.1007/BF02918368; Kaplanski G, 1997, J IMMUNOL, V158, P5435; Kobashigawa JA, 1997, TRANSPLANTATION, V63, P331, DOI 10.1097/00007890-199702150-00001; Krensky AM, 1997, KIDNEY INT, pS2; LakeBullock MH, 1997, J IMMUNOL, V158, P5079; Lider O, 1995, CRIT REV IMMUNOL, V15, P271, DOI 10.1615/CritRevImmunol.v15.i3-4.50; LOBO PI, 1995, TRANSPLANTATION, V59, P357, DOI 10.1097/00007890-199502150-00009; LU CY, 1994, FASEB J, V8, P1122, DOI 10.1096/fasebj.8.14.7958617; MACGREGOR MS, 1995, BRIT J HOSP MED, V54, P276; MATAS AJ, 1994, TRANSPLANTATION, V57, P857, DOI 10.1097/00007890-199403270-00015; MONDINO A, 1994, J LEUKOCYTE BIOL, V55, P805, DOI 10.1002/jlb.55.6.805; Orosz CG, 1996, CLIN TRANSPLANT, V10, P100; Orosz CG, 1996, J HEART LUNG TRANSPL, V15, P1063; OROSZ CG, 1995, TRANSPLANT VASCULAR, P1; Orosz CG., 1997, TRANSPLANT REV-ORLAN, V11, P38, DOI [10.1016/S0955-470X(97)80036-5, DOI 10.1016/S0955-470X(97)80036-5]; PARKER W, 1994, J IMMUNOL, V153, P3791; Piccotti JR, 1997, TRANSPLANTATION, V63, P619, DOI 10.1097/00007890-199703150-00001; PLATT JL, 1990, IMMUNOL TODAY, V11, P450, DOI 10.1016/0167-5699(90)90174-8; PRZEPIORKA D, 1994, RECENT DEV TRANSPLAN, V1, P1; RAMMENSEE HG, 1993, CURR OPIN IMMUNOL, V5, P35, DOI 10.1016/0952-7915(93)90078-7; ROSE EA, 1989, SURGERY, V106, P203; ROSENBERG AS, 1992, ANNU REV IMMUNOL, V10, P333, DOI 10.1146/annurev.immunol.10.1.333; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; RUSSELL PS, 1994, J IMMUNOL, V152, P5135; SCORNIK JC, 1992, TRANSPLANTATION, V54, P389, DOI 10.1097/00007890-199209000-00001; SHULZ M, 1995, EUR J IMMUNOL, V25, P474, DOI 10.1002/eji.1830250225; SIMMONS RL, 1994, PRINCIPLES SURGERY, P377; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; TAKEUCHI T, 1992, TRANSPLANTATION, V53, P1281, DOI 10.1097/00007890-199206000-00023; TOOSSI Z, 1992, P NATL ACAD SCI USA, V89, P11969, DOI 10.1073/pnas.89.24.11969; TULLIUS SG, 1995, TRANSPLANTATION, V59, P313, DOI 10.1097/00007890-199502150-00001; VanBuskirk AM, 1996, TRANSPLANTATION, V62, P229, DOI 10.1097/00007890-199607270-00014; VanBuskirk AM, 1996, TRANSPLANTATION, V62, P300, DOI 10.1097/00007890-199607270-00026; VANBUSKIRK AM, 1994, ROLE MHC NONMHC ANTI, P27; WAHLERS T, 1995, J HEART LUNG TRANSPL, V14, P143; ZELENOCK GB, 1993, SURG SCI PRINCIPLES, P1500	72	42	45	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1993	1999		10.1001/jama.278.22.1993	http://dx.doi.org/10.1001/jama.278.22.1993			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396662				2022-12-28	WOS:A1997YK15500023
J	Weber, RW				Weber, RW			Immunotherapy with allergens	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; HYMENOPTERA STING ALLERGY; RAGWEED HAY-FEVER; HOUSE DUST MITE; DOUBLE-BLIND; GRASS-POLLEN; VENOM IMMUNOTHERAPY; RUSH IMMUNOTHERAPY; CLINICAL EFFICACY; SUPPRESSOR CELLS	Allergen immunotherapy has been shown to be efficacious in numerous studies for the clinical indications of allergic asthma and rhinitis, as well as hymenoptera venom hypersensitivity. How allergen immunotherapy improves clinical symptoms is still not entirely clear. Decreases in specific IgE follow a complex cascade of effects: a shifting of the cytokine milieu from T(H)2 to T(H)1 predominance, with resultant decrease in interleukin 4, decreased recruitment and activation of eosinophils, and decreased proliferation of mast cells. Allergen exposure has a lessened ability to stimulate an inflammatory cell response, with decreased tar get organ hyperreactivity. Since allergen immunotherapy is not without risk, the decision needs to be made whether injection therapy is safe and provides benefit not achievable by medical management. The continued clarification of optimal allergen concentrations through careful studies of standardized extracts will allow better control of adverse events by limiting unnecessarily potent mixtures.			Weber, RW (corresponding author), NATL JEWISH MED & RES CTR, 1400 JACKSON ST, DENVER, CO 80206 USA.							AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; ALEXANDER HL, 1948, J ALLERGY, V19, P1, DOI 10.1016/0021-8707(48)90071-9; Barnes PJ, 1996, NEW ENGL J MED, V334, P531, DOI 10.1056/NEJM199602223340811; BERNSTEIN DI, 1989, J ALLERGY CLIN IMMUN, V84, P951, DOI 10.1016/0091-6749(89)90394-1; Bonno M, 1996, J ALLERGY CLIN IMMUN, V97, P680, DOI 10.1016/S0091-6749(96)70314-7; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; BROWN A, 1932, J ALLERGY, V3, P113; BROWN GT, 1934, J ALLERGY, V6, P86; COLMES ABRAHAM, 1933, JOUR ALLERGY, V4, P473, DOI 10.1016/S0021-8707(33)90100-8; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; CRIMI E, 1991, J ALLERGY CLIN IMMUN, V87, P721, DOI 10.1016/0091-6749(91)90395-5; DJURUP R, 1984, ALLERGY, V39, P433, DOI 10.1111/j.1398-9995.1984.tb01965.x; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; EBNER C, 1994, ALLERGY, V49, P38, DOI 10.1111/j.1398-9995.1994.tb00771.x; *EX COMM AM AC ALL, 1990, J ALLERGY CLIN IMMUN, V85, P526; FORTNER BR, 1981, ANN ALLERGY, V47, P147; FRANKLAND AW, 1954, LANCET, V1, P1055; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; Freeman J, 1911, LANCET, V2, P814; Freeman J, 1930, LANCET, V1, P744; FROSTAD AB, 1983, CLIN ALLERGY, V13, P337, DOI 10.1111/j.1365-2222.1983.tb02609.x; GEORGITIS JW, 1984, J ALLERGY CLIN IMMUN, V74, P694, DOI 10.1016/0091-6749(84)90232-X; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GOLDEN DBK, 1989, J ALLERGY CLIN IMMUN, V84, P162, DOI 10.1016/0091-6749(89)90320-5; GRAFT DF, 1991, J ALLERGY CLIN IMMUN, V88, P409, DOI 10.1016/0091-6749(91)90105-W; GRAFT DF, 1984, J PEDIATR-US, V104, P664, DOI 10.1016/S0022-3476(84)80940-3; GRAMMER LC, 1984, J ALLERGY CLIN IMMUN, V73, P484, DOI 10.1016/0091-6749(84)90359-2; GRAMMER LC, 1989, J ALLERGY CLIN IMMUN, V83, P750, DOI 10.1016/0091-6749(89)90010-9; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; Hedlin G, 1995, J ALLERGY CLIN IMMUN, V96, P879, DOI 10.1016/S0091-6749(95)70223-7; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; HIRSCH SR, 1981, J ALLERGY CLIN IMMUN, V68, P133, DOI 10.1016/0091-6749(81)90172-X; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; HSIEH KH, 1985, J ALLERGY CLIN IMMUN, V76, P188, DOI 10.1016/0091-6749(85)90700-6; HSIEH KH, 1988, J CLIN IMMUNOL, V8, P171, DOI 10.1007/BF00917563; HSIEH KH, 1993, J ALLERGY CLIN IMMUN, V91, P650, DOI 10.1016/0091-6749(93)90271-G; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; JUNG CM, 1995, J ALLERGY CLIN IMMUN, V95, P77, DOI 10.1016/S0091-6749(95)70155-9; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V85, P606, DOI 10.1016/0091-6749(90)90100-I; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; LICHTENSTEIN LM, 1968, J ALLERGY, V41, P49, DOI 10.1016/0021-8707(68)90007-5; LIN MS, 1993, ANN ALLERGY, V71, P557; Loveless MH, 1943, J IMMUNOL, V47, P165; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; NATAF P, 1984, CLIN ALLERGY, V14, P269, DOI 10.1111/j.1365-2222.1984.tb02206.x; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; NELSON HS, 1980, ANN ALLERGY, V45, P333; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P41, DOI 10.1016/0091-6749(81)90121-4; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1971, J ALLERGY, V47, P273, DOI 10.1016/S0091-6749(71)80005-2; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V70, P248, DOI 10.1016/0091-6749(82)90061-6; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; OSTERBALLE O, 1982, ALLERGY, V37, P379, DOI 10.1111/j.1398-9995.1982.tb02316.x; OTSUKA H, 1991, CLIN EXP ALLERGY, V21, P115, DOI 10.1111/j.1365-2222.1991.tb00812.x; PARKER WA, 1989, J ALLERGY CLIN IMMUN, V84, P667, DOI 10.1016/0091-6749(89)90294-7; PASSALACQUA G, 1995, AM J RESP CRIT CARE, V152, P461, DOI 10.1164/ajrccm.152.2.7633693; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; ROGERS BL, 1994, MOL IMMUNOL, V31, P955, DOI 10.1016/0161-5890(94)90090-6; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; STROM GB, 1983, J ALLERGY CLIN IMMUN, V72, P46, DOI 10.1016/0091-6749(83)90051-9; TAMIR R, 1987, J ALLERGY CLIN IMMUN, V79, P591, DOI 10.1016/S0091-6749(87)80154-9; TAUDORF E, 1983, ALLERGY, V38, P561, DOI 10.1111/j.1398-9995.1983.tb04140.x; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x; TIPTON WR, 1982, J ALLERGY CLIN IMMUN, V69, P194, DOI 10.1016/0091-6749(82)90099-9; TREDE NS, 1989, ALLERGY, V44, P272, DOI 10.1111/j.1398-9995.1989.tb01069.x; URBANEK R, 1985, J PEDIATR-US, V107, P367, DOI 10.1016/S0022-3476(85)80508-4; VANBEVER HP, 1989, CLIN EXP ALLERGY, V19, P399, DOI 10.1111/j.1365-2222.1989.tb02405.x; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; VERVLOET D, 1980, CLIN ALLERGY, V10, P59, DOI 10.1111/j.1365-2222.1980.tb02080.x; WARNER JO, 1978, LANCET, V2, P912; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250	90	30	33	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1881	1887		10.1001/jama.278.22.1881	http://dx.doi.org/10.1001/jama.278.22.1881			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396649				2022-12-28	WOS:A1997YK15500010
J	Welch, HG; Black, WC				Welch, HG; Black, WC			Using autopsy series to estimate the disease ''reservoir'' for ductal carcinoma in situ of the breast: How much more breast cancer can we find?	ANNALS OF INTERNAL MEDICINE			English	Review							IN-SITU; EPIDEMIOLOGIC NECROPSY; LESIONS; MAMMOGRAPHY; PREVALENCE; WOMEN; RADIOLOGISTS; VARIABILITY; THERAPY; BENIGN	Purpose: To determine how many cases of breast cancer might be found if women not known to have the disease were thoroughly examined (the disease ''reservoir''). Data Sources: MEDLINE search from 1966 to the present. Study Selection: Hospital-based and forensic autopsy series examining women not known to have had breast cancer during life. Data Extraction: Observed prevalence of occult invasive breast cancer or ductal carcinoma in situ (DCIS) in which the number of women who were given a diagnosis was the numerator and the number of women examined was the denominator. For each autopsy series, we attempted to ascertain the level of scrutiny (sampling method, number of slides examined) given to the pathologic specimens. Data Synthesis: Among seven autopsy series of women not known to have had breast cancer during life, the median prevalence of invasive breast cancer was 1.3% (range, 0% to 1.8%) and the median prevalence of DCIS was 8.9% (range, 0% to 14.7%). Prevalences were higher among women likely to have been screened (that is, women 40 to 70 years of age). The mean number of slides examined per breast ranged from 9 to 275; series that reported higher levels of scrutiny tended to discover more cases of cancer. Conclusions: A substantial reservoir of DCIS is undetected during life. How hard pathologists look for the disease and, perhaps, their threshold for making the diagnosis are potentially important factors in determining how many cases of DCIS are diagnosed. The latter has important implications for what it means to have the disease.	DARTMOUTH COLL SCH MED, CTR EVALUAT CLIN SCI, HANOVER, NH 03755 USA; DARTMOUTH HITCHCOCK MED CTR, LEBANON, NH 03766 USA	Dartmouth College; Dartmouth College	Welch, HG (corresponding author), DEPT VET AFFAIRS MED CTR, VA OUTCOMES GRP 111B, WHITE RIVER JCT, VT 05009 USA.							ALPERS CE, 1985, HUM PATHOL, V16, P796, DOI 10.1016/S0046-8177(85)80251-3; BARTOW SA, 1987, CANCER, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M; Beam CA, 1996, ARCH INTERN MED, V156, P209, DOI 10.1001/archinte.156.2.209; BHATHAL PS, 1985, BRIT J CANCER, V51, P271, DOI 10.1038/bjc.1985.39; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; CHAN CK, 1989, INT J EPIDEMIOL, V18, P315, DOI 10.1093/ije/18.2.315; ELMORE JG, 1994, NEW ENGL J MED, V331, P1493, DOI 10.1056/NEJM199412013312206; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; FEUER EJ, 1992, AM J EPIDEMIOL, V136, P1423, DOI 10.1093/oxfordjournals.aje.a116463; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; Foucar E, 1996, LANCET, V347, P707, DOI 10.1016/S0140-6736(96)90073-2; HARRIS JR, 1992, NEW ENGL J MED, V327, P390, DOI 10.1056/NEJM199208063270606; JATOI I, 1995, SURGERY, V118, P118, DOI 10.1016/S0039-6060(05)80019-4; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; KETCHAM AS, 1990, CANCER, V65, P387, DOI 10.1002/1097-0142(19900201)65:3<387::AID-CNCR2820650302>3.0.CO;2-Y; KRAMER WM, 1973, CANCER, V31, P130, DOI 10.1002/1097-0142(197301)31:1<130::AID-CNCR2820310117>3.0.CO;2-N; MCFARLANE MJ, 1987, JAMA-J AM MED ASSOC, V258, P331, DOI 10.1001/jama.258.3.331; NIELSEN M, 1984, CANCER-AM CANCER SOC, V54, P612, DOI 10.1002/1097-0142(1984)54:4<612::AID-CNCR2820540403>3.0.CO;2-B; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; POLLEI SR, 1987, RADIOLOGY, V163, P459, DOI 10.1148/radiology.163.2.3562827; ROSAI J, 1991, AM J SURG PATHOL, V15, P209, DOI 10.1097/00000478-199103000-00001; SCHNITT SJ, 1992, AM J SURG PATHOL, V16, P1133, DOI 10.1097/00000478-199212000-00001; Schwartz G F, 1994, Oncology (Williston Park), V8, P21; SEIDMAN H, 1985, CA-CANCER J CLIN, V35, P36, DOI 10.3322/canjclin.35.1.36; SHAPIRO S, 1991, J NATL CANCER I, V83, P1522, DOI 10.1093/jnci/83.21.1522; SIMONOVIS NJ, 1991, AM J EPIDEMIOL, V133, P922, DOI 10.1093/oxfordjournals.aje.a115971; STACEYCLEAR A, 1992, LANCET, V340, P991; WELLINGS SR, 1975, J NATL CANCER I, V55, P231; WHITE E, 1990, J NATL CANCER I, V82, P1546, DOI 10.1093/jnci/82.19.1546	31	232	235	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					1023	1028		10.7326/0003-4819-127-11-199712010-00014	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00014			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412284				2022-12-28	WOS:A1997YJ08000010
J	Hata, T; Miyazaki, K; Matsui, K				Hata, T; Miyazaki, K; Matsui, K			Decreased circulating adrenomedullin in pre-eclampsia	LANCET			English	Article							HYPOTENSIVE PEPTIDE		FUKUDA HOSP,DEPT OBSTET & GYNAECOL,KUMAMOTO,JAPAN		Hata, T (corresponding author), SHIMANE MED UNIV,DEPT OBSTET & GYNAECOL,IZUMO,SHIMANE 693,JAPAN.							DILORIO R, 1997, LANCET, V349, P328; ISHIYAMA Y, 1993, EUR J PHARMACOL, V241, P271, DOI 10.1016/0014-2999(93)90214-3; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; KITAMURA K, 1994, FEBS LETT, V341, P288, DOI 10.1016/0014-5793(94)80474-5	4	40	41	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1600	1600		10.1016/S0140-6736(05)64016-0	http://dx.doi.org/10.1016/S0140-6736(05)64016-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393346				2022-12-28	WOS:A1997YH98600018
J	VanderHeiden, MG; Chandel, NS; Williamson, EK; Schumacker, PT; Thompson, CB				VanderHeiden, MG; Chandel, NS; Williamson, EK; Schumacker, PT; Thompson, CB			Bcl-x(L) regulates the membrane potential and volume homeostasis of mitochondria	CELL			English	Article							CYTOCHROME-C-OXIDASE; CELL-DEATH; APOPTOSIS; OXYGEN; HEPATOCYTES; DNA	Mitochondrial physiology is disrupted in either apoptosis or necrosis. Here, we report that a wide variety of apoptotic and necrotic stimuli induce progressive mitochondrial swelling and outer mitochondrial membrane rupture. Discontinuity of the outer mitochondrial membrane results in cytochrome c redistribution from the intermembrane space to the cytosol followed by subsequent inner mitochondrial membrane depolarization. The mitochondrial membrane protein Bcl-x(L) can inhibit these changes in cells treated with apoptotic stimuli. In addition, Bcl-x(L)-expressing cells adapt to growth factor withdrawal or staurosporine treatment by maintaining a decreased mitochondrial membrane potential. Bcl-x(L) expression also prevents mitochondrial swelling in response to agents that inhibit oxidative phosphorylation. These data suggest that Bcl-x(L) promotes cell survival by regulating the electrical and osmotic homeostasis of mitochondria.	UNIV CHICAGO,COMM IMMUNOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOL GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	VanderHeiden, MG (corresponding author), UNIV CHICAGO,GWEN KNAPP CTR,CHICAGO,IL 60637, USA.			Schumacker, Paul T/0000-0001-9591-2034				ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; ALLMAN R, 1990, CYTOMETRY, V11, P822, DOI 10.1002/cyto.990110708; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Chandel NS, 1996, J BIOL CHEM, V271, P18672, DOI 10.1074/jbc.271.31.18672; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DECKER RS, 1980, AM J PATHOL, V98, P425; DEJONG D, 1994, CANCER RES, V54, P256; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEMASTERS JJ, 1987, NATURE, V325, P78, DOI 10.1038/325078a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Marchetti P, 1996, CANCER RES, V56, P2033; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; PETIT JM, 1992, EUR J BIOCHEM, V209, P267, DOI 10.1111/j.1432-1033.1992.tb17285.x; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wilson AJ, 1993, PROCEDURES ELECT MIC; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	34	1186	1197	1	72	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					627	637		10.1016/S0092-8674(00)80450-X	http://dx.doi.org/10.1016/S0092-8674(00)80450-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393856	Bronze			2022-12-28	WOS:A1997YH96000010
J	Ingenbleek, Y; Jung, L; Ferard, G; Bordet, F; Goncalves, AM; Dechoux, L				Ingenbleek, Y; Jung, L; Ferard, G; Bordet, F; Goncalves, AM; Dechoux, L			Iodised rapeseed oil for eradication of severe endemic goitre	LANCET			English	Article							IODINE-DEFICIENCY DISORDERS; IODIZED OIL	Iodised oil is traditionally based on the fatty acids (FAs) of the poppyseed, an expensive commodity, An equipotent but cheaper vehicle would be welcome, Iodination of rapeseed oil yields a product (Brassiodol) with a total iodine content of 376 mg/mL, Brassiodol has been compared with the poppyseed-based Lipiodol in two villages in Chad in the west African goitre belt, A 2 mL dose of Brassiodol is followed by urinary spillover of half the ingested iodine, The other half undergoes tissue sequestration and slow release, allowing protection against iodine deficiency for 9 months and regression of stage I/II goitre for longer than was achieved with Lipiodol. The prolonged protection offered by Brassiodol can be attributed to its unique lipid profile, The urinary output argues that 1 mL should not be exceeded, and at that dose the cost would be only 20 US cents per person per year.	UNIV LOUIS PASTEUR STRASBOURG 1, FAC PHARM, MED CHEM LAB, F-67401 ILLKIRCH GRAFFENSTADEN, FRANCE; UNIV LOUIS PASTEUR STRASBOURG 1, FAC PHARM, APPL BIOCHEM LAB, F-67401 ILLKIRCH GRAFFENSTADEN, FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ingenbleek, Y (corresponding author), UNIV LOUIS PASTEUR STRASBOURG 1, FAC PHARM, LAB NUTR, 74 ROUTE RHIN, F-67401 ILLKIRCH GRAFFENSTADEN, FRANCE.		Dechoux, Luc/G-3328-2017	Dechoux, Luc/0000-0003-3806-1848				Cochran W.G., 1967, STAT METHODS; DELANGE F, 1994, THYROID, V4, P107, DOI 10.1089/thy.1994.4.107; DELANGE F, 1993, NATO ASI SER LIFE SC, V241; Dunn JT, 1990, PRACTICAL GUIDE CORR; DUNN JT, 1986, PAHO WHO SCI PUBL, V502, P170; FURNEE CA, 1995, AM J CLIN NUTR, V61, P1257, DOI 10.1093/ajcn/61.6.1257; GUIRAL C, 1992, RAPPORT PROSPECTION; HETZEL BS, 1987, LANCET, V2, P266; Hetzel BS., 1994, SOS BILLION CONQUEST, P17; INGENBLEEK Y, 1985, INT J VITAM NUTR RES, V55, P91; INGENBLEEK Y, 1992, NUTRITION, V8, P55; IRIFUNE S, 1988, SYNTHESIS-STUTTGART, P366; JONES WO, 1963, J PEDIATR, V46, P44; JUNG L, 1995, Patent No. 8582; Marine D, 1920, ARCH INTERN MED, V25, P661, DOI 10.1001/archinte.1920.00090350088005; MCCULLAGH S. F., 1963, Medical Journal of Australia, V1, P769; PAZOSMOURA CC, 1991, AM J PHYSIOL, V260, pE175, DOI 10.1152/ajpendo.1991.260.2.E175; PEREZ C, 1960, WHO MONOGRAPHS SERIE, V44, P369; RACLOT T, 1995, AM J PHYSIOL-REG I, V269, pR1060, DOI 10.1152/ajpregu.1995.269.5.R1060; Sandell E. B., 1937, MICROCHIM ACTA, V1, P9, DOI [10.1007/BF01476194, DOI 10.1007/BF01476194]; WEI J, 1985, NUTR REP INT, V31, P1085; WOLFF J, 1948, J BIOL CHEM, V174, P555; Wyss K, 1996, TROP MED INT HEALTH, V1, P723	23	17	18	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1542	1545		10.1016/S0140-6736(97)02427-6	http://dx.doi.org/10.1016/S0140-6736(97)02427-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388412				2022-12-28	WOS:A1997YH11500042
J	Zazopoulos, E; Lalli, E; Stocco, DM; SassoneCorsi, P				Zazopoulos, E; Lalli, E; Stocco, DM; SassoneCorsi, P			DNA binding and transcriptional repression by DAX-1 blocks steroidogenesis	NATURE			English	Article							ACUTE REGULATORY PROTEIN; ADRENAL HYPOPLASIA CONGENITA; STAR GENE; EXPRESSION; CELLS; SUPERFAMILY; MOTIF; HMG1; CREM	Mutations in the DAX-1 gene are responsible for congenital X-linked adrenal hypoplasia, a disease that is associated with hypogonadotropic hypogonadism(1,2). DAX-1 expression is tissue-specific and is finely regulated throughout development(3-5), suggesting that it has a role in both adrenal and gonadal function. DAX-1 is an unusual member of the nuclear-receptor superfamily of transcription factors which contains no canonical zinc-finger or any other known DNA-binding motif(1). Binding sites for DAX-1 are found in the promoters of the dax-1 and StAR (for steroidogenic acute regulatory protein) genes. Here we show that DAX-1 binds DNA and acts as a powerful transcriptional repressor of StAR gene expression, leading to a drastic decrease in steroid production. We provide in vitro and in vivo evidence that DAX-1 binds to DNA hairpin structures. Our results establish DAX-1 as the first member of the nuclear receptor superfamily with novel DNA-binding features and reveal that it has regulatory properties critical to the understanding of its physiological functions.	CNRS, INSERM, ULP, INST GENET & BIOL MOL & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, STRASBOURG, FRANCE; TEXAS TECH UNIV, HLTH SCI CTR, DEPT BIOCHEM & CELL BIOL, LUBBOCK, TX 79430 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center			Lalli, Enzo/F-7052-2013	Lalli, Enzo/0000-0002-0584-5681	Fondazione Telethon Funding Source: Custom	Fondazione Telethon(Fondazione Telethon)		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Caron KM, 1997, MOL ENDOCRINOL, V11, P138, DOI 10.1210/me.11.2.138; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; LALLI E, IN PRESS MOL ENDOCRI; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; Schimmer B P, 1979, Methods Enzymol, V58, P570; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; Sugawara T, 1996, BIOCHEMISTRY-US, V35, P9052, DOI 10.1021/bi960057r; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Tamai KT, 1996, MOL ENDOCRINOL, V10, P1561, DOI 10.1210/me.10.12.1561; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0	25	344	354	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	1997	390	6657					311	315		10.1038/36899	http://dx.doi.org/10.1038/36899			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384387				2022-12-28	WOS:A1997YG66700070
J	Kaplan, KB; Hyman, AA; Sorger, PK				Kaplan, KB; Hyman, AA; Sorger, PK			Regulating the yeast kinetochore by ubiquitin-dependent degradation and skp1p-mediated phosphorylation	CELL			English	Article							SACCHAROMYCES-CEREVISIAE KINETOCHORE; BUDDING YEAST; CHROMOSOME SEGREGATION; IN-VITRO; CENTROMERE; PROTEIN; BINDING; CYCLE; PROTEOLYSIS; COMPLEX	In S. cerevisiae, the four-protein Cbf3 complex binds to the essential CDEIII region of centromeric DNA to initiate kinetochore assembly. We report the reconstitution of Cbf3p from recombinant proteins and an analysis of its p58(Ctf13) and p23(Skp1) subunits. p23(Skp1) has both G1- and G2-specific functions in yeast and binds to p58(Ctf13) and to the essential Cdc4p component of the ubiquitin conjugating complex Scul(Cdc4). We show that the function of p23(Skp1) in Cbf3p is to activate p58(Ctf13) by phosphorylation. p58(Ctf13) is an unstable protein that is targeted to the proteosome, probably by Scul(Cdc4)-mediated ubiquitination. Thus, p58 appears to be activated by phosphorylation in a p23(Skp1)-dependent step and degraded by the proteosome in a ubiquitin-dependent step. We propose that coupled activation and destruction link the assembly of Cbf3p to the duplication of centromeres in S phase.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; EUROPEAN MOL BIOL LAB,D-69012 HEIDELBERG,GERMANY	Massachusetts Institute of Technology (MIT); European Molecular Biology Laboratory (EMBL)			Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Sorger, Peter/0000-0002-3364-1838	NIGMS NIH HHS [GM51464] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051464] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAKER RE, 1990, MOL CELL BIOL, V10, P2458, DOI 10.1128/MCB.10.6.2458; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; COHENFIX O, 1996, GENE DEV, V15, P3071; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; GAUDET A, 1987, MOL CELL BIOL, V7, P68, DOI 10.1128/MCB.7.1.68; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hyman AA, 1995, ANNU REV CELL DEV BI, V11, P471, DOI 10.1146/annurev.cb.11.110195.002351; JIANG W, 1993, COLD SPRING HARB SYM, V58, P669, DOI 10.1101/SQB.1993.058.01.074; KAPLAN KB, 1997, PROTEIN FUNCTION PRA, P245; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LECHNER J, 1994, EMBO J, V13, P5203, DOI 10.1002/j.1460-2075.1994.tb06851.x; MCGREW J, 1986, MOL CELL BIOL, V6, P530, DOI 10.1128/MCB.6.2.530; NG R, 1987, MOL CELL BIOL, V7, P4522, DOI 10.1128/MCB.7.12.4522; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SORGER PK, 1994, J CELL BIOL, V127, P995, DOI 10.1083/jcb.127.4.995; Sorger PK, 1995, P NATL ACAD SCI USA, V92, P12026, DOI 10.1073/pnas.92.26.12026; Stemmann O, 1996, EMBO J, V15, P3611, DOI 10.1002/j.1460-2075.1996.tb00730.x; STRUNNIKOV AV, 1995, J CELL BIOL, V128, P749, DOI 10.1083/jcb.128.5.749; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	31	133	135	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					491	500		10.1016/S0092-8674(00)80435-3	http://dx.doi.org/10.1016/S0092-8674(00)80435-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390558	Bronze			2022-12-28	WOS:A1997YG49200010
J	Mitchell, P; Petfalski, E; Shevchenko, A; Mann, M; Tollervey, D				Mitchell, P; Petfalski, E; Shevchenko, A; Mann, M; Tollervey, D			The exosome: A conserved eukaryotic RNA processing complex containing multiple 3'->5' exoribonucleases	CELL			English	Article							DOUBLE-STRANDED-RNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; POLYACRYLAMIDE GELS; ANTIVIRAL SYSTEM; RIBOSOMAL-RNA; IN-VIVO; YEAST; PROTEINS	We identified a complex in S. cerevisiae, the ''exosome,'' consisting of the five essential proteins Rrp4p, Rrp41p, Rrp42p, Rrp43p, and Rrp44p (Dis3p). Remarkably, four of these proteins are homologous to characterized bacterial 3'-->5' exoribonucleases; Rrp44p is homologous to RNase II, while Rrp41p, Rrp42p, and Rrp43p are related to RNase PH. Recombinant Rrp4p, Rrp44p, and Rrp41p are 3'-->5' exoribonucleases in vitro that have distributive, processive, and phosphorolytic activities, respectively. All components of the exosome are required for 3' processing of the 5.8S rRNA. Human Rrp4p is found in a comparably sized complex, and expression of the hRRP4 gene in yeast complements the rrp4-1 mutation. We conclude that the exosome constitutes a highly conserved eukaryotic RNA processing complex.	EUROPEAN MOL BIOL LAB,EMBL,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Mann, Matthias/A-3454-2013; Tollervey, David/AAR-6662-2020	Mann, Matthias/0000-0003-1292-4799; Tollervey, David/0000-0003-2894-2772; Mitchell, Phil/0000-0002-3178-0439				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELTRAME M, 1992, EMBO J, V11, P1531, DOI 10.1002/j.1460-2075.1992.tb05198.x; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Brown CE, 1996, MOL CELL BIOL, V16, P5744; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; DEUTSCHER MP, 1991, P NATL ACAD SCI USA, V88, P3277, DOI 10.1073/pnas.88.8.3277; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DMOCHOWSKA A, 1995, CURR GENET, V28, P108, DOI 10.1007/BF00315775; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; INGOLIA TD, 1982, MOL CELL BIOL, V2, P1388, DOI 10.1128/MCB.2.11.1388; KASAI T, 1977, J BIOL CHEM, V252, P8950; KELLY KO, 1992, J BIOL CHEM, V267, P17153; KROGH A, 1994, J MOL BIOL, V235, P1501, DOI 10.1006/jmbi.1994.1104; Lafontaine D, 1996, NUCLEIC ACIDS RES, V24, P3469, DOI 10.1093/nar/24.17.3469; Laggerbauer B, 1996, NUCLEIC ACIDS RES, V24, P868, DOI 10.1093/nar/24.5.868; LAING S, 1996, MOL CELL BIOL, V16, P5139; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI ZW, 1995, P NATL ACAD SCI USA, V92, P6883, DOI 10.1073/pnas.92.15.6883; Li ZW, 1996, J BIOL CHEM, V271, P1133, DOI 10.1074/jbc.271.2.1133; LI ZW, 1994, J BIOL CHEM, V269, P6064; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Margossian SP, 1996, CELL, V84, P199, DOI 10.1016/S0092-8674(00)80975-7; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MASISON DC, 1995, MOL CELL BIOL, V15, P2763; MIAN S, 1997, NUCLEIC ACIDS RES, V25, P3187; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; MIN JJ, 1993, J BIOL CHEM, V268, P7350; Mitchell P, 1996, GENE DEV, V10, P502, DOI 10.1101/gad.10.4.502; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; RIDLEY SP, 1984, MOL CELL BIOL, V4, P761, DOI 10.1128/MCB.4.4.761; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609; TOBE T, 1992, J BACTERIOL, V174, P6359, DOI 10.1128/JB.174.20.6359-6367.1992; TOLLERVEY D, 1987, EMBO J, V6, P4169, DOI 10.1002/j.1460-2075.1987.tb02763.x; VOLCKAERT G, 1977, ANAL BIOCHEM, V83, P222, DOI 10.1016/0003-2697(77)90530-9; WIDNER WR, 1993, MOL CELL BIOL, V13, P4331, DOI 10.1128/MCB.13.7.4331; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Zhou ZH, 1997, J BACTERIOL, V179, P4391, DOI 10.1128/jb.179.13.4391-4395.1997	48	744	757	0	83	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					457	466		10.1016/S0092-8674(00)80432-8	http://dx.doi.org/10.1016/S0092-8674(00)80432-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390555	Bronze			2022-12-28	WOS:A1997YG49200007
J	Tappero, JW; Koehler, JE				Tappero, JW; Koehler, JE			Bacillary angiomatosis or Kaposi's sarcoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco	Tappero, JW (corresponding author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.								0	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	1997	337	26					1888	1888		10.1056/NEJM199712253372605	http://dx.doi.org/10.1056/NEJM199712253372605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN051	9407156				2022-12-28	WOS:000071128200005
J	Hanlon, VM				Hanlon, VM			Damascus Road	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2137	2138						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9416996				2022-12-28	WOS:000071022200013
J	Yeomans, DK; Barriot, JP; Dunham, DW; Farquhar, RW; Giorgini, JD; Helfrich, CE; Konopliv, AS; McAdams, JV; Miller, JK; Owen, WM; Scheeres, DJ; Synnott, SP				Yeomans, DK; Barriot, JP; Dunham, DW; Farquhar, RW; Giorgini, JD; Helfrich, CE; Konopliv, AS; McAdams, JV; Miller, JK; Owen, WM; Scheeres, DJ; Synnott, SP			Estimating the mass of asteroid 253 Mathilde from tracking data during the NEAR flyby	SCIENCE			English	Article							ORBIT; CERES; 243-IDA; PALLAS	The terminal navigation of the Near Earth Asteroid Rendezvous (NEAR) spacecraft during its close flyby of asteroid 253 Mathilde involved coordinated efforts to determine the heliocentric orbits of the spacecraft and Mathilde and then to determine the relative trajectory of the spacecraft with respect to Mathilde. The gravitational perturbation of Mathilde on the passing spacecraft was apparent in the spacecraft tracking data. As a result of the accurate targeting achieved, these-data could be used to determine Mathilde's mass as 1.033 (+/-0.044) x 10(20) grams. Coupled with a volume estimate provided by the NEAR imaging team, this mass suggests a low bulk density for Mathilde of 1.3 grams per cubic centimeter.	CTR NATL ETUD SPATIALES,DEPT TERR & PLANETARY GEODESY,F-31055 TOULOUSE,FRANCE; JOHNS HOPKINS UNIV,APPL PHYS LAB,LAUREL,MD 20723	Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory	Yeomans, DK (corresponding author), CALTECH,JET PROP LAB,NAVIGAT & FLIGHT MECH SECT,PASADENA,CA 91109, USA.		Dunham, David W/A-5214-2014; Barriot, Jean-Pierre/AAD-6709-2021	Dunham, David W/0000-0001-7527-4207; Barriot, Jean-Pierre/0000-0002-2112-9685; SCHEERES, DANIEL/0000-0003-0558-3842				BELTON MJS, 1992, SCIENCE, V257, P1647, DOI 10.1126/science.257.5077.1647; BELTON MJS, 1995, NATURE, V374, P785, DOI 10.1038/374785a0; BELTON MJS, 1996, ICARUS, V10, P1; GOFFIN E, 1991, ASTRON ASTROPHYS, V249, P563; LANDGRAF W, 1988, ASTRON ASTROPHYS, V191, P161; OWEN WM, 1994, ASTRON J, V107, P2295, DOI 10.1086/117037; PERRYMAN MAC, 1997, EUROPEAN SPCE AGENCY; Riedel J.E., 1990, AIAA AAS ASTR C PORT; Rivkin AS, 1997, ICARUS, V127, P255, DOI 10.1006/icar.1997.5695; SCHUBART J, 1979, ASTEROIDS, P84; STANDISH EM, 1989, ICARUS, V80, P326, DOI 10.1016/0019-1035(89)90143-7; STANDISH EM, COMMUNICATION; Stone RC, 1996, ASTRON J, V111, P1721, DOI 10.1086/117913; Veverka J, 1997, SCIENCE, V278, P2109, DOI 10.1126/science.278.5346.2109; Viateau B, 1997, ASTRON ASTROPHYS, V320, P652; VIATEAU B, 1995, ASTRON ASTROPHYS SUP, V111, P305; WILLIAMS BG, 1997, AAS AIAA SPAC FLIGHT; WILLIAMS GV, 1992, ASTEROIDS COMETS MET, P641; 1995, J ASTRONAUT SCI, V43, P345	19	170	172	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2106	2109		10.1126/science.278.5346.2106	http://dx.doi.org/10.1126/science.278.5346.2106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405343				2022-12-28	WOS:A1997YM23500048
J	Levine, S; Kaiser, L; Leferovich, J; Tikunov, B				Levine, S; Kaiser, L; Leferovich, J; Tikunov, B			Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOSIN HEAVY-CHAIN; HUMAN SKELETAL-MUSCLE; MYOFIBRILLAR PROTEIN-TURNOVER; FIBER TYPES; ELECTROPHORETIC SEPARATION; SINGLE FIBERS; SLOW MYOSIN; NORMAL MEN; FATIGUE; EXERCISE	Background In patients with severe chronic obstructive pulmonary disease, the diaphragm undergoes physiologic adaptations characterized by an increase in energy expenditure and relative resistance to fatigue. We hypothesized that these physiologic characteristics would be associated with structural adaptations consisting of an increased proportion of less-fatigable slow-twitch muscle fibers and slow isoforms of myofibrillar proteins. Methods We obtained biopsy specimens of the diaphragm from 6 patients with severe chronic obstructive pulmonary disease (mean [+/-SE] forced expiratory volume in one second, 33+/-4 percent of the predicted value; residual volume, 259+/-25 percent of the predicted value) and 10 control subjects. The proportions of the various isoforms of myosin heavy chains, myosin light chains, troponin, and tropomyosin were determined by sodium dodecyl sulfate-polyacrylamide-gel electrophoresis. We also used immunocytochemical techniques to determine the proportions of the various types of muscle fibers. Results The diaphragm-biopsy specimens from the patients had higher percentages of slow myosin heavy chain I (64+/-3 vs. 45+/-2 percent, P<0.001), and lower percentages of fast myosin heavy chains IIa (29+/-3 vs. 39+/-2 percent, P=0.01) and IIb (8+/-1 vs. 17+/-1 percent, P<0.001) than the diaphragms of the controls. Similar differences were noted when immunohistochemical techniques were used to compare the percentages of these fiber types in the two groups. In addition, the patients had higher percentages of the slow isoforms of myosin light chains, troponins, and tropomyosin, whereas the controls had higher percentages of the fast isoforms of these proteins. Conclusions Severe chronic obstructive pulmonary disease increases the slow-twitch characteristics of the muscle fibers in the diaphragm, an adaptation that increases resistance to fatigue. (C) 1997, Massachusetts Medical Society.	ALLEGHENY UNIV HLTH SCI,VET AFFAIRS MED CTR,CRIT CARE DIV,PHILADELPHIA,PA 19104; UNIV PENN,PENN MUSCLE INST,PHILADELPHIA,PA 19104; UNIV PENN,DIV THORAC SURG,PHILADELPHIA,PA 19104	Drexel University; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania	Levine, S (corresponding author), ALLEGHENY UNIV HLTH SCI,VET AFFAIRS MED CTR,DIV PULM,UNIV & WOODLAND AVES,PHILADELPHIA,PA 19104, USA.		Kaiser, Larry/L-7940-2019					AUBIER M, 1981, J APPL PHYSIOL, V50, P538, DOI 10.1152/jappl.1981.50.3.538; BATES PC, 1983, BIOCHEM J, V214, P593, DOI 10.1042/bj2140593; BAUMANN H, 1987, PFLUG ARCH EUR J PHY, V409, P349, DOI 10.1007/BF00583788; BELLEMARE F, 1987, J APPL PHYSIOL, V62, P1307, DOI 10.1152/jappl.1987.62.3.1307; BELLEMARE F, 1983, J APPL PHYSIOL, V55, P8, DOI 10.1152/jappl.1983.55.1.8; BILLETER R, 1981, EUR J BIOCHEM, V116, P389, DOI 10.1111/j.1432-1033.1981.tb05347.x; DHOOT GK, 1979, NATURE, V278, P714, DOI 10.1038/278714a0; EDWARDS RHT, 1977, J PHYSIOL-LONDON, V272, P769, DOI 10.1113/jphysiol.1977.sp012072; GRANDMONTLEBLANC A, 1977, CAN J BIOCHEM CELL B, V55, P949, DOI 10.1139/o77-142; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HAVERBERG LN, 1975, BIOCHEM J, V152, P503, DOI 10.1042/bj1520503; HOWALD H, 1985, PFLUG ARCH EUR J PHY, V403, P369, DOI 10.1007/BF00589248; HUGHES SM, 1993, DEV BIOL, V158, P183, DOI 10.1006/dbio.1993.1178; JAKOBSSON P, 1990, EUR RESPIR J, V3, P192; JOHNSON BD, 1993, J PHYSIOL-LONDON, V460, P385, DOI 10.1113/jphysiol.1993.sp019477; KANNER RE, 1984, CLIN PULMONARY FUNCT; KELSEN SG, 1996, PULMONARY REHABILITA, V91, P117; KLITGAARD H, 1990, PFLUG ARCH EUR J PHY, V416, P470, DOI 10.1007/BF00370757; KLITGAARD H, 1990, ACTA PHYSIOL SCAND, V140, P55, DOI 10.1111/j.1748-1716.1990.tb08975.x; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFRAMBOISE WA, 1990, BIOCHIM BIOPHYS ACTA, V1035, P109, DOI 10.1016/0304-4165(90)90181-U; LARSSON L, 1985, MUSCLE NERVE, V8, P714, DOI 10.1002/mus.880080815; LARSSON L, 1991, AM J PHYSIOL, V261, pC93, DOI 10.1152/ajpcell.1991.261.1.C93; LARSSON L, 1993, J PHYSIOL-LONDON, V472, P595, DOI 10.1113/jphysiol.1993.sp019964; LEFEROVICH JM, 1995, J NEUROSCI, V15, P596; LEVINE S, 1988, J APPL PHYSIOL, V64, P672, DOI 10.1152/jappl.1988.64.2.672; Levine S, 1996, AM J PHYSIOL-CELL PH, V271, pC1480, DOI 10.1152/ajpcell.1996.271.5.C1480; MADOR MJ, 1993, AM REV RESPIR DIS, V148, P1571, DOI 10.1164/ajrccm/148.6_Pt_1.1571; MANCINI DM, 1992, CIRCULATION, V86, P909, DOI 10.1161/01.CIR.86.3.909; MOXHAM J, 1981, THORAX, V36, P164, DOI 10.1136/thx.36.3.164; NARUSAWA M, 1987, J CELL BIOL, V104, P447, DOI 10.1083/jcb.104.3.447; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; POLKEY MI, 1995, AM J RESP CRIT CARE, V152, P959, DOI 10.1164/ajrccm.152.3.7663810; ROUSSOS CS, 1977, J APPL PHYSIOL, V43, P189, DOI 10.1152/jappl.1977.43.2.189; SANCHEZ J, 1985, B EUR PHYSIOPATH RES, V21, P351; SANCHEZ J, 1982, B EUR PHYSIOPATH RES, V18, P901; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SMERDU V, 1994, AM J PHYSIOL-CELL PH, V267, pC1723, DOI 10.1152/ajpcell.1994.267.6.C1723; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; TALMADGE RJ, 1993, J APPL PHYSIOL, V75, P2337, DOI 10.1152/jappl.1993.75.5.2337; Tikunov BA, 1996, J MOL CELL CARDIOL, V28, P2537, DOI 10.1006/jmcc.1996.0245; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed	44	252	263	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 18	1997	337	25					1799	1806		10.1056/NEJM199712183372503	http://dx.doi.org/10.1056/NEJM199712183372503			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL855	9400036				2022-12-28	WOS:A1997YL85500003
J	Lazaridis, T; Karplus, M				Lazaridis, T; Karplus, M			''New view'' of protein folding reconciled with the old through multiple unfolding simulations	SCIENCE			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; NUCLEATION-CONDENSATION MECHANISM; CHYMOTRYPSIN INHIBITOR-2; TRANSITION-STATE; ENERGY; PRINCIPLES	Twenty-four molecular dynamics trajectories of chymotrypsin inhibitor 2 provide a direct demonstration of the diversity of unfolding pathways. Comparison with experiments suggests that the transition state region for folding and unfolding occurs early with only 25 percent of the native contacts and that the root-mean-square deviations between contributing structures can be as large as 15 angstroms. Nevertheless, a statistically preferred unfolding pathway emerges from the simulations; disruption of tertiary interactions between the helix and a two-stranded portion of the beta sheet is the primary unfolding event. The results suggest a synthesis of the ''new'' and the classical view of protein folding with a preferred pathway on a funnel-like average energy surface.	HARVARD UNIV,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138; UNIV STRASBOURG 1,INST LE BEL,ISIS,LAB CHIM BIOPHYS,F-67000 STRASBOURG,FRANCE	Harvard University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								ALONSO DOV, 1995, J MOL BIOL, V247, P501, DOI 10.1006/jmbi.1994.0156; BALDWIN RL, 1994, NATURE, V369, P183, DOI 10.1038/369183a0; BOCZKO EM, 1995, SCIENCE, V269, P393, DOI 10.1126/science.7618103; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRYNGELSON JD, 1989, J PHYS CHEM-US, V93, P6902, DOI 10.1021/j100356a007; CAFLISCH A, 1995, J MOL BIOL, V252, P672, DOI 10.1006/jmbi.1995.0528; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; DILL KA, 1995, PROTEIN SCI, V4, P561; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; Guo ZY, 1997, P NATL ACAD SCI USA, V94, P10161, DOI 10.1073/pnas.94.19.10161; ITZHAKI LS, 1995, J MOL BIOL, V254, P260, DOI 10.1006/jmbi.1995.0616; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10428, DOI 10.1021/bi00107a010; KARPLUS M, 1995, CURR OPIN STRUC BIOL, V5, P58, DOI 10.1016/0959-440X(95)80010-X; Karplus Martin, 1992, P127; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; Li AJ, 1996, J MOL BIOL, V257, P412, DOI 10.1006/jmbi.1996.0172; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Neira JL, 1996, FOLD DES, V1, P189, DOI 10.1016/S1359-0278(96)00031-4; Neria E, 1996, J CHEM PHYS, V105, P1902, DOI 10.1063/1.472061; Nolting B, 1997, P NATL ACAD SCI USA, V94, P826, DOI 10.1073/pnas.94.3.826; ONUCHIC JN, 1995, P NATL ACAD SCI USA, V92, P3626, DOI 10.1073/pnas.92.8.3626; Onuchic JN, 1996, FOLD DES, V1, P441, DOI 10.1016/S1359-0278(96)00060-0; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; SCHOEMAKER BA, 1997, P NATL ACAD SCI USA, V94, P777; SHAKHNOVICH EI, 1989, BIOPHYS CHEM, V34, P187, DOI 10.1016/0301-4622(89)80058-4; Thirumalai D, 1996, ACCOUNTS CHEM RES, V29, P433, DOI 10.1021/ar9500933	28	486	490	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1928	1931		10.1126/science.278.5345.1928	http://dx.doi.org/10.1126/science.278.5345.1928			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395391				2022-12-28	WOS:A1997YL00200029
J	Costa, JJ; Weller, PF; Galli, SJ				Costa, JJ; Weller, PF; Galli, SJ			The cells of the allergic response - Mast cells, basophils, and eosinophils	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEUKOCYTE CYTOKINE CASCADES; AFFINITY IGE RECEPTOR; ADHESION MOLECULES; HISTAMINE-RELEASE; KIT-LIGAND; IN-VIVO; INTERLEUKIN-5; RECRUITMENT; EXPRESSION; MICE	Mast cells, basophils, and eosinophils have long been regarded as important effector cells in allergic disorders. Indeed, it is thought that the cells' cytoplasmic granule-associated or lipid mediators contribute to many of the signs and symptoms that are characteristic of these diseases. Mast cells, basophils, and eosinophils also probably contribute to protective host responses, especially to parasites. In addition, recent evidence shows that mast cells, basophils, and eosinophils can secrete a wide spectrum of cytokines and, in some cases, express functions that may permit them to regulate the development or perpetuation of allergic responses. Thus, mast cells, basophils, and eosinophils may express immunoregulatory activities, as well as serve as effector cells.	BETH ISRAEL DEACONESS MED CTR, DIV EXPT PATHOL, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Costa, JJ (corresponding author), HARVARD UNIV, SCH MED, BETH ISRAEL DEACONESS MED CTR, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							ABRAHAM WM, 1994, J CLIN INVEST, V93, P776, DOI 10.1172/JCI117032; ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BIENENSTOCK J, 1986, MAST CELL DIFFERENTI, P391; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909; BROWN SJ, 1982, J IMMUNOL, V129, P790; CAPRON M, 1995, ALLERGY, V50, P20, DOI 10.1111/j.1398-9995.1995.tb04270.x; Church M. RC. B. PH. R. MA. L., 1989, MAST CELL BASOPHIL D, P161; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; CONROY MC, 1977, J IMMUNOL, V118, P1317; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; COSTA JJ, 1997, INFLAMMATORY MECH AS, P111; COSTA JJ, 1996, CLIN IMMUNOLOGY PRIN, P408; DEMBO M, 1979, J IMMUNOL, V123, P1864; Desreumaux P, 1996, CURR OPIN IMMUNOL, V8, P790, DOI 10.1016/S0952-7915(96)80006-9; GALLI SJ, 1995, ALLERGY, V50, P851, DOI 10.1111/j.1398-9995.1995.tb02490.x; GALLI SJ, 1990, LAB INVEST, V62, P5; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; Galli SJ, 1996, NATURE, V381, P21, DOI 10.1038/381021a0; GALLI SJ, 1988, ALLERGY PRINCIPLES P, P106; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.me.44.020193.000505; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GOUNNI AS, 1994, J ALLERGY CLIN IMMUN, V94, P1214, DOI 10.1016/0091-6749(94)90334-4; HERNDON FJ, 1992, J IMMUNOL, V149, P3642; HOLGATE ST, 1993, ALLERGY PRINCIPLES P, P267; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931, DOI 10.1164/ajrccm.153.6.8665058; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404, DOI 10.1165/ajrcmb.12.4.7695919; Lemanske RF, 1993, ALLERGY PRINCIPLES P, P320; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MATSUDA H, 1990, J IMMUNOL, V144, P259; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; Ohkawara Y, 1996, J CLIN INVEST, V97, P1761, DOI 10.1172/JCI118603; PRETOLANI M, 1994, J EXP MED, V180, P795, DOI 10.1084/jem.180.3.795; Reed N. D., 1989, Mast cell and basophil differentiation and function in health and disease., P205; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349, DOI 10.1165/ajrcmb/8.4.349; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; Rott LS, 1996, J IMMUNOL, V156, P3727; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; SCHLEIMER RP, 1993, ALLERGY PRINCIPLES P, P893; SCHWARTZ L, 1993, ALLERGY PRINCIPLES P, P135; SEDGWICK JB, 1995, J ALLERGY CLIN IMMUN, V96, P375, DOI 10.1016/S0091-6749(95)70057-9; SHER A, 1990, J IMMUNOL, V145, P3911; STALLMAN PJ, 1977, INT ARCH ALLER A IMM, V54, P364, DOI 10.1159/000231849; STEEVES EBT, 1990, INT J PARASITOL, V20, P655, DOI 10.1016/0020-7519(90)90124-6; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; VALENT P, 1990, CRIT REV ONCOL HEMAT, V10, P327, DOI 10.1016/1040-8428(90)90009-H; VALONE FH, 1993, ALLERGY PRINCIPLES P, P302; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561; WEIN M, 1995, AM J RESP CELL MOL, V12, P315, DOI 10.1165/ajrcmb.12.3.7532979; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; WELLER PF, 1993, J IMMUNOL, V150, P2554; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; WELLER PF, 1993, IMMUNOPHARMACOLOGY E, P25; WELLER PF, 1994, ASTHMA RHINITIS, P225; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; Wershil BK, 1996, GASTROENTEROLOGY, V110, P1482, DOI 10.1053/gast.1996.v110.pm8613053; WERSHIL BK, 1995, J IMMUNOL, V154, P1391; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Yano K, 1997, LAB INVEST, V77, P185	69	140	155	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1815	1822		10.1001/jama.278.22.1815	http://dx.doi.org/10.1001/jama.278.22.1815			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396642				2022-12-28	WOS:A1997YK15500003
J	Galperin, C; Gershwin, E				Galperin, C; Gershwin, E			Immunopathogenesis of gastrointestinal and hepatobiliary diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PRIMARY BILIARY-CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; HEPATITIS-C VIRUS; BILE-DUCT SYNDROME; COMMON VARIABLE IMMUNODEFICIENCY; INFLAMMATORY BOWEL-DISEASE; SMALL-INTESTINAL EPITHELIUM; IL-1 RECEPTOR ANTAGONIST; AMINO-ACID SUBSTITUTIONS; CHRONIC ACTIVE HEPATITIS	The largest lymphoid organ in the body is the gut and the gut-associated lymphoid tissue. The mucosal immune system faces many challenges in protecting the body from microbial invasion. Its chief function is to maintain a diverse population of mature lymphocytes capable of responding to foreign antigens. This task is accomplished with a variety of unique features that distinguish the mucosal from the systemic immune system. In addition, the mucosal immune system plays a role in inflammatory bowel disease, Whipple disease, autoimmune gastritis, Helicobacter pylon infection, immunoproliferative small intestinal disease, hepatitis A, B, C, D, E, F, and G, autoimmune hepatitis, primary biliary cirrhosis, progressive sclerosing cholangitis, and vanishing bile duct syndrome.			Galperin, C (corresponding author), UNIV CALIF DAVIS,SCH MED,DIV RHEUMATOL & ALLERGY,TB192,DAVIS,CA 95616, USA.				NIDDK NIH HHS [DK 39588, DK50977] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039588, R01DK050977, R37DK039588] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER MJ, 1994, GASTROENTEROL CLIN N, V23, P437; ARNOLD JC, 1992, HEPATOLOGY, V16, P285, DOI 10.1002/hep.1840160202; BATTS KP, 1988, TRANSPLANTATION, V45, P376, DOI 10.1097/00007890-198802000-00026; BEGOVICH AB, 1994, TISSUE ANTIGENS, V43, P71, DOI 10.1111/j.1399-0039.1994.tb02303.x; Binion DG, 1997, GASTROENTEROLOGY, V112, P1895, DOI 10.1053/gast.1997.v112.pm9178682; BOTARELLI P, 1993, GASTROENTEROLOGY, V104, P580, DOI 10.1016/0016-5085(93)90430-K; BOTEKI S, 1996, HEPATOLOGY, V23, P436; Brandtzaeg P, 1996, BAILLIERE CLIN RHEUM, V10, P1; Briskin MJ, 1996, J IMMUNOL, V156, P719; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CASINIRAGGI V, 1995, J IMMUNOL, V154, P2434; CZAJA AJ, 1995, DIGEST DIS SCI, V40, P435, DOI 10.1007/BF02065434; CZAJA AJ, 1993, HEPATOLOGY, V18, P818; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; DEFRANCHIS R, 1995, J HEPATOL, V22, P45; DEKA N, 1994, J VIROL, V68, P7810, DOI 10.1128/JVI.68.12.7810-7815.1994; DElios MM, 1997, J IMMUNOL, V158, P962; Dickson E R, 1979, Prog Liver Dis, V6, P487; DIGIOACCHINO M, 1990, ALLERGY, V45, P161; DOHERTY DG, 1994, HEPATOLOGY, V19, P609, DOI 10.1002/hep.1840190311; Ebert EC, 1996, CELL IMMUNOL, V167, P108, DOI 10.1006/cimm.1996.0013; ECTORS NL, 1994, J PATHOL, V172, P73, DOI 10.1002/path.1711720112; EISENSTEIN EM, 1994, J IMMUNOL, V152, P5957; ERLE DJ, 1994, J IMMUNOL, V153, P517; FAIS S, 1992, GUT, V33, P472, DOI 10.1136/gut.33.4.472; FARRANT JM, 1992, HEPATOLOGY, V16, P390, DOI 10.1002/hep.1840160217; FARRANT JM, 1991, GASTROENTEROLOGY, V100, P1710, DOI 10.1016/0016-5085(91)90673-9; FARRINGTON M, 1994, P NATL ACAD SCI USA, V91, P1099, DOI 10.1073/pnas.91.3.1099; FERRETTI M, 1994, J CLIN INVEST, V94, P449, DOI 10.1172/JCI117345; FREESE DK, 1991, HEPATOLOGY, V13, P882, DOI 10.1016/0270-9139(91)90258-W; GALBRAITH RM, 1974, NEW ENGL J MED, V290, P63, DOI 10.1056/NEJM197401102900201; GILINSKY NH, 1987, MEDICINE, V66, P438, DOI 10.1097/00005792-198711000-00002; GONZALEZPERALTA RP, 1994, HEPATOLOGY, V20, pA232; Guidotti LG, 1996, P NATL ACAD SCI USA, V93, P4589, DOI 10.1073/pnas.93.10.4589; Hadziyannis S., 1995, Journal of Hepatology, V23, P78; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626; JOPLIN R, 1995, J PATHOL, V176, P381, DOI 10.1002/path.1711760409; KHOJASTEH A, 1990, AM J MED, V89, P483, DOI 10.1016/0002-9343(90)90380-V; KLEIN NC, 1970, MEDICINE, V49, P299, DOI 10.1097/00005792-197007000-00003; KONTANI K, 1992, CLIN EXP IMMUNOL, V89, P63; Koziel MJ, 1996, AM J MED, V100, P98, DOI 10.1016/S0002-9343(96)90018-2; KRAMER DR, 1995, IMMUNOL CELL BIOL, V73, P389, DOI 10.1038/icb.1995.61; LEE CM, 1993, AM J GASTROENTEROL, V88, P70; Lee M, 1996, SOUTHERN MED J, V89, P189, DOI 10.1097/00007611-199602000-00006; LEINBACH GE, 1970, GASTROENTEROLOGY, V59, P874; Lemon SM, 1997, NEW ENGL J MED, V336, P196, DOI 10.1056/NEJM199701163360307; LEUNG PSC, 1991, IMMUNOL RES, V10, P518, DOI 10.1007/BF02919751; LEUNG PSC, 1992, HEPATOLOGY, V15, P367, DOI 10.1002/hep.1840150302; LIDMAN K, 1976, CLIN EXP IMMUNOL, V24, P266; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; LOWSKY R, 1994, NEW ENGL J MED, V331, P1343, DOI 10.1056/NEJM199411173312004; LUDWIG J, 1987, HEPATOLOGY, V7, P476, DOI 10.1002/hep.1840070311; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; MA JY, 1994, SCAND J GASTROENTERO, V29, P790, DOI 10.3109/00365529409092512; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MARTH T, 1994, CLIN IMMUNOL IMMUNOP, V72, P217, DOI 10.1006/clin.1994.1134; MAYER L, 1990, J CLIN INVEST, V86, P1255, DOI 10.1172/JCI114832; MCNILLAN SA, 1991, BRIT MED J, V303, P1163; MELAMED I, 1991, AM J MED, V90, P310, DOI 10.1016/0002-9343(91)90570-N; MICHITAKA K, 1994, GASTROENTEROLOGY, V106, P1603, DOI 10.1016/0016-5085(94)90417-0; MORADPOUR D, 1994, HEPATOLOGY, V20, P1437, DOI 10.1002/hep.1840200610; MULLIN GE, 1992, GASTROENTEROLOGY, V104, P102; MURRAY A, 1995, AM J PATHOL, V146, P509; MYSZOR M, 1990, Q J MED, V75, P377; NAKANUMA Y, 1995, SEMIN LIVER DIS, V15, P313, DOI 10.1055/s-2007-1007284; NAYLOR AR, 1990, SCOT MED J, V35, P163, DOI 10.1177/003693309003500601; Nelson DR, 1997, J IMMUNOL, V158, P1473; NISHIO A, 1994, GASTROENTEROLOGY, V107, P1408, DOI 10.1016/0016-5085(94)90543-6; PAULSEN G, 1995, HUM IMMUNOL, V42, P145, DOI 10.1016/0198-8859(94)00086-6; PENA A, 1996, J CLIN INVEST, V98, P1185; PERRILLO RP, 1995, J HEPATOL, V22, P45; PROCHAZKA EJ, 1990, NEW ENGL J MED, V322, P1842, DOI 10.1056/NEJM199006283222603; PURDY MA, 1994, GASTROENTEROL CLIN N, V23, P537; Rehermann B, 1996, J CLIN INVEST, V97, P1655, DOI 10.1172/JCI118592; REHERMANN B, 1995, J EXP MED, V181, P1047, DOI 10.1084/jem.181.3.1047; RELMAN DA, 1992, NEW ENGL J MED, V327, P346; Salimi M, 1996, AM J CLIN ONCOL-CANC, V19, P18, DOI 10.1097/00000421-199602000-00004; SARTOR RB, 1995, GASTROENTEROL CLIN N, V24, P475; SCHREIBER S, 1995, GASTROENTEROLOGY, V108, P21, DOI 10.1016/0016-5085(95)90004-7; SCHULMAN HM, 1988, HEPATOLOGY, V8, P463; SHIMIZU YK, 1994, J VIROL, V68, P1494, DOI 10.1128/JVI.68.3.1494-1500.1994; SMITH PD, 1992, ANN INTERN MED, V116, P63, DOI 10.7326/0003-4819-116-1-63; SNELLER MC, 1990, J IMMUNOL, V144, P3762; Sobajima J, 1997, CLIN EXP IMMUNOL, V107, P135, DOI 10.1046/j.1365-2249.1997.d01-907.x; SOLLID LM, 1993, GASTROENTEROLOGY, V105, P910, DOI 10.1016/0016-5085(93)90912-V; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stoffel MP, 1996, CLIN EXP IMMUNOL, V104, P54, DOI 10.1046/j.1365-2249.1996.d01-654.x; STURGESS R, 1994, LANCET, V343, P758, DOI 10.1016/S0140-6736(94)91837-6; TALLEY NJ, 1992, GASTROENTEROLOGY, V103, P137, DOI 10.1016/0016-5085(92)91106-E; TORPIER G, 1990, CLIN EXP IMMUNOL, V74, P404; TRIGER DR, 1984, LIVER, V4, P195; TSAREV SA, 1994, P NATL ACAD SCI USA, V91, P10198, DOI 10.1073/pnas.91.21.10198; UIBO O, 1993, DIGEST DIS SCI, V38, P2034, DOI 10.1007/BF01297081; VANDELLEN RG, 1994, MAYO CLIN PROC, V69, P441, DOI 10.1016/S0025-6196(12)61640-1; VANDEWATER J, 1993, J CLIN INVEST, V91, P2653, DOI 10.1172/JCI116504; VANTHIEL DH, 1986, GASTROENTEROLOGY, V90, P211, DOI 10.1016/0016-5085(86)90096-X; VIERLING JM, 1985, HEPATOLOGY, V5, P1076, DOI 10.1002/hep.1840050603; WATCHER B, 1990, J HEPATOL, V11, P232; WEINER A, 1995, P NATL ACAD SCI USA, V92, P2755, DOI 10.1073/pnas.92.7.2755; WIESER H, 1995, BAILLIERE CLIN GASTR, V9, P191, DOI 10.1016/0950-3528(95)90027-6; WIESNER RH, 1989, HEPATOLOGY, V10, P430, DOI 10.1002/hep.1840100406; WIESNER RH, 1994, MAYO CLIN PROC, V69, P969, DOI 10.1016/S0025-6196(12)61822-9; WOLF HM, 1994, PEDIATR RES, V36, P235, DOI 10.1203/00006450-199408000-00016; WOLF HM, 1994, BLOOD, V83, P1278	105	23	27	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1946	1955		10.1001/jama.278.22.1946	http://dx.doi.org/10.1001/jama.278.22.1946			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396657				2022-12-28	WOS:A1997YK15500018
J	Smith, DR; Weiner, HL				Smith, DR; Weiner, HL			Immunologic aspects of neurologic and neuromuscular diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROGRESSIVE MULTIPLE-SCLEROSIS; MYELIN BASIC-PROTEIN; PLACEBO-CONTROLLED TRIAL; T-CELL ACTIVATION; MYASTHENIA-GRAVIS; INTERFERON-BETA; PERIPHERAL-BLOOD; DOUBLE-BLIND; INTERMITTENT CYCLOPHOSPHAMIDE; MONOCLONAL GAMMOPATHY	Inflammatory disorders of the nervous and neuromuscular system are not uncommon despite the fact that immune privilege exists in much of the nervous system. Common immune-mediated neurologic diseases include multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and idiopathic polymyositis. Environmental, genetic, and immunologic factors have been postulated to be involved in the pathogenesis of these diseases, but much remains to be elucidated about the specific identity and relative contributions of these factors. Several new therapies have become available for these diseases in the past few years, and many others are under investigation. Strategies that enhance the normal tolerance mechanisms of the immune system are being developed. In particular, strategies to block T(H)1-type responses or enhance T(H)2/3-type responses have generated interest.			Smith, DR (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,INST MED,CTR NEUROL DIS,77 AVE LOUIS PASTEUR,ROOM 702,BOSTON,MA 02115, USA.							ARNASON BGW, 1993, NEUROLOGY, V43, P641, DOI 10.1212/WNL.43.4.641; Balashov KE, 1997, P NATL ACAD SCI USA, V94, P599, DOI 10.1073/pnas.94.2.599; BECK RW, 1993, NEW ENGL J MED, V329, P1764, DOI 10.1056/NEJM199312093292403; BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; BENNUN A, 1981, NATURE, V292, P60, DOI 10.1038/292060a0; CHEN Y, 1994, SCIENCE, V265, P237; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DEROSBO NK, 1993, J CLIN INVEST, V92, P2602, DOI 10.1172/JCI116875; Durelli L, 1996, NEUROLOGY, V47, P123, DOI 10.1212/WNL.47.1.123; DURELLI L, 1991, J NEUROL NEUROSUR PS, V54, P406, DOI 10.1136/jnnp.54.5.406; Edan G, 1997, J NEUROL NEUROSUR PS, V62, P112, DOI 10.1136/jnnp.62.2.112; ENGEL AG, 1989, CURR OPIN NEUROL NEU, V2, P695; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; FURNEAUX H, 1990, NEUROLOGY, V7, P1085; Gerritse K, 1996, P NATL ACAD SCI USA, V93, P2499, DOI 10.1073/pnas.93.6.2499; GOODKIN DE, 1995, ANN NEUROL, V37, P30, DOI 10.1002/ana.410370108; *GROUP TIMSS, 1993, NEUROLOGY, V43, P655; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; HIRSCH RL, 1987, J CLIN INVEST, V22, P139; HOHLFELD R, 1991, NEW ENGL J MED, V324, P877, DOI 10.1056/NEJM199103283241303; Ibsen SN, 1996, ACTA NEUROL SCAND, V93, P236; *IFN BET MULT SCLE, 1995, NEUROLOGY, V45, P1277; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; KALOVIDOURIS AE, 1989, ARTHRITIS RHEUM, V32, P446, DOI 10.1002/anr.1780320414; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; KISSEL JT, 1986, NEW ENGL J MED, V314, P329, DOI 10.1056/NEJM198602063140601; KUPERSMITH MJ, 1994, NEUROLOGY, V44, P1; LATOV N, 1994, SEMIN NEUROL, V14, P118, DOI 10.1055/s-2008-1041068; Lodge PA, 1996, NEUROLOGY, V46, P1410, DOI 10.1212/WNL.46.5.1410; MILLER FW, 1992, NEW ENGL J MED, V326, P1380, DOI 10.1056/NEJM199205213262102; NORONHA A, 1993, J NEUROIMMUNOL, V46, P145, DOI 10.1016/0165-5728(93)90244-S; Notermans NC, 1996, NEUROLOGY, V47, P1227, DOI 10.1212/WNL.47.5.1227; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; PESTRONK A, 1994, NEUROLOGY, V44, P2027; PORRINI AM, 1995, J NEUROIMMUNOL, V61, P27, DOI 10.1016/0165-5728(95)00070-I; RUDICK RA, 1993, NEUROLOGY, V43, P2080, DOI 10.1212/WNL.43.10.2080; SELA M, 1995, ISRAEL J MED SCI, V31, P10; SIPE JC, 1994, LANCET, V344, P9, DOI 10.1016/S0140-6736(94)91046-4; Smith DR, 1997, ANN NEUROL, V42, P313, DOI 10.1002/ana.410420307; STEINMAN L, 1993, MONOCLONAL ANTIBODY, P253; TARGOFF IN, 1994, RHEUM DIS CLIN N AM, V20, P857; Truffault F, 1997, ANN NEUROL, V41, P731, DOI 10.1002/ana.410410609; WANG ZY, 1995, J NEUROL SCI, V128, P167, DOI 10.1016/0022-510X(94)00235-G; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WEINER HL, 1993, NEUROLOGY, V43, P910, DOI 10.1212/WNL.43.5.910; WINDHAGEN A, 1995, J EXP MED, V182, P1985, DOI 10.1084/jem.182.6.1985; YI Q, 1994, J IMMUNOL, V153, P3353; ZHANG JW, 1994, J EXP MED, V179, P973, DOI 10.1084/jem.179.3.973	49	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1956	1961		10.1001/jama.278.22.1956	http://dx.doi.org/10.1001/jama.278.22.1956			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396658				2022-12-28	WOS:A1997YK15500019
J	Biederer, T; Volkwein, C; Sommer, T				Biederer, T; Volkwein, C; Sommer, T			Role of Cue1p in ubiquitination and degradation at the ER surface	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; PROTEASOME PATHWAY; PROTEIN; COMPLEX; TRANSLOCATION; SEC61P; ENZYME	Endoplasmic reticulum (ER) degradation of aberrant proteins is mediated by the ubiquitin-proteasome pathway. Here, a membrane-bound component of the ubiquitin system, Cue1p, was identified. It was shown to recruit the soluble ubiquitin-conjugating enzyme Ubc7p to the ER membrane. In the absence of Cue1p, unassembled and thus cytosolically mislocalized Ubc7p was unable to participate in ER degradation or in the turnover of soluble non-ER proteins. Moreover, ubiquitination by Cue1p-assembled Ubc7p and Ubc6p was a prerequisite for retrograde transport of lumenal substrates out of the ER, which suggests that ubiquitination is mechanistically integrated into the ER degradation process.	MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine			Biederer, Thomas/AAZ-6133-2021	Biederer, Thomas/0000-0003-0912-1514				Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SCHWARTZ AL, 1992, P NATL ACAD SCI USA, V89, P5542, DOI 10.1073/pnas.89.12.5542; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WOLF DH, 1975, J BACTERIOL, V123, P1150, DOI 10.1128/JB.123.3.1150-1156.1975	22	312	314	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1806	1809		10.1126/science.278.5344.1806	http://dx.doi.org/10.1126/science.278.5344.1806			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388185				2022-12-28	WOS:A1997YJ90100051
J	DeAngelis, PL; Jing, W; Graves, MV; Burbank, DE; VanEtten, JL				DeAngelis, PL; Jing, W; Graves, MV; Burbank, DE; VanEtten, JL			Hyaluronan synthase of chlorella virus PBCV-1	SCIENCE			English	Article							STREPTOCOCCUS-PYOGENES; SEQUENCE; PROTEIN; ALGA	Sequence analysis of the 330-kilobase genome of the virus PBCV-1 that infects a chlorella-like green algae revealed an open reading frame, A98R, with similarity to several hyaluronan synthases. Hyaluronan is an essential polysaccharide found in higher animals as well as in a few pathogenic bacteria. Expression of the A98R gene product in Escherichia coli indicated that the recombinant protein is an authentic hyaluronan synthase. A98R is expressed early in PBCV-1 infection and hyaluronan is produced in infected algae. These results demonstrate that a virus can encode an enzyme capable of synthesizing a carbohydrate polymer and that hyaluronan exists outside of animals and their pathogens.	UNIV NEBRASKA,DEPT PLANT PATHOL,LINCOLN,NE 68583	University of Nebraska System; University of Nebraska Lincoln	DeAngelis, PL (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,940 STANTON L YOUNG BLVD,OKLAHOMA CITY,OK 73104, USA.				NIGMS NIH HHS [R01-GM56497, R01-GM32441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056497, R01GM032441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBANK DE, 1983, SCIENCE, V219, P994; CARTER GR, 1953, AM J VET RES, V14, P475; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; DeAngelis PL, 1996, BIOCHEMISTRY-US, V35, P9768, DOI 10.1021/bi960154k; DEANGELIS PL, UNPUB; GRAVES M, UNPUB; HARMON BG, 1991, AM J VET RES, V52, P1507; Kass EH, 1944, J EXP MED, V79, P319, DOI 10.1084/jem.79.3.319; KNUDSON CB, 1993, FASEB J, V7, P1234; LANDSTEIN D, UNPUB; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; MOFFATT BA, 1986, J MOL BIOL, V189, P113; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; PUMMILL PE, UNPUB; QUINN RW, 1957, BIOCHEM J, V95, P290; Reisser W., 1992, ALGAE SYMBIOSES; ROHOZINSKI J, 1989, VIROLOGY, V168, P363, DOI 10.1016/0042-6822(89)90277-8; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SKRDLA MP, 1984, VIROLOGY, V135, P308, DOI 10.1016/0042-6822(84)90188-0; TENGBLAD A, 1980, BIOCHEM J, V185, P101, DOI 10.1042/bj1850101; VANETTEN JL, 1991, MICROBIOL REV, V55, P586, DOI 10.1128/MMBR.55.4.586-620.1991; VANETTEN JL, 1995, MOL CELLS, V5, P99; VANETTEN JL, 1985, VIROLOGY, V140, P135, DOI 10.1016/0042-6822(85)90452-0; WANG IN, 1993, P NATL ACAD SCI USA, V90, P3840, DOI 10.1073/pnas.90.9.3840; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; YAMADA T, 1991, APPL ENVIRON MICROB, V57, P3433, DOI 10.1128/AEM.57.12.3433-3437.1991; ZHANG YP, 1994, VIROLOGY, V202, P1079, DOI 10.1006/viro.1994.1444	34	96	112	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1800	1803		10.1126/science.278.5344.1800	http://dx.doi.org/10.1126/science.278.5344.1800			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388183	Green Published			2022-12-28	WOS:A1997YJ90100049
J	Palkova, Z; Janderova, B; Gabriel, J; Zikanova, B; Pospisek, M; Forstova, J				Palkova, Z; Janderova, B; Gabriel, J; Zikanova, B; Pospisek, M; Forstova, J			Ammonia mediates communication between yeast colonies	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; RAS PROTEINS; LOCALIZATION; EXPRESSION; GROWTH	Under certain growth conditions unicellular organisms behave as highly organized multicellular structures. For example, the fruiting bodies of myxobacteria(1) and of the slime mould Dictyostelium discoideum(2) form structures composed of non-dividing motile cells. Although non-motile, yeasts can create organized structures, colonies in which cells communicate and act in a coordinated fashion. Colony morphologies are characteristic for different species and strains. Here we describe that, in addition to short-range intracolony cell-cell communication, yeasts exhibit long-distance signals between neighbouring colonies. The volatile alkaline compound ammonia, transmitted by yeast colonies in pulses, has been identified as a substance mediating the intercolony signal. The first alkaline pulse produced by neighbouring colonies is non-directed and is followed by acidification of the medium. The second pulse seems to be enhanced and is oriented towards the neighbour colony. Ammonia signalling results in growth inhibition of the facing parts of both colonies. This phenomenon is observed in different yeast genera. The presence of amino acids in the medium is required for ammonia production, Colonies derived from the yeast Saccharomyces cerevisiae shr3 mutant, defective in localization of amino-acid permeases(3), do not produce detectable amounts of ammonia and do not exhibit asymmetric growth inhibition.	ACAD SCI CZECH REPUBL,INST MICROBIOL,CR-14220 PRAGUE 4,CZECH REPUBLIC	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Palkova, Z (corresponding author), CHARLES UNIV,DEPT GENET & MICROBIOL,VINICNA 5,PRAGUE 12844 2,CZECH REPUBLIC.		Zikánová, Blanka/P-9993-2017; Pospisek, Martin/A-9100-2008; Gabriel, Jiri/H-2473-2014; Palkova, Zdena/M-8692-2014; Forstova, Jitka/L-7328-2017	Zikánová, Blanka/0000-0002-2599-4713; Palkova, Zdena/0000-0002-0864-8042; Gabriel, Jiri/0000-0001-9341-3434; Forstova, Jitka/0000-0003-0219-506X; Pospisek, Martin/0000-0002-9490-8911				CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; GROSS JD, 1994, MICROBIOL REV, V58, P330, DOI 10.1128/MMBR.58.3.330-351.1994; KOCKOVAKRATOCHV.A, 1990, YEASTS YEAST LIKE OR; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; MARAZ A, 1979, PROTOPLASTS APPLICAT, P35; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; MITCHELL AP, 1986, NATURE, V319, P738, DOI 10.1038/319738a0; SCHAAP P, 1995, DEV BIOL, V168, P179, DOI 10.1006/dbio.1995.1070; Serrano R, 1991, MOL CELLULAR BIOL YE, P523; SHIMKETS LJ, 1990, MICROBIOL REV, V54, P473, DOI 10.1128/MMBR.54.4.473-501.1990; SUOMALAINEN H, 1967, J I BREWING, V73, P477; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WRIGHT RM, 1993, CURR GENET, V23, P388, DOI 10.1007/BF00312623	15	170	177	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					532	536		10.1038/37398	http://dx.doi.org/10.1038/37398			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394006				2022-12-28	WOS:A1997YJ86500058
J	Goate, AM; Morris, JC				Goate, AM; Morris, JC			Notch3 mutations and the potential for diagnostic testing for CADASIL	LANCET			English	Editorial Material									WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Goate, AM (corresponding author), WASHINGTON UNIV, SCH MED, DEPT PSYCHIAT, ST LOUIS, MO 63110 USA.		Morris, John C/A-1686-2012	Goate, Alison/0000-0002-0576-2472				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; CHABRIAT H, 1995, LANCET, V346, P934, DOI 10.1016/S0140-6736(95)91557-5; GREENSPAN R J, 1990, New Biologist, V2, P595; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256	5	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1490	1490		10.1016/S0140-6736(97)22047-7	http://dx.doi.org/10.1016/S0140-6736(97)22047-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388391				2022-12-28	WOS:A1997YH11500002
J	Hamblin, R; Harrison, A; Boyle, S				Hamblin, R; Harrison, A; Boyle, S			The supertanker's not for turning	LANCET			English	Editorial Material											Hamblin, R (corresponding author), KINGS FUND, LONDON W1M 0AN, ENGLAND.							APPLEBY J, 1994, HLTH SERVICE J, V104, P36; Dixon J, 1997, BRIT MED J, V314, P86, DOI 10.1136/bmj.314.7074.86; NEWTON JN, 1995, BRIT MED J, V311, P783, DOI 10.1136/bmj.311.7008.783; *NHS EX, 1997, EX LETT, V97, P42	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1493	1494		10.1016/S0140-6736(05)63937-2	http://dx.doi.org/10.1016/S0140-6736(05)63937-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388394				2022-12-28	WOS:A1997YH11500005
J	Kunst, F; Ogasawara, N; Moszer, I; Albertini, AM; Alloni, G; Azevedo, V; Bertero, MG; Bessieres, P; Bolotin, A; Borchert, S; Borriss, R; Boursier, L; Brans, A; Braun, M; Brignell, SC; Bron, S; Brouillet, S; Bruschi, CV; Caldwell, B; Capuano, V; Carter, NM; Choi, SK; Codani, JJ; Connerton, IF; Cummings, NJ; Daniel, RA; Denizot, F; Devine, KM; Dusterhoft, A; Ehrlich, SD; Emmerson, PT; Entian, KD; Errington, J; Fabret, C; Ferrari, E; Foulger, D; Fritz, C; Fujita, M; Fujita, Y; Fuma, S; Galizzi, A; Galleron, N; Ghim, SY; Glaser, P; Goffeau, A; Golightly, EJ; Grandi, G; Guiseppi, G; Guy, BJ; Haga, K; Haiech, J; Harwood, CR; Henaut, A; Hilbert, H; Holsappel, S; Hosono, S; Hullo, MF; Itaya, M; Jones, L; Joris, B; Karamata, D; Kasahara, Y; KlaerrBlanchard, M; Klein, C; Kobayashi, Y; Koetter, P; Koningstein, G; Krogh, S; Kumano, M; Kurita, K; Lapidus, A; Lardinois, S; Lauber, J; Lazarevic, V; Lee, SM; Levine, A; Liu, H; Masuda, S; Mauel, C; Medigue, C; Medina, N; Mellado, RP; Mizuno, M; Moestl, D; Nakai, S; Noback, M; Noone, D; OReilly, M; Ogawa, K; Ogiwara, A; Oudega, B; Park, SH; Parro, V; Pohl, TM; Portetelle, D; Porwollik, S; Prescott, AM; Presecan, E; Pujic, P; Purnelle, B; Rapoport, G; Rey, M; Reynolds, S; Rieger, M; Rivolta, C; Rocha, E; Roche, B; Rose, M; Sadaie, Y; Sato, T; Scanlan, E; Schleich, S; Schroeter, R; Scoffone, F; Sekiguchi, J; Sekowska, A; Seror, SJ; Serror, P; Shin, BS; Soldo, B; Sorokin, A; Tacconi, E; Takagi, T; Takahashi, H; Takemaru, K; Takeuchi, M; Tamakoshi, A; Tanaka, T; Terpstra, P; Tognoni, A; Tosato, V; Uchiyama, S; Vandenbol, M; Vannier, F; Vassarotti, A; Viari, A; Wambutt, R; Wedler, E; Wedler, H; Weitzenegger, T; Winters, P; Wipat, A; Yamamoto, H; Yamane, K; Yasumoto, K; Yata, K; Yoshida, K; Yoshikawa, HF; Zumstein, E; Yoshikawa, H; Danchin, A				Kunst, F; Ogasawara, N; Moszer, I; Albertini, AM; Alloni, G; Azevedo, V; Bertero, MG; Bessieres, P; Bolotin, A; Borchert, S; Borriss, R; Boursier, L; Brans, A; Braun, M; Brignell, SC; Bron, S; Brouillet, S; Bruschi, CV; Caldwell, B; Capuano, V; Carter, NM; Choi, SK; Codani, JJ; Connerton, IF; Cummings, NJ; Daniel, RA; Denizot, F; Devine, KM; Dusterhoft, A; Ehrlich, SD; Emmerson, PT; Entian, KD; Errington, J; Fabret, C; Ferrari, E; Foulger, D; Fritz, C; Fujita, M; Fujita, Y; Fuma, S; Galizzi, A; Galleron, N; Ghim, SY; Glaser, P; Goffeau, A; Golightly, EJ; Grandi, G; Guiseppi, G; Guy, BJ; Haga, K; Haiech, J; Harwood, CR; Henaut, A; Hilbert, H; Holsappel, S; Hosono, S; Hullo, MF; Itaya, M; Jones, L; Joris, B; Karamata, D; Kasahara, Y; KlaerrBlanchard, M; Klein, C; Kobayashi, Y; Koetter, P; Koningstein, G; Krogh, S; Kumano, M; Kurita, K; Lapidus, A; Lardinois, S; Lauber, J; Lazarevic, V; Lee, SM; Levine, A; Liu, H; Masuda, S; Mauel, C; Medigue, C; Medina, N; Mellado, RP; Mizuno, M; Moestl, D; Nakai, S; Noback, M; Noone, D; OReilly, M; Ogawa, K; Ogiwara, A; Oudega, B; Park, SH; Parro, V; Pohl, TM; Portetelle, D; Porwollik, S; Prescott, AM; Presecan, E; Pujic, P; Purnelle, B; Rapoport, G; Rey, M; Reynolds, S; Rieger, M; Rivolta, C; Rocha, E; Roche, B; Rose, M; Sadaie, Y; Sato, T; Scanlan, E; Schleich, S; Schroeter, R; Scoffone, F; Sekiguchi, J; Sekowska, A; Seror, SJ; Serror, P; Shin, BS; Soldo, B; Sorokin, A; Tacconi, E; Takagi, T; Takahashi, H; Takemaru, K; Takeuchi, M; Tamakoshi, A; Tanaka, T; Terpstra, P; Tognoni, A; Tosato, V; Uchiyama, S; Vandenbol, M; Vannier, F; Vassarotti, A; Viari, A; Wambutt, R; Wedler, E; Wedler, H; Weitzenegger, T; Winters, P; Wipat, A; Yamamoto, H; Yamane, K; Yasumoto, K; Yata, K; Yoshida, K; Yoshikawa, HF; Zumstein, E; Yoshikawa, H; Danchin, A			The complete genome sequence of the Gram-positive bacterium Bacillus subtilis	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; DNA-SEQUENCES; REPLICATION; TERMINATORS; COMPETENCE; PROJECT; STRANDS; REGION; ACIDS	Bacillus subtilis Is the best-characterized member of the Gram-positive bacteria. Its genome of 4,214,810 base pairs comprises 4,100 protein-coding genes. Of these protein-coding genes, 53% are represented once, while a quarter of the genome corresponds to several gene families that have been greatly expanded by gene duplication, the largest family containing 77 putative ATP-binding transport proteins. In addition, a large proportion of the genetic capacity is devoted to the utilization of a variety of carbon sources, including many plant-derived molecules. The identification of five signal peptidase genes, as well as several genes for components of the secretion apparatus, is important given the capacity of Bacillus strains to secrete large amounts of industrially important enzymes. Many of the genes are involved in the synthesis of secondary metabolites, Including antibiotics, that are more typically associated with Streptomyces species. The genome contains at least ten prophages or remnants of prophages, indicating that bacteriophage Infection has played an important evolutionary role in horizontal gene transfer, in particular In the propagation of bacterial pathogenesis.	NARA INST SCI & TECHNOL, GRAD SCH BIOL SCI, NARA 63001, JAPAN; INST PASTEUR, UNITE REGULAT EXPRESS GENET, F-75724 PARIS 15, FRANCE; UNIV PAVIA, DIPARTIMENTO GENET & MICROBIOL, I-27100 PAVIA, ITALY; INRA, F-78352 JOUY EN JOSAS, FRANCE; UNIV FRANKFURT, INST MIKROBIOL, D-60439 FRANKFURT, GERMANY; HUMBOLDT UNIV BERLIN, INST GENET & MIKROBIOL, D-10115 BERLIN, GERMANY; UNIV LIEGE, CTR INGN PROT, INST CHIM B6, B-4000 LIEGE, BELGIUM; QIAGEN GMBH, D-40724 HILDEN, GERMANY; UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT MICROBIOL IMMUNOL & VIROL SCI, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND; UNIV GRONINGEN, DEPT GENET, NL-9751 NN HAREN, NETHERLANDS; UNIV PARIS 06, ATELIER BIOINFORMAT, F-75005 PARIS, FRANCE; INT CTR GENET ENGN & BIOTECHNOL, AREA SCI PK, I-34012 TRIESTE, ITALY; GENENCOR INT, PALO ALTO, CA 94304 USA; KRIBB, APPL MICROBIOL RES DIV, BACTERIAL MOL GENET RES UNIT, TAEJON 305600, SOUTH KOREA; INST NATL RECH INFORMAT & AUTOMAT, F-78153 LE CHESNAY, FRANCE; INST FOOD RES, READING LAB, DEPT FOOD MACROMOL SCI, READING RG6 6BZ, BERKS, ENGLAND; UNIV OXFORD, SIR WILLIAM DUNN SCH PATHOL, OXFORD OX1 3RE, ENGLAND; CNRS, CHIM BACTERIENNE LAB, F-13402 MARSEILLE 09, FRANCE; TRINITY COLL DUBLIN, DEPT GENET, DUBLIN, IRELAND; UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT BIOCHEM & GENET, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND; NATL INST GENET, CTR RADIOISOTOPE, MISHIMA, SHIZUOKA 411, JAPAN; FUKUYAMA UNIV, FAC ENGN, DEPT BIOTECHNOL, HIROSHIMA 72902, JAPAN; UNIV TSUKUBA, INST BIOL SCI, TSUKUBA, IBARAKI 305, JAPAN; UNIV CATHOLIQUE LOUVAIN, UNITE BIOCHIM PHYSIOL, FAC SCI AGRON, B-1348 LOUVAIN, BELGIUM; NOVO NORDISK BIOTECH, DAVIS, CA 95616 USA; ENIRICERCHE SPA, I-20097 SAN DONATO MILANESE, MILAN, ITALY; UNIV TOKYO, INST MOL & CELLULAR BIOL, BUNKYO KU, TOKYO 113, JAPAN; UNIV VERSAILLES, LAB GENOME & INFORMAT, F-78035 VERSAILLES, FRANCE; TOKYO UNIV AGR & TECHNOL, FAC AGR, FUCHU, TOKYO 183, JAPAN; MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN; INST PASTEUR, SERV INFORMAT SCI, F-75724 PARIS 15, FRANCE; UNIV LAUSANNE, INST GENET & BIOL MICROBIENNES, CH-1005 LAUSANNE, SWITZERLAND; FREE UNIV AMSTERDAM, FAC BIOL, DEPT MOL MICROBIOL, MBW BCA, NL-1081 HV AMSTERDAM, NETHERLANDS; CHONGJU UNIV, COLL SCI & ENGN, CHONJU, SOUTH KOREA; UNIV PARIS 11, INST GENET & MICROBIOL, CNRS, URA 2225, F-91405 ORSAY, FRANCE; CSIC, CTR NACL BIOTECNOL, E-28049 MADRID, SPAIN; NATL INST BASIC BIOL, OKAZAKI, AICHI 444, JAPAN; GESELL ANAL TECH & CONSULTING MBH, D-78467 CONSTANCE, GERMANY; FAC AGRON, DEPT MICROBIOL, B-5030 GEMBLOUX, BELGIUM; BMF, BIOTECH RES, D-69434 HIRSCHHORN, GERMANY; SHINSHU UNIV, FAC TEXT SCI & TECHNOL, DEPT APPL BIOL, UEDA, NAGANO 386, JAPAN; UNIV TOKYO, INST MED SCI, CTR HUMAN GENOME, MINATO KU, TOKYO 108, JAPAN; TOKAI UNIV, SCH MARINE SCI & TECHNOL, DEPT MARINE SCI, SHIZUOKA 424, JAPAN; COMMISS EUROPEAN COMMUNITIES, DG XII E 1, SDME 878, B-1049 BRUSSELS, BELGIUM; AGOWA GMBH, D-12489 BERLIN, GERMANY	Nara Institute of Science & Technology; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Pavia; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Goethe University Frankfurt; Humboldt University of Berlin; University of Liege; QIAGEN GmbH; Newcastle University - UK; University of Groningen; UDICE-French Research Universities; Sorbonne Universite; International Center for Genetic Engineering & Biotechnology (ICGEB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of Oxford; Centre National de la Recherche Scientifique (CNRS); Trinity College Dublin; Newcastle University - UK; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Fukuyama University; University of Tsukuba; Universite Catholique Louvain; Novo Nordisk; Eni SpA; University of Tokyo; UDICE-French Research Universities; Universite Paris Saclay; Tokyo University of Agriculture & Technology; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Lausanne; Vrije Universiteit Amsterdam; Cheongju University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Shinshu University; University of Tokyo; Tokai University	Kunst, F (corresponding author), INST PASTEUR, UNITE BIOCHIM MICROBIENNE, 25 RUE DR ROUX, F-75724 PARIS 15, FRANCE.		Mellado, Rafael P/D-2680-2009; Yoshida, Ken-ichi/R-8863-2016; Harwood, Colin/AGF-0120-2022; Ogasawara, Naotake/B-7971-2011; Pupin, Maude/I-7437-2015; Levine, Alex/A-6867-2008; Sekiguchi, Junichi/F-9963-2010; Ehrlich, S./Y-2423-2019; Entian, Karl-Dieter/D-3080-2011; Rocha, Eduardo/B-7009-2009; Sorokin, Alexei/AAV-4666-2020; Lapidus, Alla L/I-4348-2013; Borriss, Rainer/C-5026-2012; Rocha, Eduardo/A-4727-2008; Azevedo, Vasco/B-1556-2019; Glaser, Philippe/O-2641-2015; Daniel, Richard A./I-2850-2019; Pujic, Petar/ACY-1850-2022; Serror, Pascale/ABA-1314-2021; Azevedo, Vasco A.C/F-4315-2011; Choi, Soo-Keun/AAF-2432-2019; Bolotine, Alexandre/AAW-1156-2020; TAKEUCHI, Michio/H-6592-2013; Kasahara, Yasuhiro/C-8620-2012; Parro, Victor/K-3788-2014; Errington, Jeff/G-1832-2011; haiech, jacques J/F-2890-2010	Yoshida, Ken-ichi/0000-0002-3383-4664; Pupin, Maude/0000-0003-3197-0715; Ehrlich, S./0000-0002-7563-4046; Rocha, Eduardo/0000-0001-7704-822X; Sorokin, Alexei/0000-0002-8653-9896; Lapidus, Alla L/0000-0003-0427-8731; Borriss, Rainer/0000-0003-3726-1004; Azevedo, Vasco/0000-0002-4775-2280; Glaser, Philippe/0000-0003-4156-2782; Daniel, Richard A./0000-0002-6483-5897; Pujic, Petar/0000-0003-1957-8534; Serror, Pascale/0000-0002-8446-9011; Azevedo, Vasco A.C/0000-0002-4775-2280; Bolotine, Alexandre/0000-0002-5878-8270; Errington, Jeff/0000-0002-6977-9388; Parro, Victor/0000-0003-3738-0724; Choi, Soo-Keun/0000-0001-7757-4748; Brans, Alain/0000-0003-4001-2762; Connerton, Ian/0000-0001-8652-8938; Danchin, Antoine/0000-0002-6350-5001; Lazarevic, Vladimir/0000-0002-6839-2536; Fujita, Masaya/0000-0003-0060-5328; Capuano, Veronique/0000-0001-8738-0947; Grandi, Guido/0000-0001-9724-2185; Jones, Louis/0000-0002-3080-9770; haiech, jacques/0000-0003-2908-8053; Harwood, Colin/0000-0002-3624-0001; Bertero, Michela/0000-0002-2012-6706; Wipat, Anil/0000-0001-7310-4191; Rivolta, Carlo/0000-0002-0733-9950				ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; AZEVEDO V, 1993, P NATL ACAD SCI USA, V90, P6047, DOI 10.1073/pnas.90.13.6047; Billoud B, 1996, NUCLEIC ACIDS RES, V24, P1395, DOI 10.1093/nar/24.8.1395; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BORODOVSKY M, 1993, COMPUT CHEM, V17, P123, DOI 10.1016/0097-8485(93)85004-V; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; BURKHOLDER PR, 1947, AM J BOT, V34, P345, DOI 10.2307/2437147; CARAFA YD, 1990, J MOL BIOL, V216, P835, DOI 10.1016/S0022-2836(99)80005-9; Danchin A, 1997, DNA Res, V4, P9, DOI 10.1093/dnares/4.1.9; DANIEL RA, 1994, J MOL BIOL, V235, P209, DOI 10.1016/S0022-2836(05)80027-0; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; FICHANT GA, 1991, J MOL BIOL, V220, P659, DOI 10.1016/0022-2836(91)90108-I; FICHANT GA, 1995, NUCLEIC ACIDS RES, V23, P2900; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRANKS AH, 1995, MOL MICROBIOL, V17, P13, DOI 10.1111/j.1365-2958.1995.mmi_17010013.x; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; Glemet E, 1997, COMPUT APPL BIOSCI, V13, P137; Goffeau A, 1997, NATURE, V387, P5, DOI DOI 10.1038/387005B0.PUBMED:9169864; HARWOOD CR, 1992, TRENDS BIOTECHNOL, V10, P247, DOI 10.1016/0167-7799(92)90233-L; HENAUT A, 1996, ESCHERICHIA COLI SAL, P2047; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; ITAYA M, 1993, J BACTERIOL, V175, P741, DOI 10.1128/JB.175.3.741-749.1993; Kaneko T, 1996, DNA Res, V3, P109; KARLIN S, 1992, NUCLEIC ACIDS RES, V20, P1363, DOI 10.1093/nar/20.6.1363; Kasahara Y, 1997, DNA Res, V4, P155, DOI 10.1093/dnares/4.2.155; Krogh S, 1996, MICROBIOL-UK, V142, P2031, DOI 10.1099/13500872-142-8-2031; Kunst F., 1995, MICROBIOLOGY, V389, P84; LANDES C, 1992, NUCLEIC ACIDS RES, V20, P3631, DOI 10.1093/nar/20.14.3631; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Luttinger A, 1996, MOL MICROBIOL, V19, P343, DOI 10.1046/j.1365-2958.1996.380907.x; MEDIGUE C, 1995, GENE, V165, pGC37, DOI 10.1016/0378-1119(95)00636-K; Mizuno T, 1997, DNA Res, V4, P161, DOI 10.1093/dnares/4.2.161; Moszer I, 1996, MICROBIOL-UK, V142, P2987, DOI 10.1099/13500872-142-11-2987; MOSZER I, 1995, MICROBIOL-SGM, V141, P261, DOI 10.1099/13500872-141-2-261; NUSSINOV R, 1981, J MOL EVOL, V17, P237, DOI 10.1007/BF01732761; Ogasawara N, 1994, DNA Res, V1, P1, DOI 10.1093/dnares/1.1.1; Ogasawara N, 1996, MICROBIOL-UK, V142, P2993, DOI 10.1099/13500872-142-11-2993; Perego M, 1996, MOL MICROBIOL, V19, P1151, DOI 10.1111/j.1365-2958.1996.tb02460.x; Presecan E, 1997, MICROBIOL-SGM, V143, P3313, DOI 10.1099/00221287-143-10-3313; Solomon JM, 1996, TRENDS GENET, V12, P150, DOI 10.1016/0168-9525(96)10014-7; Sorokin A, 1996, GENOME RES, V6, P448, DOI 10.1101/gr.6.5.448; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; SUUTARI M, 1992, BIOCHIM BIOPHYS ACTA, V1126, P119, DOI 10.1016/0005-2760(92)90281-Y; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WU LJ, 1994, SCIENCE, V264, P572, DOI 10.1126/science.8160014	49	3019	7447	20	564	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 20	1997	390	6657					249	256		10.1038/36786	http://dx.doi.org/10.1038/36786			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384377	Green Submitted, hybrid, Green Accepted			2022-12-28	WOS:A1997YG66700052
J	Beasley, BW				Beasley, BW			Whispering through the keyhole	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material													Beasley, Brent/AAE-9466-2021	Beasley, Brent/0000-0002-0997-9636					0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2061	2061		10.1001/jama.278.23.2061	http://dx.doi.org/10.1001/jama.278.23.2061			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403410				2022-12-28	WOS:A1997YK98700019
J	Daly, S; Mills, JL; Molloy, AM; Conley, M; Lee, YJ; Kirke, PN; Weir, DG; Scott, JM				Daly, S; Mills, JL; Molloy, AM; Conley, M; Lee, YJ; Kirke, PN; Weir, DG; Scott, JM			Minimum effective dose of folic acid for food fortification to prevent neural-tube defects	LANCET			English	Article							SUPPLEMENTATION	Background Although a daily supplement of 400 mu g folic acid has been shown to prevent neural-tube defects (NTD), most women do not take the recommended supplement. Thus, food fortification is to be introduced in the USA and is being considered in the UK. Because of safety concerns, the USA has chosen a level of fortification that will increase the average woman's intake by only 100 mu g. Such an increase, although safe, may be ineffective; but a trial to assess its efficacy would be unethical. Because women with red-cell folate concentrations above 400 mu g/L have a very low risk of NTD, we undertook a randomised trial of several folic acid doses to find out how much is needed to reach this protective concentration. Methods We screened 323 women. 172 with red-cell folate between 150 mu g/L and 400 mu g/L were invited to take part in the trial. 121 women were randomly assigned placebo or 100 mu g, 200 mu g, or 400 mu g daily of additional folic acid. Compliance was monitored by having the women sign a dated sheet when taking the tablet. 95 women completed the 6-month study. Findings There were significant increases in red-cell folate in all folic acid groups. The placebo group showed no significant change. The median incremental changes and median post-treatment concentrations were 67 mu g/L (95% CI 43-120) and 375 mu g/L (354-444) in the 100 mu g/day group, 130 mu g/L (108-184) and 475 mu g/L (432-503) in the 200 mu g/day group, and 200 mu g/L (125-312) and 571 mu g/L(481-654) in the 400 mu g/day group. Interpretation A fortification programme that delivered 400 mu g folio acid daily to women would protect against NTD, but at the expense of unnecessarily high exposure for many people. Delivery of 200 mu g daily is also effective against NTD and safer for the general population. Based on projections from the positive folate balance in the group that received 100 mu g daily, this dose taken continually, as it will be in fortified food, will also produce an important decrease in NTD.	COOMBE WOMENS HOSP,RCSI DEPT,DUBLIN,IRELAND; NICHHD,EPIDEMIOL BRANCH,NIH,BETHESDA,MD 20892; NICHHD,BRANCH STAT,NIH,BETHESDA,MD 20892; TRINITY COLL DUBLIN,DEPT CLIN MED,DUBLIN,IRELAND; TRINITY COLL DUBLIN,DEPT BIOCHEM,DUBLIN,IRELAND; HLTH RES BOARD,DUBLIN,IRELAND	Royal College of Surgeons - Ireland; Trinity College Dublin; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Trinity College Dublin; Trinity College Dublin; Health Research Board - Ireland				Mills, James/0000-0003-4496-332X; Molloy, Anne/0000-0002-1688-9049				Brown JE, 1997, JAMA-J AM MED ASSOC, V277, P548, DOI 10.1001/jama.277.7.548; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Chanarin I, 1990, MEGALOBLASTIC ANAEMI; CLARK NAC, 1994, BRIT J OBSTET GYNAEC, V101, P709, DOI 10.1111/j.1471-0528.1994.tb13190.x; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P32; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1696; *EXP ADV GROUP, 1992, FOL AC PREV NEUR TUB; GREGORY JF, 1997, EUR J CLIN NUTR, V51, P554; Health D. O., 1996, FED REGISTER, V61, P8781; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; *MRC VIT STUD RES, 1991, LANCET, V338, P131; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; OBRION S, 1992, J CLIN PATHOL, V45, P344; SMITHELLS RW, 1981, ARCH DIS CHILD, V56, P911, DOI 10.1136/adc.56.12.911; WALD NJ, 1995, BRIT MED J, V310, P1019, DOI 10.1136/bmj.310.6986.1019; 1993, FED REGISTER, V58, P53314	16	199	209	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1666	1669		10.1016/S0140-6736(97)07247-4	http://dx.doi.org/10.1016/S0140-6736(97)07247-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400511				2022-12-28	WOS:A1997YK21100011
J	Davidson, C; Muller, HP				Davidson, C; Muller, HP			European perspectives on general medicine	LANCET			English	Editorial Material											Davidson, C (corresponding author), ROYAL SUSSEX CTY HOSP,DEPT CARDIOL,BRIGHTON BN2 5BE,E SUSSEX,ENGLAND.							*AM COLL PHYS, 1994, ANN INTERN MED, V121, P616; [Anonymous], 1997, LANCET, V350, P675; Beguin C, 1996, ACTA CLIN BELG, V51, P311, DOI 10.1080/22953337.1996.11718525; Knottnerus JA, 1997, BRIT MED J, V315, P1109; TURNBERG L, 1996, FUTURE PATTERNS CARE	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1645	1645		10.1016/S0140-6736(05)64270-5	http://dx.doi.org/10.1016/S0140-6736(05)64270-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400505				2022-12-28	WOS:A1997YK21100005
J	Busettini, C; Masson, GS; Miles, FA				Busettini, C; Masson, GS; Miles, FA			Radial optic flow induces vergence eye movements with ultra-short latencies	NATURE			English	Article							OCULAR-FOLLOWING RESPONSES; SUPERIOR TEMPORAL AREA; MACAQUE MONKEY; EXPANSION CONTRACTION; ROTATION CELLS; SELF-MOTION; DORSAL PART; MST NEURONS; DEPENDENCE; DIRECTION	An observer moving forwards through the environment experiences a radial pattern of image motion on each retina, Such patterns of optic now are a potential source of information about the observer's rate of progress(1), direction of heading(2) and time to reach objects that lie ahead(3). As the viewing distance changes there must be changes in the vergence angle between the two eyes so that both foveas remain aligned on the object of interest in the scene ahead. Here we show that radial optic flow can elicit appropriately directed (horizontal) vergence eye movements with ultra-short latencies (roughly 80 ms) in human subjects. Centrifugal flow, signalling forwards motion, increases the vergence angle, whereas centripetal now decreases the vergence angle. These vergence eye movements are still evident when the observer's view of the flow pattern is restricted to the temporal hemifield of one eye, indicating that these responses do not result from anisotropies in motion processing but from a mechanism that senses the radial pattern of now. We hypothesize that flow-induced vergence is but one of a family of rapid ocular reflexes, mediated by the medial superior temporal cortex, compensating for translational disturbance of the observer.	NEI, SENSORIMOTOR RES LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)			MASSON, Guillaume S/G-4615-2012	MASSON, Guillaume S/0000-0001-9227-0777				Busettini C, 1996, NATURE, V380, P342, DOI 10.1038/380342a0; Busettini C, 1996, J NEUROPHYSIOL, V75, P1392, DOI 10.1152/jn.1996.75.4.1392; BUSETTINI C, 1994, EXP BRAIN RES, V100, P484, DOI 10.1007/BF02738407; Busettini C., 1994, Society for Neuroscience Abstracts, V20, P1403; Cohen Gal A., 1996, Society for Neuroscience Abstracts, V22, P964; Collewijn H, 1990, Rev Oculomot Res, V4, P213; CornilleauPeres V, 1996, TRENDS NEUROSCI, V19, P196, DOI 10.1016/S0166-2236(96)10025-4; DEJONG BM, 1994, BRAIN, V117, P1039; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1329, DOI 10.1152/jn.1991.65.6.1329; DUFFY CJ, 1995, J NEUROSCI, V15, P5192; ENRIGHT JT, 1987, PERCEPTION, V16, P731, DOI 10.1068/p160731; ERKELENS CJ, 1986, J PHYSIOL-LONDON, V379, P145, DOI 10.1113/jphysiol.1986.sp016245; FUCHS AF, 1966, J APPL PHYSIOL, V21, P1068, DOI 10.1152/jappl.1966.21.3.1068; GELLMAN RS, 1990, VISUAL NEUROSCI, V5, P107, DOI 10.1017/S0952523800000158; KAWANO K, 1994, J NEUROPHYSIOL, V71, P2305, DOI 10.1152/jn.1994.71.6.2305; KAWANO K, 1997, PARIETAL LOBE CONTRI, P185; Lappe M, 1996, J NEUROSCI, V16, P6265; LEE DN, 1980, PHILOS T R SOC B, V290, P169, DOI 10.1098/rstb.1980.0089; LEE DN, 1976, PERCEPTION, V5, P437, DOI 10.1068/p050437; MASSON GS, 1997, NATURE, V389, P293; MILES FA, 1995, STUD VIS INFORM PROC, V6, P47; MILES FA, 1986, J NEUROPHYSIOL, V56, P1321, DOI 10.1152/jn.1986.56.5.1321; Prokop T, 1997, EXP BRAIN RES, V114, P63, DOI 10.1007/PL00005624; SAITO H, 1986, J NEUROSCI, V6, P145; Takemura A., 1997, Society for Neuroscience Abstracts, V23, P1557; Takeuchi T, 1997, VISION RES, V37, P2083, DOI 10.1016/S0042-6989(96)00225-8; TANAKA K, 1989, J NEUROPHYSIOL, V62, P642, DOI 10.1152/jn.1989.62.3.642; TANAKA K, 1989, J NEUROPHYSIOL, V62, P626, DOI 10.1152/jn.1989.62.3.626; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; WARREN WH, 1988, NATURE, V336, P162, DOI 10.1038/336162a0	30	71	72	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					512	515		10.1038/37359	http://dx.doi.org/10.1038/37359			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394000				2022-12-28	WOS:A1997YJ86500052
J	Frothingham, R				Frothingham, R			A medical mystery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Frothingham, R (corresponding author), VET AFFAIRS MED CTR,DURHAM,NC 27705, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 4	1997	337	23					1666	1666		10.1056/NEJM199712043372305	http://dx.doi.org/10.1056/NEJM199712043372305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ871	9385126	Bronze			2022-12-28	WOS:A1997YJ87100005
J	Avgerinos, A; Nevens, F; Raptis, S; Fevery, J; Armonis, A; Manolakopoulos, S; Poulianos, G; Tzathas, C; Katsaros, D; Soutos, D; Zacharopoulose, A; Adler, M; Bourgeois, N; Bac, DJ; VanBuuren, HR; Decruyenaere, J; Elewaut, A; Deman, M; Lepoutre, L; VanderSpek, P; Hautekeete, M; Reynaert, H; Buyse, M; Ritter, L; Burtin, B; Darcis, T; Ioannou, J; Natens, J; Natens, O				Avgerinos, A; Nevens, F; Raptis, S; Fevery, J; Armonis, A; Manolakopoulos, S; Poulianos, G; Tzathas, C; Katsaros, D; Soutos, D; Zacharopoulose, A; Adler, M; Bourgeois, N; Bac, DJ; VanBuuren, HR; Decruyenaere, J; Elewaut, A; Deman, M; Lepoutre, L; VanderSpek, P; Hautekeete, M; Reynaert, H; Buyse, M; Ritter, L; Burtin, B; Darcis, T; Ioannou, J; Natens, J; Natens, O			Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European acute bleeding oesophageal variceal episodes (ABOVE) randomised trial	LANCET			English	Article							ESOPHAGEAL-VARICES; INJECTION SCLEROTHERAPY; DOUBLE-BLIND; COMPARING SOMATOSTATIN; CIRRHOTIC-PATIENTS; BOLUS INJECTION; HEMORRHAGE; OCTREOTIDE; MANAGEMENT; TAMPONADE	Background Sclerotherapy is widely used for acute variceal bleeding, although in emergencies bleeding makes it difficult to obtain the clear view required for safe and effective treatment. We investigated whether early administration of somatostatin would improve the efficacy of sclerotherapy. Methods In this double-blind, prospective trial, patients who had cirrhosis with upper-gastrointestinal bleeding were randomly assigned natural somatostatin (6 mg per 24 h) or placebo for 120 h. In addition, intravenous bolus doses of somatostatin (250 mu g) or placebo were injected after the start of the infusion, before emergency endoscopy or sclerotherapy, and when active bleeding was observed. The primary endpoint was treatment failure, defined as the occurrence during the infusion period of at least one of: excess transfusion of blood products, haematemesis, haemodynamic instability, need for rescue therapy, or death. Findings: 205 patients were enrolled: 101 received somatostatin and 104 received placebo. Treatment failed in 35 somatostatin and 57 placebo recipients (p=0.004); death or use of rescue therapy occurred in nine and 19 patients, respectively (p=0.05). The mean quantity of blood products transfused over 120 h (adjusted for baseline haemoglobin) was 2.64 (SD 0.35) units in the somatostatin group versus 3.62 (0.35) units in the placebo group (p=0.05). At endoscopy, active bleeding from oesophageal varices was less frequent (27 vs 42 patients, p=0.012) and the sclerotherapy procedure was easier (2.8 vs 4.7 cm, p=0.0027) in the somatostatin than in the placebo group. Interpretation Early administration of natural somatostatin continued for 120 h, combined with additional bolus injections, is more effective than placebo in the overall control of acute variceal haemorrhage in patients with cirrhosis undergoing sclerotherapy.	UNIV ATHENS, EVANGELISMOS HOSP, DEPT INTERNAL MED 2, GR-10680 ATHENS, GREECE; UNIV HOSP GASTHUISBERG, DEPT LIVER & PANCREAT DIS, B-3000 LOUVAIN, BELGIUM; HELLEN RED CROSS HOSP, ATHENS, GREECE; FREE UNIV BRUSSELS, ERASME HOSP, B-1050 BRUSSELS, BELGIUM; AZ DIKZIGT, ROTTERDAM, NETHERLANDS; UNIV HOSP, GHENT, BELGIUM; ONZE LIEVE VROUW HOSP, AALST, BELGIUM; AZ JETTE VUB, JETTE, BELGIUM; D2, BRUSSELS, BELGIUM; UCB SA PHARMA SECTOR, BRAINE LALLEUD, BELGIUM	Evangelismos Hospital; National & Kapodistrian University of Athens; KU Leuven; University Hospital Leuven; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Ghent University; Ghent University Hospital; UCB Pharma SA	Avgerinos, A (corresponding author), UNIV ATHENS, EVANGELISMOS HOSP, DEPT GASTROENTEROL 2, GR-10680 ATHENS, GREECE.		Manolakopoulos, Spilios/AAD-7058-2019	Reynaert, Hendrik/0000-0002-2701-5777				[Anonymous], 1992, DESIGN ANAL SEQUENTI; AVGERINOS A, 1995, HEPATO-GASTROENTEROL, V42, P145; AVGERINOS A, 1995, J HEPATOL, V22, P379, DOI 10.1016/0168-8278(95)80295-9; AVGERINOS A, 1991, J HEPATOL, V13, P78, DOI 10.1016/0168-8278(91)90867-B; BARSOUM MS, 1982, BRIT J SURG, V69, P76, DOI 10.1002/bjs.1800690206; BESSON I, 1995, NEW ENGL J MED, V333, P555, DOI 10.1056/NEJM199508313330904; BOSCH J, 1981, GASTROENTEROLOGY, V80, P518; BURROUGHS AK, 1990, GASTROENTEROLOGY, V99, P1388, DOI 10.1016/0016-5085(90)91166-4; BURROUGHS AK, 1989, HEPATOLOGY, V9, P801, DOI 10.1002/hep.1840090602; Burroughs AK, 1996, HEPATOLOGY, V24, P737, DOI 10.1053/jhep.1996.v24.ajhep0240737; CIRERA I, 1995, HEPATOLOGY, V22, P106, DOI 10.1016/0270-9139(95)90360-7; DAMICO G, 1995, HEPATOLOGY, V22, P332, DOI 10.1002/hep.1840220145; DIMAGNO EP, 1985, MAYO CLIN PROC, V60, P149, DOI 10.1016/S0025-6196(12)60211-0; Feu F, 1996, GASTROENTEROLOGY, V111, P1291, DOI 10.1053/gast.1996.v111.pm8898643; GOMEZPAN RJ, 1974, LANCET, V1, P888; GRAHAM DY, 1981, GASTROENTEROLOGY, V80, P800; LEVACHER S, 1995, LANCET, V346, P865, DOI 10.1016/S0140-6736(95)92708-5; LO GH, 1992, GASTROINTEST ENDOSC, V38, P421, DOI 10.1016/S0016-5107(92)70469-6; MORETO M, 1988, SURG GYNECOL OBSTET, V167, P331; NEVENS F, 1994, J HEPATOL, V20, P27, DOI 10.1016/S0168-8278(05)80463-5; PANES J, 1994, HEPATOLOGY, V20, P336, DOI 10.1016/0270-9139(94)90183-X; PLANAS R, 1994, HEPATOLOGY, V20, P370, DOI 10.1016/0270-9139(94)90188-0; PRIMIGNANI M, 1995, HEPATOLOGY, V21, P1322, DOI 10.1016/0270-9139(95)90054-3; PRINDIVILLE T, 1987, AM J GASTROENTEROL, V82, P655; SHIELDS R, 1992, J HEPATOL, V16, P128, DOI 10.1016/S0168-8278(05)80105-9; SUNG JJY, 1993, LANCET, V342, P637, DOI 10.1016/0140-6736(93)91758-E; TERBLANCHE J, 1989, NEW ENGL J MED, V320, P1393, DOI 10.1056/NEJM198905253202107; WESTABY D, 1989, HEPATOLOGY, V9, P274, DOI 10.1002/hep.1840090219	28	178	180	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1495	1499		10.1016/S0140-6736(97)05099-X	http://dx.doi.org/10.1016/S0140-6736(97)05099-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388396				2022-12-28	WOS:A1997YH11500007
J	Bonis, B; Kemeny, L; Dobozy, A; Bor, Z; Szabo, G; Ignacz, F				Bonis, B; Kemeny, L; Dobozy, A; Bor, Z; Szabo, G; Ignacz, F			308 nm UVB excimer laser for psoriasis	LANCET			English	Article									ATTILA JOZSEF UNIV, DEPT OPT & QUANTUM ELECT, SZEGED, HUNGARY	Szeged University	Bonis, B (corresponding author), ALBERT SZENT GYORGYI MED UNIV, DEPT DERMATOL, POB 480, H-6701 SZEGED, HUNGARY.		Kemeny, Lajos/ABF-1339-2021	Kemeny, Lajos/0000-0002-2119-9501				LAVKER RM, 1995, J AM ACAD DERMATOL, V32, P53, DOI 10.1016/0190-9622(95)90184-1; LINDELOF B, 1991, LANCET, V338, P91, DOI 10.1016/0140-6736(91)90083-2; PARRISH JA, 1981, J INVEST DERMATOL, V76, P359, DOI 10.1111/1523-1747.ep12520022; Rhodes CK., 1979, EXCIMER LASERS; STEFAN JA, 1991, Z HAUTKR S3, V66, P82	5	126	137	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1522	1522		10.1016/S0140-6736(05)63945-1	http://dx.doi.org/10.1016/S0140-6736(05)63945-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388408				2022-12-28	WOS:A1997YH11500019
J	Bonner, RF; EmmertBuck, M; Cole, K; Pohida, T; Chuaqui, R; Goldstein, S; Liotta, LA				Bonner, RF; EmmertBuck, M; Cole, K; Pohida, T; Chuaqui, R; Goldstein, S; Liotta, LA			Cell sampling - Laser capture microdissection: Molecular analysis of tissue	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; TUMORS; CANCER		NCI,PATHOL LAB,FREDERICK,MD 21701; NIH,BIOMED ENGN PROGRAM,BETHESDA,MD 20892; NIH,COMPUTAT BIOSCI & ENGN LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Bonner, RF (corresponding author), NICHHD,LAB INTEGRAT & MED BIOPHYS,BETHESDA,MD 20892, USA.		Bonner, Robert F/C-6783-2015; Cole, Kristina/M-3922-2015; Bonner, Robert/GQO-9087-2022					Becker I, 1996, LAB INVEST, V75, P801; BOEHM M, 1997, AM J PATHOL, V151, P63; BONNER RF, UNPUB; DeRisi J, 1996, NAT GENET, V14, P457; EMMERTBUCK MR, 1994, AM J PATHOL, V145, P1285; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; Fodor SPA, 1997, SCIENCE, V277, P393, DOI 10.1126/science.277.5324.393; RADFORD DM, 1993, CANCER RES, V53, P2947; SHIBATA D, 1992, AM J PATHOL, V141, P539; WHETSELL L, 1992, ONCOGENE, V7, P2355	11	714	799	0	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1481	&		10.1126/science.278.5342.1481	http://dx.doi.org/10.1126/science.278.5342.1481			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9411767				2022-12-28	WOS:A1997YG85800052
J	Craft, N				Craft, N			Women's health - Life span: conception to adolescence	BRITISH MEDICAL JOURNAL			English	Article							FEMALE				Craft, N (corresponding author), GOWER PL PRACTICE,LONDON WC1E 6BN,ENGLAND.							*A GUTTM I, 1995, HOP REAL; BLACK JA, 1995, BRIT MED J, V310, P1590, DOI 10.1136/bmj.310.6994.1590; CALDWELL J, 1982, HLTH POLICY ED, P2; CHEN LC, 1981, POPUL DEV REV, V7, P55, DOI 10.2307/1972764; COCHRANE SH, 1982, HEALTH POLICY EDUC, V2, P213, DOI 10.1016/0165-2281(82)90011-X; Doyal L., 1995, WHAT MAKES WOMEN SIC; Harrison KA, 1997, LANCET, V349, P644, DOI 10.1016/S0140-6736(97)02192-2; Hobcraft J, 1993, HLTH TRANSITION REV, V3, P2; *INT PLANN PAR FED, 1995, WOM HLTH WOM RIGHTS; *INT PLANN PAR FED, 1997, REAL LIV; KAUR M, 1993, J FAM WELFARE, V39, P40; *MIN SOC DEV POP A, 1995, SIT WOM NIG; SEN A, 1992, BRIT MED J, V304, P587, DOI 10.1136/bmj.304.6827.587; SEN AK, 1985, COMMODITIES CAPABILI, P81; SUMMERS L, 1992, SCI AM           AUG, P108; THAPA P, 1995, DISAPPEARING WOMEN P; UN, 1995, WORLDS WOM TRENDS ST; *UN, 1995, 2 REV APPR NAIR FORW; *UN, 1995, ADV WOM NOT SPEAK; *UNESCO, 1991, STAT YB; WALDRON I, 1983, SEX DIFFERENCES MORT; Waldron I., 1986, POPUL B UN, V18, P59; *WHO, 1995, MAT ED CHILD HLTH W; WHO, 1997, FEMALE GENITAL MUTIL	24	7	7	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1227	1230		10.1136/bmj.315.7117.1227	http://dx.doi.org/10.1136/bmj.315.7117.1227			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393232	Green Published			2022-12-28	WOS:A1997YF25200034
J	Davidoff, F				Davidoff, F			Databases in the next millennium	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIAN	Predicting the likelihood that large databases will become an important instrument for medical quality improvement is at least as difficult as most prognostication. This attempt at prediction starts by trying to ask the right questions: Can data serve as the agent for meaningful improvement? Is meaningful improvement possible without data? What elements are necessary and sufficient for improving the quality of medical care? It then looks for answers, starting with an unconventional excursion into the history of database use. This is followed by a recognition that. the use of large databases for medical quality improvement is a true innovation, the future of which will probably be determined as much by the social and emotional forces that govern the diffusion of all innovations as by the technical strength of databases themselves. Finally, it examines some of the limitations and pitfalls that are likely to be associated with the increasing use of large databases in medicine.			Davidoff, F (corresponding author), AMER COLL PHYSICIANS, INDEPENDENCE MALL W, 6TH ST & RACE, PHILADELPHIA, PA 19106 USA.							BELKIN L, 1997, NY TIMES MAGAZI 0615, P28; Berwick D. M, 1990, CURING HLTH CARE NEW; BLEICK J, 1987, CHAOS MAKING NEW SCI; Braitman LE, 1996, ANN INTERN MED, V125, P406, DOI 10.7326/0003-4819-125-5-199609010-00008; DAVIDOFF F, 1996, WHO HAS SEEN BLOOD S, P152; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; Firshein J, 1997, LANCET, V349, P1459, DOI 10.1016/S0140-6736(05)63748-8; GOONAN KJ, 1995, JURAN PRESCRIPTION C, P77; Kasper J F, 1992, QRB Qual Rev Bull, V18, P129; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; Mittman B S, 1992, QRB Qual Rev Bull, V18, P413; Nowlen PM., 1988, NEW APPROACH CONTINU; Rogers E., 2003, DIFFUSION INNOVATION, VFifth; ROGERS EM, 1995, DIFFUSION INNOVATION, P161; Rogers EM, 1995, DIFFUSION INNOVATION, P252; SCHAMA S, 1995, LANDSCAPE MEMORY, P174; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549	19	9	12	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				770	774		10.7326/0003-4819-127-8_Part_2-199710151-00067	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00067			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB385	9382397				2022-12-28	WOS:A1997YB38500022
J	Rebulla, P; Finazzi, G; Marangoni, F; Avvisati, G; Gugliotta, L; Tognoni, G; Barbui, T; Mandelli, F; Sirchia, G				Rebulla, P; Finazzi, G; Marangoni, F; Avvisati, G; Gugliotta, L; Tognoni, G; Barbui, T; Mandelli, F; Sirchia, G		Grp Italiano Malattie Ematologiche Maligne Adu	The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLICY; BLOOD	Background Prophylactic platelet transfusions are usually administered to patients receiving myelotoxic chemotherapy when their platelet count falls below 20,000 per cubic millimeter. Some observations suggest that lower platelet counts can be appropriate in patients in stable condition, but the safely of lower thresholds is uncertain. Methods We evaluated 255 adolescents and adults (age, 16 to 70 years) with newly diagnosed acute myeloid leukemia (but nor acute promyelocytic leukemia), who were treated in 21 centers. One hundred thirty-five patients were randomly assigned to receive a transfusion when their platelet count fell below 10,000 per cubic millimeter (or 10,000 to 20,000 per cubic millimeter in those with a temperature above 38 degrees C, with active bleeding, or a need for invasive procedures), and 120 patients were assigned to receive a transfusion when their platelet count was less than 20,000 per cubic millimeter. Results Patients in the group with a threshold of 10,000 platelets per cubic millimeter received 21.5 percent fewer platelet transfusions than the patients in the group with a threshold of 20,000 platelets per cubic millimeter (P = 0.001). The numbers of red-cell units transfused were not significantly different between groups. Major bleeding (defined as any bleeding more than petechiae or mucosal or retinal bleeding) occurred in 21.5 and 20 percent of patients, respectively (P = 0.41), and on 3.1 and 2.0 percent of the days of hospitalization. One episode of fatal cerebral hemorrhage occurred in the group with a threshold of 10,000 platelets per cubic millimeter; none occurred in the other group (P = 0.95). Actuarial estimates of survival during induction chemotherapy, actuarial estimates of the absence of major bleeding, and the length of hospital stay were not significantly different in the two groups. Conclusions The risk of major bleeding during induction chemotherapy in adolescents and adults with acute myeloid leukemia (except acute promyelocytic leukemia, which we did not study) was similar with platelet-transfusion thresholds of 20,000 per cubic millimeter and 10,000 per cubic millimeter (or 10,000 to 20,000 per cubic millimeter when body temperature exceeded 38 degrees C, there was active bleeding, or invasive procedures were needed). Use of the lower threshold reduced platelet use by 21.5 percent, (C) 1997, Massachusetts Medical Society.	Osped Maggiore, Ctr Trasfus & Immunol Trapianti, Ist Ricovero & Cura Carattere Sci, I-20122 Milan, Italy; Osped Riuniti Bergamo, Div Ematol, I-24100 Bergamo, Italy; Univ Roma La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, Rome, Italy; Policlin S Orsola, Ist Ematol & Oncol Med L & A Seragnoli, Bologna, Italy; Ist Ric Farmacol Mario Negri, Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedali Riuniti di Bergamo; Sapienza University Rome; IRCCS Azienda Ospedaliero-Universitaria di Bologna; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Rebulla, P (corresponding author), Osped Maggiore, Ctr Trasfus & Immunol Trapianti, Ist Ricovero & Cura Carattere Sci, Via F Sforza 35, I-20122 Milan, Italy.		; Rebulla, Paolo/I-7684-2015	Avvisati, Giuseppe/0000-0002-5027-5868; Rebulla, Paolo/0000-0002-3875-5754				ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; ANDERSON KC, 1990, NEW ENGL J MED, V323, P1360; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BERTOLINI F, 1989, TRANSFUSION, V29, P605, DOI 10.1046/j.1537-2995.1989.29789369678.x; BEUTLER E, 1993, BLOOD, V81, P1411; BEUTLER E, 1993, BLOOD, V82, P683; BISHOP JF, 1991, TRANSFUSION, V31, P392, DOI 10.1046/j.1537-2995.1991.31591263191.x; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; Friedman L, 1985, FUNDAMENTALS CLIN TR, P83; Gardner MJ, 1989, BRIT MED J LONDON; GilFernandez JJ, 1996, BONE MARROW TRANSPL, V18, P931; GMUR J, 1991, LANCET, V338, P1223, DOI 10.1016/0140-6736(91)92098-M; Hanseler E, 1996, AM J CLIN PATHOL, V105, P782; HANSON SR, 1985, BLOOD, V66, P1105; Heckman KD, 1997, J CLIN ONCOL, V15, P1143, DOI 10.1200/JCO.1997.15.3.1143; HEYMAN MR, 1990, SEMIN ONCOL, V17, P198; HEYMAN MR, 1996, PRINCIPLES TRANSFUSI, P263; KELLEHER JF, 1993, BLOOD, V82, P682; LAWRENCE JB, 1994, TRANSFUSION, V34, pS53; MCCULLOUGH J, 1988, JAMA-J AM MED ASSOC, V259, P2414, DOI 10.1001/jama.259.16.2414; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MURPHY WG, 1992, LANCET, V339, P120, DOI 10.1016/0140-6736(92)91025-4; *NIH CONS C, 1987, TRANSFUS MED REV, V1, P195; PISCIOTTO PT, 1995, TRANSFUSION, V35, P498, DOI 10.1046/j.1537-2995.1995.35695288769.x; Slichter Sherrill J., 1995, P1987; SLICHTER SJ, 1978, CLIN HAEMATOL, V7, P523; SLICHTER SJ, 1976, BRIT J HAEMATOL, V34, P395, DOI 10.1111/j.1365-2141.1976.tb03586.x; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x; Wandt H., 1996, Blood, V88, p443A	29	399	412	2	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	1997	337	26					1870	1875		10.1056/NEJM199712253372602	http://dx.doi.org/10.1056/NEJM199712253372602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN051	9407153				2022-12-28	WOS:000071128200002
J	Brancati, FL; Whelton, PK; Randall, BL; Neaton, JD; Stamler, J; Klag, MJ				Brancati, FL; Whelton, PK; Randall, BL; Neaton, JD; Stamler, J; Klag, MJ			Risk of end-stage renal disease in diabetes mellitus - A prospective cohort study of men screened for MRFIT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	56th Scientific Session of the American-Diabetes-Association	JUN 08-11, 1996	SAN FRANCISCO, CA	Amer Diabet Assoc			FACTOR INTERVENTION TRIAL; RACIAL-DIFFERENCES; EXCESS INCIDENCE; BLOOD-PRESSURE; AMERICANS; FAILURE; INDIANS; RACE	Context.-Diabetes is a frequent cause of end-stage renal disease (ESRD). However, the degree of risk is uncertain. Objective.-To determine the relative risk (RR) of ESRD related to diabetes in the United States. Design.-Nonconcurrent prospective cohort study. Participants.-A total of 332 544 men aged 35 to 57 years from 18 US cities screened in 1973 to 1975 for participation in the Multiple Risk Factor Intervention Trial (MRFIT). Main Exposure.-Diabetes mellitus defined by self-reported use of medication for diabetes at baseline. Main Outcome.-Incident ESRD through 1990 assessed from a national ESRD registry and by surveillance for death from renal disease. Results.-Over an average follow-up of 16 years, there were 136 cases of ESRD in 5147 diabetic men and 678 cases in 327 397 nondiabetic men. Age-adjusted incidence of all-cause ESRD in the diabetic men was 199.8 per 100 000 person-years compared with 13.7 per 100 000 person years in their nondiabetic counterparts (RR, 12.7; 95% confidence interval [CI], 10.5-15.4). Diabetic men were also at higher risk for ESRD ascribed to causes other than diabetes (RR=4.3; 95% CI, 3.2-5.9). With simultaneous adjustment for age, ethnicity, income, blood pressure, serum cholesterol level, and history of myocardial infarction, diabetic men remained at higher risk for ail-cause ESRD (RR, 9.0; 95% CI, 7.4-11.0), ESRD ascribed to diabetes (RR, 92.3; 95% CI, 64.6-131.9), and ESRD ascribed to nondiabetic causes (RR, 3.0; 95% CI, 2.2-4.1). Conclusions.-Diabetes mellitus is a strong independent risk factor for ESRD, even for ESRD ascribed to causes other than diabetes. Improvements in the prevention and control of diabetes should produce substantial reductions in ESRD incidence.	JOHNS HOPKINS MED INST,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT EPIDEMIOL,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; UNIV MINNESOTA,SCH PUBL HLTH,DIV BIOSTAT,MINNEAPOLIS,MN 55455; NORTHWESTERN UNIV,SCH MED,DEPT PREVENT MED,CHICAGO,IL	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Minnesota System; University of Minnesota Twin Cities; Northwestern University					NHLBI NIH HHS [R01 HL28715] Funding Source: Medline; NIDDK NIH HHS [R01 DK41837] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041837] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1977, Journal of Chronic Diseases, V30, P261; BRANCATI FL, 1992, JAMA-J AM MED ASSOC, V268, P3079, DOI 10.1001/jama.268.21.3079; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; COX DR, 1972, J R STAT SOC B, V34, P187; DISCHINGER P, 1986, CONTROL CLIN TRIALS, V7, pS137; DYCK RF, 1994, CAN MED ASSOC J, V150, P203; Eggers P W, 1984, Health Care Financ Rev, V5, P69; FERTIG BJ, 1995, NIH PUBLICATION, P519; *HLTH CAR FIN ADM, 1987, HCFA PUBL; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPPEL DF, 1986, AM J KIDNEY DIS, V8, P234, DOI 10.1016/S0272-6386(86)80031-2; Kenny S.J., 1995, NIH PUBLICATION, P47; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; Krolewski M, 1996, KIDNEY INT, V50, P2041, DOI 10.1038/ki.1996.527; LEE ET, 1994, DIABETES, V43, P572, DOI 10.2337/diabetes.43.4.572; MEGILL DM, 1988, WESTERN J MED, V149, P178; *MULT RISK FACT IN, 1982, JAMA-J AM MED ASSOC, V248, P1465; *NAT HEART LUNG I, 1974, DHEW PUBL; NEATON JD, 1988, CONTROL CLIN TRIALS, V8, P415; NELSON RG, 1988, DIABETOLOGIA, V31, P730, DOI 10.1007/BF00274774; Nelson RG, 1995, DIABETES AM, V2, P349; NEWMAN JM, 1990, AM J PUBLIC HEALTH, V80, P318, DOI 10.2105/AJPH.80.3.318; PASINSKI R, 1987, ARCH INTERN MED, V147, P1093, DOI 10.1001/archinte.147.6.1093; PERNEGER TV, 1995, AM J KIDNEY DIS, V25, P722, DOI 10.1016/0272-6386(95)90548-0; PERNEGER TV, 1995, AM J EPIDEMIOL, V141, P10, DOI 10.1093/oxfordjournals.aje.a117338; Prevention CfDCa, 1992, MMWR-MORBID MORTAL W, V41, P845; PUGH JA, 1988, AM J EPIDEMIOL, V127, P135, DOI 10.1093/oxfordjournals.aje.a114773; ROSTAND SG, 1982, NEW ENGL J MED, V306, P1276, DOI 10.1056/NEJM198205273062106; SHERWIN R, 1981, PREV MED, V10, P402, DOI 10.1016/0091-7435(81)90058-X; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STEPHENS GW, 1990, AM J KIDNEY DIS, V15, P562, DOI 10.1016/S0272-6386(12)80527-0; SUGIMOTO T, 1984, AM J PUBLIC HEALTH, V74, P14, DOI 10.2105/AJPH.74.1.14; *US DEP HHS, 1988, INT CLASS DIS 9 REV; *US REN DAT SYST, 1995, USRDS 1995 ANN DAT R, P25; WELLER JM, 1985, AM J NEPHROL, V5, P84, DOI 10.1159/000166912; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270	37	218	222	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2069	2074		10.1001/jama.278.23.2069	http://dx.doi.org/10.1001/jama.278.23.2069			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403420				2022-12-28	WOS:A1997YK98700035
J	Imperiale, TF; Birgisson, S				Imperiale, TF; Birgisson, S			Somatostatin or octreotide compared with H-2 antagonists and placebo in the management of acute nonvariceal upper gastrointestinal hemorrhage: A meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	17th Annual Meeting of the Society-for-Medical-Decision-Making	OCT 14-17, 1995	TEMPE, AZ	Soc Med Decis Making			RANDOMIZED CONTROLLED TRIAL; PEPTIC-ULCER HEMORRHAGE; CLINICAL-TRIALS; METAANALYSIS; VASOPRESSIN; CIMETIDINE; RANITIDINE; TRACT; MULTICENTER	Purpose: To determine the efficacy of somatostatin or octreotide for the treatment of acute nonvariceal upper gastrointestinal hemorrhage. Data Sources: Database searches of English-language articles published between 1966 and 1996 and the bibliographies of all related articles and textbook chapters. Study Selection: Randomized clinical trials comparing somatostatin or octreotide with H-2 blockers or placebo in patients with a clinical or endoscopic diagnosis of acute nonvariceal upper gastrointestinal hemorrhage, Data Extraction: Methods and quality of the studies were evaluated, and quantitative data on outcomes, including continued bleeding, rebleeding during the treatment period, need for surgery, and transfusion requirement, were extracted. Data Synthesis: Among 1829 patients from 14 trials, the relative risk (RR) for continued bleeding or rebleeding was 0.53 (95% CI, 0.43 to 0.63) in favor of somatostatin, with a number needed to treat (NNT) of 5. Among 7 investigator-blinded trials, the relative risk was 0.73 (CI, 0.64 to 0.81) and the NNT was 11. Somatostatin was efficacious for peptic ulcer bleeding (RR, 0.48 [CI, 0.39 to 0.59]; NNT, 4) and showed a trend toward efficacy for non-peptic ulcer bleeding (RR, 0.62 [CI, 0.39 to 1.002]). Although the overall results suggested a decreased need for surgery in the somatostatin group, a subgroup analysis of investigator-blinded trials revealed a more modest effect that was not statistically significant (RR, 0.94 [CI, 0.87 to 1.001]), Conclusion: Somatostatin may reduce;he risk for continued bleeding from acutely bleeding peptic ulcer disease. Somatostatin may be useful either as an adjunct treatment before endoscopy or when endoscopy is unsuccessful, contraindicated, or unavailable.	Indiana Univ, Med Ctr, Indianapolis, IN 46202 USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA; Case Western Reserve Univ, Metrohlth Med Ctr, Cleveland, OH USA	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Case Western Reserve University; MetroHealth System	Imperiale, TF (corresponding author), Indiana Univ, Med Ctr, 975 W Walnut St,IB 424, Indianapolis, IN 46202 USA.			Imperiale, Thomas/0000-0001-7586-1073				ANTONIOLI A, 1986, HEPATO-GASTROENTEROL, V33, P71; Basile M, 1984, Ital J Surg Sci, V14, P31; BASSO N, 1986, ARCH SURG-CHICAGO, V121, P833; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BLOOM SR, 1974, LANCET, V2, P1106; BOSCH J, 1981, GASTROENTEROLOGY, V80, P518; CHRISTIANSEN J, 1989, GASTROENTEROLOGY, V97, P568, DOI 10.1016/0016-5085(89)90626-4; COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666; COLLINS R, 1985, NEW ENGL J MED, V313, P660, DOI 10.1056/NEJM198509123131104; CORAGGIO F, 1984, BRIT MED J, V289, P224, DOI 10.1136/bmj.289.6439.224; CORAGGIO F, 1989, DIGESTION, V43, P190, DOI 10.1159/000199876; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FLEISS JL, 1981, STATISTICAL METHODS, P13; GALMICHE JP, 1983, INT J CLIN PHARM RES, V3, P379; GERBARG ZB, 1988, J CLIN EPIDEMIOL, V41, P503, DOI 10.1016/0895-4356(88)90053-4; HEDGES LV, 1992, J EDUC STAT, V17, P279, DOI 10.2307/1165125; JENKINS SA, 1985, BRIT MED J, V290, P275, DOI 10.1136/bmj.290.6464.275; JOHANSSON C, 1982, EUR J CLIN INVEST, V12, P37, DOI 10.1111/j.1365-2362.1982.tb00937.x; KAYASSEH L, 1980, LANCET, V1, P844; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P299; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P340; KUTZ K, 1986, SCAND J GASTROENTERO, V21, P65, DOI 10.3109/00365528609087433; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAINE L, 1993, ALIMENT PHARM THER, V7, P207; LAINE L, 1994, NEW ENGL J MED, V331, P717, DOI 10.1056/NEJM199409153311107; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LIEBERMAN D, 1993, GASTROENTEROL CLIN N, V22, P723; Lin HJ, 1995, HEPATO-GASTROENTEROL, V42, P856; MAGNUSSON I, 1985, GUT, V26, P221, DOI 10.1136/gut.26.3.221; MOHER D, 1995, JAMA-J AM MED ASSOC, V274, P1962, DOI 10.1001/jama.274.24.1962; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; SAARI A, 1990, AM J GASTROENTEROL, V85, P804; SAPERAS E, 1988, Alimentary Pharmacology and Therapeutics, V2, P153; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SOMERVILLE KW, 1985, LANCET, V1, P130; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; TORRES AJ, 1986, BRIT J SURG, V73, P786, DOI 10.1002/bjs.1800731009; TULASSAY Z, 1989, AM J GASTROENTEROL, V84, P6; YAVORSKI RT, 1995, AM J GASTROENTEROL, V90, P568	40	77	82	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1062	1071		10.7326/0003-4819-127-12-199712150-00002	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YL262	9412308				2022-12-28	WOS:000070936600002
J	Gee, MA; Heuser, JE; Vallee, RB				Gee, MA; Heuser, JE; Vallee, RB			An extended microtubule-binding structure within the dynein motor domain	NATURE			English	Article							BETA-HEAVY CHAIN; CRYSTAL-STRUCTURE; RETROGRADE TRANSPORT; CYTOPLASMIC DYNEIN; DICTYOSTELIUM; PROTEINS; CLEAVAGE; SEQUENCE; MAP-1C; MYOSIN	Flagellar dynein was discovered over 30 years ago as the first motor protein capable of generating force along microtubules(1). A cytoplasmic form of dynein has also been identified which is involved in mitosis and a wide range of other intracellular movement(2) (reviewed in ref. 3). Rapid progress has been made on understanding the mechanism of force production by kinesins and myosins(4-8). In contrast, progress in understanding the dyneins has been limited by their great size (relative molecular mass 1,000K-2,000K) and subunit complexity. We now report evidence that the entire carboxy-terminal two-thirds of the 532K force-producing heavy chain subunit is required for ATP-binding activity. We further identify a microtubule-binding domain, which, surprisingly, lies well downstream of the entire ATPase region and is predicted to form a hairpin-like stalk Direct ultrastructural analysis of a recombinant fragment confirms this model, and suggests that the mechanism for dynein force production differs substantially from that of other motor proteins.	WORCESTER FDN BIOMED RES, SHREWSBURY, MA 01545 USA; UNIV MASSACHUSETTS, MED CTR, WORCESTER, MA 01655 USA; WASHINGTON UNIV, ST LOUIS, MO 63110 USA	Worcester Foundation for Biomedical Research; University of Massachusetts System; University of Massachusetts Worcester; Washington University (WUSTL)			Heuser, John/H-5940-2012					AMOS LA, 1989, J CELL SCI, V93, P19; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GIBBONS IR, 1965, SCIENCE, V149, P424, DOI 10.1126/science.149.3682.424; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; GOODENOUGH UW, 1982, J CELL BIOL, V95, P798, DOI 10.1083/jcb.95.3.798; HAIMO LT, 1979, P NATL ACAD SCI USA, V76, P5759, DOI 10.1073/pnas.76.11.5759; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KOONCE MP, 1992, J CELL BIOL, V119, P1597, DOI 10.1083/jcb.119.6.1597; Koonce MP, 1996, MOL BIOL CELL, V7, P935, DOI 10.1091/mbc.7.6.935; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mazumdar M, 1996, P NATL ACAD SCI USA, V93, P6552, DOI 10.1073/pnas.93.13.6552; MIKAMI A, 1993, NEURON, V10, P787, DOI 10.1016/0896-6273(93)90195-W; MITCHELL DR, 1994, J CELL SCI, V107, P635; OGAWA K, 1991, NATURE, V352, P643, DOI 10.1038/352643a0; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PORTER ME, 1989, ANNU REV CELL BIOL, V5, P119; PORTER ME, 1994, J CELL BIOL, V126, P1495, DOI 10.1083/jcb.126.6.1495; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Ruppel KM, 1996, ANNU REV CELL DEV BI, V12, P543, DOI 10.1146/annurev.cellbio.12.1.543; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SMITH EF, 1992, SCIENCE, V257, P1557, DOI 10.1126/science.1387971; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; STEUER ER, 1988, CELL MOTIL CYTOSKEL, V11, P200; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	30	256	261	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 11	1997	390	6660					636	639		10.1038/37663	http://dx.doi.org/10.1038/37663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403697				2022-12-28	WOS:A1997YK85300057
J	Keely, PJ; Westwick, JK; Whitehead, IP; Der, CJ; Parise, LV				Keely, PJ; Westwick, JK; Whitehead, IP; Der, CJ; Parise, LV			Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K	NATURE			English	Article							NUCLEOTIDE EXCHANGE FACTORS; ACTIVATED PROTEIN-KINASE; GTP-BINDING PROTEIN; STRUCTURAL SIMILARITIES; ACTIN POLYMERIZATION; EXPRESSION CLONING; RHO; FAMILY; PATHWAY; PHOSPHORYLATION	Transformation of mammary epithelial cells into invasive carcinoma results in alterations in their integrin-mediated responses to the extracellular matrix, including a loss of normal epithelial polarization and differentiation, and a switch to a more motile, invasive phenotype, Changes in the actin cytoskeleton associated with this switch suggest that the small GTPases Cdc42 and Rac, which regulate actin organization(1,2), might modulate motility and invasion, However, the role of Cdc42 and Rad in epithelial cells, especially with respect to integrin-mediated events, has not been well characterized, Here we show that activation of Cdc42 and Rad disrupts the normal polarization of mammary epithelial cells in a collagenous matrix, and promotes motility and invasion. This motility does not require the activationof PAK, JNK, p70 S6 kinase, or Rho, but instead requires phosphatidylinositol-3-OH kinase (PI(3)K). Further, direct PI(3)K activation is sufficient to disrupt epithelial polarization and induce cell motility and invasion. PI(3)K inhibition also disrupts actin structures, suggesting that activation of PI(3)K by Cdc42 and Rad alters actin organization, leading to increased motility and invasiveness.	UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	Keely, PJ (corresponding author), UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT PHARMACOL,CHAPEL HILL,NC 27599, USA.			Der, Channing/0000-0002-7751-2747				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Collard JG, 1996, INT J ONCOL, V8, P131; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KEELY PJ, 1995, J CELL SCI, V108, P595; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SANTORO SA, 1994, METHOD ENZYMOL, V245, P147; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; YAN MH, 1994, NATURE, V372, P798; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	29	628	639	2	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					632	636		10.1038/37656	http://dx.doi.org/10.1038/37656			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403696				2022-12-28	WOS:A1997YK85300056
J	Quill, TE; Dresser, R; Brock, DW				Quill, TE; Dresser, R; Brock, DW			The rule of double effect - A critique of its role in end-of-life decision making	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHYSICIAN-ASSISTED SUICIDE; EUTHANASIA; PAIN; VIEWS; DEATH		UNIV ROCHESTER, SCH MED, ROCHESTER, NY 14607 USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; BROWN UNIV, PROVIDENCE, RI 02912 USA	University of Rochester; Case Western Reserve University; Brown University								*ABIM, 1996, ED RES DOC; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Alpers A, 1997, JAMA-J AM MED ASSOC, V277, P1705, DOI 10.1001/jama.277.21.1705; Annas GJ, 1996, NEW ENGL J MED, V335, P683, DOI 10.1056/NEJM199608293350924; [Anonymous], 1992, ANN INTERN MED, V117, P947; [Anonymous], 1985, MOD PEN COD COMM, P229; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BROCK DW, 1997, MED ETHICS, P363; BRODY H, 1993, J CLIN ETHIC, V4, P112; Cantor NL, 1996, KENNEDY INST ETHIC J, V6, P107; Cherny N I, 1994, J Palliat Care, V10, P31; *COUNC ETH JUD AFF, 1992, JAMA-J AM MED ASSOC, V276, P2229; Donagan Alan, 1977, ETHICS; Foley KM, 1997, NEW ENGL J MED, V336, P54, DOI 10.1056/NEJM199701023360109; FOLEY KM, 1995, PAIN FORUM, V4, P163; FRIED C, 1978, RIGHT WRONG; GARCIA JLA, 1995, ENCY BIOETHICS, V2, P636; Graber MA, 1996, J GEN INTERN MED, V11, P71, DOI 10.1007/BF02599581; GRANFIELD D, 1971, ABORTION DECISION, P126; *HAST CTR, 1987, GUID TERM LIF SUST T; HILL CS, 1995, JAMA-J AM MED ASSOC, V274, P1881, DOI 10.1001/jama.274.23.1881; JOHNPAUL II, 1995, CATH C MARCH 30, P189; KASS LR, 1993, HASTINGS CENT REP, V23, P34, DOI 10.2307/3562279; Kenny A., 1973, ANATOMY SOUL; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KUHSE H, 1987, SANCTITYY LIFE DOCRI; Mangan J.T., 1949, THEOL STUD, V10, P41, DOI [DOI 10.1177/004056394901000102, 10.1177/004056394901000102]; MARQUIS DB, 1991, J MED PHILOS, V16, P515, DOI 10.1093/jmp/16.5.515; MEISEL A, 1995, RIGHT DIE; Nagel T., 1986, VIEW NOWHERE; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; Pellegrino E D, 1992, J Clin Ethics, V3, P95; *PRES COMM STUD ET, 1983, DEC FOR LIF SUST TRE; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; QUILL TE, IN PRESS JAMA; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V275, P1232, DOI DOI 10.1001/JAMA.1995.03530200027032; TROUG RD, 1991, NEW ENGL J MED, V327, P1678; Ventafridda V, 1990, J Palliat Care, V6, P7; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	41	229	235	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1768	1771		10.1056/NEJM199712113372413	http://dx.doi.org/10.1056/NEJM199712113372413			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YK653	9392707				2022-12-28	WOS:A1997YK65300013
J	Stadtmauer, G; CunninghamRundles, C				Stadtmauer, G; CunninghamRundles, C			Outcome analysis and cost assessment in immunologic disorders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVENOUS IMMUNOGLOBULIN THERAPY; CHRONIC GRANULOMATOUS-DISEASE; INTERFERON-GAMMA; IMMUNE GLOBULIN; HOME; IMMUNODEFICIENCY; REPLACEMENT; INFUSION; AUTOIMMUNE; SF-36	A number of novel biologic agents are being introduced to replace, enhance, or modulate immune responses in medical illnesses. The use of these therapies has become crucial in treating some of these diseases, yet there is relatively little available information about their cost-effectiveness. Two examples are presented. Interferon gamma, used in chronic granulomatous disease, costs about $140 for a 100-mu g vial; yearly costs average $21 840 per patient. Study data estimated a 69% to 76% reduction in serious illness with interferon gamma treatment; a reduced incidence of infections could cover drug costs. Intravenous immunoglobulin is used lifelong in antibody deficiency and clearly reduces the number of serious illnesses. Projected savings derive from fewer hospital admissions and reduced organ damage, but infusion costs vary widely because of the prices charged for the drug and infusion services.			Stadtmauer, G (corresponding author), MT SINAI MED CTR,1 GUSTAVE L LEVY PL,BOX 1089,NEW YORK,NY 10029, USA.							AMMANN AJ, 1982, CLIN IMMUNOL IMMUNOP, V22, P60, DOI 10.1016/0090-1229(82)90022-8; ASHIDA ER, 1986, J CLIN IMMUNOL, V6, P306, DOI 10.1007/BF00917331; BERGER M, 1980, ANN INTERN MED, V93, P55, DOI 10.7326/0003-4819-93-1-55; BIELORY L, 1995, ANN ALLERG ASTHMA IM, V74, P265; BLAISS MS, 1994, INSIGHTS ALLERGY, V9, P1; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; Bresee JS, 1996, JAMA-J AM MED ASSOC, V276, P1563, DOI 10.1001/jama.276.19.1563; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P59; COHN EJ, 1946, J AM CHEM SOC, V68, P459, DOI 10.1021/ja01207a034; CUNNINGHAMRUNDLES C, 1984, ANN INTERN MED, V101, P435, DOI 10.7326/0003-4819-101-4-435; CURNUTTE JT, 1988, HEMATOL ONCOL CLIN N, V2, P241, DOI 10.1016/S0889-8588(18)30618-X; GALLIN JI, 1995, ANN INTERN MED, V123, P216, DOI 10.7326/0003-4819-123-3-199508010-00009; GARDULF A, 1995, LANCET, V345, P365; HADDEN JW, 1992, JAMA-J AM MED ASSOC, V268, P2964, DOI 10.1001/jama.268.20.2964; HERSHFIELD MS, 1995, CLIN IMMUNOL IMMUNOP, V76, P228; HILL LE, 1971, MRC SPECIAL REPORT S, V310; *INT CHRON GRAN DI, 1991, NEW ENGL J MED, V324, P509; Janeway CA, 1970, IMMUNOGLOBULINS BIOL, P3; JOLICOEUR LM, 1992, AM J HOSP PHARM, V49, P1741, DOI 10.1093/ajhp/49.7.1741; KAPLAN G, 1993, J INFECT DIS, V167, pS18, DOI 10.1093/infdis/167.Supplement_1.S18; KOBAYASHI RH, 1990, PEDIATRICS, V85, P705; KUSKAL BA, 1994, BIOTHERAPY, V7, P249; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; LIESE JG, 1995, AJDC, V146, P325; *MED EC, 1997, 1997 DRUG TOP RED BO; Mier James W., 1993, Current Opinion in Oncology, V5, P1067, DOI 10.1097/00001622-199311000-00020; *NIH CONS C, 1990, JAMA-J AM MED ASSOC, V264, P3189; NOLTE MT, 1979, CLIN EXP IMMUNOL, V36, P237; OCHS HD, 1987, J INFECT DIS, V156, P652, DOI 10.1093/infdis/156.4.652; PARLEVLIET KJ, 1992, TRANSPLANT INT, V5, P234, DOI 10.1007/BF00336077; PIROFSKY B, 1992, DRUGS, V43, P6, DOI 10.2165/00003495-199243010-00002; RATKO TA, 1995, JAMA-J AM MED ASSOC, V273, P1865, DOI 10.1001/jama.273.23.1865; ROIFMAN CM, 1985, AM J MED, V79, P171, DOI 10.1016/0002-9343(85)90006-3; RONDA N, 1993, VOX SANG, V64, P65, DOI 10.1111/j.1423-0410.1993.tb02521.x; SCHATTNER A, 1994, CLIN IMMUNOL IMMUNOP, V70, P177, DOI 10.1006/clin.1994.1027; SCHIFF RI, 1994, NEW ENGL J MED, V331, P1649, DOI 10.1056/NEJM199412153312409; SIEGAL J, 1996, PHARMACOL THERAPEUT, V21, pS21; WALLEY T, 1995, BRIT MED J, V311, P796, DOI 10.1136/bmj.311.7008.796; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WOODMAN RC, 1992, BLOOD, V79, P1558; YIM JM, 1995, ANN PHARMACOTHER, V29, P475, DOI 10.1177/106002809502900504; 1992, MED LETT, V34, P45; 1992, MED LETT, V34, P107	43	14	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					2018	2023		10.1001/jama.278.22.2018	http://dx.doi.org/10.1001/jama.278.22.2018			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396665				2022-12-28	WOS:A1997YK15500026
J	Krack, P; Pollak, P; Limousin, P; Benazzouz, A; Benabid, AL				Krack, P; Pollak, P; Limousin, P; Benazzouz, A; Benabid, AL			Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease	LANCET			English	Letter									CHRISTIAN ALBRECHTS UNIV KIEL,DEPT NEUROL,D-24105 KIEL,GERMANY	University of Kiel	Krack, P (corresponding author), UNIV GRENOBLE,DEPT CLIN & BIOL NEUROSCI,GRENOBLE,FRANCE.		Benazzouz, Abdelhamid/E-5050-2016; Benabid, Alim L/Q-3506-2017	Krack, Paul/0000-0002-3508-7295				BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3	5	138	141	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1675	1675		10.1016/S0140-6736(97)24049-3	http://dx.doi.org/10.1016/S0140-6736(97)24049-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400514				2022-12-28	WOS:A1997YK21100014
J	Stanner, SA; Bulmer, K; Andres, C; Lantseva, OE; Borodina, V; Poteen, VV; Yudkin, JS				Stanner, SA; Bulmer, K; Andres, C; Lantseva, OE; Borodina, V; Poteen, VV; Yudkin, JS			Does malnutrition in utero determine diabetes and coronary heart disease in adulthood? Results from the Leningrad siege study, a cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; BLOOD-PRESSURE; FETAL GROWTH; BIRTH-WEIGHT; NONDIABETIC SUBJECTS; IN-UTERO; INSULIN; LIFE; MEN; HYPERTENSION	Objective: To investigate the relation between decreased maternal food intake and risk factors for coronary heart disease in adult life. Design: Cross sectional study. Subjects: 169 subjects exposed to malnutrition in utero (intrauterine group) during the siege of Leningrad (now St Petersburg) in 1941-4; 192 subjects born in Leningrad just before rationing began, before the siege (infant group); and 188 subjects born concurrently with the first two groups but outside the area of the siege (unexposed group). Setting: Ott Institute of Obstetrics and Gynaecology, St Petersburg. Main outcome measures: Development of risk factors for coronary heart disease and diabetes mellitus-obesity, blood pressure, glucose tolerance, insulin concentrations, lipids, albumin excretion rate, and clotting factors. Results: There was no difference between the subjects exposed to starvation in utero and those starved during infant life in: (a) glucose tolerance (mean fasting glucose: intrauterine group 5.2 (95% confidence interval 5.1 to 5.3), Infant group 5.3 (5.1 to 5.5), P = 0.94; mean 2 hour glucose: intrauterine group 6.1 (5.8 to 6.4), infant group 6.0 (5.7 to 6.3), P = 0.99); (b) insulin concentration; (c) blood pressure; (d) lipid concentration; or (e) coagulation factors. Concentrations of von Willebrand factor were raised in the intrauterine group (156.5 (79.1 to 309.5)) compared with the infant group (127.6 (63.9 to 254.8); P < 0.001), and female subjects in the intrauterine group had a stronger interaction between obesity and both systolic (P = 0.01) and diastolic (P = 0.04) blood pressure than in the infant group. Short adult stature was associated with raised concentrations of glucose and insulin 2 hours after a glucose load-independently of siege exposure. Subjects in the unexposed group had non-systematic differences in subscapular to triceps skinfold ratio, diastolic blood pressure, and clotting factors compared with the exposed groups. Conclusions: Intrauterine malnutrition tvas not associated with glucose intolerance, dyslipidaemia, hypertension, or cardiovascular disease in adulthood. Subjects exposed to malnutrition showed evidence of endothelial dysfunction and a stronger influence of obesity on blood pressure.	RUSSIAN ACAD MED SCI, OTT INST OBSTET & GYNAECOL, ST PETERSBURG, RUSSIA	Russian Academy of Medical Sciences; Ott Institute of Obstetrics, Gynecology & Reproductology	Stanner, SA (corresponding author), UCL, SCH MED, DEPT MED, LONDON N19 3UA, ENGLAND.		Yudkin, John S/C-1988-2008					ANTONOV AN, 1947, J PEDIATR, V30, P250, DOI 10.1016/S0022-3476(47)80160-X; Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1991, J ROY COLL PHYS LOND, V25, P129; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARKER DJP, 1995, PLACENTA, V16, P317, DOI 10.1016/0143-4004(95)90118-3; BARKER DJP, 1982, FETAL INFANT ORIGINS; BENNETT KA, 1986, HUM BIOL, V58, P751; BROWN DC, 1991, DIABETOLOGIA, V34, P531, DOI 10.1007/BF00403292; Campbell DM, 1996, BRIT J OBSTET GYNAEC, V103, P273, DOI 10.1111/j.1471-0528.1996.tb09718.x; EMANUEL I, 1992, BRIT J OBSTET GYNAEC, V99, P67, DOI 10.1111/j.1471-0528.1992.tb14396.x; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GENNSER G, 1988, BMJ-BRIT MED J, V296, P1498, DOI 10.1136/bmj.296.6635.1498; Godfrey K, 1996, BRIT MED J, V312, P410, DOI 10.1136/bmj.312.7028.410; GOULD MM, 1993, BMJ-BRIT MED J, V306, P240, DOI 10.1136/bmj.306.6872.240; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Kramer MS, 1996, LANCET, V348, P1254, DOI 10.1016/S0140-6736(05)65750-9; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Leon DA, 1996, BRIT MED J, V312, P401, DOI 10.1136/bmj.312.7028.401; MARMOT MG, 1984, LANCET, V1, P1003; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; MARTYN CN, 1995, BRIT HEART J, V73, P116; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; MOHAMEDALI V, 1995, DIABETOLOGIA, V38, P1110; Office of Population Censuses and Surveys, 1980, CLASS OCC; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PAVLOV DV, 1965, LENINGRAD 1941 BLOCK; PHILLIPS DIW, 1994, DIABETOLOGIA, V37, P150, DOI 10.1007/s001250050086; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; Robbins DC, 1996, DIABETES, V45, P242, DOI 10.2337/diabetes.45.2.242; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; ROSE GA, 1988, WHO MONOGRAPH SERIES, V56; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; Stein Z., 1975, FAMINE HUM DEV DUTCH; SWENNE I, 1987, DIABETES, V36, P454, DOI 10.2337/diabetes.36.4.454; WADSWORTH MEJ, 1985, BRIT MED J, V291, P1534, DOI 10.1136/bmj.291.6508.1534; WALKER M, 1989, INT J EPIDEMIOL, V18, P602, DOI 10.1093/ije/18.3.602; WEINKOVE C, 1974, S AFR MED J, V48, P1888; *WHO STUD GROUP, 1985, WHO TECH REP SER, V727, P9	41	331	340	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 22	1997	315	7119					1342	1348		10.1136/bmj.315.7119.1342	http://dx.doi.org/10.1136/bmj.315.7119.1342			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402775	Green Published			2022-12-28	WOS:A1997YJ21800022
J	Agreus, L; Talley, N				Agreus, L; Talley, N			Challenges in managing dyspepsia in general practice	BRITISH MEDICAL JOURNAL			English	Article							HELICOBACTER-PYLORI INFECTION; UREA BREATH TEST; CLINICAL PRESENTATION; NONULCER DYSPEPSIA; DISCRIMINANT VALUE; SYMPTOMS; PATIENT; MANAGEMENT; POPULATION; ENDOSCOPY		UPPSALA UNIV,DEPT FAMILY MED,UPPSALA,SWEDEN; UNIV SYDNEY,NEPEAN HOSP,DEPT MED,PENRITH,NSW 2751,AUSTRALIA	Uppsala University; Nepean Hospital; University of Sydney				Schaffalitzky de Muckadell, Ove B/0000-0003-1969-2329				Adang RP, 1996, DIGESTION, V57, P118, DOI 10.1159/000201325; AGREUS L, 1995, SCAND J GASTROENTERO, V30, P752, DOI 10.3109/00365529509096323; AGREUS L, 1995, GASTROENTEROLOGY, V109, P671, DOI 10.1016/0016-5085(95)90373-9; ATHERTON JC, 1994, GUT, V35, P723, DOI 10.1136/gut.35.6.723; *BRIT SOC GASTR, 1996, DYSP MAN GUID; BYTZER P, 1994, LANCET, V343, P811, DOI 10.1016/S0140-6736(94)92023-0; Bytzer P, 1996, EUR J GASTROEN HEPAT, V8, P359, DOI 10.1097/00042737-199604000-00014; BYTZER P, 1993, SCAND J GASTR   S197, V28, P28; CARLSSON R, 1996, GASTROENTEROLOGY S, V110, pA76; COLINJONES DG, 1988, LANCET, V1, P576; ENROTH H, 1996, GUT S, V2, pA117; Fass R, 1997, GASTROENTEROLOGY, V112, pA114; Gilvarry J, 1997, SCAND J GASTROENTERO, V32, P535, DOI 10.3109/00365529709025095; HAMLET AK, 1995, SCAND J GASTROENTERO, V30, P1058, DOI 10.3109/00365529509101607; HANSEN JM, 1994, GUT S4, V34, pA9; HEADING RC, 1995, J DRUG DEV CLIN PR, V7, P109; HUNGIN APS, 1994, BRIT J GEN PRACT, V44, P519; HUNGIN P, 1996, THESIS U NEWCASTLE T, P112; JOHANNESSEN T, 1990, SCAND J GASTROENTERO, V25, P689, DOI 10.3109/00365529008997594; Johannessen T, 1993, Scand J Prim Health Care, V11, P50, DOI 10.3109/02813439308994902; Kang JY, 1996, J GASTROEN HEPATOL, V11, P515, DOI 10.1111/j.1440-1746.1996.tb01694.x; Kokkola A, 1996, SCAND J GASTROENTERO, V31, P643, DOI 10.3109/00365529609009143; LASSEN AT, 1997, SCAND J GASTROE S224, V32, pF93; LINDELL GH, 1995, EUR J GASTROEN HEPAT, V7, P829; Loy CT, 1996, AM J GASTROENTEROL, V91, P1138; LYDEARD S, 1989, J ROY COLL GEN PRACT, V39, P495; Malfertheiner P, 1997, EUR J GASTROEN HEPAT, V9, P1; McColl KEL, 1997, GUT, V40, P302, DOI 10.1136/gut.40.3.302; MITCHELL HM, 1988, MED J AUSTRALIA, V149, P604, DOI 10.5694/j.1326-5377.1988.tb120800.x; *NIH CONS DEV PAN, 1994, JAMA-J AM MED ASSOC, V272, P65; PATEL P, 1995, LANCET, V346, P1315, DOI 10.1016/S0140-6736(95)92340-3; Sheu BS, 1996, AM J GASTROENTEROL, V91, P441; Sinha A, 1997, GUT, V40, pW7; Stanghellini V, 1996, GASTROENTEROLOGY, V110, P1036, DOI 10.1053/gast.1996.v110.pm8612991; Talley N, 1991, GASTROENTEROL INT, V4, P145; TALLEY NJ, 1987, GUT, V28, P40, DOI 10.1136/gut.28.1.40; TALLEY NJ, 1993, GASTROENTEROLOGY, V105, P1378, DOI 10.1016/0016-5085(93)90142-Y; vanZanten SJOV, 1996, AM J GASTROENTEROL, V91, P660; Whitaker MJ, 1997, INT J CLIN PRACT, V51, P239; WILLIAMS S, 1995, FAM PRACT, V12, P193, DOI 10.1093/fampra/12.2.193	40	66	66	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1284	1288		10.1136/bmj.315.7118.1284	http://dx.doi.org/10.1136/bmj.315.7118.1284			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390058	Green Published			2022-12-28	WOS:A1997YG64500026
J	Fallon, M; ONeill, B				Fallon, M; ONeill, B			ABC of palliative care - Constipation and diarrhoea	BRITISH MEDICAL JOURNAL			English	Article									BRITISH MED ASSOC,LONDON,ENGLAND		Fallon, M (corresponding author), UNIV GLASGOW,WESTERN INFIRM,BEATSON ONCOL CTR,GLASGOW G11 6NT,LANARK,SCOTLAND.			Fallon, Marie/0000-0001-9214-0091					0	39	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1293	1296		10.1136/bmj.315.7118.1293	http://dx.doi.org/10.1136/bmj.315.7118.1293			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390060	Green Submitted, Green Published			2022-12-28	WOS:A1997YG64500030
J	Matchar, DB; Samsa, GP; Matthews, JR; Ancukiewicz, M; Parmigiani, G; Hasselblad, V; Wolf, PA; DAgostino, RB; Lipscomb, J				Matchar, DB; Samsa, GP; Matthews, JR; Ancukiewicz, M; Parmigiani, G; Hasselblad, V; Wolf, PA; DAgostino, RB; Lipscomb, J			The stroke prevention policy model: Linking evidence and clinical decisions	ANNALS OF INTERNAL MEDICINE			English	Article							COST-EFFECTIVENESS; MEDICINE	Simulation models that support decision and cost-effectiveness analysis can further the goals of evidence-based medicine by facilitating the synthesis of information from several sources into a single comprehensive structure. The Stroke Prevention Policy Model (SPPM) performs this function for the clinical and policy questions that surround stroke prevention. This paper first describes the basic structure and functions of the SPPM, concentrating on the role of large databases (broadly defined as any database that contains many patients, regardless of study design) in providing the SPPM inputs. Next, recognizing that the use of modeling continues to be a source of some controversy in the medical community, it; discusses the philosophical underpinnings of the SPPM. Finally, it discusses conclusions in the context of both stroke prevention and other complex medical decisions. We conclude that despite the difficulties in developing comprehensive models (for example, the length and complexity of model development and validation processes, the proprietary nature of data sources, and the necessity for developing new software), the benefits of such models exceed the costs of continuing to rely on more conventional methods. Although they should not replace the clinician in decision making; comprehensive models based on the best available evidence from large databases can support decision making in medicine.	DUKE UNIV, MED CTR,SCH MED,DEPT COMMUNITY & FAMILY MED, DIV BIOMETRY, DURHAM, NC 27705 USA; MASSACHUSETTS GEN HOSP, DEPT MED, DIV RADIAT ONCOL, BOSTON, MA 02114 USA; DUKE UNIV, INST STAT & DECIS SCI, DURHAM, NC 27708 USA; BOSTON UNIV, SCH MED, DEPT MED, BOSTON, MA 02118 USA; BOSTON UNIV, SCH MED, EVANS MEM DEPT CLIN RES, PREVENT MED & EPIDEMIOL SECT, BOSTON, MA 02118 USA; BOSTON UNIV, COLL ARTS & SCI, DEPT MATH, BOSTON, MA 02215 USA; DUKE UNIV, SANFORD INST PUBL POLICY, DURHAM, NC 27708 USA; BOSTON UNIV, MED CTR, BOSTON, MA USA	Duke University; Harvard University; Massachusetts General Hospital; Duke University; Boston University; Boston University; Boston University; Duke University; Boston University	Matchar, DB (corresponding author), DUKE UNIV, CTR CLIN HLTH POLICY RES, 1ST UNION TOWER, SUITE 230, 2200 W MAIN ST, DURHAM, NC 27705 USA.		Matchar, David/M-3951-2019	Wolf, Philip/0000-0002-3628-301X; Matchar, David/0000-0003-3020-2108; Matthews, J Rosser/0000-0002-8304-2948	NHLBI NIH HHS [N01-HL-38038] Funding Source: Medline; NINDS NIH HHS [2-RO1-NS-17950-16] Funding Source: Medline; PHS HHS [282-81-0028] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; DITTUS RS, 1987, J AM COLL CARDIOL, V10, P869, DOI 10.1016/S0735-1097(87)80282-6; Douard J, 1996, MED DECIS MAKING, V16, P10, DOI 10.1177/0272989X9601600105; EDDY DM, 1980, SCREENING CANCER THE; FEINSTEIN AR, 1977, CLIN PHARMACOL THER, V21, P482; Gold MR, 1996, COST EFFECTIVENESS H, P82; GOLDSTEIN LB, 1995, NEUROLOGY, V45, P1965, DOI 10.1212/WNL.45.11.1965; IEZZONI LI, 1989, PROVIDING QUALITY CA; Laplace P. S., 1952, PHILOS ESSAY PROBABI; Matchar D. B., 1994, STROKE CLIN UPDATES, V5, P9; MATCHAR DB, 1994, ANN INTERN MED, V121, P41, DOI 10.7326/0003-4819-121-1-199407010-00008; MATCHAR DB, 1994, AHCPR PUB, P35; MATCHAR DB, 1996, SURG CEREBROVASCULAR, P680; Matthews JR., 1995, QUANTIFICATION QUEST, DOI 10.1515/9781400821808; MCNEIL BJ, 1993, DOING MORE GOOD HARM; PARMIGIANI G, 1996, BAYESIAN BIOSTATISTI; PARMIGIANI G, IN PRESS MED DECIS M; PHILLIPS LD, 1984, ACTA PSYCHOL, V56, P29, DOI 10.1016/0001-6918(84)90005-2; Polyani M., 1958, PERSONAL KNOWLEDGE P; RAIFFA H, 1980, CLIN DECISION ANAL, pIX; RANKIN J, 1957, Scott Med J, V2, P200; Sackett DL, 1996, BRIT MED J, V312, P71, DOI 10.1136/bmj.312.7023.71; SAMSA GP, 1996, JOINT STAT M CHIC; SAMSA GP, UNPUB STROKE; SAMSA GP, UNPUB J CLIN EPIDEMI; Starr P, 1982, SOCIAL TRANSFORMATIO; TANENBAUM SJ, 1994, J HEALTH POLIT POLIC, V19, P27, DOI 10.1215/03616878-19-1-27; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; Taylor TN, 1996, STROKE, V27, P1459, DOI 10.1161/01.STR.27.9.1459; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WEINSTEIN MC, 1989, J AM COLL CARDIOL, V14, pA38, DOI 10.1016/0735-1097(89)90160-5; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	32	50	50	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				704	711		10.7326/0003-4819-127-8_Part_2-199710151-00054	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00054			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB385	9382384				2022-12-28	WOS:A1997YB38500009
J	Farrell, PM; Kosorok, MR; Laxova, A; Shen, GH; Koscik, RE; Bruns, WT; Splaingard, M; Mischler, EH				Farrell, PM; Kosorok, MR; Laxova, A; Shen, GH; Koscik, RE; Bruns, WT; Splaingard, M; Mischler, EH			Nutritional benefits of neonatal screening for cystic fibrosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VITAMIN-E-DEFICIENCY; CLINICAL-TRIALS; EARLY DIAGNOSIS; INFANTS; NEWBORN; GROWTH; TRYPSINOGEN; MANAGEMENT; PROGRAM; ANEMIA	Background Many patients with cystic fibrosis are malnourished at the time of diagnosis, Whether newborn screening and early treatment may prevent the development of a nutritional deficiency is not known. Methods We compared the nutritional status of patients with cystic fibrosis identified by neonatal screening or by standard diagnostic methods. A total of 650,341 newborn infants were screened by measuring immunoreactive trypsinogen on dried blood spots (from April 1985 through June 1991) or by combining the trypsinogen test with DNA analysis (from July 1991 through June 1994). Of 325,171 infants assigned to an early-diagnosis group, cystic fibrosis was diagnosed in 74 infants, including 5 with negative screening tests. Excluding infants with meconium ileus, we evaluated nutritional status for up to 10 years by anthropometric and biochemical methods in 56 of the infants who received an early diagnosis and in 40 of the infants in whom the diagnosis was made by standard methods (the control group). Pancreatic insufficiency was managed with nutritional interventions that included high-calorie diets, pancreatic-enzyme therapy, and fat-soluble vitamin supplements. Results The diagnosis of cystic fibrosis was confirmed by a positive sweat test at a younger age in the early-diagnosis group than in the control group (mean age, 12 vs. 72 weeks). At the time of diagnosis, the early-diagnosis group had significantly higher height and weight percentiles and a higher head-circumference percentile (52nd, vs. 32nd in the control group; P=0.003). The early-diagnosis group also had significantly higher anthropometric indexes during the follow-up period, especially the children with pancreatic insufficiency and those who were homozygous for the Delta F508 mutation. Conclusions Neonatal screening provides the opportunity to prevent malnutrition in infants with cystic fibrosis. (C) 1997, Massachusetts Medical Society.	UNIV WISCONSIN,SCH MED,DEPT BIOSTAT,MADISON,WI 53706; MED COLL WISCONSIN,DEPT PEDIAT,MILWAUKEE,WI 53226	University of Wisconsin System; University of Wisconsin Madison; Medical College of Wisconsin	Farrell, PM (corresponding author), UNIV WISCONSIN,SCH MED,DEPT PEDIAT,1300 UNIV AVE,MADISON,WI 53706, USA.		Kosorok, Michael/ABB-7427-2021; Splaingard, Mark/AAL-7356-2021; Splaingard, Mark/D-9206-2012	Splaingard, Mark/0000-0002-1361-4947	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK034108, R01DK034108] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03186] Funding Source: Medline; NIDDK NIH HHS [DK 34108] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ad Hoc Committee Task Force on Neonatal Screening, 1983, PEDIATRICS, V72, P741; Allen D B, 1996, Adv Pediatr, V43, P231; BLYTHE SA, 1984, CLIN BIOCHEM, V17, P277, DOI 10.1016/S0009-9120(84)90541-1; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; COREY M, 1988, J CLIN EPIDEMIOL, V41, P583, DOI 10.1016/0895-4356(88)90063-7; CROSSLEY JR, 1979, LANCET, V1, P472; *CYST FIBR FDN, 1996, PAT REG 1995 ANN DAT; DURIE PR, 1986, PEDIATR RES, V20, P209, DOI 10.1203/00006450-198603000-00002; FARRELL P, 1993, AM J MED GENET, V45, P725, DOI 10.1002/ajmg.1320450613; Farrell P M, 1992, Adv Pediatr, V39, P35; Farrell P M, 1994, Wis Med J, V93, P415; FARRELL PM, 1977, J CLIN INVEST, V60, P233, DOI 10.1172/JCI108760; Fisher LD., 1997, BIOMETRICS, V53, P1182; FOST N, 1989, CLIN RES, V37, P495; Foster SW, 1996, J PEDIATR GASTR NUTR, V22, P238, DOI 10.1097/00005176-199604000-00004; GREGG RG, 1993, AM J HUM GENET, V52, P616; Gregg RG, 1997, PEDIATRICS, V99, P819, DOI 10.1542/peds.99.6.819; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HAMMOND KB, 1991, NEW ENGL J MED, V325, P769, DOI 10.1056/NEJM199109123251104; Hennekens C.H., 1987, EPIDEMIOLOGY MED; KARIM MR, 1988, 674 J HOPK U DEP BIO; KRAEMER R, 1978, ACTA PAEDIATR SCAND, V67, P33, DOI 10.1111/j.1651-2227.1978.tb16273.x; LAI HC, IN PRESS J PEDIAT; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MARCUS MS, 1991, AM J CLIN NUTR, V54, P578, DOI 10.1093/ajcn/54.3.578; RAMSEY BW, 1994, J PEDIATR-US, V124, P177, DOI 10.1016/S0022-3476(94)70301-9; RAMSEY BW, 1992, AM J CLIN NUTR, V55, P108, DOI 10.1093/ajcn/55.1.108; ROSENSTEIN BJ, 1982, JOHNS HOPKINS MED J, V150, P113; SHWACHMAN H, 1958, AMA J DIS CHILD, V96, P6, DOI 10.1001/archpedi.1958.02060060008002; SHWACHMAN H, 1970, PEDIATRICS, V46, P335; TLUCZEK A, 1992, J DEV BEHAV PEDIATR, V13, P181; vanEgmond AWA, 1996, AM J CLIN NUTR, V63, P746, DOI 10.1093/ajcn/63.5.746; WATERS DL, 1990, NEW ENGL J MED, V322, P303, DOI 10.1056/NEJM199002013220505; WEI LJ, 1990, BIOMETRIKA, V77, P359, DOI 10.1093/biomet/77.2.359; WILCKEN B, 1993, SCREENING, V2, P43; WILFOND BS, 1994, CLIN PEDIATR, V33, P2, DOI 10.1177/000992289403300101	37	284	292	1	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					963	969		10.1056/NEJM199710023371403	http://dx.doi.org/10.1056/NEJM199710023371403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9395429	Bronze			2022-12-28	WOS:A1997XY42300003
J	Sobel, JD				Sobel, JD			Vaginitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							VULVO-VAGINAL CANDIDIASIS; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; BACTERIAL VAGINOSIS; RISK-FACTORS; GENITAL-TRACT; VULVOVAGINAL CANDIDIASIS; CLINICAL MANIFESTATIONS; TRICHOMONAS-VAGINALIS; UNIVERSITY-STUDENTS; PRETERM DELIVERY		Wayne State Univ, Sch Med, Dept Internal Med, Div Infect Dis, Detroit, MI 48201 USA; Detroit Med Ctr, Detroit, MI USA	Wayne State University; Detroit Medical Center	Sobel, JD (corresponding author), Wayne State Univ, Sch Med, Dept Internal Med, Div Infect Dis, Suite 2140,Harper Profess Bldg,4160 John R St, Detroit, MI 48201 USA.							AHMEDJUSHUF IH, 1995, GENITOURIN MED, V71, P254; AMSEL R, 1983, AM J MED, V74, P14, DOI 10.1016/0002-9343(83)91112-9; BERG AO, 1984, JAMA-J AM MED ASSOC, V251, P620, DOI 10.1001/jama.251.5.620; CARPENTER CCJ, 1989, AM J MED, V86, P771, DOI 10.1016/0002-9343(89)90471-3; DeMeo LR, 1996, AM J OBSTET GYNECOL, V174, P1339, DOI 10.1016/S0002-9378(96)70682-8; ESCHENBACH DA, 1988, AM J OBSTET GYNECOL, V158, P819, DOI 10.1016/0002-9378(88)90078-6; ESCHENBACH DA, 1989, J CLIN MICROBIOL, V27, P251, DOI 10.1128/JCM.27.2.251-256.1989; ESCHENBACH DA, 1989, OBSTET GYN CLIN N AM, V16, P593; FERRIS DG, 1995, J FAM PRACTICE, V41, P443; Ferris DG, 1996, J FAM PRACTICE, V42, P595; Fidel PL, 1996, CLIN MICROBIOL REV, V9, P335, DOI 10.1128/CMR.9.3.335; FLEURY F J, 1981, Clinical Obstetrics and Gynecology, V24, P407, DOI 10.1097/00003081-198106000-00008; FOXMAN B, 1990, AM J PUBLIC HEALTH, V80, P329, DOI 10.2105/AJPH.80.3.329; GARDNER HL, 1955, AM J OBSTET GYNECOL, V69, P962, DOI 10.1016/0002-9378(55)90095-8; Geiger AM, 1996, EPIDEMIOLOGY, V7, P182, DOI 10.1097/00001648-199603000-00013; GEIGER AM, 1995, AM J PUBLIC HEALTH, V85, P1146, DOI 10.2105/AJPH.85.8_Pt_1.1146; HAMMILL HA, 1989, OBSTET GYN CLIN N AM, V16, P531; Hauth JC, 1995, NEW ENGL J MED, V333, P1732, DOI 10.1056/NEJM199512283332603; HAY PE, 1994, BRIT MED J, V308, P295, DOI 10.1136/bmj.308.6924.295; HILL GB, 1993, AM J OBSTET GYNECOL, V169, P450, DOI 10.1016/0002-9378(93)90339-K; HILLIER SL, 1988, NEW ENGL J MED, V319, P972, DOI 10.1056/NEJM198810133191503; Hillier SL, 1990, SEXUALLY TRANSMITTED, P547; HILTON E, 1995, J INFECT DIS, V172, P1616, DOI 10.1093/infdis/172.6.1616; HOROWITZ BJ, 1992, J CLIN PHARMACOL, V32, P248, DOI 10.1002/j.1552-4604.1992.tb03833.x; HOUANG ET, 1990, ANTIMICROB AGENTS CH, V34, P909, DOI 10.1128/AAC.34.5.909; HURLEY R, 1979, POSTGRAD MED J, V55, P645, DOI 10.1136/pgmj.55.647.645; JOESOEF MR, 1995, CLIN INFECT DIS, V20, pS72, DOI 10.1093/clinids/20.Supplement_1.S72; KRIEGER JN, 1988, JAMA-J AM MED ASSOC, V259, P1223, DOI 10.1001/jama.259.8.1223; KURKI T, 1992, OBSTET GYNECOL, V80, P173; KUROHARA ML, 1991, J ALLERGY CLIN IMMUN, V88, P279, DOI 10.1016/0091-6749(91)90341-K; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; Lossick JC, 1990, TRICHOMONADS PARASIT, P311; MACDERMOTT RIJ, 1995, BRIT J OBSTET GYNAEC, V102, P92, DOI 10.1111/j.1471-0528.1995.tb09058.x; MCGREGOR JA, 1995, AM J OBSTET GYNECOL, V173, P157, DOI 10.1016/0002-9378(95)90184-1; MORALES WJ, 1994, AM J OBSTET GYNECOL, V171, P345, DOI 10.1016/S0002-9378(94)70033-8; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; NYIRJESY P, 1995, LANCET, V346, P1110, DOI 10.1016/S0140-6736(95)91788-8; Odds FC, 1988, CANDIDA CANDIDOSIS R, V2nd, P124; Oleen-Burkey M A, 1995, Infect Dis Obstet Gynecol, V3, P149, DOI 10.1155/S1064744995000500; PETERS N, 1995, SEX TRANSM DIS, V22, P296, DOI 10.1097/00007435-199509000-00005; PLATZCHRISTENSEN JJ, 1994, ACTA OBSTET GYN SCAN, V73, P586, DOI 10.3109/00016349409006278; REEF SE, 1995, CLIN INFECT DIS, V20, pS80, DOI 10.1093/clinids/20.Supplement_1.S80; RHOADS JL, 1987, JAMA-J AM MED ASSOC, V257, P3105, DOI 10.1001/jama.257.22.3105; Schuman P, 1996, AM J OBSTET GYNECOL, V174, P1660, DOI 10.1016/S0002-9378(96)70630-0; SHEINESS D, 1992, J CLIN MICROBIOL, V30, P642, DOI 10.1128/JCM.30.3.642-648.1992; Sobel J. D., 1996, P128; SOBEL JD, 1995, AM J OBSTET GYNECOL, V172, P1263, DOI 10.1016/0002-9378(95)91490-0; Sobel JD, 1997, CLIN INFECT DIS, V24, P649, DOI 10.1093/clind/24.4.649; SOBEL JD, 1985, AM J OBSTET GYNECOL, V152, P924, DOI 10.1016/S0002-9378(85)80003-X; Sobel JD, 1996, CLIN INFECT DIS, V22, P726, DOI 10.1093/clinids/22.4.726; Sobel JD, 1996, J CLIN MICROBIOL, V34, P2497, DOI 10.1128/JCM.34.10.2497-2499.1996; SOBEL JD, 1994, AM J OBSTET GYNECOL, V171, P1215, DOI 10.1016/0002-9378(94)90135-X; SOPER DE, 1990, AM J OBSTET GYNECOL, V163, P1016, DOI 10.1016/0002-9378(90)91115-S; SPINILLO A, 1992, J REPROD MED, V37, P343; VAZQUEZ JA, 1994, J INFECT DIS, V170, P1566, DOI 10.1093/infdis/170.6.1566; WOLNERHANSSEN P, 1989, JAMA-J AM MED ASSOC, V261, P571	56	329	345	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	1997	337	26					1896	1903		10.1056/NEJM199712253372607	http://dx.doi.org/10.1056/NEJM199712253372607			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN051	9407158				2022-12-28	WOS:000071128200007
J	Daley, J; Delbanco, TL; Hartman, EE				Daley, J; Delbanco, TL; Hartman, EE			An 88-year-old woman facing the end of life, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Lynn J, 1997, JAMA-J AM MED ASSOC, V277, P1633, DOI 10.1001/jama.277.20.1633	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2184	2184						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9417014				2022-12-28	WOS:000071022200036
J	Nowell, PD; Mazumdar, S; Buysse, DJ; Dew, MA; Reynolds, CF; Kupfer, DJ				Nowell, PD; Mazumdar, S; Buysse, DJ; Dew, MA; Reynolds, CF; Kupfer, DJ			Benzodiazepines and zolpidem for chronic insomnia - A meta-analysis of treatment efficacy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Association-of-Professional-Sleep-Societies	MAY 28-JUN 02, 1996	WASHINGTON, D.C.	Assoc Profess Sleep Soc			SHORT-TERM TREATMENT; DOUBLE-BLIND; PHARMACOLOGICAL TREATMENT; WITHDRAWAL PHENOMENA; SLEEP COMPLAINTS; LEARNED INSOMNIA; DSM-III; PLACEBO; FLURAZEPAM; OUTPATIENTS	Objective.-To evaluate the efficacy of benzodiazepines and zolpidem tartrate in chronic insomnia based on a quantitative review of literature. Data Sources.-Articles from 1966 to 1998 were identified using MEDLINE, by a manual review of relevant journals, and from bibliographies of identified articles. Study Selection.-Studies using randomized, double-blind, placebo-controlled, parallel or crossover designs with benzodiazepines or zolpidem in adults younger than 65 years with chronic insomnia (modified Diagnostic and Statistical/Manual of Mental Disorders, Fourth Edition criteria for primary insomnia) were selected for review. Self-report and polysomnographic measures of sleep-onset latency, total sleep time, number of awakenings, and sleep quality were selected as outcomes. Data Extraction.-Twenty-two studies met the selection criteria. A combined test of P values was performed, pooling broadly from the 22 studies to determine whether medication was superior to placebo. A combined test of effect sizes was performed on the subset of studies that reported effect size information to determine the magnitude of medication effect. Data Synthesis.-A homogeneous sample of studies summarized 1894 patients treated for a median duration of 7 days. The combined test of P values demonstrated that medication was superior to placebo in all 4 outcome measures. Treatment response was moderate in magnitude by the combined test of effect sizes. Conclusions.-Benzodiazepines and zolpidem produced reliable improvements in commonly measured parameters of sleep in patients with chronic insomnia. Relative to the chronic and recurring course of insomnia, both the limited duration of treatments studied and the lack of follow-up data from controlled trials represent challenges for developing evidence-based guidelines for the use of hypnotics in the management of chronic insomnia.	Univ Pittsburgh, Western Psychiat Inst & Clin, Sleep & Chronobiol Ctr, Grad Sch Publ Hlth,Dept Psychiat, Pittsburgh, PA 15215 USA; Univ Pittsburgh, Sch Med, Dept Biostat, Pittsburgh, PA 15215 USA; Univ Pittsburgh, Sch Med, Dept Epidemiol, Pittsburgh, PA 15215 USA; Univ Pittsburgh, Sch Med, Dept Psychol, Pittsburgh, PA 15215 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Nowell, PD (corresponding author), Univ Pittsburgh, Western Psychiat Inst & Clin, Sleep & Chronobiol Ctr, Grad Sch Publ Hlth,Dept Psychiat, 3811 Ohara St, Pittsburgh, PA 15215 USA.		Buysse, Daniel/AAJ-1608-2021	Buysse, Daniel/0000-0002-3288-1864	NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH016804, R01MH037869] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ADEN GC, 1983, J CLIN PSYCHIAT, V44, P454; AKERSTEDT T, 1994, PERCEPT MOTOR SKILL, V79, P287, DOI 10.2466/pms.1994.79.1.287; *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P551; ANGST J, 1989, EUR ARCH PSY CLIN N, V238, P285, DOI 10.1007/BF00449810; BALTER MB, 1992, J CLIN PSYCHIAT, V53, P34; BANGERTDROWNS RL, 1986, PSYCHOL BULL, V99, P388, DOI 10.1037/0033-2909.99.3.388; BERNSTEIN MJ, 1984, JAMA-J AM MED ASSOC, V251, P2410; BLIWISE DL, 1991, J PSYCHOACTIVE DRUGS, V23, P335, DOI 10.1080/02791072.1991.10471604; BOOTZIN RR, 1992, J CLIN PSYCHIAT, V53, P37; BORKOVEC TD, 1982, J CONSULT CLIN PSYCH, V50, P880, DOI 10.1037/0022-006X.50.6.880; BUYSSE DJ, 1994, SLEEP, V17, P630, DOI 10.1093/sleep/17.7.630; BUYSSE DJ, 1993, SLEEP RES, V22, P178; CARRKAFFASHAN L, 1979, J CONSULT CLIN PSYCH, V47, P1072, DOI 10.1037/0022-006X.47.6.1072; CARSKADON MA, 1976, AM J PSYCHIAT, V133, P1382; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; COHN JB, 1984, J CLIN PSYCHIAT, V45, P104; COHN JB, 1991, J CLIN PHARMACOL, V31, P747, DOI 10.1002/j.1552-4604.1991.tb03771.x; CUANANG JR, 1982, CLIN THER, V4, P402; DECLERCK AC, 1992, PSYCHOPHARMACOLOGY, V106, P497, DOI 10.1007/BF02244821; DECLERCK AC, 1992, PSYCHOPHARMACOLOGY, V109, P254, DOI 10.1007/BF02245512; DEPAULA AJM, 1984, CLIN THER, V6, P500; *DIAGN CLASS STEER, 1990, INT CLASS SLEEP DIS, P27; DOMINGUEZ RA, 1986, J CLIN PSYCHIAT, V47, P362; ELIE R, 1990, INT CLIN PSYCHOPHARM, V5, P279, DOI 10.1097/00004850-199010000-00005; FABRE LF, 1978, J CLIN PSYCHIAT, V39, P679; FILLINGIM JM, 1979, BRIT J CLIN PHARMACO, V8, pS73, DOI 10.1111/j.1365-2125.1979.tb00461.x; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; FRANKEL BL, 1976, ARCH GEN PSYCHIAT, V33, P615; Ganguli M, 1996, J AM GERIATR SOC, V44, P778, DOI 10.1111/j.1532-5415.1996.tb03733.x; GISLASON T, 1987, ACTA MED SCAND, V221, P475; GREENBLATT DJ, 1992, J CLIN PSYCHIAT, V53, P7; HAJAK G, 1994, INT CLIN PSYCHOPHARM, V9, P251, DOI 10.1097/00004850-199400940-00004; HAURI P, 1986, SLEEP, V9, P38, DOI 10.1093/sleep/9.1.38; HAURI P, 1981, ARCH GEN PSYCHIAT, V38, P752; Hauri P., 1992, CASE STUDIES INSOMNI, P65, DOI DOI 10.1007/978-1-4757-9586-8_5; HAURI P, 1982, SLEEP DISORDERS, P1; HEDGES LV, 1994, METAANALYSIS DECISIO, P119; HERRMANN WM, 1993, J INT MED RES, V21, P306, DOI 10.1177/030006059302100602; Hoch CC, 1997, SLEEP, V20, P192, DOI 10.1093/sleep/20.3.192; HUNTER JE, 1982, METAANALYSIS CUMULAT, P12; JOHNSON LC, 1983, MIL MED, V148, P727; KALES A, 1988, J CLIN PSYCHOPHARM, V8, P340; KALES A, 1983, PSYCHOSOM MED, V45, P341, DOI 10.1097/00006842-198308000-00008; KALES A, 1987, J CLIN PHARMACOL, V27, P508, DOI 10.1002/j.1552-4604.1987.tb03058.x; KRIPKE DF, 1990, J CLIN PSYCHOPHARM, V10, pS32; Kupfer DJ, 1997, NEW ENGL J MED, V336, P341, DOI 10.1056/NEJM199701303360506; LARA RH, 1983, J INT MED RES, V11, P162, DOI 10.1177/030006058301100306; LINNOILA M, 1980, INT PHARMACOPSYCHIAT, V15, P129, DOI 10.1159/000468424; LINSEN SM, 1995, EUR PSYCHIAT, V10, P306, DOI 10.1016/0924-9338(96)80312-9; MELLINGER GD, 1985, ARCH GEN PSYCHIAT, V42, P225, DOI 10.1001/archpsyc.1985.01790260019002; MENDELS J, 1983, J INT MED RES, V11, P155, DOI 10.1177/030006058301100305; MENDELSON WB, 1984, BIOL PSYCHIAT, V19, P1261; MENDELSON WB, 1984, PSYCHIAT RES, V12, P235, DOI 10.1016/0165-1781(84)90029-5; MENDELSON WB, 1995, SLEEP, V18, P698, DOI 10.1093/sleep/18.8.698; MITLER MM, 1984, J CLIN PSYCHOPHARM, V4, P2; MONTI JM, 1994, PHARMACOPSYCHIATRY, V27, P166, DOI 10.1055/s-2007-1014298; MORIN CM, 1994, AM J PSYCHIAT, V151, P1172; MORIN CM, 1995, SLEEP, V18, P240, DOI 10.1093/sleep/18.4.240; MORIN CM, 1995, SLEEP RES, V24, P303; MURTAGH DRR, 1995, J CONSULT CLIN PSYCH, V63, P79, DOI 10.1037/0022-006X.63.1.79; NAIR NPV, 1990, INT CLIN PSYCHOPHARM, V5, P1; Orwin RG, 1983, J ED STAT, V8, P157, DOI [DOI 10.2307/1164923, 10.3102/10769986008002157]; PEARCE PL, 1994, J CLIN PSYCHIAT, V55, P163; PONCIANO E, 1990, INT CLIN PSYCHOPHARM, V5, P69; REYNOLDS CF, IN PRESS CLIN GERIAT; ROEHRS T, 1985, SLEEP, V8, P34, DOI 10.1093/sleep/8.1.34; ROSENTHAL R, 1986, PSYCHOL BULL, V99, P400, DOI 10.1037/0033-2909.99.3.400; ROSENTHAL R, 1984, METAANALYTIC PROCEDU, P93; ROTH T, 1995, SLEEP, V18, P246, DOI 10.1093/sleep/18.4.246; SCHARF MB, 1994, J CLIN PSYCHIAT, V55, P192; SCHARF MB, 1990, J CLIN PHARMACOL, V30, P461, DOI 10.1002/j.1552-4604.1990.tb03486.x; SCHRAMM E, 1995, ACTA PSYCHIAT SCAND, V91, P10, DOI 10.1111/j.1600-0447.1995.tb09735.x; STAEDT J, 1995, FORTSCHR NEUROL PSYC, V63, P368, DOI 10.1055/s-2007-996638; STEINMARK SW, 1974, J ABNORM PSYCHOL, V83, P157, DOI 10.1037/h0036489; STOLLER MK, 1994, CLIN THER, V16, P873; SUGERMAN JL, 1985, BIOL PSYCHIAT, V20, P741, DOI 10.1016/0006-3223(85)90153-2; TAN TL, 1984, AM J PSYCHIAT, V141, P357; VOLLRATH M, 1989, EUR ARCH PSY CLIN N, V239, P113, DOI 10.1007/BF01759584; WALSH JK, 1992, J CLIN PSYCHIAT, V53, P10; WALSH JK, 1984, CURR THER RES CLIN E, V36, P866; WALSH JK, 1995, HYPNOTICS ANXIOLYTIC; WARE JC, 1991, PSYCHIAT MED, V9, P245; WHORWELL PJ, 1986, GUT, V27, P37, DOI 10.1136/gut.27.1.37; WOODS JH, 1995, PSYCHOPHARMACOLOGY, V118, P107, DOI 10.1007/BF02245824; World Health Organization, 1978, MENT DIS GLOSS GUID	85	280	293	0	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2170	2177						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YM043	9417012				2022-12-28	WOS:000071022200034
J	McCarthy, M				McCarthy, M			An urban agenda for Europe	LANCET			English	Editorial Material											McCarthy, M (corresponding author), UCL, DEPT PUBL HLTH, MORTIMER ST, LONDON WC1E 6BT, ENGLAND.		McCarthy, Mark/C-1117-2009					*COMM EUR COMM, 1997, COMM REP INT HLTH RE; *COMM EUR COMM, 1997, URB AG EUR UN COM971; DERINK S, 1997, COMMUNICATION   1125; *UN, 1993, AG 21 UN PROGR ACT R	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 13	1997	350	9093					1722	1722		10.1016/S0140-6736(05)63570-2	http://dx.doi.org/10.1016/S0140-6736(05)63570-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413461				2022-12-28	WOS:A1997YL55400006
J	Bender, M; Imam, FB; Talbot, WS; Ganetzky, B; Hogness, DS				Bender, M; Imam, FB; Talbot, WS; Ganetzky, B; Hogness, DS			Drosophila ecdysone receptor mutations reveal functional differences among receptor isoforms	CELL			English	Article							SINGLE-BASE CHANGES; INDUCIBLE GENE; EARLY PUFF; ENCODES 2; METAMORPHOSIS; SUPERFAMILY; TRANSCRIPTION; MELANOGASTER; PROTEINS; E74	The steroid hormone ecdysone directs Drosophila metamorphosis via three heterodimeric receptors that differ according to which of three ecdysone receptor isoforms encoded by the EcR gene (EcR-A, EcR-B1, or EcR-B2) is activated by the orphan nuclear receptor USP. We have identified and molecularly mapped two classes of EcR mutations: those specific to EcR-B1 that uncouple metamorphosis, and embryonic-lethal mutations that map to common sequences encoding the DNA-and ligand-binding domains. In the larval salivary gland, loss of EcR-B1 results in loss of activation of ecdysone-induced genes. Comparable transgenic expression of EcR-B1, EcR-B2, and EcR-A in these mutant glands results, respectively, in full, partial, and no repair of that loss.	STANFORD UNIV,MED CTR,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305; UNIV GEORGIA,DEPT GENET,ATHENS,GA 30602; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	Stanford University; Stanford University; University System of Georgia; University of Georgia; University of Wisconsin System; University of Wisconsin Madison				Imam, Farhad/0000-0003-2854-2568	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043100, R01GM053681] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53681, GM43100] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andres A.J., 1994, DROSOPHILA MELANOGAS, P565; ANDRES AJ, 1995, DEVELOPMENT, V121, P2667; ANDRES AJ, 1993, DEV BIOL, V160, P388, DOI 10.1006/dbio.1993.1315; ASHBURNER M, 1974, DEV BIOL, V39, P141, DOI 10.1016/S0012-1606(74)80016-3; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BELYAEVA ES, 1981, CHROMOSOMA, V84, P207, DOI 10.1007/BF00399132; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; Crossgrove K, 1996, DEV BIOL, V180, P745, DOI 10.1006/dbio.1996.0343; DAI JD, 1991, DEV BIOL, V144, P309, DOI 10.1016/0012-1606(91)90424-2; DIBELLO PR, 1991, GENETICS, V129, P385; FLETCHER JC, 1995, DEVELOPMENT, V121, P1411; Fristrom Dianne, 1993, P843; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; JIANG C, 1997, IN PRESS DEVELOPMENT; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, THESIS STANFORD U ST; LEWIS EB, 1968, DROSOPHILA INFORM SE, V43, P193; MADHAVAN MM, 1980, J EMBRYOL EXP MORPH, V60, P1; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCPHAUL MJ, 1993, J CLIN ENDOCR METAB, V76, P17, DOI 10.1210/jc.76.1.17; MUNROE S, 1995, THESIS STANFORD U ST; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; REFETOFF S, 1994, ENDOCR REV, V15, P336; Riddiford Lynn M., 1993, P899; ROBINOW S, 1993, DEVELOPMENT, V119, P1251; Russell S., 1996, METAMORPHOSIS CELL B, P109, DOI [10.1016/B978-012283245-1/50005-1, DOI 10.1016/B978-012283245-1/50005-1]; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1988, THESIS STANFORD U ST; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; Skaer Helen, 1993, P941; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; UMESS LD, 1995, EMBO J, V14, P6239; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F	38	226	232	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					777	788		10.1016/S0092-8674(00)80466-3	http://dx.doi.org/10.1016/S0092-8674(00)80466-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413987	hybrid			2022-12-28	WOS:A1997YL43900009
J	Darji, A; Guzman, CA; Gerstel, B; Wachholz, P; Timmis, KN; Wehland, J; Chakraborty, T; Weiss, S				Darji, A; Guzman, CA; Gerstel, B; Wachholz, P; Timmis, KN; Wehland, J; Chakraborty, T; Weiss, S			Oral somatic transgene vaccination using attenuated S-typhimurium	CELL			English	Article							COMPLEX CLASS-I; SALMONELLA-TYPHIMURIUM; LISTERIA-MONOCYTOGENES; ESCHERICHIA-COLI; T-CELLS; BETA-GALACTOSIDASE; IMMUNE-RESPONSES; BACTERIAL-DNA; LYMPHOCYTE-T; ANTIGEN	An attenuated strain of S. typhimurium has been used as a vehicle for oral genetic immunization. Eukaryotic expression vectors containing truncated genes of ActA and listeriolysin-two virulence factors of Listeria monocytogenes-have been used to transform S. typhimurium aroA. Multiple or even single oral immunizations with such transformants induced excellent cellular and humoral responses. In addition, protective immunity was induced with listeriolysin transformants. The quality of the responses suggested a transfer of plasmid DNA from the bacterial carrier to the host. Such transfer was unequivocally shown in vitro with primary peritoneal macrophages. We describe a highly versatile system for antigen delivery, identification of protective antigens for vaccination, and efficient generation of antibodies against the product of open reading frames present on virtually any DNA segment.	GESELL BIOTECHNOL FORSCH MBH,NATL RES CTR BIOTECHNOL,DIV MICROBIOL,D-38124 BRAUNSCHWEIG,GERMANY; UNIV GIESSEN,INST MED MICROBIOL,D-35392 GIESSEN,GERMANY	Gesellschaft fur Biotechnologische Forschung mbH; Justus Liebig University Giessen	Darji, A (corresponding author), GESELL BIOTECHNOL FORSCH MBH,NATL RES CTR BIOTECHNOL,DIV CELL BIOL & IMMUNOL,MASCHERODER WEG 1,D-38124 BRAUNSCHWEIG,GERMANY.							[Anonymous], 1982, MOL CLONING LAB MANU; BROOKS AG, 1993, J IMMUNOL, V150, P3690; BROWN A, 1987, J INFECT DIS, V155, P86, DOI 10.1093/infdis/155.1.86; CHAKRABORTY T, 1992, J BACTERIOL, V174, P568, DOI 10.1128/jb.174.2.568-574.1992; Chatfield SN, 1994, MODERN VACCINOLOGY, P55; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122; Courvalin P, 1995, CR ACAD SCI III-VIE, V318, P1207; Darji A, 1995, J BIOTECHNOL, V43, P205, DOI 10.1016/0168-1656(95)00138-7; DARJI A, 1995, EUR J IMMUNOL, V25, P2967, DOI 10.1002/eji.1830251038; Darji A, 1997, EUR J IMMUNOL, V27, P1353, DOI 10.1002/eji.1830270609; DESOUSA CR, 1995, J EXP MED, V182, P841; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; FAIRWEATHER NF, 1990, RES MICROBIOL, V141, P769, DOI 10.1016/0923-2508(90)90109-4; FLYNN JL, 1990, MOL MICROBIOL, V4, P2111, DOI 10.1111/j.1365-2958.1990.tb00572.x; Fox BC, 1997, AM J VET RES, V58, P265; Geissler M, 1997, J IMMUNOL, V158, P1231; GERMANIER R, 1975, J INFECT DIS, V131, P553, DOI 10.1093/infdis/131.5.553; GUZMAN CA, 1991, INFECT IMMUN, V59, P4391; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; Hassan JO, 1996, INFECT IMMUN, V64, P938, DOI 10.1128/IAI.64.3.938-944.1996; Hess J, 1996, P NATL ACAD SCI USA, V93, P1458, DOI 10.1073/pnas.93.4.1458; HOLTEL A, 1992, NUCLEIC ACIDS RES, V20, P1755, DOI 10.1093/nar/20.7.1755; JARAQUEMADA D, 1990, J EXP MED, V172, P947, DOI 10.1084/jem.172.3.947; Kim JJ, 1997, J IMMUNOL, V158, P816; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MENGAUD J, 1988, INFECT IMMUN, V56, P766, DOI 10.1128/IAI.56.4.766-772.1988; MESSINA JP, 1991, J IMMUNOL, V147, P1759; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; NEWTON SMC, 1989, SCIENCE, V244, P70, DOI 10.1126/science.2468182; Norbury CC, 1995, IMMUNITY, V3, P783, DOI 10.1016/1074-7613(95)90067-5; OCALLAGHAN D, 1990, MOL GEN GENET, V223, P156, DOI 10.1007/BF00315809; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; RAMMENSEE HG, 1989, IMMUNOGENETICS, V30, P296, DOI 10.1007/BF02421334; ROBERTS M, 1994, NOVEL DELIVERY SYSTE, P27; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; Siebers A, 1996, TRENDS MICROBIOL, V4, P22, DOI 10.1016/0966-842X(96)81501-0; SIZEMORE DR, 1995, SCIENCE, V270, P299, DOI 10.1126/science.270.5234.299; Steinbach G, 1996, VET MICROBIOL, V48, P199, DOI 10.1016/0378-1135(95)00134-4; Tian JD, 1996, NAT MED, V2, P1348, DOI 10.1038/nm1296-1348; TURNER SJ, 1993, INFECT IMMUN, V61, P5374, DOI 10.1128/IAI.61.12.5374-5380.1993; WALKER MJ, 1992, INFECT IMMUN, V60, P4260, DOI 10.1128/IAI.60.10.4260-4268.1992; WILES MV, 1993, METHOD ENZYMOL, V225, P900; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8; YAMAMOTO S, 1992, J IMMUNOL, V148, P4072; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	50	346	414	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					765	775		10.1016/S0092-8674(00)80465-1	http://dx.doi.org/10.1016/S0092-8674(00)80465-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413986	Bronze			2022-12-28	WOS:A1997YL43900008
J	Gong, XH; Li, E; Klier, G; Huang, QL; Wu, Y; Lei, H; Kumar, NM; Horwitz, J; Gilula, NB				Gong, XH; Li, E; Klier, G; Huang, QL; Wu, Y; Lei, H; Kumar, NM; Horwitz, J; Gilula, NB			Disruption of alpha(3) connexin gene leads to proteolysis and cataractogenesis in mice	CELL			English	Article							GAP JUNCTION PROTEIN; TRANSGENIC MICE; RAT LENS; STRUCTURAL ORGANIZATION; BETA-GALACTOSIDASE; MAMMALIAN LENS; CHICK LENS; CALPAIN-II; MOUSE; CRYSTALLIN	Gap junction channels formed by alpha(3) (Cx46) and alpha(8) (Cx50) connexin provide pathways for communication between the fiber cells in the normal transparent lens. To determine the specific role of alpha(3) connexin in vivo, the alpha(3) connexin gene was disrupted in mice. Although the absence of alpha(3) connexin had no obvious influence on the early stages of lens formation and the differentiation of lens fibers, mice homozygous for the disrupted alpha(3) gene developed nuclear cataracts that were associated with the proteolysis of crystallins. This study establishes the importance of gap junctions in maintaining normal lens transparency by providing a cell-cell signaling pathway or structural component for the proper organization of lens membrane and cytoplasmic proteins.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; HARVARD UNIV, MGH, SCH MED, CARDIOVASC RES CTR, CHARLESTOWN, MA 02129 USA; UNIV CALIF LOS ANGELES, JULES STEIN EYE INST, LOS ANGELES, CA 90095 USA	Scripps Research Institute; Harvard University; University of California System; University of California Los Angeles					NATIONAL EYE INSTITUTE [R37EY003897, R01EY011093] Funding Source: NIH RePORTER; NEI NIH HHS [EY11093, R37EY3897] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AlGhoul KJ, 1996, EXP EYE RES, V62, P237, DOI 10.1006/exer.1996.0029; Bassnett S, 1997, J CELL BIOL, V137, P37, DOI 10.1083/jcb.137.1.37; BLOEMENDAL H, 1981, MOL CELLULAR BIOL EY, P85; Bond J, 1996, INVEST OPHTH VIS SCI, V37, P1557; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; BRAKENHOFF RH, 1994, HUM MOL GENET, V3, P279, DOI 10.1093/hmg/3.2.279; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; CHAUDUN E, 1994, J CELL PHYSIOL, V158, P354, DOI 10.1002/jcp.1041580218; COSTELLO MJ, 1989, INVEST OPHTH VIS SCI, V30, P975; DAVID LL, 1986, EXP EYE RES, V42, P227, DOI 10.1016/0014-4835(86)90057-6; DUNCAN G, 1994, PROG RETIN EYE RES, V13, P623, DOI 10.1016/1350-9462(94)90025-6; Dunia I, 1996, J CELL BIOL, V132, P701, DOI 10.1083/jcb.132.4.701; EVANS CW, 1993, EUR J CELL BIOL, V60, P243; Goodenough D.A., 1992, Seminars in Cell Biology, V3, P49; GORING DR, 1987, SCIENCE, V235, P456, DOI 10.1126/science.3099390; Harding JJ, 1984, EYE B, V1b, P207; JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L; JARVIS LJ, 1993, INVEST OPHTH VIS SCI, V34, P613; JIANG JX, 1995, DEV BIOL, V168, P649, DOI 10.1006/dbio.1995.1109; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI WC, 1995, J CELL BIOL, V130, P169, DOI 10.1083/jcb.130.1.169; Lin JS, 1997, EUR J CELL BIOL, V73, P141; LO WK, 1987, CURR EYE RES, V6, P433, DOI 10.3109/02713688709025199; Mackay D, 1997, AM J HUM GENET, V60, P1474, DOI 10.1086/515468; Mathias RT, 1997, PHYSIOL REV, V77, P21, DOI 10.1152/physrev.1997.77.1.21; Mitton KP, 1996, J BIOL CHEM, V271, P31803, DOI 10.1074/jbc.271.50.31803; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; Rae JL, 1996, J MEMBRANE BIOL, V150, P89, DOI 10.1007/s002329900033; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; RISEK B, 1994, DEV BIOL, V164, P183, DOI 10.1006/dbio.1994.1190; ROBINSON KR, 1983, CURR EYE RES, V2, P843, DOI 10.3109/02713688209020020; Sambrook J., 2002, MOL CLONING LAB MANU; SHEARER TR, 1992, CURR EYE RES, V11, P357, DOI 10.3109/02713689209001789; Shiels A, 1996, NAT GENET, V12, P212, DOI 10.1038/ng0296-212; SIEZEN RJ, 1988, J MOL BIOL, V199, P475, DOI 10.1016/0022-2836(88)90619-5; SPECTOR A, 1985, OCULAR LENS STRUCTUR, P405; Srivastava OP, 1996, EXP EYE RES, V62, P593, DOI 10.1006/exer.1996.0070; TAKEMOTO L, 1994, EXP EYE RES, V59, P239, DOI 10.1006/exer.1994.1103; TRUSCOTT RJW, 1990, INVEST OPHTH VIS SCI, V31, P2405; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WHITE TW, 1992, MOL BIOL CELL, V3, P711, DOI 10.1091/mbc.3.7.711; Wride MA, 1996, DIFFERENTIATION, V61, P77, DOI 10.1046/j.1432-0436.1996.6120077.x; YANCEY SB, 1992, DEVELOPMENT, V114, P203; YOSHIDA H, 1986, INVEST OPHTH VIS SCI, V27, P1269; YOSHIDA H, 1985, CURR EYE RES, V4, P983, DOI 10.3109/02713689509000005; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255	52	344	354	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					833	843		10.1016/S0092-8674(00)80471-7	http://dx.doi.org/10.1016/S0092-8674(00)80471-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413992	Bronze			2022-12-28	WOS:A1997YL43900014
J	Liu, C; Weaver, DR; Strogatz, SH; Reppert, SM				Liu, C; Weaver, DR; Strogatz, SH; Reppert, SM			Cellular construction of a circadian clock: Period determination in the suprachiasmatic nuclei	CELL			English	Article							IN-VITRO; NEURONS; HAMSTER; OSCILLATORS; ELECTRODES; MUSCIMOL; EXPRESS; RHYTHM; SYSTEM; PHASE	The circadian clock in the suprachiasmatic nuclei is composed of multiple, single-cell circadian oscillators (clock cells). We now test the hypothesis that the circadian period in behavior is determined by the mean period that arises from the coupling of clock cells with diverse circadian periods. For these studies, we monitored firing rate rhythms of individual suprachiasmatic nuclei neurons on fixed multielectrode plates and exploited the altered circadian periods expressed by heterozygous and homozygous tau mutant hamsters. The results show that circadian period in the whole animal is determined by averaging widely dispersed periods of individual clock cells. The data also demonstrate that the tau mutation affects circadian function in a cell-autonomous manner.	MASSACHUSETTS GEN HOSP,SERV PEDIAT,LAB DEV CHRONOBIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114; CORNELL UNIV,DEPT THEORET & APPL MECH,CTR APPL MATH,ITHACA,NY 14853	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Cornell University			Strogatz, Steven H/A-1641-2014	Strogatz, Steven H/0000-0003-2923-3118; Weaver, David/0000-0001-7941-6719				CARD JP, 1984, NEUROSCIENCE, V13, P415, DOI 10.1016/0306-4522(84)90240-9; DAVIES IR, 1994, NEUROREPORT, V5, P2165, DOI 10.1097/00001756-199410270-00044; DAVIS FC, 1983, AM J PHYSIOL, V244, pR93, DOI 10.1152/ajpregu.1983.244.1.R93; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; ERMENTROUT GB, 1984, SIAM J MATH ANAL, V15, P215, DOI 10.1137/0515019; ERMENTROUT GB, 1991, J MATH BIOL, V29, P195, DOI 10.1007/BF00160535; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; MASON R, 1991, BRAIN RES, V552, P53, DOI 10.1016/0006-8993(91)90659-J; MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2; OKAMURA H, 1989, NEUROSCI LETT, V102, P131, DOI 10.1016/0304-3940(89)90067-0; PINE J, 1980, J NEUROSCI METH, V2, P19, DOI 10.1016/0165-0270(80)90042-4; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REGEHR WG, 1989, J NEUROSCI METH, V30, P91, DOI 10.1016/0165-0270(89)90055-1; Reppert SM, 1997, CELL, V89, P487, DOI 10.1016/S0092-8674(00)80229-9; REPPERT SM, 1986, J NEUROSCI, V6, P2724; SMITH RD, 1989, J COMP PHYSIOL A, V164, P805, DOI 10.1007/BF00616752; STROGAIZ SH, 1994, NONLINEAR DYNAMICS C; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; TOMINAGA K, 1994, NEUROSCI LETT, V166, P81, DOI 10.1016/0304-3940(94)90845-1; VANDENPOL AN, 1986, NEUROSCIENCE, V17, P643, DOI 10.1016/0306-4522(86)90037-0; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Wagner S, 1997, NATURE, V387, P598, DOI 10.1038/42468; Welsh DK, 1996, BRAIN RES, V706, P30, DOI 10.1016/0006-8993(95)01172-2; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; WELSH DK, 1995, THESIS HARVARD U CAM; WINTREE AT, 1967, J THEOR BIOL, V16, P15; Worden, 1974, NEUROSCIENCES 3RD ST, P437	32	385	390	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					855	860		10.1016/S0092-8674(00)80473-0	http://dx.doi.org/10.1016/S0092-8674(00)80473-0			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413994	hybrid			2022-12-28	WOS:A1997YL43900016
J	Whitehead, R				Whitehead, R			Recommendations on folate intake	LANCET			English	Editorial Material											Whitehead, R (corresponding author), MRC,DUNN CLIN NUTR CTR,CAMBRIDGE CB4 1X5,ENGLAND.							[Anonymous], 1992, FOL AC PREV NEUR TUB, P1; BATES CJ, 1982, HUM NUTR-APPL NUTR, V36, P422; *DEP HLTH, 1991, 41 DEP HLTH HM STAT, P109; *FAO UN, 1988, REQ VIT A IR FOL VIT, P51; Guttormsen AB, 1996, J CLIN INVEST, V98, P2174, DOI 10.1172/JCI119024; Molloy AM, 1997, LANCET, V349, P1591, DOI 10.1016/S0140-6736(96)12049-3; *MRC VIT STUD RES, 1991, LANCET, V338, P131; *SUBC 10 ED RDAS F, 1989, REC DIET ALL, P150; *US FDA, 1996, FED REGISTER, V61, P8781; Wild J, 1997, LANCET, V350, P30, DOI 10.1016/S0140-6736(05)66239-3	10	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1642	1643		10.1016/S0140-6736(97)22049-0	http://dx.doi.org/10.1016/S0140-6736(97)22049-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400502				2022-12-28	WOS:A1997YK21100002
J	Siegel, D; Lopez, J				Siegel, D; Lopez, J			Trends in antihypertensive drug use in the United States - Do the JNC V recommendations affect prescribing?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; HYPERTENSION; THERAPY; TRIALS; MEN	Context.-The choice of pharmacological treatment for the approximately 50 million people in the United States with hypertension has important therapeutic and financial implications. Objectives.-To describe national antihypertensive medication prescribing patterns for 1992 and 1995; to explore the influence of the Fifth Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC V), published in 1993, which recommended diuretics and beta-blockers as first-line antihypertensive therapy unless contraindicated; and to estimate the impact of these prescribing patterns on the cost of antihypertensive treatment. Design.-All prescriptions for drugs approved for the treatment of hypertension dispensed by 35 000 retail pharmacies were tabulated for 1992 and 1995 (62% of all US retail pharmacies were surveyed). Main Outcome Measures.-Number of prescriptions for each dosage form of medication and national cost estimates based on wholesale costs of medications dispensed. Results.-In 1992, of the 10 most frequently prescribed antihypertensive drugs, 3 were calcium antagonists, 3 were angiotensin-converting enzyme (ACE) inhibitors, 3 were beta-blockers, and 1 was the combination of triamterene and hydrochlorothiazide. In 1995, 4 were calcium antagonists, 3 were ACE inhibitors, 1 was a beta-blocker, 1 was the combination of triamterene and hydrochlorothiazide, and 1 an alpha-blocker, In 1992, calcium antagonists accounted for 33% of antihypertensive prescriptions compared with 38% in 1995, ACE inhibitor use went from 25% to 33%, beta-blocker use from 18% to 11%, and diuretic use from 16% to 8%, The estimated wholesale costs for calcium antagonists in 1995 dollars increased from $2.67 billion in 1992 to $2.86 billion in 1995; ACE inhibitor costs increased from $1.37 billion to $1.67 billion; costs for diuretics declined from $353 million to $168 million; and costs for beta-blockers declined from $763 million to $433 million. Conclusions.-From 1992 to 1995 use of calcium antagonists and ACE inhibitors for treatment of hypertension increased and diuretics and beta-blockers declined, suggesting that the recommendations from JNC V had little effect on prescribing patterns, The cost implications of these practice patterns are enormous.	DEPT VET AFFAIRS, NO CALIF HLTH CARE SYST, SERV PHARM, MARTINEZ, CA 94553 USA; UNIV CALIF DAVIS, DEPT MED, DAVIS, CA USA	University of California System; University of California Davis	Siegel, D (corresponding author), DEPT VET AFFAIRS, NO CALIF HLTH CARE SYST, MED SERV 111, 150 MUIR RD, MARTINEZ, CA 94553 USA.							[Anonymous], 1988, ARCH INTERN MED, V148, P1023; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; COLLINS JG, 1993, VITAL HLTH STAT 10, V182, P1; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Conti C R, 1996, Am J Cardiol, V78, P13, DOI 10.1016/S0002-9149(96)00733-3; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P1577, DOI 10.1001/jama.275.20.1577; Lenfant C, 1996, JAMA-J AM MED ASSOC, V275, P1604, DOI 10.1001/jama.275.20.1604; MANOLIO TA, 1995, ARCH INTERN MED, V155, P829, DOI 10.1001/archinte.155.8.829; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; PSATY BM, 1995, JAMA-J AM MED ASSOC, V273, P1436, DOI 10.1001/jama.273.18.1436; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; RAMSPACHER S, 1996, HOSP HARM, V31, P624; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; SIEGEL D, 1992, JAMA-J AM MED ASSOC, V267, P1083, DOI 10.1001/jama.267.8.1083; SIMONSEN LLP, 1993, PHARM TIMES, V59, P29; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; Soumerai SB, 1988, AUST J HOSP PHARM S, V18, P9; *US DHHS, 1994, HEART FAIL MAN PAT L; WEBER MA, 1993, ARCH INTERN MED, V153, P149, DOI 10.1001/archinte.153.2.149; WILKES MS, 1992, ANN INTERN MED, V116, P912, DOI 10.7326/0003-4819-116-11-912; 1996, PHARM TIMES, V62, P27; 1995, 1995 DRUG TOPICS RED; 1993, AM DRUG, V207, P49; 1996, AM DRUG, V212, P18	28	165	169	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1745	1748		10.1001/jama.278.21.1745	http://dx.doi.org/10.1001/jama.278.21.1745			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388150				2022-12-28	WOS:A1997YH98700028
J	Chaturvedi, N; Rai, H; BenShlomo, Y				Chaturvedi, N; Rai, H; BenShlomo, Y			Lay diagnosis and health-care-seeking behaviour for chest pain in south Asians and Europeans	LANCET			English	Article							MYOCARDIAL-INFARCTION; GENERAL-PRACTITIONERS; EAST LONDON; CORONARY; CONSULTATIONS; THROMBOLYSIS; COMMUNITY; RESIDENTS; SERVICES; DISEASE	Background South Asian people in the UK experience greater delays than Europeans in obtaining appropriate specialist management for heart disease, but the causes are not known. We investigated whether south Asians and Europeans interpret and act upon anginal symptoms differently. Methods We randomly selected 2000 people from general practitioners' (family physicians) lists in London, UK, to receive a questionnaire that included a short fictional case history of an individual with possible anginal pain and asked how respondents would react to experiencing it. A second questionnaire seeking information on medical history, attitudes to health, and demography was sent later. The main outcome measure was the proportion who said they would seek immediate care (hospital emergency department or general practitioner) for the pain described in the case scenario. Findings The rate of response to both questionnaires was 60.2% (903 of 1500 who received both). 553 responders were of European origin, 124 were Hindu, and 235 were Sikh. There were no differences between the ethnic groups in the proportion identifying the pain as cardiac, but south Asians would be more anxious about the pain than would Europeans. Of the men, 55 (23%) Europeans, 20 (38%) Hindus, and 52 (47%) Sikhs said they would seek immediate care (p<0.0001 for heterogeneity); of women, 77 (24%), 25 (35%), and 58 (46%), respectively, would seek immediate care (p<0.0001). After adjustment for confounding variables the odds ratio for seeking immediate care in Hindus compared with Europeans was 2.67 (95% CI 1.49-4.73) and that for Sikhs compared with Europeans was 3.18 (1.98-5.12). Interpretation Hindus and Sikhs reported a greater likelihood of seeking immediate care for anginal symptoms than Europeans; this finding indicates that barriers to cardiology services for south Asians are unrelated to difficulties in interpretations of symptoms or willingness to seek care. Improvement of awareness of heart disease may not decrease delays in obtaining care. Service-related explanations must be explored, such as general practitioners' difficulties in arriving at a diagnosis or differences in management because of ethnic origin.	UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND; UCL, DEPT EPIDEMIOL & PUBL HLTH, LONDON, ENGLAND	University of Bristol; University of London; University College London			Ben-Shlomo, Yoav/ABD-2004-2021; G, G/A-3459-2012	Ben-Shlomo, Yoav/0000-0001-6648-3007; 				AHMAD WIU, 1991, FAM PRACT, V8, P52, DOI 10.1093/fampra/8.1.52; Badger F, 1989, Health Trends, V21, P31; DHAWAN J, 1994, POSTGRAD MED J, V70, P625, DOI 10.1136/pgmj.70.827.625; DONOVAN JL, 1986, WE DONT BUY SICKNESS; DRACUP K, 1995, SOC SCI MED, V40, P379, DOI 10.1016/0277-9536(94)00278-2; FINCH J, 1987, SOCIOLOGY, V21, P105, DOI 10.1177/0038038587021001008; Furnham A, 1994, Int J Soc Psychiatry, V40, P106, DOI 10.1177/002076409404000203; GILLAM SJ, 1989, BRIT MED J, V299, P953, DOI 10.1136/bmj.299.6705.953; GILLAM SJ, 1987, J ROY COLL GEN PRACT, V37, P205; HAWTHORNE K, 1994, FAM PRACT, V11, P453, DOI 10.1093/fampra/11.4.453; *HLTH ED AUTH, 1994, CLACK MIN ETHN GROUP; JOHNSON MRD, 1983, POSTGRAD MED J, V59, P664, DOI 10.1136/pgmj.59.696.664; LEAR JT, 1994, J ROY SOC MED, V87, P661; LEAR JT, 1994, J ROY COLL PHYS LOND, V28, P143; LEITCH JW, 1989, MED J AUSTRALIA, V150, P6, DOI 10.5694/j.1326-5377.1989.tb136310.x; MALCOLM PN, 1995, BRIT MED J, V310, P910, DOI 10.1136/bmj.310.6984.910; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MURRAY J, 1986, SOC PSYCH PSYCH EPID, V21, P139, DOI 10.1007/BF00582684; *OFF POP CENS SURV, 1993, CENS COUNTR REP IN 1, V1; Office of Population Censuses and Surveys, 1980, CLASS OCC; PEDOE HT, 1975, LANCET, V2, P833, DOI 10.1016/S0140-6736(75)90233-0; RASHID A, 1992, BRIT J GEN PRACT, V42, P197; SCHMIDT SB, 1990, AM J CARDIOL, V65, P1411, DOI 10.1016/0002-9149(90)91345-7; SCHROEDER JS, 1978, AM J MED, V64, P742, DOI 10.1016/0002-9343(78)90512-0; Shaukat N, 1997, BRIT MED J, V314, P639, DOI 10.1136/bmj.314.7081.639; SHAUKAT N, 1993, BRIT MED J, V307, P717, DOI 10.1136/bmj.307.6906.717; SMAJE C, 1995, HLTH RACE ETHNICITY; Watson E, 1984, Community Med, V6, P127; WEST P, 1982, REPROD NATURALLY OCC, P1; Wild S, 1997, BRIT MED J, V314, P705, DOI 10.1136/bmj.314.7082.705; WILSON M, 1994, PSYCHOL MED, V24, P113, DOI 10.1017/S003329170002688X; WRIGHT CM, 1983, J ROY COLL GEN PRACT, V33, P101	33	60	60	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1578	1583		10.1016/S0140-6736(97)06243-0	http://dx.doi.org/10.1016/S0140-6736(97)06243-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YH986	9393336				2022-12-28	WOS:A1997YH98600008
J	Kondo, M; Weissman, IL; Akashi, K				Kondo, M; Weissman, IL; Akashi, K			Identification of clonogenic common lymphoid progenitors in mouse bone marrow	CELL			English	Article							HEMATOPOIETIC STEM-CELLS; RECEPTOR-GAMMA-CHAIN; B-CELL; C-KIT; INTERLEUKIN-7 RECEPTOR; T-CELLS; TRANSCRIPTIONAL CONTROL; MURINE INTERLEUKIN-7; DENDRITIC CELLS; PRECURSOR CELLS	The existence of a common lymphoid progenitor that can only give rise to T cells, B cells, and natural killer (NK) cells remains controversial and constitutes an important gap in the hematopoietic lineage maps. Here, we report that the Lin(-)IL-7R(+)Thy-1(-)Sca-1(lo)c-Kit(lo) population from adult mouse bone marrow possessed a rapid lymphoid-restricted (T, B, and NK) reconstitution capacity in vivo but completely lacked myeloid differentiation potential either in vivo or in vitro. A single Lin(-)IL-7R(+)Thy-1(-)Sca-1(lo)c-Kit(lo) cell could generate at least both T and B cells. These data provide direct evidence for the existence of common lymphoid progenitors in sites of early hematopoiesis.	STANFORD UNIV,SCH MED,DEPT PATHOL,DEPT DEV BIOL,STANFORD,CA 94305	Stanford University					NCI NIH HHS [CA42551] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042551] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 1996, IMMUNITY, V5, P147, DOI 10.1016/S1074-7613(00)80491-4; AKASHI K, 1991, J CELL PHYSIOL, V148, P446, DOI 10.1002/jcp.1041480317; AKASHI K, 1993, LEUKEMIA RES, V17, P549, DOI 10.1016/0145-2126(93)90083-W; Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; ANTICA M, 1994, BLOOD, V84, P111; ANTIN JH, 1992, BLOOD, V80, P2964; ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Carlyle JR, 1997, J EXP MED, V186, P173, DOI 10.1084/jem.186.2.173; Clevers HC, 1996, IMMUNOL TODAY, V17, P336, DOI 10.1016/0167-5699(96)10019-0; COLLINS LS, 1987, J IMMUNOL, V138, P1082; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; FISCHER A, 1992, Immunodeficiency Reviews, V3, P83; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GODFREY DI, 1992, J IMMUNOL, V149, P2281; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARRISON DE, 1992, P NATL ACAD SCI USA, V89, P10134, DOI 10.1073/pnas.89.21.10134; HIRAYAMA F, 1995, BLOOD, V86, P4527, DOI 10.1182/blood.V86.12.4527.bloodjournal86124527; HIRAYAMA F, 1992, P NATL ACAD SCI USA, V89, P5907, DOI 10.1073/pnas.89.13.5907; IKUTA K, 1991, INT J CELL CLONING, V9, P451; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Kawamoto H, 1997, INT IMMUNOL, V9, P1011, DOI 10.1093/intimm/9.7.1011; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; Kondo M, 1997, IMMUNITY, V7, P155, DOI 10.1016/S1074-7613(00)80518-X; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; LI CL, 1992, J EXP MED, V175, P1443, DOI 10.1084/jem.175.6.1443; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Markert M L, 1994, Immunodeficiency, V5, P141; MATSUZAKI Y, 1993, J EXP MED, V178, P1283, DOI 10.1084/jem.178.4.1283; McKinstry WJ, 1997, BLOOD, V89, P65, DOI 10.1182/blood.V89.1.65.65_65_71; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; MIRRO J, 1986, BLOOD, V67, P689; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1995, ANNU REV CELL DEV BI, V11, P35, DOI 10.1146/annurev.cb.11.110195.000343; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; MULDER AH, 1987, EXP HEMATOL, V15, P99; MULLERSIEBURG CE, 1986, CELL, V44, P653, DOI 10.1016/0092-8674(86)90274-6; NAKAHATA T, 1982, J CELL PHYSIOL, V113, P455, DOI 10.1002/jcp.1041130314; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; OKADA S, 1991, BLOOD, V78, P1706; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; SMITH LG, 1991, P NATL ACAD SCI USA, V88, P2728; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SPANGRUDE GJ, 1990, J IMMUNOL, V145, P3661; SUDA J, 1984, BLOOD, V64, P393; SUDA T, 1989, BLOOD, V74, P1936; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; THOMAS ED, 1991, BLOOD CELLS, V17, P259; UCHIDA N, 1992, J EXP MED, V175, P175, DOI 10.1084/jem.175.1.175; VISSER JWM, 1990, EXP HEMATOL, V18, P248; vonFreedenJeffry U, 1997, IMMUNITY, V7, P147, DOI 10.1016/S1074-7613(00)80517-8; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WEISSMAN IL, 1994, IMMUNITY, V1, P529, DOI 10.1016/1074-7613(94)90042-6; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0	70	1584	1620	3	56	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					661	672		10.1016/S0092-8674(00)80453-5	http://dx.doi.org/10.1016/S0092-8674(00)80453-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393859	Bronze			2022-12-28	WOS:A1997YH96000013
J	McLeish, T				McLeish, T			Polymer science - Fashioning flow by self-assembly	SCIENCE			English	Editorial Material											McLeish, T (corresponding author), UNIV LEEDS,DEPT PHYS & ASTRON,RES CTR POLYMER SCI & TECHNOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.			McLeish, Tom/0000-0002-2025-0299				Aggeli A, 1997, NATURE, V386, P259, DOI 10.1038/386259a0; CATES ME, 1990, J PHYS-CONDENS MAT, V2, P6869, DOI 10.1088/0953-8984/2/33/001; Doi M., 1988, THEORY POLYM DYNAMIC; Lequeux F., 1997, THEORETICAL CHALLENG; MCLEISH T, 1995, PHYS WORLD, V8, P32; Sijbesma RP, 1997, SCIENCE, V278, P1601, DOI 10.1126/science.278.5343.1601	6	5	5	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1577	1578		10.1126/science.278.5343.1577	http://dx.doi.org/10.1126/science.278.5343.1577			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9411780				2022-12-28	WOS:A1997YJ87400026
J	Slusarski, DC; Corces, VG; Moon, RT				Slusarski, DC; Corces, VG; Moon, RT			Interaction of Wnt and a frizzled homologue triggers G-protein-linked phosphatidylinositol signalling	NATURE			English	Article							SIGNALING PATHWAY; RECEPTOR; PHOSPHOLIPASE-A2	In Drosophila, members of the frizzled family of tissue-polarity genes encode proteins that are likely to function as cell-surface receptors of the type known as Wnt receptors, and to initiate signal transduction across the cell membrane(1,2), although how they do this is unclear. We show here that the rat protein Frizzled-2 causes an increase in the release of intracellular calcium which is enhanced by Xwnt-5a, a member of the Wnt family. This release of intracellular calcium is suppressed by an inhibitor of the enzyme inositol monophosphatase and hence of the phosphatidylinositol signalling pathway; this suppression can be rescued by injection of the compound myo-inositol, which overcomes the decrease in this intermediate caused by the inhibitor. Agents that inhibit specific G-protein subunits, pertussis toxin, GDP-beta-S and alpha-transducin also inhibit the calcium release triggered by Xwnt-5a and rat Frizzled-2. Our results indicate that some Wnt proteins work through specific Frizzled homologues to stimulate the phosphatidylinositol signalling pathway via heterotrimeric G-protein subunits.	UNIV WASHINGTON, SCH MED, HOWARD HUGHES MED INST, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT PHARMACOL, SEATTLE, WA 98195 USA; JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Johns Hopkins University			Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; Corces, Victor/0000-0001-5140-4337; Slusarski, Diane/0000-0003-3793-8636				ATACK JR, 1993, J NEUROCHEM, V60, P652, DOI 10.1111/j.1471-4159.1993.tb03197.x; Ault KT, 1996, DEVELOPMENT, V122, P2033; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; LEREA CL, 1989, NEURON, V3, P367, DOI 10.1016/0896-6273(89)90261-4; REINHARD E, 1995, DEV BIOL, V170, P50, DOI 10.1006/dbio.1995.1194; SILK ST, 1989, J BIOL CHEM, V264, P21466; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Wang YS, 1996, J BIOL CHEM, V271, P4468; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1	17	526	537	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 27	1997	390	6658					410	413		10.1038/37138	http://dx.doi.org/10.1038/37138			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389482				2022-12-28	WOS:A1997YH54900066
J	Kaletta, T; Schnabel, H; Schnabel, R				Kaletta, T; Schnabel, H; Schnabel, R			Binary specification of the embryonic lineage in Caenorhabditis elegans	NATURE			English	Article							C-ELEGANS; CELLULAR INTERACTIONS; POLARITY; PROTEIN; PATTERN; LOCUS; GLP-1; AXES	In Caenorhabditis elegans, the early embryo contains five somatic founder cells (known as AB, MS, E, C and D) which give rise to very different lineages, Two simply produce twenty intestinal (E) or muscle (D) cells each, whereas the remainder produce a total of 518 cells which collectively contribute in a complex pattern to a variety of tissues(1). A central problem in embryonic development is to understand how the developmental potential of blastomeres is restricted to permit the terminal expression of such complex differentiation patterns, Here we identify a gene, lit-1, that appears to play a central role in controlling the asymmetry of cell division during embryogenesis in C. elegans. Mutants in lit-1 suggest that its product controls up to six consecutive binary snitches which cause one of the two equivalent cells produced at each cleavage to assume a posterior fate. Most blastomere identities in C, elegans may therefore stem from a process of stepwise binary diversification.	MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Kaletta, Titus/F-5361-2012					Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; GOLDSTEIN B, 1995, J CELL BIOL, V129, P1071, DOI 10.1083/jcb.129.4.1071; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; Hodgkin J, 1997, GENETICS, V146, P149; Hunter CP, 1996, CELL, V87, P217, DOI 10.1016/S0092-8674(00)81340-9; HUTTER H, 1995, DEVELOPMENT, V121, P1559; HUTTER H, 1994, DEVELOPMENT, V120, P2051; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Lin HF, 1997, TRENDS GENET, V13, P33, DOI 10.1016/S0168-9525(96)10050-0; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; RIDDLE DL, 1997, MONOGRAPH COLD SPRIN, V33; RiveraPomar R, 1996, TRENDS GENET, V12, P478, DOI 10.1016/0168-9525(96)10044-5; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; Schnabel R, 1997, DEV BIOL, V184, P234, DOI 10.1006/dbio.1997.8509; SCHNABEL R, 1990, DEVELOPMENT, V108, P107; Schnabel R, 1996, BIOESSAYS, V18, P591, DOI 10.1002/bies.950180711; STJOHNSTON D, 1992, CELL, V68, P201; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Wood WB, 1988, NEMATODE CAENORHABDI	24	134	139	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					294	298		10.1038/36869	http://dx.doi.org/10.1038/36869			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384382				2022-12-28	WOS:A1997YG66700065
J	Moritz, S; Bates, T; Henderson, SM; Humphreys, S; Michell, MJ				Moritz, S; Bates, T; Henderson, SM; Humphreys, S; Michell, MJ			Variation in management of small invasive breast cancers detected on screening in the former South East Thames region: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIAL; SURVIVAL; RADIOTHERAPY; IRRADIATION; LUMPECTOMY; SURGERY; WOMEN	Objective: To examine the variation in surgical and adjuvant treatment of breast cancer of known histology and detected on screening in a large cohort of patients treated by the surgeons of a health region, Design: Part prospective, part retrospective observational study; using the databases of a region's breast screening programme and of the cancer registry. Setting: The former South East Thames redon. Subjects: 600 women aged 49-79 who presented during 1991-2 with invasive breast cancer up to 20 mm in diameter that had been detected on screening. These patients were treated by 35 surgeons. Main outcome measures: Mastectomy rate by surgeon and the use of adjuvant treatment (radiotherapy, tamoxifen, and chemotherapy) were compared with risk factors, tumour grade, resection margins, and axillary node status. Results: The mastectomy rate varied between nil and 80%, although the numbers at these extremes were small (0/13 v 8/10). Surgeons operating on more than 20 such cases had a lower mastectomy rate (15%) than surgeons treating fewer cases (23%), but this difference was confounded by variation in casemix. There were also wide variations in mastectomy rates and in axillary sampling rates that were independent of casemix or caseload. There was broad agreement on the use of adjuvant tamoxifen (94%), but few patients received chemotherapy (2.5%). 78 patients (19%) did not receive radiotherapy, including 51 out of 317 patients with unfavourable tumours, and 26 patients did not receive tamoxifen. Whether the patient received adjuvant treatment was more dependent on referral by the surgeon than the risk factors for local recurrence and was independent of caseload. Conclusion: Mastectomy rates for similar rumours vary widely by surgeon independently of casemix or caseload, but surgeons with a higher caseload tend to have a lower mastectomy rate. Omission of postoperative radiotherapy or tamoxifen after conservative treatment is not related to risk factors for local recurrence or caseload, Confidential feedback of treatment profiles to individual surgeons has been used, but when benefit has been established treatment should be guided by evidence based protocol.	WILLIAM HARVEY HOSP, ASHFORD TN24 OLZ, KENT, ENGLAND; UNIV LONDON KINGS COLL HOSP, S THAMES E BREAST SCREENING QUAL ASSURANCE REFERE, LONDON SE5 9RS, ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London			Bates, Tom/AAB-1893-2021	Bates, Tom/0000-0001-5554-1945				ABE O, 1992, LANCET, V339, P71; ABE O, 1995, NEW ENGL J MED, V333, P1444; [Anonymous], 1992, Lancet, V339, P1; ANSELL D, 1993, CANCER, V72, P2974, DOI 10.1002/1097-0142(19931115)72:10<2974::AID-CNCR2820721019>3.0.CO;2-M; Ayanian JZ, 1996, BREAST CANCER RES TR, V40, P65, DOI 10.1007/BF01806003; BAAK JPA, 1992, HUM PATHOL, V23, P989, DOI 10.1016/0046-8177(92)90259-6; BASNETT I, 1992, EUR J CANCER, V28A, P1945, DOI 10.1016/0959-8049(92)90233-R; Baum M, 1996, BRIT MED J, V312, P1155; BELL J, 1994, BRIT MED J, V308, P1508, DOI 10.1136/bmj.308.6942.1508a; Berrino F, 1995, IARC SCI PUBLICATION, V132; BLAMEY RW, 1994, BRIT MED J, V309, P1076, DOI 10.1136/bmj.309.6961.1076; *BRIT ASS SURG ONC, 1992, BASO 2 TRIAL PROT RA; CAMPBELL I, 1993, ANN ROY COLL SURG, V75, P13; CHOUILLET AM, 1994, BRIT MED J, V308, P168, DOI 10.1136/bmj.308.6922.168; CLARK RM, 1992, JNCI-J NATL CANCER I, V84, P683, DOI 10.1093/jnci/84.9.683; *DEP HLTH, 1995, POP HLTH OUTC IND 19; *DEP HLTH, 1994, POL FRAM WORK COMM C; Dixon JM, 1996, BRIT J SURG, V83, P997, DOI 10.1002/bjs.1800830737; DIXON JM, 1995, BRIT MED J, V311, P1515, DOI 10.1136/bmj.311.7019.1515; FENTIMAN IS, 1991, LANCET, V337, P221, DOI 10.1016/0140-6736(91)92172-X; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; GELBER RD, 1994, J NATL CANCER I, V86, P652, DOI 10.1093/jnci/86.9.652; Gillis CR, 1996, BRIT MED J, V312, P145, DOI 10.1136/bmj.312.7024.145; Harries SA, 1997, BREAST, V6, P21, DOI 10.1016/S0960-9776(97)90538-5; ISCOE NA, 1994, CAN MED ASSOC J, V150, P345; LILJEGREN G, 1994, JNCI-J NATL CANCER I, V86, P717, DOI 10.1093/jnci/86.9.717; MCCARTHY M, 1991, EUR J CANCER, V27, P579, DOI 10.1016/0277-5379(91)90222-Y; MORRIS J, 1992, BRIT J SURG, V79, P1312, DOI 10.1002/bjs.1800791223; Moss S M, 1994, J Med Screen, V1, P193; *NAT COORD GROUP S, 1996, NHS BSP PUBL, V20; NATTINGER AB, 1992, NEW ENGL J MED, V326, P1102, DOI 10.1056/NEJM199204233261702; Richards MA, 1996, BRIT J CANCER, V73, P751, DOI 10.1038/bjc.1996.131; SACKS NPM, 1992, BREAST, V1, P41; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; Schnitt SJ, 1996, CANCER, V77, P1094, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1094::AID-CNCR14>3.3.CO;2-J; VANDONGEN JA, 1992, EUR J CANCER, V28A, P801, DOI 10.1016/0959-8049(92)90118-L; VERONESI U, 1990, EUR J CANCER, V26, P668, DOI 10.1016/0277-5379(90)90113-8; YARNOLD JR, 1994, BRIT MED J, V308, P714, DOI 10.1136/bmj.308.6930.714a	38	24	24	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 15	1997	315	7118					1266	1272		10.1136/bmj.315.7118.1266	http://dx.doi.org/10.1136/bmj.315.7118.1266			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390053	Green Published			2022-12-28	WOS:A1997YG64500019
J	Rose, A				Rose, A			From the green city	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									CAMINO MED GRP, LOS ALTOS, CA USA	Palo Alto Medical Foundation Research Institute									0	0	0	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					921	921		10.7326/0003-4819-127-10-199711150-00012	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382372				2022-12-28	WOS:A1997YF54500010
J	Furukawa, T; Morrow, EM; Cepko, CL				Furukawa, T; Morrow, EM; Cepko, CL			Crx, a novel otx-like homeobox gene, shows photoreceptor-specific expression and regulates photoreceptor differentiation	CELL			English	Article							RAT OPSIN GENE; TISSUE-SPECIFIC EXPRESSION; TRANSCRIPTION FACTOR GENE; NUCLEAR-PROTEIN BINDING; CIS-ACTING ELEMENT; MOLECULAR-GENETICS; NERVOUS-SYSTEM; CELL-DEVELOPMENT; UPSTREAM REGION; RHODOPSIN GENE	We have isolated a novel otx-like homeobox gene, Crx, from the mouse retina. Crx expression is restricted to developing and mature photoreceptor cells. CRX bound and transactivated the sequence TAATCC/A, which is found upstream of several photoreceptor-specific genes, including the opsin genes from many species. Overexpression of Crx using a retroviral vector increased the frequency of clones containing exclusively rod photoreceptors and reduced the frequency of clones containing amacrine interneurons and Muller glial cells. In addition, presumptive photoreceptor cells expressing a dominant-negative form of CRX failed to form proper photoreceptor outer segments and terminals. Crx is a novel photoreceptor-specific transcription factor and plays a crucial role in the differentiation of photoreceptor cells.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute			Morrow, Eric/J-2767-2013	Morrow, Eric/0000-0003-3430-3520	NATIONAL EYE INSTITUTE [R01EY008064] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY0 8064] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHMAD I, 1990, BIOCHEM BIOPH RES CO, V173, P463, DOI 10.1016/S0006-291X(05)81081-2; Ahmad I, 1995, DEV BRAIN RES, V90, P184, DOI 10.1016/0165-3806(96)83500-0; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BALLYCUIF L, 1995, MECH DEVELOP, V49, P49, DOI 10.1016/0925-4773(94)00301-3; BLITZ IL, 1995, DEVELOPMENT, V121, P993; BOBOLA N, 1995, J BIOL CHEM, V270, P1289, DOI 10.1074/jbc.270.3.1289; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CEPKO CL, 1997, CURRENT PROTOCOLS MO; Chen SM, 1996, J BIOL CHEM, V271, P28549, DOI 10.1074/jbc.271.45.28549; CHIU MI, 1994, J NEUROSCI, V14, P3426; Chou WH, 1996, NEURON, V17, P1101, DOI 10.1016/S0896-6273(00)80243-3; Conlon FL, 1996, DEVELOPMENT, V122, P2427; Dowling J. E., 1987, RETINA APPROACHABLE; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; FIELDSBERRY SC, 1992, P NATL ACAD SCI USA, V89, P693, DOI 10.1073/pnas.89.2.693; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Furukawa T, 1997, P NATL ACAD SCI USA, V94, P3088, DOI 10.1073/pnas.94.7.3088; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HICKS D, 1987, J HISTOCHEM CYTOCHEM, V35, P1317, DOI 10.1177/35.11.3655327; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; JIN YS, 1994, NATURE, V372, P780, DOI 10.1038/372780a0; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; LAVAIL MM, 1987, INVEST OPHTH VIS SCI, V28, P1043; LI YB, 1994, MECH DEVELOP, V48, P229, DOI 10.1016/0925-4773(94)90062-0; LIOU GI, 1991, BIOCHEM BIOPH RES CO, V181, P159, DOI 10.1016/S0006-291X(05)81395-6; LIOU GI, 1994, DEV BIOL, V161, P345, DOI 10.1006/dbio.1994.1036; Liu Q, 1996, ONCOGENE, V12, P207; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; MORI H, 1994, MOL BRAIN RES, V27, P221, DOI 10.1016/0169-328X(94)90004-3; NATHANS J, 1989, SCIENCE, V245, P831, DOI 10.1126/science.2788922; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NI M, 1992, CURR EYE RES, V11, P219, DOI 10.3109/02713689209001773; NIR I, 1984, J CELL BIOL, V98, P1788, DOI 10.1083/jcb.98.5.1788; PANNESE M, 1995, DEVELOPMENT, V121, P707; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; Saha MS, 1992, CURR OPIN GENET DEV, V2, P582, DOI 10.1016/S0959-437X(05)80176-5; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; STEPANIK PL, 1993, EXP EYE RES, V57, P189, DOI 10.1006/exer.1993.1114; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; TAKAO M, 1988, VISION RES, V28, P471, DOI 10.1016/0042-6989(88)90169-1; TREISMAN J, 1989, CELL, V59, P553; TUMER DL, 1987, NATURE, V328, P131; Vandendries ER, 1996, DEV BIOL, V173, P243, DOI 10.1006/dbio.1996.0020; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; YANG XJ, 1993, J NEUROSCI, V13, P3006; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; YU X, 1994, J MOL NEUROSCI, V5, P259, DOI 10.1007/BF02736726; YU X, 1993, BIOCHEM BIOPH RES CO, V191, P76, DOI 10.1006/bbrc.1993.1186; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	60	693	710	5	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					531	541		10.1016/S0092-8674(00)80439-0	http://dx.doi.org/10.1016/S0092-8674(00)80439-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390562	Bronze			2022-12-28	WOS:A1997YG49200014
J	Ivics, Z; Hackett, PB; Plasterk, RH; Izsvak, Z				Ivics, Z; Hackett, PB; Plasterk, RH; Izsvak, Z			Molecular reconstruction of Sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells	CELL			English	Article							P-ELEMENT; CAENORHABDITIS-ELEGANS; GENE-TRANSFER; MUTAGENESIS; DROSOPHILA; ZEBRAFISH; SUPERFAMILY; SEQUENCES; GENOME; TC3	Members of the Tc1/mariner superfamily of transposons isolated from fish appear to be transpositionally inactive due to the accumulation of mutations. Molecular phylogenetic data were used to construct a synthetic transposon, Sleeping Beauty, which could be identical or equivalent to an ancient element that dispersed in fish genomes in part by horizontal transmission between species. A consensus sequence of a transposase gene of the salmonid subfamily of elements was engineered by eliminating the inactivating mutations. Sleeping Beauty transposase binds to the inverted repeats of salmonid transposons in a substrate-specific manner, and it mediates precise cut-and-paste transposition in fish as well as in mouse and human cells. Sleeping Beauty is an active DNA-transposon system from vertebrates for genetic transformation and insertional mutagenesis.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108; UNIV MINNESOTA,INST HUMAN GENET,ST PAUL,MN 55108; NETHERLANDS CANC INST,DIV MOL BIOL,NL-1066 CX AMSTERDAM,NETHERLANDS; HUNGARIAN ACAD SCI,BIOL RES CTR,INST BIOCHEM,H-6701 SZEGED,HUNGARY	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Netherlands Cancer Institute; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center			Wilson, Matthew H/K-3193-2013		NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006625] Funding Source: NIH RePORTER; NCRR NIH HHS [R01-RR06625] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADEY NB, 1994, P NATL ACAD SCI USA, V91, P1569, DOI 10.1073/pnas.91.4.1569; Beall EL, 1997, GENE DEV, V11, P2137, DOI 10.1101/gad.11.16.2137; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; COLLOMS SD, 1994, NUCLEIC ACIDS RES, V22, P5548, DOI 10.1093/nar/22.25.5548; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; DEVON RS, 1995, NUCLEIC ACIDS RES, V23, P1644, DOI 10.1093/nar/23.9.1644; DOAK TG, 1994, P NATL ACAD SCI USA, V91, P942, DOI 10.1073/pnas.91.3.942; Gibbs P. D. L., 1994, Molecular Marine Biology and Biotechnology, V3, P317; GIERL A, 1988, EMBO J, V7, P4045, DOI 10.1002/j.1460-2075.1988.tb03298.x; Gonzales AE, 1996, VET MICROBIOL, V48, P283, DOI 10.1016/0378-1135(95)00143-3; GOODIER JL, 1994, J MOL BIOL, V241, P26, DOI 10.1006/jmbi.1994.1470; Gueiros FJ, 1997, SCIENCE, V276, P1716, DOI 10.1126/science.276.5319.1716; HANDLER AM, 1993, ARCH INSECT BIOCHEM, V22, P373, DOI 10.1002/arch.940220306; Hartl DL, 1997, TRENDS GENET, V13, P197, DOI 10.1016/S0168-9525(97)01087-1; Ivics Z, 1996, P NATL ACAD SCI USA, V93, P5008, DOI 10.1073/pnas.93.10.5008; IZSVAK Z, 1995, MOL GEN GENET, V247, P312, DOI 10.1007/BF00293199; IZSVAK Z, 1997, IN PRESS J BIOCH CEL; JERMANN TM, 1995, NATURE, V374, P57, DOI 10.1038/374057a0; Kidwell MG, 1992, CURR OPIN GENET DEV, V2, P868, DOI 10.1016/S0959-437X(05)80109-1; Koga A, 1996, NATURE, V383, P30, DOI 10.1038/383030a0; Lam WL, 1996, J MOL BIOL, V257, P359, DOI 10.1006/jmbi.1996.0168; Lam WL, 1996, P NATL ACAD SCI USA, V93, P10870, DOI 10.1073/pnas.93.20.10870; Lampe DJ, 1996, EMBO J, V15, P5470, DOI 10.1002/j.1460-2075.1996.tb00930.x; Lee MD, 1996, VET MICROBIOL, V50, P143, DOI 10.1016/0378-1135(96)00007-7; Lohe AR, 1997, P NATL ACAD SCI USA, V94, P1293, DOI 10.1073/pnas.94.4.1293; LOHE AR, 1995, MOL BIOL EVOL, V12, P62, DOI 10.1093/oxfordjournals.molbev.a040191; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; OOSUMI T, 1995, NATURE, V378, P873; OSBORNE BI, 1995, CURR OPIN CELL BIOL, V7, P406, DOI 10.1016/0955-0674(95)80097-2; PLASTERK RH, 1995, METHOD CELL BIOL, P59; Plasterk RHA, 1996, CURR TOP MICROBIOL, V204, P125; RADICE AD, 1994, MOL GEN GENET, V244, P606, DOI 10.1007/BF00282750; RIO DC, 1988, J MOL BIOL, V200, P411, DOI 10.1016/0022-2836(88)90250-1; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Smit AFA, 1996, P NATL ACAD SCI USA, V93, P1443, DOI 10.1073/pnas.93.4.1443; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755; VOS JC, 1994, EMBO J, V13, P6125, DOI 10.1002/j.1460-2075.1994.tb06959.x; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	41	1011	1129	4	87	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					501	510		10.1016/S0092-8674(00)80436-5	http://dx.doi.org/10.1016/S0092-8674(00)80436-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390559	Bronze			2022-12-28	WOS:A1997YG49200011
J	Smith, GD; Hart, C; Ferrell, C; Upton, M; Hole, D; Hawthorne, V; Watt, G				Smith, GD; Hart, C; Ferrell, C; Upton, M; Hole, D; Hawthorne, V; Watt, G			Birth weight of offspring and mortality in the Renfrew and Paisley study: prospective observational study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; BODY-FAT DISTRIBUTION; RISK-FACTORS; URBAN SCOTLAND; HIP RATIO; WOMEN; MEN; DETERMINANTS	Objective: To investigate the association between birth weight of offspring and mortality among fathers and mothers in the west of Scotland. Design: Prospective observational study. Participants: 794 married couples in Renfrew district of the west of Scotland. Main outcome measures: Mortality from all causes and from cardiovascular disease over 15 year follow up. Results: Women who had heavier babies were taller, had higher body mass index and better lung function, and were less likely to be smokers than mothers of lighter babies. Fathers of heavier babies were taller and less likely to be smokers than fathers of lighter babies. Mortality was inversely related to offspring's birth weight for both mothers (relative rate for a 1 kg lower birth weight 1.82 (95% confidence interval 1.23 to 2.70)) and fathers (relative rate 1.35 (1.03 to 1.79)). For mortality from cardiovascular disease, inverse associations were seen for mothers (2.00 (1.18 to 3.33)) and fathers (1.52 (1.03 to 2.17)). Adjustment for blood pressure, plasma cholesterol, body mass index, height, social class, area based deprivation category, smoking, lung function, angina, bronchitis, and electrocardiographic evidence of ischaemia had little effect on these risk estimates, although levels of statistical significance were reduced. Conclusions: Birth weight of offspring was related inversely to mortality, from all causes and cardiovascular disease, in this cohort. The strength of this association was greater than would have been expected by the degree of concordance of birth weights across generations, but an extensive range of potential confounding factors could not account for the association. Mortality is therefore influenced by a factor related to birth weight that is transmissible across generations.	UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW G12 8RZ,LANARK,SCOTLAND; UNIV GLASGOW,WOODSIDE HLTH CTR,DEPT GEN PRACTICE,GLASGOW G20 7LR,LANARK,SCOTLAND; RUCHILL HOSP,W SCOTLAND CANC SURVEILLANCE UNIT,GLASGOW G20 9NB,LANARK,SCOTLAND; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109	University of Glasgow; University of Glasgow; University of Glasgow; University of Michigan System; University of Michigan	Smith, GD (corresponding author), UNIV BRISTOL,DEPT SOCIAL MED,CANYNGE HALL,BRISTOL BS8 2PR,AVON,ENGLAND.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Upton, Mark/0000-0003-0839-1141				Alberman E, 1992, Paediatr Perinat Epidemiol, V6, P134, DOI 10.1111/j.1365-3016.1992.tb00755.x; BARKER DJP, 1995, NUTR CHILD HLTH; Brown JE, 1996, EPIDEMIOLOGY, V7, P62, DOI 10.1097/00001648-199601000-00011; EMANUEL I, 1993, ISSUES REV TERATOL, V6, P47; Emery E M, 1993, Am J Health Promot, V7, P342; Frankel S, 1996, PUBLIC HEALTH, V110, P139, DOI 10.1016/S0033-3506(96)80066-7; *GEN REG OFF, 1966, GEN REG OFF CLASS OC; Godfrey KM, 1997, BRIT J OBSTET GYNAEC, V104, P663, DOI 10.1111/j.1471-0528.1997.tb11975.x; HART N, 1993, POPULATION STUDIES, V47, P24; HAWTHORNE VM, 1995, SCOT MED J, V40, P102, DOI 10.1177/003693309504000402; *IND SCI COMM SMOK, 1988, 4 REP IND SCI COMM S; KLEBANOFF MA, 1989, PEDIATRICS, V84, P343; KOUPILOVA I, IN PRESS J EPIDEMIOL; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; LANGHOFFROOS J, 1987, CLIN GENET, V32, P240; LARSSON B, 1992, AM J EPIDEMIOL, V135, P266, DOI 10.1093/oxfordjournals.aje.a116280; Little R E, 1987, Paediatr Perinat Epidemiol, V1, P19, DOI 10.1111/j.1365-3016.1987.tb00084.x; MAGNUS P, 1984, CLIN GENET, V26, P397; OUNSTED M, 1986, ANN HUM BIOL, V13, P143, DOI 10.1080/03014468600008281; Pembrey M., 1996, Acta Geneticae Medicae et Gemellologiae, V45, P111; PETERS TJ, 1983, BRIT J OBSTET GYNAEC, V90, P1040, DOI 10.1111/j.1471-0528.1983.tb06442.x; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; POWER C, 1994, BRIT MED J, V308, P1270, DOI 10.1136/bmj.308.6939.1270; RICHEDWARDS J, 1995, AM J EPIDEMIOL, V141, pS78; SANDERSON M, 1995, PAEDIATR PERINAT EP, V9, P391, DOI 10.1111/j.1365-3016.1995.tb00162.x; *SAS I, 1991, SAS LANG PROC US 2 V; SCHMIDT MI, 1992, DIABETES CARE, V15, P912, DOI 10.2337/diacare.15.7.912; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SUTTON GC, 1980, ANN HUM BIOL, V7, P449, DOI 10.1080/03014468000004561; Wang XB, 1995, NEW ENGL J MED, V333, P1744, DOI 10.1056/NEJM199512283332606; WATT GCM, 1995, SCOT MED J, V40, P108, DOI 10.1177/003693309504000403; WILD RA, 1990, FERTIL STERIL, V54, P255; World Health Organization, 1977, INT CLASS DIS	34	106	106	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1189	1193		10.1136/bmj.315.7117.1189	http://dx.doi.org/10.1136/bmj.315.7117.1189			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393220	Green Published			2022-12-28	WOS:A1997YF25200017
J	Christiansen, CL; Morris, CN				Christiansen, CL; Morris, CN			Improving the statistical approach to health care provider profiling	ANNALS OF INTERNAL MEDICINE			English	Article							ADJUSTED MORTALITY; RATES; HOSPITALS; SEVERITY	This paper reviews and compares existing statistical methods for profiling health care providers. It recommends improvements that are based on the use of better statistical models and the adoption of more realistic, medically based criteria for judging the performance of health care providers. Unlike most profiling methods, the proposed hierarchical models allow the probability of acceptable provider performance to be calculated; thus, they can answer such questions as, ''What is the probability that a given hospital's true mortality rare for cardiac surgery patients exceeded 3.33% last year?'' The commonly encountered problems of regression-to-the-mean bias and small caseloads can be handled by using hierarchical models to extract more information from profiling data.	HARVARD PILGRIM HLTH CARE, BOSTON, MA 02215 USA; HARVARD UNIV, DEPT STAT, CTR SCI, CAMBRIDGE, MA 02138 USA	Harvard Pilgrim Health Care; Harvard University	Christiansen, CL (corresponding author), HARVARD UNIV, SCH MED, 126 BROOKLINE AVE, SUITE 200, BOSTON, MA 02215 USA.			Christiansen, Cindy/0000-0001-9951-480X	AHRQ HHS [R01 HS 07118-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALTMAN DG, 1994, JAMA-J AM MED ASSOC, V272, P129, DOI 10.1001/jama.272.2.129; Braitman LE, 1996, ANN INTERN MED, V125, P406, DOI 10.7326/0003-4819-125-5-199609010-00008; Bryk A. S., 1992, HIERARCHICAL LINEAR; Carlin B. P., 1996, BAYES EMPIRICAL BAYE; CASELLA G, 1990, STAT INFERENCE, P101; Christiansen CL, 1997, J AM STAT ASSOC, V92, P618, DOI 10.2307/2965709; CHRISTIANSEN CL, 1996, BAYESIAN BIOSTATISTI, P467; CHRISTIANSEN CL, 1996, POISSON REGRESSION I; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; GOLDSTEIN H, 1986, MULTILEVEL MODELS ED; Hannan EL, 1997, HEALTH SERV RES, V31, P659; Hannan EL, 1997, MED CARE, V35, P49, DOI 10.1097/00005650-199701000-00004; Iezzoni LI, 1996, AM J PUBLIC HEALTH, V86, P1379, DOI 10.2105/AJPH.86.10.1379; IEZZONI LI, 1994, INQUIRY-J HEALTH CAR, V31, P40; KREFT IGG, 1994, AM STAT, V48, P324, DOI 10.2307/2684845; LUFT HS, 1993, HEALTH SERV RES, V28, P419; MORRIS CN, 1987, J AM STAT ASSOC, V82, P131, DOI 10.2307/2289137; MORRIS CN, 1983, J AM STAT ASSOC, V78, P47, DOI 10.2307/2287098; NORMAND SL, 1997, IN PRESS CASE STUDIE; *NY STAT DEP HLTH, 1993, COR ART BYP SURG NEW; ROSEN AK, 1995, J CLIN EPIDEMIOL, V48, P631, DOI 10.1016/0895-4356(94)00165-M; SALEMSCHATZ S, 1994, JAMA-J AM MED ASSOC, V272, P871, DOI 10.1001/jama.272.11.871; Spiegelhalter DJ, 1996, BUGS BAYESIAN INFERE; THOMAS JW, 1993, INQUIRY-J HEALTH CAR, V30, P6; THOMAS N, 1994, STAT MED, V13, P889, DOI 10.1002/sim.4780130902; ULM K, 1990, AM J EPIDEMIOL, V131, P373, DOI 10.1093/oxfordjournals.aje.a115507	26	168	168	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				764	768		10.7326/0003-4819-127-8_Part_2-199710151-00065	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00065			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB385	9382395				2022-12-28	WOS:A1997YB38500020
J	Nerenz, DR				Nerenz, DR			Measuring plans and measuring health	ANNALS OF INTERNAL MEDICINE			English	Article							OUTCOMES; SURGERY				Nerenz, DR (corresponding author), HENRY FORD HLTH SYST, DETROIT, MI 48202 USA.							ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; HANNAN EL, 1994, ANN THORAC SURG, V58, P1852, DOI 10.1016/0003-4975(94)91726-4; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810	4	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				751	751		10.7326/0003-4819-127-8_Part_2-199710151-00062	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00062			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB385	9382392				2022-12-28	WOS:A1997YB38500017
J	Landor, M				Landor, M			A hidden agenda	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNKNOWN ORIGIN; AIDS; HIV; FEVER; DIAGNOSIS; INFECTION		Albert Einstein Coll Med, Brooklyn, NY USA; Catholic Med Ctr, Dept Med, Brooklyn, NY USA; Catholic Med Ctr, Dept Med, Queens, NY USA	Yeshiva University	Landor, M (corresponding author), St John Queens Hosp, Dept Med, 92-02 Queens Blvd, Elmhurst, NY 11373 USA.							ALONZO AA, 1995, SOC SCI MED, V41, P303, DOI 10.1016/0277-9536(94)00384-6; Alpert PL, 1996, ANN EMERG MED, V28, P159, DOI 10.1016/S0196-0644(96)70056-2; ATKINSON JH, 1994, PSYCHIAT CLIN N AM, V17, P17; BECKER W, 1993, EUR J NUCL MED, V20, P1078; BISSUEL F, 1994, J INTERN MED, V236, P529, DOI 10.1111/j.1365-2796.1994.tb00840.x; Durack D T, 1991, Curr Clin Top Infect Dis, V11, P35; Firn S, 1995, Nurs Times, V91, P37; GELFAND JA, 1994, HARRISONS PRINCIPLES, V1, P81; KASSIRER JP, 1989, ANN INTERN MED, V110, P893, DOI 10.7326/0003-4819-110-11-893; Knobel H, 1996, REV CLIN ESP, V196, P349; KUPKE T, 1995, MIL MED, V160, P85, DOI 10.1093/milmed/160.2.85; Lynch JW, 1996, CHEST, V110, P585, DOI 10.1378/chest.110.3.585; MARX JL, 1983, SCIENCE, V219, P271, DOI 10.1126/science.219.4582.271; MILLER RF, 1996, INT J STD AIDS, P7170; PLAEGERMARSHALL S, 1994, CLIN IMMUNOL IMMUNOP, V71, P19, DOI 10.1006/clin.1994.1046; SCHILLER NG, 1994, SOC SCI MED, V38, P1337, DOI 10.1016/0277-9536(94)90272-0; SOX HC, 1986, ANN INTERN MED, V104, P60, DOI 10.7326/0003-4819-104-1-60; Sullivan M, 1996, INFECT DIS CLIN N AM, V10, P149, DOI 10.1016/S0891-5520(05)70292-0	18	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	1998	338	1					46	50		10.1056/NEJM199801013380108	http://dx.doi.org/10.1056/NEJM199801013380108			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YN801	9414331				2022-12-28	WOS:000071209200008
J	Koehler, JE; Sanchez, MA; Garrido, CS; Whitfeld, MJ; Chen, FM; Berger, TG; Rodriguez-Barradas, MC; LeBoit, PE; Tappero, JW				Koehler, JE; Sanchez, MA; Garrido, CS; Whitfeld, MJ; Chen, FM; Berger, TG; Rodriguez-Barradas, MC; LeBoit, PE; Tappero, JW			Molecular epidemiology of Bartonella infections in patients with bacillary angiomatosis-peliosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Joint Session on Emerging Pathogens, Infectious-Diseases-Society-of-America National Meeting / 36th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 15-20, 1996	NEW ORLEANS, LOUISIANA	Infectious Dis Soc Amer			CAT-SCRATCH DISEASE; HUMAN-IMMUNODEFICIENCY-VIRUS; HENSELAE SP-NOV; ROCHALIMAEA-HENSELAE; EPITHELIOID ANGIOMATOSIS; IDENTIFICATION; BACTEREMIA; FEVER; SEPTICEMIA; QUINTANA	Background Bacillary angiomatosis and bacillary peliosis are vascular proliferative manifestations of infection with species of the genus bartonella that occur predominantly in patients infected with the human immunodeficiency virus, Two species, Bartonella henselae and B. quintana, have been associated with bacillary angiomatosis, but culture and speciation are difficult, and there has been little systematic evaluation ol the species-specific disease characteristics. We studied 49 patients seen over eight years who were infected with bartonella species identified by molecular techniques and who had clinical lesions consistent with bacillary angiomatosis-peliosis. Methods In this case-control study, a standardized questionnaire about exposures was administered to patients with bacillary angiomatosis-peliosis and to 96 marched controls. The infecting bartonella species were determined by molecular techniques. Results Of the 49 patients with bacillary angiomatosis-peliosis, 26 (53 percent) were infected with B. henselae and 23 (47 percent) with B. quintana. Subcutaneous and lytic bone lesions were strongly associated with B. quintana, whereas peliosis hepatis was associated exclusively with B. henselae, Patients with B, henselae infection were identified throughout the study period and were epidemiologically linked to cat and flea exposure (P less than or equal to 0.004), whereas those with B, quintana were clustered and were characterized by low income (P=0.003), homelessness (P=0.004), and exposure to lice (P=0.03), Prior treatment with macrolide antibiotics appeared to be protective against infection with either species. Conclusions B. henselae and B, quintana, the organisms that cause bacillary angiomatosis-peliosis, are associated with different epidemiologic risk factors and with predilections for involvement of different organs. (C) 1997, Massachusetts Medical Society.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif Berkeley, Sch Publ Hlth, Program Epidemiol, Berkeley, CA 94720 USA; Vet Affairs Med Ctr, Med Serv, Infect Dis Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Centers for Disease Control & Prevention - USA	Koehler, JE (corresponding author), Univ Calif San Francisco, Dept Med, Box 0654,521 Parnassus Ave,Rm C-443, San Francisco, CA 94143 USA.			Whitfeld, Margot/0000-0003-4509-4461	FOGARTY INTERNATIONAL CENTER [D43TW000003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036075] Funding Source: NIH RePORTER; FIC NIH HHS [D43-TW00003] Funding Source: Medline; NIAID NIH HHS [R29 AI36075] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAL KA, 1994, NEW ENGL J MED, V330, P1509, DOI 10.1056/NEJM199405263302108; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BAKER JA, 1946, J EXP MED, V84, P37, DOI 10.1084/jem.84.1.37; BIRTLES RJ, 1995, INT J SYST BACTERIOL, V45, P1, DOI 10.1099/00207713-45-1-1; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; Chomel BB, 1996, J CLIN MICROBIOL, V34, P1952, DOI 10.1128/JCM.34.8.1952-1956.1996; COCKERELL CJ, 1987, LANCET, V2, P654; Dean A. G., 1990, EPI INFO VERSION 5 W; DOLAN MJ, 1993, ANN INTERN MED, V118, P331, DOI 10.7326/0003-4819-118-5-199303010-00002; KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; Lawson PA, 1996, MED MICROBIOL LETT, V5, P64; LEBOIT PE, 1989, AM J SURG PATHOL, V13, P909, DOI 10.1097/00000478-198911000-00001; Margileth A M, 1993, Adv Pediatr Infect Dis, V8, P1; MARULLO S, 1992, J INFECT DIS, V166, P1462, DOI 10.1093/infdis/166.6.1462-a; MAURIN M, 1995, ANTIMICROB AGENTS CH, V39, P2387, DOI 10.1128/AAC.39.11.2387; MohleBoetani JC, 1996, CLIN INFECT DIS, V22, P794, DOI 10.1093/clinids/22.5.794; MYERS WF, 1984, ANTIMICROB AGENTS CH, V25, P690, DOI 10.1128/AAC.25.6.690; PERKOCHA LA, 1990, NEW ENGL J MED, V323, P1581, DOI 10.1056/NEJM199012063232302; REED JA, 1992, AM J SURG PATHOL, V16, P650, DOI 10.1097/00000478-199207000-00003; REGNERY RL, 1992, LANCET, V339, P1443, DOI 10.1016/0140-6736(92)92032-B; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; RODRIGUEZBARRADAS MC, 1995, J CLIN MICROBIOL, V33, P1089, DOI 10.1128/JCM.33.5.1089-1093.1995; SLATER LN, 1990, NEW ENGL J MED, V323, P1587, DOI 10.1056/NEJM199012063232303; SPACH DH, 1995, NEW ENGL J MED, V332, P424, DOI 10.1056/NEJM199502163320703; STOLER MH, 1983, AM J CLIN PATHOL, V80, P714, DOI 10.1093/ajcp/80.5.714; STRONG RP, 1918, TRENCH FEVER REPORT; TAPPERO JW, 1993, ANN INTERN MED, V118, P363, DOI 10.7326/0003-4819-118-5-199303010-00007; TAPPERO JW, 1993, JAMA-J AM MED ASSOC, V269, P770, DOI 10.1001/jama.269.6.770; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992; Whitfeld MJ, 1997, CLIN INFECT DIS, V24, P562, DOI 10.1093/clind/24.4.562; ZANGWILL KM, 1993, NEW ENGL J MED, V329, P8, DOI 10.1056/NEJM199307013290102	33	210	214	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	1997	337	26					1876	1883		10.1056/NEJM199712253372603	http://dx.doi.org/10.1056/NEJM199712253372603			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN051	9407154				2022-12-28	WOS:000071128200003
J	Empedocles, SA; Bawendi, MG				Empedocles, SA; Bawendi, MG			Quantum-confined stark effect in single CdSe nanocrystallite quantum dots	SCIENCE			English	Article							EXCITED-STATE; SPECTROSCOPY	The quantum-confined Stark effect in single cadmium selenide (CdSe) nanocrystallite quantum dots was studied. The electric field dependence of the single-dot spectrum is characterized by a highly polarizable excited state (similar to 10(5) cubic angstroms, compared to typical molecular values of order 10 to 100 cubic angstroms), in the presence of randomly oriented local electric fields that change over time. These local fields result in spontaneous spectral diffusion and contribute to ensemble inhomogeneous broadening. Stark shifts of the lowest excited state more than two orders of magnitude larger than the linewidth were observed, suggesting the potential use of these dots in electro-optic modulation devices.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)								Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Blanton SA, 1996, APPL PHYS LETT, V69, P3905, DOI 10.1063/1.117565; Brus L.E., 1991, APPL PHYS A, V53, P456; COLVIN VL, 1994, J CHEM PHYS, V101, P7122, DOI 10.1063/1.468338; COLVIN VL, 1992, J CHEM PHYS, V97, P730, DOI 10.1063/1.463573; Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y; DANEK M, 1994, J CRYST GROWTH, V145, P714, DOI 10.1016/0022-0248(94)91132-0; EFROS AL, 1996, PHYS REV B, V54, P1; Empedocles SA, 1996, PHYS REV LETT, V77, P3873, DOI 10.1103/PhysRevLett.77.3873; Gammon D, 1997, SCIENCE, V277, P85, DOI 10.1126/science.277.5322.85; HACHE F, 1989, APPL PHYS LETT, V55, P1504, DOI 10.1063/1.102257; Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562; Kagan CR, 1996, PHYS REV LETT, V76, P1517, DOI 10.1103/PhysRevLett.76.1517; LEON R, 1995, SCIENCE, V267, P1966, DOI 10.1126/science.267.5206.1966; MILLER DA, 1995, CONFINED EXCITONS PH, P875; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; Norris DJ, 1996, PHYS REV B, V53, P16347, DOI 10.1103/PhysRevB.53.16347; SACRA A, 1995, J CHEM PHYS, V103, P5236, DOI 10.1063/1.470559; SACRA A, 1996, THESIS MIT; Schmidt ME, 1997, J CHEM PHYS, V106, P5254, DOI 10.1063/1.473524; Tittel J, 1997, J PHYS CHEM B, V101, P3013, DOI 10.1021/jp963801q	23	786	821	12	263	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2114	2117		10.1126/science.278.5346.2114	http://dx.doi.org/10.1126/science.278.5346.2114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405345				2022-12-28	WOS:A1997YM23500050
J	Klaus, JW; Sneh, O; George, SM				Klaus, JW; Sneh, O; George, SM			Growth of SiO2 at room temperature with the use of catalyzed sequential half-reactions	SCIENCE			English	Article							ATOMIC LAYER EPITAXY; SILICA; TECHNOLOGY	Films of silicon dioxide (SiO2) were deposited at room temperature by means of catalyzed binary reaction sequence chemistry. The binary reaction SiCl4 + 2H(2)O --> SiO2 + 4HCl was separated into SiCl4 and H2O half-reactions, and the half-reactions were then performed in an ABAB ... sequence and catalyzed with pyridine. The pyridine catalyst lowered the deposition temperature from >600 to 300 kelvin and reduced the reactant flux required for complete reactions from similar to 10(9) to similar to 10(4) Langmuirs. Growth rates of similar to 2.1 angstroms per AB reaction cycle were obtained at room temperature for reactant pressures of 15 millitorr and 60-second exposure times with 200 millitorr of pyridine. This catalytic technique may be general and should facilitate the chemical vapor deposition of other oxide and nitride materials.	UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder			George, Steven M/O-2163-2013	George, Steven M/0000-0003-0253-9184				CURTHOYS G, 1974, J COLLOID INTERF SCI, V48, P58, DOI 10.1016/0021-9797(74)90328-2; George SM, 1996, J PHYS CHEM-US, V100, P13121, DOI 10.1021/jp9536763; GEORGE SM, 1994, APPL SURF SCI, V82-3, P460, DOI 10.1016/0169-4332(94)90259-3; GOODMAN CHL, 1986, J APPL PHYS, V60, pR65, DOI 10.1063/1.337344; HAIR ML, 1969, J PHYS CHEM-US, V73, P2372, DOI 10.1021/j100727a046; Klaus JW, 1997, APPL PHYS LETT, V70, P1092, DOI 10.1063/1.118494; LESKELA M, 1996, APPL PHYS LETT, V68, P3737; NAKAGOME Y, 1991, IEICE TRANS COMMUN, V74, P799; NOLLER N, 1972, SURF SCI, V33, P82; O'Mara W. C., 1993, LIQUID CRYSTAL FLAT; OHMI T, 1994, JPN J APPL PHYS 1, V33, P6747, DOI 10.1143/JJAP.33.6747; OTT AW, 1996, THIN SOLID FILMS, V292, P135; *SIA SEM IND ASS, 1994, NAT TECHN ROADM SEM; SNEH O, 1995, J PHYS CHEM-US, V99, P4639, DOI 10.1021/j100013a039; SNEH O, 1995, SURF SCI, V334, P135, DOI 10.1016/0039-6028(95)00471-8; SUNTOLA T, 1992, THIN SOLID FILMS, V216, P84, DOI 10.1016/0040-6090(92)90874-B; TRIPP CP, 1993, J PHYS CHEM-US, V97, P5693, DOI 10.1021/j100123a038; TRIPP CP, 1992, LANGMUIR, V8, P1961, DOI 10.1021/la00044a014	18	183	196	4	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1934	1936		10.1126/science.278.5345.1934	http://dx.doi.org/10.1126/science.278.5345.1934			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395393				2022-12-28	WOS:A1997YL00200031
J	Parniske, M; HammondKosack, KE; Golstein, C; Thomas, CM; Jones, DA; Harrison, K; Wulff, BBH; Jones, JDG				Parniske, M; HammondKosack, KE; Golstein, C; Thomas, CM; Jones, DA; Harrison, K; Wulff, BBH; Jones, JDG			Novel disease resistance specificities result from sequence exchange between tandemly repeated genes at the Cf-4/9 locus of tomato	CELL			English	Article							CLADOSPORIUM-FULVUM; AVIRULENCE GENE; MOLECULAR ANALYSIS; CF-9 GENE; PATHOGEN; RECOMBINATION; EXPRESSION; EVOLUTION; COMPLEX; PLANTS	Tomato Cf genes confer resistance to C. fulvum, reside in complex loci carrying multiple genes, and encode predicted membrane-bound proteins with extracytoplasmic leucine-rich repeats. At least two Cf-9 homologs confer novel C. fulvum resistance specificities. Comparison of 11 genes revealed 7 hypervariable amino acid positions in a motif of the leucine-rich repeats predicted to form a beta-strand/beta-turn in which the hypervariable residues are solvent exposed and potentially contribute to recognition specificity. Higher nonsynonymous than synonymous substitution rates in this region imply selection for sequence diversification. We propose that the level of polymorphism between intergenic regions determines the frequency of sequence exchange between the tandemly repeated genes. This permits sufficient exchange to generate sequence diversity but prevents sequence homogenization.	JOHN INNES CTR PLANT SCI RES,SAINSBURY LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Parniske, Martin/M-3781-2019; Wulff, Brande BH/C-7465-2013; Jones, David A/C-9507-2009; Wulff, Brande B/N-4273-2013; Parniske, Martin/F-2202-2011; Jones, Jonathan DG/J-5129-2012	Parniske, Martin/0000-0001-8561-747X; Wulff, Brande BH/0000-0003-4044-4346; Jones, David A/0000-0001-8809-5822; Parniske, Martin/0000-0001-8561-747X; Jones, Jonathan DG/0000-0002-4953-261X				Anderson PA, 1996, MOL GEN GENET, V251, P316, DOI 10.1007/s004380050172; Anderson PA, 1997, PLANT CELL, V9, P641, DOI 10.1105/tpc.9.4.641; ANDERSSON L, 1995, IMMUNOL REV, V143, P5, DOI 10.1111/j.1600-065X.1995.tb00667.x; BALINTKURTI PJ, 1994, THEOR APPL GENET, V88, P691, DOI 10.1007/BF01253972; BOTELLA MA, 1997, IN PRESS PLANT J; Boyes DC, 1997, PLANT CELL, V9, P237, DOI 10.1105/tpc.9.2.237; Dixon MS, 1996, CELL, V84, P451, DOI 10.1016/S0092-8674(00)81290-8; Dooner HK, 1997, PLANT CELL, V9, P1633, DOI 10.1105/tpc.9.9.1633; DOVER GA, 1993, METHOD ENZYMOL, V224, P525, DOI 10.1016/0076-6879(93)24039-W; FERRIS PJ, 1994, CELL, V76, P1135, DOI 10.1016/0092-8674(94)90389-1; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; Gangloff S, 1996, EMBO J, V15, P1715, DOI 10.1002/j.1460-2075.1996.tb00517.x; HAMMONDKOSACK KE, 1994, MOL PLANT MICROBE IN, V7, P58, DOI 10.1094/MPMI-7-0058; HUGHES AL, 1995, MOL BIOL EVOL, V12, P247; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; Jones DA, 1997, ADV BOT RES, V24, P89; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; JOOSTEN MHAJ, 1994, NATURE, V367, P384, DOI 10.1038/367384a0; Kanazin V, 1996, P NATL ACAD SCI USA, V93, P11746, DOI 10.1073/pnas.93.21.11746; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Leister D, 1996, NAT GENET, V14, P421, DOI 10.1038/ng1296-421; Liao DQ, 1997, EMBO J, V16, P588, DOI 10.1093/emboj/16.3.588; LOH YT, 1995, PLANT PHYSIOL, V108, P1735, DOI 10.1104/pp.108.4.1735; MARMEISSE R, 1993, MOL PLANT MICROBE IN, V6, P412, DOI 10.1094/MPMI-6-412; MASKELL D, 1993, TRENDS BIOTECHNOL, V11, P506, DOI 10.1016/0167-7799(93)90029-9; Parham P, 1996, SCIENCE, V272, P67, DOI 10.1126/science.272.5258.67; Ramsden DA, 1997, CURR OPIN IMMUNOL, V9, P114, DOI 10.1016/S0952-7915(97)80167-7; RICHTER TE, 1995, GENETICS, V141, P373; ROBERTS IN, 1989, CURR GENET, V15, P177, DOI 10.1007/BF00435503; ROHE M, 1995, EMBO J, V14, P4168, DOI 10.1002/j.1460-2075.1995.tb00090.x; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; Song WY, 1997, PLANT CELL, V9, P1279, DOI 10.1105/tpc.9.8.1279; Staden R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361; SUDUPAK MA, 1993, GENETICS, V133, P119; THOMAS CM, 1995, PLANT J, V8, P785, DOI 10.1046/j.1365-313X.1995.08050785.x; THOMAS CM, 1997, PLANT CELL, V9, P1; TIGCHELAAR EC, 1984, REP TOMATO GENET COO, V34, P55; VANDENACKERVEKEN GFJM, 1992, PLANT J, V2, P359, DOI 10.1111/j.1365-313X.1992.00359.x; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	40	459	494	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					821	832		10.1016/S0092-8674(00)80470-5	http://dx.doi.org/10.1016/S0092-8674(00)80470-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413991	Bronze			2022-12-28	WOS:A1997YL43900013
J	Ambrus, JL; Sridhar, NR				Ambrus, JL; Sridhar, NR			Immunologic aspects of renal disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ESSENTIAL MIXED CRYOGLOBULINEMIA; SYSTEMIC LUPUS-ERYTHEMATOSUS; CHURG-STRAUSS-SYNDROME; C VIRUS-INFECTION; INTERSTITIAL NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; WEGENERS GRANULOMATOSIS; GOODPASTURES-SYNDROME; CRESCENTIC GLOMERULONEPHRITIS; TUBULOINTERSTITIAL NEPHRITIS	The kidney can become involved in immune-mediated diseases through 3 mechanisms. It can be the primary target of antibody-mediated injury. Good-pasture syndrome, with antibodies directed at the glomerular basement membrane, is an example of this type. The kidney can be injured by immune complexes that are trapped in the kidney and cause local inflammation. Examples include systemic lupus erythematosus and IgA nephropathies. Finally, the kidney can be injured by immune responses initiated in other organs. In Wegener granulomatosis, inflammation begins in the airway but results in glomerulonephritis. Currently available therapies lack efficacy and specificity. New therapies based on pathophysiology are being developed in animal models.			Ambrus, JL (corresponding author), BUFFALO GEN HOSP, DIV ALLERGY IMMUNOL & RHEUMATOL, DEPT MED, 100 HIGH ST, BUFFALO, NY 14203 USA.							Abbate M, 1995, Curr Opin Nephrol Hypertens, V4, P374, DOI 10.1097/00041552-199507000-00016; Abboud H E, 1994, Curr Opin Nephrol Hypertens, V3, P329, DOI 10.1097/00041552-199405000-00015; AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; Bajema IM, 1997, J LAB CLIN MED, V129, P17, DOI 10.1016/S0022-2143(97)90157-8; BALOW JE, 1991, RHEUMATOL INT, V11, P113, DOI 10.1007/BF00304498; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BERGSTEIN J, 1975, NEW ENGL J MED, V292, P874, DOI 10.1056/NEJM197504242921701; BERNARD DB, 1988, KIDNEY INT, V33, P1184, DOI 10.1038/ki.1988.129; BEUKHOF JR, 1986, KIDNEY INT, V29, P549, DOI 10.1038/ki.1986.33; Blanco R, 1997, ARTHRITIS RHEUM, V40, P859, DOI 10.1002/art.1780400513; BOLTON WK, 1984, J CLIN INVEST, V73, P1263, DOI 10.1172/JCI111328; BOMBASSEI GJ, 1992, AM J IND MED, V21, P141, DOI 10.1002/ajim.4700210204; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BOSCH X, 1991, CLIN NEPHROL, V36, P107; BRENTJENS JR, 1989, AM J MED, V86, P603, DOI 10.1016/0002-9343(89)90394-X; BRUNS FJ, 1991, ANN INTERN MED, V114, P725, DOI 10.7326/0003-4819-114-9-725; CAMERON JS, 1991, KLIN WOCHENSCHR, V69, P536, DOI 10.1007/BF01649316; CASATO M, 1991, BLOOD, V78, P3142; CLUTTERBUCK EJ, 1990, NEPHROL DIAL TRANSPL, V5, P161, DOI 10.1093/ndt/5.3.161; DAMICO G, 1989, KIDNEY INT, V35, P1004, DOI 10.1038/ki.1989.84; DAMICO G, 1992, J AM SOC NEPHROL, V2, pS159; DAMICO G, 1995, AM J KIDNEY DIS, V26, P124, DOI 10.1016/0272-6386(95)90165-5; DCruz D, 1997, CLIN EXP RHEUMATOL, V15, P275; DEAN SE, 1991, SOUTHERN MED J, V84, P1387, DOI 10.1097/00007611-199111000-00026; DONADIO JV, 1988, KIDNEY INT, V33, P708, DOI 10.1038/ki.1988.56; DUQUESNOY B, 1991, BAILLIERE CLIN RHEUM, V5, P253, DOI 10.1016/S0950-3579(05)80282-1; FAN PY, 1995, CLIN IMMUNOL IMMUNOP, V75, P125, DOI 10.1006/clin.1995.1061; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; FINN A F JR, 1990, Current Opinion in Rheumatology, V2, P652; FRANKEL AH, 1992, Q J MED, V82, P101; FRIES JWU, 1988, KIDNEY INT, V34, P333, DOI 10.1038/ki.1988.186; GALLEGO N, 1991, PEDIATR NEPHROL, V5, P229, DOI 10.1007/BF01095959; GASKIN G, 1991, CONTRIB NEPHROL, V94, P58; GELTNER D, 1988, SPRINGER SEMIN IMMUN, V10, P103, DOI 10.1007/BF02054027; Gladman Dafna D., 1996, Current Opinion in Rheumatology, V8, P430, DOI 10.1097/00002281-199609000-00007; HAHN BH, 1990, HOSP PRACT, V25, P89; Hannigan NR, 1996, PEDIATR NEPHROL, V10, P511, DOI 10.1007/s004670050153; HARRITY P, 1991, Pediatric Pathology, V11, P635; HELCZYNSKI I, 1984, PEDIATR PATHOL, V2, P1; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; HOFFMAN GS, 1990, AM J MED, V89, P403, DOI 10.1016/0002-9343(90)90367-M; HOFFMAN GS, 1995, HOSP PRACT, V30, P33, DOI 10.1080/21548331.1995.11443178; Hudson B G, 1994, Curr Opin Nephrol Hypertens, V3, P334, DOI 10.1097/00041552-199405000-00016; HUDSON BG, 1992, KIDNEY INT, V42, P179, DOI 10.1038/ki.1992.276; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; ITAMI N, 1990, ARCH INTERN MED, V150, P688, DOI 10.1001/archinte.1990.00390150154036; JARDIM HMPF, 1992, PEDIATR NEPHROL, V6, P231, DOI 10.1007/BF00878354; JENNETTE JC, 1994, AM J KIDNEY DIS, V24, P130; Jennette JC, 1997, MED CLIN N AM, V81, P653, DOI 10.1016/S0025-7125(05)70538-1; JOHNSON JP, 1985, MEDICINE, V64, P219, DOI 10.1097/00005792-198507000-00003; KAGAMI S, 1990, AM J PATHOL, V136, P631; KASHTAN CE, 1990, CLIN NEPHROL, V33, P1; KLASA RJ, 1988, AM J MED, V84, P751, DOI 10.1016/0002-9343(88)90114-3; Kopp JB, 1996, LAB INVEST, V74, P991; KOYAMA A, 1986, IMMUNOLOGY, V58, P529; LANHAM JG, 1992, BRIT J HOSP MED, V47, P667; LAPENAS D, 1978, AM J PATHOL, V91, P243; Lefkowith JB, 1996, J CLIN INVEST, V98, P1373, DOI 10.1172/JCI118924; LIN CY, 1990, NEPHRON, V55, P258, DOI 10.1159/000185972; MATHIESON PW, 1993, J AUTOIMMUN, V6, P251, DOI 10.1006/jaut.1993.1022; MCHUGH K, 1991, PEDIATR RADIOL, V21, P552, DOI 10.1007/BF02012595; Mignon F, 1984, Adv Nephrol Necker Hosp, V13, P219; Miller JFAP, 1996, CURR OPIN IMMUNOL, V8, P815, DOI 10.1016/S0952-7915(96)80010-0; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; MIYAZATO H, 1994, AUTOIMMUNITY, V18, P259, DOI 10.3109/08916939409009527; MURPHY BF, 1988, CLIN NEPHROL, V30, P175; NEWELL GC, 1987, AM J KIDNEY DIS, V9, P183, DOI 10.1016/S0272-6386(87)80053-7; NISHIKAWA K, 1993, J EXP MED, V177, P667, DOI 10.1084/jem.177.3.667; ORFILA C, 1979, NEPHRON, V23, P14, DOI 10.1159/000181600; PARK MH, 1986, NEPHRON, V44, P309, DOI 10.1159/000184012; Pateron D, 1996, CLIN EXP RHEUMATOL, V14, P79; Penas PF, 1996, BRIT J DERMATOL, V134, P542, DOI 10.1111/j.1365-2133.1996.tb16246.x; PETERSON LS, 1995, MAYO CLIN PROC, V70, P1068, DOI 10.4065/70.11.1068; PETTERSSON EE, 1995, CLIN NEPHROL, V43, P141; Pisetsky DS, 1997, MED CLIN N AM, V81, P113, DOI 10.1016/S0025-7125(05)70507-1; Pope JE, 1996, RHEUM DIS CLIN N AM, V22, P893, DOI 10.1016/S0889-857X(05)70307-0; Rao TKS, 1996, MED CLIN N AM, V80, P1437, DOI 10.1016/S0025-7125(05)70497-1; REICHERT LJM, 1994, ANN INTERN MED, V121, P328, DOI 10.7326/0003-4819-121-5-199409010-00003; Richards J, 1991, W V Med J, V87, P61; RODGERS H, 1989, POSTGRAD MED J, V65, P515, DOI 10.1136/pgmj.65.766.515; SANJAD SA, 1974, J PEDIATR-US, V84, P873, DOI 10.1016/S0022-3476(74)80771-7; SAVAGE COS, 1985, Q J MED, V56, P467; Scheinman JI, 1997, NEPHRON, V75, P251, DOI 10.1159/000189545; SCHWARTZ RA, 1992, BRIT J DERMATOL, V127, P199, DOI 10.1111/j.1365-2133.1992.tb00114.x; Sloan RP, 1996, J AM SOC NEPHROL, V7, P299; SMILEY JD, 1992, AM J MED SCI, V304, P319, DOI 10.1097/00000441-199211000-00010; STANTON M. C., 1958, AUSTRALASEAN ANN MED, V7, P132; Stehman-Breen C, 1995, Curr Opin Nephrol Hypertens, V4, P287, DOI 10.1097/00041552-199505000-00015; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TISHER C, 1994, RENAL PATHOLOGY CLIN, P1694; Tivol EA, 1997, J IMMUNOL, V158, P5091; TOJO S, 1987, SEMIN NEPHROL, V7, P386; TRAUB YM, 1983, MEDICINE, V62, P335, DOI 10.1097/00005792-198311000-00001; UZIEL Y, 1995, PEDIATR CLIN N AM, V42, P1171; VANHAESEBROUCK P, 1985, NEPHRON, V40, P418, DOI 10.1159/000183511; WADA T, 1994, J EXP MED, V180, P1135, DOI 10.1084/jem.180.3.1135; WHITE RHR, 1994, NEPHRON, V68, P1, DOI 10.1159/000188216; WILSON CB, 1977, FED PROC, V36, P2171; WILSON CB, 1989, KIDNEY INT, V35, P938, DOI 10.1038/ki.1989.78; Wu MJ, 1996, CHUNG HUA I HSUCH TS, V57, P34; ZARCONI J, 1988, POSTGRAD MED, V84, P239	103	18	18	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1938	1945		10.1001/jama.278.22.1938	http://dx.doi.org/10.1001/jama.278.22.1938			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396656				2022-12-28	WOS:A1997YK15500017
J	Krack, P; Limousin, P; Benabid, AL; Pollak, P				Krack, P; Limousin, P; Benabid, AL; Pollak, P			Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease	LANCET			English	Letter							GPI PALLIDOTOMY		CHRISTIAN ALBRECHTS UNIV KIEL,DEPT NEUROL,D-24105 KIEL,GERMANY	University of Kiel	Krack, P (corresponding author), UNIV GRENOBLE,DEPT CLIN & BIOL NEUROSCI,GRENOBLE 9,FRANCE.		Benabid, Alim L/Q-3506-2017	Krack, Paul/0000-0002-3508-7295				Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Krack P, 1997, ANN NEUROL, V42, P129, DOI 10.1002/ana.410420122; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3; SHANNON KM, 1990, CLIN NEUROPHARMACOL, V13, P413, DOI 10.1097/00002826-199010000-00003	5	139	140	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1676	1676		10.1016/S0140-6736(05)64273-0	http://dx.doi.org/10.1016/S0140-6736(05)64273-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400515				2022-12-28	WOS:A1997YK21100015
J	Maxwell, PR; Mendall, MA; Kumar, D				Maxwell, PR; Mendall, MA; Kumar, D			Irritable bowel syndrome	LANCET			English	Article							SMOOTH-MUSCLE; DYSFUNCTION; MOTILITY; POPULATION; DEPRESSION; COMMUNITY; ATTITUDES; BEHAVIOR; SYMPTOMS; ANXIETY		ST GEORGE HOSP, SCH MED, DEPT SURG, LONDON SW17 0QT, ENGLAND; ST GEORGE HOSP, SCH MED, DIV GASTROENTEROL ENDOCRINOL & METAB, LONDON SW17 0QT, ENGLAND; MAYDAY UNIV HOSP, THORNTON HEATH, SURREY, ENGLAND	St Georges University London; St Georges University London; Croydon University Hospital								ACCARINO AM, 1995, GASTROENTEROLOGY, V108, P636, DOI 10.1016/0016-5085(95)90434-4; ALUNJONES V, 1984, J OBSTET GYNAECOL, V5, pS22, DOI 10.3109/01443618409075757; [Anonymous], 1992, GASTROENTEROL INT; BENTLEY SJ, 1983, LANCET, V2, P295; BLANCHARD EB, 1990, BEHAV RES THER, V28, P401, DOI 10.1016/0005-7967(90)90159-G; Bockus HL, 1928, AM J MED SCI, V176, P813, DOI 10.1097/00000441-192812000-00006; BOCKUS HL, 1944, FUNCTIONAL DISORDERS; Camilleri M, 1997, ALIMENT PHARM THERAP, V11, P3, DOI 10.1046/j.1365-2036.1997.84256000.x; CHRISTENSEN J, 1994, PERSPECT BIOL MED, V38, P21; COLLINS SM, 1992, SCAND J GASTROENTERO, V27, P102, DOI 10.3109/00365529209095988; COOK IJ, 1987, GASTROENTEROLOGY, V93, P727, DOI 10.1016/0016-5085(87)90434-3; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; DROSSMAN DA, 1977, GASTROENTEROLOGY, V73, P811; GOMBORONE J, 1995, J PSYCHOSOM RES, V39, P227, DOI 10.1016/0022-3999(94)00126-P; Gwee KA, 1996, LANCET, V347, P150, DOI 10.1016/S0140-6736(96)90341-4; Harris MS, 1997, POSTGRAD MED, V101, P215, DOI 10.3810/pgm.1997.03.184; HEATON KW, 1992, GASTROENTEROLOGY, V102, P1962, DOI 10.1016/0016-5085(92)90320-X; HIATT RB, 1962, AM J GASTROENTEROL, V37, P541; HURST AF, 1921, CONSTIPATION ALLIED; Jain A P, 1991, J Assoc Physicians India, V39, P385; JONES R, 1992, BRIT MED J, V304, P87, DOI 10.1136/bmj.304.6819.87; JONES VA, 1982, LANCET, V2, P1115; KATSCHINSKI M, 1990, SCAND J GASTROENTERO, V25, P761, DOI 10.3109/00365529008997605; KAY L, 1994, J INTERN MED, V236, P23, DOI 10.1111/j.1365-2796.1994.tb01115.x; KELLNER R, 1987, J NERV MENT DIS, V175, P20, DOI 10.1097/00005053-198701000-00004; KELLOW JE, 1988, GUT, V29, P1236, DOI 10.1136/gut.29.9.1236; KELLOW JE, 1990, GASTROENTEROLOGY, V98, P1208, DOI 10.1016/0016-5085(90)90335-X; KELLOW JE, 1992, SCAND J GASTROENTERO, V27, P53, DOI 10.3109/00365529209011167; KRUIS W, 1984, GASTROENTEROLOGY, V87, P1; KUMAR D, 1992, GASTROENTEROLOGY, V103, P12, DOI 10.1016/0016-5085(92)91089-M; LEE E, 1988, GASTROENTEROLOGY, V94, P409, DOI 10.1016/0016-5085(88)90430-1; MACINTOSH DG, 1992, AM J GASTROENTEROL, V87, P1407; MANNING AP, 1978, BRIT MED J, V2, P653, DOI 10.1136/bmj.2.6138.653; MAYER EA, 1994, GASTROENTEROLOGY, V107, P271, DOI 10.1016/0016-5085(94)90086-8; MAYER EA, 1995, GASTROENTEROLOGY, V108, P927, DOI 10.1016/0016-5085(95)90470-0; MCKENDRICK MW, 1994, J INFECTION, V29, P1, DOI 10.1016/S0163-4453(94)94871-2; Neal KR, 1997, BRIT MED J, V314, P779, DOI 10.1136/bmj.314.7083.779; Osler W, 1892, PRINCIPLES PRACTICE; Ryle JA, 1928, LANCET, V2, P1115; SALZMANN JL, 1989, LAB INVEST, V60, P847; SANDLER RS, 1984, GASTROENTEROLOGY, V87, P314; SETHI AK, 1991, GASTROENTEROLOGY, V100, P954, DOI 10.1016/0016-5085(91)90269-Q; SMITH RC, 1991, GASTROENTEROLOGY, V100, P591, DOI 10.1016/0016-5085(91)80002-Q; SNAPE WJ, 1976, GASTROENTEROLOGY, V70, P326; SUKHDEO MVK, 1981, J PARASITOL, V67, P906, DOI 10.2307/3280718; THOMPSON DG, 1979, LANCET, V2, P1321; Thompson W G, 1996, Semin Gastrointest Dis, V7, P217; THOMPSON WG, 1980, GASTROENTEROLOGY, V79, P283; THOMPSON WG, 1996, EVOLVING CONCEPTS GA, P200; VERMILLION DL, 1988, AM J PHYSIOL, V255, pG701, DOI 10.1152/ajpgi.1988.255.6.G701; WELCH GW, 1985, BRIT MED J, V291, P1382, DOI 10.1136/bmj.291.6506.1382; WELCH GW, 1990, NEW ZEAL MED J, V103, P418; WESTON AP, 1993, DIGEST DIS SCI, V38, P1590, DOI 10.1007/BF01303164; WHITE AM, 1991, GASTROENTEROLOGY, V100, P68, DOI 10.1016/0016-5085(91)90584-8; WHITEHEAD WE, 1982, DIGEST DIS SCI, V27, P202, DOI 10.1007/BF01296915; WHORWELL PJ, 1986, GUT, V27, P1014, DOI 10.1136/gut.27.9.1014; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	58	77	78	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 6	1997	350	9092					1691	1695		10.1016/S0140-6736(97)05276-8	http://dx.doi.org/10.1016/S0140-6736(97)05276-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400529				2022-12-28	WOS:A1997YK21100046
J	McNaughton, SJ; Banyikwa, FF; McNaughton, MM				McNaughton, SJ; Banyikwa, FF; McNaughton, MM			Promotion of the cycling of diet-enhancing nutrients by African grazers	SCIENCE			English	Article							MINERAL-NUTRITION; NATIONAL-PARK; NITROGEN; SOIL; ECOSYSTEM; HERBIVORY; GRASSLAND; SERENGETI; POPULATIONS; DEFOLIATION	Experiments in Serengeti National Park, Tanzania, provide direct evidence that large, free-ranging mammalian grazers accelerate nutrient cycling in a natural ecosystem in a way that enhances their own carrying capacity. Both nitrogen and sodium were at considerably higher plant-available levels in soils of highly grazed sites than in soils of nearby areas where animal density is sparse. Fencing that uncoupled grazers and soils indicated that the animals promote nitrogen availability on soils of inherently similar fertility and select sites of higher sodium availability as well as enhancing that availability.	SERENGETI WILDLIFE RES CTR,ARUSHA,TANZANIA; UNIV DAR ES SALAAM,DEPT BOT,DAR ES SALAAM,TANZANIA	University of Dar es Salaam	McNaughton, SJ (corresponding author), SYRACUSE UNIV,BIOL RES LABS,SYRACUSE,NY 13244, USA.							ADAMSEN FJ, 1985, COMMUN SOIL SCI PLAN, V16, P883, DOI 10.1080/00103628509367651; BERTNESS MD, 1994, TRENDS ECOL EVOL, V9, P191, DOI 10.1016/0169-5347(94)90088-4; BIANCHI TS, 1989, TRENDS ECOL EVOL, V4, P234, DOI 10.1016/0169-5347(89)90167-5; Detling J. K., 1988, CONCEPTS ECOSYSTEM E, P131; DETLING JK, 1983, OECOLOGIA, V57, P65, DOI 10.1007/BF00379563; ENRIQUEZ S, 1993, OECOLOGIA, V94, P457, DOI 10.1007/BF00566960; FRANK DA, 1994, BIOGEOCHEMISTRY, V26, P163, DOI 10.1007/BF00002905; Frank DA, 1997, ECOLOGY, V78, P2238, DOI 10.1890/0012-9658(1997)078[2238:EONGOG]2.0.CO;2; GOLD WG, 1989, OECOLOGIA, V81, P437, DOI 10.1007/BF00378949; Grime JP, 1996, OIKOS, V77, P489, DOI 10.2307/3545938; HOLLAND EA, 1992, AM NAT, V140, P685, DOI 10.1086/285435; HOLLAND EA, 1990, ECOLOGY, V71, P1040, DOI 10.2307/1937372; HUNTER AF, 1988, BIOSCIENCE, V38, P34, DOI 10.2307/1310644; JONES CG, 1994, OIKOS, V69, P373, DOI 10.2307/3545850; McNaughton S.J., 1991, P509; MCNAUGHTON SJ, 1985, ECOL MONOGR, V55, P259, DOI 10.2307/1942578; MCNAUGHTON SJ, 1983, ECOL MONOGR, V53, P291, DOI 10.2307/1942533; MCNAUGHTON SJ, 1983, OIKOS, V40, P329, DOI 10.2307/3544305; MCNAUGHTON SJ, 1989, NATURE, V341, P142, DOI 10.1038/341142a0; MCNAUGHTON SJ, 1988, NATURE, V334, P343, DOI 10.1038/334343a0; MCNAUGHTON SJ, 1990, NATURE, V345, P613, DOI 10.1038/345613a0; MCNAUGHTON SJ, IN PRESS ECOSYSTEMS; MCNAUGHTON SJ, 1995, SERENGETI, V2, P49; MCNAUGHTON SJ, IN PRESS TERRESTRIAL; MEHLICH A, 1984, COMMUN SOIL SCI PLAN, V15, P1409, DOI 10.1080/00103628409367568; MENGEL K, 1982, PRINCIPLES PLANT NUT, P61; Noss R. F., 1994, SAVING NATURES LEGAC; OESTERHELD M, 1992, NATURE, V356, P234, DOI 10.1038/356234a0; PASTOR J, 1993, ECOLOGY, V74, P467, DOI 10.2307/1939308; PASTOR J, 1988, BIOSCIENCE, V38, P770, DOI 10.2307/1310786; RAISON RJ, 1987, SOIL BIOL BIOCHEM, V19, P521, DOI 10.1016/0038-0717(87)90094-0; SEAGLE SW, 1992, ECOLOGY, V73, P1105, DOI 10.2307/1940184; SLEGEL RS, 1980, SOIL SCI SOC AM J, V44, P943; von Ende Carl N., 1993, P113; Wedin DA, 1996, SCIENCE, V274, P1720, DOI 10.1126/science.274.5293.1720; WEDIN DA, 1990, OECOLOGIA, V84, P433, DOI 10.1007/BF00328157; WOODMANSEE RG, 1978, BIOSCIENCE, V28, P448, DOI 10.2307/1307227	37	397	426	5	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1798	1800		10.1126/science.278.5344.1798	http://dx.doi.org/10.1126/science.278.5344.1798			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388182				2022-12-28	WOS:A1997YJ90100048
J	Wagner, JA; Varga, K; Ellis, EF; Rzigalinski, BA; Martin, BR; Kunos, G				Wagner, JA; Varga, K; Ellis, EF; Rzigalinski, BA; Martin, BR; Kunos, G			Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock	NATURE			English	Article							NITRIC-OXIDE; HYPOTENSIVE ACTION; BRAIN CONSTITUENT; ANANDAMIDE; ANTAGONIST; CELLS	Anandamide, an endogenous cannabinoid ligand(1), binds to CB1 cannabinoid receptors(2) in the brain and mimics the neurobehavioural actions of marijuana(3,4). Cannabinoids and anandamide also elicit hypotension mediated by peripheral CB1 receptors(5-8). Here we report that a selective CB1 receptor antagonist, SR141716A(9), elicits an increase in blood pressure in rats subjected to haemorrhagic shock, whereas similar treatment of normotensive rats or intracerebroventricular administration of the antagonist during shock do not affect blood pressure. Blood from haemorrhaged rats causes hypotension in normal rats, which can be prevented by SR141716A but not by inhibition of nitric oxide synthase in the recipient. Macrophages and platelets from haemorrhaged rats elicit CB1 receptor-mediated hypotension in normotensive recipients, and incorporate arachidonic acid or ethanolamine into a product that co-elutes with anandamide on reverse-phase high-performance liquid chromatography. Also, macrophages from control rats stimulated with ionomycin or bacterial phospholipase D produce anandamide, as identified by gas chromatography and mass spectrometry. These findings indicate that activation of peripheral CB1 cannabinoid receptors contributes to haemorrhagic hypotension, and anandamide produced by macrophages may be a mediator of this effect.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298	Virginia Commonwealth University								Aiura K, 1997, J INFECT DIS, V175, P123, DOI 10.1093/infdis/175.1.123; AMRUTHESH SC, 1992, J NEUROCHEM, V58, P503, DOI 10.1111/j.1471-4159.1992.tb09749.x; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; COLLINS JA, 1969, ARCH SURG-CHICAGO, V99, P484; CORTAS NK, 1990, CLIN CHEM, V36, P1440; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; Ellis EF, 1995, AM J PHYSIOL-HEART C, V269, pH1859, DOI 10.1152/ajpheart.1995.269.6.H1859; FELDER CC, 1992, MOL PHARMACOL, V42, P838; FRIDE E, 1993, EUR J PHARMACOL, V231, P313, DOI 10.1016/0014-2999(93)90468-W; GEBREMEDHIN G, 1996, FASEB J, V10, pA302; HOLADAY JW, 1983, ANNU REV PHARMACOL, V23, P541, DOI 10.1146/annurev.pa.23.040183.002545; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Lake KD, 1997, HYPERTENSION, V29, P1204, DOI 10.1161/01.HYP.29.5.1204; Lake KD, 1997, J PHARMACOL EXP THER, V281, P1030; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NAZIRI W, 1995, J SURG RES, V59, P146, DOI 10.1006/jsre.1995.1146; Peitzman AB, 1995, CURR PROB SURG, V32, P927; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; SMITH PB, 1994, J PHARMACOL EXP THER, V270, P219; VARGA K, 1995, EUR J PHARMACOL, V278, P279, DOI 10.1016/0014-2999(95)00181-J; Varga K, 1996, HYPERTENSION, V28, P682, DOI 10.1161/01.HYP.28.4.682	25	244	248	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					518	521		10.1038/37371	http://dx.doi.org/10.1038/37371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394002				2022-12-28	WOS:A1997YJ86500054
J	ChinDusting, JPF; Rasaratnam, B; Jennings, GLR; Dudley, FJ				ChinDusting, JPF; Rasaratnam, B; Jennings, GLR; Dudley, FJ			Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis	ANNALS OF INTERNAL MEDICINE			English	Article							ASCITES; NITRATE	Background: In patients with cirrhosis, portosystemic shunts allow intestinal bacteria and endotoxin to enter the systemic circulation. Endotoxemia may induce increased synthesis of nitric oxide, thereby contributing to arterial vasodilation. Objective: To test the hypothesis that the antibiotic norfloxacin blocks the effects of nitric oxide. Design: Placebo-controlled, double-blind, crossover study. Setting: Alfred Hospital, Melbourne, Australia. Patients: 9 patients with alcohol-related cirrhosis and 10 healthy controls. Intervention: Norfloxacin, 400 mg twice daily, for 4 weeks. Measurements: Peripheral blood flow was measured by using forearm venous occlusion plethysmography. Results: Basal forearm blood flow was higher in patients with cirrhosis than in controls (3.69 +/- 0.27 mL/100mL per minute and 2.47 +/- 0.40 mL/100mL per minute; P = 0.014) but returned toward normal after norfloxacin was given (2.64 +/- 0.31 mL/100 mL of tissue per minute in patients with cirrhosis). Responses to N-G-monomethyl-L-arginine were greater in patients with cirrhosis but returned to normal after norfloxacin was given. Conclusion: Bacterial endotoxemia in patients with cirrhosis induces increased synthesis of nitric oxide that can be corrected with norfloxacin.	ALFRED HOSP, DEPT GASTROENTEROL, PRAHRAN, VIC 3181, AUSTRALIA	Florey Institute of Neuroscience & Mental Health	ChinDusting, JPF (corresponding author), BAKER MED RES INST, ALFRED & BAKER MED UNIT, COMMERCIAL RD, PRAHRAN, VIC 3181, AUSTRALIA.		Jennings, Garry/B-3914-2009	Jennings, Garry/0000-0002-7865-5483				ALBILLOS A, 1995, AM J PHYSIOL-GASTR L, V268, pG459, DOI 10.1152/ajpgi.1995.268.3.G459; ARROYO V, 1994, INFECTION, V22, pS167, DOI 10.1007/BF01782702; BENNETT WM, 1991, DRUG PRESCRIBING REN; DUSTING GJ, 1995, J VASC RES, V32, P143, DOI 10.1159/000159089; GARCIATSAO G, 1995, GASTROENTEROLOGY, V108, P1835, DOI 10.1016/0016-5085(95)90147-7; GUARNER C, 1993, HEPATOLOGY, V18, P1139; LLACH J, 1988, GASTROENTEROLOGY, V94, P482, DOI 10.1016/0016-5085(88)90441-6; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MORENCOS FC, 1995, DIGEST DIS SCI, V40, P1252; REES DD, 1989, BRIT J PHARMACOL, V96, P418, DOI 10.1111/j.1476-5381.1989.tb11833.x; VALLANCE P, 1991, LANCET, V337, P776, DOI 10.1016/0140-6736(91)91384-7	11	55	56	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					985	988		10.7326/0003-4819-127-11-199712010-00007	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412304				2022-12-28	WOS:A1997YJ08000005
J	Schwartz, LM; Woloshin, S; Black, WC; Welch, HG				Schwartz, LM; Woloshin, S; Black, WC; Welch, HG			The role of numeracy in understanding the benefit of screening mammography	ANNALS OF INTERNAL MEDICINE			English	Article							BREAST-CANCER; PATIENTS PREFERENCES; DECISION-MAKING; PROBABILITY; RISK; PSYCHOLOGY; RESUSCITATION; CHEMOTHERAPY; INFORMATION; PERCEPTIONS	Background: Quantitative information about risks and benefits may be meaningful only to patients who have some facility with basic probability and numerical concepts, a construct called numeracy. Objective: To assess the relation between numeracy and the ability to make use of typical risk reduction expressions about the benefit of screening mammography. Design: Randomized, cross-sectional survey Setting: A simple random sample of 500 female veterans drawn from a New England registry. Intervention: One of four questionnaires, which differed only in how the same information on average risk reduction with mammography was presented. Measurements: Numeracy was scored as the total number of correct responses to three simple tasks. Participants estimated their risk for death from breast cancer with and without mammography. Accuracy was judged as each woman's ability to adjust her perceived risk in accordance with the risk reduction data presented. Results: 61% of eligible women completed the questionnaire. The median age of these women was 68 years (range, 27 to 88 years), and 96% were high school graduates. Both accuracy in applying risk reduction information and numeracy were poor (one third of respondents thought that 1000 flips of a fair coin would result in <300 heads). Accuracy was strongly related to numeracy: The accuracy rate was 5.8% (95% CI, 0.8% to 10.7%) for a numeracy score of 0, 8.9% (CI, 2.5% to 15.3%) for a score of 1, 23.7% (CI, 13.9% to 33.5%) for a score of 2, and 40% (CI, 25.1% to 54.9%) for a score of 3. Conclusions: Regardless of how information was presented, numeracy was strongly related to accurately gauging the benefit of mammography. More effective formats are needed to communicate quantitative information about risks and benefits.	DARTMOUTH COLL SCH MED, DEPT FAMILY & COMMUNITY MED, HANOVER, NH 03755 USA	Dartmouth College	Schwartz, LM (corresponding author), DEPT VET AFFAIRS MED CTR, VA OUTCOMES GRP 111B, WHITE RIVER JCT, VT 05009 USA.							BANKS SM, 1995, HEALTH PSYCHOL, V14, P178, DOI 10.1037/0278-6133.14.2.178; BEGLEY S, 1997, NEWSWEEL        0421, P54; BERGER ES, 1989, ARCH INTERN MED, V149, P1507, DOI 10.1001/archinte.149.7.1507; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; Eraker S A, 1981, Med Decis Making, V1, P29, DOI 10.1177/0272989X8100100105; FORROW L, 1992, AM J MED, V92, P121, DOI 10.1016/0002-9343(92)90100-P; Gigerenzer G, 1996, MED DECIS MAKING, V16, P273, DOI 10.1177/0272989X9601600312; HARRIS R, 1995, ANN INTERN MED, V122, P539, DOI 10.7326/0003-4819-122-7-199504010-00011; HUX JE, 1995, MED DECIS MAKING, V15, P152, DOI 10.1177/0272989X9501500208; KAHNEMAN D, 1982, SCI AM, V246, P160, DOI 10.1038/scientificamerican0182-160; KALET A, 1994, J GEN INTERN MED, V9, P402, DOI 10.1007/BF02629523; KIRSCH IW, 1993, ADULT LIT AM; KONG A, 1986, NEW ENGL J MED, V315, P740, DOI 10.1056/NEJM198609183151206; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEVINE MN, 1992, ANN INTERN MED, V117, P53, DOI 10.7326/0003-4819-117-1-53; LLEWELLYNTHOMAS HA, 1995, MED DECIS MAKING, V15, P4, DOI 10.1177/0272989X9501500103; MALENKA DJ, 1993, J GEN INTERN MED, V8, P543, DOI 10.1007/BF02599636; MAZUR DJ, 1991, J GEN INTERN MED, V6, P237, DOI 10.1007/BF02598968; MAZUR DJ, 1990, J GEN INTERN MED, V5, P402, DOI 10.1007/BF02599425; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; MEYEROWITZ BE, 1987, J PERS SOC PSYCHOL, V52, P500, DOI 10.1037/0022-3514.52.3.500; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; NAKAO MA, 1983, AM J MED, V74, P1061, DOI 10.1016/0002-9343(83)90819-7; NAYLOR CD, 1992, ANN INTERN MED, V117, P916, DOI 10.7326/0003-4819-117-11-916; O'Connor A M, 1985, Med Decis Making, V5, P453; OCONNOR AM, 1989, J CLIN EPIDEMIOL, V42, P119, DOI 10.1016/0895-4356(89)90085-1; SANDMAN PM, 1994, RISK ANAL, V14, P35, DOI 10.1111/j.1539-6924.1994.tb00026.x; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; US Census Bureau, 1994, STAT ABSTR US; *US DHHS, 1997, NIH CONS STAT; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677	32	763	769	1	47	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					966	972		10.7326/0003-4819-127-11-199712010-00003	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412301				2022-12-28	WOS:A1997YJ08000002
J	Buse, K; Walt, G; Vaughan, JP				Buse, K; Walt, G; Vaughan, JP			More dollars, more sense?	LANCET			English	Editorial Material									INT CTR DIARRHOEAL DIS RES, DHAKA, BANGLADESH	International Centre for Diarrhoeal Disease Research (ICDDR)	Buse, K (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, DEPT PUBL HLTH & POLICY, LONDON WC1E 7HT, ENGLAND.		Buse, Kent/AAK-6688-2020	Buse, Kent/0000-0002-5485-0110				World Bank, 1994, BETT HLTH AFR EXP LE; *WORLD BANK, 1997, SECT STRAT PAP HLTH; *WORLD BANK, 1993, WORLD DEV REP; *WORLD BANK, 1987, FIN HLTH SERV DEV CO	4	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1494	1494		10.1016/S0140-6736(05)63938-4	http://dx.doi.org/10.1016/S0140-6736(05)63938-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388395				2022-12-28	WOS:A1997YH11500006
J	Barrington, K; Finer, NN				Barrington, K; Finer, NN			Recent advances - Care of near term infants with respiratory failure	BRITISH MEDICAL JOURNAL			English	Review							EXTRACORPOREAL MEMBRANE-OXYGENATION; INHALED NITRIC-OXIDE; MECONIUM ASPIRATION SYNDROME; PULMONARY-HYPERTENSION; DISTRESS SYNDROME; VENTILATION; THERAPY; SUPPORT; LUNG; NEWBORN				Barrington, K (corresponding author), UNIV CALIF SAN DIEGO,DEPT PAEDIAT,DIV NEONATOL,SAN DIEGO,CA 92103, USA.			Barrington, Keith/0000-0001-9669-5094				Barefield ES, 1996, J PEDIATR-US, V129, P279, DOI 10.1016/S0022-3476(96)70255-X; BARRINGTON KJ, 1995, PEDIATR PULM, V20, P27, DOI 10.1002/ppul.1950200106; BARRINGTON KJ, IN PRESS COCHRANE DA; BARTLETT RH, 1985, PEDIATRICS, V76, P479; CLARK DA, 1987, J PEDIATR-US, V110, P765, DOI 10.1016/S0022-3476(87)80021-5; CLARK RH, 1994, J PEDIATR-US, V124, P447, DOI 10.1016/S0022-3476(94)70374-4; CORNISH JD, 1993, J PEDIATR-US, V122, P105, DOI 10.1016/S0022-3476(05)83501-2; Day RW, 1996, PEDIATRICS, V98, P698; DELIUS R, 1993, J THORAC CARDIOV SUR, V106, P329; DURANDY Y, 1990, J THORAC CARDIOV SUR, V99, P404; ETCHES PC, 1994, PEDIATR RES, V35, P15, DOI 10.1203/00006450-199401000-00004; Findlay RD, 1996, PEDIATRICS, V97, P48; FROESE AB, 1987, AM REV RESPIR DIS, V135, P1363, DOI 10.1007/BF03009896; FUHRMAN BP, 1993, CRIT CARE MED, V21, P951, DOI 10.1097/00003246-199307000-00001; GLICK PL, 1992, J PEDIATR SURG, V27, P382, DOI 10.1016/0022-3468(92)90865-5; HOGMAN M, 1994, ACTA PHYSIOL SCAND, V151, P125, DOI 10.1111/j.1748-1716.1994.tb09728.x; Kinsella John P., 1996, Pediatric Research, V39, p222A; Leach CL, 1996, NEW ENGL J MED, V335, P761, DOI 10.1056/NEJM199609123351101; LOTZE A, 1993, J PEDIATR-US, V122, P261, DOI 10.1016/S0022-3476(06)80131-9; Lotze A., 1996, Pediatric Research, V39, p226A; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; *N AM INH NITR OX, 1997, NEW ENGL J MED, V336, P597; *N AM INH NITR OX, 1997, PEDIATRICS, V99, P838; NAKAMURA Y, 1988, J PEDIATR-US, V112, P471, DOI 10.1016/S0022-3476(88)80340-8; Nizet V, 1996, INFECT IMMUN, V64, P3818, DOI 10.1128/IAI.64.9.3818-3826.1996; OROURKE PP, 1989, PEDIATRICS, V84, P957; Roberts JD, 1997, NEW ENGL J MED, V336, P605, DOI 10.1056/NEJM199702273360902; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; Song GW, 1996, ACTA ANAESTH SCAND, V40, P1154, DOI 10.1111/j.1399-6576.1996.tb05580.x; STOLAR CJH, 1991, J PEDIATR SURG, V26, P563, DOI 10.1016/0022-3468(91)90708-2; SUN B, 1993, ACTA PAEDIATR, V82, P182, DOI 10.1111/j.1651-2227.1993.tb12635.x; *UK COLL ECMO TRIA, 1996, LANCET, V348, P75; VANE JR, 1995, AM J CARDIOL, V75, pA3, DOI 10.1016/S0002-9149(99)80377-4; Wessel David, 1996, Pediatric Research, V39, p252A; Wiswell TE, 1996, PEDIATRICS, V98, P1035; Wolfson MR, 1996, PEDIATRICS, V97, P449; Zhang SP, 1996, J APPL PHYSIOL, V81, P1471, DOI 10.1152/jappl.1996.81.4.1471; Zwissler B, 1996, AM J RESP CRIT CARE, V154, P1671, DOI 10.1164/ajrccm.154.6.8970353	38	5	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1215	1218		10.1136/bmj.315.7117.1215	http://dx.doi.org/10.1136/bmj.315.7117.1215			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393229	Green Published			2022-12-28	WOS:A1997YF25200028
J	Adoue, DPF				Adoue, DPF			Werner's syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Adoue, DPF (corresponding author), GERIATR MED CTR,F-31300 TOULOUSE,FRANCE.								0	3	3	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					977	977		10.1056/NEJM199710023371405	http://dx.doi.org/10.1056/NEJM199710023371405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9395437				2022-12-28	WOS:A1997XY42300005
J	Motte, J; Trevathan, E; Arvidsson, JFV; Barrera, MN; Mullens, EL; Manasco, P; Dulac, O; Mai, J; Billard, C; Vallee, L; Oberarztin, F; Ried, S; Christe, W; Rating, D; Vigevano, F; Tassinari, C; Bernardina, BD; Majoie, H; Weber, A; Laegreid, L; EegOlofsson, O; Bermejo, M; Martinez, A; Castello, JC; Serra, MTI; Kirkham, F; Noronha, M; Wallace, S; Black, A; Berkovic, S; Pedespan, J; Echenne, B; Pinsard, N; Parain, D; Peniello, M; Carriere, J; Chauvel, P; Berquin, P; Garrel, S; Schaff, J; Talvik, T; Douchowny, M; Gilman, J; Pellock, J; Cheng, R; Crumrine, P; Lynch, B; Hahn, J; Griesemer, D; Wannamaker, B; Laxer, K; Bluestone, D; Bebin, E				Motte, J; Trevathan, E; Arvidsson, JFV; Barrera, MN; Mullens, EL; Manasco, P; Dulac, O; Mai, J; Billard, C; Vallee, L; Oberarztin, F; Ried, S; Christe, W; Rating, D; Vigevano, F; Tassinari, C; Bernardina, BD; Majoie, H; Weber, A; Laegreid, L; EegOlofsson, O; Bermejo, M; Martinez, A; Castello, JC; Serra, MTI; Kirkham, F; Noronha, M; Wallace, S; Black, A; Berkovic, S; Pedespan, J; Echenne, B; Pinsard, N; Parain, D; Peniello, M; Carriere, J; Chauvel, P; Berquin, P; Garrel, S; Schaff, J; Talvik, T; Douchowny, M; Gilman, J; Pellock, J; Cheng, R; Crumrine, P; Lynch, B; Hahn, J; Griesemer, D; Wannamaker, B; Laxer, K; Bluestone, D; Bebin, E			For generalized seizures associated with the Lennox-Gastaut syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; INTRACTABLE EPILEPSY; LAMOTRIGINE; EFFICACY; CHILDREN; TRIAL; CHILDHOOD; THERAPY	Background The Lennox-Gastaut syndrome, a severe form of epilepsy that usually begins in early childhood, is difficult to treat. Dose-related drug toxicity is common. Methods We conducted a double-blind, placebo-controlled trial of the antiepileptic drug lamotrigine in patients with the Lennox-Gastaut syndrome. Eligible patients had more than one type of predominantly generalized seizure, including tonic-clonic, atonic, tonic, and major myoclonic, and had seizures on average at least every other day. After a 4-week base-fine period in which all participants received placebo, we randomly assigned 169 patients (age range, 3 to 25 years) to 16 weeks of lamotrigine (n=79) or placebo (n=90) in addition to their other antiepileptic drugs. Results The median frequency of ail major seizures changed from base-line levels of 16.4 and 13.5 per week in the lamotrigine and placebo groups, respectively, to 9.9 and 14.2 per week after 16 weeks of treatment (P=0.002). Thirty-three percent of the patients in the lamotrigine group and 16 percent of those in the placebo group had a reduction of at least 50 percent in the frequency of seizures (P=0.01). There were no significant differences between groups in the incidence of adverse events, except for colds or viral illnesses, which were more common in the lamotrigine group (P=0.05). Conclusions Lamotrigine was an effective and well-tolerated treatment for seizures associated with the Lennox-Gastaut syndrome. (C) 1997, Massachusetts Medical Society.	UNIV KENTUCKY, COLL MED,COMPREHENS EPILEPSY CTR,DEPT NEUROL, KENTUCKY CLIN L445, LEXINGTON, KY 40536 USA; HOP ENFANTS, AMER MEM HOSP, REIMS, FRANCE; CENT CTY HOSP RYHOV, PEDIAT CLIN, JONKOPING, SWEDEN; INFANTIL VIRGEN ROCIO HOSP, SEVILLE, SPAIN; GLAXO WELLCOME RES & DEV LTD, CENT NERVOUS SYST CLIN RES, GREENFORD, MIDDX, ENGLAND; GLAXO WELLCOME INC, RES & DEV, CENT NERVOUS SYST CLIN RES, RES TRIANGLE PK, NC 27709 USA	University of Kentucky; CHU de Reims; GlaxoSmithKline; GlaxoSmithKline			Kirkham, Fenella/C-2442-2009; jiang, yu/HGU-0029-2022	Kirkham, Fenella/0000-0002-2443-7958; Trevathan, Edwin/0000-0003-2370-5970				AICARDI J, 1992, CURR OPIN NEUROL NEU, V5, P344; Anderson GD, 1996, CLIN PHARMACOL THER, V60, P145, DOI 10.1016/S0009-9236(96)90130-7; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Besag FMC, 1997, SEIZURE, V6, P51, DOI 10.1016/S1059-1311(97)80053-2; BESAG FMC, 1995, J PEDIATR-US, V127, P991, DOI 10.1016/S0022-3476(95)70047-1; BINNIE CD, 1989, EPILEPSY RES, V4, P222, DOI 10.1016/0920-1211(89)90007-7; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; BUCHANAN N, 1995, SEIZURE, V4, P233, DOI 10.1016/S1059-1311(05)80066-4; Donaldson JA, 1997, EPILEPSIA, V38, P68, DOI 10.1111/j.1528-1157.1997.tb01079.x; FITZGERALD LF, 1992, CLIN ELECTROENCEPHAL, V23, P180, DOI 10.1177/155005949202300407; GASTAUT H., 1966, EPILESPSIA, V7, P139; Gibaldi M, 1997, J CLIN PHARMACOL, V37, P667, DOI 10.1002/j.1552-4604.1997.tb04353.x; GOA KL, 1993, DRUGS, V46, P152, DOI 10.2165/00003495-199346010-00009; HAUSER WA, 1994, EPILEPSIA, V35, pS1, DOI 10.1111/j.1528-1157.1994.tb05932.x; JAWAD S, 1989, EPILEPSIA, V30, P356, DOI 10.1111/j.1528-1157.1989.tb05309.x; Mackay FJ, 1997, EPILEPSIA, V38, P881, DOI 10.1111/j.1528-1157.1997.tb01252.x; MATSUO F, 1993, NEUROLOGY, V43, P2284, DOI 10.1212/WNL.43.11.2284; May TW, 1996, THER DRUG MONIT, V18, P523, DOI 10.1097/00007691-199610000-00001; MELDRUM BS, 1994, REV CONTEMP PHARMACO, V5, P107; MESSENHEIMER J, 1994, EPILEPSIA, V35, P113, DOI 10.1111/j.1528-1157.1994.tb02920.x; Peck AW., 1994, REV CONTEMP PHARMACO, V5, P95; RITTER FJ, 1993, NEW ENGL J MED, V328, P29; SCHLUMBERGER E, 1994, EPILEPSIA, V35, P359, DOI 10.1111/j.1528-1157.1994.tb02445.x; SHIELDS WD, 1994, EPILEPSIA, V35, pS24, DOI 10.1111/j.1528-1157.1994.tb05934.x; SMITH D, 1993, EPILEPSIA, V34, P312, DOI 10.1111/j.1528-1157.1993.tb02417.x; TIMMINGS PL, 1992, EUR NEUROL, V32, P305, DOI 10.1159/000116849; Trevathan E, 1997, EPILEPSIA, V38, P1283, DOI 10.1111/j.1528-1157.1997.tb00065.x; UVEBRANT P, 1994, NEUROPEDIATRICS, V25, P284, DOI 10.1055/s-2008-1073041; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; *WALL LAB, 1994, FELB PROD INF	30	298	306	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 18	1997	337	25					1807	1812		10.1056/NEJM199712183372504	http://dx.doi.org/10.1056/NEJM199712183372504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL855	9400037	Bronze			2022-12-28	WOS:A1997YL85500004
J	Newlon, CS				Newlon, CS			Putting it all together: Building a prereplicative complex	CELL			English	Review							SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION				Newlon, CS (corresponding author), UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, DEPT MICROBIOL & MOL GENET, NEWARK, NJ 07103 USA.							Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Hardy CFJ, 1997, P NATL ACAD SCI USA, V94, P3151, DOI 10.1073/pnas.94.7.3151; Hassell J, 1996, DNA REPLICATION EUKA, P639; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hoyt MA, 1997, CELL, V91, P149, DOI 10.1016/S0092-8674(00)80396-7; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Lei M, 1996, MOL CELL BIOL, V16, P5081; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; NEWLON CS, 1993, COLD SPRING HARB SYM, V58, P415, DOI 10.1101/SQB.1993.058.01.048; NEWLON CS, 1996, DNA REPLICATION EUKA, P87; OWENS JC, 1997, IN PRESS P NATL ACAD; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Young MR, 1997, MOL BIOL CELL, V8, P1587, DOI 10.1091/mbc.8.8.1587	20	98	99	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 12	1997	91	6					717	720		10.1016/S0092-8674(00)80459-6	http://dx.doi.org/10.1016/S0092-8674(00)80459-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413980	Bronze			2022-12-28	WOS:A1997YL43900002
J	Fraser, CM; Casjens, S; Huang, WM; Sutton, GG; Clayton, R; Lathigra, R; White, O; Ketchum, KA; Dodson, R; Hickey, EK; Gwinn, M; Dougherty, B; Tomb, JF; Fleischmann, RD; Richardson, D; Peterson, J; Kerlavage, AR; Quackenbush, J; Salzberg, S; Hanson, M; vanVugt, R; Palmer, N; Adams, MD; Gocayne, J; Weidman, J; Utterback, T; Watthey, L; McDonald, L; Artiach, P; Bowman, C; Garland, S; Fujii, C; Cotton, MD; Horst, K; Roberts, K; Hatch, B; Smith, HO; Venter, JC				Fraser, CM; Casjens, S; Huang, WM; Sutton, GG; Clayton, R; Lathigra, R; White, O; Ketchum, KA; Dodson, R; Hickey, EK; Gwinn, M; Dougherty, B; Tomb, JF; Fleischmann, RD; Richardson, D; Peterson, J; Kerlavage, AR; Quackenbush, J; Salzberg, S; Hanson, M; vanVugt, R; Palmer, N; Adams, MD; Gocayne, J; Weidman, J; Utterback, T; Watthey, L; McDonald, L; Artiach, P; Bowman, C; Garland, S; Fujii, C; Cotton, MD; Horst, K; Roberts, K; Hatch, B; Smith, HO; Venter, JC			Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi	NATURE			English	Article							RIBOSOMAL-RNA GENES; LINEAR CHROMOSOME; CIRCULAR-PLASMID; ESCHERICHIA-COLI; AGENT; REPLICATION; ORGANIZATION; INFECTIVITY; ORIGIN; DNA	The genome of the bacterium Borrelia burgdorferi B31, the aetiologic agent of Lyme disease, contains a linear chromosome of 910,725 base pairs and at least 17 linear and circular plasmids with a combined size of more than 533,000 base pairs. The chromosome contains 853 genes encoding a basic set of proteins for DNA replication, transcription, translation, solute transport and energy metabolism, but, like Mycoplasma genitalium, it contains no genes for cellular biosynthetic reactions. Because B. burgdorferi and M. genitalium are distantly related eubacteria, we suggest that their limited metabolic capacities reflect convergent evolution by gene loss from more metabolically competent progenitors. Of 430 genes on 11 plasmids, most have no known biological function; 39% of plasmid genes are paralogues that form 47 gene families. The biological significance of the multiple plasmid-encoded genes is not clear, although they may be involved in antigenic variation or immune evasion.	UNIV UTAH,DEPT ONCOL SCI,DIV MOL BIOL & GENET,SALT LAKE CITY,UT 84132; MEDIMMUNE INC,GAITHERSBURG,MD 20878	Utah System of Higher Education; University of Utah; AstraZeneca; Medimmune	Fraser, CM (corresponding author), INST GENOM RES,9712 MED CTR DR,ROCKVILLE,MD 20850, USA.		Salzberg, Steven/Q-6514-2019; Salzberg, Steven L/F-6162-2011	Salzberg, Steven/0000-0002-8859-7432; Salzberg, Steven L/0000-0002-8859-7432; Quackenbush, John/0000-0002-2702-5879; Kerlavage, Anthony/0000-0002-3954-9653; Fraser, Claire/0000-0003-1462-2428				BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; BARBOUR AG, 1988, J CLIN MICROBIOL, V26, P475, DOI 10.1128/JCM.26.3.475-478.1988; BARBOUR AG, 1987, SCIENCE, V237, P409, DOI 10.1126/science.3603026; BARBOUR AG, 1983, CURR MICROBIOL, V8, P123, DOI 10.1007/BF01566969; BARBOUR AG, 1996, J BACTERIOL, V178, P6625; BARIL C, 1989, RES MICROBIOL, V140, P507, DOI 10.1016/0923-2508(89)90083-1; BRANDT ME, 1990, INFECT IMMUN, V58, P983, DOI 10.1128/IAI.58.4.983-991.1990; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Casjens S, 1997, MOL MICROBIOL, V26, P581, DOI 10.1046/j.1365-2958.1997.6051963.x; CASJENS S, 1993, MOL MICROBIOL, V8, P967, DOI 10.1111/j.1365-2958.1993.tb01641.x; CASJENS S, 1995, J BACTERIOL, V177, P2769, DOI 10.1128/jb.177.10.2769-2780.1995; Casjens S, 1997, J BACTERIOL, V179, P217, DOI 10.1128/jb.179.1.217-227.1997; CASJENS S, IN PRESS BACTERIAL G; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CUMOW AW, 1997, P NATL ACAD SCI USA, V94, P11819; DAVIDSON BE, 1992, J BACTERIOL, V174, P3766, DOI 10.1128/JB.174.11.3766-3774.1992; DUNN JJ, 1994, J BACTERIOL, V176, P2706, DOI 10.1128/JB.176.9.2706-2717.1994; FERDOWS MS, 1989, P NATL ACAD SCI USA, V86, P5969, DOI 10.1073/pnas.86.15.5969; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; GAZUMYAN A, 1994, GENE, V146, P57, DOI 10.1016/0378-1119(94)90833-8; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HINNEBUSCH J, 1990, MOL MICROBIOL, V4, P811, DOI 10.1111/j.1365-2958.1990.tb00651.x; HINNEBUSCH J, 1992, J BACTERIOL, V174, P5251, DOI 10.1128/JB.174.16.5251-5257.1992; IBBA M, IN PRESS P NATL ACAD; JOHNSON RC, 1984, INT J SYST BACTERIOL, V34, P496, DOI 10.1099/00207713-34-4-496; KITTEN T, 1990, P NATL ACAD SCI USA, V87, P6077, DOI 10.1073/pnas.87.16.6077; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; NORRIS SJ, 1995, INFECT IMMUN, V63, P2206, DOI 10.1128/IAI.63.6.2206-2212.1995; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; OJAIMI C, 1994, MICROBIOL-SGM, V140, P2931, DOI 10.1099/13500872-140-11-2931; OLD IG, 1992, FEMS MICROBIOL LETT, V99, P245, DOI 10.1111/j.1574-6968.1992.tb05575.x; Reizer J, 1996, Microb Comp Genomics, V1, P151; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SADZIENE A, 1992, J EXP MED, V176, P799, DOI 10.1084/jem.176.3.799; SALZBERG S, IN PRESS NUCL ACIDS; SCHWAN TG, 1988, INFECT IMMUN, V56, P1831, DOI 10.1128/IAI.56.8.1831-1836.1988; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TRAKTMAN P, 1996, DNA REPLICATION EUKA, P775; Xu YN, 1996, INFECT IMMUN, V64, P3870, DOI 10.1128/IAI.64.9.3870-3876.1996; Zhang JR, 1997, CELL, V89, P275, DOI 10.1016/S0092-8674(00)80206-8; Zuckert WR, 1996, J BACTERIOL, V178, P2287	49	1646	2157	3	111	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					580	586		10.1038/37551	http://dx.doi.org/10.1038/37551			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403685				2022-12-28	WOS:A1997YK85300040
J	Nightingale, SL				Nightingale, SL			Interim recommendations issued for patients exposed to fenfluramine and dexfenfluramine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1728	1728						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388135				2022-12-28	WOS:A1997YH98700007
J	Kamijo, T; Zindy, F; Roussel, MF; Quelle, DE; Downing, JR; Ashmun, RA; Grosveld, G; Sherr, CJ				Kamijo, T; Zindy, F; Roussel, MF; Quelle, DE; Downing, JR; Ashmun, RA; Grosveld, G; Sherr, CJ			Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19(ARF)	CELL			English	Article							AUSTRALIAN MELANOMA KINDREDS; CELL-CYCLE INHIBITION; FAMILIAL MELANOMA; HUMAN CANCERS; SPONTANEOUS IMMORTALIZATION; RETINOBLASTOMA-PROTEIN; P16(INK4) EXPRESSION; EMBRYO FIBROBLASTS; P53-DEFICIENT MICE; CDK INHIBITORS	The INK4a tumor suppressor locus encodes p16(INK4a), an inhibitor of cyclin D-dependent kinases, and p19(ARF), an alternative reading frame protein that also blocks cell proliferation. Surprisingly, mice lacking p19(ARF) but expressing functional p16(INK4a) develop tumors early in life. Their embryo fibroblasts (MEFs) do not senesce and are transformed by oncogenic Ha-ras alone. Conversion of ARF(+/+) or ARF(+/-) MEF strains to continuously proliferating cell lines involves loss of either p19(ARF) or p53. p53-mediated checkpoint control is unperturbed in ARF-null fibroblast strains, whereas p53-negative cell lines are resistant to p19(ARF)-induced growth arrest. Therefore, INK4a encodes growth inhibitory proteins that act upstream of the retinoblastoma protein and p53. Mutations and deletions targeting this locus in cancer cells are unlikely to be functionally equivalent.	ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT EXPT ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital			Downing, James R./N-8102-2018; Roussel, Martine F/F-1469-2016; Sherr, Charles J/N-8074-2018	Roussel, Martine F/0000-0002-1740-8139; Sherr, Charles J/0000-0002-5516-6206; Quelle, Dawn/0000-0001-8776-0122	NCI NIH HHS [CA71907, CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, P01CA071907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DURO D, 1995, ONCOGENE, V11, P21; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; FUKUSAWA K, 1996, SCIENCE, V271, P1744; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hara E, 1996, MOL CELL BIOL, V16, P859; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, ONCOGENE, V8, P2457; Herzog CR, 1996, ONCOGENE, V13, P1885; HIRAMA T, 1995, BLOOD, V86, P841; Holland EA, 1995, ONCOGENE, V11, P2289; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kubo Y, 1997, BIOCHEM BIOPH RES CO, V232, P38, DOI 10.1006/bbrc.1997.6217; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAITO M, 1989, CARCINOGENESIS, V3, P187; Noble JR, 1996, ONCOGENE, V13, P1259; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Parry D, 1996, MOL CELL BIOL, V16, P3844; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; QUELLE DE, 1997, P NATL ACAD SCI USA, V94, P3436; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REINERS JJ, 1984, CARCINOGENESIS, V5, P301, DOI 10.1093/carcin/5.3.301; REYMOND A, 1995, ONCOGENE, V11, P1173; Reznikoff CA, 1996, CANCER RES, V56, P2886; RITTLING SR, 1992, ONCOGENE, V7, P935; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, CANCER RES, V55, P2988; Swafford DS, 1997, MOL CELL BIOL, V17, P1366, DOI 10.1128/MCB.17.3.1366; Tanaka H, 1997, INT J CANCER, V70, P437, DOI 10.1002/(SICI)1097-0215(19970207)70:4<437::AID-IJC11>3.3.CO;2-I; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; VANDEURSEN J, 1995, P NATL ACAD SCI USA, V92, P7376, DOI 10.1073/pnas.92.16.7376; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WICK ST, 1995, ONCOGENE, V11, P2013; YANG R, 1995, CANCER RES, V55, P2503; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	65	1330	1378	0	25	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 28	1997	91	5					649	659		10.1016/S0092-8674(00)80452-3	http://dx.doi.org/10.1016/S0092-8674(00)80452-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393858	Bronze			2022-12-28	WOS:A1997YH96000012
J	Brown, SL; Silverman, BG; Berg, WA				Brown, SL; Silverman, BG; Berg, WA			Rupture of silicone-gel breast implants: causes, sequelae, and diagnosis	LANCET			English	Review							MAMMOGRAPHY; US; MR; COMPLICATIONS; AUGMENTATION; PROSTHESIS; SONOGRAPHY; MIGRATION; WOMEN	Silicone-gel-filled breast implants have been widely used for breast augmentation and reconstruction after mastectomy. The rate of implant rupture and its sequelae are not known. We review the frequency, causes, sequelae, and detection of Implant rupture. Materials testing of removed implants provides evidence that as implants age in vivo, they weaken and may rupture. Sequelae of rupture include migration of gel accompanied by inflammation and silicone granuloma formation. The role of free silicone gel in relation to idiopathic or atypical connective tissue disease is not clear. Magnetic resonance imaging is substantially more sensitive in the detection of rupture than is mammography or ultrasonography.	UNIV MARYLAND, SCH MED, DEPT RADIOL, DIV BREAST IMAGING, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Brown, SL (corresponding author), US FDA, CTR DEVICES & RADIOL HLTH, OFF SURVEILLANCE & BIOMETR, 1350 PICCARD DR, HFZ-541, ROCKVILLE, MD 20850 USA.			Silverman, Barbara/0000-0002-0337-4919				AHN CY, 1994, PLAST RECONSTR SURG, V94, P620, DOI 10.1097/00006534-199410000-00008; AHN CY, 1994, ANN PLAS SURG, V33, P201, DOI 10.1097/00000637-199408000-00014; ANDERSEN B, 1989, PLAST RECONSTR SURG, V84, P903, DOI 10.1097/00006534-198912000-00006; ARGENTA LC, 1983, AESTHET PLAST SURG, V7, P253, DOI 10.1007/BF01570670; BAKER JL, 1976, PLAST RECONSTR SURG, V58, P137; BERG WA, 1993, RADIOGRAPHICS, V13, P1323, DOI 10.1148/radiographics.13.6.8290727; BERG WA, 1995, RADIOLOGY, V197, P45, DOI 10.1148/radiology.197.1.7568852; CASKEY CI, 1994, RADIOLOGY, V190, P819, DOI 10.1148/radiology.190.3.8115633; CHILCOTE WA, 1994, BREAST DIS, V7, P307; DEAPEN DM, 1992, PLAST RECONSTR SURG, V89, P660, DOI 10.1097/00006534-199204000-00010; DECAMARA DL, 1993, PLAST RECONSTR SURG, V91, P828, DOI 10.1097/00006534-199304001-00012; DESTOUET JM, 1992, AM J ROENTGENOL, V159, P973, DOI 10.2214/ajr.159.5.1414810; ERDMANN MWH, 1992, BRIT J PLAST SURG, V45, P479, DOI 10.1016/0007-1226(92)90214-I; EVERSON LI, 1994, AM J ROENTGENOL, V163, P57, DOI 10.2214/ajr.163.1.8010248; GOIN JM, 1978, PLAST RECONSTR SURG, V62, P891, DOI 10.1097/00006534-197812000-00013; GORCZYCA DP, 1994, AM J ROENTGENOL, V162, P305, DOI 10.2214/ajr.162.2.8310916; GORCZYCA DP, 1994, RADIOLOGY, V190, P227, DOI 10.1148/radiology.190.1.8259410; Greenwald DP, 1996, PLAST RECONSTR SURG, V98, P269, DOI 10.1097/00006534-199608000-00008; HARRIS KM, 1993, RADIOLOGY, V187, P761, DOI 10.1148/radiology.187.3.8497626; Hennekens CH, 1996, JAMA-J AM MED ASSOC, V275, P616, DOI 10.1001/jama.275.8.616; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V270, P2607, DOI 10.1001/jama.270.21.2607; LEIBMAN AJ, 1991, PLAST RECONSTR SURG, V89, P546; MALATA CM, 1994, MED PROG TECHNOL, V20, P251; MORGENSTERN L, 1985, ARCH SURG-CHICAGO, V120, P573; PETERS W, 1994, ANN PLAS SURG, V32, P449, DOI 10.1097/00000637-199405000-00001; Phillips JW, 1996, PLAST RECONSTR SURG, V97, P1215, DOI 10.1097/00006534-199605000-00017; REYNOLDS HE, 1994, ANN PLAS SURG, V33, P247, DOI 10.1097/00000637-199409000-00003; ROBINSON OG, 1995, ANN PLAS SURG, V34, P1, DOI 10.1097/00000637-199501000-00001; Rohrich R J, 1993, Tex Med, V89, P52; ROLLAND C, 1989, J BIOMED MATER RES-A, V23, P285, DOI 10.1002/jbm.820231404; SANGER JR, 1992, PLAST RECONSTR SURG, V89, P949, DOI 10.1097/00006534-199205000-00029; SHERMIS RB, 1990, BREAST DIS, V3, P17; Shoaib Britta Ostermeyer, 1994, Keio Journal of Medicine, V43, P79; Silverman BG, 1996, ANN INTERN MED, V124, P744, DOI 10.7326/0003-4819-124-8-199604150-00008; SOLOMON G, 1994, SEMIN ARTHRITIS RHEU, V24, P29, DOI 10.1016/0049-0172(94)90107-4; Soo MS, 1996, AM J ROENTGENOL, V166, P1421, DOI 10.2214/ajr.166.6.8633456; SPIERS EM, 1994, AM J DERMATOPATH, V16, P315, DOI 10.1097/00000372-199406000-00016; TEUBER SS, 1995, ARCH DERMATOL, V131, P54, DOI 10.1001/archderm.131.1.54; VANRAPPARD JHA, 1988, ANN PLAS SURG, V21, P566, DOI 10.1097/00000637-198812000-00013; WEIZER G, 1995, ANN PLAS SURG, V34, P352, DOI 10.1097/00000637-199504000-00003	40	110	114	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1531	1537		10.1016/S0140-6736(97)03164-4	http://dx.doi.org/10.1016/S0140-6736(97)03164-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388410				2022-12-28	WOS:A1997YH11500040
J	Higgins, RM; West, N; Edmunds, ME; Dukes, DC; Kashi, H; Jurewicz, A; Lam, FT				Higgins, RM; West, N; Edmunds, ME; Dukes, DC; Kashi, H; Jurewicz, A; Lam, FT			Effect of a strict HLA matching policy on distribution of cadaveric kidney transplants to Indo-Asian and white European recipients: regional study	BRITISH MEDICAL JOURNAL			English	Article									WALSGRAVE GEN HOSP,TRANSPLANT UNIT,COVENTRY CV2 2DX,W MIDLANDS,ENGLAND		Higgins, RM (corresponding author), WALSGRAVE GEN HOSP,DIALYSIS UNIT,COVENTRY CV2 2DX,W MIDLANDS,ENGLAND.							GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; HIGGINS RM, 1995, Q J MED, V89, P522; TAKIFF H, 1988, TRANSPLANTATION, V45, P410, DOI 10.1097/00007890-198802000-00033	3	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 22	1997	315	7119					1354	1355		10.1136/bmj.315.7119.1354	http://dx.doi.org/10.1136/bmj.315.7119.1354			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402778	Green Published			2022-12-28	WOS:A1997YJ21800025
J	Rosen, ED; Chan, JCY; Idusogie, E; Clotman, F; Vlasuk, G; Luther, T; Jalbert, LR; Albrecht, S; Zhong, L; Lissens, A; Schoonjans, L; Moons, L; Collen, D; Castellino, FJ; Carmeliet, P				Rosen, ED; Chan, JCY; Idusogie, E; Clotman, F; Vlasuk, G; Luther, T; Jalbert, LR; Albrecht, S; Zhong, L; Lissens, A; Schoonjans, L; Moons, L; Collen, D; Castellino, FJ; Carmeliet, P			Mice lacking factor VII develop normally but suffer fatal perinatal bleeding	NATURE			English	Article							VISCERAL YOLK-SAC; TISSUE FACTOR; BLOOD-COAGULATION; EXPRESSION; INITIATOR; DEFICIENT; BIOLOGY; PROTEIN; EMBRYOS; CELLS	Blood coagulation in vivo is initiated by factor VII (FVII) binding to its cellular receptor tissue factor (TF)(1-4). FVII is the only known ligand for TF, so it was expected that FVII-deficient embryos would have a similar phenotype to TF-deficient embryos, which have defective vitello-embryonic circulation and die around 9.5 days of gestation(5-8), Surprisingly, we find that FVII-deficient (FVII-/-) embryos developed normally, FVII-/- mice succumbed perinatally because of fatal haemorrhaging from normal blood vessels. At embryonic day 9.5, maternal-fetal transfer of FVII was undetectable and survival of embryos did not depend on TF-FVII-initiated fibrin formation. Thus, the TF-/- embryonic lethal and the FVII-/- survival-phenotypes suggest a role for TF during embryogenesis beyond fibrin formation.	FLANDERS INTERUNIV, INST BIOTECHNOL, CTR TRANSGENE TECHNOL & GENE THERAPY, B-3000 LOUVAIN, BELGIUM; UNIV NOTRE DAME, CTR TRANSGENE RES, NOTRE DAME, IN 46556 USA; UNIV NOTRE DAME, DEPT CHEM & BIOCHEM, NOTRE DAME, IN 46556 USA; UNIV LOUVAIN, LAB DEV GENET, B-1348 LOUVAIN, BELGIUM; CORVAS INT INC, SAN DIEGO, CA 92121 USA; TECH UNIV DRESDEN, INST PATHOL, D-01307 DRESDEN, GERMANY	University of Notre Dame; University of Notre Dame; Technische Universitat Dresden			Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821; Moons, Lieve (Godelieve)/0000-0003-0186-1411				Albrecht S, 1996, THROMB HAEMOSTASIS, V75, P772; Auerbach R, 1996, STEM CELLS, V14, P269, DOI 10.1002/stem.140269; BEEBY TL, 1993, THROMB HAEMOSTASIS, V70, P465; BOURGET P, 1995, CLIN PHARMACOKINET, V28, P161, DOI 10.2165/00003088-199528020-00006; BROMBERG ME, 1995, P NATL ACAD SCI USA, V92, P8205, DOI 10.1073/pnas.92.18.8205; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; Camerer E, 1996, THROMB RES, V81, P1, DOI 10.1016/0049-3848(95)00209-X; Carmeliet P, 1997, AM J PATHOL, V150, P761; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FREEMAN SJ, 1981, J EMBRYOL EXP MORPH, V66, P223; FREEMAN SJ, 1983, J EMBRYOL EXP MORPH, V73, P307; Idusogie E, 1996, THROMB HAEMOSTASIS, V75, P481; ISHII S, 1995, ARZNEIMITTEL-FORSCH, V45-1, P644; KUMADA T, 1988, BLOOD, V71, P728; LANDOR M, 1995, ANN ALLERG ASTHMA IM, V74, P279; Luther T, 1996, AM J PATHOL, V149, P101; MORRISSEY JH, 1993, BLOOD, V81, P734; NEMERSON Y, 1995, THROMB HAEMOSTASIS, V74, P180; PETERSEN LC, 1995, THROMB RES, V79, P1, DOI 10.1016/0049-3848(95)00069-4; Sato Y, 1996, THROMB HAEMOSTASIS, V75, P389; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; Toomey JR, 1997, P NATL ACAD SCI USA, V94, P6922, DOI 10.1073/pnas.94.13.6922; Toomey JR, 1996, BLOOD, V88, P1583; VANMAELEFABRY G, 1995, TOXICOL IN VITRO, V9, P671, DOI 10.1016/0887-2333(95)00064-F	29	181	185	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					290	294		10.1038/36862	http://dx.doi.org/10.1038/36862			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384381				2022-12-28	WOS:A1997YG66700064
J	Edelmann, W; Yang, K; Umar, A; Heyer, J; Lau, K; Fan, KH; Liedtke, W; Cohen, PE; Kane, MF; Lipford, JR; Yu, NJ; Crouse, GF; Pollard, JW; Kunkel, T; Lipkin, M; Kolodner, R; Kucherlapati, R				Edelmann, W; Yang, K; Umar, A; Heyer, J; Lau, K; Fan, KH; Liedtke, W; Cohen, PE; Kane, MF; Lipford, JR; Yu, NJ; Crouse, GF; Pollard, JW; Kunkel, T; Lipkin, M; Kolodner, R; Kucherlapati, R			Mutation in the mismatch repair gene Msh6 causes cancer susceptibility	CELL			English	Article							NONPOLYPOSIS COLON-CANCER; COLORECTAL TUMORIGENESIS; HETERODUPLEX REPAIR; TUMOR-CELLS; DNA; MICE; HETERODIMER; HOMOLOG; MOUSE; DEFICIENCY	Mice carrying a null mutation in the mismatch repair gene Msh6 were generated by gene targeting. Cells that were homozygous for the mutation did not produce any detectable MSH6 protein, and extracts prepared from these cells were defective for repair of single nucleotide mismatches. Repair of 1, 2, and 4 nucleotide insertion/deletion mismatches was unaffected. Mice that were homozygous for the mutation had a reduced life span. The mice developed a spectrum of tumors, the most predominant of which were gastrointestinal tumors and B-as well as T-cell lymphomas. The tumors did not show any microsatellite instability. We conclude that MSH6 mutations, like those in some other members bf the family of mismatch repair genes, lead to cancer susceptibility, and germline mutations in this gene may be associated with a cancer predisposition syndrome that does not show microsatellite instability.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOL GENET,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV & MOL BIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,STRANG CANC RES LAB,BRONX,NY 10461; NIEHS,NIH,RES TRIANGLE PK,NC 27709; DANA FARBER CANC INST,BOSTON,MA 02115; LUDWIG INST CANC RES,LA JOLLA,CA 92093; EMORY UNIV,ATLANTA,GA 30322	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Harvard University; Dana-Farber Cancer Institute; Ludwig Institute for Cancer Research; Emory University	Edelmann, W (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,1300 MORRIS PK AVE,BRONX,NY 10461, USA.		Kucherlapati, Raju/ABC-8807-2021; Liedtke, Wolfgang B/G-4633-2011; Liedtke, Wolfgang/GNH-1878-2022		NCI NIH HHS [CA 67944, CA 54050, CA 44704] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044704, R01CA067944, R01CA054050] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BOYER JC, 1995, CANCER RES, V55, P6062; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Corradi A, 1996, GENOMICS, V36, P288, DOI 10.1006/geno.1996.0464; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; KOLODNER RD, 1995, CANCER RES, V55, P242; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PETTOMAKI P, 1997, IN PRESS GASTROENTER; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; Reitmair AH, 1996, CANCER RES, V56, P3842; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; SIROTKIN AM, 1995, P NATL ACAD SCI USA, V92, P6434, DOI 10.1073/pnas.92.14.6434; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; THOMAS DC, 1995, METHODS COMPANION ME, P187; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637	51	303	312	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					467	477		10.1016/S0092-8674(00)80433-X	http://dx.doi.org/10.1016/S0092-8674(00)80433-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390556	Bronze			2022-12-28	WOS:A1997YG49200008
J	Kenny, B; DeVinney, R; Stein, M; Reinscheid, DJ; Frey, EA; Finlay, BB				Kenny, B; DeVinney, R; Stein, M; Reinscheid, DJ; Frey, EA; Finlay, BB			Enteropathogenic E-coli (EPEC) transfers its receptor for intimate adherence into mammalian cells	CELL			English	Article							ESCHERICHIA-COLI; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; EFFACING LESIONS; GENETIC-LOCUS; PROTEIN; ACTIN; PHOSPHORYLATION; EXPRESSION; SECRETION	Enteropathogenic E. coli (EPEC) belongs to a group of bacterial pathogens that induce epithelial cell actin rearrangements resulting in pedestal formation beneath adherent bacteria. This requires the secretion of specific virulence proteins needed for signal transduction and intimate adherence. EPEC interaction induces tyrosine phosphorylation of a protein in the host membrane, Hp90, which is the receptor for the EPEC outer membrane protein, intimin. Hp90-intimin interaction is essential for intimate attachment and pedestal formation. Here, we demonstrate that Hp90 is actually a bacterial protein (Tir). Thus, this bacterial pathogen inserts its own receptor into mammalian cell surfaces, to which it then adheres to trigger additional host signaling events and actin nucleation. It is also tyrosine-phosphorylated upon transfer into the host cell.	UNIV BRITISH COLUMBIA, DEPT BIOCHEM & MOL BIOL, DEPT MICROBIOL & IMMUNOL, BIOTECHNOL LAB, VANCOUVER, BC V6T 1Z3, CANADA	University of British Columbia				, Brendan/0000-0001-7455-360X				BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; DONNENBERG MS, 1993, J CLIN INVEST, V92, P1412, DOI 10.1172/JCI116717; DONNENBERG MS, 1992, INFECT IMMUN, V60, P3953, DOI 10.1128/IAI.60.10.3953-3961.1992; DONNENBERG MS, 1990, FEMS MICROBIOL LETT, V69, P83, DOI 10.1016/0378-1097(90)90417-O; Donnenberg MS, 1997, TRENDS MICROBIOL, V5, P109, DOI 10.1016/S0966-842X(97)01000-7; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; FINLAY BB, 1992, INFECT IMMUN, V60, P2541, DOI 10.1128/IAI.60.6.2541-2543.1992; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; FOUBISTER V, 1994, J EXP MED, V179, P993, DOI 10.1084/jem.179.3.993; FOUBISTER V, 1994, INFECT IMMUN, V62, P3038, DOI 10.1128/IAI.62.7.3038-3040.1994; Frankel G, 1996, J BIOL CHEM, V271, P20359, DOI 10.1074/jbc.271.34.20359; FRANKEL G, 1994, INFECT IMMUN, V62, P1835, DOI 10.1128/IAI.62.5.1835-1842.1994; GOMEZDUARTE OG, 1995, INFECT IMMUN, V63, P1767; ISMAILI A, 1995, INFECT IMMUN, V63, P3316, DOI 10.1128/IAI.63.9.3316-3326.1995; JARVIS KG, 1995, P NATL ACAD SCI USA, V92, P7996, DOI 10.1073/pnas.92.17.7996; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; Kenny B, 1997, INFECT IMMUN, V65, P2528, DOI 10.1128/IAI.65.7.2528-2536.1997; KENNY B, 1995, P NATL ACAD SCI USA, V92, P7991, DOI 10.1073/pnas.92.17.7991; Kenny B, 1997, INFECT IMMUN, V65, P2606, DOI 10.1128/IAI.65.7.2606-2612.1997; Kenny B, 1996, MOL MICROBIOL, V20, P313, DOI 10.1111/j.1365-2958.1996.tb02619.x; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; MANJARREZHERNANDEZ HA, 1992, LANCET, V339, P521, DOI 10.1016/0140-6736(92)90340-9; McDaniel TK, 1997, MOL MICROBIOL, V23, P399, DOI 10.1046/j.1365-2958.1997.2311591.x; MCDANIEL TK, 1995, P NATL ACAD SCI USA, V92, P1664, DOI 10.1073/pnas.92.5.1664; Mecsas J, 1996, EMERG INFECT DIS, V2, P271, DOI 10.3201/eid0204.960403; Rosenshine I, 1996, INFECT IMMUN, V64, P966, DOI 10.1128/IAI.64.3.966-973.1996; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; Rosenshine I, 1996, EMBO J, V15, P2613, DOI 10.1002/j.1460-2075.1996.tb00621.x; Stein M, 1996, J BACTERIOL, V178, P6546, DOI 10.1128/jb.178.22.6546-6554.1996; Stone KD, 1996, MOL MICROBIOL, V20, P325, DOI 10.1111/j.1365-2958.1996.tb02620.x	31	958	988	0	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 14	1997	91	4					511	520		10.1016/S0092-8674(00)80437-7	http://dx.doi.org/10.1016/S0092-8674(00)80437-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390560	Bronze			2022-12-28	WOS:A1997YG49200012
J	Cleeland, CS; Gonin, R; Baez, L; Loehrer, P; Pandya, KJ				Cleeland, CS; Gonin, R; Baez, L; Loehrer, P; Pandya, KJ			Pain and treatment of pain in minority patients with cancer - The Eastern Cooperative Oncology Group minority outpatient pain study	ANNALS OF INTERNAL MEDICINE			English	Article							MANAGEMENT; SEVERITY	Background: Clinics that primarily see members of ethnic minority groups have been found to provide inadequate treatment of cancer-related pain. The extent of undertreatment of pain in these patients and the factors that contribute to undertreatment are not known. Objectives: To evaluate the severity of cancer-related pain and the adequacy of prescribed analgesics in minority outpatients with cancer. Design: Prospective clinical study. Setting: Eastern Cooperative Oncology Group. Patients: 281 minority outpatients with recurrent or metastatic cancer. Measurements: Patients and physicians independently rated severity of pain, pain-related functional impairment, and pain relief obtained by taking analgesic drugs. Analgesic adequacy was determined on the basis of accepted guidelines. Results: 77% of patients reported disease-related pain or took analgesics; 41% of patients reporting pain had severe pain. Sixty-five percent of minority patients did not receive guideline-recommended analgesic prescriptions compared with 50% of nonminority patients (P < 0.001). Hispanic patients in particular reported less pain relief and had less adequate analgesia. Conclusions: The awareness that minority patients do not receive adequate pain control and that better assessment of pain is needed may improve control of cancer-related pain in this patient population.	WESTAT CORP, ROCKVILLE, MD 20850 USA; SAN JUAN COMMUNITY CLIN ONCOL PROGRAM, SAN JUAN, PR 00936 USA; INDIANA UNIV, MED CTR, DEPT MED, DIV HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; ST MARYS HOSP, DEPT MED, HEMATOL ONCOL UNIT, ROCHESTER, NY 14611 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, HOUSTON, TX 77030 USA	Westat; Indiana University System; Indiana University-Purdue University Indianapolis; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA 21076, CA 23318, CA 49883] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA049883, U10CA023318, U10CA021076] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], [No title captured]; [Anonymous], 1991, EFFECT CANC QUALITY; ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; CLEELAND C, 1991, CANCER, V67, P823, DOI 10.1002/1097-0142(19910201)67:3+<823::AID-CNCR2820671412>3.0.CO;2-S; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Cleeland CS, 1996, PAIN, V67, P267, DOI 10.1016/0304-3959(96)03131-4; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; FORD ES, 1995, HEALTH SERV RES, V30, P237; MCDONALD DD, 1994, RES NURS HEALTH, V17, P45, DOI 10.1002/nur.4770170107; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; Raczynski James M., 1993, Ethnicity and Disease, V3, P290; SATARIANO ER, 1992, AM J PUBLIC HEALTH, V82, P195, DOI 10.2105/AJPH.82.2.195; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; TODD KH, 1994, JAMA-J AM MED ASSOC, V271, P925, DOI 10.1001/jama.271.12.925; *US DEP HHS PHS, 1994, AHCPR PUBL; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; WARD SE, 1993, PAIN, V52, P319, DOI 10.1016/0304-3959(93)90165-L	17	380	385	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					813	816		10.7326/0003-4819-127-9-199711010-00006	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YD898	9382402				2022-12-28	WOS:A1997YD89800005
J	Gostin, L				Gostin, L			Health care information and the protection of personal privacy: Ethical and legal considerations	ANNALS OF INTERNAL MEDICINE			English	Article							INSURANCE; SYSTEM	During the early 1990s, the U.S. government addressed the issue of providing universal health care to all its citizens. Although this issue has not been completely resolved, centralization of electronic data and sharing of health care information among insurers and providers have been pursued. The emergence of electronic data banks in health care has raised another issue: each citizen's right to privacy compared with the collective benefit to society when critical data on quality assurance and scientific research are shared by an array of network users. The choices we face are difficult, and the solution may necessarily reflect a compromise that alters traditional beliefs in the right to personal privacy. However, Congress can take the initiative by enacting statutes to ensure that sensitive information contained in electronic patient records is not divulged without a patient's consent and is protected against fraudulent access and abuse.			Gostin, L (corresponding author), GEORGETOWN UNIV, JOHNS HOPKINS UNIV, PROGRAM LAW & PUBL HLTH, 600 NEW JERSEY AVE NW, WASHINGTON, DC 20001 USA.							ALLEN AL, 1987, UNEASY ACCESS PRIVAC; *C OFF TECHN ASS, 1993, OTATCT576 C OFF TECH; *C OFF TECHN ASS, 1988, QUAL MED CAR INF CON; *COMM MAINT PRIV S, 1997, REC PROT ELECT HLTH; DICK RS, 1991, COMPUTER BASED RECOR; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Donaldson M.S., 1994, COMMITTEE REGIONAL H; EPSTEIN AM, 1990, NEW ENGL J MED, V323, P266, DOI 10.1056/NEJM199007263230410; *GEN ACC OFF, 1990, GAOIMTEC9070BR; GOLDMAN J, 1997, PRIVACY HLTH INFORMA; Gostin LO, 1996, JAMA-J AM MED ASSOC, V275, P1921, DOI 10.1001/jama.275.24.1921; GOSTIN LO, 1995, CORNELL LAW REV, V80, P451; Gostin LO, 1995, J LAW MED ETHICS, V23, P320, DOI 10.1111/j.1748-720X.1995.tb01374.x; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V270, P2487; IGLEHART JK, 1992, NEW ENGL J MED, V326, P1715, DOI 10.1056/NEJM199206183262526; Kuttner R, 1997, NEW ENGL J MED, V336, P386, DOI 10.1056/NEJM199701303360522; National Research Council System Security Study Committee, 1990, COMP RISK SAF COMP I; ROTENBERG M, 1991, GOV INFORM Q, V8, P79, DOI 10.1016/0740-624X(91)90026-5; Rothenberg KH, 1995, J LAW MED ETHICS, V23, P312, DOI 10.1111/j.1748-720X.1995.tb01373.x; SCHWARTZ J, 1996, WASHINGTON POST 0804, pA23; SCHWARTZ P, 1996, DATA PRIVACY LAW STU; SCHWARTZ PM, 1995, VANDERBILT LAW REV, V48, P294; VICKERY AB, 1982, COLUMBIA LAW REV, V82, P1426, DOI 10.2307/1122268; *WORK GROUP COMP P, 1993, NATL HLTH INF INFR; YENNEY SL, 1990, BUS HEALTH, V8, P41	25	47	47	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				683	690		10.7326/0003-4819-127-8_Part_2-199710151-00050	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00050			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB385	9382380				2022-12-28	WOS:A1997YB38500005
J	Liang, MH; Shadick, N				Liang, MH; Shadick, N			Feasibility and utility of adding disease-specific outcome measures to administrative databases to improve disease management	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-STATUS; FUNCTIONAL STATUS; RHEUMATOID-ARTHRITIS; QUESTIONNAIRE; DISABILITY; QUALITY; INDEX; TRIAL; LIFE	To increase the utility of administrative databases, it has been recommended that they include disease-specific, patient-centered outcome measures. This paper reviews practical and theoretical considerations and the critical evidence to support this recommendation. The strengths and weaknesses of the recommended approach are illustrated by examples of disease-specific measures for arthritis and musculoskeletal diseases. Current experience suggests that routine capture of these measures in administrative databases has formidable practical problems and would be unlikely to affect patient care. They could be used as gross indicators of a population's experience but would be insensitive to clinically meaningful improvement on the level of the individual patient. By themselves, these measures are unlikely to identify actionable strategies to improve outcomes, but they could improve efficiency. Overall, implementing this type of disease management improvement strategy would have little value in direct patient care and would be costly.			Liang, MH (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV RHEUMATOL ALLERGY & IMMUNOL, 75 FRANCIS ST, BOSTON, MA 02115 USA.				PHS HHS [P60-36308] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; CHAMBERS LW, 1982, J RHEUMATOL, V9, P780; CONVERY FR, 1977, ARCH PHYS MED REHAB, V58, P494; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; HELEWA A, 1982, J RHEUMATOL, V9, P794; JETTE AM, 1980, ARCH PHYS MED REHAB, V61, P395; Karlson EW, 1996, QUALITY LIFE PHARMAC, P1029; KAZIS LE, 1990, J CLIN EPIDEMIOL, V43, P1243, DOI 10.1016/0895-4356(90)90025-K; KAZIS LE, 1983, ARTHRITIS RHEUM, V26, P1017, DOI 10.1002/art.1780260811; Lee P, 1973, Scand J Rheumatol, V2, P71; MCVEY LJ, 1989, ANN INTERN MED, V110, P79, DOI 10.7326/0003-4819-110-1-79; MEENAN RF, 1980, ARTHRITIS RHEUM, V23, P146, DOI 10.1002/art.1780230203; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; RUBENSTEIN LV, 1995, J GEN INTERN MED, V10, P607, DOI 10.1007/BF02602744; RUBENSTEIN LV, 1989, ANN INTERN MED, V111, P836, DOI 10.7326/0003-4819-111-10-836; SCHUMACHER HR, 1993, PRIMER RHEUMATIC DIS, P81; Stucki G, 1996, Arthritis Care Res, V9, P405, DOI 10.1002/1529-0131(199610)9:5<405::AID-ANR1790090510>3.0.CO;2-2; TUGWELL P, 1987, J RHEUMATOL, V14, P446	18	18	19	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				739	742		10.7326/0003-4819-127-8_Part_2-199710151-00060	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00060			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB385	9382390				2022-12-28	WOS:A1997YB38500015
J	McHorney, CA				McHorney, CA			Generic health measurement: Past accomplishments and a measurement paradigm for the 21st century	ANNALS OF INTERNAL MEDICINE			English	Review							SICKNESS IMPACT PROFILE; QUALITY-OF-LIFE; FUNCTIONAL STATUS; RASCH ANALYSIS; PRIMARY CARE; RHEUMATOID-ARTHRITIS; POPULATION SURVEY; ITEM SELECTION; RESPONSE RATES; SURVEY SF-36	Generic health surveys have been proposed for use in increasingly diverse applications and populations. This paper describes the history of generic tools in the past 30 years and suggests a more modern measurement platform for advances in the 21st century. Many generic tools lack the precision required for effective health care decision making. A meaningful goal for the next era of development of generic measures should be the generation of equiprecise measurement for generic health concepts. Equiprecise tests yield measures of equal precision at all levels of the underlying construct. Equiprecise measurement can be achieved through conjoint use of computerized-adaptive testing as the survey platform and item response theory as the measurement theory.	UNIV WISCONSIN, SCH MED, MADISON, WI USA	University of Wisconsin System; University of Wisconsin Madison	McHorney, CA (corresponding author), WILLIAM S MIDDLETON MEM VET ADM MED CTR, PATHOL & LAB MED SERV, 2500 OVERLOOK TERRACE, MADISON, WI 53705 USA.							Andrews F. M., 1976, SOCIAL INDICATORS WE; BALABAN DJ, 1986, MED CARE, V24, P973, DOI 10.1097/00005650-198611000-00001; Bauer R. A., 1966, SOCIAL INDICATORS; Beaton DE, 1996, AM J IND MED, V29, P618, DOI 10.1002/(SICI)1097-0274(199606)29:6<618::AID-AJIM6>3.0.CO;2-F; BELLOC NB, 1971, AM J EPIDEMIOL, V93, P328, DOI 10.1093/oxfordjournals.aje.a121265; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERGSTROM BA, 1996, J AM ASS NURSE ANEST, V64, P119; BERKMAN PL, 1971, AM J EPIDEMIOL, V94, P105, DOI 10.1093/oxfordjournals.aje.a121301; BICE TW, 1976, INT J HEALTH SERV, V6, P509, DOI 10.2190/1A2A-5JNB-DB35-VWX7; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; BRAZIER J, 1993, QUAL LIFE RES, V2, P169, DOI 10.1007/BF00435221; BRESLOW L, 1972, INT J EPIDEMIOL, V1, P347, DOI 10.1093/ije/1.4.347; BROOK RH, 1979, MED CARE, V17, P1; BUSH JW, 1972, P SOC STAT, P71; CALKINS DR, 1994, J GEN INTERN MED, V9, P590, DOI 10.1007/BF02599291; Campbell A., 1976, QUALITY AM LIFE PERC, DOI DOI 10.7758/9781610441032; Cella DF, 1996, NEUROLOGY, V47, P129, DOI 10.1212/WNL.47.1.129; CHAMBERS LW, 1976, HEALTH SERV RES, V11, P430; Chambers LW, 1988, QUALITY LIFE ASSESSM, P113; Chen A L, 1993, Fam Med, V25, P536; CHEN MK, 1979, PUBLIC HEALTH REP, V94, P119; CLEARY PD, 1996, QUALITY LIFE PHARMAC, P73; CLUFF LE, 1981, J CHRON DIS, V34, P299, DOI 10.1016/0021-9681(81)90067-9; DEBONIS M, 1991, J AFFECT DISORDERS, V22, P55, DOI 10.1016/0165-0327(91)90084-6; DEYO RA, 1984, AM J PUBLIC HEALTH, V74, P569, DOI 10.2105/AJPH.74.6.569; DILLMAN DA, 1993, PUBLIC OPIN QUART, V57, P289, DOI 10.1086/269376; DUPUY HJ, 1973, US DHEW PUBLICATION; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; ENGBERG A, 1995, ACTA NEUROL SCAND, V91, P118; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; EssinkBot ML, 1996, QUAL LIFE RES, V5, P91, DOI 10.1007/BF00435973; Fields F A, 1992, J Pract Nurs, V42, P8; FISHER AG, 1993, AM J OCCUP THER, V47, P319, DOI 10.5014/ajot.47.4.319; Flaugher R., 1990, COMPUTERIZED ADAPTIV, P41; GILBERT FS, 1991, J STUD ALCOHOL, V52, P353, DOI 10.15288/jsa.1991.52.353; GILSON BS, 1975, AM J PUBLIC HEALTH, V65, P1304, DOI 10.2105/AJPH.65.12.1304; HALEY SM, 1994, J CLIN EPIDEMIOL, V47, P671, DOI 10.1016/0895-4356(94)90215-1; Hambleton R. K., 1991, FUNDAMENTALS ITEM RE; Hambleton RK, 1985, ITEM RESPONSE THEORY; HEBERLEIN TA, 1978, AM SOCIOL REV, V43, P447, DOI 10.2307/2094771; HOCHSTIM JR, 1967, J AM STAT ASSOC, V62, P976, DOI 10.2307/2283686; Hunt S M, 1980, Sociol Health Illn, V2, P231; Hunt SM, 1986, MEASURING HLTH STATU; Jachuck S J, 1982, J R Coll Gen Pract, V32, P103; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; JOBE JB, 1990, PUBLIC HEALTH REP, V105, P518; JOBE JB, 1989, AM J PUBLIC HEALTH, V79, P1053, DOI 10.2105/AJPH.79.8.1053; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; KAZIS LE, 1990, J CLIN EPIDEMIOL, V43, P1243, DOI 10.1016/0895-4356(90)90025-K; Kelley P.R., 1984, EVAL HEALTH PROF, V7, P443, DOI [10.1177/016327878400700405, DOI 10.1177/016327878400700405]; KESSLER RC, 1995, MED CARE, V33, pAS109; Kopec JA, 1996, J CLIN EPIDEMIOL, V49, P151, DOI 10.1016/0895-4356(96)00526-4; Kramer G A, 1992, J Dent Educ, V56, P684; Liang MH, 1997, ANN INTERN MED, V127, P739, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00060; LINDER F E, 1958, Science, V127, P1275, DOI 10.1126/science.127.3309.1275; LUDLOW LH, 1992, EVAL HEALTH PROF, V15, P59, DOI 10.1177/016327879201500104; Lunz ME, 1996, TEACH LEARN MED, V8, P152, DOI 10.1080/10401339609539786; MCARTHUR DL, 1991, ARCH PHYS MED REHAB, V72, P296; MCCOWN W, 1991, PSYCHOL REP, V69, P543, DOI 10.2466/PR0.69.6.543-549; MCCUSKER J, 1984, MED CARE, V22, P789, DOI 10.1097/00005650-198409000-00002; McHorney CA, 1997, J CLIN EPIDEMIOL, V50, P451, DOI 10.1016/S0895-4356(96)00424-6; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; MCHORNEY CA, 1994, MED CARE, V32, P551, DOI 10.1097/00005650-199406000-00002; MCHORNEY CA, 1997, 14 ANN M ASS HLTH SE; *NAT CTR HLTH STAT, 1963, OR PROGR OP US NATL; NELSON E, 1983, JAMA-J AM MED ASSOC, V249, P3331, DOI 10.1001/jama.249.24.3331; NELSON E, 1987, J CHRONIC DIS S1, V40, pS555; NORCINI J, 1994, J EDUC COMPUT RES, V10, P161, DOI 10.2190/FE26-NYYJ-V666-BR8F; OTT CR, 1983, HEART LUNG, V12, P162; PARKERSON GR, 1990, MED CARE, V28, P1056, DOI 10.1097/00005650-199011000-00007; PARKERSON GR, 1981, MED CARE, V19, P806, DOI 10.1097/00005650-198108000-00002; PATRICK DL, 1985, AM J PUBLIC HEALTH, V75, P1402, DOI 10.2105/AJPH.75.12.1402; PATRICK DL, 1973, J HEALTH SOC BEHAV, V14, P6, DOI 10.2307/2136932; PERNEGER TV, 1995, J CLIN EPIDEMIOL, V48, P1051, DOI 10.1016/0895-4356(94)00227-H; Renne K.S., 1974, SOC SCI RES, V3, P25, DOI [10.1016/0049-089X(74)90017-9, DOI 10.1016/0049-089X(74)90017-9]; ROSLER MJ, 1994, AM J RESP CRIT CARE, V149, P1434; ROSSER A, 1987, QUALITY LIFE ASSESSM, P138; RUBENSTEIN LV, 1995, J GEN INTERN MED, V10, P607, DOI 10.1007/BF02602744; RUBENSTEIN LV, 1989, ANN INTERN MED, V111, P836, DOI 10.7326/0003-4819-111-10-836; RUBENSTEIN LZ, 1984, J GERONTOL, V39, P686, DOI 10.1093/geronj/39.6.686; SANDERS BS, 1964, AM J PUBLIC HEALTH N, V54, P1063, DOI 10.2105/AJPH.54.7.1063; Schaeffer N. C., 1988, SOCIOL METHODOL, P271; SHEA JA, 1988, EVAL HEALTH PROF, V11, P283, DOI 10.1177/016327878801100301; SILVERSTEIN B, 1992, ARCH PHYS MED REHAB, V73, P507; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; Steward A., 1992, MEASURING FUNCTIONIN, P345; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; SULLIVAN DF, 1971, HSMHA HEALTH REP, V86, P347, DOI 10.2307/4594169; Tennant A, 1996, BRIT J RHEUMATOL, V35, P574; TERESI JA, 1995, J CLIN EPIDEMIOL, V48, P473, DOI 10.1016/0895-4356(94)00159-N; TOEVS CD, 1984, MED CARE, V22, P1088, DOI 10.1097/00005650-198412000-00004; TORRANCE GW, 1982, OPER RES, V30, P1043, DOI 10.1287/opre.30.6.1043; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 1976, DEV VALIDATION SCALE; WARE JE, 1992, MEASURING FUNCTIONIN, P291; WEISS DJ, 1985, J CONSULT CLIN PSYCH, V53, P774, DOI 10.1037/0022-006X.53.6.774; *WHO, 1947, CONST WHO; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	102	167	171	0	30	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				743	750		10.7326/0003-4819-127-8_Part_2-199710151-00061	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00061			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB385	9382391				2022-12-28	WOS:A1997YB38500016
J	Smith, DM				Smith, DM			Database research: Is happiness a humongous database?	ANNALS OF INTERNAL MEDICINE			English	Article											Smith, DM (corresponding author), INDIANA UNIV, MED CTR, REGENSTRIEF INST HLTH CARE, INDIANAPOLIS, IN 46202 USA.								0	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				725	725		10.7326/0003-4819-127-8_Part_2-199710151-00057	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00057			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB385	9382387				2022-12-28	WOS:A1997YB38500012
J	Zhou, XH; Melfi, CA; Hui, SL				Zhou, XH; Melfi, CA; Hui, SL			Methods for comparison of cost data	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-ARTERY DISEASE; HOSPITAL COSTS; SURGERY	Background: Researchers are increasingly interested in examining costs of care, and large administrative and clinical databases have made relevant data readily available. Because a few patients incur high costs relative to most patients, the distribution of cost data is often skewed. How robust are the usual methods of cost analysis against the skewed distribution of cost data? Objective: To determine the methods commonly used for comparing cost data, describe their limitations, and provide an alternate method of analysis. Design: Review of statistical methods used in studies of medical costs published in medical journals between January 1991 and January 1996. Description of a Z-score method appropriate for testing the equality of mean costs between two log-normal samples; and reanalysis of published two-sample comparison results done by using the Z-score method. Results: For two-sample comparisons, three methods were commonly used: the Student t-test on untransformed costs, the Wilcoxon test on untransformed costs, and the Student t-test on log-transformed costs. The t-test on untransformed costs ignores the skewness in cost data, the Wilcoxon test ignores unequal variances, and the S-test on log-transformed costs tests the wrong null hypothesis unless variances in the log-scale are equal. Eleven articles included two-sample tests and had enough information to allow reanalysis of the data using the Z-score method. These articles described a total of 23 Wilcoxon tests and 24 t-tests on untransformed costs. Most results did not change on reanalysis, hut six results changed enough Po alter conclusions. Specifically, reanalysis of data for which one Wilcoxon test had shown statistically significant results showed nonsignificant results; reanalysis of data for which two Wilcoxon tests had shown nonsignificant results showed statistically significant results. In articles that used t-tests on untransformed costs, two statistically significant results became nonsignificant on reanalysis and one nonsignificant result became statistically significant on reanalysis. Conclusions: The methods commonly used to compare costs of two groups have limitations. Some limitations may change some conclusions, and the direction of the change cannot be predicted. The Z-score method is designed to adjust for skewness in cost data and is appropriate for comparing means of log-normally distributed cost data.	INDIANA UNIV, MED CTR, REGENSTRIEF INST HLTH CARE, INDIANAPOLIS, IN 46202 USA; ELI LILLY & CO, LILLY CORP CTR, DIV HLTH SERV RES & POLICY, INDIANAPOLIS, IN 46285 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Eli Lilly	Zhou, XH (corresponding author), INDIANA UNIV, SCH MED,DEPT MED,DIV BIOSTAT,RILEY RES WING, 699 W DR, RR 135, INDIANAPOLIS, IN 46202 USA.			Zhou, Xiaohua/0000-0001-7935-1222				ALLISON TG, 1995, MAYO CLIN PROC, V70, P734, DOI 10.4065/70.8.734; Anderson KH, 1997, MED CARE, V35, P425, DOI 10.1097/00005650-199705000-00002; Callahan CM, 1997, ANN INTERN MED, V126, P426, DOI 10.7326/0003-4819-126-6-199703150-00002; Cowper PA, 1997, MED CARE, V35, P320, DOI 10.1097/00005650-199704000-00004; DUDLEY RA, 1993, J CLIN EPIDEMIOL, V46, P261; Fisher K S, 1991, Surg Laparosc Endosc, V1, P77; GUZMAN LA, 1994, AM J CARDIOL, V74, P22, DOI 10.1016/0002-9149(94)90485-5; HAMILTON A, 1994, CAN J CARDIOL, V10, P721; HUNINK MGM, 1994, J VASC SURG, V19, P632, DOI 10.1016/S0741-5214(94)70036-2; INCARBONE R, 1995, SURG ENDOSC-ULTRAS, V9, P151; Johnson N., 1994, CONTINUOUS UNIVARIAT, V2; NAUGHTON BJ, 1994, J AM GERIATR SOC, V42, P1045, DOI 10.1111/j.1532-5415.1994.tb06207.x; OMOLGUL NA, 1995, CIRCULATION, V91, P1070; OVERHAGE JM, 1997, IN PRESS J AM MED IN; PALADINO JA, 1994, ANN PHARMACOTHER, V28, P384, DOI 10.1177/106002809402800316; SENAGORE AJ, 1995, ANN SURG, V221, P171, DOI 10.1097/00000658-199502000-00007; STEIN MD, 1994, J ACQ IMMUN DEF SYND, V7, P469; TIERNEY WM, 1995, MED CARE, V33, P1, DOI 10.1097/00005650-199501000-00001; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; WETHERILL GB, 1960, J ROY STAT SOC B, V22, P402; WOLINSKY FD, 1994, J GERONTOL, V49, pS240; Zhou XH, 1997, STAT MED, V16, P783, DOI 10.1002/(SICI)1097-0258(19970415)16:7<783::AID-SIM488>3.3.CO;2-U; ZHOU XH, 1997, IN PRESS BIOMETRICS	23	89	90	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				752	756		10.7326/0003-4819-127-8_Part_2-199710151-00063	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00063			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB385	9382393				2022-12-28	WOS:A1997YB38500018
J	Annegers, JF; Hauser, WA; Coan, SP; Rocca, WA				Annegers, JF; Hauser, WA; Coan, SP; Rocca, WA			A population-based study of seizures after traumatic brain injuries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPILEPSY	Background The risk of seizures is increased after traumatic brain injury, but the extent and duration of the increase in risk are unknown. The purpose of this study was to identify the characteristics of brain injuries that are associated with the development of seizures. Methods We identified 4541 children and adults with traumatic brain injury (characterized by loss of consciousness, post-traumatic amnesia, or skull fracture) in Olmsted County, Minnesota, during the period from 1935 through 1984. Injuries were classified as mild (loss of consciousness or amnesia lasting less than 30 minutes), moderate (loss of consciousness for 30 minutes to 24 hours or a skull fracture), or severe (loss of consciousness or amnesia for more than 24 hours, subdural hematoma, or brain contusion). We compared the incidence of new unprovoked seizures in this cohort with population rates, using standardized incidence ratios and Cox proportional-hazards analysis. Results The overall standardized incidence ratio was 3.1 (95 percent confidence interval, 2.5 to 3.8). The standardized incidence ratio was 1.5 (95 percent confidence interval, 1.0 to 2.2) after mild injuries but with no increase over the expected number after five years, 2.9 (95 percent confidence interval, 1.9 to 4.1) after moderate injuries, and 17.0 (95 percent confidence interval, 12.3 to 23.6) after severe injuries, In the multivariate analysis, significant risk factors for later seizures were brain contusion with subdural hematoma, skull fracture, loss of consciousness or amnesia for more than one day, and an age of 65 years or older. Conclusions The increased risk of seizures after traumatic brain injury varies greatly according to the severity of the injury and the time since the injury. (C) 1998, Massachusetts Medical Society.	Univ Texas, Sch Publ Hlth, Houston, TX 77225 USA; Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Columbia University; Mayo Clinic	Annegers, JF (corresponding author), Univ Texas, Sch Publ Hlth, POB 20186, Houston, TX 77225 USA.		Hauser, W Allen/AAB-5277-2020; Ritter, Stefanie L/D-9312-2012; Rocca, Walter/Z-5335-2019		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016308] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30582] Funding Source: Medline; NINDS NIH HHS [NS16308] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANNEGERS JF, 1988, NEUROLOGY, V38, P1407, DOI 10.1212/WNL.38.9.1407; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1976, EPILEPSIA, V17, P1, DOI 10.1111/j.1528-1157.1976.tb03375.x; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Jennett B., 1975, EPILEPSY NONMISSILE, V2nd; KLEINBAUM DG, 1986, EPIDEMIOLOGIC RES PR, P103; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; PENFIELD W, 1945, RES PUBL ASSOC RES N, V24, P620; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; *STATACORP, 1997, STATA REF MAN REL 5, V1; WALKER AE, 1989, SURG NEUROL, V32, P235, DOI 10.1016/0090-3019(89)90185-7; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006	12	644	670	0	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	1998	338	1					20	24		10.1056/NEJM199801013380104	http://dx.doi.org/10.1056/NEJM199801013380104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN801	9414327				2022-12-28	WOS:000071209200004
J	Kahn, RJ; Kahn, PG				Kahn, RJ; Kahn, PG			The Medical Repository - The first US medical journal (1797-1824)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	27th Annual Meeting of the American-Osler-Society	APR 03-04, 1997	WILLIAMSBURG, VIRGINIA	Amer Osler Soc					Penobscot Bay Med Ctr, Niles Perkins Hlth Sci Lib, Rockport, ME 04856 USA		Kahn, RJ (corresponding author), Penobscot Bay Med Ctr, Niles Perkins Hlth Sci Lib, 6 Glen Cove Dr, Rockport, ME 04856 USA.							BARKER J, 1797, MANUSCRIPT COLLECTIO, V13; BEATTY WK, 1976, JAMA-J AM MED ASSOC, V236, P78; BILLINGS JS, 1879, BOSTON MED SURGICAL, V100, P1; BILLINGS JS, 1876, CENTURY AM MED 1776, P291; Butterfield L.H, 1951, LETT B RUSH, V1, P310; CASSEDY JH, 1983, J HIST MED ALL SCI, V38, P135, DOI 10.1093/jhmas/38.2.135; CASSEDY JH, 1984, AM MED STAT THINKING, P1; COGGINS CC, 1965, B MED LIBR ASSOC, V53, P426; CRONIN JE, 1973, DIARY EH SMITH 1771, P3; CRONIN JE, 1973, DIARY EH SMITH 1771, P320; CRONIN JE, 1973, DIARY EH SMITH 1771, P201; EBERT M, 1952, Bull Med Libr Assoc, V40, P243; Garrison, 1922, INTRO HIST MED, V15, P335; Kelly H. A., 1920, AM MED BIOGRAPHIES; Kronick D., 1976, HIST SCI TECHNICAL P, V2; MIDDLETON P, 1769, MED DISCOURSE HIST I, P68; MILLER S, 1814, MED WORKS E MILLER M; MITCHILL SL, 1794, NOMENCLATURE NEW CHE, P43; MITCHILL SL, 1795, REMARKS GASEOUS OXYD, P43; Porter R., 1992, MEDICAL J MEDICAL KN, P6; ROBINSON V, 1929, MED LIFE, V36, P552; THACHER J, 1828, AM MED BIOGRAPHY MEM, V2, P88; WATERHOUSE B, 1792, RISE PROGR PRESENT S, P28; Webster N, 1796, COLLECTION PAPERS SU; WEINSTEIN RJ, 1952, THESIS PRATT I	25	22	23	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	1997	337	26					1926	1930		10.1056/NEJM199712253372617	http://dx.doi.org/10.1056/NEJM199712253372617			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN051	9407162				2022-12-28	WOS:000071128200025
J	Savchenko, A; Barnes, S; Kramer, RH				Savchenko, A; Barnes, S; Kramer, RH			Cyclic-nucleotide-gated channels mediate synaptic feedback by nitric oxide	NATURE			English	Article							EXCITATORY AMINO-ACIDS; CONE PHOTORECEPTORS; HIPPOCAMPAL-NEURONS; GUANYLYL CYCLASE; HORIZONTAL CELLS; TURTLE RETINA; RELEASE; CALCIUM; GMP; TRANSMISSION	Cyclic-nucleotide-gated (CNG) channels in outer segments of vertebrate photoreceptors generate electrical signals in response to changes in cyclic GMP concentration during phototransduction(1). CNG channels also allow the influx of Ca2+, which is essential for photoreceptor adaptation(2). In cone photoreceptors, cGMP triggers an increase in membrane capacitance indicative of exocytosis, suggesting that CNG channels are also involved in synaptic function(3), Here we examine whether CNG channels reside in cone terminals and whether they regulate neurotransmitter release, specifically in response to nitric oxide (NO), a retrograde transmitter that increases cGMP synthesis and potentiates synaptic transmission in the brain(4-6). Using intact retina, we show that endogenous NO modulates synapses between cones and horizontal cells. In experiments on isolated cones, we show directly that CNG channels occur in dusters and are indirectly activated by S-nitrosocysteine (SNC), an NO donor. Furthermore, both SNC and pCPT-cGMP, a membrane-permeant analogue of cGMP, trigger the release of transmitter from the cone terminals, The NO-induced transmitter release is suppressed by guanylate cyclase inhibitors and prevented by direct activation of CNG channels, indicating that their activation is required for NO to elicit release. These results expand our view of CNG channel function to include the regulation of synaptic transmission and mediation of the presynaptic effects of NO.	UNIV MIAMI,SCH MED,DEPT MOL & CELLULAR PHARMACOL,MIAMI,FL 33101; UNIV CALGARY,NEUROSCI RES GRP,CALGARY,AB T2N 4N1,CANADA	University of Miami; University of Calgary					NEI NIH HHS [P30 EY003176] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY003176] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARANCIO O, 1995, NATURE, V376, P74, DOI 10.1038/376074a0; BARNES S, 1992, J NEUROPHYSIOL, V68, P745, DOI 10.1152/jn.1992.68.3.745; BARNES S, 1989, J GEN PHYSIOL, V94, P719, DOI 10.1085/jgp.94.4.719; BAYLOR DA, 1971, J PHYSIOL-LONDON, V214, P265, DOI 10.1113/jphysiol.1971.sp009432; Bradley J, 1997, J NEUROSCI, V17, P1993; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; COPENHAGEN DR, 1989, NATURE, V341, P536, DOI 10.1038/341536a0; DIXON DB, 1997, IN PRESS J NEUROSCI; Finn JT, 1996, ANNU REV PHYSIOL, V58, P395, DOI 10.1146/annurev.ph.58.030196.002143; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; HORN R, 1991, BIOPHYS J, V60, P433, DOI 10.1016/S0006-3495(91)82069-0; Kingston PA, 1996, P NATL ACAD SCI USA, V93, P10440, DOI 10.1073/pnas.93.19.10440; KOCH KW, 1994, EMBO J, V13, P3312, DOI 10.1002/j.1460-2075.1994.tb06633.x; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KURENNY DR, 1995, NEURON, V13, P315; LIEPE BA, 1994, J NEUROSCI, V14, P7641; MARICQ AV, 1988, NEURON, V1, P503, DOI 10.1016/0896-6273(88)90181-X; MEFFERT MK, 1994, NEURON, V12, P1235, DOI 10.1016/0896-6273(94)90440-5; MULSCH A, 1988, J PHARMACOL EXP THER, V247, P282; NORMANN RA, 1979, J PHYSIOL-LONDON, V286, P509, DOI 10.1113/jphysiol.1979.sp012634; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PICCOLINO M, 1981, J NEUROPHYSIOL, V45, P363, DOI 10.1152/jn.1981.45.3.363; RIEKE F, 1994, NEURON, V13, P863, DOI 10.1016/0896-6273(94)90252-6; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; TACHIBANA M, 1991, J NEUROSCI, V11, P2199; WATANABE SI, 1988, J NEUROSCI, V8, P2334; Wilkinson MF, 1996, J GEN PHYSIOL, V107, P621, DOI 10.1085/jgp.107.5.621; WU SM, 1994, ANNU REV PHYSIOL, V56, P141; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; ZIMMERMAN AL, 1985, P NATL ACAD SCI USA, V82, P8813, DOI 10.1073/pnas.82.24.8813	31	153	160	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					694	698		10.1038/37803	http://dx.doi.org/10.1038/37803			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414163	Green Accepted			2022-12-28	WOS:A1997YM50800034
J	Lonergan, MC				Lonergan, MC			A tunable diode based on an inorganic semiconductor vertical bar conjugated polymer interface	SCIENCE			English	Article							LIQUID; CONTACTS; JUNCTION; METAL	Although in principle semiconductor-metal (Schottky) diodes should be tunable by changing the work function of the metal, such flexibility cannot be achieved in a single device and in practice is often limited by interfacial states that cause Fermi-level pinning. A tunable diode is reported based on a hybrid inorganic-organic, n-indium phosphide\poly(pyrrole)\nonaqueous electrolyte architecture. By electrochemically manipulating the work function of the conjugated polymer poly(pyrrole), the turn-on voltage (more precisely, the forward bias potential required to pass a particular current) of the diode can be continuously and actively tuned by more than 0.6 volt. The work highlights a distinguishing feature of conjugated polymers relative to more traditional semiconductor materials, namely, the ability of dopant ions to permeate conjugated polymers, thereby enabling electrochemical manipulation.	UNIV OREGON,INST MAT SCI,EUGENE,OR 97403	University of Oregon	Lonergan, MC (corresponding author), UNIV OREGON,DEPT CHEM,EUGENE,OR 97403, USA.			Lonergan, Mark/0000-0003-4070-5067				BARDEEN J, 1947, PHYS REV, V71, P717, DOI 10.1103/PhysRev.71.717; Bethe HA, 1942, THEORY BOUNDARY LAYE; FRANK AJ, 1989, J PHYS CHEM-US, V93, P3818, DOI 10.1021/j100346a088; FREUND MS, 1994, CURRENT SEPARATIONS, V13, P66; HEBEN MJ, 1989, NATURE, V340, P621, DOI 10.1038/340621a0; HEINE V, 1965, PHYS REV, V138, P1689, DOI 10.1103/PhysRev.138.A1689; JAGER H, 1969, SOLID STATE ELECTRON, V12, P511, DOI 10.1016/0038-1101(69)90106-3; KUMAR A, 1993, CRIT REV SOLID STATE, V18, P327, DOI 10.1080/10408439308243731; LEWIS NS, 1991, ANNU REV PHYS CHEM, V42, P543, DOI 10.1146/annurev.physchem.42.1.543; LONERGAN MC, UNPUB; NEWMAN N, 1986, J VAC SCI TECHNOL B, V4, P931, DOI 10.1116/1.583494; NEWMAN N, 1985, APPL PHYS LETT, V46, P1176, DOI 10.1063/1.95749; OFER D, 1990, J AM CHEM SOC, V112, P7869, DOI 10.1021/ja00178a004; OZAKI M, 1979, APPL PHYS LETT, V35, P83, DOI 10.1063/1.90902; REISS H, 1985, J PHYS CHEM-US, V89, P4207, DOI 10.1021/j100266a013; Rhoderick EH, 1988, MONOGRAPHS ELECT ELE, V19; SPICER WE, 1980, PHYS REV LETT, V44, P420, DOI 10.1103/PhysRevLett.44.420; SZE SM, 1981, PHYSICS SEMICONDUCTO; TURNER MJ, 1968, SOLID STATE ELECTRON, V11, P291, DOI 10.1016/0038-1101(68)90041-5; WATANABE A, 1989, MACROMOLECULES, V22, P4231, DOI 10.1021/ma00201a016; YU AYC, 1968, J APPL PHYS, V39, P3008, DOI 10.1063/1.1656723	21	86	91	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2103	2106		10.1126/science.278.5346.2103	http://dx.doi.org/10.1126/science.278.5346.2103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405342				2022-12-28	WOS:A1997YM23500047
J	Mao, HK; Shen, GY; Hemley, RJ				Mao, HK; Shen, GY; Hemley, RJ			Multivariable dependence of Fe-Mg partitioning in the lower mantle	SCIENCE			English	Article							DIAMOND-ANVIL CELL; HIGH-TEMPERATURE; HIGH-PRESSURE; ELECTRICAL-CONDUCTIVITY; (MG,FE)SIO3 PEROVSKITE; SIDEROPHILE ELEMENTS; EARTHS FORMATION; PHASE-RELATIONS; MAGNESIOWUSTITE; EQUATION	High-pressure diamond-cell experiments indicate that the iron-magnesium partitioning between (Fe,Mg)SiO3-perovskite and magnesiowustite in Earth's lower mantle depends on the pressure, temperature, bulk iron/magnesium ratio, and ferric iron content, The perovskite stability field expands with increasing pressure and temperature. The ferric iron component preferentially dissolves in perovskite and raises the apparent total iron content but had little effect on the partitioning of the ferrous iron, The ferrous iron depletes in perovskite at the top of the lower mantle and gradually increases at greater depth. These changes in iron-magnesium composition should affect geochemical and geophysical properties of the deep interior.			Mao, HK (corresponding author), CARNEGIE INST WASHINGTON,GEOPHYS LAB,5251 BROAD BRANCH RD NW,WASHINGTON,DC 20015, USA.							ANDERSON DL, 1989, SCIENCE, V243, P367, DOI 10.1126/science.243.4889.367; BELL PM, 1979, CARNEGIE I WASHINGTO, V78, P618; CAMPBELL AJ, 1992, GEOPHYS RES LETT, V19, P1061, DOI 10.1029/92GL00972; ENG PJ, 1996, P SOC PHOTOOPT INSTR, V2516, P41; FEI Y, 1991, J GEOPHYS RES-SOLID, V96, P2157, DOI 10.1029/90JB02164; FEI Y, 1996, J GEOPHYS RES, V101, P11; GUYOT F, 1988, EARTH PLANET SC LETT, V90, P52, DOI 10.1016/0012-821X(88)90110-0; HILLGREN VJ, 1994, SCIENCE, V264, P1442, DOI 10.1126/science.264.5164.1442; ITO E, 1984, EARTH PLANET SC LETT, V67, P238, DOI 10.1016/0012-821X(84)90119-5; JEANLOZ R, 1995, NATURE, V378, P130, DOI 10.1038/378130a0; JONES JH, 1992, SCIENCE, V257, P1281, DOI 10.1126/science.257.5074.1281; Katsura T, 1996, GEOPHYS RES LETT, V23, P2005, DOI 10.1029/96GL02086; KESSON SE, 1991, EARTH PLANET SC LETT, V111, P229; KNITTLE E, 1991, SCIENCE, V251, P1438, DOI 10.1126/science.251.5000.1438; KNITTLE E, 1987, SCIENCE, V235, P668, DOI 10.1126/science.235.4789.668; Li J, 1996, NATURE, V381, P686, DOI 10.1038/381686a0; LI XY, 1993, J GEOPHYS RES-SOL EA, V98, P501, DOI 10.1029/92JB01816; LI XY, 1991, J GEOPHYS RES-SOLID, V96, P6113, DOI 10.1029/90JB02632; LIU LG, 1975, NATURE, V258, P510, DOI 10.1038/258510a0; Mao HK, 1996, HIGH PRESSURE RES, V14, P257, DOI 10.1080/08957959608201410; MAO HK, 1991, J GEOPHYS RES-SOLID, V96, P8069, DOI 10.1029/91JB00176; Martinez I, 1997, J GEOPHYS RES-SOL EA, V102, P5265, DOI 10.1029/96JB03188; McCammon C, 1997, NATURE, V387, P694, DOI 10.1038/42685; MEADE C, 1995, SCIENCE, V268, P1743, DOI 10.1126/science.268.5218.1743; MURTHY VR, 1991, SCIENCE, V253, P303, DOI 10.1126/science.253.5017.303; MURTHY VR, 1992, SCIENCE, V257, P1284, DOI 10.1126/science.257.5074.1284; OLSEN JS, 1991, PHYS SCRIPTA, V43, P327, DOI 10.1088/0031-8949/43/3/021; Poirier JP, 1996, PHILOS T R SOC A, V354, P1361, DOI 10.1098/rsta.1996.0052; Saxena SK, 1996, SCIENCE, V274, P1357, DOI 10.1126/science.274.5291.1357; Shen G, 1996, ADV MAT 96 NEW TREND, P149; SIMONS B, 1980, CARNEGIE I WASHINGTO, V79, P376; STIXRUDE L, 1992, SCIENCE, V257, P1099, DOI 10.1126/science.257.5073.1099; WANG YB, 1994, PHYS EARTH PLANET IN, V83, P13, DOI 10.1016/0031-9201(94)90109-0; WENG K, 1992, DEV GEOCHEMISTRY, P171; Wood BJ, 1996, SCIENCE, V273, P1522, DOI 10.1126/science.273.5281.1522; Yagi T, 1996, PHILOS T R SOC A, V354, P1371, DOI 10.1098/rsta.1996.0053; YAGI T, 1979, CARNEGIE I WASHINGTO, V78, P612; YEGANEHHAERI A, 1989, SCIENCE, V243, P787, DOI 10.1126/science.243.4892.787; ZERR A, 1993, SCIENCE, V262, P553, DOI 10.1126/science.262.5133.553	39	117	118	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2098	2100		10.1126/science.278.5346.2098	http://dx.doi.org/10.1126/science.278.5346.2098			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405340				2022-12-28	WOS:A1997YM23500045
J	Guerrero, A; Cobo, J; Fortun, J; Navas, E; Quereda, C; Asensio, A; Canon, J; Blazquez, J; GomezMampaso, E				Guerrero, A; Cobo, J; Fortun, J; Navas, E; Quereda, C; Asensio, A; Canon, J; Blazquez, J; GomezMampaso, E			Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection	LANCET			English	Article							NEW-YORK-CITY; HEALTH-CARE WORKERS; TUBERCULOSIS; OUTBREAK; EPIDEMIOLOGY; STRAINS	Background Since 1990, several nosocomial outbreaks of multidrug-resistant (MDR) tuberculosis have occurred, none of which have involved Mycobacterium bovis. We describe an epidemic of nosocomial and primary MDR M bovis tuberculosis from December, 1993, to February, 1995, among HIV-1-infected patients in a district of Madrid. Methods We undertook genetic characterisation of the M bovis strain and investigated its presence in a tuberculosis epidemic in a Madrid hospital in a case controlled study. We assessed 19 cases diagnosed with MDR tuberculosis due to M bovis during the study period. For the control group, we randomly selected 33 patients with HIV-1 infection and isolation of a strain of M tuberculosis susceptible to isoniazid, rifampicin, or both, who were treated in Ramon y Cajal Hospital. Infection-control policies and practices were implemented. Findings We detected 19 cases in HIV-1-infected patients of primary MDR tuberculosis produced by M bovis resistant to 11 antituberculosis drugs. We found phenotypic and genotypic similarities in the strains of M bovis. In the case group, the index case and two other cases had had previous contact with another hospital that had had an MDR tuberculosis outbreak. All patients died after a mean of 44 days (range 2-116), despite multidrug treatment with first-line and second-line antituberculosis drugs. The cases with M bovis MDR tuberculosis were significantly more likely than controls to have been admitted to a hospital ward at the same time as patients already infected with MDR tuberculosis during the 10 months before their diagnosis (adjusted odds ratio 94.6 [95% CI 9.4-956.3], p<0.0001). Advanced HIV-1 immunosuppression was associated with the development of MDR tuberculosis. Implementation of control measures stopped the epidemic. Interpretation An M bovis primary MDR tuberculosis epidemic that cannot be treated effectively and with high mortality has emerged in Europe and has been transmitted between hospitals.	UNIV ALCALA DE HENARES, HOSP RAMON Y CAJAL, INFECT DIS & CLIN MICROBIOL DEPT, MADRID, SPAIN; UNIV ALCALA DE HENARES, HOSP RAMON Y CAJAL, DEPT PREVENT MED, MADRID, SPAIN	Hospital Universitario Ramon y Cajal; Universidad de Alcala; Hospital Universitario Ramon y Cajal; Universidad de Alcala			Blazquez, Jesus/T-4680-2017; IBIS, EVOLUCION/O-1921-2015; Fortún, Jesús/H-1816-2017	Blazquez, Jesus/0000-0003-0495-3848; Fortún, Jesús/0000-0002-6959-5263; Asensio, Angel/0000-0003-2912-8561				ALBRECHT H, 1995, EUR J CLIN MICROBIOL, V14, P226, DOI 10.1007/BF02310361; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; ANGARANO G, 1995, MICROBIOLOGICA, V18, P69; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; Blazquez J, 1997, J CLIN MICROBIOL, V35, P1390; BLUMBERG HM, 1995, ANN INTERN MED, V122, P658, DOI 10.7326/0003-4819-122-9-199505010-00003; BOUVET E, 1993, AIDS, V7, P1453, DOI 10.1097/00002030-199311000-00008; CANETTI G, 1963, REV TUBERC PNEUMOL, V27, P263; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P585; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P131; *COMM DIS REP, 1995, COMMUN DIS REP WKLY, V5, P161; DANKNER WM, 1993, MEDICINE, V72, P11, DOI 10.1097/00005792-199301000-00002; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GRANGE JM, 1994, VET MICROBIOL, V40, P137, DOI 10.1016/0378-1135(94)90052-3; GRANGE JM, 1994, EUR RESPIR J, V7, P1564, DOI 10.1183/09031936.94.07091564; HAMBURG MA, 1994, NEW ENGL J MED, V330, P1750, DOI 10.1056/NEJM199406163302410; IKEDA RM, 1995, INFECT CONT HOSP EP, V16, P152; MORRIS RS, 1994, VET MICROBIOL, V40, P153, DOI 10.1016/0378-1135(94)90053-1; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; Rullan JV, 1996, EMERG INFECT DIS, V2, P125, DOI 10.3201/eid0202.960208; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P2834; VANSOOLINGEN D, 1994, J CLIN MICROBIOL, V32, P2425, DOI 10.1128/JCM.32.10.2425-2433.1994; VESTAL ASM, 1975, PROCEDURES ISOLATION; WENGER PN, 1995, LANCET, V345, P235, DOI 10.1016/S0140-6736(95)90228-7	28	95	101	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 13	1997	350	9093					1738	1742		10.1016/S0140-6736(97)07567-3	http://dx.doi.org/10.1016/S0140-6736(97)07567-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413465				2022-12-28	WOS:A1997YL55400010
J	Studitsky, VM; Kassavetis, GA; Geiduschek, EP; Felsenfeld, G				Studitsky, VM; Kassavetis, GA; Geiduschek, EP; Felsenfeld, G			Mechanism of transcription through the nucleosome by eukaryotic RNA polymerase	SCIENCE			English	Article							CHAIN ELONGATION; INITIATION; TEMPLATES; DNA; CHROMATIN; COMPLEXES; INVITRO	Nucleosomes, the nucleohistone subunits of chromatin, are present on transcribed eukaryotic genes but do not prevent transcription. It is shown here that the large yeast RNA polymerase III transcribes through a single nucleosome. This takes place through a direct internal nucleosome transfer in which histones never leave the DNA template, During this process, the polymerase pauses with a pronounced periodicity of 10 to 11 base pairs, which is consistent with restricted rotation in the DNA loop formed during transfer. Transcription through nucleosomes by the eukaryotic enzyme and by much smaller prokaryotic RNA polymerases thus shares many features, reflecting an important property of nucleosomes.	NIDDKD,MOL BIOL LAB,NIH,BETHESDA,MD 20892; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOL GENET,LA JOLLA,CA 92093	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of California System; University of California San Diego; University of California System; University of California San Diego			Studitsky, Vasily/A-9382-2014					BARDELEBEN C, 1994, J MOL BIOL, V235, P1193, DOI 10.1006/jmbi.1994.1073; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; CLARK DJ, 1995, NUCLEOSOME, P207; DUBANDGOULET I, 1992, J MOL BIOL, V224, P981, DOI 10.1016/0022-2836(92)90464-U; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; HANSEN JC, 1992, BIOCHEMISTRY-US, V31, P7977, DOI 10.1021/bi00149a032; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; LUSE D, 1995, CHROMATIN STRUCTURE, P104; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; NDLER E, 1997, CELL, V89, P33; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; TENHEGGELERBORDIER B, 1995, EMBO J, V14, P2561, DOI 10.1002/j.1460-2075.1995.tb07254.x; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T	25	161	162	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1960	1963		10.1126/science.278.5345.1960	http://dx.doi.org/10.1126/science.278.5345.1960			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395401				2022-12-28	WOS:A1997YL00200039
J	Lee, DH; Severin, K; Yokobayashi, Y; Ghadiri, MR				Lee, DH; Severin, K; Yokobayashi, Y; Ghadiri, MR			Emergence of symbiosis in peptide self-replication through a hypercyclic network	NATURE			English	Article							COILED-COILS; ORGANIZATION; PRINCIPLE; EVOLUTION; SYSTEM; RNA	Symbiosis is an association between different organisms that leads to a reciprocal enhancement of their ability to survive, Similar mutually beneficial relationships can operate at the molecular level in the form of a hypercycle, a collective of two or more self-replicating species interlinked through a cyclic catalytic network(1-5). The superposition of cross-catalysis onto autocatalytic replication integrates the members of the hypercycle into a single system that reproduces through a second-order (or higher) form of nonlinear autocatalysis. The hypercycle population as a whole is therefore able to compete more efficiently for existing resources than any one member on its own. In addition, the effects of beneficial mutations of any one member are spread over the entire population, The formation of hypercycles has been suggested as an important step in the transition from inanimate to living chemistry(6), and a large number of hypercycles are expected to be embedded within the complex networks of living systems(7). But only one naturally occurring hypercycle has been well documented(8), while two autocatalytic chemical systems may contain vestiges of hypercyclic organization(9,10). Here we report a chemical system that constitutes a dear example of a minimal hypercyclic network, in which two otherwise competitive self-replicating peptides symbiotically catalyse each others' production.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute			Yokobayashi, Yohei/B-5898-2009	Yokobayashi, Yohei/0000-0002-2417-1934; Severin, Kay/0000-0003-2224-7234				ACHILLES T, 1993, ANGEW CHEM INT EDIT, V32, P1198, DOI 10.1002/anie.199311981; EIGEN M, 1978, NATURWISSENSCHAFTEN, V65, P341, DOI 10.1007/BF00439699; EIGEN M, 1991, BIOCHEMISTRY-US, V30, P11005, DOI 10.1021/bi00110a001; EIGEN M, 1977, NATURWISSENSCHAFTEN, V64, P541, DOI 10.1007/BF00450633; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; EIGEN M, 1978, NATURWISSENSCHAFTEN, V65, P7, DOI 10.1007/BF00420631; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HONG JI, 1992, SCIENCE, V255, P848, DOI 10.1126/science.255.5046.848; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; Kauffman S. A., 1993, ORIGINS ORDER; KUPPERS BO, 1990, ORIGIN BIOL INFORMAT; Lee DH, 1996, NATURE, V382, P525, DOI 10.1038/382525a0; LEE DH, IN PRESS CURR OPIN C; MULLERHEROLD U, 1983, J THEOR BIOL, V102, P569, DOI 10.1016/0022-5193(83)90391-0; RICARD J, 1986, EUR J BIOCHEM, V155, P183, DOI 10.1111/j.1432-1033.1986.tb09475.x; Severin K, 1997, NATURE, V389, P706, DOI 10.1038/39556; Severin K, 1997, CHEM-EUR J, V3, P1017, DOI 10.1002/chem.19970030706; SEVERIN K, IN PRESS ANGEW CHEM; von Kiedrowski G., 1993, BIOORG CHEM FRONT, V3, P113	20	194	200	2	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					591	594		10.1038/37569	http://dx.doi.org/10.1038/37569			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403686				2022-12-28	WOS:A1997YK85300043
J	Baker, JR				Baker, JR			Autoimmune endocrine disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT DIABETES-MELLITUS; GLUTAMIC-ACID DECARBOXYLASE; THYROTROPIN RECEPTOR; GRAVES-DISEASE; THYROID PEROXIDASE; HASHIMOTOS-THYROIDITIS; IMMUNODOMINANT REGION; MOLECULAR-CLONING; ADDISONS-DISEASE; TSH RECEPTOR	Autoimmune endocrine diseases are serious disorders that utilize immense health care resources and cause tremendous disability. They include type 1 diabetes mellitus, thyroiditis, Graves disease, Addison disease, and polyglandular syndromes. Analysis of the basis of autoimmune diseases has been aided by the application of new knowledge in immunologic physiology. Recent investigations using these techniques have revealed complicated disorders that have varied pathogenesis and complex genetic predispositions. While the mainstay of treatment for these diverse diseases remains the replacement of hormones produced by the damaged endocrine organ, investigations into the pathogenesis of these disorders provide hope for the development of specific therapeutic measures to block their pathologic basis.			Baker, JR (corresponding author), UNIV MICHIGAN, SCH MED, TAUBMAN CTR 3918, DIV ALLERGY, ANN ARBOR, MI 48109 USA.							Ajjan RA, 1996, CLIN EXP IMMUNOL, V105, P523, DOI 10.1046/j.1365-2249.1996.d01-784.x; AKAMIZU T, 1995, ENDOCR J, V42, P617, DOI 10.1507/endocrj.42.617; APPELBOOM TM, 1982, CUTIS, V30, P71; Arscott PL, 1996, J BIOL CHEM, V271, P4966; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BAISCH JM, 1990, NEW ENGL J MED, V322, P1836, DOI 10.1056/NEJM199006283222602; BAKER JR, 1990, PRINCIPLES PRACTICE, P1401; Barlow ABT, 1996, CLIN ENDOCRINOL, V44, P73, DOI 10.1046/j.1365-2265.1996.634454.x; Bartley GB, 1996, AM J OPHTHALMOL, V121, P200, DOI 10.1016/S0002-9394(14)70585-9; Blanas E, 1996, SCIENCE, V274, P1707, DOI 10.1126/science.274.5293.1707; CHAZENBALK GD, 1993, J CLIN INVEST, V92, P62, DOI 10.1172/JCI116600; Chen S, 1996, J CLIN ENDOCR METAB, V81, P1871, DOI 10.1210/jc.81.5.1871; Chuang LM, 1996, CLIN ENDOCRINOL, V45, P631, DOI 10.1046/j.1365-2265.1996.00857.x; COOK DL, 1995, DIABETES RES CLIN PR, V28, pS81, DOI 10.1016/0168-8227(95)01088-U; deLeiva A, 1996, HORM RES, V45, P32, DOI 10.1159/000184826; Donner H, 1997, J CLIN ENDOCR METAB, V82, P143, DOI 10.1210/jc.82.1.143; Ellis TM, 1996, NAT MED, V2, P148, DOI 10.1038/nm0296-148; Endo T, 1996, BIOCHEM BIOPH RES CO, V224, P92, DOI 10.1006/bbrc.1996.0989; Falorni A, 1996, DIABETOLOGIA, V39, P1091; FELDMANN M, 1992, J AUTOIMMUN, V5, P115, DOI 10.1016/0896-8411(92)90026-M; Foulis AK, 1996, APMIS, V104, P161, DOI 10.1111/j.1699-0463.1996.tb00702.x; Gerstein HC, 1996, DIABETIC MED, V13, P23, DOI 10.1002/(SICI)1096-9136(199601)13:1&lt;23::AID-DIA4&gt;3.0.CO;2-D; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; HEUFELDER AE, 1993, THYROID, V3, P297, DOI 10.1089/thy.1993.3.297; Heufelder AE, 1996, J CLIN ENDOCR METAB, V81, P3733, DOI 10.1210/jc.81.10.3733; Kawai H, 1996, J MOL MED-JMM, V74, P275, DOI 10.1007/BF00196580; Kawakami A, 1996, ENDOCRINOLOGY, V137, P3163, DOI 10.1210/en.137.8.3163; KLOOS RT, 1996, CONNS CURRENT THERAP, P634; Krolewski AS, 1996, ENDOCRIN METAB CLIN, V25, P217, DOI 10.1016/S0889-8529(05)70322-4; Kurrer MO, 1997, P NATL ACAD SCI USA, V94, P213, DOI 10.1073/pnas.94.1.213; Larsen JL, 1996, DIABETES METAB, V22, P139; LIBERT F, 1991, J CLIN ENDOCR METAB, V73, P857, DOI 10.1210/jcem-73-4-857; MARCOCCI C, 1994, J CLIN ENDOCR METAB, V78, P818, DOI 10.1210/jc.78.4.818; McFarland HF, 1996, SCIENCE, V274, P2037, DOI 10.1126/science.274.5295.2037; MCLACHLAN SM, 1992, ENDOCR REV, V13, P192, DOI 10.1210/er.13.2.192; MCLACHLAN SM, 1995, CLIN EXP IMMUNOL, V101, P200; McMurray RW, 1996, AUTOIMMUNITY, V23, P9, DOI 10.3109/08916939608995325; Merriman TR, 1996, HORM METAB RES, V28, P289, DOI 10.1055/s-2007-979795; NEUFELD M, 1980, PEDIATR ANN, V9, P43, DOI 10.3928/0090-4481-19800401-07; Nistico L, 1996, HUM MOL GENET, V5, P1075, DOI 10.1093/hmg/5.7.1075; Owerbach D, 1996, DIABETES, V45, P544, DOI 10.2337/diabetes.45.5.544; PARHAM P, 1990, NATURE, V345, P662, DOI 10.1038/345662a0; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; Radosavljevic VR, 1996, EUR J ENDOCRINOL, V134, P699, DOI 10.1530/eje.0.1340699; Rapoport B, 1996, J CLIN ENDOCR METAB, V81, P2525, DOI 10.1210/jc.81.7.2525; RILEY WJ, 1990, NEW ENGL J MED, V323, P1167, DOI 10.1056/NEJM199010253231704; ROITT IM, 1987, IMMUNOL LETT, V16, P259, DOI 10.1016/0165-2478(87)90155-6; Savage MO, 1996, DIABETES METAB, V22, P257; Schatz DA, 1996, CLEV CLIN J MED, V63, P270, DOI 10.3949/ccjm.63.5.270; Shimojo N, 1996, P NATL ACAD SCI USA, V93, P11074, DOI 10.1073/pnas.93.20.11074; Skyler JS, 1996, ENDOCRIN METAB CLIN, V25, P243, DOI 10.1016/S0889-8529(05)70323-6; SRIDAMA V, 1987, ARCH INTERN MED, V147, P229, DOI 10.1001/archinte.147.2.229; TIAN J, 1953, NAT MED, V2, P1348; Tian JD, 1996, J EXP MED, V183, P1561, DOI 10.1084/jem.183.4.1561; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; Undlien DE, 1997, DIABETES, V46, P143, DOI 10.2337/diabetes.46.1.143; Verge CF, 1996, J AUTOIMMUN, V9, P379, DOI 10.1006/jaut.1996.0051; Verge CF, 1996, DIABETES, V45, P926, DOI 10.2337/diabetes.45.7.926; Verge CF, 1996, WESTERN J MED, V164, P249; Vlase H, 1997, ENDOCRINOLOGY, V138, P1658, DOI 10.1210/en.138.4.1658; WAGLE NM, 1994, AUTOIMMUNITY, V18, P103, DOI 10.3109/08916939409007983; WEETMAN AP, 1984, ENDOCR REV, V5, P309, DOI 10.1210/edrv-5-2-309; WILSON K, 1990, ANNU REV MED, V41, P497; Winqvist O, 1996, MOL MED TODAY, V2, P282, DOI 10.1016/1357-4310(96)10024-1; WORRALL G, 1994, CAN FAM PHYSICIAN, V40, P1955	65	45	46	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1931	1937						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396655				2022-12-28	WOS:A1997YK15500016
J	Erkinjuntti, T; Ostbye, T; Steenhuis, R; Hachinski, V				Erkinjuntti, T; Ostbye, T; Steenhuis, R; Hachinski, V			The effect of different diagnostic criteria on the prevalence of dementia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DSM-III-R; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; APOLIPOPROTEIN-E; NINDS-AIREN; ICD-10; POPULATION; HEALTH; DISORDERS; ATROPHY	Background There are several widely used sets of criteria for the diagnosis of dementia, but little is known about their degree of agreement and their effects on estimates of the prevalence of dementia. Methods We examined 1879 men and women 65 years of age or older who were enrolled in the Canadian Study of Health and Aging and calculated the proportion given a diagnosis of dementia according to six commonly used classification systems: the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM), third edition (DSM-III), the third edition, revised, of the DSM (DSM-III-R), the fourth edition of the DSM (DSM-IV), the World Health Organization's International Classification of Diseases (ICD), 9th revision (ICD-9) and 10th revision (ICD-10), and the Cambridge Examination for Mental Disorders of the Elderly (CAMDEX). The degree of concordance among classification schemes and the importance of various factors in determining diagnostic agreement or disagreement were examined. Results The proportion of subjects with dementia varied from 3.1 percent when we used the criteria of the ICD-10 to 29.1 percent when the DSM-III criteria were used. The six classification systems identified different groups of subjects as having dementia; only 20 subjects were given a diagnosis of dementia according to all six systems. The classifications based on the various systems differed little according to the patients' age, sex, educational level, or status with respect to institutionalization. The factors that most often caused disagreement in diagnosis between DSM-III and ICD-10 were long-term memory, executive function, social activities, and duration of symptoms. Conclusions The commonly used criteria for diagnosis can differ by a factor of 10 in the number of subjects classified as having dementia. Such disagreement has serious implications for research and treatment, as well as for the right of many older persons to drive, make a will, and handle financial affairs. (C) 1997, Massachusetts Medical Society.	UNIV WESTERN ONTARIO,DEPT EPIDEMIOL & BIOSTAT,LONDON,ON N6A 5C1,CANADA; UNIV HELSINKI,DEPT NEUROL,MEMORY RES UNIT,HELSINKI,FINLAND; UNIV WESTERN ONTARIO,DEPT CLIN NEUROL SCI,LONDON,ON N6A 5C1,CANADA; LONDON HLTH SCI CTR,PSYCHOL SERV,LONDON,ENGLAND	Western University (University of Western Ontario); University of Helsinki; Western University (University of Western Ontario)								American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BRONISCH T, 1994, PSYCHOPATHOLOGY, V27, P312, DOI 10.1159/000284889; Cummings JL, 1992, DEMENTIA CLIN APPROA; ERKINJUNTTI T, 1993, ARCH NEUROL-CHICAGO, V50, P305, DOI 10.1001/archneur.1993.00540030069017; ERKINJUNTTI T, 1993, CEREBROVASC DIS, V3, P3, DOI 10.1159/000108661; FICHTER MM, 1995, BRIT J PSYCHIAT, V166, P621, DOI 10.1192/bjp.166.5.621; Fox NC, 1996, LANCET, V348, P94, DOI 10.1016/S0140-6736(96)05228-2; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; HACHINSKI V, 1992, LANCET, V340, P645; HENDERSON AS, 1994, PSYCHOL MED, V24, P473, DOI 10.1017/S0033291700027446; HILLER W, 1994, PSYCHOPATHOLOGY, V27, P19, DOI 10.1159/000284844; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; OSTBYE T, 1994, CAN MED ASSOC J, V151, P1457; OSTBYE T, 1995, CAN MED ASSOC J, V152, P158; Pohjasvaara T, 1997, STROKE, V28, P785, DOI 10.1161/01.STR.28.4.785; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; SCHUCKIT MA, 1994, ADDICTION, V89, P1629, DOI 10.1111/j.1360-0443.1994.tb03764.x; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; Soininen HS, 1996, TRENDS NEUROSCI, V19, P224, DOI 10.1016/0166-2236(96)10027-8; STEENHUIS RE, 1995, J CLIN EXP NEUROPSYC, V17, P773, DOI 10.1080/01688639508405166; TATEMICHI T K, 1992, Neurology, V42, P413; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TOMASSON K, 1993, ACTA PSYCHIAT SCAND, V88, P311, DOI 10.1111/j.1600-0447.1993.tb03465.x; TUOKKO H, 1995, J CLIN EXP NEUROPSYC, V17, P352, DOI 10.1080/01688639508405129; Wetterling T, 1996, STROKE, V27, P30, DOI 10.1161/01.STR.27.1.30; *WHO, 1992, INT CLASS DIS, P311; World Health Organization, 1977, INT CLASS DIS; 1994, CAN MED ASSOC J, V150, P899	33	338	346	3	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 4	1997	337	23					1667	1674		10.1056/NEJM199712043372306	http://dx.doi.org/10.1056/NEJM199712043372306			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YJ871	9385127				2022-12-28	WOS:A1997YJ87100006
J	Paschke, R; Ludgate, M				Paschke, R; Ludgate, M			The thyrotropin receptor in thyroid diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							STIMULATING-HORMONE-RECEPTOR; HUMAN ENDOCRINE TUMORS; TSH RECEPTOR; HYPERFUNCTIONING ADENOMAS; CONSTITUTIVE ACTIVATION; GERMLINE MUTATIONS; SOMATIC MUTATIONS; GRAVES-DISEASE; ALPHA-SUBUNIT; GENE		UNIV WALES COLL MED, DEPT PATHOL, CARDIFF CF4 4XN, S GLAM, WALES	Cardiff University	Paschke, R (corresponding author), UNIV LEIPZIG, DEPT INTERNAL MED 3, PH ROSENTHAL STR 27, D-04103 LEIPZIG, GERMANY.			Ludgate, Marian/0000-0002-7436-0821				ASTERIA C, 1996, J ENDOCRINOL INVE S6, V19, P26; BIEBERMANN H, 1996, 10 INT C END ICE 96, V1, P643; CliftonBligh RJ, 1997, J CLIN ENDOCR METAB, V82, P1094, DOI 10.1210/jc.82.4.1094; CODACCIONI JL, 1980, J CLIN ENDOCR METAB, V50, P932, DOI 10.1210/jcem-50-5-932; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; deRoux N, 1996, J CLIN ENDOCR METAB, V81, P4229, DOI 10.1210/jc.81.12.4229; DeRoux N, 1996, J CLIN ENDOCR METAB, V81, P2023, DOI 10.1210/jc.81.6.2023; DUMONT JE, 1991, BAILLIERE CLIN ENDOC, V5, P727, DOI 10.1016/S0950-351X(10)80012-6; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; ESAPA CT, 1996, J ENDOCRINOL INVEST, V19, P71; FUHRER D, IN PRESS J CLIN ENDO; Gromoll J, 1996, J CLIN ENDOCR METAB, V81, P1367, DOI 10.1210/jc.81.4.1367; HAMBURGER JI, 1980, J CLIN ENDOCR METAB, V50, P1089, DOI 10.1210/jcem-50-6-1089; HOLZAPFEL HP, IN PRESS J CLIN ENDO; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOHLER B, 1996, 10 INT C END ICE 96, V1, P641; Kohn L D, 1995, Vitam Horm, V50, P287, DOI 10.1016/S0083-6729(08)60658-5; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; KOSUGI S, 1994, FEBS LETT, V356, P291, DOI 10.1016/0014-5793(94)01286-5; Laugwitz KL, 1996, P NATL ACAD SCI USA, V93, P116, DOI 10.1073/pnas.93.1.116; LAURBERG P, 1991, J INTERN MED, V229, P415, DOI 10.1111/j.1365-2796.1991.tb00368.x; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LUDGATE M, 1990, AUTOIMMUNITY, V7, P201, DOI 10.3109/08916939008993392; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MCKENZIE JM, 1989, J CLIN ENDOCR METAB, V69, P1093, DOI 10.1210/jcem-69-6-1093; MCLACHLAN SM, 1993, J INTERN MED, V234, P347, DOI 10.1111/j.1365-2796.1993.tb00756.x; MEDEIROSNETO GA, 1979, ACTA ENDOCRINOL-COP, V92, P62, DOI 10.1530/acta.0.0920062; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Parma J, 1997, J CLIN ENDOCR METAB, V82, P2695, DOI 10.1210/jc.82.8.2695; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PASCHKE R, 1995, CLIN ENDOCRINOL, V42, P565, DOI 10.1111/j.1365-2265.1995.tb02681.x; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; Paschke R, 1996, BAILLIERE CLIN ENDOC, V10, P9, DOI 10.1016/S0950-351X(96)80266-7; PORCELLINI A, 1994, J CLIN ENDOCR METAB, V79, P657, DOI 10.1210/jc.79.2.657; Russo D, 1996, J CLIN ENDOCR METAB, V81, P1548, DOI 10.1210/jc.81.4.1548; RUSSO D, 1995, J CLIN ENDOCR METAB, V80, P1347, DOI 10.1210/jc.80.4.1347; RUSSO D, 1995, ONCOGENE, V11, P1907; RUSSO D, 1996, J ENDOCRINOL INVE S6, V19, P1; SANDROCK D, 1993, ACTA ENDOCRINOL-COP, V128, P51, DOI 10.1530/acta.0.1280051; Schwab KO, 1996, EXP CLIN ENDOCR DIAB, V104, P124, DOI 10.1055/s-0029-1211719; SHCIPANI E, 1996, NEW ENGL J MED, V335, P708; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SMITH BR, 1988, ENDOCR REV, V9, P106, DOI 10.1210/edrv-9-1-106; Spambalg D, 1996, J CLIN ENDOCR METAB, V81, P3898, DOI 10.1210/jc.81.11.3898; SPIEGEL AM, 1993, J CLIN INVEST, V92, P1119, DOI 10.1172/JCI116680; STEIN SA, 1994, MOL ENDOCRINOL, V8, P129, DOI 10.1210/me.8.2.129; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUNTHORNTHEPVARAKUL T, 1995, NEW ENGL J MED, V332, P155, DOI 10.1056/NEJM199501193320305; TAKAMATSU J, 1993, J CLIN ENDOCR METAB, V77, P1569, DOI 10.1210/jc.77.6.1569; TAKESHITA A, 1995, J CLIN ENDOCR METAB, V80, P2607, DOI 10.1210/jc.80.9.2607; TAKESHITA A, 1994, THYROID, V4, P255, DOI 10.1089/thy.1994.4.255; THOMAS JL, 1982, ACTA ENDOCRINOL-COP, V100, P512, DOI 10.1530/acta.0.1000512; Tonacchera M, 1996, J CLIN ENDOCR METAB, V81, P547, DOI 10.1210/jc.81.2.547; USADEL KH, 1987, THYROID AUTOIMMUNITY, P207; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577; YOSHIMOTO K, 1993, CANCER, V72, P1386, DOI 10.1002/1097-0142(19930815)72:4<1386::AID-CNCR2820720439>3.0.CO;2-J	57	184	188	2	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 4	1997	337	23					1675	1681		10.1056/NEJM199712043372307	http://dx.doi.org/10.1056/NEJM199712043372307			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ871	9385128				2022-12-28	WOS:A1997YJ87100007
J	Agretelis, J; Avorn, J; Blatt, CM; Bedell, SE; Bennett, SE; Bor, DH; Frei, E; Gonzalez, E; Gordon, S; Graboys, T; Hatem, C; Himmelstein, DU; Holtz, TH; Levy, BS; Lown, B; Master, RJ; McCall, TB; Rabkin, MT; Scavron, J; Stoeckle, JD; Swislow, L; Walsh, J; Woolhandler, S				Agretelis, J; Avorn, J; Blatt, CM; Bedell, SE; Bennett, SE; Bor, DH; Frei, E; Gonzalez, E; Gordon, S; Graboys, T; Hatem, C; Himmelstein, DU; Holtz, TH; Levy, BS; Lown, B; Master, RJ; McCall, TB; Rabkin, MT; Scavron, J; Stoeckle, JD; Swislow, L; Walsh, J; Woolhandler, S			For our patients, not for profits - A call to action	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									AD HOC COMM DEFEND HLTH CARE,CAMBRIDGE,MA									COLUMBIA HCA, 1995, 10Q REPORT FILED SEC; CRAWSHAW R, 1995, JAMA-J AM MED ASSOC, V273, P1553, DOI 10.1001/jama.273.19.1553; Levit KR, 1996, HEALTH AFFAIR, V15, P130, DOI 10.1377/hlthaff.15.2.130; 1996, MANAGED HEALTHC 0630, V4, P1	4	29	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1733	1738						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388138				2022-12-28	WOS:A1997YH98700012
J	Fonseca, R; Hartmann, LC; Petersen, IA; Donohue, JH; Crotty, TB; Gisvold, JJ				Fonseca, R; Hartmann, LC; Petersen, IA; Donohue, JH; Crotty, TB; Gisvold, JJ			Ductal carcinoma in situ of the breast	ANNALS OF INTERNAL MEDICINE			English	Review							TERM FOLLOW-UP; IN-SITU; INTRADUCTAL CARCINOMA; LOCAL RECURRENCE; CONSERVING SURGERY; RADIATION-THERAPY; FEMALE BREAST; DEFINITIVE IRRADIATION; PATHOLOGICAL FINDINGS; CONSERVATIVE SURGERY	Purpose: The increasing incidence and biological heterogeneity of ductal carcinoma in situ (DCIS) of the breast have made the management of th is entity challenging a nd controversial. This paper reviews data on the natural history of the disease and results obtained with various management approaches. Data Sources: Computerized MEDLINE search of articles related to DCIS published since 1966. Study Selection: Randomized trials were given higher value; however, because these were relatively scarce, retrospective studies and data published in abstract form were also included. Data Extraction: The authors reviewed all sources critically. No formal statistical calculations were made. Data Synthesis: The incidence of DCIS is increasing, and a greater proportion of diagnoses are being made in asymptomatic patients. No data from randomized trials compare mastectomy and breast-conserving therapy for the treatment of DCIS. A large randomized trial comparing lumpectomy with lumpectomy plus radiotherapy showed lumpectomy plus radiotherapy to be effective for management of this disease. The presence of comedo necrosis and surgical margin status are frequently used as predictors of subsequent recurrence, although this practice is controversial. The risk for in-breast recurrence at 5 years after lumpectomy and radiotherapy is approximately 8%. With more refined molecular analysis, the relation of DCIS to invasive breast cancer will be better defined. Conclusions: Treatment strategies for DCIS have evolved, and lumpectomy followed by radiotherapy is an appropriate alternative for most patients. The use of lumpectomy alone in selected patients remains controversial.	MAYO CLIN & MAYO FDN, DEPT MED ONCOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DIV RADIAT ONCOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT SURG, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DIV ANAT PATHOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT DIAGNOST RADIOL, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic				Fonseca, Rafael/0000-0002-5938-3769				ALPERS CE, 1985, HUM PATHOL, V16, P796, DOI 10.1016/S0046-8177(85)80251-3; ARNESSON LG, 1989, BRIT J SURG, V76, P672, DOI 10.1002/bjs.1800760707; ASHIKARI R, 1977, CANCER, V39, P435, DOI 10.1002/1097-0142(197702)39:2<435::AID-CNCR2820390211>3.0.CO;2-W; BARNES DM, 1991, BREAST CANCER RES TR, V18, P11, DOI 10.1007/BF01975438; BARNES DM, 1992, EUR J CANCER, V28A, P644, DOI 10.1016/S0959-8049(05)80117-0; BARTOW SA, 1987, CANCER, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M; BETSILL WL, 1978, JAMA-J AM MED ASSOC, V239, P1863, DOI 10.1001/jama.239.18.1863; BORNSTEIN BA, 1991, CANCER-AM CANCER SOC, V67, P7, DOI 10.1002/1097-0142(19910101)67:1<7::AID-CNCR2820670103>3.0.CO;2-B; BUR ME, 1992, CANCER-AM CANCER SOC, V69, P1174; Bush D S, 1994, Wis Med J, V93, P483; CAMUS MG, 1994, CANCER, V74, P1289, DOI 10.1002/1097-0142(19940815)74:4<1289::AID-CNCR2820740418>3.0.CO;2-7; Carlson R W, 1996, Oncology (Williston Park), V10, P47; CARPENTER R, 1989, BRIT J SURG, V76, P564, DOI 10.1002/bjs.1800760612; CARTER D, 1977, CANCER, V40, P1189, DOI 10.1002/1097-0142(197709)40:3<1189::AID-CNCR2820400330>3.0.CO;2-X; Choi WS, 1996, CANCER EPIDEM BIOMAR, V5, P317; CUTULI BF, 1992, B CANCER, V79, P1045; DEPOTTER CR, 1995, HUM PATHOL, V26, P601, DOI 10.1016/0046-8177(95)90163-9; DERSHAW DD, 1989, RADIOLOGY, V170, P411, DOI 10.1148/radiology.170.2.2536185; DOUGLASJONES AG, 1995, HUM PATHOL, V26, P217, DOI 10.1016/0046-8177(95)90040-3; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; EUSEBI V, 1994, SEMIN DIAGN PATHOL, V11, P223; EVANS A, 1994, AM J ROENTGENOL, V162, P1307, DOI 10.2214/ajr.162.6.8191988; Farrow J H, 1970, Cancer, V25, P468, DOI 10.1002/1097-0142(197002)25:2<468::AID-CNCR2820250226>3.0.CO;2-0; FEUER EJ, 1992, AM J EPIDEMIOL, V136, P1423, DOI 10.1093/oxfordjournals.aje.a116463; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FISHER ER, 1991, J SURG ONCOL, V47, P139, DOI 10.1002/jso.2930470302; FISHER ER, 1986, CANCER-AM CANCER SOC, V57, P197, DOI 10.1002/1097-0142(19860115)57:2<197::AID-CNCR2820570203>3.0.CO;2-N; FISHER ER, 1995, CANCER-AM CANCER SOC, V75, P1310, DOI 10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G; FRYKBERG ER, 1994, CANCER, V74, P350, DOI 10.1002/cncr.2820741321; GALLAGHER WJ, 1989, J CLIN ONCOL, V7, P376, DOI 10.1200/JCO.1989.7.3.376; GARFINKEL L, 1994, CANCER, V74, P222, DOI 10.1002/cncr.2820741304; GRAHAM MD, 1991, EUR J SURG ONCOL, V17, P258; GUMP FE, 1987, SURGERY, V102, P790; HARRISON M, 1995, J PATHOL, V175, P303, DOI 10.1002/path.1711750308; Hillner BE, 1996, J CLIN ONCOL, V14, P70, DOI 10.1200/JCO.1996.14.1.70; HOLLAND R, 1994, SEMIN DIAGN PATHOL, V11, P181; HOLLAND R, 1990, LANCET, V335, P519, DOI 10.1016/0140-6736(90)90747-S; HOLLAND R, 1994, SEMIN DIAGN PATHOL, V11, P167; IKEDA DM, 1989, RADIOLOGY, V172, P661, DOI 10.1148/radiology.172.3.2549563; KESSLER LG, 1991, PREV MED, V20, P170, DOI 10.1016/0091-7435(91)90018-Y; KINNE DW, 1989, ARCH SURG-CHICAGO, V124, P33; KNUTZEN AM, 1993, MAYO CLIN PROC, V68, P454, DOI 10.1016/S0025-6196(12)60194-3; KURTZ JM, 1989, CANCER, V63, P1630, DOI 10.1002/1097-0142(19890415)63:8<1630::AID-CNCR2820630833>3.0.CO;2-U; KUSKE RR, 1993, INT J RADIAT ONCOL, V26, P391, DOI 10.1016/0360-3016(93)90955-U; LAGIOS MD, 1982, CANCER-AM CANCER SOC, V50, P1309, DOI 10.1002/1097-0142(19821001)50:7<1309::AID-CNCR2820500716>3.0.CO;2-#; LAGIOS MD, 1989, CANCER, V63, P618, DOI 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J; LAGIOS MD, 1990, SURG CLIN N AM, V70, P853; LAGIOS MD, 1993, J CELL BIOCHEM, P49; LAGIOS MD, 1994, CURRENT PERSPECTIVES, P1; LEAL CB, 1995, CANCER, V75, P2123, DOI 10.1002/1097-0142(19950415)75:8<2123::AID-CNCR2820750815>3.0.CO;2-V; LENNINGTON WJ, 1994, CANCER, V73, P118, DOI 10.1002/1097-0142(19940101)73:1<118::AID-CNCR2820730121>3.0.CO;2-R; LIFF JM, 1991, AM J PUBLIC HEALTH, V81, P462, DOI 10.2105/AJPH.81.4.462; LIU E, 1992, ONCOGENE, V7, P1027; MAGUIRE HC, 1992, PATHOBIOLOGY, V60, P117; MARIUZZI GM, 1994, PATHOL RES PRACT, V190, P1056, DOI 10.1016/S0344-0338(11)80901-5; MCCORMICK B, 1991, INT J RADIAT ONCOL, V21, P289, DOI 10.1016/0360-3016(91)90773-W; Munn KE, 1996, BRIT J CANCER, V73, P636, DOI 10.1038/bjc.1996.110; OTTESEN GL, 1992, AM J SURG PATHOL, V16, P1183, DOI 10.1097/00000478-199212000-00005; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; PALLIS L, 1992, ANTICANCER RES, V12, P2113; POLLER DN, 1994, MODERN PATHOL, V7, P257; POLLER DN, 1993, BRIT J CANCER, V68, P156, DOI 10.1038/bjc.1993.305; PRICE P, 1990, BRIT J CANCER, V61, P869, DOI 10.1038/bjc.1990.194; ROSEN PP, 1979, ANN SURG, V189, P377, DOI 10.1097/00000658-197903000-00021; ROSEN PP, 1980, CANCER, V46, P919, DOI 10.1002/1097-0142(19800815)46:4+<919::AID-CNCR2820461311>3.0.CO;2-Z; Schnitt SJ, 1996, CANCER, V77, P2189, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2189::AID-CNCR1>3.0.CO;2-L; SCHNITT SJ, 1992, AM J SURG PATHOL, V16, P1133, DOI 10.1097/00000478-199212000-00001; SCHUH ME, 1986, ARCH SURG-CHICAGO, V121, P1303, DOI 10.1001/archsurg.121.11.1303; SCHWARTZ GF, 1992, CANCER, V70, P2468, DOI 10.1002/1097-0142(19921115)70:10<2468::AID-CNCR2820701013>3.0.CO;2-K; Sibbering D. M., 1996, Journal of Pathology, V178, p6A; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; SILVERSTEIN MJ, 1992, EUR J CANCER, V28A, P630, DOI 10.1016/S0959-8049(05)80114-5; SILVERSTEIN MJ, 1994, CANCER-AM CANCER SOC, V73, P664, DOI 10.1002/1097-0142(19940201)73:3<664::AID-CNCR2820730326>3.0.CO;2-S; SILVERSTEIN MJ, 1995, EUR J CANCER, V31A, P1425, DOI 10.1016/0959-8049(95)00283-O; Silverstein MJ, 1996, CANCER-AM CANCER SOC, V77, P2267, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V; SILVERSTEIN MJ, 1996, BREAST J, V2, P38; SIMON MS, 1993, CANCER, V71, P769, DOI 10.1002/1097-0142(19930201)71:3<769::AID-CNCR2820710320>3.0.CO;2-4; SKJORTEN F, 1986, EUR J SURG ONCOL, V12, P117; Solin LJ, 1996, J CLIN ONCOL, V14, P754, DOI 10.1200/JCO.1996.14.3.754; SOLIN LJ, 1990, INT J RADIAT ONCOL, V19, P843, DOI 10.1016/0360-3016(90)90003-3; SOLIN LJ, 1994, INT J RADIAT ONCOL, V30, P3, DOI 10.1016/0360-3016(94)90512-6; SOMERVILLE JE, 1992, J CLIN PATHOL, V45, P16, DOI 10.1136/jcp.45.1.16; STOMPER PC, 1989, RADIOLOGY, V172, P235, DOI 10.1148/radiology.172.1.2544922; STRATTON MR, 1995, J PATHOL, V175, P195, DOI 10.1002/path.1711750207; SUNSHINE JA, 1985, AM J SURG, V150, P44, DOI 10.1016/0002-9610(85)90008-X; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VONRUEDEN DG, 1984, SURG GYNECOL OBSTET, V158, P105; WALKER RA, 1991, J PATHOL, V165, P203, DOI 10.1002/path.1711650303; WARD BA, 1992, ARCH SURG-CHICAGO, V127, P1392; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; WELLINGS SR, 1975, J NATL CANCER I, V55, P231; WHITE J, 1995, INT J RADIAT ONCOL, V31, P791, DOI 10.1016/0360-3016(94)00486-2; WINCHESTER DP, 1995, ANN SURG ONCOL, V2, P207, DOI 10.1007/BF02307025; WOBBES T, 1989, BRIT J SURG, V76, P185, DOI 10.1002/bjs.1800760226; ZHUANG ZP, 1995, CANCER RES, V55, P467; 1996, PDQ, V3, pP41	98	45	45	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					1013	1022		10.7326/0003-4819-127-11-199712010-00013	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00013			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412283				2022-12-28	WOS:A1997YJ08000009
J	Craft, N				Craft, N			Women's health - The childbearing years and after	BRITISH MEDICAL JOURNAL			English	Article											Craft, N (corresponding author), GOWER PL PRACTICE,LONDON WC1E 6BN,ENGLAND.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				BONITA R, 1995, 3 M WHO GLOB COMM WO; Craft N, 1997, BRIT MED J, V315, P1154, DOI 10.1136/bmj.315.7116.1154; Doyal L., 1995, WHAT MAKES WOMEN SIC; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; *INT PLANN PAR FED, 1995, WOM HLTH WOM RIGHTS; *INT PLANN PAR FED, 1997, REAL LIV; MEAGHER D, 1997, LANCET S, V349, P117; NEWNHAM HH, 1997, LANCET S, V349, P13; *OFF POPO CENS SUR, 1996, POP TRENDS 84; Peto R, 1996, JAMA-J AM MED ASSOC, V275, P1683, DOI 10.1001/jama.275.21.1683; SAUNDERS N, 1997, LANCET S, V349, P17; SYMKE P, 1991, WOMEN HLTH; *UN, 1995, LOOK BACK MOV FORW S; *UN, 1995, STAT WORLDS CHILDR; *UN, 1995, WORLDS WOM 1995 TREN; *UN FUND POP ASS, 1994, STAT WORLDS POP; vanWijk CMTG, 1996, SOC SCI MED, V43, P707, DOI 10.1016/0277-9536(96)00115-3; *WHO, 1991, WOM HLTH TOW BETT WO; *WHO, 1994, WOM AIDS AG ACT; *WHO, 1995, WOM HLTH IMPR OUR HL; *WHO, 1994, CHALL REPR HLTH RES, P120; *WHO, 1994, CREAT COMM GROUND AS; *WORLD BANK, 1993, WORLD DEV REP	23	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1301	1304		10.1136/bmj.315.7118.1301	http://dx.doi.org/10.1136/bmj.315.7118.1301			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390062	Green Published			2022-12-28	WOS:A1997YG64500037
J	Gottesman, S; Maurizi, MR; Wickner, S				Gottesman, S; Maurizi, MR; Wickner, S			Regulatory subunits of energy-dependent proteases	CELL			English	Review							ESCHERICHIA-COLI; CLPAP PROTEASE; MEMBRANE; COMPLEX; ATP; LON		NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gottesman, S (corresponding author), NCI, MOL BIOL LAB, BLDG 37, BETHESDA, MD 20892 USA.							Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Groettrup M, 1996, IMMUNOL TODAY, V17, P429, DOI 10.1016/0167-5699(96)10051-7; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; Richmond C, 1997, J BIOL CHEM, V272, P13403, DOI 10.1074/jbc.272.20.13403; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; SINGH SK, 1994, J BIOL CHEM, V269, P29537; VanMelderen L, 1996, J BIOL CHEM, V271, P27730, DOI 10.1074/jbc.271.44.27730; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945	18	145	148	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 14	1997	91	4					435	438		10.1016/S0092-8674(00)80428-6	http://dx.doi.org/10.1016/S0092-8674(00)80428-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390551	Bronze			2022-12-28	WOS:A1997YG49200003
J	Palmer, RH				Palmer, RH			Process-based measures of quality: The need for detailed clinical data in large health care databases	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; PERFORMANCE REPORTS; MEDICARE PATIENTS	The Institute of Medicine defines health care quality as increasing ''the likelihood of desired health outcomes'' using ''services... consistent with current professional knowledge.'' This definition implies that quality measures can be based on either achieving health care outcomes or completing processes that experts agree have been shown by scientific evidence to improve outcomes. Process-based measures are especially suitable when the user needs to know how to improve quality, when provider comparisons show equivalent outcomes but all providers should improve processes, when measures are needed to evaluate health care that is intended to improve long-term outcomes, or when the contribution of individual providers (especially providers who have a small number of cases) needs to be defined. However, many different process-based measures are needed to comprehensively assess quality, and many process-based measures require detailed clinical data currently found only in medical records. Therefore, the expense of abstracting records is a barrier to process-based measurement. Fortunately, large-scale process-based measures are becoming more feasible because the required clinical data are being included in large databases. The merging of existing inpatient and outpatient data bases with pharmacy and laboratory data bases is an important step toward obtaining data that link all patient admissions, appointments, diagnostic procedures, and prescriptions with diagnoses and test results. Other data that are valuable for process-based measures must still be obtained by abstracting data from records, including clinical findings, patient preferences, and medical and family history. In the future, such data may be added to large databases to create computerized medical records.			Palmer, RH (corresponding author), HARVARD UNIV, SCH PUBL HLTH, CTR QUAL CARE RES & EDUC, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.							CLEARY PD, 1991, HEALTH AFFAIR, V10, P254, DOI 10.1377/hlthaff.10.4.254; Cronin C, 1996, INT J QUAL HEALTH C, V8, P505, DOI 10.1093/intqhc/8.5.505; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; *INF SYST WORK GRO, 1997, ROAD MAP INF SYST EV, V4; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; LARSEN ML, 1990, NEW ENGL J MED, V323, P1021, DOI 10.1056/NEJM199010113231503; Lohr K., 1990, MEDICARE STRATEGY QU, V1, P21; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; Palmer RH, 1995, HEALTH AFFAIR, V14, P89, DOI 10.1377/hlthaff.14.4.89; Palmer RH, 1996, JAMA-J AM MED ASSOC, V275, P1851, DOI 10.1001/jama.275.23.1851; Palmer RH, 1996, MED CARE, V34, pSS3; PALMER RH, 1995, AHCPR US DEPT HHS PU, P3; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; Schneider EC, 1996, NEW ENGL J MED, V335, P251, DOI 10.1056/NEJM199607253350406; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; *US GEN ACC OFF, 1995, GAOHEHS95201; WEINER JP, 1995, JAMA-J AM MED ASSOC, V273, P1503, DOI 10.1001/jama.273.19.1503	20	80	83	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				733	738		10.7326/0003-4819-127-8_Part_2-199710151-00059	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00059			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB385	9382389				2022-12-28	WOS:A1997YB38500014
J	Overgaard, M; Hansen, PS; Overgaard, J; Rose, C; Andersson, M; Bach, F; Kjaer, M; Gadeberg, CC; Mouridsen, HT; Jensen, MB; Zedeler, K				Overgaard, M; Hansen, PS; Overgaard, J; Rose, C; Andersson, M; Bach, F; Kjaer, M; Gadeberg, CC; Mouridsen, HT; Jensen, MB; Zedeler, K			Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; FOLLOW-UP; POSTMASTECTOMY RADIOTHERAPY; RADICAL-MASTECTOMY; IRRADIATION; THERAPY; CYCLOPHOSPHAMIDE; RADIATION; ONCOLOGY	Background Irradiation after mastectomy can reduce locoregional recurrences in women with breast cancer, but whether it prolongs survival remains controversial. We conducted a randomized trial of radiotherapy after mastectomy in high-risk premenopausal women, all of whom also received adjuvant systemic chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF). Methods A total of 1708 women who had undergone mastectomy for pathological stage II or III breast cancer were randomly assigned to receive eight cycles of CMF plus irradiation of the chest wall and regional lymph nodes (852 women) or nine cycles of CMF alone (856 women). The median length of follow-up was 114 months. The end points were locoregional recurrence, distant metastases, disease-free survival, and overall survival. Results The frequency of locoregional recurrence alone or with distant metastases was 9 percent among the women who received radiotherapy plus CMF and 32 percent among those who received CMF alone (P<0.001). The probability of survival free of disease after 10 years was 48 percent among the women assigned to radiotherapy plus CMF and 34 percent among those treated only with CMF (P<0.001). Overall survival at 10 years was 54 per cent among those given radiotherapy and CMF and 45 percent among those who received CMF alone (P<0.001). Multivariate analysis demonstrated that irradiation after mastectomy significantly improved disease-free survival and overall survival, irrespective of tumor size, the number of positive nodes, or the histopathological grade. Conclusions The addition of postoperative irradiation to mastectomy and adjuvant chemotherapy reduces locoregional recurrences and prolongs survival in high-risk premenopausal women with breast cancer. (C) 1997, Massachusetts Medical Society.	VIBORG CTY HOSP, DEPT MED, VIBORG, DENMARK; AARHUS UNIV HOSP, DEPT EXPT CLIN ONCOL, DK-8000 AARHUS C, DENMARK; AARHUS UNIV HOSP, DANISH CANC SOC, DK-8000 AARHUS C, DENMARK; ODENSE UNIV HOSP, DEPT ONCOL, DK-5000 ODENSE, DENMARK; RIGSHOSP, DEPT ONCOL, DK-2100 COPENHAGEN, DENMARK; UNIV COPENHAGEN HOSP, DEPT ONCOL, HERLEV, DENMARK; AALBORG CTY HOSP, DEPT ONCOL, AALBORG, DENMARK; VEJLE CTY HOSP, DEPT ONCOL, VEJLE, DENMARK; RIGSHOSP, DANISH BREAST CANC COOPERAT GRP SECRETARIAT, DK-2100 COPENHAGEN, DENMARK	Aarhus University; Aarhus University; Aarhus University; Danish Cancer Society; University of Southern Denmark; Odense University Hospital; Rigshospitalet; University of Copenhagen; University of Copenhagen; Aalborg University; Aalborg University Hospital; University of Southern Denmark; Lillebaelt Hospital; Danish Breast Cancer Cooperative Group (DBCG); Rigshospitalet; University of Copenhagen	Overgaard, M (corresponding author), AARHUS UNIV HOSP, DEPT ONCOL, NORREBROGADE 44, BLDG 5, DK-8000 AARHUS C, DENMARK.							ABE O, 1992, LANCET, V339, P71; ABE O, 1995, NEW ENGL J MED, V333, P1444; Abe O, 1996, NEW ENGL J MED, V334, P1003; ANDERSEN KW, 1988, ACTA ONCOL, V27, P627, DOI 10.3109/02841868809091763; ANDERSEN KW, 1981, DAN MED BULL, V28, P102; [Anonymous], 1992, Lancet, V339, P1; BENTZEN SM, 1989, INT J RADIAT BIOL, V56, P711, DOI 10.1080/09553008914551941; BLOMQVIST C, 1992, BRIT J CANCER, V66, P1171, DOI 10.1038/bjc.1992.430; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; BONADONNA G, 1995, NEW ENGL J MED, V332, P901, DOI 10.1056/NEJM199504063321401; CUZICK J, 1987, CANCER TREAT REP, V71, P15; CUZICK J, 1994, J CLIN ONCOL, V12, P447, DOI 10.1200/JCO.1994.12.3.447; CUZICK J, 1987, CANCER TREAT REP, V71, P7; DOMBERNOWSKY P, 1988, ACTA ONCOL, V27, P691, DOI 10.3109/02841868809091771; GELMAN R, 1990, J CLIN ONCOL, V8, P548, DOI 10.1200/JCO.1990.8.3.548; GRIEM KL, 1987, J CLIN ONCOL, V5, P1546, DOI 10.1200/JCO.1987.5.10.1546; Harris J, 1996, DIS BREAST, P487; Harris JR, 1996, INT J RADIAT ONCOL, V35, P641, DOI 10.1016/0360-3016(96)00215-5; JOHANSEN H, 1990, ACTA ONCOL, V29, P709, DOI 10.3109/02841869009092988; LEVITT SH, 1988, INT J RADIAT ONCOL, V14, P787, DOI 10.1016/0360-3016(88)90101-0; MCARDLE CS, 1986, BRIT J SURG, V73, P264, DOI 10.1002/bjs.1800730407; MOURIDSEN HT, 1988, ACTA ONCOL, V27, P699, DOI 10.3109/02841868809091772; MUSS HB, 1991, BREAST CANCER RES TR, V19, P77, DOI 10.1007/BF01980937; OVERGAARD M, 1988, ACTA ONCOL, V27, P707, DOI 10.3109/02841868809091773; PIERCE LJ, 1994, CANCER-AM CANCER SOC, V74, P477, DOI 10.1002/cncr.2820741337; RAGAZ J, 1993, P AN M AM SOC CLIN, V12, P60; Scarff R.W., 1968, HISTOLOGICAL TYPING, Vfirst; VELEZGARCIA E, 1992, EUR J CANCER, V28A, P1833, DOI 10.1016/0959-8049(92)90015-T; WATTBOOLSEN S, 1988, ACTA ONCOL, V27, P663, DOI 10.3109/02841868809091765; WOOD WC, 1994, NEW ENGL J MED, V331, P139	30	2002	2060	2	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					949	955		10.1056/NEJM199710023371401	http://dx.doi.org/10.1056/NEJM199710023371401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9395428	Bronze			2022-12-28	WOS:A1997XY42300001
J	Williams, I; Smith, MG; Sinha, D; Kernan, D; Minor-Babin, G; Garcia, E; Robertson, BH; Di Pentima, R; Shapiro, CN				Williams, I; Smith, MG; Sinha, D; Kernan, D; Minor-Babin, G; Garcia, E; Robertson, BH; Di Pentima, R; Shapiro, CN			Hepatitis B virus transmission in an elementary school setting	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAY-CARE-CENTER; SURFACE-ANTIGEN; INFECTION; CHILD; RISK; SALIVA	Context.-The risk of transmission of hepatitis B virus (HBV) in day care centers and schools is low. Objective.-To investigate the source of HBV transmission for an elementary schoolteacher with acute hepatitis B. Design.-Serologic survey for HBV infection among elementary school students, school staff, and household members of an HBV-infected teacher and student. Setting.-General community and elementary school. Patients.-Elementary school students and staff members and household members of an HBV-infected teacher. Main Outcome Measures.-Elementary school students, school staff, and household members of an HBV-infected teacher were tested for markers of HBV infection. Samples positive far hepatitis B surface antigen (HBsAg) were tested for HBsAg subtype using monoclonal antibodies and examined for HBV DNA homology by polymerase chain reaction techniques. Results.-An HBV-infected student and the teacher were found to have the same HBV subtype (ayw1-2) and to have identical HBV DNA sequences. The teacher reported no ne of the usual risk factors for acquiring HBV infection, and no ne of her family members had been infected prior to her illness. The specific means of HBV transmission from student to teacher was not identified. Of 108 total children in the same grade as the HBV-infected student, 102 (94%) were tested for serologic markers of HBV infection, and none was positive. Conclusions.-This investigation documented transmission from an HBV-infected student to a teacher in an elementary school setting without a reported overt percutaneous or permucosal exposure to blood or infectious body fluids. Transmission of HBV to other students or staff members in the school was not observed.	Ctr Dis Control & Prevent, Hepatitis Branch,MS G37, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; New Hampshire Div Publ Hlth Serv, Concord, NH USA; Mt Hlth Serv, Gorham, NH USA	Centers for Disease Control & Prevention - USA	Williams, I (corresponding author), Ctr Dis Control & Prevent, Hepatitis Branch,MS G37, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA.							ALTER HJ, 1977, INFECT IMMUN, V16, P928, DOI 10.1128/IAI.16.3.928-933.1977; ALTER MJ, 1994, GASTROENTEROL CLIN N, V23, P437; *AM AC PED, 1994, 1994 RED BOOK REP CO, P87; BANCROFT WH, 1977, J INFECT DIS, V135, P79, DOI 10.1093/infdis/135.1.79; BERNIER RH, 1982, AM J EPIDEMIOL, V116, P199, DOI 10.1093/oxfordjournals.aje.a113406; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P1; *CDCP, 1995, 56 CDCP; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P574; DESEDA CC, 1994, PEDIATR INFECT DIS J, V13, P828, DOI 10.1097/00006454-199409000-00017; FOLLETT EAC, 1978, BRIT MED J, V1, P1279, DOI 10.1136/bmj.1.6122.1279-d; FOY HM, 1994, PEDIATRICS, V94, P1002; Francis D P, 1981, Semin Liver Dis, V1, P27, DOI 10.1055/s-2008-1063927; HAYASHI J, 1987, AM J EPIDEMIOL, V125, P492, DOI 10.1093/oxfordjournals.aje.a114555; HURWITZ ES, 1994, PEDIATRICS, V94, P1023; Jackson LA, 1996, PEDIATR INFECT DIS J, V15, P584, DOI 10.1097/00006454-199607000-00005; McIntosh EDG, 1996, LANCET, V347, P118, DOI 10.1016/S0140-6736(96)90241-X; NIGRO G, 1989, LANCET, V1, P1451; OLESKE J, 1980, J PEDIATR-US, V97, P770, DOI 10.1016/S0022-3476(80)80262-9; PATTISON CP, 1974, JAMA-J AM MED ASSOC, V230, P854; PON EW, 1993, PEDIATRICS, V92, P574; REPP R, 1994, LANCET, V344, P961, DOI 10.1016/S0140-6736(94)92320-5; SHAPIRO CN, 1989, PEDIATR INFECT DIS J, V8, P870, DOI 10.1097/00006454-198912000-00009; SHAPIRO ED, 1987, J PEDIATR-US, V110, P90, DOI 10.1016/S0022-3476(87)80296-2; SWENSON PD, 1991, J VIROL METHODS, V33, P27, DOI 10.1016/0166-0934(91)90004-J; SZMUNESS W, 1975, AM J MED SCI, V270, P293, DOI 10.1097/00000441-197509000-00009	25	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2167	2169		10.1001/jama.278.24.2167	http://dx.doi.org/10.1001/jama.278.24.2167			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9417011				2022-12-28	WOS:000071022200033
J	Pawson, T; Scott, JD				Pawson, T; Scott, JD			Signaling through scaffold, anchoring, and adaptor proteins	SCIENCE			English	Review							PLECKSTRIN HOMOLOGY DOMAIN; PHOSPHOTYROSINE-BINDING DOMAIN; RECEPTOR TYROSINE KINASE; GROWTH-FACTOR RECEPTORS; HIGH-AFFINITY BINDING; SH2 DOMAIN; CRYSTAL-STRUCTURES; INSULIN-RECEPTOR; SKELETAL-MUSCLE; 14-3-3 PROTEIN	The process by which extracellular signals are relayed from the plasma membrane to specific intracellular sites is an essential facet of cellular regulation. Many signaling pathways do so by altering the phosphorylation state of tyrosine, serine, or threonine residues of target proteins. Recently, it has become apparent that regulatory mechanisms exist to influence where and when protein kinases and phosphatases are activated in the cell. The role of scaffold, anchoring, and adaptor proteins that contribute to the specificity of signal transduction events by recruiting active enzymes into signaling networks or by placing enzymes close to their substrates is discussed.	HOWARD HUGHES MED INST, VOLLUM INST, PORTLAND, OR 97201 USA	Howard Hughes Medical Institute	Pawson, T (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, 600 UNIV AVE, TORONTO, ON M5G 1X5, CANADA.		Pawson, Tony J/E-4578-2013		NIGMS NIH HHS [GM48231] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048231, R01GM048231] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Burton KA, 1997, P NATL ACAD SCI USA, V94, P11067, DOI 10.1073/pnas.94.20.11067; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CHOI KY, 1994, CELL, V78, P499; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Huang LJS, 1997, J BIOL CHEM, V272, P8057, DOI 10.1074/jbc.272.12.8057; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LESTER LB, IN PRESS P NATL ACAD; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; PRINTEN JA, 1994, GENETICS, V138, P609; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TRUB T, 1995, J BIOL CHEM, V270, P18205; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; Vihinen M, 1997, FEBS LETT, V413, P205, DOI 10.1016/S0014-5793(97)00912-5; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	103	1831	1880	3	158	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 19	1997	278	5346					2075	2080		10.1126/science.278.5346.2075	http://dx.doi.org/10.1126/science.278.5346.2075			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405336				2022-12-28	WOS:A1997YM23500041
J	deShazo, RD; Kemp, SF				deShazo, RD; Kemp, SF			Allergic reactions to drugs and biologic agents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STEVENS-JOHNSON-SYNDROME; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RADIOGRAPHIC CONTRAST-MEDIA; CUTANEOUS REACTIONS; HYPERSENSITIVITY REACTIONS; ANAPHYLACTOID REACTIONS; PENICILLIN ALLERGY; LOCAL-ANESTHETICS; ADVERSE REACTIONS; CLINICAL-TRIAL	Drug allergies are adverse reactions resulting from immunologic responses to drugs or their metabolites. These reactions result in predictable patterns of organ-specific or systemic hypersensitivity that usually recur on subsequent exposure to the same drug. Although diagnostic testing for drug allergy is available for only a few drugs, protocols have been developed to assist in management of allergic reactions to many drugs and biologic agents. Other protocols assist in the management of patients who develop drug reactions while under-going multiple drug therapy or those with a history of adverse drug reactions who again require treatment for the same condition.			deShazo, RD (corresponding author), UNIV S ALABAMA,COLL MED,DEPT MED,4TH FLOOR,MASTIN BLDG,2451 FILLINGIM ST,MOBILE,AL 36617, USA.							ACKER CG, 1995, NEW ENGL J MED, V333, P1572, DOI 10.1056/NEJM199512073332316; ADAMS RM, 1991, ANN ALLERGY, V6, P552; ADKINSON NF, 1984, J ALLERGY CLIN IMMUN, V74, P567, DOI 10.1016/0091-6749(84)90108-8; ANDERSON JA, 1992, JAMA-J AM MED ASSOC, V268, P2845, DOI 10.1001/jama.1992.03490200097011; ANDERSON MV, 1991, DIFFICULT MED MANAGE, P25; ARMSTRONG B, 1976, AM J SURG, V132, P643, DOI 10.1016/0002-9610(76)90362-7; ATKINSON TP, 1992, MED CLIN N AM, V76, P841; ATTAWAY N J, 1991, Journal of Allergy and Clinical Immunology, V87, P227, DOI 10.1016/0091-6749(91)91632-4; Beall G, 1997, IMMUNOL ALLERGY CLIN, V17, P319, DOI 10.1016/S0889-8561(05)70309-X; BECKER LC, 1973, JOHNS HOPKINS MED J, V133, P38; BIELORY LC, 1988, MEDICINE, V6, P40; BIGBY M, 1986, JAMA-J AM MED ASSOC, V256, P3358; BIGBY M, 1985, J AM ACAD DERMATOL, V12, P866, DOI 10.1016/S0190-9622(85)70110-7; BLANCA M, 1994, CLIN EXP ALLERGY, V24, P407, DOI 10.1111/j.1365-2222.1994.tb00928.x; BORDA IT, 1968, J AMER MED ASSOC, V205, P645, DOI 10.1001/jama.205.9.645; BOSSO JV, 1991, J ALLERGY CLIN IMMUN, V88, P830, DOI 10.1016/0091-6749(91)90238-J; *BOST COLL DRUG SU, 1973, JAMA-J AM MED ASSOC, V224, P613; BUSH RK, 1990, CLIN REV ALLERG, V8, P159; BUSH WH, 1995, IMMUNOL ALLERGY CLIN, V15, P597; CHERIYAN S, 1995, ALLERGY PROC, V16, P151, DOI 10.2500/108854195778666793; CHRISTIE PE, 1991, AM REV RESPIR DIS, V144, P957, DOI 10.1164/ajrccm/144.4.957; CHUTKA DS, 1995, MAYO CLIN PROC, V70, P685, DOI 10.4065/70.7.685; DAWSON P, 1983, BRIT J RADIOL, V56, P653, DOI 10.1259/0007-1285-56-669-653; DESHAZO RD, 1982, J ALLERGY CLIN IMMUN, V69, P229, DOI 10.1016/0091-6749(82)90104-X; DESHAZO RD, 1979, J ALLERGY CLIN IMMUN, V63, P387, DOI 10.1016/0091-6749(79)90211-2; DESHAZO RD, 1997, CONNS CURRENT THERAP, V1, P766; DESWARTE RD, 1993, ALLERGIC DIS DIAGNOS, P395; DOOMSGOOSSENS AE, 1989, J AM ACAD DERMATOL, V21, P538, DOI 10.1016/S0190-9622(89)70222-X; DYKEWICZ M S, 1986, Archives of Internal Medicine, V146, P305, DOI 10.1001/archinte.146.2.305; EARL HS, 1987, J ALLERGY CLIN IMMUN, V79, P477, DOI 10.1016/0091-6749(87)90365-4; ENRIGHT T, 1989, ANN ALLERGY, V62, P302; FAICH GA, 1986, NEW ENGL J MED, V314, P1589, DOI 10.1056/NEJM198606123142427; GADDE J, 1993, JAMA-J AM MED ASSOC, V270, P2456, DOI 10.1001/jama.270.20.2456; Gall H, 1996, J ALLERGY CLIN IMMUN, V97, P933, DOI 10.1016/S0091-6749(96)80067-4; GALLOWAY JA, 1990, DIABETES MELLITUS, P497; GIRARD JP, 1976, ANN CLIN RES, V8, P74; GREENBERGER PA, 1991, J ALLERGY CLIN IMMUN, V87, P867, DOI 10.1016/0091-6749(91)90135-B; HEDNER T, 1992, BRIT MED J, V304, P941, DOI 10.1136/bmj.304.6832.941; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; IVES TJ, 1987, ARCH INTERN MED, V147, P1117, DOI 10.1001/archinte.147.6.1117; JACOBS RL, 1982, JAMA-J AM MED ASSOC, V247, P40, DOI 10.1001/jama.247.1.40; JAMES JM, 1995, NEW ENGL J MED, V332, P1262, DOI 10.1056/NEJM199505113321904; KAMADA MM, 1991, ALLERGY PROC, V12, P347, DOI 10.2500/108854191778879124; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; Kesarwala Hemant H., 1995, P460; LALLI AF, 1980, RADIOLOGY, V134, P1; Landor M, 1996, ANN ALLERG ASTHMA IM, V77, P273, DOI 10.1016/S1081-1206(10)63319-4; LANG DM, 1995, J ALLERGY CLIN IMMUN, V95, P813, DOI 10.1016/S0091-6749(95)70123-0; LEE WM, 1995, NEW ENGL J MED, V333, P1118, DOI 10.1056/NEJM199510263331706; LIEBERMAN P, 1991, ANN ALLERGY, V67, P91; LIN RY, 1992, ARCH INTERN MED, V152, P930, DOI 10.1001/archinte.152.5.930; MACKOWIAK PA, 1987, ANN INTERN MED, V106, P728, DOI 10.7326/0003-4819-106-5-728; MAIBACH HI, 1993, ALLERGY PRINCIPLES P, P1605; MEEKINS CV, 1994, J ALLERGY CLIN IMMUN, V94, P1017, DOI 10.1016/0091-6749(94)90120-1; MEYERS S, 1987, GASTROENTEROLOGY, V93, P1255, DOI 10.1016/0016-5085(87)90253-8; MORENO JN, 1995, ANN ALLERG ASTHMA IM, V74, P140; NACLERIO R, 1987, J ALLERGY CLIN IMMUN, V79, P523; PARKER CW, 1962, J EXP MED, V115, P789, DOI 10.1084/jem.115.4.789; PARKER PJ, 1991, J ALLERGY CLIN IMMUN, V88, P213, DOI 10.1016/0091-6749(91)90331-H; PATTERSON R, 1994, ANN ALLERGY, V73, P27; PATTERSON R, 1995, DRUG ALLERGY PROTOCO, P1; PETER G, 1991, REPORT COMMITTEE INF, P29; PODEVIN P, 1995, CLIN REV ALLERG IMMU, V13, P223; PORTER J, 1977, JAMA-J AM MED ASSOC, V237, P879, DOI 10.1001/jama.237.9.879; PURDY BH, 1984, ANN INTERN MED, V100, P512, DOI 10.7326/0003-4819-100-4-512; RASMUSSEN JE, 1995, ARCH DERMATOL, V131, P726, DOI 10.1001/archderm.131.6.726; Rawlins MD, 1991, TXB ADVERSE DRUG REA, P18; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; SCHAEFER RM, 1994, CLIN NEPHROL S1, V44, pS44; SETTIPANE RA, 1995, J ALLERGY CLIN IMMUN, V96, P480, DOI 10.1016/S0091-6749(95)70290-3; SMITH DL, 1995, IMMUNOL ALLERGY CLIN, V15, P613; SMITH DL, 1996, CURRENT THERAPY ALLE, P156; SOGN DD, 1992, ARCH INTERN MED, V152, P1025, DOI 10.1001/archinte.152.5.1025; STANLEY J, 1978, ARCH DERMATOL, V114, P1350, DOI 10.1001/archderm.114.9.1350; STARK BJ, 1987, J ALLERGY CLIN IMMUN, V79, P523, DOI 10.1016/0091-6749(87)90371-X; STEVENSON DD, 1995, IMMUNOL ALLERGY CLIN, V15, P529; STROM BL, 1987, ARTHRITIS RHEUM, V30, P1142, DOI 10.1002/art.1780301009; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; SULLIVAN TJ, 1989, J ALLERGY CLIN IMMUN, V83, P270; Sullivan TJ, 1993, ALLERGY PRINCIPLES P, P1726; TORRES MJ, 1995, J ALLERGY CLIN IMMUN, V96, P130, DOI 10.1016/S0091-6749(95)70042-0; TUNONDELARA JM, 1992, LANCET, V340, P908, DOI 10.1016/0140-6736(92)93314-D; VITTORIO CC, 1995, ARCH INTERN MED, V155, P2285, DOI 10.1001/archinte.155.21.2285; WEILER JM, 1990, J ALLERGY CLIN IMMUN, V85, P713, DOI 10.1016/0091-6749(90)90189-B; WILSON JT, 1978, BRIT MED J, V1, P1583, DOI 10.1136/bmj.1.6127.1583; WOOD AJJ, 1994, HARRISONS PRINCIPLES, P407; ZIMMERMAN GC, 1995, ARCH DERMATOL, V131, P202, DOI 10.1001/archderm.131.2.202	90	165	167	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1895	1906		10.1001/jama.278.22.1895	http://dx.doi.org/10.1001/jama.278.22.1895			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396651				2022-12-28	WOS:A1997YK15500012
J	Greenberger, PA				Greenberger, PA			Immunologic aspects of lung diseases and cystic fibrosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; HYPERSENSITIVITY PNEUMONITIS; HYPEREOSINOPHILIC SYNDROME; WEGENERS GRANULOMATOSIS; PULMONARY SARCOIDOSIS; AIRWAY EPITHELIA; EOSINOPHILIA; ALVEOLITIS; MORBIDITY; BLEOMYCIN	Immunologic lung disorders are accompanied by an array of laboratory abnormalities, some of which contribute to disease pathogenesis. Allergic bronchopulmonary aspergillosis, which complicates asthma and cystic fibrosis, causes mucous plugging of airways, eosinophilic pneumonia, and bronchiolitis obliterans. Aspergillus fumigatus, growing saprophytically in bronchial mucus, is responsible for most cases, and prednisone, not antifungal agents, is the drug of choice because it controls the immunologic responses of the lung. In cystic fibrosis, epithelial surface fluid from the lung does not kill Pseudomonas aeruginosa, in part because antibodies to P aeruginosa are plentiful but ineffective in opsonizing bacteria. Neutrophil-derived elastase cleaves immunoglobulins and digests the C3b receptor on neutrophils, which limits phagocytosis of pathogens. In helminth infections and infestations, pulmonary and peripheral blood eosinophilia can be accompanied by increases in total and antiparasite IgE concentrations and generate T(H)2 CD4(+) T-lymphocyte responses. Understanding the immunologic abnormalities of lung disorders may lead to more effective therapies.			Greenberger, PA (corresponding author), NORTHWESTERN UNIV, SCH MED, DIV ALLERGY IMMUNOL, MC S207, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.		Greenberger, Paul/L-2770-2019	Greenberger, Paul/0000-0003-3882-8498				ALLEN JN, 1994, AM J RESP CRIT CARE, V150, P1423, DOI 10.1164/ajrccm.150.5.7952571; ANDO M, 1991, AM REV RESPIR DIS, V144, P765, DOI 10.1164/ajrccm/144.4.765; AUERBACH HS, 1985, LANCET, V2, P686; BACKMAN KS, 1995, ANN ALLERG ASTHMA IM, V75, P391; Bajema IM, 1997, J LAB CLIN MED, V129, P17, DOI 10.1016/S0022-2143(97)90157-8; BALMES J, 1990, CHEST MED ESSENTIALS, P277; Becker JW, 1996, CHEST, V109, P1536, DOI 10.1378/chest.109.6.1536; BIRRER P, 1994, AM J RESP CRIT CARE, V150, P207, DOI 10.1164/ajrccm.150.1.7912987; Boehme MWJ, 1996, AM J MED, V101, P387, DOI 10.1016/S0002-9343(96)00230-6; BROWN JE, 1995, ANN ALLERG ASTHMA IM, V74, P484; Chauhan B, 1996, J CLIN INVEST, V97, P2324, DOI 10.1172/JCI118675; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; CRAIGHEAD JE, 1988, ARCH PATHOL LAB MED, V112, P673; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DAVIS PB, 1991, NEW ENGL J MED, V325, P575, DOI 10.1056/NEJM199108223250809; DENIS M, 1992, AM J RESP CELL MOL, V7, P156, DOI 10.1165/ajrcmb/7.2.156; DENNING DW, 1991, CHEST, V100, P813, DOI 10.1378/chest.100.3.813; Fink Jordan N., 1997, P543; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; GOLDINER PL, 1978, BRIT MED J, V1, P1664, DOI 10.1136/bmj.1.6128.1664; GONZALESCHAMBERS R, 1991, AM J HEMATOL, V36, P157, DOI 10.1002/ajh.2830360219; GRAMMER LC, IN PRESS ENV OCCUPAT; GREENBERGER PA, 1993, ANN ALLERGY, V70, P333; GREENBERGER PA, 1989, AM J MED, V86, P119, DOI 10.1016/0002-9343(89)90243-X; GREENBERGER PA, 1988, J ALLERGY CLIN IMMUN, V82, P164, DOI 10.1016/0091-6749(88)90995-5; Greenberger Paul A., 1997, P555; HEATLY T, 1994, J HEART LUNG TRANSPL, V13, P720; Hogan MB, 1996, CHEST, V110, P854, DOI 10.1378/chest.110.3.854; HOLOYE PY, 1978, ANN INTERN MED, V88, P47, DOI 10.7326/0003-4819-88-1-47; HUNNINGHAKE CW, 1994, AM J RESP CRIT CARE, V149, P893, DOI 10.1164/ajrccm.149.4.8143052; Jagirdar J, 1996, AM J RESP CRIT CARE, V154, P1076, DOI 10.1164/ajrccm.154.4.8887610; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KONSTAN MW, 1993, AM REV RESPIR DIS, V148, P896, DOI 10.1164/ajrccm/148.4_Pt_1.896; KONSTAN MW, 1995, NEW ENGL J MED, V332, P848, DOI 10.1056/NEJM199503303321303; LAUFER P, 1984, J ALLERGY CLIN IMMUN, V73, P44, DOI 10.1016/0091-6749(84)90482-2; LINDEMANN A, 1991, J CLIN ONCOL, V9, P2120, DOI 10.1200/JCO.1991.9.12.2120; MALMBERG P, 1993, CHEST, V103, P1202, DOI 10.1378/chest.103.4.1202; Mapel DW, 1996, CHEST, V110, P1058, DOI 10.1378/chest.110.4.1058; Matteson EL, 1996, AM J MED, V101, P129, DOI 10.1016/S0002-9343(96)80066-0; MCPHERSON C, 1990, AM J DIS CHILD, V144, P1311; Miller PW, 1996, AM J HUM GENET, V59, P45; NakagawaYoshida K, 1997, CHEST, V111, P245, DOI 10.1378/chest.111.1.245; NIKOLAIZIK WH, 1995, AM J RESP CRIT CARE, V152, P634, DOI 10.1164/ajrccm.152.2.7633719; PATTERSON R, 1977, AM J MED, V63, P257, DOI 10.1016/0002-9343(77)90240-6; PHILLS JA, 1972, NEW ENGL J MED, V286, P965, DOI 10.1056/NEJM197205042861802; PISANI CV, 1991, BLOOD, V78, P1538, DOI 10.1182/blood.V78.6.1538.1538; PRIN L, 1991, BLOOD, V78, P2626; REGELMANN WE, 1990, AM REV RESPIR DIS, V141, P914, DOI 10.1164/ajrccm/141.4_Pt_1.914; SEMENZATO G, 1993, CHEST, V103, pS139; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; STEINBACH S, 1994, NEW ENGL J MED, V331, P981, DOI 10.1056/NEJM199410133311504; TRENTIN L, 1990, J IMMUNOL, V145, P2147; WEBB JKG, 1960, LANCET, V1, P835; WILSON CB, 1996, CLIN IMMUNOLOGY, P1185; Zissel G, 1996, AM J RESP CRIT CARE, V154, P713, DOI 10.1164/ajrccm.154.3.8810610; Zissel G, 1997, J INVEST MED, V45, P75	58	38	52	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1924	1930		10.1001/jama.278.22.1924	http://dx.doi.org/10.1001/jama.278.22.1924			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396654				2022-12-28	WOS:A1997YK15500015
J	McNamee, D				McNamee, D			Communicating drug-safety information	LANCET			English	Editorial Material																		Horton R, 1997, LANCET, V350, P1043, DOI 10.1016/S0140-6736(05)70449-9; Horton R, 1997, LANCET, V350, P1627, DOI 10.1016/S0140-6736(05)64041-X; McNamee D, 1996, LANCET, V348, P908, DOI 10.1016/S0140-6736(05)65336-6; Nurse P, 1997, LANCET, V350, P1626, DOI 10.1016/S0140-6736(97)26048-4	4	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1646	1646		10.1016/S0140-6736(05)64272-9	http://dx.doi.org/10.1016/S0140-6736(05)64272-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400507				2022-12-28	WOS:A1997YK21100007
J	Delmas, PD; Bjarnason, NH; Mitlak, BH; Ravoux, AC; Shah, AS; Huster, WJ; Draper, M; Christiansen, C				Delmas, PD; Bjarnason, NH; Mitlak, BH; Ravoux, AC; Shah, AS; Huster, WJ; Draper, M; Christiansen, C			Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAST-CANCER; OVARIECTOMIZED RATS; LY139481 HCL; OSTEOPOROSIS; TAMOXIFEN; TURNOVER; TRIAL; ESTROGEN; THERAPY; MARKERS	Background Long-term estrogen therapy can reduce the risk of osteoporotic fracture and cardiovascular disease in postmenopausal women. At present, however, these beneficial effects are not separable from undesirable stimulation of breast and endometrial tissues. Methods We studied the effect of raloxifene, a non-steroidal benzothiophene, on bone mineral density, serum lipid concentrations, and endometrial thickness in 601 postmenopausal women. The women were randomly assigned to receive 30, 60, or 150 mg of raloxifene or placebo daily for 24 months. Results The women receiving each dose of raloxifene had significant increases from base-line values in bone mineral density of the lumbar spine, hip, and total body, whereas those receiving placebo had decreases in bone mineral density. For example, at 24 months, the mean (+/-SE) difference in the change in bone mineral density between the women receiving 60 mg of raloxifene per day and those receiving placebo was 2.4+/-0.4 percent for the lumbar spine, 2.4+/-0.4 percent for the total hip, and 2.0+/-0.4 percent for the total body (P<0.001 for all comparisons). Serum concentrations of total cholesterol and low-density lipoprotein cholesterol decreased in all the raloxifene groups, whereas serum concentrations of high-density lipoprotein cholesterol and triglycerides did not change. Endometrial thickness was similar in the raloxifene and placebo groups at all times during the study. The proportion of women receiving raloxifene who reported hot flashes or vaginal bleeding was not different from that of the women receiving placebo. Conclusions Daily therapy with raloxifene increases bone mineral density, lowers serum concentrations of total and low-density lipoprotein cholesterol, and does not stimulate the endometrium. (C) 1997, Massachusetts Medical Society.	INSERM,RES UNIT 403,F-69437 LYON 03,FRANCE; CTR CLIN & BASIC RES,BALLERUP,DENMARK; LILLY CORP CTR,LILLY RES LABS,INDIANAPOLIS,IN 46285	Institut National de la Sante et de la Recherche Medicale (Inserm); Center Clinical & Basic Research; Eli Lilly	Delmas, PD (corresponding author), HOP EDOUARD HERRIOT,PAVILLON F,F-69437 LYON 03,FRANCE.							ADAMI S, 1995, BONE, V17, P383, DOI 10.1016/S8756-3282(95)00262-6; Anzano MA, 1996, J NATL CANCER I, V88, P123, DOI 10.1093/jnci/88.2.123; ARMITAGE P, 1969, J R STAT SOC SER A-G, V132, P235, DOI 10.2307/2343787; BASS KM, 1993, ARCH INTERN MED, V153, P2209, DOI 10.1001/archinte.153.19.2209; Beresford SAA, 1997, LANCET, V349, P458, DOI 10.1016/S0140-6736(96)07365-5; Bjarnason NH, 1997, CIRCULATION, V96, P1964, DOI 10.1161/01.CIR.96.6.1964; BLACK LJ, 1994, J CLIN INVEST, V93, P63, DOI 10.1172/JCI116985; BONDE M, 1994, CLIN CHEM, V40, P2022; BOSS SM, IN PRESS AM J OBSTET; CLEMENS JA, 1983, LIFE SCI, V32, P2869, DOI 10.1016/0024-3205(83)90323-5; COHEN I, 1994, GYNECOL ONCOL, V52, P185, DOI 10.1006/gyno.1994.1029; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Draper MW, 1996, J BONE MINER RES, V11, P835; DRAPER MW, 1994, CALCIFIED TISSUE INT, V54, P339; GARNERO P, 1993, J CLIN ENDOCR METAB, V77, P1046, DOI 10.1210/jc.77.4.1046; Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; GREY AB, 1995, AM J MED, V99, P636, DOI 10.1016/S0002-9343(99)80251-4; HARRIS ST, 1993, AM J MED, V95, P557, DOI 10.1016/0002-9343(93)90350-X; Heaney RP, 1997, J CLIN ENDOCR METAB, V82, P3425, DOI 10.1210/jc.82.10.3425; HOSKING DJ, 1996, J BONE MINER RES  S1, V11, pS133; KEDAR RP, 1994, LANCET, V343, P1318, DOI 10.1016/S0140-6736(94)92466-X; *LIP RES CLIN PROG, 1984, JAMA-J AM MED ASSOC, V251, P351, DOI DOI 10.1001/JAMA.251.3.351; MIETTINEN M, 1972, LANCET, V2, P835; Powles T, 1996, J CLIN ONCOL, V14, P78, DOI 10.1200/JCO.1996.14.1.78; SHAO J, 1996, STATISTICS, V22, P49; TURNER CH, 1994, ENDOCRINOLOGY, V135, P2001, DOI 10.1210/en.135.5.2001; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V273, P199; *WRIT GROUP PEPI T, 1995, JAMA-J AM MED ASSOC, V274, P1676; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222; Yang NN, 1997, SCIENCE, V275, P1249	32	1321	1383	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 4	1997	337	23					1641	1647		10.1056/NEJM199712043372301	http://dx.doi.org/10.1056/NEJM199712043372301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ871	9385122				2022-12-28	WOS:A1997YJ87100001
J	Hamm, CW; Goldmann, BU; Heeschen, C; Kreymann, G; Berger, J; Meinertz, T				Hamm, CW; Goldmann, BU; Heeschen, C; Kreymann, G; Berger, J; Meinertz, T			Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; KINASE ISOENZYME-MB; UNSTABLE ANGINA; PROGNOSTIC VALUE; CLINICAL-CRITERIA; SERUM; ASSAY; RISK; DISEASE; INJURY	Background Evaluation of patients with acute chest pain in emergency rooms is time-consuming and expensive, and it often results in uncertain diagnoses. We prospectively investigated the usefulness of bedside tests for the detection of cardiac troponin T and troponin I in the evaluation of patients with acute chest pain. Methods In 773 consecutive patients who had had acute chest pain for less than 12 hours without ST-segment elevation on their electrocardiograms, troponin T and troponin I status (positive or negative) was determined at least twice by sensitive, qualitative bedside tests based on the use of specific monoclonal antibodies, Testing was performed on arrival and four or more hours later so that one sample was taken at least six hours after the onset of pain. The troponin T results were made available to the treating physicians. Results Troponin T tests were positive in 123 patients (16 percent), and troponin I tests were positive in 171 patients (22 percent). Among 47 patients with evolving myocardial infarction, troponin T tests were positive in 44 (94 percent) and troponin I tests Were positive in all 47. Among 315 patients with unstable angina, troponin T tests were positive in 70 patients (22 percent), and troponin I tests were positive in 114 patients (36 percent). During 30 days of follow-up, there were 20 deaths and 14 nonfatal myocardial infarctions. Troponin T and troponin I proved to be strong, independent predictors of cardiac events. The event rates in patients with negative tests were only 1.1 percent for troponin T and 0.3 percent for troponin I. Conclusions Bedside tests for cardiac-specific troponins are highly sensitive for the early detection of myocardial-cell injury in acute coronary syndromes. Negative test results are associated with low risk and allow rapid and safe discharge of patients with an episode of acute chest pain from the emergency room. (C) 1997, Massachusetts Medical Society.	UNIV HAMBURG,HOSP EPPENDORF,INST MATH & COMP SCI MED,D-20246 HAMBURG,GERMANY	University of Hamburg	Hamm, CW (corresponding author), UNIV HAMBURG,HOSP EPPENDORF,MED CLIN,DEPT CARDIOL,MARTINISTR 52,D-20246 HAMBURG,GERMANY.		Guba, Markus/M-4309-2019; Hamm, Christian W./I-3155-2017	Hamm, Christian W./0000-0001-6763-4161; Heeschen, Christopher/0000-0002-1158-8554				ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; ANTMAN EM, 1995, JAMA-J AM MED ASSOC, V273, P1279, DOI 10.1001/jama.273.16.1279; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; BAKKER AJ, 1993, LANCET, V342, P1220, DOI 10.1016/0140-6736(93)92192-V; Bertinchant JP, 1996, CLIN BIOCHEM, V29, P587, DOI 10.1016/S0009-9120(96)00105-1; BHAYANA V, 1995, CLIN CHEM, V41, P312; BRAUNWALD E, 1994, CIRCULATION, V90, P613, DOI 10.1161/01.CIR.90.1.613; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; BRUSH JE, 1985, NEW ENGL J MED, V312, P1137, DOI 10.1056/NEJM198505023121801; CHAPELLE JP, 1990, CLIN CHEM, V36, P99; DAVIES E, IN PRESS J CLIN BIOC; DAVIES MJ, 1986, CIRCULATION, V73, P418, DOI 10.1161/01.CIR.73.3.418; DEWINTER RJ, 1995, CIRCULATION, V92, P3401, DOI 10.1161/01.CIR.92.12.3401; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; *FIBR THER TRIAL C, 1994, LANCET, V343, P742; *FIBR THER TRIAL C, 1994, LANCET, V343, P311; FINEBERG HV, 1984, NEW ENGL J MED, V310, P1301, DOI 10.1056/NEJM198405173102006; GERHARDT W, 1991, CLIN CHEM, V37, P1405; GIBLER WB, 1992, ANN EMERG MED, V21, P504; Goldman L, 1996, NEW ENGL J MED, V334, P1498, DOI 10.1056/NEJM199606063342303; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HEESCHEN C, 1996, CIRCULATION S1, V94, P322; HOSMER DW, 1989, APPL LOGISTIC REGRES; KATUS HA, 1992, CLIN CHEM, V38, P386; LARUE C, 1993, CLIN CHEM, V39, P972; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEE TH, 1987, ANN INTERN MED, V106, P181, DOI 10.7326/0003-4819-106-2-181; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; Lindahl B, 1996, CIRCULATION, V93, P1651, DOI 10.1161/01.CIR.93.9.1651; MCCARTHY BD, 1993, ANN EMERG MED, V22, P579, DOI 10.1016/S0196-0644(05)81945-6; MULLERBARDORFF M, 1995, CIRCULATION, V92, P2869, DOI 10.1161/01.CIR.92.10.2869; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; RAVKILDE J, 1995, J AM COLL CARDIOL, V25, P574, DOI 10.1016/0735-1097(94)00430-X; RAVKILDE J, 1993, SCAND J CLIN LAB INV, V53, P677, DOI 10.3109/00365519309092571; RUDE RE, 1983, AM J CARDIOL, V52, P936, DOI 10.1016/0002-9149(83)90508-8; RUSNAK RA, 1989, ANN EMERG MED, V18, P1029, DOI 10.1016/S0196-0644(89)80924-2; *TIMI IIIB INV, 1994, CIRCULATION, V89, P1545; WU AHB, 1995, AM J CARDIOL, V76, P970, DOI 10.1016/S0002-9149(99)80274-4	41	820	844	3	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 4	1997	337	23					1648	1653		10.1056/NEJM199712043372302	http://dx.doi.org/10.1056/NEJM199712043372302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ871	9385123	Bronze			2022-12-28	WOS:A1997YJ87100002
J	Monaghan, AP; Bock, D; Gass, P; Schwager, A; Wolfer, DP; Lipp, HP; Schutz, G				Monaghan, AP; Bock, D; Gass, P; Schwager, A; Wolfer, DP; Lipp, HP; Schutz, G			Defective limbic system in mice lacking the tailless gene	NATURE			English	Article							RECEPTOR SUPERFAMILY; DROSOPHILA; MOUSE; HIPPOCAMPUS; RAT	The gene tailless is a member of the superfamily of genes that encode transcription factors of the ligand-activated nuclear receptor type, and is expressed in the invertebrate and vertebrate brain(1-4). In mice, its transcripts are restricted to the periventricular zone of the forebrain(4), the site of origin of neurons and glia. Here we use homologous recombination to generate mice that lack a functional tailless protein. Homozygous mutant mice are viable at birth, indicating that tailless is not required for prenatal survival; however, adult mutant mice show a reduction in the size of rhinencephalic and limbic structures, including the olfactory, infrarhinal and entorhinal cortex, amygdala and dentate gyrus. Both male and female mice are more aggressive than usual and females lack normal maternal instincts. These animals therefore enable a molecular approach to be taken towards understanding the genetic architecture and morphogenesis of the forebrain.	GERMAN CANC RES CTR,DIV MOL BIOL CELL 1,D-69120 HEIDELBERG,GERMANY; UNIV ZURICH IRCHEL,INST ANAT,CH-8057 ZURICH,SWITZERLAND	Helmholtz Association; German Cancer Research Center (DKFZ); University of Zurich			Wolfer, David P/B-3293-2016	Wolfer, David P/0000-0002-5957-1401				ALBERT DJ, 1984, NEUROSCI BIOBEHAV R, V8, P5, DOI 10.1016/0149-7634(84)90017-4; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; EDWARDS DA, 1993, PHYSIOL BEHAV, V53, P611, DOI 10.1016/0031-9384(93)90162-9; GASS P, 1992, NEUROSCIENCE, V48, P315, DOI 10.1016/0306-4522(92)90493-L; GILAD GM, 1979, BRAIN RES, V160, P17, DOI 10.1016/0006-8993(79)90597-3; GOODLETT CR, 1982, PHYSIOL BEHAV, V28, P1077, DOI 10.1016/0031-9384(82)90178-0; Gray JA, 1982, NEUROPSYCHOLOGY ANXI, DOI 10.1002/9780470720394.ch2; KAESTNER KH, 1994, GENE, V148, P67, DOI 10.1016/0378-1119(94)90234-8; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; Kandel E., 1995, APPLETON LANGE NORWA, V6, P425; Keefe J. O., 1978, HIPPOCAMPUS COGNITIV; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MONAGHAN AP, 1995, DEVELOPMENT, V121, P839; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; REZNIKOV KY, 1991, ADV ANAT EMBRYOL CEL, V122, P1; TAMURA T, 1991, NUCLEIC ACIDS RES, V19, P3861, DOI 10.1093/nar/19.14.3861; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; YU RT, 1994, NATURE, V370, P375, DOI 10.1038/370375a0	20	150	158	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					515	517		10.1038/37364	http://dx.doi.org/10.1038/37364			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394001				2022-12-28	WOS:A1997YJ86500053
J	Ransohoff, DF; Harris, RP				Ransohoff, DF; Harris, RP			Lessons from the mammography screening controversy: Can we improve the debate?	ANNALS OF INTERNAL MEDICINE			English	Article							BREAST-CANCER; DECISION; RISK	The debate about breast cancer screening for women in their 40s has become so contentious that effective communication and rational discussion on this topic have been compromised. This contentiousness might be defused by understanding the reasons for it. The debate is less about facts than it is about perceptions and values. There is disagreement about how to fairly describe facts about risk and how to avoid misperceptions that may distort assessment of risk. Other sources of disagreement concern the potential harms of screening, the relative roles of physicians and patients in decision making, and how to factor cost into screening decisions. The entire decision-making process has also been highly charged by single-issue advocacy groups and a kind of gender rivalry. Several approaches might help defuse the debate and improve discussion. First, those on both sides of the debate might agree on several things: 1) that the evidence from clinical trials is widely agreed-upon and thus that a main task now is to factor in the values of individual women who are making decisions; 2) that the values of women may differ substantially and that those differences should be respected; 3) that both individuals and the public should be fully and fairly informed about the pros and cons of screening; and 4) that cost-effectiveness should at least be considered during the decision-making process. Lessons from this debate may apply to other medical problems that have small degrees of risk and whose management is strongly debated.			Ransohoff, DF (corresponding author), UNIV N CAROLINA, SCH MED, CB 7105, CHAPEL HILL, NC 27599 USA.							*ACS, 1997, WORKSH GUID BREAST C; BARRY MJ, 1995, MED CARE, V33, P771, DOI 10.1097/00005650-199508000-00003; BERNSTEIN PL, 1997, GODS REMARKABLE STOD; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; BRODY J, 1997, NY TIMES        1007, pB9; BRODY J, 1997, NY TIMES        1007, pB14; Coley CM, 1997, ANN INTERN MED, V126, P468, DOI 10.7326/0003-4819-126-6-199703150-00010; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P441, DOI 10.1001/jama.263.3.441; Elmore J. G., 1997, JGIM, V12, P107; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; ERNSTER VL, 1997, NIH CONS DEV C BREAS; Fisher R., 1991, GETTING YES NEGOTIAT; Flood AB, 1996, J GEN INTERN MED, V11, P342, DOI 10.1007/BF02600045; Gordis L, 1997, J NATL CANCER I, V89, P1015, DOI 10.1093/jnci/89.14.1015; HARRIS R, 1995, ANN INTERN MED, V122, P539, DOI 10.7326/0003-4819-122-7-199504010-00011; Harris R., 1996, JGIM, V11, P124; JAROFF L, 1996, TIME            0401, P58; Kasper J F, 1992, QRB Qual Rev Bull, V18, P183; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; MILLER BA, 1993, NIH PUB; Morgan M. W., 1997, JGIM, V12, P62; *NAT CANC I, 1997, NAT CANC ADV BOARD I; REDELMEIER DA, 1993, JAMA-J AM MED ASSOC, V270, P72, DOI 10.1001/jama.270.1.72; REDELMEIER DA, 1995, JAMA-J AM MED ASSOC, V273, P302, DOI 10.1001/jama.273.4.302; Roter DL, 1997, JAMA-J AM MED ASSOC, V277, P350, DOI 10.1001/jama.277.4.350; SHAPIRO S, 1971, J AMER MED ASSOC, V215, P1777; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Thune I, 1997, NEW ENGL J MED, V336, P1269, DOI 10.1056/NEJM199705013361801; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; WAGNER JL, 1995, BPH146 OFF TECHN ASS; Willan AR, 1997, CONTROL CLIN TRIALS, V18, P121, DOI 10.1016/S0197-2456(96)00092-X; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; Woolf SH, 1997, BRIT MED J, V314, P989, DOI 10.1136/bmj.314.7086.989; WOOLF SH, 1997, WASHINGTON POST 0504, pC5; WOOLF SH, 1997, WASHINGTON POST 0504, pC1; 1997, NY TIMES        0320, P10	41	51	51	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					1029	1034		10.7326/0003-4819-127-11-199712010-00016	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00016			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412285				2022-12-28	WOS:A1997YJ08000011
J	Poland, GA				Poland, GA			Still more questions on pertussis vaccines	LANCET			English	Editorial Material							CONTROLLED TRIAL		MAYO CLIN & MAYO FDN,DEPT CLIN PHARMACOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,MAYO VACCINE RES GRP,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	Poland, GA (corresponding author), MAYO CLIN & MAYO FDN,DEPT MED,200 1ST ST SW,ROCHESTER,MN 55905, USA.							Cherry JD, 1997, PEDIATR INFECT DIS J, V16, pS90, DOI 10.1097/00006454-199704001-00004; Decker MD, 1996, J INFECT DIS, V174, pS270, DOI 10.1093/infdis/174.Supplement_3.S270; EDWARDS KM, 1995, PEDIATRICS, V96, P548; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; Poirer MK, 1996, VACCINE, V14, P25, DOI 10.1016/0264-410X(95)00170-6; Poland GA, 1996, LANCET, V347, P209, DOI 10.1016/S0140-6736(96)90398-0; Sweden Ad Hoc Group for the Study of Pertussis Vaccines, 1988, Lancet, Vi, P955; TROLLFORS B, 1995, NEW ENGL J MED, V333, P1045, DOI 10.1056/NEJM199510193331604	9	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1564	1565		10.1016/S0140-6736(97)22048-9	http://dx.doi.org/10.1016/S0140-6736(97)22048-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393330				2022-12-28	WOS:A1997YH98600002
J	Hoey, T				Hoey, T			Signal transduction - A new player in cell death	SCIENCE			English	Editorial Material							TRANSCRIPTION; PATHWAY; PHOSPHORYLATION; INTERFERON; ACTIVATION; TYROSINE				Hoey, T (corresponding author), TULARIK,S SAN FRANCISCO,CA 94080, USA.							Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FRASER A, 1995, SCIENCE, V85, P781; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9	13	16	17	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1578	1579		10.1126/science.278.5343.1578	http://dx.doi.org/10.1126/science.278.5343.1578			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9411781				2022-12-28	WOS:A1997YJ87400027
J	Daley, J; Delbanco, TL; Hartman, EE				Daley, J; Delbanco, TL; Hartman, EE			21-year-old woman with menstrual irregularity, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Davis A, 1997, JAMA-J AM MED ASSOC, V277, P1308, DOI 10.1001/jama.277.16.1308	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1699	1699						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388091				2022-12-28	WOS:A1997YG85900033
J	vandenBerg, C; Willemsen, V; Hendriks, G; Weisbeek, P; Scheres, B				vandenBerg, C; Willemsen, V; Hendriks, G; Weisbeek, P; Scheres, B			Short-range control of cell differentiation in the Arabidopsis root meristem	NATURE			English	Article							SHOOT; REGULATOR; CLAVATA1; GENES; FATE	Meristems are distinctive regions of plants that have capacity for continuous growth. Their developmental activity generates the majority of plant organs(1). It is currently unknown how cell division and cell differentiation are orchestrated in meristems, although genetic studies have demonstrated the relevance of a proper balance between the two processes(2-6), Root meristems contain a distinct central region of mitotically inactive cells, the quiescent centre(7), the function of which has remained elusive until now. Here we present laser ablation and genetic data that show that in Arabidopsis thalinna the quiescent centre inhibits differentiation of surrounding cells. Differentiation regulation occurs within the range of a single cell, in a manner strikingly similar to examples in animal development, such as during delamination of Drosophila neuroblasts(8). Our data indicate that pattern formation in the root meristem is controlled by a balance between short-range signals inhibiting differentiation and signals that reinforce cell fate decisions(9).	UNIV UTRECHT,DEPT MOL CELL BIOL,NL-3584 CH UTRECHT,NETHERLANDS	Utrecht University			Hendriks, Giel/A-9731-2010	Scheres, Ben/0000-0001-5400-9578				BARLOW P, 1974, NEW PHYTOL, V73, P937, DOI 10.1111/j.1469-8137.1974.tb01323.x; CHENG JC, 1995, PLANT PHYSIOL, V107, P365, DOI 10.1104/pp.107.2.365; CLARK SE, 1993, DEVELOPMENT, V119, P397; Clark SE, 1996, DEVELOPMENT, V122, P1567; CLARK SE, 1995, DEVELOPMENT, V121, P2057; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; CLOWES F. A. L., 1956, NEW PHYTOL, V55, P29, DOI 10.1111/j.1469-8137.1956.tb05264.x; Endrizzi K, 1996, PLANT J, V10, P967, DOI 10.1046/j.1365-313X.1996.10060967.x; FELDMAN LJ, 1975, CAN J BOT, V53, P2796, DOI 10.1139/b75-307; HEJNOWICZ Z, 1991, PLANTA, V184, P1, DOI 10.1007/BF00208228; JACKSON D, 1994, DEVELOPMENT, V120, P405; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Meyerowitz EM, 1997, CELL, V88, P299, DOI 10.1016/S0092-8674(00)81868-1; MUSKAVITCH MAT, 1994, DEV BIOL, V166, P415, DOI 10.1006/dbio.1994.1326; Scheres B, 1996, PLANT SOIL, V187, P97, DOI 10.1007/BF00011661; SCHERES B, 1994, DEVELOPMENT, V120, P2475; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0	18	498	516	4	81	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					287	289		10.1038/36856	http://dx.doi.org/10.1038/36856			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384380	Green Submitted			2022-12-28	WOS:A1997YG66700063
J	[Anonymous]				[Anonymous]			1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus	ANNALS OF INTERNAL MEDICINE			English	Article																		*USPHS IDSA PREV O, 1997, MMWR, V46; *USPHS IDSA PREV O, 1996, ANN INTERN MED, V124, P348	2	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	1997	127	10					922	946		10.7326/0003-4819-127-10-199711150-00015	http://dx.doi.org/10.7326/0003-4819-127-10-199711150-00015			25	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF545	9382373	Green Submitted, Green Published			2022-12-28	WOS:A1997YF54500011
J	Wald, NJ; Law, MR; Morris, JK; Bagnall, AM				Wald, NJ; Law, MR; Morris, JK; Bagnall, AM			Helicobacter pylori infection and mortality from ischaemic heart disease: negative result from a large, prospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; MYOCARDIAL-INFARCTION; SEROPOSITIVITY; ASSOCIATION; CANCER	Objective-To determine whether there is an independent association between Hel Design-Prospective study with measurement of IgG antibody titres specific to H pylori on stored serum samples from 648 men who died from ischaemic heart disease and 1296 age matched controls who did not (nested case-control design). Subjects-21 520 professional men aged 35-64 who attended the British United Provident Association (BUPA) medical centre in London between 1975 and 1982 for routine medical examination. Main outcome measure-Death from ischaemic heart disease. Results-The odds of death from ischaemic heart disease in men with H pylori infection relative to that in men without infection was 1.06 (95% confidence interval 0.86 to 1.31), In a separate group of 206 people attending the centre, plasma fibrinogen was virtually the same in those who were positive for H pylori (2.62 g/l) and those who were negative (2.64 g/l). Conclusions-A study that by its size and design minimised both random error and socioeconomic bias found no relation between H pylori infection and ischaemic heart disease. The validity of the study was shown by its confirmation of the recognised association between H pylori infection and stomach cancer (odds ratio 4.0 (1.9 to 8.2); P < 0.001). Eradication of H pylori infection may greatly reduce the incidence of stomach cancer, one of the most common causes of death from cancer worldwide, but it cannot be expected to have any effect in preventing ischaemic heart disease.	ROYAL LONDON SCH MED & DENT, LONDON EC1M 6BQ, ENGLAND	University of London; Queen Mary University London	Wald, NJ (corresponding author), ST BARTHOLOMEWS, BUPA EPIDEMIOL RES GRP, DEPT ENVIRONM & PREVENT MED, WOLFSON INST PREVENT MED, LONDON, ENGLAND.		Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021; Morris, Joan/AAT-9211-2020	Morris, Joan/0000-0002-7164-612X				Aceti A, 1996, BRIT MED J, V313, P428; AROMAA A, 1996, GUT S2, V3, pA91; Balaban DH, 1996, GASTROENTEROLOGY, V110, pA55; Caselli M., 1996, Gut, V39, pA91; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; Gerning N. Ossei, 1996, Gut, V39, pA91; Lip GYH, 1996, BRIT MED J, V312, P250; MALNICK SDH, 1996, GUT, V39, pA63; MARTINDEARGILA C, 1995, LANCET, V346, P310, DOI 10.1016/S0140-6736(95)92195-8; MCDONAGH TA, 1996, GUT               S1, V38, pA1; MENDALL MA, 1994, BRIT HEART J, V71, P437; MORGANDO A, 1995, LANCET, V345, P1380; MURRAY LJ, 1995, BRIT HEART J, V74, P497; Niemela S, 1996, HEART, V75, P573, DOI 10.1136/hrt.75.6.573; Parente F, 1997, BRIT MED J, V314, P1318, DOI 10.1136/bmj.314.7090.1318; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; Ponzetto A, 1996, BRIT MED J, V312, P251; Rathbone B, 1996, HEART, V76, P308, DOI 10.1136/hrt.76.4.308; Strandberg T. E., 1996, Gut, V39, pA92; Strandberg TE, 1997, BRIT MED J, V314, P1317, DOI 10.1136/bmj.314.7090.1317; Vakil N., 1996, Gut, V39, pA91; WALD N, 1980, LANCET, V2, P813; WALD NJ, 1994, LANCET, V343, P75, DOI 10.1016/S0140-6736(94)90814-1; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; Whincup PH, 1996, HEART, V75, P568, DOI 10.1136/hrt.75.6.568	27	127	134	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 8	1997	315	7117					1199	1201		10.1136/bmj.315.7117.1199	http://dx.doi.org/10.1136/bmj.315.7117.1199			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393222	Green Published			2022-12-28	WOS:A1997YF25200019
J	Warkentin, TE; Elavathil, LJ; Hayward, CPM; Johnston, MA; Russett, JI; Kelton, JG				Warkentin, TE; Elavathil, LJ; Hayward, CPM; Johnston, MA; Russett, JI; Kelton, JG			The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia	ANNALS OF INTERNAL MEDICINE			English	Article						warfarin; heparin; thrombocytopenia; thrombophlebitis; gangrene	ACTIVATED PROTEIN-C; PLATELET-DERIVED MICROPARTICLES; INDUCED SKIN NECROSIS; WHITE CLOT SYNDROME; PROCOAGULANT ACTIVITY; COUMARIN NECROSIS; S DEFICIENCY; FACTOR-V; ANTICOAGULANT; COFACTOR	Background: Platelet-mediated arterial occlusion is a well-recognized cause of limb loss in patients with heparin-induced thrombocytopenia. However, the syndrome of distal ischemic necrosis complicating the deep venous thrombosis (venous limb gangrene) sometimes associated with heparin-induced thrombocytopenia has not been well characterized. Objective: To study the pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Design: Characterization (based on descriptive and case-control studies) of a novel syndrome of limb loss and hypothesis testing by analysis of plasma samples. Setting: Five university-associated hospitals in one medical community. Patients: Clinical and laboratory records of 158 patients with heparin-induced thrombocytopenia were reviewed to identify patients with venous limb gangrene (n = 8), limb arterial thrombosis (n = 10), and uncomplicated deep venous thrombosis (n = 58). Measurements: Clinical and laboratory factors associated with venous limb gangrene, including thrombin-antithrombin complexes and vitamin K-dependent procoagulant and anticoagulant factors. Results: Warfarin treatment was more frequently associated with venous limb gangrene than with limb arterial thrombosis (8 of 8 patients compared with 3 of 10 patients; P = 0.004). The anticoagulant effect of warfarin seemed greater in the 8 patients with venous limb gangrene than in the 58 patients who did not develop gangrene (median international normalized ratio, 5.8 compared with 3.1; P < 0.001). Compared with plasma from controls, plasma from patients with venous limb gangrene had a higher ratio of thrombin-antithrombin complex to protein C activity during warfarin treatment. No hereditable abnormalities of the protein C anticoagulant pathway were seen in any patient. Conclusions: Warfarin treatment of deep venous thrombosis associated with heparin-induced thrombocytopenia is a possible cause of venous limb gangrene, perhaps because of acquired failure of the protein C anticoagulant pathway to regulate thrombin generation.	HAMILTON CIV HOSP RES CTR, HAMILTON, ON L8V 1C3, CANADA; HAMILTON HLTH SCI CORP, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, HAMILTON, ON, CANADA	McMaster University; McMaster University; McMaster University	Warkentin, TE (corresponding author), HAMILTON HLTH SCI CORP, DEPT LAB MED, HAMILTON GEN CAMPUS, 237 BARTON ST E, HAMILTON, ON L8L 2X2, CANADA.			Hayward, Catherine/0000-0002-2843-0817				ABURAHMA AF, 1991, AM J SURG, V162, P175, DOI 10.1016/0002-9610(91)90183-E; ANDERSSON NE, 1991, THROMB HAEMOSTASIS, V65, P912; BABCOCK RB, 1976, NEW ENGL J MED, V295, P237, DOI 10.1056/NEJM197607292950501; Bauer KA, 1994, HEMOSTASIS THROMBOSI, P1197; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOSHKOV LK, 1993, BRIT J HAEMATOL, V84, P322, DOI 10.1111/j.1365-2141.1993.tb03072.x; BROEKMANS AW, 1983, THROMB HAEMOSTASIS, V49, P251; CIMO PL, 1979, AM J HEMATOL, V6, P125, DOI 10.1002/ajh.2830060204; COLE MS, 1988, SURGERY, V103, P271; COMP PC, 1990, SEMIN THROMB HEMOST, V16, P293, DOI 10.1055/s-2007-1002682; COMP PC, 1986, BLOOD, V67, P504; CRAIG A, 1990, POSTGRAD MED J, V66, P389, DOI 10.1136/pgmj.66.775.389; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; Denson KWE, 1976, HUMAN BLOOD COAGULAT, P310; DEUTZTERLOUW PP, 1990, CLIN CHIM ACTA, V186, P321, DOI 10.1016/0009-8981(90)90318-M; EBY CS, 1993, HEMATOL ONCOL CLIN N, V7, P1291, DOI 10.1016/S0889-8588(18)30209-0; GRIMAUDO V, 1989, BRIT MED J, V298, P233, DOI 10.1136/bmj.298.6668.233; HALMOVICI H, 1987, J VASC SURG, V5, P655; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; KELTON JG, 1988, BLOOD, V72, P925; LASTER J, 1987, SURGERY, V102, P763; MATTHEWS DE, 1988, USING UNDERSTANDING, P20; MCGEHEE WG, 1984, ANN INTERN MED, V101, P59, DOI 10.7326/0003-4819-101-1-59; McKean J. W., 1977, ACM Transactions on Mathematical Software, V3, P183, DOI 10.1145/355732.355740; PABINGER I, 1986, BLUT, V52, P365, DOI 10.1007/BF00320783; PELZER H, 1988, THROMB HAEMOSTASIS, V59, P101; ROSE VL, 1986, AM J CLIN PATHOL, V86, P653, DOI 10.1093/ajcp/86.5.653; SHERIDAN D, 1986, BLOOD, V67, P27; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SOBEL M, 1988, J VASC SURG, V8, P395, DOI 10.1067/mva.1988.avs0080395; STANTON PE, 1988, SOUTH MED J, V81, P616, DOI 10.1097/00007611-198805000-00018; TANS G, 1991, BLOOD, V77, P2641; THOMAS DG, 1971, APPLIED STATISTICS, V20, P105, DOI DOI 10.2307/2346643; TOWNE JB, 1979, ARCH SURG-CHICAGO, V114, P372; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; WARKENTIN TE, 1994, BLOOD, V84, P3691, DOI 10.1182/blood.V84.11.3691.bloodjournal84113691; WARKENTIN TE, 1992, J LAB CLIN MED, V120, P371; Warkentin TE, 1996, AM J MED, V101, P502, DOI 10.1016/S0002-9343(96)00258-6; WARKENTIN TE, 1994, FUND CL CAR, V19, P75	40	327	330	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					804	+		10.7326/0003-4819-127-9-199711010-00005	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382401				2022-12-28	WOS:A1997YD89800004
J	Rubin, DB				Rubin, DB			Estimating causal effects from large data sets using propensity scores	ANNALS OF INTERNAL MEDICINE			English	Article							CARE; DISTRIBUTIONS; BIAS	The aim of many analyses of large databases is to draw causal inferences about the effects of actions, treatments, or interventions. Examples include the effects of various options available to a physician for treating a particular patient, the relative efficacies of various health care providers, and the consequences of implementing a new national health care policy. A complication of using large databases to achieve such aims is that their data are almost always observational rather than experimental. That is, the data in most large data sets are not based on the results of carefully conducted randomized clinical trials, but rather represent data collected through the observation of systems as they operate in normal practice without any interventions implemented by randomized assignment rules. Such data are relatively inexpensive to obtain, however, and often do represent the spectrum of medical practice better than the settings of randomized experiments. Consequently, it is sensible to try to estimate the effects of treatments from such large data sets, even if only to help design a new randomized experiment or shed light on the generalizability of results from existing randomized experiments. However, standard methods of analysis using available statistical software (such as linear or logistic regression) can be deceptive for these objectives because they provide no warnings about their propriety. Propensity score methods are more reliable tools for addressing such objectives because the assumptions needed to make their answers appropriate are more assessable and transparent to the investigator.			Rubin, DB (corresponding author), HARVARD UNIV, DEPT STAT, CTR SCI, 6TH FLOOR, 1 OXFORD ST, CAMBRIDGE, MA 02138 USA.							AIKEN LH, 1994, MED CARE, V32, P771, DOI 10.1097/00005650-199408000-00002; COCHRAN WG, 1968, BIOMETRICS, V24, P295, DOI 10.2307/2528036; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; COOK EF, 1989, J CLIN EPIDEMIOL, V42, P317; COOK EF, 1988, AM J EPIDEMIOL, V127, P626, DOI 10.1093/oxfordjournals.aje.a114838; DRAKE C, 1995, INT J EPIDEMIOL, V24, P183, DOI 10.1093/ije/24.1.183; DRAKE C, 1993, BIOMETRICS, V49, P1231, DOI 10.2307/2532266; EASTWOOD EA, 1988, AM J MENT RETARD, V93, P75; FIEBACH NH, 1990, AM J MED, V89, P15, DOI 10.1016/0002-9343(90)90091-Q; FINCH PE, 1988, ENCY STAT SCI, V8, P629; Gu Xing S., 1993, J COMPUTATIONAL GRAP, V2, P405, DOI [DOI 10.1080/10618600.1993.10474623, DOI 10.7326/0003-4819-152-6-201003160-00008]; HARRELL FE, 1990, J CLIN EPIDEMIOL, V43, pS89, DOI 10.1016/0895-4356(90)90227-G; KANE RL, 1991, J AM GERIATR SOC, V39, P359, DOI 10.1111/j.1532-5415.1991.tb02900.x; LAVORI PW, 1988, STAT MED, V7, P727, DOI 10.1002/sim.4780070702; LAVORI PW, 1988, J PSYCHIAT RES, V22, P249, DOI 10.1016/0022-3956(88)90034-9; LIN DY, 1997, 144 U WASH SCH PUBL; MYERS WO, 1987, ANN THORAC SURG, V44, P471, DOI 10.1016/S0003-4975(10)62104-2; REINISCH JM, 1995, JAMA-J AM MED ASSOC, V274, P1518, DOI 10.1001/jama.274.19.1518; ROSENBAUM PR, 1985, BIOMETRICS, V41, P103, DOI 10.2307/2530647; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; ROSENBAUM PR, 1983, J ROY STAT SOC B MET, V45, P212; RUBIN DB, 1992, BIOMETRIKA, V79, P797, DOI 10.1093/biomet/79.4.797; RUBIN DB, 1980, BIOMETRICS, V36, P293, DOI 10.2307/2529981; RUBIN DB, 1992, ANN STAT, V20, P1079, DOI 10.1214/aos/1176348671; Rubin DB, 1996, BIOMETRICS, V52, P249, DOI 10.2307/2533160; RUBIN DB, 1984, J AM STAT ASSOC, V79, P79, DOI 10.2307/2288338; STONE RA, 1995, MED CARE, V33, pAS56; *US GEN ACC OFF, 1994, GAOPEMD959; WILLOUGHBY A, 1990, PEDIATRICS, V85, P485	31	2201	2229	4	115	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				757	763		10.7326/0003-4819-127-8_Part_2-199710151-00064	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00064			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB385	9382394				2022-12-28	WOS:A1997YB38500019
J	Huala, E; Oeller, PW; Liscum, E; Han, IS; Larsen, E; Briggs, WR				Huala, E; Oeller, PW; Liscum, E; Han, IS; Larsen, E; Briggs, WR			Arabidopsis NPH1: A protein kinase with a putative redox-sensing domain	SCIENCE			English	Article							LIGHT-INDUCED PHOSPHORYLATION; AZOTOBACTER-VINELANDII NIFL; NUCLEOTIDE-SEQUENCE; POTASSIUM CHANNEL; SIGNAL-TRANSDUCTION; MEMBRANE-PROTEIN; GENE-EXPRESSION; HIGHER-PLANTS; THALIANA; DROSOPHILA	The NPH1 (nonphototropic hypocotyl 1) gene encodes an essential component acting very early in the signal-transduction chain for phototropism. Arabidopsis NPH? contains a serine-threonine kinase domain and LOV1 and LOV2 repeats that share similarity (36 to 56 percent) with Halobacterium salinarium Bat, Azotobacter vinelandii NIFL, Neurospora crassa White Collar-1, Escherichia call Aer, and the fag family of potassium-channel proteins from Drosophila and mammals. Sequence similarity with a known (NIFL) and a suspected (Aer) flavoprotein suggests that NPH1 LOV1 and LOV2 may be flavin-binding domains that regulate kinase activity in response to blue light-induced redox changes.	CARNEGIE INST WASHINGTON, DEPT PLANT BIOL, STANFORD, CA 94305 USA	Carnegie Institution for Science			Huala, Eva L/B-1377-2009	Liscum, Emmanuel/0000-0002-8672-9315; Huala, Eva/0000-0003-4631-7241				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ALLMEIER H, 1992, GENE, V111, P11, DOI 10.1016/0378-1119(92)90597-I; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1988, MOL REPROD DEV; Ballario P, 1996, EMBO J, V15, P1650, DOI 10.1002/j.1460-2075.1996.tb00510.x; BAUR B, 1994, PLANT PHYSIOL, V106, P1225, DOI 10.1104/pp.106.3.1225; Bibikov SI, 1997, J BACTERIOL, V179, P4075, DOI 10.1128/jb.179.12.4075-4079.1997; BLANCO G, 1993, MOL MICROBIOL, V9, P869, DOI 10.1111/j.1365-2958.1993.tb01745.x; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DRUMMOND MH, 1987, MOL MICROBIOL, V1, P37, DOI 10.1111/j.1365-2958.1987.tb00524.x; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; GROPP F, 1994, P NATL ACAD SCI USA, V91, P5475, DOI 10.1073/pnas.91.12.5475; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hill S, 1996, P NATL ACAD SCI USA, V93, P2143, DOI 10.1073/pnas.93.5.2143; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; KHURANA J P, 1989, Planta (Heidelberg), V178, P400, DOI 10.1007/BF00391868; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LEONG D, 1988, J BACTERIOL, V170, P4903, DOI 10.1128/jb.170.10.4903-4909.1988; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; Lin C., 1996, PLANT PHYSIOL, V110, P1047; LIN X, 1991, P NATL ACAD SCI USA, V88, P6951, DOI 10.1073/pnas.88.16.6951; LISCUM E, 1995, PLANT CELL, V7, P473, DOI 10.1105/tpc.7.4.473; LISCUM E, ANAL BIOTECHNOLOGY G; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; NARBERHAUS F, 1995, J BACTERIOL, V177, P5078, DOI 10.1128/jb.177.17.5078-5087.1995; PALMER JM, 1993, PLANT PHYSIOL, V102, P1211, DOI 10.1104/pp.102.4.1211; RAINA R, 1993, MOL GEN GENET, V237, P400, DOI 10.1007/BF00279444; Rebbapragada A, 1997, P NATL ACAD SCI USA, V94, P10541, DOI 10.1073/pnas.94.20.10541; REYMOND P, 1992, PLANT PHYSIOL, V100, P655, DOI 10.1104/pp.100.2.655; REYMOND P, 1992, P NATL ACAD SCI USA, V89, P4718, DOI 10.1073/pnas.89.10.4718; SHORT TW, 1994, PLANT PHYSIOL, V104, P1317, DOI 10.1104/pp.104.4.1317; SHORT TW, 1994, ANNU REV PLANT PHYS, V45, P143, DOI 10.1146/annurev.pp.45.060194.001043; Siddavattam D, 1995, MOL GEN GENET, V249, P629, DOI 10.1007/BF00418032; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; TYTGAT J, 1993, J BIOL CHEM, V268, P23777; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; WADA M, COMMUNICATION; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; ZABEAU M, 1993, Patent No. 4026297; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	45	585	622	0	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 19	1997	278	5346					2120	2123		10.1126/science.278.5346.2120	http://dx.doi.org/10.1126/science.278.5346.2120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405347				2022-12-28	WOS:A1997YM23500052
J	Daoud, EG; Strickberger, SA; Man, KC; Goyal, R; Deeb, GM; Bolling, SF; Pagani, FD; Bitar, D; Meissner, MD; Morady, F				Daoud, EG; Strickberger, SA; Man, KC; Goyal, R; Deeb, GM; Bolling, SF; Pagani, FD; Bitar, D; Meissner, MD; Morady, F			Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARTERY BYPASS-SURGERY; LOW-DOSE AMIODARONE; PLACEBO-CONTROLLED TRIAL; CORONARY-ARTERY; SUPRAVENTRICULAR TACHYARRHYTHMIAS; SINUS RHYTHM; RISK-FACTORS; PREVENTION; ARRHYTHMIAS; PROPRANOLOL	Background Atrial fibrillation occurs commonly after open-heart surgery and may delay hospital discharge. The purpose of this study was to assess the use of preoperative amiodarone as prophylaxis against atrial fibrillation after cardiac surgery. Methods In this double-blind, randomized study, 124 patients were given either oral amiodarone (64 patients) or placebo (60 patients) for a minimum of seven days before elective cardiac surgery. Therapy consisted of 600 mg of amiodarone per day for seven days, then 200 mg per day until the day of discharge from the hospital. The mean (+/-SD) preoperative total dose of amiodarone was 4.8+/-0.96 g over a period of 13+/-7 days. Results Postoperative atrial fibrillation occurred in 16 of the 64 patients in the amiodarone group (25 percent) and 32 of the 60 patients in the placebo group (53 percent) (P=0.003). Patients in the amiodarone group were hospitalized for significantly fewer days than were patients in the placebo group (6.5+/-2.6 vs. 7.9+/-4.3 days, P=0.04). Nonfatal postoperative complications occurred in eight amiodarone-treated patients (12 percent) and in six patients receiving placebo (10 percent, P=0.78). Fatal postoperative complications occurred in three patients who received amiodarone (5 percent) and in two who received placebo (3 percent, P=1.00). Total hospitalization costs were significantly less for the amiodarone group than for the placebo group ($18,375+/-$13,863 vs. $26,491+/-$23,837, P=0.03). Conclusions Preoperative oral amiodarone in patients undergoing complex cardiac surgery is well tolerated and significantly reduces the incidence of postoperative atrial fibrillation and the duration and cost of hospitalization. (C) 1997, Massachusetts Medical Society.	UNIV MICHIGAN HOSP,DEPT INTERNAL MED,DIV CARDIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN HOSP,DEPT SURG,DIV THORAC SURG,ANN ARBOR,MI 48109; WAYNE STATE UNIV,HARPER HOSP,DEPT INTERNAL MED,DIV CARDIOL,DETROIT,MI	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Wayne State University				Pagani, Francis/0000-0003-4430-9969				ABEL RM, 1983, ARCH SURG-CHICAGO, V118, P727; Aranki SF, 1996, CIRCULATION, V94, P390, DOI 10.1161/01.CIR.94.3.390; BLEVINS RD, 1987, ARCH INTERN MED, V147, P1401, DOI 10.1001/archinte.147.8.1401; BRODSKY MA, 1987, AM J CARDIOL, V60, P572, DOI 10.1016/0002-9149(87)90307-9; CARETTA Q, 1991, EUR HEART J, V12, P1107, DOI 10.1093/oxfordjournals.eurheartj.a059845; Chun Sung, 1993, Journal of the American College of Cardiology, V21, p203A; CROSBY LH, 1990, AM J CARDIOL, V66, P1520, DOI 10.1016/0002-9149(90)90550-K; DAUDON P, 1986, AM J CARDIOL, V58, P933, DOI 10.1016/S0002-9149(86)80014-5; FROST L, 1992, INT J CARDIOL, V36, P253, DOI 10.1016/0167-5273(92)90293-C; FULLER JA, 1989, J THORAC CARDIOV SUR, V97, P821; GOLD RL, 1986, AM J CARDIOL, V57, P124, DOI 10.1016/0002-9149(86)90964-1; GOSSELINK ATM, 1992, JAMA-J AM MED ASSOC, V267, P3289, DOI 10.1001/jama.267.24.3289; GREENSPON AJ, 1991, CIRCULATION, V84, P407; HAMER AWF, 1989, J AM COLL CARDIOL, V14, P1768, DOI 10.1016/0735-1097(89)90030-2; HARRIS L, 1983, CIRCULATION, V67, P45, DOI 10.1161/01.CIR.67.1.45; HOHNLOSER SH, 1991, AM HEART J, V121, P89, DOI 10.1016/0002-8703(91)90960-P; HONDEGHEM LM, 1995, CARDIAC ELECTROPHYSI, P1330; HOROWITZ LN, 1985, J AM COLL CARDIOL, V6, P1402, DOI 10.1016/S0735-1097(85)80232-1; IVEY MF, 1983, J THORAC CARDIOV SUR, V85, P214; JANSSEN J, 1986, ANGIOLOGY, V37, P601, DOI 10.1177/000331978603700807; JOHNSON LW, 1976, CIRCULATION, V53, P819, DOI 10.1161/01.CIR.53.5.819; KAY GN, 1988, AM J CARDIOL, V62, P490, DOI 10.1016/0002-9149(88)90991-5; LAMB RK, 1988, EUR HEART J, V9, P32; LAUER MS, 1989, PROG CARDIOVASC DIS, V31, P367, DOI 10.1016/0033-0620(89)90031-5; LEITCH JW, 1990, J THORAC CARDIOV SUR, V100, P338; LEVY S, 1992, CIRCULATION, V86, P1415, DOI 10.1161/01.CIR.86.5.1415; MARTINUSSEN HJ, 1988, THORAC CARDIOV SURG, V36, P206, DOI 10.1055/s-2007-1020079; MASON JW, 1987, NEW ENGL J MED, V316, P455; *MED EC, 1997, RED BOOK UPD, P16; MICHELSON EL, 1979, AM HEART J, V97, P442, DOI 10.1016/0002-8703(79)90390-9; MIDDLEKAUFF HR, 1993, AM J CARDIOL, V72, pF75, DOI 10.1016/0002-9149(93)90967-H; NACCARELLI GV, 1985, PHARMACOTHERAPY, V5, P298; NICKLAS JM, 1991, AM HEART J, V122, P1016, DOI 10.1016/0002-8703(91)90466-U; NYSTROM U, 1993, THORAC CARDIOV SURG, V41, P34, DOI 10.1055/s-2007-1013817; ORMEROD OJM, 1984, BRIT HEART J, V51, P618; PARIKKA H, 1993, EUR HEART J, V14, P251, DOI 10.1093/eurheartj/14.2.251; RUBIN DA, 1987, J THORAC CARDIOV SUR, V94, P331; SHAFEI H, 1988, THORAC CARDIOV SURG, V36, P202, DOI 10.1055/s-2007-1020078; SILVERMAN NA, 1982, ANN SURG, V196, P194, DOI 10.1097/00000658-198208000-00012; SUTTORP MJ, 1990, J THORAC CARDIOV SUR, V100, P921; VANMIEGHEM W, 1994, CHEST, V105, P1642, DOI 10.1378/chest.105.6.1642; WHITE HD, 1984, CIRCULATION, V70, P479, DOI 10.1161/01.CIR.70.3.479; YOUSIF H, 1990, INT J CARDIOL, V26, P313, DOI 10.1016/0167-5273(90)90087-L	43	345	358	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 18	1997	337	25					1785	1791		10.1056/NEJM199712183372501	http://dx.doi.org/10.1056/NEJM199712183372501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL855	9400034				2022-12-28	WOS:A1997YL85500001
J	Katz, SL				Katz, SL			Future vaccines and a global perspective	LANCET			English	Article								Advances in medical biotechnology mean that vaccines to prevent more than 75 infectious diseases are being or have been developed. Vaccination is unfortunately not reliant purely on biotechnology but also on politics and resources. Countries with the greatest demand for vaccines have the least ability to pay for or produce them. Health-care infrastructure and diagnostic facilities also hamper immunisation projects in developing countries. Charitable organisations are relied on heavily to support such projects but the challenge to ensure all infants are immunised against the most common infections of childhood is still enormous. Difficulties that present themselves now should not prevent us looking into future possibilities such as immunisation during pregnancy and targeting of children for immunisation against sexually transmitted diseases. Other avenues for research are in administration of vaccines. A move to mucosal immunisation rather than use of the syringe and needle would be positive both economically and from the point of view of risk of needle contamination. Plant science may also provide a new vehicle for vaccines by engineering plants such as the banana tree to be naturally bioencapsulated vaccines. Prospects for control and eradication of infectious disease in the next century are certainly good.			Katz, SL (corresponding author), DUKE UNIV, SCH MED, DIV PEDIAT INFECT DIS, DURHAM, NC 27710 USA.							ALONSO MJ, 1994, VACCINE, V12, P299, DOI 10.1016/0264-410X(94)90092-2; ARNTZEN CJ, 1996, EDIBLE VACCINES PROD, P43; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BROWN F, 1996, MOL APPROACHES CONTR, P1; *CDC, 1994, MMWR-MORBID MORTAL W, V43, P605; Clemens J, 1996, JAMA-J AM MED ASSOC, V275, P390, DOI 10.1001/jama.275.5.390; Edelman R, 1997, VACCINE, V15, P463, DOI 10.1016/S0264-410X(96)00235-6; FIEBACH N, 1994, ARCH INTERN MED, V154, P2545, DOI 10.1001/archinte.154.22.2545; Foulds J, 1997, ASM NEWS, V63, P256; GUPTA RK, 1995, VACCINE, V13, P1263, DOI 10.1016/0264-410X(95)00011-O; Haynes BF, 1996, SCIENCE, V271, P324, DOI 10.1126/science.271.5247.324; Insel R A, 1994, Int J Technol Assess Health Care, V10, P143; LIU MA, 1995, ANN NY ACAD SCI, V772, P1; McDonnell WM, 1996, NEW ENGL J MED, V334, P42, DOI 10.1056/NEJM199601043340110; MILLER SD, 1994, IMMUNOL TODAY, V15, P356, DOI 10.1016/0167-5699(94)90173-2; MITCHELL VS, 1993, CHILDRENS VACCINE IN, P1; Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; RABINOVICH NR, 1994, SCIENCE, V265, P1401, DOI 10.1126/science.7521064; Russell PK, 1996, VACCINES MALARIA HOP; Steinhoff MC, 1997, LANCET, V349, P1186, DOI 10.1016/S0140-6736(97)22017-9; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; THANAVALA Y, 1995, P NATL ACAD SCI USA, V92, P3358, DOI 10.1073/pnas.92.8.3358; ZHENKUU P, 1995, NAT MED, V1, P471	24	13	18	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 13	1997	350	9093					1767	1770		10.1016/S0140-6736(97)05358-0	http://dx.doi.org/10.1016/S0140-6736(97)05358-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413480				2022-12-28	WOS:A1997YL55400043
J	Dimitrov, DS				Dimitrov, DS			How do viruses enter cells? The HIV coreceptors teach us a lesson of complexity	CELL			English	Editorial Material							INFLUENZA HEMAGGLUTININ; ENVELOPE GLYCOPROTEIN; HUMAN RHINOVIRUS-14; MEMBRANE-FUSION; RECEPTOR; INFECTION; RESOLUTION; DOMAIN; COFACTOR; ANTIBODY				Dimitrov, DS (corresponding author), NCI, LAB EXPT & COMPUTAT BIOL,DBS,FCRDC,BLDG 469, ROOM 216, MILLER DR, FREDERICK, MD 21702 USA.							Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Alkhatib G, 1997, NATURE, V388, P238, DOI 10.1038/40789; BLUMENTHAL R, 1991, ANN NY ACAD SCI, V635, P285, DOI 10.1111/j.1749-6632.1991.tb36499.x; Blumenthal R, 1996, J CELL BIOL, V135, P63, DOI 10.1083/jcb.135.1.63; Broder CC, 1996, PATHOBIOLOGY, V64, P171, DOI 10.1159/000164032; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHERNOMORDIK L, 1994, J VIROL, V68, P7115, DOI 10.1128/JVI.68.11.7115-7123.1994; Chernomordik LV, 1997, J CELL BIOL, V136, P81, DOI 10.1083/jcb.136.1.81; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Chowdhury IH, 1995, AIDS RES HUM RETROV, V11, P1467, DOI 10.1089/aid.1995.11.1467; CLAPHAM PR, 1992, J VIROL, V66, P3531, DOI 10.1128/JVI.66.6.3531-3537.1992; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Dimitrov DS, 1996, NAT MED, V2, P640, DOI 10.1038/nm0696-640; DIMITROV DS, 1997, HIV MEMBRANE RECEPTO; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Doranz BJ, 1997, IMMUNOL RES, V16, P15, DOI 10.1007/BF02786321; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P4005, DOI 10.1073/pnas.94.8.4005; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465; Fass D, 1997, SCIENCE, V277, P1662, DOI 10.1126/science.277.5332.1662; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GRANT RA, 1994, CURR BIOL, V4, P784, DOI 10.1016/S0960-9822(00)00176-7; Januszeski MM, 1997, J VIROL, V71, P3613, DOI 10.1128/JVI.71.5.3613-3619.1997; Kirpotin D, 1997, BIOCHEMISTRY-US, V36, P66, DOI 10.1021/bi962148u; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; Pak CC, 1997, BIOCHEMISTRY-US, V36, P8890, DOI 10.1021/bi9702851; Picard L, 1997, J VIROL, V71, P5003, DOI 10.1128/JVI.71.7.5003-5011.1997; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; RAPAPORT D, 1995, EMBO J, V14, P5524, DOI 10.1002/j.1460-2075.1995.tb00239.x; Reeves JD, 1997, VIROLOGY, V231, P130, DOI 10.1006/viro.1997.8508; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; Schnell MJ, 1997, CELL, V90, P849, DOI 10.1016/S0092-8674(00)80350-5; Smith TJ, 1996, NATURE, V383, P350, DOI 10.1038/383350a0; SMITH TJ, 1986, SCIENCE, V233, P1286, DOI 10.1126/science.3018924; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Trus BL, 1997, NAT STRUCT BIOL, V4, P413, DOI 10.1038/nsb0597-413; Ugolini S, 1997, J IMMUNOL, V159, P3000; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; ZIMMERBERG J, 1994, J CELL BIOL, V127, P1885, DOI 10.1083/jcb.127.6.1885	52	96	99	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 12	1997	91	6					721	730		10.1016/S0092-8674(00)80460-2	http://dx.doi.org/10.1016/S0092-8674(00)80460-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413981	Bronze			2022-12-28	WOS:A1997YL43900003
J	Scherer, K; Fichtner, H; Anderson, JD; Lau, EL				Scherer, K; Fichtner, H; Anderson, JD; Lau, EL			A pulsar, the Heliosphere, and Pioneer 10: Probable mimicking of a planet of PSR B1257+12 by solar rotation	SCIENCE			English	Article							WIND; ULYSSES; PERIOD	Doppler data generated with the Pioneer 10 spacecraft's radio carrier wave between 1987 and 1995 show a 25.3-day periodicity which is related to the solar rotation. The timing data of the pulsar PSR B1257+12 also show a periodicity of 25.34 days, which has been explained as a signature of the pulsar's barycentric motion in response to the existence of a small moon-like object. However, because PSR B1257+12 is located close to the ecliptic and because the timing variations are in the range of microseconds, it is likely that the pulsar signal is affected by the same mechanism acting on the Pioneer 10 Doppler data. Hence, the hypothesized inner planet around PSR B1257+12 is probably an artifact of the heliosphere.	JET PROP LAB,PASADENA,CA 91119; UNIV BONN,INST ASTROPHYS & EXTRATERR FORSCH,D-53121 BONN,GERMANY	National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Bonn				Fichtner, Horst/0000-0002-9151-5127				ANDERSON JD, 1974, EXPT GRAVITATION, P163; Bird M.K., 1981, SOLAR WIND, P78; BIRD MK, 1982, SPACE SCI REV, V33, P99, DOI 10.1007/BF00213250; BURLAGA LF, 1988, J GEOPHYS RES, V93, P4103, DOI 10.1029/JA093iA05p04103; FIMMEL RO, 1980, SP446 NASA; Gray DF, 1997, NATURE, V385, P795, DOI 10.1038/385795a0; MALHOTRA R, 1993, ASTROPHYS J, V407, P266, DOI 10.1086/172511; MOYER TD, 1971, 321527 JPL TR; MUHLEMAN DO, 1981, ASTROPHYS J, V247, P1093, DOI 10.1086/159119; Mursula K, 1996, J GEOPHYS RES-SPACE, V101, P27077, DOI 10.1029/96JA02470; PHILLIPS JL, 1995, SCIENCE, V268, P1030, DOI 10.1126/science.268.5213.1030; RASIO FA, 1993, ASTR SOC P, V36, P107; RICHARDSON JD, 1994, GEOPHYS RES LETT, V21, P1559, DOI 10.1029/94GL01076; SCHERER K, 1995, EOS S, V76, pF332; TAPLEY BD, 1973, RECENT ADV DYNAMICAL, P396; VONSTEIGER R, 1995, SPACE SCI REV, V72, P71, DOI 10.1007/BF00768756; WOLSZCZAN A, 1994, SCIENCE, V264, P538, DOI 10.1126/science.264.5158.538; WOLSZCZAN A, 1996, IAU C, V160, P91	18	17	17	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1919	1921		10.1126/science.278.5345.1919	http://dx.doi.org/10.1126/science.278.5345.1919			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395388				2022-12-28	WOS:A1997YL00200026
J	McKernan, MG; ShinnickGallagher, P				McKernan, MG; ShinnickGallagher, P			Fear conditioning induces a lasting potentiation of synaptic currents in vitro	NATURE			English	Article							PAIRED-PULSE FACILITATION; LONG-TERM POTENTIATION; MEDIAL GENICULATE-BODY; LATERAL NUCLEUS; RAT HIPPOCAMPUS; NMDA RECEPTORS; PATCH-CLAMP; CA1 REGION; AMYGDALA; TRANSMISSION	The amygdala plays a critical role in the mediation of emotional responses, particularly fear, in both humans and animals(1-4). Fear conditioning, a conditioned learning paradigm, has served as a model for emotional learning in animals, and the neuroanatomical circuitry underlying the auditory fear-conditioning paradigm is well characterized(5). Synaptic transmission in the medial geniculate nucleus (MGN) to lateral nucleus of the amygdala (LA) pathway, a key segment of the auditory fear conditioning circuit, is mediated largely through N-methyl-D-aspartate (NMDA) and non-NMDA (such as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)) glutamate receptors(6); the potential for neural plasticity in this pathway is suggested by its capacity to support long-term potentiation (LTP)(7,8). Here we report a long-lasting increase in the synaptic efficacy of the MGN-LA pathway attributable to fear-conditioning itself, rather than an electrically induced model of learning. Fear-conditioned animals show a presynaptic facilitation of AMPA-receptor-mediated transmission, directly measured in vitro with whole-cell recordings in lateral amygdala neurons. These findings represent one of the first in vitro measures of synaptic plasticity resulting from emotional learning by whole animals.	UNIV TEXAS,MED BRANCH,DEPT PHARMACOL & TOXICOL,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston								ALDOLPHS R, 1994, NATURE, V372, P669; ANDREASEN M, 1994, J NEUROPHYSIOL, V72, P326, DOI 10.1152/jn.1994.72.1.326; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; CASSELLA JV, 1986, PHYSIOL BEHAV, V36, P377, DOI 10.1016/0031-9384(86)90032-6; CLARK KA, 1994, EXP BRAIN RES, V101, P272, DOI 10.1007/BF00228747; CLUGNET MC, 1990, J NEUROSCI, V10, P2818; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; DAVIS M, 1993, BEHAV BRAIN RES, V58, P175, DOI 10.1016/0166-4328(93)90102-V; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KIM M, 1993, BEHAV NEURAL BIOL, V59, P5, DOI 10.1016/0163-1047(93)91075-X; KUHNT U, 1994, NEUROSCIENCE, V62, P391, DOI 10.1016/0306-4522(94)90374-3; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; LEDOUX JE, 1985, J COMP NEUROL, V242, P182, DOI 10.1002/cne.902420204; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; LI XF, 1995, EXP BRAIN RES, V105, P87; LIN JW, 1988, J NEUROSCI, V8, P1313; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; Maren S, 1996, MOL NEUROBIOL, V13, P1, DOI 10.1007/BF02740749; McKernan M. G., 1996, Society for Neuroscience Abstracts, V22, P1536; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MULLER D, 1990, SYNAPSE, V5, P94, DOI 10.1002/syn.890050203; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; Neugebauer V, 1997, J NEUROSCI, V17, P983; PARSONS CG, 1994, NEUROPHARMACOLOGY, V33, P589, DOI 10.1016/0028-3908(94)90163-5; ROGAN MT, 1995, NEURON, V15, P127, DOI 10.1016/0896-6273(95)90070-5; Scott SK, 1997, NATURE, V385, P254, DOI 10.1038/385254a0; SHULZ P, 1994, J NEUROSCI, V14, P5325	29	611	620	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					607	611		10.1038/37605	http://dx.doi.org/10.1038/37605			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403689				2022-12-28	WOS:A1997YK85300049
J	Uozumi, N; Kume, K; Nagase, T; Nakatani, N; Ishii, S; Tashiro, F; Komagata, Y; Maki, K; Ikuta, K; Ouchi, Y; Miyazaki, J; Shimizu, T				Uozumi, N; Kume, K; Nagase, T; Nakatani, N; Ishii, S; Tashiro, F; Komagata, Y; Maki, K; Ikuta, K; Ouchi, Y; Miyazaki, J; Shimizu, T			Role of cytosolic phospholipase A(2) in allergic response and parturition	NATURE			English	Article							PLATELET-ACTIVATING-FACTOR; ARACHIDONIC-ACID; MAST-CELLS; GENE DISRUPTION; DEFICIENT MICE; RECEPTOR; MOUSE; PHOSPHORYLATION; TRANSLOCATION; KINASE	Phospholipase A(2) (PLA(2)) comprises a superfamily of enzymes that hydrolyse the ester bond of phospholipids at the sn-2 position(1-3). Among the members of this superfamily, cytosolic PLA(2) has attracted attention because it preferentially hydrolyses arachidonoyl phospholipids and is activated by submicromolar concentrations of Ca2+ ions and by phosphorylation by mitogen-activated protein kinases (MAP kinases)(4-8). Here we investigate the function of cytosolic PLA(2) in vivo by using homologous recombination to generate mice deficient in this enzyme. These mice showed a marked decrease in their production of eicosanoids and platelet-activating factor in peritoneal macrophages. Their ovalbumin-induced anaphylactic responses were significantly reduced, as was their bronchial reactivity to methacholine. Female mutant mice failed to deliver offspring, but these could be rescued by administration of a progesterone-receptor antagonist to the mother at term. Considered together with previous findings(9-15), our results indicate that cytosolic PLA(2) plays a non-redundant role in allergic responses and reproductive physiology.	UNIV TOKYO,FAC MED,DEPT BIOCHEM & MOL BIOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT GERIATR,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DIS RELATED GENE REGULAT RES SANDOZ,BUNKYO KU,TOKYO 113,JAPAN; TOHOKU UNIV,INST DEV AGING & CANC,AOBA KU,SENDAI,MIYAGI 98077,JAPAN	University of Tokyo; University of Tokyo; University of Tokyo; Tohoku University			Miyazaki, Jun-ichi/N-1976-2015; Uozumi, Nobuyuki/AAG-3252-2019	Miyazaki, Jun-ichi/0000-0003-2475-589X; Ikuta, Koichi/0000-0003-1319-1021; Kume, Kazuhiko/0000-0003-4232-1657				AOKI Y, 1995, J IMMUNOL METHODS, V186, P225, DOI 10.1016/0022-1759(95)00147-3; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CURRIE S, 1994, BIOCHEM J, V304, P923, DOI 10.1042/bj3040923; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dudley DJ, 1996, BIOL REPROD, V55, P992, DOI 10.1095/biolreprod55.5.992; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GOLDBERG VJ, 1975, PHYSIOL REV, V55, P325, DOI 10.1152/physrev.1975.55.3.325; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; Irvin CG, 1997, AM J PHYSIOL-LUNG C, V272, pL1053, DOI 10.1152/ajplung.1997.272.6.L1053; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nagase T, 1996, AM J RESP CRIT CARE, V154, P504, DOI 10.1164/ajrccm.154.2.8756829; NAKATANI Y, 1994, J IMMUNOL, V153, P796; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; ONEILL C, 1989, LANCET, V2, P769; Prescott SM, 1997, J BIOL CHEM, V272, P15043, DOI 10.1074/jbc.272.24.15043; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X	30	582	602	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					618	622		10.1038/37622	http://dx.doi.org/10.1038/37622			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403692				2022-12-28	WOS:A1997YK85300052
J	deShazo, RD				deShazo, RD			Future trends in allergy and immunology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASTHMA; IMMUNOTHERAPY; INFECTION; THERAPY; DISEASE; GENE				deShazo, RD (corresponding author), UNIV S ALABAMA,COLL MED,DEPT MED,4TH FLOOR,MASTIN BLDG,2451 FILLINGIM ST,MOBILE,AL 36617, USA.							ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; ANDERSON JA, 1991, J ALLERGY CLIN IMMUN, V88, P17, DOI 10.1016/0091-6749(91)90296-Z; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; CEROTTINI JC, 1997, IMMUNOLOGIST, V5, P27; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; HANANIA EG, 1995, AM J MED, V99, P537, DOI 10.1016/S0002-9343(99)80232-0; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Holgate ST, 1996, J ALLERGY CLIN IMMUN, V98, P1, DOI 10.1016/S0091-6749(96)70220-8; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MCCOMBS CC, 1997, AVERYS DRUG TREATMEN, P1295; MCHUGH RS, 1995, P NATL ACAD SCI USA, V92, P8059, DOI 10.1073/pnas.92.17.8059; NORMAN PS, 1995, J ALLERGY CLIN IMMUN, V95, P259; OBrien KP, 1996, IMMUNOL ALLERGY CLIN, V16, P809, DOI 10.1016/S0889-8561(05)70273-3; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	17	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					2024	2025		10.1001/jama.278.22.2024	http://dx.doi.org/10.1001/jama.278.22.2024			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396666				2022-12-28	WOS:A1997YK15500027
J	Yung, YL; Miller, CE				Yung, YL; Miller, CE			Isotopic fractionation of stratospheric nitrous oxide	SCIENCE			English	Article							ULTRAVIOLET-ABSORPTION; N2O; PHOTODISSOCIATION; TEMPERATURE; SPECTRA; CF2CL2; REGION; CFCL3; SINK; O2	We propose an isotopic fractionation mechanism, based on photolytic destruction, to explain the N-15/N-14 and O-18/O-16 fractionation of stratospheric nitrous oxide (N2O) and reconcile laboratory experiments with atmospheric observations. The theory predicts that (i) the isotopomers (NNO)-N-15-N-14-O-16 and (NNO)-N-14-N-15-O-16 have very different isotopic fractionations in the stratosphere, and (ii) laboratory photolysis experiments conducted at 205 nanometers should better simulate the observed isotopic fractionation of stratospheric N2O. Modeling results indicate that there is no compelling reason to invoke a significant chemical source of N2O in the middle atmosphere and that individual N2O isotopomers might be useful tracers of stratospheric air parcel motion.	CALTECH, JET PROP LAB, ATMOSPHER KINET & PHOTOCHEM GRP, PASADENA, CA 91109 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Yung, YL (corresponding author), CALTECH, DIV GEOL & PLANETARY SCI, MAIL STOP 150-21, PASADENA, CA 91125 USA.		Yung, Yuk/AAM-4850-2021; Miller, Charles/G-7854-2017	Yung, Yuk/0000-0002-4263-2562; 				CICERONE RJ, 1989, J GEOPHYS RES-ATMOS, V94, P18265, DOI 10.1029/JD094iD15p18265; CICERONE RJ, 1980, GEOPHYS RES LETT, V7, P251, DOI 10.1029/GL007i004p00251; Cliff SS, 1997, SCIENCE, V278, P1774, DOI 10.1126/science.278.5344.1774; DEMORE WB, 1996, JPL PUBLICATION, V9426, P125; FELDER P, 1991, CHEM PHYS LETT, V186, P177, DOI 10.1016/S0009-2614(91)85125-G; FROIDEVAUX L, 1982, GEOPHYS RES LETT, V9, P854, DOI 10.1029/GL009i008p00854; HANISCO TF, 1993, J PHYS CHEM-US, V97, P7242, DOI 10.1021/j100130a020; HOPPER DG, 1984, J CHEM PHYS, V80, P4290, DOI 10.1063/1.447260; HOUGHTON LG, 1995, INTERGOVERNMENTAL PA; HUBRICH C, 1980, J PHOTOCHEM, V12, P93, DOI 10.1016/0047-2670(80)85031-3; JOHNSTON JC, 1995, J GEOPHYS RES-ATMOS, V100, P16801, DOI 10.1029/95JD01646; Kaye J. A., 1994, NASA REFERENCE PUBLI, V1339; KHALIL MAK, 1992, J GEOPHYS RES-ATMOS, V97, P14651, DOI 10.1029/92JD01222; KIM KR, 1993, SCIENCE, V262, P1855, DOI 10.1126/science.262.5141.1855; KOLMA J, 1983, J MOL SPECTROSC, V101, P278; McElroy MB, 1996, GLOBAL BIOGEOCHEM CY, V10, P651, DOI 10.1029/96GB02346; MERIENNE MF, 1990, PLANET SPACE SCI, V38, P617, DOI 10.1016/0032-0633(90)90067-Z; MINSCHWANER K, 1993, J GEOPHYS RES-ATMOS, V98, P10543, DOI 10.1029/93JD00223; MOLINA MJ, 1974, NATURE, V249, P810, DOI 10.1038/249810a0; NORTON RH, 1991, APPL OPTICS, V30, P389, DOI 10.1364/AO.30.000389; Prasad SS, 1994, J GEOPHYS RES-ATMOS, V99, P5285, DOI 10.1029/93JD01911; Rahn T, 1997, SCIENCE, V278, P1776, DOI 10.1126/science.278.5344.1776; ROWLAND FS, 1975, REV GEOPHYS, V13, P1, DOI 10.1029/RG013i001p00001; SELWYN GS, 1981, J CHEM PHYS, V74, P3791, DOI 10.1063/1.441608; SHAFER N, 1991, J CHEM PHYS, V95, P6218, DOI 10.1063/1.461567; SHIA RL, 1989, J GEOPHYS RES-ATMOS, V94, P18467, DOI 10.1029/JD094iD15p18467; SPRINGSTEEN LL, 1993, J PHYS CHEM-US, V97, P7239, DOI 10.1021/j100130a019; THIEMENS MH, 1991, SCIENCE, V251, P932, DOI 10.1126/science.251.4996.932; TOTH RA, 1986, J OPT SOC AM B, V3, P1263, DOI 10.1364/JOSAB.3.001263; TOTH RA, 1987, J OPT SOC AM B, V4, P357, DOI 10.1364/JOSAB.4.000357; *WORLD MET ORG, 1995, 37 WORLD MET ORG; YOSHINO K, 1984, PLANET SPACE SCI, V32, P1219, DOI 10.1016/0032-0633(84)90065-5	32	139	141	1	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 5	1997	278	5344					1778	1780		10.1126/science.278.5344.1778	http://dx.doi.org/10.1126/science.278.5344.1778			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388176				2022-12-28	WOS:A1997YJ90100042
J	Dufour, JF; DeLellis, R; Kaplan, MM				Dufour, JF; DeLellis, R; Kaplan, MM			Reversibility of hepatic fibrosis in autoimmune hepatitis	ANNALS OF INTERNAL MEDICINE			English	Article								Background: Hepatic fibrosis and cirrhosis occur in many types of chronic liver injury and generally seem to be irreversible. Objective: To determine whether cirrhosis caused by autoimmune hepatitis can be reversible. Design: Retrospective study. Patients: Eight patients with autoimmune hepatitis and cirrhosis who responded to medical therapy and had follow-up liver biopsy while in clinical and biochemical remission. Measurements: Biopsy specimens were randomly coded in an unpaired manner according to patient and were read independently by two pathologists using the Knodell scoring system. Results: The median alanine aminotransferase level decreased from 10.30 mu kat/L to 0.37 mu kat/L, the median serum bilirubin level decreased from 70 mu mol/L to 10 mu mol/L, and the median serum albumin level increased from 34 g/L to 43 g/L. Cirrhosis, extensive fibrosis, or both were present in all patients at diagnosis but were not present on follow-up liver biopsy. The median Knodell score decreased from 14.0 to 1.3, and the median fibrosis score decreased from 3.3 to 0.8. Conclusion: Hepatic fibrosis and cirrhosis may be reversible in some patients in whom autoimmune hepatitis responds to treatment.	TUFTS UNIV NEW ENGLAND MED CTR, DIV GASTROENTEROL, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT PATHOL, BOSTON, MA 02111 USA; TUFTS UNIV, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts Medical Center; Tufts University			Dufour, Jean Francois Jacques/AAL-9866-2020	Dufour, Jean Francois Jacques/0000-0002-8062-1346	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007701] Funding Source: NIH RePORTER; NIDDK NIH HHS [T32-DK07701] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDI W, 1979, ARCH INTERN MED, V139, P667, DOI 10.1001/archinte.139.6.667; Crawford JM, 1994, PATHOLOGIC BASIS DIS, P831; DUNN MA, 1994, AM J TROP MED HYG, V50, P499, DOI 10.4269/ajtmh.1994.50.499; FALKMER S, 1970, Pediatrics, V45, P260; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GREENWEL P, 1994, LIVER BIOLOGY RADIOB; Hall PD, 1987, PATHOLOGY LIVER, P291; JOHNSON PJ, 1993, HEPATOLOGY, V18, P998, DOI 10.1002/hep.1840180435; Kaplan MM, 1997, ANN INTERN MED, V126, P682, DOI 10.7326/0003-4819-126-9-199705010-00002; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; POWELL LW, 1970, AUSTRALAS ANN MED, V19, P54; TASSONI JP, 1991, GASTROENTEROLOGY, V100, P1462; The French METAVIR Cooperative Study Group, 1994, HEPATOLOGY 1, V20, P15; ZIMMERMANN H, 1992, GASTROENTEROLOGY, V103, P579, DOI 10.1016/0016-5085(92)90850-X	14	228	232	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					981	985		10.7326/0003-4819-127-11-199712010-00006	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412303				2022-12-28	WOS:A1997YJ08000004
J	Olin, P; Rasmussen, F; Gustafsson, L; Hallander, HO; Heijbel, H				Olin, P; Rasmussen, F; Gustafsson, L; Hallander, HO; Heijbel, H			Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine	LANCET			English	Article							BORDETELLA-PERTUSSIS; EFFICACY; SEROLOGY; INFANTS	Background Trials in Italy and Sweden showed high efficacy for three-component and five-component pertussis vaccines, and poor efficacy for a whole-cell vaccine licensed in the USA and a two-component vaccine, We compared the efficacy of three acellular vaccines with a UK whole-cell vaccine. Methods We enrolled 82 892 babies aged 2-3 months. Babies were vaccinated at age 3 months, 5 months, and 12 months, or age 2 months, 4 months, and 6 months. They were randomly assigned a two-component acellular diphtheria-tetanus-pertussis (DTP) vaccine (n=20 697), a three-component acellular DTP vaccine (n=20 728), a five-component acellular DTP vaccine (n=20 747), or a UK whole-cell DTP vaccine (n=20 720). We collected data for all reported cases of culture-confirmed pertussis during 3 years of follow-up. The treatment status of the two-component-vaccine group had to be made known midway through the trial for boosting because of poor efficacy. We included data for the two-component vaccine in the analysis of safety and immunogenicity, and data up its unmasking in secondary analyses of relative efficacy. Analyses were by intention to treat. Findings During follow-up from the third dose (mean 22 months), in the 3 months, 5 months, 12 months schedule, there were 15 cases of culture-confirmed pertussis with at least 21 days of paroxysmal cough in the whole-cell group, relative risk 1.00, compared with 13 in the five-component group (0.85 [95% CI 0.41-1.79]), and 21 in the three-component group (1.38 [0.71-2.69]). For culture-confirmed pertussis, with or without cough, there were 19 cases in the whole-cell group (1.00), 27 in the five-component group (1.40 [0.78-2.52]), and 49 in the three-component group (2.55 [1.50-4.33]). In the intention-to-treat analyses, from the first dose in the 3 months, 5 months, 12 months schedule the whole-cell vaccine was significantly more protective than the three-component vaccine against typical pertussis. Between the second and the third doses, culture-confirmed pertussis with any cough and with at least 21 days of paroxysmal cough was significantly more frequent in the two-component group than in the three-component group, and in the three-component group than in the five-component and the whole-cell groups, respectively. The serological response of the acellular vaccines in the 2 months, 4 months, 6 months schedule were similar to those previously reported, The whole-cell vaccine was highly immunogenic for fimbriae, pertactin, and filamentous haemagglutinin, but had a low antipertussis toxin response. Hypotonic hyporesponsiveness occurred significantly more frequently in the whole-cell group (p<0.05) and was more frequent in the acellular groups than previously reported. High fever and seizures occurred more frequently after whole-cell vaccine than after any of the acellular vaccines (p<0.001). Interpretations The efficacy of the UK whole-cell vaccine and the five-component and three-component vaccines was similar against culture-confirmed pertussis with at least 21 days of paroxysmal cough. The lower efficacy of the three-component vaccine against mild disease suggests that fimbriae have a role in protection against infection. The efficacy of acellular vaccines depends on the number of components, and different whole-cell vaccines have variable efficacies.			Olin, P (corresponding author), SWEDISH INST INFECT DIS CONTROL,S-10521 STOCKHOLM,SWEDEN.			Rasmussen, Finn/0000-0001-7915-7809	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015125] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-15125] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1951, Br Med J, V1, P1463; BLENNOW M, 1988, BRIT MED J, V296, P1570, DOI 10.1136/bmj.296.6636.1570; CODY CL, 1981, PEDIATRICS, V68, P650; DECKER MD, 1995, PEDIATRICS, V96, P557; Edwards KM, 1996, NEW ENGL J MED, V334, P391, DOI 10.1056/NEJM199602083340609; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; HALLANDER HO, 1991, J INFECT DIS, V163, P1046, DOI 10.1093/infdis/163.5.1046; HALSEY NA, 1995, PEDIATRICS, V96, P970; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; Lynn F, 1996, CLIN DIAGN LAB IMMUN, V3, P689, DOI 10.1128/CDLI.3.6.689-700.1996; MEADE BD, 1995, PEDIATRICS, V96, P570; MILLER E, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P97; Olin P, 1997, PEDIATR INFECT DIS J, V16, P517, DOI 10.1097/00006454-199705000-00012; OLIN P, 1997, INT J INFECT DIS, V1, P143; Olin P, 1997, EFFICACY TRIAL ACELL, V116, P1; Plotkin SA, 1997, PEDIATR INFECT DIS J, V16, P508, DOI 10.1097/00006454-199705000-00011; Poland GA, 1996, LANCET, V347, P209, DOI 10.1016/S0140-6736(96)90398-0; POLLOCK TM, 1982, BRIT MED J, V285, P357; PRESTON NW, 1985, LANCET, V1, P510; Rappuoli R, 1997, NAT MED, V3, P374, DOI 10.1038/nm0497-374; REIZENSTEIN E, 1995, J IMMUNOL METHODS, V183, P279, DOI 10.1016/0022-1759(95)00067-K; Schneerson R, 1996, LANCET, V348, P1289, DOI 10.1016/S0140-6736(96)05243-9; SHAHIN RD, 1990, J EXP MED, V171, P63, DOI 10.1084/jem.171.1.63; STORSAETER J, 1992, VACCINE, V10, P142, DOI 10.1016/0264-410X(92)90002-2; TARANGER J, 1996, DEV BIOL STAND, V89, P105; *WHO, 1991, WHO M CAS DEF PERT G, V1, P4	27	246	255	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1569	1577		10.1016/S0140-6736(97)06508-2	http://dx.doi.org/10.1016/S0140-6736(97)06508-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393335				2022-12-28	WOS:A1997YH98600007
J	Smith, OP; White, B; Vaughan, D; Rafferty, M; Claffey, L; Lyons, B; Casey, W				Smith, OP; White, B; Vaughan, D; Rafferty, M; Claffey, L; Lyons, B; Casey, W			Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans	LANCET			English	Article							DISSEMINATED INTRAVASCULAR COAGULATION; HUMAN MONONUCLEAR PHAGOCYTES; ESCHERICHIA-COLI; DEFICIENCY; INHIBITOR; NECROSIS; ASSOCIATION; ACTIVATION; MORTALITY; RESPONSES	Background Inflammatory and coagulation processes are both affected in meningococcaemia. Severe acquired protein-C deficiency in meningococcaemia is usually associated with substantial mortality; in survivors, skin grafts, amputation, and end-organ failure are not uncommon. Protein C is a natural anticoagulant and also has important anti-inflammatory activity. We assessed the effects of early replacement therapy with protein-C, concentrate together with continuous veno-venous haemodiafiltration and conventional treatment in meningococcaemia. Methods 12 patients aged between 3 months and 27 years with meningococcaemia and severe acquired protein-C deficiency (mean 0.20 IU/mL) were studied. Ail patients had septic shock, widespread purpura, skin necrosis, and disseminated intravascular coagulopathy, After a test dose of protein-C concentrate, patients received a continuous infusion with the dose adjusted daily to keep the plasma concentration between 0.8 and 12 IU/mL, 11 patients were given unfractionated intravenous heparin (10-15 IU kg(-1) h(-1)). Nine patients had haemodiafiltration and one had peritoneal dialysis. The Glasgow meningococcal septicaemia prognostic score and the paediatric risk of mortality score predicted a minimum mortality of 80% and 57%, respectively. Findings No patient died, No adverse reactions to the treatment were seen. Two patients had lower-limb amputations, one of whom had a thrombotic cerebrovascular accident; both patients had received the protein-C concentrate and heparin later than the rest of the group (60 h [16.97] vs 12 h [3.13].). One patient developed chronic renal failure despite receiving protein-e infusion 15 h after admission. Interpretation The acquired severe deficiency of protein C in meningococcaemia contributes to the pathogenesis of the thrombotic necrotic lesions in the shin and other organs and probably has an important role in the inflammatory response, Protein-C therapy is merely one approach to improve the host response in this syndrome, We suggest that-a double-blind, randomised, controlled multicentre trial is needed to confirm our results.	ST JAMES HOSP,DEPT PAEDIAT HAEMATOL,DUBLIN 2,IRELAND; OUR LADYS HOSP SICK CHILDREN,DEPT ANAESTHESIA,CRUMLIN,NORTH IRELAND; CHILDRENS HOSP,DEPT ANAESTHESIA,DUBLIN,IRELAND	Trinity College Dublin; Our Ladys Children Hospital Crumlin; Trinity College Dublin	Smith, OP (corresponding author), NATL CHILDRENS HOSP,DEPT PAEDIAT HAEMATOL,HARCOURT ST,DUBLIN 2,IRELAND.		Vaughan, David/AAZ-3873-2020; Smith, Owen/AAU-8929-2020	Lyons, Barry/0000-0002-8806-1195				ATTANASIO M, 1997, THROMB HAEMOST S, V77, P9; BELLOMO R, 1993, CRIT CARE MED, V21, P522, DOI 10.1097/00003246-199304000-00011; Best C, 1996, LANCET, V347, P202, DOI 10.1016/S0140-6736(96)90389-X; BRANDTZAEG P, 1989, THROMB RES, V55, P459, DOI 10.1016/0049-3848(89)90054-6; BRANSON HE, 1983, LANCET, V2, P1165; DAUBENER W, 1995, EUR J IMMUNOL, V25, P688, DOI 10.1002/eji.1830250309; DREYFUS M, 1991, NEW ENGL J MED, V325, P1565, DOI 10.1056/NEJM199111283252207; ESMON CT, 1991, THROMB HAEMOSTASIS, V66, P160; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FEINSTEIN DI, 1982, BLOOD, V60, P284; FIJNVANDRAAT K, 1995, THROMB HAEMOSTASIS, V73, P15; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; GIRAUD T, 1991, ARCH INTERN MED, V151, P310, DOI 10.1001/archinte.151.2.310; GREY ST, 1994, J IMMUNOL, V153, P3664; GRINNELL BW, 1994, GLYCOBIOLOGY, V4, P221, DOI 10.1093/glycob/4.2.221; Hancock WW, 1995, TRANSPLANTATION, V60, P1525, DOI 10.1097/00007890-199560120-00026; HAVENS PL, 1989, PEDIATR INFECT DIS J, V8, P8, DOI 10.1097/00006454-198901000-00003; HEYDERMAN RS, 1993, ARCH DIS CHILD, V68, P621, DOI 10.1136/adc.68.5.621; HEYDERMAN RS, 1992, THROMB RES, V67, P677, DOI 10.1016/0049-3848(92)90071-H; KUPPERMANN N, 1994, PEDIATR INFECT DIS J, V13, P867, DOI 10.1097/00006454-199410000-00004; LASZIK Z, IN PRESS J CLIN INVE; MANIOS S G, 1971, Scandinavian Journal of Infectious Diseases, V3, P127, DOI 10.3109/inf.1971.3.issue-2.06; MARLAR RA, 1985, BLOOD, V66, P59; MCGEJEE WG, 1967, ANN INTERN MED, V67, P250, DOI 10.7326/0003-4819-67-2-250; POLLACK MM, 1986, CRIT CARE MED, V14, P215; POWARS D, 1993, CLIN INFECT DIS, V17, P254, DOI 10.1093/clinids/17.2.254; RIVARD GE, 1995, J PEDIATR-US, V126, P646, DOI 10.1016/S0022-3476(95)70369-1; SCULLY MF, 1993, THROMB HAEMOSTASIS, V69, P448; SELIGSOHN U, 1991, NEW ENGL J MED, V325, P1565; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; TAYLOR F, 1991, BLOOD, V78, P357, DOI 10.1182/blood.V78.2.357.357; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; THOMSON APJ, 1991, CRIT CARE MED, V19, P26, DOI 10.1097/00003246-199101000-00010; WAAGE A, 1987, LANCET, V1, P355	34	172	178	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1590	1593		10.1016/S0140-6736(97)06356-3	http://dx.doi.org/10.1016/S0140-6736(97)06356-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393338				2022-12-28	WOS:A1997YH98600010
J	Correll, CC; Freeborn, B; Moore, PB; Steitz, TA				Correll, CC; Freeborn, B; Moore, PB; Steitz, TA			Metals, motifs, and recognition in the crystal structure of a 5S rRNA domain	CELL			English	Article							5-S RIBOSOMAL-RNA; ESCHERICHIA-COLI; BINDING-SITES; MAJOR GROOVE; HAMMERHEAD RIBOZYME; ALPHA-SARCIN; PROTEINS; LOOP; CONFORMATION; COMPLEX	Two new RNA structures portray how non-Watson-Crick base pairs and metal ions can produce a unique RNA shape suitable for recognition by proteins. The crystal structures of a 62 nt domain of E. coli 5S ribosomal RNA and a duplex dodecamer encompassing an internal loop E have been determined at 3.0 and 1.5 Angstrom, respectively. This loop E region is distorted by three ''cross-strand purine stacks'' and three novel, water-mediated noncanonical base pairs and stabilized by a four metal ion zipper. These features give its minor groove a unique hydrogen-bonding surface and make the adjacent major groove wide enough to permit recognition by the ribosomal protein L25, which is expected to bind to this surface.	YALE UNIV, DEPT MOL BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA; YALE UNIV, DEPT CHEM, NEW HAVEN, CT 06520 USA; HOWARD HUGHES MED INST, NEW HAVEN, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute			Steitz, Thomas A./C-6559-2009		NIGMS NIH HHS [GM-54216, GM-22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMEGUID SS, 1983, J MOL BIOL, V171, P207, DOI 10.1016/S0022-2836(83)80353-2; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; Biswas R, 1997, J MOL BIOL, V267, P1149, DOI 10.1006/jmbi.1997.0936; BRUNEL C, 1991, J MOL BIOL, V221, P293; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1997, STRUCTURE, V5, P325, DOI 10.1016/S0969-2126(97)00190-1; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cate JH, 1996, STRUCTURE, V4, P1221, DOI 10.1016/S0969-2126(96)00129-3; Cate JH, 1997, NAT STRUCT BIOL, V4, P553, DOI 10.1038/nsb0797-553; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Correll CC, 1997, J BIOMOL STRUCT DYN, V15, P165, DOI 10.1080/07391102.1997.10508183; Dallas A, 1995, BIOCHEM CELL BIOL, V73, P887, DOI 10.1139/o95-096; DOUTHWAITE S, 1982, BIOCHEMISTRY-US, V21, P2313, DOI 10.1021/bi00539a007; DOUTHWAITE S, 1979, NUCLEIC ACIDS RES, V6, P2453, DOI 10.1093/nar/6.7.2453; GAUTHERET D, 1995, RNA, V1, P807; Gluck A, 1996, J MOL BIOL, V256, P838, DOI 10.1006/jmbi.1996.0130; HARTMANN RK, 1988, NUCLEIC ACIDS RES, V16, P3511, DOI 10.1093/nar/16.8.3511; HUBER PW, 1984, P NATL ACAD SCI-BIOL, V81, P322, DOI 10.1073/pnas.81.2.322; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM JL, 1992, THESIS YALE U NEW HA; LEONTIS NB, 1984, NUCLEIC ACIDS RES, V12, P2193, DOI 10.1093/nar/12.4.2193; LEONTIS NB, 1986, BIOCHEMISTRY-US, V25, P7386, DOI 10.1021/bi00371a021; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOORE PB, 1996, RIBOSOMAL RNA STRUCT, P199; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan  T., 1993, RNA WORLD, P271; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; RABINOVICH D, 1988, J MOL BIOL, V200, P151, DOI 10.1016/0022-2836(88)90340-3; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P120; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SHEN Z, 1994, J MOL BIOL, V241, P415, DOI 10.1006/jmbi.1994.1517; SZEWCZAK AA, 1995, J MOL BIOL, V247, P81, DOI 10.1006/jmbi.1994.0124; TOUKIFIMPA R, 1989, BIOCHEMISTRY-US, V28, P5840, DOI 10.1021/bi00440a021; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; WU M, 1995, BIOCHEMISTRY-US, V34, P3204, DOI 10.1021/bi00010a009	43	357	359	2	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 28	1997	91	5					705	712		10.1016/S0092-8674(00)80457-2	http://dx.doi.org/10.1016/S0092-8674(00)80457-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393863	Bronze			2022-12-28	WOS:A1997YH96000017
J	Pohlschroder, M; Prinz, WA; Hartmann, E; Beckwith, J				Pohlschroder, M; Prinz, WA; Hartmann, E; Beckwith, J			Protein translocation in the three domains of life: Variations on a theme	CELL			English	Review							ENDOPLASMIC-RETICULUM; COMPONENTS; MEMBRANES; COMPLEX; ARCHAEA		HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; MAX DELBRUCK CTR MOL MED,D-13122 BERLIN,GERMANY	Harvard University; Harvard Medical School; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Pohlschroder, M (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115, USA.		Pohlschroder, Mechy/P-3206-2019; Hartmann, Enno/C-5687-2013					BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; KEELING PJ, 1995, P NATL ACAD SCI USA, V92, P5761, DOI 10.1073/pnas.92.13.5761; MURPHY CK, 1996, CELL MOL BIOL, P967; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; WICKNER WT, 1994, SCIENCE, V266, P1197, DOI 10.1126/science.7973701; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088	16	145	148	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					563	566		10.1016/S0092-8674(00)80443-2	http://dx.doi.org/10.1016/S0092-8674(00)80443-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393849	Bronze			2022-12-28	WOS:A1997YH96000003
J	Kurinczuk, JJ; Bower, C				Kurinczuk, JJ; Bower, C			Birth defects in infants conceived by intracytoplasmic sperm injection: an alternative interpretation	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL-MALFORMATIONS; WESTERN-AUSTRALIA; MALE-INFERTILITY; CHILDREN BORN; ICSI	Objective: To test the hypothesis that liveborn infants conceived by intracytoplasmic sperm injection are at an increased risk of having a major birth defect. Design: Reclassification of the birth defects reported in infants born after intracytoplasmic sperm injection in Belgium and comparison with prevalence estimated in Western Australian population by means of same classification system. Setting and subjects: 420 liveborn infants who were conceived after intracytoplasmic sperm injection in Belgium and 100 454 liveborn infants in Western Australia delivered during die same period, Main outcome measures: Estimates of birth prevalence of birth defects and comparisons of odds ratios between cohort conceived after intracytoplasmic sperm injection and Western Australian infants, Results: Infants horn after intracytoplasmic sperm injection were twice as likely as Western Australian infants to hare a major birth defect (odds ratio 2.03 (95% confidence interval 1.40 to 2.93); P = 0.0002) and nearly 50% more likely to hale a minor defect (1.49 (0.48 to 4.66): P = 0.49). Secondary data-led analyses, to he interpreted with caution, found an excess of major cardiovascular defects (odds ratio 3.99), genitourinary defects (1.33), and gastrointestinal defects (1.84), in particular cleft palate (5.11) and diaphragmatic hernia (7.73). Conclusions: These results do not confirm the apparently reassuring results published by the Belgian researchers of intracytoplasmic sperm injection, Further research is clearly required. Meanwhile, doctors practising intracytoplasmic sperm injection should bear this alternative interpretation in mind when they counsel couples and obtain informed consent for the procedure.	KING EDWARD MEM HOSP WOMEN,WESTERN AUSTRALIAN BIRTH DEFECTS REGISTRY,SUBIACO,WA 6008,AUSTRALIA	King Edward Memorial Hospital; University of Western Australia	Kurinczuk, JJ (corresponding author), INST CHILD HLTH RES,POB 855 W,PERTH,WA 6872,AUSTRALIA.			Bonduelle, Mary-Louise/0000-0002-1805-9962				BONDUELLE M, 1994, HUM REPROD, V9, P1765, DOI 10.1093/oxfordjournals.humrep.a138791; Bonduelle M, 1996, HUM REPROD, V11, P1558; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; BOWER C, 1990, COMMUNITY HEALTH ST, V14, P274; BOWER C, 1994, J PAEDIATR CHILD H, V30, P414, DOI 10.1111/j.1440-1754.1994.tb00691.x; BOWER C, 1989, MED J AUSTRALIA, V151, P245, DOI 10.5694/j.1326-5377.1989.tb101188.x; BOWER C, 1983, MED J AUSTRALIA, V2, P189, DOI 10.5694/j.1326-5377.1983.tb122403.x; BOWER C, 1996, REPORT BIRTH DEFECTS; BOWER C, 1995, PERSPECT HUM BIOL, V1, P29; British Paediatric Association, 1979, BRIT PAED ASS CLASS; BURN J, 1995, MULTIPLE PREGNANCY; CONDON RJ, 1993, MED J AUSTRALIA, V158, P379, DOI 10.5694/j.1326-5377.1993.tb121830.x; CUMMINS JM, 1994, HUM REPROD, V9, P1214, DOI 10.1093/oxfordjournals.humrep.a138681; DEKRETSER DM, 1995, REPROD FERT DEVELOP, V7, P137; *EUR, 1991, 4 EUR CENTR REG; GEE V, 1992, PERINATAL STAT W AUS; Hills, 1993, STAT MODELS EPIDEMIO; KEELING JW, 1995, MULTIPLE PREGNANCY; LANCASTER P, 1995, ASSISTED CONCEPTION, V1; LIEBAERS I, 1995, FERTILITY STERILITY; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; PATRIZIO P, 1995, HUM REPROD, V10, P2520, DOI 10.1093/oxfordjournals.humrep.a135734; TOURNAYE H, 1995, REPROD FERT DEVELOP, V7, P269, DOI 10.1071/RD9950269; VANSTEIRTEGHEM AC, 1994, REPROD MED REV, V3, P199	24	159	162	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1260	1265		10.1136/bmj.315.7118.1260	http://dx.doi.org/10.1136/bmj.315.7118.1260			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390051	Green Published			2022-12-28	WOS:A1997YG64500017
J	Li, P; Nijhawan, D; Budihardjo, I; Srinivasula, SM; Ahmad, M; Alnemri, ES; Wang, XD				Li, P; Nijhawan, D; Budihardjo, I; Srinivasula, SM; Ahmad, M; Alnemri, ES; Wang, XD			Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade	CELL			English	Article							PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; CYSTEINE PROTEASE; INTERLEUKIN-1-BETA-CONVERTING ENZYME; ICE/CED-3 PROTEASE; BCL-2 PROTEIN; LAMIN-A; GENE; ENCODES; HOMOLOG	We report here the purification of the third protein factor, Apaf-3, that participates in caspase-3 activation in vitro. Apaf-3 was identified as a member of the caspase family, caspase-9. Caspase-9 and Apaf-1 bind to each other via their respective NH2-terminal CED-3 homologous domains in the presence of cytochrome c and dATP, an event that leads to caspase-9 activation. Activated caspase-9 in turn cleaves and activates caspase-3. Depletion of caspase-9 from S-100 extracts diminished caspase-3 activation. Mutation of the active site of caspase-9 attenuated the activation of caspase-3 and cellular apoptotic response in vivo, indicating that caspase-9 is the most upstream member of the apoptotic protease cascade that is triggered by cytochrome c and dATP.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; THOMAS JEFFERSON UNIV,CTR APOPTOSIS RES,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,KIMMEL CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Jefferson University; Jefferson University			Alnemri, Emad S/B-4526-2010	Wang, Xiaodong/0000-0001-9885-356X	NIA NIH HHS [AG13487] Funding Source: Medline; NIGMS NIH HHS [GMRO1-55942, GM08014] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; An B, 1996, FEBS LETT, V399, P158, DOI 10.1016/S0014-5793(96)01311-7; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CACIOLAROSEN L, 1996, J EXP MED, V183, P1957; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DEJONG D, 1994, CANCER RES, V54, P256; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Eguchi Y, 1997, CANCER RES, V57, P1835; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICHOLSON WD, 1997, TRENDS BIOCHEM SCI, V257, P299; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Sambrook J., 2002, MOL CLONING LAB MANU; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SKOOG L, 1974, J BIOL CHEM, V249, P6434; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; SRINIVASULA SM, 1996, P NATL ACAD SCI USA, V93, P14488; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Ubeda M, 1997, J BIOL CHEM, V272, P19562, DOI 10.1074/jbc.272.31.19562; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	62	6044	6275	16	419	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					479	489		10.1016/S0092-8674(00)80434-1	http://dx.doi.org/10.1016/S0092-8674(00)80434-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390557	Bronze			2022-12-28	WOS:A1997YG49200009
J	Lazaridis, EN				Lazaridis, EN			Database standardization, linkage, and the protection of privacy	ANNALS OF INTERNAL MEDICINE			English	Article											Lazaridis, EN (corresponding author), INDIANA UNIV, MED CTR, REGENSTRIEF INST HLTH CARE, INDIANAPOLIS, IN 46202 USA.							LAZARIDIS EN, IN PRESS AM STAT	1	6	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				696	696		10.7326/0003-4819-127-8_Part_2-199710151-00052	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00052			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB385	9382382				2022-12-28	WOS:A1997YB38500007
J	Brown, DR; Qin, KF; Herms, JW; Madlung, A; Manson, J; Strome, R; Fraser, PE; Kruck, T; vonBohlen, A; SchulzSchaeffer, W; Giese, A; Westaway, D; Kretzschmar, H				Brown, DR; Qin, KF; Herms, JW; Madlung, A; Manson, J; Strome, R; Fraser, PE; Kruck, T; vonBohlen, A; SchulzSchaeffer, W; Giese, A; Westaway, D; Kretzschmar, H			The cellular prion protein binds copper in vivo	NATURE			English	Article							SERUM-ALBUMIN; HIGH-AFFINITY; COMPLEX; REGION; SITE; PRP	The normal cellular form of prion protein (PrPC) is a precursor to the pathogenic protease-resistant forms (PrPSc) believed to cause scrapie, bovine spongiform encephalopathy (BSE) and Creutzfeldt-Jakob disease(1). Its amino terminus contains the octapeptide PHGGGWGQ, which is repeated four times and is among the best-preserved regions of mammalian PrPC. Here we show that the amino-terminal domain of PrPC exhibits five to six sites that bind copper (Cu(II)) presented as a glycine chelate. At neutral pH, binding occurs with positive cooperativity, with binding affinity compatible with estimates for extracellular, labile copper. Two lines of independently derived PrPC gene-ablated (Prnp(0/0)) mice exhibit severe reductions in the copper content of membrane-enriched brain extracts and similar reductions in synaptosomal and endosome-enriched subcellular fractions. Prnp(0/0) mice also have altered cellular phenotypes, including a reduction in the activity of copper/zinc superoxide dismutase and altered electrophysiological responses in the presence of excess copper. These findings indicate that PrPC can exist in a Cu-metalloprotein form in vivo.	UNIV GOTTINGEN,DEPT NEUROPATHOL,D-37075 GOTTINGEN,GERMANY; UNIV TORONTO,CTR RES NEURODEGENERAT DIS,TORONTO,ON M5S 3H2,CANADA; UNIV TORONTO,DEPT LAB MED & PATHOBIOL,TORONTO,ON M5S 3H2,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5S 3H2,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5S 3H2,CANADA; NEUROPATHOGENESIS UNIT,EDINBURGH EA 3TF,MIDLOTHIAN,SCOTLAND; INST SPEKTROCHEM & ANGEW SPEKTROSKOPIE,D-44013 DORTMUND,GERMANY	University of Gottingen; University of Toronto; University of Toronto; University of Toronto; University of Toronto			von Bohlen, Alex/C-2450-2008; Giese, Armin/F-3271-2010; Brown, David/A-4083-2008; Herms, Jochen/D-3518-2011	von Bohlen, Alex/0000-0002-1572-6176; Giese, Armin/0000-0002-8238-4102; 				Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; CURZON G, 1960, BIOCHEM J, V74, P279, DOI 10.1042/bj0740279; GIROUX E, 1981, J INORG BIOCHEM, V14, P359, DOI 10.1016/S0162-0134(00)80292-5; GOLDFARB LG, 1991, P NATL ACAD SCI USA, V88, P10926, DOI 10.1073/pnas.88.23.10926; HARTTER DE, 1988, J BIOL CHEM, V263, P799; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; KLOCKENKAMPER R, 1992, ANAL CHEM, V64, pA1115, DOI 10.1021/ac00047a001; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LAU SJ, 1971, J BIOL CHEM, V246, P5938; Linder M, 1991, BIOCH COPPER; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Martell A. E., 1974, CRITICAL STABILITY C; MASUOKA J, 1993, J BIOL CHEM, V268, P21533; Miura T, 1996, FEBS LETT, V396, P248, DOI 10.1016/0014-5793(96)01104-0; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; NARAHASHI T, 1994, CELL MOL NEUROBIOL, V14, P599, DOI 10.1007/BF02088671; NEUMANN PZ, 1967, J CLIN INVEST, V46, P646, DOI 10.1172/JCI105566; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; SARKAR B, 1968, CAN J BIOCHEM CELL B, V46, P601, DOI 10.1139/o68-092; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOLDATI T, 1995, METHOD ENZYMOL, V257, P253; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4	27	1108	1138	4	129	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					684	687		10.1038/37783	http://dx.doi.org/10.1038/37783			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414160				2022-12-28	WOS:A1997YM50800031
J	Lander, J; Brady-Fryer, B; Metcalfe, JB; Nazarali, S; Muttitt, S				Lander, J; Brady-Fryer, B; Metcalfe, JB; Nazarali, S; Muttitt, S			Comparison of ring block, dorsal penile nerve block, and topical anesthesia for neonatal circumcision - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEWBORN CIRCUMCISION; INFANTS; PAIN; ANALGESIA	Context.-Beliefs about the safety and effectiveness of current anesthetics have resulted in many newborns being circumcised without the benefit of anesthesia. Objective.-To compare ring block, dorsal penile nerve block, a topical eutectic mixture of local anesthetics (EMLA), and topical placebo when used for neonatal circumcision. The placebo represented current practice, with no anesthetic for neonatal circumcision. Design.-A randomized controlled trial. Setting.-Antenatal units in 2 tertiary care hospitals in Edmonton, Alberta. Participants.-A consecutive sample of 52 healthy, full-term, male newborns, aged 1 to 3 days. Interventions.-Physiological and behavioral monitoring occurred in a series of trials: baseline, drug application, preparation, circumcision, and postcircumcision. Surgical procedures defined the following 4 stages of the circumcision: cleansing, separation, clamp on, and clamp off. Methemoglobin level was assessed 6 hours after surgery. Main Outcome Measures.-Heart rate, cry, and methemoglobin level. Results.-Newborns in the untreated placebo group exhibited homogeneous responses that consisted of sustained elevation of heart rate and high-pitched cry throughout the circumcision and following. Two newborns in the placebo group became ill following circumcision (choking and apnea). The 3 treatment groups all had significantly less crying and lower heart rates during and following circumcision compared with the untreated group. The ring block was equally effective through all stages of the circumcision, whereas the dorsal penile nerve block and EMLA were not effective during foreskin separation and incision. Methemoglobin levels were highest in the EMLA group, although no newborn required treatment. Conclusions.-The most effective anesthetic is the ring block; EMLA is the least effective. It is our recommendation that an anesthetic should be administered to newborns prior to undergoing circumcision.	Univ Alberta, Fac Med, Edmonton, AB T6G 2G3, Canada; Univ Alberta, Fac Nursing, Edmonton, AB T6G 2G3, Canada; Univ Alberta Hosp, Div Res Adm, Edmonton, AB T6G 2B7, Canada; Univ Alberta Hosp, Div Pharm, Edmonton, AB T6G 2B7, Canada	University of Alberta; University of Alberta; University of Alberta; University of Alberta	Lander, J (corresponding author), Univ Alberta, Fac Med, Edmonton, AB T6G 2G3, Canada.	janice.lander@ualberta.ca						BENINI F, 1993, JAMA-J AM MED ASSOC, V270, P850, DOI 10.1001/jama.270.7.850; BROADMAN LM, 1987, ANESTHESIOLOGY, V67, P399, DOI 10.1097/00000542-198709000-00019; FONTAINE P, 1994, J FAM PRACTICE, V39, P243; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; GRUNAU RVE, 1990, PAIN, V42, P295, DOI 10.1016/0304-3959(90)91142-6; GUNNAR MR, 1985, CHILD DEV, V56, P824, DOI 10.1111/j.1467-8624.1985.tb00155.x; HARPIN VA, 1982, ARCH DIS CHILD, V57, P691, DOI 10.1136/adc.57.9.691; HOLVE RL, 1983, CLIN PEDIATR, V22, P813, DOI 10.1177/000992288302201205; KIRYA C, 1978, J PEDIATR-US, V92, P998, DOI 10.1016/S0022-3476(78)80386-2; Lander J, 1996, PAIN, V64, P89, DOI 10.1016/0304-3959(95)00100-X; MADEN C, 1993, JNCI-J NATL CANCER I, V85, P19, DOI 10.1093/jnci/85.1.19; MOSES S, 1990, INT J EPIDEMIOL, V19, P693, DOI 10.1093/ije/19.3.693; Neter J., 1983, APPL LINEAR REGRESSI; OWENS ME, 1984, PAIN, V20, P77, DOI 10.1016/0304-3959(84)90813-3; POLAND RL, 1990, NEW ENGL J MED, V322, P1312, DOI 10.1056/NEJM199005033221811; RABINOWITZ R, 1995, BIRTH-ISS PERINAT C, V22, P45; RAWLINGS DJ, 1980, AM J DIS CHILD, V134, P676, DOI 10.1001/archpedi.1980.02130190044011; SCHOEN EJ, 1991, CLIN PEDIATR, V30, P429, DOI 10.1177/000992289103000704; SNELLMAN LW, 1995, PEDIATRICS, V95, P705; STANG HJ, 1988, JAMA-J AM MED ASSOC, V259, P1507, DOI 10.1001/jama.259.10.1507; STAV A, 1995, WORLD J UROL, V13, P251; Streiner DL., 1995, HLTH MEASUREMENT SCA, V2nd ed.; Taddio A, 1997, NEW ENGL J MED, V336, P1197, DOI 10.1056/NEJM199704243361701; Toffler W L, 1990, J Am Board Fam Pract, V3, P171; WALLERSTEIN E, 1985, UROL CLIN N AM, V12, P123; WELLINGTON N, 1993, PEDIATRICS, V92, P541; WILLIAMSON PS, 1983, PEDIATRICS, V71, P36; WISWELL TE, 1986, PEDIATRICS, V78, P96	28	121	122	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2157	2162		10.1001/jama.278.24.2157	http://dx.doi.org/10.1001/jama.278.24.2157			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9417009				2022-12-28	WOS:000071022200031
J	Veverka, J; Thomas, P; Harch, A; Clark, B; Bell, JF; Carcich, B; Joseph, J; Chapman, C; Merline, W; Robinson, M; Malin, M; McFadden, LA; Murchie, S; Hawkins, SE; Farquhar, R; Izenberg, N; Cheng, A				Veverka, J; Thomas, P; Harch, A; Clark, B; Bell, JF; Carcich, B; Joseph, J; Chapman, C; Merline, W; Robinson, M; Malin, M; McFadden, LA; Murchie, S; Hawkins, SE; Farquhar, R; Izenberg, N; Cheng, A			NEAR's flyby of 253 Mathilde: Images of a C asteroid	SCIENCE			English	Article							SURFACE-FEATURES; SMALL SATELLITES; EJECTA BLOCKS; 243-IDA; PHOBOS; SHAPE; IDA; DACTYL; 253-MATHILDE; DISCOVERY	On 27 June 1997, the Near Earth Asteroid Rendezvous (NEAR) spacecraft flew within 1212 kilometers of asteroid 253 Mathilde. Mathilde is an irregular, heavily cratered body measuring 66 kilometers by 48 kilometers by 46 kilometers. The asteroid's surface is dark (estimated albedo between 0.035 and 0.050) and similar in color to some CM carbonaceous chondrites. No albedo or color variations were detected. The volume derived from the images and the mass from Doppler tracking of the spacecraft yield a mean density of 1.3 +/- 0.2 grams per cubic centimeter, about half that of CM chondrites, indicating a porous interior structure.	SW RES INST,BOULDER,CO 80302; NORTHWESTERN UNIV,DEPT GEOL SCI,EVANSTON,IL 60208; MALIN SPACE SCI SYST,SAN DIEGO,CA 92191; UNIV MARYLAND,DEPT ASTRON,COLLEGE PK,MD 20742; JOHNS HOPKINS UNIV,APPL PHYS LAB,LAUREL,MD 20723	Northwestern University; University System of Maryland; University of Maryland College Park; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory	Veverka, J (corresponding author), CORNELL UNIV,CTR RADIOPHYS & SPACE RES,ITHACA,NY 14853, USA.		Murchie, Scott L/E-8030-2015; McFadden, Lucy-Ann/I-4902-2013; Izenberg, Noam R/F-3952-2015	Murchie, Scott L/0000-0002-1616-8751; McFadden, Lucy-Ann/0000-0002-0537-9975; Izenberg, Noam R/0000-0003-1629-6478				Asphaug E, 1996, ICARUS, V120, P158, DOI 10.1006/icar.1996.0043; ASPHAUG E, 1993, ICARUS, V101, P144, DOI 10.1006/icar.1993.1012; AVENESOV GA, 1991, PLANET SPACE SCI, V39, P281; BELTON MJS, 1995, NATURE, V374, P785, DOI 10.1038/374785a0; Binzel R.P., 1989, ASTEROIDS, P416; Binzel RP, 1996, ICARUS, V119, P447, DOI 10.1006/icar.1996.0029; BINZEL RP, 1985, ICARUS, V63, P99, DOI 10.1016/0019-1035(85)90022-3; Bowell E., 1989, ASTEROIDS, VII, P524; Britt D.T., 1989, LUNAR PLANET SCI, V20, P109; CHAPMAN CR, 1975, ICARUS, V25, P104, DOI 10.1016/0019-1035(75)90191-8; Chapman CR, 1996, METEORIT PLANET SCI, V31, P699, DOI 10.1111/j.1945-5100.1996.tb02107.x; CHAPMAN CR, 1995, NATURE, V374, P783, DOI 10.1038/374783a0; Chapman CR, 1996, ICARUS, V120, P77, DOI 10.1006/icar.1996.0038; CHAPMAN CR, 1978, ASTEROIDS EXPLORATIO, V2053, P145; CHAPMAN CR, 1986, SATELLITES, P492; CROFT SK, 1992, ICARUS, V99, P402, DOI 10.1016/0019-1035(92)90156-2; Davis D.R., 1979, ASTER 528; DELMOS BG, 1988, P LUNAR PLANET SCI C, V19, P1274; Farquhar RW, 1995, J ASTRONAUT SCI, V43, P353; Geissler P, 1996, ICARUS, V120, P140, DOI 10.1006/icar.1996.0042; Greenberg R, 1996, ICARUS, V120, P106, DOI 10.1006/icar.1996.0040; HAMILTON DP, 1991, ICARUS, V92, P118, DOI 10.1016/0019-1035(91)90039-V; Harch AP, 1995, J ASTRONAUT SCI, V43, P399; HARRIS AW, 1994, ICARUS, V107, P209, DOI 10.1006/icar.1994.1017; HARRIS AW, 1983, B AM ASTRON SOC, V15, P828; HELFENSTEIN P, 1994, ICARUS, V107, P37, DOI 10.1006/icar.1994.1005; HIROI T, 1993, SCIENCE, V261, P1016, DOI 10.1126/science.261.5124.1016; JOHNSON TV, 1973, J GEOPHYS RES, V78, P8507, DOI 10.1029/JB078i035p08507; Krimigis SM, 1995, J ASTRONAUT SCI, V43, P345; Lee P, 1996, ICARUS, V120, P87, DOI 10.1006/icar.1996.0039; LEE SW, 1986, ICARUS, V68, P77, DOI 10.1016/0019-1035(86)90075-8; Love SG, 1996, ICARUS, V124, P141, DOI 10.1006/icar.1996.0195; LOVE SG, 1996, ICARUS, V124, P14; Melosh H.J., 1989, OXFORD MONOGRAPHS GE; MILLIS R, 1987, ICARUS, V72, P502; Mottola S, 1995, PLANET SPACE SCI, V43, P1609, DOI 10.1016/0032-0633(95)00127-1; NEUKUM G, 1994, HAZARDS DUE COMETS A, P369; Rivkin AS, 1997, ICARUS, V127, P255, DOI 10.1006/icar.1997.5695; RYAN VC, 1995, EOS S, V76, P336; Santo AG, 1995, J ASTRONAUT SCI, V43, P373; Scheidegger AE., 1961, THEORETICAL GEOMORPH, DOI 10.1007/978-3-662-01034-1; Schultz P. H., 1976, MOON MORPHOLOGY; SIMONELLI DP, 1993, ICARUS, V103, P49, DOI 10.1006/icar.1993.1057; SMITH DE, 1995, GEOPHYS RES LETT, V22, P2171, DOI 10.1029/95GL01801; Sullivan R, 1996, ICARUS, V120, P119, DOI 10.1006/icar.1996.0041; TEDESCO EF, 1989, ASTEROIDS, V2, P1090; TEDESCO EF, 1989, ASTEROIDS, V2, P290; THOMAS P, 1979, J GEOPHYS RES, V84, P8457, DOI 10.1029/JB084iB14p08457; THOMAS P, 1979, ICARUS, V40, P223, DOI 10.1016/0019-1035(79)90069-1; THOMAS P, 1979, ICARUS, V40, P394, DOI 10.1016/0019-1035(79)90032-0; Thomas PC, 1997, SCIENCE, V277, P1492, DOI 10.1126/science.277.5331.1492; THOMAS PC, 1995, ICARUS, V117, P128, DOI 10.1006/icar.1995.1147; Thomas PC, 1996, ICARUS, V120, P20, DOI 10.1006/icar.1996.0033; THOMAS PC, 1994, ICARUS, V107, P23, DOI 10.1006/icar.1994.1004; THOMAS PC, 1993, ICARUS, V105, P326, DOI 10.1006/icar.1993.1130; THOMAS PC, 1989, ICARUS, V77, P248, DOI 10.1016/0019-1035(89)90089-4; THOMAS PC, 1981, J GEOPHYS RES, V86, P8675; VEVERKA J, 1994, ICARUS, V107, P72, DOI 10.1006/icar.1994.1007; Veverka J, 1997, J GEOPHYS RES-PLANET, V102, P23709, DOI 10.1029/97JE01742; Veverka J, 1996, ICARUS, V120, P200, DOI 10.1006/icar.1996.0045; Veverka J, 1996, ICARUS, V120, P66, DOI 10.1006/icar.1996.0037; Yeomans DK, 1997, SCIENCE, V278, P2106, DOI 10.1126/science.278.5346.2106	62	159	161	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2109	2114		10.1126/science.278.5346.2109	http://dx.doi.org/10.1126/science.278.5346.2109			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405344				2022-12-28	WOS:A1997YM23500049
J	Olshansky, B				Olshansky, B			Amiodarone-induced pulmonary toxicity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Olshansky, B (corresponding author), LOYOLA UNIV,MED CTR,2160 S 1ST AVE,MAYWOOD,IL 60153, USA.		Olshansky, Brian/S-3671-2016	Olshansky, Brian/0000-0002-6044-045X					0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 18	1997	337	25					1814	1814		10.1056/NEJM199712183372506	http://dx.doi.org/10.1056/NEJM199712183372506			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL855	9400039				2022-12-28	WOS:A1997YL85500006
J	Stiell, IG; Wells, GA; Hoag, RH; Sivilotti, MLA; Cacciotti, TF; Verbeek, PR; Greenway, KT; McDowell, I; Cwinn, AA; Greenberg, GH; Nichol, G; Michael, JA				Stiell, IG; Wells, GA; Hoag, RH; Sivilotti, MLA; Cacciotti, TF; Verbeek, PR; Greenway, KT; McDowell, I; Cwinn, AA; Greenberg, GH; Nichol, G; Michael, JA			Implementation of the Ottawa Knee Rule for the use of radiography in acute knee injuries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 18-22, 1997	WASHINGTON, D.C.	Soc Acad Emergency Med			ACUTE ANKLE INJURIES; MEDICINE RESIDENCY PROGRAM; CLINICAL-PREDICTION RULES; DECISION RULES; PROSPECTIVE VALIDATION; EMERGENCY	Context.-The Ottawa Knee Rule is a previously validated clinical decision rule that was developed to allow physicians to be more selective and efficient in their use of plain radiography for patients with acute knee injuries. Objective.-To assess the impact on clinical practice of implementing the Ottawa Knee Rule. Design.-Controlled clinical trial with before-after and concurrent controls. Setting.-Emergency departments of 2 teaching and 2 community hospitals. Patients.-All 3907 consecutive eligible adults seen with acute knee injuries during two 12-month periods before and after the intervention. Intervention.-During the after period in the 2 intervention hospitals, the Ottawa Knee Rule was taught to ail house staff and attending physicians who were encouraged to order knee radiography according to the rule. Main Outcome Measures.-Referral for knee radiography, accuracy and reliability of the rule, mean time in emergency department, and mean charges. Results.-There was a relative reduction of 26.4% in the proportion of patients referred for knee radiography in the intervention group (77.6% vs 57.1%; P<.001), but a relative reduction of only 1.3% in the control group (76.9% vs 75.9%; P=.60). These changes over ti me were significant when the intervention and control groups were compared (P<.001). The rule was found to have a sensitivity of 1.0 (95% confidence interval [CI], 0.94-1.0) for detecting 58 knee fractures. The kappa coefficient for interpretation of the rule was 0.91 (95% CI, 0.82-1.0). Compared with nonfracture patients who underwent radiography during the after-intervention period, those discharged without radiography spent less time in the emergency department (85.7 minutes vs 118.8 minutes) and incurred lower estimated total medical charges for physician visits and radiography (US $80 vs US $183). Conclusions.-Implementation of the Ottawa Knee Rule led to a decrease in use of knee radiography without patient dissatisfaction or missed fractures and was associated with reduced waiting times and costs. Widespread use of the rule could lead to important health care savings without jeopardizing patient care.	UNIV OTTAWA, DIV EMERGENCY MED, OTTAWA, ON, CANADA; UNIV OTTAWA, DEPT MED, OTTAWA, ON, CANADA; UNIV OTTAWA, DEPT EPIDEMIOL & COMMUNITY MED, OTTAWA, ON, CANADA; UNIV OTTAWA, CLIN EPIDEMIOL UNIT, OTTAWA, ON, CANADA; QUEENSWAY CARLETON HOSP, DEPT EMERGENCY MED, NEPEAN, ON, CANADA; UNIV TORONTO, DIV EMERGENCY MED, TORONTO, ON, CANADA; PEEL MEM HOSP, DEPT EMERGENCY MED, BRAMPTON, ON, CANADA	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of Toronto			Sivilotti, Marco L.A./AAR-8892-2020; Nichol, Graham/Z-4996-2019	Sivilotti, Marco L.A./0000-0001-6641-1118; Stiell, Ian/0000-0002-2583-6408				ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; ANIS AH, 1995, ANN EMERG MED, V26, P422, DOI 10.1016/S0196-0644(95)70108-7; Auleley Guy-Robert, 1997, JAMA (Journal of the American Medical Association), V277, P1935, DOI 10.1001/jama.277.24.1935; Feinstein AR, 1987, CLINIMETRICS; FLEISS JL, 1989, STAT METHODS RATES P, V63, P99; GLEADHILL DNS, 1987, BRIT MED J, V294, P943, DOI 10.1136/bmj.294.6577.943; GRATTON MC, 1990, ANN EMERG MED, V19, P497, DOI 10.1016/S0196-0644(05)82175-4; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; LEE TH, 1990, J GEN INTERN MED, V5, P528, DOI 10.1007/BF02600886; McCaig L F, 1994, Adv Data, P1; MCCONNOCHIE KM, 1990, PEDIATRICS, V86, P45; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; MOLONEY TW, 1979, NEW ENGL J MED, V301, P1413, DOI 10.1056/NEJM197912273012603; *NAT CTR HLTH STAT, 1994, NAT HOSP AMB MED CAR; Nitowski LA, 1996, ACAD EMERG MED, V3, P782, DOI 10.1111/j.1553-2712.1996.tb03515.x; *ONT MIN HLTH, 1992, ONT STAT REP SYST 19; STIELL I, 1995, BRIT MED J, V311, P594, DOI 10.1136/bmj.311.7005.594; STIELL IG, 1993, JAMA-J AM MED ASSOC, V269, P1127, DOI 10.1001/jama.269.9.1127; STIELL IG, 1992, ANN EMERG MED, V21, P384, DOI 10.1016/S0196-0644(05)82656-3; STIELL IG, 1995, ACAD EMERG MED, V2, P966, DOI 10.1111/j.1553-2712.1995.tb03123.x; Stiell IG, 1996, JAMA-J AM MED ASSOC, V275, P611, DOI 10.1001/jama.275.8.611; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; STIELL IG, 1995, ANN EMERG MED, V26, P405, DOI 10.1016/S0196-0644(95)70106-0; Wasson JH, 1996, JAMA-J AM MED ASSOC, V275, P641, DOI 10.1001/jama.275.8.641; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306	26	125	126	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2075	2079		10.1001/jama.278.23.2075	http://dx.doi.org/10.1001/jama.278.23.2075			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YK987	9403421				2022-12-28	WOS:A1997YK98700036
J	Lemanske, RF; Busse, WW				Lemanske, RF; Busse, WW			Asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							EXERCISE-INDUCED ASTHMA; VOCAL-CORD DYSFUNCTION; METERED-DOSE INHALER; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; CHRONIC SINUS DISEASE; SERUM IGE LEVELS; NEDOCROMIL SODIUM; CROMOLYN SODIUM; BECLOMETHASONE DIPROPIONATE; BRONCHIAL RESPONSIVENESS	For unknown reasons, the morbidity and mortality from asthma are increasing in many parts of the world, making it a global health concern. The heterogeneous nature of the clinical manifestations and therapeutic responses of asthma in both adult and pediatric patients indicate that it may be more of a syndrome rather than a specific disease entity. Numerous factors, including viral infections, allergen and irritant exposure, and exercise, among others, complicate both the short- and long-term management of asthma. Therapeutic intervention has focused on the appreciation that airway obstruction in asthma consists of bronchial smooth muscle spasm and variable degrees of airway inflammation characterized by edema, mucous secretion, and the influx of a variety of inflammatory cells. Choosing appropriate medications depends on the disease severity (intermittent, mild persistent, moderate persistent, severe persistent), patterns of disease activity (exacerbations related to viruses, allergens, exercise, etc), and the age at onset (infancy, childhood, adulthood).	UNIV WISCONSIN HOSP & CLIN, DEPT MED, MADISON, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Lemanske, RF (corresponding author), UNIV WISCONSIN HOSP & CLIN, DIV ALLERGY, 600 HIGHLAND AVE, ROOM H4-432, MADISON, WI 53792 USA.				NHLBI NIH HHS [HL56396] Funding Source: Medline; NIAID NIH HHS [AI34891] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034891, U01AI034891] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; Alton EWFW, 1996, AM J RESP CELL MOL, V14, P380, DOI 10.1165/ajrcmb.14.4.8600943; ANDERSON GP, 1994, TRENDS PHARMACOL SCI, V15, P324, DOI 10.1016/0165-6147(94)90027-2; ANDERSON SD, 1993, ALLERGY PRINCIPLES P, P1343; APPEL D, 1989, J ALLERGY CLIN IMMUN, V84, P90, DOI 10.1016/0091-6749(89)90182-6; ARMENIO L, 1993, ARCH DIS CHILD, V68, P193, DOI 10.1136/adc.68.2.193; BAI TR, 1990, AM REV RESPIR DIS, V141, P552, DOI 10.1164/ajrccm/141.3.552; BAI TR, 1992, AM J RESP CELL MOL, V6, P647, DOI 10.1165/ajrcmb/6.6.647; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; BANNER AS, 1995, CHEST, V108, P301, DOI 10.1378/chest.108.2.301; Barnes PJ, 1996, AM J RESP CRIT CARE, V154, pS21, DOI 10.1164/ajrccm/154.2_Pt_2.S21; BEL EH, 1990, AM REV RESPIR DIS, V141, P21, DOI 10.1164/ajrccm/141.1.21; BENDER B, 1992, JAMA-J AM MED ASSOC, V267, P2621; BENDER BG, 1991, PEDIATR PULM, V11, P233, DOI 10.1002/ppul.1950110309; BERENBERG MJ, 1985, J ASTHMA, V22, P87, DOI 10.3109/02770908509079893; BERRY RB, 1989, CHEST, V96, P1241, DOI 10.1378/chest.96.6.1241; BHAGAT R, 1995, CHEST, V108, P1235, DOI 10.1378/chest.108.5.1235; BITTLEMAN DB, 1994, CHEST, V106, P615, DOI 10.1378/chest.106.2.615; BLEECKER ER, 1995, CLIN EXP ALLERGY, V25, P84, DOI 10.1111/j.1365-2222.1995.tb00430.x; BROGDEN RN, 1993, DRUGS, V45, P693, DOI 10.2165/00003495-199345050-00007; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; BRUNETTE MG, 1988, PEDIATRICS, V81, P624; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BUSH RK, 1995, ASTHMA RHINITIS, P1429; BUSSE WW, 1995, AM J RESP CRIT CARE, V151, P249, DOI 10.1164/ajrccm.151.1.7812562; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CARRUTHERS DM, 1995, THORAX, V50, P186, DOI 10.1136/thx.50.2.186; CARTER E, 1993, J PEDIATR-US, V122, P470, DOI 10.1016/S0022-3476(05)83443-2; ChanYeung M, 1996, AM J RESP CRIT CARE, V154, P889, DOI 10.1164/ajrccm.154.4.8887581; CHAPMAN KR, 1991, NEW ENGL J MED, V324, P788, DOI 10.1056/NEJM199103213241202; CHATHAM M, 1982, AM REV RESPIR DIS, V126, P235; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; CHRISTOPHER KL, 1983, NEW ENGL J MED, V308, P1566, DOI 10.1056/NEJM198306303082605; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1991, ASTHMA ITS PATHOLOGY, P51; COLASURDO GN, 1995, ASTHMA RHINITIS, P1044; CONNETT G, 1993, ARCH DIS CHILD, V68, P85, DOI 10.1136/adc.68.1.85; COOKSON WOCM, 1989, LANCET, V1, P1292; CORBRIDGE TC, 1995, AM J RESP CRIT CARE, V151, P1296, DOI 10.1164/ajrccm.151.5.7735578; CRAPO RO, 1994, NEW ENGL J MED, V331, P25, DOI 10.1056/NEJM199407073310107; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; CUNNINGHAM SJ, 1994, CHEST, V106, P753, DOI 10.1378/chest.106.3.753; CUTZ E, 1978, HISTOPATHOLOGY, V2, P407, DOI 10.1111/j.1365-2559.1978.tb01735.x; CYPCAR D, 1994, CLIN CHEST MED, V15, P351; CYPCAR D, 1992, PEDIATR CLIN N AM, V39, P1259; DEJONG JW, 1994, AM J RESP CRIT CARE, V149, P91, DOI 10.1164/ajrccm.149.1.8111606; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; DUFF AL, 1992, PEDIATR CLIN N AM, V39, P1277; DUFF AL, 1993, PEDIATRICS, V92, P535; Einarsson O, 1996, J CLIN INVEST, V97, P915, DOI 10.1172/JCI118514; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; FANTA CH, 1986, AM J MED, V80, P5, DOI 10.1016/0002-9343(86)90041-0; FERGUSON AC, 1982, J ALLERGY CLIN IMMUN, V69, P461, DOI 10.1016/0091-6749(82)90122-1; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746, DOI 10.1164/ajrccm/145.4_Pt_1.746; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; FITZSIMONS R, 1986, J ALLERGY CLIN IMMUN, V78, P349, DOI 10.1016/S0091-6749(86)80088-4; FRASER CM, 1993, ALLERGY PRINCIPLES P, P778; FRICK RB, 1987, J APPL PHYSIOL, V63, P1147; FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; FURUKAWA CT, 1984, PEDIATRICS, V74, P453; GARDINER PV, 1994, AM J RESP CRIT CARE, V150, P1006, DOI 10.1164/ajrccm.150.4.7921429; GERN JE, 1993, IMMUNOL ALLERGY CLIN, V13, P839; GOLDENHERSH MJ, 1990, J ALLERGY CLIN IMMUN, V85, P1030, DOI 10.1016/0091-6749(90)90047-8; GOLDMAN J, 1991, THORAX, V46, P401, DOI 10.1136/thx.46.6.401; GREEN CP, 1992, ARCH DIS CHILD, V67, P1014, DOI 10.1136/adc.67.8.1014; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P645, DOI 10.1016/0091-6749(84)90223-9; GROSS NJ, 1984, AM REV RESPIR DIS, V129, P856, DOI 10.1164/arrd.1984.129.5.856; HALFON N, 1993, PEDIATRICS, V91, P56; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866, DOI 10.1164/ajrccm/146.4.866; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARGREAVE FE, 1986, J ALLERGY CLIN IMMUN, V78, P825, DOI 10.1016/0091-6749(86)90226-5; HENDELES L, 1992, J PEDIATR-US, V120, P177, DOI 10.1016/S0022-3476(05)80423-8; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; HOAG JE, 1991, ANN ALLERGY, V66, P53; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; HUANG D, 1993, ANN INTERN MED, V119, P1155, DOI 10.7326/0003-4819-119-12-199312150-00001; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; JAMES JM, 1994, AM J RESP CRIT CARE, V149, P59, DOI 10.1164/ajrccm.149.1.8111598; JARJOUR NN, 1992, J ALLERGY CLIN IMMUN, V89, P60, DOI 10.1016/S0091-6749(05)80041-7; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; JUSKO WJ, 1979, J PHARM SCI, V68, P1358, DOI 10.1002/jps.2600681106; Kalra S, 1996, CHEST, V109, P953, DOI 10.1378/chest.109.4.953; Kamada AK, 1996, AM J RESP CRIT CARE, V153, P1739, DOI 10.1164/ajrccm.153.6.8665030; Karpel JP, 1996, CHEST, V110, P611, DOI 10.1378/chest.110.3.611; KAWABORI I, 1976, J ALLERGY CLIN IMMUN, V58, P447, DOI 10.1016/0091-6749(76)90188-3; KEREM E, 1993, J PEDIATR-US, V123, P313, DOI 10.1016/S0022-3476(05)81710-X; KINGSTON HGG, 1984, ANESTH ANALG, V63, P844; KONIG P, 1993, EUR J NEUROSCI, V5, P501, DOI 10.1111/j.1460-9568.1993.tb00516.x; LAI CKW, 1989, AM REV RESPIR DIS, V140, P917, DOI 10.1164/ajrccm/140.4.917; LAL S, 1993, CHEST, V104, P438, DOI 10.1378/chest.104.2.438; LEFF AR, 1991, AM J PHYSIOL, V260, pL189, DOI 10.1152/ajplung.1991.260.4.L189; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LEMANSKE RF, 1989, PERSPECTIVES EXERCIS, P465; LEMANSKE RF, 1989, PROVOCATIVE CHALLENG, P131; Lemanske RF, 1993, ALLERGY PRINCIPLES P, P320; LENFANT C, 1993, GLOBAL STRATEGY ASTH, V1, P1; LINDGREN S, 1992, NEW ENGL J MED, V327, P926, DOI 10.1056/NEJM199209243271305; LITTENBERG B, 1988, JAMA-J AM MED ASSOC, V259, P1678, DOI 10.1001/jama.259.11.1678; LUNDGREN JD, 1990, J ALLERGY CLIN IMMUN, V85, P399, DOI 10.1016/0091-6749(90)90147-V; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; MARTINEZ FD, 1991, AM REV RESPIR DIS, V143, P312, DOI 10.1164/ajrccm/143.2.312; MAYEFSKY JH, 1992, PEDIATR EMERG CARE, V8, P262, DOI 10.1097/00006565-199210000-00003; MCFADDEN ER, 1995, J ALLERGY CLIN IMMUN, V95, P641, DOI 10.1016/S0091-6749(95)70166-4; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; MCFADDEN ER, 1993, AM REV RESPIR DIS, V147, P1306, DOI 10.1164/ajrccm/147.5.1306; MELTZER EO, 1991, J ASTHMA, V28, P141, DOI 10.3109/02770909109082738; Meltzer SS, 1996, AM J RESP CRIT CARE, V153, P931, DOI 10.1164/ajrccm.153.3.8630575; MESTITZ H, 1989, CHEST, V96, P1237, DOI 10.1378/chest.96.6.1237; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; MOFFATT MF, 1992, CLIN EXP ALLERGY, V22, P1046, DOI 10.1111/j.1365-2222.1992.tb00128.x; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; MORGAN WJ, 1992, PEDIATR CLIN N AM, V39, P1185; MORROW PE, 1974, AM REV RESPIR DIS, V110, P88; NEELD DA, 1990, AM REV RESPIR DIS, V142, P1200, DOI 10.1164/ajrccm/142.5.1200; NELSON HS, 1995, NEW ENGL J MED, V333, P499, DOI 10.1056/NEJM199508243330807; NEWHOUSE MT, 1986, NEW ENGL J MED, V315, P870, DOI 10.1056/NEJM198610023151406; NEWHOUSE MT, 1993, CHEST, V103, P661, DOI 10.1378/chest.103.3.661; NEWHOUSE MT, 1993, AM J ASTHMA ALLERGY, V7, P23; Nicholson KG, 1996, BMJ-BRIT MED J, V313, P1119, DOI 10.1136/bmj.313.7065.1119; NIEMEIJER NR, 1992, ALLERGY, V47, P431, DOI 10.1111/j.1398-9995.1992.tb02084.x; *NIH, 1991, GUID DIAGN MAN ASTHM; OH SH, 1974, J ALLERGY CLIN IMMUN, V53, P345, DOI 10.1016/0091-6749(74)90118-3; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Oliveti JF, 1996, AM J EPIDEMIOL, V143, P570; ORTEGACARR D, 1995, MANUAL ASTHMA MANAGE, P653; OSMOND MH, 1995, ACAD EMERG MED, V2, P651, DOI 10.1111/j.1553-2712.1995.tb03607.x; PAGE C, 1992, RESP MED, V86, P477, DOI 10.1016/S0954-6111(96)80005-9; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; PETTY TL, 1989, AM REV RESPIR DIS, V139, P694, DOI 10.1164/ajrccm/139.3.694; Pizzichini MMM, 1996, EUR RESPIR J, V9, P449, DOI 10.1183/09031936.96.09030449; PLATTSMILLS TAE, 1982, LANCET, V2, P675; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; QUINN JM, 1994, INSIGHTS ALLERGY, V9, P1; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; RACHELEFSKY GS, 1986, PEDIATRICS, V78, P1133; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; ROBERTSON CF, 1985, J PEDIATR-US, V106, P672, DOI 10.1016/S0022-3476(85)80101-3; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROHR AS, 1987, ANN ALLERGY, V59, P107; ROTH A, 1993, ANN ALLERGY, V71, P533; SALVATO G, 1968, THORAX, V23, P168, DOI 10.1136/thx.23.2.168; SALZMAN GA, 1988, J ALLERGY CLIN IMMUN, V81, P424, DOI 10.1016/0091-6749(88)90911-6; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749, DOI 10.1164/ajrccm.153.6.8665031; SCHATZ M, 1995, AM J RESP CRIT CARE, V151, P1170; SCHLEIMER RP, 1993, ALLERGY PRINCIPLES P, P893; SCHUH S, 1995, J PEDIATR-US, V126, P639, DOI 10.1016/S0022-3476(95)70368-3; SCHUH S, 1989, PEDIATRICS, V83, P513; Schwartz HJ, 1996, CHEST, V109, P945, DOI 10.1378/chest.109.4.945; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SELNER JC, 1987, J ALLERGY CLIN IMMUN, V79, P726, DOI 10.1016/0091-6749(87)90203-X; SETTIPANE GA, 1979, JAMA-J AM MED ASSOC, V241, P811, DOI 10.1001/jama.241.8.811; SHAPIRO GG, 1991, J ALLERGY CLIN IMMUN, V88, P742, DOI 10.1016/0091-6749(91)90181-M; SHEFFER AL, 1991, J ALLERGY CLIN IMMUN, V87, P468, DOI 10.1016/0091-6749(91)90002-6; SIMPSON WG, 1995, ARCH INTERN MED, V155, P798, DOI 10.1001/archinte.155.8.798; SLAVIN RG, 1993, ALLERGY PRINCIPLES P, P1455; SLY RM, 1967, ANN ALLERGY, V25, P324; SMITH L, 1995, ANN ALLERG ASTHMA IM, V74, P454; SONTAG SJ, 1992, GUT, V33, P872, DOI 10.1136/gut.33.7.872; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STRAUSS RE, 1994, PEDIATRICS, V93, P205; SUMMER W, 1989, ARCH INTERN MED, V149, P618, DOI 10.1001/archinte.149.3.618; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; Tamaoki J, 1997, AM J RESP CRIT CARE, V155, P1235, DOI 10.1164/ajrccm.155.4.9105060; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; TIPTON WR, 1987, ANN ALLERGY, V58, P252; TOOGOOD JH, 1994, J RESPIR DIS, V15, P151; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; TWENTYMAN OP, 1991, AM REV RESPIR DIS, V144, P782, DOI 10.1164/ajrccm/144.4.782; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VIRANT FS, 1993, CHILDHOOD ASTHMA PAT, P303; VITTORI E, 1992, AM REV RESPIR DIS, V146, P1320, DOI 10.1164/ajrccm/146.5_Pt_1.1320; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302; WEINBERGER M, 1993, ALLERGY PRINCIPLES P, V120, P816; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; WOLFE JD, 1985, JAMA-J AM MED ASSOC, V253, P2068, DOI 10.1001/jama.253.14.2068; WOLTHERS OD, 1993, ARCH DIS CHILD, V68, P673, DOI 10.1136/adc.68.5.673; WRENN K, 1991, ANN INTERN MED, V115, P241, DOI 10.7326/0003-4819-115-4-241	196	98	101	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1855	1873		10.1001/jama.278.22.1855	http://dx.doi.org/10.1001/jama.278.22.1855			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396647				2022-12-28	WOS:A1997YK15500008
J	Rieder, R; Economou, T; Wanke, H; Turkevich, A; Crisp, J; Bruckner, J; Dreibus, G; McSween, HY				Rieder, R; Economou, T; Wanke, H; Turkevich, A; Crisp, J; Bruckner, J; Dreibus, G; McSween, HY			The chemical composition of Martian soil and rocks returned by the mobile alpha proton x-ray spectrometer: Preliminary results from the x-ray mode	SCIENCE			English	Article								The alpha proton x-ray spectrometer (APXS) on board the rover of the Mars Pathfinder mission measured the chemical composition of six soils and five rocks at the Ares Vallis landing site, The soil analyses show similarity to those determined by the Viking missions. The analyzed rocks were partially covered by dust but otherwise compositionally similar to each other. They are unexpectedly high in silica and potassium, but low in magnesium compared to martian soils and martian meteorites, The analyzed rocks are similar in composition to terrestrial andesites and close to the mean composition of Earth's crust. Addition of a mafic component and reaction products of volcanic gases to the local rock material is necessary to explain the soil composition.	MAX PLANCK INST CHEM,D-55020 MAINZ,GERMANY; UNIV CHICAGO,ENRICO FERMI INST,CHICAGO,IL 60637; CALTECH,JET PROP LAB,PASADENA,CA 91109; UNIV TENNESSEE,DEPT GEOL SCI,KNOXVILLE,TN 37996	Max Planck Society; University of Chicago; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Tennessee System; University of Tennessee Knoxville			Crisp, Joy/H-8287-2016	Crisp, Joy/0000-0002-3202-4416				BAIRD AK, 1976, SCIENCE, V194, P1288, DOI 10.1126/science.194.4271.1288; BANIN A., 2000, MARS, P594; CLARK BC, 1993, GEOCHIM COSMOCHIM AC, V57, P4575, DOI 10.1016/0016-7037(93)90183-W; CLARK BC, 1979, GEOPHYS RES LETT, V6, P811, DOI 10.1029/GL006i010p00811; CLARK BC, 1982, J GEOPHYS RES, V87, P59, DOI 10.1029/JB087iB12p10059; ECONOMOU TE, 1976, NUCL INSTRUM METHODS, V134, P391, DOI 10.1016/0029-554X(76)90298-6; ECONOMOU TE, 1970, J GEOPHYS RES, V75, P6514, DOI 10.1029/JB075i032p06514; Eugster O, 1997, GEOCHIM COSMOCHIM AC, V61, P2749, DOI 10.1016/S0016-7037(97)00115-4; Golombek MP, 1997, J GEOPHYS RES-PLANET, V102, P3967, DOI 10.1029/96JE03318; LEBAS MJ, 1986, J PETROL, V27, P745, DOI 10.1093/petrology/27.3.745; Longhi J., 1992, MARS, V1, P184, DOI [10.2307/j.ctt207g59v.10, DOI 10.2307/J.CTT207G59V.10]; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; Rieder R, 1997, J GEOPHYS RES-PLANET, V102, P4027, DOI 10.1029/96JE03918; WANKE H, 1988, PHILOS T R SOC A, V325, P545, DOI 10.1098/rsta.1988.0067	14	370	377	1	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1771	1774		10.1126/science.278.5344.1771	http://dx.doi.org/10.1126/science.278.5344.1771			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388173				2022-12-28	WOS:A1997YJ90100039
J	Zhang, BL; Gallegos, M; Puoti, A; Durkin, E; Fields, S; Kimble, J; Wickens, MP				Zhang, BL; Gallegos, M; Puoti, A; Durkin, E; Fields, S; Kimble, J; Wickens, MP			A conserved RNA-binding protein that regulates sexual fates in the C-elegans hermaphrodite germ line	NATURE			English	Article							3' UNTRANSLATED REGION; CAENORHABDITIS-ELEGANS; MESSENGER-RNA; TRANSLATIONAL REGULATION; DROSOPHILA EMBRYO; SPLICING FACTORS; GENE; NANOS; PATTERN; PUMILIO	The nematode Caenorhabditis elegans has two sexes, males and hermaphrodites. Hermaphrodites initially produce sperm but switch to producing oocytes. This switch appears to be controlled by the 3' untranslated region of fem-3 messenger RNA. We have now identified a binding factor (FBF) which is a cytoplasmic protein that binds specifically to the regulatory region of fem-3 3'UTR and mediates the sperm/oocyte switch. The RNA-binding domain of FBF consists of a stretch of eight tandem repeats and two short flanking regions. This structural element is conserved in several proteins Including Drosophila Pumilio, a regulatory protein that controls pattern formation in the fly by binding to a 3'UTR. We propose that FBF and Pumilio are members of a widespread family of sequence-specific RNA-binding proteins.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT GENET,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT MED,SEATTLE,WA 98195; UNIV WISCONSIN,HOWARD HUGHES MED INST,DEPT MED GENET,MADISON,WI 53706; UNIV WISCONSIN,LAB CELL & MOL BIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Puoti, Alessandro/E-5700-2012; Puoti, Alessandro/ABE-9963-2021	Puoti, Alessandro/0000-0002-1396-7662				AHRINGER J, 1992, EMBO J, V11, P2303, DOI 10.1002/j.1460-2075.1992.tb05289.x; AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; AHRINGER J, 1991, THESIS U WISCONSIN M; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BARTON MK, 1987, GENETICS, V115, P107; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; COGLIEVINA M, 1995, YEAST, V11, P767, DOI 10.1002/yea.320110808; CRITTENDEN SL, 1994, DEVELOPMENT, V120, P2901; Curtis D, 1997, EMBO J, V16, P834, DOI 10.1093/emboj/16.4.834; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; FITCH DHA, 1997, C ELEGANS, V2, P815; FU XD, 1995, RNA, V1, P663; GEBAUER R, 1997, BIOESSAYS, V19, P23; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; GRAHAM PL, 1993, DEV GENET, V14, P471, DOI 10.1002/dvg.1020140608; GRAHAM PL, 1993, GENETICS, V133, P919; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1986, GENETICS, V114, P15; Hodgkin J, 1997, C ELEGANS, P881; LEHMANN R, 1991, DEVELOPMENT, V112, P679; Macdonald PM, 1996, CURR OPIN GENET DEV, V6, P403, DOI 10.1016/S0959-437X(96)80060-8; MACDONALD PM, 1992, DEVELOPMENT, V114, P221; MEYER BJ, 1997, C ELEGANS, V2, P209; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; SCHEDL T, 1989, GENETICS, V123, P755; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; SHEDL T, 1988, GENETICS, V119, P43; SINGER RH, 1993, CURR BIOL, V3, P719, DOI 10.1016/0960-9822(93)90079-4; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WARD S, 1986, J CELL BIOL, V102, P1778, DOI 10.1083/jcb.102.5.1778; Waterston Robert H., 1997, Cold Spring Harbor Monograph Series, V33, P23; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WHARTON RP, 1992, SEMINARS DEV BIOL, V3, P391; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Wickens M., 1996, TRANSLATIONAL CONTRO, P411; ZAMORE P, IN PRESS RNA; [No title captured]	46	416	431	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					477	484		10.1038/37297	http://dx.doi.org/10.1038/37297			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9393998				2022-12-28	WOS:A1997YJ86500041
J	Fiebach, NH				Fiebach, NH			Rise and fall	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Fiebach, NH (corresponding author), YALE PRIMARY CARE INTERNAL MED RESIDENCY PROGRAM, DEPT INTERNAL MED, BOX 802033, NEW HAVEN, CT 06520 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					1037	1038		10.7326/0003-4819-127-11-199712010-00018	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00018			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412287				2022-12-28	WOS:A1997YJ08000013
J	Mulrow, C; Langhorne, P; Grimshaw, J				Mulrow, C; Langhorne, P; Grimshaw, J			Integrating heterogeneous pieces of evidence in systematic reviews	ANNALS OF INTERNAL MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CORONARY HEART-DISEASE; TRIALS; METAANALYSIS; PRAVASTATIN; METHODOLOGY	Researchers preparing systematic reviews often encounter various types of evidence, which can generally be categorized as direct or indirect. The former directly relates an exposure, diagnostic strategy, or therapeutic intervention to the occurrence of a principal health outcome. Evidence is indirect if two or more bodies of evidence are required to relate the exposure, diagnostic strategy, or intervention to the principal health outcome. Heterogeneity of data sources complicates integration of both direct and indirect evidence. Participants in different studies may have a wide spectrum of baseline risk and sociodemographic and cultural characteristics. A variety of formulations and intensities of exposures, diagnostic strategies, and interventions, as well as diversity in the selection and definition of control groups, may be encountered. Outcome measures may be different, and similar outcomes may be measured or reported differently. Heterogeneity of study designs and of methodologic features and quality within a given design may be found. The effective integration of direct and indirect evidence requires development of explicit models that serve as analytic frameworks for linking the important pieces of evidence. A model can be viewed as a series of subquestions, with each important subquestion warranting a systematic review. Several subjective and quantitative methods can then be used to integrate the evidence. Tabular displays of major findings and strength of evidence for each subquestion can help reviewers, patients, and providers to integrate the differing research findings and draw reasonable conclusions. Various quantitative techniques, such as decision analysis and the confidence profile method, are also available. No single integration approach is clearly superior, none obviates uncertainty, and all underscore the role of careful judgment in integrating evidence.	GLASGOW ROYAL INFIRM, GERIATR MED SECT, GLASGOW G4 0SF, LANARK, SCOTLAND; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78285 USA; UNIV ABERDEEN, ABERDEEN, SCOTLAND	University of Glasgow; University of Texas System; University of Texas Health San Antonio; University of Aberdeen	Mulrow, C (corresponding author), AUDIE L MURPHY MEM VET ADM MED CTR, 7400 MERTON MINTER BLVD 11C6, SAN ANTONIO, TX 78284 USA.		Grimshaw, Jeremy/D-8726-2013	Grimshaw, Jeremy/0000-0001-8015-8243				[Anonymous], 1994, BMJ, V308, P235; Badgett RG, 1997, ANN INTERN MED, V126, P886, DOI 10.7326/0003-4819-126-11-199706010-00006; BATTISTA R N, 1988, American Journal of Preventive Medicine, V4, P53; Berger J.O., 1995, STAT DECISION THEORY, V2nd ed; Berkey CS, 1996, STAT MED, V15, P537, DOI 10.1002/(SICI)1097-0258(19960315)15:5<537::AID-SIM176>3.3.CO;2-J; Bero LA, 1997, ANN INTERN MED, V127, P37, DOI 10.7326/0003-4819-127-1-199707010-00007; CADMAN D, 1984, JAMA-J AM MED ASSOC, V251, P1580, DOI 10.1001/jama.251.12.1580; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; CARRUTHERS SG, 1993, CAN MED ASSOC J, V149, P289; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Cook DJ, 1997, ANN INTERN MED, V127, P210, DOI 10.7326/0003-4819-127-3-199708010-00006; COOK DJ, 1995, CHEST, V108, pS227, DOI 10.1378/chest.108.4_Supplement.227S; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; COOPER HM, 1984, INTEGRATIVE RES REV, P79; Counsell C, 1997, ANN INTERN MED, V127, P380, DOI 10.7326/0003-4819-127-5-199709010-00008; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; Eddy DM., 1992, META ANAL CONFIDENCE; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; Grimshaw J, 1995, COMPLEXITY SYSTEMATI; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HUFF J, 1992, SCAND J WORK ENV HEA, V18, P74; Hunt DL, 1997, ANN INTERN MED, V126, P532, DOI 10.7326/0003-4819-126-7-199704010-00006; KERLINGER FN, 1973, F BEHAVIORAL RES; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Light R.J., 1984, SUMMING SCI REV RES; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; Meade MO, 1997, ANN INTERN MED, V127, P531, DOI 10.7326/0003-4819-127-7-199710010-00005; MULROW CD, 1991, J GEN INTERN MED, V6, P249, DOI 10.1007/BF02598971; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; PEDERSEN TR, 1994, LANCET, V344, P1383; Ross S. M., 1985, INTRO PROBABILITY MO; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; TIJMS HC, 1986, STOCHASTIC MODELLING; U.S. Preventive Services Task Force, 1996, GUID CLIN PREV SERV; US Department of Health and Human Services; Public Health Service; Agency for Health Care and Policy Research, 1992, AC PAIN MAN OP MED P; WARLOW C, 1995, STROKE MODULE COCHRA; Weinstein MC, 1980, CLIN DECISION ANAL; WOLFF SH, 1991, AHCPR PUBLICATION; 1979, CAN MED ASS J, V121, P1193	48	75	79	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					989	995		10.7326/0003-4819-127-11-199712010-00008	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412305				2022-12-28	WOS:A1997YJ08000006
J	Fernandez, H				Fernandez, H			Methotrexate in tubal pregnancy	LANCET			English	Letter											Fernandez, H (corresponding author), ANTOINE BECLERES HOSP, DEPT OBSTET & GYNAECOL, F-92141 CLAMART, FRANCE.							FERNANDEZ H, 1994, FERTIL STERIL, V62, P943; FERNANDEZ H, 1995, FERTIL STERIL, V63, P25, DOI 10.1016/S0015-0282(16)57291-4; Hajenius PJ, 1997, LANCET, V350, P774, DOI 10.1016/S0140-6736(97)05487-1; Seifer DB, 1997, FERTIL STERIL, V68, P402, DOI 10.1016/S0015-0282(97)00271-9; Yao ML, 1997, FERTIL STERIL, V67, P421, DOI 10.1016/S0015-0282(97)80064-7	5	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1555	1555		10.1016/S0140-6736(05)63993-1	http://dx.doi.org/10.1016/S0140-6736(05)63993-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388433				2022-12-28	WOS:A1997YH11500068
J	Toelle, SP; Albisetti, M; Holzmann, D; Steinlin, M				Toelle, SP; Albisetti, M; Holzmann, D; Steinlin, M			A 9-year-old girl who swung on a rope	LANCET			English	Article							LATERAL MEDULLARY SYNDROME		UNIV ZURICH HOSP, ENT DEPT, CH-8091 ZURICH, SWITZERLAND	University of Zurich; University Zurich Hospital	Toelle, SP (corresponding author), UNIV ZURICH, CHILDRENS HOSP, DEPT PAEDIAT, STEINWIESSTR 75, CH-8032 ZURICH, SWITZERLAND.		Holzmann, David/ABC-7620-2020; Steinlin, Maja/G-5991-2010	Holzmann, David/0000-0002-8176-8358; Toelle, Sandra/0000-0001-7999-9854				KLEIN RA, 1976, JAMA-J AM MED ASSOC, V235, P940; KOVACS SO, 1993, AM J DIS CHILD, V147, P823, DOI 10.1001/archpedi.1993.02160320025013; KRUEGER BR, 1980, MAYO CLIN PROC, V55, P322; Riechwien R, 1966, MSCHR KINDERHEILK, V8, P442; Serrano M L, 1995, Rev Neurol, V23, P414	5	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1516	1516		10.1016/S0140-6736(97)09415-4	http://dx.doi.org/10.1016/S0140-6736(97)09415-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388400				2022-12-28	WOS:A1997YH11500011
J	Vesikari, T				Vesikari, T			Rotavirus vaccines against diarrhoeal disease	LANCET			English	Article							YOUNG-CHILDREN; WC3 VACCINE; INFANTS; PROTECTION; EFFICACY; RIT-4237; TRIAL; SAFETY; IMMUNOGENICITY; INFECTION	Rotaviruses are responsible for more diarrhoeal disease-associated mortality than any other single agent. Vaccination may therefore hold the key to combating diarrhoeal disease worldwide. Natural immunity to rotavirus infection indicates that rather than protection from reinfection such immunity gives rise to less severe and less frequent attacks of diarrhoea. Early attempts to design a rotavirus vaccine with bovine rotavirus failed because of poor efficacy in some developing countries. Research into rhesus rotavirus, particularly the high-titre rhesus rotavirus tetravalent (RRV-TV) vaccine, has given slightly better results. A stumbling block to truly effective oral vaccines seems to be immunogenicity in developing countries. If efficacy can be ensured by trials in the developing countries, money spent on rotavirus vaccines will be well spent.			Vesikari, T (corresponding author), TAMPERE UNIV, SCH MED, POB 607, FIN-33101 TAMPERE, FINLAND.							BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; BERNSTEIN DI, 1995, JAMA-J AM MED ASSOC, V273, P1191, DOI 10.1001/jama.273.15.1191; BHAN MK, 1993, J INFECT DIS, V168, P282, DOI 10.1093/infdis/168.2.282; BISHOP RF, 1983, NEW ENGL J MED, V309, P72, DOI 10.1056/NEJM198307143090203; Burns JW, 1996, SCIENCE, V272, P104, DOI 10.1126/science.272.5258.104; CHRISTY C, 1988, PEDIATR INFECT DIS J, V7, P645, DOI 10.1097/00006454-198809000-00009; Clark HF, 1996, J INFECT DIS, V174, pS73, DOI 10.1093/infdis/174.Supplement_1.S73; Clark HF, 1996, ARCH VIROL, P187; CLARK HF, 1988, J INFECT DIS, V158, P570, DOI 10.1093/infdis/158.3.570; Conner ME, 1996, J INFECT DIS, V174, pS88, DOI 10.1093/infdis/174.Supplement_1.S88; DEMOL P, 1986, LANCET, V2, P108; DEZOYSA I, 1985, B WORLD HEALTH ORGAN, V63, P569; Franco MA, 1996, J INFECT DIS, V174, pS47, DOI 10.1093/infdis/174.Supplement_1.S47; GEORGESCOURBOT MC, 1991, RES VIROLOGY, V142, P405, DOI 10.1016/0923-2516(91)90008-Q; GOTHEFORS L, 1989, J INFECT DIS, V159, P753, DOI 10.1093/infdis/159.4.753; HANLON P, 1987, LANCET, V1, P1342; Herrmann JE, 1996, J INFECT DIS, V174, pS93, DOI 10.1093/infdis/174.Supplement_1.S93; JOENSUU J, 1997, IN PRESS LANCET; KAPIKIAN AZ, 1986, J INFECT DIS, V153, P815, DOI 10.1093/infdis/153.5.815; Kapikian AZ, 1996, J INFECT DIS, V174, pS65, DOI 10.1093/infdis/174.Supplement_1.S65; KOTLOFF KL, 1995, VACCINE, V13, P495, DOI 10.1016/0264-410X(94)00011-B; Lanata CF, 1996, J INFECT DIS, V174, P268, DOI 10.1093/infdis/174.2.268; LANATA CF, 1989, J INFECT DIS, V159, P452, DOI 10.1093/infdis/159.3.452; Linhares AC, 1996, B WORLD HEALTH ORGAN, V74, P491; MIGASENA S, 1995, VACCINE, V13, P168, DOI 10.1016/0264-410X(95)93131-R; Offit PA, 1996, J INFECT DIS, V174, pS59, DOI 10.1093/infdis/174.Supplement_1.S59; ORYAN ML, 1994, J INFECT DIS, V169, P504, DOI 10.1093/infdis/169.3.504; PerezSchael I, 1997, NEW ENGL J MED, V337, P1181, DOI 10.1056/NEJM199710233371701; RENNELS MB, 1990, AM J DIS CHILD, V144, P601, DOI 10.1001/archpedi.1990.02150290095037; Rennels MB, 1996, PEDIATRICS, V97, P7; Ryan MJ, 1996, J INFECT DIS, V174, pS12, DOI 10.1093/infdis/174.Supplement_1.S12; SVENNERHOLM AM, 1995, ADV EXP MED BIOL, V371, P1623; SVENSSON L, 1987, J GEN VIROL, V68, P1993, DOI 10.1099/0022-1317-68-7-1993; Trach DD, 1997, LANCET, V349, P231, DOI 10.1016/S0140-6736(96)06107-7; Velazquez FR, 1996, NEW ENGL J MED, V335, P1022, DOI 10.1056/NEJM199610033351404; VESIKARI T, 1984, LANCET, V1, P977; VESIKARI T, 1986, J INFECT DIS, V153, P832, DOI 10.1093/infdis/153.5.832; Vesikari T, 1996, J INFECT DIS, V174, pS81, DOI 10.1093/infdis/174.Supplement_1.S81; VESIKARI T, 1983, LANCET, V2, P807; Ward RL, 1996, J INFECT DIS, V174, pS51, DOI 10.1093/infdis/174.Supplement_1.S51; WARD RL, 1995, VACCINE, V13, P1226, DOI 10.1016/0264-410X(95)00060-E; ZISSIS G, 1983, J INFECT DIS, V148, P1061, DOI 10.1093/infdis/148.6.1061	42	45	47	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1538	1541		10.1016/S0140-6736(97)03254-6	http://dx.doi.org/10.1016/S0140-6736(97)03254-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388411				2022-12-28	WOS:A1997YH11500041
J	Zonana, H				Zonana, H			The civil commitment of sex offenders	SCIENCE			English	Editorial Material									YALE UNIV,SCH LAW,NEW HAVEN,CT 06519; YALE UNIV,SCH MED,NEW HAVEN,CT 06519	Yale University; Yale University								ADLER C, 1984, CRIM JUSTICE BEHAV, V11, P157; *AM BAR ASS, 1989, 781 AM BAR ASS CRIM, P457; *AM PSYCH ASS DIAG, 1994, AM PSYCH ASS DIAGN S, P522; BRADFORD JMW, 1995, REV PSYCHIAT, V14, P755; Group for the Advancement of Psychiatry, 1977, PSYCH SEX PSYCH LEG; *PAT I, 1977, B AM ACAD PSYCHIAT, V5, P116; PITHERS W, 1995, SEX OFFENDER CORRECT	7	17	17	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1248	1249		10.1126/science.278.5341.1248	http://dx.doi.org/10.1126/science.278.5341.1248			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9411753				2022-12-28	WOS:A1997YG04300034
J	Jones, CM; OBrien, K; Blinkhorn, AS; Rood, JP				Jones, CM; OBrien, K; Blinkhorn, AS; Rood, JP			Dentists' agreement on treatment of asymptomatic impacted third molar teeth: interview study	BRITISH MEDICAL JOURNAL			English	Article							3RD MOLARS; REMOVAL		UNIV MANCHESTER,DEPT DENT MED & SURG,MANCHESTER M15 6FH,LANCS,ENGLAND	University of Manchester				O'Brien, Kevin/0000-0001-5747-247X				[Anonymous], 1980, J Oral Surg, V38, P235; ISMAIL SM, 1989, BRIT MED J, V298, P707, DOI 10.1136/bmj.298.6675.707; LOPES V, 1995, BRIT J ORAL MAX SURG, V33, P33, DOI 10.1016/0266-4356(95)90083-7; MERCIER P, 1992, INT J ORAL MAX SURG, V21, P17, DOI 10.1016/S0901-5027(05)80447-3; SHEPHERD JP, 1994, BRIT MED J, V309, P620, DOI 10.1136/bmj.309.6955.620	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1204	1204		10.1136/bmj.315.7117.1204	http://dx.doi.org/10.1136/bmj.315.7117.1204			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393225	Green Published			2022-12-28	WOS:A1997YF25200022
J	Vijan, S; Hofer, TP; Hayward, RA				Vijan, S; Hofer, TP; Hayward, RA			Estimated benefits of glycemic control in microvascular complications in type 2 diabetes	ANNALS OF INTERNAL MEDICINE			English	Article						diabetes mellitus, non-insulin-dependent; blood glucose; diabetic angiopathies; kidney failure, chronic; diabetic retinopathy	INTENSIVE INSULIN THERAPY; METABOLIC CONTROL; VASCULAR-DISEASE; RISK-FACTORS; GLYCOSYLATED HEMOGLOBIN; CLINICAL PROTEINURIA; GLYCATED HEMOGLOBIN; PLASMA-GLUCOSE; RENAL-FAILURE; LONDON COHORT	Background: The benefits of intensive glycemic control in patients with type 2 diabetes are not well quantified. It is therefore not clear which patients will benefit most from aggressive glycemic control. Objective: To evaluate the efficacy of glycemic control in type 2 diabetes. Design: Markov decision model. Patients: Diabetic patients at a health maintenance organization. Main Outcome Measures: Risks for developing blindness and end-stage renal disease; number of patients and patient-years needed to treat to prevent complications. Results: For a patient in whom diabetes developed before 50 years of age, reducing hemoglobin A(1c) levels from 9% to 7% results in an estimated 2.3-percentage point decrease (from 2.6% to 0.3%) in lifetime risk for blindness due to retinopathy. The same change in a patient with diabetes onset at 65 years of age would be expected to decrease the risk for blindness by 0.5 percentage points (from 0.5% to < 0.1%). However, the Markov model predicts substantially greater benefit when moving from poor to moderate glycemic control than when moving from moderate to almost-normal glycemic control. Targeting less than 20% of the patients at one health maintenance organization for intensified therapy may prevent more than 80% of the preventable patient-time spent blind. The risks for end-stage renal disease and the risk reduction provided by improved glycemic control are lower than those for blindness. Conclusions: This probability model, based on extrapolation from the experience with type 1 diabetes, suggests that patients with early onset of type 2 diabetes will accrue substantial benefit from almost-normal glycemic control. In patients with later onset, moderate glycemic control prevents most end-stage complications caused by microvascular disease. These results have important implications for informing patients and allocating health care resources.	VET AFFAIRS CTR PRACTICE MANAGEMENT & OUTCOMES RE, ANN ARBOR, MI USA; UNIV MICHIGAN, SCH MED, ANN ARBOR, MI USA	University of Michigan System; University of Michigan			Hofer, Timothy Philip/AAC-9238-2022	Hofer, Timothy/0000-0003-0434-8787	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006665] Funding Source: NIH RePORTER; AHRQ HHS [HSO 6665-01] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; [Anonymous], 1995, Diabetes, V44, P1249; [Anonymous], 1995, DIABETES, V44, P968; [Anonymous], 1994, DIABETES CARE, V17, P616; [Anonymous], 1991, Ophthalmology, V98, P786; AVORN J, 1984, NEW ENGL J MED, V310, P1294, DOI 10.1056/NEJM198405173102005; BABA T, 1992, DIABETES RES CLIN PR, V16, P157, DOI 10.1016/0168-8227(92)90088-9; Clark CM, 1996, ANN INTERN MED, V124, P184, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00022; CLOSE CF, 1995, BMJ-BRIT MED J, V311, P973; Colwell JA, 1996, ANN INTERN MED, V124, P178, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00020; Colwell JA, 1996, DIABETES CARE, V19, P896, DOI 10.2337/diacare.19.8.896; COOPER ME, 1988, DIABETIC MED, V5, P361, DOI 10.1111/j.1464-5491.1988.tb01006.x; DECKERT T, 1991, DIABETIC MED, V8, P533; DWYER MS, 1985, DIABETES CARE, V8, P316, DOI 10.2337/diacare.8.4.316; ENGERMAN R, 1977, DIABETES, V26, P760, DOI 10.2337/diabetes.26.8.760; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; GALL MA, 1993, DIABETOLOGIA, V36, P1071, DOI 10.1007/BF02374501; Harris MI, 1996, ANN INTERN MED, V124, P117, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00007; HAYWARD RA, 1997, IN PRESS JAMA; Henry RR, 1996, ANN INTERN MED, V124, P175, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00019; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; Jarrett R J, 1984, Diabet Med, V1, P17; JOHN L, 1994, DIABETES CARE, V17, P888, DOI 10.2337/diacare.17.8.888; Klein R, 1996, ANN INTERN MED, V124, P90, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00003; KLEIN R, 1988, JAMA-J AM MED ASSOC, V260, P2864, DOI 10.1001/jama.260.19.2864; KLEIN R, 1993, DIABETES CARE, V16, P1325, DOI 10.2337/diacare.16.10.1325; KLEIN R, 1985, DIABETES AM, P1; KROLEWSKI AS, 1977, DIABETOLOGIA, V13, P345, DOI 10.1007/BF01223277; KROLEWSKI AS, 1995, NEW ENGL J MED, V332, P1251, DOI 10.1056/NEJM199505113321902; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; LIU QZ, 1993, DIABETOLOGIA, V36, P428, DOI 10.1007/BF00402279; MATLOCK MB, 1988, DIABETLOGIA, V31, P82; MCCANCE DR, 1994, BRIT MED J, V308, P1323, DOI 10.1136/bmj.308.6940.1323; Medhi J, 1994, STOCHASTIC PROCESSES; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; MORISAKI N, 1994, J AM GERIATR SOC, V42, P142, DOI 10.1111/j.1532-5415.1994.tb04941.x; MORRISH NJ, 1990, DIABETOLOGIA, V33, P542, DOI 10.1007/BF00404142; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; MOSS SE, 1988, OPHTHALMOLOGY, V95, P1340; MOSS SE, 1994, OPHTHALMOLOGY, V101, P1061; MOSS SE, 1992, ARCH INTERN MED, V152, P610, DOI 10.1001/archinte.152.3.610; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; MUGGEO M, 1995, DIABETOLOGIA, V38, P318, DOI 10.1007/s001250050288; *NAT CTR HLTH STAT, 1995, VIT STAT US B, V2; Nathan DM, 1996, ANN INTERN MED, V124, P86, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00002; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; PANZRAM G, 1981, DIABETOLOGIA, V20, P587; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; Peters B.G., 1994, J EUROPEAN PUBLIC PO, V1, P9, DOI [10.1080/13501769408406945, DOI 10.1080/13501769408406945]; PIART J, 1978, DIABETES CARE, V1, P252; PIART J, 1978, DIABETES CARE, V1, P168; POWRIE JK, 1994, BRIT MED J, V309, P1608, DOI 10.1136/bmj.309.6969.1608; RUDBERG S, 1993, DIABETOLOGIA, V36, P1309, DOI 10.1007/BF00400811; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHENFIELD GM, 1979, DIABETES METAB, V5, P149; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; STEPHENSON JM, 1995, DIABETIC MED, V12, P149, DOI 10.1111/j.1464-5491.1995.tb00446.x; TEUSCHER A, 1994, LANCET, V343, P1097, DOI 10.1016/S0140-6736(94)90206-2; TURNER RC, 1991, DIABETOLOGIA, V34, P877; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; VANDERZWAAG R, 1983, DIABETES CARE, V6, P341, DOI 10.2337/diacare.6.4.341; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; VIBERTI GC, 1983, BRIT MED J, V286, P598, DOI 10.1136/bmj.286.6365.598; WELBORN TA, 1984, DIABETOLOGIA, V27, P568, DOI 10.1007/BF00276969; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361; YIP J, 1993, BRIT MED J, V306, P1235; 1989, MMWR-MORBID MORTAL W, V38, P546	69	166	167	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					788	+		10.7326/0003-4819-127-9-199711010-00003	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382399				2022-12-28	WOS:A1997YD89800002
J	Gangakhedkar, RR; Bentley, ME; Divekar, AD; Gadkari, D; Mehendale, SM; Shepherd, ME; Bollinger, RC; Quinn, TC				Gangakhedkar, RR; Bentley, ME; Divekar, AD; Gadkari, D; Mehendale, SM; Shepherd, ME; Bollinger, RC; Quinn, TC			Spread of HIV infection in married monogamous women in India	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUALLY-TRANSMITTED DISEASES; IMMUNODEFICIENCY-VIRUS TYPE-1; EPIDEMIC; CLINICS	Context.-A high prevalence of human immunodeficiency virus (HIV) infection in female sex workers (FSWs) and men who attend sexually transmitted disease (STD) clinics poses al risk for spread of infection to other populations. Objective.-To examine spread of HIV to a low-risk population by comparing prevalence of, and risk factors for, HIV and STDs in FSWs and non-FSWs. Methods.-Women attending STD clinics in Pune, India, were assessed for STDs and HIV from May 13, 1993, to July 11, 1996. Demographic and behavioral information was collected, and clinical and laboratory assessment was performed. Main Outcome Measure.-Prevalence and risk determinants of HIV infection. Results.-Of 916 women enrolled, 525 were FSWs and 391 were non-FSWs. Prevalence of HIV in FSWs and non-FSWs was 49.9% and 13.6%, respectively (P<.001). In multivariate analysis, inconsistent condom use and genital ulcer disease or genital warts were associated with prevalent HIV in FSWs. History of sexual contact with a partner with an STD was associated with HIV in non-FSWs. Conclusions.-Infection with HIV is increasing in non-FSWs, previously thought to be at low risk in India. Since history of sexual contact with their only sex partner was the only risk factor significantly associated with HIV infection, it is likely that these women are being infected by their spouses. This underscores the need for strengthening partner-notification strategies and counseling facilities in India.	JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205; NATL AIDS RES INST,PUNE,MAHARASHTRA,INDIA; NIAID,BETHESDA,MD 20892; NIH,BETHESDA,MD 20892	Johns Hopkins University; Indian Council of Medical Research (ICMR); ICMR - National AIDS Research Institute (NARI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA			Quinn, Thomas/A-2494-2010	Bollinger, Robert/0000-0002-6798-6834	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033879] Funding Source: NIH RePORTER; FIC NIH HHS [D43-TW0000] Funding Source: Medline; NCRR NIH HHS [RR-00722] Funding Source: Medline; NIAID NIH HHS [AI-33879] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOLLINGER RC, 1995, MEDICINE, V74, P97, DOI 10.1097/00005792-199503000-00005; GUPTA GR, 1996, WOMENS EXPERIENCE; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; Lalvani A, 1996, LANCET, V347, P1349, DOI 10.1016/S0140-6736(96)91007-7; MANE P, 1992, AIDS PREVENTION; MEHENDALE SM, 1995, J INFECT DIS, V172, P1486, DOI 10.1093/infdis/172.6.1486; Mehendale SM, 1996, INDIAN J MED RES, V104, P327; NAG M, 1996, SEXUAL BEHAV AIDS IN, P26; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; RAMASUBBAN R, 1994, WOMEN HLTH DEV INDIA, P212; RODRIGUES JJ, 1995, BRIT MED J, V311, P283, DOI 10.1136/bmj.311.7000.283; STONE AB, 1994, AIDS S1, V8, pS285; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001	15	210	212	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2090	2092		10.1001/jama.278.23.2090	http://dx.doi.org/10.1001/jama.278.23.2090			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403424				2022-12-28	WOS:A1997YK98700039
J	Von Korff, M; Gruman, J; Schaefer, J; Curry, SJ; Wagner, EH				Von Korff, M; Gruman, J; Schaefer, J; Curry, SJ; Wagner, EH			Collaborative management of chronic illness	ANNALS OF INTERNAL MEDICINE			English	Article							BEHAVIORAL MEDICINE INTERVENTIONS; ACUTE MYOCARDIAL-INFARCTION; ARTHRITIS SELF-MANAGEMENT; CONGESTIVE-HEART-FAILURE; QUALITY-OF-LIFE; PATIENT EDUCATION; PSYCHOSOCIAL INTERVENTIONS; DIABETES-MELLITUS; CONTROLLED TRIAL; CANCER-PATIENTS	In chronic illness, day-to-day care responsibilities fall most heavily on patients and their families. Effective collaborative relationships with health care providers can help patients and families better handle self-care tasks. Collaborative management is care that strengthens and supports self-care in chronic illness while assuring that effective medical, preventive, and health maintenance interventions take place. In this paper, the following essential elements of collaborative management developed in light of behavioral principles and empirical evidence about effective care in chronic illness are discussed: 1) collaborative definition of problems, in which patient-defined problems are identified along with medical problems diagnosed by physicians; 2) targeting, goal setting, and planning, in which patients and providers focus on a specific problem, set realistic objectives, and develop an action plan for attaining those objectives in the context of patient preferences and readiness; 3) creation of a continuum of selfmanagement training and support services, in which patients have access to services that teach skills needed to carry out medical regimens, guide health behavior changes, and provide emotional support; and 4) active and sustained follow-up, in which patients are contacted at specified intervals to monitor health status, identify potential complications, and check and reinforce progress in implementing the care plan. These elements make up a common core of services for chronic illness care that need not be reinvented for each disease.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Ctr Advancement Hlth, Washington, DC 20009 USA	Group Health Cooperative	Von Korff, M (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.		Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213; VonKorff, Michael/0000-0001-5386-8477				ALARANTA H, 1994, SPINE, V19, P1339, DOI 10.1097/00007632-199406000-00007; ANDERSEN BL, 1992, J CONSULT CLIN PSYCH, V60, P552, DOI 10.1037/0022-006X.60.4.552; BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; BAUM D, 1986, J ASTHMA, V23, P49, DOI 10.3109/02770908609077475; BERESFORD SAA, 1992, AM J PUBLIC HEALTH, V82, P79, DOI 10.2105/AJPH.82.1.79; BOLTON MB, 1991, J GEN INTERN MED, V6, P401, DOI 10.1007/BF02598160; BROWN SA, 1992, RES NURS HEALTH, V15, P409, DOI 10.1002/nur.4770150603; Burg MM., 1994, ANN BEHAV MED, V16, P109, DOI 10.1093/abm/16.2.109; CLARK NM, 1992, GERONTOLOGIST, V32, P438, DOI 10.1093/geront/32.4.438; CLARK NM, 1992, HEALTH EDUC QUART, V19, P341, DOI 10.1177/109019819201900306; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; CLARK NM, 1994, J ASTHMA, V31, P427, DOI 10.3109/02770909409089484; CLARK NM, 1989, CHEST, V95, P1110, DOI 10.1378/chest.95.5.1110; Clark NM., 1991, SAGE J, V3, P3, DOI DOI 10.1177/089826439100300101; CURRY SJ, 1993, J CONSULT CLIN PSYCH, V61, P790, DOI 10.1037/0022-006X.61.5.790; CURRY SJ, 1994, ANNU REV PUBL HEALTH, V15, P345; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; FAWZY FI, 1995, ARCH GEN PSYCHIAT, V52, P100; FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P720; FIATARONE MA, 1993, J AM GERIATR SOC, V41, P333, DOI 10.1111/j.1532-5415.1993.tb06714.x; Frasure-Smith N, 1995, J Cardiopulm Rehabil, V15, P103; GILOTH BE, 1990, PATIENT EDUC COUNS, V15, P29, DOI 10.1016/0738-3991(90)90005-6; GLASGOW RE, 1992, DIABETES CARE, V15, P1423, DOI 10.2337/diacare.15.10.1423; GLASGOW RE, 1989, HEALTH PSYCHOL, V8, P285, DOI 10.1037/0278-6133.8.3.285; GLASGOW RE, 1992, PATIENT EDUC COUNS, V19, P61, DOI 10.1016/0738-3991(92)90102-O; GLASGOW RE, 1995, DIABETES CARE, V18, P117, DOI 10.2337/diacare.18.1.117; Glasgow RE, 1996, DIABETES CARE, V19, P835, DOI 10.2337/diacare.19.8.835; GLYNN TJ, 1990, HEALTH EDUC QUART, V17, P329, DOI 10.1177/109019819001700308; GOODALL TA, 1991, HEALTH PSYCHOL, V10, P1, DOI 10.1037/0278-6133.10.1.1; GREENE B, 1994, J CONSULT CLIN PSYCH, V62, P576, DOI 10.1037/0022-006X.62.3.576; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; GRUESSER M, 1993, DIABETES CARE, V16, P1268, DOI 10.2337/diacare.16.9.1268; GUSTAFSON DH, 1994, J AM MED INFORM ASSN, P604; Haynes R. B., 1979, COMPLIANCE HLTH CARE; HELLER RF, 1993, AM J CARDIOL, V72, P759, DOI 10.1016/0002-9149(93)91058-P; HELLMAN CJC, 1990, BEHAV MED, V16, P165, DOI 10.1080/08964289.1990.9934605; HILTON S, 1986, LANCET, V1, P26; HIRANO PC, 1994, PATIENT EDUC COUNS, V24, P9, DOI 10.1016/0738-3991(94)90024-8; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Holman H, 1988, Trans Assoc Am Physicians, V101, P173; IGNACIOGARCIA JM, 1995, AM J RESP CRIT CARE, V151, P353, DOI 10.1164/ajrccm.151.2.7842191; INUI TS, 1985, MED CARE, V23, P521, DOI 10.1097/00005650-198505000-00013; JAMES LD, 1993, BEHAV THER, V24, P305, DOI 10.1016/S0005-7894(05)80271-0; JENKINS CD, 1995, BEHAV MED, V21, P53, DOI 10.1080/08964289.1995.9933742; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KELLY JA, 1993, AM J PSYCHIAT, V150, P1679; KIRKMAN MS, 1994, DIABETES CARE, V17, P840, DOI 10.2337/diacare.17.8.840; KOSTIS JB, 1994, CHEST, V106, P996, DOI 10.1378/chest.106.4.996; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; LEWIN B, 1992, LANCET, V339, P1036, DOI 10.1016/0140-6736(92)90547-G; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; LORIG K, 1993, HEALTH EDUC QUART, V20, P17, DOI 10.1177/109019819302000104; LORIG K, 1984, GERONTOLOGIST, V24, P455; Lorig K, 1993, GENERATIONS, V3, P11; Lorig K., 1994, LIVING HLTH LIFE CHR; MALONE JM, 1989, AM J SURG, V158, P520, DOI 10.1016/0002-9610(89)90183-9; MAZZE RS, 1994, DIABETES CARE, V17, P5; MAZZE RS, 1994, DIABETES CARE, V17, P56; MAZZUCA SA, 1982, J CHRON DIS, V35, P521, DOI 10.1016/0021-9681(82)90071-6; MEYER TJ, 1995, HEALTH PSYCHOL, V14, P101, DOI 10.1037/0278-6133.14.2.101; MONTGOMERY EB, 1994, AM J MED, V97, P429, DOI 10.1016/0002-9343(94)90322-0; OSMAN LM, 1994, BRIT MED J, V308, P568, DOI 10.1136/bmj.308.6928.568; Patterson J.M., 1994, ANN BEHAV MED, V16, P131, DOI [DOI 10.1093/ABM/16.2.131, 10.1093/abm/16.2.131]; Payne T H, 1995, HMO Pract, V9, P101; PAYNE TJ, 1994, J PSYCHOSOM RES, V38, P409, DOI 10.1016/0022-3999(94)90102-3; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; RENE J, 1992, ARTHRITIS RHEUM, V35, P511, DOI 10.1002/art.1780350504; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; ROBINSON TN, 1989, COMPUT METH PROG BIO, V30, P137, DOI 10.1016/0169-2607(89)90065-5; Ruggiero L., 1993, DIABETES SPECTRUM, V6, P22; RUTTAN VW, 1988, GENERATION DIFFUSION, P69; SCHAFER LC, 1986, DIABETES CARE, V9, P179, DOI 10.2337/diacare.9.2.179; Sikkema KJ, 1996, ANN BEHAV MED, V18, P40, DOI 10.1007/BF02903938; SOBEL DS, 1995, PSYCHOSOM MED, V57, P234, DOI 10.1097/00006842-199505000-00005; SPIEGEL D, 1989, LANCET, V2, P888; STEWART AL, 1994, J CLIN EPIDEMIOL, V47, P719, DOI 10.1016/0895-4356(94)90169-4; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; TOBIN D, 1986, HDB CLIN INTERVENTIO; Turner JA, 1996, SPINE, V21, P2851, DOI 10.1097/00007632-199612150-00010; *U CAL, 1996, CHRON CAR AM 21 CENT; VANELDERENVANKEMENADE T, 1994, BRIT J CLIN PSYCHOL, V33, P367, DOI 10.1111/j.2044-8260.1994.tb01133.x; VINICOR F, 1987, J CHRON DIS, V40, P345, DOI 10.1016/0021-9681(87)90050-6; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; WEINBERER M, 1995, J GEN INTERN MED, V10, P59, DOI 10.1007/BF02600227	85	837	844	2	81	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1097	1102		10.7326/0003-4819-127-12-199712150-00008	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YL262	9412313				2022-12-28	WOS:000070936600007
J	Kume, S; Muto, A; Inoue, T; Suga, K; Okano, H; Mikoshiba, K				Kume, S; Muto, A; Inoue, T; Suga, K; Okano, H; Mikoshiba, K			Role of inositol 1,4,5-trisphosphate receptor in ventral signaling in Xenopus embryos	SCIENCE			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; BONE MORPHOGENETIC PROTEIN-4; EARLY AMPHIBIAN EMBRYOS; MESODERM INDUCTION; NEURAL INDUCTION; HOMEOBOX GENE; SPEMANN ORGANIZER; LAEVIS EMBRYOS; EARLY RESPONSE; LITHIUM	The inositol 1,4,5-trisphosphate (IP3) receptor is a calcium ion channel involved in the release of free Ca2+ from intracellular stores. For analysis of the role of IP3-induced Ca2+ release (IICR) on patterning of the embryonic body, monoclonal antibodies that inhibit IICR were produced. Injection of these blocking antibodies into the ventral part of early Xenopus embryos induced modest dorsal differentiation. A close correlation between IICR blocking potencies and ectopic dorsal axis induction frequency suggests that an active IP3-Ca2+ signal may participate in the modulation of ventral differentiation.	UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,MINATO KU,TOKYO 108,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT NEUROANAT,SUITA,OSAKA 565,JAPAN; CORE RES EVOLUT SCI & TECHNOL,JST,SUITA,OSAKA 565,JAPAN; RIKEN,BRAIN SCI INST,WAKO,SAITAMA 35101,JAPAN	University of Tokyo; Osaka University; Japan Science & Technology Agency (JST); RIKEN	Kume, S (corresponding author), ERATO,JST,MIKOSHIBA CALCIOSIGNAL NET PROJECT,MEGURO KU,2-9-3 SHIMO MEGURO,TOKYO 153,JAPAN.		Kume, Shoen/M-4356-2016; Okano, Hideyuki/I-7584-2019; Mikoshiba, Katsuhiko/N-7943-2015; Inoue, Takafumi/AAM-9533-2020	Kume, Shoen/0000-0002-4292-205X; Inoue, Takafumi/0000-0002-2728-0060				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATACK JR, 1993, J NEUROCHEM, V60, P652, DOI 10.1111/j.1471-4159.1993.tb03197.x; Ault KT, 1996, DEVELOPMENT, V122, P2033; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; CHEN YP, 1994, DEV BIOL, V161, P70, DOI 10.1006/dbio.1994.1008; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COOKE J, 1988, DEVELOPMENT, V102, P85; DALE L, 1992, DEVELOPMENT, V115, P573; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FUKUDA K, 1987, NATURE, V327, P623, DOI 10.1038/327623a0; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KUEM S, 1997, MECH DEVELOP, V66, P157; Kume S, 1997, DEV BIOL, V182, P228, DOI 10.1006/dbio.1996.8479; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KUME S, UNPUB; LETTICE LA, 1993, DEVELOPMENT, V117, P263; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; Muto A, 1996, J CELL BIOL, V135, P181, DOI 10.1083/jcb.135.1.181; NIEUWKOOP PD, 1967, NORMAL DEV TABLE XEN; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; SMITH JC, 1983, J EMBRYOL EXP MORPH, V78, P299; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; STUTZ F, 1986, J MOL BIOL, V187, P349, DOI 10.1016/0022-2836(86)90438-9; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355	44	98	99	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1940	1943		10.1126/science.278.5345.1940	http://dx.doi.org/10.1126/science.278.5345.1940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395395				2022-12-28	WOS:A1997YL00200033
J	Slavin, RG				Slavin, RG			Nasal polyps and sinusitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MAXILLARY SINUSITIS; RESPIRATORY ALLERGY; FUNGAL SINUSITIS; CYSTIC-FIBROSIS; DOUBLE-BLIND; MAST-CELLS; CHILDREN; DISEASE; ASTHMA; BACTERIOLOGY	Despite the prevalence and long history of nasal polyps, many questions still exist with respect to incidence and pathogenesis. Although allergy has been commonly thought to be a major cause, much compelling evidence argues against this. Medical therapy consists of a short course of systemic steroids followed by intranasal steroids. Sinusitis is the most commonly reported chronic disease in the United States. Decrease in ostial size, retention of secretions, and decrease in mucociliary action all contribute to the pathogenesis of sinusitis. The clinical presentation of chronic sinusitis is generally subtle and the clinical index of suspicion must be high. Limited coronal computed tomography is regarded as the most definitive and cost-effective imaging technique for the diagnosis of sinusitis. Appropriate antibiotics must be administered for a sufficient period. In medically resistant sinusitis, functional endoscopic sinus surgery has emerged as the procedure of choice.			Slavin, RG (corresponding author), ST LOUIS UNIV, SCH MED, 1402 S GRAND BLVD, R209, ST LOUIS, MO 63104 USA.							BAROODY FM, 1995, ARCH OTOLARYNGOL, V121, P1396; BENSON V, 1993, VITAL HLTH STAT, V182; BROOK I, 1989, ANN OTO RHINOL LARYN, V98, P426, DOI 10.1177/000348948909800605; BROWN BL, 1979, ARCH OTOLARYNGOL, V105, P413; CAPLIN I, 1971, ANN ALLERGY, V29, P631; CHANDRA RK, 1974, J LARYNGOL OTOL, V88, P1019, DOI 10.1017/S0022215100079676; DRAKELEE AB, 1984, J LARYNGOL OTOL, V98, P783, DOI 10.1017/S0022215100147462; ELOVIC A, 1994, J ALLERGY CLIN IMMUN, V93, P864, DOI 10.1016/0091-6749(94)90379-4; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; FINOTTO S, 1994, CLIN EXP IMMUNOL, V95, P343; FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; FULLER CG, 1994, CLIN PEDIATR, V33, P712, DOI 10.1177/000992289403301202; GEORGITIS JW, 1995, INT ARCH ALLERGY IMM, V106, P416, DOI 10.1159/000236875; GLIKLICH RE, 1995, OTOLARYNG HEAD NECK, V113, P104, DOI 10.1016/S0194-5998(95)70152-4; GOLDENHERSH MJ, 1990, J ALLERGY CLIN IMMUN, V85, P1030, DOI 10.1016/0091-6749(90)90047-8; Gottlieb MJ, 1925, J AMER MED ASSOC, V85, P105, DOI 10.1001/jama.1925.02670020025013; GUNTERT VG, 1963, HNO, V11, P77; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197; HENDERSON WR, 1992, J PATHOL, V166, P395, DOI 10.1002/path.1711660412; HORA JF, 1965, LARYNGOSCOPE, V75, P768, DOI 10.1288/00005537-196505000-00004; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; KEITH PK, 1994, J ALLERGY CLIN IMMUN, V93, P567, DOI 10.1016/S0091-6749(94)70068-0; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P643, DOI 10.1001/archotol.1985.00800120037003; KOVATCH AL, 1984, PEDIATRICS, V73, P306; LANZA DC, 1992, J ALLERGY CLIN IMMUN, V90, P543, DOI 10.1016/0091-6749(92)90182-2; LUND VJ, 1995, ANN OTO RHINOL LARYN, V104, P17, DOI 10.1177/000348949510410s02; MANN W, 1977, ARCH OTO-RHINO-LARYN, V215, P67, DOI 10.1007/BF00463193; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MELN I, 1986, ACTA OTOLARYNGOL, V101, P44; MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V92, P812, DOI 10.1016/0091-6749(93)90058-N; MEYER RD, 1994, MEDICINE, V73, P69, DOI 10.1097/00005792-199403000-00001; MILGRIM LM, 1994, J OTOLARYNGOL, V23, P450; MINGS R, 1988, AM J RHINOL, V71, P123; MOLONEY JR, 1977, J LARYNGOL OTOL, V91, P837, DOI 10.1017/S0022215100084450; MORGAN MA, 1984, AM J CLIN PATHOL, V82, P597, DOI 10.1093/ajcp/82.5.597; MYGIND N, 1975, Clinical Allergy, V5, P159, DOI 10.1111/j.1365-2222.1975.tb01848.x; MYGIND N, 1976, ACTA OTO-LARYNGOL, V82, P252, DOI 10.3109/00016487609120897; OHNO I, 1995, AM J RESP CELL MOL, V13, P639, DOI 10.1165/ajrcmb.13.6.7576701; OLIVERIO PJ, 1995, OTOLARYNG CLIN N AM, V28, P585; OXELIUS VA, 1981, NEW ENGL J MED, V304, P1476, DOI 10.1056/NEJM198106113042408; PARSONS DS, 1993, LARYNGOSCOPE, V103, P899; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; RAMADAN HH, 1995, AM J OTOLARYNG, V16, P303, DOI 10.1016/0196-0709(95)90057-8; ROHR AS, 1984, CLIN REV ALLERG, V2, P387; ROSSI OVJ, 1994, INT ARCH ALLERGY IMM, V103, P209, DOI 10.1159/000236629; RUHNO J, 1990, J ALLERGY CLIN IMMUN, V86, P946, DOI 10.1016/S0091-6749(05)80158-7; SCHENCK NL, 1974, T AM ACAD OPHTHALMOL, V78, P109; SETTIPANE G A, 1982, Journal of Allergy and Clinical Immunology, V69, P148; SETTIPANE GA, 1974, J ALLERGY CLIN IMMUN, V53, P200, DOI 10.1016/0091-6749(74)90081-5; SETTIPANE GA, 1987, IMMUNOL ALLERGY CLIN, V7, P105; SHAPIRO G, 1989, J ALLERGY CLIN IMMUN, V77, P59; SHAPIRO GG, 1985, PEDIATR INFECT DIS J, V4, pS55, DOI 10.1097/00006454-198511001-00003; SHEFFIELD RW, 1978, POSTGRAD MED, V63, P93, DOI 10.1080/00325481.1978.11714779; SLAVIN RG, 1992, ARCH OTOLARYNGOL, V118, P771; SLAVIN RG, 1996, ATLAS ALLERGIES, P169; SORENSEN H, 1976, ACTA OTO-LARYNGOL, V82, P260, DOI 10.3109/00016487609120899; SPECTOR SL, 1981, J ALLERGY CLIN IMMUN, V67, P22, DOI 10.1016/0091-6749(81)90040-3; STERN RC, 1982, AM J DIS CHILD, V136, P1067, DOI 10.1001/archpedi.1982.03970480033008; Stiehm ER, 1989, IMMUNOLOGIC DISORDER, P157; STOOP AE, 1993, J ALLERGY CLIN IMMUN, V91, P616, DOI 10.1016/0091-6749(93)90267-J; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; UPADHYAY S, 1995, LARYNGOSCOPE, V105, P1058, DOI 10.1288/00005537-199510000-00009; WALD ER, 1989, J PEDIATR-US, V115, P28, DOI 10.1016/S0022-3476(89)80324-5; WALD ER, 1986, PEDIATRICS, V77, P795; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302; WALD ER, 1995, J PEDIATR-US, V127, P339, DOI 10.1016/S0022-3476(95)70061-7; WIPPOLD FJ, 1995, ALLERGY PROC, V16, P165, DOI 10.2500/108854195778666801	70	66	72	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1849	1854		10.1001/jama.278.22.1849	http://dx.doi.org/10.1001/jama.278.22.1849			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396646				2022-12-28	WOS:A1997YK15500007
J	Chang, KP; Veitch, PC				Chang, KP; Veitch, PC			Fever, haematuria, proteinuria, and a parrot	LANCET			English	Article							PSITTACOSIS		ROYAL N SHORE HOSP,DEPT AGED CARE & REHABIL MED,ST LEONARDS,NSW 2065,AUSTRALIA	Royal North Shore Hospital								JEFFREY RF, 1992, AM J KIDNEY DIS, V20, P94, DOI 10.1016/S0272-6386(12)80325-8; MANDELL GL, 1995, PRINICPLES PRACTICE, P1693; PALMER SR, 1982, J ROY SOC MED, V75, P262; REGAN RJ, 1979, BRIT HEART J, V42, P349, DOI 10.1136/hrt.42.3.349; YUNG AP, 1988, MED J AUSTRALIA, V148, P228, DOI 10.5694/j.1326-5377.1988.tb99430.x	5	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1674	1674		10.1016/S0140-6736(97)09389-6	http://dx.doi.org/10.1016/S0140-6736(97)09389-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400513				2022-12-28	WOS:A1997YK21100013
J	Templin, M; Franck, A; DuChesne, A; Leist, H; Zhang, YM; Ulrich, R; Schadler, V; Wiesner, U				Templin, M; Franck, A; DuChesne, A; Leist, H; Zhang, YM; Ulrich, R; Schadler, V; Wiesner, U			Organically modified aluminosilicate mesostructures from block copolymer phases	SCIENCE			English	Article							MESOPOROUS MOLECULAR-SIEVES; DIBLOCK COPOLYMERS; INORGANIC MATERIALS; THIN-FILMS; ORGANIZATION; NANOCLUSTERS; ORIENTATION; SURFACTANT; ASSEMBLIES; IONOMERS	Organically modified aluminosilicate mesostructures were synthesized from two metal alkoxides with the use of poly(isoprene-b-ethyleneoxide) block copolymers (PI-b-PEO) as the structure-directing molecules. By increasing the fraction of the inorganic precursors with respect to the polymer, morphologies expected from the phase diagrams of diblock copolymers were obtained. The length scale of the microstructures and the state of alignment were varied using concepts known from the study of block copolymers. These results suggest that the use of higher molecular weight block copolymer mesophases instead of conventional low-molecular weight surfactants may provide a simple, easily controlled pathway for the preparation of various silica-type mesostructures that extends the accessible length scale of these structures by about an order of magnitude.	MAX PLANCK INST POLYMER RES,D-55021 MAINZ,GERMANY	Max Planck Society								Allgaier J, 1997, MACROMOLECULES, V30, P1582, DOI 10.1021/ma961311q; Antonietti M, 1995, ADV MATER, V7, P1000, DOI 10.1002/adma.19950071205; ANTONIETTI M, 1997, ANGEW CHEM, V109, P944; ATTARD GS, 1995, NATURE, V378, P366, DOI 10.1038/378366a0; BAGSHAW SA, 1995, SCIENCE, V269, P1242, DOI 10.1126/science.269.5228.1242; BATES FS, 1991, SCIENCE, V251, P898, DOI 10.1126/science.251.4996.898; BEHRENS P, 1993, ADV MATER, V5, P127, DOI 10.1002/adma.19930050212; Braun PV, 1996, NATURE, V380, P325, DOI 10.1038/380325a0; CHAN YNC, 1992, CHEM MATER, V4, P24, DOI 10.1021/cm00019a010; Clay R. T., 1995, SUPRAMOL SCI, V2, P183; COULON G, 1989, MACROMOLECULES, V22, P2581, DOI 10.1021/ma00196a006; DUCHESNE A, 1994, COLLOID POLYM SCI, V272, P1329; DuChesne A, 1997, ACTA POLYM, V48, P142, DOI 10.1002/actp.1997.010480403; EHLICH D, 1993, MACROMOLECULES, V26, P189, DOI 10.1021/ma00053a029; Firouzi A, 1997, J AM CHEM SOC, V119, P3596, DOI 10.1021/ja963007i; FIROUZI A, 1995, SCIENCE, V267, P1138, DOI 10.1126/science.7855591; Golden JH, 1996, SCIENCE, V273, P782, DOI 10.1126/science.273.5276.782; HASHIMOTO T, 1974, MACROMOLECULES, V7, P364, DOI 10.1021/ma60039a019; HENKEE CS, 1988, J MATER SCI, V23, P1685, DOI 10.1007/BF01115708; HEYWOOD BR, 1994, ADV MATER, V6, P9, DOI 10.1002/adma.19940060103; HILLMYER MA, 1996, CIENCE, V271, P976; Honeker CC, 1996, CHEM MATER, V8, P1702, DOI 10.1021/cm960146q; HUO QS, 1994, NATURE, V368, P317, DOI 10.1038/368317a0; HUO QS, 1995, SCIENCE, V268, P1324, DOI 10.1126/science.268.5215.1324; Huo QS, 1996, CHEM MATER, V8, P1147, DOI 10.1021/cm960137h; Kane RS, 1996, CHEM MATER, V8, P1919, DOI 10.1021/cm960072i; Krause S., 1978, POLYM BLENDS, V1, P16; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Liu Y, 1996, MACROMOLECULES, V29, P899, DOI 10.1021/ma950605t; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; Mann S, 1996, NATURE, V382, P313, DOI 10.1038/382313a0; Marentette JM, 1997, ADV MATER, V9, P647, DOI 10.1002/adma.19970090813; Mercier L, 1997, ADV MATER, V9, P500, DOI 10.1002/adma.19970090611; MOFFITT M, 1995, CHEM MATER, V7, P1185, DOI 10.1021/cm00054a018; Raman NK, 1996, CHEM MATER, V8, P1682, DOI 10.1021/cm960138+; REIMER L, 1991, ADV ELECT ELECT PHYS, V81, P67; ROBESON L, 1982, POLYM COMPATIBILITY, V2, P177; SANKARAN V, 1990, J AM CHEM SOC, V112, P6858, DOI 10.1021/ja00175a019; SCHMIDT H, 1990, J NON-CRYST SOLIDS, V121, P428, DOI 10.1016/0022-3093(90)90171-H; SCHUTH F, 1995, BER BUNSEN PHYS CHEM, V99, P1306, DOI 10.1002/bbpc.199500076; SPATZ JP, 1995, ADV MATER, V7, P731, DOI 10.1002/adma.19950070811; Templin M, 1997, ADV MATER, V9, P814, DOI 10.1002/adma.19970091011	42	567	603	2	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1795	1798		10.1126/science.278.5344.1795	http://dx.doi.org/10.1126/science.278.5344.1795			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388181				2022-12-28	WOS:A1997YJ90100047
J	Brambilla, R; Gnesutta, N; Minichiello, L; White, G; Roylance, AJ; Herron, CE; Ramsey, M; Wolfer, DP; Cestari, V; RossiArnaud, C; Grant, SGN; Chapman, PF; Lipp, HP; Sturani, E; Klein, R				Brambilla, R; Gnesutta, N; Minichiello, L; White, G; Roylance, AJ; Herron, CE; Ramsey, M; Wolfer, DP; Cestari, V; RossiArnaud, C; Grant, SGN; Chapman, PF; Lipp, HP; Sturani, E; Klein, R			A role for the Ras signalling pathway in synaptic transmission and long-term memory	NATURE			English	Article							MUSCARINIC RECEPTORS; EXCHANGE FACTOR; PROTEIN; POTENTIATION; ACTIVATION; AMYGDALA; MICE; IDENTIFICATION; PLASTICITY; INDUCTION	Members of the Ras subfamily of small guanine-nucleotide-binding proteins are essential for controlling normal and malignant cell proliferation as well as cell differentiation(1). The neuronal-specific guanine-nucleotide-exchange factor, Ras-GRF/CDC25Mm (refs 2-4), induces Ras signalling in response to Ca2+ influx(5) and activation of G-protein-coupled receptors in vitro(6), suggesting that it plays a role in neurotransmission and plasticity in vivo(7). Here we report that mice lacking Ras-GRF are impaired in the process of memory consolidation, as revealed by emotional conditioning tasks that require the function of the amygdala; learning and short-term memory are intact. Electrophysiological measurements in the basolateral amygdala reveal that long-term plasticity is abnormal in mutant mice. In contrast, Ras-GRF mutants do not reveal major deficits in spatial learning tasks such as the Morris water maze, a test that requires hippocampal function. Consistent with apparently normal hippocampal functions, Ras-GRF mutants show normal NMDA (N-methyl-D-aspartate) receptor-dependent long-term potentiation in this structure. These results implicate Ras-GRF signalling via the Ras/MAP kinase pathway in synaptic events leading to formation of long-term memories.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY; UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,I-20133 MILAN,ITALY; UNIV WALES COLL CARDIFF,SCH MOL & MED BIOSCI,PHYSIOL UNIT,CARDIFF CF1 3US,S GLAM,WALES; UNIV EDINBURGH,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,CTR NEUROSCI,EDINBURGH EH8 9LE,MIDLOTHIAN,SCOTLAND; UNIV ZURICH,INST ANAT,CH-8057 ZURICH,SWITZERLAND; CNR,IST PSICOBIOL & PSICOFARMACOL,I-00198 ROME,ITALY; UNIV ROMA LA SAPIENZA,DIPARTIMENTO PSICOL,I-00185 ROME,ITALY	European Molecular Biology Laboratory (EMBL); University of Milan; Cardiff University; University of Edinburgh; University of Edinburgh; University of Zurich; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome			Brambilla, Riccardo/A-6082-2010; Wolfer, David P/B-3293-2016; Klein, Ruediger/C-6147-2008; ROSSI-ARNAUD, Clelia/J-7870-2019; Gnesutta, Nerina/I-5432-2015; Minichiello, Liliana/AAA-7190-2022	Wolfer, David P/0000-0002-5957-1401; Klein, Ruediger/0000-0002-3109-0163; ROSSI-ARNAUD, Clelia/0000-0001-5006-6583; Gnesutta, Nerina/0000-0002-2465-8881; Cestari, Vincenzo/0000-0002-9623-157X; Grant, Seth/0000-0001-8732-8735; Brambilla, Riccardo/0000-0003-3569-5706	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAHILL L, 1990, BEHAV NEUROSCI, V104, P532, DOI 10.1037/0735-7044.104.4.532; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHAPMAN PF, 1992, SYNAPSE, V11, P310, DOI 10.1002/syn.890110406; CHAPMAN PF, 1990, SYNAPSE, V6, P271, DOI 10.1002/syn.890060306; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Maren S, 1996, NEURON, V16, P237, DOI 10.1016/S0896-6273(00)80041-0; Marshall C., 1995, GUIDEBOOK SMALL GTPA, P65; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Martinez JL, 1996, ANNU REV PSYCHOL, V47, P173, DOI 10.1146/annurev.psych.47.1.173; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MAYFORD M, 1995, CURR OPIN NEUROBIOL, V5, P141, DOI 10.1016/0959-4388(95)80019-0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; OLTON DS, 1978, BRAIN RES, V139, P215; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Plass C, 1996, NAT GENET, V14, P106, DOI 10.1038/ng0996-106; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SCHUTZ RA, 1979, PHYSIOL BEHAV, V23, P97, DOI 10.1016/0031-9384(79)90128-8; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Sturani E, 1997, EXP CELL RES, V235, P117, DOI 10.1006/excr.1997.3660; WATANABE Y, 1995, NEUROSCI RES, V21, P317, DOI 10.1016/0168-0102(94)00867-F; ZIPPEL R, 1997, MOL BRAIN RES, V48, P140; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	30	389	399	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					281	286		10.1038/36849	http://dx.doi.org/10.1038/36849			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384379				2022-12-28	WOS:A1997YG66700062
J	Green, DR				Green, DR			Apoptosis - A Myc-induced apoptosis pathway surfaces	SCIENCE			English	Editorial Material							T-CELL HYBRIDOMAS; ACTIVATION-INDUCED APOPTOSIS; C-MYC; FAS CD95; DEATH; FIBROBLASTS; PROTEIN; BCL-2; ALPHA; MAX				Green, DR (corresponding author), LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,SAN DIEGO,CA 92121, USA.		Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; BISSONNETTE RP, 1994, J EXP MED, V180, P2413, DOI 10.1084/jem.180.6.2413; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Houghton JA, 1997, P NATL ACAD SCI USA, V94, P8144, DOI 10.1073/pnas.94.15.8144; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Packham G, 1995, Curr Top Microbiol Immunol, V194, P283; SCHAUB LBO, 1995, MOL CELL BIOL, V15, P3032; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; ZORNIG M, 1995, ONCOGENE, V10, P2397	26	44	46	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1246	1247		10.1126/science.278.5341.1246	http://dx.doi.org/10.1126/science.278.5341.1246			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9411752				2022-12-28	WOS:A1997YG04300033
J	Wu, Y; Kuzma, J; Marechal, E; Graeff, R; Lee, HC; Foster, R; Chua, NH				Wu, Y; Kuzma, J; Marechal, E; Graeff, R; Lee, HC; Foster, R; Chua, NH			Abscisic acid signaling through cyclic ADP-Ribose in plants	SCIENCE			English	Article							SEA-URCHIN EGGS; ARABIDOPSIS-THALIANA; CA2+ RELEASE; INOSITOL TRISPHOSPHATE; TRANSDUCTION PATHWAYS; PROTEIN PHOSPHATASE; TRANSGENIC PLANTS; CYTOSOLIC CA-2+; GUARD-CELLS; EXPRESSION	Abscisic acid (ABA) is the primary hormone that mediates plant responses to stresses such as cold, drought, and salinity. Single-cell microinjection experiments in tomato were used to identify possible intermediates involved in ABA signal transduction. Cyclic ADP-ribose (cADPR) was identified as a signaling molecule in the ABA response and Mras shown to exert its effects by way of calcium. Bioassay experiment is showed that the amounts of cADPR in Arabidopsis thaliana plants increased in response to ABA treatment and before ASA-induced gene expression.	ROCKEFELLER UNIV, PLANT MOL BIOL LAB, NEW YORK, NY 10021 USA; UNIV MINNESOTA, DEPT PHYSIOL, MINNEAPOLIS, MN 55455 USA	Rockefeller University; University of Minnesota System; University of Minnesota Twin Cities			Lee, Hon Cheung/C-4329-2009; Graeff, Richard Milton/B-3425-2011	Kuzma, Jennifer/0000-0003-4456-9613	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; [Anonymous], UNPUB; Barnes SA, 1996, PLANT CELL, V8, P601, DOI 10.1105/tpc.8.4.601; BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOWLER C, 1994, GENE DEV, V8, P2188, DOI 10.1101/gad.8.18.2188; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BOWLER C, 1994, CELL, V79, P743; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CHANDLER PM, 1994, ANNU REV PLANT PHYS, V45, P113, DOI 10.1146/annurev.pp.45.060194.000553; CHANG YC, 1991, PLANT PHYSIOL, V97, P1260, DOI 10.1104/pp.97.3.1260; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; deBruxelles GL, 1996, PLANT PHYSIOL, V111, P381, DOI 10.1104/pp.111.2.381; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GIRAUDAT J, 1994, PLANT MOL BIOL, V26, P1557, DOI 10.1007/BF00016490; Hey SJ, 1997, PLANTA, V202, P85, DOI 10.1007/s004250050106; HIRAYAMA T, 1995, P NATL ACAD SCI USA, V92, P3903, DOI 10.1073/pnas.92.9.3903; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; JEFFERSON RA, 1987, EMBO J, V6, P3901; KEARNS EV, 1993, PLANT PHYSIOL, V102, P711, DOI 10.1104/pp.102.3.711; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; Knetsch MLW, 1996, PLANT CELL, V8, P1061, DOI 10.1105/tpc.8.6.1061; Kuo AL, 1996, PLANT CELL, V8, P259, DOI 10.1105/tpc.8.2.259; KURKELA S, 1992, PLANT MOL BIOL, V19, P689, DOI 10.1007/BF00026794; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; Lee HC, 1996, BIOL SIGNAL, V5, P101; LEE HC, 1991, J BIOL CHEM, V266, P2276; LEE HC, 1995, RYANODINE RECEPTORS, P31; Lee YS, 1996, PLANT PHYSIOL, V110, P987, DOI 10.1104/pp.110.3.987; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Masuda W, 1997, FEBS LETT, V405, P104, DOI 10.1016/S0014-5793(97)00168-3; MCAINSH MR, 1990, NATURE, V343, P186, DOI 10.1038/343186a0; Merlot S, 1997, PLANT PHYSIOL, V114, P751, DOI 10.1104/pp.114.3.751; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; Muir SR, 1996, FEBS LETT, V395, P39, DOI 10.1016/0014-5793(96)01000-9; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; NEUHAUS G, 1994, CELL, V79, P743; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; Pei ZM, 1997, PLANT CELL, V9, P409, DOI 10.1105/tpc.9.3.409; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; SCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9535, DOI 10.1073/pnas.92.21.9535; SCHROEDER JI, 1990, P NATL ACAD SCI USA, V87, P9305, DOI 10.1073/pnas.87.23.9305; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; Terry MJ, 1996, J BIOL CHEM, V271, P21681, DOI 10.1074/jbc.271.35.21681; THOMASHOW MF, 1994, ARABIDOPSIS, P807, DOI DOI 10.1101/0.807-834; VASIL V, 1995, PLANT CELL, V7, P1511, DOI 10.1105/tpc.7.9.1511; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; Wu Y, 1996, PLANT J, V10, P1149, DOI 10.1046/j.1365-313X.1996.10061149.x; YAMAGUCHISHINOZAKI K, 1993, MOL GEN GENET, V236, P331, DOI 10.1007/BF00277130	56	307	345	2	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2126	2130		10.1126/science.278.5346.2126	http://dx.doi.org/10.1126/science.278.5346.2126			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405349				2022-12-28	WOS:A1997YM23500054
J	Meehan, TP; Fine, MJ; Krumholz, HM; Scinto, JD; Galusha, DH; Mockalis, JT; Weber, GF; Petrillo, MK; Houck, PM; Fine, JM				Meehan, TP; Fine, MJ; Krumholz, HM; Scinto, JD; Galusha, DH; Mockalis, JT; Weber, GF; Petrillo, MK; Houck, PM; Fine, JM			Quality of care, process, and outcomes in elderly patients with pneumonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; MEDICARE PATIENTS; HEALTH-CARE; SEVERITY; THERAPY	Context.-Pneumonia is a frequent cause of hospitalization and death among elderly patients, but the relationships between processes of care for pneumonia and outcomes are uncertain, making quality improvement a challenge. Objectves.-To assess quality of care for Medicare patients hospitalized with pneumonia and to determine whether process of care performance is associated with lower 30-day mortality. Design.-Multicenter retrospective cohort study with medical record review. Setting.-A total of 3555 acute care hospitals throughout the United States. Patients.-A total of 14069 patients at least 65 years old hospitalized with pneumonia. Main Outcome Measures.-Four processes of care: time from hospital arrival to initial antibiotic administration; blood culture collection before initial hospital antibiotics; blood culture collection within 24 hours of hospital arrival; and oxygenation assessment within 24 hours of hospital arrival. Associations between processes of care and 30-day mortality were determined with logistic regression analysis. Results.-National estimates of process-of-care performance were antibiotic administration within 8 hours of hospital arrival, 75.5% (95% confidence interval [CI], 73.1-77.9); blood cultures before antibiotics, 57.3% (95% CI, 54.5-60.1); initial blood culture collection, 68.7% (95% CI, 66.2-71.2); and initial oxygenation assessment, 89.3% (95% CI, 87.5-90.9). Lower 30-day mortality was associated with antibiotic administration within 8 hours of hospital arrival (odds ratio [OR], 0.85; 95% CI, 0.75-0.96) and blood culture collection within 24 hours of arrival (OR, 0.90; 95% CI, 0.81-1.00). State and territory performance estimates varied from 49.0% to 89.7% for antibiotics given within 8 hours and from 45.6% to 82.6% for blood cultures drawn within 24 hours. Conclusions-Administering antibiotics within 8 hours of hospital arrival and collecting blood cultures within 24 hours were associated with improved survival. The fact that states varied widely in the performance of these measures suggests that opportunities exist to improve hospital care of elderly patients with pneumonia.	CONNECTICUT PEER REVIEW OGR,MIDDLETOWN,CT; HLTH CARE FINANCING ADM,REG 10,SEATTLE,WA; UNIV PITTSBURGH,CTR RES HLTH CARE,PITTSBURGH,PA; UNIV PITTSBURGH,DIV GEN INTERNAL MED,PITTSBURGH,PA; YALE UNIV,SCH MED,DEPT MED,SECT CARDIOVASC MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,SECT CHRON DIS EPIDEMIOL,NEW HAVEN,CT 06510; YALE NEW HAVEN MED CTR,CTR OUTCOMES RES & EVALUAT,NEW HAVEN,CT 06504; NORWALK HOSP,PULM & CRIT CARE MED SECT,NORWALK,CT 06856	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Yale University; Yale University; Yale University			, Harlan/AAI-2875-2020		PHS HHS [500-96-P549] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P535; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; FINE JM, 1996, AM J RESP CRIT CARE, V153, pA756; FINE MJ, 1993, MED CARE, V31, P371, DOI 10.1097/00005650-199304000-00008; FINE MJ, 1995, J GEN INTERN MED, V10, P359, DOI 10.1007/BF02599830; FINE MJ, 1993, AM J MED, V94, P153, DOI 10.1016/0002-9343(93)90177-Q; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; FINE MJ, 1996, JAMA-J AM MED ASSOC, V275, P194; HAND R, 1994, AM J MED SCI, V307, P329, DOI 10.1097/00000441-199405000-00003; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; *HLTH CAR FIN ADM, 1996, INP MAN PNEUM MED BE; *HLTH CAR FIN ADM, 1995, 03364 HCFA US DEP HL, P75; HOSMER DW, 1989, APPL LOGISTIC REGRES; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KAHN KL, 1990, JAMA-J AM MED ASSOC, V264, P1969, DOI 10.1001/jama.264.15.1969; LANDWEHR J, 1984, J AM STAT ASSOC, V76, P61; McGarvey R N, 1993, QRB Qual Rev Bull, V19, P124; MCMAHON LF, 1989, MED CARE, V27, P623, DOI 10.1097/00005650-198906000-00005; *NAT CTR HLTH STAT, 1993, VIT HLTH STAT, V13, P6; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; Roos N P, 1988, Health Care Financ Rev, V9, P53; *US PHS, 1988, INT CLASS DIS 9 REV; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WHITTLE J, 1996, J GEN INTERN MED S, V11, pA93	27	666	686	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2080	2084		10.1001/jama.278.23.2080	http://dx.doi.org/10.1001/jama.278.23.2080			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403422				2022-12-28	WOS:A1997YK98700037
J	Tugwell, P; Dennis, DT; Weinstein, A; Wells, G; Nichol, G; Shea, B; Hayward, R; Lightfoot, R; Baker, P; Steere, AC				Tugwell, P; Dennis, DT; Weinstein, A; Wells, G; Nichol, G; Shea, B; Hayward, R; Lightfoot, R; Baker, P; Steere, AC			Guidelines for laboratory evaluation in the diagnosis of Lyme disease	ANNALS OF INTERNAL MEDICINE			English	Article									Amer Coll Physicians, Philadelphia, PA 19106 USA	American College of Physicians	Tugwell, P (corresponding author), Amer Coll Physicians, Independence Mall W,6th St Race, Philadelphia, PA 19106 USA.		Baker, Philip R A/J-1109-2012; Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556					0	76	77	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1106	1108		10.7326/0003-4819-127-12-199712150-00011	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412315				2022-12-28	WOS:000070936600009
J	Century, KS; Shapiro, AD; Repetti, PP; Dahlbeck, D; Holub, E; Staskawicz, BJ				Century, KS; Shapiro, AD; Repetti, PP; Dahlbeck, D; Holub, E; Staskawicz, BJ			NDR1, a pathogen-induced component required for Arabidopsis disease resistance	SCIENCE			English	Article							LEUCINE-RICH REPEAT; ARTIFICIAL CHROMOSOME LIBRARY; PERONOSPORA-PARASITICA; YAC LIBRARY; THALIANA; GENE; IDENTIFICATION; TOMATO; LOCUS; CONSTRUCTION	Plant disease resistance (R) genes confer an ability to resist infection by pathogens expressing specific corresponding avirulence genes. In Arabidopsis thaliana, resistance to both bacterial and fungal pathogens, mediated by several R gene products, requires the NDR1 gene. Positional cloning was used to isolate NDR1, which encodes a 660-base pair open reading frame. The predicted 219-amino acid sequence suggests that NDR1 may be associated with a membrane. NDR1 expression is induced in response to pathogen challenge and may function to integrate various pathogen recognition signals.	UNIV CALIF BERKELEY, DEPT PLANT & MICROBIAL BIOL, BERKELEY, CA 94720 USA; HORT RES INT, DEPT PLANT PATHOL & WEED SCI, WELLESBOURNE CV35 9EF, WARWICK, ENGLAND	University of California System; University of California Berkeley; University of Warwick								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; CENTURY KS, 1995, P NATL ACAD SCI USA, V92, P6597, DOI 10.1073/pnas.92.14.6597; CREUSOT F, 1995, PLANT J, V8, P763, DOI 10.1046/j.1365-313X.1995.08050763.x; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Freialdenhoven A, 1996, PLANT CELL, V8, P5, DOI 10.1105/tpc.8.1.5; Gopalan S, 1996, PLANT J, V10, P591, DOI 10.1046/j.1365-313X.1996.10040591.x; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HOLUB EB, 1994, MOL PLANT MICROBE IN, V7, P223, DOI 10.1094/MPMI-7-0223; JORGENSEN RA, 1987, PLANT MOL BIOL, V8, P3, DOI 10.1007/BF00016429; KARRER EE, IN PRESS PLANT MOL B; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; KUNKEL BN, 1993, PLANT CELL, V5, P865, DOI 10.1105/tpc.5.8.865; Parker JE, 1996, PLANT CELL, V8, P2033, DOI 10.1105/tpc.8.11.2033; PONGOR S, 1994, NUCLEIC ACIDS RES, V22, P3610; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; SCHMIDT R, 1992, AUST J PLANT PHYSIOL, V19, P341, DOI 10.1071/PP9920341; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WHALEN MC, 1988, P NATL ACAD SCI USA, V85, P6743, DOI 10.1073/pnas.85.18.6743; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49	29	282	308	3	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 12	1997	278	5345					1963	1965		10.1126/science.278.5345.1963	http://dx.doi.org/10.1126/science.278.5345.1963			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395402				2022-12-28	WOS:A1997YL00200040
J	Chen, WB; Kelly, MA; OpitzAraya, X; Thomas, RE; Low, MJ; Cone, RD				Chen, WB; Kelly, MA; OpitzAraya, X; Thomas, RE; Low, MJ; Cone, RD			Exocrine gland dysfunction in MC5-R-deficient mice: Evidence for coordinated regulation of exocrine gland function by melanocortin peptides	CELL			English	Article							MELANOCYTE-STIMULATING HORMONE; RAT LACRIMAL GLAND; MOLECULAR-CLONING; HARDERIAN-GLAND; ALPHA-MSH; MALE-MOUSE; RECEPTOR; EXPRESSION; SECRETION; SYSTEM	The effects of pituitary-derived melanocortin peptides are primarily attributed to ACTH-mediated adrenocortical glucocorticoid production. Identification of a widely distributed receptor for ACTH/MSH peptides, the melanocortin-5 receptor (MC5-R), suggested non-steroidally mediated systemic effects of these peptides. Targeted disruption of the MC5-R produced mice with a severe defect in water repulsion and thermoregulation due to decreased production of sebaceous lipids. High levels of MC5-R was found in multiple exocrine tissues, including Harderian, preputial, lacrimal, and sebaceous glands, and was also shown to be required for production and stress-regulated synthesis of porphyrins by the Harderian gland and ACTH/MSH-regulated protein secretion by the lacrimal gland. These data show a requirement for the MC5-R in multiple exocrine glands for the production of numerous products, indicative of a coordinated system for regulation of exocrine gland function by melanocortin peptides.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA	Oregon Health & Science University			Chen, Wenbiao/ABG-1276-2020	Chen, Wenbiao/0000-0002-0750-8275; Low, Malcolm/0000-0002-9900-3708; Kelly, Michele/0000-0003-1799-055X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD030236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042415] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42415] Funding Source: Medline; NICHD NIH HHS [HD30236] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABEL EL, 1994, HORM BEHAV, V28, P139, DOI 10.1006/hbeh.1994.1011; ABEL EL, 1992, PSYCHONEUROENDOCRINO, V17, P255, DOI 10.1016/0306-4530(92)90065-F; BARRETT P, 1994, J MOL ENDOCRINOL, V12, P203, DOI 10.1677/jme.0.0120203; BIJLSMA WA, 1983, EUR J PHARMACOL, V92, P231, DOI 10.1016/0014-2999(83)90291-1; BOTELHO SY, 1973, AM J PHYSIOL, V224, P1119, DOI 10.1152/ajplegacy.1973.224.5.1119; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONSON FH, 1971, J REPROD FERTIL, V25, P279; BUCKLEY DI, 1981, P NATL ACAD SCI-BIOL, V78, P7431, DOI 10.1073/pnas.78.12.7431; CARR WJ, 1970, J COMP PHYSIOL PSYCH, V71, P223, DOI 10.1037/h0029164; CATANIA A, 1993, ENDOCR REV, V14, P564, DOI 10.1210/er.14.5.564; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; COSSU G, 1989, DEV BIOL, V131, P331, DOI 10.1016/S0012-1606(89)80006-5; DARTT DA, 1994, ADV EXP MED BIOL, V350, P1; EBLING FJ, 1969, J ENDOCRINOL, V45, P257, DOI 10.1677/joe.0.0450257; EBLING FJ, 1974, J INVEST DERMATOL, V62, P161, DOI 10.1111/1523-1747.ep12676781; EBLING FJ, 1975, J ENDOCRINOL, V66, P407, DOI 10.1677/joe.0.0660407; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; FENG JD, 1987, BRAIN RES BULL, V18, P473, DOI 10.1016/0361-9230(87)90111-0; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1994, BIOCHEM BIOPH RES CO, V200, P1214, DOI 10.1006/bbrc.1994.1580; GANTZ I, 1993, J BIOL CHEM, V268, P8246; GOOLAMALI SK, 1974, J INVEST DERMATOL, V63, P253, DOI 10.1111/1523-1747.ep12680076; GRIFFON N, 1994, BIOCHEM BIOPH RES CO, V200, P1007, DOI 10.1006/bbrc.1994.1550; GRUBER KA, 1989, AM J PHYSIOL, V257, pR681, DOI 10.1152/ajpregu.1989.257.4.R681; HARLOW HJ, 1984, PHYSIOL ZOOL, V57, P349, DOI 10.1086/physzool.57.3.30163724; Huang QH, 1997, J NEUROSCI, V17, P3343; JAHN R, 1982, EUR J BIOCHEM, V126, P623, DOI 10.1111/j.1432-1033.1982.tb06826.x; LABBE O, 1994, BIOCHEMISTRY-US, V33, P4543, DOI 10.1021/bi00181a015; LEEMAN SE, 1967, ENDOCRINOLOGY, V81, P803, DOI 10.1210/endo-81-4-803; LEIBA H, 1990, EUR J PHARMACOL, V181, P71, DOI 10.1016/0014-2999(90)90246-3; Li SJ, 1996, J NEUROSCI, V16, P5182; MACALUSO A, 1994, J NEUROSCI, V14, P2377; MARGOLIS FL, 1971, ARCH BIOCHEM BIOPHYS, V145, P373, DOI 10.1016/0003-9861(71)90050-6; Mogil Jefrey S., 1996, Physiology and Behavior, V59, P123, DOI 10.1016/0031-9384(95)02073-X; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; NOWELL NW, 1980, PHYSIOL BEHAV, V24, P5, DOI 10.1016/0031-9384(80)90006-2; ORSULAK PJ, 1972, BIOL REPROD, V6, P219, DOI 10.1093/biolreprod/6.2.219; PAWELEK JM, 1976, J INVEST DERMATOL, V66, P201, DOI 10.1111/1523-1747.ep12482134; PAYNE AP, 1994, J ANAT, V185, P1; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SCHAUER E, 1994, J CLIN INVEST, V93, P2258, DOI 10.1172/JCI117224; SIEGRIST W, 1989, CANCER RES, V49, P6352; SMOCK T, 1981, BRAIN RES, V212, P202, DOI 10.1016/0006-8993(81)90052-4; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Spike R.C., 1992, HARDERIAN GLANDS POR, P165; STEWART ME, 1991, ADV LIPID RES, V24, P263; Strand F L, 1993, Rev Neurosci, V4, P321; TATRO JB, 1987, ENDOCRINOLOGY, V121, P1900, DOI 10.1210/endo-121-5-1900; TATRO JB, 1990, BRAIN RES, V536, P124, DOI 10.1016/0006-8993(90)90016-5; THIESSEN DD, 1980, PHYSIOL BEHAV, V24, P417, DOI 10.1016/0031-9384(80)90229-2; THODY AJ, 1983, PHYSIOL BEHAV, V31, P67, DOI 10.1016/0031-9384(83)90097-5; THODY AJ, 1973, NATURE, V245, P207, DOI 10.1038/245207a0; THODY AJ, 1976, J ENDOCRINOL, V71, P279, DOI 10.1677/joe.0.0710279; VALENTA JG, 1968, SCIENCE, V161, P599, DOI 10.1126/science.161.3841.599; WATSON SJ, 1979, EUR J PHARMACOL, V58, P101, DOI 10.1016/0014-2999(79)90351-0; WETTERBERG L, 1970, SCIENCE, V168, P996, DOI 10.1126/science.168.3934.996; YU JH, 1983, P SOC EXP BIOL MED, V173, P467	61	397	426	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 12	1997	91	6					789	798		10.1016/S0092-8674(00)80467-5	http://dx.doi.org/10.1016/S0092-8674(00)80467-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413988	Bronze			2022-12-28	WOS:A1997YL43900010
J	Riehle, A; Grun, S; Diesmann, M; Aertsen, A				Riehle, A; Grun, S; Diesmann, M; Aertsen, A			Spike synchronization and rate modulation differentially involved in motor cortical function	SCIENCE			English	Article							VISUAL-CORTEX; BEHAVING MONKEYS; AUDITORY-CORTEX; CELL ASSEMBLIES; FRONTAL-CORTEX; NEURAL-NETWORK; MOVEMENT; OSCILLATIONS; DIRECTION; CAT	It is now commonly accepted that planning and execution of movements are based on distributed processing by neuronal populations in motor cortical areas. It is less clear, though, how these populations organize dynamically to cope with the momentary computational demands. Simultaneously recorded activities of neurons in the primary motor cortex of monkeys during performance of a delayed-pointing task exhibited context-dependent, rapid changes in the patterns of coincident action potentials. Accurate spike synchronization occurred in relation tcr external events (stimuli, movements) and was commonly accompanied by discharge rate modulations but without precise time locking of the spikes to these external events. Spike synchronization also occurred in relation to purely internal events (stimulus expectancy), where firing rate modulations were distinctly absent. These findings indicate ?hat internally generated synchronization of individual spike discharges may subserve the cortical organization of cognitive motor processes.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT PHYSIOL,IL-91120 JERUSALEM,ISRAEL; UNIV FREIBURG,INST BIOL 3,DEPT NEUROBIOL & BIOPHYS,D-79104 FREIBURG,GERMANY	Hebrew University of Jerusalem; University of Freiburg	Riehle, A (corresponding author), CNRS,CTR RES COGNIT NEUROSCI,31 CHEMIN JOSEPH AIGUIER,F-13402 MARSEILLE 20,FRANCE.		Diesmann, Markus/H-3722-2013; Grün, Sonja/I-6321-2013	Diesmann, Markus/0000-0002-2308-5727; Grün, Sonja/0000-0003-2829-2220				ABELES M, 1982, ISRAEL J MED SCI, V18, P83; ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; Abeles M., 1982, LOCAL CORTICAL CIRCU; Abeles M., 1991, CORTICONICS; AERTSEN A, 1991, J HIRNFORSCH, V32, P735; AERTSEN AMHJ, 1985, BRAIN RES, V340, P341, DOI 10.1016/0006-8993(85)90931-X; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; AHISSAR M, 1992, J NEUROPHYSIOL, V67, P203, DOI 10.1152/jn.1992.67.1.203; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; BRLOW HB, 1992, INFORMATION PROCESSI, P169; deCharms RC, 1996, NATURE, V381, P610, DOI 10.1038/381610a0; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; EGGERMONT JJ, 1994, J NEUROPHYSIOL, V71, P246, DOI 10.1152/jn.1994.71.1.246; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; GEORGOPOULOS AP, 1993, SCIENCE, V260, P47, DOI 10.1126/science.8465199; GERSTEIN GL, 1989, IEEE T BIO-MED ENG, V36, P4, DOI 10.1109/10.16444; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GRUN S, 1996, UNITARY JOINT EVENTS; HEBB DO, 1949, ORG BEHAVIOR; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; HUMPHREY DR, 1970, SCIENCE, V170, P758, DOI 10.1126/science.170.3959.758; LUKASHIN AV, 1990, BIOL CYBERN, V63, P377, DOI 10.1007/BF00202754; LUKASHIN AV, 1993, BIOL CYBERN, V69, P517, DOI 10.1007/BF01185423; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; MOUNTCASTLE VB, 1991, J NEUROSCI METH, V36, P77, DOI 10.1016/0165-0270(91)90140-U; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; MUSSAIVALDI FA, 1988, NEUROSCI LETT, V91, P106, DOI 10.1016/0304-3940(88)90257-1; National Institutes of Health, NIH GUID CAR US LAB, V80-23; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; PALM G, 1988, BIOL CYBERN, V5, P1; Palm G, 1990, CONC NEUROSCI, V1, P133; Requin J., 1991, HDB COGNITIVE PSYCHO, P357; RIEHLE A, 1989, J NEUROPHYSIOL, V61, P534, DOI 10.1152/jn.1989.61.3.534; Riehle A., 1996, Artificial Neural Networks - ICANN 96. 1996 International Conference Proceedings, P673; Riehle A., 1995, Society for Neuroscience Abstracts, V21, P2077; RIEHLE A, 1995, SUPERCOMPUTERS BRAIN, P281; Roelfsema PR, 1996, J COGNITIVE NEUROSCI, V8, P603, DOI 10.1162/jocn.1996.8.6.603; Sakurai Y, 1996, NEUROSCI RES, V26, P1; SANES JN, 1993, P NATL ACAD SCI USA, V90, P4470, DOI 10.1073/pnas.90.10.4470; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SOFTKY WR, 1993, J NEUROSCI, V13, P334; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; VONDERMALSBURG C, 1981, 812 MAX PLANCK I; WICKENS J, 1994, J MOTOR BEHAV, V26, P66, DOI 10.1080/00222895.1994.9941663	48	697	703	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1950	1953		10.1126/science.278.5345.1950	http://dx.doi.org/10.1126/science.278.5345.1950			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395398				2022-12-28	WOS:A1997YL00200036
J	Knowlton, JR; Johnston, SC; Whitby, FG; Realini, C; Zhang, ZG; Rechsteiner, M; Hill, CP				Knowlton, JR; Johnston, SC; Whitby, FG; Realini, C; Zhang, ZG; Rechsteiner, M; Hill, CP			Structure of the proteasome activator REG alpha (PA28 alpha)	NATURE			English	Article							PROTEIN-DEGRADATION; 20S PROTEASOME; MULTICATALYTIC PROTEASE; 20-S PROTEASOME; REGULATOR PA28; PURIFICATION	The specificity of the 20S proteasome, which degrades many intracellular proteins, is regulated by protein complexes that bind to one or both ends of the cylindrical proteasome structure(1-5). One of these regulatory complexes, the 11S regulator (known as REG or PA28), stimulates proteasome peptidase activity(6,7) and enhances the production of antigenic peptides for presentation by class I molecules of the major histocompatibility complex (MHC)(8,9). The three REG subunits that have been identified REG alpha, REG beta and REG gamma (also known as the Ki antigen).	UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah								AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1996, XPLOR VERSION 3 843; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hoffman L, 1996, CURR TOP CELL REGUL, V34, P1, DOI 10.1016/S0070-2137(96)80001-X; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Johnston SC, 1997, PROTEIN SCI, V6, P2469; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1993, J BIOL CHEM, V268, P22514; MA CP, 1992, J BIOL CHEM, V267, P10515; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; REALINI C, 1994, J BIOL CHEM, V269, P20727; Song XL, 1996, J BIOL CHEM, V271, P26410, DOI 10.1074/jbc.271.42.26410; USTRELL V, 1995, FEBS LETT, V376, P155, DOI 10.1016/0014-5793(95)01257-9; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199	30	147	150	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 11	1997	390	6660					639	643		10.1038/37670	http://dx.doi.org/10.1038/37670			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403698				2022-12-28	WOS:A1997YK85300058
J	Huston, DP				Huston, DP			The biology of the immune system	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CELL ANTIGEN RECEPTOR; HUMAN B-CELLS; BETA-T-CELLS; 3-DIMENSIONAL STRUCTURE; BINDING-SITE; HISTOCOMPATIBILITY ANTIGEN; RHEUMATOID-ARTHRITIS; IMMUNOGLOBULIN-A; MESSENGER-RNAS; CD28 RECEPTOR	Intact immunity is fundamental for survival. The human immune system has evolved with the sophisticated biologic capacity to distinguish self from nonself and for memory through the process of clonal expansion. The ability to distinguish even subtle differences from self, and among myriad antigens, is possible by the rearrangement of genes that encode immunoglobulins and T-cell receptors, as well as by the requirement for T cells to recognize antigens in the context of presentation by HLA molecules encoded within the major histocompatibility complex. Modulation of immune function initiated by antigenic stimulation and cell-cell interactions is facilitated by a plethora of soluble mediators such as cytokines. This overview of the biology of the immune system provides a framework for understanding physiologic immune responses and how lacunar defects within the immune system explain the pathogenesis of immunologic disorders. Through such understanding, potential targets can be identified for therapeutic modulation of the immune system.			Huston, DP (corresponding author), BAYLOR COLL MED, 1 BAYLOR PLAZA, FBRN B567, 6565 FANNIN ST, HOUSTON, TX 77030 USA.			Huston, David/0000-0002-2332-0010				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; AGER A, 1997, IMMUNOL TODAY, V1, P1; ALT FW, 1980, CELL, V20, P293, DOI 10.1016/0092-8674(80)90615-7; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; ARMITAGE RJ, 1993, J IMMUNOL, V150, P3671; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BANCHEREAU J, 1992, ADV IMMUNOL, V52, P125, DOI 10.1016/S0065-2776(08)60876-7; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BERLINER S, 1981, SCAND J RHEUMATOL, V10, P280, DOI 10.3109/03009748109095315; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1989, COLD SH Q B, V54, P365; Bjorkman PJ, 1997, CELL, V89, P167, DOI 10.1016/S0092-8674(00)80195-6; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; BREWERTON DA, 1973, LANCET, V1, P904; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DAVIES DR, 1975, ANNU REV BIOCHEM, V44, P639, DOI 10.1146/annurev.bi.44.070175.003231; DAVIS MM, 1990, ANNU REV BIOCHEM, V59, P475, DOI 10.1146/annurev.biochem.59.1.475; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143; Defranco Anthony L., 1993, P505; DEXTER TM, 1987, ANNU REV CELL BIOL, V3, P423; DORMAN JS, 1990, P NATL ACAD SCI USA, V87, P7370, DOI 10.1073/pnas.87.19.7370; DRAKE CG, 1992, J CLIN IMMUNOL, V12, P149, DOI 10.1007/BF00918083; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Ferguson TA, 1997, J CLIN IMMUNOL, V17, P1, DOI 10.1023/A:1027343210080; FIGUEROA JE, 1991, CLIN MICROBIOL REV, V4, P359, DOI 10.1128/CMR.4.3.359-395.1991; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; Frank S J, 1991, Semin Immunol, V3, P299; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GLASS D, 1976, J CLIN INVEST, V58, P853, DOI 10.1172/JCI108538; GOODMAN JW, 1994, BASIC CLIN IMMUNOL, P58; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; Haynes B F, 1990, Semin Immunol, V2, P67; HAYNES BF, 1989, IMMUNOL TODAY, V10, P87, DOI 10.1016/0167-5699(89)90232-6; HUSTON DP, 1991, J ALLERGY CLIN IMMUN, V87, P1, DOI 10.1016/0091-6749(91)90203-Z; HUSTON DP, 1992, MED CLIN N AM, V76, P805, DOI 10.1016/S0025-7125(16)30327-3; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JERNE NK, 1984, IMMUNOL REV, V79, P5, DOI 10.1111/j.1600-065X.1984.tb00484.x; JULIUS M, 1993, IMMUNOL TODAY, V14, P177; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; KISHIMOTO TK, 1992, INFLAMMATION BASIC P, P353; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KRUISBEEK AM, 1993, CURR OPIN IMMUNOL, V5, P227, DOI 10.1016/0952-7915(93)90009-H; LEBMAN DA, 1990, P NATL ACAD SCI USA, V87, P3962, DOI 10.1073/pnas.87.10.3962; Leonard WJ, 1996, J INVEST MED, V44, P304; LEWIS D, 1996, CLIN IMMUNOLOGY PRIN, V1, P15; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; MACLEAN L, 1992, ANN RHEUM DIS, V51, P929, DOI 10.1136/ard.51.8.929; MICELI MC, 1993, ADV IMMUNOL, V53, P59, DOI 10.1016/S0065-2776(08)60498-8; MOLLER G, 1993, IMMUNOL REV, V132, P1; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; MOSMANN T, 1996, CLIN IMMUNOLOGY PRIN, P217; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NELSON D, 1989, IMMUNOLOGICAL DISORD, P15; NEPOM GT, 1989, ARTHRITIS RHEUM, V32, P15, DOI 10.1002/anr.1780320104; NIKOLICZUGIC J, 1991, IMMUNOL TODAY, V12, P65, DOI 10.1016/0167-5699(91)90160-U; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PARHAM P, 1987, IMMUNOBIOLOGY HLA, V2, P10; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.iy.10.040192.000525; RODGERS JR, 1996, CLIN IMMUNOLOGY PRIN, P114; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SIEGEL JN, 1996, CLIN IMMUNOLOGY PRIN, V1, P192; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; SILVERTON EW, 1977, P NATL ACAD SCI USA, V74, P5140, DOI 10.1073/pnas.74.11.5140; SKOSKIEWICZ MJ, 1985, J EXP MED, V162, P1645, DOI 10.1084/jem.162.5.1645; SMITH CW, 1996, CLIN IMMUNOLOGY PRIN, P176; STEINMAN L, 1993, SCI AM, V269, P106, DOI 10.1038/scientificamerican0993-106; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; TIWARI JL, 1985, HLA DISEASE ASS; TODD JA, 1987, NATURE, V329, P599, DOI 10.1038/329599a0; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; TROWSDALE J, 1991, IMMUNOL TODAY, V12, P443, DOI 10.1016/0167-5699(91)90017-N; WEISSMAN IL, 1993, SCI AM, V269, P64, DOI 10.1038/scientificamerican0993-64	90	44	47	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1804	1814		10.1001/jama.278.22.1804	http://dx.doi.org/10.1001/jama.278.22.1804			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396641				2022-12-28	WOS:A1997YK15500002
J	Wiesmann, C; Fuh, G; Christinger, HW; Eigenbrot, C; Wells, JA; deVos, AM				Wiesmann, C; Fuh, G; Christinger, HW; Eigenbrot, C; Wells, JA; deVos, AM			Crystal structure at 1.7 angstrom resolution of VEGF in complex with domain 2 of the Flt-1 receptor	CELL			English	Article							ENDOTHELIAL GROWTH-FACTOR; IMMUNOGLOBULIN SUPERFAMILY; SIGNAL-TRANSDUCTION; TYROSINE KINASE; LIGAND-BINDING; ANGIOGENESIS; IDENTIFICATION; VASCULOGENESIS; EXPRESSION; LETHALITY	Vascular endothelial growth factor (VEGF) is a homodimeric hormone that induces proliferation of endothelial cells through binding to the kinase domain receptor and the Fms-like tyrosine kinase receptor (Flt-1), the extracellular portions of which consist of seven immunoglobulin domains. We show that the second and third domains of Flt-1 are necessary and sufficient for binding VEGF with near-native affinity, and that domain 2 alone binds only 60-fold less tightly than wild-type. The crystal structure of the complex between VEGF and the second domain of Flt-1 shows domain 2 in a predominantly hydrophobic interaction with the ''poles'' of the VEGF dimer. Based on this structure and on mutational data, we present a model of VEGF bound to the first four domains of Flt-1.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech			Wells, Jim A/O-9854-2016	Wiesmann, Christian/0000-0002-4092-9880				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Barleon B, 1997, J BIOL CHEM, V272, P10382; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Christinger HW, 1996, PROTEINS, V26, P353, DOI 10.1002/(SICI)1097-0134(199611)26:3<353::AID-PROT9>3.0.CO;2-E; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V231, P596, DOI 10.1006/bbrc.1997.6156; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; FINNERTY H, 1993, ONCOGENE, V8, P2293; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HEMMINGSEN JM, 1994, PROTEIN SCI, V3, P1927, DOI 10.1002/pro.5560031104; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HUANG CC, 1991, J MOL GRAPHICS, V9, P230, DOI 10.1016/0263-7855(91)80016-S; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemmon MA, 1997, J BIOL CHEM, V272, P6311, DOI 10.1074/jbc.272.10.6311; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MERRIT EA, 1994, ACTA CRYSTALLOGR D, V53, P240; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; [No title captured]	41	410	474	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					695	704		10.1016/S0092-8674(00)80456-0	http://dx.doi.org/10.1016/S0092-8674(00)80456-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393862	Bronze			2022-12-28	WOS:A1997YH96000016
J	Fichera, ME; Roos, DS				Fichera, ME; Roos, DS			A plastid organelle as a drug target in apicomplexan parasites	NATURE			English	Article							TOXOPLASMA-GONDII; MACROLIDE ANTIBIOTICS; CLINDAMYCIN; ENCEPHALITIS; AZITHROMYCIN; INHIBITION; QUINOLONES; SPIRAMYCIN; RESISTANT; MUTANTS	Parasites of the phylum Apicomplexa include many important human and veterinary pathogens such as Plasmodium (malaria), Toxoplasma (a leading opportunistic infection associated with AIDS and congenital neurological birth defects), and Eimeria (an economically significant disease of poultry and cattle)(1-4). Recent studies have identified an unusual organelle in these parasites(5-7): a plastid that appears to have been acquired by secondary endosymbiosis of a green alga(7). Here ive show that replication of the apicomplexan plastid (apicoplast) genome in Toxoplasma gondii tachyzoites can be specifically inhibited using ciprofloxacin, and that this inhibition blocks parasite replication. Moreover, parasite death occurs with peculiar kinetics that are identical to those observed after exposure to clindamycin and macrolide antibiotics(8,9), which have been proposed to target protein synthesis in the apicoplast(9,10). Conversely, clindamycin (and functionally related compounds) immediately inhibits plastid replication upon drug application-the earliest effect so far described for these antibiotics. Our results directly link apicoplast function with parasite survival, validating this intriguing organelle as an effective target for parasiticidal drug design.	UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104	University of Pennsylvania				Roos, David Siker/0000-0001-6725-4089				ARAUJO FG, 1991, EUR J CLIN MICROBIOL, V10, P519, DOI 10.1007/BF01963942; BECKERS CJM, 1995, J CLIN INVEST, V95, P367, DOI 10.1172/JCI117665; *CDC, HLTH INF; CUNDLIFFE E, 1990, RIBOSOME, P479; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; FICHERA ME, 1995, ANTIMICROB AGENTS CH, V39, P1530, DOI 10.1128/AAC.39.7.1530; FURET YX, 1991, EUR J CLIN MICROBIOL, V10, P249, DOI 10.1007/BF01966997; Haberkorn A, 1996, PARASITOL RES, V82, P193, DOI 10.1007/s004360050094; Khan AA, 1996, ANTIMICROB AGENTS CH, V40, P1855, DOI 10.1128/AAC.40.8.1855; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; KRAJCOVIC J, 1989, ANTIMICROB AGENTS CH, V33, P1883, DOI 10.1128/AAC.33.11.1883; LANE HC, 1994, ANN INTERN MED, V120, P945, DOI 10.7326/0003-4819-120-11-199406010-00007; Le Bras Jacques, 1996, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V190, P471; LEVINE ND, 1988, J PROTOZOOL, V35, P518, DOI 10.1111/j.1550-7408.1988.tb04141.x; Lewis RJ, 1996, BIOESSAYS, V18, P661, DOI 10.1002/bies.950180810; LUFT BJ, 1993, NEW ENGL J MED, V329, P995, DOI 10.1056/NEJM199309303291403; MCCABE RE, 1989, DRUGS, V38, P973, DOI 10.2165/00003495-198938060-00008; McConkey GA, 1997, J BIOL CHEM, V272, P2046, DOI 10.1074/jbc.272.4.2046; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; PFEFFERKORN ER, 1992, ANTIMICROB AGENTS CH, V36, P1091, DOI 10.1128/AAC.36.5.1091; PFEFFERKORN ER, 1994, ANTIMICROB AGENTS CH, V38, P31, DOI 10.1128/AAC.38.1.31; PFEFFERKORN ER, 1993, J PARASITOL, V79, P559, DOI 10.2307/3283383; ROGERS MJ, 1997, RNA, V3, P1; ROIZEN N, 1995, PEDIATRICS, V95, P11; ROOS DS, 1994, METHOD CELL BIOL, V45, P28; Srivastava IK, 1997, J BIOL CHEM, V272, P3961, DOI 10.1074/jbc.272.7.3961; Vogel G, 1997, SCIENCE, V275, P1422, DOI 10.1126/science.275.5305.1422; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; YOON CK, 1997, NY TIMES        0311, pC3	30	454	472	1	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					407	409		10.1038/37132	http://dx.doi.org/10.1038/37132			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389481				2022-12-28	WOS:A1997YH54900065
J	Bennett, P; Edwards, D				Bennett, P; Edwards, D			Use of magnesium sulphate in obstetrics	LANCET			English	Editorial Material							CEREBRAL-PALSY; PRETERM LABOR; SULFATE; RISK				Bennett, P (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED, DIV PAEDIAT OBSTET & GYNAECOL, LONDON W12 0HS, ENGLAND.			Bennett, Phillip/0000-0002-6253-4919				ATKINSON MW, 1995, AM J OBSTET GYNECOL, V173, P1219, DOI 10.1016/0002-9378(95)91357-2; COTTON DB, 1984, J REPROD MED, V29, P92; deHaan HH, 1997, AM J OBSTET GYNECOL, V176, P18, DOI 10.1016/S0002-9378(97)80005-1; DULEY L, 1995, LANCET, V345, P1455; HIGBY K, 1993, AM J OBSTET GYNECOL, V168, P1247, DOI 10.1016/0002-9378(93)90376-T; LUCAS MJ, 1995, NEW ENGL J MED, V333, P201, DOI 10.1056/NEJM199507273330401; NELSON KB, 1995, PEDIATRICS, V95, P263; PANETH N, 1997, PEDIATRICS, V99, pE11; PENRICE J, 1997, PEDIATR RES, V41, P1; Schendel DE, 1996, JAMA-J AM MED ASSOC, V276, P1805, DOI 10.1001/jama.276.22.1805; Witlin AG, 1997, AM J OBSTET GYNECOL, V176, P623, DOI 10.1016/S0002-9378(97)70558-1	11	29	29	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1491	1491		10.1016/S0140-6736(05)63935-9	http://dx.doi.org/10.1016/S0140-6736(05)63935-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388392				2022-12-28	WOS:A1997YH11500003
J	Spoeri, RK; Ullman, R				Spoeri, RK; Ullman, R			Measuring and reporting managed care performance: Lessons learned and new initiatives	ANNALS OF INTERNAL MEDICINE			English	Article								Performance measurement has become increasingly popular in the health care delivery system of the United States. Until recently, the hospital was the most commonly scrutinized setting. With the expansion of managed care and the resulting compilation of large administrative databases, interest in performance measurement beyond the hospital setting has increased considerably. In particular, the performance of health maintenance organizations is now being assessed and reported publicly. The performance of individual physicians is also garnering considerable attention. This paper summarizes some of the many developments in performance measurement in managed care. The Health Plan Employer Data and Information Set (HEDIS) is described in the context of the Rational Report Card Pilot Project and with respect to local report card projects emerging around the United States, The lessons learned are identified, particularly with respect to external auditing of HEDIS data. Finally, the new initiatives of physician profiling and outcomes reporting are discussed.			Spoeri, RK (corresponding author), NYLCARE HLTH PLANS INC, 1 LIBERTY PLAZA, SUITE 8-6, NEW YORK, NY 10006 USA.							Balas EA, 1996, J GEN INTERN MED, V11, P584, DOI 10.1007/BF02599025; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; DAVIES AR, 1991, CONSUMER SATISFACTIO; Iezzoni LI, 2012, RISK ADJUSTMENT MEAS, V4th; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; Longo D R, 1994, Am J Med Qual, V9, P104, DOI 10.1177/0885713X9400900302; McGlynn EA, 1997, HEALTH AFFAIR, V16, P7, DOI 10.1377/hlthaff.16.3.7; *NAT COMM QUAL ASS, 1997, HEDIS 3 0; *NAT COMM QUAL ASS, 1993, HEDIS 2 0; *NAT COMM QUAL ASS, 1996, HEDIS 2 5; *NAT COMM QUAL ASS, 1995, REP CARD PIL PROJ TE; 1995, HLTH PAGES PITTS FAL, V18, P36	12	58	58	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				726	732		10.7326/0003-4819-127-8_Part_2-199710151-00058	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00058			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB385	9382388				2022-12-28	WOS:A1997YB38500013
J	Shirasaki, R; Katsumata, R; Murakami, F				Shirasaki, R; Katsumata, R; Murakami, F			Change in chemoattractant responsiveness of developing axons at an intermediate target	SCIENCE			English	Article							NERVOUS-SYSTEM; FLOOR PLATE; COMMISSURAL AXONS; DIRECTED GROWTH; GUIDANCE; EMBRYO; CHICK; PROJECTIONS; EXPRESSION; PROTEINS	Developing axons reach their final targets as a result of a series of axonal projections to successive intermediate targets. Long-range chemoattraction by intermediate targets plays a key role in this process. Growing axons, however, do not stall at the intermediate targets, where the chemoattractant concentration is expected to be maximal. Commissural axons in the metencephalon, initially attracted by a chemoattractant released from the floor plate, were shown to lose responsiveness to the chemoattractant when they crossed the floor plate in vitro. Such changes in axon responsiveness to chemoattractants may enable developing axons to continue to navigate toward their final destinations.	Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Neurosci Lab, Osaka 560, Japan	Osaka University	Shirasaki, R (corresponding author), Osaka Univ, Grad Sch Engn Sci, Div Biophys Engn, Neurosci Lab, Osaka 560, Japan.			Shirasaki, Ryuichi/0000-0001-8561-7023				BOLZ J, 1990, NATURE, V346, P359, DOI 10.1038/346359a0; CAMPBELL RM, 1993, DEVELOPMENT, V119, P1217; COLAMARINO SA, 1995, ANNU REV NEUROSCI, V18, P497, DOI 10.1146/annurev.ne.18.030195.002433; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Livesey FJ, 1997, MOL CELL NEUROSCI, V8, P417, DOI 10.1006/mcne.1997.0598; LUMSDEN AGS, 1986, NATURE, V323, P538, DOI 10.1038/323538a0; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MARTI E, 1995, DEVELOPMENT, V121, P2537; PHELPS PE, 1993, J COMP NEUROL, V330, P1, DOI 10.1002/cne.903300102; PLACZEK M, 1990, DEVELOPMENT, V110, P19; Richards LJ, 1997, J NEUROSCI, V17, P2445; SATO M, 1994, NEURON, V13, P791, DOI 10.1016/0896-6273(94)90246-1; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHEPHERD IT, 1995, J COMP NEUROL, V354, P501, DOI 10.1002/cne.903540403; SHIRASAKI R, 1995, NEURON, V14, P961, DOI 10.1016/0896-6273(95)90334-8; Shirasaki R, 1996, NEURON, V17, P1079, DOI 10.1016/S0896-6273(00)80241-X; SHIRASAKI R, UNPUB; TAMADA A, 1995, NEURON, V14, P1083, DOI 10.1016/0896-6273(95)90347-X; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; WOLFER DP, 1994, J COMP NEUROL, V345, P1, DOI 10.1002/cne.903450102; YAGINUMA H, 1991, J NEUROSCI, V11, P2598; YAMAMOTO M, 1986, J NEUROSCI, V6, P3576	32	149	152	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					105	107		10.1126/science.279.5347.105	http://dx.doi.org/10.1126/science.279.5347.105			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417018				2022-12-28	WOS:000071323900051
J	Schnieke, AE; Kind, AJ; Ritchie, WA; Mycock, K; Scott, AR; Ritchie, M; Wilmut, I; Colman, A; Campbell, KHS				Schnieke, AE; Kind, AJ; Ritchie, WA; Mycock, K; Scott, AR; Ritchie, M; Wilmut, I; Colman, A; Campbell, KHS			Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts	SCIENCE			English	Article							EMBRYONIC-CELL-LINES; MOUSE GENOME; COMPENDIUM; KNOCKOUTS; CHALLENGES; EXPRESSION; CATTLE; GENE; MICE	Ovine primary fetal fibroblasts were cotransfected with a neomycin resistance marker gene (neo) and a human coagulation factor IX genomic construct designed for expression of the encoded protein in sheep milk. Two cloned transfectants and a population ol neomycin (G418)-resistant cells were used as donors for nuclear transfer to enucleated oocytes. Six transgenic lambs were liveborn: Three produced from cloned cells contained factor IX and neo transgenes, whereas three produced from the uncloned population contained the marker gene only. Somatic cells can therefore be subjected to genetic manipulation in vitro and produce viable animals by nuclear transfer. Production of transgenic sheep by nuclear transfer requires fewer than half the animals needed for pronuclear microinjection.	ROSLIN INST, ROSLIN EH25 9PS, MIDLOTHIAN, SCOTLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Schnieke, AE (corresponding author), PPL THERAPEUT, ROSLIN EH25 9PP, MIDLOTHIAN, SCOTLAND.			Schnieke, Angelika/0000-0002-5761-9635				BOWEN RA, 1994, BIOL REPROD, V50, P664, DOI 10.1095/biolreprod50.3.664; BRANDON EP, 1995, CURR BIOL, V5, P873, DOI 10.1016/S0960-9822(95)00177-1; BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960-9822(95)00127-8; BRANDON EP, 1995, CURR BIOL, V5, P758, DOI 10.1016/S0960-9822(95)00152-7; BROWNLEE GG, 1987, BIOCHEM SOC T, V15, P1; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CARVER AS, 1993, BIO-TECHNOL, V11, P1263; Cibelli J. B., 1997, Theriogenology, V47, P241, DOI 10.1016/S0093-691X(97)82368-0; Damak S, 1996, BIO-TECHNOL, V14, P185, DOI 10.1038/nbt0296-185; EYESTONE WH, 1994, REPROD FERT DEVELOP, V6, P647, DOI 10.1071/RD9940647; Gerfen RW, 1995, ANIM BIOTECHNOL, V6, P1, DOI 10.1080/10495399509525828; GRIFFITHS R, 1993, MOL ECOL, V2, P405, DOI 10.1111/j.1365-294X.1993.tb00034.x; HAMMER RE, 1985, NATURE, V315, P680, DOI 10.1038/315680a0; JALLAT S, 1990, EMBO J, V9, P3295, DOI 10.1002/j.1460-2075.1990.tb07529.x; KILL IR, 1991, J CELL SCI, V100, P869; KIRKPATRICK BW, 1993, J REPROD FERTIL, V98, P335, DOI 10.1530/jrf.0.0980335; Kruip TAM, 1997, THERIOGENOLOGY, V47, P43, DOI 10.1016/S0093-691X(96)00338-X; NOTARIANNI E, 1991, J REPROD FERTIL, P255; Ramirez-Solis Ramiro, 1994, Current Opinion in Biotechnology, V5, P528, DOI 10.1016/0958-1669(94)90069-8; SHIM H, 1997, THERIOGENOLOGY, V47, P425; Stice SL, 1996, BIOL REPROD, V54, P100, DOI 10.1095/biolreprod54.1.100; Takada T, 1997, NAT BIOTECHNOL, V15, P458, DOI 10.1038/nbt0597-458; THOMPSON EM, 1995, P NATL ACAD SCI USA, V92, P1317, DOI 10.1073/pnas.92.5.1317; Walker SK, 1996, THERIOGENOLOGY, V45, P111, DOI 10.1016/0093-691X(95)00360-K; WALL RJ, 1992, THERIOGENOLOGY, V38, P337, DOI 10.1016/0093-691X(92)90239-N; Wells DN, 1997, BIOL REPROD, V57, P385, DOI 10.1095/biolreprod57.2.385; WHEELER MB, 1994, REPROD FERT DEVELOP, V6, P563, DOI 10.1071/RD9940563; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; YULL F, 1995, P NATL ACAD SCI USA, V92, P10899, DOI 10.1073/pnas.92.24.10899	30	650	849	2	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 19	1997	278	5346					2130	2133		10.1126/science.278.5346.2130	http://dx.doi.org/10.1126/science.278.5346.2130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405350				2022-12-28	WOS:A1997YM23500055
J	Woolf, SH; Lawrence, RS				Woolf, SH; Lawrence, RS			Preserving scientific debate and patient choice - Lessons from the consensus panel on mammography screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BREAST-CANCER; DECISION-MAKING; PARTICIPATE; PHYSICIANS		JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD USA	Johns Hopkins University	Woolf, SH (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT FAMILY PRACTICE, 3712 CHARLES STEWART DR, FAIRFAX, VA 22033 USA.							BEGLEY S, 1997, NEWSWEEK        0224, P55; Berwick DM, 1996, JAMA-J AM MED ASSOC, V275, P877, DOI 10.1001/jama.275.11.877; BJURSTAM N, 1997, MONOGR NATL CANC I, V22, P53; Budetti PP, 1997, JAMA-J AM MED ASSOC, V277, P193; Coley CM, 1997, ANN INTERN MED, V126, P480; DEBER RB, 1994, CAN MED ASSOC J, V151, P423; Ernster VL, 1997, AM J PUBLIC HEALTH, V87, P1103, DOI 10.2105/AJPH.87.7.1103; Fletcher SW, 1997, NEW ENGL J MED, V336, P1180, DOI 10.1056/NEJM199704173361612; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; Gordis L, 1997, J NATL CANCER I, V89, P1015, DOI 10.1093/jnci/89.14.1015; GRADY D, 1992, ANN INTERN MED, V117, P1038; GRIFFITH RS, 1992, PRIMARY CARE, V19, P535; HARRIS R, 1995, ANN INTERN MED, V122, P539, DOI 10.7326/0003-4819-122-7-199504010-00011; Hendrick R E, 1997, J Natl Cancer Inst Monogr, P87; HOROWITZ M, 1985, JAMA-J AM MED ASSOC, V253, P1929, DOI 10.1001/jama.253.13.1929; Kassirer JP, 1997, NEW ENGL J MED, V336, P1747, DOI 10.1056/NEJM199706123362409; KASSIRER JP, 1983, NEW ENGL J MED, V308, P898, DOI 10.1056/NEJM198304143081511; KASSIRER JP, 1981, NEW ENGL J MED, V305, P1465, DOI 10.1056/NEJM198112103052409; Kerlikowske K, 1997, J Natl Cancer Inst Monogr, P79; KOLATA G, 1997, NY TIMES        0224, pA1; Kolata G., 1997, NY TIMES        0128, pC1; KOLATA G, 1997, NY TIMES        0124, pA12; Marwick C, 1997, JAMA-J AM MED ASSOC, V277, P519, DOI 10.1001/jama.277.7.519; MCCONNELL JD, 1994, AHCPR PUBL; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; *NCAB, 1997, JNCI-J NATL CANCER I, V89, P417; Pauker SG, 1997, NEW ENGL J MED, V336, P1243, DOI 10.1056/NEJM199704243361708; SHAPIRO J, 1979, NEW ENGL J MED, V301, P211, DOI 10.1056/NEJM197907263010410; SLACK WV, 1977, LANCET, V2, P240; SNOWE OJ, 1997, WASHINGTON POST 0211, pA21; STRULL WM, 1984, JAMA-J AM MED ASSOC, V252, P2990, DOI 10.1001/jama.252.21.2990; Tabar L, 1996, INT J CANCER, V68, P693; Taubes G, 1997, SCIENCE, V276, P27, DOI 10.1126/science.276.5309.27; Taubes G, 1997, SCIENCE, V275, P1056, DOI 10.1126/science.275.5303.1056; Woolf SH, 1997, J FAM PRACTICE, V45, P205; WOOLF SH, 1993, ARCH INTERN MED, V153, P2646, DOI 10.1001/archinte.153.23.2646	36	29	29	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2105	2108		10.1001/jama.278.23.2105	http://dx.doi.org/10.1001/jama.278.23.2105			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403427				2022-12-28	WOS:A1997YK98700042
J	Morimoto, A; Uzu, T; Fujii, T; Nishimura, M; Kuroda, S; Nakamura, S; Inenaga, T; Kimura, G				Morimoto, A; Uzu, T; Fujii, T; Nishimura, M; Kuroda, S; Nakamura, S; Inenaga, T; Kimura, G			Sodium sensitivity and cardiovascular events in patients with essential hypertension	LANCET			English	Article							BLOOD-PRESSURE; RISK-FACTORS; MICROALBUMINURIA; DISEASE; INSULIN; MEN	Background In patients with sodium-sensitive hypertension, glomerular pressure is increased and microalbuminuria, a marker of glomerular hypertension, is a predictor of cardiovascular events. Similarly, the lack of a nocturnal decrease in blood pressure in these patients is also associated with an increased risk of cardiovascular events. We hypothesised that sodium sensitivity may be the common factor and carried out a retrospective study of cardiovascular events in patients with essential hypertension who had had sodium sensitivity measured in our clinic. Methods Sodium sensitivity was assessed in about 350 patients with essential hypertension during the initial investigation of their disorder. The definition of sodium sensitivity was a 10% or greater difference in blood pressure on low-sodium or high-sodium diets. By alphabetical order, the records of 201 patients were obtained and 156 patients without pre-existing disorders were followed up. The records of patients who had a cardiovascular event or died were reviewed without knowledge of the patient's sodium-sensitivity status. Findings 62 patients were deemed sodium sensitive and 94 non-sodium sensitive, Left-ventricular hypertrophy was found more frequently in the sodium-sensitive group than in the non-sodium-sensitive group (38 vs 16%; p<0.01), whereas significantly fewer patients in this group smoked (23 vs 42%; p<0.05). There were 17 cardiovascular events in the sodium-sensitive group and 14 in the non-sodium-sensitive group. The rate of total, non-fatal and fatal cardiovascular events, was 2.0 per 100 patient-years in the non-sodium-sensitive group and 4.3 per 100 patient-years in the sodium-sensitive group. Cox's proportional-hazards model identified sodium sensitivity (p<0.01), mean arterial pressure (p<0.01), and smoking (p<0.01) as independent cardiovascular risk factors. Interpretation Cardiovascular events occurred more frequently in patients with sodium-sensitive hypertension. Sodium sensitivity is an independent cardiovascular risk factor in Japanese patients with essential hypertension.	NATL CARDIOVASC CTR,DIV NEPHROL,SUITA,OSAKA 565,JAPAN	National Cerebral & Cardiovascular Center - Japan			Koya, Daisuke/J-3257-2014					AGEWALL S, 1995, AM J HYPERTENS, V8, P337, DOI 10.1016/0895-7061(94)00246-8; Alderman MH, 1997, AM J HYPERTENS, V10, P1, DOI 10.1016/S0895-7061(96)00301-9; ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; Bakris GL, 1996, AM J HYPERTENS, V9, pS200, DOI 10.1016/S0895-7061(96)90103-X; Bigazzi R, 1996, AM J HYPERTENS, V9, P24, DOI 10.1016/0895-7061(95)00268-5; BIGAZZI R, 1994, HYPERTENSION, V23, P195, DOI 10.1161/01.HYP.23.2.195; Campese VM, 1994, HYPERTENSION, V23, P531, DOI 10.1161/01.HYP.23.4.531; Cappuccio FP, 1996, J HYPERTENS, V14, P909, DOI 10.1097/00004872-199607000-00015; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FUJITA T, 1980, AM J MED, V69, P334, DOI 10.1016/0002-9343(80)90002-9; HEIMANN JC, 1991, J CARDIOVASC PHARM, V17, pS122, DOI 10.1097/00005344-199117002-00028; KAWASAKI T, 1978, AM J MED, V64, P193, DOI 10.1016/0002-9343(78)90045-1; KIMURA G, 1987, HYPERTENSION, V10, P11, DOI 10.1161/01.HYP.10.1.11; Kimura G, 1997, Hypertens Res, V20, P143, DOI 10.1291/hypres.20.143; Kimura G, 1997, J HYPERTENS, V15, P1055, DOI 10.1097/00004872-199715100-00002; Kimura Genjiro, 1995, P1569; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; KUUSISTO J, 1995, CIRCULATION, V91, P831, DOI 10.1161/01.CIR.91.3.831; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LUFT FC, 1991, HYPERTENSION S1, V17, P102; OBRIEN E, 1988, LANCET, V2, P397; Sanai T, 1996, J LAB CLIN MED, V128, P89, DOI 10.1016/S0022-2143(96)90117-1; SCHMIEDER RE, 1988, CIRCULATION, V78, P951, DOI 10.1161/01.CIR.78.4.951; SHIMADA K, 1990, HYPERTENSION, V16, P692, DOI 10.1161/01.HYP.16.6.692; Uzu T, 1997, CIRCULATION, V96, P1859, DOI 10.1161/01.CIR.96.6.1859; Uzu T, 1996, HYPERTENSION, V28, P139, DOI 10.1161/01.HYP.28.1.139; VERDECCHIA P, 1990, CIRCULATION, V81, P528, DOI 10.1161/01.CIR.81.2.528; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793; WEINBERGER MH, 1991, HYPERTENSION, V18, P67, DOI 10.1161/01.HYP.18.1.67; YOSHIOKA T, 1987, CIRC RES, V61, P531, DOI 10.1161/01.RES.61.4.531	30	351	370	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 13	1997	350	9093					1734	1737		10.1016/S0140-6736(97)05189-1	http://dx.doi.org/10.1016/S0140-6736(97)05189-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413464				2022-12-28	WOS:A1997YL55400009
J	Lee, WM				Lee, WM			Medical progress - Hepatitis B virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TERM FOLLOW-UP; ORTHOTOPIC LIVER-TRANSPLANTATION; RANDOMIZED CONTROLLED TRIAL; CHRONIC ACTIVE HEPATITIS; SURFACE-ANTIGEN; INTERFERON-ALFA; ALPHA-INTERFERON; VIRAL-INFECTION; AUSTRALIA-ANTIGEN; POSITIVE PATIENTS				Lee, WM (corresponding author), UNIV TEXAS, SW MED SCH, DEPT INTERNAL MED, LIVER DIV, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Yang, Chen/G-1379-2010					AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; Alexopoulou A, 1997, J HEPATOL, V26, P748, DOI 10.1016/S0168-8278(97)80238-3; Alter H J, 1981, Semin Liver Dis, V1, P1; Aye TT, 1997, J HEPATOL, V26, P1148, DOI 10.1016/S0168-8278(97)80125-0; Bartholomew MM, 1997, LANCET, V349, P20, DOI 10.1016/S0140-6736(96)02266-0; BENHAMOU Y, 1995, LANCET, V345, P396, DOI 10.1016/S0140-6736(95)90388-7; BENNER KG, 1992, GASTROENTEROLOGY, V103, P1307, DOI 10.1016/0016-5085(92)91521-5; BLUMBERG BS, 1977, SCIENCE, V197, P17, DOI 10.1126/science.325649; BOKER KHW, 1994, TRANSPLANTATION, V57, P1706; BONKOVSKY HL, 1995, J CLIN GASTROENTEROL, V21, P42; Brugger SA, 1997, LANCET, V349, P996, DOI 10.1016/S0140-6736(05)62893-0; Carr A, 1997, LANCET, V349, P995, DOI 10.1016/S0140-6736(05)62892-9; CARRENO V, 1992, J HEPATOL, V15, P102, DOI 10.1016/0168-8278(92)90019-L; Cavanaugh VJ, 1997, J VIROL, V71, P3236, DOI 10.1128/JVI.71.4.3236-3243.1997; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; CHISARI FV, 1995, SPRINGER SEMIN IMMUN, V17, P261, DOI 10.1007/BF00196169; Chisari FV, 1997, J CLIN INVEST, V99, P1472, DOI 10.1172/JCI119308; CONJEEVARAM HS, 1993, VIRAL HEPATITIS, P341; CUI LX, 1995, J CLIN INVEST, V95, P555, DOI 10.1172/JCI117698; DAVIES SE, 1991, HEPATOLOGY, V13, P150, DOI 10.1002/hep.1840130122; DEJONGH FE, 1992, GASTROENTEROLOGY, V103, P1630, DOI 10.1016/0016-5085(92)91188-A; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; Dusheiko GM, 1995, HEPATOLOGY, V22, P1863, DOI 10.1016/0270-9139(95)90216-3; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; FARCI P, 1994, NEW ENGL J MED, V330, P88, DOI 10.1056/NEJM199401133300202; FATTOVICH G, 1988, HEPATOLOGY, V8, P1651, DOI 10.1002/hep.1840080630; FATTOVICH G, 1995, HEPATOLOGY, V21, P77; FATTOVICH G, 1992, HEPATOLOGY, V15, P584, DOI 10.1002/hep.1840150405; FEITELSON MA, 1994, LAB INVEST, V71, P324; FERRARI C, 1991, J CLIN INVEST, V88, P214, DOI 10.1172/JCI115280; FERRARI C, 1994, VIRAL HEPATITIS A F; FRANCIS DP, 1995, JAMA-J AM MED ASSOC, V274, P1242, DOI 10.1001/jama.274.15.1242; Gilson RJC, 1996, HEPATOLOGY, V24, P620; GOVINDARAJAN S, 1984, GASTROENTEROLOGY, V86, P1417; GREENBERG HB, 1976, NEW ENGL J MED, V295, P517, DOI 10.1056/NEJM197609022951001; Grellier L, 1996, LANCET, V348, P1212, DOI 10.1016/S0140-6736(96)04444-3; Guidotti LG, 1996, CURR OPIN IMMUNOL, V8, P478, DOI 10.1016/S0952-7915(96)80034-3; Guidotti LG, 1996, P NATL ACAD SCI USA, V93, P4589, DOI 10.1073/pnas.93.10.4589; GUILLEVIN L, 1995, MEDICINE, V74, P238, DOI 10.1097/00005792-199509000-00002; HADZIYANNIS S, 1990, J HEPATOL, V11, pS133, DOI 10.1016/0168-8278(90)90180-Y; Harpaz R, 1996, NEW ENGL J MED, V334, P549, DOI 10.1056/NEJM199602293340901; HONKOOP P, 1995, LANCET, V346, P1156, DOI 10.1016/S0140-6736(95)91829-9; Honkoop P, 1997, J HEPATOL, V26, P1393, DOI 10.1016/S0168-8278(97)80476-X; Honkoop P., 1997, Journal of Hepatology, V26, P81; HOU JL, 1995, HEPATOLOGY, V21, P273, DOI 10.1016/0270-9139(95)90080-2; JUNG MC, 1994, EUR J CLIN INVEST, V24, P641, DOI 10.1111/j.1365-2362.1994.tb01055.x; KANE M, 1995, VACCINE, V13, pS47; KIM SC, 1995, PEDIATRICS, V95, P764; KORENMAN J, 1991, ANN INTERN MED, V114, P629, DOI 10.7326/0003-4819-114-8-629; Krogsgaard K, 1996, J HEPATOL, V25, P803, DOI 10.1016/S0168-8278(96)80282-0; Kruger M, 1997, J HEPATOL, V26, P935, DOI 10.1016/S0168-8278(97)80263-2; Lai C. L., 1997, Journal of Hepatology, V26, P79; Lai CL, 1997, HEPATOLOGY, V25, P241, DOI 10.1002/hep.510250144; LAU JYN, 1993, LANCET, V342, P1335; LEE WM, 1994, NEW ENGL J MED, V330, P584; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347; LISKERMELMAN M, 1989, ANN INTERN MED, V111, P479, DOI 10.7326/0003-4819-111-6-479; LOK ASF, 1993, GASTROENTEROLOGY, V105, P1833, DOI 10.1016/0016-5085(93)91082-S; LOK ASF, 1988, HEPATOLOGY, V8, P1130, DOI 10.1002/hep.1840080527; LOK ASF, 1988, LANCET, V2, P298; LOK ASF, 1991, GASTROENTEROLOGY, V100, P756, DOI 10.1016/0016-5085(91)80022-2; MAGNIUS LO, 1972, J IMMUNOL, V109, P1017; Main J, 1996, J VIRAL HEPATITIS, V3, P211, DOI 10.1111/j.1365-2893.1996.tb00098.x; Marinos G, 1996, HEPATOLOGY, V24, P991; McGory R, 1996, TRANSPLANT P, V28, P1687; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; MCMAHON BJ, 1990, ARCH INTERN MED, V150, P1051, DOI 10.1001/archinte.150.5.1051; MILICH DR, 1995, SPRINGER SEMIN IMMUN, V17, P149; MORADPOUR D, 1995, NEW ENGL J MED, V332, P1092, DOI 10.1056/NEJM199504203321610; MUTCHNICK MG, 1996, LIVER; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404; PERRILLO R, 1995, GASTROENTEROLOGY, V109, P908, DOI 10.1016/0016-5085(95)90401-8; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; PERRILLO RP, 1994, GASTROENTEROL CLIN N, V23, P581; PURCELL RH, 1993, GASTROENTEROLOGY, V104, P955, DOI 10.1016/0016-5085(93)90261-A; Rehermann B, 1996, J VIROL, V70, P7092, DOI 10.1128/JVI.70.10.7092-7102.1996; RIZZETTO M, 1977, GUT, V18, P997, DOI 10.1136/gut.18.12.997; RIZZETTO M, 1985, J HEPATOL, V1, P187, DOI 10.1016/S0168-8278(85)80766-2; SCHARSCHMIDT BF, 1992, ANN INTERN MED, V117, P837, DOI 10.7326/0003-4819-117-10-837; SCHINAZI RF, 1994, ANTIMICROB AGENTS CH, V38, P2172, DOI 10.1128/AAC.38.9.2172; Schnittman SM, 1996, CLIN INFECT DIS, V23, P638, DOI 10.1093/clinids/23.3.638; Shaw T, 1996, HEPATOLOGY, V24, P996; SMEDILE A, 1982, LANCET, V2, P945, DOI 10.1016/S0140-6736(82)90156-8; Sterneck M, 1997, J HEPATOL, V26, P754, DOI 10.1016/S0168-8278(97)80239-5; Thomas HC, 1996, LANCET, V348, P1417, DOI 10.1016/S0140-6736(96)05409-8; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; Tipples GA, 1996, HEPATOLOGY, V24, P714, DOI 10.1053/jhep.1996.v24.pm0008781348; TODO S, 1991, HEPATOLOGY, V13, P619, DOI 10.1002/hep.1840130402; TYRELL LDJ, 1993, HEPATOLOGY S, V18, pA112; Tyrrell D. L. J., 1993, Clinical and Investigative Medicine, V16, pB77; VILLENEUVE JP, 1994, GASTROENTEROLOGY, V106, P1000, DOI 10.1016/0016-5085(94)90760-9; WATERS JA, 1992, J CLIN INVEST, V90, P2543, DOI 10.1172/JCI116148; WEI Y, 1994, VIRAL HEPATITIS A F; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; WONG JB, 1995, ANN INTERN MED, V122, P664, DOI 10.7326/0003-4819-122-9-199505010-00004; 1995, JAMA-J AM MED ASSOC, V274, P603; 1994, MMWR-MORBID MORTAL W, V43, P311; 1994, MMWR-MORBID MORTAL W, V43, P317; 1994, MMWR-MORBID MORTAL W, V43, P605	104	1890	2012	2	173	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1733	1745		10.1056/NEJM199712113372406	http://dx.doi.org/10.1056/NEJM199712113372406			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK653	9392700				2022-12-28	WOS:A1997YK65300006
J	McDonnell, WM; Askari, FK				McDonnell, WM; Askari, FK			Immunization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VACCINES	Immunization is undergoing important changes, with improved vaccines replacing less immunogenic or less safe vaccines, new vaccines for common diseases such as chickenpox and hepatitis A infection, and improved immunization schedules. Immunization is also being transformed by basic work in molecular medicine. Vaccines made of DNA are being developed as a form of gene therapy that use the patient's own cellular machinery to make foreign proteins that stimulate an immune response. Currently immunization is used to protect patients prior to exposure to an infectious agent or during the incubation phase after exposure, but before disease has occurred. New technologies are being investigated to induce the immune system to fight infections that have already produced chronic disease such as acquired immunodeficiency syndrome and chronic hepatitis B virus infection.	UNIV MICHIGAN,SCH MED,DIV GASTROENTEROL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	McDonnell, WM (corresponding author), WESTERN WASHINGTON MED GRP,3216 NORTON AVE,SUITE 102,EVERETT,WA 98201, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002438] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 02438] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM AC PED COMM IN, 1992, PEDIATRICS, V89, P79; *AM AC PED COMM IN, 1997, PEDIATRICS, V99, P136; *AM AC PED COMM IN, 1997, PEDIATRICS, V99, P282; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P709; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P657; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P36; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P720; *CDCP, 1993, MMWR-MORBID MORTAL W, V442, P1; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P665; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Centers for Disease Control & Prevention, 1994, MMWR-MORBID MORTAL W, V43, P718; DENNEHY PH, 1992, TXB INFECT DIS, P2231; GARDNER P, 1994, GUIDE ADULT IMMUNIZA; GARDNER P, 1996, ANN INTERN MED, V12, P35; GILSDORF JR, 1994, J PEDIATR-US, V125, P339, DOI 10.1016/S0022-3476(05)83273-1; HILL HF, 1997, SCIENCE, V275, P40; Immunization Practices Advisory Committee, 1991, MMWR-MORBID MORTAL W, V40, P1; Lemon SM, 1997, NEW ENGL J MED, V336, P196, DOI 10.1056/NEJM199701163360307; McDonnell WM, 1996, NEW ENGL J MED, V334, P42, DOI 10.1056/NEJM199601043340110; PETER G, 1992, NEW ENGL J MED, V327, P1794, DOI 10.1056/NEJM199212173272507; PETER G, 1997, 1997 RED BOOK REPORT; STIEHM ER, 1992, TXB PEDIAT INFECT DI, P2261; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VITIELLO A, 1995, J CLIN INVEST, V95, P341, DOI 10.1172/JCI117662	25	12	14	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					2000	2007		10.1001/jama.278.22.2000	http://dx.doi.org/10.1001/jama.278.22.2000			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396663				2022-12-28	WOS:A1997YK15500024
J	Saitoh, O; Kubo, Y; Miyatani, Y; Asano, T; Nakata, H				Saitoh, O; Kubo, Y; Miyatani, Y; Asano, T; Nakata, H			RGS8 accelerates G-protein-mediated modulation of K+ currents	NATURE			English	Article							MUSCARINIC POTASSIUM CHANNEL; GTPASE-ACTIVATING PROTEINS; BETA-GAMMA-SUBUNITS; INWARD RECTIFIER; XENOPUS OOCYTES; ALPHA-SUBUNITS; FAMILY; CELLS; DESENSITIZATION; INHIBITION	Transmembrane signal transduction via heterotrimeric G proteins is reported to be inhibited by RGS (regulators of G-protein signalling) proteins(1-4). These RGS proteins work by increasing the GTPase activity of G protein alpha-subunits (G alpha), thereby driving G proteins into their inactive GDP-bound form(5-7). However, it is not known how RGS proteins regulate the kinetics of physiological responses that depend on G proteins. Here we report the isolation of a full-length complementary DNA encoding a neural-tissue-specific RGS protein, RGS8, and the determination of its function. We show that RGS8 binds preferentially to the alpha-subunits G alpha o and G alpha i3 and that it functions as a GTPase-activating protein (GAP). When co-expressed in Xenopus oocytes with a G-protein-coupled receptor and a G-protein-coupled inwardly rectifying K+ channel (GIRK1/2), RGS8 accelerated not only the turning off but also the turning on of the GIRK1/2 current upon receptor stimulation, without affecting the dose-response relationship. We conclude that RGS8 accelerates the modulation of G-protein-coupled channels and is not just a simple negative regulator. This property of RGS8 may be crucial for the rapid regulation of neuronal excitability upon stimulation of G-protein-coupled receptors.	TOKYO METROPOLITAN INST NEUROSCI,DEPT NEUROPHYSIOL,FUCHU,TOKYO 183,JAPAN; INST DEV RES,AICHI HUMAN SERV CTR,DEPT BIOCHEM,KASUGAI,AICHI 48003,JAPAN	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Saitoh, O (corresponding author), TOKYO METROPOLITAN INST NEUROSCI,DEPT MOL & CELLULAR NEUROBIOL,2-6 MUSASHIDAI,FUCHU,TOKYO 183,JAPAN.			Kubo, Yoshihiro/0000-0001-6707-0837				Abe M, 1996, EXP CELL RES, V229, P48, DOI 10.1006/excr.1996.0342; ASANO T, 1988, J BIOCHEM-TOKYO, V103, P950, DOI 10.1093/oxfordjournals.jbchem.a122392; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Saugstad JA, 1996, J NEUROSCI, V16, P5979; SHUI Z, 1995, J PHYSIOL-LONDON, V487, P359, DOI 10.1113/jphysiol.1995.sp020885; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; Sodickson DL, 1996, J NEUROSCI, V16, P6374; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Werner P, 1996, MOL PHARMACOL, V49, P656; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865	24	183	189	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					525	529		10.1038/37385	http://dx.doi.org/10.1038/37385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394004				2022-12-28	WOS:A1997YJ86500056
J	Sellers, TA; Mink, PJ; Cerhan, JR; Zheng, W; Anderson, KE; Kushi, LH; Folsom, AR				Sellers, TA; Mink, PJ; Cerhan, JR; Zheng, W; Anderson, KE; Kushi, LH; Folsom, AR			The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer	ANNALS OF INTERNAL MEDICINE			English	Article							POSTMENOPAUSAL WOMEN; MENOPAUSAL ESTROGEN; OLDER WOMEN; FOLLOW-UP; METAANALYSIS; DISEASE	Background: The risks and benefits of hormone replacement therapy (HRT) are of considerable interest and importance, especially in terms of whether they differ among subsets of women. Objective: To determine whether HRT is associated with increased risks for breast cancer and total mortality in women with a family history of breast cancer. Design: Prospective cohort study. Setting: Population-based sample of midwestern post-menopausal women enrolled in an observational study of risk factors for cancer. Participants: Random sample of 41 837 female Iowa residents 55 to 69 years of age. Measurements: Incidence rates of and relative risks for breast cancer (n = 1085) and total mortality (n = 2035) th rough 8 years of follow-up were calculated by using data from the State Health Registry of Iowa and the National Death Index. Results: A family history of breast cancer was reported by 12.2% of the cohort at risk. Among women with a family history of breast cancer, those who currently used HRT and had done so for at least 5 years developed breast cancer at an age-adjusted annual rate of 61 cases per 10 000 person-years (95% CI, 28 to 94 cases); this rate was not statistically significantly higher than the rate in women who had never used HRT (46 cases per 10 000 person-years ICI, 36 to 55 cases]). Among women with a family history, those who used HRT had a significantly lower risk for total mortality than did women who had never used HRT (relative risk, 0.67 [CI, 0.51 to 0.89]), including total cancer-related mortality (relative risk, 0.75 [CI, 0.50 to 1.12]). The age-adjusted annual mortality rate for women using HRT for at least 5 years was 46 deaths per 10 000 person-years (CI, 19 to 74 deaths); this is roughly half the rate seen in women who had never used HRT (80 deaths per In 000 person-years [CI, 69 to 92 deaths]). Conclusions: These data suggest that HRT use in women with a family history of breast cancer is not associated with a significantly increased incidence of breast cancer but is associated with a significantly reduced total mortality rate.	UNIV IOWA, IOWA CITY, IA 52242 USA	University of Iowa	Sellers, TA (corresponding author), UNIV MINNESOTA, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.		Zheng, Wei/O-3351-2013; zhang, weihua/GXV-1334-2022	Zheng, Wei/0000-0003-1226-070X; Kushi, Lawrence/0000-0001-9136-1175; Cerhan, James/0000-0002-7482-178X	NCI NIH HHS [R01 CA39742, T32CA09607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039742, T32CA009607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1994, NIH PUBLICATION, V94-1447; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BLACKMAN JA, 1995, NEW ENGL J MED, V333, P1355; Breslow N., 1987, STATISTICAL METHODS; BRINTON LA, 1993, EPIDEMIOL REV, V15, P66, DOI 10.1093/oxfordjournals.epirev.a036117; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; Colditz GA, 1996, J NATL CANCER I, V88, P365, DOI 10.1093/jnci/88.6.365; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; FOLSOM AR, 1995, AM J PUBLIC HEALTH, V85, P1128, DOI 10.2105/AJPH.85.8_Pt_1.1128; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; GO RCP, 1983, J NATL CANCER I, V71, P455; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HEMMINKI E, 1988, AM J PUBLIC HEALTH, V78, P1478, DOI 10.2105/AJPH.78.11.1479; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON BE, 1996, CANC EPIDEMIOLOGY PR, P1022; HOOVER R, 1981, J NATL CANCER I, V67, P815; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KUSHI LH, 1988, AM J EPIDEMIOL, V128, P740, DOI 10.1093/oxfordjournals.aje.a115027; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; NEWCOMB PA, 1995, AM J EPIDEMIOL, V142, P788, DOI 10.1093/oxfordjournals.aje.a117717; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; *SAS I, 1985, SAS US GUID; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; SILLEROARENAS M, 1992, OBSTET GYNECOL, V79, P286; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; WHO (World Health Organization), 1977, MAN INT STAT CLASS D; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360	40	146	150	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					973	980		10.7326/0003-4819-127-11-199712010-00004	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412302				2022-12-28	WOS:A1997YJ08000003
J	Collins, FS; Guyer, MS; Chakravarti, A				Collins, FS; Guyer, MS; Chakravarti, A			Variations on a theme: Cataloging human DNA sequence variation	SCIENCE			English	Editorial Material							DEPENDENT DIABETES-MELLITUS; POSITIONAL CLONING; HUMAN GENOME; GENE; MUTATION; CANCER; BREAST		CASE WESTERN RESERVE UNIV,CTR HUMAN GENET,DEPT GENET,CLEVELAND,OH 44106	Case Western Reserve University	Collins, FS (corresponding author), NATL HUMAN GENOME RES INST,NIH,BETHESDA,MD 20892, USA.							BALLABIO A, 1993, NAT GENET, V3, P277, DOI 10.1038/ng0493-277; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; COLLINS FS, 1991, NAT GENET, V1, P3; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Gerhold D, 1996, BIOESSAYS, V18, P973, DOI 10.1002/bies.950181207; GRANT SFA, 1996, NAT GENET, V14, P205; KAISER J, 1996, SCIENCE, V271, P749; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Marshall E, 1997, SCIENCE, V277, P1752, DOI 10.1126/science.277.5333.1752; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; PAPADOPOULOS N, 1994, SCIENCE, V263; Pastinen T, 1997, GENOME RES, V7, P606, DOI 10.1101/gr.7.6.606; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Shuber AP, 1997, HUM MOL GENET, V6, P337, DOI 10.1093/hmg/6.3.337; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	29	783	834	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1580	1581		10.1126/science.278.5343.1580	http://dx.doi.org/10.1126/science.278.5343.1580			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9411782				2022-12-28	WOS:A1997YJ87400028
J	Hornberger, J; Wrone, E				Hornberger, J; Wrone, E			When to base clinical policies on observational versus randomized trial data	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; CANCER PREVENTION; HEART-FAILURE; DIGITALIS; HYPERHOMOCYSTEINEMIA; HOMOCYSTEINE; WITHDRAWAL; TECHNOLOGY; DIALYSIS	Physicians must decide when the evidence is sufficient to adopt a new clinical policy. Analysis of large clinical and administrative databases is becoming an important source of evidence for changing clinical policies. Because such analysis cannot control for the effects of all potential confounding variables, physicians risk drawing the wrong conclusion about the cause-and-effect relation between a change in clinical policy and outcomes. Randomized studies offer protection against drawing a conclusion that would lead to adoption of an inferior policy. However, a randomized study may be difficult to justify because of the extra costs of collecting data for a randomized study and concerns that a study will not directly benefit the patients enrolled in the study. This article reviews the advantages and disadvantages of basing clinical policy on analysis of large databases compared with conducting a randomized study. A technique is described and illustrated for accessing the potential costs and benefits of conducting such a study. This type of analysis formed the basis for a physician-managed health care organization deciding to sponsor a randomized study among patients with end-stage renal disease as part of a quality-improvement initiative.	STANFORD UNIV, SCH MED, DEPT MED, STANFORD, CA 94305 USA	Stanford University	Hornberger, J (corresponding author), STANFORD UNIV, SCH MED, DEPT HLTH RES & POLICY, HAP REDWOOD BLDG, ROOM T254A, STANFORD, CA 94305 USA.		Hornberger, John/M-4932-2019					Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; ARNADOTTIR M, 1993, CLIN NEPHROL, V40, P236; BERGER JO, 1986, STATISTICAL DECISION; Bernardo JM, 1994, BAYESIAN THEORY; Berry DA, 1991, DRUG INF J, V25, P345; Berry DA, 1996, BAYESIAN BIOSTATISTI; BLUMBERG J, 1994, NUTR REV, V52, P242, DOI 10.1111/j.1753-4887.1994.tb01430.x; Bostom AG, 1996, KIDNEY INT, V49, P147, DOI 10.1038/ki.1996.19; BOSTOM AG, 1995, ATHEROSCLEROSIS, V114, P93, DOI 10.1016/0021-9150(94)05470-4; BROPHY JM, 1995, JAMA-J AM MED ASSOC, V273, P871, DOI 10.1001/jama.273.11.871; BROWN BW, 1984, STAT MED, V3, P307, DOI 10.1002/sim.4780030403; BYAR DP, 1980, BIOMETRICS, V36, P337, DOI 10.2307/2529989; BYAR DP, 1991, STAT MED, V10, P663, DOI 10.1002/sim.4780100417; CANNER PL, 1970, J AM STAT ASSOC, V65, P293, DOI 10.2307/2283593; CAREY RG, 1997, MEASURING QUALITY IM; CHAUVEAU P, 1993, KIDNEY INT, V43, pS72; COLTON T, 1963, J AM STAT ASSOC, V58, P388, DOI 10.2307/2283274; Committee for Evaluating Medical Technologies in Clinical Use, 1985, ASS MED TECHN; *DEP AMB CAR PREV, 1997, HMO RES NETW C CAMBR; DETSKY AS, 1989, JAMA-J AM MED ASSOC, V262, P1795, DOI 10.1001/jama.262.13.1795; DETSKY AS, 1990, STAT MED, V9, P173, DOI 10.1002/sim.4780090124; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; FUCHS VR, 1990, NEW ENGL J MED, V323, P673, DOI 10.1056/NEJM199009063231011; Gilbert J, 1977, COSTS RISKS BENEFITS, P124; Greenberg ER, 1996, NEW ENGL J MED, V334, P1189, DOI 10.1056/NEJM199605023341810; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; HORNBERGER JC, 1995, STAT MED, V14, P2249, DOI 10.1002/sim.4780142008; HORNBERGER JC, 1993, J AM SOC NEPHROL, V4, P1004; HORNBERGER JC, 1997, IN PRESS AM J PUBLIC; Kadane Joseph B., 1996, BAYESIAN METHODS ETH; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; LANDGREN F, 1995, J INTERN MED, V237, P381, DOI 10.1111/j.1365-2796.1995.tb01190.x; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LAVORI PW, 1986, MED USES STATISTICS, P41; MADSEN EB, 1984, J AM COLL CARDIOL, V3, P681, DOI 10.1016/S0735-1097(84)80243-0; Matheson J., 1968, PRINCIPLES APPL DECI, VI, P17; Mayer EL, 1996, J AM COLL CARDIOL, V27, P517, DOI 10.1016/0735-1097(95)00508-0; MOSES LE, 1995, MED CARE, V33, pAS8; MOSES LE, 1997, STAT PUBLIC POLICY, P212; MOSS AJ, 1981, CIRCULATION, V64, P1150, DOI 10.1161/01.CIR.64.6.1150; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PACKER M, 1993, NEW ENGL J MED, V329, P1, DOI 10.1056/NEJM199307013290101; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; Perry G, 1997, NEW ENGL J MED, V336, P525; Robert C., 2001, BAYESIAN CHOICE DECI; RUBIN DB, 1978, ANN STAT, V6, P34, DOI 10.1214/aos/1176344064; Russel L, 1997, COST EFFECTIVENESS H; RYAN TJ, 1983, CIRCULATION, V67, P735, DOI 10.1161/01.CIR.67.4.735; SHORTLIFFE EH, 1990, MED INFORMATICS COMP, P466; SYLVESTER R, 1990, BIOMETRICS, V46, P537; SYLVESTER RJ, 1988, BIOMETRICS, V44, P823, DOI 10.2307/2531594; URETSKY BF, 1993, J AM COLL CARDIOL, V22, P955, DOI 10.1016/0735-1097(93)90403-N; *US REN DAT SYST, 1996, ANN DAT REP; VANPOPPEL G, 1993, EUR J CANCER, V29A, P1335, DOI 10.1016/0959-8049(93)90087-V; WEINSTEIN MC, 1983, SCIENCE, V221, P17, DOI 10.1126/science.6407110; Weinstein MC, 1980, CLIN DECISION ANAL; YUSUF S, 1986, CIRCULATION, V73, P14, DOI 10.1161/01.CIR.73.1.14	57	58	58	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				697	703		10.7326/0003-4819-127-8_Part_2-199710151-00053	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00053			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB385	9382383				2022-12-28	WOS:A1997YB38500008
J	Ray, WA				Ray, WA			Policy and program analysis using administrative databases	ANNALS OF INTERNAL MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NURSING-HOMES; UNITED-STATES; MEDICAID DATA; CARE; PHARMACOEPIDEMIOLOGY; INTERVENTION; MORTALITY; THERAPY; QUALITY	Administrative policies and programs play an important and growing role as determinants of the use of medical care. Although some policies and programs may be harmful or ineffectual, randomized, controlled trials or prospective evaluations are rarely done for political or logistic reasons. Most evaluations are retrospective and often use administrative databases. Major problems with such evaluations include poor data quality, lack of concurrent controls, inability to ascertain important study outcomes, and incomplete data on case mix. This article uses published evaluations to illustrate these problems and suggests strategies that can minimize their impact. Such strategies include thorough assessment of data quality, interrupted time-series or policy gradient analysis, restriction of studies to those clinical outcomes that reliably result in medical care, and use of data on medical encounters as surrogates for determining case mix. However, even when these strategies are used, adequate evaluation of the effects of many policies and programs may continue to be impossible. Prospective evaluations need to be used more frequently to ensure that changes are held to the same standard used for other therapeutic interventions.			Ray, WA (corresponding author), VANDERBILT UNIV, SCH MED, DEPT PREVENT MED, A-1124 MCN, NASHVILLE, TN 37232 USA.				AHRQ HHS [HS07768] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1985, PREV LOW BIRTHW; ARMSTRONG BK, 1992, PRINCIPLES EXPOSURE, P1; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V42, P937, DOI 10.1016/0895-4356(89)90158-3; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; CAPER P, 1988, NEW ENGL J MED, V318, P1535, DOI 10.1056/NEJM198806093182310; CHERRY JK, 1988, NEW ENGL J MED, V319, P800; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; Cook T.D., 1979, QUASIEXPERIMENTATION, P1; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; *DRUG FACTS COMP, 1992, FACTS COMP; FISHER ES, 1990, AM J PUBLIC HEALTH, V80, P1487, DOI 10.2105/AJPH.80.12.1487; KESSNER DM, 1973, INFANT DEATH ANAL MA; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; Meador KG, 1997, J AM GERIATR SOC, V45, P207, DOI 10.1111/j.1532-5415.1997.tb04509.x; OSTER G, 1995, CONTROL CLIN TRIALS, V16, P3, DOI 10.1016/0197-2456(94)00028-2; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; POLLACK MM, 1987, NEW ENGL J MED, V316, P134, DOI 10.1056/NEJM198701153160304; Ray WA, 1997, AM J PREV MED, V13, P292, DOI 10.1016/S0749-3797(18)30178-8; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; RAY WA, 1992, J GERONTOL, V47, pM9, DOI 10.1093/geronj/47.1.M9; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; RUTHER M, 1986, PROGRAM STAT MED MED; SARDELL A, 1990, J HEALTH POLIT POLIC, V15, P271, DOI 10.1215/03616878-15-2-271; SHAPIRO S, 1989, CLIN PHARMACOL THER, V46, P371, DOI 10.1038/clpt.1989.154; SHORR RI, 1994, JAMA-J AM MED ASSOC, V271, P358; SMALLEY WE, 1995, NEW ENGL J MED, V332, P1612, DOI 10.1056/NEJM199506153322406; Smalley WE, 1996, J GEN INTERN MED, V11, P461, DOI 10.1007/BF02599040; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1995, NEW ENGL J MED, V332, P1641, DOI 10.1056/NEJM199506153322411; STERGACHIS AS, 1988, DRUG INTEL CLIN PHAR, V22, P157, DOI 10.1177/106002808802200216; STROM BL, 1990, EPIDEMIOL REV, V12, P87, DOI 10.1093/oxfordjournals.epirev.a036064; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; TORRES A, 1989, FAM PLANN PERSPECT, V21, P19, DOI 10.2307/2135414; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906	37	65	66	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				712	718		10.7326/0003-4819-127-8_Part_2-199710151-00055	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00055			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB385	9382385				2022-12-28	WOS:A1997YB38500010
J	Hardman, CMJ; Garioch, JJ; Leonard, JN; Thomas, HJW; Walker, MM; Lortan, JE; Lister, A; Fry, L				Hardman, CMJ; Garioch, JJ; Leonard, JN; Thomas, HJW; Walker, MM; Lortan, JE; Lister, A; Fry, L			Absence of toxicity of oats in patients with dermatitis herpetiformis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELIAC-DISEASE	Background People with gluten sensitivity should avoid foods containing wheat, rye, and barley, but there has been debate about whether they should avoid oats. Although patients with celiac disease have recently been shown to tolerate oats, less is known about the effects of oats on patients with dermatitis herpetiformis. Methods We studied seven men and three women (mean age, 58 years) with biopsy-confirmed dermatitis herpetiformis. They had followed a strict gluten-free diet for a mean of 15.8 years, which controlled their rash and enteropathy. The patients added oats that were not contaminated with gluten to their diets for 12 weeks (mean [+/-SD] daily intake, 62.5+/-10.8 g). Results None of the patients had any adverse effects. Serologic tests for antigliadin, antireticulin, and antiendomysial antibodies were negative before oats were introduced into the diet and after they were discontinued. Villous architecture remained normal: the mean (+/-SE) ratio of the height of vilii to the depth of crypts was 3.59+/-0.11 before the diet and 3.71+/-0.09 afterward (normal, 3 to 5), and the mean enterocyte heights were 31.36+/-0.58 mu m and 31.75+/-44 mu m, respectively (normal range, 29 to 34), Duodenal intraepithelial lymphocyte counts all remained within normal limits (mean, 13.8+/-1.03 per 100 enterocytes before the diet and 14.2+/-1.2 per 100 enterocytes afterward; normal range, 10 to 30). Dermal IgA showed no significant changes. Conclusions Patients with dermatitis herpetiformis can include moderate amounts of oats in their gluten-free diets without deleterious effects to the skin or intestine. (C) 1997, Massachusetts Medical Society.	St Marys Hosp, Dept Dermatol, London W2 1NY, England; St Marys Hosp, Dept Gastroenterol, London W2 1NY, England; St Marys Hosp, Dept Histopathol, London W2 1NY, England; St Marys Hosp, Dept Immunol, London W2 1NY, England; St Marys Hosp, Dept Nutr, London W2 1NY, England	Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London	Hardman, CMJ (corresponding author), St Marys Hosp, Dept Dermatol, Praed St, London W2 1NY, England.							BROW JR, 1971, GASTROENTEROLOGY, V60, P355; DICKE W K, 1953, Acta Paediatr, V42, P34, DOI 10.1111/j.1651-2227.1953.tb05563.x; DISSANAYAKE AS, 1974, BMJ-BRIT MED J, V4, P189, DOI 10.1136/bmj.4.5938.189; FRY L, 1978, BRIT J DERMATOL, V99, P31, DOI 10.1111/j.1365-2133.1978.tb01957.x; FRY L, 1974, BRIT J DERMATOL, V90, P137, DOI 10.1111/j.1365-2133.1974.tb06377.x; FRY L, 1968, LANCET, V1, P557; FRY L, 1974, J CLIN PATHOL, V27, P817, DOI 10.1136/jcp.27.10.817; GARIOCH JJ, 1994, BRIT J DERMATOL, V131, P541; JANATUINEN EK, 1995, NEW ENGL J MED, V333, P1033, DOI 10.1056/NEJM199510193331602; KASARDA DD, IN PRESS COELIAC DIS; KUMAR PJ, 1988, ARCH DIS CHILD, V63, P916, DOI 10.1136/adc.63.8.916; LEONARD J, 1983, NEW ENGL J MED, V308, P816, DOI 10.1056/NEJM198304073081406; LINDSAY A, 1959, ARCH DIS CHILD, V34, P51; MAKI M, 1995, BAILLIERE CLIN GASTR, V9, P231, DOI 10.1016/0950-3528(95)90030-6; MAKI M, 1992, GLUTEN SENSITIVE ENT, V19, P108; REUNALA T, 1976, ANN CLIN RES, V8, P254; RUBIN CYRUS E., 1962, CIBA FOUND STUDY GROUP, V14, P67; SAVILAHTI E, 1983, LANCET, V1, P320; SAVILAHTI E, 1992, GUT, V33, P206, DOI 10.1136/gut.33.2.206; Schmitz J, 1997, BRIT MED J, V314, P159, DOI 10.1136/bmj.314.7075.159; SCOTT H, 1992, COELIAC DIS, P239; Shewry P., 1992, COELIAC DIS, P305; SHIDRAWI RG, 1994, J CLIN PATHOL, V47, P693, DOI 10.1136/jcp.47.8.693; Srinivasan U, 1996, BRIT MED J, V313, P1300, DOI 10.1136/bmj.313.7068.1300; VAN DE KAMER J H, 1953, Acta Paediatr, V42, P223, DOI 10.1111/j.1651-2227.1953.tb05586.x; WEINSTEIN WM, 1973, GASTROENTEROLOGY, V64, P819	26	104	104	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	1997	337	26					1884	1887		10.1056/NEJM199712253372604	http://dx.doi.org/10.1056/NEJM199712253372604			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN051	9407155				2022-12-28	WOS:000071128200004
J	Klein, MA; Frigg, R; Flechsig, E; Raeber, AJ; Kalinke, U; Bluethmann, H; Bootz, F; Suter, M; Zinkernagel, RM; Aguzzi, A				Klein, MA; Frigg, R; Flechsig, E; Raeber, AJ; Kalinke, U; Bluethmann, H; Bootz, F; Suter, M; Zinkernagel, RM; Aguzzi, A			A crucial role for B cells in neuroinvasive scrapie	NATURE			English	Article							FOLLICULAR DENDRITIC CELLS; NECROSIS-FACTOR RECEPTOR-1; MICE LACKING; DEFICIENT MICE; T-CELLS; PROTEIN; MOUSE; PRP; REPLICATION; RESISTANT	Although prion proteins are most efficiently propagated through intracerebral inoculation, peripheral administration has caused the diseases kuru, iatrogenic Creutzfeldt-Jakob disease (CJD), bovine spongiform encephalopathy (BSE) and new-variant CJD(1,2). The development of neurological disease after peripheral inoculation depends on prion expansion within cells of the lymphoreticular system(3,4). Here we investigate the identity of these cells by using a panel of immune-deficient mice inoculated with prions intraperitoneally: we found that defects affecting only T lymphocytes had no apparent effect, but that all mutations that disrupted the differentiation and response of B lymphocytes prevented the development of clinical scrapie. As an absence of B cells and of antibodies correlates with severe defects in follicular dendritic cells, a lack of any of these three components may prevent the development of clinical scrapie. However, we found that scrapie developed after peripheral inoculation in mice expressing immunoglobulins that were exclusively of the M subclass and without detectable specificity for the normal form of the prion PrPc, and in mice which had differentiated B cells but no functional follicular dendritic cells. We conclude that differentiated B cells are crucial for neuroinvasion by scrapie, regardless of the specificity of their receptors.	UNIV ZURICH,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,INST MOL BIOL,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,INST EXPT IMMUNOL,CH-8091 ZURICH,SWITZERLAND; HOFFMANN LA ROCHE AG,CH-4070 BASEL,SWITZERLAND; UNIV ZURICH,INST LAB ANIM SCI,CH-8057 ZURICH,SWITZERLAND	University of Zurich; University of Zurich; University of Zurich; Roche Holding; University of Zurich				Kalinke, Ulrich/0000-0003-0503-9564; Aguzzi, Adriano/0000-0002-0344-6708				Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Eigen M, 1996, BIOPHYS CHEM, V63, pA1, DOI 10.1016/S0301-4622(96)02250-8; FARQUHAR CF, 1989, J VIROL METHODS, V24, P215, DOI 10.1016/0166-0934(89)90023-2; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Fraser H, 1996, J GEN VIROL, V77, P1935, DOI 10.1099/0022-1317-77-8-1935; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HUMPHREY JH, 1984, EUR J IMMUNOL, V14, P859, DOI 10.1002/eji.1830140916; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kalinke U, 1996, IMMUNITY, V5, P639, DOI 10.1016/S1074-7613(00)80277-0; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Lasmezas CI, 1996, J VIROL, V70, P1292; LeHir M, 1996, J EXP MED, V183, P2367, DOI 10.1084/jem.183.5.2367; LEUNG WPF, 1991, CELL, V65, P443; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; NONOYAMA S, 1993, J IMMUNOL, V150, P3817; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	29	417	425	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					687	690		10.1038/37789	http://dx.doi.org/10.1038/37789			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414161				2022-12-28	WOS:A1997YM50800032
J	Gillman, MW; Cupples, LA; Millen, BE; Ellison, RC; Wolf, PA				Gillman, MW; Cupples, LA; Millen, BE; Ellison, RC; Wolf, PA			Inverse association of dietary fat with development of ischemic stroke in men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; SPONTANEOUSLY HYPERTENSIVE RATS; JAPANESE MEN; BLOOD-PRESSURE; FOLLOW-UP; MORTALITY; RISK; POPULATIONS; CALIFORNIA; PROGRAM	Context.-A few ecological and cohort studies in Asian populations suggest an inverse association of the intake of both fat and saturated fat with risk of stroke. However, data among western populations are scant. Objective.-To examine the association of stroke incidence with intake of fat and type of fat among middle-aged US men during 20 years of follow-up. Design and Setting.-The Framingham Heart Study, a population-based cohort study. Participants.-A total of 832 men, aged 45 through 65 years, who were free of cardiovascular disease at baseline (1966-1969). Measurements and Data Analysis.-The diet of each subject was assessed at baseline by a single 24-hour dietary recall, from which intakes of energy and macronutrients were estimated. In Kaplan-Meier analyses, we calculated age-adjusted cumulative incidence rates of stroke. Using Cox regression, we estimated stroke incidence relative risks during 20 years of follow-up. Main Outcome Measure.-Incidence of ischemic stroke, which occurred in 61 subjects during the follow-up period. Results.-Mean intakes were 10 975 kJ for energy; 114g (39% of energy) for total fat; 44g (15%) for saturated fat; 46 g (16%) for monounsaturated fat; and 16 g (5%) for polyunsaturated fat. Risk of ischemic stroke declined across the increasing quintile of total fat (log-rank trend P=.008), saturated fat (P=.002), and monounsaturated fat (P=.008) but not polyunsaturated fat (P=.33). The age-and energy-adjusted relative risk for each increment of 3% of energy from total fat was 0.85 (95% confidence interval [CI], 0.78-0.94); for an increment of 1% from saturated fat, 0.91 (95% CI, 0.85-0.98); and for 1% from monounsaturated fat, 0.89 (95% CI, 0.83-0.96). Adjustment for cigarette smoking, glucose intolerance, body mass index, blood pressure, blood cholesterol level, physical activity, and intake of vegetables and fruits and alcohol did not materially change the results. Too few cases of hemorrhagic stroke (n=14) occurred to draw inferences. Conclusion.-Intakes of fat, saturated fat, and monounsaturated fat were associated with reduced risk of ischemic stroke in men.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Boston Univ, Sch Publ Hlth, Boston, MA USA; Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Boston University; Boston University; Boston University	Gillman, MW (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 126 Brookline Ave,Suite 200, Boston, MA 02215 USA.			Ellison, Robert Curtis/0000-0002-0582-7467; Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01HC 38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; BRONNER LL, 1995, NEW ENGL J MED, V333, P1392, DOI 10.1056/NEJM199511233332106; CUPPLES LA, 1995, STAT MED, V14, P1731, DOI 10.1002/sim.4780141603; CUPPLES LA, 1987, NIH PUBLICATION; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; GARCIAPALMIERI MR, 1980, AM J CLIN NUTR, V33, P1818, DOI 10.1093/ajcn/33.8.1818; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; Gillman MW, 1997, EPIDEMIOLOGY, V8, P144, DOI 10.1097/00001648-199703000-00004; GORDON T, 1981, CIRCULATION, V63, P500, DOI 10.1161/01.CIR.63.3.500; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; IKEDA K, 1987, J NUTR SCI VITAMINOL, V33, P31, DOI 10.3177/jnsv.33.31; KANNEL WB, 1987, AM HEART J, V113, P1489, DOI 10.1016/0002-8703(87)90666-1; Katan MB, 1997, NEW ENGL J MED, V337, P563; Key TJA, 1996, BMJ-BRIT MED J, V313, P775, DOI 10.1136/bmj.313.7060.775; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KIMURA N, 1983, PREV MED, V12, P222, DOI 10.1016/0091-7435(83)90198-6; KLATSKY AL, 1987, J AM COLL CARDIOL, V9, pA78; KULLER L, 1971, AM J EPIDEMIOL, V93, P1; LAPIDUS L, 1986, AM J CLIN NUTR, V44, P444, DOI 10.1093/ajcn/44.4.444; MANN GV, 1962, AM J CLIN NUTR, V11, P200, DOI 10.1093/ajcn/11.3.200; MANSON JE, 1994, CIRCULATION, V89, P932; MCGEE D, 1985, INT J EPIDEMIOL, V14, P97, DOI 10.1093/ije/14.1.97; OMURA T, 1987, SOC SCI MED, V24, P401, DOI 10.1016/0277-9536(87)90212-7; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; Qizilbash N, 1995, LANCET, V346, P1647; REED D, 1985, HYPERTENSION, V7, P405, DOI 10.1161/01.HYP.7.3_Pt_1.405; REED DM, 1990, AM J EPIDEMIOL, V131, P579, DOI 10.1093/oxfordjournals.aje.a115542; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SHIMOKAWA T, 1988, LIFE SCI, V43, P2067, DOI 10.1016/0024-3205(88)90356-6; SIMON JA, 1995, STROKE, V26, P778, DOI 10.1161/01.STR.26.5.778; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; SYME SL, 1975, AM J EPIDEMIOL, V102, P477, DOI 10.1093/oxfordjournals.aje.a112185; TAKEYA Y, 1984, STROKE, V15, P15, DOI 10.1161/01.STR.15.1.15; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TILLOTSON JL, 1973, AM J CLIN NUTR, V26, P177, DOI 10.1093/ajcn/26.2.177; Willett W., 1990, NUTR EPIDEMIOLOGY; YAMORI Y, 1977, JPN HEART J, V18, P551; YAMORI Y, 1987, PREVENTION CARDIOVAS, P163	41	149	152	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2145	2150		10.1001/jama.278.24.2145	http://dx.doi.org/10.1001/jama.278.24.2145			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9417007				2022-12-28	WOS:000071022200029
J	Barbas, CF; Heine, A; Zhong, GF; Hoffmann, T; Gramatikova, S; Bjornestedt, R; List, B; Anderson, J; Stura, EA; Wilson, IA; Lerner, RA				Barbas, CF; Heine, A; Zhong, GF; Hoffmann, T; Gramatikova, S; Bjornestedt, R; List, B; Anderson, J; Stura, EA; Wilson, IA; Lerner, RA			Immune versus natural selection: Antibody aldolases with enzymic rates but broader scope	SCIENCE			English	Article							RABBIT MUSCLE ALDOLASE; AMINO-ACID SEQUENCE; ACTIVE-SITE; ACETOACETATE DECARBOXYLASE; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; REACTIVE IMMUNIZATION; CATALYTIC ANTIBODIES; IONIZATION CONSTANT; REPORTER GROUP	Structural and mechanistic studies show that when the selection criteria of the immune system are changed, catalytic antibodies that have the efficiency of natural enzymes evolve, but the catalytic antibodies are much more accepting of a wide range of substrates. The catalytic antibodies were prepared by reactive immunization, a process whereby the selection criteria of the immune system are changed from simple binding to chemical reactivity. This process yielded aldolase catalytic antibodies that approximated the rate acceleration of the natural enzyme used in glycolysis. Unlike the natural enzyme, however, the antibody aldolases catalyzed a variety of aldol reactions and decarboxylations. The crystal structure of one of these antibodies identified the reactive lysine residue that was selected in the immunization process. This lysine is deeply buried in a hydrophobic pocket at the base of the binding site, thereby accounting for its perturbed pK(a).			Barbas, CF (corresponding author), Scripps Res Inst, SKAGGS INST CHEM BIOL, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Stura, Enrico A./A-2793-2010; List, Benjamin/A-2121-2014	Stura, Enrico A./0000-0001-6718-2118; 	NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NCI NIH HHS [CA27489] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERY WJ, 1977, ANGEW CHEM INT EDIT, V16, P285, DOI 10.1002/anie.197702851; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; BALDWIN JE, 1982, TETRAHEDRON, V38, P2939, DOI 10.1016/0040-4020(82)85023-0; BALDWIN JE, UNPUB; Bjornestedt R, 1996, J AM CHEM SOC, V118, P11720, DOI 10.1021/ja9620797; BRADY RL, 1992, J MOL BIOL, V227, P253, DOI 10.1016/0022-2836(92)90695-G; BRUICE PY, 1990, J AM CHEM SOC, V112, P7361, DOI 10.1021/ja00176a041; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Castellano J.A., 1992, HDB DISPLAY TECHNOLO; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; FASTREZ J, 1973, BIOCHEMISTRY-US, V12, P1067, DOI 10.1021/bi00730a008; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREY PA, 1971, J AM CHEM SOC, V93, P7266, DOI 10.1021/ja00755a024; GUDDAT LW, 1994, J MOL BIOL, V236, P247, DOI 10.1006/jmbi.1994.1133; HANSCH C, 1970, J PHARM SCI, V59, P731, DOI 10.1002/jps.2600590602; HESTER G, 1991, FEBS LETT, V292, P237, DOI 10.1016/0014-5793(91)80875-4; Highbarger LA, 1996, BIOCHEMISTRY-US, V35, P41, DOI 10.1021/bi9518306; HINE J, 1972, J AM CHEM SOC, V94, P190, DOI 10.1021/ja00756a033; HsiehWilson LC, 1996, P NATL ACAD SCI USA, V93, P5363, DOI 10.1073/pnas.93.11.5363; Jencks W. P., 1975, CATALYSIS CHEM ENZYM; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat EA, 1991, SEQUENCES PROTEINS I; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KOKESH FC, 1971, J AM CHEM SOC, V93, P7270, DOI 10.1021/ja00755a025; LAI CY, 1974, SCIENCE, V183, P1204, DOI 10.1126/science.183.4130.1204; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JK, 1997, SCIENCE, V276, P942, DOI 10.1126/science.276.5314.942; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; MARSH JJ, 1992, TRENDS BIOCHEM SCI, V17, P110, DOI 10.1016/0968-0004(92)90247-7; MORRIS AJ, 1994, BIOCHEMISTRY-US, V33, P12291, DOI 10.1021/bi00206a036; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REYMOND JL, 1995, J ORG CHEM, V60, P6970, DOI 10.1021/jo00126a057; Richardson J.S., 1990, PREDICTION PROTEIN S, P1; RUTTER WJ, 1964, FED PROC, V23, P1248; SCHMIDT DE, 1971, BIOCHEMISTRY-US, V10, P1249; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHELDRICK GM, 1996, SHELXL 96 PROGRAM CR; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; VLAHOS CJ, 1986, J BIOL CHEM, V261, P1049; WADA H, 1962, J BIOL CHEM, V237, P133; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775; WONG CH, 1995, ANGEW CHEM INT EDIT, V34, P412, DOI 10.1002/anie.199504121; Zhong GF, 1997, J AM CHEM SOC, V119, P8131, DOI 10.1021/ja970944x; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	51	340	355	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2085	2092		10.1126/science.278.5346.2085	http://dx.doi.org/10.1126/science.278.5346.2085			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405338				2022-12-28	WOS:A1997YM23500043
J	Lee, SJ; Kuntz, KM; Horowitz, MM; McGlave, PB; Goldman, JM; Sobocinski, KA; Hegland, J; Kollman, C; Parsons, SK; Weinstein, MC; Weeks, JC; Antin, JH				Lee, SJ; Kuntz, KM; Horowitz, MM; McGlave, PB; Goldman, JM; Sobocinski, KA; Hegland, J; Kollman, C; Parsons, SK; Weinstein, MC; Weeks, JC; Antin, JH			Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: A decision analysis	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; CHRONIC GRANULOCYTIC-LEUKEMIA; GRAFT-VERSUS-LEUKEMIA; INTERFERON-ALPHA THERAPY; CHRONIC-PHASE; MULTIVARIATE-ANALYSIS; HOST DISEASE; PROGNOSTIC DISCRIMINATION; PATIENT CHARACTERISTICS; CYTOGENETIC RESPONSE	Background: Chronic myelogenous leukemia (CML) is an indolent but ultimately fatal disease. Because the natural history of CML varies and quality of life with CML may be excellent until shortly before death, deciding whether and when to pursue unrelated donor bone marrow transplantation is often difficult. Objective: To compare early transplantation, delayed transplantation, and no transplantation ?or patients with chronic-phase CML on the basis of discounted, quality-adjusted life expectancy. Design: A Markov model comparing different strategies was constructed. This model considers patient age, quality of life, risk aversion, and the competing risks for CML progression and transplant toxicity. Setting: Therapeutic decision at the time of diagnosis of CML. Patients: The base case is a 35-year-old patient with intermediate-prognosis CML. Younger and older patients with better and worse prognoses are also evaluated. Intervention: Early transplantation, delayed transplantation, and no transplantation. Measurements: Quality-adjusted, discounted life expectancy. Results: For patients with newly diagnosed CML, transplantation within the first year provides the greatest quality-adjusted expected survival, although this benefit decreases with increasing patient age. For a 35-year-old patient with intermediate-prognosis CML, transplantation within the first year results in 5.3 more discounted, quality-adjusted years of life expectancy than does no transplantation. This finding is robust even with varying baseline assumptions. Conclusions: These results support the use of early unrelated donor bone marrow transplantation for most patients with CML.	Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Natl Marrow Donor Program, Minneapolis, MN 55413 USA; Royal Postgrad Med Sch, Dept Haematol, London W12 0NN, England; Med Coll Wisconsin, Int Bone Marrow Transplant Registry, Ctr Stat, Milwaukee, WI 53226 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; University of Minnesota System; University of Minnesota Twin Cities; National Marrow Donor Program; Imperial College London; Medical College of Wisconsin	Lee, SJ (corresponding author), Dana Farber Canc Inst, Ctr Outcomes & Policy Res, 454 Brookline Ave,Suite 23, Boston, MA 02115 USA.		horowitz, Mary/ABH-2173-2021		NCI NIH HHS [P01-CA-40053, CP-21161] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; ANTIN JH, 1993, BLOOD, V82, P2273; BACIGALUPO A, 1993, BONE MARROW TRANSPL, V12, P443; BEATTY PG, 1988, TRANSPLANTATION, V45, P714, DOI 10.1097/00007890-198804000-00010; Bhatia R, 1997, BLOOD, V89, P2623, DOI 10.1182/blood.V89.8.2623; BIGGS JC, 1992, BLOOD, V80, P1352; BORTIN MM, 1993, BONE MARROW TRANSPL, V12, P97; CERVANTES F, 1982, BLOOD, V60, P1298; CHAMPLIN RE, 1988, SEMIN HEMATOL, V25, P74; CHAPMAN GB, 1995, MED DECIS MAKING, V15, P373, DOI 10.1177/0272989X9501500408; DEVERGIE A, 1990, BONE MARROW TRANSPL, V5, P379; DROBYSKI WR, 1993, BLOOD, V82, P2310; Duell T, 1997, ANN INTERN MED, V126, P184, DOI 10.7326/0003-4819-126-3-199702010-00002; Enright H, 1996, BLOOD, V88, P714, DOI 10.1182/blood.V88.2.714.bloodjournal882714; Enright H, 1996, BONE MARROW TRANSPL, V17, P537; GALIMBERTI M, 1994, BONE MARROW TRANSPL, V13, P197; GIRALT S, 1995, BLOOD, V86, P4337, DOI 10.1182/blood.V86.11.4337.bloodjournal86114337; Gluckman E, 1996, BLOOD, V88, P2436; GOLDMAN JM, 1993, BLOOD, V82, P2235; GRATWOHL A, 1993, BONE MARROW TRANSPL, V12, P509; Gratwohl A, 1996, BRIT J HAEMATOL, V92, P35, DOI 10.1046/j.1365-2141.1996.00292.x; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; Hasford J, 1996, BLOOD, V87, P5384, DOI 10.1182/blood.V87.12.5384.bloodjournal87125384; HEHLMANN R, 1993, BLOOD, V82, P398, DOI 10.1182/blood.V82.2.398.bloodjournal822398; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; KANTARJIAN HM, 1995, ANN INTERN MED, V122, P254, DOI 10.7326/0003-4819-122-4-199502150-00003; Kantarjian HM, 1996, BLOOD, V87, P3069, DOI 10.1182/blood.V87.8.3069.bloodjournal8783069; KANTARJIAN HM, 1990, AM J MED, V88, P1, DOI 10.1016/0002-9343(90)90119-X; KANTARJIAN HM, 1985, BLOOD, V66, P1326; KARANAS A, 1968, BLOOD, V32, P445, DOI 10.1182/blood.V32.3.445.445; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; MACKINNON S, 1995, BLOOD, V86, P1261, DOI 10.1182/blood.V86.4.1261.bloodjournal8641261; MARKS DI, 1993, ANN INTERN MED, V119, P207, DOI 10.7326/0003-4819-119-3-199308010-00005; MARTIN PJ, 1988, BLOOD, V72, P1978; MCGLAVE P, 1993, BLOOD, V81, P543; MCGLAVE PB, 1994, LANCET, V343, P1486, DOI 10.1016/S0140-6736(94)92589-5; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; OHNISHI K, 1995, BLOOD, V86, P906; OZER H, 1993, BLOOD, V82, P2975; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PORTER DL, 1994, NEW ENGL J MED, V330, P100, DOI 10.1056/NEJM199401133300204; REDELMEIER DA, 1993, MED DECIS MAKING, V13, P212, DOI 10.1177/0272989X9301300306; SACCHI S, 1995, J CLIN ONCOL, V13, P2401, DOI 10.1200/JCO.1995.13.9.2401; SEGEL GB, 1986, BLOOD, V68, P1055; SIMON W, 1988, BRIT J HAEMATOL, V70, P31, DOI 10.1111/j.1365-2141.1988.tb02430.x; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; SOKAL JE, 1985, BLOOD, V66, P1352; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SPIERS ASD, 1979, BRIT J HAEMATOL, V41, P1, DOI 10.1111/j.1365-2141.1979.tb03675.x; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TURA S, 1994, NEW ENGL J MED, V330, P820; TURA S, 1981, BRIT J HAEMATOL, V47, P105, DOI 10.1111/j.1365-2141.1981.tb02765.x; TURA S, 1992, HAEMATOLOGICA, V77, P204; von Neumann J., 1953, THEORY GAMES EC BEHA; WAGNER JE, 1992, J CLIN ONCOL, V10, P779, DOI 10.1200/JCO.1992.10.5.779; WETZLER M, 1995, AM J MED, V99, P402, DOI 10.1016/S0002-9343(99)80189-2	56	60	60	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1080	1088		10.7326/0003-4819-127-12-199712150-00005	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412310				2022-12-28	WOS:000070936600004
J	Fellin, R; Ble, A				Fellin, R; Ble, A			The disease of Immanuel Kant	LANCET			English	Article											Fellin, R (corresponding author), UNIV FERRARA,DEPT INTERNAL MED 2,VIA SAVONAROLA 9,I-44100 FERRARA,ITALY.							Alzheimer A., 1907, ALLGEMEINE Z PSYCHIA, V64, P146, DOI DOI 10.1002/CA.980080612; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Borowski L.E., 1912, I KANT SEIN LEBEN DA; CASSANO GB, 1994, TRATTATO ITALIANO PS; Cassirer E., 1918, KANTS LEBEN LEHRE; DIETSCH H, 1982, MED WELT, V33, P570; EVDOKIMOV PP, 1986, KLIN MED MOSCOW+, V64, P148; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; THOM M, 1982, I KANT	10	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 13	1997	350	9093					1771	1773		10.1016/S0140-6736(97)03202-9	http://dx.doi.org/10.1016/S0140-6736(97)03202-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413481				2022-12-28	WOS:A1997YL55400044
J	Powell, RJ; Holbrook, MR; Stevens, A				Powell, RJ; Holbrook, MR; Stevens, A			Pyoderma gangrenosum and its treatment	LANCET			English	Editorial Material									QUEENS MED CTR,DEPT HISTOPATHOL,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	Powell, RJ (corresponding author), QUEENS MED CTR,DEPT CLIN IMMUNOL,NOTTINGHAM NG7 2UH,ENGLAND.							ABUELMAGD K, 1991, TRANSPLANT P, V23, P3328; BECHSTEIN WO, 1993, TRANSPLANT P, V25, P702; Bulvik S, 1997, BRIT J DERMATOL, V136, P637, DOI 10.1111/j.1365-2133.1997.tb02169.x; CHAMPION RH, 1992, TXB DERMATOLOGY, P1922; Chow RKP, 1996, J AM ACAD DERMATOL, V34, P1047, DOI 10.1016/S0190-9622(96)90285-6; Enk AH, 1997, LANCET, V350, P494, DOI 10.1016/S0140-6736(05)63084-X; MARTIS WL, 1992, ARCH DERMATOL, V128, P1060; NORWACK R, 1997, LANCET, V349, P774; Ostraat O, 1995, TRANSPLANT P, V27, P3540; Tamir A, 1996, DERMATOLOGY, V192, P252, DOI 10.1159/000246377	10	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 13	1997	350	9093					1720	1721		10.1016/S0140-6736(05)63568-4	http://dx.doi.org/10.1016/S0140-6736(05)63568-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413459				2022-12-28	WOS:A1997YL55400004
J	Hiramatsu, K; Aritaka, N; Hanaki, H; Kawasaki, S; Hosoda, Y; Hori, S; Fukuchi, Y; Kobayashi, I				Hiramatsu, K; Aritaka, N; Hanaki, H; Kawasaki, S; Hosoda, Y; Hori, S; Fukuchi, Y; Kobayashi, I			Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin	LANCET			English	Article							METHICILLIN-RESISTANT; TEICOPLANIN; SUSCEPTIBILITY; EVOLUTION; SET	Background Since the discovery of the vancomycin-resistant Staphylococcus aureus (VRSA) strain Mu50 (minimum inhibitory concentration [MIG] 8 mg/L), there has been concern about the potential spread of such strains throughout Japanese hospitals. Two important questions need to be answered: (1) what is the prevalence of VRSA, and (2) by what mechanism does vancomycin resistance occur. Methods The vancomycin susceptibilities of three methicillin-resistant S aureus (MRSA) strains (Mu50, Mu3, and H1) and the methicillin-susceptible S aureus type strain FDA209P were compared by MIC determinations and population analysis. Mu3 (MIC 3 mg/L) was isolated from the sputum of a patient with pneumonia after surgery who had failed vancomycin therapy. H1 (MIG 2 mg/L), which is a representative vancomycin-susceptible MRSA strain, was isolated from a patient with pneumonia who responded favourably to vancomycin therapy. Subclones of Mu3 with increased resistance against vancomycin were selected with serial concentrations of vancomycin and their MICs were determined. The prevalence of VRSA and Mu3-like strains in Japanese hospitals was estimated by population analysis from 1149 clinical MRSA isolates obtained from 203 hospitals throughout Japan. The genetic traits of the Mu3 and Mu50 strains were compared with clonotypes of MRSA from around the world. Findings Mu3 and Mu50 had an identical pulsed-field gel electrophoresis banding pattern. When grown in a drug-free medium, Mu3 produced subpopulation of cells with varying degrees of vancomycin resistance, thus demonstrating natural heterogeneity, or variability, in susceptibility to vancomycin. In the presence of vancomycin, Mu3 produced subclones with resistance roughly proportional to the concentrations of vancomycin used, Selection of Mu3 with 8 mg/L or more of vancomycin gave rise to subclones with vancomycin resistance equal to that of Mu50 (MIG 8 mg/L) at a frequency of 1/1 000 000. During screening of Japanese MRSA strains, no strain of VRSA additional to Mu50 was found. The prevalence of MRSA isolates heterogeneously resistant to vancomycin was 20% in Juntendo University Hospital, 9.3% in the other seven university hospitals, and 1.3% in non-university hospitals or clinics. Interpretation Heterogeneously resistant VRSA is a preliminary stage that allows development into VRSA upon exposure to vancomycin. Heterogeneously resistant VRSA was found in hospitals throughout Japan. This finding could explain, at least partly, the frequent therapeutic failure of MRSA infection with vancomycin in Japan.	JUNTENDO UNIV,DEPT CARDIOTHORAC SURG,BUNKYO KU,TOKYO 113,JAPAN; JUNTENDO UNIV,DEPT RESP MED,BUNKYO KU,TOKYO 113,JAPAN; MITSUBISHI CHEM BCL,TOKYO,JAPAN	Juntendo University; Juntendo University	Hiramatsu, K (corresponding author), JUNTENDO UNIV,DEPT BACTERIOL,BUNKYO KU,2-1-1 HONGO,TOKYO 113,JAPAN.			HORI, Satoshi/0000-0001-5205-1270				AOKI Y, 1995, ASEAN JAP SEM WORKSH, P47; Asada K, 1995, ACTA BIOCHIM POL, V42, P517; BARBER M, 1964, J GEN MICROBIOL, V35, P183, DOI 10.1099/00221287-35-2-183; BERGERBACHI B, 1986, EUR J CLIN MICROBIOL, V5, P697, DOI 10.1007/BF02013308; BRUNET F, 1994, EUR J CLIN MICROBIOL, V9, P145; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P635; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P626; COURVALIN P, 1990, ANTIMICROB AGENTS CH, V34, P2291, DOI 10.1128/AAC.34.12.2291; DAUM RS, 1992, J INFECT DIS, V166, P1066, DOI 10.1093/infdis/166.5.1066; DYKE KGH, 1969, J MED MICROBIOL, V2, P261, DOI 10.1099/00222615-2-3-261; Hashimoto Hajime, 1994, Japanese Journal of Antibiotics, V47, P618; HIRAMATSU K, 1995, MICROBIOL IMMUNOL, V39, P531, DOI 10.1111/j.1348-0421.1995.tb02239.x; Hiramatsu K, 1996, J INFECT CHEMOTHER, V2, P117, DOI [10.1007/bf02351563, 10.1007/BF02351563, DOI 10.1007/BF02351563]; KAATZ GW, 1990, J INFECT DIS, V162, P103, DOI 10.1093/infdis/162.1.103; MAINARDI JL, 1995, J INFECT DIS, V171, P1646, DOI 10.1093/infdis/171.6.1646; NIITSUMA K, 1996, ANTIBIOT CHEMOTHER, V122, P123; PETERSON LR, 1997, CLIN MICROBIOL REV, V5, P420; Shimada K, 1995, JPN J CHEMOTHER, V43, P1048; SHLAES DM, 1995, CLIN INFECT DIS, V20, P1071, DOI 10.1093/clinids/20.4.1071; Sieradzki K, 1997, J BACTERIOL, V179, P2557, DOI 10.1128/jb.179.8.2557-2566.1997; Tanaka T, 1995, J INFECT CHEMOTHER, V1, P40; TORRESR JR, 1979, J ANTIMICROB CHEMOTH, V5, P475, DOI 10.1093/jac/5.4.475; WADA A, 1993, J BACTERIOL, V175, P7483, DOI 10.1128/JB.175.22.7483-7487.1993; Wayne P.A, 1997, PERF VOL ANT SUSC FL, Vsixth	24	948	1028	1	70	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1670	1673		10.1016/S0140-6736(97)07324-8	http://dx.doi.org/10.1016/S0140-6736(97)07324-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400512				2022-12-28	WOS:A1997YK21100012
J	Jacobs, C				Jacobs, C			Life in the balance: Cell walls and antibiotic resistance	SCIENCE			English	Article							BETA-LACTAMASE INDUCTION; ESCHERICHIA-COLI; AMPD				Jacobs, C (corresponding author), STANFORD UNIV,DEPT DEV BIOL,STANFORD,CA 94305, USA.							GOODELL EW, 1985, J BACTERIOL, V163, P305, DOI 10.1128/JB.163.1.305-310.1985; Jacobs C, 1997, CELL, V88, P823, DOI 10.1016/S0092-8674(00)81928-5; JACOBS C, 1995, MOL MICROBIOL, V15, P553, DOI 10.1111/j.1365-2958.1995.tb02268.x; JACOBS C, 1994, EMBO J, V13, P4684, DOI 10.1002/j.1460-2075.1994.tb06792.x; KORFMANN G, 1989, ANTIMICROB AGENTS CH, V33, P1946, DOI 10.1128/AAC.33.11.1946; LINDBERG F, 1987, J BACTERIOL, V169, P1923, DOI 10.1128/jb.169.5.1923-1928.1987; LINDBERG F, 1985, P NATL ACAD SCI USA, V82, P4620, DOI 10.1073/pnas.82.14.4620; MenginLecreulx D, 1996, J BACTERIOL, V178, P5347, DOI 10.1128/jb.178.18.5347-5352.1996; NORMARK S, 1994, N COMP BIOC, V27, P485	9	25	27	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1731	1732		10.1126/science.278.5344.1731b	http://dx.doi.org/10.1126/science.278.5344.1731b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9411793				2022-12-28	WOS:A1997YJ90100031
J	Fahlke, C; Yu, HT; Beck, CL; Rhodes, TH; George, AL				Fahlke, C; Yu, HT; Beck, CL; Rhodes, TH; George, AL			Pore-forming segments in voltage-gated chloride channels	NATURE			English	Article							MOLECULAR-BASIS; DOMINANT; MYOTONIA; CELLS	The ability to differentiate between ions is a property of ion channels that is crucial for their biological functions', However, the fundamental structural features that define anion selectivity and distinguish anion-permeable from cation-permeable channels are poorly understood, Voltage-gated chloride (Cl-) channels belonging to the ClC family are ubiquitous and have been predicted to play important roles in many diverse physiological(2) and pathophysiological(3-5) processes. We have identified regions of a human skeletal muscle ClC isoform that contribute to formation of its anion-selective conduction pathway. A core structural element (pi region) of the CIC channel pore spans an accessibility barrier between the internal and external milieu, and contains an evolutionarily conserved sequence motif: GKxGPxxH. Neighbouring sequences in the third and fifth transmembrane segments also contribute to isoform-specific differences in anion selectivity, The conserved motif in the Cl- channel Pl region may constitute a 'signature' sequence for an anion-selective ion pore by analogy with the homologous GYG sequence that is essential for selectivity in voltage-gated potassium ion (K+) channel pores(6-8).	VANDERBILT UNIV,SCH MED,DEPT MED NEPHROL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,CTR MOL NEUROSCI,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University			Fahlke, Christoph/G-3635-2013	Fahlke, Christoph/0000-0001-8602-9952				AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; DANI JA, 1983, J GEN PHYSIOL, V81, P255, DOI 10.1085/jgp.81.2.255; Fahlke C, 1997, P NATL ACAD SCI USA, V94, P2729, DOI 10.1073/pnas.94.6.2729; Fahlke C, 1996, BIOPHYS J, V71, P695, DOI 10.1016/S0006-3495(96)79269-X; FAHLKE C, 1995, NEURON, V15, P463, DOI 10.1016/0896-6273(95)90050-0; FAHLKE C, J GEN PHYSIOL, V110, P551; GEORGE AL, 1993, NAT GENET, V3, P305, DOI 10.1038/ng0493-305; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hille B., 1992, IONIC CHANNELS EXCIT; JENTSCH TJ, 1994, CURR TOP MEMBR, V42, P35, DOI 10.1016/S0070-2161(08)60817-5; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0	21	159	161	2	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					529	532		10.1038/37391	http://dx.doi.org/10.1038/37391			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394005				2022-12-28	WOS:A1997YJ86500057
J	Pidoplichko, VI; DeBiasi, M; Williams, JT; Dani, JA				Pidoplichko, VI; DeBiasi, M; Williams, JT; Dani, JA			Nicotine activates and desensitizes midbrain dopamine neurons	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; SYNAPTIC TRANSMISSION; RAT; ADDICTION; SYSTEM	Tobacco use in developed countries is estimated to be the single largest cause of premature death(1), Nicotine is the primary component of tobacco that drives use, and like other addictive drugs, nicotine reinforces self-administration and place preference in animal studies(2-5). Midbrain dopamine neurons normally help to shape behaviour by reinforcing biologically rewarding events, but addictive drugs such as cocaine can inappropriately exert a reinforcing influence by acting upon the mesolimbic dopamine system(3-6). Here we show that the same concentration of nicotine achieved by smokers activates and desensitizes multiple nicotinic receptors thereby regulating the activity of mesolimbic dopamine neurons, Initial application of nicotine can increase the activity of the dopamine neurons, which could mediate the rewarding aspects of tobacco use, Prolonged exposure to even these low concentrations of nicotine, however, can cause desensitization of the nicotinic receptors, which helps to explain acute tolerance to nicotine's effects, The effects suggest a cellular basis for reports that the first cigarette of the day is the most pleasurable, whereas the effect of subsequent cigarettes may depend on the interplay between activation and desensitization of multiple nicotinic receptors(5).	BAYLOR COLL MED, DIV NEUROSCI, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOL PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA; OREGON HLTH SCI UNIV, VOLLUM INST ADV BIOMED RES, PORTLAND, OR 97201 USA	Baylor College of Medicine; Baylor College of Medicine; Oregon Health & Science University			De Biasi, Mariella/M-7646-2017	De Biasi, Mariella/0000-0002-0687-8872				ALKONDON M, 1993, J PHARMACOL EXP THER, V265, P1455; BENOWITZ NL, 1989, PROG BRAIN RES, V79, P279; Bonci A, 1996, NEURON, V16, P631, DOI 10.1016/S0896-6273(00)80082-3; Briggs CA, 1996, NEUROPHARMACOLOGY, V35, P407, DOI 10.1016/0028-3908(96)00006-8; CALABRESI P, 1989, BRIT J PHARMACOL, V98, P135, DOI 10.1111/j.1476-5381.1989.tb16873.x; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; CLARKE PBS, 1993, PROG BRAIN RES, V98, P77; CLARKE PBS, 1991, ADV PHAR SC, P285; CORRIGALL WA, 1994, BRAIN RES, V653, P278, DOI 10.1016/0006-8993(94)90401-4; CORRIGALL WA, 1991, PSYCHOPHARMACOLOGY, V104, P171, DOI 10.1007/BF02244174; CORRIGALL WA, 1989, PSYCHOPHARMACOLOGY, V99, P473, DOI 10.1007/BF00589894; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; Gray R, 1996, NATURE, V383, P713, DOI 10.1038/383713a0; HENNINGFIELD JE, 1993, DRUG ALCOHOL DEPEN, V33, P23, DOI 10.1016/0376-8716(93)90030-T; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; KANG Y, 1993, NEUROSCI RES, V18, P209, DOI 10.1016/0168-0102(93)90056-V; LESTER RAJ, 1994, NEUROPHARMACOLOGY, V33, P27, DOI 10.1016/0028-3908(94)90093-0; MARKS MJ, 1992, J NEUROSCI, V12, P2765; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MERCURI NB, 1995, EUR J NEUROSCI, V7, P462, DOI 10.1111/j.1460-9568.1995.tb00342.x; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; Pich EM, 1997, SCIENCE, V275, P83; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SEGUELA P, 1993, J NEUROSCI, V13, P596; STOLERMAN IP, 1991, TRENDS PHARMACOL SCI, V12, P467, DOI 10.1016/0165-6147(91)90638-9; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WONNACOTT S, 1990, TRENDS PHARMACOL SCI, V11, P216, DOI 10.1016/0165-6147(90)90242-Z	30	566	573	0	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 27	1997	390	6658					401	404		10.1038/37120	http://dx.doi.org/10.1038/37120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389479				2022-12-28	WOS:A1997YH54900063
J	Culpepper, L; Froom, J				Culpepper, L; Froom, J			Routine antimicrobial treatment of acute otitis media - Is it necessary?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; PLACEBO-CONTROLLED TRIAL; ANTIBIOTIC-TREATMENT; BACTERIAL-MENINGITIS; DRUG-RESISTANCE; DAY-CARE; CHILDREN; PENICILLIN; DIAGNOSIS; THERAPY		SUNY STONY BROOK, SCH MED, DEPT FAMILY MED, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Culpepper, L (corresponding author), BOSTON UNIV, SCH MED, DEPT FAMILY MED, 1 BOSTON MED CTR PL, BOSTON, MA 02118 USA.			Culpepper, Larry/0000-0002-7655-0477	AHRQ HHS [R01 HS0703503] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		APPELBAUM PC, 1987, EUR J CLIN MICROBIOL, V6, P367, DOI 10.1007/BF02013089; APPELMAN CLM, 1991, BMJ-BRIT MED J, V303, P1450, DOI 10.1136/bmj.303.6815.1450; BAIN J, 1985, BRIT MED J, V291, P1243, DOI 10.1136/bmj.291.6504.1243; BARNETT ED, 1995, PEDIATR CLIN N AM, V42, P509; BLUESTONE CD, 1988, OTITIS MEDIA INFANTS, P45; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; Centers for Disease Control, 1994, MORBIDITY MORTALITY, V43, P1; CLAESSEN JQPJ, 1992, CLIN OTOLARYNGOL, V17, P251, DOI 10.1111/j.1365-2273.1992.tb01838.x; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DENEELING AJ, 1993, RESISTENTIE TEGEN AN; DESAINTONGE DMC, 1982, BRIT MED J, V284, P1078; EAVEY RD, 1985, J PEDIATR-US, V106, P402, DOI 10.1016/S0022-3476(85)80664-8; FADEN H, 1992, ANN OTO RHINOL LARYN, V101, P87, DOI 10.1177/000348949210100119; FADEN H, 1994, PEDIATR INFECT DIS J, V13, P609, DOI 10.1097/00006454-199407000-00005; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; Froom J, 1993, Arch Fam Med, V2, P841, DOI 10.1001/archfami.2.8.841; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; HALSTED C, 1968, AM J DIS CHILD, V115, P542, DOI 10.1001/archpedi.1968.02100010544003; HARRISON CJ, 1985, PEDIATR INFECT DIS J, V4, P641, DOI 10.1097/00006454-198511000-00009; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; HENDRICKSE WA, 1988, PEDIATR INFECT DIS J, V7, P14, DOI 10.1097/00006454-198801000-00005; HOWIE VM, 1972, CLIN PEDIATR, V11, P205, DOI 10.1177/000992287201100407; KALEIDA PH, 1991, PEDIATRICS, V87, P466; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; KLEIN JO, 1994, CLIN INFECT DIS, V19, P823, DOI 10.1093/clinids/19.5.823; KOSHLAND DE, 1992, SCIENCE, V257, P1021, DOI 10.1126/science.257.5073.1021; LAXDAL OE, 1970, CAN MED ASSOC J, V102, P263; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MEISTRUPLARSEN KI, 1983, ACTA OTO-LARYNGOL, V96, P99, DOI 10.3109/00016488309132879; MYGIND N, 1981, CLIN OTOLARYNGOL, V6, P5, DOI 10.1111/j.1365-2273.1981.tb01781.x; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; ROSENFELD RM, 1994, J PEDIATR-US, V124, P355, DOI 10.1016/S0022-3476(94)70356-6; SLOAS MM, 1992, PEDIATR INFECT DIS J, V11, P662; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P175, DOI 10.1001/jama.275.3.175; SUGITA R, 1983, INT J PEDIATR OTORHI, V6, P135; TOUWOTTEN FWMM, 1992, FAM PRACT, V9, P255, DOI 10.1093/fampra/9.3.255; TRUJILLO H, 1989, PEDIATR INFECT DIS J, V8, P361, DOI 10.1097/00006454-198906000-00007; VAN DISHOECK H A, 1959, Acta Otolaryngol, V50, P250; van Klingeren B, 1992, Ned Tijdschr Geneeskd, V136, P860; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VANBUCHEM FL, 1981, LANCET, V2, P883	42	47	47	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1643	1645		10.1001/jama.278.20.1643	http://dx.doi.org/10.1001/jama.278.20.1643			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388073				2022-12-28	WOS:A1997YG85900002
J	Xue, D; Horvitz, HR				Xue, D; Horvitz, HR			Caenorhabditis elegans CED-9 protein is a bifunctional cell-death inhibitor	NATURE			English	Article							C-ELEGANS; CYSTEINE PROTEASE; BCL-2; GENE; P35; APOPTOSIS; SURVIVAL; ENCODES; EXPRESSION; PREVENTION	The Caenorhabditis elegans gene ced-9 prevents cells from undergoing programmed cell death and encodes a protein similar to the mammalian cell-death inhibitor Bcl-2 (refs 1-7). We show here that the CED-9 protein is a substrate for the C. elegans cell-death protease CED-3 (refs 8, 9), which is a member of a family of cysteine proteases first defined by CED-3 and human interleukin-1 beta converting enzyme (ICE)(10-12). CED-9 can be cleaved by CED-3 at two sites near its amino terminus, and the presence of at least one of these sites is important for complete protection by CED-9 against cell death. Cleavage of CED-9 by CED-3 generates a carboxy-terminal product that resembles Bcl-2 in sequence and in function. Bcl-2 and the baculovirus protein p35, which inhibits cell death in different species through a mechanism that depends on the presence of its cleavage site for the CED-3/ICE family of proteases(9,13-17), inhibit cell death additively in C. elegans, Our results indicate that CED-9 prevents programmed cell death in C. elegans through two distinct mechanisms: first, CED-9 may, by analogy with p35 (refs 9, 17), directly inhibit the CED-3 protease by an interaction involving the CED-3 cleavage sites in CED-9; second, CED-9 may directly or indirectly inhibit CED-3 by means of a protective mechanism similar to that used by mammalian Bcl-2.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)				XUE, DING/0000-0002-8429-8136				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; NUNEZ G, 1990, J IMMUNOL, V144, P3602; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sambrook J., 2002, MOL CLONING LAB MANU; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	30	98	111	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					305	308		10.1038/36889	http://dx.doi.org/10.1038/36889			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384385				2022-12-28	WOS:A1997YG66700068
J	Imai, T; Hieshima, K; Haskell, C; Baba, M; Nagira, M; Nishimura, M; Kakizaki, M; Takagi, S; Nomiyama, H; Schall, TJ; Yoshie, O				Imai, T; Hieshima, K; Haskell, C; Baba, M; Nagira, M; Nishimura, M; Kakizaki, M; Takagi, S; Nomiyama, H; Schall, TJ; Yoshie, O			Identification and molecular characterization of fractalkine receptor CX(3)CR1, which mediates both leukocyte migration and adhesion	CELL			English	Article							PROTEIN-COUPLED RECEPTOR; CHEMOATTRACTANT RECEPTORS; CHEMOKINE RECEPTORS; EXPRESSION; INFLAMMATION; BIOLOGY; GENE	Leukocyte trafficking at the endothelium requires both cellular adhesion molecules and chemotactic factors. Fractalkine, a novel transmembrane molecule with a CX3C-motif chemokine domain atop a mucin stalk, induces both adhesion and migration of leukocytes. Here we identify a seven-transmembrane high-affinity receptor for fractalkine and show that it mediates both the adhesive and migratory functions of fractalkine. The receptor, now termed CX(3)CR1, requires pertussis toxin-sensitive G protein signaling to induce migration but not to support adhesion, which also occurs without other adhesion molecules but requires the architecture of a chemokine domain atop the mucin stalk. Natural killer cells predominantly express CX(3)CR1 and respond to fractalkine in both migration and adhesion. Thus, fractalkine and CX(3)CR1 represent new types of leukocyte trafficking regulators, performing both adhesive and chemotactic functions.	KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT IMMUNOL,PALO ALTO,CA 94304	Kumamoto University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Imai, T (corresponding author), SHIONOGI INST MED SCI,SETTSU 566,JAPAN.		Nomiyama, Hisayuki/F-2840-2013; Hieshima, Kunio/AAF-7040-2019	Nomiyama, Hisayuki/0000-0002-2716-4043; Hieshima, Kunio/0000-0002-7786-4646; Yoshie, Osamu/0000-0003-4353-5809				Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; OIN S, 1996, EUR J IMMUNOL, V26, P640; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; RAPORT CJ, 1995, GENE, V163, P295, DOI 10.1016/0378-1119(95)00336-5; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	21	1096	1162	2	64	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					521	530		10.1016/S0092-8674(00)80438-9	http://dx.doi.org/10.1016/S0092-8674(00)80438-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390561	Bronze			2022-12-28	WOS:A1997YG49200013
J	Lynch, JW; Kaplan, GA; Shema, SJ				Lynch, JW; Kaplan, GA; Shema, SJ			Cumulative impact of sustained economic hardship on physical, cognitive, psychological, and social functioning	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALAMEDA COUNTY; UNITED-STATES; SOCIOECONOMIC-STATUS; RISK-FACTORS; MORTALITY; HEALTH; INCOME; HOSTILITY; DYNAMICS; DISEASE	Background Although the relation between low income and poor health is well established, most previous research has measured income at only one time. Methods We used income information collected in 1965, 1974, and 1983 from a representative sample of adults in Alameda County, California, to examine the cumulative effect of economic hardship (defined as a total household income of less than 200 percent of the federal poverty level) on participants who were alive in 1994. Results Because of missing information, analyses were based on between 1081 and 1124 participants (median age, 65 years in 1994). After adjustment for age and sex, there were significant graded associations between the number of times income was less than 200 percent of the poverty level (range, 0 to 3) and all measures of functioning examined except social isolation. As compared with subjects without economic hardship, those with economic hardship in 1965, 1974, and 1983 were much more likely to have difficulties with independent activities of daily living (such as cooking, shopping, and managing money) (odds ratio, 3.38; 95 percent confidence interval, 1.49 to 7.64), activities of daily living (such as walking, eating, dressing, and using the toilet) (odds ratio, 3.79; 95 percent confidence interval, 1.32 to 9.81), and clinical depression (odds ratio, 3.24; 95 percent confidence interval, 1.32 to 7.89) in 1994. We found little evidence of reverse causation - that is, that episodes of illness might have caused subsequent sconomic hardship. Conclusions Sustained economic hardship leads to poorer physical, psychological, and cognitive functioning.	Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA; Inst Publ Hlth, Human Populat Lab, Berkeley, CA USA	University of Michigan System; University of Michigan; Public Health Institute	Lynch, JW (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 109 Observ St, Ann Arbor, MI 48109 USA.		Kaplan, George/AAJ-2398-2020; Lynch, John W/A-4797-2008	Lynch, John W/0000-0003-2781-7902	NIA NIH HHS [1R37AG11375] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG011375] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Bartley M, 1996, BRIT MED J, V313, P445; Berkman LF, 1983, HLTH WAYS LIVING ALA; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; BRENNER MH, 1995, SOC HLTH, P211; Cox D. R., 1984, ANAL SURVIVAL DATA; DANZIGER S, 1995, AM UNEQUAL; Duncan GJ, 1996, INT J HEALTH SERV, V26, P419, DOI 10.2190/1KU0-4Y3K-ACFL-BYU7; DUNCAN GJ, 1993, J POPUL ECON, V6, P215, DOI 10.1007/BF00163068; Geronimus AT, 1996, NEW ENGL J MED, V335, P1552, DOI 10.1056/NEJM199611213352102; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; HAAN MN, 1989, PATHWAYS HLTH ROLE S, P76; HOSMER DW, 1989, APPL LOGISTIC REGRES; JULKUNEN J, 1994, PSYCHOSOM MED, V56, P519, DOI 10.1097/00006842-199411000-00007; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P818; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; KAPLAN GA, 1985, J CHRON DIS, V38, P195, DOI 10.1016/0021-9681(85)90092-X; Kaplan GA, 1996, BRIT MED J, V312, P1253; Kaplan GA, 1996, BRIT MED J, V312, P999; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Link BG, 1996, AM J PUBLIC HEALTH, V86, P471, DOI 10.2105/AJPH.86.4.471; LIU K, 1988, AM J EPIDEMIOL, V127, P864, DOI 10.1093/oxfordjournals.aje.a114870; Lynch J, 1996, ANN EPIDEMIOL, V6, P21, DOI 10.1016/1047-2797(95)00120-4; Lynch J W, 1997, J Health Psychol, V2, P297, DOI 10.1177/135910539700200303; Lynch JW, 1996, AM J EPIDEMIOL, V144, P934, DOI 10.1093/oxfordjournals.aje.a008863; Lynch JW, 1997, SOC SCI MED, V44, P809, DOI 10.1016/S0277-9536(96)00191-8; McDonough P, 1997, AM J PUBLIC HEALTH, V87, P1476, DOI 10.2105/AJPH.87.9.1476; MILLER TQ, 1995, J APPL SOC PSYCHOL, V25, P1142, DOI 10.1111/j.1559-1816.1995.tb02611.x; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; OAKLEY A, 1991, SOCIOLOGY, V25, P31, DOI 10.1177/0038038591025001003; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2344; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PAPPAS G, 1993, NEW ENGL J MED, V329, P1139; REYNOLDS P, 1990, BEHAV MED, V16, P101, DOI 10.1080/08964289.1990.9934597; ROBERTS RE, 1990, SOC SCI MED, V31, P527, DOI 10.1016/0277-9536(90)90087-9; *SAS I, 1989, SAS STAT US GUID VER, V2; SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063; Smith GD, 1996, AM J PUBLIC HEALTH, V86, P486, DOI 10.2105/AJPH.86.4.486; TURNER RJ, 1994, J HEALTH SOC BEHAV, V35, P193, DOI 10.2307/2137276; *US BUR CENS, 1995, 1995 STAT ABSTR US; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027	42	575	586	0	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 25	1997	337	26					1889	1895		10.1056/NEJM199712253372606	http://dx.doi.org/10.1056/NEJM199712253372606			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YN051	9407157	Bronze, Green Submitted			2022-12-28	WOS:000071128200006
J	Kramer, A; Keitel, T; Winkler, K; Stocklein, W; Hohne, W; SchneiderMergener, J				Kramer, A; Keitel, T; Winkler, K; Stocklein, W; Hohne, W; SchneiderMergener, J			Molecular basis for the binding promiscuity of an anti-p24 (HIV-1) monoclonal antibody	CELL			English	Article							PEPTIDE COMBINATORIAL LIBRARIES; ANTIGEN INTERACTIONS; CROSS-REACTIVITY; ESCHERICHIA-COLI; HIGH-AFFINITY; B-CELLS; PROTEIN; GENERATION; EXPRESSION; SURFACE	Multiple binding capabilities utilized by specific protein-to-protein interactions in molecular recognition events are being documented increasingly but remain poorly understood at the molecular level. We identified five unrelated peptides that compete with each other for binding to the paratope region of the monoclonal anti-p24 (HIV-1) antibody CB4-1 by using a synthetic positional scanning combinatorial library XXXX[B-1,B-2,B-3,X-1,X-2,X-3]XXXX (14 mers; 68,590 peptide mixtures in total) prepared by spot synthesis. Complete sets of substitution analogs of the five peptides revealed key interacting residues, information that led to the construction of binding supertopes derived from each peptide. These supertope sequences were identified in hundreds of heterologous proteins, and those proteins that could be obtained were shown to bind CB4-1. Implications of these findings for immune escape mechanisms and autoimmunity are discussed.	HUMBOLDT UNIV BERLIN,KLINIKUM CHARITE,INST MED IMMUNOL,D-10098 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,KLINIKUM CHARITE,INST BIOCHEM,D-10098 BERLIN,GERMANY; MAX DELBRUCK CENTRUM,UNIV POTSDAM,INST BIOCHEM & MOL PHYSIOL,D-13122 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Potsdam				Kramer, Achim/0000-0001-9671-6078				Appel JR, 1996, MOL DIVERS, V2, P29, DOI 10.1007/BF01718697; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BACCALA R, 1989, P NATL ACAD SCI USA, V86, P4624, DOI 10.1073/pnas.86.12.4624; BEREK C, 1988, IMMUNOL REV, V105, P5, DOI 10.1111/j.1600-065X.1988.tb00763.x; BURASTERO SE, 1988, J EXP MED, V168, P1979, DOI 10.1084/jem.168.6.1979; CARDOZO T, 1995, PROTEINS, V23, P403, DOI 10.1002/prot.340230314; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHRISTIAN RB, 1992, J MOL BIOL, V227, P711, DOI 10.1016/0022-2836(92)90219-A; Cornall RJ, 1995, CURR OPIN IMMUNOL, V7, P804, DOI 10.1016/0952-7915(95)80052-2; CUMANO A, 1986, EMBO J, V5, P2459, DOI 10.1002/j.1460-2075.1986.tb04522.x; DECIECHI PA, 1995, MOL DIV, V1, P79; Demangel C, 1996, MOL IMMUNOL, V33, P909, DOI 10.1016/S0161-5890(96)00058-2; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Ehrhard B, 1996, BIOCHEMISTRY-US, V35, P9097, DOI 10.1021/bi9603534; Forster T. H., 1946, NATURWISSENSCHAFTEN, V6, P166; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; Geysen H M, 1988, J Mol Recognit, V1, P32, DOI 10.1002/jmr.300010107; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GUILBERT B, 1982, J IMMUNOL, V128, P2779; HAUSDORF G, 1994, J VIROL METHODS, V50, P1, DOI 10.1016/0166-0934(94)90158-9; Hohne W E, 1993, Mol Immunol, V30, P1213, DOI 10.1016/0161-5890(93)90140-7; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JAHN S, 1995, IMMUNOBIOLOGY, V193, P400, DOI 10.1016/S0171-2985(11)80427-4; KAPLAN MH, 1962, LANCET, V1, P706; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; Keitel T, 1997, CELL, V91, P811, DOI 10.1016/S0092-8674(00)80469-9; KRAMER A, 1995, MOL IMMUNOL, V32, P459, DOI 10.1016/0161-5890(95)00006-Z; KRAMER A, 1997, IN PRESS METH MOL BI, V87; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; MALIN R, 1995, J AM CHEM SOC, V117, P11821, DOI 10.1021/ja00152a031; MARIUZZA RA, 1993, CURR OPIN IMMUNOL, V5, P50, DOI 10.1016/0952-7915(93)90080-C; NEEDELS MC, 1993, P NATL ACAD SCI USA, V90, P10700, DOI 10.1073/pnas.90.22.10700; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; OSHANNESSY DJ, 1990, ANAL BIOCHEM, V191, P1, DOI 10.1016/0003-2697(90)90377-L; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; PINILLA C, 1995, PEPTIDE RES, V8, P250; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; PINILLA C, 1993, MOL IMMUNOL, V30, P577, DOI 10.1016/0161-5890(93)90032-7; ROGGENBUCK D, 1994, SCAND J IMMUNOL, V40, P64, DOI 10.1111/j.1365-3083.1994.tb03434.x; ROSSLER D, 1995, MED MICROBIOL IMMUN, V184, P23, DOI 10.1007/BF00216786; SCHNEIDERMERGEN.J, 1996, COMBINATORIAL LIB, P53; SHARON J, 1990, P NATL ACAD SCI USA, V87, P4814, DOI 10.1073/pnas.87.12.4814; STIGLER RD, 1995, PROTEIN ENG, V8, P471, DOI 10.1093/protein/8.5.471; Valadon P, 1996, J MOL BIOL, V261, P11, DOI 10.1006/jmbi.1996.0438; VANREGENMORTEL MHV, 1994, IMMUNOCHEMISTRY, P277; VOLKMERENGERT R, 1994, LETT PEPT SCI, V1, P243; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WING MG, 1995, CLIN EXP IMMUNOL, V99, P313, DOI 10.1111/j.1365-2249.1995.tb05551.x; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; ZHANG ZX, 1994, CLIN EXP IMMUNOL, V96, P403	55	159	172	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					799	809		10.1016/S0092-8674(00)80468-7	http://dx.doi.org/10.1016/S0092-8674(00)80468-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413989	Bronze			2022-12-28	WOS:A1997YL43900011
J	Hershey, GKK; Friedrich, MF; Esswein, LA; Thomas, ML; Chatila, TA				Hershey, GKK; Friedrich, MF; Esswein, LA; Thomas, ML; Chatila, TA			The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMATOPOIETIC-CELL PHOSPHATASE; HYPER-IGE SYNDROME; TYROSINE PHOSPHORYLATION; GAMMA-CHAIN; SH2 DOMAIN; IL-4; ERYTHROPOIETIN; ALLERGENS; EXPOSURE; ASTHMA	Background Atopic diseases are very common, and atopy has a strong genetic predisposition. Methods Using single-strand conformation polymorphism analysis and DNA sequencing, we searched for mutations in the alpha subunit of the interleukin-4 receptor that would predispose persons to atopy. We examined the prevalence of the alleles among patients with allergic inflammatory disorders and among 50 prospectively recruited adults. Subjects with atopy were identified on the basis of an elevated serum IgE level (greater than or equal to 95 IU per milliliter) or a positive radioimmunosorbent test in response to standard inhalant allergens. The signaling function of mutant interleukin-4 receptor alpha was examined by flow cytometry, binding assays, and immunoblotting. Results A novel interleukin-4 receptor alpha allele was identified in which guanine was substituted for adenine at nucleotide 1902, causing a change from glutamine to arginine at position 576 (R576) in the cytoplasmic domain of the interleukin-4 receptor alpha protein. The R576 allele was common among patients with allergic inflammatory disorders (found in 3 of 3 patients with the hyper-IgE syndrome and 4 of 7 patients with severe atopic dermatitis) and among the 50 prospectively recruited adults (found in 13 of 20 subjects with atopy and 5 of 30 without atopy; P=0.001; relative risk of atopy among those with a mutant allele, 9.3). The R576 allele was associated with higher levels of expression of CD23 by interleukin-4 than the wild-type allele. This enhanced signaling was associated with a change in the binding specificity of the adjacent tyrosine residue at position 575 to signal-transducing molecules. Conclusions The R576 allele of interleukin-4 receptor alpha is strongly associated with atopy. This mutation may predispose persons to allergic diseases by altering the signaling function of the receptor. (C) 1997, Massachusetts Medical Society.	WASHINGTON UNIV, SCH MED, DEPT PEDIAT, DIV IMMUNOL RHEUMATOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, CTR IMMUNOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)				Chatila, Talal/0000-0001-7439-2762; Khurana Hershey, Gurjit/0000-0001-6663-977X				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; Bonnefoy JY, 1996, ANN NY ACAD SCI, V796, P59, DOI 10.1111/j.1749-6632.1996.tb32567.x; BUCKLEY RH, 1996, IMMUNOLOGIC DISORDER, P409; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; COOKSON WOCM, 1988, LANCET, V1, P86; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; Geha R S, 1989, Immunodefic Rev, V1, P155; Gelderloos JA, 1996, ONCOGENE, V13, P2367; Glantz SA., 1997, PRIMER BIOSTATISTICS; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUANG SK, 1993, ANN ALLERGY, V70, P347; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; Imani F, 1997, J BIOL CHEM, V272, P7927, DOI 10.1074/jbc.272.12.7927; ISHIZAKA A, 1990, IMMUNOLOGY, V70, P414; KIRCHNER SG, 1985, RADIOLOGY, V156, P362, DOI 10.1148/radiology.156.2.4011897; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEWIS DB, 1993, P NATL ACAD SCI USA, V90, P11618, DOI 10.1073/pnas.90.24.11618; MARSH DG, 1982, J EXP MED, V155, P1439, DOI 10.1084/jem.155.5.1439; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Oakes SA, 1996, IMMUNITY, V5, P605, DOI 10.1016/S1074-7613(00)80274-5; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; SOKOL L, 1995, BLOOD, V86, P15, DOI 10.1182/blood.V86.1.15.bloodjournal86115; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stavnezer J, 1996, ADV IMMUNOL, V61, P79, DOI 10.1016/S0065-2776(08)60866-4; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; VERCELLI D, 1990, J CLIN INVEST, V85, P1666, DOI 10.1172/JCI114618; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x; YOUNG RP, 1992, CLIN EXP ALLERGY, V22, P205, DOI 10.1111/j.1365-2222.1992.tb03074.x; ZEIGER RS, 1993, ALLERGY PRINCIPLES P, V2, P1137	48	587	631	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1720	1725		10.1056/NEJM199712113372403	http://dx.doi.org/10.1056/NEJM199712113372403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK653	9392697				2022-12-28	WOS:A1997YK65300003
J	Naclerio, R; Solomon, W				Naclerio, R; Solomon, W			Rhinitis and inhalant allergens	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; EXPOSURE; SYMPTOMS; DISEASE; ASTHMA; MITES; SPRAY	Allergic rhinitis affects about 20% of the US population. The diagnosis is based on patterns of symptoms, physical examination, and assessment of IgE antibodies by skin or in vitro testing. The most common offending allergens are pollens of grasses, trees, and weeds; fungi; animal allergens; and dust mites. In an individual with nasal allergy, exposure leads to rapid release of mast cell-derived mediators. This immediate response is followed by a cell-dominated response, including eosinophils and lymphocytes. Cytokines from T(H)2 lymphocytes, such as interleukin 4 and interleukin 5, orchestrate allergic inflammation. Resulting tissue changes produce symptoms of the disease and augment responses on subsequent exposure to allergens and irritants. Strategies for avoiding offending agents are important in management. In intermittent disease, antihistamines and/or decongestants are first prescribed. More continuous symptoms may mandate intranasal steroids. Immunotherapy is often helpful for patients who respond poorly to pharmacotherapy and avoidance.	UNIV MICHIGAN,DIV ALLERGY,TAUBMAN CTR 3918,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	Naclerio, R (corresponding author), UNIV CHICAGO,5841 S MARYLAND AVE,MC 1035,CHICAGO,IL 60637, USA.							*AAAI EX COMM, 1986, J ALLERGY CLIN IMMUN, V78, P271; BURGE HA, 1982, J ALLERGY CLIN IMMUN, V70, P101, DOI 10.1016/0091-6749(82)90236-6; DEBLAY F, 1994, J ALLERGY CLIN IMMUN, V93, P136, DOI 10.1016/0091-6749(94)90242-9; DOLOVICH J, 1987, J ALLERGY CLIN IMMUN, V80, P274, DOI 10.1016/0091-6749(87)90031-5; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734, DOI 10.1164/ajrccm.151.6.7767514; Doty RL., 1991, SMELL TASTE HLTH DIS, P449; DREBORG S K G, 1991, Journal of Allergy and Clinical Immunology, V87, P169, DOI 10.1016/0091-6749(91)91404-H; EDWARDS AM, 1995, CLIN EXP ALLERGY, V25, P16, DOI 10.1111/j.1365-2222.1995.tb01127.x; Evans R., 1993, ALLERGY PRINCIPLES P, P1109; FRASER CM, 1993, ALLERGY PRINCIPLES P, V1, P636; HUANG SK, 1993, ANN ALLERGY, V70, P347; JUNIPER EF, 1989, J ALLERGY CLIN IMMUN, V83, P627, DOI 10.1016/0091-6749(89)90075-4; KANG BC, 1990, CLIN REV ALLERG, V8, P87; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; KLUCKA CV, 1995, J ALLERGY CLIN IMMUN, V95, P1164, DOI 10.1016/S0091-6749(95)70072-2; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LIM MC, 1995, AM J RESP CRIT CARE, V151, P136, DOI 10.1164/ajrccm.151.1.7812543; Malone DC, 1997, J ALLERGY CLIN IMMUN, V99, P22, DOI 10.1016/S0091-6749(97)81040-8; MATERNOWSKI CJ, 1962, J ALLERGY, V33, P130; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; Naclerio RM, 1993, ALLERGIC NONALLERGIC, P114; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V97, P1193, DOI 10.1016/S0091-6749(96)70184-7; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1989, IMMUNOL ALLERGY CLIN, V9, P269; PUSTUSZAK A, 1996, J ALLERGY CLIN IMMUN, V98, P748; SCHWARTZ L, 1993, ALLERGY PRINCIPLES P, P135; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; SHIRAKAWA T, 1997, SCIENCE, V9, P275; SIEGEL SC, 1982, J ALLERGY CLIN IMMUN, V69, P345, DOI 10.1016/0091-6749(82)90144-0; SIMONS FE, 1996, HISTAMINE H 1 RECEPT; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V94, P139, DOI 10.1016/0091-6749(94)90031-0; SOLOMON WR, 1974, J ALLERGY CLIN IMMUN, V54, P222, DOI 10.1016/0091-6749(74)90064-5; SPIEKSMA FTM, 1991, CLIN EXP ALLERGY, V21, P655, DOI 10.1111/j.1365-2222.1991.tb03192.x; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Torfs CP, 1996, TERATOLOGY, V54, P84, DOI 10.1002/(SICI)1096-9926(199606)54:2<84::AID-TERA4>3.0.CO;2-4; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V82, P270, DOI 10.1016/0091-6749(88)91011-1; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5; Young T, 1997, J ALLERGY CLIN IMMUN, V99, P757	38	42	71	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1842	1848		10.1001/jama.278.22.1842	http://dx.doi.org/10.1001/jama.278.22.1842			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396645				2022-12-28	WOS:A1997YK15500006
J	Sampson, HA				Sampson, HA			Food allergy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXERCISE-INDUCED ANAPHYLAXIS; SKIN-PRICK TESTS; 1ST 3 YEARS; ATOPIC-DERMATITIS; COWS MILK; ADVERSE REACTIONS; GASTROESOPHAGEAL REFLUX; CROSS-REACTIVITY; IMMUNE-RESPONSES; NATURAL-HISTORY	The evaluation of adverse reactions to foods involving abnormal immune responses to food allergens remains an important part of the practice of allergy and immunology. Approximately 5% of children younger than 3 years and 1.5% of the general population experience food allergic disorders, indicating that about 4 million Americans suffer from food allergies. The evaluation of adverse reactions to foods depends on a careful clinical history, diagnostic studies including appropriate skin testing or in vitro testing with food extracts, and/or endoscopy and biopsy. The mainstay of therapy remains avoidance of incriminated foods and education to deal with inadvertent exposures. Experience over the past decade suggests that the ready availability and early introduction of highly allergenic foods (eg, peanuts and nuts) into the diet will only increase the number of individuals suffering from hypersensitivity reactions to foods. Research has focused on the identification and characterization of allergenic proteins and the development of new therapeutic strategies, eg, plasmid DNA vaccines, to treat these disorders.			Sampson, HA (corresponding author), MT SINAI HOSP, DEPT PEDIAT ALLERGY & IMMUNOL, 1 GUSTAVE L LEVY PL, BOX 1198, NEW YORK, NY 10029 USA.							ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; AHLROTH M, 1995, J ALLERGY CLIN IMMUN, V96, P167, DOI 10.1016/S0091-6749(95)70004-8; BERNHISELBROADBENT J, 1995, ANN ALLERG ASTHMA IM, V75, P295; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1987, PEDIATRICS, V79, P683; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BRUCE MG, 1987, CLIN EXP IMMUNOL, V70, P611; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Brunner M, 1928, ARCH INTERN MED, V42, P172, DOI 10.1001/archinte.1928.00130200024002; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; Fuglsang G, 1993, Pediatr Allergy Immunol, V4, P123, DOI 10.1111/j.1399-3038.1993.tb00080.x; FURRIE E, 1994, IMMUNOLOGY, V83, P562; HALL RP, 1987, J AM ACAD DERMATOL, V16, P1129, DOI 10.1016/S0190-9622(87)70148-0; HANSON DG, 1977, INT ARCH ALLER A IMM, V55, P1518; HEINER DC, 1960, AM J DIS CHILD, V100, P500; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; HIDE DW, 1983, BRIT J CLIN PRACT, V37, P285; Hoffman KM, 1997, J ALLERGY CLIN IMMUN, V99, P360, DOI 10.1016/S0091-6749(97)70054-X; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; HOST A, 1994, PEDIATR ALLERGY IMMU, V5, P5; HUSBY S, 1994, J IMMUNOL, V152, P4663; Iacono G, 1996, J ALLERGY CLIN IMMUN, V97, P822, DOI 10.1016/S0091-6749(96)80160-6; James JM, 1996, AM J RESP CRIT CARE, V153, P597, DOI 10.1164/ajrccm.153.2.8564104; JANSEN JJN, 1994, J ALLERGY CLIN IMMUN, V93, P446; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; JONES SM, 1996, ATOPIC DERMATITIS PA, P41; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; KOERNER CB, 1991, FOOD ALLERGY ADVERSE, P332; KUITUNEN P, 1975, ARCH DIS CHILD, V50, P351, DOI 10.1136/adc.50.5.351; LEE CM, 1993, AM J GASTROENTEROL, V88, P70; MCNEISH AS, 1979, ARCH DIS CHILD, V54, P783, DOI 10.1136/adc.54.10.783; METCALFE DD, 1990, J ALLERGY CLIN IMMUN, V86, P421, DOI 10.1016/S0091-6749(05)80252-0; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; MUDDE GC, 1995, IMMUNOL TODAY, V16, P380, DOI 10.1016/0167-5699(95)80005-0; NOVEMBRE E, 1988, J ALLERGY CLIN IMMUN, V81, P1059, DOI 10.1016/0091-6749(88)90181-9; ODZE RD, 1995, J PEDIATR-US, V126, P163, DOI 10.1016/S0022-3476(95)70540-6; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; PANUSH RS, 1990, J RHEUMATOL, V17, P291; PASTORELLO EA, 1989, J ALLERGY CLIN IMMUN, V84, P475, DOI 10.1016/0091-6749(89)90360-6; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROMANO A, 1995, ALLERGY, V50, P817, DOI 10.1111/j.1398-9995.1995.tb05055.x; SAMPSON H, 1996, ALLERGIC NONALLERGIC; SAMPSON HA, 1988, ANN ALLERGY, V60, P262; SAMPSON HA, 1992, ANN ALLERGY, V69, P469; SAMPSON HA, 1993, ALLERGY PROC, V14, P259, DOI 10.2500/108854193778811991; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; SAMPSON HA, 1986, J ALLERGY CLIN IMMUN, V78, P212, DOI 10.1016/0091-6749(86)90014-X; SAMPSON HA, 1993, SPRINGER SEMIN IMMUN, V15, P89; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SAMPSON HA, 1992, JAMA-J AM MED ASSOC, V268, P2840, DOI 10.1001/jama.268.20.2840; SAMPSON HA, 1995, PROVOCATION TESTING, P623; SCHRANDER JJP, 1993, EUR J PEDIATR, V152, P640, DOI 10.1007/BF01955238; SIGURS N, 1992, PEDIATRICS, V89, P735; Steinman HA, 1996, J ALLERGY CLIN IMMUN, V98, P241, DOI 10.1016/S0091-6749(96)70146-X; TRIER JS, 1993, GASTROINTESTINAL DIS, P1078; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909; Walzer M, 1941, J LAB CLIN MED, V26, P1867; WEBER RW, 1991, IMMUNOL ALLERGY CLIN, V11, P831; YOCUM MW, 1994, MAYO CLIN PROC, V69, P16, DOI 10.1016/S0025-6196(12)61606-1; YOUNG E, 1987, J ROY COLL PHYS LOND, V21, P241; YOUNG E, 1994, LANCET, V343, P1127, DOI 10.1016/S0140-6736(94)90234-8; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1995, NESTLE NUTR WORKS SE, V34, P203	74	128	133	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1888	1894		10.1001/jama.278.22.1888	http://dx.doi.org/10.1001/jama.278.22.1888			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396650				2022-12-28	WOS:A1997YK15500011
J	Stewart, DR; Sprinzak, D; Marcus, CM; Duruoz, CI; Harris, JS				Stewart, DR; Sprinzak, D; Marcus, CM; Duruoz, CI; Harris, JS			Correlations between ground and excited state spectra of a quantum dot	SCIENCE			English	Article							COULOMB ISLAND; HALL REGIME; TRANSPORT; SPECTROSCOPY	The ground and excited state spectra of a semiconductor quantum dot with successive electron occupancy were studied with linear and nonlinear magnetoconductance measurements. A direct correlation was observed between the mth excited state of the N-electron system and the ground state of the (N + m)-electron system for m up to 4. The results are consistent with a single-particle picture in which a fixed spectrum of energy levels is successively filled, except for a notable absence of spin degeneracy. Further departures from the single-particle picture due to electron-electron interaction were also observed. Magnetoconductance fluctuations of ground states show anticrossings where wave function characteristics are exchanged between adjacent levels.	STANFORD UNIV,DEPT PHYS,STANFORD,CA 94305; STANFORD UNIV,DEPT APPL PHYS,STANFORD,CA 94305; WEIZMANN INST SCI,DEPT CONDENSED MATTER PHYS,CTR SUBMICRON RES,IL-76100 REHOVOT,ISRAEL; STANFORD UNIV,DEPT ELECT ENGN,STANFORD,CA 94305	Stanford University; Stanford University; Weizmann Institute of Science; Stanford University			Marcus, Charles M./M-4526-2014	Marcus, Charles M./0000-0003-2420-4692; Sprinzak, David/0000-0001-6776-6957				Agam O, 1997, PHYS REV LETT, V78, P1956, DOI 10.1103/PhysRevLett.78.1956; ALTSHULER BL, 1995, MESOSCOPIC QUANTUM P, P1; ASHOORI RC, 1994, SURF SCI, V305, P558, DOI 10.1016/0039-6028(94)90953-9; BEENAKKER CWJ, 1991, PHYS REV B, V44, P1646, DOI 10.1103/PhysRevB.44.1646; Beenakker CWJ, 1997, REV MOD PHYS, V69, P731, DOI 10.1103/RevModPhys.69.731; BEENAKKER CWJ, 1991, PHYS REV B, V43, P12066, DOI 10.1103/PhysRevB.43.12066; Berkovits R, 1997, PHYS REV B, V55, P5297, DOI 10.1103/PhysRevB.55.5297; Blanter YM, 1997, PHYS REV LETT, V78, P2449, DOI 10.1103/PhysRevLett.78.2449; Gutzwiller M.C., 1990, CHAOS CLASSICAL QUAN; Jauregui K, 1996, PHYS REV B, V53, pR1713, DOI 10.1103/PhysRevB.53.R1713; KOUWENHOVEN L, 1997, P ADV STUD I MES EL; Kouwenhoven LP, 1997, SCIENCE, V278, P1788, DOI 10.1126/science.278.5344.1788; MCEUEN PL, 1993, PHYSICA B, V189, P70, DOI 10.1016/0921-4526(93)90147-X; MCEUEN PL, 1991, PHYS REV LETT, V66, P1926, DOI 10.1103/PhysRevLett.66.1926; MCEUEN PL, 1992, PHYS REV B, V45, P11419, DOI 10.1103/PhysRevB.45.11419; MEIRAV U, 1995, SEMICONDUCTOR SCI TE, V10, P255; PFANNKUCHE D, 1995, PHYS REV LETT, V74, P1194, DOI 10.1103/PhysRevLett.74.1194; PFEFFER P, 1995, PHYS REV B, V52, P14332, DOI 10.1103/PhysRevB.52.R14332; Ralph DC, 1997, PHYS REV LETT, V78, P4087, DOI 10.1103/PhysRevLett.78.4087; TAKAMI T, 1992, PHYS REV LETT, V68, P3371, DOI 10.1103/PhysRevLett.68.3371; WEINMANN D, 1995, PHYS REV LETT, V74, P984, DOI 10.1103/PhysRevLett.74.984; WEIS J, 1993, PHYS REV LETT, V71, P4019, DOI 10.1103/PhysRevLett.71.4019	25	90	90	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1784	1788		10.1126/science.278.5344.1784	http://dx.doi.org/10.1126/science.278.5344.1784			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388178	Green Submitted			2022-12-28	WOS:A1997YJ90100044
J	Halm, EA; Causino, N; Blumenthal, D				Halm, EA; Causino, N; Blumenthal, D			Is gatekeeping better than traditional care? A survey of physicians' attitudes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-PRACTICE; HEALTH-CARE; EXPERIENCE; LESSONS	Context.-Nearly all managed care plans rely on a physician ''gatekeeper'' to control use of specialty, hospital, and other expensive services. Gatekeeping is intended to reduce costs while maintaining or improving quality of care by increasing coordination and prevention and reducing duplicative or inappropriate care. Whether gatekeeping achieves these goals remains largely unproven. Objective.-To assess physicians' attitudes about the effects of gatekeeping compared with traditional care on administrative work, quality of patient care, appropriateness of resource use, and cost. Design.-Cross-sectional survey of primary care physicians Setting.-Outpatient facilities in metropolitan Boston, Mass. Participants.-All physicians who served as both primary care gatekeepers and traditional Blue Cross/Blue Shield providers for the employees of Massachusetts General Hospital, Boston. Of the 330 physicians surveyed, 202 (61%) responded. Outcomes Measures.-Physician ratings of the effects of gatekeeping on 21 aspects of care, including administrative work, physician-patient interactions, decision making, appropriateness of resource use, cost, and quality of care. Results.-Physicians reported that gatekeeping (compared with traditional care) had a positive effect on control of costs, frequency, and appropriateness of preventive services and knowledge of a patient's overall care (P<.001), They also felt that gatekeeping increased paperwork and telephone calls and negatively affected the overall quality of care, access to specialists, ability to order expensive tests and procedures, freedom in clinical decisions, time spent with patients, physician-patient relationships, and appropriate use of hospitalizations and laboratory tests (P<.001). Overall, 32% of physicians rated gatekeeping as better than traditional care, 40% the same, 21% gatekeeping as worse, and 7% were of mixed opinion, Positive ratings of gatekeeping were associated with fewer years in clinical practice, generalist training, and experience with gatekeeping and health maintenance organization plans. Conclusions.-Physicians identified both positive and negative effects of gatekeeping. Overall, 72% of physicians thought gatekeeping was better than or comparable to traditional care arrangements.	MASSACHUSETTS GEN HOSP,DEPT MED,GEN INTERNAL MED UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,HLTH POLICY RES & DEV UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					BHP HRSA HHS [PE11001-08] Funding Source: Medline	BHP HRSA HHS		ALPER PR, 1994, JAMA-J AM MED ASSOC, V272, P1523, DOI 10.1001/jama.272.19.1523; Cykert S, 1997, J GEN INTERN MED, V12, P192; DOYLE E, 1994, AM COLL PHYSICIANS O, V14, P1; EISENBERG JM, 1985, ANN INTERN MED, V102, P537, DOI 10.7326/0003-4819-102-4-537; Ellsbury K, 1990, QRB Qual Rev Bull, V16, P294; ELLSBURY KE, 1989, J FAM PRACTICE, V28, P698; ELLSBURY KE, 1987, J FAM PRACTICE, V25, P616; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GUERVAS J, 1994, FAM PRACT, V11, P307; HERD B, 1995, BRIT MED J, V310, P1042, DOI 10.1136/bmj.310.6986.1042; HURLEY RE, 1991, J FAM PRACTICE, V32, P167; HURLEY RE, 1989, AM J PUBLIC HEALTH, V79, P843, DOI 10.2105/AJPH.79.7.843; KLEINBAUM DG, 1988, APPLIED REGRESSION A; KREIER R, 1996, AM MED NEWS, V39, P1; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; MARTIN DP, 1989, AM J PUBLIC HEALTH, V79, P1628, DOI 10.2105/AJPH.79.12.1628; MOORE SH, 1983, NEW ENGL J MED, V309, P1400, DOI 10.1056/NEJM198312013092239; SHENKIN BN, 1995, JAMA-J AM MED ASSOC, V273, P1937, DOI 10.1001/jama.273.24.1937; SHORTELL SM, 1994, INT SERV NETW HLTH C; TAYLOR TR, 1989, BRIT MED J, V299, P1323, DOI 10.1136/bmj.299.6711.1323; TUNIS SR, 1994, ANN INTERN MED, V120, P956, DOI 10.7326/0003-4819-120-11-199406010-00008; WELCH HG, 1991, ANN INTERN MED, V115, P223, DOI 10.7326/0003-4819-115-3-223; 1997, NY TIMES        0202, pA1	23	99	100	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1677	1681		10.1001/jama.278.20.1677	http://dx.doi.org/10.1001/jama.278.20.1677			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388087				2022-12-28	WOS:A1997YG85900029
J	Robinson, JK				Robinson, JK			A 28-year-old fair-skinned woman with multiple moles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CUTANEOUS MALIGNANT-MELANOMA; ACADEMY-OF-DERMATOLOGY; RENAL-TRANSPLANT RECIPIENTS; MELANOCYTIC NEVI; RISK-FACTORS; DYSPLASTIC NEVI; SUN EXPOSURE; CLINICAL-DIAGNOSIS; ULTRAVIOLET-LIGHT; PIGMENTED LESIONS		NORTHWESTERN UNIV, SCH MED, CHICAGO, IL USA	Northwestern University								*AM CANC SOC INC, 1997, CANC FACTS FIG 1997; ARMSTRONG BK, 1993, MELANOMA RES, V3, P395, DOI 10.1097/00008390-199311000-00002; ARMSTRONG BK, 1994, CANCER SURV, V20, P219; Autier P, 1991, Melanoma Res, V1, P69, DOI 10.1097/00008390-199104000-00009; AUTIER P, 1994, INT J CANCER, V58, P809, DOI 10.1002/ijc.2910580610; BAIRD EA, 1992, BRIT MED J, V305, P799, DOI 10.1136/bmj.305.6857.799; BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BARNHILL RL, 1992, J AM ACAD DERMATOL, V26, P185, DOI 10.1016/0190-9622(92)70023-9; Bartoli C, 1996, CANCER, V77, P888, DOI 10.1002/(SICI)1097-0142(19960301)77:5<888::AID-CNCR12>3.0.CO;2-#; Bavinck JNB, 1996, TRANSPLANTATION, V61, P715, DOI 10.1097/00007890-199603150-00008; BERAL V, 1983, BRIT J DERMATOL, V109, P165, DOI 10.1111/j.1365-2133.1983.tb07077.x; Berg P, 1997, ARCH DERMATOL, V133, P295, DOI 10.1001/archderm.133.3.295; Berwick M, 1996, J NATL CANCER I, V88, P17, DOI 10.1093/jnci/88.1.17; CASCINELLI N, 1987, J AM ACAD DERMATOL, V16, P361, DOI 10.1016/S0190-9622(87)70050-4; DIFFEY BL, 1991, J PHOTOCH PHOTOBIO B, V8, P219, DOI 10.1016/1011-1344(91)80062-M; DOLAN NC, IN PRESS J GEN INTER; DROBETSKY EA, 1995, P NATL ACAD SCI USA, V92, P2350, DOI 10.1073/pnas.92.6.2350; ELDER DE, 1993, SEMIN DIAGN PATHOL, V10, P18; ELWOOD JM, 1992, WORLD J SURG, V16, P157, DOI 10.1007/BF02071515; FRIEDMAN RJ, 1985, CA-CANCER J CLIN, V35, P130, DOI 10.3322/canjclin.35.3.130; GALLAGHER RP, 1990, ARCH DERMATOL, V126, P770, DOI 10.1001/archderm.126.6.770; GANGE RW, 1985, J INVEST DERMATOL, V85, P362, DOI 10.1111/1523-1747.ep12276983; GARI LM, 1988, PEDIATR DERMATOL, V5, P151, DOI 10.1111/j.1525-1470.1988.tb01161.x; Gerbert B, 1996, ARCH DERMATOL, V132, P1030, DOI 10.1001/archderm.132.9.1030; Goldsmith L, 1996, J AM ACAD DERMATOL, V34, P822, DOI 10.1016/S0190-9622(96)90036-5; Goldstein AM, 1996, MELANOMA RES, V6, P441, DOI 10.1097/00008390-199612000-00006; GRAHAM S, 1985, AM J EPIDEMIOL, V122, P606, DOI 10.1093/oxfordjournals.aje.a114140; GRANSTEIN RD, 1990, SEMIN DERMATOL, V9, P16; GREEN A, 1985, MED J AUSTRALIA, V142, P446, DOI 10.5694/j.1326-5377.1985.tb113446.x; GREENE MH, 1985, ANN INTERN MED, V102, P458, DOI 10.7326/0003-4819-102-4-458; GREENE MH, 1981, LANCET, V1, P1196, DOI 10.1016/S0140-6736(81)92359-X; GREENE MH, 1984, HOSP PRACT, V19, P91; Grob JJ, 1996, J INVEST DERMATOL, V107, P694, DOI 10.1111/1523-1747.ep12365586; HACHAM H, 1991, PHOTOCHEM PHOTOBIOL, V53, P559, DOI 10.1111/j.1751-1097.1991.tb03671.x; HALL WH, 1992, JAMA-J AM MED ASSOC, V268, P1314, DOI 10.1001/jama.1992.03490100112037; Hanrahan PF, 1997, ARCH DERMATOL, V133, P301, DOI 10.1001/archderm.133.3.301; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P459, DOI 10.1016/S0190-9622(87)70230-8; HOLLY EA, 1995, AM J EPIDEMIOL, V141, P923, DOI 10.1093/oxfordjournals.aje.a117359; HOLMAN CDJ, 1984, JNCI-J NATL CANCER I, V72, P257; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KJEMS E, 1993, ACTA ONCOL, V32, P371, DOI 10.3109/02841869309093613; Knable A, 1997, J AM ACAD DERMATOL, V36, P467, DOI 10.1016/S0190-9622(97)80227-7; Koh HK, 1996, J AM ACAD DERMATOL, V34, P971, DOI 10.1016/S0190-9622(96)90274-1; KOPF AW, 1986, JAMA-J AM MED ASSOC, V256, P1915; KOPF AW, 1975, ARCH DERMATOL, V111, P1291, DOI 10.1001/archderm.111.10.1291; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; LEFFELL DJ, 1993, J AM ACAD DERMATOL, V28, P1003, DOI 10.1016/S0190-9622(08)80653-6; MACKIE RM, 1989, LANCET, V2, P487; MAIZE JC, 1979, CLIN EXP DERMATOL, V4, P49, DOI 10.1111/j.1365-2230.1979.tb01590.x; MARGHOOB AA, 1995, CANCER-AM CANCER SOC, V75, P707, DOI 10.1002/1097-0142(19950115)75:2+<707::AID-CNCR2820751415>3.0.CO;2-W; Menzies SW, 1996, ARCH DERMATOL, V132, P1178, DOI 10.1001/archderm.132.10.1178; MOVSHOVITZ M, 1973, JNCI-J NATL CANCER I, V51, P777, DOI 10.1093/jnci/51.3.777; NACHBAR F, 1994, J AM ACAD DERMATOL, V30, P551, DOI 10.1016/S0190-9622(94)70061-3; Naylor MF, 1997, ARCH DERMATOL, V133, P373, DOI 10.1001/archderm.133.3.373; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; Pennoyer JW, 1997, J AM ACAD DERMATOL, V36, P378, DOI 10.1016/S0190-9622(97)80212-5; RHODES AR, 1987, JAMA-J AM MED ASSOC, V258, P3146, DOI 10.1001/jama.258.21.3146; Rigel DS, 1996, J AM ACAD DERMATOL, V34, P839, DOI 10.1016/S0190-9622(96)90041-9; RIGEL DS, 1989, CANCER, V63, P386, DOI 10.1002/1097-0142(19890115)63:2<386::AID-CNCR2820630231>3.0.CO;2-6; Robinson JK, 1997, PREV MED, V26, P364, DOI 10.1006/pmed.1997.0156; Robinson JK, 1997, J AM ACAD DERMATOL, V37, P179, DOI 10.1016/S0190-9622(97)80122-3; ROUSH GC, 1988, PREV MED, V17, P273, DOI 10.1016/0091-7435(88)90003-5; RuizMaldonado R, 1997, ARCH DERMATOL, V133, P363, DOI 10.1001/archderm.133.3.363; SALOPEK TG, 1995, J AM ACAD DERMATOL, V33, P441, DOI 10.1016/0190-9622(95)91390-4; SALOPEK TG, 1995, J AM ACAD DERMATOL, V33, P451, DOI 10.1016/0190-9622(95)91391-2; SMITH CH, 1993, J AM ACAD DERMATOL, V28, P51, DOI 10.1016/0190-9622(93)70008-H; SOBER AJ, 1979, JAMA-J AM MED ASSOC, V242, P2795, DOI 10.1001/jama.242.25.2795; SPENCER JM, 1995, J AM ACAD DERMATOL, V33, P288, DOI 10.1016/0190-9622(95)90263-5; *STAND AUSTR STAND, 1997, PUBL AS NZS; STENBACK F, 1975, EUR J CANCER, V11, P241, DOI 10.1016/0014-2964(75)90004-3; Stern RS, 1997, NEW ENGL J MED, V336, P1041, DOI 10.1056/NEJM199704103361501; TUCKER MA, 1993, J INVEST DERMATOL, V100, pS350, DOI 10.1111/1523-1747.ep12470264; Tucker MA, 1997, JAMA-J AM MED ASSOC, V277, P1439, DOI 10.1001/jama.277.18.1439; WEINSTOCK MA, 1989, PEDIATRICS, V84, P199; Weinstock MA, 1996, J AM ACAD DERMATOL, V34, P1063, DOI 10.1016/S0190-9622(96)90287-X; WESTERDAHL J, 1994, AM J EPIDEMIOL, V140, P691, DOI 10.1093/oxfordjournals.aje.a117317; Whited JD, 1997, ARCH INTERN MED, V157, P985, DOI 10.1001/archinte.157.9.985; WILLIAMS ML, 1994, J PEDIATR-US, V124, P833, DOI 10.1016/S0022-3476(05)83168-3; ZANETTI R, 1992, EUR J CANCER, V28A, P1172, DOI 10.1016/0959-8049(92)90480-P	79	11	11	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1693	1699		10.1001/jama.278.20.1693	http://dx.doi.org/10.1001/jama.278.20.1693			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388090				2022-12-28	WOS:A1997YG85900032
J	Boeijinga, JK; vanMeegen, E; vandenEnde, R; Schook, CE; Cohen, AF				Boeijinga, JK; vanMeegen, E; vandenEnde, R; Schook, CE; Cohen, AF			Is there interaction between tramadol and phenprocoumon?	LANCET			English	Letter									BYK NEDERLAND BV, ZWANENBURG, NETHERLANDS; THROMBOSIS SERV GRAVENHAGE, RIJSWIJK, NETHERLANDS	Altana	Boeijinga, JK (corresponding author), LEIDEN UNIV, CTR HUMAN DRUG RES, NL-2333 CL LEIDEN, NETHERLANDS.		Cohen, Adam/G-3756-2010; Brosen, Kim/F-6023-2011	Brosen, Kim/0000-0001-8444-7835; Madsen, Hanne/0000-0002-2915-3161				BOEIJINGA JJ, 1982, LANCET, V1, P506; Ehrlich A, 1996, EUR J CLIN PHARMACOL, V51, P277, DOI 10.1007/s002280050198; Madsen H, 1997, LANCET, V350, P637, DOI 10.1016/S0140-6736(05)63325-9	3	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1552	1552		10.1016/S0140-6736(05)63986-4	http://dx.doi.org/10.1016/S0140-6736(05)63986-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388428				2022-12-28	WOS:A1997YH11500061
J	Hemingway, H; Stafford, M; Stansfeld, S; Shipley, M; Marmot, M				Hemingway, H; Stafford, M; Stansfeld, S; Shipley, M; Marmot, M			Is the SF-36 a valid measure of change in population health? Results from the Whitehall II study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; SURVEY QUESTIONNAIRE; SCALING ASSUMPTIONS; OUTCOME MEASURE; PRIMARY-CARE; SENSITIVITY; OLD; RELIABILITY; PREDICTORS; VERSION	Objective: To measure within-person change in scores on the short form general health survey (SF-36) by age, sex, employment grade, and disease status. Design: Longitudinal study with a mean of 36 months (range 23-59 months) follow up, with screening examination and questionnaire to detect physical and psychiatric morbidity. Setting: 20 civil service departments originally located in London. Participants: 5070 male and 2197 female office based civil servants aged 39-63 years. Main outcome measures: Change in the eight scales of the SF-36 (adjusted for baseline score and length of follow up) and effect sizes (adjusted change/standard deviation of differences). Results: Within-person declines (worsening health) with age were greater than estimated by cross sectional data alone. General mend health showed greater declines among younger participants (P for linear trend < 0.001). Employment grade was inversely related to change; lower grades had greater deteriorations than higher grades (P < 0.001 for each scale in men; P < 0.05 for each scale in women except general health perceptions and role limitations due to physical problems). The greatest declines were seen among participants with disease at baseline, with the effects of physical and psychiatric morbidity being additive. Effect sizes ranged from 0.20 to 0.65 in participants with both physical and psychiatric morbidity. Conclusions: Health functioning as measured by the SF-36, changed in hypothesised directions with age, employment grade, and disease status. These changes occurred within a short follow up period in an occupational, high functioning cohort which has not been the subject of intervention, suggesting that the SF-36 is sensitive to changes in health in general populations.	KENSINGTON & CHELSEA & WESTMINSTER HLTH AUTHOR, DEPT PUBL HLTH, LONDON W2 6LX, ENGLAND		Hemingway, H (corresponding author), UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, INT CTR HLTH & SOC, MORTIMER ST, LONDON WC1E 6BT, ENGLAND.		Marmot, M G/Y-3920-2019; Hemingway, Harry/C-1219-2009	Marmot, M G/0000-0002-2431-6419; Hemingway, Harry/0000-0003-2279-0624	Medical Research Council [G8802774] Funding Source: researchfish; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013196] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALONSO J, 1995, MED CLIN-BARCELONA, V104, P771; BARSKY AJ, 1988, NEW ENGL J MED, V318, P414, DOI 10.1056/NEJM198802183180705; Beckett LA, 1996, AM J EPIDEMIOL, V143, P766; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; BULLINGER M, 1995, SOC SCI MED, V41, P1359, DOI 10.1016/0277-9536(95)00115-N; CAIN KC, 1992, STAT MED, V11, P783, DOI 10.1002/sim.4780110609; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; FERRIE JE, 1995, BRIT MED J, V311, P1264, DOI 10.1136/bmj.311.7015.1264; FITZPATRICK R, 1992, BRIT MED J, V305, P1074, DOI 10.1136/bmj.305.6861.1074; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; GLIKLICH RE, 1995, QUAL LIFE RES, V4, P27, DOI 10.1007/BF00434380; GLYNN RJ, 1982, CIRCULATION, V66, P724, DOI 10.1161/01.CIR.66.4.724; Goldberg D.P, 1972, DETECTION PSYCHIAT I; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; GUYATT GH, 1989, CAN MED ASSOC J, V140, P1441; HARRIS T, 1989, AM J PUBLIC HEALTH, V79, P698, DOI 10.2105/AJPH.79.6.698; Hemingway H, 1997, AM J PUBLIC HEALTH, V87, P1484, DOI 10.2105/AJPH.87.9.1484; JENKINSON C, 1995, QUAL LIFE RES, V4, P47, DOI 10.1007/BF00434383; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; KATZ JN, 1992, MED CARE, V30, P917, DOI 10.1097/00005650-199210000-00004; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; Kuh D, 1997, LIFE COURSE APPROACH; LYDICK E, 1993, QUAL LIFE RES, V2, P221, DOI 10.1007/BF00435226; LYONS RA, 1995, J PUBLIC HEALTH MED, V17, P46; LYONS RA, 1994, J EPIDEMIOL COMMUN H, V48, P388, DOI 10.1136/jech.48.4.388; MARKIDES KS, 1990, J GERONTOL, V45, pS69, DOI 10.1093/geronj/45.2.S69; MCCALLUM J, 1995, AUST J PUBLIC HEALTH, V19, P160; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; *MED RES COUNC, 1976, QUEST RESP SYMPT INS; PALMORE EB, 1985, J GERONTOL, V40, P244, DOI 10.1093/geronj/40.2.244; PERNEGER TV, 1995, J CLIN EPIDEMIOL, V48, P1051, DOI 10.1016/0895-4356(94)00227-H; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; ROSE G. A., 1982, Monograph Series. World Health Organisation, V56; ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702; SEEMAN TE, 1994, J GERONTOL, V49, pM97, DOI 10.1093/geronj/49.3.M97; SEEMAN TE, 1995, J GERONTOL A-BIOL, V50, pM177, DOI 10.1093/gerona/50A.4.M177; SPITZER RL, 1995, JAMA-J AM MED ASSOC, V274, P1511, DOI 10.1001/jama.274.19.1511; STRAWBRIDGE WJ, 1993, GERONTOLOGIST, V33, P603, DOI 10.1093/geront/33.5.603; SULLIVAN M, 1995, SOC SCI MED, V41, P1349, DOI 10.1016/0277-9536(95)00125-Q; WARE JE, 1990, EFFECTIVENESS AND OUTCOMES IN HEALTH CARE, P107; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE Jr, 1993, SF 36 HLTH SURVEY MA; *WHO STUD GROUP, 1985, DIAB MELL REP WHO ST	45	223	232	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 15	1997	315	7118					1273	1279		10.1136/bmj.315.7118.1273	http://dx.doi.org/10.1136/bmj.315.7118.1273			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YG645	9390054	Green Published			2022-12-28	WOS:A1997YG64500021
J	Russell, SJ				Russell, SJ			Science, medicine, and the future - Gene therapy	BRITISH MEDICAL JOURNAL			English	Review							MODIFIED SKIN FIBROBLASTS; MICE				Russell, SJ (corresponding author), MRC,CAMBRIDGE CTR PROT ENGN,CAMBRIDGE CB2 2QH,ENGLAND.							BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; Bohl D, 1997, HUM GENE THER, V8, P195, DOI 10.1089/hum.1997.8.2-195; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; Cosset FL, 1996, GENE THER, V3, P946; Evans CH, 1996, HUM GENE THER, V7, P1261, DOI 10.1089/hum.1996.7.10-1261; FELGNER PL, 1997, SCI AM, V276, P86; Freeman SM, 1996, SEMIN ONCOL, V23, P31; FRIEDMANN T, 1997, SCI AM, V276, P80; Gill DR, 1997, GENE THER, V4, P199, DOI 10.1038/sj.gt.3300391; Hawkins RE, 1997, HUM GENE THER, V8, P1287, DOI 10.1089/hum.1997.8.10-1287; Marcel T, 1997, HUM GENE THER, V8, P775, DOI 10.1089/hum.1997.8.6-775; MOULLIER P, 1993, NAT GENET, V4, P154, DOI 10.1038/ng0693-154; NAFFAKH N, 1995, P NATL ACAD SCI USA, V92, P3194, DOI 10.1073/pnas.92.8.3194; Porteous DJ, 1997, GENE THER, V4, P210, DOI 10.1038/sj.gt.3300390; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; Vacanti C A, 1995, Tissue Eng, V1, P1, DOI 10.1089/ten.1995.1.1; Zhang J, 1996, CANCER METAST REV, V15, P385, DOI 10.1007/BF00046349	17	30	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1289	1292		10.1136/bmj.315.7118.1289	http://dx.doi.org/10.1136/bmj.315.7118.1289			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390059	Green Published			2022-12-28	WOS:A1997YG64500028
J	Babe, LM; Craik, CS				Babe, LM; Craik, CS			Viral proteases: Evolution of diverse structural motifs to optimize function	CELL			English	Review							CRYSTAL-STRUCTURE; SERINE PROTEASES; PROTEINASE; COFACTOR		UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MOL & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Babe, LM (corresponding author), ARRIS PHARMACEUT CORP,S SAN FRANCISCO,CA 94080, USA.							BABE LM, 1995, P NATL ACAD SCI USA, V92, P10069, DOI 10.1073/pnas.92.22.10069; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; Ding JZ, 1996, EMBO J, V15, P1778, DOI 10.1002/j.1460-2075.1996.tb00526.x; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; MATTHEWS DA, 1994, CELL, V77, P761, DOI 10.1016/0092-8674(94)90059-0; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Qiu XY, 1996, NATURE, V383, P275, DOI 10.1038/383275a0; TONG L, 1993, J MOL BIOL, V230, P228, DOI 10.1006/jmbi.1993.1139; WLODAWER A, 1989, SCIENCE, V245, P619	11	67	69	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					427	430		10.1016/S0092-8674(00)80426-2	http://dx.doi.org/10.1016/S0092-8674(00)80426-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390549	Bronze			2022-12-28	WOS:A1997YG49200001
J	Meystre, CJN; Burley, NMJ; Ahmedzai, S				Meystre, CJN; Burley, NMJ; Ahmedzai, S			What investigations and procedures do patients in hospices want? Interview based survey of patients and their nurses	BRITISH MEDICAL JOURNAL			English	Article							CARDIOPULMONARY-RESUSCITATION; CANCER; VIEWS		UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,SECT PALLIAT MED,DEPT SURG & ANAESTHET SCI,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield	Meystre, CJN (corresponding author), LEICESTERSHIRE HOSPICE,LEICESTER LE3 9QE,LEICS,ENGLAND.			Ahmedzai, Sam/0000-0002-2028-8510				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; HILL ME, 1994, BRIT MED J, V308, P1677, DOI 10.1136/bmj.308.6945.1677; MORGAN R, 1994, BRIT MED J, V308, P1677, DOI 10.1136/bmj.308.6945.1677a; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; WHO, 1979, WHO HDB REP RES CANC	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1202	1203		10.1136/bmj.315.7117.1202	http://dx.doi.org/10.1136/bmj.315.7117.1202			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393223	Green Published			2022-12-28	WOS:A1997YF25200020
J	Shisler, JL; Senkevich, TG; Berry, MJ; Moss, B				Shisler, JL; Senkevich, TG; Berry, MJ; Moss, B			Ultraviolet-induced cell death blocked by a selenoprotein from a human dermatotropic poxvirus	SCIENCE			English	Article							MOLLUSCUM CONTAGIOSUM VIRUS; VACCINIA VIRUS; SELENOCYSTEINE INCORPORATION; GENE-EXPRESSION; MAMMALIAN-CELLS; SEQUENCE; EUKARYOTES; APOPTOSIS; BIOLOGY; ELEMENT	Selenium, an essential trace element, is a component of prokaryotic and eukaryotic antioxidant proteins, A candidate selenoprotein homologous to glutathione peroxidase was deduced from the sequence of molluscum contagiosum, a poxvirus that causes persistent skin neoplasms in children and acquired immunodeficiency syndrome (AIDS) patients. Selenium was incorporated into this protein during biosynthesis, and a characteristic stem-loop structure near the end of the messenger RNA was required for alternative selenocysteine decoding of a potential UGA stop codon within the open reading frame. The selenoprotein protected human keratinocytes against cytotoxic effects of ultraviolet irradiation and hydrogen peroxide, providing a mechanism for a virus to defend itself against environmental stress.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Inst Med, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University	Moss, B (corresponding author), NIAID, Viral Dis Lab, NIH, 4 Ctr Dr,MSC 0445, Bethesda, MD 20892 USA.			Moss, Bernard/0000-0002-2154-8564; Shisler, Joanna/0000-0003-4833-1557	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047320] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47320] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BSL MR, 1997, P NATL ACAD SCI USA, V94, P5531; BULLER RML, 1995, VIROLOGY, V213, P655, DOI 10.1006/viro.1995.0037; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Fife KH, 1996, VIROLOGY, V226, P95, DOI 10.1006/viro.1996.0631; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTLIEB SL, 1994, INT J DERMATOL, V33, P453, DOI 10.1111/j.1365-4362.1994.tb02853.x; HAAKE AR, 1993, J INVEST DERMATOL, V101, P107, DOI 10.1111/1523-1747.ep12363594; Henseleit U, 1996, ARCH DERMATOL RES, V288, P676, DOI 10.1007/s004030050123; Hu SM, 1997, J BIOL CHEM, V272, P9621; Lee BJ, 1996, MOL CELLS, V6, P509; LOW CC, 1996, TRENDS BIOCHEM SCI, V21, P203; Manji GA, 1997, J VIROL, V71, P4509, DOI 10.1128/JVI.71.6.4509-4516.1997; Martin GW, 1996, RNA, V2, P171; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; Porter C D, 1992, Mol Cell Biol Hum Dis Ser, V1, P233; Senkevich TG, 1997, VIROLOGY, V233, P19, DOI 10.1006/viro.1997.8607; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Walczak R, 1996, RNA, V2, P367; WARD GA, 1995, P NATL ACAD SCI USA, V92, P6773, DOI 10.1073/pnas.92.15.6773; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	30	127	134	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					102	105		10.1126/science.279.5347.102	http://dx.doi.org/10.1126/science.279.5347.102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417017				2022-12-28	WOS:000071323900050
J	Reading, PJ; Will, RG				Reading, PJ; Will, RG			Unwelcome orgasms	LANCET			English	Article									WESTERN GEN HOSP,DEPT CLIN NEUROSCI,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh								BENTE D, 1953, ARCH PSYCHOL FRANKFU, V190, P635; FALCONER MA, 1959, BRAIN, V82, P483, DOI 10.1093/brain/82.4.483; GAUTIERSMITH PC, 1995, NEUROLOGY GEN MED, P545; REMILLARD GM, 1983, NEUROLOGY, V33, P323, DOI 10.1212/WNL.33.3.323; TOONE B, 1991, WOMAN EPILEPSY, P201	5	17	17	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 13	1997	350	9093					1746	1746		10.1016/S0140-6736(97)08456-0	http://dx.doi.org/10.1016/S0140-6736(97)08456-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413467				2022-12-28	WOS:A1997YL55400012
J	Swerdlow, AJ; DeStavola, BL; Swanwick, MA; Maconochie, NES				Swerdlow, AJ; DeStavola, BL; Swanwick, MA; Maconochie, NES			Risks of breast and testicular cancers in young adult twins in England and Wales: Evidence on prenatal and genetic aetiology	LANCET			English	Article							FAMILY HISTORY; RELATIVES; MEMBERSHIP; DISEASE; WOMEN; PAIR; AGE	Background Aetiology of breast and testicular cancers may have prenatal factors, possibly exposure of the fetus to high concentrations of maternal oestrogen. Dizygotic twinning probably involves high hormone concentrations, and therefore, dizygotic twins might be at raised risk of these cancers. The aetiologies of breast and testicular cancers have genetic components, for breast cancer, especially at younger ages. Twins of these probands may, therefore, be at high risk. We investigated risk in twins of patients with breast cancer at young ages or with testicular cancer. Methods We identified twins with breast cancer incident at ages younger than 45 years and with incident testicular cancer in England and Wales during 1971-89 by cross-matching national cancer-registration and births records. We determined zygosity by questionnaires to the patients. The twins of probands were followed up for cancer incidence and death. We analysed risks of breast and testicular cancer in dizygotic twins compared with monozygotic twins, and in monozygotic and dizygotic twins of probands. Findings We identified 500 twins with breast cancer and 194 with testicular cancer. We found a non-significantly raised risk of breast cancer in dizygotic compared with monozygotic twins younger than 30 years (odds ratio 2.3 [95% CI 0.9-5.9]) but not older. The overall risk of testicular cancer was significantly higher in dizygotic twins than in monozygotic twins (1.5 [1.1-2.2]) consequent on a risk for seminomas was high (3.2 [1.6-6.5]; p=0.001). Risk of breast cancer was significantly raised in female twins of probands (standardised incidence ratio 7.7 [4.9-12.2], p<0.001). The relative risk of breast cancer was 34.7 (9.5-126.5) in monozygotic twins of women in whom breast cancer had occurred before age 35 years. The cumulative risk of breast cancer for these twins by age 40 years was 29% (13-56). The relative risk of testicular cancer was 37.5 (12.3-115.6) in twins of men with testicular cancer. The cumulative risk by age 40 years in monozygotic twins of men with testicular cancer was 14% (4-46). Interpretation The higher risks of these cancers in dizygotic than in monozygotic twins support a prenatal aetiology, and are compatible with aetiology related to raised maternal concentrations of free, unbound oestrogens. The results for twins of probands have implications for genetic aetiology; appropriate clinical action for monozygotic twins needs consideration.			Swerdlow, AJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,EPIDEMIOL MONITORING UNIT,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.			De Stavola, Bianca Lucia/0000-0001-7853-0528; Swerdlow, Anthony/0000-0001-5550-4159				AALEN O, 1976, SCAND J STAT, V3, P5; BAIN C, 1980, AM J EPIDEMIOL, V111, P301, DOI 10.1093/oxfordjournals.aje.a112901; BARON JA, 1984, J NATL CANCER I, V72, P1307; Braun M. M., 1995, Acta Geneticae Medicae et Gemellologiae, V44, P189; BRAUN MM, 1995, CANCER CAUSE CONTROL, V6, P519, DOI 10.1007/BF00054160; BRAUN MM, 1994, AM J EPIDEMIOL, V140, P575, DOI 10.1093/oxfordjournals.aje.a117286; Breslow N, 1980, STATISTICAL METHODS, V32; CALLE EE, 1993, AM J EPIDEMIOL, V138, P675, DOI 10.1093/oxfordjournals.aje.a116904; CLAUS EB, 1988, THESIS YALE U; EASTON D, 1990, CANCER SURV, V9, P395; EASTON DF, 1995, AM J HUM GENET, V56, P265; FORD D, 1995, AM J HUM GENET, V57, P1457; FORMAN D, 1992, BRIT J CANCER, V65, P255, DOI 10.1038/bjc.1992.51; GITTELSOHN AM, 1965, BRIT J PREV SOC MED, V19, P8; GOLDGAR DE, 1994, J NATL CANCER I, V86, P1600, DOI 10.1093/jnci/86.21.1600; HENDERSO.BE, 1974, J NATL CANCER I, V53, P609, DOI 10.1093/jnci/53.3.609; Henderson BE, 1983, EPIDEMIOLOGY TESTIS, p[237, 50]; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HOLM NV, 1982, CANCER SURV, V1, P17; HRUBEC Z, 1984, NEW ENGL J MED, V310, P435, DOI 10.1056/NEJM198402163100706; HSIEH CC, 1992, AM J EPIDEMIOL, V136, P1321, DOI 10.1093/oxfordjournals.aje.a116444; KAPPEL B, 1985, ACTA GENET MED GEMEL, V34, P59, DOI 10.1017/S000156600000492X; KELSEY JL, 1990, EPIDEMIOL REV, V12, P228, DOI 10.1093/oxfordjournals.epirev.a036056; Krainer M, 1997, NEW ENGL J MED, V336, P1416, DOI 10.1056/NEJM199705153362003; LEMARCHAND L, 1988, BRIT J CANCER, V57, P437, DOI 10.1038/bjc.1988.99; MACK TM, 1995, NEW ENGL J MED, V332, P413, DOI 10.1056/NEJM199502163320701; MARTIN NG, 1984, ACTA GENET MED GEMEL, V33, P131, DOI 10.1017/S0001566000007613; NYLANDER PPS, 1981, ACTA GENET MED GEMEL, V30, P189, DOI 10.1017/S0001566000007650; *OFF POP CENS SURV, 1987, BIRT STAT HIST SERIE, V13; OTTMAN R, 1986, AM J EPIDEMIOL, V123, P15, DOI 10.1093/oxfordjournals.aje.a114209; Peto J, 1996, INT J CANCER, V65, P275, DOI 10.1002/(SICI)1097-0215(19960126)65:3&lt;275::AID-IJC1&gt;3.0.CO;2-X; PETO J, 1980, BANBURY REPORT, V4, P203; Sanderson M, 1996, EPIDEMIOLOGY, V7, P34, DOI 10.1097/00001648-199601000-00007; SCHWARTZ AG, 1985, JNCI-J NATL CANCER I, V75, P665; Swerdflow A. J., 1997, P643; Swerdlow AJ, 1996, INT J CANCER, V67, P472; THOMAS DC, 1990, GENET EPIDEMIOL, V7, P121, DOI 10.1002/gepi.1370070203; TORGERSEN S, 1979, ACTA GENET MED GEMEL, V28, P225, DOI 10.1017/S0001566000009077; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; Westergaard T, 1996, INT J CANCER, V66, P627, DOI 10.1002/(SICI)1097-0215(19960529)66:5<627::AID-IJC8>3.3.CO;2-Y; [No title captured]	41	153	156	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 13	1997	350	9093					1723	1728		10.1016/S0140-6736(97)05526-8	http://dx.doi.org/10.1016/S0140-6736(97)05526-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413462				2022-12-28	WOS:A1997YL55400007
J	DiAlberti, L; Piattelli, A; Artese, L; Favia, G; Patel, S; Saunders, N; Porter, SR; Scully, CM; Ngui, SL; Teo, CG				DiAlberti, L; Piattelli, A; Artese, L; Favia, G; Patel, S; Saunders, N; Porter, SR; Scully, CM; Ngui, SL; Teo, CG			Human herpesvirus 8 variants in sarcoid tissues	LANCET			English	Article							POLYMERASE CHAIN-REACTION; KAPOSIS-SARCOMA; DNA-SEQUENCES; PULMONARY SARCOIDOSIS; GRANULOMA-FORMATION; MYCOBACTERIAL DNA; ZOSTER SCARS; INFECTION; BLOOD; IDENTIFICATION	Background The cause of sarcoidosis is unknown, although mycobacteria have been implicated. We examined sarcoid tissues for human herpesvirus 8 (HHV-8) in addition to mycobacterial genomic sequences. Methods Biopsy samples from 17 patients with sarcoidosis were studied (eight transbronchial, 27 lymph node, two skin, and two oral mucosa). We used tissues (n=137) from 96 patients without sarcoidosis as negative controls. A nested PCR was applied to amplify a segment of open reading frame (ORF) 26 of the HHV-8 genome, and a heminested PCR was used to amplify a segment of ORF 25 of HHV-8 and of the 16 S rRNA gene of mycobacteria. Differences in base sequences of the amplified fragments were resolved with single-strand conformation polymorphism and dideoxy sequencing. Findings HHV-8 ORF 26 DNA was detected in significantly higher proportions of sarcoid than of non-sarcoid tissue samples from lung (8/8 vs 0/54; p<0.0001), lymph nodes (26/27 vs 6/29; p<0.0001), skin (2/2 vs 0/17; p=0.006), and oral tissues (2/2 vs 1/13; p=0.029). 31 (82%) of the 38 ORF 26 DNA-positive sarcoid specimens were also positive for ORF 25 DNA. For mycobacteria-like. 16 S rRNA DNA, the proportion positive was significantly higher in sarcoid than non-sarcoid tissues for lymph node samples (11/27 vs 2/29; p=0.003) but not for other tissues (lung 3/8 vs 22/54; skin 2/2 vs 15/17; and oral tissues 1/2 vs 0/13). Overall, the prevalence of HHV-8 ORF 26 sequences was higher in sarcoid tissues than in non-sarcoid tissues (p<0.0001). When patients whose tissues were included in a masked phase of the study were treated as units of analysis, eight of eight sarcoidosis patients were positive for HHV-8 ORF 26 DNA, compared with three of 56 control patients (p<0.0001); for mycobacteria-like sequences, three of eight sarcoidosis patients were positive, compared with four of 56 controls (p=0.0464). The HHV-8 ORF 26 sequences, ten of which were unique, could be segregated into four groups according to peptide motifs. In seven of nine patients from whom biopsy samples were taken from various sites, different sequences were recovered. The mycobacterial sequences amplified from sarcoid tissues were also varied, but none was homologous to those of known species. Interpretation Variant HHV-8 DNA sequences are found in a wide range of sarcoid but not non-sarcoid tissues. Mycobacteria-like 16 S rRNA sequences are more frequently present in sarcoid lymph nodes and not in other tissue types, but do not indicate infection by a particular mycobacterial species.	CENT PUBL HLTH LAB, PHLS VIRUS REFERENCE DIV, LONDON NW9 5HT, ENGLAND; UNIV CHIETI, DEPT ORAL PATHOL, CHIETI, ITALY; UNIV CHIETI, DEPT PATHOL, CHIETI, ITALY; UNIV BARI, DEPT ORAL PATHOL, BARI, ITALY; UNIV LONDON, EASTMAN DENT INST, DEPT ORAL MED, LONDON, ENGLAND	Public Health England; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Universita degli Studi di Bari Aldo Moro; University of London; University College London				Favia, Gianfranco/0000-0002-6746-7241; Porter, Stephen/0000-0002-3328-2759				Almenoff PL, 1996, THORAX, V51, P530, DOI 10.1136/thx.51.5.530; Bigoni B, 1996, J INFECT DIS, V173, P542, DOI 10.1093/infdis/173.3.542; BISACCIA E, 1983, ARCH DERMATOL, V119, P788, DOI 10.1001/archderm.119.9.788; BOCART D, 1992, AM REV RESPIR DIS, V145, P1142, DOI 10.1164/ajrccm/145.5.1142; BRESNITZ EA, 1983, EPIDEMIOL REV, V5, P124, DOI 10.1093/oxfordjournals.epirev.a036255; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Davis DA, 1997, J INFECT DIS, V175, P1071, DOI 10.1086/516444; DiAlberti L, 1997, J INFECT DIS, V175, P703, DOI 10.1093/infdis/175.3.703; ElZaatari FAK, 1996, J CLIN MICROBIOL, V34, P2240, DOI 10.1128/JCM.34.9.2240-2245.1996; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GHOSSEIN RA, 1994, AM J CLIN PATHOL, V101, P733, DOI 10.1093/ajcp/101.6.733; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; JAMES DG, 1994, SARCOIDOSIS OTHER GR, P1; Johnson LA, 1996, SARCOIDOSIS VASC DIF, V13, P38; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; KITUTA H, 1997, J MED VIROL, V53, P81; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Luppi M, 1996, BLOOD, V87, P3903, DOI 10.1182/blood.V87.9.3903.bloodjournal8793903; MANGIAPAN G, 1995, SARCOIDOSIS, V12, P20; MITCHELL DN, 1977, J CLIN PATHOL, V30, P395, DOI 10.1136/jcp.30.5.395; Monini P, 1996, NEW ENGL J MED, V334, P1168, DOI 10.1056/NEJM199605023341805; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; NEEFS JM, 1991, NUCLEIC ACIDS RES, V19, P1987, DOI 10.1093/nar/19.suppl.1987; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; REDONDO P, 1992, DERMATOLOGY, V185, P137, DOI 10.1159/000247430; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; Righter E, 1996, AM J RESP CRIT CARE, V153, P375, DOI 10.1164/ajrccm.153.1.8542146; ROGALL T, 1990, INT J SYST BACTERIOL, V40, P323, DOI 10.1099/00207713-40-4-323; Silver RF, 1996, IMMUNOLOGY, V88, P516, DOI 10.1046/j.1365-2567.1996.d01-683.x; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; WRIGHT AL, 1989, DERMATOLOGICA, V179, P45, DOI 10.1159/000248101; YUSOF JHM, 1994, J INFECT DIS, V169, P62, DOI 10.1093/infdis/169.1.62; Zong JC, 1997, J VIROL, V71, P2505, DOI 10.1128/JVI.71.3.2505-2511.1997	35	108	112	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 6	1997	350	9092					1655	1661		10.1016/S0140-6736(97)10102-7	http://dx.doi.org/10.1016/S0140-6736(97)10102-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400509				2022-12-28	WOS:A1997YK21100009
J	Friedli, K; King, MB; Lloyd, M; Horder, J				Friedli, K; King, MB; Lloyd, M; Horder, J			Randomised controlled assessment of non-directive psychotherapy versus routine general-practitioner care	LANCET			English	Article							SOCIAL-ADJUSTMENT; CLINICAL-TRIALS	Background We compared the efficacy of and patients' satisfaction with general-practice-based psychotherapists with those of general practitioners in providing treatment to people with emotional difficulties. Methods We carried out a prospective, randomised, controlled trial of brief, non-directive psychotherapy and routine general-practice care. Therapists adhered to a nondirective Rogerian model of psychotherapy. Between one and 12 sessions of psychotherapy were given over 12 weeks in 14 general practices in north London, UK. Of 136 patients with emotional difficulties, mainly depression, 70 patients were randomly assigned to the therapist and 66 to the general practitioner. Depression, anxiety, other mental-disorder symptoms, and social adjustment were measured by self-report al baseline, 3 months, and 9 months. Patients' satisfaction was also measured by self-report at 3 and 9 months. Findings All patients improved significantly over time. There were no significant differences between the groups receiving brief psychotherapy and routine general-practitioner care. Patients assigned brief psychotherapy were more satisfied with the help they received than those assigned to the general practitioner at both 3 and 9 months' follow-up (mean scores on satisfaction scale 50.9 [SD 7.9] vs 44.4 [9.8] and 45.6 [9.4] vs 37.1 11.2], respectively). Interpretation General-practitioner care is as effective as brief psychotherapy for patients usually referred by doctors to practice-based psychotherapists. Patients with emotional difficulties prefer brief psychotherapy from a counsellor to care from their general practitioner.	UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT PSYCHIAT,LONDON NW3 2PF,ENGLAND; UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE & POPULAT SCI,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Friedli, Karin/A-4219-2009; King, Michael B/D-7477-2011	King, Michael B/0000-0003-4715-7171				Beck A.T., 1987, BECK DEPRESSION INVE; BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; *BRIT ASS COUNC, 1992, ACCR CRIT; COOPER P, 1982, BRIT J PSYCHIAT, V141, P68, DOI 10.1192/bjp.141.1.68; Corney Roslyn, 1992, International Review of Psychiatry, V4, P331, DOI 10.3109/09540269209066337; DEROGATIS LR, 1992, BRIEF SYMPTOM INVENT, V2; ELLIOTT R, 1988, BRIT J MED PSYCHOL, V61, P141, DOI 10.1111/j.2044-8341.1988.tb02773.x; EVERITT BS, 1995, J ROY STAT SOC D-STA, V44, P113, DOI 10.2307/2348622; Fairhurst K, 1996, J Health Serv Res Policy, V1, P77; FRIEDLI K, 1996, PRIMARY CARE PSYCHIA, V2, P205; FRISON L, 1992, STAT MED, V11, P1685, DOI 10.1002/sim.4780111304; KATON W, 1994, PSYCHOSOM MED, V56, P97, DOI 10.1097/00006842-199403000-00004; KING M, 1995, RES FDN PSYCHOTHERAP, P281; LEWIS G, 1901, PROQSY MANUAL; MARKS I, 1994, BRIT MED J, V309, P1071, DOI 10.1136/bmj.309.6961.1071; NELSONJONES R, 1982, THEORY PRCTICE COUNS; PAYKEL ES, 1971, J NERV MENT DIS, V152, P158, DOI 10.1097/00005053-197103000-00002; PETO V, 1993, FAM PRACT, V10, P207, DOI 10.1093/fampra/10.2.207; Roth A., 1996, WHAT WORKS WHOM CRIT; SIBBALD B, 1993, BMJ-BRIT MED J, V306, P29, DOI 10.1136/bmj.306.6869.29; Weich S, 1997, PSYCHOL MED, V27, P73, DOI 10.1017/S0033291796004023	21	69	69	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1662	1665		10.1016/S0140-6736(97)05298-7	http://dx.doi.org/10.1016/S0140-6736(97)05298-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YK211	9400510				2022-12-28	WOS:A1997YK21100010
J	Sharp, D				Sharp, D			Half-way at Kyoto - but to where?	LANCET			English	Editorial Material																		Bouma MJ, 1997, LANCET, V350, P1435, DOI 10.1016/S0140-6736(97)04509-1; Broecker WS, 1997, SCIENCE, V278, P1582, DOI 10.1126/science.278.5343.1582	2	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1646	1646		10.1016/S0140-6736(05)64271-7	http://dx.doi.org/10.1016/S0140-6736(05)64271-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400506				2022-12-28	WOS:A1997YK21100006
J	Kouwenhoven, LP; Oosterkamp, TH; Danoesastro, MWS; Eto, M; Austing, DG; Honda, T; Tarucha, S				Kouwenhoven, LP; Oosterkamp, TH; Danoesastro, MWS; Eto, M; Austing, DG; Honda, T; Tarucha, S			Excitation spectra of circular, few-electron quantum dots	SCIENCE			English	Article							MAGNETIC-FIELD; SPECTROSCOPY; ENERGIES; SYSTEMS; HELIUM	Studies of the ground and excited states in semiconductor quantum dots containing 1 to 12 electrons showed that the quantum numbers of the states in the excitation spectra can be identified and compared with exact calculations. A magnetic field induces transitions between the ground and excited states. These transitions were analyzed in terms of crossings between single-particle states, singlet-triplet transitions, spin polarization, and Hund's rule. These impurity-free quantum dots allow ''atomic physics'' experiments to be performed in magnetic field regimes not accessible for atoms.	DELFT UNIV TECHNOL, DELFT INST MICROELECT & SUBMICRON TECHNOL, NL-2600 GA DELFT, NETHERLANDS; KEIO UNIV, FAC SCI & TECHNOL, DEPT PHYS, KOHOKU KU, YOKOHAMA, KANAGAWA 223, JAPAN; NIPPON TELEGRAPH & TEL PUBL CORP, BASIC RES LABS, ATSUGI, KANAGAWA 24301, JAPAN	Delft University of Technology; Keio University; Nippon Telegraph & Telephone Corporation	Kouwenhoven, LP (corresponding author), DELFT UNIV TECHNOL, DEPT APPL PHYS, POB 5046, NL-2600 GA DELFT, NETHERLANDS.		TARUCHA, SEIGO/I-7030-2012; Eto, Mikio/D-6021-2014					Alonso M., 1968, QUANTUM STAT PHYSICS; ASHOORI RC, 1993, PHYS REV LETT, V71, P613, DOI 10.1103/PhysRevLett.71.613; Ashoori RC, 1996, NATURE, V379, P413, DOI 10.1038/379413a0; AUSTING DG, 1996, SEMICOND SCI TECH, V11, P212; Darwin CG, 1931, P CAMB PHILOS SOC, V27, P86; Eto M, 1997, JPN J APPL PHYS 1, V36, P3924, DOI 10.1143/JJAP.36.3924; Fock V, 1928, Z PHYS, V47, P446, DOI 10.1007/BF01390750; JOHNSON NF, 1995, J PHYS-CONDENS MAT, V7, P965, DOI 10.1088/0953-8984/7/6/005; KOUWENHOVEN LP, 1996, P ADV STUD I MES EL; PALACIOS JJ, 1994, PHYS REV B, V50, P5760, DOI 10.1103/PhysRevB.50.5760; PFANNKUCHE D, 1993, PHYSICA B, V189, P6, DOI 10.1016/0921-4526(93)90141-R; Schmidt T, 1997, PHYS REV LETT, V78, P1544, DOI 10.1103/PhysRevLett.78.1544; Stewart DR, 1997, SCIENCE, V278, P1784, DOI 10.1126/science.278.5344.1784; SU B, 1992, PHYS REV B, V46, P7644, DOI 10.1103/PhysRevB.46.7644; THURNER G, 1982, PHYS LETT A, V89, P133, DOI 10.1016/0375-9601(82)90875-1; WAGNER M, 1992, PHYS REV B, V45, P1951, DOI 10.1103/PhysRevB.45.1951	18	394	401	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 5	1997	278	5344					1788	1792		10.1126/science.278.5344.1788	http://dx.doi.org/10.1126/science.278.5344.1788			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388179	Green Submitted			2022-12-28	WOS:A1997YJ90100045
J	Schedelbeck, G; Wegscheider, W; Bichler, M; Abstreiter, G				Schedelbeck, G; Wegscheider, W; Bichler, M; Abstreiter, G			Coupled quantum dots fabricated by cleaved edge overgrowth: From artificial atoms to molecules	SCIENCE			English	Article							PHOTOLUMINESCENCE; WIRES; GAAS; LUMINESCENCE; EXCITONS; SPECTRA; ENERGY; FIELD	Atomically precise quantum dots of mesoscopic size have been fabricated in the gallium arsenide-aluminum gallium arsenide material system by cleaved edge overgrowth, with a high degree of control over shape, composition, and position. The formation of bonding and antibonding states between two such ''artificial atoms'' was studied as a function of quantum dot separation by microscopic photoluminescence (PL) spectroscopy. The coupling strength within these ''artificial molecules'' is characterized by a systematic dependence, of the separation of the bonding and antibonding levels, and of the PL linewidth, on the ''interatomic'' distance. This model system opens new insights into the physics of coupled quantum objects.	TECH UNIV MUNICH,WALTER SCHOTTKY INST,D-85748 GARCHING,GERMANY	Technical University of Munich			Wegscheider, Werner H/D-1493-2010					ARAKAWA Y, 1986, IEEE J QUANTUM ELECT, V22, P1887, DOI 10.1109/JQE.1986.1073185; ASHOORI RC, 1993, PHYS REV LETT, V71, P613, DOI 10.1103/PhysRevLett.71.613; Ashoori RC, 1996, NATURE, V379, P413, DOI 10.1038/379413a0; BRUNNER K, 1992, PHYS REV LETT, V69, P3216, DOI 10.1103/PhysRevLett.69.3216; BRUNNER K, 1994, PHYS REV LETT, V73, P1138, DOI 10.1103/PhysRevLett.73.1138; CHANG YC, 1985, APPL PHYS LETT, V47, P1324, DOI 10.1063/1.96268; Gammon D, 1996, SCIENCE, V273, P87, DOI 10.1126/science.273.5271.87; Gammon D, 1996, PHYS REV LETT, V76, P3005, DOI 10.1103/PhysRevLett.76.3005; GONI AR, 1992, APPL PHYS LETT, V61, P1956, DOI 10.1063/1.108375; GRUNDMANN M, 1995, PHYS REV LETT, V74, P4043, DOI 10.1103/PhysRevLett.74.4043; Grundmann M, 1997, PHYS REV B, V55, P4054, DOI 10.1103/PhysRevB.55.4054; Hasen J, 1997, NATURE, V390, P54, DOI 10.1038/36299; HESS HF, 1994, SCIENCE, V264, P1740, DOI 10.1126/science.264.5166.1740; KASTNER MA, 1993, PHYS TODAY, V46, P24, DOI 10.1063/1.881393; KLEIN O, 1995, PHYS REV LETT, V74, P785, DOI 10.1103/PhysRevLett.74.785; KOUWENHOVEN L, 1995, SCIENCE, V268, P1440, DOI 10.1126/science.268.5216.1440; LEON R, 1995, SCIENCE, V267, P1966, DOI 10.1126/science.267.5206.1966; MARZIN JY, 1994, PHYS REV LETT, V73, P716, DOI 10.1103/PhysRevLett.73.716; PFEIFFER L, 1990, APPL PHYS LETT, V56, P1697, DOI 10.1063/1.103121; PLATZMAN PM, COMMUNICATION; SOMEYA T, 1995, PHYS REV LETT, V74, P3664, DOI 10.1103/PhysRevLett.74.3664; Someya T, 1996, PHYS REV LETT, V76, P2965, DOI 10.1103/PhysRevLett.76.2965; VANDERVAART NC, 1995, PHYS REV LETT, V74, P4702, DOI 10.1103/PhysRevLett.74.4702; WAUGH FR, 1995, PHYS REV LETT, V75, P705, DOI 10.1103/PhysRevLett.75.705; Wegscheider W, 1997, PHYS REV LETT, V79, P1917, DOI 10.1103/PhysRevLett.79.1917; WEGSCHEIDER W, 1993, PHYS REV LETT, V71, P4071, DOI 10.1103/PhysRevLett.71.4071; ZRENNER A, 1994, PHYS REV LETT, V72, P3382, DOI 10.1103/PhysRevLett.72.3382	28	251	255	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1792	1795		10.1126/science.278.5344.1792	http://dx.doi.org/10.1126/science.278.5344.1792			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388180				2022-12-28	WOS:A1997YJ90100046
J	Morris, AD; Boyle, DIR; McMahon, AD; Greene, SA; MacDonald, TM; Newton, RW				Morris, AD; Boyle, DIR; McMahon, AD; Greene, SA; MacDonald, TM; Newton, RW			Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus	LANCET			English	Article							COMPLICATIONS; BEHAVIORS	Background Intensive insulin treatment effectively delays the onset and slows the progression of microvascular complications in insulin-dependent diabetes mellitus (IDDM). Variable adherence to insulin treatment is thought to contribute to poor glycaemic control, diabetic ketoacidosis, and brittle diabetes in adolescents and young adults with IDDM. We assessed the association between the prescribed insulin dose and the amount dispensed from all community pharmacies with the Diabetes Audit and Research in Tayside Scotland (DARTS) database. Methods We studied 89 patients, mean age 16 (SD 7) years, diabetes duration 8 (4) years, and glycosylated haemoglobin (HbA(1c)) 8.4 (1.9)%, who attended a teaching hospital paediatric or young-adult diabetes clinic in 1993 and 1994. The medically recommended insulin dose and cumulative volume of insulin prescriptions supplied were used to calculate the days of maximum possible insulin coverage per annum, expressed as the adherence index. Associations between glycaemic control (HbA(1c)), episodes of diabetic ketoacidosis, and all hospital admissions for acute complications and the adherence index were modelled. Findings Insulin was prescribed at 48 (19) IU/day and mean insulin collected from pharmacies was 58 (25) IU/day. 25 (28%) of the 89 patients obtained less insulin than their prescribed dose (mean deficit 115 [68; range 9-246] insulin days/annum). There was a significant inverse association between HbA(1c) and the adherence index (R-2=0.39; p<0.001). In the top quartile (HbA(1c)>10%), 14 (64%) of individuals had an adherence index suggestive of a missed dose of insulin (mean deficit 55 insulin days/annum). There were 36 admissions for complications related to diabetes. The adherence index was inversely related to hospital admissions for diabetic ketoacidosis (p<0.001) and all hospital admissions related to acute diabetes complications (p=0.008). The deterioration in glycaemic control observed in patients aged 10-20 years was associated with a significant reduction (p=0.01) in the adherence index. Interpretation We found direct evidence of poor compliance with insulin therapy in young patients with IDDM. We suggest that poor adherence to insulin treatment is the major factor that contributes to long-term poor glycaemic control and diabetic ketoacidosis in this age group.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, CTR DIABET, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, MED MONITORING UNIT, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CHILD HLTH, DUNDEE DD1 9SY, SCOTLAND	University of Dundee; University of Dundee; University of Dundee	Morris, AD (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT MED, DUNDEE DD1 9SY, SCOTLAND.		Morris, Andrew D/C-2837-2009; McMahon, Alex D/C-4304-2008; Boyle, Douglas/B-9193-2017	Boyle, Douglas/0000-0002-4779-7083; MacDonald, Thomas/0000-0001-5189-6669	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acerini CL, 1997, LANCET, V350, P1199, DOI 10.1016/S0140-6736(97)06467-2; BEARDON PHG, 1988, PHARM MED, V3, P185; CERKONEY KAB, 1980, DIABETES CARE, V3, P594, DOI 10.2337/diacare.3.5.594; CONOVER WJ, 1982, BIOMETRICS, V38, P715, DOI 10.2307/2530051; DeFronzo RA, 1994, DIABETES REV, V2, P209; DUNGER DB, 1995, PRACTICAL DIABETES I, V12, P63, DOI [10.1002/pdi.1960120205, DOI 10.1002/PDI.1960120205]; GILL GV, 1985, DIABETOLOGIA, V28, P579, DOI 10.1007/BF00281992; Gill GV, 1996, QJM-MON J ASSOC PHYS, V89, P839, DOI 10.1093/qjmed/89.11.839; GILL GV, 1991, BRIT MED J, V303, P285, DOI 10.1136/bmj.303.6797.285; GLASGOW RE, 1987, J CHRON DIS, V40, P399, DOI 10.1016/0021-9681(87)90173-1; Kurtz S M, 1990, Diabetes Educ, V16, P50, DOI 10.1177/014572179001600112; LEESE GP, 1992, DIABETIC MED, V9, P459, DOI 10.1111/j.1464-5491.1992.tb01817.x; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; McNabb WL, 1997, DIABETES CARE, V20, P215, DOI 10.2337/diacare.20.2.215; Morris AD, 1997, BMJ-BRIT MED J, V315, P524, DOI 10.1136/bmj.315.7107.524; POLONSKY WH, 1994, DIABETES CARE, V17, P1178, DOI 10.2337/diacare.17.10.1178; Pound N, 1996, DIABETIC MED, V13, P510, DOI 10.1002/(SICI)1096-9136(199606)13:6<510::AID-DIA122>3.0.CO;2-W; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; RODIN GM, 1986, INT J PSYCHIAT MED, V16, P49, DOI 10.2190/HULH-CTPR-4V17-383C; Rydall AC, 1997, NEW ENGL J MED, V336, P1849, DOI 10.1056/NEJM199706263362601; SCHAFER LC, 1986, DIABETES CARE, V9, P179, DOI 10.2337/diacare.9.2.179; SCOBIE IN, 1981, LANCET, V2, P521; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STEEL JM, 1994, LANCET, V344, P765, DOI 10.1016/S0140-6736(94)92333-7; THOMPSON CJ, 1995, DIABETIC MED, V12, P429, DOI 10.1111/j.1464-5491.1995.tb00508.x; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y	26	364	366	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1505	1510		10.1016/S0140-6736(97)06234-X	http://dx.doi.org/10.1016/S0140-6736(97)06234-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388398				2022-12-28	WOS:A1997YH11500009
J	RichEdwards, JW; Gillman, MW				RichEdwards, JW; Gillman, MW			A hypothesis challenged - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							CORONARY HEART-DISEASE; BIRTH-WEIGHT; BREAST-CANCER; RISK		HARVARD PILGRIM CARE,BOSTON,MA 02215	Harvard Pilgrim Health Care	RichEdwards, JW (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,126 BROOKLINE AVE,SUITE 200,BOSTON,MA 02215, USA.							ANTONOV AN, 1947, J PEDIATR, V30, P250, DOI 10.1016/S0022-3476(47)80160-X; Barker D. J. P., 1994, MOTHERS BABIES DIS L; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; Frankel S, 1996, LANCET, V348, P1478, DOI 10.1016/S0140-6736(96)03482-4; MCCANCE DR, 1994, BRIT MED J, V308, P945; Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; Rich-Edwards J. W., 1996, American Journal of Epidemiology, V143, pS39; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; Sanderson M, 1996, EPIDEMIOLOGY, V7, P34, DOI 10.1097/00001648-199601000-00007; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P571, DOI 10.1038/bjc.1987.116; Trichopoulos D, 1990, Epidemiology, V1, P95; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157	15	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 22	1997	315	7119					1348	1349		10.1136/bmj.315.7119.1348	http://dx.doi.org/10.1136/bmj.315.7119.1348			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402776	Green Published			2022-12-28	WOS:A1997YJ21800023
J	Ferry, JG				Ferry, JG			Methane: Small molecule, big impact	SCIENCE			English	Editorial Material							CRYSTAL-STRUCTURE; BACTERIA; ARCHAEON		PENN STATE UNIV,CTR MICROBIAL STRUCT BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ferry, JG (corresponding author), PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,UNIVERSITY PK,PA 16802, USA.							Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; DIMARCO AA, 1990, ANNU REV BIOCHEM, V59, P355, DOI 10.1146/annurev.biochem.59.1.355; ERMLER U, 1997, SCIENCE, V27, P1457; Ferry JG, 1997, BIOFACTORS, V6, P25, DOI 10.1002/biof.5520060104; HOGAN KB, 1991, NATURE, V354, P181, DOI 10.1038/354181a0; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; Kisker C, 1996, EMBO J, V15, P2323, DOI 10.1002/j.1460-2075.1996.tb00588.x; KUMAR M, 1995, SCIENCE, V270, P628, DOI 10.1126/science.270.5236.628; SMITH D, IN PRESS J BACTERIOL; SPIRO T, 1995, SCIENCE, V270, P21; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Zinder Stephen H., 1993, P128	13	35	38	2	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 21	1997	278	5342					1413	1414		10.1126/science.278.5342.1413	http://dx.doi.org/10.1126/science.278.5342.1413			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG858	9411766				2022-12-28	WOS:A1997YG85800029
J	Salvesen, GS; Dixit, VM				Salvesen, GS; Dixit, VM			Caspases: Intracellular signaling by proteolysis	CELL			English	Review							CRMA-INHIBITABLE PROTEASE; APOPTOSIS; DEATH		GENENTECH INC,DEPT MOL ONCOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech	Salvesen, GS (corresponding author), BURNHAM INST,SAN DIEGO,CA 92037, USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326				Bredesen DE, 1996, NEUROSCIENTIST, V2, P181, DOI 10.1177/107385849600200313; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016; Zhou Q, 1997, BIOCHEM J, V324, P361, DOI 10.1042/bj3240361	20	1883	1953	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					443	446		10.1016/S0092-8674(00)80430-4	http://dx.doi.org/10.1016/S0092-8674(00)80430-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390553	Bronze			2022-12-28	WOS:A1997YG49200005
J	Lau, J; Ioannidis, JPA; Schmid, CH				Lau, J; Ioannidis, JPA; Schmid, CH			Quantitative synthesis in systematic reviews	ANNALS OF INTERNAL MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIALS; STRESS-ULCER PROPHYLAXIS; DOSE-RESPONSE DATA; CLINICAL-TRIALS; PUBLICATION BIAS; MYOCARDIAL-INFARCTION; CUMULATIVE METAANALYSIS; CONSORT STATEMENT; DIAGNOSTIC-TEST; CRITICALLY ILL	The final common pathway for most systematic reviews is a statistical summary of the data, or meta-analysis. The complex methods used in meta-analyses should always be complemented by clinical acumen and common sense in designing the protocol of a systematic review, deciding which data can be combined, and determining whether data should be combined. Both continuous and binary data can be pooled. Most meta-analyses summarize data from randomized trials, but other applications, such as the evaluation of diagnostic test performance and observational studies, have also been developed. The statistical methods of meta-analysis aim at evaluating the diversity (heterogeneity) among the results of different studies, exploring and explaining observed heterogeneity, and estimating a common pooled effect with increased precision. Fixed-effects models assume that an intervention has a single true effect, whereas random-effects models assume that an effect may vary across studies. Meta-regression analyses, by using each study rather than each patient as a unit of observation, can help to evaluate the effect of individual variables on the magnitude of an observed effect and thus may sometimes explain why study results differ. It is also important to assess the robustness of conclusions through sensitivity analyses and a formal evaluation of potential sources of bias, including publication bias and the effect of the quality of the studies on the observed effect.	TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts University	Lau, J (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DIV CLIN CARE RES, 750 WASHINGTON ST, BOX 63, BOSTON, MA 02111 USA.		Schmid, Christopher H./J-2398-2014; Ioannidis, John P. A./G-9836-2011	Schmid, Christopher H./0000-0002-0855-5313; 	AHRQ HHS [R01 HS 08532, R01 HS07782] Funding Source: Medline; NIAID NIH HHS [T32 AI07389] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007782, R01HS008532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007389] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman DG, 1996, BRIT MED J, V313, P570; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BEGG CB, 1994, HDB RES SYNTHESIS; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BERLIN JA, 1994, ONLINE J CURR C 0604; BORZAK S, 1995, ANN INTERN MED, V123, P873, DOI 10.7326/0003-4819-123-11-199512010-00010; Cappelleri JC, 1996, JAMA-J AM MED ASSOC, V276, P1332, DOI 10.1001/jama.276.16.1332; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; COOK DJ, 1991, AM J MED, V91, P519, DOI 10.1016/0002-9343(91)90189-5; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; Counsell C, 1997, ANN INTERN MED, V127, P380, DOI 10.7326/0003-4819-127-5-199709010-00008; Dear K.B.G., 1992, STAT SCI, V7, P237, DOI DOI 10.1214/SS/1177011363; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; DUMOUCHEL W, 1995, STAT MED, V14, P679, DOI 10.1002/sim.4780140524; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; EDDY DM, 1991, META ANAL CONFIDENCE; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Fleiss JL, 1981, STAT METHODS RATES P, P161; GELMAN A, 1995, BAYESIAN DATA ANAL, P148; GREENLAND S, 1990, STAT MED, V9, P247, DOI 10.1002/sim.4780090307; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P290, DOI 10.1093/oxfordjournals.aje.a117248; GREENLAND S, 1994, AM J EPIDEMIOL, V139, P747, DOI 10.1093/oxfordjournals.aje.a117069; GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237; Hedges L, 1985, STATISTICAL METHODS; Hedges LV, 1992, STAT SCI, V7, P246, DOI DOI 10.1214/SS/1177011364; HOLME I, 1993, BRIT HEART J, V69, pS42; IOANNIDIS JPA, 1995, ANN INTERN MED, V122, P856, DOI 10.7326/0003-4819-122-11-199506010-00009; Ioannidis JPA, 1996, LANCET, V348, P756, DOI 10.1016/S0140-6736(05)65647-4; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; LANGBEIN LI, 1978, SAGE U PAPER SERIES; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LAU J, 1995, J CLIN EPIDEMIOL, V48, P45, DOI 10.1016/0895-4356(94)00106-Z; Light R.J., 1984, SUMMING SCI REV RES; Lilford RJ, 1995, BMJ-BRIT MED J, V311, P1621, DOI 10.1136/bmj.311.7020.1621; MANTEL N, 1959, J NATL CANCER I, V22, P719; McIntosh MW, 1996, STAT MED, V15, P1713, DOI 10.1002/(SICI)1097-0258(19960830)15:16<1713::AID-SIM331>3.0.CO;2-D; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; Meade MO, 1997, ANN INTERN MED, V127, P531, DOI 10.7326/0003-4819-127-7-199710010-00005; Michels KB, 1996, LANCET, V348, P1152, DOI 10.1016/S0140-6736(96)05418-9; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; MORRIS CN, 1992, BAYESIAN STAT, V4; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; MULROW CD, 1989, J GEN INTERN MED, V4, P288, DOI 10.1007/BF02597398; OLKIN I, 1995, J CLIN EPIDEMIOL, V48, P133, DOI 10.1016/0895-4356(94)00136-E; Orwin R.G., 1994, HDB RES SYNTHESIS; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SINCLAIR JC, 1994, J CLIN EPIDEMIOL, V47, P881, DOI 10.1016/0895-4356(94)90191-0; SMITH SJ, 1995, STAT MED, V14, P531, DOI 10.1002/sim.4780140513; Smith TC, 1995, STAT MED, V14, P2685, DOI 10.1002/sim.4780142408; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; TRYBA M, 1991, J CLIN GASTROENTE S2, V3, P544; TWEEDIE RL, 1995, STAT MED, V14, P545, DOI 10.1002/sim.4780140514; VEVEA JL, 1995, PSYCHOMETRIKA, V60, P419, DOI 10.1007/BF02294384; VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	63	2106	2156	4	65	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					820	826		10.7326/0003-4819-127-9-199711010-00008	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382404				2022-12-28	WOS:A1997YD89800007
J	McDonald, CJ; Overhage, JM; Dexter, P; Takesue, BY; Dwyer, DM				McDonald, CJ; Overhage, JM; Dexter, P; Takesue, BY; Dwyer, DM			A framework for capturing clinical data sets from computerized sources	ANNALS OF INTERNAL MEDICINE			English	Article							RECORDS	The pressure to improve health care and provide better care at a lower cost has generated the need for efficient capture of clinical data. Many data sets are now being defined to analyze health care. Historically, review and research organizations have simply determined what data they wanted to collect, developed forms, and then gathered the information through chart review without regard to what is already available institutionally in computerized databases. Today, much electronic patient information is available in operational data systems (for example, laboratory systems, pharmacy systems, and surgical scheduling systems) and is accessible by agencies and organizations through standards for messages, codes, and encrypted electronic mail. Such agencies and organizations should define the elements of their data sets in terms of standardized operational data, and data producers should fully adopt these code and message standards. The Health Plan Employer Data and Information Set and the Council of State and Territorial Epidemiologists in collaboration with the Centers for Disease Control and Prevention and the Association of State and Territorial Public Health Laboratory Directors provide examples of how this can be done.	MARYLAND DEPT HLTH & MENTAL HYG, EPIDEMIOL & DIS CONTROL PROGRAM, BALTIMORE, MD 21201 USA	Maryland Department of Health & Mental Hygiene	McDonald, CJ (corresponding author), INDIANA UNIV, MED CTR,DEPT MED,REGENSTRIEF INST HLTH CARE, SCH MED,5TH FLOOR RHC, 1001 W 10TH ST, INDIANAPOLIS, IN 46202 USA.			Overhage, Joseph/0000-0003-0223-0195	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007719] Funding Source: NIH RePORTER; AHRQ HHS [HS 07719-03] Funding Source: Medline; NLM NIH HHS [N01-LM-4-3410, N01-LM-6-3456] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ABERNATHY S, 1997, IMMUNICATION DATA T; ACKERMAN MJ, 1994, J AM MED INFORM ASSN, V1, P1; ALLER RD, 1996, CAP TODAY, V10, P1137; *AM AC ORTH SURG, MODEMS MUSC OUTC DAT; *AM COLL PATH, 1996, SNOMED SYST NOM MED, V1; *AM COLL PATH, 1996, SNOMED SYST NOM MED, V2; *AM COLL SURG, 1996, NAT TRACS; *AM MED ASS, 1994, CURR PROC TERM CPT95; *AM SOC TEST MAT, 1994, E123894 AM SOC TEST; Barrows RC, 1996, J AM MED INFORM ASSN, V3, P139, DOI 10.1136/jamia.1996.96236282; *DAT INT STAND ASS, 1992, AS X 12 834 BEN ENR; *DIG IM COMM MED, 1995, PS31PS312 DIG IM COM; *DOM STAND WORK GR, 1996, CARD DAT STAND C STA; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; FRIES JF, 1972, J AMER MED ASSOC, V222, P1536, DOI 10.1001/jama.222.12.1536; HARRIS LE, 1993, AM J KIDNEY DIS, V21, P161, DOI 10.1016/S0272-6386(12)81087-0; *HLTH CAR FIN ADM, 1983, INT CLASS DIS REV 9; *HLTH CAR FIN ADM, 1997, OUTC ASS INF SET; Jones RH, 1996, J AM COLL CARDIOL, V28, P1478, DOI 10.1016/S0735-1097(96)00359-2; KENNELLY RJ, 1994, J AM MED INFORM ASSN, P531; KRAKAUER H, 1990, EFFECTIVENESS AND OUTCOMES IN HEALTH CARE, P120; LOCKE B, 1997, TRENDS HEALTHCARE CO; MORRIS JN, 1991, RESIDENT ASSESSMENT; *NAT COMM QUAL ASS, 1996, HEDIS 3 0 HLTH PLAN; *NAT COMM VIT HLTH, 1996, 199677267783245 NATL; *NAT COUNC PRESCR, 1992, TEL STAND FORM VERS; Pine M, 1997, ANN INTERN MED, V126, P347, DOI 10.7326/0003-4819-126-5-199703010-00002; *QUEENS PRINT ONT, 1995, REP MIN HLTH LAB SER; SHIH C, 1966, REQUIREMENTS INTEROP; STIELL IG, 1994, JAMA-J AM MED ASSOC, V271, P827, DOI 10.1001/jama.271.11.827; Strom BL, 1994, PHARMACOEPIDEMIOLOGY	31	48	48	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				675	682		10.7326/0003-4819-127-8_Part_2-199710151-00049	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00049			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB385	9382379				2022-12-28	WOS:A1997YB38500004
J	Schuchat, A; Robinson, K; Wenger, JD; Harrison, LH; Farley, M; Reingold, AL; Lefkowitz, L; Perkins, BA				Schuchat, A; Robinson, K; Wenger, JD; Harrison, LH; Farley, M; Reingold, AL; Lefkowitz, L; Perkins, BA			Bacterial meningitis in the United States in 1995	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLUENZAE TYPE-B; HAEMOPHILUS-INFLUENZAE; CONJUGATE VACCINE; HEMOPHILUS-INFLUENZAE; ANTIMICROBIAL RESISTANCE; MENINGOCOCCAL-DISEASE; RISK-FACTORS; CHILDREN; POLYSACCHARIDE; EMERGENCE	Background Before the introduction of the conjugate vaccines, Haemophilus influenzae type b was the major cause of bacterial meningitis in the United States, and meningitis was primarily a disease of infants and young children. We describe the epidemiologic features of bacterial meningitis five years after the H. influenzae type b conjugate vaccines were licensed for routine immunization of infants. Methods Data were collected from active, population-based surveillance for culture-confirmed meningitis and other invasive bacterial disease during 1995 in laboratories serving all the acute care hospitals in 22 counties of four states (total population, more than 10 million). The rates were compared with those for 1986 obtained by similar surveillance. Results On the basis of 248 cases of bacterial meningitis in the surveillance areas, the rates of meningitis (per 100,000) for the major pathogens in 1995 were Streptococcus pneumoniae, 1.1; Neisseria meningitidis, 0.6; group B streptococcus, 0.3; Listeria monocytogenes, 0.2; and H. influenzae, 0.2. Group B streptococcus was the predominant pathogen among newborns, N. meningitidis among children 2 to 18 years old, and S. pneumoniae among adults. Pneumococcal meningitis had the highest case fatality rate (21 percent) and in 36 percent of cases was caused by organisms that were not susceptible to penicillin. From these data, we estimate that 5755 cases of bacterial meningitis were caused by these five pathogens in the United States in 1995, as compared with 12,920 cases in 1986, a reduction of 55 percent. The median age of persons with bacterial meningitis increased greatly, from 15 months in 1986 to 25 years in 1995, largely as a result of a 94 percent reduction in the number of cases of ii. influenzae meningitis. Conclusions Because of the vaccine-related decline in meningitis due to H. influenzae type b, bacterial meningitis in the United Slates is now a disease predominantly of adults rather than of infants and young children. (C) 1997, Massachusetts Medical Society.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, SPECIAL PATHOGENS BRANCH, ATLANTA, GA 30333 USA; JOHNS HOPKINS SCH HYG & PUBL HLTH, BALTIMORE, MD USA; VET AFFAIRS MED CTR, ATLANTA, GA 30033 USA; EMORY UNIV, SCH MED, ATLANTA, GA USA; CALIF EMERGING INFECT PROGRAM, BERKELEY, CA USA; VANDERBILT UNIV, MED CTR, NASHVILLE, TN USA	Centers for Disease Control & Prevention - USA; Johns Hopkins University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Emory University; California Emerging Infections Program; Vanderbilt University	Schuchat, A (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV BACTERIAL & MYCOT DIS, RESP DIS BRANCH, ATLANTA, GA 30333 USA.							ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; Blumberg HM, 1996, J INFECT DIS, V173, P365, DOI 10.1093/infdis/173.2.365; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; COCHI SL, 1985, JAMA-J AM MED ASSOC, V253, P521, DOI 10.1001/jama.253.4.521; *COMM OBST PRACT, 1996, 173 ACOG COMM OBST P; DEMORAES C, 1992, LANCET, V340, P1554; DEMORAES JC, 1992, LANCET, V340, P1074; DOERN GV, 1986, DIAGN MICR INFEC DIS, V4, P95, DOI 10.1016/0732-8893(86)90143-4; FRASCH CE, 1989, CLIN MICROBIOL REV, V2, pS134, DOI 10.1128/CMR.2.Suppl.S134-S138.1989; FRASER DW, 1975, AM J EPIDEMIOL, V102, P394, DOI 10.1093/oxfordjournals.aje.a112178; FRASER DW, 1974, AM J EPIDEMIOL, V100, P29, DOI 10.1093/oxfordjournals.aje.a112005; FRASER DW, 1973, J INFECT DIS, V127, P271, DOI 10.1093/infdis/127.3.271; GOTSCHLICH EC, 1969, J EXP MED, V129, P1349, DOI 10.1084/jem.129.6.1349; Halsey NA, 1997, PEDIATRICS, V99, P489, DOI 10.1542/peds.99.3.489; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; JONSDOTTIR KE, 1992, LANCET, V340, P252, DOI 10.1016/0140-6736(92)90529-C; JORGENSEN JH, 1990, ANTIMICROB AGENTS CH, V34, P2075, DOI 10.1128/AAC.34.11.2075; Kaspar DL, 1996, J CLIN INVEST, V98, P2308, DOI 10.1172/JCI119042; MACLEOD CM, 1945, J EXP MED, V82, P445, DOI 10.1084/jem.82.6.445; MOHLEBOETANI JC, 1993, PEDIATR INFECT DIS J, V12, P589, DOI 10.1097/00006454-199307000-00009; MURPHY TV, 1993, J PEDIATR-US, V122, P517, DOI 10.1016/S0022-3476(05)83529-2; NCCLS, 1997, METH DIL ANT SUSC TE; Quagliarello VJ, 1997, NEW ENGL J MED, V336, P708, DOI 10.1056/NEJM199703063361007; RODRIGUES LP, 1971, J IMMUNOL, V107, P1071; Scheifele DW, 1996, CAN MED ASSOC J, V154, P1041; Scheifele DW, 1996, CAN MED ASSOC J, V154, P1319; SCHOENDORF KC, 1994, PEDIATRICS, V93, P663; SCHUCHAT A, 1992, JAMA-J AM MED ASSOC, V267, P2041, DOI 10.1001/jama.267.15.2041; SIERRA G V G, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P195; TAKALA AK, 1994, LARYNGOSCOPE, V104, P731; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; TAPPERO JW, 1995, JAMA-J AM MED ASSOC, V273, P1118, DOI 10.1001/jama.273.14.1118; WARD J, 1994, VACCINES, P337; WENGER JD, 1990, J INFECT DIS, V162, P1316, DOI 10.1093/infdis/162.6.1316; WHALEN CM, 1995, JAMA-J AM MED ASSOC, V273, P390, DOI 10.1001/jama.273.5.390; 1996, MMWR-MORBID MORTAL W, V45, P853; 1996, MMWR-MORBID MORTAL W, V45, P1010	41	838	892	1	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	1997	337	14					970	976		10.1056/NEJM199710023371404	http://dx.doi.org/10.1056/NEJM199710023371404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	XY423	9395430	Bronze			2022-12-28	WOS:A1997XY42300004
J	Grace, AA; Camm, J				Grace, AA; Camm, J			Quinidine	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ANTIARRHYTHMIC DRUG-THERAPY; CORONARY-ARTERY DISEASE; TORSADE-DE-POINTES; SUSTAINED VENTRICULAR TACHYARRHYTHMIAS; PAROXYSMAL ATRIAL-FIBRILLATION; ACTION-POTENTIAL PROLONGATION; CANINE PURKINJE-FIBERS; REVERSE USE-DEPENDENCE; POTASSIUM CHANNEL; SINUS RHYTHM		St Georges Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England; Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England; Univ Cambridge, Dept Biochem, Cambridge CB2 2QQ, England; Papworth Hosp, Dept Cardiol, Cambridge CB3 8RE, England	St Georges University London; University of Cambridge; University of Cambridge; Papworth Hospital	Camm, J (corresponding author), St Georges Hosp, Sch Med, Dept Cardiol Sci, Cranmer Terrace, London SW17 0RE, England.							BAJAJ AK, 1987, CIRCULATION, V75, P1065, DOI 10.1161/01.CIR.75.5.1065; BALSER JR, 1991, CIRC RES, V69, P519, DOI 10.1161/01.RES.69.2.519; BAUMAN JL, 1984, AM HEART J, V107, P425, DOI 10.1016/0002-8703(84)90081-4; BIGGER JT, 1987, AM J CARDIOL, V59, pE2, DOI 10.1016/0002-9149(87)90195-0; BIRGERSDOTTER UM, 1992, BRIT J CLIN PHARMACO, V33, P275, DOI 10.1111/j.1365-2125.1992.tb04035.x; BONAVITA GJ, 1994, AM HEART J, V127, P847; BORGEAT A, 1986, AM J CARDIOL, V58, P496, DOI 10.1016/0002-9149(86)90022-6; Brodsky MA, 1996, ARCH INTERN MED, V156, P2553, DOI 10.1001/archinte.156.22.2553; Brodsky MA, 1996, AM J CARDIOL, V78, P1152, DOI 10.1016/S0002-9149(96)90070-3; CAPORASO NE, 1991, ARCH INTERN MED, V151, P1985, DOI 10.1001/archinte.151.10.1985; CARMELIET E, 1993, CARDIOVASC DRUG THER, V7, P599, DOI 10.1007/BF00877626; CHONG BH, 1991, BLOOD, V77, P2190; COHEN IS, 1977, PROG CARDIOVASC DIS, V20, P151, DOI 10.1016/0033-0620(77)90004-4; COLATSKY TJ, 1990, CIRCULATION, V82, P2235, DOI 10.1161/01.CIR.82.6.2235; COPLEN SE, 1991, CIRCULATION, V83, P714; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; DATA JL, 1976, NEW ENGL J MED, V294, P699, DOI 10.1056/NEJM197603252941305; DAVIDENKO JM, 1989, CIRCULATION, V79, P674, DOI 10.1161/01.CIR.79.3.674; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; DIMARCO JP, 1983, AM J CARDIOL, V51, P90, DOI 10.1016/S0002-9149(83)80017-4; Domanski MJ, 1997, CIRCULATION, V95, P2694, DOI 10.1161/01.CIR.95.12.2694; Drici MD, 1996, CIRCULATION, V94, P1471, DOI 10.1161/01.CIR.94.6.1471; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; EVANS JJ, 1984, CIRC RES, V55, P185, DOI 10.1161/01.RES.55.2.185; FALK RH, 1992, ANN INTERN MED, V117, P141, DOI 10.7326/0003-4819-117-2-141; FALK RH, 1992, ANN INTERN MED, V117, P446, DOI 10.7326/0003-4819-117-5-446; FELD GK, 1990, CIRCULATION, V82, P2248, DOI 10.1161/01.CIR.82.6.2248; FELD GK, 1986, CIRCULATION, V74, P197, DOI 10.1161/01.CIR.74.1.197; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; FRANZ MR, 1988, CIRCULATION, V77, P1177, DOI 10.1161/01.CIR.77.5.1177; FRIEHLING TD, 1990, AM J CARDIOL, V65, P1328, DOI 10.1016/0002-9149(90)91322-W; GAZZANIGA AB, 1969, NEW ENGL J MED, V280, P711, DOI 10.1056/NEJM196903272801309; Gilman, 1996, GOODMAN GILMANS PHAR, P1707; HAGER WD, 1979, NEW ENGL J MED, V300, P1238, DOI 10.1056/NEJM197905313002202; HARDY BG, 1983, AM J CARDIOL, V52, P172, DOI 10.1016/0002-9149(83)90091-7; HII JTY, 1992, CIRCULATION, V86, P1376, DOI 10.1161/01.CIR.86.5.1376; HOHNLOSER SH, 1995, J AM COLL CARDIOL, V26, P852, DOI 10.1016/0735-1097(95)00286-5; HOHNLOSER SH, 1994, NEW ENGL J MED, V331, P31; HONDEGHEM LM, 1990, CIRCULATION, V81, P686, DOI 10.1161/01.CIR.81.2.686; HONDEGHEM LM, 1987, CIRCULATION, V75, P514, DOI 10.1161/01.CIR.75.3.514; HOROWITZ LN, 1987, J AM COLL CARDIOL, V9, P459, DOI 10.1016/S0735-1097(87)80405-9; HUGHES B, 1987, AM HEART J, V114, P908, DOI 10.1016/0002-8703(87)90809-X; JOHNSON EA, 1957, J PHARMACOL EXP THER, V120, P460; JOSEPHSON ME, 1974, AM HEART J, V87, P55, DOI 10.1016/0002-8703(74)90391-3; JUULMOLLER S, 1990, CIRCULATION, V82, P1932, DOI 10.1161/01.CIR.82.6.1932; KADISH AH, 1990, CIRCULATION, V81, P14, DOI 10.1161/01.CIR.81.1.14; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; KOREN G, 1988, J PHARMACOL EXP THER, V247, P1193; KUS T, 1990, AM HEART J, V120, P855, DOI 10.1016/0002-8703(90)90201-8; LAU CP, 1992, AM HEART J, V124, P645, DOI 10.1016/0002-8703(92)90272-W; Lehmann MH, 1996, CIRCULATION, V94, P2535, DOI 10.1161/01.CIR.94.10.2535; LEVINE JH, 1989, CIRCULATION, V80, P1063, DOI 10.1161/01.CIR.80.4.1063; Lewis T, 1922, AM J MED SCI, V163, P781; MAHMARIAN JJ, 1987, CIRCULATION, V76, P324, DOI 10.1161/01.CIR.76.2.324; MAISEL AS, 1985, NEW ENGL J MED, V312, P167, DOI 10.1056/NEJM198501173120308; Maisel WH, 1997, ANN INTERN MED, V127, P281, DOI 10.7326/0003-4819-127-4-199708150-00004; MASON JW, 1977, J CLIN INVEST, V59, P481, DOI 10.1172/JCI108663; MASON JW, 1993, NEW ENGL J MED, V329, P452, DOI 10.1056/NEJM199308123290702; Mason JW, 1996, PROG CARDIOVASC DIS, V38, P347, DOI 10.1016/S0033-0620(96)80028-4; MINARDO JD, 1988, NEW ENGL J MED, V319, P257, DOI 10.1056/NEJM198808043190501; MOOSVI AR, 1990, AM J CARDIOL, V65, P1192, DOI 10.1016/0002-9149(90)90972-4; MORGANROTH J, 1991, CIRCULATION, V84, P1977, DOI 10.1161/01.CIR.84.5.1977; Naccarelli GV, 1996, AM J CARDIOL, V77, pA53, DOI 10.1016/S0002-9149(97)89118-7; NADEMANEE K, 1990, CIRCULATION, V81, P790, DOI 10.1161/01.CIR.81.3.790; NATTEL S, 1991, DRUGS, V41, P672, DOI 10.2165/00003495-199141050-00002; NISHIMURA M, 1988, J PHARMACOL EXP THER, V244, P780; NYGAARD TW, 1986, JAMA-J AM MED ASSOC, V256, P55, DOI 10.1001/jama.256.1.55; OBERG KC, 1994, AM J CARDIOL, V74, P192, DOI 10.1016/0002-9149(94)90101-5; PILATI G, 1991, CURR THER RES CLIN E, V49, P140; PLATIA EV, 1988, AM J CARDIOL, V61, P1284, DOI 10.1016/0002-9149(88)91170-8; PRITCHETT ELC, 1992, NEW ENGL J MED, V326, P1264; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; QU YS, 1995, P NATL ACAD SCI USA, V92, P11839, DOI 10.1073/pnas.92.25.11839; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; RODEN DM, 1994, NEW ENGL J MED, V331, P785; RODEN DM, 1985, CIRC RES, V56, P857, DOI 10.1161/01.RES.56.6.857; RUBIN RL, 1992, J CLIN INVEST, V90, P165, DOI 10.1172/JCI115832; SALATA JJ, 1988, CIRC RES, V62, P324, DOI 10.1161/01.RES.62.2.324; SALERNO DM, 1991, CIRCULATION, V84, P2196, DOI 10.1161/01.CIR.84.5.2196; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SCHELLENS JHM, 1991, CLIN PHARMACOL THER, V50, P520, DOI 10.1038/clpt.1991.177; SELZER A, 1964, CIRCULATION, V30, P17, DOI 10.1161/01.CIR.30.1.17; SHALIT M, 1985, ARCH INTERN MED, V145, P2051, DOI 10.1001/archinte.145.11.2051; SHEN XT, 1986, CIRCULATION, V73, P1342, DOI 10.1161/01.CIR.73.6.1342; SINDRUP SH, 1992, EUR J CLIN PHARMACOL, V42, P587; SNYDERS DJ, 1992, MOL PHARMACOL, V41, P322; Steinbeck G, 1996, PROG CARDIOVASC DIS, V38, P419, DOI 10.1016/S0033-0620(96)80006-5; SZEKERES L, 1984, DISCOVERIES PHARM, V2, P185; TARTINI R, 1982, LANCET, V1, P1327; TEO KK, 1993, JAMA-J AM MED ASSOC, V270, P1589, DOI 10.1001/jama.270.13.1589; THOMPSON KA, 1987, J PHARMACOL EXP THER, V241, P84; TWUMBARIMA Y, 1981, NEW ENGL J MED, V304, P1466, DOI 10.1056/NEJM198106113042405; UEDA CT, 1992, APPL PHARMACOKINETIC, P23; VERME CN, 1992, CLIN PHARMACOKINET, V22, P468, DOI 10.2165/00003088-199222060-00005; VERME CN, 1992, CLIN PHARMACOKINET, V23, P68, DOI 10.1007/BF03259377; VITOLO E, 1981, ACTA CARDIOL, V36, P431; Waktare JEP, 1997, HEART, V77, P393, DOI 10.1136/hrt.77.5.393; WANG Z, 1990, CIRCULATION, V82, P274, DOI 10.1161/01.CIR.82.1.274; WANG ZG, 1995, J PHARMACOL EXP THER, V272, P184; WEIDMANN S, 1955, J PHYSIOL-LONDON, V129, P568, DOI 10.1113/jphysiol.1955.sp005379; WOODINGSCOTT RA, 1987, AM HEART J, V113, P302, DOI 10.1016/0002-8703(87)90269-9; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1532, DOI 10.1001/jama.269.12.1532; WRIGHT GJ, 1987, BIOPHARM DRUG DISPOS, V8, P159, DOI 10.1002/bdd.2510080207; Yang T, 1996, CIRCULATION, V93, P407, DOI 10.1161/01.CIR.93.3.407; Yeola SW, 1996, CIRC RES, V78, P1105, DOI 10.1161/01.RES.78.6.1105; ZEHENDER M, 1992, J AM COLL CARDIOL, V19, P1054, DOI 10.1016/0735-1097(92)90294-W; ZHOU HH, 1990, CLIN PHARMACOL THER, V47, P686, DOI 10.1038/clpt.1990.94	107	104	108	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	1998	338	1					35	45		10.1056/NEJM199801013380107	http://dx.doi.org/10.1056/NEJM199801013380107			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN801	9414330				2022-12-28	WOS:000071209200007
J	Sivaram, CA; Beckman, KJ				Sivaram, CA; Beckman, KJ			Amiodarone-induced skin discoloration	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Sivaram, CA (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,OKLAHOMA CITY,OK 73190, USA.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 18	1997	337	25					1813	1813		10.1056/NEJM199712183372505	http://dx.doi.org/10.1056/NEJM199712183372505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL855	9400038				2022-12-28	WOS:A1997YL85500005
J	Cheng, EHY; Kirsch, DG; Clem, RJ; Ravi, R; Kastan, MB; Bedi, A; Ueno, K; Hardwick, JM				Cheng, EHY; Kirsch, DG; Clem, RJ; Ravi, R; Kastan, MB; Bedi, A; Ueno, K; Hardwick, JM			Conversion of Bcl-2 to a Bax-like death effector by caspases	SCIENCE			English	Article							CELL-DEATH; CONSERVED DOMAINS; APOPTOSIS; BCL-X(L); PROTEASE; DISTINCT; HETERODIMERIZATION; MODULATION; PATHWAYS; FODRIN	Caspases are a family of cysteine proteases implicated in the biochemical and morphological changes that occur during apoptosis (programmed cell death). The loop domain of Bcl-2 is cleaved at Asp(34) by caspase-3 (CPP32) in vitro, in cells overexpressing caspase-3, and after induction of apoptosis by Fas ligation and interleukin-3 withdrawal. The carboxyl-terminal Bcl-2 cleavage product triggered cell death and accelerated Sindbis virus-induced apoptosis, which was dependent on the BH3 homology and transmembrane domains of Bcl-2, Inhibitor studies indicated that cleavage of Bcl-2 may further activate downstream caspases and contribute to amplification of the caspase cascade. Cleavage-resistant mutants of Bcl-2 had increased protection from interleukin-3 withdrawal and Sindbis virus-induced apoptosis. Thus, cleavage of Bcl-2 by caspases may ensure the inevitability of cell death.	JOHNS HOPKINS SCH PUBL HLTH,DEPT MOL MICROBIOL & IMMUNOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205; KAGOSHIMA UNIV,FAC MED,KAGOSHIMA 890,JAPAN	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Kagoshima University				Clem, Rollie/0000-0002-2368-720X				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Haldar S, 1996, CANCER RES, V56, P1253; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hardwick J M, 1997, Adv Pharmacol, V41, P295, DOI 10.1016/S1054-3589(08)61063-7; HARDWICK JP, UNPUB; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; HUTNER JJ, 1996, MOL CELL BIOL, V16, P877; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LEWIS LN, UNPUB; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Middleton G, 1996, DEVELOPMENT, V122, P695; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126	46	935	1041	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1966	1968		10.1126/science.278.5345.1966	http://dx.doi.org/10.1126/science.278.5345.1966			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395403				2022-12-28	WOS:A1997YL00200041
J	Harmon, JK; Ostro, SJ; Benner, LAM; Rosema, KD; Jurgens, RF; Winkler, R; Yeomans, DK; Choate, D; Cormier, R; Giorgini, JD; Mitchell, DL; Chodas, PW; Rose, R; Kelley, D; Slade, MA; Thomas, ML				Harmon, JK; Ostro, SJ; Benner, LAM; Rosema, KD; Jurgens, RF; Winkler, R; Yeomans, DK; Choate, D; Cormier, R; Giorgini, JD; Mitchell, DL; Chodas, PW; Rose, R; Kelley, D; Slade, MA; Thomas, ML			Radar detection of the nucleus and Coma of Comet Hyakutake (C/1996 B2)	SCIENCE			English	Article							GRAINS	Radar observations of comet Hyakutake (C/1996 B2) made at the Goldstone Deep Space Communications Complex in California have detected echoes from the nucleus and from large grains in the inner coma. The nucleus of this bright comet was estimated to be only 2 to 3 kilometers in diameter. Models of the coma echo indicate backscatter from porous, centimeter-size grains ejected anisotropically at velocities of tens of meters per second. The radar observations suggest that a comet's activity may be a poor indicator of its size and provide evidence that large grains constitute an important component of the mass loss from a typical active comet.	CALTECH,JET PROP LAB,PASADENA,CA 91109	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Harmon, JK (corresponding author), NATL ASTRON & IONOSPHERE CTR,ARECIBO OBSERV,POB 995,ARECIBO,PR 00614, USA.							ALTENHOFF WJ, 1996, BAAS, V28, P928; BENNER LAM, IN PRESS ICARUS; CAMPBELL DB, 1989, ASTROPHYS J, V338, P1094, DOI 10.1086/167259; dePater I, 1997, PLANET SPACE SCI, V45, P731, DOI 10.1016/S0032-0633(97)00078-0; Fernandez YR, 1997, PLANET SPACE SCI, V45, P735, DOI 10.1016/S0032-0633(97)00079-2; FERNANDEZ YR, 1996, B AM ASTRON SOC, V28, P1088; GOLDSTEIN RM, 1984, ASTRON J, V89, P1745, DOI 10.1086/113683; HAGE JI, 1990, ASTROPHYS J, V361, P251, DOI 10.1086/169190; HANNER MS, 1987, ASTRON J, V94, P1081, DOI 10.1086/114544; HARMON JK, 1989, ASTROPHYS J, V338, P1071, DOI 10.1086/167258; HARMON JP, UNPUB; Harris WM, 1997, SCIENCE, V277, P676, DOI 10.1126/science.277.5326.676; JEWITT D, 1992, ICARUS, V100, P187, DOI 10.1016/0019-1035(92)90028-6; Jewitt DC, 1997, ASTRON J, V113, P1145, DOI 10.1086/118333; JORDA L, 1996, 6344 INT ASTR UN; KAMOUN PG, 1982, SCIENCE, V216, P293, DOI 10.1126/science.216.4543.293; KAMOUN PG, 1983, THESIS MIT; KELLER HU, 1987, ASTRON ASTROPHYS, V187, P807; KELLER HU, 1991, GEOPHYS RES LETT, V18, P249, DOI 10.1029/90GL02591; Kuhrt E, 1997, PLANET SPACE SCI, V45, P665, DOI 10.1016/S0032-0633(96)00163-8; LARSON S, 1996, B AM ASTRON SOC, V28, P926; MUMMA MJ, 1996, 6366 INT ASTR UN; OSTRO SJ, 1991, ASTRON J, V102, P1490, DOI 10.1086/115975; Sarmecanic J, 1997, ASTROPHYS J, V483, pL69, DOI 10.1086/310726; Sarmecanic J., 1996, B AM ASTRON SOC, V28, P1089; SCHLEICHER D, 1996, 6372 INT ASTR UN; SCHLEICHER DG, 1996, BAAS, V28, P926; SEKANINA Z, 1988, ASTRON J, V95, P1876, DOI 10.1086/114783; SHAPIRO I, 1983, B AM ASTRON SOC, V15, P800; WEST RM, 1996, 6343 INT ASTR UN; WRIGHT EL, 1989, ASTROPHYS J, V346, pL89, DOI 10.1086/185586; YEOMANS DK, COMMUNICATION	32	45	45	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1921	1924		10.1126/science.278.5345.1921	http://dx.doi.org/10.1126/science.278.5345.1921			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395389				2022-12-28	WOS:A1997YL00200027
J	Keitel, T; Kramer, A; Wessner, H; Scholz, C; SchneiderMergener, J; Hohne, W				Keitel, T; Kramer, A; Wessner, H; Scholz, C; SchneiderMergener, J; Hohne, W			Crystallographic analysis of anti-p24 (HIV-1) monoclonal antibody cross-reactivity and polyspecificity	CELL			English	Article							ELECTRON-DENSITY MAPS; 3-DIMENSIONAL STRUCTURE; CAPSID PROTEIN; ANTIGEN INTERACTIONS; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; COMPLEX; BINDING; REARRANGEMENTS; CONFORMATIONS	The X-ray crystal structures of an anti-p24 (HIV-1) monoclonal antibody Fab fragment alone and in complexes with the epitope peptide GATPQDLNTnL (n = norleucine), an epitope-homologous peptide GATPED LNQKLAGN, as well as two unrelated peptides GLYEW GGARITNTD and efslkGpIIqwrsG (D-peptide), are presented to a maximum resolution of 2.6 Angstrom. The latter three peptides were identified from screening synthetic combinatorial peptide libraries. Although all peptides bind to the same antigen combining site, the nonhomologous peptides adopt different binding conformations and also form their critical contacts with different antibody residues. Only small readjustments are observed within the framework of the Fab fragment upon binding.	HUMBOLDT UNIV BERLIN, KLINIKUM CHARITE, INST BIOCHEM, D-10098 BERLIN, GERMANY; HUMBOLDT UNIV BERLIN, KLINIKUM CHARITE, INST MED IMMUNOL, D-10098 BERLIN, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin				Kramer, Achim/0000-0001-9671-6078				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Abu-Shakra Mahmoud, 1996, P408, DOI 10.1016/B978-044482383-0/50063-7; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1992, X PLOR VERSION 3 0 S; Chacko S, 1996, PROTEINS, V26, P55, DOI 10.1002/(SICI)1097-0134(199609)26:1<55::AID-PROT5>3.0.CO;2-F; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; *COLL COMP PROJ NU, 1994, CCP4 SUIT PROGR PROT; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; Ehrhard B, 1996, BIOCHEMISTRY-US, V35, P9097, DOI 10.1021/bi9603534; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; GELIN BR, 1979, BIOCHEMISTRY-US, V18, P1256, DOI 10.1021/bi00574a022; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; Glaser RW, 1996, J IMMUNOL METHODS, V189, P1, DOI 10.1016/0022-1759(95)00221-9; GRUNOW R, 1990, Z KLIN MED, V45, P367; Hohne W E, 1993, Mol Immunol, V30, P1213, DOI 10.1016/0161-5890(93)90140-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE A, 1990, CRYSTALLOGRAPHIC COM, P110; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; Rullmann J, 1996, AQUA COMPUTER PROGRA; SCHNEIDERMERGEN.J, 1996, COMBINATORIAL LIB, P53; SCHULZEGAHMEN U, 1993, J MOL BIOL, V234, P1098, DOI 10.1006/jmbi.1993.1663; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; Shirai H, 1996, FEBS LETT, V399, P1, DOI 10.1016/S0014-5793(96)01252-5; SHOHAM M, 1993, J MOL BIOL, V232, P1169, DOI 10.1006/jmbi.1993.1469; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; TORMO J, 1994, EMBO J, V13, P2247, DOI 10.1002/j.1460-2075.1994.tb06506.x; Wade H, 1997, ANNU REV BIOPH BIOM, V26, P461, DOI 10.1146/annurev.biophys.26.1.461; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WINKLER K, 1996, THESIS HUMBOLDT U BE	49	106	115	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 12	1997	91	6					811	820		10.1016/S0092-8674(00)80469-9	http://dx.doi.org/10.1016/S0092-8674(00)80469-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413990	Bronze			2022-12-28	WOS:A1997YL43900012
J	Ledford, DK				Ledford, DK			Immunologic aspects of vasculitis and cardiovascular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RHEUMATOLOGY 1990 CRITERIA; HEPATITIS-B VIRUS; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; CHURG-STRAUSS-SYNDROME; POLYARTERITIS-NODOSA; WEGENERS GRANULOMATOSIS; KAWASAKI SYNDROME; CLASSIFICATION; ARTERITIS; ATHEROSCLEROSIS	The immunologic cardiovascular diseases are a heterogeneous group of conditions. Many of these entities are associated with serious morbidity and mortality resulting from cardiac impairment, ischemic complications, or organ dysfunction, particularly of the kidneys, lung, and nervous system. The systemic nature of these conditions, coupled with vague symptoms and nonspecific initial physical findings, makes the differential diagnosis complicated. Research has identified specific mediators and primary origins in some conditions, with infections often being responsible. Immunosuppressive therapy, despite the potential complications, has improved the prognosis of some of the more serious immunologic cardiovascular diseases. Improvement in the treatment of immunologic cardiovascular diseases awaits identification of additional causes, improved definition of host factors that predispose an individual to develop these conditions, and better understanding of the immune dysregulation responsible for the progression of disease. The potential pathophysiologic role of immunologic mechanisms in common disorders such as congestive heart failure and atherosclerosis is intriguing and offers the possibility of novel therapies in these prevalent conditions.			Ledford, DK (corresponding author), UNIV S FLORIDA, DIV ALLERGY & IMMUNOL, 13000 BRUCE B DOWNS BLVD, TAMPA, FL 33613 USA.							BALAJI S, 1994, BRIT HEART J, V72, P354; BLOCH DA, 1990, ARTHRITIS RHEUM, V33, P1068; CALABRESE LH, 1990, ARTHRITIS RHEUM, V33, P1108; COHENTERVAERT JW, 1991, AM J MED, V91, P59; Cotch MF, 1996, ARTHRITIS RHEUM, V39, P87, DOI 10.1002/art.1780390112; DAJANI AS, 1992, JAMA-J AM MED ASSOC, V268, P2069, DOI 10.1001/jama.1992.03490150121036; DALE JB, 1993, J IMMUNOL, V151, P2188; FALK E, 1996, ATHEROSCLEROSIS CORO, V2, P492; Frank M. M., 1995, SAMTERS IMMUNOLOGIC; Frostegard J, 1996, ATHEROSCLEROSIS, V121, P93, DOI 10.1016/0021-9150(95)05706-4; GEORGE J, 1996, IMMUNOL RES, V155, P315; GUILLEVIN L, 1994, ANN RHEUM DIS, V53, P334, DOI 10.1136/ard.53.5.334; GUILLEVIN L, 1993, J RHEUMATOL, V20, P1345; GUILLEVIN L, 1995, MEDICINE, V74, P238, DOI 10.1097/00005792-199509000-00002; HOFFMAN GS, 1992, ARTHRITIS RHEUM, V35, P1322, DOI 10.1002/art.1780351113; HOFFMAN GS, 1992, ANN INTERN MED, V116, P48; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1065; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; HYYPIA T, 1993, SCAND J INFECT DIS, P25; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; JORDAN SC, 1995, J CLIN IMMUNOL, V15, pS76, DOI 10.1007/BF01540897; Josefson D, 1997, BRIT MED J, V315, P330; JOSEPH S, 1994, J VASC INTERV RADIOL, V5, P573, DOI 10.1016/S1051-0443(94)71556-6; Kassem AS, 1996, PEDIATRICS, V97, P992; Kerr Gail, 1994, Current Opinion in Rheumatology, V6, P32, DOI 10.1097/00002281-199401000-00006; KERR GS, 1994, ANN INTERN MED, V120, P919, DOI 10.7326/0003-4819-120-11-199406010-00004; KOHLER PF, 1981, CLIN IMMUNOLOGY UPDA, P293; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; LEUNG DYM, 1990, J RHEUMATOL, V17, P15; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LIE JT, 1994, ARTHRITIS RHEUM-US, V37, P181, DOI 10.1002/art.1780370205; LIGHTFOOT RW, 1990, ARTHRITIS RHEUM, V33, P1088; LOCKSHIN MD, 1988, ARTHRITIS RHEUM, V31, P697, DOI 10.1002/art.1780310601; MAIONE S, 1993, CARDIOLOGY, V83, P234, DOI 10.1159/000175975; Marx N, 1997, J AM COLL CARDIOL, V30, P165, DOI 10.1016/S0735-1097(97)00116-2; Maseri A, 1997, NEW ENGL J MED, V336, P1014, DOI 10.1056/NEJM199704033361409; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; MASON JW, 1995, NEW ENGL J MED, V333, P269, DOI 10.1056/NEJM199508033330501; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; MELISH ME, 1990, J RHEUMATOL, V17, P2; Neumann FJ, 1997, CIRCULATION, V95, P2387, DOI 10.1161/01.CIR.95.10.2387; NEUMANN FJ, 1995, CIRCULATION, V92, P748, DOI 10.1161/01.CIR.92.4.748; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; Paul W., 1993, FUNDAMENTAL IMMUNOLO, P1211; PUANAMIYA K, 1997, CATHET CARDIOVASC DI, V40, P276; RICH RR, 1996, CLIN IMMUNOLOGY; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; ROSENFELD SI, 1986, AM J MED, V80, P143, DOI 10.1016/0002-9343(86)90066-5; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SCHULTZ DR, 1995, SEMIN ARTHRITIS RHEU, V25, P143, DOI 10.1016/S0049-0172(95)80027-1; SPECKS U, 1993, ADV EXP MED BIOL, V336, P65; SPECKS U, 1994, MAYO CLIN PROC, V69, P1197, DOI 10.1016/S0025-6196(12)65775-9; Stegeman CA, 1996, NEW ENGL J MED, V335, P16, DOI 10.1056/NEJM199607043350103; SZEKANECZ Z, 1994, AGENTS ACTIONS, V42, P159, DOI 10.1007/BF01983484; *TREATM LYM DIS, 1997, MED LETT DRUGS THER, V39, P47; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; VASILJEVIC JD, 1990, AM HEART J, V120, P1370, DOI 10.1016/0002-8703(90)90250-2; WICK G, 1995, IMMUNOL TODAY, V16, P27, DOI 10.1016/0167-5699(95)80067-0	58	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1962	1971		10.1001/jama.278.22.1962	http://dx.doi.org/10.1001/jama.278.22.1962			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396659				2022-12-28	WOS:A1997YK15500020
J	Winkelstein, A; Kiss, JE				Winkelstein, A; Kiss, JE			Immunohematologic disorders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CHRONIC LYMPHOCYTIC-LEUKEMIA; AUTOIMMUNE HEMOLYTIC-ANEMIA; INTRAVENOUS GAMMA-GLOBULIN; NECROSIS-FACTOR-ALPHA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; HEPARIN-INDUCED THROMBOCYTOPENIA; SYSTEMIC LUPUS-ERYTHEMATOSUS; DIRECT ANTIGLOBULIN-TEST; ACUTE LUNG INJURY; LONG-TERM FOLLOW	Immunohematology encompasses a broad array of clinical disorders in which immune reactions are involved in the pathogenesis of hematologic diseases. Immune reactions can involve the formed elements of the blood, producing hemolytic anemia, thrombocytopenia, or neutropenia. Autoimmune phenomena and drug-induced reactions are the most common mechanisms. In newborns, maternal antibodies can cross the placenta and destroy red blood cells, platelets, or neutrophils. Immune reactions can also occur during transfusion of blood products, leading to hemolysis, febrile reactions, allergic reactions, and lung injury. The role of leukocytes and cytokines released during blood component storage in mediating febrile transfusion reactions has prompted the increased use of leukocyte-reduced components. Immune reactions can occur to soluble clotting factors and can produce bleeding or thrombosis. Finally, immunohematologic features of B-cell disorders are considered.										ANDERSON KC, 1989, NEW ENGL J MED, V323, P15; ASHERSON RA, 1989, AM J MED, V86, P391, DOI 10.1016/0002-9343(89)90335-5; AYE MT, 1995, TRANSFUSION, V35, P117, DOI 10.1046/j.1537-2995.1995.35295125733.x; BJERRUM OJ, 1971, VOX SANG, V21, P411, DOI 10.1111/j.1423-0410.1971.tb04797.x; BLANCHETTE VS, 1993, J PEDIATR-US, V123, P989, DOI 10.1016/S0022-3476(05)80400-7; BOWMAN JM, 1991, CLIN OBSTET GYNECOL, V34, P296, DOI 10.1097/00003081-199106000-00010; BOWMAN JM, 1994, SCI BASIS TRANSFUSIO, V4, P403; BRETTLER DB, 1989, ARCH INTERN MED, V149, P1381, DOI 10.1001/archinte.149.6.1381; Bussel JB, 1997, NEW ENGL J MED, V337, P22, DOI 10.1056/NEJM199707033370104; Bussel JB, 1996, AM J OBSTET GYNECOL, V174, P1414, DOI 10.1016/S0002-9378(96)70582-3; BUSSEL JB, 1991, BLOOD, V77, P1884; BUSSEL JB, 1990, HEMATOL ONCOL CLIN N, V4, P179, DOI 10.1016/S0889-8588(18)30512-4; BUTLER J, 1991, BRIT J HAEMATOL, V79, P525, DOI 10.1111/j.1365-2141.1991.tb08069.x; BUX J, 1992, SEMIN HEMATOL, V29, P45; CANOSO RT, 1988, AM J HEMATOL, V27, P272, DOI 10.1002/ajh.2830270408; CAPON SM, 1995, TRANSFUSION, V35, P513, DOI 10.1046/j.1537-2995.1995.35695288773.x; CHAPEL HM, 1987, SEMIN HEMATOL, V24, P291; CHITKARA U, 1988, OBSTET GYNECOL, V71, P393; CHONG BH, 1991, BLOOD, V77, P2190; Cowchock S, 1997, NEW ENGL J MED, V337, P197, DOI 10.1056/NEJM199707173370311; CRAWFORD J, 1985, AM J MED, V79, P13, DOI 10.1016/0002-9343(85)90540-6; DAVENPORT RD, 1991, BRIT J HAEMATOL, V78, P540, DOI 10.1111/j.1365-2141.1991.tb04485.x; DENOTTOLANDER GJ, 1984, SCAND J HAEMATOL, V32, P101; DHAWAN M, 1993, BLOOD, V82, pA582; DZIK WH, 1992, TRANSFUSION, V32, P594, DOI 10.1046/j.1537-2995.1992.32692367210.x; EHRENFORTH S, 1992, LANCET, V339, P594, DOI 10.1016/0140-6736(92)90874-3; ENGELFRIET CP, 1992, SEMIN HEMATOL, V29, P3; ENGELFRIET CP, 1994, TRANSFUSION, V34, P617, DOI 10.1046/j.1537-2995.1994.34794330018.x; FERRI C, 1993, BLOOD, V81, P1132; FISK NM, 1994, AM J OBSTET GYNECOL, V171, P50, DOI 10.1016/S0002-9378(94)70076-1; FLORES G, 1993, AM J HEMATOL, V44, P237, DOI 10.1002/ajh.2830440404; FRANK MM, 1989, J ALLERGY CLIN IMMUN, V84, P411, DOI 10.1016/0091-6749(89)90350-3; Galli M, 1996, BRIT J HAEMATOL, V93, P1, DOI 10.1046/j.1365-2141.1996.390969.x; GARRATTY G, 1992, TRANSFUSION, V32, P269, DOI 10.1046/j.1537-2995.1992.32392213813.x; Garratty George, 1993, Transfusion Medicine Reviews, V7, P255; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; GERTZ MA, 1988, ARCH INTERN MED, V148, P929, DOI 10.1001/archinte.148.4.929; GILLILAND BC, 1971, NEW ENGL J MED, V285, P252, DOI 10.1056/NEJM197107292850503; GonzalezConejero R, 1996, BRIT J HAEMATOL, V93, P464, DOI 10.1046/j.1365-2141.1996.00502.x; GREIPP PR, 1981, AM J HEMATOL, V11, P443, DOI 10.1002/ajh.2830110414; GRINDON AJ, 1981, TRANSFUSION, V21, P313, DOI 10.1046/j.1537-2995.1981.21381201803.x; HACKETT T, 1982, SEMIN THROMB HEMOST, V8, P116, DOI 10.1055/s-2007-1005047; HAMBLIN TJ, 1986, J CLIN PATHOL, V39, P713, DOI 10.1136/jcp.39.7.713; HARRIS EN, 1988, ANNU REV MED, V39, P261, DOI 10.1146/annurev.med.39.1.261; HEDDLE NM, 1988, TRANSFUSION, V28, P29, DOI 10.1046/j.1537-2995.1988.28188127947.x; HEDDLE NM, 1994, NEW ENGL J MED, V331, P625, DOI 10.1056/NEJM199409083311001; HEDDLE NM, 1993, TRANSFUSION, V33, P794, DOI 10.1046/j.1537-2995.1993.331094054613.x; HIPPE E, 1970, BLOOD-J HEMATOL, V35, P68, DOI 10.1182/blood.V35.1.68.68; HOLMGREN G, 1993, LANCET, V341, P1113, DOI 10.1016/0140-6736(93)93127-M; Hoxie James A., 1995, P2171; JUDD WJ, 1990, TRANSFUSION, V30, P175, DOI 10.1046/j.1537-2995.1990.30290162907.x; JUDD WJ, 1986, TRANSFUSION, V26, P220, DOI 10.1046/j.1537-2995.1986.26386209372.x; KADEN BR, 1979, BLOOD, V53, P545; KANTARJIAN HM, 1990, SEMIN ONCOL, V17, P66; KARPATKIN S, 1995, P NATL ACAD SCI USA, V92, P2263, DOI 10.1073/pnas.92.6.2263; KAY NE, 1981, BLOOD, V57, P418, DOI 10.1182/blood.V57.3.418.418; KELTON JG, 1994, BLOOD, V83, P3232; KEVY SV, 1962, TRANSFUSION, V2, P7, DOI 10.1111/j.1537-2995.1962.tb00187.x; Kiefel V, 1996, ANN HEMATOL, V72, P280, DOI 10.1007/s002770050173; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KLEIN HG, 1996, STANDARDS BLOOD BANK; KOURI YH, 1993, BLOOD, V81, P2664; KUREC AS, 1992, BRIT J HAEMATOL, V81, P45, DOI 10.1111/j.1365-2141.1992.tb08169.x; KYLE RA, 1978, MAYO CLIN PROC, V53, P719; KYLE RA, 1989, SEMIN HEMATOL, V26, P176; Laskin CA, 1997, NEW ENGL J MED, V337, P148, DOI 10.1056/NEJM199707173370302; Law C, 1997, NEW ENGL J MED, V336, P1494, DOI 10.1056/NEJM199705223362104; LECHNER K, 1985, HAEMOSTASIS, V15, P254; LEVO Y, 1977, NEW ENGL J MED, V296, P1501, DOI 10.1056/NEJM197706302962605; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; MANGAN KF, 1982, J CLIN INVEST, V70, P1148, DOI 10.1172/JCI110713; MCFARLAND JG, 1991, BLOOD, V78, P2276; MOLTHAN L, 1967, NEW ENGL J MED, V277, P123, DOI 10.1056/NEJM196707202770303; MUELLERECKHARDT C, 1988, BLUT, V57, P163, DOI 10.1007/BF00319544; MUYLLE L, 1993, TRANSFUSION, V33, P195, DOI 10.1046/j.1537-2995.1993.33393174443.x; NESS PM, 1992, CURRENT THERAPY HEMA, P25; NEWMAN PJ, 1989, J CLIN INVEST, V83, P1778, DOI 10.1172/JCI114082; NYDEGGER UE, 1991, SEMIN HEMATOL, V28, P66; OKSENHENDLER E, 1990, Immunodeficiency Reviews, V2, P221; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; PERMPIKUL P, 1994, BLOOD, V83, P2878, DOI 10.1182/blood.V83.10.2878.2878; Petz Lawrence D., 1993, Transfusion Medicine Reviews, V7, P242, DOI 10.1016/S0887-7963(93)70144-3; Petz LD, 1980, ACQUIRED IMMUNE HEMO; PINEDA AA, 1978, TRANSFUSION, V18, P1, DOI 10.1046/j.1537-2995.1978.18178118550.x; PIROFSKY B, 1976, SEMIN HEMATOL, V13, P251; PIZZUTO J, 1984, BLOOD, V64, P1179; POPOVSKY MA, 1992, TRANSFUSION, V32, P589, DOI 10.1046/j.1537-2995.1992.32692367207.x; POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x; PRUZANSKI W, 1977, NEW ENGL J MED, V297, P583, DOI 10.1056/NEJM197709152971105; Przepiorka D, 1996, AM J CLIN PATHOL, V106, P6; QUEENAN JT, 1993, AM J OBSTET GYNECOL, V168, P1370, DOI 10.1016/S0002-9378(11)90767-4; ROBERT SHR, 1996, AUTOIMMUNE DISORDERS, P151; ROSOVE MH, 1990, OBSTET GYNECOL, V75, P630; RUBO J, 1992, J PEDIATR-US, V121, P93, DOI 10.1016/S0022-3476(05)82551-X; SANDLER SG, 1995, TRANSFUS MED REV, V9, P1, DOI 10.1016/S0887-7963(05)80026-4; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; SCHLEIDER MA, 1976, BLOOD, V48, P499; Schulman I., 1983, PEDIATR REV, V5, P173; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; SOKOL RJ, 1992, J CLIN PATHOL, V45, P1047, DOI 10.1136/jcp.45.12.1047; STEPHEN CR, 1955, JAMA-J AM MED ASSOC, V158, P525, DOI 10.1001/jama.1955.02960070001001; SUAREZ CR, 1987, AM J HEMATOL, V26, P247, DOI 10.1002/ajh.2830260306; SULTAN Y, 1984, LANCET, V2, P765; THALER M, 1989, NEW ENGL J MED, V321, P25, DOI 10.1056/NEJM198907063210105; TRIPLETT DA, 1988, JAMA-J AM MED ASSOC, V259, P550, DOI 10.1001/jama.259.4.550; Varterasian M L, 1995, Oncology (Williston Park), V9, P417; WALKER RH, 1990, TECHNICAL MANUAL, P293; WALKER RW, 1984, ARCH DIS CHILD, V59, P316, DOI 10.1136/adc.59.4.316; Warkentin T E, 1991, Prog Hemost Thromb, V10, P1; WARKENTIN TE, 1994, BLOOD, V84, P3691, DOI 10.1182/blood.V84.11.3691.bloodjournal84113691; WARKENTIN TE, 1994, LOW MOL WEIGHT HEPAR, P75; WATERS AH, 1992, SEMIN HEMATOL, V29, P18	113	7	8	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1982	1992						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396661				2022-12-28	WOS:A1997YK15500022
J	Kwiatkowski, D; Marsh, K				Kwiatkowski, D; Marsh, K			Development of a malaria vaccine	LANCET			English	Article							PLASMODIUM-FALCIPARUM MALARIA; TRANSMISSION-BLOCKING ANTIBODIES; SURFACE-ANTIGEN; CIRCUMSPOROZOITE PROTEIN; AOTUS MONKEYS; PROTECTIVE IMMUNITY; SPOROZOITE VACCINE; HUMAN ERYTHROCYTES; RECOMBINANT; IMMUNIZATION	Development of an effective malaria vaccine poses a major scientific challenge both in the laboratory and in the field. Such a vaccine is necessary because of the massive disease burden of malaria in the developing world, the global spread of drug resistance, and the difficulty of sustainable control of the mosquito vector. Animal models have shown the immunological feasibility of vaccines targeted against different stages of parasite development, and studies in human volunteers have shown that a recombinant protein vaccine can protect against challenge with the homologous strain of parasite. However, both natural and vaccine-induced Immunity are hampered by the remarkable capacity of the parasites to vary critical antigenic structures; large field trials of a synthetic peptide vaccine gave equivocal results. In an attempt to overcome the dual difficulty of poor immunogenicity and parasite diversity, much experimental work is now focused on complex antigenic constructs, delivered as DNA vaccines or in live vectors such as vaccinia, with multiple targets at each stage of parasite development.	WELLCOME TRUST RES LABS, KILIFI, KENYA		Kwiatkowski, D (corresponding author), JOHN RADCLIFFE HOSP, DEPT PAEDIAT, INT CHILD HLTH GRP, OXFORD OX3 9DU, ENGLAND.			Kwiatkowski, Dominic/0000-0002-5023-0176	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; Allsopp CEM, 1996, EUR J IMMUNOL, V26, P1951, DOI 10.1002/eji.1830260841; BALLOU WR, 1987, LANCET, V1, P1277; BARR PJ, 1991, J EXP MED, V174, P1203, DOI 10.1084/jem.174.5.1203; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BATE CAW, 1994, INFECT IMMUN, V62, P3086, DOI 10.1128/IAI.62.8.3086-3091.1994; Boyd M. F., 1936, American Journal of Tropical Medicine, V16, P447; CARTER R, 1976, NATURE, V263, P57, DOI 10.1038/263057a0; CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002; COLLINS WE, 1994, AM J TROP MED HYG, V51, P711, DOI 10.4269/ajtmh.1994.51.711; COLLINS WE, 1986, NATURE, V323, P259, DOI 10.1038/323259a0; CRANDALL I, 1994, PARASITOLOGY, V108, P257, DOI 10.1017/S0031182000076101; DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1; Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739; Duffy PE, 1997, INFECT IMMUN, V65, P1109, DOI 10.1128/IAI.65.3.1109-1113.1997; EDELMAN R, 1993, J INFECT DIS, V168, P1066, DOI 10.1093/infdis/168.4.1066; Egan AF, 1996, J INFECT DIS, V173, P765, DOI 10.1093/infdis/173.3.765; ELLIS J, 1983, NATURE, V302, P536, DOI 10.1038/302536a0; ETLINGER HM, 1991, INFECT IMMUN, V59, P3498, DOI 10.1128/IAI.59.10.3498-3503.1991; FRIES LF, 1992, P NATL ACAD SCI USA, V89, P358, DOI 10.1073/pnas.89.1.358; GODSON GN, 1983, NATURE, V305, P29, DOI 10.1038/305029a0; GONZALEZ C, 1994, J INFECT DIS, V169, P927, DOI 10.1093/infdis/169.4.927; GOOD MF, 1992, IMMUNOL TODAY, V13, P126, DOI 10.1016/0167-5699(92)90108-J; GRAVES PM, 1990, AM J TROP MED HYG, V42, P515, DOI 10.4269/ajtmh.1990.42.515; GWADZ RW, 1976, SCIENCE, V193, P1150, DOI 10.1126/science.959832; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; Hoffman SL, 1995, ANN NY ACAD SCI, V772, P88, DOI 10.1111/j.1749-6632.1995.tb44734.x; HOFFMAN SL, 1994, AM J TROP MED HYG, V51, P603, DOI 10.4269/ajtmh.1994.51.603; HOLDER AA, 1994, PARASITOL TODAY, V10, P182, DOI 10.1016/0169-4758(94)90025-6; Holder AA, 1981, NATURE, V294, P361, DOI 10.1038/294361a0; INSELBURG J, 1991, INFECT IMMUN, V59, P1247, DOI 10.1128/IAI.59.4.1247-1250.1991; KASLOW DC, 1991, SCIENCE, V252, P1310, DOI 10.1126/science.1925544; KASLOW DC, 1988, NATURE, V333, P74, DOI 10.1038/333074a0; KHUSMITH S, 1991, SCIENCE, V252, P715, DOI 10.1126/science.1827210; KUMAR S, 1995, MOL MED, V1, P325, DOI 10.1007/BF03401557; KWIATKOWSKI D, 1995, PARASITOL TODAY, V11, P206, DOI 10.1016/0169-4758(95)80079-4; Nosten F, 1996, LANCET, V348, P701, DOI 10.1016/S0140-6736(96)04465-0; PATARROYO ME, 1987, NATURE, V328, P629, DOI 10.1038/328629a0; PLAYFAIR JHL, 1990, IMMUNOL TODAY, V11, P25; POTOCNJAK P, 1980, J EXP MED, V151, P1504, DOI 10.1084/jem.151.6.1504; QUAKYI IA, 1987, J IMMUNOL, V139, P4213; RIDLEY RG, 1990, PARASITOLOGY, V101, P187, DOI 10.1017/S0031182000063228; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; SIM BKL, 1990, J CELL BIOL, V111, P1877, DOI 10.1083/jcb.111.5.1877; SLONDO PL, 1994, LSNVRY, V344, P1175; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206; SMYTHE JA, 1988, P NATL ACAD SCI USA, V85, P5195, DOI 10.1073/pnas.85.14.5195; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; STURCHLER D, 1995, AM J TROP MED HYG, V53, P423; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; TAM JP, 1990, J EXP MED, V171, P299, DOI 10.1084/jem.171.1.299; Tine JA, 1996, INFECT IMMUN, V64, P3833, DOI 10.1128/IAI.64.9.3833-3844.1996; VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W; *WHO, 1994, WKLY EPIDEMIOL REC, V69, P309	57	34	35	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 6	1997	350	9092					1696	1701		10.1016/S0140-6736(97)03256-X	http://dx.doi.org/10.1016/S0140-6736(97)03256-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400530				2022-12-28	WOS:A1997YK21100047
J	Heldin, CH; Miyazono, K; tenDijke, P				Heldin, CH; Miyazono, K; tenDijke, P			TGF-beta signalling from cell membrane to nucleus through SMAD proteins	NATURE			English	Review							GROWTH-FACTOR-BETA; MAD-RELATED PROTEIN; II RECEPTOR; SIGNALING PATHWAYS; ACTIVIN RECEPTOR; TRANSFERASE-ALPHA; ACTS DOWNSTREAM; HOMEOBOX GENE; C-MYC; ACTIVATION	The recent identification of the SMAD family of signal transducer proteins has unravelled the mechanisms by which transforming growth factor-beta (TGF-beta) signals from the cell membrane to the nucleus. Pathway-restricted SMADs are phosphorylated by specific cell-surface receptors that have serine/threonine kinase activity, then they oligomerize with the common mediator Smad4 and translocate to the nucleus where they direct transcription to effect the cell's response to TGF-beta. Inhibitory SMADs have been identified that block the activation of these pathway-restricted SMADs.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,TOKYO 170,JAPAN	Japanese Foundation for Cancer Research	Heldin, CH (corresponding author), LUDWIG INST CANC RES,CTR BIOMED,BOX 595,S-75124 UPPSALA,SWEDEN.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; ATKI A, 1997, J BIOL CHEM, V272, P1429; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Charng MJ, 1996, J BIOL CHEM, V271, P22941, DOI 10.1074/jbc.271.38.22941; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Frey RS, 1997, CANCER RES, V57, P628; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Iavarone A, 1997, NATURE, V387, P417; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kaufmann E, 1996, EMBO J, V15, P6739, DOI 10.1002/j.1460-2075.1996.tb01063.x; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Ladher R, 1996, DEVELOPMENT, V122, P2385; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lawler S, 1997, J BIOL CHEM, V272, P14850, DOI 10.1074/jbc.272.23.14850; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LIU F, 1995, MOL CELL BIOL, V15, P3479; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LU KX, 1996, EMBO J, V15, P4485; Luo KX, 1997, EMBO J, V16, P1970, DOI 10.1093/emboj/16.8.1970; MARCIASSILVA M, 1996, CELL, V87, P1215; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; McCaffrey TA, 1995, J CLIN INVEST, V96, P2667, DOI 10.1172/JCI118333; Meersseman G, 1997, MECH DEVELOP, V61, P127, DOI 10.1016/S0925-4773(96)00629-6; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; NAKAMURA T, 1992, J BIOL CHEM, V267, P18924; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; Newfeld SJ, 1997, DEVELOPMENT, V124, P3167; NOHNO T, 1995, J BIOL CHEM, V270, P22522, DOI 10.1074/jbc.270.38.22522; Padgett Richard W., 1997, Cytokine and Growth Factor Reviews, V8, P1, DOI 10.1016/S1359-6101(96)00050-0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; RAFTERY LA, 1995, GENETICS, V139, P241; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P309, DOI 10.1021/bi951880a; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; RIGGINS RG, 1997, CANCER RES, V57, P2578; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Sankar S, 1996, J CLIN INVEST, V97, P1436, DOI 10.1172/JCI118565; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; Suzuki A, 1997, DEVELOPMENT, V124, P3037; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; Ventura F, 1996, J BIOL CHEM, V271, P13931, DOI 10.1074/jbc.271.24.13931; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; Watanabe TK, 1997, GENOMICS, V42, P446, DOI 10.1006/geno.1997.4753; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; Wilson PA, 1997, DEVELOPMENT, V124, P3177; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	101	3147	3401	15	289	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					465	471		10.1038/37284	http://dx.doi.org/10.1038/37284			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9393997				2022-12-28	WOS:A1997YJ86500039
J	Lobel, HO; Kozarsky, PE				Lobel, HO; Kozarsky, PE			Update on prevention of malaria for travelers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT PLASMODIUM-VIVAX; MEFLOQUINE PROPHYLAXIS; FALCIPARUM-MALARIA; UNITED-STATES; ANTIMALARIAL-DRUGS; CHLOROQUINE; CHEMOPROPHYLAXIS; PREGNANCY; DOXYCYCLINE; REGIMENS	Individuals from industrialized nations frequently travel to countries with malaria, so health care providers need to be familiar with current recommendations for prevention of malaria, Changes in drug susceptibility of malaria parasites and evolving knowledge of how well drugs are tolerated necessitate periodic review of guidelines for prophylaxis of malaria, especially of chloroquine-resistant Plasmodium falciparum malaria, Mefloquine is the drug of choice for chemoprophylaxis for most travelers, with doxycycline and chloroquine being less effective alternatives. Mefloquine is well tolerated at prophylactic dosages, but anecdotal reports have raised concerns about its adverse effects, Resistance to this drug has emerged in parts of Southeast Asia and may spread to other regions of the world, The major disadvantages of doxycycline are the need for daily dosing, its contraindication for young children and pregnant women. and its adverse effects, Chloroquine is effective for prophylaxis only in Central America, the Caribbean, and parts of the Middle East. Few new drugs will be available in the near future because of reduced funding for antimalarial drug research and development; therefore, the usefulness of currently available drugs needs to be prolonged by rational use. Increased efforts should be made to ensure that alternative drugs will be available for prevention of malaria.	EMORY UNIV, SCH MED, DEPT MED, ATLANTA, GA 30322 USA	Emory University	Lobel, HO (corresponding author), CTR DIS CONTROL & PREVENT, MALARIA SECT, EPIDEMIOL BRANCH, DIV PARASIT DIS, NATL CTR INFECT DIS, ATLANTA, GA 30333 USA.							ARTHUR JD, 1990, LANCET, V335, P972, DOI 10.1016/0140-6736(90)91035-9; ARTHUR JD, 1990, AM J TROP MED HYG, V43, P608, DOI 10.4269/ajtmh.1990.43.608; BALOCCO R, 1992, LANCET, V340, P309, DOI 10.1016/0140-6736(92)92403-3; Barrett PJ, 1996, BRIT MED J, V313, P525, DOI 10.1136/bmj.313.7056.525; BEHRENS RH, 1993, BRIT MED BULL, V49, P363, DOI 10.1093/oxfordjournals.bmb.a072615; BERNARD KW, 1982, JAMA-J AM MED ASSOC, V248, P3136, DOI 10.1001/jama.248.23.3136; BOUDREAU E, 1993, TROP MED PARASITOL, V44, P257; BRASSEUR P, 1992, AM J TROP MED HYG, V46, P8, DOI 10.4269/ajtmh.1992.46.8; BRUCECHWATT LJ, 1950, BMJ-BRIT MED J, V2, P7, DOI 10.1136/bmj.2.4669.7; Buma APCCH, 1996, J INFECT DIS, V173, P1506, DOI 10.1093/infdis/173.6.1506; *CDCP, 1997, HLTH INF INT TRAV 19; Choo V, 1996, LANCET, V347, P891, DOI 10.1016/S0140-6736(96)91362-8; Collins WE, 1996, AM J TROP MED HYG, V55, P243, DOI 10.4269/ajtmh.1996.55.243; COOK GC, 1995, BRIT MED J, V311, P190, DOI 10.1136/bmj.311.6998.190b; CREAGH TH, 1992, NATO ADV SCI I A-LIF, V224, P53; Croft AMJ, 1996, LANCET, V347, P326, DOI 10.1016/S0140-6736(96)90500-0; Croft AMJ, 1997, T ROY SOC TROP MED H, V91, P199, DOI 10.1016/S0035-9203(97)90223-6; Davis TME, 1996, BRIT J CLIN PHARMACO, V42, P415, DOI 10.1111/j.1365-2125.1996.tb00003.x; DELANEY TJ, 1974, ACTA DERM-VENEREOL, V54, P487; FISH DR, 1988, BRIT MED J, V297, P526, DOI 10.1136/bmj.297.6647.526; GREENBERG AE, 1990, ANN INTERN MED, V113, P326, DOI 10.7326/0003-4819-113-4-326; HAUSER WA, 1983, EPILEPSY, P267; HELD TK, 1994, Q J MED, V87, P17; HOFFMAN SL, 1992, MED CLIN N AM, V76, P1327, DOI 10.1016/S0025-7125(16)30290-5; Huzly, 1996, J Travel Med, V3, P148, DOI 10.1111/j.1708-8305.1996.tb00729.x; Jaspers CAJJ, 1996, AM J TROP MED HYG, V55, P230, DOI 10.4269/ajtmh.1996.55.230; Keystone, 1994, J Travel Med, V1, P72, DOI 10.1111/j.1708-8305.1994.tb00566.x; LAMPE AS, 1994, EUR J CLIN MICROBIOL, V13, P332; Lobel H. O., 1986, Clinics in Tropical Medicine and Communicable Diseases, V1, P225; LOBEL HO, 1990, B WORLD HEALTH ORGAN, V68, P209; LOBEL HO, 1993, LANCET, V341, P848, DOI 10.1016/0140-6736(93)93058-9; LOBEL HO, IN PRESS AM J TROP M; LOBEL HO, 1993, 42 ANN M AM SOC TROP; LOVESTONE S, 1991, BRIT J PSYCHIAT, V159, P164, DOI 10.1192/bjp.159.1.164b; Luxemburger C, 1996, ANN TROP PAEDIATR, V16, P281, DOI 10.1080/02724936.1996.11747839; MACPHERSON D, 1997, 5 INT C TRAV MED MAR, P220; NOSTEN F, 1994, J INFECT DIS, V169, P595, DOI 10.1093/infdis/169.3.595; Ohrt C, 1997, ANN INTERN MED, V126, P963, DOI 10.7326/0003-4819-126-12-199706150-00006; PANG LW, 1987, LANCET, V1, P1161; PENNIE RA, 1993, T ROY SOC TROP MED H, V87, P459, DOI 10.1016/0035-9203(93)90036-P; PERAGALLO MS, 1997, 5 INT C TRAV MED MAR; PhillipsHoward PA, 1996, DRUG SAFETY, V14, P131, DOI 10.2165/00002018-199614030-00001; Regier Darrel, 1995, P135; Schlagenhauf P, 1997, AM J TROP MED HYG, V56, P235, DOI 10.4269/ajtmh.1997.56.235; SCHUURKAMP GJ, 1992, T ROY SOC TROP MED H, V86, P121, DOI 10.1016/0035-9203(92)90531-G; SCHWARTZ IK, 1991, NEW ENGL J MED, V324, P927; Shanks, 1994, J Travel Med, V1, P40, DOI 10.1111/j.1708-8305.1994.tb00554.x; SHANKS GD, 1994, MIL MED, V159, P275, DOI 10.1093/milmed/159.4.275; SINGHARAJ P, 1987, R THAI ARMY MED J, V40, P165; Smoak BL, 1997, J INFECT DIS, V176, P831, DOI 10.1086/517315; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W; Steketee RW, 1996, AM J TROP MED HYG, V55, P50, DOI 10.4269/ajtmh.1996.55.50; Takeshima S., 1994, Japanese Journal of Tropical Medicine and Hygiene, V22, P185; THAN M, 1995, T R SOC TROP MED HYG, V89, P307; TSAI TF, 1992, SEMIN PEDIAT INFECT, V3, P62; VANHAUWERE B, IN PRESS AM J TROP M; Vuurman EFPM, 1996, EUR J CLIN PHARMACOL, V50, P475, DOI 10.1007/s002280050144; Wallace MR, 1996, AM J MED, V100, P49, DOI 10.1016/S0002-9343(96)90011-X; WATANASOOK C, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P61; *WHO, 1997, INT TRAVEL HLTH VACC; Winstanley P, 1996, BRIT J CLIN PHARMACO, V42, P411, DOI 10.1111/j.1365-2125.1996.tb00002.x; WYLER DJ, 1993, NEW ENGL J MED, V329, P31, DOI 10.1056/NEJM199307013290107; 1988, LANCET, V2, P610	63	62	63	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1767	1771		10.1001/jama.278.21.1767	http://dx.doi.org/10.1001/jama.278.21.1767			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388154				2022-12-28	WOS:A1997YH98700032
J	Nichol, G; Walls, R; Goldman, L; Pearson, S; Hartley, LH; Antman, E; Stockman, M; Teich, JM; Cannon, CP; Johnson, PA; Kuntz, KM; Lee, TH				Nichol, G; Walls, R; Goldman, L; Pearson, S; Hartley, LH; Antman, E; Stockman, M; Teich, JM; Cannon, CP; Johnson, PA; Kuntz, KM; Lee, TH			A critical pathway for management of patients with acute chest pain who are at low risk for myocardial ischemia: Recommendations and potential impact	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED INTERVENTIONAL TRIAL; CORONARY-ARTERY DISEASE; CREATINE-KINASE MB; PRACTICE GUIDELINES; EMERGENCY ROOM; PREDICTIVE INSTRUMENT; MEDICAL-PRACTICE; OPINION LEADERS; EXERCISE TEST; INFARCTION	Background: Use of resources for patients with acute chest pain may be improved with clinical strategies that integrate research, Bayesian analysis, and expert opinion, Objectives: To 1) develop a critical pathway for management of patients with acute chest pain who are at low risk for complications of ischemic heart disease and 2) assess the potential effects of implementation of the pathway on patient safety and resource use. Design: Evidence-based consensus and prospective cohort study. Setting: Urban teaching hospital. Patients: Patients at least 30 years of age who were seen in the emergency department for chest pain and who did not have a history of trauma or abnormalities on radiologic study. Intervention: Physician-opinion leaders defined criteria for patient inclusion in the pathway and for remaining on the pathway after 6 or 12 hours of observation. Criteria were defined for appropriateness of direct admission, direct discharge, or 6 hours of observation followed by exercise treadmill testing. Measurements: Number of patients admitted to the hospital, number of days that patients were hospitalized, and clinical outcome. Results: 2898 of 4585 patients (63%) were admitted to the hospital; of the 2898, 1152 (40%) were classified as potentially eligible for the pathway and 1068 (93%) had a benign clinical course during the initial observation period. The 1068 patients had a mean length of stay of 2.8 +/- 4.8 days. If 47% of these patients had been discharged after observation and exercise testing, implementation of the pathway would have reduced the number of admissions by 505 (17%) and days of hospitalization by 1407 (11%). Conclusions: Retrospective analysis suggests that a critical pathway for patients with acute chest pain may substantially reduce resource use, Prospective study is needed to ensure increased efficiency without increased adverse outcomes.	HARVARD COMMUNITY HLTH PLAN, BOSTON, MA 02215 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SCH MED, SAN FRANCISCO, CA 94143 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT EMERGENCY MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Francisco; Harvard University; Brigham & Women's Hospital; Harvard Medical School					AHRQ HHS [R01 HS06452] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; CANNON CP, 1994, J THROMB THROMBOLYS, V1, P27; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHO MK, 1994, JAMA-J AM MED ASSOC, V272, P101, DOI 10.1001/jama.272.2.101; Coffey R J, 1992, Qual Manag Health Care, V1, P45; *COLL PHYS SURG ON, 1988, POL DEEP VEIN THROMB; ELLRODT AG, 1995, ANN INTERN MED, V122, P277, DOI 10.7326/0003-4819-122-4-199502150-00007; Falconer J A, 1993, QRB Qual Rev Bull, V19, P8; FIELD D L, 1988, Journal of Emergency Medicine, V6, P363, DOI 10.1016/0736-4679(88)90002-9; FLEISCHMANN KE, 1994, J AM COLL CARDIOL, V23, P1390, DOI 10.1016/0735-1097(94)90382-4; GASPOZ JM, 1994, J AM COLL CARDIOL, V24, P1249, DOI 10.1016/0735-1097(94)90106-6; GIBLER WB, 1995, ANN EMERG MED, V25, P1, DOI 10.1016/S0196-0644(95)70347-0; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRAFF L, 1992, ANN EMERG MED, V21, P967, DOI 10.1016/S0196-0644(05)82937-3; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HIGGINS GL, 1993, AM J EMERG MED, V11, P576, DOI 10.1016/0735-6757(93)90004-U; HILTON TC, 1994, J AM COLL CARDIOL, V23, P1016, DOI 10.1016/0735-1097(94)90584-3; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KERNS JR, 1993, ANN EMERG MED, V22, P794, DOI 10.1016/S0196-0644(05)80793-0; LEE TH, 1992, AM J CARDIOL, V69, P145, DOI 10.1016/0002-9149(92)91294-E; LEE TH, 1995, ANN INTERN MED, V122, P434, DOI 10.7326/0003-4819-122-6-199503150-00006; LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEWIS LM, 1995, ANN EMERG MED, V25, P9, DOI 10.1016/S0196-0644(95)70348-9; LEWIS WR, 1994, AM J CARDIOL, V74, P987, DOI 10.1016/0002-9149(94)90845-1; LIM R, 1994, BRIT HEART J, V71, P334; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; MARIN MM, 1992, AM HEART J, V123, P354, DOI 10.1016/0002-8703(92)90646-D; ODDERSON IR, 1993, STROKE, V24, P1823, DOI 10.1161/01.STR.24.12.1823; OGILVIEHARRIS DJ, 1993, J ORTHOP TRAUMA, V7, P428, DOI 10.1097/00005131-199310000-00005; Patton M D, 1995, Cancer Pract, V3, P286; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; RATNAIKE S, 1993, MED J AUSTRALIA, V159, P666, DOI 10.5694/j.1326-5377.1993.tb138081.x; RIBISL PM, 1992, ARCH INTERN MED, V152, P1618, DOI 10.1001/archinte.152.8.1618; RICHARDS JS, 1994, CLIN PATHS TOOLS OUT, P265; Schriefer J, 1995, Qual Manag Health Care, V3, P30; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SHESSER R, 1994, ANN EMERG MED, V23, P334, DOI 10.1016/S0196-0644(94)70047-8; SOX HC, 1988, MED DECIS MAKING, P406; SPATH PL, 1994, CLIN PATHS TOOLS OUT, P265; STRATMANN HG, 1994, AM J CARDIOL, V73, P647, DOI 10.1016/0002-9149(94)90927-X; TUCKER JF, 1994, ANN EMERG MED, V24, P704, DOI 10.1016/S0196-0644(94)70282-9; TURLEY K, 1994, ANN THORAC SURG, V58, P57, DOI 10.1016/0003-4975(94)91072-3; *US DHHS, 1994, AHCPR PUBL; VARETTO T, 1993, J AM COLL CARDIOL, V22, P1804, DOI 10.1016/0735-1097(93)90761-O; WACHTEL T, 1986, MED DECIS MAKING, V6, P101, DOI 10.1177/0272989X8600600208; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; WEINGARTEN S, 1993, AM J CARDIOL, V71, P259, DOI 10.1016/0002-9149(93)90787-D; WEINGARTEN S, 1990, ANN INTERN MED, V113, P283, DOI 10.7326/0003-4819-113-4-283; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; YOUNG GP, 1993, AM J EMERG MED, V11, P444, DOI 10.1016/0735-6757(93)90079-Q	56	72	73	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					996	1005		10.7326/0003-4819-127-11-199712010-00009	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412306				2022-12-28	WOS:A1997YJ08000007
J	Klenk, HP; Clayton, RA; Tomb, JF; White, O; Nelson, KE; Ketchum, KA; Dodson, RJ; Gwinn, M; Hickey, EK; Peterson, JD; Richardson, DL; Kerlavage, AR; Graham, DE; Kyrpides, NC; Fleischmann, RD; Quackenbush, J; Lee, NH; Sutton, GG; Gill, S; Kirkness, EF; Dougherty, BA; McKenney, K; Adams, MD; Loftus, B; Peterson, S; Reich, CI; McNeil, LK; Badger, JH; Glodek, A; Zhou, LX; Overbeek, R; Gocayne, JD; Weidman, JF; McDonald, L; Utterback, T; Cotton, MD; Spriggs, T; Artiach, P; Kaine, BP; Sykes, SM; Sadow, PW; DAndrea, KP; Bowman, C; Fujii, C; Garland, SA; Mason, TM; Olsen, GJ; Fraser, CM; Smith, HO; Woese, CR; Venter, JC				Klenk, HP; Clayton, RA; Tomb, JF; White, O; Nelson, KE; Ketchum, KA; Dodson, RJ; Gwinn, M; Hickey, EK; Peterson, JD; Richardson, DL; Kerlavage, AR; Graham, DE; Kyrpides, NC; Fleischmann, RD; Quackenbush, J; Lee, NH; Sutton, GG; Gill, S; Kirkness, EF; Dougherty, BA; McKenney, K; Adams, MD; Loftus, B; Peterson, S; Reich, CI; McNeil, LK; Badger, JH; Glodek, A; Zhou, LX; Overbeek, R; Gocayne, JD; Weidman, JF; McDonald, L; Utterback, T; Cotton, MD; Spriggs, T; Artiach, P; Kaine, BP; Sykes, SM; Sadow, PW; DAndrea, KP; Bowman, C; Fujii, C; Garland, SA; Mason, TM; Olsen, GJ; Fraser, CM; Smith, HO; Woese, CR; Venter, JC			The complete genome sequence of the hyperthermophilic, sulphate-reducing archaeon Archaeoglobus fulgidus	NATURE			English	Article							MONOXIDE DEHYDROGENASE PATHWAY; ARCHAEBACTERIA; OXIDOREDUCTASE; CO2; OXIDATION; BACTERIA; PROTEIN; ENZYME	Archaeoglobus fulgidus is the first sulphur-metabolizing organism to have its genome sequence determined. Its genome of 2,178,400 base pairs contains 2,436 open reading frames (ORFs). The Information processing systems and the biosynthetic pathways for essential components (nucleotides, amino acids and cofactors) have extensive correlation with their counterparts in the archaeon Methanococcus jannaschii. The genomes of these two Archaea indicate dramatic differences in the way these organisms sense their environment, perform regulatory and transport functions, and gain energy. In contrast to M. jannaschii, A. fulgidus has fewer restriction-modification systems, and none of its genes appears to contain inteins. A quarter (651 ORFs) of the A. fulgidus genome encodes functionally uncharacterized yet conserved proteins, two-thirds of which are shared with M. jannaschii (428 ORFs). Another quarter of the genome encodes new proteins indicating substantial archaeal gene diversity.	INST GENOM RES TIGR,ROCKVILLE,MD 20850; UNIV ILLINOIS,DEPT MICROBIOL,CHAMPAIGN,IL 61801; ARGONNE NATL LAB,DIV MATH & COMP SCI,ARGONNE,IL 60439	J. Craig Venter Institute; University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Energy (DOE); Argonne National Laboratory			Kyrpides, Nikos C./A-6305-2014; Graham, David E/F-8578-2010	Kyrpides, Nikos C./0000-0002-6131-0462; Graham, David E/0000-0001-8968-7344; Fraser, Claire/0000-0003-1462-2428; Sykes, Sean/0000-0001-8344-5176; Kerlavage, Anthony/0000-0002-3954-9653; Quackenbush, John/0000-0002-2702-5879; loftus, brendan/0000-0001-8871-8356				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Clark D. P., 1996, ESCHERICHIA COLI SAL, P343; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cooling FB, 1996, APPL ENVIRON MICROB, V62, P2999, DOI 10.1128/AEM.62.8.2999-3004.1996; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; DAI YR, UNPUB ARCH MICROBIOL; Edgell DR, 1997, J BACTERIOL, V179, P2632, DOI 10.1128/jb.179.8.2632-2640.1997; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GORRIS LGM, 1991, BIOFACTORS, V3, P29; HUBER R, 1995, NATURE, V376, P57, DOI 10.1038/376057a0; IBBA M, UNPUB P NATL ACAD SC; KAGAWA HK, 1995, J MOL BIOL, V253, P712, DOI 10.1006/jmbi.1995.0585; Kletzin A, 1996, J BACTERIOL, V178, P248, DOI 10.1128/jb.178.1.248-257.1996; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; KUNOW J, 1994, EUR J BIOCHEM, V223, P503, DOI 10.1111/j.1432-1033.1994.tb19019.x; LaPaglia C, 1997, APPL ENVIRON MICROB, V63, P3158, DOI 10.1128/AEM.63.8.3158-3163.1997; MARSH TL, 1994, P NATL ACAD SCI USA, V91, P4180, DOI 10.1073/pnas.91.10.4180; MOLLERZINKHAN D, 1990, ARCH MICROBIOL, V153, P215, DOI 10.1007/BF00249070; NISHIHARA M, 1995, J BIOCHEM-TOKYO, V117, P933, DOI 10.1093/oxfordjournals.jbchem.a124822; NOLL KM, 1988, J BACTERIOL, V170, P4315, DOI 10.1128/jb.170.9.4315-4321.1988; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SCHAUDER R, 1986, ARCH MICROBIOL, V145, P162, DOI 10.1007/BF00446775; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; SPEICH N, 1994, MICROBIOL-UK, V140, P1273, DOI 10.1099/00221287-140-6-1273; STETTER KO, 1995, ASM NEWS, V61, P285; STETTER KO, 1988, SYST APPL MICROBIOL, V10, P172, DOI 10.1016/S0723-2020(88)80032-8; STETTER KO, 1993, NATURE, V365, P743, DOI 10.1038/365743a0; STETTER KO, 1987, SCIENCE, V236, P822, DOI 10.1126/science.236.4803.822; STETTER KO, 1992, PROKARYOTES, P707; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Tersteegen A, 1997, EUR J BIOCHEM, V244, P862, DOI 10.1111/j.1432-1033.1997.00862.x; THAUER RK, 1995, BIOTECH HAN, V8, P33; THORNEBENE TG, 1979, SCIENCE, V203, P51; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; VORHOLT J, 1995, ARCH MICROBIOL, V163, P112, DOI 10.1007/s002030050179; WALDMANN T, 1995, HOPPESEYLERS BIOL CH, V376, P119; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; Yeliseev AA, 1997, P NATL ACAD SCI USA, V94, P5101, DOI 10.1073/pnas.94.10.5101; Zhang Q, 1996, J BIOCHEM-TOKYO, V120, P587	43	1183	2282	1	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					364	&		10.1038/37052	http://dx.doi.org/10.1038/37052			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389475	Bronze			2022-12-28	WOS:A1997YH54900052
J	Barraclough, J				Barraclough, J			ABC of palliative care - Depression, anxiety, and confusion	BRITISH MEDICAL JOURNAL			English	Review											Barraclough, J (corresponding author), CHURCHILL HOSP,OXFORD RADCLIFFE NHS TRUST,OXFORD,ENGLAND.								0	33	34	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 22	1997	315	7119					1365	1368		10.1136/bmj.315.7119.1365	http://dx.doi.org/10.1136/bmj.315.7119.1365			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402782	Green Published			2022-12-28	WOS:A1997YJ21800030
J	Jenkins, SA; Baxter, JN; Critchley, M; Kingsnorth, AN; Makin, CA; Ellenbogen, S; Grime, JS; Love, JG; Sutton, R				Jenkins, SA; Baxter, JN; Critchley, M; Kingsnorth, AN; Makin, CA; Ellenbogen, S; Grime, JS; Love, JG; Sutton, R			Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage	BRITISH MEDICAL JOURNAL			English	Article							BLEEDING ESOPHAGEAL-VARICES; PORTAL HYPERTENSIVE RATS; INJECTION SCLEROTHERAPY; SOMATOSTATIN ANALOG; REPERFUSION; SURVIVAL; LIGATION; PRESSURE	Objective: To assess the efficacy of long term octreotide as adjuvant treatment to programmed endoscopic sclerotherapy after acute variceal haemorrhage in cirrhotic portal hypertension. Design: Randomised clinical trial. Setting: University hospital. Subjects: 32 patients with cirrhotic portal hypertension. Interventions: Programmed injection sclerotherapy with subcutaneous octreotide 50 mu g twice daily for 6 months, or programmed injection sclerotherapy alone. Main outcome measures: Episodes of recurrent variceal bleeding and survival. Results: Significantly fewer patients receiving combined octreotide and sclerotherapy had episodes of recurrent variceal bleeding compared with patients given sclerotherapy alone (1/16 v 7/16; P = 0.037, Fisher's exact test), and their survival was significantly improved (P < 0.02, log rank test); this improvement was maintained for 12 months after the end of the study. Combined treatment also resulted in a sustained decrease in portal pressure (median decrease -6.0 mm Hg, interquartile range -10 to -4.75 mm Hg, P = 0.0002) compared with sclerotherapy alone (median increase 1.5 mm Hg, interquartile range 0.25 to 3.25 mm Hg), as well as a significant improvement in liver function as assessed by plasma concentrations of bilirubin, albumin, and alanine aminotransferase and by hepatocyte metabolism of aminopyrine labelled with carbon-14. Conclusion: Long term octreotide may be a valuable adjuvant to endoscopic sclerotherapy for acute variceal haemorrhage in cirrhotic portal hypertension.	ROYAL LIVERPOOL UNIV HOSP,CLIN & CANC TRIAL UNIT,DEPT SURG,LIVERPOOL L7 8XP,MERSEYSIDE,ENGLAND; ROYAL LIVERPOOL UNIV HOSP,DEPT NUCL MED,LIVERPOOL L7 8XP,MERSEYSIDE,ENGLAND; UNIV GLASGOW,ROBERTSON CTR BIOSTAT,GLASGOW G12 8QQ,LANARK,SCOTLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of Glasgow								ALBILLOS A, 1993, GASTROENTEROLOGY, V104, P575, DOI 10.1016/0016-5085(93)90429-G; BATTERSHILL PE, 1989, DRUGS, V38, P658, DOI 10.2165/00003495-198938050-00002; BAXTER JN, 1985, BRIT J SURG, V72, P1005, DOI 10.1002/bjs.1800721224; BESSON I, 1995, NEW ENGL J MED, V333, P555, DOI 10.1056/NEJM199508313330904; Child C G, 1964, Major Probl Clin Surg, V1, P1; *COP ES VAR SCLER, 1984, NEW ENGL J MED, V311, P594; FEU F, 1995, LANCET, V346, P1056, DOI 10.1016/S0140-6736(95)91740-3; Gardner M. J., 1989, STAT CONFIDENCE; GIMSON AES, 1993, LANCET, V342, P391, DOI 10.1016/0140-6736(93)92812-8; GRIME JS, 1983, NUCL MED COMMUN, V3, P282; Hanisch E, 1992, Drugs, V44 Suppl 2, P24, DOI 10.2165/00003495-199200442-00005; HEPNER GW, 1975, ANN INTERN MED, V83, P632, DOI 10.7326/0003-4819-83-5-632; JENKINS SA, 1985, BRIT J SURG, V72, P1009, DOI 10.1002/bjs.1800721225; KUHN JM, 1994, BRIT J CLIN PHARMACO, V38, P213, DOI 10.1111/j.1365-2125.1994.tb04344.x; LANCRANJAN I, 1995, METABOLISM, V44, P18, DOI 10.1016/0026-0495(95)90306-2; LANDA I, 1992, HEPATOLOGY, V16, P1474, DOI 10.1002/hep.1840160624; MERKEL C, 1994, J HEPATOL, V21, P918, DOI 10.1016/S0168-8278(94)80265-3; NAVASA M, 1988, H HEPATOL, V123, pS64; RIMOLA A, 1984, HEPATOLOGY, V4, P53, DOI 10.1002/hep.1840040109; SIEBER CC, 1992, AM J PHYSIOL, V262, pG274, DOI 10.1152/ajpgi.1992.262.2.G274; STIEGMANN GV, 1992, NEW ENGL J MED, V326, P1527, DOI 10.1056/NEJM199206043262304; TERBLANCHE J, 1983, LANCET, V2, P1328; WESTABY D, 1985, HEPATOLOGY, V5, P827, DOI 10.1002/hep.1840050520; YATES J, 1994, BRIT J SURG, V81, P750	24	41	46	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 22	1997	315	7119					1338	1341		10.1136/bmj.315.7119.1338	http://dx.doi.org/10.1136/bmj.315.7119.1338			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402774	Green Published			2022-12-28	WOS:A1997YJ21800021
J	Mittendorf, R; Covert, R; Boman, J; Khoshnood, B; Lee, KS; Siegler, M				Mittendorf, R; Covert, R; Boman, J; Khoshnood, B; Lee, KS; Siegler, M			Is tocolytic magnesium sulphate associated with increased total paediatric mortality?	LANCET			English	Article							SULFATE; PREVENTION; BIRTH		UNIV CHICAGO, PRITZKER SCH MED, DEPT PAEDIAT, SECT NEONATOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, PRITZKER SCH MED, MACLEAN CTR CLIN MED ETH, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago	Mittendorf, R (corresponding author), UNIV CHICAGO, PRITZKER SCH MED, DEPT OBSTET & GYNAECOL, CHICAGO, IL 60637 USA.		Khoshnood, Babak/N-9096-2017	Khoshnood, Babak/0000-0002-4031-4915				COX SM, 1990, AM J OBSTET GYNECOL, V163, P767, DOI 10.1016/0002-9378(90)91065-K; DULEY L, 1995, LANCET, V345, P1455; LUCAS MJ, 1995, NEW ENGL J MED, V333, P201, DOI 10.1056/NEJM199507273330401; NELSON KB, 1995, PEDIATRICS, V95, P263	4	165	168	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1517	1518		10.1016/S0140-6736(97)24047-X	http://dx.doi.org/10.1016/S0140-6736(97)24047-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388401				2022-12-28	WOS:A1997YH11500012
J	Draper, GJ; Little, MP; Sorahan, T; Kinlen, LJ; Bunch, KJ; Conquest, AJ; Kendall, GM; Kneale, GW; Lancashire, RJ; Muirhead, CR; OConnor, CM; Vincent, TJ				Draper, GJ; Little, MP; Sorahan, T; Kinlen, LJ; Bunch, KJ; Conquest, AJ; Kendall, GM; Kneale, GW; Lancashire, RJ; Muirhead, CR; OConnor, CM; Vincent, TJ			Cancer in the offspring of radiation workers: a record linkage study	BRITISH MEDICAL JOURNAL			English	Article							NON-HODGKINS-LYMPHOMA; CHILDHOOD LEUKEMIA; PATERNAL EXPOSURE; WEST-BERKSHIRE; YOUNG-PEOPLE; NUCLEAR SITE; MICE; CHILDREN; IRRADIATION; SURVIVORS	Objectives: To test the ''Gardner hypothesis'' that childhood leukaemia and non-Hodgkin lymphoma can be caused by fathers' exposure to ionising radiation before the conception of the child, and, more generally, to investigate whether such radiation exposure of either parent is a cause of childhood cancer. Design: Case-control study. Setting: Great Britain. Subjects: 35 949 children diagnosed as having cancer, together with matched controls. Main outcome measures: Parental employment as radiation worker as defined by inclusion in the National Registry for Radiation Workers and being monitored for external radiation before conception of child; cumulative dose of external ionising radiation for various periods of employment before conception; dose during pregnancy. Results: After cases studied by Gardner and colleagues were excluded, fathers of children with leukaemia or non-Hodgkin lymphoma were significantly more likely than fathers of controls to have been radiation workers (relative risk 1.77, 95% confidence interval 1.05 to 3.03) but there was no dose-response relation for any of the exposure periods studied; indeed, the association was greatest for those with doses below the level of detection. No increased risk was found for fathers with a lifetime preconception dose of 100 mSv or more, or with a dose in the 6 months before conception of 10 mSv or more. There was no increased risk for the group of other childhood cancers. Mothers' radiation work was associated with a significant increase of childhood cancer (relative risk 5.00, 1.42 to 26.94; based on 15 cases and 3 controls). Only four of the case mothers and no controls were radiation workers during pregnancy. Conclusions: These results do not support the hypothesis that paternal preconception irradiation is a cause of childhood leukaemia and non-Hodgkin lymphoma; the observed associations may be chance findings or result from exposure to infective or other agents. If there is any increased risk for the children of fathers who are radiation workers, it is small in absolute terms: in Britain the average risk by age 15 years is 6.5 per 10 000; our best estimate, using all available data, is that the increase is 5.4 per 10 000. For mothers, the numbers are too small for reliable estimates of the risk, if any, to be made.	NATL RADIOL PROTECT BOARD,DIDCOT OX11 0RQ,OXON,ENGLAND; UNIV BIRMINGHAM,INST OCCUPAT HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV OXFORD,CRC,CANC EPIDEMIOL RES GRP,DEPT PUBL HLTH,OXFORD OX2 6HE,ENGLAND; UNIV BIRMINGHAM,DEPT PUBL HLTH & EPIDEMIOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham; University of Oxford; University of Birmingham	Draper, GJ (corresponding author), UNIV OXFORD,CHILDHOOD CANC RES GRP,S PARKS RD,OXFORD OX2 6HJ,ENGLAND.		Kendall, Gerald/AAW-5538-2021	Muirhead, Colin/0000-0001-5394-1267; Little, Mark/0000-0003-0980-7567				Alexander FE, 1997, BRIT J CANCER, V75, P457, DOI 10.1038/bjc.1997.77; ANDERSSON M, 1994, J NATL CANCER I, V86, P1866, DOI 10.1093/jnci/86.24.1866; BRESLOW N, 1982, IARC SCI PUBLICATION, V32; CATTANACH BM, 1995, INT J RADIAT BIOL, V67, P607, DOI 10.1080/09553009514550721; *COMM MED ASP RAD, 1996, 4 COMARE DEP HLTH; COSGROVE GE, 1993, MUTAT RES, V319, P71, DOI 10.1016/0165-1218(93)90032-9; *CYT SOFTW, 1993, LOGX TURB VERS 1 1; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; DRAPER GJ, 1997, R298 NAT RAD PROT BO; DRAPER GJ, 1989, IARC SCI PUBL, V96, P275; GARDNER MJ, 1992, BRIT MED J, V305, P715, DOI 10.1136/bmj.305.6855.715; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GILMAN E A, 1988, Journal of Radiological Protection, V8, P3, DOI 10.1088/0952-4746/8/1/301; HAWKINS MM, 1995, BRIT J CANCER, V71, P1335, DOI 10.1038/bjc.1995.259; Health and Safety Executive, 1993, HSE INV LEUK OTH CAN; HOWE GR, 1981, COMPUT BIOMED RES, V14, P327, DOI 10.1016/0010-4809(81)90004-5; KENDALL GM, 1992, R251 NAT RAD PROT BO; KINLEN L, 1988, LANCET, V2, P1323; Kinlen L. J., 1997, Journal of Radiological Protection, V17, P63, DOI 10.1088/0952-4746/17/2/003; KINLEN LJ, 1993, BRIT MED J, V306, P1153, DOI 10.1136/bmj.306.6886.1153; KINLEN LJ, 1991, BRIT J CANCER, V64, P549, DOI 10.1038/bjc.1991.348; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1993, BRIT MED J, V306, P1718, DOI 10.1136/bmj.306.6894.1718; KINLEN LJ, 1995, BMJ-BRIT MED J, V310, P763, DOI 10.1136/bmj.310.6982.763; KINLEN LJ, 1995, CANCER CAUSE CONTROL, V6, P445, DOI 10.1007/BF00052185; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; KOHN HI, 1965, RADIAT RES, V25, P423, DOI 10.2307/3571983; Little M. P., 1996, Journal of Radiological Protection, V16, P25, DOI 10.1088/0952-4746/16/1/004; Little M. P., 1994, Journal of Radiological Protection, V14, P187, DOI 10.1088/0952-4746/14/3/001; Little M. P., 1994, Journal of Radiological Protection, V14, P203, DOI 10.1088/0952-4746/14/3/002; Little M. P., 1993, Journal of Radiological Protection, V13, P161, DOI 10.1088/0952-4746/13/3/001; Little M. P., 1992, Journal of Radiological Protection, V12, P203, DOI 10.1088/0952-4746/12/4/001; LITTLE MP, 1993, J RADIOL PROTECT, V13, P295; MCLAUGHLIN JR, 1993, BRIT MED J, V307, P959, DOI 10.1136/bmj.307.6910.959; MCLAUGHLIN JR, 1993, BRIT MED J, V307, P1257; MCLAUGHLIN JR, 1993, BRIT MED J, V307, P1462; MICHAELIS J, 1994, ARBEITSMED SOZIALMED, V29, P324; MICHAELIS J, 1995, ARBEITSMED SOZIALMED, V30, P78; NOMURA T, 1991, J RADIAT RES, V32, P64, DOI 10.1269/jrr.32.SUPPLEMENT2_64; NOMURA T, 1982, NATURE, V296, P575, DOI 10.1038/296575a0; PARKER L, 1993, BRIT MED J, V307, P966, DOI 10.1136/bmj.307.6910.966; Petridou E, 1996, BRIT J CANCER, V73, P1278, DOI 10.1038/bjc.1996.245; Pobel D, 1997, BRIT MED J, V314, P101, DOI 10.1136/bmj.314.7074.101; PRESTON DL, 1996, EPICURE RELEASE 2 0; ROMAN E, 1993, BMJ-BRIT MED J, V306, P615, DOI 10.1136/bmj.306.6878.615; STEWART A, 1958, BRIT MED J, V1, P1495, DOI 10.1136/bmj.1.5086.1495; Stiller CA, 1996, BMJ-BRIT MED J, V313, P1297, DOI 10.1136/bmj.313.7068.1297; Stiller CA, 1995, EUR J CANCER, V31A, P2028, DOI 10.1016/0959-8049(95)00428-9; TAKAHASHI T, 1992, CANCER RES, V52, P1948; United Nations Scientific Committee on the Effects of Atomic Radiation Sources, 1982, ION RAD SOURC BIOL E; YOSHIMOTO Y, 1990, AM J HUM GENET, V46, P1041	51	85	88	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1181	1188		10.1136/bmj.315.7117.1181	http://dx.doi.org/10.1136/bmj.315.7117.1181			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393219	Green Published			2022-12-28	WOS:A1997YF25200015
J	Katz, BP				Katz, BP			Biostatistics to improve the power of large databases	ANNALS OF INTERNAL MEDICINE			English	Article											Katz, BP (corresponding author), INDIANA UNIV, SCH MED, INDIANAPOLIS, IN 46202 USA.							BYAR DP, 1991, STAT MED, V10, P663, DOI 10.1002/sim.4780100417	1	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				769	769		10.7326/0003-4819-127-8_Part_2-199710151-00066	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00066			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YB385	9382396				2022-12-28	WOS:A1997YB38500021
J	Quill, TE; Lo, B; Brock, DW				Quill, TE; Lo, B; Brock, DW			Palliative options of last resort - A comparison of voluntarily stopping eating and drinking, terminal sedation, physician-assisted suicide, and voluntary active euthanasia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WASHINGTON-STATE; PATIENT REQUESTS; DEATH; NETHERLANDS; DOCTORS; OREGON; DIE; ATTITUDES; WILL; CARE	Palliative care is generally agreed to be the standard of care for the dying, but there remain some patients for whom intolerable suffering persists, In the face of ethical and legal controversy about the acceptability of physician-assisted suicide and voluntary active euthanasia, voluntarily stopping eating and drinking and terminal sedation have been proposed as ethically superior responses of last resort that do not require changes in professional standards or the law, The clinical and ethical differences and similarities between these 4 practices are critically compared in light of the doctrine of double effect, the active/passive distinction, patient voluntariness, proportionality between risks and benefits, and the physician's potential conflict of duties, Terminal sedation and voluntarily stopping eating and drinking would allow clinicians to remain responsive to a wide range of patient suffering, but they are ethically and clinically more complex and closer to physician-assisted suicide and voluntary active euthanasia than is ordinarily acknowledged, Safeguards are presented for any medical action that may hasten death, including determining that palliative care is ineffective, obtaining informed consent, ensuring diagnostic and prognostic clarity, obtaining an independent second opinion, and implementing reporting and monitoring processes, Explicit public policy about which of these practices are permissible would reassure the many patients who fear a bad death in their future and allow for a predictable response for the few whose suffering becomes intolerable in spite of optimal palliative care.	UNIV ROCHESTER, SCH MED & DENT, PROGRAM BIOPSYCHOSOCIAL STUDIES, ROCHESTER, NY USA; UNIV CALIF SAN FRANCISCO, PROGRAM MED ETH, SAN FRANCISCO, CA 94143 USA; BROWN UNIV, CTR BIOMED ETH, PROVIDENCE, RI 02912 USA	University of Rochester; University of California System; University of California San Francisco; Brown University					NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Admiraal P V, 1995, Ned Tijdschr Geneeskd, V139, P265; Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Alpers A, 1997, JAMA-J AM MED ASSOC, V277, P1705, DOI 10.1001/jama.277.21.1705; ALPERS A, 1995, JAMA-J AM MED ASSOC, V274, P483, DOI 10.1001/jama.274.6.483; American Board of Internal Medicine, 1996, CAR DYING ID PROM PH; Angell M, 1997, NEW ENGL J MED, V336, P50, DOI 10.1056/NEJM199701023360108; Bachman JG, 1996, NEW ENGL J MED, V334, P303, DOI 10.1056/NEJM199602013340506; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Baron CH, 1996, HARVARD J LEGIS, V33, P1; Beauchamp TL, 2009, PRINCIPLES BIOMEDICA; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; Billings JA, 1996, J PALLIAT CARE, V12, P21, DOI 10.1177/082585979601200404; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; BROCK DW, 1992, HASTINGS CENT REP, V22, P10, DOI 10.2307/3562560; BRODY H, 1993, J CLIN ETHIC, V4, P112; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; Byock I R, 1993, J Palliat Care, V9, P25; Cherny N I, 1994, J Palliat Care, V10, P31; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; Coyle N, 1990, J Pain Symptom Manage, V5, P83; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; Drickamer MA, 1997, ANN INTERN MED, V126, P146, DOI 10.7326/0003-4819-126-2-199701150-00009; DUBERSEIN PR, 1995, J AM GERIATR SOC, V43, P395, DOI 10.1111/j.1532-5415.1995.tb05814.x; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; EDWARDS MJ, 1992, ANN INTERN MED, V117, P254, DOI 10.7326/0003-4819-117-3-254; EMANUEL EJ, 1993, NEW ENGL J MED, V329, P879, DOI 10.1056/NEJM199309163291213; ENCK RE, 1994, MED CARE TERMINALLY; EVANS JM, 1987, GEN ANESTHESIA, P184; FOLEY KM, 1995, PAIN FORUM, V4, P163; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; *HAST CTR REP, 1987, GUID TERM LIF SUST T; HENDIN H, 1994, ISSUES LAW MED, V10, P123; Ingham JM, 1996, HEMATOL ONCOL CLIN N, V10, P21, DOI 10.1016/S0889-8588(05)70325-7; Kamisar Yale, 1995, Univ Detroit Mercy Law Rev, V72, P735; KAMM FM, 1991, J MED PHILOS, V16, P571, DOI 10.1093/jmp/16.5.571; KASTING GA, 1993, PHYSICIAN ASSISTED D, P25; Lee MA, 1996, ANN INTERN MED, V124, P267, DOI 10.7326/0003-4819-124-2-199601150-00014; Lee MA, 1996, NEW ENGL J MED, V334, P310, DOI 10.1056/NEJM199602013340507; MARQUIS DB, 1991, J MED PHILOS, V16, P515, DOI 10.1093/jmp/16.5.515; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; MOERMAN N, 1993, ANESTHESIOLOGY, V79, P454, DOI 10.1097/00000542-199309000-00007; Morrison R S, 1995, Trends Health Care Law Ethics, V10, P91; Mount B, 1996, J PALLIAT CARE, V12, P31, DOI 10.1177/082585979601200405; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; Orentlicher D, 1996, NEW ENGL J MED, V335, P663, DOI 10.1056/NEJM199608293350912; *PC STUD ETH PROBL, 1982, DEC FOR LIF SUST TRE; PRESTON TA, 1996, J PHARM CARE PAIN SY, V1, P183; PRINTZ LA, 1992, ARCH INTERN MED, V152, P697, DOI 10.1001/archinte.152.4.697; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; QUILL TE, 1995, ARCH INTERN MED, V155, P1250, DOI 10.1001/archinte.155.12.1250; QUILL TE, 1993, DEATH DIGNITY MAKING, P1; ROLLIN B, 1985, LAST WISH; Ryan CJ, 1996, NEW ENGL J MED, V334, P326, DOI 10.1056/NEJM199602013340512; Saunders C., 1993, MANAGEMENT TERMINAL, P1; TENO J, 1991, J AM GERIATR SOC, V39, P827, DOI 10.1111/j.1532-5415.1991.tb02707.x; TROUG RD, 1991, NEW ENGL J MED, V327, P1678; UTTING JE, 1987, GEN ANESTHESIA, P171; van der Maas P. J., 1992, EUTHANASIA OTHER MED; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; Ventafridda V, 1990, J Palliat Care, V6, P7; WELIE JVM, 1992, J MED PHILOS, V17, P419, DOI 10.1093/jmp/17.4.419	66	275	279	2	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2099	2104		10.1001/jama.278.23.2099	http://dx.doi.org/10.1001/jama.278.23.2099			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YK987	9403426				2022-12-28	WOS:A1997YK98700041
J	Tugwell, P; Dennis, DT; Weinstein, A; Wells, G; Shea, B; Nichol, G; Hayward, R; Lightfoot, R; Baker, P; Steere, AC				Tugwell, P; Dennis, DT; Weinstein, A; Wells, G; Shea, B; Nichol, G; Hayward, R; Lightfoot, R; Baker, P; Steere, AC			Laboratory evaluation in the diagnosis of Lyme disease	ANNALS OF INTERNAL MEDICINE			English	Article							BORRELIA-BURGDORFERI DNA; CENTRAL-NERVOUS-SYSTEM; LINKED IMMUNOSORBENT-ASSAY; ERYTHEMA MIGRANS; ARTHRITIS; SERODIAGNOSIS; ANTIBODY; NEUROBORRELIOSIS; FIBROMYALGIA; EPIDEMIC	Purpose: To provide a quantitative and qualitative evaluation of the predictive value of the laboratory diagnosis of Lyme disease and to use the resultant data to formulate guidelines for clinical diagnosis. Data Sources: A MEDLINE search of English-language articles or articles with English-language abstracts published from 1982 to 1996. Data Extraction: Sensitivity, specificity, and likelihood ratios were calculated, and a random-effects model was used to combine the proportions from the eligible studies. Prespecified criteria were used to determine which studies were eligible for analysis. Data Synthesis: Laboratory testing in general is not clinically useful if the pretest probability of Lyme disease is less than 0.20 or greater than 0.80. When the pretest probability is 0.20 to 0.80, sequential testing with enzyme-linked immunosorbent assay and Western blot is the most accurate method for ruling in or ruling out the possibility of Lyme disease. Conclusions: Laboratory testing is recommended only in patients whose pretest probability of Lyme disease is 0.20 to 0.80. If the pretest probability is less than 0.20, testing will result in more false-positive results than true-positive results; a negative test result in this situation effectively rules out the disease.	Univ Ottawa, Dept Med, Ottawa, ON K1H 8L6, Canada; Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA; New York Med Coll, Div Rheumat Dis & Immunol, Valhalla, NY 10595 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; McMaster Univ, Med Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada	University of Ottawa; Centers for Disease Control & Prevention - USA; New York Medical College; Tufts Medical Center; McMaster University	Tugwell, P (corresponding author), Ottawa Gen Hosp, Dept Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.		Baker, Philip R A/J-1109-2012; Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556; Steere, Allen/0000-0002-5268-9853				ALPERT B, 1992, NEW YORK STATE J MED, V92, P5; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; BERGER BW, 1992, J CLIN MICROBIOL, V30, P359, DOI 10.1128/JCM.30.2.359-361.1992; BERGER BW, 1983, AM J DERMATOPATH, V5, P111, DOI 10.1097/00000372-198304000-00008; BOWEN GS, 1984, AM J EPIDEMIOL, V120, P387; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P590; CIESIELSKI CA, 1988, ANN NY ACAD SCI, V539, P283, DOI 10.1111/j.1749-6632.1988.tb31862.x; Coyle BS, 1996, J INFECT DIS, V173, P1260, DOI 10.1093/infdis/173.5.1260; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; Dennis D. T., 1993, Lyme disease., P27; DENNIS DT, 1991, JAMA-J AM MED ASSOC, V266, P1269, DOI 10.1001/jama.266.9.1269; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DRESSLER F, 1991, ANN INTERN MED, V115, P533, DOI 10.7326/0003-4819-115-7-533; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; FAWCETT PT, 1992, J RHEUMATOL, V19, P582; GOODMAN JL, 1991, INFECT IMMUN, V59, P269, DOI 10.1128/IAI.59.1.269-278.1991; HALPERIN JJ, 1991, NEUROLOGY, V41, P1571, DOI 10.1212/WNL.41.10.1571; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HANSEN K, 1988, J CLIN MICROBIOL, V26, P338, DOI 10.1128/JCM.26.2.338-346.1988; HEDBERG CW, 1987, J INFECT DIS, V155, P1325, DOI 10.1093/infdis/155.6.1325; HEDGES LV, 1985, STAT METHODS META AN; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; Johnson BJB, 1996, J INFECT DIS, V174, P346, DOI 10.1093/infdis/174.2.346; JOHNSTON YE, 1985, AM J PATHOL, V118, P26; JONES JM, 1991, ANN INTERN MED, V114, P1064, DOI 10.7326/0003-4819-114-12-1064_1; KELLER TL, 1992, NEUROLOGY, V42, P32, DOI 10.1212/WNL.42.1.32; KOWAL K, 1994, ARTHRITIS RHEUM-US, V37, P1206, DOI 10.1002/art.1780370815; KRAMER N, 1986, AM J MED, V81, P149, DOI 10.1016/0002-9343(86)90200-7; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; LIGHTFOOT RW, 1993, ANN INTERN MED, V119, P503, DOI 10.7326/0003-4819-119-6-199309150-00010; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V267, P1364, DOI 10.1001/jama.267.10.1364; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; MALAWISTA SE, 1986, ADV INTERNAL MED, V31, P147; MARCUS LC, 1985, ANN INTERN MED, V103, P374, DOI 10.7326/0003-4819-103-3-374; MELCHERS W, 1991, J CLIN MICROBIOL, V29, P2401, DOI 10.1128/JCM.29.11.2401-2406.1991; MILLER GL, 1992, P 5 INT C LYM DIS AR; NADELMAN RB, 1990, AM J MED, V88, P21, DOI 10.1016/0002-9343(90)90122-T; NICHOL G, IN PRESS ANN INTERN; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; PACHNER AR, 1992, NEUROLOGY, V42, P2185, DOI 10.1212/WNL.42.11.2185; PACHNER AR, 1989, ARCH NEUROL-CHICAGO, V46, P790, DOI 10.1001/archneur.1989.00520430086023; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SCHULZE TL, 1986, ZBL BAKT-INT J MED M, V263, P65; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SNYDMAN DR, 1986, ANN INTERN MED, V104, P798, DOI 10.7326/0003-4819-104-6-798; SOX HC, 1997, MED DECISION MAKING; STEERE AC, 1990, J INFECT DIS, V161, P1203, DOI 10.1093/infdis/161.6.1203; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1977, ANN INTERN MED, V86, P685, DOI 10.7326/0003-4819-86-6-685; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; WEINSTEIN A, 1989, NEW YORK STATE J MED, V89, P566; Wharton M, 1990, MMWR Recomm Rep, V39, P1; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; WORMSER GP, 1992, JAMA-J AM MED ASSOC, V268, P1311, DOI 10.1001/jama.268.10.1311; ZOSCHKE DC, 1992, POSTGRAD MED, V91, P46; 1992, FED REG         0228, V57; 1995, MMWR MORB MORTAL WKL, V44, P459; 1996, MMWR MORB MORTAL WKL, V45, P481; 1994, MMWR MORB MORTAL WKL, V43, P564	66	174	182	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1109	1123		10.7326/0003-4819-127-12-199712150-00011	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00011			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412316				2022-12-28	WOS:000070936600010
J	Folkner, WM; Yoder, CF; Yuan, DN; Standish, EM; Preston, RA				Folkner, WM; Yoder, CF; Yuan, DN; Standish, EM; Preston, RA			Interior structure and seasonal mass redistribution of Mars from radio tracking of Mars Pathfinder	SCIENCE			English	Article							INERTIA; OBLIQUITY; MOMENT; CYCLE	Doppler and range measurements to the Mars Pathfinder lander made using its radio communications system have been combined with similar measurements from the Viking landers to estimate improved values of the precession of Mars' pole of rotation and the variation in Mars' rotation rate. The observed precession of -7576 +/- 35 milliarc seconds of angle per year implies a dense core and constrains possible models of interior composition. The estimated annual variation in rotation is in good agreement with a model of seasonal mass exchange of carbon dioxide between the atmosphere and ice caps.			Folkner, WM (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.							BILLS BG, 1989, GEOPHYS RES LETT, V16, P385, DOI 10.1029/GL016i005p00385; CAZENAVE A, 1981, GEOPHYS RES LETT, V8, P245, DOI 10.1029/GL008i003p00245; CHAO BF, 1990, J GEOPHYS RES-SOLID, V95, P14755, DOI 10.1029/JB095iB09p14755; Davies M., 1996, CELESTIAL MECH, V63, P127, DOI DOI 10.1007/BF00693410; FOLKNER WM, 1994, ASTRON ASTROPHYS, V287, P279; Folkner WM, 1997, J GEOPHYS RES-PLANET, V102, P4057, DOI 10.1029/96JE02125; FRANCOIS LM, 1990, J GEOPHYS RES-SOLID, V95, P14761, DOI 10.1029/JB095iB09p14761; KAULA WM, 1979, GEOPHYS RES LETT, V6, P194, DOI 10.1029/GL006i003p00194; KONOPLIV AS, 1995, PUBLICATION JET PROP; LAUL JC, 1986, GEOCHIM COSMOCHIM AC, V50, P875, DOI 10.1016/0016-7037(86)90370-4; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; REASENBERG RD, 1977, J GEOPHYS RES, V82, P369, DOI 10.1029/JB082i002p00369; ROSEN RD, 1983, J GEOPHYS RES-OCEANS, V88, P5451, DOI 10.1029/JC088iC09p05451; Sears F.W., 1968, INTRO THEORY RELATIV; SMITH DE, 1993, J GEOPHYS RES-PLANET, V98, P20871, DOI 10.1029/93JE01839; Sohl F, 1997, J GEOPHYS RES-PLANET, V102, P1613, DOI 10.1029/96JE03419; TILLMAN JE, 1993, J GEOPHYS RES-PLANET, V98, P10963, DOI 10.1029/93JE01084; TOUMA J, 1993, SCIENCE, V259, P1294, DOI 10.1126/science.259.5099.1294; WARD WR, 1974, J GEOPHYS RES, V79, P3375, DOI 10.1029/JC079i024p03375; Yoder CF, 1997, J GEOPHYS RES-PLANET, V102, P4065, DOI 10.1029/96JE03642	20	232	242	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1749	1752		10.1126/science.278.5344.1749	http://dx.doi.org/10.1126/science.278.5344.1749			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388168				2022-12-28	WOS:A1997YJ90100034
J	Sheng, HZ; Moriyama, K; Yamashita, T; Li, H; Potter, SS; Mahon, KA; Westphal, H				Sheng, HZ; Moriyama, K; Yamashita, T; Li, H; Potter, SS; Mahon, KA; Westphal, H			Multistep control of pituitary organogenesis	SCIENCE			English	Article							HOMEOBOX GENE LHX3; HOMEODOMAIN FACTOR; PIT-1; LIM; EXPRESSION	Lhx3 and Lhx4 (Gsh4), two closely related LIM homeobox genes, determine formation of the pituitary gland in mice. Rathke's pouch is formed in two steps-first as a rudiment and later as a definitive pouch. Lhx3 and Lhx4 have redundant control over formation of the definitive pouch. Lhx3 controls a subsequent step of pituitary fate commitment. Thereafter, Lhx3 and Lhx4 together regulate proliferation and differentiation of pituitary-specific cell lineages. Thus, Lhx3 and Lhx4 dictate pituitary organ identity by controlling developmental decisions at multiple stages of organogenesis.	NICHHD,LAB MAMMALIAN GENES & DEV,NIH,BETHESDA,MD 20892; SHIMANE MED UNIV,DEPT ANAT,IZUMO,SHIMANE 693,JAPAN; ACAD SINICA,INST MOL BIOL,TAIPEI 11529,TAIWAN; UNIV CINCINNATI,COLL MED,CHILDRENS HOSP RES FDN,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Shimane University; Academia Sinica - Taiwan; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Baylor College of Medicine								BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; CAMPER SA, 1990, GENOMICS, V8, P586, DOI 10.1016/0888-7543(90)90050-5; CASTRILLO JL, 1991, SCIENCE, V253, P197, DOI 10.1126/science.1677216; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; DIAKOKU S, 1982, DEV BIOL, V90, P198; ETKIN W, 1967, NEUROENDOCRINOLOGY, P261; FERRAND R, 1972, Archives de Biologie, V83, P297; KAUFMAN MH, 1992, ATLAS MOUSE DEVELOPM; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; RHODES SJ, 1994, CURR OPIN GENET DEV, V4, P709, DOI 10.1016/0959-437X(94)90138-S; ROBINSON GW, 1991, NEW BIOL, V3, P1183; Schwind JL, 1928, AM J ANAT, V41, P295, DOI 10.1002/aja.1000410206; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; Sornson MW, 1996, NATURE, V384, P327, DOI 10.1038/384327a0; Treier M, 1996, CURR OPIN CELL BIOL, V8, P833, DOI 10.1016/S0955-0674(96)80085-8; Yamashita T, 1997, GENOMICS, V44, P144, DOI 10.1006/geno.1997.4852; ZHADANOV AB, 1995, DEV DYNAM, V202, P354, DOI 10.1002/aja.1002020405	18	296	296	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1809	1812		10.1126/science.278.5344.1809	http://dx.doi.org/10.1126/science.278.5344.1809			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388186				2022-12-28	WOS:A1997YJ90100052
J	Berkwits, M; Gluckman, SJ				Berkwits, M; Gluckman, SJ			Seeking an expert interpretation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DIAGNOSIS		VET AFFAIRS MED CTR,PHILADELPHIA,PA; UNIV PENN,MED CTR,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DIV INFECT DIS,PHILADELPHIA,PA 19104	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania								Gadamer HG, 1989, TRUTH METHOD; Kahneman D., 1982, JUDGMENT UNCERTAINTY; KASSIRER JP, 1989, AM J MED, V86, P433, DOI 10.1016/0002-9343(89)90342-2; KASSIRER JP, 1995, NEW ENGL J MED, V332, P1507, DOI 10.1056/NEJM199506013322210; Kassirer JP., 2009, LEARNING CLIN REASON; LARSON EB, 1982, MEDICINE, V61, P269, DOI 10.1097/00005792-198209000-00001; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; MIELANTS H, 1993, PRIMER RHEUMATIC DIS, P163; POSES RM, 1991, MED DECIS MAKING, V11, P159, DOI 10.1177/0272989X9101100303	9	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 4	1997	337	23					1682	1684		10.1056/NEJM199712043372308	http://dx.doi.org/10.1056/NEJM199712043372308			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ871	9385129				2022-12-28	WOS:A1997YJ87100008
J	Bao, WH; Srinivasan, SR; Valdez, R; Greenlund, KJ; Wattigney, WA; Berenson, GS				Bao, WH; Srinivasan, SR; Valdez, R; Greenlund, KJ; Wattigney, WA; Berenson, GS			Longitudinal changes in cardiovascular risk from childhood to young adulthood in offspring of parents with coronary artery disease - The Bogalusa Heart Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLLOW-UP; CHILDREN; OVERWEIGHT; OBESITY; CHOLESTEROL; HISTORY; ADOLESCENTS; TRENDS	Context.-Although the association between parental coronary artery disease (CAD) and its risk factors in the offspring is known, the timing and the course of development of risk factors from childhood to adulthood in the offspring is not known. Objective.-To examine the association between parental CAD and longitudinal changes in risk factor profile from childhood to young adulthood in offspring. Design.-Cohort study. Setting.-Bogalusa, La, a semirural, biracial community. Participants.-Individuals with clinically verified parental history of CAD (n = 271) vs those without such a history (n=1253) Mean age at first CAD event was 50 years for fathers and 52 years for mothers. Main Outcome Measures.-Body mass index, subscapular skinfolds, blood pressure, and triglyceride, cholesterol (total, very low-density lipoprotein [VLDL-C], low-density lipoprotein [LDL-C], and high-density lipoprotein [HDL-C] cholesterols), glucose, and insulin levels. Results.-The offspring of parents with CAD were consistently overweight beginning in childhood. Their levels of total serum cholesterol, LDL-C, plasma glucose, and insulin became significantly higher at older ages, because of a higher rate of increase in these risk factors over time. In adulthood, the offspring with a positive parental history had a higher prevalence of obesity (body mass index >85th percentile in the National Health and Nutrition Examination Survey I, 35% vs 26%, P=.01), elevated total cholesterol (>6.2 mmol/L [240 mg/dL], 8.4% vs 4.8%, P=.05) and LDL-C levels (>4.1 mmol/L [160 mg/dL], 12.4% vs 4.7%, P=.05), and hyperglycemia (glucose, >6.6 mmol/L, 2.7% vs 0.4%, P<.001), as well as a higher coexistence of these conditions (P=.01). Further, the prevalence of dyslipidemia, either involving only LDL-C or LDL-C in combination with HDL-C or triglycerides or both, was significantly higher in the adult offspring with parental CAD. Conclusions.-Offspring of parents with early CAD were overweight beginning in childhood and developed an adverse cardiovascular risk factor profile ai an increased rate. These observations have important implications for prevention and intervention.	TULANE UNIV,SCH PUBL HLTH & TROP MED,TULANE CTR CARDIOVASC HLTH,NEW ORLEANS,LA 70112	Tulane University				Valdez, Rodolfo/0000-0001-9979-3140	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032194] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038844, U01HL038844] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-38844] Funding Source: Medline; NICHD NIH HHS [HD-32194] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; BAO WH, 1995, CIRCULATION, V91, P365, DOI 10.1161/01.CIR.91.2.365; BAO WH, 1994, ARCH INTERN MED, V154, P1842; Bao WH, 1996, ARCH INTERN MED, V156, P1315, DOI 10.1001/archinte.156.12.1315; *BECKM INSTR INC, 1976, BECKM GLUC AN OP MAN; BERENSON GS, 1992, AM J CARDIOL, V70, P851, DOI 10.1016/0002-9149(92)90726-F; BLONDE CV, 1981, PREV MED, V10, P25, DOI 10.1016/0091-7435(81)90003-7; BUCOLO G, 1973, CLIN CHEM, V19, P476; BURKE GL, 1991, CIRCULATION, V84, P1176, DOI 10.1161/01.CIR.84.3.1176; CRIQUI MH, 1980, PREV MED, V9, P525, DOI 10.1016/0091-7435(80)90047-X; *EXP PAN BLOOD CHO, 1992, PEDIATRICS S, V89, P529; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GIDDING SS, 1995, J PEDIATR-US, V127, P868, DOI 10.1016/S0022-3476(95)70020-X; Greenlund KJ, 1997, AM J MED SCI, V313, P220, DOI 10.1097/00000441-199704000-00005; HARLAN WR, 1993, ANN NY ACAD SCI, V699, P1, DOI 10.1111/j.1749-6632.1993.tb18831.x; HIMES JH, 1994, AM J CLIN NUTR, V59, P307, DOI 10.1093/ajcn/59.2.307; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; KANNEL WB, 1974, MED CLIN N AM, V58, P363, DOI 10.1016/S0025-7125(16)32163-0; KARIM MR, 1988, GEE ASAS MACRO LONGI; KHAW K, 1982, CIRCULATION, V74, P239; KHOURY P, 1980, AM J EPIDEMIOL, V112, P524, DOI 10.1093/oxfordjournals.aje.a113022; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; Lipid Research Clinics Program, 1974, DHEW PUBL; MOSSBERG HO, 1989, LANCET, V2, P491; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; MUST A, 1991, AM J CLIN NUTR, V53, P839, DOI 10.1093/ajcn/53.4.839; *NAT CHOL ED PROGR, 1993, JAMA-J AM MED ASSOC, V269, P3015; POLONSKY SM, 1993, PEDIATRICS, V91, P92; RISSANEN AM, 1977, BRIT HEART J, V39, P875, DOI 10.1136/hrt.39.8.875; ROSE G, 1964, BRIT J PREV SOC MED, V18, P75; ROSENMAN RH, 1975, JAMA-J AM MED ASSOC, V233, P872, DOI 10.1001/jama.233.8.872; *SAS I INC, 1989, SAS STAT 7 US GUID V; SHEAR CL, 1985, AM J EPIDEMIOL, V122, P762, DOI 10.1093/oxfordjournals.aje.a114159; SMOAK CG, 1987, AM J EPIDEMIOL, V125, P364, DOI 10.1093/oxfordjournals.aje.a114543; Srinivasan SR, 1996, METABOLISM, V45, P235, DOI 10.1016/S0026-0495(96)90060-8; Srinivasan SR., 1983, CRC HDB ELECTROPHORE, P185; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005; WEBBER LS, 1979, PREV MED, V8, P407, DOI 10.1016/0091-7435(79)90018-5; [No title captured]; 1990, JAMA-J AM MED ASSOC, V264, P3018	40	125	130	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1749	1754		10.1001/jama.278.21.1749	http://dx.doi.org/10.1001/jama.278.21.1749			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388151				2022-12-28	WOS:A1997YH98700029
J	Landen, MG; Beller, M; Funk, E; Propst, M; Middaugh, J; Moolenaar, RL				Landen, MG; Beller, M; Funk, E; Propst, M; Middaugh, J; Moolenaar, RL			Alcohol-related injury death and alcohol availability in remote Alaska	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Injury is a major public health problem in Alaska, and alcohol consumption and injury death are associated. Objective.-To determine the association between injury death, particularly alcohol-related injury death, and alcohol availability in remote Alaska. Design, Setting, and Participants.-Survey using death certificate data and medical examiner records to compare mortality rates for total injury and alcohol-related injury during 1990 through 1993 among Alaskans aged 15 years and older who had resided in remote villages of fewer than 1000 persons. Main Outcome Measures.-Rate ratios of injury death among residents of wet villages tie, those without a restrictive alcohol law) as compared with injury death among residents of dry villages tie, those with laws that prohibited the sale and importation of alcohol). Results.-Of 302 injury deaths, blood alcohol concentrations (BACs) were available for 200 deaths (66.2%). Of these, 130 (65.0%) had a BAC greater than or equal to 17 mmol/L (greater than or equal to 80 mg/dL) and were, therefore, classified as alcohol related. The total injury mortality rate was greater among Alaska Natives from wet villages (rate ratio [RR],1.6; 95% confidence interval [CI], 1.3-2.1), whereas this difference was not present for nonnatives (RR, 1.1; 95% CI, 0.3-3.8), For Alaska Natives, the alcohol-related injury mortality rate was greater among residents of wet villages (RR, 2.7; 95% CI, 1.9-3.8) than among residents of dry villages. The strength of this association was greatest for deaths due to motor vehicle injury, homicide, and hypothermia. Conclusions.-Although insufficient data existed to adjust for the effects of all potential confounders, residence in a wet village was associated with alcohol-related injury death among Alaska Native residents of remote Alaska villages. These findings indicate that measures limiting access to alcoholic beverages in this region may decrease alcohol-related injury deaths.	CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,EPIDEMIOL PROGRAM OFF,ATLANTA,GA; ALASKA DIV PUBL HLTH,OFF MED EXAMINER,ANCHORAGE,AK	Centers for Disease Control & Prevention - USA								*AL DEP HLTH SOC S, 1993, BEHV RISK FACT SURV; *AL DEP LAB, 1993, AL POP OV; *AL DEP LAB, 1995, AL POP OV; *AL DEP LAB, 1994, AL POP OV; *AL DIV PUBL HLTH, 1997, AL HLTH PEOPL 2000 H; Berkelman R L, 1985, Am J Prev Med, V1, P21; BREWER RD, 1994, NEW ENGL J MED, V331, P513, DOI 10.1056/NEJM199408253310806; *CDCP, 1995, INJ MORT NAT SUMM IN; Chaloupka F. J., 1993, ALCOHOL HEALTH RES W, V17, P46; Cook P. J., 1993, ALCOHOL HEALTH RES W, V17, P151; COOK PJ, 1980, PAN ALT POL PREV ALC; GALLAHER MM, 1992, JAMA-J AM MED ASSOC, V267, P1345, DOI 10.1001/jama.267.10.1345; GOODMAN RA, 1991, J STUD ALCOHOL, V52, P156, DOI 10.15288/jsa.1991.52.156; LANDEN MG, 1996, J RURAL HEALTH, V13, P38; MANNING WG, 1989, JAMA-J AM MED ASSOC, V261, P1604, DOI 10.1001/jama.261.11.1604; MAY PA, 1976, THESIS U MONTANA; SMART RG, 1979, J STUD ALCOHOL, V40, P908, DOI 10.15288/jsa.1979.40.908; SMITH SM, 1989, AM J PREV MED, V52, P296; *US BUR CENS, 1993, 1990 CENS POP	19	39	39	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1755	1758		10.1001/jama.278.21.1755	http://dx.doi.org/10.1001/jama.278.21.1755			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YH987	9388152				2022-12-28	WOS:A1997YH98700030
J	Nightingale, SL				Nightingale, SL			New warning information for Rezulin labeling	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1728	1728						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388135				2022-12-28	WOS:A1997YH98700008
J	Haber, DA				Haber, DA			Splicing into senescence: The curious case of p(16) and p19(ARF)	CELL			English	Review							CYCLIN-DEPENDENT KINASES; FAMILIAL MELANOMA; CELL; MUTATIONS; P16; TRANSCRIPT; INHIBITORS; CANCER; LOCUS; CDK4		HARVARD UNIV,SCH MED,CHARLESTOWN,MA 02129	Harvard University	Haber, DA (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,CHARLESTOWN,MA 02129, USA.							DURO D, 1995, ONCOGENE, V11, P21; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hara E, 1996, MOL CELL BIOL, V16, P859; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1997, P NATL ACAD SCI USA, V94, P3436; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, CANCER RES, V55, P2988; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	20	129	130	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					555	558		10.1016/S0092-8674(00)80441-9	http://dx.doi.org/10.1016/S0092-8674(00)80441-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393847	Bronze			2022-12-28	WOS:A1997YH96000001
J	Reed, JC				Reed, JC			Cytochrome c: Can't live with it - Can't live without it	CELL			English	Review							MITOCHONDRIA				Reed, JC (corresponding author), BURNHAM INST,10901 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BOSSYWETZEL E, 1997, IN PRESS EMBO J; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0; IMLER M, 1997, FEBS LETT, V406, P189; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	22	673	707	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					559	562		10.1016/S0092-8674(00)80442-0	http://dx.doi.org/10.1016/S0092-8674(00)80442-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393848	Bronze			2022-12-28	WOS:A1997YH96000002
J	Thomas, SA; Palmiter, RD				Thomas, SA; Palmiter, RD			Impaired maternal behavior in mice lacking norepinephrine and epinephrine	CELL			English	Article							OLFACTORY-BULB; TARGETED DISRUPTION; RECEPTOR SUBTYPE; POSTPARTUM RATS; SHEEP; RECOGNITION; EXPERIENCE; PARTURITION; GENE; CYCLOHEXIMIDE	The roles of norepinephrine (NE) and epinephrine in behavior were investigated by targeted disruption of the dopamine beta-hydroxylase (Dbh) gene, thereby eliminating these compounds in vivo. Most heterozygous pups born to Dbh(-/-) females died within several days of birth and were often found scattered within the bedding. Potential causes including deficits in olfaction and lactation were not apparent. A deficit in maternal behavior was confirmed by the lack of pup retrieval exhibited by Dbh(-/-) virgin females. Restoration of NE shortly before but not after birth induced females that previously abandoned their litters to act maternally. Our results suggest that NE is responsible for longlasting changes that promote maternal behavior during both development and parturition in mice.	UNIV WASHINGTON,DEPT BIOCHEM,HOWARD HUGHES MED INST,SEATTLE,WA 98195	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle					NICHD NIH HHS [HD09172] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD009172, R01HD009172] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARNES CD, 1991, PROGR BRAIN RES, V88; BLASS EM, 1980, SCIENCE, V210, P15, DOI 10.1126/science.6997992; BRENNAN P, 1990, SCIENCE, V250, P1223, DOI 10.1126/science.2147078; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; CALAMANDREI G, 1994, BEHAV NEUROSCI, V108, P113, DOI 10.1037/0735-7044.108.1.113; CALAMANDREI G, 1992, PHYSIOL BEHAV, V52, P901, DOI 10.1016/0031-9384(92)90369-D; DICKINSON C, 1988, PHYSIOL BEHAV, V43, P313, DOI 10.1016/0031-9384(88)90193-X; FLEMING AS, 1974, J COMP PHYSIOL PSYCH, V86, P957, DOI 10.1037/h0036414; FLEMING AS, 1990, BEHAV NEURAL BIOL, V53, P64, DOI 10.1016/0163-1047(90)90814-M; GRANDELMAN R, 1970, SCIENCE, V171, P210; Holets V.R., 1990, PHARM NORADRENALINE, P1; KABA H, 1988, NEUROSCIENCE, V25, P1007, DOI 10.1016/0306-4522(88)90053-X; KENDRICK KM, 1992, SCIENCE, V256, P833, DOI 10.1126/science.1589766; KENDRICK KM, 1988, BRAIN RES, V439, P1, DOI 10.1016/0006-8993(88)91455-2; KEVERNE EB, 1982, NATURE, V296, P148, DOI 10.1038/296148a0; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; KEVERNE EB, 1988, PSYCHONEUROENDOCRINO, V13, P127, DOI 10.1016/0306-4530(88)90010-8; LEVIMONT.R, 1966, PHARMACOL REV, V18, P619; LEVY F, 1993, BEHAV NEUROSCI, V107, P662, DOI 10.1037/0735-7044.107.4.662; LEVY F, 1990, BEHAV NEUROSCI, V104, P464, DOI 10.1037/0735-7044.104.3.464; Link RE, 1996, SCIENCE, V273, P803, DOI 10.1126/science.273.5276.803; MacMillan LB, 1996, SCIENCE, V273, P801, DOI 10.1126/science.273.5276.801; MALENFANT SA, 1991, PHYSIOL BEHAV, V49, P289, DOI 10.1016/0031-9384(91)90045-P; MOLTZ H, 1975, NEUROENDOCRINOLOGY, V19, P252, DOI 10.1159/000122445; Nishimori K, 1996, P NATL ACAD SCI USA, V93, P11699, DOI 10.1073/pnas.93.21.11699; NUMAN M, 1988, BEHAV NEUROSCI, V102, P381, DOI 10.1037/0735-7044.102.3.381; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PISSONNIER D, 1985, PHYSIOL BEHAV, V35, P361, DOI 10.1016/0031-9384(85)90309-9; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; ROSENBERG P, 1977, PHARMACOL BIOCHEM BE, V6, P21, DOI 10.1016/0091-3057(77)90155-1; ROSENBERG P, 1976, PHARMACOL BIOCHEM BE, V4, P647, DOI 10.1016/0091-3057(76)90215-X; ROSENBLATT JS, 1967, SCIENCE, V156, P1512, DOI 10.1126/science.156.3781.1512; ROSSER AE, 1985, NEUROSCIENCE, V15, P1141, DOI 10.1016/0306-4522(85)90258-1; Sallinen J, 1997, MOL PHARMACOL, V51, P36, DOI 10.1124/mol.51.1.36; SMOTHERMAN WP, 1974, BEHAV BIOL, V12, P55, DOI 10.1016/S0091-6773(74)91026-8; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; Szabadi E, 1991, ADRENOCEPTORS STRUCT; Tafari AT, 1997, J NEUROSCI, V17, P4275; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; Thomas SA, 1997, BEHAV NEUROSCI, V111, P579, DOI 10.1037/0735-7044.111.3.579; Thomas SA, 1997, NATURE, V387, P94, DOI 10.1038/387094a0	41	133	133	2	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					583	592		10.1016/S0092-8674(00)80446-8	http://dx.doi.org/10.1016/S0092-8674(00)80446-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393852	Bronze			2022-12-28	WOS:A1997YH96000006
J	Iwahashi, H; Eguchi, Y; Yasuhara, N; Hanafusa, T; Matsuzawa, Y; Tsujimoto, Y				Iwahashi, H; Eguchi, Y; Yasuhara, N; Hanafusa, T; Matsuzawa, Y; Tsujimoto, Y			Synergistic anti-apoptotic activity between Bcl-2 and SMN implicated in spinal muscular atrophy	NATURE			English	Article							MOTOR-NEURON GENE; MITOCHONDRIAL-MEMBRANES; ENDOPLASMIC-RETICULUM; CELL-DEATH; SURVIVAL; PROTEIN; EXPRESSION; BCL-X(L); ADULT; BAD	Spinal muscular atrophy (SMA) is a motor neuron disease characterized by degeneration of the anterior horn cells of the spinal cord. It is a common fatal autosomal recessive disorder and linkage studies have identified two candidate genes, SMN (ref. 1) and NAIP (ref. 2), both on chromosome 5q13. Although NAIP protein is know to have an anti-apoptotic function(3), the function of SMN has been unclear and it shows no significant sequence similarity to any other protein. The SMN gene is deleted or interrupted on both chromosomes in nearly all SMA patients(1) Here we show that SMN interacts with Bcl-2, another anti-apoptotic that co-expression of SMN with Bcl-2 confers a synergistic preventive effect against Bar-induced or Fas-mediated apoptosis, although SMN itself has only a weak anti-apoptotic activity. SMNY272C, which carries a missense mutation and was found in an SMA patient who exceptionally retained SMN on one allele(1), exerts no synergism with Bcl-2. Furthermore, the product of a truncated transcript lacking exon 7, which was derived from an SMN gene carrying an intragenic mutation or from the SMN copy gene (C)BCD541 (ref. 1) retained in all SMA patients, had no synergistic activity but instead had a dominant-negative effect on full-length SMN. Our results indicate that an absent or decreased anti-apoptotic activity of SMN in concert with Bcl-2 underlies the pathogenesis of SMA.	OSAKA UNIV,SCH MED,DEPT MED GENET,BIOMED RES CTR,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED 2,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Iwahashi, Hitoshi/S-1360-2019					AKAO Y, 1994, CANCER RES, V54, P2468; Burlet P, 1996, J MED GENET, V33, P281, DOI 10.1136/jmg.33.4.281; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GENNARELLI M, 1995, BIOCHEM BIOPH RES CO, V213, P342, DOI 10.1006/bbrc.1995.2135; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; MERRY DE, 1994, DEVELOPMENT, V120, P301; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	17	170	173	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					413	417		10.1038/37144	http://dx.doi.org/10.1038/37144			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389483				2022-12-28	WOS:A1997YH54900067
J	Donnellan, CA; Fook, L; McDonald, P; Playfer, JR				Donnellan, CA; Fook, L; McDonald, P; Playfer, JR			Lesson of the week - Oxybutynin and cognitive dysfunction	BRITISH MEDICAL JOURNAL			English	Review							PARKINSONS-DISEASE; RECEPTORS				Donnellan, CA (corresponding author), ROYAL LIVERPOOL UNIV HOSP,DEPT GERIATR MED,LIVERPOOL L7 8XP,MERSEYSIDE,ENGLAND.							ARENDT T, 1983, ACTA NEUROPATHOL, V61, P101, DOI 10.1007/BF00697388; ASAHINA M, 1995, ACTA NEUROL SCAND, V91, P437; *BRIT MED ASS, 1997, 34 BRIT MED ASS; CALNE DB, 1993, NEW ENGL J MED, V329, P1021; KOYANAGI T, 1986, Nishinihon Journal of Urology, V48, P1052; LANGE KW, 1993, J NEUROCHEM, V60, P197, DOI 10.1111/j.1471-4159.1993.tb05838.x; MALONELEE J, 1992, BRIT MED J, V304, P1053, DOI 10.1136/bmj.304.6833.1053; MITCHELSON F, 1988, PHARMACOL THERAPEUT, V37, P357, DOI 10.1016/0163-7258(88)90005-8; OUSLANDER JG, 1988, J UROLOGY, V140, P47, DOI 10.1016/S0022-5347(17)41482-0; PEITZKO A, 1994, EUR J CLIN PHARMACOL, V47, P337; PERRY EK, 1986, CAN J NEUROL SCI, V13, P521; PERRY RH, 1983, LANCET, V2, P789; RABNEY JM, 1991, ANNNEUROL, V30, P847	13	99	100	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 22	1997	315	7119					1363	1364		10.1136/bmj.315.7119.1363	http://dx.doi.org/10.1136/bmj.315.7119.1363			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402781	Green Published			2022-12-28	WOS:A1997YJ21800029
J	Kelly, JA; Murphy, DA; Sikkema, KJ; McAuliffe, TL; Roffman, RA; Solomon, LJ; Winett, RA; Kalichman, SC; Heckman, TG; Perry, MJ; Stevenson, LY; Hauth, AC; Koob, JJ; Morgan, MG; Norman, A; Lemke, A; Steiner, S; Trenary, B; Flynn, B; Ayotte, DR; Desiderato, LL; Lombard, DN; Yaffe, DM				Kelly, JA; Murphy, DA; Sikkema, KJ; McAuliffe, TL; Roffman, RA; Solomon, LJ; Winett, RA; Kalichman, SC; Heckman, TG; Perry, MJ; Stevenson, LY; Hauth, AC; Koob, JJ; Morgan, MG; Norman, A; Lemke, A; Steiner, S; Trenary, B; Flynn, B; Ayotte, DR; Desiderato, LL; Lombard, DN; Yaffe, DM			Randomised, controlled, community-level HIV-prevention intervention for sexual-risk behaviour among homosexual men in US cities	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BISEXUAL MEN; SAN-FRANCISCO; GAY MEN; REDUCTION INTERVENTION; AIDS PREVENTION; ADOLESCENTS; INFECTION; HEALTH; SAMPLE	Background Community-level interventions may be helpful in population-focused HIV prevention, If members of populations at risk of HIV infection who are popular with other members can be engaged to advocate the benefits of behaviour change to peers, decreases in risk behaviour may be possible. We assessed a community-level intervention to lower the risk of HIV infection, focusing on men patronising gay bars in eight small US cities. Methods We used a randomised community-level field design. Four cities received the intervention and four control cities did not. Participants were men from each city who went to gay bars. Men completed surveys about their sexual behaviour on entering the bars during 3-night periods at baseline and a 1-year follow-up. In the control cities, HIV educational materials were placed in the bars. In the intervention cities, we recruited popular homosexual men in the community and trained them to spread behaviour-change endorsements and recommendations to their peers through conversation. Findings Population-level rates of risk behaviour decreased significantly in the intervention cities compared with the control cities at 1-year follow-up, after exclusion of surveys completed by transients and men with exclusive sexual partners. In a city-level analysis, in the intervention cities we found a reduction in the mean frequency of unprotected anal intercourse during the previous 2 months (baseline 1.68 occasions: follow-up 0.59; p=0.04) and an increase in the mean percentage of occasions of anal intercourse protected by condoms (baseline 44.7%; follow-up 66.8%, p=0.02). Increased numbers of condoms taken from dispensers in intervention-city bars corroborated risk-behaviour self-reports. Interpretation Popular and well-liked members of a community who systematically endorse and recommend risk-reduction behaviour can influence the sexual-risk practices of others in their social networks. Natural styles of communication, such as conversations, brought about population-level changes in risk behaviour.	UNIV CALIF LOS ANGELES, DEPT PSYCHIAT, LOS ANGELES, CA USA; UNIV WASHINGTON, SCH SOCIAL WORK, SEATTLE, WA 98195 USA; UNIV VERMONT, DEPT PSYCHOL, BURLINGTON, VT 05405 USA; VIRGINIA POLYTECH INST & STATE UNIV, DEPT PSYCHOL, BLACKSBURG, VA 24061 USA	University of California System; University of California Los Angeles; University of Washington; University of Washington Seattle; University of Vermont; Virginia Polytechnic Institute & State University	Kelly, JA (corresponding author), MED COLL WISCONSIN, DEPT PSYCHIAT & BEHAV MED, CAIR, 8701 WATERTOWN PLANK RD, MILWAUKEE, WI 53226 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH052776, R01MH042908] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH42908, P30-MH52776] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 1996, MMWR Recomm Rep, V45, P1; CATANIA JA, 1991, HEALTH PSYCHOL, V10, P190, DOI 10.1037/0278-6133.10.3.190; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P849; DICLEMENTE RJ, 1995, JAMA-J AM MED ASSOC, V274, P1271, DOI 10.1001/jama.274.16.1271; DONNER A, 1987, STAT MED, V6, P43, DOI 10.1002/sim.4780060106; EKSTRAND M, 1993, 9 INT C AIDS BERL JU; FELDMAN HA, 1994, STAT MED, V13, P61, DOI 10.1002/sim.4780130108; FISHER JD, 1990, SOCIAL INFLUENCE PRO; Ford K, 1996, AIDS, V10, P213, DOI 10.1097/00002030-199602000-00013; HOBFOLL SE, 1994, HEALTH PSYCHOL, V13, P397, DOI 10.1037/0278-6133.13.5.397; JEMMOTT JB, 1992, AM J PUBLIC HEALTH, V82, P372, DOI 10.2105/AJPH.82.3.372; KARON JM, 1991, J ACQ IMMUN DEF SYND, V4, P1179; Kauth M R, 1991, AIDS Educ Prev, V3, P207; Kegeles SM, 1996, AM J PUBLIC HEALTH, V86, P1129, DOI 10.2105/AJPH.86.8_Pt_1.1129; KELLY JA, 1992, ARCH INTERN MED, V152, P2293, DOI 10.1001/archinte.152.11.2293; KELLY JA, 1992, AM J PUBLIC HEALTH, V82, P1483, DOI 10.2105/AJPH.82.11.1483; KELLY JA, 1995, J CONSULT CLIN PSYCH, V63, P101; KELLY JA, 1991, AM J PUBLIC HEALTH, V81, P168, DOI 10.2105/AJPH.81.2.168; KINGSLEY LA, 1987, LANCET, V1, P345; LEMP GF, 1994, JAMA-J AM MED ASSOC, V272, P449, DOI 10.1001/jama.272.6.449; MCKUSICK L, 1985, AM J PUBLIC HEALTH, V75, P493, DOI 10.2105/AJPH.75.5.493; MURRAY DM, 1990, J CONSULT CLIN PSYCH, V58, P458, DOI 10.1037/0022-006X.58.4.458; MURRAY DM, 1994, J COMMUNITY PSYCHOL, P140; OSMOND DH, 1994, AM J PUBLIC HEALTH, V84, P1933, DOI 10.2105/AJPH.84.12.1933; Pauw J, 1996, AIDS, V10, P537, DOI 10.1097/00002030-199605000-00014; Peterson JL, 1996, AIDS, V10, P319, DOI 10.1097/00002030-199603000-00011; Rogers EM., 1983, DIFFUSION INNOVATION; STLAWRENCE JS, 1995, J CONSULT CLIN PSYCH, V63, P221, DOI 10.1037/0022-006X.63.2.221; VALDISERRI RO, 1989, AIDS, V3, P21, DOI 10.1097/00002030-198903010-00005; WINETT RA, 1995, APPL PREV PSYCHOL, V4, P233, DOI 10.1016/S0962-1849(05)80025-3	30	383	392	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1500	1505		10.1016/S0140-6736(97)07439-4	http://dx.doi.org/10.1016/S0140-6736(97)07439-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YH115	9388397				2022-12-28	WOS:A1997YH11500008
J	Roubey, RAS; Hoffman, M				Roubey, RAS; Hoffman, M			From antiphospholipid syndrome to antibody-mediated thrombosis	LANCET			English	Editorial Material							SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTICARDIOLIPIN ANTIBODIES; PROCOAGULANT ACTIVITY; ANTICOAGULANT; BINDING; MEMBRANES; MONOCYTES; IGG		DUKE UNIV, DEPT PATHOL, DURHAM, NC 27706 USA	Duke University	Roubey, RAS (corresponding author), UNIV N CAROLINA, DIV RHEUMATOL & IMMUNOL, CHAPEL HILL, NC 27599 USA.		Hoffman, Maureane/D-1025-2009	Hoffman, Maureane/0000-0001-7123-0100				Cuadrado MJ, 1997, ARTHRITIS RHEUM-US, V40, P834, DOI 10.1002/art.1780400509; DELPAPA N, 1995, CLIN EXP RHEUMATOL, V13, P179; GINSBERG JS, 1993, BLOOD, V81, P2958; GINSBURG KS, 1992, ANN INTERN MED, V117, P997, DOI 10.7326/0003-4819-117-12-997; KITTNER SJ, 1992, STROKE, V23, pI19; KORNBERG A, 1994, J IMMUNOL, V153, P1328; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; Pradier O, 1996, BLOOD, V87, P3768, DOI 10.1182/blood.V87.9.3768.bloodjournal8793768; Rand JH, 1997, NEW ENGL J MED, V337, P154, DOI 10.1056/NEJM199707173370303; Rao LVM, 1996, BLOOD, V88, P4173; Roubey RAS, 1996, ARTHRITIS RHEUM-US, V39, P1444, DOI 10.1002/art.1780390903; SCHVED JF, 1992, AM J HEMATOL, V41, P92, DOI 10.1002/ajh.2830410205; SIMANTOV R, 1995, J CLIN INVEST, V96, P2211, DOI 10.1172/JCI118276; Takeya H, 1997, J CLIN INVEST, V99, P2260, DOI 10.1172/JCI119401; Willems GM, 1996, BIOCHEMISTRY-US, V35, P13833, DOI 10.1021/bi960657q	15	78	80	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1491	1493		10.1016/S0140-6736(05)63936-0	http://dx.doi.org/10.1016/S0140-6736(05)63936-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388393				2022-12-28	WOS:A1997YH11500004
J	Naren, AP; Nelson, DJ; Xie, WW; Jovov, B; Pevsner, J; Bennett, MK; Benos, DJ; Quick, MW; Kirk, KL				Naren, AP; Nelson, DJ; Xie, WW; Jovov, B; Pevsner, J; Bennett, MK; Benos, DJ; Quick, MW; Kirk, KL			Regulation of CFTR chloride channels by syntaxin and Munc18 isoforms	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; N-TYPE; CALCIUM CHANNELS; EPITHELIAL-CELLS; PROTEIN-KINASE; CL CHANNEL; COMPLEX; PHOSPHORYLATION; TRANSPORT	The cystic fibrosis gene encodes a cyclic AMP-gated chloride channel (CFTR) that mediates electrolyte transport across the luminal surfaces of a variety of epithelial cells(1-4). The molecular mechanisms that modulate CFTR activity in epithelial tissues are poorly understood, Here we show that CFTR is regulated by an epithelially expressed syntaxin (syntaxin 1A), a membrane protein that also modulates neurosecretion(5-7) and calcium-channel gatings(8-11) in brain, Syntaxin 1A physically interacts with CFTR chloride channels and regulates CFTR-mediated currents both in Xenopus oocytes and in epithelial cells that normally express these proteins. The physical and functional interactions between syntaxin 1A and CFTR are blocked by a syntaxin-binding protein of the Munc18 protein family (also called n-Sec1; refs 12-14). Our results indicate that CFTR function in epithelial cells is regulated by an interplay between syntaxin and Munc18 isoforms.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT NEUROBIOL,BIRMINGHAM,AL 35294; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60037; UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60037; KENNEDY KRIEGER INST,DEPT NEUROSCI,BALTIMORE,MD 21250; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21250; UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Chicago; University of Chicago; Kennedy Krieger Institute; Johns Hopkins University; University of California System; University of California Berkeley								ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLIFF WH, 1992, AM J PHYSIOL, V262, pC1154, DOI 10.1152/ajpcell.1992.262.5.C1154; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; MCCARTY NA, 1993, J GEN PHYSIOL, V102, P1, DOI 10.1085/jgp.102.1.1; Meffert MK, 1996, NEURON, V16, P1229, DOI 10.1016/S0896-6273(00)80149-X; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WEBER E, 1994, J CELL BIOL, V125, P538; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092	26	179	181	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					302	305		10.1038/36882	http://dx.doi.org/10.1038/36882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384384				2022-12-28	WOS:A1997YG66700067
J	Macfarlane, J; Prewett, M; Rose, D; Gard, P; Cunningham, R; Saikku, P; Euden, S; Myint, S				Macfarlane, J; Prewett, M; Rose, D; Gard, P; Cunningham, R; Saikku, P; Euden, S; Myint, S			Prospective case-control study of role of infection in patients who reconsult after initial antibiotic treatment for lower respiratory tract infection in primary care	BRITISH MEDICAL JOURNAL			English	Article							C-REACTIVE PROTEIN; CHLAMYDIA-PNEUMONIAE; GENERAL-PRACTICE; ACUTE BRONCHITIS; COMMUNITY; ETIOLOGY; EXACERBATIONS; SAMPLES; PCR	Objective: To assess direct and indirect evidence of active infection which may benefit from further antibiotics in adults who reconsult within 4 weeks of initial antibiotic management of acute lower respiratory tract infection in primary care. Design: Observational study with a nested case-control group. Setting: Two suburban general practices in Arnold, Nottingham, over 7 winter months. Subjects: 367 adults aged 16 years and over fulfilling a definition of lower respiratory tract infection and treated with antibiotics. 74 (20%) patients who reconsulted within 4 weeks for the same symptoms and 82 ''control'' patients who did not were investigated in detail at follow up. Main outcome measures: Direct and indirect evidence of active infection at the time of the reconsultation or the follow up visit with nurse for the controls. Investigations performed included sputum culture, pneumococcal antigen detecting viral and atypical pathogens by culture and polymerase chain reaction, and chest radiographs. Results: Demographic and clinical features of the groups were similar. Two thirds of the 74 patients who reconsulted received another antibiotic because the general practitioner suspected continuing infection. Any evidence of infection warranting antibiotic treatment was uncommon at reconsultation. The findings for the two groups were similar for the occurrence of identified pathogens; chest x ray changes ofinfection (present in 13%); and C reactive protein concentrations, which had nearly all fallen towards normal. Only three patients in the reconsultation group had concentrations greater than or equal to 40 mg/L. Pathogens identified at follow up in the 156 patients in both groups included ampicillin sensitive bacteria in six. Atypical infections diagnosed in 27 (Chlamydia pneumoniae in 22) and viral infections in 54 had probably been present at the initial presentation. Conclusion: Our study suggests that active infection, which may benefit from further antibiotics, is uncommon in patients who reconsult after a lower respiratory tract infection, and a repeat antibiotic prescription should be the exception rather than the rule. Other factors, such as patients' perception of their illness, may be more important than disease and infection in their decision to reconsult.	ARNOLD HLTH CTR,NOTTINGHAM NG5 7BQ,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT MICROBIOL,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM HOSP,PUBL HLTH LAB SERV,NOTTINGHAM NG7 2UH,ENGLAND; NATL PUBL HLTH INST,CHLAMYDIA LAB,DEPT OULU,OULU 90101,FINLAND; UNIV LEICESTER,DEPT MICROBIOL & IMMUNOL,LEICESTER LE1 9HN,LEICS,ENGLAND	University of Nottingham; University of Nottingham; Finland National Institute for Health & Welfare; University of Leicester	Macfarlane, J (corresponding author), CITY HOSP NOTTINGHAM,RESP INFECT UNIT,NOTTINGHAM NG5 1PB,ENGLAND.							*AUD COMM, 1994, PRESCR IMPR MOR RAT; BABU G, 1989, TROP GEOGR MED, V41, P309; BLASI F, 1993, EUR RESPIR J, V6, P19; BOURKE SJ, 1993, BRIT MED J, V306, P1219, DOI 10.1136/bmj.306.6887.1219; BRITTEN N, 1995, BRIT MED J, V310, P1084, DOI 10.1136/bmj.310.6987.1084; DAVEY P, 1994, BRIT J GEN PRACT, V44, P509; GONZALES R, 1995, LANCET, V345, P665, DOI 10.1016/S0140-6736(95)90861-7; HANSEN JG, 1995, BRIT MED J, V311, P233, DOI 10.1136/bmj.311.6999.233; HOLMES WF, IN PRESS BR J GEN PR; HOWIE JGR, 1978, BRIT MED J, V2, P1342, DOI 10.1136/bmj.2.6148.1342; Johnson PH, 1996, RESP MED, V90, P87, DOI 10.1016/S0954-6111(96)90203-6; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kauppinen MT, 1996, THORAX, V51, P185, DOI 10.1136/thx.51.2.185; LENG ZT, 1994, MOL CELL PROBE, V8, P125, DOI 10.1006/mcpr.1994.1017; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Macfarlane J, 1997, BMJ-BRIT MED J, V315, P1211, DOI 10.1136/bmj.315.7117.1211; Macfarlane JT, 1996, BRIT J GEN PRACT, V46, P357; MACFARLANE JT, 1993, LANCET, V341, P511, DOI 10.1016/0140-6736(93)90275-L; MACFARLANE JT, 1991, RECENT ADV RESPIRATO, P109; MARTIN E, 1991, BRIT MED J, V303, P289, DOI 10.1136/bmj.303.6797.289; MELBYE H, 1992, Scandinavian Journal of Primary Health Care, V10, P234, DOI 10.3109/02813439209014067; Melbye Hasse, 1994, Tidsskrift for den Norske Laegeforening, V114, P814; Office of Population Censuses and Surveys, 1995, MORB STAT GEN PRACT; PUTTO A, 1986, ARCH DIS CHILD, V61, P24, DOI 10.1136/adc.61.1.24; RUUSKANEN O, 1985, J PEDIATR-US, V107, P97, DOI 10.1016/S0022-3476(85)80624-7; TONG CYW, 1993, J CLIN PATHOL, V46, P313, DOI 10.1136/jcp.46.4.313; VERHEIJ TJM, 1989, FAM PRACT, V6, P66, DOI 10.1093/fampra/6.1.66; WHICHER JT, 1985, J CLIN PATHOL, V38, P312, DOI 10.1136/jcp.38.3.312; WOODHEAD MA, 1987, LANCET, V1, P671	29	35	35	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1206	1210		10.1136/bmj.315.7117.1206	http://dx.doi.org/10.1136/bmj.315.7117.1206			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393227	Green Published			2022-12-28	WOS:A1997YF25200025
J	Pegoraro, A; Singh, A; Bakir, AA; Arruda, JAL; Dunea, G				Pegoraro, A; Singh, A; Bakir, AA; Arruda, JAL; Dunea, G			Simplified screening for microalbuminuria	ANNALS OF INTERNAL MEDICINE			English	Article							URINARY ALBUMIN EXCRETION; DIABETIC-PATIENTS; PREDICTOR	Background: Screening for microalbuminuria is increasingly advocated as a way to diagnose early renal involvement in diabetes and other diseases. It usually entails the use of a radioimmunoassay that is expensive and not always readily available. Objective: To assess the efficacy of three simple and inexpensive tests for ruling out microalbuminuria. Design: Cross-sectional study. Setting: Outpatient clinics. Patients: 221 patients from primary care clinics and a diabetes clinic. Measurements: Random urine specimens were tested for albumin by using Micral-Test immunoassay strips (Boehringer Mannheim, Mannheim, Germany) and for protein by using sulfosalicylic acid testing and impregnated dipsticks (Chemstrips, Boehringer Mannheim). Radioimmunoassay for albumin was used for all specimens as standard for comparison. Results: When less than 20 mg/L was considered the upper limit of normal for albumin concentration, Micral-Test, sulfosalicylic acid testing, and Chemstrips had negative predictive values of 99%, 95%, and 96%, respectively. Seventy-four specimens tested negative on both sulfosalicylic acid and Chemstrips; the negative predictive value of these two tests combined was 99%. Conclusions: The combination of sulfosalicylic acid testing and Chemstrips was as good as and less expensive than Micral-Test in ruling out microalbuminuria.	UNIV ILLINOIS, NEPHROL SECT, CHICAGO, IL 60612 USA; W SIDE VET ADM MED CTR, CHICAGO, IL USA; HEKTOEN INST MED RES, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Pegoraro, A (corresponding author), COOK CTY HOSP, NEPHROL SECT, 637 S WOOD ST, CHICAGO, IL 60612 USA.							BASHYAM MM, 1993, DIABETES CARE, V16, P634, DOI 10.2337/diacare.16.4.634; BORCHJOHNSEN K, 1993, BRIT MED J, V306, P1722, DOI 10.1136/bmj.306.6894.1722; COWELL CT, 1986, DIABETOLOGIA, V29, P97, DOI 10.1007/BF00456117; DEGRAUW WJC, 1995, DIABETIC MED, V12, P657; ESHOJ O, 1987, DIABETIC MED, V4, P531, DOI 10.1111/j.1464-5491.1987.tb00924.x; GYURE WL, 1977, CLIN CHEM, V23, P876; HASSLACHER C, 1993, CLIN BIOCHEM, V26, P283, DOI 10.1016/0009-9120(93)90126-Q; HUTCHISON AS, 1988, CLIN CHEM, V34, P2019; JOHNSTON J, 1993, BRIT MED J, V306, P493, DOI 10.1136/bmj.306.6876.493-a; KUTTER D, 1995, EUR J CLIN CHEM CLIN, V33, P243; LEFLOCH JP, 1994, DIABETIC MED, V11, P349; MARSHALL SM, 1992, CLIN CHEM, V38, P588; MEYER NL, 1994, AM J OBSTET GYNECOL, V170, P137; MOGENSEN CE, 1987, KIDNEY INT, V31, P673, DOI 10.1038/ki.1987.50; MOGENSEN CE, 1985, UREMIA INVEST, V9, P85, DOI 10.3109/08860228509088195; SILVER A, 1986, CLIN CHEM, V32, P1303; TAI J, 1990, DIABETES RES CLIN PR, V9, P137, DOI 10.1016/0168-8227(90)90105-3; TIU SC, 1993, DIABETES CARE, V16, P616, DOI 10.2337/diacare.16.4.616; WINOCOUR PH, 1992, BRIT MED J, V304, P1196, DOI 10.1136/bmj.304.6836.1196	19	20	20	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					817	819		10.7326/0003-4819-127-9-199711010-00007	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382403				2022-12-28	WOS:A1997YD89800006
J	Berckmans, P; Dawans, V; Schmets, G; Vandenbergh, D; Autier, P				Berckmans, P; Dawans, V; Schmets, G; Vandenbergh, D; Autier, P			Inappropriate drug-donation practices in Bosnia and Herzegovina, 1992 to 1996	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EARTHQUAKE		EUROPEAN ASSOC HLTH & DEV,B-1000 BRUSSELS,BELGIUM; EUROPEAN INST ONCOL,I-20141 MILAN,ITALY	IRCCS European Institute of Oncology (IEO)			Autier, Philippe/A-4402-2014	Autier, Philippe/0000-0003-1538-5321				ALI HM, 1988, LANCET, V333, P538; AUTIER P, 1990, LANCET, V335, P1388; BERCKMANS P, 1996, DRUG DONATION PRACTI; COHEN S, 1990, LANCET, V336, P745, DOI 10.1016/0140-6736(90)92233-8; GODLEE F, 1994, BRIT MED J, V309, P1424, DOI 10.1136/bmj.309.6966.1424; Hogerzeil HV, 1997, BRIT MED J, V314, P737, DOI 10.1136/bmj.314.7082.737; Michael M, 1996, JAMA-J AM MED ASSOC, V276, P364, DOI 10.1001/jama.276.5.364; OFFERHAUS L, 1992, LANCET, V339, P607; *RES MED DEV, 1996, ECH MED ENTR PAYS EU; SCHOUTEN E, 1995, BRIT MED J, V311, P684, DOI 10.1136/bmj.311.7006.684; *UN INF MED ETH DE, 1994, MED UT EUR REC DESTR; United Nations Environment Programme, 1989, BAS CONV CONTR TRANS; VANDERHEIDE B, 1995, BRIT MED J, V311, P684, DOI 10.1136/bmj.311.7006.684a; *WAR HLTH CROSS BR, 1996, EUR COR ANN REP 1995; *WEMOS PHARM PROJ, 1991, EXP DEADL EXP STOR E; *WHO, 1994, WHO MISS FORM YUG; *WHO, 1996, WHODAP962; *WHO, 1992, WHO TECH REP SER, V825, P1; *WHO, 1994, MED SUPPL DON GUID W; ZEBALLOS JL, 1986, DISASTERS, V10, P141, DOI 10.1111/j.1467-7717.1986.tb00579.x	20	24	26	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 18	1997	337	25					1842	1845		10.1056/NEJM199712183372512	http://dx.doi.org/10.1056/NEJM199712183372512			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL855	9400045				2022-12-28	WOS:A1997YL85500012
J	McNagny, SE; Wenger, NK; Frank, E				McNagny, SE; Wenger, NK; Frank, E			Personal use of postmenopausal hormone replacement therapy by women physicians in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							PREVENT OSTEOPOROSIS; ESTROGEN REPLACEMENT; ATTITUDES; DISEASE	Background: Women physicians' use of postmenopausal hormone replacement therapy (HRT) is unknown. Objective: To study use of HRT by women physicians in the United States. Design: Stratified random-sample mail survey. Setting: United States. Participants: 1466 postmenopausal women U.S. physicians in the Women Physicians' Health Study. Measurements: Self-reported personal use of HRT and information on demographic, professional, and behavioral characteristics and medical history. Results: Overall, 47.4% of participants currently use HRT; the prevalence of use is 59.8% in women 40 to 49 years of age, 49.4% in women 50 to 59 years of age, and 36.4% in women 60 to 70 years of age (P < 0.001). In an adjusted logistic regression model, current users were significantly more likely to be gynecologists, to be younger, to be white, to be sexually active, to be previous users of oral contraceptives, to live in Pacific or Mountain states, to have had a hysterectomy, and to have no personal or family history of breast cancer. Conclusions: Women physicians have a higher rate of HRT use than that reported in cross-sectional U.S. surveys. This may presage greater use of HRT for U.S. women in the future.	Emory Univ, Sch Med, Div Gen Med, Atlanta, GA 30303 USA	Emory University	McNagny, SE (corresponding author), Emory Univ, Sch Med, Div Gen Med, 69 Butler St, Atlanta, GA 30303 USA.			Frank, Erica/0000-0001-7159-5417	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007034] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32-HL-07034] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barrett-Connor E., 1995, J WOMENS HEALTH, V4, P143; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; *COMM TECHN B AM C, 1992, ACOG TECHN B, V166, P1; Frank E, 1995, J Am Med Womens Assoc (1972), V50, P64; Frank E, 1997, WESTERN J MED, V166, P179; FRANK E, 1995, PREV MED, V24, P543, DOI 10.1006/pmed.1995.1086; FRANK E, IN PRESS ARCH INTERN; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREENDALE GA, 1990, J GEN INTERN MED, V5, P464, DOI 10.1007/BF02600870; GRISSO JA, 1990, J BONE MINER RES, V5, P213, DOI 10.1002/jbmr.5650050303; Handa VL, 1996, J AM GERIATR SOC, V44, P1; HEMMINKI E, 1991, DICP ANN PHARMAC, V25, P418, DOI 10.1177/106002809102500416; ISAACS AJ, 1995, BRIT MED J, V311, P1399, DOI 10.1136/bmj.311.7017.1399; NELSON DE, 1994, JAMA-J AM MED ASSOC, V271, P1273, DOI 10.1001/jama.271.16.1273; ODDENS BJ, 1992, MATURITAS, V15, P171, DOI 10.1016/0378-5122(92)90200-N; PILOTE L, 1995, AM HEART J, V129, P1237, DOI 10.1016/0002-8703(95)90426-3; *RES TRIANGL I, 1996, SUDAAN US MAN VERS 6; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F; [No title captured]	19	48	48	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1093	1096		10.7326/0003-4819-127-12-199712150-00007	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412312				2022-12-28	WOS:000070936600006
J	Doyle, LW				Doyle, LW			Kangaroo mother care	LANCET			English	Editorial Material							BIRTH-WEIGHT INFANTS				Doyle, LW (corresponding author), ROYAL WOMENS HOSP,DEPT OBSTET & GYNAECOL,CARLTON,VIC 3053,AUSTRALIA.		Doyle, Lex/AAJ-5205-2021	Doyle, Lex/0000-0002-7667-7312				Charpak N, 1997, PEDIATRICS, V100, P682, DOI 10.1542/peds.100.4.682; CHARPAK N, 1994, PEDIATRICS, V94, P804; *CONS COUNC OBST P, 1996, ANN REP YEAR 1995 IN; SLOAN NL, 1994, LANCET, V344, P782, DOI 10.1016/S0140-6736(94)92341-8; WHITELAW A, 1990, PEDIATRICS, V85, P604	5	14	14	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 13	1997	350	9093					1721	1722		10.1016/S0140-6736(05)63569-6	http://dx.doi.org/10.1016/S0140-6736(05)63569-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413460				2022-12-28	WOS:A1997YL55400005
J	vanderPijl, JW; vanderWoude, FJ; Swart, W; vanEs, LA; Lemkes, HHPJ				vanderPijl, JW; vanderWoude, FJ; Swart, W; vanEs, LA; Lemkes, HHPJ			Effect of danaparoid sodium on hard exudates in diabetic retinopathy	LANCET			English	Article							EXTRACELLULAR-MATRIX COMPONENTS; NEPHROPATHY; MEMBRANE	Background In diabetes mellitus, both retinopathy and nephropathy represent specific microvascular disease with increased capillary permeability resulting in hard exudates, foveal oedema, and albuminuria. The decrease of heparan-sulphate content of the glomerular-basement membrane is quantitatively related to the rate of proteinuria in nephropathy associated with insulin-dependent diabetes mellitus (IDDM). Several short-term studies in patients with IDDM and non-IDDM have shown that a reduction of microalbuminuria and macroalbuminuria can be achieved with the supplementation of glycosaminoglycans. After completion of a study on the effect of danaparoid sodium on albumin excretion in patients with IDDM and macroalbuminuria, we hypothesised that treatment with danaparoid sodium also influenced retinal leakage in the patients in that trial. Methods In this retrospective study nine patients with nephropathy received 750 anti-Xa units danaparoid sodium once a day for 6 weeks in a placebo-controlled double-blind cross-over study. Fundus photographs, done at baseline and at the end of the study, were semiquantitatively scored for the severity of hard exudates. Findings At baseline 14 eyes had grade 1 to 5 severity of hard exudates and four eyes were without hard exudates (grade 0). There was no progression in the latter four eyes. In ten eyes an improvement was observed: four patients showed a favourable response to treatment in both eyes and two patients showed improvement in one eye. We found improvement of hard exudates after 6 weeks of treatment with danaparoid sodium. Interpretation Our uncontrolled observation indicates that the supplementation of danaparoid sodium influences both the permeability of retinal vessels as well as of glomerular vessels. Danaparoid-sodium therapy as a systemic adjuvant is worth considering for treatment strategies for foveal oedema and hard exudates in diabetic maculopathy.	LEIDEN UNIV HOSP, DEPT OPHTHALMOL, NL-2300 RC LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT ENDOCRINOL, NL-2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	vanderPijl, JW (corresponding author), LEIDEN UNIV HOSP, DEPT NEPHROL, BLDG 1, C3-P, POB 9600, NL-2300 RC LEIDEN, NETHERLANDS.							Cheng H, 1972, Trans Ophthalmol Soc U K, V92, P407; Chew EY, 1996, ARCH OPHTHALMOL-CHIC, V114, P1079, DOI 10.1001/archopht.1996.01100140281004; DAS A, 1990, ARCH OPHTHALMOL-CHIC, V108, P421, DOI 10.1001/archopht.1990.01070050119045; FERRIS FL, 1984, SURV OPHTHALMOL, V28, P452, DOI 10.1016/0039-6257(84)90227-3; KANWAR YS, 1991, SEMIN NEPHROL, V11, P390; MYRUP B, 1995, LANCET, V345, P421, DOI 10.1016/S0140-6736(95)90403-4; PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015; Solini A, 1997, DIABETES CARE, V20, P819, DOI 10.2337/diacare.20.5.819; Tamsma JT, 1996, NEPHROL DIAL TRANSPL, V11, P182; TAMSMA JT, 1994, DIABETOLOGIA, V37, P313, DOI 10.1007/BF00398060; VanderPijl JW, 1997, J AM SOC NEPHROL, V8, P456	11	17	20	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 13	1997	350	9093					1743	1745		10.1016/S0140-6736(97)07126-2	http://dx.doi.org/10.1016/S0140-6736(97)07126-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413466				2022-12-28	WOS:A1997YL55400011
J	Hwang, CY				Hwang, CY			An inverse Compton process for the excess diffuse EUV emission from the Virgo and Coma galaxy clusters	SCIENCE			English	Article							X-RAY-EMISSION; MAGNETIC-FIELD; ULTRAVIOLET EMISSION; RADIO-EMISSION; HALO; SUPERCLUSTER; ROTATION; GASES	The excess extreme-ultraviolet (EUV) emission detected in the Virgo and Coma clusters is explained by inverse Compton scattering of cosmic microwave background photons, which are scattered by the relativistic electrons that account for the extended radio synchrotron emission of these clusters. The lower limits of the average magnetic fields of these clusters estimated from the EUV excess are close to the equipartition magnetic fields derived from radio observations, indicating that the electron energies and magnetic field energies might be close to equipartition. The excess emission suggests energy reservoirs of similar to 10(61) and similar to 10(60) ergs for the Coma and Virgo clusters, respectively.			Hwang, CY (corresponding author), ACAD SINICA,INST ASTRON & ASTROPHYS,POB 1-87,TAIPEI 115,TAIWAN.							ANDERNACH H, 1979, ASTRON ASTROPHYS, V74, P93; BLUMENTHAL GR, 1970, REV MOD PHYS, V42, P237, DOI 10.1103/RevModPhys.42.237; Bowyer S, 1996, SCIENCE, V274, P1338, DOI 10.1126/science.274.5291.1338; DENNISON B, 1980, ASTROPHYS J, V236, P761, DOI 10.1086/157801; Dixon WV, 1996, ASTROPHYS J, V469, pL77, DOI 10.1086/310271; Fabian AC, 1996, SCIENCE, V271, P1244, DOI 10.1126/science.271.5253.1244; Fabian AC, 1997, SCIENCE, V275, P48, DOI 10.1126/science.275.5296.48; FABIAN AC, 1994, ANNU REV ASTRON ASTR, V32, P277, DOI 10.1146/annurev.aa.32.090194.001425; FERETTI L, 1995, ASTRON ASTROPHYS, V302, P680; GIOVANNINI G, 1993, ASTROPHYS J, V406, P399, DOI 10.1086/172451; HANISCH RJ, 1985, ASTRON ASTROPHYS, V153, P9; HANISCH RJ, 1980, ASTRON J, V85, P183, DOI 10.1086/112660; HANISCH RJ, 1980, ASTRON J, V85, P1565, DOI 10.1086/112834; HARRIS DE, 1979, MON NOT R ASTRON SOC, V188, P25, DOI 10.1093/mnras/188.1.25; HARRIS DE, 1990, LECT NOTE PHYS, V362, P252; KIM KT, 1989, NATURE, V341, P720, DOI 10.1038/341720a0; KIM KT, 1990, ASTROPHYS J, V355, P29, DOI 10.1086/168737; LIEEU R, 1996, ASTROPHYS J, V458, pL5; Lieu R, 1996, SCIENCE, V274, P1335, DOI 10.1126/science.274.5291.1335; Mewe R., 1985, Astronomy & Astrophysics Supplement Series, V62, P197; PTUSKIN VS, 1990, ASTROPHYSICS COSMIC, P171; REPHAELI Y, 1994, ASTROPHYS J, V429, P554, DOI 10.1086/174343; SARAZIN CL, 1986, REV MOD PHYS, V58, P1, DOI 10.1103/RevModPhys.58.1; VALLEE JP, 1990, ASTRON J, V99, P459, DOI 10.1086/115343	24	58	58	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1917	1919		10.1126/science.278.5345.1917	http://dx.doi.org/10.1126/science.278.5345.1917			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395387				2022-12-28	WOS:A1997YL00200025
J	Kim, JM; Mayfield, SP				Kim, JM; Mayfield, SP			Protein disulfide isomerase as a regulator of chloroplast translational activation	SCIENCE			English	Article							PSBA MESSENGER-RNA; CHLAMYDOMONAS-REINHARDTII; GENE-EXPRESSION; PHOTOSYSTEM-II; THIOREDOXIN REDUCTASE; NUCLEAR; BINDING; BIOGENESIS; BARLEY; MUTANT	Light-regulated translation of chloroplast messenger RNAs (mRNAs) requires transacting factors that interact with the 5' untranslated region (UTR) of these mRNAs, Chloroplast polyadenylate-binding protein (cPABP) specifically binds to the 5'-UTR of the psbA mRNA and is essential for translation of this mRNA, A protein disulfide isomerase that is localized to the chloroplast and copurifies with cPABP was shown to modulate the binding of cPABP to the 5'-UTR of the psbA mRNA by reversibly changing the redox status of cPABP through redox potential or adenosine 5'-diphosphate-dependent phosphorylation. This mechanism allows for a simple reversible switch regulating gene expression in the chloroplast.	Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	Kim, JM (corresponding author), SCRIPPS RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA.			Kim, Jungmook/0000-0003-1735-5564	NIGMS NIH HHS [GM54659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FROMM H, 1985, EMBO J, V4, P291, DOI 10.1002/j.1460-2075.1985.tb03628.x; GIRARDBASCOU J, 1992, CURR GENET, V22, P47, DOI 10.1007/BF00351741; Hauser CR, 1996, J BIOL CHEM, V271, P1486, DOI 10.1074/jbc.271.3.1486; JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KLEIN RR, 1987, J BIOL CHEM, V262, P4341; KRUPINSKA K, 1989, MOL GEN GENET, V219, P467, DOI 10.1007/BF00259621; KUCHKA MR, 1988, EMBO J, V7, P319, DOI 10.1002/j.1460-2075.1988.tb02815.x; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; MALNOE P, 1988, J CELL BIOL, V106, P609, DOI 10.1083/jcb.106.3.609; MAYFIELD SP, 1994, J CELL BIOL, V127, P1537, DOI 10.1083/jcb.127.6.1537; MAYFIELD SP, 1995, ANNU REV PLANT PHYS, V46, P147, DOI 10.1146/annurev.pp.46.060195.001051; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOIVA R, 1992, J BIOL CHEM, V267, P3553; Robinson C., 1994, V139, P273; ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x; Staples CR, 1996, BIOCHEMISTRY-US, V35, P11425, DOI 10.1021/bi961007p; Yohn CB, 1996, MOL CELL BIOL, V16, P3560; YOHN CB, UNPUB	25	190	203	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1954	1957		10.1126/science.278.5345.1954	http://dx.doi.org/10.1126/science.278.5345.1954			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395399				2022-12-28	WOS:A1997YL00200037
J	Becquemin, JP				Becquemin, JP			Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERMITTENT CLAUDICATION; MULTICENTER TRIAL; ASPIRIN; DIPYRIDAMOLE; PREVENTION; DISEASE; STROKE; OCCLUSION; STIMS; RISK	Background Optimal therapy to prevent late occlusion of arterial bypass grafts in the legs has not been determined. We assessed the effect of ticlopidine, an inhibitor of platelet aggregation, on the long-term patency of saphenous-vein bypass grafts for the treatment of peripheral vascular disease. Methods A total of 243 patients with femoropopliteal or femorotibial saphenous-vein bypass grafts were randomly assigned to receive either ticlopidine (250 mg twice a day) or matching placebo for two years. The primary end point was graft patency at two years, as assessed by physical examination, measurement of the ankle brachial index, and duplex ultrasonography or arteriography. The incidence of death and major ischemic events was also analyzed in the two groups. Results After two years, 66.4 percent of the patients were alive with a patent graft in the ticlopidine group, as compared with 51.2 percent in the placebo group (95 percent confidence interval for the difference between the two groups, 2.9 to 27.4 percent; P = 0.02). The two-year cumulative patency rate was 82 percent in the ticlopidine group and 63 percent in the placebo group (P = 0.002). There was no significant difference between groups in overall mortality or major ischemic events. Conclusions Ticlopidine significantly improved the long-term patency of saphenous-vein bypass grafts in the legs. Since the drug was well tolerated, its use can be recommended after peripheral-vein bypass surgery. (C) 1997, Massachusetts Medical Society.	SANOFI RECH, CRETEIL, FRANCE; SIMED, CRETEIL, FRANCE; CTR HOSP REG UNIV, HOP CHARLES NICOLLE, ROUEN, FRANCE; CTR HOSP REG UNIV, HOP LAENNEC, NANTES, FRANCE; CLIN POIRIER, CHAMBERY, FRANCE; HOP NORD ST PRIEST JAREZ, ST PRIEST EN JAREZ, FRANCE; CHU BESANCON, HOP JEAN MINJOZ, F-25030 BESANCON, FRANCE; HOP ENFANTS LA TIMONE, MARSEILLE, FRANCE; HOP SUD, MARSEILLE, FRANCE; CTR HOSP REG UNIV, HOP REPUBL, NICE, FRANCE; CTR HOSP REG UNIV NORD, GRENOBLE, FRANCE; CTR HOSP UNIV, HOP JEAN BERNARD, POITIERS, FRANCE; FREE UNIV BRUSSELS, HOP ERASME, B-1070 BRUSSELS, BELGIUM; CTR HOSP ST PHILLIBERT, LOMME LES LILLE, FRANCE; CTR HOSP REG & UNIV, HOP PURPAN, TOULOUSE, FRANCE; CTR HOSP REG & UNIV, HOP BRABOIS, VANDOEUVRE LES NANCY, FRANCE; CTR HOSP REG & UNIV, HOP CIVIL, STRASBOURG, FRANCE; CTR HOSP REG & UNIV, ANGERS, FRANCE; CTR HOSP REG & UNIV, HOP ARNAUD DE VILLENEUVE, MONTPELLIER, FRANCE; CTR HOSP GEN PASTEUR, LANGON, FRANCE; HOP BEAUJON, CLICHY, FRANCE; CTR HOSP REG UNIV, HOP BOCAGE, DIJON, FRANCE; HOP ST MICHEL, PARIS, FRANCE; CTR HOSP REG UNIV, HOP COTE DE NACRE, CAEN, FRANCE; HOP ANDRE MIGNOT, LE CHESNAY, FRANCE; CLIN LABROUSTE, PARIS, FRANCE	Sanofi-Aventis; CHU de Rouen; Nantes Universite; CHU de Nantes; Universite de Franche-Comte; CHU Besancon; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Nice; CHU Poitiers; Universite de Poitiers; Universite Libre de Bruxelles; Vrije Universiteit Brussel; CHU de Toulouse; CHU de Nancy; CHU Strasbourg; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite de Montpellier; CHU de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Dijon Bourgogne; CHU de Caen NORMANDIE; Universite de Caen Normandie; Centre Hospitalier de Versailles	Becquemin, JP (corresponding author), CHU HENRI MONDOR, DEPT VASC SURG, 51 AVE DE LATTRE DE TASSIGNY, F-94000 CRETEIL, FRANCE.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81; ARCAN JC, 1988, ANGIOLOGY, V39, P802, DOI 10.1177/000331978803900904; BERGQVIST D, 1995, EUR J VASC ENDOVASC, V10, P69, DOI 10.1016/S1078-5884(05)80200-X; BLANCHARD J, 1993, NOUV REV FR HEMATOL, V35, P523; BOISSEL JP, 1989, THROMB HAEMOSTASIS, V62, P681; Breslow NE, 1980, IARC SCI PUBL, V1, P142; CHESEBRO JH, 1986, J AM COLL CARDIOL, V8, pB57, DOI 10.1016/S0735-1097(86)80007-9; CHESEBRO JH, 1982, NEW ENGL J MED, V307, P73, DOI 10.1056/NEJM198207083070201; CHEVIGNE M, 1984, ANN THORAC SURG, V37, P370, DOI 10.1016/S0003-4975(10)60757-6; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P159, DOI [10.1136/bmj.308.6922.159, DOI 10.1136/BMJ.308.6922.159]; Dalman R L, 1990, Ann Vasc Surg, V4, P309, DOI 10.1007/BF02009464; EDMONDSON, 1994, LANCET, V344, P1307; EDMONDSON RA, 1994, LANCET, V344, P914, DOI 10.1016/S0140-6736(94)92269-1; FUCHS JCA, 1978, ANN SURG, V188, P1, DOI 10.1097/00000658-197807000-00001; FUSTER V, 1986, CIRCULATION, V73, P227, DOI 10.1161/01.CIR.73.2.227; GENT M, 1989, LANCET, V1, P1215, DOI 10.1016/S0140-6736(89)92327-1; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; JANZON L, 1990, J INTERN MED, V227, P301, DOI 10.1111/j.1365-2796.1990.tb00164.x; JANZON L, 1990, J INTERN MED, V228, P659; KOHLER TR, 1984, SURGERY, V96, P462; KRETSCHMER G, 1986, BRIT J SURG, V73, P689, DOI 10.1002/bjs.1800730903; LIMET R, 1987, J THORAC CARDIOV SUR, V94, P773; LORENZ RL, 1984, LANCET, V1, P1261; MCCOLLUM C, 1991, J VASC SURG, V13, P150, DOI 10.1016/0741-5214(91)90022-M; ROSENTHAL D, 1987, AM SURGEON, V53, P477; *SAN PHARM, 1993, TICL PROD MON; SHEEHAN SJ, 1987, BRIT J SURG, V74, P330; WATELET J, 1986, ANN VASC SURG, V1, P441	29	110	111	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1726	1731		10.1056/NEJM199712113372404	http://dx.doi.org/10.1056/NEJM199712113372404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK653	9392698				2022-12-28	WOS:A1997YK65300004
J	Rogan, MT; Staubli, UV; LeDoux, JE				Rogan, MT; Staubli, UV; LeDoux, JE			Fear conditioning induces associative long-term potentiation in the amygdala	NATURE			English	Article							NEURONAL TRANSMISSION; BRAIN TEMPERATURE; EVOKED-POTENTIALS; HIPPOCAMPUS; BEHAVIOR; NMDA; RAT; RECORDINGS; RESPONSES; RECEPTORS	Long-term potentiation (LTP) is an experience-dependent form of neural plasticity believed to involve mechanisms that underlie memory formation(1-3). Lip has been studied most extensively in the hippocampus, but the relation between hippocampal Lip and memory has been difficult to establish(4-6). Here we explore the relation between LTP and memory in fear conditioning, an amygdala-dependent form of learning in which an innocuous conditioned stimulus (CS) elicits fear responses after being associatively paired with an aversive unconditioned stimulus (US). We have previously shown that Lip induction in pathways that transmit auditory CS information to the lateral nucleus of the amygdala (LA) increases auditory-evoked field potentials in this nucleus(7). Now we show that fear conditioning alters auditory CS-evoked responses in LA in the same way as Lip induction, The changes parallel the acquisition of CS-elicited fear behaviour, are enduring, and do not occur if the CS and US remain unpaired. LTP-like associative processes thus occur during fear conditioning, and these may underlie the long-term associative plasticity that constitutes memory of the conditioning experience.			Rogan, MT (corresponding author), NYU,CTR NEURAL SCI,6 WASHINGTON PL,NEW YORK,NY 10003, USA.							BARNES CA, 1995, NEURON, V15, P751, DOI 10.1016/0896-6273(95)90166-3; BLANCHAR.RJ, 1969, J COMP PHYSIOL PSYCH, V68, P129, DOI 10.1037/h0027676; BLANCHARD RJ, 1969, J COMP PHYSIOL PSYCH, V67, P370, DOI 10.1037/h0026779; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLLES RC, 1980, BEHAV BRAIN SCI, V3, P291, DOI 10.1017/S0140525X0000491X; BOUTON ME, 1980, ANIM LEARN BEHAV, V8, P429, DOI 10.3758/BF03199629; BROWN TH, 1994, MODELS NEURAL NETWOR, V2, P287; BUZSAKI G, 1981, BRAIN RES, V225, P235, DOI 10.1016/0006-8993(81)90833-7; DEADWYLER SA, 1985, BEHAV NEURAL BIOL, V44, P201, DOI 10.1016/S0163-1047(85)90198-0; EICHENBAUM H, 1995, NATURE, V378, P131, DOI 10.1038/378131a0; Farb CR, 1997, SYNAPSE, V27, P106, DOI 10.1002/(SICI)1098-2396(199710)27:2<106::AID-SYN2>3.3.CO;2-F; Gewirtz JC, 1997, NATURE, V388, P471, DOI 10.1038/41325; Jeffery KJ, 1997, HIPPOCAMPUS, V7, P95; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LEUNG LS, 1980, BRAIN RES, V198, P95; LI XF, 1995, EXP BRAIN RES, V105, P87; Li XF, 1996, LEARN MEMORY, V3, P229, DOI 10.1101/lm.3.2-3.229; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Maren S, 1996, BEHAV NEUROSCI, V110, P1365, DOI 10.1037/0735-7044.110.6.1365; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MOSER E, 1993, SCIENCE, V259, P1324, DOI 10.1126/science.8446900; MOSER EI, 1994, LEARN MEMORY, V1, P55; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; QUIRK GJ, 1995, NEURON, V15, P1029, DOI 10.1016/0896-6273(95)90092-6; Rogan M. T., 1995, Society for Neuroscience Abstracts, V21, P1930; ROGAN MT, 1995, NEURON, V15, P127, DOI 10.1016/0896-6273(95)90070-5; Rogan MT, 1997, J NEUROSCI, V17, P5928; SKELTON RW, 1987, J NEUROSCI, V7, P3081; STAUBLI UV, 1995, BRAIN MEMORY MODULAT, P303; WINSON J, 1978, J NEUROPHYSIOL, V41, P716, DOI 10.1152/jn.1978.41.3.716	30	954	971	3	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					604	607		10.1038/37601	http://dx.doi.org/10.1038/37601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403688				2022-12-28	WOS:A1997YK85300048
J	Puck, JM				Puck, JM			Primary immunodeficiency diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLASS-II DEFICIENCY; CHRONIC GRANULOMATOUS-DISEASE; X-LINKED AGAMMAGLOBULINEMIA; COMBINED IMMUNE-DEFICIENCY; WISKOTT-ALDRICH SYNDROME; HYPER-IGM SYNDROME; LYMPHOPROLIFERATIVE SYNDROME; TYROSINE KINASE; GENE; MUTATIONS	Primary immunodeficiencies are rare, but important for 3 reasons. First, a high index of suspicion and prompt diagnosis can lead to lifesaving treatment or significant improvement in quality of life. Second, appreciation of the genetic nature of a host defense defect makes possible family counseling and carrier and prenatal diagnosis. Finally, the large and growing list of human genetic defects in immune pathways provides an important tool for understanding human immunoregulation. Many inherited immunodeficiency diseases have had their genetic cause proven with the discovery of their disease genes within the past 5 years. These diseases provide a framework into which additional diseases and disease gene discoveries can be added as the rapid progress in molecular immunology and genetics continues.			Puck, JM (corresponding author), NATL HUMAN GENOME RES INST, IMMUNOL DIS SECT,LAB GENE TRANSFER,NIH,BLDG 49, ROOM 3A14, BETHESDA, MD 20892 USA.							Bemiller LS, 1995, BLOOD CELL MOL DIS, V21, P239, DOI 10.1006/bcmd.1995.0028; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; Buckley RH, 1997, J PEDIATR-US, V130, P378, DOI 10.1016/S0022-3476(97)70199-9; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CONLEY ME, 1994, J CLIN INVEST, V94, P1404, DOI 10.1172/JCI117476; CUNNINGHAMRUNDL.C, 1996, IMMUNOLOGIC DISORDER, P423; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; ETZIONI A, 1994, CELL ADHES COMMUN, V2, P257, DOI 10.3109/15419069409004445; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Flake AW, 1996, NEW ENGL J MED, V335, P1806, DOI 10.1056/NEJM199612123352404; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gong WK, 1996, HUM MOL GENET, V5, P789, DOI 10.1093/hmg/5.6.789; Hershfield MS, 1995, METABOLIC MOL BASES, V2, P1725; HIRSCHFIELD MS, 1993, PEDIAT RES S, V3, pS42; Hirschhorn R, 1991, IMMUNOL REV, V3, P45; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; *IMM DEF FDN, 1993, PAT FAM HDB PRIM IMM; KLEIN C, 1993, J PEDIATR-US, V123, P921, DOI 10.1016/S0022-3476(05)80388-9; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; Levy J, 1997, J PEDIATR-US, V131, P47, DOI 10.1016/S0022-3476(97)70123-9; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MULLER W, 1989, EUR J PEDIATR, V149, P96, DOI 10.1007/BF01995856; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; Notarangelo LD, 1996, IMMUNOL TODAY, V17, P511, DOI 10.1016/0167-5699(96)30059-5; OCHS H, IN PRESS PRIMARY IMM; ORKIN SH, 1989, ANNU REV IMMUNOL, V7, P277; PAGON RA, 1997, HELIX DIRECTORY MED; Perou CM, 1996, NAT GENET, V13, P303, DOI 10.1038/ng0796-303; Puck J M, 1997, Semin Immunol, V9, P77, DOI 10.1006/smim.1996.0056; Puck JM, 1997, BLOOD, V89, P1968; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; PUCK JM, 1987, J CLIN INVEST, V79, P1395, DOI 10.1172/JCI112967; Puck JM, 1996, IMMUNOL TODAY, V17, P507, DOI 10.1016/0167-5699(96)30062-5; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; RILEY RJ, 1995, CLIN EXP IMMUNOL, V99, P1; Roos D, 1996, IMMUNOL TODAY, V17, P517; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Saar K, 1997, AM J HUM GENET, V60, P605; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHUSTER V, 1994, EUR J PEDIATR, V153, P432; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Schwarz K, 1996, IMMUNOL TODAY, V17, P496, DOI 10.1016/0167-5699(96)30061-3; Steimle V, 1996, ADV IMMUNOL, V61, P327, DOI 10.1016/S0065-2776(08)60870-6; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEPHAN JL, 1993, J PEDIATR-US, V123, P564, DOI 10.1016/S0022-3476(05)80951-5; Stiehm E.R., 1996, IMMUNOLOGIC DISORDER; SULLIVAN KE, 1994, J PEDIATR-US, V125, P876, DOI 10.1016/S0022-3476(05)82002-5; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vihinen M, 1996, IMMUNOL TODAY, V17, P502, DOI 10.1016/0167-5699(96)30058-3; WEEMAES CMR, 1994, INT J RADIAT BIOL, V66, pS185; Winfield JB, 1997, CLIN EXP IMMUNOL, V109, P1, DOI 10.1046/j.1365-2249.1997.00439.x; WINKELSTEIN JA, 1995, METABOLIC BASIS INHE, P3912; Yel L, 1996, NEW ENGL J MED, V335, P1486, DOI 10.1056/NEJM199611143352003; ZHOU H, 1995, IMMUNITY, V2, P545, DOI 10.1016/1074-7613(95)90034-9	59	25	26	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1835	1841						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396644				2022-12-28	WOS:A1997YK15500005
J	Shu, SY; Plautz, GE; Krauss, JC; Chang, AE				Shu, SY; Plautz, GE; Krauss, JC; Chang, AE			Tumor immunology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFILTRATING LYMPHOCYTES; T-LYMPHOCYTES; ADOPTIVE IMMUNOTHERAPY; IN-VIVO; THERAPEUTIC EFFICACY; CANCER-IMMUNOTHERAPY; METASTATIC MELANOMA; ANTITUMOR IMMUNITY; MICE BEARING; CELLS	Malignant tumors express antigens that may stimulate and serve as targets for antitumor immunity. Virally induced tumors usually contain integrated proviral genomes in their cellular genomes and often express viral genome-encoded proteins that may stimulate specific host immune responses. Antigens unique to individual tumors that stimulate specific rejection of transplanted tumors have been demonstrated only in experimental animals. Other tumor antigens that potentially can stimulate immune responses are shared by different tumors. These include products of mutated or rearranged oncogenes or tumor-suppressor genes. Tumors may also overexpress tissue differentiation antigens or embryonic antigens, which also have the potential to be recognized by the immune system. The recent identification of tumor antigens recognized by cytotoxic T cells opens up new possibilities for constructing chemically defined antigens for specific immunotherapy. Treatment of malignant tumors in humans by immunologic approaches, although theoretically attractive, has not yet succeeded on a large scale. Important progress in immunotherapy of cancer is emerging with several different treatment modalities.	UNIV MICHIGAN, TAUBMAN CTR 2920K, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	Shu, SY (corresponding author), CLEVELAND CLIN FDN FF50, DIV SURG, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.							AALTOMAA S, 1992, EUR J CANCER, V28A, P859, DOI 10.1016/0959-8049(92)90134-N; BAST RC, 1974, NEW ENGL J MED, V290, P1413, DOI 10.1056/NEJM197406202902506; BAST RC, 1974, NEW ENGL J MED, V290, P1458, DOI 10.1056/NEJM197406272902605; Bocchia M, 1996, BLOOD, V87, P3587, DOI 10.1182/blood.V87.9.3587.bloodjournal8793587; BOON T, 1977, P NATL ACAD SCI USA, V74, P272, DOI 10.1073/pnas.74.1.272; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; CANAANI E, 1991, CHRONIC MYELOGENOU 3; CELIS E, 1994, P NATL ACAD SCI USA, V91, P2105, DOI 10.1073/pnas.91.6.2105; Chang AE, 1997, J CLIN ONCOL, V15, P796, DOI 10.1200/JCO.1997.15.2.796; CHANG AE, 1993, CANCER RES, V53, P1043; CHEEVER MA, 1995, IMMUNOL REV, V145, P33, DOI 10.1111/j.1600-065X.1995.tb00076.x; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CHEN W, 1992, P NATL ACAD SCI USA, V89, P1468, DOI 10.1073/pnas.89.4.1468; CONNOR J, 1993, J EXP MED, V177, P1127, DOI 10.1084/jem.177.4.1127; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Dudley ME, 1996, J EXP MED, V184, P441, DOI 10.1084/jem.184.2.441; FU YX, 1991, J IMMUNOL, V146, P783; GRIMM EA, 1983, J EXP MED, V158, P1356, DOI 10.1084/jem.158.4.1356; HEWITT HB, 1976, BRIT J CANCER, V33, P241, DOI 10.1038/bjc.1976.37; HOUBIERS JGA, 1993, EUR J IMMUNOL, V23, P2072, DOI 10.1002/eji.1830230905; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Huang AYC, 1996, J EXP MED, V183, P769, DOI 10.1084/jem.183.3.769; Kaminski MS, 1996, J CLIN ONCOL, V14, P1974, DOI 10.1200/JCO.1996.14.7.1974; KLARNET JP, 1989, J EXP MED, V169, P457, DOI 10.1084/jem.169.2.457; LEVINE AM, 1994, ANN ONCOL, V5, pS29, DOI 10.1093/annonc/5.suppl_2.S29; MATSUMURA T, 1994, CANCER RES, V54, P2744; McLaughlin JP, 1996, CANCER RES, V56, P2361; MILLER AR, 1994, ANN SURG ONCOL, V1, P436, DOI 10.1007/BF02303818; MORGAN DA, 1976, SCIENCE, V193, P1007, DOI 10.1126/science.181845; MURRAY JL, 1985, CANCER RES, V45, P2376; NORTH RJ, 1985, ADV CANCER RES, V45, P1, DOI 10.1016/S0065-230X(08)60265-1; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; PASTORFIDE GC, 1992, J CUTAN PATHOL, V19, P390, DOI 10.1111/j.1600-0560.1992.tb00611.x; PEACE DJ, 1993, J IMMUNOTHER, V14, P110, DOI 10.1097/00002371-199308000-00005; PORGADOR A, 1993, J IMMUNOL, V150, P1458; PREHN RT, 1957, J NATL CANCER I, V18, P769; ROSENBERG SA, 1986, ANNU REV IMMUNOL, V4, P681, DOI 10.1146/annurev.immunol.4.1.681; Rosenberg SA, 1996, J IMMUNOTHER, V19, P81, DOI 10.1097/00002371-199601000-00009; ROSENBERG SA, 1989, ANN SURG, V210, P474, DOI 10.1097/00000658-198910000-00008; ROSENBERG SA, 1994, J NATL CANCER I, V86, P1159, DOI 10.1093/jnci/86.15.1159; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291; SHU S, 1987, J IMMUNOL, V139, P295; SHU S, 1989, J IMMUNOL, V143, P740; SPIESS PJ, 1987, JNCI-J NATL CANCER I, V79, P1067; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; TSANG KY, 1995, J NATL CANCER I, V87, P982, DOI 10.1093/jnci/87.13.982; VANPEL A, 1995, IMMUNOL REV, V145, P229, DOI 10.1111/j.1600-065X.1995.tb00084.x; VIEWEG J, 1995, CANCER INVEST, V13, P193, DOI 10.3109/07357909509011690; VINUELA JE, 1991, INT J CANCER, V47, P86, DOI 10.1002/ijc.2910470116; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; YOSHIZAWA H, 1991, J IMMUNOL, V147, P729	53	56	59	2	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1972	1981		10.1001/jama.278.22.1972	http://dx.doi.org/10.1001/jama.278.22.1972			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396660				2022-12-28	WOS:A1997YK15500021
J	Chiu, AY; Perez, PE; Parker, RN				Chiu, AY; Perez, PE; Parker, RN			Impact of banning alcohol on outpatient visits in Barrow, Alaska	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AVAILABILITY; DRINKING; IOWA	Context.-Community availability of alcohol affects alcohol consumption patterns and alcohol-related health and social problems. In Barrow, Alaska, an isolated community at the northernmost reaches of the United States, during a 33-month period, possession and importation of alcohol were legal, completely banned, made legal again, and then banned again. Objective.-To determine the impact of these public policy changes on alcohol-related outpatient visits at the area hospital. Design.-Retrospective review of outpatient records; time-series analysis of alcohol-related visits with respect to community alcohol policy. Main Outcome Measures.-Total monthly outpatient visits for alcohol-related problems. Results.-There was a substantial decrease in the number of alcohol-related outpatient visits when the ban on possession and importation was imposed compared with baseline. When the ban was lifted, outpatient visits increased; when the ban was reimposed, the number of outpatient visits again decreased. Interrupted time-series analyses confirm that the alcohol ban, its lifting, and its reimposition had a statistically significant and negative effect on the number of alcohol-related outpatient visits (P<.05). Conclusion.-In a geographically isolated community, the prohibition of alcohol can be an effective public health intervention, reducing the health problems associated with alcohol use.	N SLOPE BOROUGH PHYS SERV,BARROW,AK; SAMUEL SIMMONDS MEM HOSP PHYS SERV,BARROW,AK; PREVENT RES CTR,BERKELEY,CA	Pacific Institute for Research & Evaluation (PIRE)					NIAAA NIH HHS [AA09146] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009146] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALBRECHT E, 1984, CIRCUMPOLAR HLTH 84, P327; [Anonymous], 1976, TIME SERIES ANAL; BONDY S, 1995, JAMA-J AM MED ASSOC, V274, P1832, DOI 10.1001/jama.274.23.1832; BROWER CD, 1942, 50 YEARS ZERO, P137; CAMPBELL DT, 1966, EXPT QUASI-EXPT DESI; Gruenewald PJ, 1996, ADDICTION, V91, P967, DOI 10.1111/j.1360-0443.1996.tb03594.x; HILD CM, 1981, CIRCUMPOLAR HLTH, V81, P502; HOLDER HD, 1990, BRIT J ADDICT, V85, P1615; HOLDER HD, 1988, CONT DRUG PROBL, V15, P47; LOFTIN C, 1982, AM SOCIOL REV, V47, P393, DOI 10.2307/2094995; MCCLEARY R, 1988, APPLIED TIME SERIES; OMALLEY PM, 1991, J STUD ALCOHOL, V52, P478, DOI 10.15288/jsa.1991.52.478; PARKER RN, 1997, ANN M KETT BRUUN SOC; Parker Robert N., 1995, ALCOHOL HOMICIDE DEA; SKOG OJ, 1986, BRIT J ADDICT, V81, P365; VINGILIS ER, 1979, J CRIM JUST, V12, P161; WAGENAAR AC, 1991, J STUD ALCOHOL, V52, P162, DOI 10.15288/jsa.1991.52.162; WAGENAAR AC, 1983, ALCOHOL YOUNG DRIVER; WOOD JB, 1996, BARROW RECLAMATION	19	29	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1775	1777		10.1001/jama.278.21.1775	http://dx.doi.org/10.1001/jama.278.21.1775			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YH987	9388156				2022-12-28	WOS:A1997YH98700034
J	Elena, SF; Lenski, RE				Elena, SF; Lenski, RE			Test of synergistic interactions among deleterious mutations in bacteria	NATURE			English	Article							ESCHERICHIA-COLI; EVOLUTION; FITNESS; SEX; ADAPTATION; ADVANTAGE	Identifying the forces responsible for the origin and maintenance of sexuality remains one of the greatest unsolved problems in biology(1-6). The mutational deterministic hypothesis postulates that sex is an adaptation that allows deleterious mutations to be purged from the genome; it requires synergistic interactions, which means that two mutations would be more harmful together than expected from their separate effects(4,5), We generated 225 genotypes of Escherichia coli carrying one, two or three successive mutations and measured their fitness relative to an unmutated competitor. The relationship between mutation number and average fitness is nearly log-linear, We also constructed 27 recombinant genotypes having pairs of mutations whose separate and combined effects on fitness were determined. Several pairs exhibit significant interactions for fitness, but they are antagonistic as often as they are synergistic These results do not support the mutational deterministic hypothesis for the evolution of sex.			Elena, SF (corresponding author), MICHIGAN STATE UNIV, CTR MICROBIAL ECOL, E LANSING, MI 48824 USA.		Elena, Santiago F./A-4191-2011	Elena, Santiago F./0000-0001-8249-5593; Lenski, Richard/0000-0002-1064-8375				Bell G., 1982, MASTERPIECE NATURE; CHAO L, 1988, J THEOR BIOL, V133, P99, DOI 10.1016/S0022-5193(88)80027-4; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; DEVISSER JAG, IN PRESS EVOLUTION; deVisser JAGM, 1996, P ROY SOC B-BIOL SCI, V263, P193, DOI 10.1098/rspb.1996.0031; ELENA SF, IN PRESS GENETICA; HAIGH J, 1978, THEOR POPUL BIOL, V14, P251, DOI 10.1016/0040-5809(78)90027-8; Hurst Laurence D., 1996, Trends in Ecology and Evolution, V11, P46, DOI 10.1016/0169-5347(96)81041-X; Kibota TT, 1996, NATURE, V381, P694, DOI 10.1038/381694a0; KIMURA M, 1966, GENETICS, V54, P1337; KITIGAWA O, 1969, GENETICS, V57, P809; KLECKNER N, 1991, METHOD ENZYMOL, V204, P139; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1993, J HERED, V84, P372, DOI 10.1093/oxfordjournals.jhered.a111358; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; MAYNARD SMITH J., 1978, EVOLUTION SEX; MUKAI T, 1969, GENETICS, V61, P749; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; Otto SP, 1997, THEOR POPUL BIOL, V51, P134, DOI 10.1006/tpbi.1997.1301; Redfield RJ, 1997, GENETICS, V146, P27; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; Sniegowski PD, 1997, NATURE, V387, P703, DOI 10.1038/42701; Sokal R. R, 1981, BIOMETRY; SPASSKY B, 1965, GENETICS, V52, P653; Williams G.C., 1975, Journal Cell Biol, VNo. 8, pi; WILLIS JH, 1993, EVOLUTION, V47, P864, DOI 10.2307/2410190; Zeyl C, 1997, NATURE, V388, P465, DOI 10.1038/41312; ZYSKIND J, 1989, RECOMBINANT DNA LAB	30	319	323	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 27	1997	390	6658					395	398		10.1038/37108	http://dx.doi.org/10.1038/37108			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389477				2022-12-28	WOS:A1997YH54900061
J	SchlagRey, M; Amador, N; Sanchez, H; Schlag, J				SchlagRey, M; Amador, N; Sanchez, H; Schlag, J			Antisaccade performance predicted by neuronal activity in the supplementary eye field	NATURE			English	Article							POSITRON EMISSION TOMOGRAPHY; RHESUS-MONKEYS; MOVEMENTS; SACCADES; CONNECTIONS; INITIATION; FIXATION; LESIONS; SYSTEM; GOAL	The voluntary control of gaze implies the ability to make saccadic eye movements specified by abstract instructions, as well as the ability to repress unwanted orientating to sudden stimuli, Both of these abilities are challenged in the antisaccade task, because it requires subjects to look at an unmarked location opposite to a dashed stimulus, without glancing at it(1,2). Performance on this task depends on the frontal/prefrontal cortex and related structures(3-8), but the neuronal operations underlying antisaccades are not understood. It is not known, for example, how excited visual neurons that normally trigger a saccade to a target (a prosaccade) can activate oculomotor neurons directing gaze in the opposite direction, Visual neurons might, perhaps, alter their receptive fields depending on whether they receive a pro-or antisaccade instruction, If the receptive field is not altered, the antisaccade goal must be computed and imposed from the top down to the appropriate oculomotor neurons. Here we show, using recordings from the supplementary eye field (a frontal cortex oculomotor centre) in monkeys, that visual and movement neurons retain the same spatial selectivity across randomly mixed pro-and antisaccade trials, However, these neurons consistently fire more before antisaccades than prosaccades with the same trajectories, suggesting a mechanism through which voluntary antisaccade commands can override reflexive glances.	UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	SchlagRey, M (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROBIOL,LOS ANGELES,CA 90095, USA.							BECKER W, 1979, VISION RES, V19, P967, DOI 10.1016/0042-6989(79)90222-0; Chen LTL, 1996, J NEUROSCI, V16, P3067; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FISCHER B, 1992, EXP BRAIN RES, V89, P415; FUNAHASHI S, 1993, NATURE, V365, P753, DOI 10.1038/365753a0; Goldberg ME, 1989, NEUROBIOLOGY SACCADI, P283; GUITTON D, 1985, EXP BRAIN RES, V58, P455; HALLETT PE, 1978, VISION RES, V18, P1279, DOI 10.1016/0042-6989(78)90218-3; Hanes DP, 1996, SCIENCE, V274, P427, DOI 10.1126/science.274.5286.427; HUERTA MF, 1990, J COMP NEUROL, V293, P299, DOI 10.1002/cne.902930211; ODRISCOLL GA, 1995, P NATL ACAD SCI USA, V92, P925, DOI 10.1073/pnas.92.3.925; Passingham RE., 1993, FRONTAL LOBES VOLUNT; PIERROTDESEILLIGNY C, 1991, BRAIN, V114, P1473, DOI 10.1093/brain/114.3.1473; REMINGTON RW, 1992, PERCEPT PSYCHOPHYS, V51, P279, DOI 10.3758/BF03212254; RUGG MC, 1995, ELECTROPHYSIOLOGY MI; Russo GS, 1996, J NEUROPHYSIOL, V76, P825, DOI 10.1152/jn.1996.76.2.825; SALZMAN CD, 1994, SCIENCE, V264, P231, DOI 10.1126/science.8146653; SCHALL JD, 1991, J NEUROPHYSIOL, V66, P530, DOI 10.1152/jn.1991.66.2.530; SCHILLER PH, 1987, J NEUROPHYSIOL, V57, P1033, DOI 10.1152/jn.1987.57.4.1033; SCHLAG J, 1987, J NEUROPHYSIOL, V57, P179, DOI 10.1152/jn.1987.57.1.179; SCHLAG J, 1992, EXP BRAIN RES, V90, P302; Schlag J., 1993, Society for Neuroscience Abstracts, V19, P785; SCHLAG J, IN PRESS J NEUROPHYS; SCHLAGREY M, 1992, J NEUROPHYSIOL, V67, P1003, DOI 10.1152/jn.1992.67.4.1003; SEGRAVES MA, 1993, J NEUROPHYSIOL, V69, P1880, DOI 10.1152/jn.1993.69.6.1880; SHOOK BL, 1990, J COMP NEUROL, V301, P618, DOI 10.1002/cne.903010410; Sweeney JA, 1996, J NEUROPHYSIOL, V75, P454, DOI 10.1152/jn.1996.75.1.454; Thompson KG, 1996, J NEUROPHYSIOL, V76, P4040, DOI 10.1152/jn.1996.76.6.4040; TIAN JR, 1991, NEUROLOGY, V41, P875, DOI 10.1212/WNL.41.6.875; Weber H, 1995, PERCEPTION, V24, P1265, DOI 10.1068/p241265	30	279	282	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					398	401		10.1038/37114	http://dx.doi.org/10.1038/37114			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389478				2022-12-28	WOS:A1997YH54900062
J	Mayho, P				Mayho, P			Multidrug resistant tuberculosis and HIV: a personal experience	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1317	1317		10.1136/bmj.315.7118.1317	http://dx.doi.org/10.1136/bmj.315.7118.1317			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390087	Green Published			2022-12-28	WOS:A1997YG64500076
J	Iezzoni, LI				Iezzoni, LI			Assessing quality using administrative data	ANNALS OF INTERNAL MEDICINE			English	Article							PROSPECTIVE-PAYMENT SYSTEM; MEDICARE PATIENTS; SEVERITY MEASURES; MORTALITY-RATES; HOSPITAL DEATH; DISCHARGE DATA; CABG SURGERY; HEALTH-CARE; OUTCOMES; DISEASE	Administrative data result from administering health care delivery, enrolling members into health insurance plans, and reimbursing for services. The primary producers of administrative data are the federal government, state governments, and private health care insurers. Although the clinical content of administrative data includes only the demographic characteristics and diagnoses of patients and codes for procedures, these data are often used to evaluate the quality of health care. Administrative data are readily available, are inexpensive to acquire, ape computer readable, and typically encompass large populations, They have identified startling practice variations across small geographic areas and supported research about outcomes of care. Many hospital report cards (which compare patient mortality rates) and physician profiles (which compare resource consumption) are derived from administrative data. However, gaps in clinical in-formation and the billing context compromise the ability to derive valid quality appraisals from administrative data. With some exceptions, administrative data allow limited insight into the quality of processes of care, errors of omission or commission, and the appropriateness of care. In addition, questions about the accuracy and completeness of administrative data abound. Current administrative data are probably most useful as screening tools that highlight areas in which quality should be investigated in greater depth. The growing availability of electronic clinical information will change the nature of administrative data in the future, enhancing opportunities for quality measurement.	HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard Medical School								BORZO G, 1996, AM MED NEWS     0729, V39, P4; BORZO G, 1996, AM MED NEWS     0722, V39, P7; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V42, P937, DOI 10.1016/0895-4356(89)90158-3; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; Brook RH, 1996, JAMA-J AM MED ASSOC, V276, P476, DOI 10.1001/jama.276.6.476; *BUR DAT MAN STRAT, 1995, DAT US REF GUID; *BUR DAT MAN STRAT, 1996, OV HLTH CAR FIN ADM; Cimino JJ, 1996, METHOD INFORM MED, V35, P273; *DARTM MED SCH CTR, 1996, DARTM ATL HLTH CAR; Donabedian A, 1980, EXPLORATIONS QUALITY, V1; DONALDSON MS, 1994, HLTH DATA INFORMATIO; Epstein M H, 1992, J AHIMA, V63, P32; Fowles J B, 1995, Health Care Financ Rev, V16, P189; GARNICK DW, 1996, J OUTCOMES MANAGE, V3, P18; GOLDFIELD N, 1996, PHYSICIAN PROFILING; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; Hannan EL, 1997, HEALTH SERV RES, V31, P659; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; HSIA DC, 1992, JAMA-J AM MED ASSOC, V268, P896, DOI 10.1001/jama.268.7.896; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; Hughes JS, 1996, J GEN INTERN MED, V11, P303, DOI 10.1007/BF02598273; IEZZONI L, 1987, RISK ADJUSTMENT MEAS; IEZZONI LI, 1995, ANN INTERN MED, V123, P763, DOI 10.7326/0003-4819-123-10-199511150-00004; Iezzoni LI, 1996, MED CARE, V34, P11, DOI 10.1097/00005650-199601000-00002; IEZZONI LI, 1995, INT J QUAL HEALTH C, V7, P81, DOI 10.1093/intqhc/7.2.81; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; Iezzoni LI, 1996, J GEN INTERN MED, V11, P23, DOI 10.1007/BF02603481; Iglehart JK, 1996, NEW ENGL J MED, V335, P995, DOI 10.1056/NEJM199609263351322; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; JOHNSSON J, 1996, AM MED NEWS     0624, V39, P28; KONG D, 1994, BOSTON GLOBE    1003, P6; KONG D, 1994, BOSTON GLOBE    1003, P7; KONG D, 1994, BOSTON GLOBE    1003, P1; KOSKA M, 1989, J AM HOSP ASS, V63, P24; KU L, 1990, HLTH CARE FINANCIN S, P35; Landon B, 1996, INQUIRY-J HEALTH CAR, V33, P155; LAVE JR, 1994, MED CARE, V32, pJS77; LOHR KN, 1988, INQUIRY-J HEALTH CAR, V25, P37; MCMAHON LF, 1986, ANN INTERN MED, V104, P562, DOI 10.7326/0003-4819-104-4-562; Meistrell M, 1996, MED CARE, V34, pMS91; MITCHELL JB, 1994, MED CARE, V32, pJS38; Payne T H, 1993, Proc Annu Symp Comput Appl Med Care, P705; PAYNE TH, 1993, P ANN S COMP APPL ME, P654; Romano PS, 1995, JOINT COMM J QUAL IM, V21, P668, DOI 10.1016/S1070-3241(16)30195-X; ROMANO PS, 1994, MED CARE, V32, P81, DOI 10.1097/00005650-199401000-00006; Roos LL, 1996, MED CARE, V34, P570, DOI 10.1097/00005650-199606000-00007; SHAPIRO MF, 1994, HEALTH SERV RES, V29, P95; SIMBORG DW, 1981, NEW ENGL J MED, V304, P1602, DOI 10.1056/NEJM198106253042611; STEEN PM, 1993, INQUIRY-J HEALTH CAR, V30, P128; *US C OFF TECHN AS, 1995, OTAITC624 US C OFF T; *US C OFF TECHN AS, 1994, OTAH608 US C OFF TEC; Waterstraat F L, 1990, J Am Med Rec Assoc, V61, P52; WEINER JP, 1995, JAMA-J AM MED ASSOC, V273, P1503, DOI 10.1001/jama.273.19.1503; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; WILSON P, 1996, 2 REPORT CALIFORNIA; YOUNG WW, 1994, HEALTH SERV RES, V29, P367; 1995, AM MED NEWS     0724, V38, P26	57	696	704	0	25	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				666	674		10.7326/0003-4819-127-8_Part_2-199710151-00048	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00048			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB385	9382378				2022-12-28	WOS:A1997YB38500003
J	Selby, JV				Selby, JV			Linking automated databases for research in managed care settings	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH MAINTENANCE ORGANIZATION; MYOCARDIAL-INFARCTION; RISK-ADJUSTMENT; CHRONIC DISEASE; MEDICAL-CARE; MORTALITY; POPULATION; CAPITATION; CALIFORNIA; OUTCOMES	Spurred by demands for data from employer-purchasers and accreditation agencies and the adoption of strategies for disease management and outcome-based quality assurance, managed care organizations have recognized the need for rapid, convenient access to clinical information. Large investments in administrative and clinical data systems have also produced unprecedented opportunities for research on health care and epidemiology in large, defined populations. There is a long history of contributions to research by investigators who are based in the older nonprofit group and staff models of health maintenance organizations (HMOs). Many of these organizations maintain research units that are primarily funded by outside sources. Research includes descriptive and etiologic studies of epidemiology, randomized and observational studies of the effectiveness of treatment regimens, studies of disease costs and estimation of cost-effectiveness, investigations of risk predictions in populations, of risk and changes in organizational behavior, and evaluations of interventions to alter physician and patient behavior. The work is often conducted in collaboration with academic researchers. The HMO Research Network has recently been established to foster a scientific exchange among HMO-based researchers. As managed care organizations come to provide health care coverage to most U.S. citizens, research conducted by these organizations increasingly overlaps with public health research. Collaboration between HMO-based research centers and researchers from academia and government will undoubtedly continue to increase.			Selby, JV (corresponding author), KAISER PERMANENTE MED CARE PROGRAM, DIV RES, 3505 BROADWAY, OAKLAND, CA 94611 USA.							ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BERNSTEIN SJ, 1992, PUBL RAND; CHERKIN DC, 1992, SOC SCI MED, V34, P33, DOI 10.1016/0277-9536(92)90064-W; CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004; COLLEN M F, 1990, Journal of Medical Systems, V14, P323, DOI 10.1007/BF00996713; COLLEN MF, 1990, HIST MED INFORMATICS, P290; CORRIGAN JM, 1995, MED CARE, V33, pJS18; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DONAHUE JG, 1995, ARCH INTERN MED, V155, P1605, DOI 10.1001/archinte.155.15.1605; DURHAM ML, 1994, GERONTOLOGIST, V34, P481, DOI 10.1093/geront/34.4.481; Epstein RS, 1996, ANN INTERN MED, V124, P832, DOI 10.7326/0003-4819-124-9-199605010-00008; ESCOBAR GJ, 1995, PEDIATRICS, V96, P918; Fowles JB, 1996, JAMA-J AM MED ASSOC, V276, P1316, DOI 10.1001/jama.276.16.1316; FRIEDMAN GD, 1981, NEW ENGL J MED, V304, P1407, DOI 10.1056/NEJM198106043042308; GLAUBER H, 1994, J CLIN EPIDEMIOL, V47, P1133, DOI 10.1016/0895-4356(94)90100-7; Hart IG, 1997, HEALTH AFFAIR, V16, P55, DOI 10.1377/hlthaff.16.1.55; Hornbrook MC, 1996, HEALTH SERV RES, V31, P283; HUNKELER EM, 1995, HMO PRACTICE, V9, P163; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; KRIEGER N, 1991, J EPIDEMIOL COMMUN H, V45, P35, DOI 10.1136/jech.45.1.35; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; LIEU TA, 1994, JAMA-J AM MED ASSOC, V271, P375, DOI 10.1001/jama.271.5.375; Luft HS, 1996, MILBANK Q, V74, P445, DOI 10.2307/3350389; MOSSEY JM, 1987, J CHRON DIS, V40, pS41, DOI 10.1016/S0021-9681(87)80031-0; Nerenz DR, 1996, J FAM PRACTICE, V42, P186; Nudelman PM, 1996, NEW ENGL J MED, V334, P1057, DOI 10.1056/NEJM199604183341611; ORDONEZ JD, 1990, AM J PUBLIC HEALTH, V80, P47, DOI 10.2105/AJPH.80.1.47; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; Petitti DB, 1996, NEW ENGL J MED, V335, P8, DOI 10.1056/NEJM199607043350102; PLATT R, 1990, NEW ENGL J MED, V322, P153, DOI 10.1056/NEJM199001183220303; PSATY BM, 1989, JAMA-J AM MED ASSOC, V261, P2087, DOI 10.1001/jama.261.14.2087; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; ROGERS WJ, 1994, CIRCULATION, V90, P2103, DOI 10.1161/01.CIR.90.4.2103; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; Selby JV, 1996, NEW ENGL J MED, V334, P635, DOI 10.1056/NEJM199603073341006; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; SELBY JV, 1997, IN PRESS DIABETES CA; Sennett C, 1996, HOSP PRACT, V31, P147; Simon GE, 1996, JAMA-J AM MED ASSOC, V275, P1897, DOI 10.1001/jama.275.24.1897; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G; WAGNER EH, 1995, MED CARE, V33, P765, DOI 10.1097/00005650-199508000-00002; Ware JE, 1993, SF36 HLTH SURVEY MAN; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WELCH WP, 1985, MED CARE, V23, P1234, DOI 10.1097/00005650-198511000-00002	45	134	134	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				719	724		10.7326/0003-4819-127-8_Part_2-199710151-00056	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00056			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB385	9382386				2022-12-28	WOS:A1997YB38500011
J	Weaver, WD; Simes, RJ; Betriu, A; Grines, CL; Zijlstra, F; Garcia, E; Grinfeld, L; Gibbons, RJ; Ribeiro, EE; DeWood, MA; Ribichini, F				Weaver, WD; Simes, RJ; Betriu, A; Grines, CL; Zijlstra, F; Garcia, E; Grinfeld, L; Gibbons, RJ; Ribeiro, EE; DeWood, MA; Ribichini, F			Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction - A quantitative review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							2X2 CONTINGENCY-TABLES; CLINICAL-TRIALS; IMMEDIATE ANGIOPLASTY; RANDOMIZED TRIAL; PUBLICATION BIAS; MORTALITY; STREPTOKINASE; REPERFUSION	Objective.-To provide a quantitative review of the treatment effects of primary coronary angioplasty vs intravenous thrombolysis for acute myocardial infarction. Data Sources.-Ten randomized trials were identified through computerized bibliographic search of MEDLINE from January 1985 through March 1996 and by queries of principal investigators. Study Selection.-Single-center and multicenter randomized trials comparing primary angioplasty with intravenous thrombolytic therapy among 2606 patients were included. Four trials compared angioplasty with streptokinase, 3 compared angioplasty with a 3- to 4-hour infusion of tissue-type plasminogen activator, and 3 compared angioplasty with ''accelerated'' administration of tissue-type plasminogen activator over 90 minutes. Data Extraction.-Each investigator provided definitions and exact data for outcome events. Odds ratios (ORs), 95% confidence intervals (CIs), and P values were calculated using exact tests for categorical data. Data Synthesis.-Mortality at 30 days or less was 4.4% for the 1290 patients treated with primary angioplasty compared with 6.5% for the 1316 patients treated with thrombolysis (34% reduction; OR, 0.66; 95% CI, 0.46-0.94; P=.02). The effect was similar among thrombolytic regimens, and no subgroup demonstrated a significant reduction in death. The rates of death or nonfatal reinfarction were 7.2% for angioplasty and 11.9% for thrombolytic therapy (OR, 0.58; 95% CI, 0.44-0.76; P<.001). Angioplasty was associated with a significant reduction in total stroke (0.7% vs 2.0%; P=.007) and hemorrhagic stroke (0.1% vs 1.1%; P<.001). Conclusions.-Based on outcomes at hospital discharge or 30 days, primary angioplasty appears to be superior to thrombolytic therapy for treatment of patients with acute myocardial infarction, with the proviso that success rates for angioplasty are as good as those achieved in these trials. Data evaluating longer-term outcomes, operator experience, and time delay before treatment are needed before primary angioplasty can be universally recommended as the preferred treatment.	NATL HLTH & MED RES COUNCIL CLIN TRIALS CTR, SYDNEY, NSW, AUSTRALIA; HOSP CLIN BARCELONA, BARCELONA, SPAIN; WILLIAM BEAUMONT HOSP, ROYAL OAK, MI 48072 USA; ZIEKENHUIS DE WEEZENLANDEN, ZWOLLE, NETHERLANDS; HOSP GEN GREGORIO MARANON, E-28007 MADRID, SPAIN; HOSP ITALIANO BUENOS AIRES, BUENOS AIRES, DF, ARGENTINA; MAYO CLIN, ROCHESTER, MN USA; UNICOR HOSP, SAO PAULO, BRAZIL; SPOKANE HEART RES FDN, SPOKANE, WA USA; OSPED SANTA CROCE, CUNEO, ITALY	University of Sydney; University of Barcelona; Hospital Clinic de Barcelona; Beaumont Health; General University Gregorio Maranon Hospital; Hospital Italiano de Buenos Aires; University of Buenos Aires; Mayo Clinic	Weaver, WD (corresponding author), HENRY FORD HLTH SYST, INST HEART & VASC, 2799 W GRAND BLVD, DETROIT, MI 48202 USA.		Ribichini, Flavio/AAB-7767-2022					Akhras F., 1997, Journal of the American College of Cardiology, V29, p235A; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BERLIN JA, 1989, J AM STAT ASSOC, V84, P381; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Braunwald E, 1996, J AM COLL CARDIOL, V27, P1333, DOI 10.1016/0735-1097(96)00007-1; Caputo Ronald P., 1996, Journal of the American College of Cardiology, V27, p62A; DEBOER MJ, 1995, AM J CARDIOL, V76, P830, DOI 10.1016/S0002-9149(99)80238-0; DEWOOD MA, 1990, P THROMB INT THER AC, P28; ELIZAGA J, 1993, CIRCULATION, V88, P411; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; Garcia E., 1997, Journal of the American College of Cardiology, V29, p389A; GERSH BJ, 1993, CIRCULATION, V88, P296, DOI 10.1161/01.CIR.88.1.296; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GOLDMAN L, 1995, J AM COLL CARDIOL, V25, pS38; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Grinfeld Liliana, 1996, Journal of the American College of Cardiology, V27, p222A; Jhangiani Anil H., 1996, Journal of the American College of Cardiology, V27, p61A; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARK DB, 1995, J AM COLL CARDIOL, V26, P688, DOI 10.1016/0735-1097(95)00246-Z; MEHTA C, 1991, STAT SOFTWARE EXACT; MEHTA CR, 1992, AM STAT, V46, P146, DOI 10.2307/2684185; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MICHELS KB, 1995, CIRCULATION, V91, P476, DOI 10.1161/01.CIR.91.2.476; OKEEFE JH, 1993, AM J CARDIOL, V72, pG107, DOI 10.1016/0002-9149(93)90115-S; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; Ribeiro EE, 1993, J AM COLL CARDIOL, V22, P376, DOI 10.1016/0735-1097(93)90040-8; Ribichini Flavio, 1996, Journal of the American College of Cardiology, V27, p221A; SIMES RJ, 1995, CIRCULATION, V91, P1923, DOI 10.1161/01.CIR.91.7.1923; SIMES RJ, 1987, STAT MED, V6, P11, DOI 10.1002/sim.4780060104; Stone GW, 1996, CIRCULATION, V94, P3336; STONE GW, 1995, J AM COLL CARDIOL, V26, P66, DOI 10.1016/0735-1097(95)00138-P; Stone GW, 1997, J AM COLL CARDIOL, V29, P901, DOI 10.1016/S0735-1097(97)00041-7; TIEFENBRUNN AJ, 1996, CIRCULATION S1, V92, P138; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; Zahn R, 1997, J AM COLL CARDIOL, V29, P90311; ZELEN M, 1971, BIOMETRIKA, V58, P129, DOI 10.1093/biomet/58.1.129; Zijlstra F, 1997, J AM COLL CARDIOL, V29, P908, DOI 10.1016/S0735-1097(97)00018-1; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	42	732	778	0	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2093	2098		10.1001/jama.278.23.2093	http://dx.doi.org/10.1001/jama.278.23.2093			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403425				2022-12-28	WOS:A1997YK98700040
J	Salpeter, SR; Sanders, GD; Salpeter, EE; Owens, DK				Salpeter, SR; Sanders, GD; Salpeter, EE; Owens, DK			Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: A risk-benefit and cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article							PREVENTIVE THERAPY; DECISION-ANALYSIS; UNITED-STATES; YOUNG-ADULTS; SKIN-TEST; CHEMOPROPHYLAXIS; HEPATITIS; LIVER; INFECTION; CHILDREN	Background: Isoniazid chemoprophylaxis effectively prevents the development of active infectious tuberculosis. Current guidelines recommend withholding this prophylaxis for low-risk tuberculin reactors older than 35 years of age because of the risk for fatal isoniazid-induced hepatitis. However, recent studies have shown that monitoring for hepatotoxicity can significantly reduce the risk for isoniazid-related death. Objective: To evaluate the effectiveness and cost-effectiveness of monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age. Design: A Markov model was used to compare the health and economic outcomes of prescribing or withholding a course of prophylaxis for low-risk reactors 35, 50, or 70 years of age. Subsequent analyses evaluated costs and benefits when the effect of transmission of Mycobacterium tuberculosis to contacts was included. Measurements: Probability of survival at 1 year, number needed to treat, life expectancy, and cost per year of life gained for individual persons and total population. Results: Isoniazid prophylaxis increased the probability of survival at 1 year and for all subsequent years. For 35-year-old, 50-year-old, and 70-year-old tuberculin reactors, life expectancy increased by 4.9 days, 4.7 days, and 3.1 days, respectively, and costs per person decreased by $101, $69, and $11, respectively. When the effect of secondary transmission to contacts was included, the gains in life expectancy per person receiving prophylaxis were 10.0 days for 35-year-old reactors, 9.0 days for 50-year-old reactors, and 6.0 days for 70-year-old reactors. Costs per person for these cohorts decreased by $259, $203, and $100, respectively. The magnitude of the benefit of isoniazid prophylaxis is moderately sensitive to the effect of isoniazid on quality of life. The hypothetical provision of isoniazid prophylaxis for all low-risk reactors older than 35 years of age in the U.S. population could prevent 35 176 deaths and save $2.11 billion. Conclusions: Monitored isoniazid prophylaxis reduces mortality rates and health care costs for low-risk tuberculin reactors older than 35 years of age, although reductions for individual patients are small. For the U.S. population, however, the potential health benefits and economic savings resulting from wider use of monitored isoniazid prophylaxis are substantial. We should consider expanding current recommendations to include prophylaxis for tuberculin reactors of all ages with no contraindications.	Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; Stanford Univ, Sch Med, Sect Med Informat, Stanford, CA 94305 USA; Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA	Santa Clara Valley Medical Center; Stanford University; Cornell University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Salpeter, EE (corresponding author), Santa Clara Valley Med Ctr, 2400 Moorpark Ave,Suite 118, San Jose, CA 95128 USA.							ALCABES P, 1989, AM REV RESPIR DIS, V140, P1194, DOI 10.1164/ajrccm/140.5.1194; *AM MED ASS, 1995, PHYS CURR PROC TERM; *AM MED ASS, 1996, MED RBRVS PHYS GUID; BAILEY TC, 1995, ANN INTERN MED, V122, P580, DOI 10.7326/0003-4819-122-8-199504150-00004; BAILEY WC, 1983, AM REV RESPIR DIS, V127, P790; BAILEY WC, 1974, ANN INTERN MED, V81, P200, DOI 10.7326/0003-4819-81-2-200; BAILEY WC, 1973, AM REV RESPIR DIS, V107, P523, DOI 10.1164/arrd.1973.107.4.523; BAILEY WC, 1985, CHEST, V87, pS128; BARLOW PB, 1974, AM REV RESPIR DIS, V110, P371; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BARNES PF, 1993, ANN INTERN MED, V119, P400, DOI 10.7326/0003-4819-119-5-199309010-00009; BEAUDRY PH, 1974, AM REV RESPIR DIS, V110, P581; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BLACK M, 1975, GASTROENTEROLOGY, V69, P289; BLUM RN, 1993, CHEST, V103, P1670, DOI 10.1378/chest.103.6.1670; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; BURRILL D, 1985, CAN MED ASSOC J, V132, P137; BYRD RB, 1979, JAMA-J AM MED ASSOC, V241, P1239, DOI 10.1001/jama.241.12.1239; BYRD RB, 1972, J AMER MED ASSOC, V220, P1471, DOI 10.1001/jama.1972.03200110051009; *CDC, 1994, COR CURR TUB, P13; *CDC, 1992, TUB US, P67; *CDC, 1991, TUB US, P14; *CDC PREV, 1996, REP TUB US 1995, P5; COLICE GL, 1990, ARCH INTERN MED, V150, P2517, DOI 10.1001/archinte.150.12.2517; COMSTOCK GW, 1976, PUBLIC HEALTH REP, V91, P276; COMSTOCK GW, 1967, AM REV RESPIR DIS, V95, P935; COMSTOCK GW, 1975, AM J EPIDEMIOL, V101, P363, DOI 10.1093/oxfordjournals.aje.a112105; COMSTOCK GW, 1974, AM REV RESPIR DIS, V110, P195; COMSTOCK GW, 1981, ANN INTERN MED, V94, P817, DOI 10.7326/0003-4819-94-6-817; COOPER JK, 1986, J AM GERIATR SOC, V34, P814, DOI 10.1111/j.1532-5415.1986.tb03988.x; CULLINAN P, 1991, THORAX, V46, P347, DOI 10.1136/thx.46.5.347; DASH LA, 1980, AM REV RESPIR DIS, V121, P1039; DICKINSON DS, 1981, J CLIN GASTROENTEROL, V3, P271, DOI 10.1097/00004836-198109000-00012; DOLAN JG, 1994, MED DECIS MAKING, V14, P1, DOI 10.1177/0272989X9401400101; FEREBEE SH, 1963, AM REV RESPIR DIS, V88, P161; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; FITZGERALD JM, 1990, AM REV RESPIR DIS, V142, P848, DOI 10.1164/ajrccm/142.4.848; FITZGERALD JM, 1990, AM REV RESPIR DIS, V1415, pA438; FRANKS AL, 1989, PUBLIC HEALTH REP, V104, P151; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; GARIBALDI RA, 1972, AM REV RESPIR DIS, V106, P357, DOI 10.1164/arrd.1972.106.3.357; GIRLING DJ, 1992, AM REV RESPIR DIS, V145, P36; GLASSROTH J, 1990, AM REV RESPIR DIS, V141, P1236, DOI 10.1164/ajrccm/141.5_Pt_1.1236; GOLD MR, 1996, COST EFFECTIVENESS H, P214; GRZYBOWSKI S, 1976, CAN MED ASSOC J, V114, P607; GRZYBOWSKI S, 1969, CAN MED ASSOC J, V101, P555; GURUMURTHY P, 1984, AM REV RESPIR DIS, V129, P58; HANSON ML, 1967, PUBLIC HEALTH REP, V82, P1045, DOI 10.2307/4593193; *HLTH CAR INV AN I, 1996, MED DRG HDB; HORWITZ O, 1969, B WORLD HEALTH ORGAN, V41, P95; HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P46, DOI 10.1080/00039896.1968.10665013; HSU KHK, 1974, JAMA-J AM MED ASSOC, V229, P528, DOI 10.1001/jama.229.5.528; Jordan T J, 1990, Bull Int Union Tuberc Lung Dis, V66 Suppl, P21; JORDAN TJ, 1991, AM REV RESPIR DIS, V144, P1357, DOI 10.1164/ajrccm/144.6.1357; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; KULLER LH, 1974, PREV MED, V3, P61, DOI 10.1016/0091-7435(74)90063-2; LEVIN ML, 1974, MARYLAND STATE MED J, V23, P64; LITT IF, 1976, J PEDIATR-US, V89, P133, DOI 10.1016/S0022-3476(76)80949-3; MACKAY AD, 1984, Q J MED, V53, P497; MADDREY WC, 1973, ANN INTERN MED, V79, P1, DOI 10.7326/0003-4819-79-1-1; *MED, 1997, FEE COD STAND; MEHTA JB, 1988, CHEST, V94, P138, DOI 10.1378/chest.94.1.138; Millard PS, 1996, WESTERN J MED, V164, P486; MITCHELL JR, 1975, CHEST, V68, P181, DOI 10.1378/chest.68.2.181; MOHLEBOETANI JC, 1995, JAMA-J AM MED ASSOC, V274, P613, DOI 10.1001/jama.274.8.613; MORI MA, 1992, ARCH INTERN MED, V152, P547, DOI 10.1001/archinte.152.3.547; NAKAJO MM, 1989, PEDIATR INFECT DIS J, V8, P649, DOI 10.1097/00006454-198909000-00019; *NAT CTR HLTH STAT, 1995, MONTHL VIT STAT REP; *NAT CTR HLTH STAT, 1991, VIT STAT US 1988 A, V2; NAZAR V, 1990, American Review of Respiratory Disease, V141, pA438; NOLAN CM, 1986, AM REV RESPIR DIS, V133, P431; OBRIEN RJ, 1990, AM REV RESPIR DIS, V141, P821, DOI 10.1164/ajrccm/141.4_Pt_1.821; Protection against viral hepatitis, 1990, MMWR RECOMM REP, V39, P1; Quillan S, 1990, J Am Coll Health, V38, P165; Rabindran E, 1991, Md Med J, V40, P793; RAPP RS, 1978, AM REV RESPIR DIS, V118, P794, DOI 10.1164/arrd.1978.118.4.794; ROSE DN, 1986, JAMA-J AM MED ASSOC, V256, P2709, DOI 10.1001/jama.256.19.2709; ROSENBERG T, 1993, AM REV RESPIR DIS, V148, P1537, DOI 10.1164/ajrccm/148.6_Pt_1.1537; SALPETER EE, IN PRESS AM J EPIDEM; SALPETER S, 1992, WESTERN J MED, V157, P421; SALPETER SR, 1993, WESTERN J MED, V159, P560; SCHARER L, 1969, ANN INTERN MED, V71, P1113, DOI 10.7326/0003-4819-71-6-1113; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SPYRIDIS P, 1979, ARCH DIS CHILD, V54, P65, DOI 10.1136/adc.54.1.65; STEAD WW, 1987, ANN INTERN MED, V107, P843, DOI 10.7326/0003-4819-107-6-843; STERLING TR, 1995, ARCH INTERN MED, V155, P1622, DOI 10.1001/archinte.155.15.1622; TAYLOR WC, 1981, ANN INTERN MED, V94, P808, DOI 10.7326/0003-4819-94-6-808; THOMAS PA, 1979, ARCH SURG-CHICAGO, V114, P597; THOMPSON JE, 1978, MED J AUSTRALIA, V1, P165, DOI 10.5694/j.1326-5377.1978.tb107815.x; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; TRUMP DH, 1993, ARCH INTERN MED, V153, P211, DOI 10.1001/archinte.153.2.211; TSEVAT J, 1988, AM REV RESPIR DIS, V137, P215, DOI 10.1164/ajrccm/137.1.215; VADASZ I, 1974, Bulletin of the International Union Against Tuberculosis, V49, P294; WADHAWAN D, 1990, P ABSTR 6 INT C AIDS, V1, pA249; 1980, MMWR MORB MORTAL WKL, V29, P589; 1997, EC REPORT PRESIDENT; [No title captured]	97	86	87	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1051	1061		10.7326/0003-4819-127-12-199712150-00001	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00001			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412307				2022-12-28	WOS:000070936600001
J	Yaffe, MB; Schutkowski, M; Shen, MH; Zhou, XZ; Stukenberg, PT; Rahfeld, JU; Xu, J; Kuang, J; Kirschner, MW; Fischer, G; Cantley, LC; Lu, KP				Yaffe, MB; Schutkowski, M; Shen, MH; Zhou, XZ; Stukenberg, PT; Rahfeld, JU; Xu, J; Kuang, J; Kirschner, MW; Fischer, G; Cantley, LC; Lu, KP			Sequence-specific and phosphorylation-dependent proline isomerization: A potential mitotic regulatory mechanism	SCIENCE			English	Article							PROLYL CIS/TRANS ISOMERASES; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; CELL-CYCLE; M-PHASE; MITOSIS; FAMILY; ASSOCIATION; ANTIBODY; BINDING	Pin1 is an essential and conserved mitotic peptidyl-prolyl isomerase (PPlase) that is distinct from members of two other families of conventional PPlases, cyclophilins and FKBPs (FK-506 binding proteins). In response to their phosphorylation during mitosis, Pin1 binds and regulates members of a highly conserved set of protein; that overlaps with antigens recognized by the mitosis-specific monoclonal antibody MPM-2. Pin1 is here shown to be a phosphorylation-dependent PPlase that specifically recognizes the phosphoserine-proline or phosphothreonine-proline bonds present in mitotic phosphoproteins. Both Pin1 and MPM-2 selected similar phosphorylated serine-proline-containing peptides, providing the basis for the specific interaction between Pin1 and MPM-2 antigens. Pin1 preferentially isomerized proline residues preceded by phosphorylated serine or threonine with up to 1300-fold selectivity compared with unphosphorylated peptides. Pin1 may thus regulate mitotic progression by catalyzing sequence-specific and phosphorylation-dependent proline isomerization.	BETH ISRAEL DEACONESS MED CTR, DEPT MED, DIV HEMATOL ONCOL, CANC BIOL PROGRAM, BOSTON, MA 02215 USA; BETH ISRAEL DEACONESS MED CTR, DIV SIGNAL TRANSDUCT, DEPT MED, BOSTON, MA 02215 USA; BETH ISRAEL DEACONESS MED CTR, DEPT SURG, BOSTON, MA 02215 USA; MAX PLANCK RES UNIT ENZYMOL PROT FOLDING, D-06120 HALLE, GERMANY; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CLIN INVEST, HOUSTON, TX 77030 USA; HARVARD UNIV, SCH MED, DIV AGING, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Max Planck Society; Harvard University; Harvard Medical School; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Harvard Medical School			Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Schutkowski, MIke/0000-0003-0919-7076; Stukenberg, Todd/0000-0002-6788-2111	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056230, R01GM056203] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056203, GM56230, GM56203] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BERNHARDT A, 1997, INT J PEPT PROT RES, V50, P143; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFRON JL, 1991, BIOCHEMISTRY-US, V30, P6127, DOI 10.1021/bi00239a007; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lu KP, 1996, NATURE, V380, P544; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; RAHFELD JU, 1994, FEBS LETT, V352, P180, DOI 10.1016/0014-5793(94)00932-5; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; RUDD KE, 1995, TRENDS BIOCHEM SCI, V20, P12, DOI 10.1016/S0968-0004(00)88940-9; SCHMID FX, 1995, CURR BIOL, V5, P993, DOI 10.1016/S0960-9822(95)00197-7; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHUTKOWSKI M, 1995, BIOCHEMISTRY-US, V34, P13016, DOI 10.1021/bi00040a012; SHEN M, UNPUB; TAAGEPERA S, 1994, MOL BIOL CELL, V5, P1243, DOI 10.1091/mbc.5.11.1243; VOLINIA S, UNPUB; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	671	700	2	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 12	1997	278	5345					1957	1960		10.1126/science.278.5345.1957	http://dx.doi.org/10.1126/science.278.5345.1957			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395400				2022-12-28	WOS:A1997YL00200038
J	Hillberg, RE; Johnson, DC				Hillberg, RE; Johnson, DC			Current concepts - Noninvasive ventilation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							POSITIVE-PRESSURE VENTILATION; ACUTE RESPIRATORY-FAILURE; CONGESTIVE-HEART-FAILURE; OBSTRUCTIVE PULMONARY-DISEASE; NOCTURNAL NASAL VENTILATION; CHEYNE-STOKES RESPIRATION; TERM FOLLOW-UP; MECHANICAL VENTILATION; AIRWAY PRESSURE; SUPPORT VENTILATION		HARVARD UNIV,SCH MED,BOSTON,MA 02138; MASSACHUSETTS GEN HOSP,DEPT MED,PULM & CRIT CARE UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Hillberg, RE (corresponding author), SPAULDING REHABIL HOSP,DEPT RESP SERV,BOSTON,MA 02114, USA.							AbouShala N, 1996, CRIT CARE MED, V24, P705, DOI 10.1097/00003246-199604000-00025; Ambrosino N, 1996, EUR RESPIR J, V9, P795, DOI 10.1183/09031936.96.09040795; AMBROSINO N, 1992, CHEST, V101, P385, DOI 10.1378/chest.101.2.385; AMBROSINO N, 1992, EUR RESPIR REV, V2, P353; APPENDINI L, 1994, AM J RESP CRIT CARE, V149, P1069, DOI 10.1164/ajrccm.149.5.8173743; Bach J R, 1995, Monaldi Arch Chest Dis, V50, P223; BACH JR, 1987, CHEST, V92, P168, DOI 10.1378/chest.92.1.168; BACH JR, 1990, CHEST, V97, P52, DOI 10.1378/chest.97.1.52; BENHAMOU D, 1992, CHEST, V102, P912, DOI 10.1378/chest.102.3.912; BERGOFSKY EH, 1979, AM REV RESPIR DIS, V119, P643; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; BLACK JW, 1988, CHEST, V93, P333, DOI 10.1378/chest.93.2.333; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BRADLEY TD, 1992, AM REV RESPIR DIS, V145, P377, DOI 10.1164/ajrccm/145.2_Pt_1.377; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; Claman DM, 1996, CHEST, V110, P1581, DOI 10.1378/chest.110.6.1581; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; CONFALONIERI M, 1994, RESPIRATION, V61, P310; Confalonieri M, 1996, EUR RESPIR J, V9, P422, DOI 10.1183/09031936.96.09030422; Corrado A, 1996, EUR RESPIR J, V9, P1531, DOI 10.1183/09031936.96.09071531; CURRAN FJ, 1981, ARCH PHYS MED REHAB, V62, P270; ELLIOTT MW, 1993, ANAESTHESIA, V48, P8; ELLIS ER, 1988, CHEST, V94, P811, DOI 10.1378/chest.94.4.811; FERGUSON GT, 1995, AM J RESP CRIT CARE, V151, P1126; FOGLIO C, 1992, CHEST, V101, P1533, DOI 10.1378/chest.101.6.1533; GARAY SM, 1981, AM J MED, V70, P269, DOI 10.1016/0002-9343(81)90761-0; GAY PC, 1991, MAYO CLIN PROC, V66, P695, DOI 10.1016/S0025-6196(12)62081-3; GOLDBERG P, 1995, EUR RESPIR J, V8, P1894, DOI 10.1183/09031936.95.08111894; GOLDSTEIN RS, 1987, AM REV RESPIR DIS, V135, P1049; Hanly PJ, 1996, AM J RESP CRIT CARE, V153, P272, DOI 10.1164/ajrccm.153.1.8542128; HILL NS, 1993, AM REV RESPIR DIS, V147, P1050, DOI 10.1164/ajrccm/147.4.1050; HILL NS, 1992, AM REV RESPIR DIS, V145, P365, DOI 10.1164/ajrccm/145.2_Pt_1.365; HILL NS, 1986, CHEST, V90, P897, DOI 10.1378/chest.90.6.897; HOO GWS, 1994, CRIT CARE MED, V22, P1253, DOI 10.1097/00003246-199408000-00009; HORMANN C, 1994, EUR J ANAESTH, V11, P37; JAVAHERI S, 1995, ANN INTERN MED, V123, P77; JAVAHERI S, 1995, ANN INTERN MED, V122, P487, DOI 10.7326/0003-4819-122-7-199504010-00002; JONES DJM, 1995, AM J RESP CRIT CARE, V152, P538; JUBRAN A, 1995, AM J RESP CRIT CARE, V152, P129, DOI 10.1164/ajrccm.152.1.7599811; KRAMER N, 1995, AM J RESP CRIT CARE, V151, P1799, DOI 10.1164/ajrccm.151.6.7767523; LAPINSKY SE, 1994, CHEST, V105, P229, DOI 10.1378/chest.105.1.229; LEGER P, 1989, Respiratory Care, V34, P73; LEGER P, 1994, CHEST, V105, P100, DOI 10.1378/chest.105.1.100; LIN M, 1995, CHEST, V107, P1379, DOI 10.1378/chest.107.5.1379; LOFASO F, 1995, CHEST, V108, P772, DOI 10.1378/chest.108.3.772; Lofaso F, 1996, AM J RESP CRIT CARE, V153, P1591, DOI 10.1164/ajrccm.153.5.8630607; MARINO W, 1991, CHEST, V99, P681, DOI 10.1378/chest.99.3.681; Masa JF, 1997, CHEST, V112, P207, DOI 10.1378/chest.112.1.207; Meduri GU, 1996, CHEST, V110, P767, DOI 10.1378/chest.110.3.767; Meduri GU, 1996, CHEST, V109, P179, DOI 10.1378/chest.109.1.179; Meduri GU, 1996, CLIN CHEST MED, V17, P513, DOI 10.1016/S0272-5231(05)70330-0; Mehta S, 1997, CRIT CARE MED, V25, P620, DOI 10.1097/00003246-199704000-00011; MEYER TJ, 1994, ANN INTERN MED, V120, P760, DOI 10.7326/0003-4819-120-9-199405010-00008; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V152, P473, DOI 10.1164/ajrccm.152.2.7633695; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V151, P92, DOI 10.1164/ajrccm.151.1.7812579; NAVA S, 1990, CHEST, V98, P857, DOI 10.1378/chest.98.4.857; PINTO AC, 1995, J NEUROL SCI, V129, P19, DOI 10.1016/0022-510X(95)00052-4; Pollack CV, 1996, ANN EMERG MED, V27, P189, DOI 10.1016/S0196-0644(96)70321-9; Quaranta AJ, 1997, CHEST, V111, P467, DOI 10.1378/chest.111.2.467; RENSTON JP, 1994, CHEST, V105, P1053, DOI 10.1378/chest.105.4.1053; SACCHETTI AD, 1995, ACAD EMERG MED, V2, P714, DOI 10.1111/j.1553-2712.1995.tb03623.x; SHAPIRO SH, 1992, LANCET, V340, P1425, DOI 10.1016/0140-6736(92)92620-U; SOMERS VK, 1993, NEW ENGL J MED, V328, P303, DOI 10.1056/NEJM199302043280502; Soudon P, 1995, Monaldi Arch Chest Dis, V50, P228; Spessert C K, 1993, Am J Crit Care, V2, P54; STRUMPF DA, 1991, AM REV RESPIR DIS, V144, P1234, DOI 10.1164/ajrccm/144.6.1234; TAKASAKI Y, 1989, AM REV RESPIR DIS, V140, P1578, DOI 10.1164/ajrccm/140.6.1578; UNTERBORN JN, 1994, CLIN CHEST MED, V15, P765; Vitacca M, 1996, INTENS CARE MED, V22, P94, DOI 10.1007/BF01720714	70	102	107	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1746	1752		10.1056/NEJM199712113372407	http://dx.doi.org/10.1056/NEJM199712113372407			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK653	9392701				2022-12-28	WOS:A1997YK65300007
J	Livesey, FJ; OBrien, JA; Li, M; Smith, AG; Murphy, LJ; Hunt, SP				Livesey, FJ; OBrien, JA; Li, M; Smith, AG; Murphy, LJ; Hunt, SP			A Schwann cell mitogen accompanying regeneration of motor neurons	NATURE			English	Article							PANCREATITIS-ASSOCIATED PROTEIN; SPINAL MOTONEURONS; SENSORY NEURONS; MESSENGER-RNA; EXPRESSION; RECEPTOR; RAT; IDENTIFICATION; SURVIVAL; AXOTOMY	Motor neurons are the only adult mammalian neurons of the central nervous system to regenerate following injury(1). This ability is dependent on the environment of the peripheral nerve and an intrinsic capacity of motor neurons for regrowth(2). We report here the identification, using a technique known as messenger RNA differential display(3), of an extracellular signalling molecule, previously described as the pancreatic secreted protein Reg-2 (ref. 4), that is expressed solely in regenerating and developing rat motor and sensory neurons. Axon-stimulated Schwann cell proliferation is necessary for successful regeneration(5,6), and we show that Reg-2 is a potent Schwann cell mitogen in vitro. In vivo, Reg-2 protein is transported along regrowing axons and inhibition of Reg-2 signalling significantly retards the regeneration of Reg-2-containing axons. During development, Reg-2 production by motor and sensory neurons is regulated by contact with peripheral targets. Strong candidates for peripheral factors regulating Reg-2 production are cytokines of the LIF/CNTF family, because Reg-2 is not exp,ressed in developing motor or sensory neurons of mice carrying a targeted disruption of the LIF receptor gene, a common component of the receptor complexes for all of the LIF/CNTF family(7).	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV EDINBURGH,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND; UNIV MANITOBA,DEPT INTERNAL MED,WINNIPEG,MB R3E 3J7,CANADA; UNIV MANITOBA,DEPT PHYSIOL,WINNIPEG,MB R3E 3J7,CANADA	MRC Laboratory Molecular Biology; University of Edinburgh; University of Manitoba; University of Manitoba			HUNT, STEPHEN P/C-1646-2008; Li, Meng/I-6941-2013	Smith, Austin/0000-0002-3029-4682; Hunt, Stephen/0000-0001-9453-5505; Livesey, Rick/0000-0001-6128-3372				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANNER LR, 1994, P NATL ACAD SCI USA, V91, P7109, DOI 10.1073/pnas.91.15.7109; Carroll SL, 1997, J NEUROSCI, V17, P1642; CHAKRABORTY C, 1995, J ENDOCRINOL, V145, P461, DOI 10.1677/joe.0.1450461; DEFELIPE C, 1994, J NEUROSCI, V14, P2911; DELAMONTE SM, 1990, J CLIN INVEST, V86, P1004, DOI 10.1172/JCI114762; DUMOULIN FL, 1991, EUR J NEUROSCI, V3, P338, DOI 10.1111/j.1460-9568.1991.tb00820.x; DUSETTI NJ, 1995, J BIOL CHEM, V270, P22417, DOI 10.1074/jbc.270.38.22417; ECCLESTON PA, 1992, EXP CELL RES, V199, P1, DOI 10.1016/0014-4827(92)90455-H; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FRIGERIO JM, 1993, BIOCHIM BIOPHYS ACTA, V1216, P329, DOI 10.1016/0167-4781(93)90167-C; FRIGERIO JM, 1993, BIOCHEMISTRY-US, V32, P9236, DOI 10.1021/bi00086a032; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; Greensmith L, 1996, TRENDS NEUROSCI, V19, P450, DOI 10.1016/S0166-2236(96)20034-7; HALL SM, 1986, NEUROPATH APPL NEURO, V12, P401, DOI 10.1111/j.1365-2990.1986.tb00151.x; IOVANNA J, 1991, J BIOL CHEM, V266, P25664; JENKINS R, 1991, NEUROSCI LETT, V129, P107, DOI 10.1016/0304-3940(91)90731-8; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; Reynolds M L, 1993, Curr Opin Neurobiol, V3, P683, DOI 10.1016/0959-4388(93)90139-P; Scherer S.S., 1996, GLIAL CELL DEV, P165; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHMALBRUCH H, 1995, BRAIN RES, V700, P254, DOI 10.1016/0006-8993(95)00982-V; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; WEINMASTER G, 1990, EMBO J, V9, P915, DOI 10.1002/j.1460-2075.1990.tb08189.x; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	30	155	157	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					614	618		10.1038/37615	http://dx.doi.org/10.1038/37615			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403691				2022-12-28	WOS:A1997YK85300051
J	Blaiss, MS				Blaiss, MS			Outcomes analysis in asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; FORM HEALTH SURVEY; COST-EFFECTIVENESS; BRONCHIAL-ASTHMA; SELF-MANAGEMENT; LUNG-FUNCTION; CARE; QUESTIONNAIRE; PROGRAM; ADULTS	Physicians, patients, employers, managed care organizations, insurance companies, and government all want to know how different approaches to management of asthma are improving care. To this end, the field of outcomes analysis in asthma is playing a major role. Clinical, physiologic, humanistic, and economic outcomes are being assessed using different types of general and asthma-specific instruments. Historically, clinical and physiologic outcomes have been of most concern to clinicians. However, humanistic outcomes, such as health-related quality of life and patient satisfaction, shift the focus to the patient. Economic outcomes, especially cost-effectiveness, evaluate how to achieve the best outcomes at the lowest cost. These outcomes have been used to evaluate asthma intervention programs. Several large asthma outcomes research projects, which should define the future of outcomes analysis in asthma, are under way.			Blaiss, MS (corresponding author), UNIV TENNESSEE, MED GRP, 777 WASHINGTON AVE, SUITE P110, MEMPHIS, TN 38105 USA.							AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; BARNETT TE, 1992, J ASTHMA, V29, P109, DOI 10.3109/02770909209059879; Bender BG, 1996, ANN ALLERG ASTHMA IM, V77, P438, DOI 10.1016/S1081-1206(10)63347-9; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERGNER M, 1985, MED CARE, V23, P696, DOI 10.1097/00005650-198505000-00028; BOE J, 1992, ANN ALLERGY, V68, P255; BOLTON MB, 1991, J GEN INTERN MED, V6, P401, DOI 10.1007/BF02598160; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371, DOI 10.1164/ajrccm.149.2.8306032; BROOKS SM, 1990, J ALLERGY CLIN IMMUN, V85, P17, DOI 10.1016/0091-6749(90)90216-Q; Bukstein DA, 1996, IMMUNOL ALLERGY CLIN, V16, P859, DOI 10.1016/S0889-8561(05)70276-9; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P350; CHRISTIE MJ, 1993, PSYCHOSOM MED, V55, P541, DOI 10.1097/00006842-199311000-00010; CREER TL, 1993, J ASTHMA, V30, P467, DOI 10.3109/02770909309056756; Doan T, 1996, ANN ALLERG ASTHMA IM, V76, P513, DOI 10.1016/S1081-1206(10)63270-X; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; ENRIGHT PL, 1994, AM J RESP CRIT CARE, V149, pS9, DOI 10.1164/ajrccm/149.2_Pt_2.S9; Epstein RS, 1996, ANN INTERN MED, V124, P832, DOI 10.7326/0003-4819-124-9-199605010-00008; FEENY D, 1990, QUALITY LIFE ASSESSM, P71; FERGUSON JH, 1991, MED CARE, V29, pJS1; FITZPATRICK R, 1992, BRIT MED J, V305, P1074, DOI 10.1136/bmj.305.6861.1074; FRITZ GK, 1989, PSYCHOSOM MED, V51, P347, DOI 10.1097/00006842-198905000-00009; GREINEDER DK, 1995, ARCH PEDIAT ADOL MED, V149, P415, DOI 10.1001/archpedi.1995.02170160069010; GRIFFIN E, 1991, J ALLERGY CLIN IMMUN, V87, P548, DOI 10.1016/0091-6749(91)90014-F; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; HYLAND ME, 1995, BRIT J CLIN PSYCHOL, V34, P601, DOI 10.1111/j.2044-8260.1995.tb01494.x; JACKSON A, 1995, CHEST, V151, P353; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Kaplan RM, 1988, QUALITY LIFE ASSESSM, P51; KELSO TM, 1995, AM J EMERG MED, V13, P632, DOI 10.1016/0735-6757(95)90046-2; KORENBLAT PE, 1995, J ALLERGY CLIN IMMUN, V95, P222; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; Lahdensuo A, 1996, BRIT MED J, V312, P748; Li JTC, 1996, ANN ALLERG ASTHMA IM, V76, P1, DOI 10.1016/S1081-1206(10)63400-X; Lohr KN, 1996, CLIN THER, V18, P979, DOI 10.1016/S0149-2918(96)80054-3; MALO JL, 1993, J ALLERGY CLIN IMMUN, V91, P1121, DOI 10.1016/0091-6749(93)90313-5; MARKS GB, 1993, J CLIN EPIDEMIOL, V46, P1103, DOI 10.1016/0895-4356(93)90109-E; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; MCFADDEN ER, 1995, AM J MED, V99, P651, DOI 10.1016/S0002-9343(99)80253-8; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V77, P1, DOI 10.1016/0091-6749(86)90313-1; McSweeny A J, 1995, Dis Mon, V41, P1; MEIJER AM, 1995, J ASTHMA, V32, P265, DOI 10.3109/02770909509044834; MURLOW CD, 1986, J GEN INTERN MED, V1, P364; *NAT ASTHM ED PREV, 1997, 2 NIH; *NIH, 1994, NIH PUBL, pCH8; NOVISKI N, 1991, ARCH DIS CHILD, V66, P952, DOI 10.1136/adc.66.8.952; OCONNOR GT, 1994, AM J RESP CRIT CARE, V149, pS21, DOI 10.1164/ajrccm/149.2_Pt_2.S21; OCONNOR GT, 1994, AM J RESP CRIT CARE, V149, pS29; RICHARDS JM, 1994, AM J RESP CRIT CARE, V149, pS31, DOI 10.1164/ajrccm/149.2_Pt_2.S31; RICHARDS JM, 1988, J ASTHMA, V25, P363, DOI 10.3109/02770908809071376; RICHARDS JM, 1994, AM J RESP CRIT CARE, V149, pS40; Rose R, 1996, IMMUNOL ALLERGY CLIN, V16, P841, DOI 10.1016/S0889-8561(05)70275-7; ROWE BH, 1993, AM REV RESPIR DIS, V148, P675, DOI 10.1164/ajrccm/148.3.675; SPITERI MA, 1988, LANCET, V1, P873; STEINWACHS DM, 1994, HEALTH AFFAIR, V13, P153, DOI 10.1377/hlthaff.13.4.153; STEINWACHS DM, 1995, MANAGED HLTH CARE AS; Storms B, 1995, ANN ALLERG ASTHMA IM, V75, P491; Sullivan S, 1996, AM J RESP CRIT CARE, V154, pS84, DOI 10.1164/ajrccm/154.3_Pt_2.S84; Sullivan SD, 1996, IMMUNOL ALLERGY CLIN, V16, P819, DOI 10.1016/S0889-8561(05)70274-5; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; USHERWOOD TP, 1990, ARCH DIS CHILD, V65, P779, DOI 10.1136/adc.65.7.779; Ware J E Jr, 1983, Eval Program Plann, V6, P247, DOI 10.1016/0149-7189(83)90005-8; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WOOLCOCK AJ, 1990, MED CLIN N AM, V74, P753, DOI 10.1016/S0025-7125(16)30550-8; World Health Organization, 1958, 1 10 YEARS WORLD HLT; WU AW, 1996, CECIL TXB MED, V1, P122; 1996, MED OUTCOMES TRUST M, V1, P3	75	51	51	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1874	1880		10.1001/jama.278.22.1874	http://dx.doi.org/10.1001/jama.278.22.1874			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YK155	9396648				2022-12-28	WOS:A1997YK15500009
J	Raj, R				Raj, R			Crossing over	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1721	1721						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388130				2022-12-28	WOS:A1997YH98700001
J	Postlethwaite, RJ; Wilson, B				Postlethwaite, RJ; Wilson, B			Ultrasonography vs cystourethrography to exclude vesicoureteric reflux in babies	LANCET			English	Editorial Material									ROYAL MANCHESTER CHILDRENS HOSP,DEPT RADIOL,PENDLEBURY M27 4HA,ENGLAND	Royal Manchester Children's Hospital	Postlethwaite, RJ (corresponding author), ROYAL MANCHESTER CHILDRENS HOSP,DEPT NEPHROL,PENDLEBURY M27 4HA,ENGLAND.							Avni EF, 1997, BRIT J RADIOL, V70, P977, DOI 10.1259/bjr.70.838.9404197; Dudley JA, 1997, ARCH DIS CHILD-FETAL, V76, pF31, DOI 10.1136/fn.76.1.F31; ERICSSON N O, 1960, Acta Paediatr, V49, P196, DOI 10.1111/j.1651-2227.1960.tb07722.x; LEBOWITZ RL, 1992, J UROLOGY, V148, P1640, DOI 10.1016/S0022-5347(17)36991-4; MARSHALL JL, 1990, RADIOLOGY, V175, P355, DOI 10.1148/radiology.175.2.2183279; PILLING D, 1996, CLIN OPINION IMAGING; Scott JES, 1997, LANCET, V350, P396, DOI 10.1016/S0140-6736(97)01515-8; SHERIDAN M, 1991, PEDIATR SURG INT, V6, P214; Tibballs JM, 1996, ARCH DIS CHILD, V75, P444, DOI 10.1136/adc.75.5.444; VERRIERJONES K, 1997, LANCET, V350, P380	10	2	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1567	1568		10.1016/S0140-6736(05)64009-3	http://dx.doi.org/10.1016/S0140-6736(05)64009-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393333				2022-12-28	WOS:A1997YH98600005
J	Power, C; Matthews, S				Power, C; Matthews, S			Origins of health inequalities in a national population sample	LANCET			English	Article							FOLLOW-UP; CARDIOVASCULAR-DISEASE; BRITISH ADULTS; BIRTH COHORT; SOCIAL-CLASS; MORTALITY; CHILDHOOD; MEN; ILLNESS; GROWTH	Background Explanations for social inequalities in health are often explored but remain largely unresolved. To elucidate the origins of health inequalities, we investigated the extent to which adult-disease risk factors vary systematically according to social position over three decades of early life. Methods We used the 1958 birth cohort (all children born in England, Scotland, and Wales on March 3-9, 1958) with data up to age 33 years from parents, teachers, doctors, and cohort members (n=11 407 for age 33 interview). Findings Social class of origin was associated with physical risk factors (birthweight, height, and adult body-mass index); economic circumstances, including household overcrowding, basic amenities, and low income; health behaviour of parents (breastfeeding and smoking) and of participants (smoking and diet); social and family functioning and structure, such as divorce or separation of participants or their parents, emotional adjustment in adolescence, social support in early adulthood; and educational achievement and working career, in particular no qualifications, unemployment, job strain, and insecurity. With few exceptions, there were strong significant trends of increasing risk from classes I and II to classes IV and V. Self-perceived health status and symptoms were worse in participants with lower class origins. Interpretation An individual's chance of encountering multiple adverse health risks throughout life is influenced powerfully by social position. Social trends in adult-disease risk factors do not emerge exclusively in mid-life, but accumulate over decades. Investment in educational and emotional development is needed in all social groups to strengthen prevention strategies relating to health behaviour, work-place environment, and income inequality.			Power, C (corresponding author), INST CHILD HLTH,DEPT EPIDEMIOL & PUBL HLTH,30 GUILFORD ST,LONDON WC1N 1EH,ENGLAND.			Matthews, Sharon/0000-0003-3105-7029				AMATO PR, 1991, J MARRIAGE FAM, V53, P43, DOI 10.2307/353132; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1992, FETAL INFANT ORIGING; CARPENTER L, 1989, BRIT MED J, V299, P357, DOI 10.1136/bmj.299.6695.357; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; *DEP HLTH, 1995, HLTH NAT VAR HLTH WH; DOORNBOS G, 1990, INT J EPIDEMIOL, V19, P374, DOI 10.1093/ije/19.2.374; Elo IT, 1996, SOC SCI MED, V42, P47, DOI 10.1016/0277-9536(95)00062-3; FERRI E, 1993, LIFE 33 5 FOLLOW UP; GLIKSMAN MD, 1995, J EPIDEMIOL COMMUN H, V49, P10, DOI 10.1136/jech.49.1.10; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hertzman C, 1996, SOC SCI MED, V43, P1083, DOI 10.1016/0277-9536(96)00028-7; KAPLAN GA, 1983, AM J EPIDEMIOL, V117, P292, DOI 10.1093/oxfordjournals.aje.a113541; Karasek R., 1990, HLTH WORK STRESS PRO; Kuh D, 1997, LIFE COURSE APPROACH; LEON DA, 1995, J EPIDEMIOL COMMUN H, V49, P5, DOI 10.1136/jech.49.1.5; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; LUNDBERG O, 1993, SOC SCI MED, V36, P1047, DOI 10.1016/0277-9536(93)90122-K; Lynch JW, 1997, SOC SCI MED, V44, P809, DOI 10.1016/S0277-9536(96)00191-8; MANN SL, 1992, J EPIDEMIOL COMMUN H, V46, P286, DOI 10.1136/jech.46.3.286; MARGETTS BM, 1993, BMJ-BRIT MED J, V307, P1381, DOI 10.1136/bmj.307.6916.1381; MARMOT M, 1997, BR MED B, P53; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1984, LANCET, V1, P1003; Maughan B, 1997, BRIT MED BULL, V53, P156; *MRC, 1970, QUEST RESP SYMPT; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; Power C, 1997, AM J PUBLIC HEALTH, V87, P1499, DOI 10.2105/AJPH.87.9.1499; Power C, 1996, BRIT MED J, V313, P449; Power C., 1991, HLTH CLASS EARLY YEA; RUTTER M, 1967, J CHILD PSYCHOL PSYC, V8, P1, DOI 10.1111/j.1469-7610.1967.tb02175.x; RUTTER M, 1989, J CHILD PSYCHOL PSYC, V30, P23, DOI 10.1111/j.1469-7610.1989.tb00768.x; RUTTER M, 1970, ED HLTH BEHAVIOR; Stott D. H., 1969, SOCIAL ADJUSTMENT CH; Strachan DP, 1997, LIFE COURSE APPROACH; VAGERO D, 1994, LANCET, V343, P1224, DOI 10.1016/S0140-6736(94)92432-5; Wald NJ, 1996, BRIT MED BULL, V52, P3, DOI 10.1093/oxfordjournals.bmb.a011530; Wannamethee SG, 1996, LANCET, V348, P1259, DOI 10.1016/S0140-6736(96)02465-8	38	249	252	2	41	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1584	1589		10.1016/S0140-6736(97)07474-6	http://dx.doi.org/10.1016/S0140-6736(97)07474-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YH986	9393337				2022-12-28	WOS:A1997YH98600009
J	Spitzer, WO				Spitzer, WO			Balanced view of risks of oral contraceptives	LANCET			English	Editorial Material											Spitzer, WO (corresponding author), STANFORD UNIV,SCH MED,DEPT MED,PALO ALTO,CA 94301, USA.							Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Spitzer WO, 1997, HUM REPROD, V12, P2347, DOI 10.1093/humrep/12.11.2347; *WHO COLL STUD CAR, 1997, LANCET, V349, P1202	3	13	13	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1566	1567		10.1016/S0140-6736(05)64008-1	http://dx.doi.org/10.1016/S0140-6736(05)64008-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393332				2022-12-28	WOS:A1997YH98600004
J	Jamora, C; Takizawa, PA; Zaarour, RF; Denesvre, C; Faulkner, J; Malhotra, V				Jamora, C; Takizawa, PA; Zaarour, RF; Denesvre, C; Faulkner, J; Malhotra, V			Regulation of Golgi structure through heterotrimeric G proteins	CELL			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; TRIMERIC G-PROTEINS; ALPHA-SUBUNITS; MEMBRANES REQUIRES; GUANINE-NUCLEOTIDE; VESICLE FORMATION; COATED VESICLES; BREFELDIN-A; TRANSPORT	We have previously shown that ilimaquinone (IQ), a marine sponge metabolite, causes complete vesiculation of the Golgi stacks. By reconstituting the I-mediated vesiculation of the Golgi apparatus in permeabilized cells, we now demonstrate that this process does not require ARF and coatomers, which are necessary for the formation of Golgi-derived COPI vesicles. We find that IQ-mediated Golgi vesiculation is inhibited by G-alpha(s)-GDP and G-alpha(13)-GDP. Interestingly, adding beta-gamma subunits in the absence of IQ is sufficient to vesiculate Golgi stacks. Our findings reveal that I-mediated Golgi vesiculation occurs through activation of heterotrimeric G proteins and that it is the free beta-gamma, and not the activated alpha subunit, that triggers Golgi vesiculation.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography			Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943; Zaarour, Rania/0000-0001-9132-5940	NIGMS NIH HHS [GM46224] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; Benli M, 1996, EMBO J, V15, P6460, DOI 10.1002/j.1460-2075.1996.tb01037.x; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GRABER SG, 1994, METHOD ENZYMOL, V237, P212; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HIDALGO J, 1995, J CELL SCI, V108, P1805; Jedd G, 1997, J CELL BIOL, V137, P563, DOI 10.1083/jcb.137.3.563; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; MAIER O, 1995, BIOCHEM BIOPH RES CO, V208, P135, DOI 10.1006/bbrc.1995.1315; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MALLABIABARRENA A, 1995, CELL, V83, P667, DOI 10.1016/0092-8674(95)90177-9; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Schekman R, 1997, CELL, V90, P197, DOI 10.1016/S0092-8674(00)80326-8; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; TAYLOR TC, 1994, MOL BIOL CELL, V5, P237, DOI 10.1091/mbc.5.2.237; VEIT B, 1993, J CELL BIOL, V122, P1197, DOI 10.1083/jcb.122.6.1197; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WILSON BS, 1994, J CELL BIOL, V125, P557, DOI 10.1083/jcb.125.3.557	40	99	99	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					617	626		10.1016/S0092-8674(00)80449-3	http://dx.doi.org/10.1016/S0092-8674(00)80449-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393855	Bronze			2022-12-28	WOS:A1997YH96000009
J	MacDonald, TM; Morant, SV; Robinson, GC; Shield, MJ; McGilchrist, MM; Murray, FE; McDevitt, DG				MacDonald, TM; Morant, SV; Robinson, GC; Shield, MJ; McGilchrist, MM; Murray, FE; McDevitt, DG			Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BLEEDING PEPTIC-ULCER; ELDERLY PERSONS; ASPIRIN; COMPLICATIONS; ANALGESICS; RISK	Objectives: To determine the profile of risk of upper gastrointestinal toxicity during continuous treatment with, and after cessation of, non-steroidal anti-inflammatory drugs. Design: Cohort study with a prospectively constructed, population based, record linkage database containing details of exposure to all community dispensed non-steroidal anti-inflammatory drugs and also all admissions to hospital for upper gastrointestinal diagnoses. Setting: The population of Tayside, Scotland. Subjects: 52 293 subjects aged 50 and over who received one or more non-steroidal anti-inflammatory between 1 January 1989 and 31 December 1991 and 73 792 subjects who did not receive one during the same period (controls). Main outcome measures: Admission to hospital for upper gastrointestinal bleeding and perforation, and admission for other upper gastrointestinal diagnoses. Results: About 2% of the non-steroidal anti-inflammatory cohort were admitted with an upper gastrointestinal event during the study period compared with 1.4% of controls. The risk of admission for upper gastrointestinal haemorrhage and perforation was constant during continuous non-steroidal anti-inflammatory exposure and carried over after the end of exposure. The results were similar for admissions for all upper gastrointestinal events. Conclusion: This study provides evidence that non-steroidal anti-inflammatory toxicity persists with continuous exposure. There seems to be carryover toxicity after the end of prescribing. These findings have implications for the management of patients requiring non-steroidal anti-inflammatory drugs.	SEARLE, HIGH WYCOMBE HP12 4HL, BUCKS, ENGLAND	Pfizer	MacDonald, TM (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, MED MONITORING UNIT, DEPT CLIN PHARMACOL, DUNDEE DD1 9SY, SCOTLAND.			MacDonald, Thomas/0000-0001-5189-6669; Morant, Steven/0000-0001-5674-3784				BEARD K, 1987, ARCH INTERN MED, V147, P1621, DOI 10.1001/archinte.147.9.1621; BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; BEARDON PHG, 1989, Q J MED, V71, P497; *BRIT MED ASS ROYA, 1994, BRIT NAT FORM, P34; CARSON JL, 1987, ARCH INTERN MED, V147, P1054, DOI 10.1001/archinte.147.6.1054; Dornan S, 1995, Health Bull (Edinb), V53, P274; FRIES JF, 1989, GASTROENTEROLOGY, V96, P647, DOI 10.1016/S0016-5085(89)80061-7; GRAHAM DY, 1988, GASTROENTEROLOGY, V95, P327, DOI 10.1016/0016-5085(88)90487-8; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HENRY D, 1993, GASTROENTEROLOGY, V105, P1078, DOI 10.1016/0016-5085(93)90952-9; HENRY DA, 1987, BRIT MED J, V295, P1227, DOI 10.1136/bmj.295.6608.1227; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEVY M, 1988, ARCH INTERN MED, V148, P281, DOI 10.1001/archinte.148.2.281; MACDONALD TM, 1994, PHARMACOEPIDEM DR S, P245; MCCULLAGH P, 1989, MONOGRAPHS STAT APPL, V37, P193; *OFF POP SENS SURV, 1990, TAB LIST CLASS SURG; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; SHORROCK CJ, 1990, GASTROENTEROLOGY, V99, P334, DOI 10.1016/0016-5085(90)91013-V; SOMERVILLE K, 1986, LANCET, V1, P462; World Health Organization, 1977, INT CLASS DIS; YOLA M, 1994, J CLIN EPIDEMIOL, V47, P731, DOI 10.1016/0895-4356(94)90170-8	23	236	246	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 22	1997	315	7119					1333	1337		10.1136/bmj.315.7119.1333	http://dx.doi.org/10.1136/bmj.315.7119.1333			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402773	Green Published			2022-12-28	WOS:A1997YJ21800020
J	Poole, CJM; Hill, DJ; Christie, JL; Birch, J				Poole, CJM; Hill, DJ; Christie, JL; Birch, J			Deficient colour vision and interpretation of histopathology slides: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							PATHOLOGISTS; BLINDNESS	Objective: To determine whether histopathologists with deficient colour vision make more errors in slide interpretation than those with normal colour vision. Design: Examination of projected transparencies of histopathological slides under standardised conditions by subjects whose colour discriminating ability was accurately assessed. Setting: Departments of histopathology in 45 hospitals in the United Kingdom. Subjects: 270 male histopathologists and medical laboratory scientific officers. Main outcome measures: Number of slides correctly identified by subjects whose colour vision was measured on the Ishihara, City University, and Farnsworth-Munsell 100 hue tests. Results: Mean (SD) scores (out of 10) for doctors with colour deficient vision were 9.4 (0.7) for 9.9 (0.4) for controls (P < 0.01) and 7.5 (1.6) v 9.4 (0.7) for scientific officers (P < 0.001). When subjects with colour deficient vision were categorised into severe, moderate, or mild, there was a significant trend towards those with severe deficiency making more mistakes (P < 0.001). Conclusions: Histopathologists and medical laboratory scientific officers should have their colour vision tested; if they are found to have a severe prolan or deutan deficiency, they should be advised to adopt a safe system of working.	DUDLEY GRP HOSP NHS TRUST,DEPT HISTOPATHOL,DUDLEY DY2 7BX,ENGLAND; CITY UNIV LONDON,DEPT OPTOMETRY & VISUAL SCI,LONDON EC1V 0HB,ENGLAND	City University London	Poole, CJM (corresponding author), DUDLEY PRIOR HLTH NHS TRUST,CENT CLIN,DEPT OCCUPAT HLTH,DUDLEY DY2 7BX,ENGLAND.							Birch J., 1993, DIAGNOSIS DEFECTIVE; BOGMAN MJJT, 1992, LANCET, V339, P185, DOI 10.1016/0140-6736(92)90255-2; CURRIER RD, 1994, ARCH NEUROL-CHICAGO, V51, P1090, DOI 10.1001/archneur.1994.00540230028008; LEACH C, 1979, INTRO STATISTICS NON; RIGBY HS, 1991, J CLIN PATHOL, V44, P745, DOI 10.1136/jcp.44.9.745; SPALDING JAB, 1993, BRIT J GEN PRACT, V43, P32; VORSTER BJ, 1979, LANCET, V2, P1295; 1991, LANCET, V338, P1302	8	34	34	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1279	1281		10.1136/bmj.315.7118.1279	http://dx.doi.org/10.1136/bmj.315.7118.1279			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390055	Green Published			2022-12-28	WOS:A1997YG64500022
J	Stevens, J; Cai, JW; Pamuk, ER; Williamson, DF; Thun, MJ; Wood, JL				Stevens, J; Cai, JW; Pamuk, ER; Williamson, DF; Thun, MJ; Wood, JL			The effect of age on the association between body-mass index and mortality	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WEIGHT; WOMEN; MEN	Background The effect of age on optimal body weight is controversial, and few studies have had adequate numbers of subjects to analyze mortality as a function of body-mass index across age groups. Methods We studied mortality over 12 years among white men and women who participated in the American Cancer Society's Cancer Prevention Study I (from 1960 through 1972). The 62,116 men and 262,019 women included in this analysis had never smoked cigarettes, had no history of heart disease, stroke, or cancer (other than skin cancer) at base line in 1959-1960, and had no history of recent unintentional weight loss. The date and cause of death for subjects who died were determined from death certificates. The associations between body-mass index (defined as the weight in kilograms divided by the square of the height in meters) and mortality were examined for six age groups in analyses in which we adjusted for age, educational level, physical activity, and alcohol consumption. Results Greater body-mass index was associated with higher mortality from all causes and from cardiovascular disease in men and women up to 75 years of age. However, the relative risk associated with greater body-mass index declined with age. For example, for mortality from cardiovascular disease, the relative risk associated with an increment of 1 in the body-mass index was 1.10 (95 percent confidence interval, 1.04 to 1.16) for 30-to-44-year-old men and 1.03 (95 percent confidence interval, 1.02 to 1.05) for 65-to-74-year-old men. For women, the corresponding relative risk estimates were 1.08 (95 percent confidence interval, 1.05 to 1.11) and 1.02 (95 percent confidence interval, 1.02 to 1.03). Conclusions Excess body weight increases the risk of death from any cause and from cardiovascular disease in adults between 30 and 74 years of age. The relative risk associated with greater body weight is higher among younger subjects. (C) 1998, Massachusetts Medical Society.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA; Amer Canc Soc, Atlanta, GA 30329 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; American Cancer Society	Stevens, J (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, CB 7400, Chapel Hill, NC 27599 USA.				NIDDK NIH HHS [R01 DK50776] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050776] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON DB, 1996, OBES RES S1, V4, pS12; [Anonymous], 1983, Stat Bull Metrop Life Found, V64, P3; Cox D. R., 1984, ANAL SURVIVAL DATA; *DIET GUID AM, 1990, DIET GUID AM PUBL; *DIET GUID AM, 1995, DIET GUID AM PUBL; GARFINKEL L, 1984, AM HEART J, V108, P802, DOI 10.1016/0002-8703(84)90675-6; GREENLAND S, 1988, AM J EPIDEMIOL, V128, P1185, DOI 10.1093/oxfordjournals.aje.a115073; LEW EA, 1985, ANN INTERN MED, V103, P1024, DOI 10.7326/0003-4819-103-6-1024; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; Lindsted KD, 1997, AM J EPIDEMIOL, V146, P1, DOI 10.1093/oxfordjournals.aje.a009185; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; PETERSON B, 1994, CONTROL CLIN TRIALS, V15, P326; PETERSON B, 1993, CONTROL CLIN TRIALS, V14, P511, DOI 10.1016/0197-2456(93)90031-8; PLANKEY MW, 1995, OBESITY RES S3, V3, pS386; RISSANEN A, 1989, J CLIN EPIDEMIOL, V42, P781, DOI 10.1016/0895-4356(89)90076-0; RISSANEN A, 1991, J CLIN EPIDEMIOL, V44, P787, DOI 10.1016/0895-4356(91)90131-R; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; *SOC ACT ASS LIF I, 1980, BUILD STUD 1979; SORKIN JD, 1996, OBES RES S1, V4, pS12; Steel R. G. D., 1980, Principles and procedures of statistics, a biometrical approach.; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; WAALER HT, 1984, ACTA MED SCAND, P1; WILLIAMSON DF, 1991, AM J CLIN NUTR, V53, pS1515, DOI 10.1093/ajcn/53.6.1515S; World Health Organization (WHO), 1957, INT CLASS DIS	25	1035	1072	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 1	1998	338	1					1	7		10.1056/NEJM199801013380101	http://dx.doi.org/10.1056/NEJM199801013380101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN801	9414324	Green Published			2022-12-28	WOS:000071209200001
J	Nageotte, MP; Larson, D; Rumney, PJ; Sidhu, M; Hollenbach, K				Nageotte, MP; Larson, D; Rumney, PJ; Sidhu, M; Hollenbach, K			Epidural analgesia compared with combined spinal-epidural analgesia during labor in nulliparous women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CESAREAN-SECTION; RISK-FACTORS; BIRTH; TRIAL; SUFENTANIL; MANAGEMENT; DYSTOCIA; DELIVERY; PROGRESS; FENTANYL	Background Among nulliparous women, there appears to be an association between the use of epidural analgesia during labor and an increased risk of dystocia. We tested the hypothesis that combined spinal-epidural analgesia, which permits ambulation during labor, is associated with a lower incidence of dystocia than continuous lumbar epidural analgesia. Methods Between July 1995 and September 1996, we randomly assigned 761 nulliparous women in spontaneous labor at term who requested epidural analgesia to receive either continuous lumbar epidural analgesia or a combination of spinal and epidural analgesia. Among the women who received combined spinal-epidural analgesia, some were discouraged from walking and others were encouraged to walk. Maternal and neonatal outcomes, the incidence of dystocia necessitating cesarean section, and measures of patients' satisfaction were compared in the two groups. Results There were no significant differences in the overall rate of cesarean section, the incidence of dystocia, the frequency of maternal or fetal complications, the patients' or nursing staff's assessment of the adequacy of analgesia, or the degree of overall satisfaction between the two groups. Significantly more women receiving combined spinal-epidural analgesia had pruritus (P<0.001) and requested additional epidural bolus doses of local anesthetic (P=0.01). For all the women, dystocia necessitating cesarean section was significantly more likely when analgesia was administered with the fetal vertex at a negative station (odds ratio, 2.5; P<0.001) or at less than 4 cm of cervical dilatation (odds ratio, 2.2; P<0.001). Conclusions As compared with continuous lumbar epidural analgesia, the combination of spinal and epidural analgesia is not associated with an overall decrease in the incidence of cesarean delivery. (C) 1997, Massachusetts Medical Society.	WOMENS HOSP MED CTR,LONG BEACH MEM MED CTR,LONG BEACH,CA; UNIV CALIF SAN DIEGO,DEPT FAMILY PREVENT MED,SAN DIEGO,CA 92103	University of California System; University of California San Diego								BREEN TW, 1993, ANESTH ANALG, V77, P919; BUTLER J, 1993, AM J OBSTET GYNECOL, V168, P1407, DOI 10.1016/S0002-9378(11)90773-X; CAMANN WR, 1992, ANESTHESIOLOGY, V77, P884, DOI 10.1097/00000542-199211000-00008; CHESTNUT DH, 1994, ANESTHESIOLOGY, V80, P1201, DOI 10.1097/00000542-199406000-00006; CHESTNUT DH, 1994, ANESTHESIOLOGY, V80, P1193, DOI 10.1097/00000542-199406000-00005; Collis R E, 1994, Int J Obstet Anesth, V3, P75, DOI 10.1016/0959-289X(94)90173-2; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; DIRO M, 1985, J NATL MED ASSOC, V78, P569; FRIGOLETTO FD, 1995, NEW ENGL J MED, V333, P1163; FRIGOLETTO FD, 1995, NEW ENGL J MED, V333, P745, DOI 10.1056/NEJM199509213331201; GOYERT GL, 1989, NEW ENGL J MED, V320, P706, DOI 10.1056/NEJM198903163201106; GRIBBLE RK, 1991, OBSTET GYNECOL, V78, P231; HONET JE, 1992, ANESTH ANALG, V75, P734; LEIGHTON BL, 1989, ANESTH ANALG, V69, P122; Lieberman E, 1996, OBSTET GYNECOL, V88, P993, DOI 10.1016/S0029-7844(96)00359-6; LUPE PJ, 1986, OBSTET GYNECOL, V67, P727, DOI 10.1097/00006250-198605000-00023; Mendez-Bauer C, 1975, J Perinat Med, V3, P89, DOI 10.1515/jpme.1975.3.2.89; MITRE IN, 1974, INT J GYNECOL OBSTET, V12, P181; MORGAN MA, 1992, AM J OBSTET GYNECOL, V166, P810, DOI 10.1016/0002-9378(92)91338-B; NEUHOFF D, 1989, OBSTET GYNECOL, V73, P915; PEACEMAN AM, 1993, AM J OBSTET GYNECOL, V169, P940, DOI 10.1016/0002-9378(93)90031-D; PEISERT JF, 1993, OBSTET GYNECOL, V81, P200; PHILIPSEN T, 1989, EUR J OBSTET GYN R B, V30, P27, DOI 10.1016/0028-2243(89)90090-7; RADIN TG, 1993, BIRTH-ISS PERINAT C, V20, P14, DOI 10.1111/j.1523-536X.1993.tb00174.x; RAMIN SM, 1995, OBSTET GYNECOL, V86, P783, DOI 10.1016/0029-7844(95)00269-W; READ JA, 1981, AM J OBSTET GYNECOL, V139, P669, DOI 10.1016/0002-9378(81)90482-8; SCOTT RT, 1989, MIL MED, V154, P365; SOSA R, 1980, NEW ENGL J MED, V303, P597, DOI 10.1056/NEJM198009113031101; THORP JA, 1991, AM J PERINAT, V8, P402, DOI 10.1055/s-2007-999426; THORP JA, 1989, AM J OBSTET GYNECOL, V161, P670, DOI 10.1016/0002-9378(89)90377-3; THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851, DOI 10.1016/0002-9378(93)90015-B; TURNER MJ, 1990, OBSTET GYNECOL, V76, P159; WUITCHIK M, 1989, OBSTET GYNECOL, V73, P35	33	138	148	1	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1715	1719		10.1056/NEJM199712113372402	http://dx.doi.org/10.1056/NEJM199712113372402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK653	9392696				2022-12-28	WOS:A1997YK65300002
J	Ballow, M; Nelson, R				Ballow, M; Nelson, R			Immunopharmacology - Immunomodulation and immunotherapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; INTERCELLULAR-ADHESION MOLECULE-1; REFRACTORY RHEUMATOID-ARTHRITIS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; MONOCLONAL-ANTIBODY; FACTOR-ALPHA; INTRAVENOUS IMMUNOGLOBULIN; RECOMBINANT INTERLEUKIN-2	Immunopharmacology has changed dramatically over the past 25 years. Although a variety of traditional nonspecific immunosuppressive drug therapies are available for the treatment of autoimmune disease and organ transplantation rejection, with advances in cell biology and monoclonal antibody technology, a highly specific antibody can be engineered to cell surface determinants on immune cells or tumors or to neutralize inflammatory and immune mediators from an immune response. Many of these modalities are still in early phases of study for the treatment of autoimmune disease. In addition to therapies that suppress immune responses, advances in molecular biology have led to new agents and methods to enhance immune responses and correct immune deficits, such as growth factor replacement and cytokine therapies. Finally, gene therapy is a method for the long-term treatment of disorders in which a defective gene leads to disease.	UNIV S FLORIDA, ALL CHILDRENS HOSP, DIV CLIN IMMUNOL & ALLERGY, ST PETERSBURG, FL 33701 USA	State University System of Florida; University of South Florida	Ballow, M (corresponding author), CHILDRENS HOSP BUFFALO, DIV ALLERGY IMMUNOL & PEDIAT RHEUMATOL, 219 BRYANT ST, BUFFALO, NY 14222 USA.							ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; ANTMAN KS, 1988, NEW ENGL J MED, V319, P593, DOI 10.1056/NEJM198809083191001; AREND WP, 1991, J CLIN INVEST, V88, P1445, DOI 10.1172/JCI115453; BALKWILL FR, 1989, LANCET, V1, P1060; Ballow M, 1997, J ALLERGY CLIN IMMUN, V100, P151, DOI 10.1016/S0091-6749(97)70217-3; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P1333; BJORKANDER J, 1988, AM J MED, V84, P107, DOI 10.1016/0002-9343(88)90016-2; BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BOUGNERES PF, 1990, DIABETES, V39, P1264, DOI 10.2337/diabetes.39.10.1264; BOUMPAS DT, 1995, ANN INTERN MED, V122, P940, DOI 10.7326/0003-4819-122-12-199506150-00009; Brazelton TR, 1996, CURR OPIN IMMUNOL, V8, P710, DOI 10.1016/S0952-7915(96)80090-2; BROSTOFF J, 1991, CLIN IMMUNOLOGY; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; CALABRESI P, 1993, GOODMAN GILMANS PHAR; CALIGIURI MA, 1991, J CLIN ONCOL, V9, P2110, DOI 10.1200/JCO.1991.9.12.2110; Candotti F, 1996, BLOOD, V87, P3097, DOI 10.1182/blood.V87.8.3097.bloodjournal8783097; Chatenoud L, 1990, Semin Immunol, V2, P437; CHEHIMI J, 1994, J CLIN IMMUNOL, V14, P149, DOI 10.1007/BF01533364; CHOY EHS, 1992, SCAND J IMMUNOL, V36, P291, DOI 10.1111/j.1365-3083.1992.tb03102.x; CUNNINGHAMRUNDLES C, 1995, J INTERF CYTOK RES, V15, P269, DOI 10.1089/jir.1995.15.269; CUSH JJ, 1995, RHEUM DIS CLIN N AM, V21, P797; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; DORR RT, 1993, DRUGS, V45, P177, DOI 10.2165/00003495-199345020-00003; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; ELLIS CN, 1991, NEW ENGL J MED, V324, P277, DOI 10.1056/NEJM199101313240501; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FLOWER RJ, 1989, ANTIINFLAMMATORY STE; FURUSHO K, 1984, LANCET, V2, P1055; GIANNINI EH, 1992, NEW ENGL J MED, V326, P1043, DOI 10.1056/NEJM199204163261602; GILBERT SC, 1990, ARCH INTERN MED, V150, P889, DOI 10.1001/archinte.150.4.889; GRANT SM, 1992, DRUGS, V43, P516, DOI 10.2165/00003495-199243040-00008; GREENBERG PL, 1990, CANCER SURV, V9, P199; HERSHFIELD MS, 1995, CLIN IMMUNOL IMMUNOP, V76, pS228, DOI 10.1016/S0090-1229(95)90306-2; HERZOG C, 1989, J AUTOIMMUN, V2, P627, DOI 10.1016/S0896-8411(89)80002-2; HIRSCHHORN R, 1993, PEDIATR RES, V33, pS35; HORNEFF G, 1993, BRIT J RHEUMATOL, V32, P39; IMBACH P, 1985, LANCET, V2, P464; KAVANAUGH AF, 1994, ARTHRITIS RHEUM, V37, P992, DOI 10.1002/art.1780370703; KIMCHI A, 1987, INTERFERON, V8, P86; KOHN DB, 1995, NAT MED, V1, P1017, DOI 10.1038/nm1095-1017; Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803; KRESSEBUCH H, 1992, PEDIATR INFECT DIS J, V11, P894, DOI 10.1097/00006454-199210000-00020; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; LEVITT SH, 1975, LANCET, V2, P1258; LOTZE MT, 1986, CANCER, V58, P2764, DOI 10.1002/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO;2-Z; MASUDA K, 1989, LANCET, V1, P1093; Mattila PS, 1996, BIOCHEM SOC T, V24, P45, DOI 10.1042/bst0240045; MAYFORTH RD, 1990, NEW ENGL J MED, V323, P173; MORELAND LW, 1993, ARTHRITIS RHEUM, V36, P307, DOI 10.1002/art.1780360304; MORRIS RE, 1995, NEW DEV TRANSPLANT M, V2, P10; MULLARKEY M, 1995, ALLERGY PROC, V16, P81, DOI 10.2500/108854195778771462; Muraoka K, 1996, J CLIN INVEST, V97, P2433, DOI 10.1172/JCI118690; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; PRESENT DH, 1980, NEW ENGL J MED, V302, P981, DOI 10.1056/NEJM198005013021801; RANKIN ECC, 1995, BRIT J RHEUMATOL, V34, P334; RATKO TA, 1995, JAMA-J AM MED ASSOC, V273, P1865, DOI 10.1001/jama.273.23.1865; ROENIGK HH, 1988, J AM ACAD DERMATOL, V19, P145, DOI 10.1016/S0190-9622(88)80237-8; ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707; ROSENBERG S, 1991, BIOL THERAPY CANC; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; ROSENBERG SA, 1989, ANN SURG, V210, P474, DOI 10.1097/00000658-198910000-00008; RUBIN LA, 1990, ANN INTERN MED, V113, P619, DOI 10.7326/0003-4819-113-8-619; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Sehgal S N, 1995, Curr Opin Nephrol Hypertens, V4, P482, DOI 10.1097/00041552-199511000-00004; SHUMAK KH, 1984, NEW ENGL J MED, V310, P762, DOI 10.1056/NEJM198403223101206; Siemasko KF, 1996, TRANSPLANTATION, V61, P635, DOI 10.1097/00007890-199602270-00020; SORENSEN RU, 1984, AM J MED, V76, P83, DOI 10.1016/0002-9343(84)90325-5; STEWART GE, 1994, J ALLERGY CLIN IMMUN, V94, P482, DOI 10.1016/0091-6749(94)90204-6; SULLIVAN KM, 1992, BONE MARROW TRANSPL, V10, P127; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; VALLERA DA, 1994, BLOOD, V83, P309; VANDERLUBBE PA, 1995, ARTHRITIS RHEUM, V38, P1097, DOI 10.1002/art.1780380812; VANDERMEER JWM, 1988, P NATL ACAD SCI USA, V85, P1620; VITETTA ES, 1993, IMMUNOL TODAY, V14, P252, DOI 10.1016/0167-5699(93)90041-I; WALLACH D, 1988, J IMMUNOL, V140, P2994; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WELTE K, 1990, BLOOD, V75, P1056; Yocum DE, 1996, RHEUM DIS CLIN N AM, V22, P133, DOI 10.1016/S0889-857X(05)70266-0; ZAHARKO DS, 1977, CANCER RES, V37, P1602; 1994, MMWR MORBID MORTAL W, V43, P505; 1994, JAMA-J AM MED ASSOC, V272, P424	90	41	58	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					2008	2017		10.1001/jama.278.22.2008	http://dx.doi.org/10.1001/jama.278.22.2008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396664				2022-12-28	WOS:A1997YK15500025
J	Fleisher, TA; Tomar, RH				Fleisher, TA; Tomar, RH			Introduction to diagnostic laboratory immunology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC GRANULOMATOUS-DISEASE; LEUKOCYTES	Assays performed in the diagnostic immunology laboratory support the diagnosis and management of a wide spectrum of clinical conditions. This chapter reviews immunologic principles as they apply to diagnostic laboratory assays. Most of the determinations are based on well-established principles of antigen-antibody reactions. Some of the specific areas discussed include flow cytometric analyses, critical in the care of patients with hematologic malignancies, with the acquired immunodeficiency syndrome, or undergoing transplantation, and protein electrophoretic assays to identify the presence of monoclonal gammopathies. We also discuss the use of molecular techniques in the diagnosis of hematologic malignancies and primary immunodeficiencies, characterization of the major histocompatibility complex, and enumeration of viral burden.	UNIV WISCONSIN HOSP & CLIN,DEPT PATHOL & LAB MED,CLIN SCI CTR E5483,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison	Fleisher, TA (corresponding author), NIH,WARREN G MAGNUSON CLIN CTR,SERV IMMUNOL,9000 ROCKVILLE PIKE,BLDG 10,ROOM 2C410,BETHESDA,MD 20892, USA.							ABBAS AK, 1996, CLIN IMMUNOLOGY PRIN, P264; ADELMAN DC, 1994, IMMUNOL ALLERGY CLIN, V14, P241; BASELER MW, 1997, MANUAL CLIN LAB IMMU, P764; BAWA N, 1996, CLIN DIAGNOSIS MANAG, P913; BELMONT JW, 1996, CLIN IMMUNOLOGY PRIN, P2187; Berliner Nancy, 1995, P1193; BIRX DL, 1993, J ACQ IMMUN DEF SYND, V6, P1248; Carpenter AB, 1997, MANUAL CLIN LAB IMMU; Check IJ, 1997, MANUAL CLIN LAB IMMU, P134; CORMICAN MU, 1996, CLIN DIAGNOSIS MANAG, P1300; DJEU JY, 1992, MANUAL CLIN LAB IMMU, P231; DOUGAL JS, 1902, J LAB CLIN MED, V69, P287; FAHEY JL, 1965, J IMMUNOL, V94, P84; FLEISHER TA, 1994, IMMUNOL ALLERGY CLIN, V14, P225; FLEISHER TA, 1996, ADV INTERNAL MED, P1; FLETCHER MA, 1997, MANUAL CLIN LAB IMMU, P313; FRANK MM, 1994, BASIC CLIN IMMUNOL, P124; Giclas PC, 1997, MANUAL CLIN LAB IMMU, V5, P181; HAYASHI K, 1993, HUM MUTAT, V2, P338, DOI 10.1002/humu.1380020503; HAYNES BF, 1989, IMMUNOL TODAY, V10, P87, DOI 10.1016/0167-5699(89)90232-6; HOLERS VM, 1997, MANUAL CLIN LAB IMMU, P192; HURLEY CK, 1997, MANUAL CLIN LAB IMMU, P1098; Jackson A, 1990, CLIN IMMUNOL NEWSL, V10, P43; JAFFE ES, 1997, MANUAL CLIN LAB IMMU, P1055; Janeway CA., 2001, IMMUNOBIOLOGY IMMUNE, V5th edition; Kasahara Y, 1996, CLIN DIAGNOSIS MANAG, P851; KEREN DF, 1987, HIGH RESOLUTION ELEC; KHAN AK, 1996, CLIN DIAGNOSIS MANAG, P928; KOHLER G, 1975, NATURE, V256, P445; KRICKA LJ, 1997, MANUAL CLIN LAB IMMU, P49; LANDAY AL, 1992, MANUAL CLIN LABORATO, P191; LANIER LL, 1992, MANUAL CLIN LABORATO, P157; LEWIS DE, 1992, MANUAL CLIN LABORATO, P164; Look A. Thomas, 1995, P1047; LOPEZ M, 1992, JAMA-J AM MED ASSOC, V268, P2970, DOI 10.1001/jama.268.20.2970; LUCEY DR, 1996, CLIN IMMUNOLOGY PRIN, P2124; MAKGOBA MW, 1989, IMMUNOL TODAY, V10, P417, DOI 10.1016/0167-5699(89)90039-X; MALECH HL, 1993, CURR OPIN HEMATOL, V1, P123; MOXLEY G, 1993, TXB RHEUMATOLOGY, P188; MYRICK JE, 1997, MANUAL CLIN LAB IMMU, P30; NAKAMURA RM, 1997, MANUAL CLIN LAB IMMU, P39; NATARAJAN V, 1997, MANUAL CLIN LAB IMMU, P773; OCHS HD, 1973, J PEDIATR-US, V83, P77, DOI 10.1016/S0022-3476(73)80316-6; OGORMAN MRG, 1997, MANUAL CLIN LAB IMMU, P329; PATARCA R, 1997, MANUAL CLIN LAB IMMU, P296; PODZORSKI RP, 1997, MANUAL CLIN LAB IMMU, P77; PUNT JA, 1996, CLIN IMMUNOLOGY PRIN, P157; QUIE PG, 1992, MANUAL CLIN LABORATO, P419; RASSENTI LZ, 1997, MANUAL CLIN LAB IMMU, P147; RODGERS RPC, 1994, BASIC CLIN IMMUNOL, P151; ROSSIO JL, 1997, MANUAL CLIN LAB IMMU, P348; SAKAR G, 1992, GENOMICS, V13, P441; SALZMAN GC, 1975, ACTA CYTOL, V19, P374; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SOC HC, 1988, MED DECIS MAKING, P103; SPRINGER TA, 1984, J EXP MED, V160, P1901, DOI 10.1084/jem.160.6.1901; VECCHIO TJ, 1966, NEW ENGL J MED, V274, P1171, DOI 10.1056/NEJM196605262742104; VOWELLS SJ, 1995, J IMMUNOL METHODS, V178, P89, DOI 10.1016/0022-1759(94)00247-T; Vowells SJ, 1996, J PEDIATR-US, V128, P104, DOI 10.1016/S0022-3476(96)70437-7; Winchester RJ, 1986, MANUAL CLIN IMMUNOLO, P212; YANG KD, 1996, CLIN IMMUNOLOGY PRIN, P2141; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184	62	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1823	1834		10.1001/jama.278.22.1823	http://dx.doi.org/10.1001/jama.278.22.1823			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396643				2022-12-28	WOS:A1997YK15500004
J	Chung, CD; Liao, JY; Liu, B; Rao, XP; Jay, P; Berta, P; Shuai, K				Chung, CD; Liao, JY; Liu, B; Rao, XP; Jay, P; Berta, P; Shuai, K			Specific inhibition of Stat3 signal transduction by PIAS3	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; ACTIVATION; GENE; TRANSCRIPTION; PROTEINS; CLONING; PATHWAY; GAMMA; DNA	The signal transducer and activator of transcription-3 (Stat3) protein is activated by the interleukin 6 (IL-6) family of cytokines, epidermal growth factor, and leptin. A protein named PIAS3 (protein inhibitor of activated STAT) that binds to Stat3 was isolated and characterized. The association of PIAS3 with Stat3 in vivo was only observed in cells stimulated with ligands that cause the activation of Stat3. PIAS3 blocked the DNA-binding activity of Stat3 and inhibited Stat3-mediated gene activation. Although Stat1 is also phosphorylated in response to IL-6, PIAS3 did not interact with Stat1 or affect its DNA-binding or transcriptional activity. The results indicate that PIAS3 is a specific inhibitor of Stat3.	UNIV CALIF LOS ANGELES,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095; CTR RECH BIOCHIM MACROMOL,F-34000 MONTPELLIER,FRANCE; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; Universite de Montpellier; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Jay, Philippe/ABD-9223-2020	Jay, Philippe/0000-0003-0156-5700	NATIONAL CANCER INSTITUTE [T32CA009056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039612] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09056] Funding Source: Medline; NIAID NIH HHS [AI39612] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Chung C.-A., UNPUB; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Leveillard Thierry, 1993, Gene Expression, V3, P135; LIAO J, UNPUB, P63509; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	21	778	834	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1803	1805		10.1126/science.278.5344.1803	http://dx.doi.org/10.1126/science.278.5344.1803			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388184				2022-12-28	WOS:A1997YJ90100050
J	Simons, FER; Dolovich, J; Moote, DW; Mazza, JA; Lyttle, B; Becker, AB; Watson, WTA; Gold, M; Zinman, R; Feanny, SJ; Ferguson, A; Cockcroft, DW; Taylor, B; Bouchard, J; Simard, F; Lavi, S; Mazer, B				Simons, FER; Dolovich, J; Moote, DW; Mazza, JA; Lyttle, B; Becker, AB; Watson, WTA; Gold, M; Zinman, R; Feanny, SJ; Ferguson, A; Cockcroft, DW; Taylor, B; Bouchard, J; Simard, F; Lavi, S; Mazer, B			A comparison of beclomethasone, salmeterol, and placebo in children with asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-TERM TREATMENT; INHALED CORTICOSTEROID BUDESONIDE; CHILDHOOD ASTHMA; PREPUBERTAL CHILDREN; GROWTH-RETARDATION; DIPROPIONATE; AEROSOL; MILD	Background An inhaled glucocorticoid is currently the medication of choice for long-term control of persistent asthma in children. The role of long-acting beta(2)-adrenergic-receptor agonists, such as salmeterol, needs to be defined. Methods We conducted a randomized, double-blind, placebo-controlled, parallel-group, one-year study of 241 children (mean [+/-SD] age, 9.3+/-2.4 years) with clinically stable asthma and less than one month of prior glucocorticoid use. We compared inhaled beclomethasone dipropionate (200 mu g twice daily) with salmeterol xinafoate (50 mu g twice daily) and placebo (lactose). The primary outcome measure, airway responsiveness (as assessed with a methacholine challenge), was evaluated before treatment; after 3, 6, 9, and 12 months of treatment (12 and 36 hours after study medications had been withheld); and 2 weeks after the end of treatment, Spirometry, symptoms, use of rescue medication (200 mu g of albuterol inhaled as needed), and adverse effects were also assessed. Results During months 1 through 12 overall, beclomethasone was associated with significantly less airway hyperresponsiveness than salmeterol (P=0.003) or placebo (P<0.001). This effect was lost two weeks after treatment had been stopped. As compared with placebo, beclomethasone was associated with less variability between morning and evening in the peak expiratory flow (P=0.002), as was salmeterol (P=0.02). Beclomethasone was also associated with a reduced need for albuterol as rescue therapy (P<0.001) and fewer withdrawals because of asthma exacerbations (P=0.03), but salmeterol was not (P=0.09 and P=0.55, respectively). During months 1 through 12, linear growth was 3.96 cm in the children receiving beclomethasone, as compared with 5.40 cm in the salmeterol group (P=0.004) and 5.04 cm in the placebo group (P=0.018). Height was not measured after treatment ended. Conclusions Beclomethasone was effective in reducing airway hyperresponsiveness and in controlling symptoms of asthma, but it was associated with decreased linear growth. Salmeterol was not as effective as beclomethasone in reducing airway hyperresponsiveness or in controlling symptoms; however, it was an effective bronchodilator and was not associated with rebound airway hyperresponsiveness, masking of symptoms, or adverse effects. (C) 1997, Massachusetts Medical Society.			Simons, FER (corresponding author), CHILDRENS HOSP WINNIPEG,820 SHERBROOK ST,WINNIPEG,MB R3A 1R9,CANADA.							AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Crowder M.J., 1990, ANAL REPEATED MEASUR; CROWLEY S, 1995, J PEDIATR-US, V126, P297, DOI 10.1016/S0022-3476(95)70566-X; DONAHUE JG, 1997, JAMA-J AM MED ASSOC, V277, P877; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; DRAPER NR, 1981, APPLIED REGRESSION A; GARDNER RM, 1988, ANN INTERN MED, V108, P217, DOI 10.7326/0003-4819-108-2-217; GODFREY S, 1974, ARCH DIS CHILD, V49, P591, DOI 10.1136/adc.49.8.591; GREEN CP, 1992, ARCH DIS CHILD, V67, P1014, DOI 10.1136/adc.67.8.1014; HUNT GJJ, 1994, THORAX, V49, pP399; Inoue T, 1995, Arerugi, V44, P678; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LITTLEWOOD JM, 1988, LANCET, V1, P115; MEIJER GG, 1995, AM J RESP CRIT CARE, V152, P1887, DOI 10.1164/ajrccm.152.6.8520751; MERKUS PJFM, 1993, PEDIATRICS, V91, P1121; MURPHY S, 1997, NIH PUBLICATION; Saha MT, 1997, ACTA PAEDIATR, V86, P138, DOI 10.1111/j.1651-2227.1997.tb08854.x; Silverstein MD, 1997, J ALLERGY CLIN IMMUN, V99, P466, DOI 10.1016/S0091-6749(97)70072-1; SIMONS FER, 1992, J ALLERGY CLIN IMMUN, V90, P840, DOI 10.1016/0091-6749(92)90110-N; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; THOMAS BC, 1994, ACTA PAEDIATR, V83, P196, DOI 10.1111/j.1651-2227.1994.tb13050.x; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; VANESSENZANDVLIET EE, 1994, EUR RESPIR J, V7, P63, DOI 10.1183/09031936.94.07010063; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; VERBERNE AAP, 1996, AM J RESP CRIT CARE, V153, pA408; Verberne AAPH, 1996, J ALLERGY CLIN IMMUN, V97, P938, DOI 10.1016/S0091-6749(96)80068-6; VERBERNE AAPH, 1993, J ALLERGY CLIN IMMUN, V91, P127, DOI 10.1016/0091-6749(93)90305-Y; VOLOVITZ B, 1993, NEW ENGL J MED, V329, P1703, DOI 10.1056/NEJM199312023292305; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; WALES JKH, 1991, LANCET, V338, P1535, DOI 10.1016/0140-6736(91)92362-6; WARNER JO, IN PRESS PEDIAT PULM; White A. J., 1997, Journal of Allergy and Clinical Immunology, V99, pS325	35	233	241	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 4	1997	337	23					1659	1665		10.1056/NEJM199712043372304	http://dx.doi.org/10.1056/NEJM199712043372304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ871	9385125				2022-12-28	WOS:A1997YJ87100004
J	Duncan, A				Duncan, A			New therapies for severe meningococcal disease but better outcomes?	LANCET			English	Editorial Material							TISSUE-PLASMINOGEN-ACTIVATOR; PLACEBO-CONTROLLED TRIAL; SEPTIC SHOCK; FULMINANT MENINGOCOCCEMIA; DOUBLE-BLIND; COAGULATION				Duncan, A (corresponding author), PRINCESS MARGARET HOSP CHILDREN,PAEDIAT INTENS CARE UNIT,PERTH,WA 6008,AUSTRALIA.							BELLOMO R, 1993, CRIT CARE MED, V21, P522, DOI 10.1097/00003246-199304000-00011; FIJNVANDRAAT K, 1995, THROMB HAEMOSTASIS, V73, P15; FOURRIER F, 1993, CHEST, V104, P882, DOI 10.1378/chest.104.3.882; Giroir BP, 1997, LANCET, V350, P1439, DOI 10.1016/S0140-6736(97)06468-4; Goldman AP, 1997, LANCET, V349, P466, DOI 10.1016/S0140-6736(96)12106-1; KEELEY SR, 1991, LANCET, V337, P1359, DOI 10.1016/0140-6736(91)93048-E; MCCLOSKEY RV, 1994, ANN INTERN MED, V121, P1, DOI 10.7326/0003-4819-121-1-199407010-00001; RIVARD GE, 1995, J PEDIATR-US, V126, P646, DOI 10.1016/S0022-3476(95)70369-1; VANDEUREN M, 1992, CLIN INFECT DIS, V15, P424, DOI 10.1093/clind/15.3.424; ZENZ W, 1995, PEDIATRICS, V96, P144	10	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1565	1566		10.1016/S0140-6736(05)64007-X	http://dx.doi.org/10.1016/S0140-6736(05)64007-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393331				2022-12-28	WOS:A1997YH98600003
J	Deming, TJ				Deming, TJ			Facile synthesis of block copolypeptides of defined architecture	NATURE			English	Article							ANHYDRIDES; ACID	Many natural polymeric materials (particularly structural proteins) display a hierarchy of structure over several length scales. Block copolymers are able to self-assemble into ordered nanostructures(1,2), but the random-coiled nature of their polymer chains usually suppresses any further levels of organization. The use of components with regular structures, such as rigid-rod polymers, can increase the extent of spatial organization in self-assembling materials(3). But the synthesis of such polymeric components typically involves complicated reaction steps that are not suitable for large-scale production. Proteins form hierarchically organized structures in which the fundamental motifs are generally alpha-helical coils and beta-sheets(4). Attempts to synthesize polypeptides with well-defined amino-acid sequences, which might adopt similar organized structures, have been plagued by unwanted side reactions(5) that give rise to products with a wide range of molecular weights(6-10), hampering the formation of well-defined peptide block copolymers(11-17). Here I describe a polymerization strategy that overcomes these difficulties by using organonickel initiators which suppress chain-transfer and termination side reactions. This approach allows the facile synthesis of block copolypeptides with well-defined sequences, which might provide new peptide-based biomaterials with potential applications in tissue engineering, drug delivery and biomimetic composite formation.	UNIV CALIF SANTA BARBARA,DEPT CHEM,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara	Deming, TJ (corresponding author), UNIV CALIF SANTA BARBARA,DEPT MAT,SANTA BARBARA,CA 93106, USA.		Deming, Timothy/I-5411-2013	Deming, Timothy/0000-0002-0594-5025				Bamford C.H.E.A., 1956, SYNTHETIC POLYPEPTID; BLOCK H, 1983, POLY GAMMA BENZYL LA; CARDINAUX F, 1977, BIOPOLYMERS, V16, P2005, DOI 10.1002/bip.1977.360160914; CASTANO AM, 1994, ORGANOMETALLICS, V13, P2262, DOI 10.1021/om00018a020; COLLMAN JP, 1987, PRINCIPLES APPLICATI; Deming TJ, 1997, J AM CHEM SOC, V119, P2759, DOI 10.1021/ja962625w; Deming TJ, 1997, ADV MATER, V9, P299, DOI 10.1002/adma.19970090404; Fetters L., 1987, ENCY POLYM SCI ENG, V10, P19; GRATZER WB, 1963, J AM CHEM SOC, V85, P1193, DOI 10.1021/ja00891a035; Hillmyer MA, 1996, SCIENCE, V271, P976, DOI 10.1126/science.271.5251.976; HOWARD JC, 1977, BIOPOLYMERS, V16, P2029, DOI 10.1002/bip.1977.360160915; IDELSON M, 1957, J AM CHEM SOC, V79, P3948, DOI 10.1021/ja01572a002; IDELSON M, 1958, J AM CHEM SOC, V80, P2387, DOI 10.1021/ja01543a012; INOUE K, 1994, J AM CHEM SOC, V116, P10783, DOI 10.1021/ja00102a053; Kricheldorf H. R., 1987, ALPHA AMINOACID N CA; Kricheldorf H. R., 1990, MODELS BIOPOLYMERS R; KUBOTA S, 1975, BIOPOLYMERS, V14, P305; LUNDBERG RD, 1957, J AM CHEM SOC, V79, P3961, DOI 10.1021/ja01572a004; Matsen MW, 1996, MACROMOLECULES, V29, P7641, DOI 10.1021/ma960744q; NOSHAY A, 1977, BLOCK COPOLYMERS; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SANO K, 1984, B CHEM SOC JPN, V57, P2741, DOI 10.1246/bcsj.57.2741; Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384; UHLIG E, 1980, Z ANORG ALLG CHEM, V465, P141, DOI 10.1002/zaac.19804650115; WEBSTER OW, 1991, SCIENCE, V251, P887, DOI 10.1126/science.251.4996.887	25	522	608	6	247	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					386	389		10.1038/37084	http://dx.doi.org/10.1038/37084			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389476				2022-12-28	WOS:A1997YH54900058
J	McAnulty, J; Halperin, B; Kron, J; Larsen, G; Raitt, M; Swenson, R; Florek, R; Marchant, C; Hamlin, M; Heywood, G; Friedman, P; Stevenson, W; Swat, M; Ganz, L; Sweeney, M; Shea, J; Steinberg, J; Ehlert, F; Zelenkofske, S; MenchavezTan, E; DeStefano, M; Brown, G; Anderson, J; Karagounis, L; Crandall, B; Osborn, J; Rawling, D; Summers, K; Jacobsen, M; Herre, J; Bernstein, R; Klevan, L; Cannon, D; Bhandari, A; Lerman, R; Firth, B; Klein, R; Freedman, R; Marks, M; Delahunty, M; Spratt, C; Marinchak, R; Rials, S; Kowey, P; Filart, R; Hernandez, M; Scher, D; Zukerman, L; Farrell, S; Kolk, D; Criner, H; Tait, B; Wilkoff, B; Pinski, S; Cross, J; Shewchik, J; Epstein, A; Cooper, R; Dailey, S; Kay, G; Plumb, V; Bubien, R; KnottsDolson, S; McKenna, P; Tidwell, C; Kim, S; Fisher, J; Ferrick, K; Gross, J; BenZur, U; Durkin, J; Ferrick, A; Beckman, K; McClelland, J; Gonzalez, M; Widman, L; Lane, R; Deaton, T; Foster, J; Straughn, G; Wade, L; Brodsky, M; Allen, B; Ehrlich, S; Wolff, L; MacariHinson, M; Coromilas, J; Bigger, T; Livelli, F; Reiffel, J; Hickey, K; Akiyama, T; Daubert, J; Kim, C; Switzer, D; Pande, P; Flynn, D; Keller, M; Ocampo, C; Wahl, K; Vogt, J; Kutalek, S; Hessen, S; Movsowitz, C; Samuels, F; Wilber, S; Baessler, C; Soto, D; Schuster, M; Scott, G; CovelaskyRobinson, R; Fletcher, S; Siegl, K; Finn, L; Saari, C; Almquist, A; Baldwin, P; Hauser, R; Milstein, S; Pritzker, M; Schreiber, V; Torres, V; Pai, S; Platt, M; Timothy, P; Bishop, V; Zipes, D; Engelstein, E; Miles, W; Foreman, L; Love, J; Cutler, J; BosworthFarrell, S; RizoPatron, C; Belco, K; Payne, J; Arnold, D; Zhu, W; Pratt, C; Martins, J; Lee, H; Hopson, J; Hopson, R; Tullo, N; Irmiere, C; Henry, A; Wathen, M; Echt, D; Roden, D; Lee, J; Murray, K; Rottman, J; Crawford, D; Connors, N; Berns, E; Lippman, N; Barry, M; Dalamagas, H; Cook, J; Kabell, G; Kirchhoffer, J; Warwick, D; Burkott, B; Tomaszewski, D; Buxton, A; Hsia, H; Miller, J; Rothman, S; Adelizzi, N; Gastineau, M; Thome, L; Whitley, D; Greer, G; Santoro, I; Swaim, J; Whittle, S; Rome, M; Kresge, K; Tregoning, C; Howard, C; Carlson, M; Rosenbaum, D; Lewis, W; Biblo, L; Mackall, J; Waldo, A; Kandrac, J; Foster, P; Crevey, B; Genovely, H; Schutzman, J; Viater, K; Coyle, C; Pacifico, A; Nasir, N; Trainor, K; Sung, R; Liem, B; Young, C; Lauer, M; Peterson, J; Ottoboni, L; Goold, P; Curtis, A; Conti, J; Nelson, C; Mounsey, P; Nath, S; Haines, D; Ackerman, S; Bowman, L; Nora, M; OToole, M; Collura, R; Enger, E; Russo, A; Waxman, H; Morrissey, J; Raspa, D; Jadonath, R; Goldner, B; Merkatz, K; Chepurko, L; Saksena, S; Krol, R; Munsif, A; Lewis, C; Luceri, R; Zilo, P; Weiss, D; Jonas, A; Vardeman, L; Stamato, N; Whiting, D; Chilson, D; Lessmeier, T; Pochis, W; Baxter, J; Nademanee, K; Weinberger, J; Bailey, W; Reiter, M; Blankenship, M; Page, R; Jessen, M; Canby, R; Horton, R; Welch, P; Kessler, D; Joglar, J; Hamdan, M; Nelson, L; Erwin, G; Chien, W; Stevenot, R; Merillat, J; McPherson, M; Gold, M; Shorofsky, S; Peters, R; Kavesh, N; Froman, D; Scott, H; Shih, HT; Dougherty, A; Jalal, S; Naccarrelli, G; Wolbrette, D; Wilson, D; Roth, J; Gadhoke, A; Mauermann, S; Schwartz, K; Asbell, C; Scheinman, M; Eisenberg, S; Epstein, L; Fitzpatrick, A; Griffin, G; Lee, R; Lesh, M; Wong, M; Zebede, J; Samet, P; Tolentino, A; Rubin, S; Podrid, P; Fuchs, T; Mazur, M; Wyse, G; Duff, H; Gillis, A; Mitchell, B; Rothschild, J; Sheldon, R; Cassidy, P; Karaian, C; Dorian, P; Newman, D; Mitchell, J; Greene, M; Roy, D; Dubuc, M; Talajic, M; Thibault, B; Morrissette, D; Jenkins, L; Connolly, S; Hallstrom, A; Greene, L; Scholz, M; Powell, J; Renfroe, E; Ledingham, R; Morris, M; Lancaster, S; Moore, R; Olarte, A; Yao, Q; Brooks, MM; Hofer, B; Sullivan, S; Schron, E; Domanski, M; Follmann, D; Rosenberg, Y; Jennings, C; Richardson, D; Cobb, L; Furman, S; DiMarco, J; Knatterud, G; Levine, R; Strauss, H; Woosley, R; Singh, B; Mason, J; Griffin, J; Ruskin, J; Yusuf, S				McAnulty, J; Halperin, B; Kron, J; Larsen, G; Raitt, M; Swenson, R; Florek, R; Marchant, C; Hamlin, M; Heywood, G; Friedman, P; Stevenson, W; Swat, M; Ganz, L; Sweeney, M; Shea, J; Steinberg, J; Ehlert, F; Zelenkofske, S; MenchavezTan, E; DeStefano, M; Brown, G; Anderson, J; Karagounis, L; Crandall, B; Osborn, J; Rawling, D; Summers, K; Jacobsen, M; Herre, J; Bernstein, R; Klevan, L; Cannon, D; Bhandari, A; Lerman, R; Firth, B; Klein, R; Freedman, R; Marks, M; Delahunty, M; Spratt, C; Marinchak, R; Rials, S; Kowey, P; Filart, R; Hernandez, M; Scher, D; Zukerman, L; Farrell, S; Kolk, D; Criner, H; Tait, B; Wilkoff, B; Pinski, S; Cross, J; Shewchik, J; Epstein, A; Cooper, R; Dailey, S; Kay, G; Plumb, V; Bubien, R; KnottsDolson, S; McKenna, P; Tidwell, C; Kim, S; Fisher, J; Ferrick, K; Gross, J; BenZur, U; Durkin, J; Ferrick, A; Beckman, K; McClelland, J; Gonzalez, M; Widman, L; Lane, R; Deaton, T; Foster, J; Straughn, G; Wade, L; Brodsky, M; Allen, B; Ehrlich, S; Wolff, L; MacariHinson, M; Coromilas, J; Bigger, T; Livelli, F; Reiffel, J; Hickey, K; Akiyama, T; Daubert, J; Kim, C; Switzer, D; Pande, P; Flynn, D; Keller, M; Ocampo, C; Wahl, K; Vogt, J; Kutalek, S; Hessen, S; Movsowitz, C; Samuels, F; Wilber, S; Baessler, C; Soto, D; Schuster, M; Scott, G; CovelaskyRobinson, R; Fletcher, S; Siegl, K; Finn, L; Saari, C; Almquist, A; Baldwin, P; Hauser, R; Milstein, S; Pritzker, M; Schreiber, V; Torres, V; Pai, S; Platt, M; Timothy, P; Bishop, V; Zipes, D; Engelstein, E; Miles, W; Foreman, L; Love, J; Cutler, J; BosworthFarrell, S; RizoPatron, C; Belco, K; Payne, J; Arnold, D; Zhu, W; Pratt, C; Martins, J; Lee, H; Hopson, J; Hopson, R; Tullo, N; Irmiere, C; Henry, A; Wathen, M; Echt, D; Roden, D; Lee, J; Murray, K; Rottman, J; Crawford, D; Connors, N; Berns, E; Lippman, N; Barry, M; Dalamagas, H; Cook, J; Kabell, G; Kirchhoffer, J; Warwick, D; Burkott, B; Tomaszewski, D; Buxton, A; Hsia, H; Miller, J; Rothman, S; Adelizzi, N; Gastineau, M; Thome, L; Whitley, D; Greer, G; Santoro, I; Swaim, J; Whittle, S; Rome, M; Kresge, K; Tregoning, C; Howard, C; Carlson, M; Rosenbaum, D; Lewis, W; Biblo, L; Mackall, J; Waldo, A; Kandrac, J; Foster, P; Crevey, B; Genovely, H; Schutzman, J; Viater, K; Coyle, C; Pacifico, A; Nasir, N; Trainor, K; Sung, R; Liem, B; Young, C; Lauer, M; Peterson, J; Ottoboni, L; Goold, P; Curtis, A; Conti, J; Nelson, C; Mounsey, P; Nath, S; Haines, D; Ackerman, S; Bowman, L; Nora, M; OToole, M; Collura, R; Enger, E; Russo, A; Waxman, H; Morrissey, J; Raspa, D; Jadonath, R; Goldner, B; Merkatz, K; Chepurko, L; Saksena, S; Krol, R; Munsif, A; Lewis, C; Luceri, R; Zilo, P; Weiss, D; Jonas, A; Vardeman, L; Stamato, N; Whiting, D; Chilson, D; Lessmeier, T; Pochis, W; Baxter, J; Nademanee, K; Weinberger, J; Bailey, W; Reiter, M; Blankenship, M; Page, R; Jessen, M; Canby, R; Horton, R; Welch, P; Kessler, D; Joglar, J; Hamdan, M; Nelson, L; Erwin, G; Chien, W; Stevenot, R; Merillat, J; McPherson, M; Gold, M; Shorofsky, S; Peters, R; Kavesh, N; Froman, D; Scott, H; Shih, HT; Dougherty, A; Jalal, S; Naccarrelli, G; Wolbrette, D; Wilson, D; Roth, J; Gadhoke, A; Mauermann, S; Schwartz, K; Asbell, C; Scheinman, M; Eisenberg, S; Epstein, L; Fitzpatrick, A; Griffin, G; Lee, R; Lesh, M; Wong, M; Zebede, J; Samet, P; Tolentino, A; Rubin, S; Podrid, P; Fuchs, T; Mazur, M; Wyse, G; Duff, H; Gillis, A; Mitchell, B; Rothschild, J; Sheldon, R; Cassidy, P; Karaian, C; Dorian, P; Newman, D; Mitchell, J; Greene, M; Roy, D; Dubuc, M; Talajic, M; Thibault, B; Morrissette, D; Jenkins, L; Connolly, S; Hallstrom, A; Greene, L; Scholz, M; Powell, J; Renfroe, E; Ledingham, R; Morris, M; Lancaster, S; Moore, R; Olarte, A; Yao, Q; Brooks, MM; Hofer, B; Sullivan, S; Schron, E; Domanski, M; Follmann, D; Rosenberg, Y; Jennings, C; Richardson, D; Cobb, L; Furman, S; DiMarco, J; Knatterud, G; Levine, R; Strauss, H; Woosley, R; Singh, B; Mason, J; Griffin, J; Ruskin, J; Yusuf, S			A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; CARDIOVERTER-DEFIBRILLATOR; MYOCARDIAL-INFARCTION; CLINICAL-TRIALS; LEAD SYSTEMS; SURVIVORS; CLASSIFICATION; MORTALITY; DISEASE	Background Patients who survive life-threatening ventricular arrhythmias are at risk for recurrent arrhythmias. They can be treated with either an implantable cardioverter-defibrillator or antiarrhythmic drugs, but the relative efficacy of these two treatment strategies is unknown. Methods To address this issue, we conducted a randomized comparison of these two treatment strategies in patients who had been resuscitated from near-fatal ventricular fibrillation or who had undergone cardioversion from sustained ventricular tachycardia, Patients with ventricular tachycardia also had either syncope or other serious cardiac symptoms, along with a left ventricular ejection fraction of 0.40 or less. One group of patients was treated with implantation of a cardioverter-defibrillator; the other received class III antiarrhythmic drugs, primarily amiodarone at empirically determined doses. Fifty-six clinical centers screened all patients who presented with ventricular tachycardia or ventricular fibrillation during a period of nearly four years. Of 1016 patients (45 percent of whom had ventricular fibrillation, and 55 percent ventricular tachycardia), 507 were randomly assigned to treatment with implantable cardioverter-defibrillators and 509 to antiarrhythmic-drug therapy. The primary end point was overall mortality. Results Follow-up was complete for 1013 patients (99.7 percent). Overall survival was greater with the implantable defibrillator, with unadjusted estimates of 89.3 percent, as compared with 82.3 percent in the antiarrhythmic-drug group at one year, 81.6 percent versus 74.7 percent at two years, and 75.4 percent versus 64.1 percent at three years (P<0.02). The corresponding reductions in mortality (with 95 percent confidence limits) with the implantable defibrillator were 39+/-20 percent, 27+/-21 percent, and 31+/-21 percent. Conclusions Among survivors of ventricular fibrillation or sustained ventricular tachycardia causing severe symptoms, the implantable cardioverter-defibrillator is superior to antiarrhythmic drugs for increasing overall survival. (C) 1997, Massachusetts Medical Society.	INDIANA UNIV, INDIANAPOLIS, IN 46204 USA; UNIV CALGARY, CALGARY, AB, CANADA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; UNIV ALABAMA, BIRMINGHAM, AL USA; NHLBI, BETHESDA, MD 20892 USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Calgary; Harvard University; Brigham & Women's Hospital; University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	McAnulty, J (corresponding author), UNIV WASHINGTON, AVID CLIN TRIAL CTR, 1107 NE 45TH ST, RM 505, SEATTLE, WA 98105 USA.		Daubert, James P./ABC-1476-2021; Roden, Dan/ABD-5412-2021; Greene, Lewis J/L-6098-2017; Woosley, Raymond/AAE-4874-2020	Greene, Lewis J/0000-0003-0144-9726; Woosley, Raymond/0000-0002-2588-328X; Fisher, John/0000-0003-2748-8715	NHLBI NIH HHS [N01-HC-25117] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025117] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1989, NEW ENGL J MED, V321, P406; BORGGREFE M, 1992, J CARDIOVASC PHARM, V20, pS32, DOI 10.1097/00005344-199220002-00007; Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; COBB LA, 1975, CIRCULATION, V52, P223; CONNOLLY SJ, 1993, AM J CARDIOL, V72, pF103, DOI 10.1016/0002-9149(93)90972-F; DUSMAN RE, 1990, CIRCULATION, V82, P51, DOI 10.1161/01.CIR.82.1.51; Epstein AE, 1996, J AM COLL CARDIOL, V27, P433, DOI 10.1016/0735-1097(95)00482-3; EPSTEIN AE, 1995, AM J CARDIOL, V75, P470; FOGOROS RN, 1989, PACE, V12, P1465, DOI 10.1111/j.1540-8159.1989.tb06151.x; GOLDSTEIN S, 1985, CIRCULATION, V71, P873, DOI 10.1161/01.CIR.71.5.873; GREENE HL, 1993, AM J CARDIOL, V72, P280; GREENE HL, 1989, AM J CARDIOL, V63, P1, DOI 10.1016/0002-9149(89)91065-5; Josephson M, 1996, AM J CARDIOL, V77, P859, DOI 10.1016/S0002-9149(97)89182-5; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; JULIAN DG, 1997, LANCET, V349, P1180; KADISH AH, 1987, J AM COLL CARDIOL, V10, P90, DOI 10.1016/S0735-1097(87)80165-1; Kim SG, 1997, AM J CARDIOL, V80, P454, DOI 10.1016/S0002-9149(97)00394-9; KIM SG, 1993, PACE, V16, P1358, DOI 10.1111/j.1540-8159.1993.tb01728.x; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LEHMANN MH, 1988, AM J CARDIOL, V62, P803, DOI 10.1016/0002-9149(88)91226-X; MALONEY J, 1991, PACE, V14, P280, DOI 10.1111/j.1540-8159.1991.tb05107.x; MASON JW, 1993, NEW ENGL J MED, V329, P452, DOI 10.1056/NEJM199308123290702; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; NEWMAN D, 1992, AM J CARDIOL, V69, P899, DOI 10.1016/0002-9149(92)90789-2; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; POWELL AC, 1993, CIRCULATION, V88, P1083, DOI 10.1161/01.CIR.88.3.1083; SAKSENA S, 1993, PACE, V16, P202, DOI 10.1111/j.1540-8159.1993.tb01562.x; SIEBELS J, 1994, AM HEART J, V127, P1139, DOI 10.1016/0002-8703(94)90101-5; THOMAS AC, 1988, PACE, V11, P2053, DOI 10.1111/j.1540-8159.1988.tb06349.x; Waldo, 1996, LANCET, V348, P416; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0; ZIPES DP, 1994, CIRCULATION, V89, P2934, DOI 10.1161/01.CIR.89.6.2934; ZIPES DP, 1995, CIRCULATION, V92, P59, DOI 10.1161/01.CIR.92.1.59	34	2307	2370	1	52	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 27	1997	337	22					1576	1583						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH521	9411221				2022-12-28	WOS:A1997YH52100002
J	Hayward, RA; Manning, WG; Kaplan, SH; Wagner, EH; Greenfield, S				Hayward, RA; Manning, WG; Kaplan, SH; Wagner, EH; Greenfield, S			Starting insulin therapy in patients with type 2 diabetes - Effectiveness, complications, and resource utilization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POPULATION; MELLITUS; GLUCOSE; DISEASE; CARE; OUTCOMES; ILLNESS; IMPACT; TRIAL; BLOOD	Context.-Although experimental studies show that insulin therapy can be safe and efficacious in improving glycemic control in type 2 diabetes under optimal conditions (ie, using patient volunteers with close monitoring under strict study protocols), little is known about its effectiveness, complication rates, and associated resource utilization in actual clinical practice. Design.-Cohort study. Setting.-Large staff-model health maintenance organization. Participants.-A total of 8668 patients with type 2 diabetes cared for by generalist physicians from 1990 through 1993. Outcome Measures.-Resource use (hospitalizations, outpatient visits, laboratory testing, and home glucose monitoring) and glycemic control were evaluated using combined clinical, survey, and administrative information systems data. Detailed clinical case-mix data, including a newly validated case-mix method, the Total Illness Burden Index, were collected on a subsample of 1738 patients. Results.-Among patients starting insulin therapy, hemoglobin A(1c) (HbA(1c)) decreased by 0.9 percentage point (95% confidence interval, 0.7-1.0) at 1 year compared with those receiving stable medication regimens; however, 2 years after starting insulin therapy, 60% still had HbA(1c) levels of 8% or greater. There was no evidence that some primary care physicians achieved better results than other primary care physicians when starting insulin therapy in their patients. Patients with the poorest baseline glycemic control achieved substantially greater HbA(1c), reductions; those with a baseline HbA(1c) level of 13% had a 3-fold greater decline in HbA(1c) than those whose baseline HbA(1c) level was 9%, For a subset of all patients for whom detailed clinical case-mix data were obtained, those taking insulin had higher resource use than those taking sulfonylureas, independent of illness severity. After adjusting for age, sex, race, socioeconomic status, disease duration, and severity of diabetes and comorbidities, insulin: users had slightly more laboratory tests performed, 2.4 more outpatient visits per year, and almost 300 more fingersticks for home glucose testing per year compared with sulfonylurea users (all P<.01). Although 15% of patients receiving insulin therapy reported weekly symptoms of hypoglycemia, insulin therapy was not associated with an increase in emergency department visits (after case-mix adjustment) and resulted in only 0.5 hypoglycemia-related hospitalizations per 100 patient-years. Conclusions.-For patients with type 2 diabetes who were cared for by generalist physicians, starting insulin therapy was generally safe and effective in achieving moderate glycemic control in patients who initially had poor glycemic control. However, insulin therapy was associated with increases in resource use and was rarely effective in achieving tight glycemic control, even for those with moderate control.	ANN ARBOR VET AFFAIRS MED CTR, VET AFFAIRS CTR PRACTICE MANAGEMENT & OUTCOMES RE, ANN ARBOR, MI USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV HLTH SERV RES & POLICY, MINNEAPOLIS, MN 55455 USA; TUFTS UNIV NEW ENGLAND MED CTR, PRIMARY CARE OUTCOMES RES INST, BOSTON, MA 02111 USA; GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, SEATTLE, WA 98101 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities; Tufts Medical Center; Group Health Cooperative				Kaplan, Sherrie/0000-0002-8644-5849; Greenfield, Sheldon/0000-0003-4628-1998	AHRQ HHS [HSO 666501] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAIRA C, 1995, DIABETES CARE, V18, P1113, DOI 10.2337/diacare.18.8.1113; ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; ALLEN BT, 1990, DIABETES CARE, V13, P1044, DOI 10.2337/diacare.13.10.1044; ANDERSON RM, 1988, DIABETES CARE, V11, P519, DOI 10.2337/diacare.11.7.519; [Anonymous], 1996, DIABETES CARE, V19, pS8; CAVE D, 1995, BENEFITS Q, V2, P6; Colwell JA, 1996, ANN INTERN MED, V124, P178, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00020; Colwell JA, 1996, DIABETES CARE, V19, P896, DOI 10.2337/diacare.19.8.896; Duan N., 1983, J BUS STAT, V1, P115, DOI DOI 10.2307/1391852; GLAUBER HS, 1992, DIABETES CARE, V15, P870, DOI 10.2337/diacare.15.7.870; GREENFIELD S, 1994, DIABETES CARE, V17, P32; Greenfield S., 1995, JGIM, V10, P67; GREENFIELD S, 1993, MED CARE, V31, P141, DOI 10.1097/00005650-199302000-00005; GREENFIELD S, 1995, MED CARE, V33, pAS47; GREENFIELD S, 1994, AM J KIDNEY DIS, V24, P298, DOI 10.1016/S0272-6386(12)80195-8; KLEIN CE, 1993, J GEN INTERN MED, V8, P597, DOI 10.1007/BF02599711; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1987, AM J EPIDEMIOL, V126, P415, DOI 10.1093/oxfordjournals.aje.a114673; KrouselWood MA, 1996, J GEN INTERN MED, V11, P32, DOI 10.1007/BF02603483; LITTLE RR, 1991, CLIN CHEM, V37, P1725; Manning W. G., 1981, HLTH EC HLTH EC; MANNING WG, 1987, J ECONOMETRICS, V35, P59, DOI 10.1016/0304-4076(87)90081-9; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MCMAHON LF, 1989, ANN INTERN MED, V111, P318, DOI 10.7326/0003-4819-111-4-318; *MED EC CO INC, 1996, 1996 RED BOOK; NEWMAN WP, 1990, ARCH INTERN MED, V150, P107, DOI 10.1001/archinte.150.1.107; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; Peters B.G., 1994, J EUROPEAN PUBLIC PO, V1, P9, DOI [10.1080/13501769408406945, DOI 10.1080/13501769408406945]; PREGIBON D, 1980, APPL STAT, V29, P115; RAMSEY JB, 1969, J ROY STAT SOC B, V31, P350; Rettig B A, 1985, Nebr Med J, V70, P370; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TUKEY JW, 1949, BIOMETRICS, V5, P232, DOI 10.2307/3001938; TURNER RC, 1991, DIABETOLOGIA, V34, P877; Vijan S, 1997, ANN INTERN MED, V127, P788, DOI 10.7326/0003-4819-127-9-199711010-00003; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; WEST KM, 1983, DIABETES CARE, V6, P361, DOI 10.2337/diacare.6.4.361	37	196	198	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1663	1669		10.1001/jama.278.20.1663	http://dx.doi.org/10.1001/jama.278.20.1663			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388085				2022-12-28	WOS:A1997YG85900027
J	Fukuda, M; Asano, S; Nakamura, T; Adachi, M; Yoshida, M; Yanagida, M; Nishida, E				Fukuda, M; Asano, S; Nakamura, T; Adachi, M; Yoshida, M; Yanagida, M; Nishida, E			CRM1 is responsible for intracellular transport mediated by the nuclear export signal	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ORDER CHROMOSOME STRUCTURE; CELL-CYCLE; PROTEIN; LOCALIZATION; REV; IDENTIFICATION; SEQUENCE; TRANSCRIPTION; NUCLEOPORIN	The discovery of nuclear export signals (NESs) in a number of proteins revealed the occurrence of signal-dependent transport of proteins from the nucleus to the cytoplasm(1-14). Although the consensus motif of the NESs has been shown to be a leucine-rich, short amino-acid sequence(2,6,7), its receptor has not been identified. A cytotoxin leptomycin B (LMB) has recently been suggested to inhibit the NES-mediated transport of Rev protein(15). Here we show that LMB is a potent and specific inhibitor of the NES-dependent nuclear export of proteins. Moreover, we have found a protein of relative molecular mass 110K (p110) in Xenopus oocyte extracts that binds to the intact NES but not to the mutated, non-functional NES. The binding of p110 to NES is inhibited by LMB. We show that p110 is CRM1, which is an evolutionarily conserved protein(16-18) originally found as an essential nuclear protein in fission yeas(16) and known as a likely target of LMB19. We also show that nuclear export of a fission yeast protein, Dsk1, which has a leucine-rich NES, is disrupted in wildtype yeast treated with LMB or in the crm1 mutant. These results indicate that CRM1 is an essential mediator of the NES-dependent nuclear export of proteins in eukaryotic cells.	KYOTO UNIV,GRAD SCH SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 60601,JAPAN; UNIV TOKYO,GRAD SCH AGR & LIFE SCI,DEPT BIOTECHNOL,BUNKYO KU,TOKYO 113,JAPAN	Kyoto University; University of Tokyo			Fukuda, Makoto/S-9748-2019; Yoshida, Minoru/C-8049-2014; Fukuda, Makoto/C-9745-2009; Fukuda, Makoto/I-7915-2014	Fukuda, Makoto/0000-0003-0112-9925; Yoshida, Minoru/0000-0002-4376-5674; Fukuda, Makoto/0000-0003-0112-9925; Fukuda, Makoto/0000-0003-0112-9925				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FORMEROD M, 1997, EMBO J, V16, P807; Fornerod M, 1996, ONCOGENE, V13, P1801; FORNEROD M, 1997, CELL, V98, P1051; Fridell RA, 1996, EMBO J, V15, P5408, DOI 10.1002/j.1460-2075.1996.tb00924.x; Fridell RA, 1996, P NATL ACAD SCI USA, V93, P2936, DOI 10.1073/pnas.93.7.2936; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; Meyer BE, 1996, J VIROL, V70, P2350, DOI 10.1128/JVI.70.4.2350-2359.1996; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHI K, 1994, J BIOL CHEM, V269, P6320; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Richards SA, 1996, J CELL BIOL, V134, P1157, DOI 10.1083/jcb.134.5.1157; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STUZT F, 1995, CELL, V82, P495; TAKEUCHI M, 1993, MOL BIOL CELL, V4, P247, DOI 10.1091/mbc.4.3.247; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	29	1015	1029	1	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					308	311		10.1038/36894	http://dx.doi.org/10.1038/36894			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG667	9384386				2022-12-28	WOS:A1997YG66700069
J	Meier, CR; Jick, H				Meier, CR; Jick, H			Omeprazole, H-2 blockers, and polyarthralgia: case-control study	BRITISH MEDICAL JOURNAL			English	Article							ANTIULCER				Meier, CR (corresponding author), BOSTON UNIV,MED CTR,COLLABORAT DRUG SURVEILLANCE PROGRAM,11 MUZZEY ST,LEXINGTON,MA 02173, USA.			Jick, Hershel/0000-0003-4270-5992				BEUTLER M, 1994, BRIT MED J, V309, P1620, DOI 10.1136/bmj.309.6969.1620; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; RODRIGUEZ LAG, 1994, BRIT MED J, V308, P503, DOI 10.1136/bmj.308.6927.503; RODRIGUEZ LAG, 1995, LANCET, V345, P1059, DOI 10.1016/S0140-6736(95)90805-6; *SAS I, 1995, SAS STAT VERS 6 11	5	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1283	1283		10.1136/bmj.315.7118.1283	http://dx.doi.org/10.1136/bmj.315.7118.1283			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390057	Green Published			2022-12-28	WOS:A1997YG64500025
J	Bruera, E				Bruera, E			ABC of palliative care - Anorexia, cachexia, and nutrition	BRITISH MEDICAL JOURNAL			English	Review									GREY NUNS HOSP,EDMONTON,AB,CANADA		Bruera, E (corresponding author), UNIV ALBERTA,EDMONTON,AB T6G 2M7,CANADA.		Bruera, Eduardo/AAA-1550-2022						0	189	199	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1219	1222		10.1136/bmj.315.7117.1219	http://dx.doi.org/10.1136/bmj.315.7117.1219			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393230	Green Published			2022-12-28	WOS:A1997YF25200030
J	Marrazzo, JM; White, CL; Krekeler, B; Celum, CL; Lafferty, WE; Stamm, WE; Handsfield, HH				Marrazzo, JM; White, CL; Krekeler, B; Celum, CL; Lafferty, WE; Stamm, WE; Handsfield, HH			Community-based urine screening for Chlamydia trachomatis with a ligase chain reaction assay	ANNALS OF INTERNAL MEDICINE			English	Article						Chlamydia trachomatis; urine; adolescence; polymerase chain reaction; ligase chain reaction	LEUKOCYTE ESTERASE TEST; SEXUALLY-TRANSMITTED DISEASE; PELVIC INFLAMMATORY DISEASE; FAMILY-PLANNING CLINICS; ADOLESCENT GIRLS; INFECTION; WOMEN; PREVALENCE; DIAGNOSIS; SPECIMENS	Background: Urine tests for Chlamydia trachomatis permit expansion of screening beyond traditional clinic environments. Prevention of infection in teenagers is a high priority. Objective: To define the prevalence of C. trachomatis among teenagers by using the ligase chain reaction assay on urine specimens and to evaluate leukocyte esterase testing of urine specimens as an indicator of infection. Design: Cross-sectional study. Setting: An adolescent clinic, a juvenile detention facility, seven school-based clinics, and three community-based youth organizations in Seattle, Washington. Participants: 10 118 sexually active teenagers and young adults. Measurements: Chlamydia trachomatis infection detected in urine specimens by ligase chain reaction assay and leukocyturia detected by leukocyte esterase testing. Results: The prevalence of chlamydial infection among female participants was 8.6% and declined with increasing age; among male participants, it was 5.4% and increased with increasing age. In female participants, independent predictors of infection were being 17 years of age or younger (odds ratio [OR], 1.49), having had two or more sex partners in the previous 2 months (OR, 1.61), and having genitourinary symptoms (OR, 1.46). In male participants, independent predictors were being of nonwhite race or ethnicity (OR, 2.00 to 3.08), having had two or more sex partners in the previous 2 months (OR, 1.57), and having used a condom during the most recent sexual encounter (OR, 0.67). For identifying infection in male participants, the sensitivity of leukocyte esterase testing was 58.9%, the specificity was 94.9%, the positive predictive value was 38.4%, and the negative predictive value was 97.7%. Conclusions: Chlamydial infection is common in teenagers and young adults in community settings. The urine ligase chain reaction assay will permit widespread screening for C. trachomatis, but leukocyte esterase testing had low sensitivity for selecting persons for screening with this assay. Indicators of chlamydial infection differed substantially in male and female participants.	UNIV WASHINGTON, HARBORVIEW MED CTR, SEXUALLY TRANSMITTED DIS CLIN, SEATTLE, WA 98104 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, DIV INFECT DIS, SEATTLE, WA 98104 USA; UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, DEPT HLTH SERV, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA USA; SEATTLE KING CTY DEPT PUBL HLTH, SEATTLE, WA USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Marrazzo, Jeanne/0000-0002-9277-7364	NIAID NIH HHS [T32 AI-07140, U19 AI/MH-31448] Funding Source: Medline; PHS HHS [R30/CCR011496] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007140, U19AI031448] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADDISS DG, 1990, SEX TRANSM DIS, V17, P138, DOI 10.1097/00007435-199007000-00006; ADDISS DG, 1993, SEX TRANSM DIS, V20, P28, DOI 10.1097/00007435-199301000-00006; ANESTAD G, 1995, J CLIN MICROBIOL, V33, P2483, DOI 10.1128/JCM.33.9.2483-2484.1995; BASS CA, 1993, J CLIN MICROBIOL, V31, P2648, DOI 10.1128/JCM.31.10.2648-2653.1993; BIRO FM, 1994, PEDIATRICS, V93, P476; BRITTON TF, 1992, AM J GYNECOL HLTH, V6, P24; CARPENTER WR, 1993, CLIN CHEM, V39, P1934; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P375; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P193; DILLE BJ, 1993, J CLIN MICROBIOL, V31, P729, DOI 10.1128/JCM.31.3.729-731.1993; *DIV STD PREV, 1996, SEX TRANSM DIS SURV; GAYDOS CA, 1996, 1996 NAT STD PREV C; GENC M, 1993, JAMA-J AM MED ASSOC, V270, P2057, DOI 10.1001/jama.270.17.2057; Hadgu A, 1996, LANCET, V348, P592, DOI 10.1016/S0140-6736(96)05122-7; HANDSFIELD HH, 1986, JAMA-J AM MED ASSOC, V255, P1730, DOI 10.1001/jama.255.13.1730; HILLIS SD, 1995, FAM PLANN PERSPECT, V27, P108, DOI 10.2307/2136107; HUMPHREYS JT, 1992, SEX TRANSM DIS, V19, P47, DOI 10.1097/00007435-199201000-00010; Katz BP, 1996, SEX TRANSM DIS, V23, P226, DOI 10.1097/00007435-199605000-00011; KLAUSNER JD, 1996, 1996 NAT STD PREV C; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; LEONARDI GP, 1992, J CLIN MICROBIOL, V30, P2793, DOI 10.1128/JCM.30.11.2793-2796.1992; Males M, 1996, AM J PUBLIC HEALTH, V86, P565, DOI 10.2105/AJPH.86.4.565; Marrazzo JM, 1997, SEX TRANSM DIS, V24, P131, DOI 10.1097/00007435-199703000-00003; MCNAGNY SE, 1992, J INFECT DIS, V165, P573, DOI 10.1093/infdis/165.3.573; MORRIS RE, 1993, SEX TRANSM DIS, V20, P198, DOI 10.1097/00007435-199307000-00004; Mosure DJ, 1997, J ADOLESCENT HEALTH, V20, P6, DOI 10.1016/S1054-139X(96)00157-7; PATRICK DM, 1994, GENITOURIN MED, V70, P187; Ridgway GL, 1996, J CLIN PATHOL, V49, P116, DOI 10.1136/jcp.49.2.116; Rietmeijer CA, 1997, SEX TRANSM DIS, V24, P429, DOI 10.1097/00007435-199708000-00008; SADOF MD, 1987, JAMA-J AM MED ASSOC, V258, P1932, DOI 10.1001/jama.258.14.1932; SCHACHTER J, 1995, J INFECT DIS, V172, P1411, DOI 10.1093/infdis/172.5.1411; Schachter J, 1996, LANCET, V348, P1308, DOI 10.1016/S0140-6736(05)65783-2; SCHACHTER J, 1994, J CLIN MICROBIOL, V32, P2540, DOI 10.1128/JCM.32.10.2540-2543.1994; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103; SHAFER MA, 1993, JAMA-J AM MED ASSOC, V270, P2065, DOI 10.1001/jama.270.17.2065; Stamm WE, 1990, SEXUALLY TRANSMITTED, P181; WASHINGTON AE, 1985, J ADOLESCENT HEALTH, V6, P298, DOI 10.1016/S0197-0070(85)80067-X; WEINSTOCK HS, 1992, AM J EPIDEMIOL, V135, P41, DOI 10.1093/oxfordjournals.aje.a116200; WERNER MJ, 1991, J ADOLESCENT HEALTH, V12, P326, DOI 10.1016/0197-0070(91)90008-A; WINTER L, 1990, SEX TRANSM DIS, V17, P30, DOI 10.1097/00007435-199017010-00007; WOOD DL, 1990, PEDIATRICS, V86, P666; 1996, MMWR-MORBID MORTAL W, V45, P883; 1994, MMWR-MORBID MORTAL W, V43, P366	44	107	108	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					796	+		10.7326/0003-4819-127-9-199711010-00004	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382400				2022-12-28	WOS:A1997YD89800003
J	Lillard, LA; Farmer, MM				Lillard, LA; Farmer, MM			Linking Medicare and national survey data	ANNALS OF INTERNAL MEDICINE			English	Article							DECEDENTS; SERVICES; SYSTEM; TIME	Administrative records from the Medicare Program of the Health Care Financing Administration provide a valuable source of information for research on medical and public policy issues. This administrative database contains information on utilization of covered medical services, diagnoses, episodes of illness, and Medicare-covered costs of health care. Combining such data with information from national surveys on health status, demographics, and socioeconomic attributes substantially expands the scope of potential research questions that can be addressed. This article discusses the benefits and difficulties of linking Medicare administrative data with survey data and provides brief summaries of five national surveys of elderly U.S. citizens. These surveys can be valuable resources for examining the health status and life experiences of the Medicare population.			Lillard, LA (corresponding author), RAND CORP, CTR STUDY AGING, 1700 MAIN ST, POB 2138, SANTA MONICA, CA 90407 USA.				NIA NIH HHS [P20-AG12815, P01-AG08291] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG008291, P20AG012815] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Callahan CM, 1996, J GERONTOL A-BIOL, V51, pM276, DOI 10.1093/gerona/51A.6.M276; CULLER SD, 1995, MED CARE, V33, P1089, DOI 10.1097/00005650-199511000-00003; HILL MS, 1992, GUIDES MAJOR SOCIAL; Kovar M G, 1992, Vital Health Stat 1, P1; LILLARD L, 1997, DOES SUPPLEMENTAL PR; LIU KB, 1994, MED CARE, V32, P315, DOI 10.1097/00005650-199404000-00001; MANTON KG, 1993, HEALTH SERV RES, V28, P269; MANTON KG, 1993, GERONTOLOGIST, V33, P168, DOI 10.1093/geront/33.2.168; McCoy J L, 1992, Health Care Financ Rev, V13, P65; McCoy J L, 1994, Health Care Financ Rev, V15, P61; MOR V, 1994, AM J PUBLIC HEALTH, V84, P1274, DOI 10.2105/AJPH.84.8.1274; Soldo BJ, 1997, J GERONTOL B-PSYCHOL, V52, P1, DOI 10.1093/geronb/52B.Special_Issue.1; WILLIAMS B, 1994, MED CARE, V32, P1134, DOI 10.1097/00005650-199411000-00006; WOLINSKY FD, 1995, J GERONTOL B-PSYCHOL, V50, pS88, DOI 10.1093/geronb/50B.2.S88; YCAS MA, 1992, SOC SECUR BULL, V55, P20	15	23	23	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1997	127	8	2				691	695		10.7326/0003-4819-127-8_Part_2-199710151-00051	http://dx.doi.org/10.7326/0003-4819-127-8_Part_2-199710151-00051			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YB385	9382381				2022-12-28	WOS:A1997YB38500006
J	Feudtner, C				Feudtner, C			Reflections of a lake	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Childrens Hosp, Seattle, WA 98105 USA	Seattle Children's Hospital	Feudtner, C (corresponding author), Childrens Hosp, Seattle, WA 98105 USA.		Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434					0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	1998	338	1					57	58		10.1056/NEJM199801013380111	http://dx.doi.org/10.1056/NEJM199801013380111			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN801	9414334				2022-12-28	WOS:000071209200011
J	Sawyer, LA; Hennessy, JM; Peixoto, AA; Rosato, E; Parkinson, H; Costa, R; Kyriacou, CP				Sawyer, LA; Hennessy, JM; Peixoto, AA; Rosato, E; Parkinson, H; Costa, R; Kyriacou, CP			Natural variation in a Drosophila clock gene and temperature compensation	SCIENCE			English	Article							PERIOD GENE; REPETITIVE REGION; MELANOGASTER; POLYMORPHISM; EVOLUTION; BEHAVIOR; SIMULANS; REPEAT	The threonine-glycine (Thr-Gly) encoding repeat within the clock gene period of Drosophila melanogaster is polymorphic in length. The two major variants (Thr-Gly)17 and (Thr-Gly)20 are distributed as a highly significant latitudinal dine in Europe and North Africa. Thr-Gly length variation from both wild-caught and transgenic individuals is related to the flies' ability to maintain a circadian period at different temperatures. This phenomenon provides a selective explanation for the geographical distribution of Thr-Gly lengths and gives a rare glimpse of the interplay between molecular polymorphism, behavior, population biology, and natural selection.	UNIV LEICESTER,DEPT GENET,LEICESTER LE1 7RH,LEICS,ENGLAND; UNIV PADUA,DIPARTIMENTO BIOL,I-35121 PADUA,ITALY	University of Leicester; University of Padua				Parkinson, Helen/0000-0003-3035-4195; Rosato, Ezio/0000-0001-7297-4697				AQUADRO CF, 1992, TRENDS GENET, V8, P355, DOI 10.1016/0168-9525(92)90281-8; CASTIGLIONEMORELLI MA, 1995, P ROY SOC B-BIOL SCI, V260, P155, DOI 10.1098/rspb.1995.0073; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COSTA R, 1991, J MOL EVOL, V32, P238, DOI 10.1007/BF02342746; COSTA R, 1992, P ROY SOC B-BIOL SCI, V250, P43, DOI 10.1098/rspb.1992.0128; DOWSE HB, 1989, J THEOR BIOL, V139, P487, DOI 10.1016/S0022-5193(89)80067-0; Hulme M, 1995, INT J CLIMATOL, V15, P1333, DOI 10.1002/joc.3370151204; KIMURA M, 1962, GENETICS, V47, P713; KLIMAN RM, 1993, GENETICS, V133, P375; KONOPKA RJ, 1997, J NEUROGENET, V11, P117; Kyriacou CP, 1996, SEMIN CELL DEV BIOL, V7, P803, DOI 10.1006/scdb.1996.0098; MINIS DH, 1972, P NATL ACAD SCI USA, V69, P1537; NIELSEN J, 1994, MOL BIOL EVOL, V11, P839; PEIXOTO AA, 1993, MOL BIOL EVOL, V10, P127; PEIXOTO AA, UNPUB; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; PITTENDRIGH CS, 1954, P NATL ACAD SCI USA, V40, P1018, DOI 10.1073/pnas.40.10.1018; Rosato E, 1997, GENET RES, V69, P89, DOI 10.1017/S001667239700267X; Rosato E, 1996, J MOL EVOL, V42, P392, DOI 10.1007/BF02498633; ROSATO E, 1994, GENETICS, V138, P693; ROSATO E, IN PRESS BIOESSAYS; SAWYER L, UNPUB; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; WHEELER DA, 1991, SCIENCE, V251, P1082, DOI 10.1126/science.1900131; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895; YU Q, 1987, NATURE, V326, P765, DOI 10.1038/326765a0	27	252	255	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2117	2120		10.1126/science.278.5346.2117	http://dx.doi.org/10.1126/science.278.5346.2117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405346				2022-12-28	WOS:A1997YM23500051
J	Sledge, WH; Feinstein, AR				Sledge, WH; Feinstein, AR			A clinimetric approach to the components of the patient-physician relationship	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICINE; CARE; MODEL	Although patient-physician relationships have been expressed with diverse concepts and models, we have formulated a clinimetric classification derived from several years of observation and discussions at weekly housestaff conferences devoted to ''difficult'' patients. The observed phenomena are classified into the following components: (1) background factors intrinsic to patient and physician before they meet, (2) individual anticipations and hopes for what may happen, (3) extrinsic features of the setting, (4) individual reactions during the encounter, and (5) the consequences thereafter. These interacting components are usually too complex for characterizations based on single models for the relationship or single titles (such as ''hateful'' or ''noncompliant'') for the patient. The components can serve as a ''review of systems'' for identifying manifestations, sources, and solutions to such common problems as discordant hopes, the physician's unawareness of the patient's pertinent extramedical status, psychiatric and mental-status challenges, and cogent factors in chronic illness.	YALE UNIV,SCH MED,DEPT INTERNAL MED & EPIDEMIOL,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT PSYCHIAT,NEW HAVEN,CT 06520	Yale University; Yale University								Balint M., 1964, DOCTOR HIS PATIENT I; BRANCH WT, 1991, ANN INTERN MED, V114, P482, DOI 10.7326/0003-4819-114-6-482; BURBACK R, 1991, J GEN INTERN MED, V6, P335; CHRISMAN NJ, 1978, J FAM PRACTICE, V7, P713; COTT A, 1992, CAN J PUBLIC HLTH S1, V77, P51; DELBANCO TL, 1992, ANN INTERN MED, V116, P414, DOI 10.7326/0003-4819-116-5-414; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Feinstein AR, 1987, CLINIMETRICS; Glass RM, 1996, JAMA-J AM MED ASSOC, V275, P147, DOI 10.1001/jama.275.2.147; GROVES JE, 1978, NEW ENGL J MED, V298, P883, DOI 10.1056/NEJM197804202981605; KAPLAN C, 1988, J GEN INTERN MED, V3, P177, DOI 10.1007/BF02596128; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; LAZARE A, 1987, ARCH INTERN MED, V147, P1653, DOI 10.1001/archinte.147.9.1653; LAZARE A, 1975, ARCH GEN PSYCHIAT, V32, P553; MARTIN PA, 1975, COUNTERTRANSFERENCE, V2, P96; MATTHEWS DA, 1988, AM J MED SCI, V295, P159, DOI 10.1097/00000441-198803000-00001; MIZRAHI T, 1985, SOCIOL HEALTH ILL, V7, P214, DOI 10.1111/1467-9566.ep10949079; Mizrahi T, 1984, J Ambul Care Manage, V7, P51; ODOWD RC, 1988, BRIT MED J, V97, P528; Parsons T, 1951, SOCIAL SYSTEM, P428; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; SIEGLER M, 1982, ARCH INTERN MED, V142, P1899, DOI 10.1001/archinte.142.10.1899; STEWART MA, 1984, SOC SCI MED, V19, P167, DOI 10.1016/0277-9536(84)90284-3; SZASZ TS, 1956, ARCH INTERN MED, V97, P585, DOI 10.1001/archinte.1956.00250230079008; Thomasma D C, 1983, Pharos Alpha Omega Alpha Honor Med Soc, V46, P2; THOMASMA DC, 1983, ANN INTERN MED, V98, P243, DOI 10.7326/0003-4819-98-2-243	27	11	12	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2043	2048		10.1001/jama.278.23.2043	http://dx.doi.org/10.1001/jama.278.23.2043			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403404				2022-12-28	WOS:A1997YK98700001
J	Bostom, AG; Gohh, RY; Beaulieu, AJ; Nadeau, MR; Hume, AL; Jacques, PF; Selhub, J; Rosenberg, IH				Bostom, AG; Gohh, RY; Beaulieu, AJ; Nadeau, MR; Hume, AL; Jacques, PF; Selhub, J; Rosenberg, IH			Treatment of hyperhomocysteinemia in renal transplant recipients - A randomized, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							FOLIC-ACID; HOMOCYSTEINE METABOLISM; COORDINATE REGULATION; FOLATE-DEFICIENCY; VITAMIN-B-6; DISEASE; PLASMA; RATS	Background: Stable renal transplant recipients have an excess prevalence of hyperhomocysteinemia, which is a risk factor for arteriosclerosis. Objective: To determine the effect of treatment with 1) vitamin B-6 or 2) folic acid plus vitamin B-12 on fasting and post-methionine-loading plasma total homocysteine levels in renal transplant recipients. Design: Block-randomized, placebo-controlled, 2x2 factorial study. Setting: University-affiliated transplantation program. Patients: 29 clinically stable renal transplant recipients. Intervention: Patients were randomly assigned to one of four regimens: placebo (n = 8); vitamin B-6, 50 mg/d (n = 7); folic acid, 5 mg/d, and vitamin B-12, 0.4 mg/d (n = 7); or vitamin B-6, 50 mg/d, folic acid, 5 mg/d, and vitamin B-12, 0.4 mg/d (n = 7). Measurements: Pasting and 2-hour post-methionine-loading plasma total homocysteine levels. Results: Vitamin B-6 treatment resulted in a 22.1% reduction in geometric-mean post-methionine-loading increases in plasma total homocysteine levels (P = 0.042), and folic acid plus vitamin B-12 treatment caused a 26.2% reduction in geometric-mean fasting plasma total homocysteine levels (P = 0.027). These results occurred after adjustment for age; sex; and pretreatment levels of total homocysteine, B vitamins, and creatinine. Conclusions: Vitamin B-6 should be added to the combination of folic acid and vitamin B-12 for effective reduction of both post-methionine-loading and fasting plasma total homocysteine levels in renal transplant recipients.	Mem Hosp, Dept Gen Internal Med, Pawtucket, RI 02860 USA; Jean Mayer USDA, Human Nutr Res Ctr, Viatmin Bioavailabil Lab, Boston, MA 02111 USA; Rhode Isl Hosp, Div Renal Dis, Providence, RI 02903 USA	United States Department of Agriculture (USDA); Lifespan Health Rhode Island; Rhode Island Hospital	Bostom, AG (corresponding author), Mem Hosp, Dept Gen Internal Med, 111 Brewster St, Pawtucket, RI 02860 USA.							ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; Bostom AG, 1997, ARTERIOSCL THROM VAS, V17, P1894, DOI 10.1161/01.ATV.17.10.1894; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; FRANKEN DG, 1994, J INHERIT METAB DIS, V17, P159, DOI 10.1007/BF00735426; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; HORNE DW, 1988, CLIN CHEM, V34, P2357; Kasiske BL, 1996, J AM SOC NEPHROL, V7, P158; MILLER JW, 1994, AM J CLIN NUTR, V59, P1033, DOI 10.1093/ajcn/59.5.1033; MILLER JW, 1994, BIOCHEM J, V298, P415, DOI 10.1042/bj2980415; NAURATH HJ, 1995, LANCET, V346, P85, DOI 10.1016/S0140-6736(95)92113-3; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; SHIN-BUEHRING Y S, 1981, Journal of Inherited Metabolic Disease, V4, P123, DOI 10.1007/BF02263621; Ubbink JB, 1996, J CLIN INVEST, V98, P177, DOI 10.1172/JCI118763; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; WILCKEN DEL, 1981, CLIN SCI, V61, P743, DOI 10.1042/cs0610743	16	105	107	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1089	1092		10.7326/0003-4819-127-12-199712150-00006	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412311				2022-12-28	WOS:000070936600005
J	Goodrich, J; Khardori, N				Goodrich, J; Khardori, N			Cytomegalovirus: the taming of the beast?	LANCET			English	Editorial Material							MARROW TRANSPLANTATION; GANCICLOVIR; RECIPIENTS				Goodrich, J (corresponding author), SO ILLINOIS UNIV,SCH MED,DIV INFECT DIS,SPRINGFIELD,IL 62794, USA.							BOECKH M, 1992, BLOOD, V80, P1358; Boeckh M, 1996, BLOOD, V88, P4063, DOI 10.1182/blood.V88.10.4063.bloodjournal88104063; GOODRICH JM, 1993, ANN INTERN MED, V118, P173, DOI 10.7326/0003-4819-118-3-199302010-00003; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; ImbertMarcille BM, 1997, TRANSPLANTATION, V63, P1476, DOI 10.1097/00007890-199705270-00018; RIDDELL SR, 1992, SCIENCE, V257, P238; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; WINSTON DJ, 1993, ANN INTERN MED, V118, P179, DOI 10.7326/0003-4819-118-3-199302010-00004; WINSTON DJ, 1995, LANCET, V346, P69, DOI 10.1016/S0140-6736(95)92110-9; ZACNY VL, 1997, 37 INT C ANT AG CHEM	10	8	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 13	1997	350	9093					1718	1719		10.1016/S0140-6736(97)22050-7	http://dx.doi.org/10.1016/S0140-6736(97)22050-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413457				2022-12-28	WOS:A1997YL55400002
J	Bloland, PB; Kazembe, PN; Watkins, WM; Doumbo, OK; Nwanyanwu, OC; Ruebush, TK				Bloland, PB; Kazembe, PN; Watkins, WM; Doumbo, OK; Nwanyanwu, OC; Ruebush, TK			Malarone-donation programme in Africa	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM MALARIA; EFFICACY; CHLOROQUINE; RESISTANCE		LILONGWE CENT HOSP,LILONGWE,MALAWI; WELLCOME TRUST RES LABS,NAIROBI,KENYA; UNIV MALI,FAC MED & PHARM,DEPT EPIDEMIOL & PARASIT DIS,BAMAKO,MALI; US AGCY INT DEV,LILONGWE,MALAWI	University of Bamako; United States Agency for International Development (USAID)	Bloland, PB (corresponding author), CTR DIS CONTROL & PREVENT,MALARIA EPIDEMIOL SECT,DIV PARASIT DIS F22,NATL CTR INFECT DIS,ATLANTA,GA 30341, USA.							[Anonymous], 1986, CHEMOTHERAPY MALARIA; BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; Looareesuwan S, 1996, AM J TROP MED HYG, V54, P62, DOI 10.4269/ajtmh.1996.54.62; Nwanyanwu OC, 1996, TROP MED INT HEALTH, V1, P231; Plowe CV, 1996, AM J TROP MED HYG, V55, P467, DOI 10.4269/ajtmh.1996.55.467; Radloff PD, 1996, LANCET, V347, P1511, DOI 10.1016/S0140-6736(96)90671-6; Radloff PD, 1996, T ROY SOC TROP MED H, V90, P682, DOI 10.1016/S0035-9203(96)90435-6; SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515, DOI 10.4269/ajtmh.1994.51.515; Trigg JK, 1997, ACTA TROP, V63, P185, DOI 10.1016/S0001-706X(96)00617-1; WHITE NJ, 1994, T ROY SOC TROP MED H, V88, P63, DOI 10.1016/0035-9203(94)90479-0; WHO, 1994, WHOMAL941067	11	18	18	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1624	1625		10.1016/S0140-6736(97)06082-0	http://dx.doi.org/10.1016/S0140-6736(97)06082-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393355				2022-12-28	WOS:A1997YH98600046
J	Roberts, RR; Zalenski, RJ; Mensah, EK; Rydman, RJ; Ciavarella, G; Gussow, L; Das, K; Kampe, LM; Dickover, B; McDermott, MF; Hart, A; Straus, HE; Murphy, DG; Rao, R				Roberts, RR; Zalenski, RJ; Mensah, EK; Rydman, RJ; Ciavarella, G; Gussow, L; Das, K; Kampe, LM; Dickover, B; McDermott, MF; Hart, A; Straus, HE; Murphy, DG; Rao, R			Costs of an emergency department-based accelerated diagnostic protocol vs hospitalization in patients with chest pain - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 05-08, 1996	DENVER, CO	Soc Acad Emergency Med			ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY DISEASE; UNSTABLE ANGINA-PECTORIS; CREATINE-KINASE MB; LOW-RISK PATIENTS; HEART-DISEASE; ROOM PATIENTS; STAY; ISCHEMIA; MEDICINE	Context.-More than 3 million patients are hospitalized yearly in the United states for chest pain, The cost is over $3 billion just for those found to be free of acute disease, New rapid diagnostic tests for acute myocardial infarction (AMI) have resulted in the proliferation of accelerated diagnostic protocols (ADPs) and chest pain observation units. Objective.-To determine whether use of an emergency department (ED)-based ADP can reduce hospital admission rate, total cost, and length of stay (LOS) for patients needing admission for evaluation of chest pain. Design.-Prospective randomized controlled trial comparing admission rate, total cost, and LOS for patients treated using ADP vs inpatient controls, Total costs were determined using empirically measured resource utilization and microcosting techniques. Setting.-A large urban public teaching hospital serving a predominantly African American and Hispanic population. Patients.-A sample of 165 patients was randomly selected from a larger consecutive sample of 429 patients with chest pain concurrently enrolled in an ADP diagnostic cohort trial, Eligible patients presented to the ED with clinical findings suggestive of AMI or acute cardiac ischemia (ACI) but at low risk using a validated predictive algorithm. Main Outcome Measures.-Primary outcomes measured for each subject were LOS and total cost of treatment. Results.-The hospital admission rate for ADP vs control patients was 45.2% vs 100% (P<.001). The mean total cost per patient for ADP vs control patients was $1528 vs $2095 (P<.001), The mean LOS measured in hours for ADP vs control patients was 33.1 hours vs 44.8 hours (P<.01). Conclusions.-In this trial, ADP saved $567 in total hospital costs per patient treated, Use of ED-based ADPs can reduce hospitalization rates, LOS, and total cost for low-risk patients with chest pain needing evaluation for possible AMI or ACI.	UNIV ILLINOIS,SCH PUBL HLTH,CTR HLTH SERV RES,CHICAGO,IL 60680; COOK CTY HOSP,DEPT INTERNAL MED,CHICAGO,IL; UNIV ILLINOIS,SCH PUBL HLTH,DIV HLTH POLICY & ADM,CHICAGO,IL 60680	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roberts, RR (corresponding author), RUSH UNIV,COOK CTY HOSP,DEPT EMERGENCY MED,1900 W POLK ST,10TH FLOOR,CHICAGO,IL 60612, USA.		McDermott, Michael Francis/GZM-5330-2022	McDermott, Michael F./0000-0002-1015-0745	AHRQ HHS [R01HS-07103] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABBOTT JA, 1973, AM J MED, V55, P608, DOI 10.1016/0002-9343(73)90182-4; Angus DC, 1996, JAMA-J AM MED ASSOC, V276, P1075, DOI 10.1001/jama.276.13.1075; APPLE FS, 1992, AM J CLIN PATHOL, V97, P217, DOI 10.1093/ajcp/97.2.217; BERKI SE, 1984, MED CARE, V22, P126, DOI 10.1097/00005650-198402000-00004; CALVIN JE, 1995, JAMA-J AM MED ASSOC, V273, P136; COLLINSON PO, 1992, ANN CLIN BIOCHEM, V29, P43, DOI 10.1177/000456329202900105; DELEON AC, 1989, SOUTHERN MED J, V82, P1083, DOI 10.1097/00007611-198909000-00006; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; FINKLER SA, 1994, ESSENTIALS COST ACCO, P43; GASPOZ JM, 1994, J AM COLL CARDIOL, V24, P1249, DOI 10.1016/0735-1097(94)90106-6; GIBLER WB, 1992, ANN EMERG MED, V21, P504; GIBLER WB, 1995, ANN EMERG MED, V25, P1, DOI 10.1016/S0196-0644(95)70347-0; Gibler WB, 1997, ANN EMERG MED, V29, P168; Gillum RF, 1996, NEW ENGL J MED, V335, P1597, DOI 10.1056/NEJM199611213352110; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; Gomez MA, 1996, J AM COLL CARDIOL, V28, P25, DOI 10.1016/0735-1097(96)00093-9; GRAFF LG, 1993, OBSERVATION MED, P83; GRAFF LG, 1993, OBSERVATION MED, P99; HEDGES JR, 1993, OBSERVATION MED, P133; HERLITZ J, 1988, CLIN CARDIOL, V11, P209, DOI 10.1002/clc.4960110404; HILL M, 1989, QRC ADVISOR, V6, P2; Hoekstra J W, 1994, Acad Emerg Med, V1, P103; JONES KR, 1985, MED CARE, V23, P220, DOI 10.1097/00005650-198503000-00004; JOSEPHSON RA, 1990, CIRCULATION, V81, P20, DOI 10.1161/01.CIR.81.1.20; KARCZ A, 1993, ANN EMERG MED, V22, P553, DOI 10.1016/S0196-0644(05)81941-9; KARLSON BW, 1993, CLIN CARDIOL, V16, P397, DOI 10.1002/clc.4960160506; KASSIRER JP, 1995, NEW ENGL J MED, V333, P1348, DOI 10.1056/NEJM199511163332009; Katz DA, 1996, JAMA-J AM MED ASSOC, V276, P1568; KERNS JR, 1993, ANN EMERG MED, V22, P36; Lambrew CT, 1997, ANN EMERG MED, V29, P163; LAVE JR, 1984, ANNU REV PUBL HEALTH, V5, P193; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LEMROW N, 1991, HCFA PUBLICATION; LEWIS WR, 1994, AM J CARDIOL, V74, P987, DOI 10.1016/0002-9149(94)90845-1; LINDBERG K, 1985, ACTA MED SCAND, V217, P559; LOWE RA, 1991, ANN EMERG MED, V20, P790, DOI 10.1016/S0196-0644(05)80844-3; MAIR J, 1995, CLIN CHEM, V41, P1266; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MCCARTHY BD, 1990, J GEN INTERN MED, V5, P365, DOI 10.1007/BF02600409; MCCARTHY BD, 1993, ANN EMERG MED, V22, P579, DOI 10.1016/S0196-0644(05)81945-6; MENSAH EK, 1995, AM PUBL HLTH ASS ANN; *NAT HEART ATT AL, 1993, NIH PUBL; *NAT HEART LUNG BL, 1994, REP WORK GROUP RES C; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; RAPOPORT J, 1990, MED CARE, V28, P338, DOI 10.1097/00005650-199004000-00005; ROBERTS R, 1994, CIRCULATION, V89, P872, DOI 10.1161/01.CIR.89.2.872; RUSNAK RA, 1989, ANN EMERG MED, V18, P1029, DOI 10.1016/S0196-0644(89)80924-2; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; Rydman RJ, 1997, ANN EMERG MED, V29, P109, DOI 10.1016/S0196-0644(97)70316-0; SCHWARTZ WB, 1991, NEW ENGL J MED, V324, P1037, DOI 10.1056/NEJM199104113241506; SELKER HP, 1988, J ELECTROCARDIOL, V21, pS11, DOI 10.1016/0022-0736(88)90047-7; Selker HP, 1997, ANN EMERG MED, V29, P1, DOI 10.1016/S0196-0644(97)70297-X; Selker HP, 1997, ANN EMERG MED, V29, P13, DOI 10.1016/S0196-0644(97)70298-1; SHESSER R, 1994, ANN EMERG MED, V23, P334, DOI 10.1016/S0196-0644(94)70047-8; SOX HC, 1989, ANN INTERN MED, V110, P456, DOI 10.7326/0003-4819-110-6-456; Steinbrook R, 1996, NEW ENGL J MED, V334, P657, DOI 10.1056/NEJM199603073341010; SUVER JD, 1992, MANAGE ACCOUNTING, P205; SUVER JD, 1992, MANAGE ACCOUNTING, P278; TANDBERG D, 1994, ANN EMERG MED, V23, P299, DOI 10.1016/S0196-0644(94)70044-3; Tatum JL, 1997, ANN EMERG MED, V29, P116, DOI 10.1016/S0196-0644(97)70317-2; TIERNEY WM, 1986, MED DECIS MAKING, V6, P12, DOI 10.1177/0272989X8600600103; TOPOL EJ, 1987, AM J CARDIOL, V60, P958, DOI 10.1016/0002-9149(87)90332-8; Torrance GW, 1987, METHODS EC EVALUATIO; UDVARHELYI IS, 1992, J GEN INTERN MED, V7, P1, DOI 10.1007/BF02599092; WEARS R L, 1989, Annals of Emergency Medicine, V18, P953, DOI 10.1016/S0196-0644(89)80460-3; WEINER DA, 1979, NEW ENGL J MED, V301, P230, DOI 10.1056/NEJM197908023010502; WHITE LD, 1990, J AM COLL CARDIOL, V16, P304, DOI 10.1016/0735-1097(90)90577-C; WILCOX I, 1991, AM J CARDIOL, V67, P89, DOI 10.1016/0002-9149(91)90106-U; Williams RM, 1996, NEW ENGL J MED, V334, P642, DOI 10.1056/NEJM199603073341007; Zalenski RJ, 1997, ARCH INTERN MED, V157, P1085, DOI 10.1001/archinte.157.10.1085; Zalenski RJ, 1997, ANN EMERG MED, V29, P99, DOI 10.1016/S0196-0644(97)70315-9	73	259	260	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1670	1676		10.1001/jama.278.20.1670	http://dx.doi.org/10.1001/jama.278.20.1670			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388086				2022-12-28	WOS:A1997YG85900028
J	Joutel, A; Vahedi, K; Corpechot, C; Troesch, A; Chabriat, H; Vayssiere, C; Cruaud, C; Maciazek, J; Weissenbach, J; Bousser, MG; Bach, JF; TournierLasserve, E				Joutel, A; Vahedi, K; Corpechot, C; Troesch, A; Chabriat, H; Vayssiere, C; Cruaud, C; Maciazek, J; Weissenbach, J; Bousser, MG; Bach, JF; TournierLasserve, E			Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients	LANCET			English	Article							EPIDERMAL GROWTH-FACTOR; AUTOSOMAL-DOMINANT ARTERIOPATHY; MULTI-INFARCT DEMENTIA; SUBCORTICAL INFARCTS; LEUKOENCEPHALOPATHY; DROSOPHILA; RECEPTOR; GENE; ACTIVATION; SERRATE	Background CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy) is commonly overlooked or misdiagnosed owing to its recent identification and its variable mode of presentation. The defective gene in CADASIL is Notch3, which encodes a large transmembrane receptor. To set up a diagnostic test and to delineate the Notch3 domains involved in CADASIL, we undertook mutations analysis in this gene in a group of CADASIL patients. Methods 50 unrelated patients with CADASIL and 100 healthy controls were screened for mutations along the entire Notch3 sequence, by means of single-strand conformation polymorphism, heteroduplex, and sequence analysis. Findings Strongly stereotyped mis-sense mutations, located within the epidermal-growth-factor-like (EGF-like) repeats, in the extracellular domain of Notch3, were detected in 45 patients, Clustering of mutations within the two exons encoding the first five EGF-like repeats was observed (32 patients). All these mutations lead to toss or gain of a cysteine residue and therefore to an unpaired number of cysteine residues within a given EGF domain. None of these mutations was found in the 100 controls. Interpretation Because of the strong clustering and highly stereotyped nature of the pathogenetic mutations detected in CADASIL patients, an easy and reliable diagnostic test for CADASIL is feasible, The findings suggest that aberrant dimerisation of Notch3, due to abnormal disulphide bridging with another Notch3 molecule or with another protein, may be involved in the pathogenesis of this disorder.	UNIV PARIS 05, INSERM, U25, F-75730 PARIS, FRANCE; HOP LARIBOISIERE, F-75475 PARIS, FRANCE; BIOMERIEUX, LYON, FRANCE; GENETHON, EVRY, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; bioMerieux			Tournier-Lasserve, Elisabeth/N-7134-2017; Joutel, Anne/K-5601-2017; Chabriat, Hugues/G-5699-2010	Tournier-Lasserve, Elisabeth/0000-0002-3039-1677; Joutel, Anne/0000-0003-3963-3860; Cruaud, Corinne/0000-0002-4752-7278; Chabriat, Hugues/0000-0001-8436-6074				ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; BAUDRIMONT M, 1993, STROKE, V24, P122, DOI 10.1161/01.STR.24.1.122; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHABRIAT H, 1995, LANCET, V346, P934, DOI 10.1016/S0140-6736(95)91557-5; DAVOUS P, 1991, REV NEUROL-FRANCE, V147, P376; DECELIS JF, 1991, P NATL ACAD SCI USA, V88, P632, DOI 10.1073/pnas.88.2.632; Ducros A, 1996, AM J HUM GENET, V58, P171; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; NYE JS, 1995, CURR BIOL, V5, P966, DOI 10.1016/S0960-9822(95)00189-8; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; RUCHOUX MM, 1995, ACTA NEUROPATHOL, V89, P500; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SONNINEN V, 1987, EUR NEUROL, V27, P209, DOI 10.1159/000116158; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; SOURANDER P, 1977, ACTA NEUROPATHOL, V39, P247, DOI 10.1007/BF00691704; STEVENS DL, 1977, LANCET, V1, P1364; TOURNIERLASSERVE E, 1991, STROKE, V22, P1297, DOI 10.1161/01.STR.22.10.1297; TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256	24	507	531	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1511	1515		10.1016/S0140-6736(97)08083-5	http://dx.doi.org/10.1016/S0140-6736(97)08083-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9388399				2022-12-28	WOS:A1997YH11500010
J	Dale, R; Barton, R				Dale, R; Barton, R			Ethical debate - Why are doctors ambivalent about patients who misuse alcohol? The case history and survey of doctors' attitudes	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,N TYNESIDE HOSP,ACAD DEPT,N SHIELDS NE29 8NH,TYNE & WEAR,ENGLAND	Newcastle University - UK								CHICK J, 1995, MED ASPECTS FITNESS, P157; *DRIV VEH LIC AG, 1996, MED PRACT GLANC GUID; *GEN MED COUNC, 1995, CONF GUID GEN MED CO	3	4	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 15	1997	315	7118					1297	1298		10.1136/bmj.315.7118.1297	http://dx.doi.org/10.1136/bmj.315.7118.1297			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG645	9390061	Green Published			2022-12-28	WOS:A1997YG64500031
J	Freund, CL; GregoryEvans, CY; Furukawa, T; Papaioannou, M; Looser, J; Ploder, L; Bellingham, J; Ng, D; Herbrick, JAS; Duncan, A; Scherer, SW; Tsui, LC; LoutradisAnagnostou, A; Jacobson, SG; Cepko, CL; Bhattacharya, SS; McInnes, RR				Freund, CL; GregoryEvans, CY; Furukawa, T; Papaioannou, M; Looser, J; Ploder, L; Bellingham, J; Ng, D; Herbrick, JAS; Duncan, A; Scherer, SW; Tsui, LC; LoutradisAnagnostou, A; Jacobson, SG; Cepko, CL; Bhattacharya, SS; McInnes, RR			Cone-rod dystrophy due to mutations in a novel photoreceptor-specific homeobox gene (CRX) essential for maintenance of the photoreceptor	CELL			English	Article							RETINITIS-PIGMENTOSA; RETINAL DYSTROPHY; CHROMOSOME 19Q; HUMAN GENOME; CONGENITAL AMAUROSIS; CRYSTAL-STRUCTURE; LINKAGE ANALYSIS; DNA; DIFFERENTIATION; HOMEODOMAIN	Genes associated with inherited retinal degeneration have been found to encode proteins required for phototransduction, metabolism, or structural support of photoreceptors. Here we show that mutations in a novel photoreceptor-specific homeodomain transcription factor gene (CRX) cause an autosomal dominant form of cone-rod dystrophy (adCRD) at the CORD2 locus on chromosome 19q13. In affected members of a CORD2-linked family, the highly conserved glutamic acid at the first position of the recognition helix is replaced by alanine (E80A). In another CRD family, a 1 bp deletion (E168 [Delta bp]) within a novel sequence, the WSP motif, predicts truncation of the C-terminal 132 residues of CRX. Mutations in the CRX gene cause adCRD either by haploinsufficiency or by a dominant negative effect and demonstrate that CRX is essential for the maintenance of mammalian photoreceptors.	HOSP SICK CHILDREN, RES INST, PROGRAM DEV BIOL, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, RES INST, DEPT GENET, TORONTO, ON M5G 1X8, CANADA; HOSP SICK CHILDREN, RES INST, DEPT PEDIAT, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT MOL & MED GENET, TORONTO, ON M5G 1A8, CANADA; UCL, INST OPHTHALMOL, DEPT MOL GENET, LONDON EC1V 9EL, ENGLAND; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CTR THALASSEMIA, UNIT PRENATAL DIAG, GR-11526 ATHENS, GREECE; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA; UNIV PENN, SCHEIE EYE INST, PHILADELPHIA, PA 19104 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of London; University College London; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Queens University - Canada; University of Pennsylvania; Pennsylvania Medicine			Scherer, Stephen W./B-3785-2013; Gregory-Evans, Cheryl Y/G-9550-2011; Bhattacharya, Shom/N-2926-2016; Bellingham, James/GVS-8955-2022; Tsui, Lap-chee/A-1081-2010	Scherer, Stephen W./0000-0002-8326-1999; Bhattacharya, Shom/0000-0002-1601-6344; Bellingham, James/0000-0003-3368-5221; Jacobson, Samuel/0000-0003-2122-169X	NEI NIH HHS [EY05627, R01 EY0 8064] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008064, R01EY005627] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acampora D, 1996, NAT GENET, V14, P218, DOI 10.1038/ng1096-218; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ALLIKMETS R, 1997, IN PRESS SCIENCE; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BALCIUNIENE J, 1995, GENOMICS, V30, P281, DOI 10.1006/geno.1995.9876; BASCOM RA, 1995, HUM MOL GENET, V4, P1895, DOI 10.1093/hmg/4.10.1895; Berson EL, 1996, P NATL ACAD SCI USA, V93, P4526, DOI 10.1073/pnas.93.10.4526; BIRD AC, 1995, AM J OPHTHALMOL, V119, P543, DOI 10.1016/S0002-9394(14)70212-0; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; Cau E, 1997, DEVELOPMENT, V124, P1611; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CHUMAKOV IM, 1995, NATURE, V377, P175; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; DUNCAN AMV, 1994, GENOMICS, V19, P400, DOI 10.1006/geno.1994.1084; EVANS K, 1994, NAT GENET, V6, P210, DOI 10.1038/ng0294-210; EVANS K, 1995, ARCH OPHTHALMOL-CHIC, V113, P195, DOI 10.1001/archopht.1995.01100020079033; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; Fulton AB, 1996, ARCH OPHTHALMOL-CHIC, V114, P698, DOI 10.1001/archopht.1996.01100130690009; Furukawa T, 1997, CELL, V91, P531, DOI 10.1016/S0092-8674(00)80439-0; Furukawa T, 1997, P NATL ACAD SCI USA, V94, P3088, DOI 10.1073/pnas.94.7.3088; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Gal A, 1997, PROG RETIN EYE RES, V16, P51, DOI 10.1016/S1350-9462(96)00021-3; GREGORY CY, 1994, AM J HUM GENET, V55, P1061; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kelsell RE, 1997, HUM MOL GENET, V6, P597, DOI 10.1093/hmg/6.4.597; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLYSTRA JA, 1993, CAN J OPHTHALMOL, V28, P79; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNZLER P, 1995, BIOL CHEM H-S, V376, P201; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LIN CC, 1985, CYTOGENET CELL GENET, V39, P269, DOI 10.1159/000132156; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; Oliver G, 1997, TRENDS NEUROSCI, V20, P415, DOI 10.1016/S0166-2236(97)01082-5; PAPAIOANNOU M, 1997, IN PRESS J MED GENET; Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; SCHERER S, 1991, P33; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SZYLYK JP, 1993, ARCH OPHTHALMOL-CHIC, V111, P781; TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; Tomita K, 1996, GENES CELLS, V1, P765, DOI 10.1111/j.1365-2443.1996.tb00016.x; Tomita K, 1996, NEURON, V16, P723, DOI 10.1016/S0896-6273(00)80093-8; WALTER MA, 1994, NAT GENET, V7, P22, DOI 10.1038/ng0594-22; WARBURG M, 1991, AM J MED GENET, V39, P288, DOI 10.1002/ajmg.1320390309; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WU PX, 1997, DEVELOPMENT, V124, P219; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239; YAGASAKI K, 1989, ARCH OPHTHALMOL-CHIC, V107, P701, DOI 10.1001/archopht.1989.01070010719034; Yokoyama M, 1996, DNA Res, V3, P311, DOI 10.1093/dnares/3.5.311; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700	66	429	445	0	18	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 14	1997	91	4					543	553		10.1016/S0092-8674(00)80440-7	http://dx.doi.org/10.1016/S0092-8674(00)80440-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390563	Green Published, hybrid			2022-12-28	WOS:A1997YG49200015
J	Wennberg, PO; Hanisco, TF; Jaegle, L; Jacob, DJ; Hintsa, EJ; Lanzendorf, EJ; Anderson, JG; Gao, RS; Keim, ER; Donnelly, SG; Del Negro, LA; Fahey, DW; McKeen, SA; Salawitch, RJ; Webster, CR; May, RD; Herman, RL; Proffitt, MH; Margitan, JJ; Atlas, EL; Schauffler, SM; Flocke, F; McElroy, CT; Bui, TP				Wennberg, PO; Hanisco, TF; Jaegle, L; Jacob, DJ; Hintsa, EJ; Lanzendorf, EJ; Anderson, JG; Gao, RS; Keim, ER; Donnelly, SG; Del Negro, LA; Fahey, DW; McKeen, SA; Salawitch, RJ; Webster, CR; May, RD; Herman, RL; Proffitt, MH; Margitan, JJ; Atlas, EL; Schauffler, SM; Flocke, F; McElroy, CT; Bui, TP			Hydrogen radicals, nitrogen radicals, and the production of O-3 in the upper troposphere	SCIENCE			English	Article							IN-SITU MEASUREMENTS; AIRCRAFT-BORNE; NASA ER-2; OH; OZONE; LASER; STRATOSPHERE; INTERFERENCE; ATMOSPHERE; CHEMISTRY	The concentrations of the hydrogen radicals OH and HO2 in the middle and upper troposphere were measured simultaneously with those of NO, O-3, CO, H2O, CH4, non-methane hydrocarbons, and with the ultraviolet and visible radiation field. The data allow a direct examination of the processes that produce O-3 in this region of the atmosphere. Comparison of the measured concentrations of OH and HO2 with calculations based on their production from water vapor, ozone, and methane demonstrate that these sources are insufficient to explain the observed radical concentrations in the upper troposphere. The photolysis of carbonyl and peroxide compounds transported to this region from the lower troposphere may provide the source of HOx required to sustain the measured abundances of these radical species. The mechanism by which NO affects the production of O-3 is also illustrated by the measurements. In the upper tropospheric air masses sampled, the production rate for ozone (determined from the measured concentrations of HO2 and NO) is calculated to be about I part per billion by volume each day. This production rate is faster than previously thought and implies that anthropogenic activities that add NO to the upper troposphere, such as biomass burning and aviation, will lead to production of more O-3 than expected.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; NOAA, Aeron Lab, Boulder, CO 80303 USA; CALTECH, Jet Prop Lab, NASA, Pasadena, CA 91109 USA; Natl Ctr Atmospher Res, Div Atmospher Chem, Boulder, CO 80307 USA; ARQX, Atmospher Environm Serv, Downsview, ON M3H 5T4, Canada; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA	California Institute of Technology; Harvard University; Harvard University; National Oceanic Atmospheric Admin (NOAA) - USA; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Center Atmospheric Research (NCAR) - USA; Environment & Climate Change Canada; Meteorological Service of Canada; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Wennberg, PO (corresponding author), CALTECH, Div Geol & Planetary Sci, 1200 E Calif Blvd, Pasadena, CA 91125 USA.		Jaegle, Lyatt/M-6536-2015; Atlas, Elliot/J-8171-2015; Herman, Robert L./AAK-1986-2020; Herman, Robert/H-9389-2012; Webster, Chris/M-9315-2019; Fahey, David W/G-4499-2013; McKeen, Stuart A/H-9516-2013; Hanisco, Thomas/G-5310-2013; Atlas, Elliot/AAE-4605-2021; Salawitch, Ross/B-4605-2009; Flocke, Frank/AAD-1356-2019; Wennberg, Paul O/A-5460-2012; Gao, Ru-Shan/H-7455-2013	Jaegle, Lyatt/0000-0003-1866-801X; Herman, Robert L./0000-0001-7063-6424; Herman, Robert/0000-0001-7063-6424; Fahey, David W/0000-0003-1720-0634; McKeen, Stuart A/0000-0001-9700-6166; Hanisco, Thomas/0000-0001-9434-8507; Salawitch, Ross/0000-0001-8597-5832; Flocke, Frank/0000-0002-2661-6394; Wennberg, Paul O/0000-0002-6126-3854; Gao, Ru-Shan/0000-0001-6985-1637; Atlas, Elliot/0000-0003-3847-5346; Del Negro, Lori/0000-0002-5194-2749; HINTSA, ERIC/0000-0002-5289-630X				Ball SM, 1997, CHEM PHYS LETT, V264, P531, DOI 10.1016/S0009-2614(96)01363-2; BRADSHAW J, IN PRESS REV GEOPHYS; Brasseur GP, 1996, J GEOPHYS RES-ATMOS, V101, P1423, DOI 10.1029/95JD02363; BRUNE WH, IN PRESS GEOPHYS RES; CHATFIELD RB, 1984, J GEOPHYS RES-ATMOS, V89, P7111, DOI 10.1029/JD089iD05p07111; COHEN RC, 1994, GEOPHYS RES LETT, V21, P2539, DOI 10.1029/94GL01713; CRUTZEN P, 1973, PURE APPL GEOPHYS, V106, P1385, DOI 10.1007/BF00881092; DAVIS DD, 1976, GEOPHYS RES LETT, V3, P331, DOI 10.1029/GL003i006p00331; DEMORE WB, 1997, JET PROPULSION LAB P, V974; Dubey MK, 1996, GEOPHYS RES LETT, V23, P3215, DOI 10.1029/96GL03008; FAHEY DW, 1985, J ATMOS CHEM, V3, P435, DOI 10.1007/BF00053871; FAHEY DW, 1993, NATURE, V363, P509, DOI 10.1038/363509a0; Folkins I, 1997, GEOPHYS RES LETT, V24, P3185, DOI 10.1029/97GL03047; HANSEN H, 1997, J GEOPHYS RES, V102, P6831; HEIDT LE, 1989, J GEOPHYS RES-ATMOS, V94, P11599, DOI 10.1029/JD094iD09p11599; *INT PAN CLIM CHAN, 1994, CLIM CHANG RAD FORC; Jacob DJ, 1996, J GEOPHYS RES-ATMOS, V101, P24235, DOI 10.1029/96JD00336; Jaegle L, 1997, GEOPHYS RES LETT, V24, P3181, DOI 10.1029/97GL03004; JAEGLE L, IN PRESS GEOPHYS RES; Kley D, 1997, SCIENCE, V276, P1043, DOI 10.1126/science.276.5315.1043; Kliner DAV, 1997, J GEOPHYS RES-ATMOS, V102, P10759, DOI 10.1029/96JD03816; LACIS AA, 1990, J GEOPHYS RES-ATMOS, V95, P9971, DOI 10.1029/JD095iD07p09971; LEVY H, 1972, PLANET SPACE SCI, V20, P919, DOI 10.1016/0032-0633(72)90177-8; LOGAN JA, 1981, J GEOPHYS RES-OCEANS, V86, P7210, DOI 10.1029/JC086iC08p07210; MCELROY CT, 1995, GEOPHYS RES LETT, V22, P1361, DOI 10.1029/95GL01391; McKeen SA, 1997, GEOPHYS RES LETT, V24, P3177, DOI 10.1029/97GL03349; MICHELSEN HA, 1994, GEOPHYS RES LETT, V21, P2227, DOI 10.1029/94GL02052; OSullivan DW, 1996, J PHYS CHEM-US, V100, P3241, DOI 10.1021/jp951168n; Prather MJ, 1997, GEOPHYS RES LETT, V24, P3189, DOI 10.1029/97GL03027; PROFFITT MH, 1983, REV SCI INSTRUM, V54, P1719, DOI 10.1063/1.1137316; Silvente E, 1997, CHEM PHYS LETT, V264, P309, DOI 10.1016/S0009-2614(96)01342-5; SINGH HB, 1994, J GEOPHYS RES-ATMOS, V99, P1805, DOI 10.1029/93JD00764; SINGH HB, 1995, NATURE, V378, P50, DOI 10.1038/378050a0; SMITH GP, 1990, J GEOPHYS RES-ATMOS, V95, P16427, DOI 10.1029/JD095iD10p16427; Takahashi K, 1996, J PHYS CHEM-US, V100, P4084, DOI 10.1021/jp9528065; Talukdar RK, 1997, GEOPHYS RES LETT, V24, P1091, DOI 10.1029/97GL00831; WANG CC, 1974, PHYS REV LETT, V32, P349, DOI 10.1103/PhysRevLett.32.349; WEBSTER CR, 1994, APPL OPTICS, V33, P454, DOI 10.1364/AO.33.000454; WEINSTOCK EM, 1994, REV SCI INSTRUM, V65, P3544, DOI 10.1063/1.1144536; WENNBERG PO, 1995, J ATMOS SCI, V52, P3413, DOI 10.1175/1520-0469(1995)052<3413:ISMOOA>2.0.CO;2; WENNBERG PO, 1994, REV SCI INSTRUM, V65, P1858, DOI 10.1063/1.1144835; WENNBERG PO, 1994, SCIENCE, V266, P398, DOI 10.1126/science.266.5184.398; WILSON JC, 1993, SCIENCE, V261, P1140, DOI 10.1126/science.261.5125.1140; [No title captured]	44	295	300	6	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					49	53		10.1126/science.279.5347.49	http://dx.doi.org/10.1126/science.279.5347.49			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417019				2022-12-28	WOS:000071323900034
J	Malacrida, R; Genoni, M; Maggioni, AP; Spataro, V; Parish, S; Palmer, A; Collins, R; Moccetti, T				Malacrida, R; Genoni, M; Maggioni, AP; Spataro, V; Parish, S; Palmer, A; Collins, R; Moccetti, T		Third Int Study Infarct Survival Collaborative	A comparison of the early outcome of acute myocardial infarction in women and men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; THROMBOLYTIC THERAPY; SEX-DIFFERENCES; MORTALITY; GENDER; STROKE; TRIAL; TERM; BASE	Background In previous studies, unadjusted comparisons of mortality and major morbidity after acute myocardial infarction have generally indicated that women have a poorer outcome than men. Much larger studies are needed, with more complete adjustment for coexisting conditions, to determine whether this difference is explained by the older age of the women studied or by the presence of other unfavorable prognostic factors, or both. Methods As part of the Third International Study of lnfarct Survival (ISIS-3), information was collected on deaths during days 0 to 35 and on major clinical events during hospitalization up to day 35 for 9600 women and 26,480 men with suspected acute myo cardial infarction who were considered to have a clear indication for fibrinolytic therapy, We compared the outcome among women and men, first without adjustment, then with adjustment for age, and finally with adjustment for other recorded baseline characteristics by means of multiple logistic regression. Results The unadjusted odds ratio for death among women as compared with men was 1.73 (95 percent confidence interval, 1.61 to 1.86). The women were significantly older than the men, and after adjustment for age the odds ratio was reduced markedly to 1.20 (95 percent confidence interval, 1.11 to 1.29), Adjustment for other differences in base-line clinical features further reduced the odds ratio to 1.14 (95 percent confidence interval, 1.05 to 1.23), Excesses in other major clinical events among women were generally reduced to a similar extent by adjustment. Conclusions It seems likely that there is at most only a small independent association between female sex and early mortality and morbidity after suspected acute myocardial infarction. (C) 1998, Massachusetts Medical Society.	Civic Hosp, Dept Med, CH-6900 Lugano, Switzerland; Mario Negri Inst Pharmacol Res, Dept Cardiovasc Res, I-20157 Milan, Italy; Univ Oxford, Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford, England; Univ Oxford, Nuffield Dept Clin Med, Epidemiol Studies Unit, Oxford, England	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Oxford; University of Oxford	Moccetti, T (corresponding author), Civic Hosp, Dept Med, Via Tesserete 46, CH-6900 Lugano, Switzerland.		Maggioni, Aldo Pietro/AAL-5334-2020	Maggioni, Aldo Pietro/0000-0003-2764-6779				ARMITAGE P, 1994, STAT METHODS MED RES, P422; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Collins R, 1997, NEW ENGL J MED, V336, P847, DOI 10.1056/NEJM199703203361207; HUNT D, 1992, LANCET, V339, P753; Kober L, 1996, AM J CARDIOL, V77, P1052, DOI 10.1016/S0002-9149(96)00129-4; KOSTIS JB, 1994, CIRCULATION, V90, P1715, DOI 10.1161/01.CIR.90.4.1715; Kudenchuk PJ, 1996, AM J CARDIOL, V78, P9, DOI 10.1016/S0002-9149(96)00218-4; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MAURI F, 1989, AM J CARDIOL, V63, P1291, DOI 10.1016/0002-9149(89)91037-0; STONE GW, 1995, AM J CARDIOL, V75, P987, DOI 10.1016/S0002-9149(99)80709-7; VACCARINO V, 1995, CIRCULATION, V91, P1861, DOI 10.1161/01.CIR.91.6.1861; VOLPI A, 1993, CIRCULATION, V88, P416, DOI 10.1161/01.CIR.88.2.416; Weaver WD, 1996, JAMA-J AM MED ASSOC, V275, P777, DOI 10.1001/jama.275.10.777; WHITE HD, 1993, CIRCULATION, V88, P2097, DOI 10.1161/01.CIR.88.5.2097; Woodfield SL, 1997, J AM COLL CARDIOL, V29, P35, DOI 10.1016/S0735-1097(96)00449-4; Woods KL, 1996, LANCET, V347, P1203, DOI 10.1016/S0140-6736(96)90732-1; Yarzebski J, 1996, AM HEART J, V131, P43, DOI 10.1016/S0002-8703(96)90049-6	19	217	223	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	1998	338	1					8	14		10.1056/NEJM199801013380102	http://dx.doi.org/10.1056/NEJM199801013380102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN801	9414325				2022-12-28	WOS:000071209200002
J	Davies, SJA; Fitch, MT; Memberg, SP; Hall, AK; Raisman, G; Silver, J				Davies, SJA; Fitch, MT; Memberg, SP; Hall, AK; Raisman, G; Silver, J			Regeneration of adult axons in white matter tracts of the central nervous system	NATURE			English	Article							DORSAL-ROOT GANGLION; NEURITE OUTGROWTH; SPINAL-CORD; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; OLIGODENDROCYTES; ASTROCYTES; INVITRO; PROTEOGLYCANS; INHIBITION	It is widely accepted that the adult mammalian central nervous system (CNS) is unable to regenerate axons(1), In addition to physical or molecular barriers presented by glial scarring at the lesion site(2-4), it has been suggested that the normal myelinated CNS environment contains potent growth inhibitors(5,6) or lacks growth-promoting molecules(1,7). Here we investigate whether adult CNS white matter can support long-distance regeneration of adult axons in the absence of glial scarring, by using a microtransplantation technique(8) that minimizes scarring(9) to inject minute volumes of dissociated adult rat dorsal root ganglia directly into adult rat CNS pathways. This atraumatic injection procedure allowed considerable numbers of regenerating adult axons immediate access to the host glial terrain, where we found that they rapidly extended for long distances in white matter, eventually invading grey matter. Abortive regeneration correlated precisely with increased levels of proteoglycans within the extracellular matrix at the transplant interface, whereas successfully regenerating transplants were associated with minimal upregulation of these molecules, Our results demonstrate, to our knowledge for the first time, that reactive glial extracellular matrix at the lesion site is directly associated with failure of axon regrowth in vivo, and that adult myelinated white matter tracts beyond the glial scar can be highly permissive for regeneration.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROSCI,CLEVELAND,OH 44106; NATL INST MED RES,DIV NEUROBIOL,NORMAN & SADIE LEE RES CTR,LONDON NW7 1AA,ENGLAND	Case Western Reserve University; MRC National Institute for Medical Research			Raisman, Geoffrey/B-3215-2009	Hall, Alison/0000-0002-7237-7945				ARD MD, 1991, GLIA, V4, P70, DOI 10.1002/glia.440040109; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; BRITTIS PA, 1995, MOL CELL NEUROSCI, V6, P413, DOI 10.1006/mcne.1995.1031; Cajal S., 1928, DEGENERATION REGENER; CARLSTEDT T, 1987, NEUROSCI LETT, V74, P14, DOI 10.1016/0304-3940(87)90043-7; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; Davies SJA, 1996, EXP NEUROL, V142, P203, DOI 10.1006/exnr.1996.0192; DAVIES SJA, 1993, EUR J NEUROSCI, V5, P95, DOI 10.1111/j.1460-9568.1993.tb00474.x; DAVIES SJA, 1994, J NEUROSCI, V14, P1596, DOI 10.1523/JNEUROSCI.14-03-01596.1994; FAWCETT JW, 1995, J CELL SCI, V103; FITCH MT, IN PRESS EXP NEUROL; GIBSON SJ, 1984, J NEUROSCI, V4, P3101, DOI 10.1523/jneurosci.04-12-03101.1984; GIULIAN D, 1994, DEV NEUROSCI-BASEL, V16, P128, DOI 10.1159/000112099; Grill R, 1997, J NEUROSCI, V17, P5560; KOBAYASHI H, 1995, DEV BIOL, V168, P383, DOI 10.1006/dbio.1995.1088; Krekoski CA, 1996, J NEUROSCI RES, V43, P1, DOI 10.1002/jnr.490430102; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; PINDZOLA RR, 1993, DEV BIOL, V156, P34, DOI 10.1006/dbio.1993.1057; REIER PJ, 1983, SPINAL CORD RECONSTR, P163; ROHRER H, 1985, DEV BIOL, V111, P95, DOI 10.1016/0012-1606(85)90438-5; RUDGE JS, 1990, J NEUROSCI, V10, P3594; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SMITHTHOMAS LC, 1994, J CELL SCI, V107, P1687; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STEINDLER DA, 1990, EXP NEUROL, V109, P35, DOI 10.1016/S0014-4886(05)80007-X; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VAUDANO E, 1995, J NEUROSCI, V15, P3594; WICTORIN K, 1990, NATURE, V347, P556, DOI 10.1038/347556a0	30	628	653	0	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					680	683		10.1038/37776	http://dx.doi.org/10.1038/37776			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414159				2022-12-28	WOS:A1997YM50800030
J	Matsumoto, K; Miyake, S; Yano, M; Ueki, Y; Tominaga, Y				Matsumoto, K; Miyake, S; Yano, M; Ueki, Y; Tominaga, Y			Increase of lipoprotein (a) with troglitazone	LANCET			English	Article											Matsumoto, K (corresponding author), SASEBO CHUOU HOSP,DEPT INTERNAL MED,NAGASAKI 85711,JAPAN.							Borona E, 1989, J CLIN ENDOCR METAB, V68, P374; CHAPMAN MJ, 1994, ATHEROSCLEROSIS, V110, pS69, DOI 10.1016/0021-9150(94)05385-V; Kumar S, 1996, DIABETOLOGIA, V39, P701; Petrie J, 1997, LANCET, V349, P70, DOI 10.1016/S0140-6736(97)22002-7; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999	5	43	43	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 13	1997	350	9093					1748	1749		10.1016/S0140-6736(05)63572-6	http://dx.doi.org/10.1016/S0140-6736(05)63572-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413470				2022-12-28	WOS:A1997YL55400015
J	Bonventre, JV; Huang, ZH; Taheri, MR; OLeary, E; Li, E; Moskowitz, MA; Sapirstein, A				Bonventre, JV; Huang, ZH; Taheri, MR; OLeary, E; Li, E; Moskowitz, MA; Sapirstein, A			Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A(2)	NATURE			English	Article							ARACHIDONIC-ACID; GERBIL BRAIN; ISCHEMIA; REPERFUSION; MITOCHONDRIAL; IMPLANTATION; DAMAGE; PLA(2); KIDNEY; FORMS	Phospholipase A(2) (PLA(2)) enzymes are critical regulators of prostaglandin and leukotriene synthesis and can directly modify the composition of cellular membranes(1,2). PLA(2) enzymes release fatty acids and lysophospholipids, including the precursor of platelet-activating factor, PAF, from phospholipids. Free fatty acids, eicosanoids, lysophospholipids and PAF are potent regulators of inflammation(1,3,4), reproduction(5-7) and neurotoxicity(1,8,9). The physiological roles of the various forms of PLA(2) are not well defined. The cytosolic form, cPLA(2), preferentially releases arachidonic acid from phospholipids and is regulated by changes in intracellular calcium concentration(10,11). We have now created 'knockout' (cPLA(2)(-/-)) mice that lack this enzyme, in order to evaluate its physiological importance. We find that cPLA(2)(-/-) mice develop normally, but that the females produce only small litters in which the pups are usually dead, Stimulated peritoneal macrophages from cPLA(2)(-/-) animals did not produce prostaglandin E-2 or leukotriene B-4 or C-4. After transient middle cerebral artery occlusion, cPLA(2)(-/-) mice had smaller infarcts and developed less brain oedema and fewer neurological deficits. Thus cPLA(2) is important for macrophage production of inflammatory mediators, fertility, and in the pathophysiology of neuronal death after transient focal cerebral ischaemia.	MASSACHUSETTS GEN HOSP, NEUROSURG SERV, DEPT MED, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, CARDIAC SERV, DEPT MED, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, ANESTHESIA SERV, DEPT MED, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, MED SERV, DEPT NEUROSURG, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, NEUROSURG SERV, DEPT NEUROSURG, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, CARDIAC SERV, DEPT NEUROSURG, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, ANESTHESIA SERV, DEPT NEUROSURG, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, ANESTHESIA SERV, DEPT ANESTHESIA, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, MED SERV, DEPT ANESTHESIA, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, NEUROSURG SERV, DEPT ANESTHESIA, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, CARDIAC SERV, DEPT ANESTHESIA, CHARLESTOWN, MA 02129 USA; HARVARD MIT DIV HLTH SCI & TECHNOL, CHARLESTOWN, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Bonventre, JV (corresponding author), MASSACHUSETTS GEN HOSP, MED SERV, DEPT MED, 149 13TH ST, CHARLESTOWN, MA 02129 USA.		Moskowitz, Michael A/D-9916-2011					ABRAHAMSOHN PA, 1993, J EXP ZOOL, V266, P603, DOI 10.1002/jez.1402660610; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAZAN NG, 1989, ANN NY ACAD SCI, V559, P1; BONVENTRE JV, 1993, J LIPID MEDIATOR, V6, P457; BONVENTRE JV, 1992, J AM SOC NEPHROL, V3, P128; Challis John R. G., 1994, P985; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Clemens JA, 1996, STROKE, V27, P527, DOI 10.1161/01.STR.27.3.527; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; GILBOE DD, 1991, J NEUROCHEM, V56, P311, DOI 10.1111/j.1471-4159.1991.tb02597.x; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; KIM DK, 1993, BIOCHEM J, V294, P261, DOI 10.1042/bj2940261; Kol S, 1997, ENDOCRINOLOGY, V138, P314, DOI 10.1210/en.138.1.314; MALIS CD, 1986, J BIOL CHEM, V261, P14201; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; Novaro V, 1996, PROSTAGLANDINS, V51, P363, DOI 10.1016/0090-6980(96)00043-3; RAJABI MR, 1995, AM J PHYSIOL-ENDOC M, V269, pE940, DOI 10.1152/ajpendo.1995.269.5.E940; Rice GE, 1995, REPROD FERT DEVELOP, V7, P1471, DOI 10.1071/RD9951471; RORDORF G, 1991, J NEUROSCI, V11, P1829; ROSS BM, 1995, J NEUROCHEM, V64, P2213; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Teslenko V, 1997, BBA-LIPID LIPID MET, V1344, P189, DOI 10.1016/S0005-2760(96)00137-3; vanderWeiden RMF, 1996, J REPROD FERTIL, V107, P161; VERITY MA, 1993, ANN NY ACAD SCI, V679, P110; WINKLER JD, 1997, BIOCHIM BIOPHYS ACTA, P173; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165	28	717	725	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 11	1997	390	6660					622	625		10.1038/37635	http://dx.doi.org/10.1038/37635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403693				2022-12-28	WOS:A1997YK85300053
J	Petricoin, EF; Ito, S; Williams, BL; Audet, S; Stancato, LF; Gamero, A; Clouse, K; Grimley, P; Weiss, A; Beeler, J; Finbloom, DS; Shores, EW; Abraham, R; Larner, AC				Petricoin, EF; Ito, S; Williams, BL; Audet, S; Stancato, LF; Gamero, A; Clouse, K; Grimley, P; Weiss, A; Beeler, J; Finbloom, DS; Shores, EW; Abraham, R; Larner, AC			Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling	NATURE			English	Article							ANTIGEN RECEPTOR; TYROSINE PHOSPHATASE; KINASE; TRANSDUCTION; EXPRESSION; PROTEINS; CD45	Signal transduction through both cytokine and lymphocyte antigen receptors shares some common pathways by which they initiate cellular responses, such as activation of mitogen-activated protein kinase(s)(1,2). However, other signalling components appear to be uniquely coupled to each receptor. For example, the interferon receptors transduce regulatory signals through the JAK/ STAT pathway, resulting in an inhibition of growth and of antiviral effects, whereas this pathway apparently plays no role in T-cell-receptor (TCR)-dependent gene expression(3,4). Conversely, signal transduction through the TCR requires the tyrosine kinases Lck and ZAP-70 and the tyrosine phosphatase CD45 (ref. 5). Here we show that, unexpectedly, transmission of growth-inhibitory signals by interferon-alpha (IFN-alpha) in T cells requires the expression and association of CD45, Lck and ZAP-70 with the IFN-alpha-receptor signalling complex.	US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892; MAYO CLIN & MAYO FDN,DEPT IMMUNOL & PHARMACOL,ROCHESTER,MN 55905; USUHS,DEPT PATHOL,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	US Food & Drug Administration (FDA); Mayo Clinic; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco								BEADLING C, 1994, EMBO J, V13; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS BL, UNPUB MOL CELL BIOL	10	137	140	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					629	632		10.1038/37648	http://dx.doi.org/10.1038/37648			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403695				2022-12-28	WOS:A1997YK85300055
J	Leung, DYM; Diaz, LA; DeLeo, V; Soter, NA				Leung, DYM; Diaz, LA; DeLeo, V; Soter, NA			Allergic and immunologic skin disorders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATOPIC-DERMATITIS; CHRONIC URTICARIA; AUTOIMMUNITY; MASTOCYTOSIS; ANTIBODIES; PEMPHIGUS; DISEASES; ANTIGEN	The skin represents a unique immunologic organ poised to protect the host from invading organisms and environmental antigens. The skin is also an important target for a variety of allergic and autoimmune responses. Mast cells are key to the pathogenesis of urticaria, angioedema, and mastocytosis. Atopic dermatitis is the consequence of an immunoregulatory abnormality resulting in a skin-directed T helper type 2 response. Allergic contact dermatitis is an example of classic delayed type hypersensitivity. Circulating autoantibodies against the epidermis are a key mechanism by which bullous skin diseases occur.	ROOSEVELT HOSP,DEPT DERMATOL,NEW YORK,NY 10019; MED COLL WISCONSIN,DEPT DERMATOL,MILWAUKEE,WI 53226; NYU,MED CTR,DEPT DERMATOL,NEW YORK,NY 10016	Mount Sinai West; Medical College of Wisconsin; New York University	Leung, DYM (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV PEDIAT ALLERGY IMMUNOL,1400 JACKSON ST,ROOM K926,DENVER,CO 80206, USA.			Soter, Nicholas/0000-0003-3518-3209				ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; ANHALT GJ, 1990, NEW ENGL J MED, V323, P1729, DOI 10.1056/NEJM199012203232503; [Anonymous], 1995, AM J CONTACT DERMAT; BELSITO DV, 1991, PATHOPHYSIOLOGY SKIN; Charlesworth EN, 1996, ANN ALLERG ASTHMA IM, V76, P484, DOI 10.1016/S1081-1206(10)63267-X; CRUZ PD, 1994, AM J CONTACT DERMAT, V5, P189; FOWLER JF, 1995, FISHERS CONTACT DERM; GAMMON WR, 1993, DERMATOL CLIN, V11, P535, DOI 10.1016/S0733-8635(18)30249-3; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; JONES SM, 1993, CLIN REV ALLERG, V11, P471; LACOUR M, 1993, CLIN REV ALLERG, V11, P491; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEUNG DYM, 1996, ATOPIC DERMATITIS PA, P1; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; LONGLEY BJ, 1993, NEW ENGL J MED, V328, P1302, DOI 10.1056/NEJM199305063281803; Markss JG, 1997, CONTACT OCCUPATIONAL; MUTASIM DF, 1993, DERMATOL CLIN, V11, P499, DOI 10.1016/S0733-8635(18)30246-8; Rumbyrt JS, 1995, J ALLERGY CLIN IMMUN, V96, P901, DOI 10.1016/S0091-6749(95)70226-1; SAMPAIO SAP, 1994, DERMATOL CLIN, V12, P765, DOI 10.1016/S0733-8635(18)30140-2; SHORNICK JK, 1983, J AM ACAD DERMATOL, V8, P214, DOI 10.1016/S0190-9622(83)70027-7; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; SMITH EP, 1993, DERMATOL CLIN, V11, P511, DOI 10.1016/S0733-8635(18)30247-X; SOTER NA, 1991, J INVEST DERMATOL, V96, pS32, DOI 10.1111/1523-1747.ep12468973; SOTER NA, 1985, URTICARIAS, P141; Stanley J., 1993, DERMATOLOGY GEN MED, P606	27	31	31	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1914	1923						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396653				2022-12-28	WOS:A1997YK15500014
J	Hess, RA; Bunick, D; Lee, KH; Bahr, J; Taylor, JA; Korach, KS; Lubahn, DB				Hess, RA; Bunick, D; Lee, KH; Bahr, J; Taylor, JA; Korach, KS; Lubahn, DB			A role for oestrogens in the male reproductive system	NATURE			English	Article							ESTROGEN-RECEPTOR GENE; DUCTULI-EFFERENTES; SPERM COUNTS; EPIDIDYMIS; TESTIS; MOUSE; RAT; DISRUPTION; SECRETION; ESTRADIOL	Oestrogen is considered to be the 'female' hormone, whereas testosterone is considered the 'male' hormone. However,both hormones are present in both sexes. Thus sexual distinctions are not qualitative differences, but rather result from quantitative divergence in hormone concentrations and differential expressions of steroid hormone receptors. In males, oestrogen is present in low concentrations in blood, but can be extraordinarily high in semen, and as high as 250 pg ml(-1) in rete testis fluids(1,2), which is higher than serum oestradiol in the female(3). It is well known that male reproductive tissues express oestrogen receptors(4-7), but the role of oestrogen in male reproduction has remained unclear. Here we provide evidence of a physiological role for oestrogen in male reproductive organs. We show that oestrogen regulates the reabsorption of luminal fluid in the head of the epididymis. Disruption of this essential function causes sperm to enter the epididymis diluted, rather than concentrated, resulting in infertility. This finding raises further concern over the potential direct effects of environmental oestrogens on male reproduction and reported declines in human sperm counts(8,9).	UNIV ILLINOIS,DEPT ANIM SCI,URBANA,IL 61801; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65211; UNIV MISSOURI,DEPT CHILD HLTH,COLUMBIA,MO 65211; NIEHS,RES TRIANGLE PK,NC 27709	University of Illinois System; University of Illinois Urbana-Champaign; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hess, RA (corresponding author), UNIV ILLINOIS,DEPT VET BIOSCI,2001 S LINCOLN AVE,URBANA,IL 61802, USA.			Hess, Rex/0000-0003-2649-3563; Korach, Kenneth/0000-0002-7765-418X	FIC NIH HHS [F06 TW002317] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F06TW002317] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		AUGER J, 1995, NEW ENGL J MED, V332, P281, DOI 10.1056/NEJM199502023320501; Carani C, 1997, NEW ENGL J MED, V337, P91, DOI 10.1056/NEJM199707103370204; CHAN HC, 1995, J CELL PHYSIOL, V164, P271, DOI 10.1002/jcp.1041640207; CLULOW J, 1994, EXP PHYSIOL, V79, P915, DOI 10.1113/expphysiol.1994.sp003817; COOKE PS, 1991, ENDOCRINOLOGY, V128, P2874, DOI 10.1210/endo-128-6-2874; Eddy EM, 1996, ENDOCRINOLOGY, V137, P4796, DOI 10.1210/en.137.11.4796; Fisher JS, 1997, J ENDOCRINOL, V153, P485, DOI 10.1677/joe.0.1530485; FREE MJ, 1979, BIOL REPROD, V20, P269, DOI 10.1095/biolreprod20.2.269; GANJAM VK, 1976, ENDOCRINOLOGY, V99, P1618, DOI 10.1210/endo-99-6-1618; GRECO TL, 1993, ENDOCR REV, V14, P59, DOI 10.1210/er.14.1.59; Hess R.A., 1993, METHODS REPROD TOXIC, P52; HESS RA, 1991, FUND APPL TOXICOL, V17, P733, DOI 10.1016/0272-0590(91)90181-3; Hess RA, 1997, J ANDROL, V18, P602; ILIO KY, 1994, MICROSC RES TECHNIQ, V29, P432, DOI 10.1002/jemt.1070290604; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KRAUSE W, 1992, INT J ANDROL, V15, P14, DOI 10.1111/j.1365-2605.1992.tb01110.x; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Robaire B., 1988, P999; SCHLEICHER G, 1984, HISTOCHEMISTRY, V81, P139, DOI 10.1007/BF00490107; SHARPE RM, 1993, J ENDOCRINOL, V136, P357, DOI 10.1677/joe.0.1360357; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; SMITH EP, 1995, NEW ENGL J MED, V332, P131; SMITH GILLIAN, 1962, JOUR ENDOCRINOL, V23, P385, DOI 10.1677/joe.0.0230385; SMITH MS, 1975, ENDOCRINOLOGY, V96, P219, DOI 10.1210/endo-96-1-219; WAKELING AE, 1991, CANCER RES, V51, P3867; WEST NB, 1990, BIOL REPROD, V42, P533, DOI 10.1095/biolreprod42.3.533; YEUNG CH, 1991, AM J ANAT, V191, P261, DOI 10.1002/aja.1001910306	31	712	741	2	68	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					509	512		10.1038/37352	http://dx.doi.org/10.1038/37352			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9393999	Green Accepted			2022-12-28	WOS:A1997YJ86500051
J	Spanswick, D; Smith, MA; Groppi, VE; Logan, SD; Ashford, MLJ				Spanswick, D; Smith, MA; Groppi, VE; Logan, SD; Ashford, MLJ			Leptin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels	NATURE			English	Article							K+ CHANNELS; OBESE GENE; RAT FATTY; OB-R; RECEPTOR; IDENTIFICATION; EXPRESSION; CLONING; BRAIN; MICE	Leptin, the protein encoded by the obese (ob) gene, is secreted from adipose tissue and is thought to act in the central nervous system to regulate food intake and body weight(1,2). It has been proposed that leptin acts in the hypothalamus(3-5), the main control centre for satiety and energy expenditure(6). Mutations in leptin or the receptor isoform (Ob-R-L) present in hypothalamic neurons result in profound obesity and symptoms of non-insulin-dependent diabetes(7-10). Here we show that leptin hyperpolarizes glucose-receptive hypothalamic neurons of lean Sprague-Dawley and Zucker rats, but is ineffective on neurons of obese Zucker (fa/fa) rats. This hyperpolarization is due to the activation of a potassium current, and is not easily recovered on removal of leptin, but is reversed by applying the sulphonylurea, tolbutamide. Single-channel recordings demonstrate that leptin activates an ATP-sensitive potassium (K-ATP) channel. Our data indicate that the K-ATP channel may function as the molecular end-point of the pathway following leptin activation of the Ob-R-L receptor in hypothalamic neurons.	UNIV ABERDEEN,INST MED SCI,DEPT BIOMED SCI,ABERDEEN AB25 2ZD,SCOTLAND; PHARMACIA & UPJOHN INC,KALAMAZOO,MI 49001	University of Aberdeen; Pfizer			Smith, Mark/K-5792-2017	Smith, Mark/0000-0003-1474-5225; Ashford, Michael/0000-0002-0861-7676	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASHFORD MLJ, 1990, PFLUG ARCH EUR J PHY, V415, P479, DOI 10.1007/BF00373626; ASHFORD MLJ, 1990, BRIT J PHARMACOL, V101, P531, DOI 10.1111/j.1476-5381.1990.tb14116.x; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Cusin I, 1996, DIABETES, V45, P1446, DOI 10.2337/diabetes.45.10.1446; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Glaum SR, 1996, MOL PHARMACOL, V50, P230; Harvey J, 1997, J PHYSIOL-LONDON, V504, P527, DOI 10.1111/j.1469-7793.1997.527bd.x; KEIFFER TJ, 1997, DIABETES, V26, P1087; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LEE K, 1995, J PHYSIOL-LONDON, V488, P319, DOI 10.1113/jphysiol.1995.sp020969; LEVIN BE, 1996, AM J PHYSIOL-REG I, V40, pR491; Matson C.A., 1996, DIABETES REV, V4, P488; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; OOMURA Y, 1969, NATURE, V222, P282, DOI 10.1038/222282a0; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Rock FL, 1996, HORM METAB RES, V28, P748, DOI 10.1055/s-2007-979892; Rosenblum CI, 1996, ENDOCRINOLOGY, V137, P5178, DOI 10.1210/en.137.11.5178; Satoh N, 1997, NEUROSCI LETT, V224, P149, DOI 10.1016/S0304-3940(97)00163-8; Schwartz MW, 1996, J CLIN INVEST, V98, P1101, DOI 10.1172/JCI118891; Seeley RJ, 1996, HORM METAB RES, V28, P664, DOI 10.1055/s-2007-979874; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; STREAMSON C, 1996, DIABETES, V45, P1141; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TREHERNE JM, 1991, J NEUROENDOCRINOL, V3, P323, DOI 10.1111/j.1365-2826.1991.tb00282.x; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Woods AJ, 1996, NATURE, V381, P745, DOI 10.1038/381745a0; Yamashita T, 1997, DIABETES, V46, P1077, DOI 10.2337/diabetes.46.6.1077; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	30	521	553	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 4	1997	390	6659					521	525		10.1038/37379	http://dx.doi.org/10.1038/37379			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ865	9394003				2022-12-28	WOS:A1997YJ86500055
J	Donnelly, WJ				Donnelly, WJ			The language of medical case histories	ANNALS OF INTERNAL MEDICINE			English	Article							PATIENT-PHYSICIAN RELATIONSHIP; STORY				Donnelly, WJ (corresponding author), VET AFFAIRS EDWARD HINES JR HOSP, MED SERV 111, HINES, IL 60141 USA.							ANSPACH RR, 1988, J HEALTH SOC BEHAV, V29, P357, DOI 10.2307/2136869; BANKS JT, 1992, LIT MED, V11, pR7; CHARON R, 1986, LIT MED, V5, P58; CHARON R, 1992, LIT MED, V11, P115; COULEHAN JL, 1992, MED INTERVIEW PRIMER, P43; DELBANCO TL, 1992, ANN INTERN MED, V116, P414, DOI 10.7326/0003-4819-116-5-414; DONNELLY WJ, 1988, JAMA-J AM MED ASSOC, V260, P823, DOI 10.1001/jama.260.6.823; Donnelly WJ, 1996, ACAD MED, V71, P730, DOI 10.1097/00001888-199607000-00004; DONNELLY WJ, 1986, PERSPECT BIOL MED, V30, P81; DONNELLY WJ, 1992, ARCH INTERN MED, V152, P480; Good Byron., 1994, MED RATIONALITY EXPE, P65; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; HUNTER KM, 1992, LIT MED, V11, P163; KERMONDE F, 1979, GENESIS SECRECY INTE, P117; Kleinman A., 1988, ILLNESS NARRATIVES; KLEINMAN A, 1995, WRITING MARGIN DISCO, P32; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; SEARLE JR, 1992, REDISCOVERY MIND, P19; SMITH RC, 1991, ANN INTERN MED, V115, P470, DOI 10.7326/0003-4819-115-6-470; STEWART M, 1995, PATIENT CENTERED MED; TOOMBS SK, 1987, J MED PHILOS, V12, P219, DOI 10.1093/jmp/12.3.219; TOOMBS SK, 1996, HUMANE HLTH CARE INT, V12, P14; Tracy D, 1987, PLURALITY AMBIGUITY, P49; Weed LL, 1969, MED RECORDS MED ED P; 1993, NEW SHORTER OXFORD E, V1, P459	25	53	56	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					1045	1048		10.7326/0003-4819-127-11-199712010-00035	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00035			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412299				2022-12-28	WOS:A1997YJ08000030
J	Salzmann, P; Kerlikowske, K; Phillips, K				Salzmann, P; Kerlikowske, K; Phillips, K			Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age	ANNALS OF INTERNAL MEDICINE			English	Article							BREAST-CANCER; RECOMMENDATIONS; METAANALYSIS; STRATEGIES; MEDICINE; BENEFIT; YOUNGER; PROGRAM; TRIALS; HEALTH	Background: Screening mammography is recommended for women 50 to 69 years of age because of its proven efficacy and reasonable cost-effectiveness. Extending screening recommendations to include women 40 to 49 years of age remains controversial. Objective: To compare the cost-effectiveness of screening mammography in women of different age groups. Design: Cost-effectiveness analysis done using Markov and Monte Carlo models. Patients: General population of women 40 years of age and older. Interventions: Biennial screening from 50 to 69 years of age was compared with no screening. Screening done every 18 months from ages 40 to 49 years, followed by biennial screening from ages 50 to 69 years, was compared with biennial screening from ages 50 to 69 years. Measurements: Life-expectancy, costs, and incremental cost-effectiveness. Results: Screening women from 50 to 69 years of age improved life expectancy by 12 days at a cost of $704 per woman, resulting in a cost-effectiveness ratio of $21 400 per year of life saved. Extending screening to include women 40 to 49 years of age improved life expectancy by 2.5 days at a cost of $676 per woman. The incremental cost-effectiveness of screening women 40 to 49 years of age was $105 000 per year of life saved. On the basis of a multiway sensitivity analysis, there is a 75% chance that screening mammography in women 50 to 69 years of age costs less than $50 000 per year of life saved, compared with a 7% chance in women 40 to 49 years of age. Conclusion: The cost-effectiveness of screening mammography in women 40 to 49 years of age is almost five times that in older women. When breast cancer screening policies are being set, the incremental cost-effectiveness of extending mammographic screening to younger women should be considered.	VET AFFAIRS MED CTR, GEN INTERNAL MED SECT, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [P50CA058207, U01CA063740] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA58207, 1 U01 CA 63740] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		American College of Radiology, 1982, POL STAT GUID MAMM; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; Black WC, 1996, JAMA-J AM MED ASSOC, V275, P111, DOI 10.1001/jama.1996.03530260025021; Boer R, 1996, JAMA-J AM MED ASSOC, V275, P111, DOI 10.1001/jama.1996.03530260025022; BROWN ML, 1995, AM J ROENTGENOL, V165, P1373, DOI 10.2214/ajr.165.6.7484568; BROWN ML, 1993, BREAST CANCER RES TR, V25, P113, DOI 10.1007/BF00662136; BROWN ML, 1995, RADIOLOGY, V195, P529, DOI 10.1148/radiology.195.2.7724778; DEKONING HJ, 1997, NIH CONS DEV C BREAS, P40; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; ELWOOD JM, 1993, ONLINE J CURR CLIN T, V2; FEIG SA, 1995, CANCER, V76, P2097, DOI 10.1002/1097-0142(19951115)76:10+<2097::AID-CNCR2820761332>3.0.CO;2-B; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; GLASZIOU PP, 1995, MED J AUSTRALIA, V162, P625, DOI 10.5694/j.1326-5377.1995.tb126047.x; HALL J, 1992, SOC SCI MED, V34, P993, DOI 10.1016/0277-9536(92)90130-I; HARRIS R, 1995, ANN INTERN MED, V122, P539, DOI 10.7326/0003-4819-122-7-199504010-00011; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; KERLIKOWSKE K, 1997, MONOGR NATL CANC I, V22, P105; KERLIKOWSKE K, 1997, MONOGR NATL CANC I, V22, P79; KOSARY CL, 1995, NIH PUBLICATION; Lee TT, 1997, ANN INTERN MED, V126, P337, DOI 10.7326/0003-4819-126-5-199703010-00001; LINDFORS KK, 1995, JAMA-J AM MED ASSOC, V274, P881, DOI 10.1001/jama.274.11.881; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; PEER PGM, 1994, J NATL CANCER I, V86, P436, DOI 10.1093/jnci/86.6.436; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; SHAPIRO S, 1994, AM J PUBLIC HEALTH, V84, P10, DOI 10.2105/AJPH.84.1.10; Shapiro S, 1988, PERIODIC SCREENING B; SICKLES EA, 1995, ANN INTERN MED, V122, P534, DOI 10.7326/0003-4819-122-7-199504010-00010; SICKLES EA, 1993, J NATL CANCER I, V85, P1621, DOI 10.1093/jnci/85.20.1621; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; SOX HC, 1995, ANN INTERN MED, V122, P550, DOI 10.7326/0003-4819-122-7-199504010-00013; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TAPLIN SH, 1995, J NATL CANCER I, V87, P417, DOI 10.1093/jnci/87.6.417; *TREEAG SOFTW, 1996, DATA 3 0; *US BUR CENS, 1991, STAT ABSTR US, P84; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; 1997, CANC LETT, V23, P4; 1986, CAN MED ASSOC J, V134, P724	43	193	193	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					955	965		10.7326/0003-4819-127-11-199712010-00001	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00001			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412300				2022-12-28	WOS:A1997YJ08000001
J	Calman, KC				Calman, KC			Literature in the education of the doctor	LANCET			English	Editorial Material							MEDICAL-EDUCATION; HUMANITIES				Calman, KC (corresponding author), DEPT HLTH,RICHMOND HOUSE,79 WHITEHALL,LONDON SW1A 2NS,ENGLAND.		Calman, Kenneth C/C-9855-2010					Bolton G, 1994, BRIT EDUC RES J, V20, P55, DOI DOI 10.1080/0141192940200106; CALMAN K, 1994, BRIT MED J, V309, P1140, DOI 10.1136/bmj.309.6962.1140; Calman K, 1996, LANCET, V347, P1499, DOI 10.1016/S0140-6736(96)90665-0; CALMAN KC, 1988, MED EDUC, V22, P488, DOI 10.1111/j.1365-2923.1988.tb00790.x; CALMAN KC, 1988, MED EDUC, V22, P265, DOI 10.1111/j.1365-2923.1988.tb00752.x; CAPLAN RM, 1985, J AM ACAD DERMATOL, V12, P901, DOI 10.1016/S0190-9622(85)80143-2; CHARON R, 1995, ANN INTERN MED, V122, P599, DOI 10.7326/0003-4819-122-8-199504150-00008; COLES R, 1987, JAMA-J AM MED ASSOC, V257, P1644, DOI 10.1001/jama.257.12.1644; Downie RS, 1997, MED EDUC, V31, P276, DOI 10.1111/j.1365-2923.1997.tb02925.x; DOWNIE RS, 1994, HEALING RATS OXFORD; Doyle Roddy, 1996, WOMAN WHO WALKED DOO; GARDINER H, 1995, LEADING MINDS ANATOM; HUNTER KM, 1995, ACAD MED, V70, P787, DOI 10.1097/00001888-199509000-00014; Jones AH, 1997, LANCET, V349, P275, DOI 10.1016/S0140-6736(96)12240-6; Jones AH, 1996, LANCET, V348, P1360, DOI 10.1016/S0140-6736(96)09219-7; Jones AH, 1997, LANCET, V349, P1243, DOI 10.1016/S0140-6736(97)03395-3; Mathiasen H, 1997, AM J CARDIOL, V79, P1222, DOI 10.1016/S0002-9149(97)00037-4; McLellan MF, 1997, LANCET, V349, P564, DOI 10.1016/S0140-6736(97)80120-1; McLellan MF, 1996, LANCET, V348, P109, DOI 10.1016/S0140-6736(96)03521-0; McLellan MF, 1996, LANCET, V348, P1014, DOI 10.1016/S0140-6736(96)07316-3; McLellan MF, 1997, LANCET, V349, P1618, DOI 10.1016/S0140-6736(97)04429-2; MOORE AR, 1977, J MED ETHICS, V3, P26, DOI 10.1136/jme.3.1.26; MOYLE W, 1995, J ADV NURS, V21, P960, DOI 10.1046/j.1365-2648.1995.21050960.x; PETERS RS, 1966, ETHICS ED; RADWANY SM, 1987, JAMA-J AM MED ASSOC, V257, P1629, DOI 10.1001/jama.257.12.1629; SCHNEIDERMAN H, 1995, ANN INTERN MED, V122, P618, DOI 10.7326/0003-4819-122-8-199504150-00011; Stowe A C, 1996, Nurse Educ, V21, P16, DOI 10.1097/00006223-199609000-00008; TAUBER AI, 1992, J ROY SOC MED, V85, P598; WARREN KS, 1984, ANN INTERN MED, V101, P697, DOI 10.7326/0003-4819-101-5-697; Welsh I., 1993, TRAINSPOTTING	30	30	35	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1622	1624						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393354				2022-12-28	WOS:A1997YH98600045
J	Raskin, DM; deBoer, PAJ				Raskin, DM; deBoer, PAJ			The MinE ring: An FtsZ-independent cell structure required for selection of the correct division site in E-coli	CELL			English	Article							TOPOLOGICAL SPECIFICITY FACTOR; GREEN FLUORESCENT PROTEIN; ESCHERICHIA-COLI; SEPTUM PLACEMENT; BINDING-PROTEIN; MUTANTS; ENCODES; LOCUS; INHIBITORS; HOMOLOGS	E. coli cell division is mediated by the FtsZ ring and associated factors. Selection of the correct division site requires the combined action of an inhibitor of FtsZ ring formation (MinCD) and of a topological specificity factor that somehow prevents MinCD action at the middle of the cell (MinE). Here we show that a biologically active MinE-Gfp fusion accumulates in an annular structure near the middle of young cells. Formation of the MinE ring required MinD but was independent of MinC and continued in nondividing cells in which FtsZ function was inhibited. The results indicate that the MinE ring represents a novel cell structure, which allows FtsZ ring formation at midcell by suppressing MinCD activity at this site.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,CLEVELAND,OH 44106	Case Western Reserve University			Raskin, David/AAZ-5973-2021	Raskin, David/0000-0001-7421-7809; de Boer, Piet/0000-0002-5375-6317	NIGMS NIH HHS [T32GM08056] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008056] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Addinall SG, 1996, J BACTERIOL, V178, P7167, DOI 10.1128/jb.178.24.7167-7172.1996; Addinall SG, 1996, J BACTERIOL, V178, P3877, DOI 10.1128/jb.178.13.3877-3884.1996; ADLER HI, 1967, P NATL ACAD SCI USA, V57, P321, DOI 10.1073/pnas.57.2.321; Baumann P, 1996, P NATL ACAD SCI USA, V93, P6726, DOI 10.1073/pnas.93.13.6726; BI E, 1993, J BACTERIOL, V175, P1118, DOI 10.1128/JB.175.4.1118-1125.1993; BI E, 1990, J BACTERIOL, V172, P5610, DOI 10.1128/jb.172.10.5610-5616.1990; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Cha JH, 1997, J BACTERIOL, V179, P1671, DOI 10.1128/jb.179.5.1671-1683.1997; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; DEBOER PAJ, 1992, J BACTERIOL, V174, P63, DOI 10.1128/jb.174.1.63-70.1992; DEBOER PAJ, 1990, P NATL ACAD SCI USA, V87, P1129, DOI 10.1073/pnas.87.3.1129; DEBOER PAJ, 1988, J BACTERIOL, V170, P2106, DOI 10.1128/jb.170.5.2106-2112.1988; Donachie WD, 1996, J BACTERIOL, V178, P5971, DOI 10.1128/jb.178.20.5971-5976.1996; Edwards DH, 1997, MOL MICROBIOL, V24, P905, DOI 10.1046/j.1365-2958.1997.3811764.x; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; Hale CA, 1997, CELL, V88, P175, DOI 10.1016/S0092-8674(00)81838-3; HIGASHITANI A, 1995, BIOCHEM BIOPH RES CO, V209, P198, DOI 10.1006/bbrc.1995.1489; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; Huang J, 1996, J BACTERIOL, V178, P5080, DOI 10.1128/jb.178.17.5080-5085.1996; LEE SY, 1993, MOL MICROBIOL, V7, P601, DOI 10.1111/j.1365-2958.1993.tb01151.x; LEVIN PA, 1992, J BACTERIOL, V174, P6717, DOI 10.1128/JB.174.21.6717-6728.1992; LUTKENHAUS J, 1993, MOL MICROBIOL, V9, P403, DOI 10.1111/j.1365-2958.1993.tb01701.x; LUTKENHAUS J, 1996, ESCHERICHIA COLI SAL, P1615; Ma XL, 1996, P NATL ACAD SCI USA, V93, P12998, DOI 10.1073/pnas.93.23.12998; Margolin W, 1996, J BACTERIOL, V178, P1320, DOI 10.1128/jb.178.5.1320-1327.1996; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; PICHOFF S, 1995, MOL MICROBIOL, V18, P321, DOI 10.1111/j.1365-2958.1995.mmi_18020321.x; RAYCHAUDHURI D, 1992, NATURE, V359, P251, DOI 10.1038/359251a0; Rothfield LI, 1996, CELL, V84, P183, DOI 10.1016/S0092-8674(00)80971-X; Rothfield LI, 1997, CELL, V88, P581, DOI 10.1016/S0092-8674(00)81899-1; TEATHER RM, 1974, J BACTERIOL, V118, P407, DOI 10.1128/JB.118.2.407-413.1974; VARLEY AW, 1992, J BACTERIOL, V174, P6729, DOI 10.1128/JB.174.21.6729-6742.1992; WANG XD, 1991, EMBO J, V10, P3363, DOI 10.1002/j.1460-2075.1991.tb04900.x; WARD JE, 1985, CELL, V42, P941, DOI 10.1016/0092-8674(85)90290-9; ZHAO CR, 1995, P NATL ACAD SCI USA, V92, P4314	39	196	200	1	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					685	694		10.1016/S0092-8674(00)80455-9	http://dx.doi.org/10.1016/S0092-8674(00)80455-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393861	Bronze			2022-12-28	WOS:A1997YH96000015
J	Nicholl, J; Turner, J				Nicholl, J; Turner, J			Effectiveness of a regional trauma system in reducing mortality from major trauma: before and after study	BRITISH MEDICAL JOURNAL			English	Article							INJURED PATIENTS; PREVENTABLE DEATHS; CARE; COUNTY; CENTERS; IMPACT; TRISS	Objective: To assess the effect of the development of an experimental trauma centre and regional trauma system on the survival of patients with major trauma. Design: Controlled before and after study examining outcomes between 1990 and 1993, spanning the introduction of the system in 1991-2. Setting: Trauma centre in North Staffordshire Royal Infirmary and five associated district general hospitals in the North West Midlands regional trauma system, and two control regions in Lancashire and Humberside. Subjects: All trauma patients taken by the ambulance services serving the regions or arriving other than by ambulance with injury severity scores > 15, whether or not they had vital signs on arrival at hospital. Main outcome measures: Survival rates standardised for age, severity of injury, and revised trauma score. Results: In 1990, 33% of major trauma patients in the experimental region were taken to the trauma centre, and by 1993 this had risen to only 39%, Crude death rates changed by the same amount in the control regions (46.5% in 1990-1 to 44.4% in 1992-3) as in the experimental region (44.8% to 41.3%), After standardisation, the estimated change in the probability of dying in the experimental region compared with the control regions was -0.8% per year (95% confidence interval -3.6% to 2.2%); for out of hours care, the change was 1.6% per year (-2.3% to 5.6%), and, for multiply injured patients, the change was -1.6% (-6.1% to 2.6%). Conclusion: Any reductions in mortality from regionalising major trauma care in shire areas of England would probably be modest compared with reports fr om the United States.			Nicholl, J (corresponding author), UNIV SHEFFIELD,MED CARE RES UNIT,REGENT COURT,30 REGENT ST,SHEFFIELD S1 4DA,S YORKSHIRE,ENGLAND.		Nicholl, Jon/B-8257-2008	Turner, Janette/0000-0003-3884-7875				*AM COLL SURG COMM, 1990, RES OPT CAR INJ PAT; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BULL JP, 1991, INJURY, V121, P127; CALES RH, 1984, ANN EMERG MED, V13, P1, DOI 10.1016/S0196-0644(84)80375-3; CALES RH, 1985, JAMA-J AM MED ASSOC, V254, P1058; CAMPBELL S, 1989, AM SURGEON, V55, P478; CAYTEN CG, 1991, ANN SURG, V214, P510, DOI 10.1097/00000658-199110000-00015; GUSS DA, 1989, ANN EMERG MED, V18, P1141, DOI 10.1016/S0196-0644(89)80048-4; KANE G, 1992, J TRAUMA, V32, P576, DOI 10.1097/00005373-199205000-00007; LOWE DK, 1983, J TRAUMA, V23, P503, DOI 10.1097/00005373-198306000-00011; Mullins RJ, 1996, J TRAUMA, V40, P536, DOI 10.1097/00005373-199604000-00004; MYERS RAM, 1990, J ROY SOC MED, V83, P281, DOI 10.1177/014107689008300501; Nicholl J, 1995, COST EFFECTIVENESS R; REDMOND AD, 1993, ANN ROY COLL SURG, V75, P317; ROY PD, 1987, CAN J SURG, V30, P17; *ROYAL COLL SURG E, 1988, MAN PAT MAJ INJ; RUTLEDGE R, 1992, J TRAUMA, V33, P29, DOI 10.1097/00005373-199207000-00007; SHACKFORD SR, 1986, J TRAUMA, V26, P812, DOI 10.1097/00005373-198609000-00006; YATES DW, 1992, BRIT MED J, V305, P737, DOI 10.1136/bmj.305.6856.737; ZOLTIE N, 1993, BMJ-BRIT MED J, V307, P906, DOI 10.1136/bmj.307.6909.906	22	71	71	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 22	1997	315	7119					1349	1354		10.1136/bmj.315.7119.1349	http://dx.doi.org/10.1136/bmj.315.7119.1349			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402777	Green Published			2022-12-28	WOS:A1997YJ21800024
J	Wang, JM; Hartling, JA; Flanagan, JM				Wang, JM; Hartling, JA; Flanagan, JM			The structure of ClpP at 2.3 angstrom resolution suggests a model for ATP-dependent proteolysis	CELL			English	Article							BACTERIAL CHAPERONIN GROEL; ESCHERICHIA-COLI CLPP; CRYSTAL-STRUCTURE; MOLECULAR CHAPERONES; SERINE PROTEASES; SUBSTRATE-SPECIFICITY; PROTEIN; DEGRADATION; COMPONENT; 2-COMPONENT	We have determined the crystal structure of the proteolytic component of the caseinolytic Clp protease (ClpP) from E. coli at 2.3 Angstrom resolution using an ab initio phasing procedure that exploits the internal 14-fold symmetry of the oligomer. The structure of a ClpP monomer has a distinct fold that defines a fifth structural family of serine proteases but a conserved catalytic apparatus. The active protease resembles a hollow, solid-walled cylinder composed of two 7-fold symmetric rings stacked back-to-back. Its 14 proteolytic active sites are located within a central, roughly spherical chamber similar to 51 Angstrom in diameter. Access to the proteolytic chamber is controlled by two axial pores, each having a minimum diameter of similar to 10 Angstrom. From the structural features of ClpP, we suggest a model for its action in degrading proteins.	BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520	United States Department of Energy (DOE); Brookhaven National Laboratory; Yale University					NIGMS NIH HHS [GM-22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; BLOW DM, 1970, ANN REV BIOCH, V39, P60; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRUNGER AT, 1992, X PLCR VERSION 3 1 S; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Chen P, 1996, CELL, V86, P835, DOI 10.1016/S0092-8674(00)80157-9; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Drenth J, 1994, PRINCIPLES PROTEIN X; FLANAGAN JM, 1995, BIOCHEMISTRY-US, V34, P10910, DOI 10.1021/bi00034a025; Goldberg A L, 1990, Semin Cell Biol, V1, P423; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HARADA Y, 1981, ACTA CRYSTALLOGR A, V37, P398, DOI 10.1107/S0567739481000867; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HORWICH AL, 1995, CURR BIOL, V5, P455, DOI 10.1016/S0960-9822(95)00089-3; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, CCP4 STUDY WEEKEND 1, P91; KANDROR O, 1994, J BIOL CHEM, V269, P23575; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; KLUG A, 1972, QUANT BIOL, V36, P483; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOSTER AJ, 1995, MOL BIOL REP, V21, P1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1997, IN PRESS TRENDS BIOC; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P315; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERONA JJ, 1995, PROTEIN SCI, V4, P337; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; SHANKLIN J, 1995, PLANT CELL, V7, P1713, DOI 10.1105/tpc.7.10.1713; Shin DH, 1996, J MOL BIOL, V262, P71, DOI 10.1006/jmbi.1996.0499; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; STEITZ TA, 1982, ANNU REV BIOPHYS BIO, V11, P419, DOI 10.1146/annurev.bb.11.060182.002223; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOO KM, 1989, J BIOL CHEM, V264, P2088	62	480	489	1	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					447	456		10.1016/S0092-8674(00)80431-6	http://dx.doi.org/10.1016/S0092-8674(00)80431-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390554	hybrid			2022-12-28	WOS:A1997YG49200006
J	McNamara, RL; Lima, JAC; Whelton, PK; Powe, NR				McNamara, RL; Lima, JAC; Whelton, PK; Powe, NR			Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article						cerebrovascular disorders; echocardiography, transesophageal; cost-benefit analysis; embolism and thrombosis; thrombolytic therapy	NONVALVULAR ATRIAL-FIBRILLATION; TRANSIENT ISCHEMIC ATTACKS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CEREBRAL-ISCHEMIA; DECISION-ANALYSIS; CARDIAC SOURCE; TRANSTHORACIC ECHOCARDIOGRAPHY; NATIONAL PERSPECTIVE; ARTERY DISEASE; BREAST-CANCER	Background: No consensus exists about the use of imaging strategies to identify potential cardiovascular sources of emboli in patients who have had strokes. Objective: To;determine the cost-effectiveness of various cardiac imaging strategies after stroke. Design: A Markov model decision analysis was used to evaluate the benefits and costs of nine diagnostic strategies, including transthoracic echocardiography, transesophageal echocardiography, sequential approaches, selective imaging, and no imaging. Setting: Simulated clinical practice in the United States. Patients: Hypothetical patients with a first stroke who were in normal sinus rhythm. Measurements: Echocardiographic detection rates of potential sources of emboli were ascertained by doing a systematic review of the literature. Values for event rates, anticoagulation effects, utilities, and costs were obtained from the literature and Medicare data. Results: When visualized left atrial thrombus was used as the only indication for anticoagulation, transesophageal echocardiography performed only in patients with a history of cardiac problems cost $9000 per quality-adjusted life-year; transesophageal echocardiography in all patients cost $13 000 per quality-adjusted life-year. Cost savings and decreased morbidity and mortality rates associated with reduction in preventable recurrent strokes substantially offset examination costs and risks of anticoagulation. These results were moderately sensitive to efficacy of anticoagulation and incidence of intracranial bleeding during anticoagulation and were mildly sensitive to prevalence of left atrial thrombus, rate of recurrent stroke in patients with thrombus, quality of life after stroke, cost of transesophageal echocardiography, and specificity of transesophageal echocardiography. Transthoracic echocardiography, alone or in sequence with transesophageal echocardiography, was not cost-effective compared with transesophageal echocardiography. Conclusion: Physicians should consider doing transesophageal echocardiography in all patients with new; onset stroke.	JOHNS HOPKINS MED INST, WELCH CTR PREVENT EPIDEMIOL & CLIN RES, BALTIMORE, MD 21250 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA; TULANE UNIV, MED CTR, SCH PUBL HLTH & TROP MED, NEW ORLEANS, LA 70112 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Tulane University					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG000561] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01RR00722] Funding Source: Medline; NHLBI NIH HHS [T32 HL07024-21] Funding Source: Medline; NIA NIH HHS [KO1 AG00561] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Amarenco P, 1996, NEW ENGL J MED, V334, P1216; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; [Anonymous], 1989, Arch Neurol, V46, P727; Ashraf T, 1996, AM J CARDIOL, V78, P409, DOI 10.1016/S0002-9149(96)00328-1; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; BOWEN J, 1994, NEUROLOGY, V44, P1961, DOI 10.1212/WNL.44.10.1961; COMESS KA, 1994, J AM COLL CARDIOL, V23, P1598, DOI 10.1016/0735-1097(94)90662-9; CUJEC B, 1991, STROKE, V22, P727, DOI 10.1161/01.STR.22.6.727; DAHL T, 1995, J INTERN MED, V237, P323, DOI 10.1111/j.1365-2796.1995.tb01182.x; DEBELDER MA, 1992, BRIT HEART J, V67, P297; DEROOK FA, 1992, ANN INTERN MED, V117, P922, DOI 10.7326/0003-4819-117-11-922; DESBIENS NA, 1992, J GEN INTERN MED, V7, P131, DOI 10.1007/BF02598001; DIENER HC, 1991, STROKE, V22, P1229; DOBKIN B, 1995, NEUROLOGY, V45, pS6; ECKMAN MH, 1992, CHEST, V102, pS538, DOI 10.1378/chest.102.4_Supplement.538S; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; Fatkin D, 1996, AM J CARDIOL, V77, P321, DOI 10.1016/S0002-9149(97)89406-4; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; GARDE A, 1983, STROKE, V14, P677, DOI 10.1161/01.STR.14.5.677; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; Gold MR, 1996, COST EFFECTIVENESS H; GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457; HILLNER BE, 1992, JAMA-J AM MED ASSOC, V267, P2055, DOI 10.1001/jama.267.15.2055; HOFMANN T, 1990, LANCET, V336, P1421; JONES EF, 1993, AUST NZ J MED, V23, P477, DOI 10.1111/j.1445-5994.1993.tb01833.x; KESTLE J, 1989, CLIN RES, V37, pA316; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KUPERSMITH J, 1995, PROG CARDIOVASC DIS, V37, P307, DOI 10.1016/S0033-0620(05)80017-9; KUPERSMITH J, 1995, PROG CARDIOVASC DIS, V37, P243, DOI 10.1016/S0033-0620(05)80009-X; LABOVITZ AJ, 1993, AM J CARDIOL, V72, P1448, DOI 10.1016/0002-9149(93)90195-I; LANDEFELD CS, 1989, AM J MED, V87, P144; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; Lee AJ, 1996, MED CARE, V34, P811, DOI 10.1097/00005650-199608000-00008; LEUNG DY, 1995, STROKE, V26, P1820, DOI 10.1161/01.STR.26.10.1820; MAGAR DS, 1995, CANADIAN J CLIN PHAR, V2, P109; MANNING WJ, 1995, ANN INTERN MED, V123, P817, DOI 10.7326/0003-4819-123-11-199512010-00001; MATCHAR DB, 1994, ANN INTERN MED, V121, P41, DOI 10.7326/0003-4819-121-1-199407010-00008; MATCHAR DB, 1987, JAMA-J AM MED ASSOC, V258, P793, DOI 10.1001/jama.258.6.793; Matsumoto N, 1973, STROKE, V4, P20, DOI 10.1161/01.STR.4.1.20; MILLS E, 1978, NEW ENGL J MED, V299, P415, DOI 10.1056/NEJM197808242990810; NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401; OSTER G, 1994, STROKE, V25, P1149, DOI 10.1161/01.STR.25.6.1149; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; Persson U, 1990, Int J Technol Assess Health Care, V6, P125; POP G, 1990, STROKE, V21, P560, DOI 10.1161/01.STR.21.4.560; SACCO RL, 1982, STROKE, V13, P290, DOI 10.1161/01.STR.13.3.290; SACCO RL, 1989, STROKE, V20, P983, DOI 10.1161/01.STR.20.8.983; SANSOY V, 1995, AM J CARDIOL, V75, P166, DOI 10.1016/S0002-9149(00)80068-5; Seto TB, 1997, J AM COLL CARDIOL, V29, P122, DOI 10.1016/S0735-1097(96)00448-2; SHYU KG, 1994, CARDIOLOGY, V85, P53, DOI 10.1159/000176646; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; TERENT A, 1994, STROKE, V25, P2363, DOI 10.1161/01.STR.25.12.2363; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; *US AG HLTH CAR PO, 1995, AHCPR PUBL; Whisnant JP, 1971, STROKE, V2, P11, DOI 10.1161/01.STR.2.1.11	57	74	77	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					775	+		10.7326/0003-4819-127-9-199711010-00001	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382398				2022-12-28	WOS:A1997YD89800001
J	Miller, RA; Gardner, RM				Miller, RA; Gardner, RM			Summary recommendations for responsible monitoring and regulation of clinical software systems	ANNALS OF INTERNAL MEDICINE			English	Article								Clinical software systems are becoming ubiquitous. A growing literature documents how these systems can improve health care delivery, but concerns about patient safety must now be formally addressed. In 1996, the U.S. Food and Drug Administration (FDA) called for discussions on regulation of software programs as medical devices. In response, a consortium of organizations dedicated to improving health care through information technology developed recommendations for the responsible regulation and monitoring of clinical software systems by users, vendors, and regulatory agencies. These recommendations were revised and approved by the American Medical Informatics Association Public Policy Committee and Board. Other organizations reviewed, modified, and approved the recommendations, and the Boards of Directors of most of the organizations in the consortium endorsed the guidelines. The consortium proposes four categories of clinical system risk and four classes of monitoring and regulatory action that can be applied on the basis of the risk level. The consortium recommends that most clinical software systems be supervised locally and that developers of health care information systems adopt a code of good business practices. Budgetary and other constraints limit the type and number of systems that the FDA can regulate effectively; therefore, the FDA should exempt most clinical software systems and focus on systems that pose high clinical risk and provide limited opportunity for competent human intervention.	AMER MED INFORMAT ASSOC, BETHESDA, MD USA						NLM NIH HHS [5-G08-LM-05443, 1-R01-LM-06226] Funding Source: Medline; NATIONAL LIBRARY OF MEDICINE [R01LM006226, G08LM005443] Funding Source: NIH RePORTER	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		GEISSBUHLER AJ, IN PRESS INT J MED I; MILLER RA, IN PRESS J AM MED IN; YOUNG FE, 1987, ANN INTERN MED, V106, P628, DOI 10.7326/0003-4819-106-4-628; 1996, FED REG         0715, V61, P36886	4	40	47	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					842	845		10.7326/0003-4819-127-9-199711010-00014	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00014			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382409				2022-12-28	WOS:A1997YD89800012
J	Tollner, K; PopovitzBiro, R; Lahav, M; Milstein, D				Tollner, K; PopovitzBiro, R; Lahav, M; Milstein, D			Impact of molecular order in Langmuir-Blodgett films on catalysis	SCIENCE			English	Article							HOMOGENEOUS CATALYSIS; COMPLEXES; LIGANDS	Catalytically active Langmuir-Blodgett films of a rhodium complex were prepared and characterized to determine the possible effect of the molecular order of metal complexes on catalytic activity. The hydrogenation of carbon-oxygen double bonds was used as a model reaction. The complex in solution exhibited low catalytic activity, whereas it was highly active in the film. The catalytic activity was found to be highly dependent on the orientation of the complex within the film. The reactions were also highly selective with regard to the substrate. These observations and the observed rate dependence on temperature strongly implicate the molecular order of a metal complex as an important dimension in catalysis.	WEIZMANN INST SCI, DEPT MAT & INTERFACES, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT ORGAN CHEM, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science			Milstein, David/E-9092-2012	Milstein, David/0000-0002-2320-0262				Als-Nielsen J., 1994, Physics Reports, V246, P251, DOI 10.1016/0370-1573(94)90046-9; ATWOOD JL, 1996, COMPREHENSIVE SUPRAM, V9; DEUHY RA, 1990, ACS SYM SER, V447, P192; ELLISON DK, 1983, TETRAHEDRON LETT, V24, P31, DOI 10.1016/S0040-4039(00)81318-0; JACQUEMAIN D, 1992, ANGEW CHEM INT EDIT, V31, P130, DOI 10.1002/anie.199201301; MESTRONI G, 1977, J ORGANOMET CHEM, V140, P63, DOI 10.1016/S0022-328X(00)84397-1; Parshall G.W., 1992, HOMOGENEOUS CATALYSI, V2nd; Petrucci MGL, 1996, ADV MATER, V8, P251, DOI 10.1002/adma.19960080315; PETRUCCI MGL, 1995, J CHEM SOC CHEM COMM, P1577, DOI 10.1039/c39950001577; POPOVITZBIRO R, 1994, J AM CHEM SOC, V116, P1179, DOI 10.1021/ja00083a003; ULMAN A, 1995, THIN FILMS ORGANIC T, V20	11	117	117	2	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2100	2102		10.1126/science.278.5346.2100	http://dx.doi.org/10.1126/science.278.5346.2100			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405341				2022-12-28	WOS:A1997YM23500046
J	Haywood, AM				Haywood, AM			Transmissible spongiform encephalopathies	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CREUTZFELDT-JAKOB-DISEASE; PRION PROTEIN; SCRAPIE PRION; CEREBROSPINAL-FLUID; STRAIN VARIATION; NERVOUS-SYSTEM; MESSENGER-RNA; PRP; MICE; PATHOGENESIS		UNIV ROCHESTER, MED CTR, DEPT MICROBIOL, ROCHESTER, NY 14642 USA	University of Rochester	Haywood, AM (corresponding author), UNIV ROCHESTER, MED CTR, DEPT PEDIAT, ROCHESTER, NY 14642 USA.							Beekes M, 1996, J GEN VIROL, V77, P1925, DOI 10.1099/0022-1317-77-8-1925; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BROWN P, 1992, REV NEUROL, V148, P317; BROWN P, 1986, NEW ENGL J MED, V314, P547, DOI 10.1056/NEJM198602273140904; BROWN P, 1992, LANCET, V340, P24, DOI 10.1016/0140-6736(92)92431-E; BROWN P, 1993, JAMA-J AM MED ASSOC, V269, P3168, DOI 10.1001/jama.269.24.3168; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BRUCE ME, 1991, J GEN VIROL, V72, P595, DOI 10.1099/0022-1317-72-3-595; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CHANDLER RL, 1961, LANCET, V1, P1378; CHESEBRO B, 1985, NATURE, V315, P331, DOI 10.1038/315331a0; CHESEBRO B, 1996, FIELDS VIROLOGY, V2, P2845; Collee JG, 1997, LANCET, V349, P715, DOI 10.1016/S0140-6736(96)08496-6; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; CUILLE J., 1936, Compte Rendu de l'Academie des Sciences, V203, P1552; DEARMOND SJ, 1995, AM J PATHOL, V146, P785; DICKINSON AG, 1988, CIBA F SYMP, V135, P63; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; Estibeiro JP, 1996, TRENDS NEUROSCI, V19, P257, DOI 10.1016/S0166-2236(96)30010-6; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; Ghetti B, 1996, SEMIN VIROL, V7, P189, DOI 10.1006/smvy.1996.0024; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HAYWOOD AM, 1986, NEW ENGL J MED, V315, P939, DOI 10.1056/NEJM198610093151506; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; HUNTER N, 1992, J GEN VIROL, V73, P2751, DOI 10.1099/0022-1317-73-10-2751; Ironside JW, 1996, BRAIN PATHOL, V6, P379, DOI 10.1111/j.1750-3639.1996.tb00869.x; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; KIMBERLIN RH, 1989, VIRUS RES, V12, P213, DOI 10.1016/0168-1702(89)90040-3; KIMBERLIN RH, 1988, CIBA F SYMP, V135, P37; KIMBERLIN RH, 1996, BOVINE SPONGIFORM EN, P155; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Lasmezas CI, 1996, NATURE, V381, P743, DOI 10.1038/381743a0; MANUELIDIS L, 1994, ANN NY ACAD SCI, V724, P259, DOI 10.1111/j.1749-6632.1994.tb38916.x; MANUELIDIS L, 1994, TRANSFUSION, V34, P915, DOI 10.1046/j.1537-2995.1994.341095026981.x; McKenzie D, 1996, SEMIN VIROL, V7, P201, DOI 10.1006/smvy.1996.0025; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MERZ PA, 1984, SCIENCE, V225, P437, DOI 10.1126/science.6377496; Michell AR, 1996, LANCET, V347, P1704, DOI 10.1016/S0140-6736(96)91540-8; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; PETERSEN, 1995, NEUROLOGY, V45, P1430; PETERSEN RB, 1995, NEUROLOGY, V45, P1062, DOI 10.1212/WNL.45.6.1062; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; RICHARDSON EP, 1995, BRAIN PATHOL, V5, P33, DOI 10.1111/j.1750-3639.1995.tb00575.x; Rohwer R G, 1991, Curr Top Microbiol Immunol, V172, P195; Safar J, 1996, SEMIN VIROL, V7, P207, DOI 10.1006/smvy.1996.0026; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; SARKOZI E, 1994, AM J PATHOL, V145, P1280; SCHREUDER BEC, 1993, VET QUART, V15, P167, DOI 10.1080/01652176.1993.9694399; SCHREUDER BEC, 1994, VET QUART, V16, P174, DOI 10.1080/01652176.1994.9694444; SCHREUDER BEC, 1994, VET QUART, V16, P182, DOI 10.1080/01652176.1994.9694445; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; WELLS GAH, 1995, BRAIN PATHOL, V5, P91, DOI 10.1111/j.1750-3639.1995.tb00580.x; WELLS GAH, 1995, BRAIN PATHOL, V5, P200; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Williams E.S., 1992, Revue Scientifique et Technique Office International des Epizooties, V11, P551; ZERR I, 1995, LANCET, V345, P1609, DOI 10.1016/S0140-6736(95)90118-3	71	62	67	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 18	1997	337	25					1821	1828		10.1056/NEJM199712183372508	http://dx.doi.org/10.1056/NEJM199712183372508			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL855	9400041				2022-12-28	WOS:A1997YL85500008
J	Radhakrishnan, I; PerezAlvarado, GC; Parker, D; Dyson, HJ; Montminy, MR; Wright, PE				Radhakrishnan, I; PerezAlvarado, GC; Parker, D; Dyson, HJ; Montminy, MR; Wright, PE			Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: A model for activator:Coactivator interactions	CELL			English	Article							TRANSCRIPTION FACTOR CREB; NUCLEAR-MAGNETIC-RESONANCE; DEPENDENT PROTEIN-KINASE; AROMATIC SIDE-CHAINS; C-13-LABELED PROTEINS; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; CHEMICAL-SHIFTS; J-COUPLINGS; BINDING	The nuclear factor CREB activates transcription of target genes in part through direct interactions with the KIX domain of the coactivator CBP in a phosphorylation-dependent manner. The solution structure of the complex formed by the phosphorylated kinase-inducible domain (pKID) of CREB with KIX reveals that pKID undergoes a coil-->helix folding transition upon binding to KIX, forming two alpha helices. The amphipathic helix alpha B of pKID interacts with a hydrophobic groove defined by helices alpha 1 and alpha 3 of KIX. The other pKID helix, alpha A, contacts a different face of the alpha 3 helix. The phosphate group of the critical phosphoserine residue of pKID forms a hydrogen bond to the side chain of Tyr-658 of KIX. The structure provides a model for interactions between other transactivation domains and their targets.	Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA; HARVARD UNIV, SCH MED,JOSLIN DIABET CTR,DIV RES,DEPT CELL BIOL, BOSTON, MA 02215 USA	Scripps Research Institute; Scripps Research Institute; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.			Dyson, Jane/D-4160-2011; Radhakrishnan, Ishwar/R-8442-2018; Radhakrishnan, Ishwar/AHA-7392-2022	Dyson, Jane/0000-0001-6855-3398; Radhakrishnan, Ishwar/0000-0002-0195-9710; Radhakrishnan, Ishwar/0000-0002-0195-9710; Wright, Peter/0000-0002-1368-0223				Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; COPLEY RR, 1994, J MOL BIOL, V242, P321; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; Lohr F, 1996, J MAGN RESON SER B, V112, P259, DOI 10.1006/jmrb.1996.0140; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; Parker D, 1996, MOL CELL BIOL, V16, P694; PEARLMAN DA, 1995, AMBER 4 1; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Shih HM, 1996, P NATL ACAD SCI USA, V93, P13896, DOI 10.1073/pnas.93.24.13896; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YAMAZAKI T, 1993, J AM CHEM SOC, V115, P11054, DOI 10.1021/ja00076a099; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	56	607	623	0	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					741	752		10.1016/S0092-8674(00)80463-8	http://dx.doi.org/10.1016/S0092-8674(00)80463-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413984	Bronze			2022-12-28	WOS:A1997YL43900006
J	Nightingale, SL				Nightingale, SL			Final standards for mammography facilities issued	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Nightingale, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1728	1728						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388135				2022-12-28	WOS:A1997YH98700009
J	Yeung, WL; Ip, M; Ng, HK; Fok, TF				Yeung, WL; Ip, M; Ng, HK; Fok, TF			An infant with encephalitis	LANCET			English	Article							POLIOMYELITIS		CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT PAEDIAT,SHATIN,HONG KONG; CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MICROBIOL,SHATIN,HONG KONG; CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT MORBID ANAT,SHATIN,HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital			Ng, Ho Keung/I-3952-2015; Ip, Margaret/K-1096-2013	Ip, Margaret/0000-0003-1291-6537				DAVIS LE, 1977, NEW ENGL J MED, V297, P241, DOI 10.1056/NEJM197708042970503; NKOWANE BM, 1987, JAMA-J AM MED ASSOC, V257, P1335, DOI 10.1001/jama.257.10.1335; WYATT HV, 1973, J INFECT DIS, V128, P802, DOI 10.1093/infdis/128.6.802	3	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 29	1997	350	9091					1594	1594		10.1016/S0140-6736(97)09514-7	http://dx.doi.org/10.1016/S0140-6736(97)09514-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH986	9393339				2022-12-28	WOS:A1997YH98600011
J	Grassme, H; Gulbins, E; Brenner, B; Ferlinz, K; Sandhoff, K; Harzer, K; Lang, F; Meyer, TF				Grassme, H; Gulbins, E; Brenner, B; Ferlinz, K; Sandhoff, K; Harzer, K; Lang, F; Meyer, TF			Acidic sphingomyelinase mediates entry of N-gonorrhoeae into nonphagocytic cells	CELL			English	Article							HUMAN EPITHELIAL-CELLS; CULTURED-MAMMALIAN-CELLS; NEISSERIA-GONORRHOEAE; SIGNALING PATHWAY; HEPARAN-SULFATE; INDUCED APOPTOSIS; BACTERIAL ENTRY; TYROSINE PHOSPHORYLATION; SALMONELLA-TYPHIMURIUM; SHIGELLA-FLEXNERI	Invasion of human mucosal cells by N. gonorrhoeae via the binding to heparansulfate proteoglycan receptors is considered a crucial event of the infection. Using different human epithelial cells and primary fibroblasts, we show here an activation of the phosphatidylcholine-specific phospholipase C (PC-PLC) and acidic sphingomyelinase (ASM) by N. gonorrhoeae, resulting in the release of diacylglycerol and ceramide. Genetic and/or pharmacological blockade of ASM and PC-PLC cause inhibition of cellular invasion by N. gonorrhoeae. Complementation of ASM-deficient fibroblasts from Niemann-Pick disease patients restored N. gonorrhoeae-induced signaling and entry processes. The activation of PC-PLC and ASM, therefore, is an essential requirement for the entry of N. gonorrhoeae into distinct nonphagocytic human cell types including several epithelial cells and primary fibroblasts.	MAX PLANCK INST BIOL,INFEKT BIOL ABT,D-72076 TUBINGEN,GERMANY; MAX PLANCK INST INFEKT BIOL,MOL BIOL ABT,D-10117 BERLIN,GERMANY; UNIV TUBINGEN,INST PHYSIOL,D-72076 TUBINGEN,GERMANY; UNIV TUBINGEN,INST HIRNFORSCH,D-72070 TUBINGEN,GERMANY; UNIV BONN,D-53121 BONN,GERMANY	Max Planck Society; Max Planck Society; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; University of Bonn			Meyer, Thomas F. F/J-2485-2013; Gulbins, Erich/L-6989-2014	Meyer, Thomas F. F/0000-0002-6120-8679; Gulbins, Erich/0000-0002-3117-1342				Adam T, 1996, EMBO J, V15, P3315, DOI 10.1002/j.1460-2075.1996.tb00696.x; Apicella MA, 1996, J INFECT DIS, V173, P636, DOI 10.1093/infdis/173.3.636; BESSEN D, 1986, INFECT IMMUN, V54, P154, DOI 10.1128/IAI.54.1.154-160.1986; BHAT KS, 1991, MOL MICROBIOL, V6, P1073; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; Bos MP, 1997, INFECT IMMUN, V65, P2353, DOI 10.1128/IAI.65.6.2353-2361.1997; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; CHEN T, 1995, J EXP MED, V182, P511, DOI 10.1084/jem.182.2.511; Chen T, 1996, P NATL ACAD SCI USA, V93, P14851, DOI 10.1073/pnas.93.25.14851; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; Duensing TD, 1997, INFECT IMMUN, V65, P964, DOI 10.1128/IAI.65.3.964-970.1997; Fussenegger M, 1996, MOL MICROBIOL, V19, P1357, DOI 10.1111/j.1365-2958.1996.tb02479.x; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GomezDuarte OG, 1997, INFECT IMMUN, V65, P3857; GOTSCHLICH EC, 1987, P NATL ACAD SCI USA, V84, P8135, DOI 10.1073/pnas.84.22.8135; Grassme HUC, 1996, INFECT IMMUN, V64, P1621; GrayOwen SD, 1997, EMBO J, V16, P3435, DOI 10.1093/emboj/16.12.3435; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hedlund M, 1996, J EXP MED, V183, P1037, DOI 10.1084/jem.183.3.1037; Higuchi M, 1996, J IMMUNOL, V157, P297; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; HURWITZ R, 1994, BIOL CHEM H-S, V375, P447, DOI 10.1515/bchm3.1994.375.7.447; Ireton K, 1996, SCIENCE, V274, P780, DOI 10.1126/science.274.5288.780; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISSACS RD, 1994, J CLIN INVEST, V93, P809; KISS Z, 1995, BBA-LIPID LIPID MET, V1259, P105, DOI 10.1016/0005-2760(95)00148-6; KUPSCH EM, 1993, EMBO J, V12, P641, DOI 10.1002/j.1460-2075.1993.tb05697.x; LAMBDEN PR, 1979, J GEN MICROBIOL, V114, P305, DOI 10.1099/00221287-114-2-305; LIANG OD, 1992, INFECT IMMUN, V60, P899, DOI 10.1128/IAI.60.3.899-906.1992; MAKINO S, 1991, EMBO J, V10, P1307, DOI 10.1002/j.1460-2075.1991.tb07649.x; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MCGEE ZA, 1983, REV INFECT DIS, V5, P708; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; PACE J, 1993, CELL, V72, P505, DOI 10.1016/0092-8674(93)90070-7; PARUCHURI DK, 1990, P NATL ACAD SCI USA, V87, P333, DOI 10.1073/pnas.87.1.333; ROSENSHINE I, 1992, EMBO J, V11, P3551, DOI 10.1002/j.1460-2075.1992.tb05438.x; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; RUDEL T, 1992, MOL MICROBIOL, V6, P3439, DOI 10.1111/j.1365-2958.1992.tb02211.x; RUDEL T, 1995, NATURE, V373, P357, DOI 10.1038/373357a0; Rudel T, 1996, CELL, V85, P391, DOI 10.1016/S0092-8674(00)81117-4; SAUER G, 1984, P NATL ACAD SCI-BIOL, V81, P3263, DOI 10.1073/pnas.81.11.3263; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; STERN A, 1986, CELL, V47, P61, DOI 10.1016/0092-8674(86)90366-1; SWANSON J, 1988, J EXP MED, V168, P2121, DOI 10.1084/jem.168.6.2121; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; VANPUTTEN JPM, 1993, EMBO J, V12, P4043, DOI 10.1002/j.1460-2075.1993.tb06088.x; VANPUTTEN JPM, 1995, EMBO J, V14, P2144, DOI 10.1002/j.1460-2075.1995.tb07208.x; VANPUTTEN JPM, 1990, J MED MICROBIOL, V33, P35, DOI 10.1099/00222615-33-1-35; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Virji M, 1996, MOL MICROBIOL, V22, P941, DOI 10.1046/j.1365-2958.1996.01551.x; VIRJI M, 1984, J GEN MICROBIOL, V130, P1089; Watarai M, 1996, J EXP MED, V183, P991, DOI 10.1084/jem.183.3.991; WEEL JFL, 1991, J EXP MED, V174, P705, DOI 10.1084/jem.174.3.705; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; ZHANG JP, 1992, CELL, V69, P861, DOI 10.1016/0092-8674(92)90296-O	64	246	255	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					605	615		10.1016/S0092-8674(00)80448-1	http://dx.doi.org/10.1016/S0092-8674(00)80448-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393854	Green Published, Bronze			2022-12-28	WOS:A1997YH96000008
J	Buckle, PW				Buckle, PW			Fortnightly review - Work factors and upper limb disorders	BRITISH MEDICAL JOURNAL			English	Review							CARPAL-TUNNEL SYNDROME; MUSCULOSKELETAL DISORDERS; RISK FACTOR; OCCUPATIONAL FACTORS; PROCESSING INDUSTRY; MEDIAN NERVE; PREVALENCE; EPICONDYLITIS; MUSCLE; TENOSYNOVITIS				Buckle, PW (corresponding author), UNIV SURREY,ROBENS CTR HLTH ERGON,GUILDFORD GU2 5XH,SURREY,ENGLAND.		Buckle, Peter/A-4387-2008	Buckle, Peter/0000-0002-3985-2441				ARMSTRONG TJ, 1993, SCAND J WORK ENV HEA, V19, P73, DOI 10.5271/sjweh.1494; BARTON NJ, 1992, BRIT MED J, V304, P309, DOI 10.1136/bmj.304.6822.309; BONGERS PM, 1993, SCAND J WORK ENV HEA, V19, P297, DOI 10.5271/sjweh.1470; CANNON LJ, 1981, J OCCUP ENVIRON MED, V23, P255; CHIANG HC, 1993, SCAND J WORK ENV HEA, V19, P126, DOI 10.5271/sjweh.1496; Cooper C, 1996, OCCUP MED-OXFORD, V46, P435, DOI 10.1093/occmed/46.6.435; DEKROM MCTFM, 1990, AM J EPIDEMIOL, V132, P1102, DOI 10.1093/oxfordjournals.aje.a115753; DENNETT X, 1988, LANCET, V1, P905; FRANKLIN GM, 1991, AM J PUBLIC HEALTH, V81, P741, DOI 10.2105/AJPH.81.6.741; GELBERMAN R, 1981, J BONE JOINT SURG AM, V63, P235; Hagberg M, 1996, BRIT MED J, V313, P419; HAGBERG M, 1995, WORK RELATED MUSCULO; JARVHOLM U, 1988, J ORTHOP RES, V6, P230, DOI 10.1002/jor.1100060210; Jones DA, 1990, SKELETAL MUSCLE HLTH; KIVI P, 1984, SCAND J RHEUMATOL, V13, P101, DOI 10.3109/03009748409100371; KURPPA K, 1991, SCAND J WORK ENV HEA, V17, P32, DOI 10.5271/sjweh.1737; LARSSON SE, 1988, ACTA ORTHOP SCAND, V59, P552, DOI 10.3109/17453678809148783; LUNDBORG G, 1982, J HAND SURG-AM, V7, P252, DOI 10.1016/S0363-5023(82)80175-5; LUOPAJARVI T, 1979, SCAND J WORK ENV HEA, V5, P48, DOI 10.5271/sjweh.2675; MCCORMACK RR, 1990, J RHEUMATOL, V17, P958; Moon S.D., 1996, BIOMECHANICS PSYCHOS; NATHAN PA, 1992, J OCCUP ENVIRON MED, V34, P379; NATHAN PA, 1988, J HAND SURG-BRIT EUR, V13B, P167, DOI 10.1016/0266-7681(88)90130-1; NATHAN PA, 1994, J HAND SURG-BRIT EUR, V19B, P30, DOI 10.1016/0266-7681(94)90044-2; PUNNETT L, 1985, SCAND J WORK ENV HEA, V11, P417, DOI 10.5271/sjweh.2205; Ramazzini B., 1713, MORBIS ARTIFICUM; RANNEY D, 1995, ERGONOMICS, V38, P1408, DOI 10.1080/00140139508925198; Ritz BR, 1995, SCAND J WORK ENV HEA, V21, P478, DOI 10.5271/sjweh.64; ROTO P, 1984, SCAND J WORK ENV HEA, V10, P203, DOI 10.5271/sjweh.2344; Silverstein B. A., 1985, THESIS U MICHIGAN; SILVERSTEIN BA, 1987, AM J IND MED, V11, P343, DOI 10.1002/ajim.4700110310; STEVENS JC, 1988, NEUROLOGY, V38, P134, DOI 10.1212/WNL.38.1.134; STOCK SR, 1991, AM J IND MED, V19, P87, DOI 10.1002/ajim.4700190111; VEIERSTED KB, 1994, INT J IND ERGONOM, V14, P333, DOI 10.1016/0169-8141(94)90021-3; VENDER MI, 1995, J HAND SURG-AM, V20A, P534, DOI 10.1016/S0363-5023(05)80263-1; VIIKARIJUNTURA E, 1991, SCAND J WORK ENV HEA, V17, P38, DOI 10.5271/sjweh.1736; WAERSTED M, 1991, ERGONOMICS, V34, P265, DOI 10.1080/00140139108967312; WIESLANDER G, 1989, BRIT J IND MED, V46, P43; Woolf Clifford J., 1994, Current Opinion in Neurobiology, V4, P525, DOI 10.1016/0959-4388(94)90053-1	39	36	39	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 22	1997	315	7119					1360	1363		10.1136/bmj.315.7119.1360	http://dx.doi.org/10.1136/bmj.315.7119.1360			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402780	Green Published			2022-12-28	WOS:A1997YJ21800028
J	Larsen, CN; Finley, D				Larsen, CN; Finley, D			Protein translocation channels in the proteasome and other proteases	CELL			English	Review							CRYSTAL-STRUCTURE; RESOLUTION; COMPLEX		HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School				Larsen, Christopher N/0000-0002-1051-5767	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019359] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM019359] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumeister W, 1997, CURR OPIN STRUC BIOL, V7, P273, DOI 10.1016/S0959-440X(97)80036-X; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; BURLEY SK, 1990, P NATL ACAD SCI USA, V87, P6878, DOI 10.1073/pnas.87.17.6878; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; WENTZEL T, 1995, NAT STRUCT BIOL, V2, P199	18	133	135	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					431	434		10.1016/S0092-8674(00)80427-4	http://dx.doi.org/10.1016/S0092-8674(00)80427-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390550	Bronze			2022-12-28	WOS:A1997YG49200002
J	Mange, K; Matsuura, D; Cizman, B; Soto, H; Ziyadeh, FN; Goldfarb, S; Neilson, EG				Mange, K; Matsuura, D; Cizman, B; Soto, H; Ziyadeh, FN; Goldfarb, S; Neilson, EG			Language guiding therapy: The case of dehydration versus volume depletion	ANNALS OF INTERNAL MEDICINE			English	Article							RENAL WATER EXCRETION; SODIUM HOMEOSTASIS; FLUID VOLUME; SET POINT; PLASMA; VASOPRESSIN; HYPERGLYCEMIA; HYPONATREMIA; STIMULATION; SECRETION		UNIV PENN, RENAL ELECTROLYTE & HYPERTENS DIV, PHILADELPHIA, PA 19104 USA	University of Pennsylvania					NIDDK NIH HHS [DK-07006] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007006] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adolph EF, 1947, PHYSL MAN DESERT; ARIEFF AI, 1973, J CLIN INVEST, V52, P571, DOI 10.1172/JCI107218; ARIEFF AI, 1976, KIDNEY INT, V10, P104, DOI 10.1038/ki.1976.82; Bech JN, 1996, AM J PHYSIOL-RENAL, V270, pF845, DOI 10.1152/ajprenal.1996.270.5.F845; BERL T, 1974, J CLIN INVEST, V53, P219, DOI 10.1172/JCI107541; BOLGER PM, 1978, NATURE, V271, P467; BONVENTRE JV, 1982, KIDNEY INT, V21, P880, DOI 10.1038/ki.1982.113; COGAN MG, 1986, AM J PHYSIOL, V250, pF710, DOI 10.1152/ajprenal.1986.250.4.F710; Darrow DC, 1935, J CLIN INVEST, V14, P266, DOI 10.1172/JCI100674; DAUGHARTY TM, 1971, AM J PHYSIOL, V220, P2021, DOI 10.1152/ajplegacy.1971.220.6.2021; EARLEY LE, 1969, NEW ENGL J MED, V281, P72, DOI 10.1056/NEJM196907102810205; EDELMAN IS, 1959, AM J MED, V27, P256, DOI 10.1016/0002-9343(59)90346-8; EDELMAN IS, 1958, J CLIN INVEST, V37, P1236, DOI 10.1172/JCI103712; EDELMAN IS, 1952, SCIENCE, V115, P447, DOI 10.1126/science.115.2991.447; FEIG PU, 1977, NEW ENGL J MED, V297, P1444, DOI 10.1056/NEJM197712292972608; GAMBLE JL, 1947, HARVEY LECT, V42, P247; Gamble JL, 1923, J BIOL CHEM, V57, P633; GAMBLE JL, 1939, CHEM ANATOMY PHYSL P; GENNARI FJ, 1974, NEW ENGL J MED, V291, P714, DOI 10.1056/NEJM197410032911408; Gilman A, 1937, AM J PHYSIOL, V120, P323, DOI 10.1152/ajplegacy.1937.120.2.323; GOLDBERG M, 1981, MED CLIN N AM, V65, P251, DOI 10.1016/S0025-7125(16)31523-1; HOLLENBERG NK, 1980, KIDNEY INT, V17, P423, DOI 10.1038/ki.1980.50; Holt LE, 1915, AM J DIS CHILD, V9, P215; KATZ MA, 1973, NEW ENGL J MED, V289, P843, DOI 10.1056/NEJM197310182891607; Kleinzeller A., 1990, Comparative Physiology, V4, P59; Landis EM, 1934, PHYSIOL REV, V14, P0404, DOI 10.1152/physrev.1934.14.3.404; LEAF A, 1962, NEW ENGL J MED, V267, P77, DOI 10.1056/NEJM196207122670206; LEAF A, 1954, J CLIN INVEST, V33, P1261, DOI 10.1172/JCI103001; LEAF A, 1970, AM J MED, V49, P291, DOI 10.1016/S0002-9343(70)80019-5; LIEN YHH, 1990, J CLIN INVEST, V85, P1427, DOI 10.1172/JCI114587; Lucke B, 1932, PHYSIOL REV, V12, P0068, DOI 10.1152/physrev.1932.12.1.68; MACKNIGHT ADC, 1992, KIDNEY PHYSL PATHOPH, P1779; MAFFLY RH, 1959, J GEN PHYSIOL, V42, P1257, DOI 10.1085/jgp.42.6.1257; MCCURDY DK, 1970, MED CLIN N AM, V54, P683, DOI 10.1016/S0025-7125(16)32636-0; MCDOWELL ME, 1955, AM J PHYSIOL, V180, P545, DOI 10.1152/ajplegacy.1955.180.3.545; MERRILL AJ, 1949, AM J MED, V6, P357, DOI 10.1016/0002-9343(49)90173-4; MOORE FD, 1966, ANN SURG, V163, P485, DOI 10.1097/00000658-196604000-00001; MOORE FD, 1958, NEW ENGL J MED, V258, P325, DOI 10.1056/NEJM195802132580705; Moore FD, 1963, BODY CELL MASS ITS S; PETERS JP, 1948, NEW ENGL J MED, V239, P353, DOI 10.1056/NEJM194809022391001; PETERS JP, 1935, BODY WATER EXCHANGE, P1; PETERS JP, 1935, BODY WATER EXCHANGE, P274; Pitts RF, 1963, PHYSL KIDNEY BODY FL; ROBERTSON GL, 1976, J CLIN ENDOCR METAB, V42, P613, DOI 10.1210/jcem-42-4-613; ROBERTSON GL, 1973, J CLIN INVEST, V52, P2340, DOI 10.1172/JCI107423; ROEMMELT JC, 1949, AM J PHYSIOL, V159, P124, DOI 10.1152/ajplegacy.1949.159.1.124; ROSE BD, 1986, AM J MED, V81, P1033, DOI 10.1016/0002-9343(86)90401-8; SAXENHOFER H, 1990, AM J PHYSIOL, V259, pF832, DOI 10.1152/ajprenal.1990.259.5.F832; SCHRIER RW, 1975, NEW ENGL J MED, V292, P141, DOI 10.1056/NEJM197501162920306; SCHRIER RW, 1975, NEW ENGL J MED, V292, P81, DOI 10.1056/NEJM197501092920207; SCHRIER RW, 1990, ANN INTERN MED, V113, P155, DOI 10.7326/0003-4819-113-2-155; SCHUSTER VL, 1984, J CLIN INVEST, V73, P507, DOI 10.1172/JCI111237; Silver SM, 1997, KIDNEY INT, V51, P1237, DOI 10.1038/ki.1997.169; SKOTT O, 1987, SCIENCE, V237, P1618, DOI 10.1126/science.3306925; SMITH HW, 1960, CIRCULATION, V21, P808, DOI 10.1161/01.CIR.21.5.808; Starling E H, 1896, J Physiol, V19, P312; STRAUSS MB, 1957, BODY WATER MAN ACQUI; THAMES MD, 1980, AM J PHYSIOL, V239, pH784, DOI 10.1152/ajpheart.1980.239.6.H784; Winkler AW, 1944, J CLIN INVEST, V23, P103, DOI 10.1172/JCI101464	59	102	106	2	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	1997	127	9					848	853		10.7326/0003-4819-127-9-199711010-00020	http://dx.doi.org/10.7326/0003-4819-127-9-199711010-00020			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YD898	9382413				2022-12-28	WOS:A1997YD89800018
J	Ichikawa, T; Suzuki, Y; Czaja, I; Schommer, C; Lessnick, A; Schell, J; Walden, R				Ichikawa, T; Suzuki, Y; Czaja, I; Schommer, C; Lessnick, A; Schell, J; Walden, R			RETRACTED: Identification and role of adenylyl cyclase in auxin signalling in higher plants (Retracted article. See vol 396, pg 390, 1998)	NATURE			English	Article; Retracted Publication							SACCHAROMYCES-CEREVISIAE; INDEPENDENT GROWTH; CYCLIC-AMP; GENE; EXPRESSION; CELLS; TRANSDUCTION; ACTIVATION; SEQUENCE; PROTEINS	Cyclic AMP is an important signalling molecule in prokaryotes and eukaryotes(1), but its significance in higher plants has been generally doubted(2) because they have low adenylyl cyclase activity and barely detectable amounts of cAMP(3), Here we used activation T-DNA tagging to create tobacco cell lines that can proliferate in the absence of the phytohormone auxin in the culture media(4,5). The sequence tagged in one line, axi 141, was used to isolate a complementary DNA encoding adenylyl cyclase, the first from a higher plant. Sequence analysis reveals that the tobacco adenylyl cyclase is probably soluble, contains characteristic leucine-rich repeats, and bears similarity with adenylyl cyclase from the yeast Schizosaccharomyces pombe. Expression of the cDNA in Escherichia coli results in an increase in endogenous cAMP levels, and in yeast its expression functionally complements the cry1 mutation. Tobacco protoplasts treated with cAMP, or the adenylyl cyclase activator forskolin, no longer require auxin to divide. This finding, together with the observation that the adenylyl cyclase inhibitor dideoxyadenosine inhibits cell proliferation in the presence of auxin, suggests that cAMP is involved in auxin-triggered cell division in higher plants.	MAX PLANCK INST ZUCHTUNGSFORSCH, D-50829 COLOGNE, GERMANY	Max Planck Society				Suzuki, Yoshihito/0000-0002-4574-9504				ARCHDEACON J, 1995, FEMS MICROBIOL LETT, V128, P177, DOI 10.1111/j.1574-6968.1995.tb07519.x; ASSMANN SM, 1995, PLANT PHYSIOL, V108, P885, DOI 10.1104/pp.108.3.885; FRANCIS SH, 1996, SIGNAL TRANSDUCTION, P223; FRITZE K, 1994, PLANT J, V7, P101; HARTZELL HC, 1991, NATURE, V351, P573, DOI 10.1038/351573a0; HAYASHI H, 1992, SCIENCE, V258, P1350, DOI 10.1126/science.1455228; HOLGATE ST, 1985, P NATL ACAD SCI USA, V77, P6800; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KROLL DJ, 1993, DNA CELL BIOL, V12, P441, DOI 10.1089/dna.1993.12.441; LALLI E, 1994, J BIOL CHEM, V269, P17359; LI WW, 1994, PLANT PHYSIOL, V106, P957, DOI 10.1104/pp.106.3.957; Macdonald H, 1997, PHYSIOL PLANTARUM, V100, P423, DOI 10.1034/j.1399-3054.1997.1000303.x; MATSUMOTO K, 1984, J BACTERIOL, V157, P277, DOI 10.1128/JB.157.1.277-282.1984; Millner PA, 1996, J EXP BOT, V47, P983, DOI 10.1093/jxb/47.8.983; NAGATA T, 1970, PLANTA, V92, P301, DOI 10.1007/BF00385097; Rohrig H, 1996, P NATL ACAD SCI USA, V93, P13389, DOI 10.1073/pnas.93.23.13389; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TOPFER R, 1993, METHOD ENZYMOL, V217, P66; TREWAVAS A, 1991, TRENDS GENET, V7, P356, DOI 10.1016/0168-9525(91)90255-O; WALDEN R, 1993, PLANT CELL REP, V12, P551, DOI 10.1007/BF00233058; WALDEN R, 1994, PLANT MOL BIOL, V26, P1521, DOI 10.1007/BF00016488; WALDEN R, 1994, EMBO J, V13, P4729, DOI 10.1002/j.1460-2075.1994.tb06798.x; YAMAWAKIKATAOKA Y, 1989, P NATL ACAD SCI USA, V86, P5693, DOI 10.1073/pnas.86.15.5693	27	35	42	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 25	1997	390	6661					698	701		10.1038/37810	http://dx.doi.org/10.1038/37810			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414164				2022-12-28	WOS:A1997YM50800035
J	Bu, XH; Feng, PY; Stucky, GD				Bu, XH; Feng, PY; Stucky, GD			Large-cage zeolite structures with multidimensional 12-ring channels	SCIENCE			English	Article							MOLECULAR-SIEVE	Zeolite type structures with large cages interconnected by multidimensional 12-ring (rings of 12 tetrahedrally coordinated atoms) channels have been synthesized; more than a dozen large-pore materials were created in three different topologies with aluminum (or gallium), cobalt (or manganese, magnesium, or zinc), and phosphorus at the tetrahedral coordination sites. Tetragonal UCSB-8 has an unusually large cage built from 64 tetrahedral atoms and connected by an orthogonal channel system with 12-ring apertures in two dimensions and 8-ring apertures in the third. Rhombohedral UCSB-10 and hexagonal UCSB-8 are structurally related to faujasite and its hexagonal polymorph, respectively, and have large cages connected by 12-ring channels in all three dimensions.			Bu, XH (corresponding author), UNIV CALIF SANTA BARBARA, DEPT CHEM, SANTA BARBARA, CA 93106 USA.		Bu, Xianhui/L-9403-2013	Bu, Xianhui/0000-0002-2994-4051				ANDRIES KJ, UNPUB; Baerlocher C., 1996, ATLAS ZEOLITE STRUCT; BENNETT JM, 1980, INNOVATION ZEOLITE M, P269; Breck D. W., 1974, ZEOLITE MOL SIEVES; BU X, IN PRESS MICROPOROUS; Chippindale AM, 1997, ZEOLITES, V18, P176, DOI 10.1016/S0144-2449(96)00150-9; DAVIS ME, 1988, NATURE, V331, P698, DOI 10.1038/331698a0; DAVIS ME, 1996, SYNTHESIS POROUS MAT, P1; DESSAU RM, 1990, ZEOLITES, V10, P552; ESTERMANN M, 1991, NATURE, V352, P320, DOI 10.1038/352320a0; Feng PY, 1997, NATURE, V388, P735, DOI 10.1038/41937; FENG PY, 1995, ANGEW CHEM INT EDIT, V34, P1745, DOI 10.1002/anie.199517451; Freyhardt CC, 1996, NATURE, V381, P295, DOI 10.1038/381295a0; Gaffney TR, 1996, CURR OPIN SOLID ST M, V1, P69, DOI 10.1016/S1359-0286(96)80013-1; HUO QS, 1995, SCIENCE, V268, P1324, DOI 10.1126/science.268.5215.1324; KESSLER H, 1994, STUD SURF SCI CATAL, V85, P75; Khan MI, 1996, CHEM MATER, V8, P43, DOI 10.1021/cm950249t; MCCUSCKER LB, 1996, COMPREHENSIVE SUPRAM, V7, P393; MCCUSKER LB, 1990, ACTA CRYSTALLOGR, V46, pC55; PLUTH JJ, 1988, J PHYS CHEM-US, V92, P2734, DOI 10.1021/j100321a008; RICHARD RH, 1993, J SOLID STATE CHEM, V102, P204; SHANNON RD, 1976, ACTA CRYSTALLOGR A, V32, P751, DOI 10.1107/S0567739476001551; VALYOCSIK EW, 1985, ZEOLITES, V5, P123, DOI 10.1016/0144-2449(85)90084-3; van Bekkum H., 1991, INTRO ZEOLITE SCI PR; WILSON ST, 1989, ACS SYM SER, V398, P329; WRIGHT PA, 1993, J CHEM SOC CHEM COMM, P633, DOI 10.1039/c39930000633	26	276	287	0	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 19	1997	278	5346					2080	2085		10.1126/science.278.5346.2080	http://dx.doi.org/10.1126/science.278.5346.2080			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405337				2022-12-28	WOS:A1997YM23500042
J	Bernstein, DI				Bernstein, DI			Allergic reactions to workplace allergens	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WESTERN RED CEDAR; AIRWAYS DYSFUNCTION SYNDROME; HISTAMINE-RELEASING FACTORS; INDUCED OCCUPATIONAL ASTHMA; LABORATORY-ANIMAL ALLERGY; ISOCYANATE-INDUCED ASTHMA; BAKERS ASTHMA; LATEX ALLERGY; THUJA-PLICATA; FOLLOW-UP	Allergic sensitization to workplace allergens can result in occupational asthma (OA), rhinitis, and dermatoses. Occupational asthma, accounting for 2% to 15% of all new cases of asthma, is caused by more than 240 reactive chemicals or natural proteins. Diisocyanates, used in urethane production and spray painting, are the leading causes of OA. Occupational asthma must be objectively confirmed by demonstrating significant decreases in lung function associated with exposure to a causative agent. An early diagnosis of OA followed by elimination of exposure to a causative agent may be curative and prevent progression to chronic asthma. In the last decade, protein allergens in natural rubber latex gloves have emerged as the leading cause of work-related cutaneous and respiratory allergic disorders in health care workers. In the workplace, occupational allergic contact dermatitis is almost always caused by chemicals, including nickel, chromates, and epoxy resins, whereas contact urticarial reactions are most often due to protein allergens. The primary treatment of occupational allergic disorders is strict avoidance of exposure to the inciting agent.			Bernstein, DI (corresponding author), UNIV CINCINNATI,DIV IMMUNOL,ML 563,231 BETHESDA AVE,CINCINNATI,OH 45267, USA.							AELING JL, 1990, ALLERGY ASTHMA IMMUN; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; BAUR X, 1986, LANCET, V1, P43; BAUR X, 1988, RESPIRATION, V54, P720; Becklake Margaret R., 1993, P29; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; Bernstein David I., 1993, P103; Bernstein David I., 1993, P373; BERNSTEIN DI, 1993, J ALLERGY CLIN IMMUN, V92, P387, DOI 10.1016/0091-6749(93)90117-X; BERNSTEIN DI, 1987, J ALLERGY CLIN IMMUN, V80, P791, DOI 10.1016/S0091-6749(87)80267-1; BERNSTEIN DI, 1984, J ALLERGY CLIN IMMUN, V74, P794, DOI 10.1016/0091-6749(84)90181-7; BERNSTEIN DI, 1993, ALLERGY PRINCIPLES P, P1369; BERNSTEIN DI, 1993, ASTHMA WORKPLACE, P1; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71, DOI 10.1164/ajrccm.149.1.8111601; BLANC P, 1987, CHEST, V92, P613, DOI 10.1378/chest.92.4.613; BLANCO C, 1994, ANN ALLERGY, V73, P309; BLOCK G, 1983, CLIN ALLERGY, V13, P359, DOI 10.1111/j.1365-2222.1983.tb02610.x; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; Brooks Stuart M., 1993, P533; BURGE PS, 1982, THORAX, V37, P348, DOI 10.1136/thx.37.5.348; BUTCHER BT, 1977, J ALLERGY CLIN IMMUN, V64, P146; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P823, DOI 10.1016/0091-6749(89)90346-1; CHANYEUNG M, 1992, AM REV RESPIR DIS, V146, P1606, DOI 10.1164/ajrccm/146.6.1606; CHANYEUNG M, 1987, J ALLERGY CLIN IMMUN, V79, P792, DOI 10.1016/0091-6749(87)90212-0; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; CHANYEUNG M, 1977, AM REV RESPIR DIS, V116, P1023; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V89, P23, DOI 10.1016/S0091-6749(05)80037-5; EGGLESTON PA, 1989, J ALLERGY CLIN IMMUN, V84, P347, DOI 10.1016/0091-6749(89)90419-3; FRANZ T, 1971, J ALLERGY, V47, P170, DOI 10.1016/S0091-6749(71)80295-6; FREW AJ, 1995, AM J RESP CRIT CARE, V151, P340, DOI 10.1164/ajrccm.151.2.7842189; GAUTRIN D, 1994, J ALLERGY CLIN IMMUN, V93, P12, DOI 10.1016/0091-6749(94)90228-3; GORDON S, 1992, BRIT J IND MED, V49, P416; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; HERD ZL, 1994, AM J RESP CRIT CARE, V150, P988, DOI 10.1164/ajrccm.150.4.7522854; Introna F, 1966, Minerva Medicoleg, V86, P176; Kanerva L, 1996, CONTACT DERMATITIS, V35, P229, DOI 10.1111/j.1600-0536.1996.tb02363.x; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V93, P813, DOI 10.1016/0091-6749(94)90370-0; Kimber I, 1996, FUND APPL TOXICOL, V33, P1, DOI 10.1006/faat.1996.0136; KLAUSTERMEYER WB, 1977, CLIN ALLERGY, V7, P227, DOI 10.1111/j.1365-2222.1977.tb01447.x; LISS GM, 1984, J ALLERGY CLIN IMMUN, V73, P348, DOI 10.1016/0091-6749(84)90407-X; LISS GM, 1988, J ALLERGY CLIN IMMUN, V82, P55, DOI 10.1016/0091-6749(88)90051-6; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; LOSADA E, 1986, J ALLERGY CLIN IMMUN, V77, P635, DOI 10.1016/0091-6749(86)90358-1; Lummus ZL, 1996, TOXICOLOGY, V111, P191, DOI 10.1016/0300-483X(96)03376-8; LYBARGER JA, 1982, J ALLERGY CLIN IMMUN, V69, P448, DOI 10.1016/0091-6749(82)90120-8; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V151, P607; MAIBACH HI, 1993, ALLERGY PRINCIPLES P; MALO JL, 1993, CLIN REV ALLERG, V11, P223; MALO JL, 1991, AM REV RESPIR DIS, V143, P528, DOI 10.1164/ajrccm/143.3.528; MEREDITH SK, 1991, BRIT J IND MED, V48, P292; MERGET R, 1993, J ALLERGY CLIN IMMUN, V92, P264, DOI 10.1016/0091-6749(93)90170-K; MOLLER DR, 1986, CHEST, V90, P494, DOI 10.1378/chest.90.4.494; MONERETVAUTRIN DA, 1993, J ALLERGY CLIN IMMUN, V92, P668, DOI 10.1016/0091-6749(93)90009-5; MOSCATO G, 1995, J ALLERGY CLIN IMMUN, V96, P295; Newman Taylor A. J., 1993, P399; NOVEY HS, 1979, J ALLERGY CLIN IMMUN, V63, P98, DOI 10.1016/0091-6749(79)90198-2; ORFAN NA, 1994, J ALLERGY CLIN IMMUN, V94, P826, DOI 10.1016/0091-6749(94)90149-X; PATTERSON R, 1982, J ALLERGY CLIN IMMUN, V70, P19, DOI 10.1016/0091-6749(82)90196-8; PEPYS J, 1975, NEW ENGL J MED, V192, P758; PERRIN B, 1991, J ALLERGY CLIN IMMUN, V87, P630, DOI 10.1016/0091-6749(91)90381-W; QUIRCE S, 1995, AM J RESP CRIT CARE, V152, P1100, DOI 10.1164/ajrccm.152.3.7663790; SAETTA M, 1995, AM J RESP CRIT CARE, V151, P489, DOI 10.1164/ajrccm.151.2.7842211; SIRACUSA A, 1992, AM REV RESPIR DIS, V146, P408, DOI 10.1164/ajrccm/146.2.408; SJOSTEDT L, 1989, AM J IND MED, V16, P199, DOI 10.1002/ajim.4700160211; SLAVIN RG, 1997, ALLERGIC DIS DIAGNOS; SLOVAK AJM, 1981, BRIT J IND MED, V38, P38; SMITH AB, 1987, AM J IND MED, V12, P205, DOI 10.1002/ajim.4700120209; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; Tarlo SM, 1997, J ALLERGY CLIN IMMUN, V99, P396, DOI 10.1016/S0091-6749(97)70058-7; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TARLO SM, 1995, CHEST, V107, P634, DOI 10.1378/chest.107.3.634; TERHO EO, 1982, ALLERGY, V37, P15, DOI 10.1111/j.1398-9995.1982.tb04112.x; THIEL H, 1980, CHEST, V78, P400, DOI 10.1378/chest.78.2.400; THIEL H, 1987, OCCUP ENV DERMATOSES, V35, P81; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887; VENABLES KM, 1989, BRIT J IND MED, V46, P222; VENABLES KM, 1989, BMJ-BRIT MED J, V299, P939, DOI 10.1136/bmj.299.6705.939; VENABLES KM, 1988, BRIT J IND MED, V45, P667; VOELKER R, 1995, JAMA-J AM MED ASSOC, V273, P764; WARREN CPW, 1983, ANN ALLERGY, V50, P30; YASSIN MS, 1994, ANN ALLERGY, V72, P245; YOUNG RP, 1995, AM J RESP CRIT CARE, V151, P219, DOI 10.1164/ajrccm.151.1.7812558; 1976, THORAX, V31, P621	89	47	47	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	1997	278	22					1907	1913		10.1001/jama.278.22.1907	http://dx.doi.org/10.1001/jama.278.22.1907			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK155	9396652				2022-12-28	WOS:A1997YK15500013
J	Riezman, H				Riezman, H			The ins and outs of protein translocation	SCIENCE			English	Editorial Material											Riezman, H (corresponding author), UNIV BASEL,BIOCTR,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.			Riezman, Howard/0000-0003-4680-9422				BIEDERER T, 1997, SCIENCE, V287, P1806; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Johnson AE, 1997, TRENDS CELL BIOL, V7, P90, DOI 10.1016/S0962-8924(97)01029-5; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0	8	19	19	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1728	1729		10.1126/science.278.5344.1728	http://dx.doi.org/10.1126/science.278.5344.1728			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9411792				2022-12-28	WOS:A1997YJ90100029
J	Madhani, HD; Styles, CA; Fink, GR				Madhani, HD; Styles, CA; Fink, GR			MAP kinases with distinct inhibitory functions impart signaling specificity during yeast differentiation	CELL			English	Article							PHEROMONE RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; FILAMENTOUS GROWTH; PROTEIN-KINASES; INVASIVE GROWTH; SHUTTLE VECTORS; FUS3; CASCADE; KSS1; TRANSDUCTION	Filamentous invasive growth of S. cerevisiae requires multiple elements of the mitogen-activated protein kinase (MAPK) signaling cascade that are also components of the mating pheromone response pathway. Here we show that, despite sharing several constituents, the two pathways use different MAP kinases. The Fus3 MAPK regulates mating, whereas the Kss1 MAPK regulates filamentation and invasion; Remarkably, in addition to their kinase-dependent activation functions, Kss1 and Fus3 each have a distinct kinase-independent inhibitory function. Kss1 inhibits the filamentation pathway by interacting with its target transcription factor Ste12. Fus3 has a different inhibitory activity that prevents the inappropriate activation of invasion by the pheromone response pathway. In the absence of Fus3, there is erroneous crosstalk in which mating pheromone now activates filamentation-specific gene expression using the Kss1 MAPK.			Madhani, HD (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Madhani, Hiten/0000-0001-7400-6657				Bardwell L, 1996, MOL CELL BIOL, V16, P3637; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHENEVERT J, 1994, GENETICS, V136, P1287; CHOI KY, 1994, CELL, V78, P499; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; Guthrie C, 1991, GUIDE YEAST GENETICS; HAGEN DC, 1991, MOL CELL BIOL, V11, P2952, DOI 10.1128/MCB.11.6.2952; Hall JP, 1996, MOL CELL BIOL, V16, P6715; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIGUCHI R, 1989, PCR TECHNOLOGY; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; HWANGSHUM JJ, 1991, MOL GEN GENET, V227, P197, DOI 10.1007/BF00259671; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MA D, 1995, MOL BIOL CELL, V6, P889, DOI 10.1091/mbc.6.7.889; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Mosch HU, 1997, GENETICS, V145, P671; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; PRINTEN JA, 1994, GENETICS, V138, P609; Roberts RL, 1997, CELL, V89, P1055, DOI 10.1016/S0092-8674(00)80293-7; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Watanabe Y, 1997, MOL CELL BIOL, V17, P2615, DOI 10.1128/MCB.17.5.2615; YASHAR B, 1995, MOL CELL BIOL, V15, P6545; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	43	363	369	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 28	1997	91	5					673	684		10.1016/S0092-8674(00)80454-7	http://dx.doi.org/10.1016/S0092-8674(00)80454-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393860	Bronze			2022-12-28	WOS:A1997YH96000014
J	Palmeirim, I; Henrique, D; IshHorowicz, D; Pourquie, O				Palmeirim, I; Henrique, D; IshHorowicz, D; Pourquie, O			Avian hairy gene expression identifies a molecular clock linked to vertebrate segmentation and somitogenesis	CELL			English	Article							LOOP-HELIX REPRESSOR; CHICK-EMBRYO; SOMITE FORMATION; DROSOPHILA; EVOLUTION; PROTEINS; HOMOLOG; EMBRYOGENESIS; TRANSCRIPTION; NEUROGENESIS	We have identified and characterized c-hairy1, an avian homolog of the Drosophila segmentation gene, hairy. c-hairy1 is strongly expressed in the presomitic mesoderm, where its mRNA exhibits cyclic waves of expression whose temporal periodicity corresponds to the formation time of one somite (90 min). The apparent movement of these waves is due to coordinated pulses of c-hairy1 expression, not to cell displacement along the anteroposterior axis, nor to propagation of an activating signal. Rather, the rhythmic c-hairy mRNA expression is an autonomous property of the paraxial mesoderm. These results provide molecular evidence for a developmental clock linked to segmentation and somitogenesis of the paraxial mesoderm, and support the possibility that segmentation mechanisms used by invertebrates and vertebrates have been conserved.	DEV BIOL INST MARSEILLE IBDM,LGPD,CNRS,UMR 6545,F-13288 MARSEILLE 9,FRANCE; CNRS,INST EMBRYOL CELLULAIRE & MOL,F-94736 NOGENT SUR MARNE,FRANCE; COLL FRANCE,F-94736 NOGENT SUR MARNE,FRANCE; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; Cancer Research UK			Henrique, Domingos M/E-5460-2010; Pourquié, Olivier/CAJ-5443-2022; Palmeirim, Isabel/F-4522-2012	Henrique, Domingos M/0000-0001-8869-1894; Pourquié, Olivier/0000-0001-5189-1227; Palmeirim, Isabel/0000-0003-2282-7829; Ish-Horowicz, David/0000-0001-5684-7129				BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; CONLON RA, 1995, DEVELOPMENT, V121, P1533; COOKE J, 1976, J THEOR BIOL, V58, P455, DOI 10.1016/S0022-5193(76)80131-2; DAVIDSON D, 1988, DEVELOPMENT, V104, P221; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; DeRobertis EM, 1997, NATURE, V387, P25, DOI 10.1038/387025a0; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Dunwoodie SL, 1997, DEVELOPMENT, V124, P3065; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Holland LZ, 1997, DEVELOPMENT, V124, P1723; ISHHOROWICZ D, 1985, COLD SPRING HARB SYM, V50, P135, DOI 10.1101/SQB.1985.050.01.019; ISPIZUABELMONTE JC, 1993, CELL, V74, P645; Jimenez G, 1996, EMBO J, V15, P7088, DOI 10.1002/j.1460-2075.1996.tb01100.x; Johnston SH, 1997, DEVELOPMENT, V124, P2245; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; Kimmel CB, 1996, TRENDS GENET, V12, P329, DOI 10.1016/S0168-9525(96)80001-1; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MEIER S, 1984, CELL DIFFER DEV, V14, P235, DOI 10.1016/0045-6039(84)90012-5; MEINHARDT H, 1986, SOMITES DEV EMBRYOS, P179; MENKES B, 1977, BRIT SOC DEV BIOL S, V3, P405; Muller M, 1996, DEVELOPMENT, V122, P2071; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; OKA C, 1995, DEVELOPMENT, V121, P3291; PACKARD DS, 1976, DEV BIOL, V53, P36, DOI 10.1016/0012-1606(76)90207-4; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; PATEL NH, 1992, NATURE, V357, P339, DOI 10.1038/357339a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PRIMMETT DRN, 1989, DEVELOPMENT, V105, P119; SANDER K, 1988, DEVELOPMENT, V104, P112; SASSONECORSI P, 1994, CELL, V78, P361, DOI 10.1016/0092-8674(94)90415-4; STERN CD, 1988, DEVELOPMENT, V104, P231; TAM PPL, 1994, ANAT EMBRYOL, V189, P275; TAM PPL, 1986, SOMITES DEV EMBRYOS, P17; TAUTZ D, 1995, TRENDS GENET, V11, P23, DOI 10.1016/S0168-9525(00)88982-9; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; WEISBLAT DA, 1994, CURR TOP DEV BIOL, V29, P101, DOI 10.1016/S0070-2153(08)60548-7	42	703	720	2	39	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 28	1997	91	5					639	648		10.1016/S0092-8674(00)80451-1	http://dx.doi.org/10.1016/S0092-8674(00)80451-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393857	Bronze			2022-12-28	WOS:A1997YH96000011
J	Paradise, JL				Paradise, JL			Short-course antimicrobial treatment for acute otitis media - Not best for infants and young children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CLINICAL-TRIAL; DOUBLE-BLIND; DECONGESTANT-ANTIHISTAMINE; PENICILLIN TREATMENT; AMOXICILLIN; EFFICACY; CEFTRIAXONE; THERAPY; EFFUSION; 3-DAY		UNIV PITTSBURGH, SCH MED, DEPT PEDIAT, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BAIN J, 1985, BRIT MED J, V291, P1243, DOI 10.1136/bmj.291.6504.1243; Barnett ED, 1997, PEDIATRICS, V99, P23, DOI 10.1542/peds.99.1.23; Bernstein J M, 1995, J RESP DIS, V16, P88; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; CANTEKIN EI, 1983, NEW ENGL J MED, V308, P297, DOI 10.1056/NEJM198302103080601; CARLIN SA, 1991, J PEDIATR-US, V118, P178, DOI 10.1016/S0022-3476(05)80479-2; CASSELBRANT ML, 1992, PEDIATR INFECT DIS J, V11, P278, DOI 10.1097/00006454-199204000-00004; CHAMBERLAIN JM, 1994, CLIN PEDIATR, V33, P642, DOI 10.1177/000992289403301101; CUNNINGHAM AS, 1994, CONT PEDIATR, V11, P17; DESAINTONGE DMC, 1982, BRIT MED J, V284, P1078; Gooch WM, 1996, PEDIATR INFECT DIS J, V15, P157, DOI 10.1097/00006454-199602000-00013; GREEN SM, 1993, PEDIATRICS, V91, P23; HARSTEN G, 1989, ACTA OTO-LARYNGOL, V108, P253, DOI 10.3109/00016488909125525; HATHAWAY TJ, 1994, PEDIATRICS, V94, P143; HENDRICKSE WA, 1988, PEDIATR INFECT DIS J, V7, P14, DOI 10.1097/00006454-198801000-00005; Hoberman A, 1996, PEDIATR INFECT DIS J, V15, P955, DOI 10.1097/00006454-199610000-00034; Hoberman A, 1997, PEDIATR INFECT DIS J, V16, P463, DOI 10.1097/00006454-199705000-00002; INGVARSSON L, 1982, ACTA OTO-LARYNGOL, V94, P283, DOI 10.3109/00016488209128915; JONES R, 1986, J ROY COLL GEN PRACT, V36, P356; KALEIDA PH, 1991, PEDIATRICS, V87, P466; MANDEL EM, 1987, NEW ENGL J MED, V316, P432, DOI 10.1056/NEJM198702193160803; MEISTRUPLARSEN KI, 1983, ACTA OTO-LARYNGOL, V96, P99, DOI 10.3109/00016488309132879; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; NELSON CR, 1993, DRUG UTILIZATION OFF; NELSON WL, 1987, 27 INT C ANT AG CHEM; PARADISE JL, 1987, J PEDIATR-US, V111, P948, DOI 10.1016/S0022-3476(87)80226-3; Paradise JL, 1997, PEDIATRICS, V99, P318, DOI 10.1542/peds.99.3.318; PARADISE JL, 1995, PEDIATRICS, V96, P712; PARADISE JL, 1995, PEDIATR INFECT DIS J, V14, P429, DOI 10.1097/00006454-199505001-00005; PUCZYNSKI MS, 1987, LARYNGOSCOPE, V97, P16; SCHAPPERT SM, 1992, OFFICE VISITS OTITIS; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VARSANO I, 1988, CHEMOTHERAPY, V34, P39, DOI 10.1159/000238646	35	53	54	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1640	1642		10.1001/jama.278.20.1640	http://dx.doi.org/10.1001/jama.278.20.1640			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388072				2022-12-28	WOS:A1997YG85900001
J	Plotnick, GD; Corretti, MC; Vogel, RA				Plotnick, GD; Corretti, MC; Vogel, RA			Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; CHOLESTEROL-LOWERING THERAPY; RISK-FACTORS; NITRIC-OXIDE; HYPERCHOLESTEROLEMIC PATIENTS; CARDIOVASCULAR-DISEASE; VASCULAR ENDOTHELIUM; SERUM-CHOLESTEROL; E CONSUMPTION	Context.-Much has been written about the potential role of antioxidants in the prevention of atherosclerosis. Objective.-To assess the short-term effect of a single high-fat meal with and without pretreatment with antioxidant vitamins on endothelial function in healthy, normocholesterolemic subjects. Design.-Observer-blinded randomized trial. Setting.-University hospital. Participants.-Twenty healthy, normocholesterolemic (total and low-density lipoprotein cholesterol <5.2 mmol/L and <3.4 mmol/L [<200 mg/dL and <130 mg/dL], respectively), male (7) and female (13) hospital employee volunteers, aged 24 to 54 years. Intervention.-Three randomly administered breakfasts: (1) a high-fat meal (3766 J [900 calories], 50 g of fat); (2) a low-fat meal (3766 J [900 calories], 0 g of fat); and (3) a high-fat meal and pretreatment with oral administration of vitamins C (1 g) and E (800 IU) (high-fat meal with vitamins). A subgroup of 10 subjects also ate the low-fat meal with the same vitamin pretreatment (low-fat meal with vitamins). Main Outcome Measure.-High-resolution ultrasound assessed flow-mediated (endothelium-dependent) brachial artery vasodilation measured as percent diameter change before and hourly for 6 hours following each meal. Results.-Flow-mediated vasodilation fell from a mean+/-SD of 20%+8% before to 12%+/-6%, 10%+/-6%, and 8%+/-9% at 2, 3, and 4 hours, respectively, after the high-fat meal (P<.001). No significant changes in flow-mediated vasodilation occurred after the low-fat meal, high-fat meal with vitamins, or low-fat meal with vitamins. The change in flow-mediated vasodilation after the low-fat and high-fat meals correlated inversely with the 2-hour postprandial change in triglyceride levels (r=-0.54; P<.001). Conclusion.-A single high-fat meal transiently reduces endothelial function for up to 4 hours in healthy, normocholesterolemic subjects, probably through the accumulation of triglyceride-rich lipoproteins. This decrease is blocked by pretreatment with antioxidant vitamins C and E, suggesting an oxidative mechanism.	UNIV MARYLAND, SCH MED, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore								Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; Anderson TJ, 1996, CIRCULATION, V93, P1647, DOI 10.1161/01.CIR.93.9.1647; ANDERSON TJ, 1995, NEW ENGL J MED, V332, P488, DOI 10.1056/NEJM199502233320802; AUSTIN MA, 1991, AM J CARDIOL, V68, pA22, DOI 10.1016/0002-9149(91)90856-G; CASTELLI WP, 1986, AM HEART J, V112, P432, DOI 10.1016/0002-8703(86)90296-6; CAYATTE AJ, 1994, ARTERIOSCLER THROMB, V14, P753, DOI 10.1161/01.ATV.14.5.753; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; CELERMAJER DS, 1994, J AM COLL CARDIOL, V24, P1468, DOI 10.1016/0735-1097(94)90141-4; CONNOR SL, 1986, LANCET, V1, P1229; CORRETTI MC, 1995, AM J PHYSIOL-HEART C, V268, pH1397, DOI 10.1152/ajpheart.1995.268.4.H1397; EGASHIRA K, 1994, CIRCULATION, V89, P2519, DOI 10.1161/01.CIR.89.6.2519; ELLIOTT TG, 1995, AM J CARDIOL, V76, P1188, DOI 10.1016/S0002-9149(99)80335-X; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; GILLIGAN DM, 1994, J AM COLL CARDIOL, V24, P1611, DOI 10.1016/0735-1097(94)90164-3; Glasser SP, 1996, AM HEART J, V131, P379, DOI 10.1016/S0002-8703(96)90370-1; HAMON M, 1994, CIRCULATION, V90, P1357, DOI 10.1161/01.CIR.90.3.1357; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; Heitzer T, 1996, CIRCULATION, V94, P6, DOI 10.1161/01.CIR.94.1.6; Jeremy RW, 1996, CIRCULATION, V94, P498, DOI 10.1161/01.CIR.94.3.498; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; JOANNIDES R, 1995, CIRCULATION, V91, P1314, DOI 10.1161/01.CIR.91.5.1314; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; LEFROY DC, 1993, CIRCULATION, V88, P43, DOI 10.1161/01.CIR.88.1.43; LEUNG WH, 1993, LANCET, V341, P1496, DOI 10.1016/0140-6736(93)90634-S; Levine GN, 1996, CIRCULATION, V93, P1107, DOI 10.1161/01.CIR.93.6.1107; Mano T, 1996, AM HEART J, V131, P231, DOI 10.1016/S0002-8703(96)90346-4; MEISTER A, 1994, J BIOL CHEM, V269, P9397; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; REDDY KG, 1994, J AM COLL CARDIOL, V23, P833, DOI 10.1016/0735-1097(94)90627-0; Reilly M, 1996, CIRCULATION, V94, P19, DOI 10.1161/01.CIR.94.1.19; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Roberts KA, 1996, CIRCULATION, V94, P2248, DOI 10.1161/01.CIR.94.9.2248; SEILER C, 1993, CIRCULATION, V88, P2139, DOI 10.1161/01.CIR.88.5.2139; SEILER C, 1995, J AM COLL CARDIOL, V26, P1615, DOI 10.1016/0735-1097(95)00379-7; Shiode N, 1996, AM HEART J, V131, P1051, DOI 10.1016/S0002-8703(96)90076-9; SIMON BC, 1990, J CLIN INVEST, V86, P75, DOI 10.1172/JCI114718; SIMPSON HS, 1990, ATHEROSCLEROSIS, V85, P193, DOI 10.1016/0021-9150(90)90111-U; SLYPER AH, 1992, LANCET, V340, P289, DOI 10.1016/0140-6736(92)92368-P; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; STROES ESG, 1995, LANCET, V346, P467, DOI 10.1016/S0140-6736(95)91322-X; Ting HH, 1997, CIRCULATION, V95, P2617, DOI 10.1161/01.CIR.95.12.2617; TREASURE CB, 1995, NEW ENGL J MED, V332, P481, DOI 10.1056/NEJM199502233320801; VANE JR, 1990, NEW ENGL J MED, V323, P27; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131; VITA JA, 1990, CIRCULATION, V81, P491, DOI 10.1161/01.CIR.81.2.491; Vogel RA, 1996, AM J CARDIOL, V77, P37, DOI 10.1016/S0002-9149(97)89131-X; Vogel RA, 1997, AM J CARDIOL, V79, P350, DOI 10.1016/S0002-9149(96)00760-6; VOGEL RA, 1993, CIRCULATION, V88, P325, DOI 10.1161/01.CIR.88.1.325; Weber C, 1996, CIRCULATION, V93, P1488, DOI 10.1161/01.CIR.93.8.1488; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473	54	371	385	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 26	1997	278	20					1682	1686		10.1001/jama.278.20.1682	http://dx.doi.org/10.1001/jama.278.20.1682			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YG859	9388088				2022-12-28	WOS:A1997YG85900030
J	Kasting, JF				Kasting, JF			Update: Planetary Science - The early Mars climate question heats up	SCIENCE			English	Editorial Material											Kasting, JF (corresponding author), PENN STATE UNIV,DEPT GEOSCI,STATE COLL,PA 16802, USA.		Kasting, James/AAF-6851-2020					Forget F, 1997, SCIENCE, V278, P1273, DOI 10.1126/science.278.5341.1273; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; Kasting JF, 1997, SCIENCE, V276, P1213, DOI 10.1126/science.276.5316.1213; Kasting JF, 1997, ORIGINS LIFE EVOL B, V27, P291, DOI 10.1023/A:1006586517202; LEGER A, 1993, ASTRON ASTROPHYS, V277, P309; Sagan C, 1997, SCIENCE, V276, P1217, DOI 10.1126/science.276.5316.1217	7	13	13	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 14	1997	278	5341					1245	1245		10.1126/science.278.5341.1245	http://dx.doi.org/10.1126/science.278.5341.1245			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YG043	9411751				2022-12-28	WOS:A1997YG04300032
J	Werb, Z				Werb, Z			ECM and cell surface proteolysis: Regulating cellular ecology	CELL			English	Review							CANCER				Werb, Z (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.							Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; Cairns JA, 1997, J CLIN INVEST, V99, P1313, DOI 10.1172/JCI119290; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; Kispert A, 1996, DEVELOPMENT, V122, P3627; Martin DC, 1996, ONCOGENE, V13, P569; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Shapiro SD, 1997, MATRIX BIOL, V15, P527, DOI 10.1016/S0945-053X(97)90027-5; STERNLICHT M, IN PERSS GUIDEBOOK E; STOCKER W, 1995, PROTEIN SCI, V4, P823; Suzuki N, 1996, DEVELOPMENT, V122, P3587; Tsirka SE, 1997, J NEUROSCI, V17, P543; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YE E, 1996, J BIOL CHEM, V271, P13055	20	1099	1136	1	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 14	1997	91	4					439	442		10.1016/S0092-8674(00)80429-8	http://dx.doi.org/10.1016/S0092-8674(00)80429-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YG492	9390552	Bronze			2022-12-28	WOS:A1997YG49200004
J	Picton, P; Chisholm, M				Picton, P; Chisholm, M			Aseptic meningitis associated with high dose immunoglobulin: case report	BRITISH MEDICAL JOURNAL			English	Article							THERAPY		SOUTHAMPTON UNIV HOSP,DEPT HAEMATOL,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND	University of Southampton								CHAUDHRY HJ, 1991, POSTGRAD MED, V90, P65; Schiavotto C, 1993, Haematologica, V78, P35; SCRIBNER CL, 1994, ANN INTERN MED, V121, P305, DOI 10.7326/0003-4819-121-4-199408150-00014; SEKUL EA, 1994, ANN INTERN MED, V121, P259, DOI 10.7326/0003-4819-121-4-199408150-00004; VERARAMIREZ M, 1992, NEUROLOGY, V42, P1636, DOI 10.1212/WNL.42.8.1636-a	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1203	1204		10.1136/bmj.315.7117.1203	http://dx.doi.org/10.1136/bmj.315.7117.1203			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393224	Green Published			2022-12-28	WOS:A1997YF25200021
J	Gaal, T; Bartlett, MS; Ross, W; Turnbough, CL; Gourse, RL				Gaal, T; Bartlett, MS; Ross, W; Turnbough, CL; Gourse, RL			Transcription regulation by initiating NTP concentration: RRNA synthesis in bacteria	SCIENCE			English	Article							RIBOSOMAL-RNA TRANSCRIPTION; ESCHERICHIA-COLI K-12; NUCLEOTIDE-SENSITIVE SELECTION; FACTOR-INDEPENDENT ACTIVATION; RATE-DEPENDENT REGULATION; PYRBI OPERON EXPRESSION; GROWTH-RATE CONTROL; FEEDBACK-REGULATION; GUANOSINE TETRAPHOSPHATE; ALPHA-SUBUNIT	The sequence of a promoter determines not only the efficiency with which it forms a complex with RNA polymerase, but also the concentration of nucleoside triphosphate (NTP) required for initiating transcription. Escherichia coli ribosomal RNA (rrn PI) promoters required high initiating NTP concentrations for efficient transcription because they form unusually short-lived complexes with RNA polymerase; high initiating NTP concentrations [adenosine or guanosine triphosphate (ATP or GTP), depending on the rrn P1 promoter] are needed lo bind to and stabilize the open complex. ATP and GTP concentrations, and therefore rrn P1 promoter activity, increase with growth rate. Because ribosomal RNA transcription determines the rate of ribosome synthesis, the control of ribosomal RNA transcription by NTP concentration provides a molecular explanation for the growth rate-dependent control and homeostatic regulation of ribosome synthesis.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294	University of Wisconsin System; University of Wisconsin Madison; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037048, R01GM029466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37048, GM29466] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER MD, 1978, J BACTERIOL, V133, P149, DOI 10.1128/JB.133.1.149-157.1978; Alper S, 1996, J MOL BIOL, V260, P165, DOI 10.1006/jmbi.1996.0390; APPLEMAN JA, 1983, GENE EXPRESSION, P65; APPLEMAN JA, UNPUB; Bachmann B.J., 1987, CELLULAR MOL BIOL, P1190; BAGNARA AS, 1973, EUR J BIOCHEM, V36, P422, DOI 10.1111/j.1432-1033.1973.tb02927.x; BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; BARTLETT MS, 1994, J BACTERIOL, V176, P5560, DOI 10.1128/JB.176.17.5560-5564.1994; BARTLETT MS, UNPUB; BECK C, 1973, J MOL BIOL, V78, P117, DOI 10.1016/0022-2836(73)90431-2; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; BOCK A, 1966, J BACTERIOL, V92, P470; Bokal AJ, 1997, EMBO J, V16, P154, DOI 10.1093/emboj/16.1.154; CASHEL M, 1968, J MOL BIOL, V34, P317, DOI 10.1016/0022-2836(68)90256-8; CASHEL M, 1996, CELLULAR MOL BIOL, P1458; COLE JR, 1987, J MOL BIOL, V198, P383, DOI 10.1016/0022-2836(87)90288-9; CONDON C, 1993, EMBO J, V12, P4305, DOI 10.1002/j.1460-2075.1993.tb06115.x; CONDON C, 1995, MICROBIOL REV, V59, P623, DOI 10.1128/MMBR.59.4.623-645.1995; de Boer H, 1979, J Biol Chem, V254, P5609; DONAHUE JP, 1994, J BIOL CHEM, V269, P18185; DONAHUE JP, 1990, J BIOL CHEM, V265, P19091; FRANZEN JS, 1961, J BIOL CHEM, V236, P515; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; GAAL T, UNPUB; GAFNY R, 1994, J MOL BIOL, V243, P152, DOI 10.1006/jmbi.1994.1641; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; Gourse RL, 1996, ANNU REV MICROBIOL, V50, P645, DOI 10.1146/annurev.micro.50.1.645; GOURSE RL, 1985, P NATL ACAD SCI USA, V82, P1069, DOI 10.1073/pnas.82.4.1069; GRUMMT I, 1976, CELL, V7, P447, DOI 10.1016/0092-8674(76)90175-6; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; JENSEN KF, 1993, J BACTERIOL, V175, P3401, DOI 10.1128/jb.175.11.3401-3407.1993; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; JOSAITIS CA, 1995, P NATL ACAD SCI USA, V92, P117; KEENER J, 1996, CELLULAR MOL BIOL, P1417; KUPPER H, 1976, RNA POLYMERASE, P473; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; LITTLE R, 1983, ANAL BIOCHEM, V126, P381; LIU CG, 1994, GENE DEV, V8, P2904, DOI 10.1101/gad.8.23.2904; LIU J, 1994, J BACTERIOL, V176, P2938, DOI 10.1128/JB.176.10.2938-2945.1994; LUND E, 1979, P NATL ACAD SCI USA, V76, P5480, DOI 10.1073/pnas.76.11.5480; LUND E, 1972, EUR J BIOCHEM, V28, P316, DOI 10.1111/j.1432-1033.1972.tb01916.x; MaalOe O, 1966, CONTROL MACROMOLECUL; MARR AG, 1991, MICROBIOL REV, V55, P316, DOI 10.1128/MMBR.55.2.316-333.1991; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; MCQUADE KL, UNPUB; MULLIGAN ME, 1985, J BIOL CHEM, V260, P3529; NEIDHARDT F, 1961, COLD SPRING HARB SYM, V26, P63, DOI 10.1101/SQB.1961.026.01.012; NEIDHARDT FC, 1996, CELLULAR MOL BIOL, pR11; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; NEUHARD J, 1987, CELLULAR MOL BIOL, P445; NIERMAN WC, 1979, J BIOL CHEM, V254, P7921; NILSSON L, 1994, J BIOL CHEM, V269, P9460; NINFA A, 1996, CELLULAR MOL BIOL, P1246; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OHLSEN KL, 1992, J BIOL CHEM, V267, P19813; OHLSEN KL, 1992, J BACTERIOL, V174, P6071, DOI 10.1128/JB.174.19.6071-6075.1992; OHLSEN KL, 1992, MOL MICROBIOL, V6, P2243, DOI 10.1111/j.1365-2958.1992.tb01400.x; POULSEN P, 1987, MOL GEN GENET, V208, P152, DOI 10.1007/BF00330436; QI FX, 1995, J MOL BIOL, V254, P552, DOI 10.1006/jmbi.1995.0638; RAO L, 1994, J MOL BIOL, V235, P1421, DOI 10.1006/jmbi.1994.1098; RECORD MT, 1996, CELLULAR MOL BIOL, P792; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; ROSS W, UNPUB; ROWLEY KB, 1993, J BACTERIOL, V175, P1309, DOI 10.1128/JB.175.5.1309-1315.1993; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; SCHAECHTER M, 1958, J GEN MICROBIOL, V19, P592, DOI 10.1099/00221287-19-3-592; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; SHEN V, 1977, J BACTERIOL, V130, P1109, DOI 10.1128/JB.130.3.1109-1116.1977; SINGER M, 1991, J BACTERIOL, V173, P6249, DOI 10.1128/jb.173.19.6249-6257.1991; SMITH RC, 1964, BIOCHIM BIOPHYS ACTA, V86, P229, DOI 10.1016/0304-4165(64)90047-9; SQUIRES CL, 1993, P NATL ACAD SCI USA, V90, P970, DOI 10.1073/pnas.90.3.970; TRAVERS A, 1976, NATURE, V263, P641, DOI 10.1038/263641a0; Tu AHT, 1997, J BACTERIOL, V179, P6665, DOI 10.1128/jb.179.21.6665-6673.1997; TURNBOUGH CL, 1983, P NATL ACAD SCI-BIOL, V80, P368, DOI 10.1073/pnas.80.2.368; Villemain J, 1997, J MOL BIOL, V273, P958, DOI 10.1006/jmbi.1997.1358; VOGEL U, 1991, J BACTERIOL, V173, P1168, DOI 10.1128/jb.173.3.1168-1174.1991; WILSON HR, 1992, J BACTERIOL, V174, P514, DOI 10.1128/jb.174.2.514-524.1992; YAMAGISHI M, 1987, J MOL BIOL, V198, P547, DOI 10.1016/0022-2836(87)90299-3; ZENGEL JM, 1994, PROG NUCLEIC ACID RE, V47, P331, DOI 10.1016/S0079-6603(08)60256-1	84	289	292	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2092	2097		10.1126/science.278.5346.2092	http://dx.doi.org/10.1126/science.278.5346.2092			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405339				2022-12-28	WOS:A1997YM23500044
J	Monath, TP				Monath, TP			Early indicators in acute dengue infection	LANCET			English	Editorial Material											Monath, TP (corresponding author), ORAVAX INC,RES & MED AFFAIRS,38 SIDNEY ST,CAMBRIDGE,MA 02139, USA.							BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; Kalayanarooj S, 1997, J INFECT DIS, V176, P313, DOI 10.1086/514047; KURANE I, 1991, J CLIN INVEST, V88, P1473, DOI 10.1172/JCI115457; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504; Teeraratkul A., 1990, Southeast Asian Journal of Tropical Medicine and Public Health, V21, P696; *WHO, 1986, DENG HAEM FEV DIAGN, P1	8	11	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 13	1997	350	9093					1719	1720		10.1016/S0140-6736(05)63567-2	http://dx.doi.org/10.1016/S0140-6736(05)63567-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413458				2022-12-28	WOS:A1997YL55400003
J	Riezman, H; Woodman, PG; van Meer, G; Marsh, M				Riezman, H; Woodman, PG; van Meer, G; Marsh, M			Molecular mechanisms of endocytosis	CELL			English	Editorial Material							MEMBRANE-FUSION; RAB5		UNIV MANCHESTER, SCH BIOL SCI, DIV BIOCHEM, MANCHESTER M13 9PT, LANCS, ENGLAND; UNIV AMSTERDAM, ACAD MED CTR, DEPT CELL BIOL & HISTOL, NL-1105 AZ AMSTERDAM, NETHERLANDS; UNIV LONDON UNIV COLL, MRC, MOL CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND	University of Manchester; University of Amsterdam; Academic Medical Center Amsterdam; University of London; University College London	Riezman, H (corresponding author), UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND.		van Meer, Gerrit/AAH-1560-2021; Marsh, Mark/B-4105-2009	Marsh, Mark/0000-0002-0213-3259; van Meer, Gerrit/0000-0002-5976-6436; Riezman, Howard/0000-0003-4680-9422				DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Riezman H, 1996, EXPERIENTIA, V52, P1033, DOI 10.1007/BF01952099; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Sandvig K, 1996, PHYSIOL REV, V76, P949, DOI 10.1152/physrev.1996.76.4.949; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Stang E, 1997, MOL BIOL CELL, V8, P47, DOI 10.1091/mbc.8.1.47; SturgillKoszycki S, 1996, EMBO J, V15, P6960, DOI 10.1002/j.1460-2075.1996.tb01088.x; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	23	116	121	3	21	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 12	1997	91	6					731	738		10.1016/S0092-8674(00)80461-4	http://dx.doi.org/10.1016/S0092-8674(00)80461-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413982	Bronze, Green Published			2022-12-28	WOS:A1997YL43900004
J	Bouma, MJ; Dye, C				Bouma, MJ; Dye, C			Cycles of malaria associated with El Nino in Venezuela	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOUTHERN OSCILLATION; EPIDEMICS; MAIZE	Context.-Malaria has been increasing globally, and epidemics tend to occur when weather conditions favor this vector-borne disease, Long-term meteorologic forecasting using El Nino Southern Oscillation (ENSO) may assist in anticipating epidemics and targeting scarce resources. Objective.-To determine whether malaria epidemics in Venezuela are related to ENSO and rainfall and to determine whether such a relationship could be used to predict outbreaks. Design.-Retrospective analysis of national malaria morbidity (1975-1995) and mortality (1910-1935) data in the coastal zone and interior of Venezuela in relation to El Nino events and rainfall. Main Outcome Measure.-Correlation between malaria mortality and morbidity and sea surface temperatures (SSTs) in the Eastern Tropical Pacific, a parameter of ENSO. Results.-Malaria mortality and morbidity have increased by an average of 36.5% (95% confidence interval, 3.7%-69.3%; P=.004) in years following recognized El Nino events, A moderate correlation was found between Pacific tropical SST during a Nino event and malaria 1 year later (r=0.50, P<.001). Malaria mortality is more strongly related to drought in the year preceding outbreaks than to rainfall during epidemic years. Conclusions.-Historic and recent data from Venezuela demonstrate that malaria increases by an average of about one third in the year following a Nino event; change in malaria risk can be predicted from Pacific SSTs in the previous year, Therefore, the occurrence of an EI Nino event may help predict malaria epidemics in this part of South America.			Bouma, MJ (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED, KEPPEL ST, LONDON WC1E 7HT, ENGLAND.		Dye, Christopher/AIC-4659-2022	Dye, Christopher/0000-0002-2957-1793				[Anonymous], WHO TECHN REP SER; Bouma MJ, 1996, TROP MED INT HEALTH, V1, P86, DOI 10.1046/j.1365-3156.1996.d01-7.x; BOUMA MJ, 1994, LANCET, V343, P1440, DOI 10.1016/S0140-6736(94)92569-0; CANE MA, 1994, NATURE, V370, P204, DOI 10.1038/370204a0; CHRISTOPHERS R, 1911, SCI MEMOIRS OFFICERS; *DEP MET, 1978, B CLIM ANN; FONTAINE RE, 1961, AM J TROP MED HYG, V10, P795, DOI 10.4269/ajtmh.1961.10.795; GABALDON A., 1946, Tijeretazos sobre Malaria, V10, P191; GABALDON A, 1949, T ROY SOC TROP MED H, V43, P113, DOI 10.1016/0035-9203(49)90037-1; GABALDON A, 1949, MALARIOLOGY; GIGLIOLI G., 1939, Agric. J. Brit. Guiana, V10, P4; GONZALEZ PE, 1948, DATOS DETALLADOS CLI; Kiladis GN, 1989, J CLIMATE, V2, P1069, DOI 10.1175/1520-0442(1989)002<1069:GCAAWE>2.0.CO;2; MCDONALD G, 1953, TROP DIS B, V50, P871; MOLINEAUX L, 1988, MALARIA; NICHOLLS N, 1993, LANCET, V342, P1284, DOI 10.1016/0140-6736(93)92368-4; Nisbet RM, 1982, MODELLING FLUCTUATIN; PACKARD RM, 1984, J AFR HIST, V25, P189, DOI 10.1017/S0021853700022854; PARKER DE, 1994, J GEOPHYS RES, V99, P373; Ropelewski CF, 1989, J CLIMATE, V2, P268, DOI 10.1175/1520-0442(1989)002<0268:PPAWTH>2.0.CO;2; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; *SMITHS I, 1961, WORLD WEATH REC; *SMITHS I, 1971, WORLD WEATH REC; SWELLENGREBEL NH, 1940, COLONIAL I AMSTERDAM, V16; *WHO, 1977, WKLY EPIDEMIOL REC; *WORLD MET ORG, 1992, CLIM SYST MON MON B; YACOB KBM, 1946, J MALAR I INDIA, V6, P273; Zurbrigg S., 1994, Parassitologia (Rome), V36, P121	28	130	143	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1772	1774		10.1001/jama.278.21.1772	http://dx.doi.org/10.1001/jama.278.21.1772			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH987	9388155				2022-12-28	WOS:A1997YH98700033
J	Cromwell, J; Bartosch, WJ; Fiore, MC; Hasselblad, V; Baker, T				Cromwell, J; Bartosch, WJ; Fiore, MC; Hasselblad, V; Baker, T			Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CIGARETTE-SMOKING; SMOKERS; ADJUNCT; STATES; QUIT	Context.-The Agency for Health Care Policy and Research (AHCPR) published the Smoking Cessation: Clinical Practice Guideline in 1996, Based on the results of meta-analyses and expert opinion, the guideline identifies efficacious interventions for primary care clinicians and smoking cessation specialty providers, Objective.-To determine the cost-effectiveness of clinical recommendations in AHCPR's guideline. Design.-The guideline's 15 recommended smoking cessation interventions were analyzed to determine their relative cost-effectiveness. Then, using decision probabilities, the interventions were combined into a global model of the guideline's overall cost-effectiveness. Patients.-The analysis assumes that primary care clinicians screen all presenting adults for smoking status and advise and motivate all smokers to quit during the course of a routine office visit or hospitalization. Smoking cessation interventions are provided to 75% of US smokers 18 years and older who are assumed to be willing to make a quit attempt during a year's time. Intervention.-Three counseling interventions for primary care clinicians and 2 counseling interventions for smoking cessation specialists were modeled with and without transdermal nicotine and nicotine gum. Main Outcome Measure.-Cost (1995 dollars) per life-year or quality-adjusted life-year (QALY) saved, at a discount of 3%. Results.-The guideline would cost $6.3 billion to implement in its first year, As a result, society could expect to gain 1.7 million new quitters at an average cost of $3779 per quitter, $2587 per life-year saved, and $1915 for every QALY saved. Costs per QALY saved ranged from $1108 to $4542, with more intensive interventions being more cost-effective, Group intensive cessation counseling exhibited the lowest cost per QALY saved, but only 5% of smokers appear willing to undertake this type of intervention. Conclusions.-Compared with other preventive interventions, smoking cessation is extremely cost-effective, The more intensive the intervention, the lower the cost per QALY saved, which suggests that greater spending on interventions yields more net benefit. While all these clinically delivered interventions seem a reasonable societal investment, those involving more intensive counseling and the nicotine patch as adjuvant therapy are particularly meritorious.	UNIV WISCONSIN,SCH MED,CTR TOBACCO RES & INTERVENT,MADISON,WI; UNIV WISCONSIN,SCH MED,DEPT MED,GEN INTERNAL MED SECT,MADISON,WI; UNIV WISCONSIN,SCH MED,CTR COMPREHENS CANC,MADISON,WI; UNIV WISCONSIN,SCH MED,DEPT PSYCHOL,MADISON,WI; DUKE UNIV,CTR HLTH POLICY RES & EDUC,DURHAM,NC	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Duke University	Cromwell, J (corresponding author), HLTH ECON RES INC,300 5TH AVE,6TH FLOOR,WALTHAM,MA 02154, USA.				PHS HHS [282-95-2002] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS WH, 1992, J MATH CHEM, V10, P1, DOI 10.1007/BF01169168; *AM HOSP ASS, 1994, HOSP STAT 1994 1995; *CDCP, 1993, MMWR-MORBID MORTAL W, V43, P925; *CDCP, 1995, MMWR-MORBID MORTAL W, V42, P645; Centers for Disease Control and Prevention, 1993, MMWR-MORBID MORTAL W, V42, P504; COHEN S, 1989, AM PSYCHOL, V44, P1355, DOI 10.1037/0003-066X.44.11.1355; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; EDDY DM, 1992, HARVARD HLTH LET JUL, P10; FIORE MC, 1996, CLIN PRACTICE GUIDEL, V18; Fiscella K, 1996, JAMA-J AM MED ASSOC, V275, P1247, DOI 10.1001/jama.275.16.1247; Gilpin EA, 1997, J NATL CANCER I, V89, P572, DOI 10.1093/jnci/89.8.572; Gold MR, 1996, COST EFFECTIVENESS H; HODGSON TA, 1992, MILBANK Q, V70, P81, DOI 10.2307/3350086; *NAT CTR HLTH STAT, 1994, PUBL PHS; OSTER G, 1986, JAMA-J AM MED ASSOC, V256, P1315, DOI 10.1001/jama.256.10.1315; ROBINSON MD, 1995, J FAM PRACTICE, V40, P556; ROGERS RG, 1991, SOC SCI MED, V32, P1151, DOI 10.1016/0277-9536(91)90092-Q; Russell LB., 1986, IS PREVENTION BETTER; *SMOK CESS CLIN PR, 1996, JAMA-J AM MED ASSOC, V275, P1270; TENGS TO, 1995, 500 LIFE SAVING INTE; Torrance GW, 1987, METHODS EC EVALUATIO; *US DEP HHS, 1990, DHHS PUBLIC; *US DEP HHS, 1989, DHHS PUBL; Warner KE, 1982, COST BENEFIT COST EF; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; *YB INC, 1996, 1996 PHYS GENRX COMP	26	350	352	0	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	1997	278	21					1759	1766		10.1001/jama.278.21.1759	http://dx.doi.org/10.1001/jama.278.21.1759			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YH987	9388153				2022-12-28	WOS:A1997YH98700031
J	Luck, SJ; Vogel, EK				Luck, SJ; Vogel, EK			The capacity of visual working memory for features and conjunctions	NATURE			English	Article							PREFRONTAL CORTEX; ATTENTION; INFORMATION; STORAGE; SEARCH	Short-term memory storage can be divided into separate subsystems for verbal information and visual information(1), and recent studies have begun to delineate the neural substrates of these working-memory systems(2-6). Although the verbal storage system has been well characterized, the storage capacity of visual working memory has not yet been established for simple, suprathreshold features or for conjunctions of features. Here we demonstrate that it is possible to retain information about only four colours or orientations in visual working memory at one time. However, it is also possible to retain both the colour and the orientation of four objects, indicating that visual working memory stores integrated objects rather than individual features. Indeed, objects defined by a conjunction of four features can be retained in working memory just as well as single-feature objects, allowing sixteen individual features to be retained when distributed across four objects. Thus, the capacity of visual working memory must be understood in terms of integrated objects rather than individual features, which places significant constraints on cognitive and neurobiological models of the temporary storage of visual information(7).			Luck, SJ (corresponding author), UNIV IOWA,DEPT PSYCHOL,IOWA CITY,IA 52242, USA.		Vogel, Edward K/AAW-9466-2021					Baddeley A.D., 1986, WORKING MEMORY THOUG; COHEN A, 1989, J EXP PSYCHOL HUMAN, V15, P650, DOI 10.1037/0096-1523.15.4.650; DUNCAN J, 1984, J EXP PSYCHOL GEN, V113, P501, DOI 10.1037/0096-3445.113.4.501; Fuster JM, 1995, MEMORY CEREBRAL CORT; GREEN DM, 1961, J ACOUST SOC AM, V33, P897, DOI 10.1121/1.1908839; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; LISMAN JE, 1995, SCIENCE, V267, P1512, DOI 10.1126/science.7878473; LUCK SJ, IN PRESS VISUAL ATTE; Miller EK, 1996, J NEUROSCI, V16, P5154; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; NIEBUR E, 1993, VISION RES, V33, P2789, DOI 10.1016/0042-6989(93)90236-P; PAHLER H, 1988, PERCEPT PSYCHOPHYS, V44, P369; PALMER J, 1994, VISION RES, V34, P1703, DOI 10.1016/0042-6989(94)90128-7; PALMER J, 1993, J EXP PSYCHOL HUMAN, V19, P108, DOI 10.1037/0096-1523.19.1.108; PALMER J, 1990, J EXP PSYCHOL HUMAN, V16, P332, DOI 10.1037/0096-1523.16.2.332; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; PHILLIPS WA, 1974, PERCEPT PSYCHOPHYS, V16, P283, DOI 10.3758/BF03203943; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SPERLING G, 1960, PSYCHOL MONOGRAPHS, V74; Treisman A, 1996, CURR OPIN NEUROBIOL, V6, P171, DOI 10.1016/S0959-4388(96)80070-5; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	21	2612	2680	24	401	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 20	1997	390	6657					279	281		10.1038/36846	http://dx.doi.org/10.1038/36846			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YG667	9384378				2022-12-28	WOS:A1997YG66700061
J	Zwerling, C; Whitten, PS; Davis, CS; Sprince, NL				Zwerling, C; Whitten, PS; Davis, CS; Sprince, NL			Occupational injuries among workers with disabilities - The National Health Interview Survey, 1985-1994	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; INDUSTRIAL	Context.-As the baby boom generation ages, more people will be working with disabilities, but we have little information regarding how disabilities affect risk for occupational injury. Objective.-To test the hypothesis that work-limiting disabilities in general and hearing and visual impairments in particular are risk factors for occupational Injuries. Design.-Retrospective cohort study. Setting.-The National Health Interview Survey (NHIS), 1985 to 1994. Participants.-The 459 827 participants in the NHIS from 1985 to 1994 who listed "working" as their primary activity, who were not farmers, and who were between 18 and 65 years of age. Main Outcome Measure.-Occupational injuries in the year preceding the interview causing a residual impairment at the time of interview. Results.-After adjusting for occupation, self-employment, and age, occupational injury was associated with preceding work disability (odds ratio [OR], 1.36; 95% confidence interval [CI], 1.19-1.56); blindness (OR, 3.21; 95% CI, 1.32-7.85); deafness (OR, 2.19; 95% CI, 1.17-4.12); hearing impairment (OR,1.55; 95% CI, 1.29-1.87); upper extremity impairment (OR, 1.46; 95% CI, 1.05-2.05); and arthritis (OR, 1.34; 95% CI, 1.07-1.68). Visual impairment was not associated with a significantly increased risk (OR, 137; 95% CI, 0.87-2.17). Conclusions.-Workers with disabilities, especially sensory impairments, appear to have an elevated risk for occupational injury. Further research in the design and evaluation of improved workplace accommodations for workers with these disabilities is needed.	Univ Iowa, Injury Prevent Res Ctr, Iowa City, IA 52242 USA; Univ Iowa, Dept Prevent Med & Environm Hlth, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Zwerling, C (corresponding author), Univ Iowa, Injury Prevent Res Ctr, 134 IREH,100 Oakdale Campus, Iowa City, IA 52242 USA.				PHS HHS [R49CCR703640-07] Funding Source: Medline; NIOSH CDC HHS [1 K01 OHAG00150-03] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NIOSH CDC HHS		ADAMS PF, 1995, VITAL HLTH STAT, V10; BRESLOW NE, 1980, STAT METHODS CANC RE, V1, P74; FULLERTON HN, 1993, MON LABOR REV, V116, P31; National Center for Health Statistics, 1989, CLASS IND IND OCC 19; POPE AM, 1991, DISABILITY AM NATL A, P48; *SAS I INC, 1995, SAS VERS 6 11 WIND; *US DEP HHS, 1989, NAT HLTH INT SURV 19; VANCHARANTE AWM, 1990, AM J EPIDEMIOL, V131, P652, DOI 10.1093/oxfordjournals.aje.a115549; Wallhagen MI, 1997, AM J PUBLIC HEALTH, V87, P440, DOI 10.2105/AJPH.87.3.440; Zwerling C, 1996, AM J PUBLIC HEALTH, V86, P1306, DOI 10.2105/AJPH.86.9.1306; ZWERLING C, 1993, SPINE, V18, P1242, DOI 10.1097/00007632-199307000-00020; ZWERLING C, 1995, J AGR SAFETY HLTH, V0001	12	76	80	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2163	2166		10.1001/jama.278.24.2163	http://dx.doi.org/10.1001/jama.278.24.2163			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YM043	9417010				2022-12-28	WOS:000071022200032
J	Beckmann, R; Bubeck, D; Grassucci, R; Penczek, P; Verschoor, A; Blobel, G; Frank, J				Beckmann, R; Bubeck, D; Grassucci, R; Penczek, P; Verschoor, A; Blobel, G; Frank, J			Alignment of conduits for the nascent polypeptide chain in the Ribosome-Sec61 complex	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; CRYOELECTRON MICROSCOPY; ELECTRON-MICROSCOPY; SECRETORY PROTEINS; ENVIRONMENT; RESOLUTION; HOMOLOG; SEC61P	An oligomer of the Sec61 trimeric complex is thought to form the protein-conducting channel for protein transport across the endoplasmic reticulum. A purified yeast Sec61 complex bound to monomeric yeast ribosomes as an oligomer in a saturable fashion. Cryo-electron microscopy of the ribosome-Sec61 complex and a three-dimensional reconstruction showed that the Sec61 oligomer is attached to the large ribosomal subunit by a single connection. Moreover, a funnel-shaped pore in the Sec61 oligomer aligned with the exit of a tunnel traversing the large ribosomal subunit, strongly suggesting that both structures function together in the translocation of proteins across the endoplasmic reticulum membrane.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR,ALBANY,NY 12201; SUNY ALBANY,DEPT BIOMED SCI,ALBANY,NY 12201	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Beckmann, R (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029169] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01 GM29169] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; BERNABEU C, 1983, J CELL BIOL, V96, P1471, DOI 10.1083/jcb.96.5.1471; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; LATA KR, 1995, ULTRAMICROSCOPY, V58, P381, DOI 10.1016/0304-3991(95)00002-I; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Penczek PA, 1996, ULTRAMICROSCOPY, V63, P205, DOI 10.1016/0304-3991(96)00037-X; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STRAMBIODECASTILLIA C, 1995, J CELL BIOL, V131, P19, DOI 10.1083/jcb.131.1.19; Verschoor A, 1996, J CELL BIOL, V133, P495, DOI 10.1083/jcb.133.3.495; VERSCHOOR A, IN PRESS NUCL ACIDS; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1	28	292	298	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2123	2126		10.1126/science.278.5346.2123	http://dx.doi.org/10.1126/science.278.5346.2123			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405348				2022-12-28	WOS:A1997YM23500053
J	Bollinger, RC; Brookmeyer, RS; Mehendale, SM; Paranjape, RS; Shepherd, ME; Gadkari, DA; Quinn, TC				Bollinger, RC; Brookmeyer, RS; Mehendale, SM; Paranjape, RS; Shepherd, ME; Gadkari, DA; Quinn, TC			Risk factors and clinical preservation of acute primary HIV infection in India	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; EPIDEMIC; VIREMIA	Context.-Most previous studies of clinical presentation and risk factors in early human immunodeficiency virus (HIV) infection have relied on retrospective analyses and referred seroconverters, and thus were subject to possible bias. Objectives.-To apply a method based on measurement of prevalent HIV-1 p24 antigenemia for identification of risk factors for newly acquired HIV infection and to describe the signs and symptoms of acute HIV infection. Design and Setting.-Nested case-control study in Pune, India. Participants.-HIV antibody-negative persons attending 2 sexually transmitted disease (STD) clinics between May 1993 and June 1996. Outcome Measures.-Prevalent p24 antigenemia, risk factors for HIV infection, and clinical symptoms of acute primary HIV infection. Results.-Of 3874 HIV antibody-negative persons tested, 58 (1.5%) were p24 antigen positive at initial presentation to the clinics. Unprotected sexual contact with a commercial sex worker (CSW) was reported by 39 (77%) of the 51 p24 antigenemic men, compared with 131 (51%) of 255 control men (adjusted odds ratio [AOR], 3.4; 95% confidence interval [CI], 1.2-9.6; P=.02). The presence of an active genital ulcer at the time of screening was found in 46 (79%) of the 58 p24 antigenemic men and women, compared with 137 (47%) of the 290 control subjects (AOR, 4.2; 95% CI, 2.0-9.0; P<.001). Signs and symptoms independently associated with p24 antigenemia in HIV antibody-seronegative persons included fever, which was reported by 28 (48%) of the 58 p24 antigenemic subjects, but only 52 (18%) of the 290 control subjects (AOR, 4.7; 95% CI, 2.4-9.0; P<.001). Joint pain was reported by 10% of subjects recently HIV infected, compared with 2% of the control subjects (AOR, 6.5; 95% CI, 1.7-24.8; P=.006), Night sweats were reported by 9% of the p24 antigenemic, but only 1% of the control subjects (AOR, 9.1; 95% CI, 1.7-47.6; P=.009), Overall, fever, joint pain, and/or night sweats were reported in 27 (47%) of the 58 subjects with recent HIV infection. Conclusions.-This systematic case-control study of p24 antigen screening in HIV-seronegative patients attending STD clinics in India identified unprotected sex with a CSW and a genital ulcer as independent risk factors associated with newly acquired HIV infection. In addition, p24 antigen positivity identified recent fever, night sweats, and arthralgias as symptoms that may be predictive of recent HIV infection, In a study of patients attending STD clinics in India, screening for p24 antigen in HIV antibody-negative persons was found to be a reliable and effective research method for determining recent risk behavior and identifying clinical signs of acute primary HIV infection.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DIV INFECT DIS,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; NATL AIDS RES INST,PUNE,MAHARASHTRA,INDIA; NIAID,NIH,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins University; Indian Council of Medical Research (ICMR); ICMR - National AIDS Research Institute (NARI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Paranjape, Ramesh/0000-0003-2948-9148; Bollinger, Robert/0000-0002-6798-6834	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033879] Funding Source: NIH RePORTER; FIC NIH HHS [D43TW0000] Funding Source: Medline; NIAID NIH HHS [AI 33879-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOLLINGER RC, 1995, MEDICINE, V74, P97, DOI 10.1097/00005792-199503000-00005; BROOKMEYER R, 1995, AM J EPIDEMIOL, V142, P709, DOI 10.1093/oxfordjournals.aje.a117700; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P19; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; FOX R, 1987, AIDS, V1, P35; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; MEHENDALE SM, 1995, J INFECT DIS, V172, P1486, DOI 10.1093/infdis/172.6.1486; Mehendale SM, 1996, INDIAN J MED RES, V104, P327; RODRIGUES JJ, 1995, BRIT MED J, V311, P283, DOI 10.1136/bmj.311.7000.283; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SINICCO A, 1990, J ACQ IMMUN DEF SYND, V3, P260; VONSYDOW M, 1988, BMJ-BRIT MED J, V296, P238, DOI 10.1136/bmj.296.6617.238; 1996, 11 INT C AIDS JUL	15	87	88	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2085	2089		10.1001/jama.278.23.2085	http://dx.doi.org/10.1001/jama.278.23.2085			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403423				2022-12-28	WOS:A1997YK98700038
J	Wing, L				Wing, L			The autistic spectrum	LANCET			English	Article							HERPES-SIMPLEX ENCEPHALITIS; INFANTILE-AUTISM; TUBEROUS SCLEROSIS; ASPERGERS SYNDROME; CHILDHOOD AUTISM; CASE-HISTORIES; FOLLOW-UP; CHILDREN; DISORDER; EPIDEMIOLOGY				Wing, L (corresponding author), CTR SOCIAL & COMMUN DISORDERS,ELLIOT HOUSE,113 MASONS HILL,BROMLEY BR2 9HT,KENT,ENGLAND.							American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P66; ANDERSON G, 1997, AUTISM PERVASIVE DEV, P325; Arvidsson T., 1997, AUTISM, V2, P163; Asperger H., 1991, AUTISM ASPERGER SYND, P37, DOI [10.1017/CBO9780511526770.002, DOI 10.1017/CBO9780511526770.002]; BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099; BAILEY A, 1993, LANCET, V341, P1225, DOI 10.1016/0140-6736(93)91065-T; BARTAK L, 1976, J AUTISM CHILD SCHIZ, V6, P109, DOI 10.1007/BF01538054; Bauman M.L, 1994, NEUROBIOLOGY AUTISM, P119; BOLTON P, 1994, J CHILD PSYCHOL PSYC, V35, P877, DOI 10.1111/j.1469-7610.1994.tb02300.x; BORDEN MC, 1994, J AUTISM DEV DISORD, V24, P23, DOI 10.1007/BF02172210; BOWLER DM, 1992, J CHILD PSYCHOL PSYC, V33, P877, DOI 10.1111/j.1469-7610.1992.tb01962.x; BROOK SL, 1992, J AUTISM DEV DISORD, V22, P61, DOI 10.1007/BF01046403; CASS HD, 1994, ARCH DIS CHILD, V70, P192, DOI 10.1136/adc.70.3.192; CASTELLOE P, 1993, J AUTISM DEV DISORD, V23, P229, DOI 10.1007/BF01046217; CHESS S, 1971, J AUTISM CHILD SCHIZ, V1, P33, DOI 10.1007/BF01537741; CHESS S, 1977, J AUTISM CHILD SCHIZ, V7, P69, DOI 10.1007/BF01531116; CLARKE ADB, 1976, EARLY EXPERIENCE MYT; COX A, 1975, BRIT J PSYCHIAT, V126, P146, DOI 10.1192/bjp.126.2.146; Critchley M, 1932, BRAIN, V55, P311, DOI 10.1093/brain/55.3.311; DAMASIO AR, 1978, ARCH NEUROL-CHICAGO, V35, P777, DOI 10.1001/archneur.1978.00500360001001; DEMYER MK, 1973, J AUTISM CHILD SCHIZ, V3, P199, DOI 10.1007/BF01538281; DEMYER MK, 1972, J AUTISM CHILD SCHIZ, V2, P49, DOI 10.1007/BF01537626; DeMyer MK., 1976, EARLY CHILDHOOD AUTI, P169; EAVES LC, 1994, J AUTISM DEV DISORD, V24, P3, DOI 10.1007/BF02172209; EHLERS S, 1993, J CHILD PSYCHOL PSYC, V34, P1327, DOI 10.1111/j.1469-7610.1993.tb02094.x; Eisenmajer R, 1996, J AM ACAD CHILD PSY, V35, P1523, DOI 10.1097/00004583-199611000-00022; Frith U., 1989, AUTISM EXPLAINING EN, V6th; GHAZIUDDIN M, 1992, J AUTISM DEV DISORD, V22, P107, DOI 10.1007/BF01046406; GILLBERG C, 1986, BRIT J PSYCHIAT, V149, P68, DOI 10.1192/bjp.149.1.68; GILLBERG C, 1991, BRIT J PSYCHIAT, V158, P403, DOI 10.1192/bjp.158.3.403; GILLBERG C, 1981, J AUTISM DEV DISORD, V11, P365; GILLBERG C, 1989, J AUTISM DEV DISORD, V19, P545, DOI 10.1007/BF02212857; GILLBERG C, 1994, J AUTISM DEV DISORD, V24, P381, DOI 10.1007/BF02172235; GILLBERG C, 1986, J AUTISM DEV DISORD, V16, P369, DOI 10.1007/BF01531665; GILLBERG CL, 1992, J CHILD PSYCHOL PSYC, V33, P813, DOI 10.1111/j.1469-7610.1992.tb01959.x; GILLBERG G, DIAGNOSIS TREATMENT; GILLBERG G, 1989, DIAGNOSIS TREATMENT; GILLBERG G, 1992, BIOL AUTISTIC SYNDRO; Grandin T., 1992, HIGH FUNCTIONING IND, P105, DOI [10.1007/978-1-4899-2456-8_6, DOI 10.1007/978-1-4899-2456-8_6]; GRANDIN T, 1986, EMERGENCE LABELLED A; Grandin T., 1995, THINKING PICTURES; Hobson R, 1993, AUTISM DEV MIND; Howlin P, 1997, EUR CHILD ADOLES PSY, V6, P55, DOI 10.1007/BF00566668; Howlin P., 1997, AUTISM PREPARING ADU; Howlin P, 1987, TREATMENT AUTISTIC C; HUNT A, 1987, DEV MED CHILD NEUROL, V29, P190; HUNT A, 1993, J AUTISM DEV DISORD, V23, P323, DOI 10.1007/BF01046223; Jordan R., 1995, UNDERSTANDING TEACHI; Kanner L., 1973, CHILDHOOD PSYCHOSIS; Kanner L, 1943, NERV CHILD, V2, P217; Kemper TL., 1994, NEUROBIOLOGY AUTISM; KLIN A, 1992, J CHILD PSYCHOL PSYC, V33, P861, DOI 10.1111/j.1469-7610.1992.tb01961.x; Lane H., 1977, WILD BOY AVEYRON; LECOUTEUR A, 1989, J AUTISM DEV DISORD, V19, P363, DOI 10.1007/BF02212936; LOTTER V, 1974, J AUTISM CHILD SCHIZ, V4, P263, DOI 10.1007/BF02115232; Lotter V., 1966, SOC PSYCHIATR, V1, P124, DOI [10.1007/BF00584048, https://doi.org/10.1007/BF00584048]; MERYASH DL, 1982, J AUTISM DEV DISORD, V12, P295, DOI 10.1007/BF01531374; MORGAN H, 1996, ADULTS AUTISM GUIDE; OCONNOR N, 1988, J CHILD PSYCHOL PSYC, V29, P391, DOI 10.1111/j.1469-7610.1988.tb00732.x; POWELL S, 1997, AUTISM LEARNING GUID; REALMUTO GM, 1982, J AUTISM DEV DISORD, V12, P367, DOI 10.1007/BF01538324; RUTTER M, 1970, SEMIN PSYCHIAT, V2, P435; SHAH A, 1982, APPL RES MENT RETARD, V3, P303, DOI 10.1016/0270-3092(82)90022-4; SHAH A, 1986, SOCIAL BEHAVIOR AUTI, P153; TAFT LT, 1971, J AUTISM CHILD SCHIZ, V1, P327, DOI 10.1007/BF01557352; TANTAM D, 1988, BRIT J PSYCHIAT, V153, P777, DOI 10.1192/bjp.153.6.777; TREFFERT D, 1989, EXTRAORDINARY PEOPLE; Tuchman RF, 1997, PEDIATRICS, V99, P560, DOI 10.1542/peds.99.4.560; Turk J., 1997, AUTISM, V1, P175, DOI [10.1177/1362361397012005, DOI 10.1177/1362361397012005]; VOLKMAR FR, 1989, J AM ACAD CHILD PSY, V28, P82, DOI 10.1097/00004583-198901000-00015; WAKABAYASHI S, 1979, J AUTISM DEV DISORD, V9, P31, DOI 10.1007/BF01531289; Williams D., 1996, AUTISM INSIDE OUT AP; WING L, 1980, BRIT J PSYCHIAT, V137, P410, DOI 10.1192/bjp.137.5.410; Wing L, 1996, BRIT MED J, V312, P327; WING L, 1981, PSYCHIAT RES, V5, P129, DOI 10.1016/0165-1781(81)90043-3; Wing L, 1997, J FORENSIC PSYCHIATR, V8, P253, DOI 10.1080/09585189708412008; Wing L, 1993, Eur Child Adolesc Psychiatry, V2, P61, DOI 10.1007/BF02098832; WING L, 1981, PSYCHOL MED, V11, P115, DOI 10.1017/S0033291700053332; WING L, 1977, J CHILD PSYCHOL PSYC, V18, P167, DOI 10.1111/j.1469-7610.1977.tb00426.x; WING L, 1979, J AUTISM DEV DISORD, V9, P11, DOI 10.1007/BF01531288; WING L, 1978, J AUTISM CHILD SCHIZ, V8, P79, DOI 10.1007/BF01550280; Wing L., 1988, DIAGNOSIS ASSESSMENT, P91, DOI 10.1007/978-1-4899-0792-9_7; Wing L., 1992, HIGH FUNCTIONING IND, P129; WING L, 1991, AUTISM ASPERGER SYND, P93, DOI [DOI 10.1017/CB09780511526770.003, DOI 10.1017/CBO9780511526770.003]; Wing L., 1996, AUTISTIC SPECTRUM; WING L, 1996, CLIN DEV MED, V119, P268; Wolff S., 1995, LONERS LIFE PATH UNU; World Health Organisation, 1992, ICD 10 CLASS MENT BE, P252; World Health Organization, 1993, ICD 10 CLASS MENT BE, P147; [No title captured]; [No title captured]	91	252	261	3	66	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 13	1997	350	9093					1761	1766		10.1016/S0140-6736(97)09218-0	http://dx.doi.org/10.1016/S0140-6736(97)09218-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YL554	9413479				2022-12-28	WOS:A1997YL55400042
J	Brown, KE; Guest, SS; Smale, ST; Hahm, K; Merkenschlager, M; Fisher, AG				Brown, KE; Guest, SS; Smale, ST; Hahm, K; Merkenschlager, M; Fisher, AG			Association of transcriptionally silent genes with Ikaros complexes at centromeric heterochromatin	CELL			English	Article							TERMINAL TRANSFERASE GENE; CELL-CYCLE; INTERPHASE NUCLEI; TRANSGENIC MICE; GAGA FACTOR; HUNCHBACK; PROMOTER; DNA; ULTRABITHORAX; CHROMOSOME	Ikaros proteins are required for normal T, B, and NK cell development and are postulated to activate lymphocyte-specific gene expression. Here we examined Ikaros distribution in the nucleus of B lymphocytes using confocal microscopy and a novel immunofluorescence in situ hybridization (immune-FISH) approach. Unexpectedly, Ikaros localized to discrete heterochromatin-containing foci in interphase nuclei, which comprise clusters of centromeric DNA as defined by gamma-satellite sequences and the abundance of heterochromatin protein-1 (HP-1). Using locus-specific probes for CD2, CD4, CD8 alpha, CD19, CD45, and lambda 5 genes, we show that transcriptionally inactive but not transcriptionally active genes associate with Ikaros-heterochromatin foci. These findings support a model of organization of the nucleus in which repressed genes are selectively recruited into centromeric domains.	HAMMERSMITH HOSP, UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED,MRC, CLIN SCI CTR, LONDON W12 0NN, ENGLAND; UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	Imperial College London; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Merkenschlager, Matthias/0000-0003-2889-3288	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043726, R29DK043726] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43726] Funding Source: Medline; NIGMS NIH HHS [GM-07104] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axcrona K, 1996, EUR J IMMUNOL, V26, P2203, DOI 10.1002/eji.1830260936; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; Boveri T., 1909, ARCH ZELLFORSCH, V3, P181; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN KE, 1994, HUM MOL GENET, V3, P1227, DOI 10.1093/hmg/3.8.1227; BROWN KE, 1995, THESIS U OXFORD OXFO; Buckle VJ, 1993, HUMAN GENETIC DISEAS, P59; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; COMINGS DE, 1968, AM J HUM GENET, V20, P440; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; EARNSHAW WC, 1994, FASEB J, V8, P947, DOI 10.1096/fasebj.8.12.8088460; Ernst P, 1996, MOL CELL BIOL, V16, P6121; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FISHER AG, 1995, INT IMMUNOL, V7, P415, DOI 10.1093/intimm/7.3.415; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; HAAF T, 1989, HUM GENET, V81, P137, DOI 10.1007/BF00293889; HAAF T, 1991, EXP CELL RES, V192, P325, DOI 10.1016/0014-4827(91)90048-Y; HADLACZKY G, 1986, EXP CELL RES, V167, P1, DOI 10.1016/0014-4827(86)90199-0; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HENIKOFF S, 1996, GENOMES; Hostert A, 1997, J IMMUNOL, V158, P4270; HUANG S, 1992, P NATL ACAD SCI USA, V89, P305, DOI 10.1073/pnas.89.1.305; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KIM KJ, 1979, J IMMUNOL, V122, P549; KLUG CA, 1997, IN PRESS P NATL ACAD; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Marshall WF, 1997, CURR OPIN GENET DEV, V7, P259, DOI 10.1016/S0959-437X(97)80136-0; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; Merkenschlager M, 1997, J EXP MED, V186, P1149, DOI 10.1084/jem.186.7.1149; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; MOORTHIBHAT K, 1996, DEVELOPMENT, V122, P1113; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; Poux S, 1996, EMBO J, V15, P4713, DOI 10.1002/j.1460-2075.1996.tb00848.x; Rabl C, 1885, MORPHOL JB, V10, P214; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; RALPH P, 1975, J IMMUNOL, V114, P898; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; RODERICK TH, 1996, GENETIC VARIANTS STR, P926; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; SAGA Y, 1988, MOL CELL BIOL, V8, P4889, DOI 10.1128/MCB.8.11.4889; SCHMID I, 1991, CYTOMETRY, V12, P279, DOI 10.1002/cyto.990120312; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; Strouboulis J, 1996, J CELL SCI, V109, P1991; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511; ZHOU LJ, 1992, IMMUNOGENETICS, V35, P102, DOI 10.1007/BF00189519; Zirbel RM, 1993, CHROMOSOME RES, V1, P93, DOI 10.1007/BF00710032	67	644	661	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 12	1997	91	6					845	854		10.1016/S0092-8674(00)80472-9	http://dx.doi.org/10.1016/S0092-8674(00)80472-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413993	Bronze			2022-12-28	WOS:A1997YL43900015
J	Elich, TD; Chory, J				Elich, TD; Chory, J			Phytochrome: If it looks and smells like a histidine kinase, is it a histidine kinase?	CELL			English	Review							PROTEIN-KINASE; SIGNAL TRANSDUCTION; PHOSPHORYLATION; SENSOR		SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Howard Hughes Medical Institute; Salk Institute	Elich, TD (corresponding author), MONSANTO CO,700 CHESTERFIELD PKWY N,ST LOUIS,MO 63198, USA.							BIERMANN BJ, 1994, PLANT PHYSIOL, V105, P243, DOI 10.1104/pp.105.1.243; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; FANKHAUSER C, 1997, IN PRESS ANN REV CEL; GRIMM R, 1989, PLANTA, V178, P199, DOI 10.1007/BF00393195; HARRIS RA, 1995, ADV ENZYME REGUL, V35, P147, DOI 10.1016/0065-2571(94)00020-4; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Jordan ET, 1997, PLANT PHYSIOL, V115, P693, DOI 10.1104/pp.115.2.693; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; KIM IS, 1989, PHOTOCHEM PHOTOBIOL, V49, P319, DOI 10.1111/j.1751-1097.1989.tb04113.x; Lagarias DM, 1995, PLANT MOL BIOL, V29, P1127, DOI 10.1007/BF00020457; Lapko VN, 1997, BIOCHEMISTRY-US, V36, P10595, DOI 10.1021/bi970708z; MCMICHAEL RW, 1990, CURR T PL B, V9, P259; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; Quail PH, 1997, BIOESSAYS, V19, P571, DOI 10.1002/bies.950190708; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; SCHNEIDERPOETSCH HAW, 1992, PHOTOCHEM PHOTOBIOL, V56, P839, DOI 10.1111/j.1751-1097.1992.tb02241.x; STOCKHAUS J, 1992, GENE DEV, V6, P2364, DOI 10.1101/gad.6.12a.2364; WurglerMurphy SM, 1997, TRENDS BIOCHEM SCI, V22, P172, DOI 10.1016/S0968-0004(97)01036-0; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	20	49	51	1	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					713	716		10.1016/S0092-8674(00)80458-4	http://dx.doi.org/10.1016/S0092-8674(00)80458-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413979	Bronze			2022-12-28	WOS:A1997YL43900001
J	Sunahara, RK; Tesmer, JJG; Gilman, AG; Sprang, SR				Sunahara, RK; Tesmer, JJG; Gilman, AG; Sprang, SR			Crystal structure of the adenylyl cyclase activator G(S alpha)	SCIENCE			English	Article							G-PROTEIN; GTP HYDROLYSIS; ALPHA-SUBUNITS; CHOLERA-TOXIN; BETA-GAMMA; TRANSDUCIN; MECHANISM; RECEPTORS; STIMULATION; EXPRESSION	The crystal structure of G(S alpha), the heterotrimeric G protein alpha subunit that stimulates adenylyl cyclase, was determined at 2.5 Angstrom in a complex with guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S). G(S alpha) is the prototypic member of a family of GTP-binding proteins that regulate the activities of effectors in a hormone-dependent manner. Comparison of the structure of G(S alpha).GTP gamma S with that of G(i alpha).GTP gamma S suggests that their effector specificity is primarily dictated by the shape of the binding surface formed by the switch II helix and the alpha 3-beta 5 loop, despite the high sequence homology of these elements. In contrast, sequence divergence explains the inability of regulators of G protein signaling to stimulate the GTPase activity of G(S alpha). The beta gamma binding surface of G(S alpha) is largely conserved in sequence ana structure to that of G(i alpha), whereas differences in the surface formed by the carboxyl-terminal helix and the alpha 4-beta 6 loop may mediate receptor specificity.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Sunahara, Roger/AAJ-8667-2020	Tesmer, John/0000-0003-1125-3727	NIDDK NIH HHS [DK46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENJAMIN DR, 1995, J MOL BIOL, V254, P681, DOI 10.1006/jmbi.1995.0647; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BERMAN DM, IN PRESS J BIOL CHEM; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR VERSION 3 1; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Farfel Z, 1996, J BIOL CHEM, V271, P19653, DOI 10.1074/jbc.271.33.19653; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; Iiri T, 1997, P NATL ACAD SCI USA, V94, P5656, DOI 10.1073/pnas.94.11.5656; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; ITOH H, 1991, J BIOL CHEM, V266, P16226; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE E, 1994, METHOD ENZYMOL, V237, P146; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; RASENICK MM, 1994, J BIOL CHEM, V269, P21519; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; VANDOP C, 1984, J BIOL CHEM, V259, P696; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1	42	247	255	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1943	1947		10.1126/science.278.5345.1943	http://dx.doi.org/10.1126/science.278.5345.1943			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9395396				2022-12-28	WOS:A1997YL00200034
J	Hurwitz, J				Hurwitz, J			Subdural hematoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Hurwitz, J (corresponding author), HOSP UNIV PENN,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1732	1732		10.1056/NEJM199712113372405	http://dx.doi.org/10.1056/NEJM199712113372405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK653	9392699				2022-12-28	WOS:A1997YK65300005
J	Thun, MJ; Peto, R; Lopez, AD; Monaco, JH; Henley, SJ; Heath, CW; Doll, R				Thun, MJ; Peto, R; Lopez, AD; Monaco, JH; Henley, SJ; Heath, CW; Doll, R			Alcohol consumption and mortality among middle-aged and elderly US adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; FATAL COLON CANCER; SHAPED CURVE; RISK; WOMEN; MEN; STROKE; DEATH	Background Alcohol consumption has both adverse and beneficial effects on survival. We examined the balance of these in a large prospective study of mortality among U.S. adults. Methods Of 490,000 men and women (mean age, 56 years; range, 30 to 104) who reported their alcohol and tobacco use in 1982, 46,000 died during nine years of follow-up. We compared cause-specific death rates and rates of death from all causes across categories of base-line alcohol consumption, adjusting for other risk factors, and related drinking and smoking habits to the cumulative probability of dying between the ages of 35 and 69 years. Results Causes of death associated with drinking were cirrhosis and alcoholism; cancers of the mouth, esophagus, pharynx, larynx, and liver combined; breast cancer in women; and injuries and other external causes in men. The mortality from breast cancer was 30 percent higher among women reporting at least one drink daily than among nondrinkers (relative risk, 1.3; 95 percent confidence interval, 1.1 to 1.6). The rates of death from all cardiovascular diseases were 30 to 40 percent lower among men (relative risk, 0.7; 95 percent confidence interval, 0.7 to 0.8) and women (relative risk, 0.6; 95 percent confidence interval, 0.6 to 0.7) reporting at least one drink daily than among nondrinkers, with little relation to the level of consumption. The overall death rates were lowest among men and women reporting about one drink daily. Mortality from all causes increased with heavier drinking, particularly among adults under age 60 with lower risk of cardiovascular disease. Alcohol consumption was associated with a small reduction in the overall risk of death in middle age (ages 35 to 69), whereas smoking approximately doubled this risk. Conclusions In this middle-aged and elderly population, moderate alcohol consumption slightly reduced overall mortality. The benefit depended in part on age and background cardiovascular risk and was far smaller than the large increase in risk produced by tobacco. (C) 1997, Massachusetts Medical Society.	UNIV OXFORD,CLIN TRIAL SERV UNIT,OXFORD,ENGLAND; UNIV OXFORD,EPIDEMIOL STUDIES UNIT,OXFORD,ENGLAND; WHO,PROGRAMME SUBST ABUSE,CH-1211 GENEVA,SWITZERLAND	University of Oxford; University of Oxford; World Health Organization	Thun, MJ (corresponding author), AMER CANC SOC,EPIDEMIOL & SURVEILLANCE RES,1599 CLIFTON RD NE,ATLANTA,GA 30329, USA.		Lopez, Alan D/F-1487-2010; Henley, Jane/A-4698-2010; Lopez, Alan/AAA-2734-2022	Lopez, Alan D/0000-0001-5818-6512; Henley, S Jane/0000-0002-2420-306X				ANDERSON P, 1995, ALCOHOL PUBLIC POLIC, P82; ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; BLACKWELDER WC, 1980, AM J MED, V68, P164, DOI 10.1016/0002-9343(80)90350-2; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; CALLE EE, 1993, AM J EPIDEMIOL, V137, P235, DOI 10.1093/oxfordjournals.aje.a116664; CAMACHO TC, 1987, J CHRON DIS, V40, P229, DOI 10.1016/0021-9681(87)90158-5; COX DR, 1972, J R STAT SOC B, V34, P187; DELABRY LO, 1992, J STUD ALCOHOL, V53, P25, DOI 10.15288/jsa.1992.53.25; *DIET GUID ADV COM, 1995, NTIS PUBL; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; FARCHI G, 1992, INT J EPIDEMIOL, V21, P74, DOI 10.1093/ije/21.1.74; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; Fuchs CS, 1997, NEW ENGL J MED, V336, P523; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; GARFINKEL L, 1985, HIH PUBLICATION, P49; GAZANIO JM, 1993, NEW ENGL J MED, V329, P1829; GORDON T, 1987, AM J EPIDEMIOL, V125, P263, DOI 10.1093/oxfordjournals.aje.a114525; *INT AG RES CANC, 1988, IARC MON EV CARC RIS, V44; KKRAUSS RM, 1996, CIRCULATION, V94, P1795; Klatsky AL, 1997, AM J CARDIOL, V80, P416, DOI 10.1016/S0002-9149(97)00388-3; KLATSKY AL, 1989, STROKE, V20, P741, DOI 10.1161/01.STR.20.6.741; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KONO S, 1986, INT J EPIDEMIOL, V15, P527, DOI 10.1093/ije/15.4.527; MARMOT MG, 1981, LANCET, V1, P580; MILLER GJ, 1990, INT J EPIDEMIOL, V19, P923, DOI 10.1093/ije/19.4.923; *NAT CTR HLTH STAT, 1994, VIT STAT US A, V2, P312; *NAT CTR HLTH STAT, 1988, VITAL HLTH STAT 10, V166; NORTON R, 1987, BMJ-BRIT MED J, V295, P80, DOI 10.1136/bmj.295.6590.80; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; SALONEN JT, 1983, J CHRON DIS, V36, P533, DOI 10.1016/0021-9681(83)90131-5; SHAPER AG, 1988, LANCET, V2, P1267; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; *WHO, 1977, 29 WORLD HLTH ASS GE; 1995, MMWR-MORBID MORTAL W, V44, P869	39	918	935	1	83	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 11	1997	337	24					1705	1714		10.1056/NEJM199712113372401	http://dx.doi.org/10.1056/NEJM199712113372401			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK653	9392695				2022-12-28	WOS:A1997YK65300001
J	Tabaqchali, S				Tabaqchali, S			Vancomycin-resistant Staphylococcus aureus: apocalypse now?	LANCET			English	Editorial Material							ENTEROCOCCUS-FAECIUM; TEICOPLANIN				Tabaqchali, S (corresponding author), ST BARTHOLOMEWS & ROYAL LONDON SCH MED & DENT,DEPT MED MICROBIOL,LONDON EC1A 7BE,ENGLAND.							Ayliffe GAJ, 1997, CLIN INFECT DIS, V24, pS74, DOI 10.1093/clinids/24.Supplement_1.S74; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P813; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P624; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P626; DAUM RS, 1992, J INFECT DIS, V166, P1066, DOI 10.1093/infdis/166.5.1066; Hashimoto Hajime, 1994, Japanese Journal of Antibiotics, V47, P618; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; HIRAMATSU K, 1997, ANTIBIOT CHEMOTHER, V1, P5; KREMERY V, 1997, ANTIBIOT CHEMOTHER, V1, P6; LECLERCQ R, 1989, ANTIMICROB AGENTS CH, V33, P10, DOI 10.1128/AAC.33.1.10; NICAS TI, 1989, ANTIMICROB AGENTS CH, V33, P1121, DOI 10.1128/AAC.33.7.1121; NOBLE WC, 1992, FEMS MICROBIOL LETT, V93, P195; SCHWALBE RS, 1987, NEW ENGL J MED, V316, P927, DOI 10.1056/NEJM198704093161507; SCHWALBE RS, 1990, J INFECT DIS, V161, P45, DOI 10.1093/infdis/161.1.45; 1996, CDR WEEKLY, V6, P197	15	46	47	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 6	1997	350	9092					1644	1645		10.1016/S0140-6736(05)64269-9	http://dx.doi.org/10.1016/S0140-6736(05)64269-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK211	9400504				2022-12-28	WOS:A1997YK21100004
J	Cliff, SS; Thiemens, MH				Cliff, SS; Thiemens, MH			The O-18/O-16 and O-17/O-16 ratios in atmospheric nitrous oxide: A mass-independent anomaly	SCIENCE			English	Article							OXYGEN ISOTOPE RATIOS; N2O; FRACTIONATION; NITRIFICATION; WATER; OZONE	Measurements of the oxygen isotope ratios (O-18/O-16 and O-17/O-16) in atmosphere nitrous oxide (N2O) from La Jolla, Pasadena, and the White Mountain Research Station (elevation, 3801 meters) in California and the White Sands Missile Range in New Mexico show that N2O has a mass-independent composition. These data suggest the presence of a previously undefined atmospheric process. The La Jolla samples can be explained by a mixing between an atmospherically derived source of mass-independent N2O and biologically derived mass-dependent N2O. Possible origins of the mass-independent anomaly in N2O are discussed.	UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego								ANDERSON SM, 1992, ACS SYM SER, V502, P155; ANDERSON SM, 1995, PROGR PROBLEMS ATMOS, P473; CANTRELL CA, 1994, J GEOPHYS RES-ATMOS, V99, P3739, DOI 10.1029/93JD02659; CLIFF SS, 1994, ANAL CHEM, V66, P2761; CRAIG H, 1997, EOS S, V78, pS83; Gellene GI, 1996, SCIENCE, V274, P1344, DOI 10.1126/science.274.5291.1344; GRIFFITH KS, 1992, J CHEM PHYS, V96, P4403, DOI 10.1063/1.462831; GROTH WE, 1957, J CHEM PHYS, V27, P973, DOI 10.1063/1.1743895; HARTECK P, 1954, J CHEM PHYS, V22, P758, DOI 10.1063/1.1740175; Huff AK, 1997, ANAL CHEM, V69, P4267, DOI 10.1021/ac970256w; JOHNSTON JC, 1995, J GEOPHYS RES-ATMOS, V100, P16801, DOI 10.1029/95JD01646; JOHNSTON JC, 1996, THESIS U CALIFORNIA, pCH4; JOHNSTON JC, 1995, EOS S, V76, pF85; KAYE JA, 1987, REV GEOPHYS, V25, P1609, DOI 10.1029/RG025i008p01609; KIM KR, 1993, SCIENCE, V262, P1855, DOI 10.1126/science.262.5141.1855; KIM KR, 1990, NATURE, V347, P58, DOI 10.1038/347058a0; McElroy MB, 1996, GLOBAL BIOGEOCHEM CY, V10, P651, DOI 10.1029/96GB02346; MINSCHWANER K, 1993, J GEOPHYS RES-ATMOS, V98, P10543, DOI 10.1029/93JD00223; Prasad SS, 1994, J GEOPHYS RES-ATMOS, V99, P5285, DOI 10.1029/93JD01911; Rahn T, 1997, SCIENCE, V278, P1776, DOI 10.1126/science.278.5344.1776; THIEMENS MH, 1991, SCIENCE, V251, P932, DOI 10.1126/science.251.4996.932; WAHLEN M, 1985, NATURE, V313, P780, DOI 10.1038/313780a0; WEN J, 1993, J GEOPHYS RES-ATMOS, V98, P12801, DOI 10.1029/93JD00565; *WORLD MET ORG, 1995, 37 WORLD MET ORG, P2; YOSHIDA N, 1988, NATURE, V335, P528, DOI 10.1038/335528a0; YOSHINARI T, 1985, NATURE, V317, P349, DOI 10.1038/317349a0; Yung YL, 1997, SCIENCE, V278, P1778, DOI 10.1126/science.278.5344.1778; ZIPF EC, 1997, EOS S, V78, pS82	28	101	102	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1774	1776		10.1126/science.278.5344.1774	http://dx.doi.org/10.1126/science.278.5344.1774			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388174				2022-12-28	WOS:A1997YJ90100040
J	Hviid, SF; Madsen, MB; Gunnlaugsson, HP; Goetz, W; Knudsen, JM; Hargraves, RB; Smith, P; Britt, D; Dinesen, AR; Mogensen, CT; Olsen, M; Pedersen, CT; Vistisen, L				Hviid, SF; Madsen, MB; Gunnlaugsson, HP; Goetz, W; Knudsen, JM; Hargraves, RB; Smith, P; Britt, D; Dinesen, AR; Mogensen, CT; Olsen, M; Pedersen, CT; Vistisen, L			Magnetic properties experiments on the Mars Pathfinder lander: Preliminary results	SCIENCE			English	Article							SNC METEORITES; SOIL; CLUES; DUST	Many of the particles currently suspended in the martian atmosphere are magnetic, with an average saturation magnetization of about 4 A.m(2)/kg (amperes times square meters per kilogram). The particles appear to consist of claylike aggregates stained or cemented with ferric oxide (Fe2O3); at least some of the stain and cement is probably maghemite (gamma-Fe2O3). The presence of the gamma phase would imply that Fe2+ ions leached from the bedrock, passing through a state as free Fe2+ ions dissolved in liquid water. These particles could be a freeze-dried precipitate from ground water poured out on the surface. An alternative is that the magnetic particles are titanomagnetite occurring in palagonite and inherited directly from a basaltic precursor.	PRINCETON UNIV,DEPT GEOSCI,PRINCETON,NJ 08544; UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721	Princeton University; University of Arizona	Hviid, SF (corresponding author), UNIV COPENHAGEN,NIELS BOHR INST ASTRON PHYS & GEOPHYS,OERSTED LAB,COPENHAGEN,DENMARK.		Madsen, Morten Bo/D-2082-2011; Gunnlaugsson, Haraldur/L-6535-2016	Madsen, Morten Bo/0000-0001-8909-5111; Gunnlaugsson, Haraldur/0000-0002-8958-0245				ALT JC, 1988, MAR GEOL, V81, P227, DOI 10.1016/0025-3227(88)90029-1; BANIN A, 1993, J GEOPHYS RES-PLANET, V98, P20831, DOI 10.1029/93JE02500; BELL JF, 1990, J GEOPHYS RES-SOLID, V95, P14447, DOI 10.1029/JB095iB09p14447; BURNS RG, 1980, NATURE, V285, P647, DOI 10.1038/285647a0; BURNS RG, 1993, GEOCHIM COSMOCHIM AC, V57, P4555, DOI 10.1016/0016-7037(93)90182-V; Clark B. C.  III, 1977, Journal of Geophysical Research, V82, P4577, DOI 10.1029/JS082i028p04577; COEY JMD, 1990, J GEOPHYS RES-SOLID, V95, P14423, DOI 10.1029/JB095iB09p14423; GOODING JL, 1992, ICARUS, V99, P28, DOI 10.1016/0019-1035(92)90168-7; GUNNLAUGSSON HP, IN PRESS PLANET SPAC; HANEL R, 1972, ICARUS, V17, P423, DOI 10.1016/0019-1035(72)90009-7; Hapke B., 1993, THEORY REFLECTANCE E; Hargraves R. B., 1977, Journal of Geophysical Research, V82, P4547, DOI 10.1029/JS082i028p04547; HUNT GR, 1973, ICARUS, V18, P459, DOI 10.1016/0019-1035(73)90155-3; KOCH CB, 1995, PHYS CHEM MINER, V22, P333; MCSWEEN HY, 1985, REV GEOPHYS, V23, P391, DOI 10.1029/RG023i004p00391; MORRIS RV, 1989, J GEOPHYS RES-SOLID, V94, P2760, DOI 10.1029/JB094iB03p02760; MORRIS RV, 1990, J GEOPHYS RES-SOLID, V95, P14427, DOI 10.1029/JB095iB09p14427; Oyama V. I., 1977, Journal of Geophysical Research, V82, P4669, DOI 10.1029/JS082i028p04669; Pollack J. B., 1977, Journal of Geophysical Research, V82, P4479, DOI 10.1029/JS082i028p04479; POLLACK JB, 1995, J GEOPHYS RES-PLANET, V100, P5235, DOI 10.1029/94JE02640; Rieder R, 1997, SCIENCE, V278, P1771, DOI 10.1126/science.278.5344.1771; SINGER RB, 1984, B AM ASTRON SOC, V16, P679; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; SMITH PH, 1997, J GEOPHYS RES, V102, P3953; Wendlandt W.W., 1966, REFLECTANCE SPECTROS; [No title captured]	26	88	90	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1768	1770		10.1126/science.278.5344.1768	http://dx.doi.org/10.1126/science.278.5344.1768			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388172				2022-12-28	WOS:A1997YJ90100038
J	Mayo, MW; Wang, CY; Cogswell, PC; RogersGraham, KS; Lowe, SW; Der, CJ; Baldwin, AS				Mayo, MW; Wang, CY; Cogswell, PC; RogersGraham, KS; Lowe, SW; Der, CJ; Baldwin, AS			Requirement of NF-kappa B activation to suppress p53-independent apoptosis induced by oncogenic Ras	SCIENCE			English	Article							UBIQUITIN-PROTEASOME PATHWAY; C-JUN; CELL-DEATH; ALPHA PROTEOLYSIS; CANCER-THERAPY; R-RAS; H-RAS; PHOSPHORYLATION; TRANSFORMATION; PROTEIN	The ras proto-oncogene is frequently mutated in human tumors and functions to chronically stimulate signal transduction cascades resulting in the synthesis or activation of specific transcription factors, including Ets, c-Myc, c-Jun, and nuclear factor kappa B (NF-kappa B). These Ras-responsive transcription factors are required for transformation, but the mechanisms by which these proteins facilitate oncogenesis have not been fully established. Oncogenic Ras was shown to initiate a p53-independent apoptotic response that was suppressed through the activation of NF-kappa B. These results provide an explanation for the requirement of NF-kappa B for Ras-mediated oncogenesis and provide evidence that Ras-transformed cells are susceptible to apoptosis even if they do not express the p53 tumor-suppressor gene product.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, SCH MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH DENT, CURRICULUM GENET & MOL BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH DENT, DEPT ENDODONT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Cold Spring Harbor Laboratory; University of North Carolina; University of North Carolina Chapel Hill				Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA052072, R01CA072771, P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA52072, CA72771, CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CHEN CY, 1995, ONCOGENE, V11, P1487; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Colman MS, 1996, NUCLEIC ACIDS RES, V24, P1971, DOI 10.1093/nar/24.10.1971; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; FINCO TS, 1993, J BIOL CHEM, V268, P17676; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HOLMESMCNARY M, UNPUB; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LIN HJ, 1997, MOL CELL BIOL, V15, P4536; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MAYO MW, UNPUB; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUIN RG, 1995, NATURE, V374, P457; QUO ML, 1997, MOL CARCINOG, V18, P221; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Yang BS, 1996, MOL CELL BIOL, V16, P538	59	500	521	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 5	1997	278	5344					1812	1815		10.1126/science.278.5344.1812	http://dx.doi.org/10.1126/science.278.5344.1812			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388187	Green Submitted			2022-12-28	WOS:A1997YJ90100053
J	Smith, PH; Bell, JF; Bridges, NT; Britt, DT; Gaddis, L; Greeley, R; Keller, HU; Herkenhoff, KE; Jaumann, R; Johnson, JR; Kirk, RL; Lemmon, M; Maki, JN; Malin, MC; Murchie, SL; Oberst, J; Parker, TJ; Reid, RJ; Sablotny, R; Soderblom, LA; Stoker, C; Sullivan, R; Thomas, N; Tomasko, MG; Ward, W; Wegryn, E				Smith, PH; Bell, JF; Bridges, NT; Britt, DT; Gaddis, L; Greeley, R; Keller, HU; Herkenhoff, KE; Jaumann, R; Johnson, JR; Kirk, RL; Lemmon, M; Maki, JN; Malin, MC; Murchie, SL; Oberst, J; Parker, TJ; Reid, RJ; Sablotny, R; Soderblom, LA; Stoker, C; Sullivan, R; Thomas, N; Tomasko, MG; Ward, W; Wegryn, E			Results from the Mars Pathfinder camera	SCIENCE			English	Article							SPECTRAL REFLECTANCE; VIKING LANDERS; IRON-OXIDES; DUST; SPECTROSCOPY; MINERALOGY; HEMATITE; PYROXENE; SURFACE	Images of the martian surface returned by the Imager for Mars Pathfinder (IMP) show a complex surface of ridges and troughs covered by rocks that have been transported and modified by fluvial, aeolian, and impact processes. Analysis of the spectral signatures in the scene (at 440- to 1000-nanometer wavelength) reveal three types of rock and four classes of soil. Upward-looking IMP images of the predawn sky show thin, bluish clouds that probably represent water ice forming on local atmospheric haze (opacity similar to 0.5). Haze particles are about 1 micrometer in radius and the water vapor column abundance is about 10 precipitable micrometers.	CORNELL UNIV,ITHACA,NY 14853; CALTECH,JET PROP LAB,PASADENA,CA 91109; US GEOL SURVEY,FLAGSTAFF,AZ 86001; ARIZONA STATE UNIV,TEMPE,AZ 85287; MAX PLANCK INST AERON,KATHENBURG LINDAU,GERMANY; DLR,BERLIN,GERMANY; MALIN SPACE SCI SYST,SAN DIEGO,CA; JOHNS HOPKINS UNIV,APPL PHYS LAB,BALTIMORE,MD 21218; NASA,AMES RES CTR,MOFFETT FIELD,CA 94035	Cornell University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); United States Department of the Interior; United States Geological Survey; Arizona State University; Arizona State University-Tempe; Max Planck Society; Helmholtz Association; German Aerospace Centre (DLR); Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Smith, PH (corresponding author), UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721, USA.		Murchie, Scott L/E-8030-2015; Stoker, Carol/ABE-1381-2021; Lemmon, Mark/X-2333-2019; Johnson, Jeffrey R/F-3972-2015; Jaumann, Ralf/N-1001-2018; Lemmon, Mark T/E-9983-2010; Sullivan, Robert/AAR-8193-2020; Bridges, Nathan T/D-6341-2016; Thomas, Nicolas/G-4693-2015	Murchie, Scott L/0000-0002-1616-8751; Stoker, Carol/0000-0001-7265-292X; Lemmon, Mark/0000-0002-4504-5136; Johnson, Jeffrey R/0000-0002-5586-4901; Jaumann, Ralf/0000-0002-9759-6597; Lemmon, Mark T/0000-0002-4504-5136; Thomas, Nicolas/0000-0002-0146-0071				ADAMS JB, 1974, J GEOPHYS RES, V79, P4829, DOI 10.1029/JB079i032p04829; ARVIDSON RE, 1989, REV GEOPHYS, V27, P39, DOI 10.1029/RG027i001p00039; BAGNOLD RA, 1954, PHYSICS BLOWN SAND D; BELL JF, 1990, J GEOPHYS RES-SOLID, V95, P14447, DOI 10.1029/JB095iB09p14447; BELL JF, 1996, MINERAL SPECTROSCOPY, P359; BISHOP JL, 1993, GEOCHIM COSMOCHIM AC, V57, P4583, DOI 10.1016/0016-7037(93)90184-X; CLANCY T, 1997, COMMUNICATION; CLOUTIS EA, 1991, J GEOPHYS RES-PLANET, V96, P22809, DOI 10.1029/91JE02512; COSTA JE, 1983, GEOL SOC AM BULL, V94, P986, DOI 10.1130/0016-7606(1983)94<986:PROFPF>2.0.CO;2; FRENCH LM, 1988, ICARUS, V75, P127, DOI 10.1016/0019-1035(88)90131-5; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; GREELEY R, 1984, WIND GEOLOGICAL PROC; Greeley R., 1992, MARS, P730; Grundy WM, 1992, ASTEROIDS COMETS MET, P215; GUINNESS EA, 1987, J GEOPHYS RES-SOLID, V92, pE575, DOI 10.1029/JB092iB04p0E575; Hviid SF, 1997, SCIENCE, V278, P1768, DOI 10.1126/science.278.5344.1768; Jakosky B. M., 1992, MARS, P969; JAMES P, 1997, COMMUNICATION; KAHN R, 1981, J GEOPHYS RES-SPACE, V86, P5833, DOI 10.1029/JA086iA07p05833; KLASSEN KP, 1979, J GEOPHYS RES, V84, P8478; KOMAR PD, 1987, SEDIMENTOLOGY, V34, P1165, DOI 10.1111/j.1365-3091.1987.tb00599.x; KOMAR PD, 1989, FLOODS HYDROLOGICAL, P107; KOMAR PD, 1991, SEDIMENTOLOGY, V38; Komatsu G, 1997, J GEOPHYS RES-PLANET, V102, P4151, DOI 10.1029/96JE02564; Malin M. C., 1988, 4041 NASA, P502; MALIN MC, 1981, 84211 NASA, P272; MCCORD TB, 1977, ICARUS, V31, P25, DOI 10.1016/0019-1035(77)90069-0; MORRIS RV, 1995, J GEOPHYS RES-PLANET, V100, P5319, DOI 10.1029/94JE01500; MORRIS RV, 1985, J GEOPHYS RES-SOLID, V90, P3126, DOI 10.1029/JB090iB04p03126; MURCHIE S, 1993, ICARUS, V105, P454, DOI 10.1006/icar.1993.1141; MUSTARD JF, 1993, J GEOPHYS RES-PLANET, V98, P3387, DOI 10.1029/92JE02682; Mutch T. A., 1977, Journal of Geophysical Research, V82, P4452, DOI 10.1029/JS082i028p04452; MUTCH TA, 1976, SCIENCE, V194, P87, DOI 10.1126/science.194.4260.87; MUTCH TA, 1976, SCIENCE, V193, P791, DOI 10.1126/science.193.4255.791; OCONNOR JE, 1992, GEOL SOC AM BULL, V104, P267, DOI 10.1130/0016-7606(1992)104<0267:MAIOPD>2.3.CO;2; POLLACK JB, 1981, J ATMOS SCI, V38, P3, DOI 10.1175/1520-0469(1981)038<0003:AMGCEW>2.0.CO;2; POLLACK JB, 1995, J GEOPHYS RES-PLANET, V100, P5235, DOI 10.1029/94JE02640; POLLACK JB, 1980, J ATMOS SCI, V37, P868, DOI 10.1175/1520-0469(1980)037<0868:SBNPOS>2.0.CO;2; REID R, 1997, THESIS U ARIZONA; Rieder R, 1997, SCIENCE, V278, P1771, DOI 10.1126/science.278.5344.1771; RODDY DJ, 1977, IMPACT EXPLOSION CRA, P489; SCHOFIELD T, 1997, SCIENCE, V278, P1752; SHARP RP, 1984, GEOL SOC AM BULL, V95, P1398, DOI 10.1130/0016-7606(1984)95<1398:SGFVLO>2.0.CO;2; SHERMAN DM, 1982, J GEOPHYS RES, V87, P169, DOI 10.1029/JB087iB12p10169; SINGER RB, 1982, J GEOPHYS RES, V87, P159, DOI 10.1029/JB087iB12p10159; Smith PH, 1997, J GEOPHYS RES-PLANET, V102, P4003, DOI 10.1029/96JE03568; Zellner B., 1994, LUNAR PLANET SCI C, V25, P1541; ZUREK RW, 1982, ICARUS, V50, P288, DOI 10.1016/0019-1035(82)90127-0	48	215	216	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 5	1997	278	5344					1758	1765		10.1126/science.278.5344.1758	http://dx.doi.org/10.1126/science.278.5344.1758			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ901	9388170				2022-12-28	WOS:A1997YJ90100036
J	Taipale, P; Hiilesmaa, V; Salonen, R; Ylostalo, P				Taipale, P; Hiilesmaa, V; Salonen, R; Ylostalo, P			Increased nuchal translucency as a marker for fetal chromosomal defects	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FIRST-TRIMESTER; TRANSVAGINAL SONOGRAPHY; CYSTIC HYGROMA; 1ST TRIMESTER; ALPHA-FETOPROTEIN; GESTATIONAL-AGE; DOWNS-SYNDROME; ULTRASOUND; THICKNESS; FETUSES	Background Screening for trisomy 21 (Down's syndrome) by measuring maternal serum alpha-fetoprotein, chorionic gonadotropin, and estriol concentrations and then performing chorionic-villus sampling or amniocentesis identifies approximately 60 percent of fetuses with this disorder. We used ultrasonography to detect increased nuchal translucency and cystic hygroma, which are characteristic features of fetuses with chromosomal defects. Methods We performed transvaginal ultrasonography in 10,010 unselected adolescents and women less than 40 years of age with live singleton fetuses at 10 to 15.9 weeks of gestation. Increased fetal nuchal translucency was defined as an area of translucency at least 3 mm in width, and cystic hygromas were defined as septated, fluid-filled sacs in the nuchal region. Subjects whose fetuses had these findings were offered fetal karyotyping. Information on pregnancies, deliveries, and neonates was subsequently obtained from hospital records and national birth and malformation registries. Results Nuchal translucency or cystic hygroma was seen in 76 fetuses (0.8 percent), of which 18 (24 percent) had an abnormal karyotype. The sensitivity for trisomies 21, 18, and 13 combined was 62 percent (13 of 21 fetuses), and the sensitivity for trisomy 21 alone was 54 percent (7 of 13 fetuses). Conclusions The use of transvaginal ultrasonography to detect increased nuchal translucency and cystic hygroma is a sensitive test for fetal aneuploidy. It can be done earlier in pregnancy than serum screening, and it decreases the subsequent need for chorionic-villus sampling or amniocentesis. (C) 1997, Massachusetts Medical Society.	JORVI HOSP,DEPT OBSTET & GYNECOL,SF-02740 ESPOO,FINLAND		Taipale, P (corresponding author), UNIV HELSINKI,CENT HOSP,DEPT OBSTET & GYNECOL,HAARTMANINKATU 2,SF-00290 HELSINKI,FINLAND.							BENACERRAF BR, 1992, RADIOLOGY, V184, P239, DOI 10.1148/radiology.184.1.1535162; BEWLEY S, 1995, BRIT J OBSTET GYNAEC, V102, P386, DOI 10.1111/j.1471-0528.1995.tb11290.x; BRAITHWAITE JM, 1995, BRIT J RADIOL, V68, P720, DOI 10.1259/0007-1285-68-811-720; BRONSHTEIN M, 1992, PRENATAL DIAG, V12, P587, DOI 10.1002/pd.1970120704; COMAS C, 1995, ULTRASOUND OBST GYN, V5, P26, DOI 10.1046/j.1469-0705.1995.05010026.x; CULLEN MT, 1990, PRENATAL DIAG, V10, P643, DOI 10.1002/pd.1970101004; DAYA S, 1993, AM J OBSTET GYNECOL, V168, P903, DOI 10.1016/S0002-9378(12)90842-X; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; HAFNER E, 1995, ULTRASOUND OBST GYN, V6, P330, DOI 10.1046/j.1469-0705.1995.06050330.x; JACKSON S, 1995, ULTRASOUND OBST GYN, V5, P55, DOI 10.1046/j.1469-0705.1995.05010055.x; MACGREGOR SN, 1987, OBSTET GYNECOL, V70, P344; MOONEY RA, 1994, OBSTET GYNECOL, V84, P298; NADEL A, 1993, OBSTET GYNECOL, V82, P43; NICOLAIDES KH, 1994, BRIT J OBSTET GYNAEC, V101, P782, DOI 10.1111/j.1471-0528.1994.tb11946.x; NICOLAIDES KH, 1992, BRIT MED J, V304, P867, DOI 10.1136/bmj.304.6831.867; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; PANDYA PP, 1995, ULTRASOUND OBST GYN, V5, P334, DOI 10.1046/j.1469-0705.1995.05050334.x; PANDYA PP, 1994, OBSTET GYNECOL, V84, P420; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353; SABBAGHA RE, 1994, DIAGNOSTIC ULTRASOUN, P155; Salonen R, 1997, ACTA OBSTET GYN SCAN, V76, P817, DOI 10.3109/00016349709024358; SALVESEN KA, 1995, ULTRASOUND OBST GYN, V6, P293, DOI 10.1046/j.1469-0705.1995.06040293.x; SANTOLAYA J, 1992, OBSTET GYNECOL, V79, P256; SHULMAN LP, 1992, OBSTET GYNECOL, V80, P80; SNIJDERS RJM, 1994, PRENATAL DIAG, V14, P543, DOI 10.1002/pd.1970140706; TIMORTRITSCH IE, 1993, OBSTET GYNECOL, V81, P742; VANZALENSPROCK RM, 1992, AM J OBSTET GYNECOL, V167, P94, DOI 10.1016/S0002-9378(11)91634-2; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WILSON RD, 1992, PRENATAL DIAG, V12, P755, DOI 10.1002/pd.1970120908	29	144	156	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 4	1997	337	23					1654	1658		10.1056/NEJM199712043372303	http://dx.doi.org/10.1056/NEJM199712043372303			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ871	9385124	Bronze			2022-12-28	WOS:A1997YJ87100003
J	Duong, F; Eichler, J; Price, A; Leonard, MR; Wickner, W				Duong, F; Eichler, J; Price, A; Leonard, MR; Wickner, W			Biogenesis of the gram-negative bacterial envelope	CELL			English	Review							SIGNAL RECOGNITION PARTICLE; MALTOSE-BINDING PROTEIN; OUTER-MEMBRANE PROTEIN; COLI INNER MEMBRANE; RAPID TRANSMEMBRANE MOVEMENT; POSITIVELY CHARGED RESIDUES; DISTINCT ATP-BINDING; ESCHERICHIA-COLI; SECA PROTEIN; TRIGGER FACTOR				Duong, F (corresponding author), DARTMOUTH COLL SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA.		EICHLER, JERRY/F-2351-2012	EICHLER, JERRY/0000-0001-9409-8026	NIGMS NIH HHS [GM23377] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023377, R01GM023377] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5225; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; Bassilana M, 1996, EMBO J, V15, P5202, DOI 10.1002/j.1460-2075.1996.tb00905.x; BATENBURG AM, 1988, BIOCHEMISTRY-US, V27, P5678, DOI 10.1021/bi00415a043; Bliss JM, 1997, J BACTERIOL, V179, P1400, DOI 10.1128/jb.179.4.1400-1403.1997; BRAUN V, 1970, EUR J BIOCHEM, V13, P336, DOI 10.1111/j.1432-1033.1970.tb00936.x; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRIGGS MS, 1985, SCIENCE, V228, P1096, DOI 10.1126/science.3158076; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DOLAN KM, 1991, J BIOL CHEM, V266, P23329; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; Eichler J, 1997, EMBO J, V16, P2188, DOI 10.1093/emboj/16.9.2188; GANNON PM, 1989, J BACTERIOL, V171, P813, DOI 10.1128/jb.171.2.813-818.1989; GUTHRIE B, 1990, J BACTERIOL, V172, P5555, DOI 10.1128/jb.172.10.5555-5562.1990; Hardie KR, 1996, EMBO J, V15, P978, DOI 10.1002/j.1460-2075.1996.tb00434.x; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; HIRST TR, 1987, J BACTERIOL, V169, P1037, DOI 10.1128/jb.169.3.1037-1045.1987; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KANDROR O, 1995, EMBO J, V14, P6021, DOI 10.1002/j.1460-2075.1995.tb00290.x; KATO M, 1992, J BIOL CHEM, V267, P413; KAWASAKI S, 1993, J BIOL CHEM, V268, P8193; KENNEDY EP, 1987, ESCHERICHIA COLI SAL; KIM YJ, 1994, CELL, V78, P845; KLAUSER T, 1992, EMBO J, V11, P2327, DOI 10.1002/j.1460-2075.1992.tb05292.x; KORONAKIS V, 1994, BACTERIAL CELL WALL; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; LANGLEY KE, 1979, P NATL ACAD SCI USA, V76, P6245, DOI 10.1073/pnas.76.12.6245; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MACINTYRE S, 1988, J BIOL CHEM, V263, P19053; Majdalani N, 1996, J BACTERIOL, V178, P3742, DOI 10.1128/jb.178.13.3742-3747.1996; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; NORGREN M, 1987, MOL MICROBIOL, V1, P169, DOI 10.1111/j.1365-2958.1987.tb00509.x; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PEEK JA, 1992, P NATL ACAD SCI USA, V89, P6210, DOI 10.1073/pnas.89.13.6210; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; Prinz WA, 1996, EMBO J, V15, P5209, DOI 10.1002/j.1460-2075.1996.tb00906.x; PUGSLEY AP, 1992, P NATL ACAD SCI USA, V89, P12058, DOI 10.1073/pnas.89.24.12058; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; Ramamurthy V, 1997, J BIOL CHEM, V272, P23239, DOI 10.1074/jbc.272.37.23239; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RANDALL LL, 1994, BIOL HEAT SHOCK PROT, P285; ROHRER J, 1990, SCIENCE, V250, P1418, DOI 10.1126/science.2124001; ROTHMAN JE, 1977, P NATL ACAD SCI USA, V74, P1821, DOI 10.1073/pnas.74.5.1821; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHNEIDER E, 1995, J BACTERIOL, V177, P5364, DOI 10.1128/jb.177.18.5364-5367.1995; Seluanov A, 1997, J BIOL CHEM, V272, P2053; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; SUMMERS RG, 1989, J BIOL CHEM, V264, P20082; TOMMASSEN J, 1983, EMBO J, V2, P1275, DOI 10.1002/j.1460-2075.1983.tb01581.x; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WHITLEY P, 1995, J BIOL CHEM, V270, P29831; WICKNER W, 1988, BIOCHEMISTRY-US, V27, P1081, DOI 10.1021/bi00404a001; WOLFE PB, 1984, CELL, V36, P1067, DOI 10.1016/0092-8674(84)90056-4; Yang YB, 1997, J BIOL CHEM, V272, P13660, DOI 10.1074/jbc.272.21.13660	84	128	130	2	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 28	1997	91	5					567	573		10.1016/S0092-8674(00)80444-4	http://dx.doi.org/10.1016/S0092-8674(00)80444-4			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YH960	9393850	hybrid			2022-12-28	WOS:A1997YH96000004
J	Boehm, T; Folkman, J; Browder, T; OReilly, MS				Boehm, T; Folkman, J; Browder, T; OReilly, MS			Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance	NATURE			English	Article							ANGIOGENESIS	Acquired drug resistance is a major problem in the treatment of cancer. Of the more than 500,000 annual deaths from cancer in the United States', many follow the development of resistance to chemotherapy. The emergence of resistance depends in part on the genetic instability, heterogeneity and high mutational rate of tumour cells'. In contrast, endothelial cells are genetically stable, homogenous and have a low mutational rate. Therefore, anti-angiogenic therapy directed against a tumour's endothelial cells should, in principle, induce little or no drug resistance, Endostatin(3), a potent angiogenesis inhibitor, was administered to mice bearing Lewis lung carcinoma, T241 fibrosarcoma or B16F10 melanoma. Treatment was stopped when tumours had regressed. Tumours were then allowed to re-grow and endostatin therapy was resumed. After 6, 4 or 2 treatment cycles, respectively, no tumours recurred after discontinuation of therapy, These experiments show that drug resistance does not develop in three tumour types treated with a potent angiogenesis inhibitor, An unexpected finding is that repeated cycles of antiangiogenic therapy are followed by prolonged tumour dormancy without further therapy.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC CTR,DEPT PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Boehm, T (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT SURG,HUNNEWELL 103,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							Brem Harold, 1994, Surgical Forum, V45, P674; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GOLDIN A, 1981, EUR J CANCER, V17, P129, DOI 10.1016/0014-2964(81)90027-X; Hill D. L., 1975, REV CYCLOPHOSPHAMIDE; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; LI PL, 1993, CANC MED, V1, P322; MORROW CS, 1993, CANC MED, V1, P618; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562	13	1449	1675	2	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 27	1997	390	6658					404	407		10.1038/37126	http://dx.doi.org/10.1038/37126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YH549	9389480				2022-12-28	WOS:A1997YH54900064
J	Atri, J; Falshaw, M; Gregg, R; Robson, J; Omar, RZ; Dixon, S				Atri, J; Falshaw, M; Gregg, R; Robson, J; Omar, RZ; Dixon, S			Improving uptake of breast screening in multiethnic populations: a randomised controlled trial using practice reception staff to contact non-attenders	BRITISH MEDICAL JOURNAL			English	Article							WOMEN; CARE	Objectives: To determine whether a two hour training programme for general practice reception staff could improve uptake in patients who had failed to attend for breast screening, and whether women from different ethnic groups benefited equally. Design: Controlled trial, randomised by general practice. Setting: Inner London borough of Newham. Subjects: 2064 women aged 50-64 years who had failed to attend for breast screening. Women came from 26 of 37 eligible practices. 31% were white, 17% were Indian, 10% Pakistani, 14% black, 6% Bangladeshi, 1% Chinese, 4% were from other ethnic groups, and in 16% the ethnic group was not reported. Main outcome measures: Attendance for breast screening in relation to ethnic group in women who had not taken up their original invitation. Results: Attendance in the intervention group was significantly better than in the control group (9% v 4%). The response was best in Indian women-it was 19% in the intervention group and 5% in the control gorup. Conclusions: This simple, low cost intervention improved breast screening rates modestly. Improvement was greatest in Indian women-probably because many practice staff shared their cultural and linguistic background. This intervention could be effective as part of a multifaceted strategy to improve uptake in areas with low rates.	UNIV LONDON QUEEN MARY & WESTFIELD COLL,ST BARTHOLOMEWS,DEPT GEN PRACTICE & PRIMARY CARE,LONDON E1 4NS,ENGLAND; UNIV LONDON QUEEN MARY & WESTFIELD COLL,ROYAL LONDON SCH MED & DENT,LONDON E1 4NS,ENGLAND; ROYAL POSTGRAD MED SCH,DEPT MED STAT,LONDON W12 0NN,ENGLAND; N THAMES BREAST PROGRAMME QUAL ASSURANCE,LONDON EC1A 7ED,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London; Imperial College London			Robson, John/H-3904-2014	Robson, John/0000-0001-6889-0415; Omar, Rumana/0000-0003-1483-1932				Atri J, 1996, BRIT MED J, V312, P614; AUSTOKER J, 1994, BRIT MED J, V309, P168, DOI 10.1136/bmj.309.6948.168; AUSTOKER J, 1993, UKCCR HNSBSP WORKSH; BOOMLA K, 1995, BRIT MED J, V310, P1004, DOI 10.1136/bmj.310.6985.1004a; Botha Johannes L., 1993, Ethnicity and Disease, V3, P189; CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; CLOVER KA, 1991, MED J AUSTRALIA, V156, P91; CREIGHTON PA, 1995, BRIT MED J, V310, P204, DOI 10.1136/bmj.310.6974.204; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; HOARE T, 1994, J PUBLIC HEALTH MED, V16, P179, DOI 10.1093/oxfordjournals.pubmed.a042954; HOARE T, 1993, BREAST SCREENING ACC, P24; Hoare TA, 1992, HLTH ED J, V51, P157; HOLLYOAK V, 1995, BRIT MED J, V310, P1004, DOI 10.1136/bmj.310.6985.1004b; Kee F, 1992, Eur J Cancer Prev, V1, P231, DOI 10.1097/00008469-199204000-00004; LAUDER LI, 1995, HLTH VISITOR, V68, P420; Majeed A, 1997, J Med Screen, V4, P19; Majeed F A, 1995, J Med Screen, V2, P119; Mohler P J, 1995, Fam Med, V27, P117; RUDIMAN R, 1995, BRIT MED J, V310, P229, DOI 10.1136/bmj.310.6974.229; Sharp DJ, 1996, J EPIDEMIOL COMMUN H, V50, P72, DOI 10.1136/jech.50.1.72; STEPHENSON J, 1995, BRIT MED J, V310, P1004, DOI 10.1136/bmj.310.6985.1004c; Thompson S G, 1993, Stat Methods Med Res, V2, P173, DOI 10.1177/096228029300200205; Ubel PA, 1996, NEW ENGL J MED, V334, P1174, DOI 10.1056/NEJM199605023341807	23	36	36	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 22	1997	315	7119					1356	1359		10.1136/bmj.315.7119.1356	http://dx.doi.org/10.1136/bmj.315.7119.1356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402779	Green Published			2022-12-28	WOS:A1997YJ21800027
J	Bonellie, SR; Raab, GM				Bonellie, SR; Raab, GM			Why are babies getting heavier? Comparison of Scottish births from 1980 to 1992	BRITISH MEDICAL JOURNAL			English	Article							WEIGHT				Bonellie, SR (corresponding author), NAPIER UNIV,DEPT MATH,EDINBURGH EH10 5DT,MIDLOTHIAN,SCOTLAND.							Barker DJP, 1992, FETAL INFANT ORIGINS; BROOKE OG, 1989, BRIT MED J, V298, P795, DOI 10.1136/bmj.298.6676.795; *OFF POP CENS SURV, 1996, LIV BRIT RES 1994 GE; POWER C, 1994, BRIT MED J, V308, P1270, DOI 10.1136/bmj.308.6939.1270; WILCOX M, 1993, BRIT MED J, V307, P588, DOI 10.1136/bmj.307.6904.588	5	28	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1205	1205		10.1136/bmj.315.7117.1205	http://dx.doi.org/10.1136/bmj.315.7117.1205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393226	Green Published			2022-12-28	WOS:A1997YF25200023
J	Turner, G; Robinson, H; Wake, S; Laing, S; Partington, M				Turner, G; Robinson, H; Wake, S; Laing, S; Partington, M			Case finding for the fragile X syndrome and its consequences	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; CARRIERS; ALLELES		SYDNEY CHILDRENS HOSP,FRAGILE X PROGRAM,SYDNEY,NSW,AUSTRALIA	University of Sydney	Turner, G (corresponding author), HUNTER GENET,FRAGILE X PROGRAM,POB 84,NEWCASTLE,NSW 2298,AUSTRALIA.							Kooy RF, 1996, AM J MED GENET, V64, P241, DOI 10.1002/(SICI)1096-8628(19960809)64:2<241::AID-AJMG1>3.0.CO;2-X; Partington MW, 1996, AM J MED GENET, V64, P370, DOI 10.1002/(SICI)1096-8628(19960809)64:2<370::AID-AJMG27>3.0.CO;2-B; Robinson H, 1996, AM J MED GENET, V64, P198, DOI 10.1002/(SICI)1096-8628(19960712)64:1<198::AID-AJMG36>3.0.CO;2-G; ROUSSEAU F, 1995, AM J HUM GENET, V57, P1006; SMITH RA, 1990, BRIT MED J, V300, P1112, DOI 10.1136/bmj.300.6732.1112; TURNER G, 1986, NEW ENGL J MED, V315, P607, DOI 10.1056/NEJM198609043151002; TURNER G, 1992, LANCET, V339, P1210, DOI 10.1016/0140-6736(92)91142-U; Turner G, 1996, AM J MED GENET, V64, P196, DOI 10.1002/(SICI)1096-8628(19960712)64:1<196::AID-AJMG35>3.0.CO;2-G; WEBB T, 1987, J MED GENET, V23, P396; Zhong N, 1996, AM J MED GENET, V64, P261, DOI 10.1002/(SICI)1096-8628(19960809)64:2<261::AID-AJMG5>3.0.CO;2-X	10	16	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 8	1997	315	7117					1223	1226		10.1136/bmj.315.7117.1223	http://dx.doi.org/10.1136/bmj.315.7117.1223			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YF252	9393231	Green Published			2022-12-28	WOS:A1997YF25200032
